


Scientific
2021 Report
IdiPAZ
Instituto de Investigación
Hospital Universitario La Paz

Index

Introduction



Information Groups by Area



Executive Summary



Associated Clinicians



Introduction



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

The IdiPAZ 2021 scientific report presented today details the scientific institute activity during 2021. But this document also reflects the results of basic and clinical research during the previous year; that is during the COVID pandemic and confinement, that for obvious reasons were published in 2021. Unsurprisingly, the number and quality of publications was maintained, in spite of all the difficulties you know so well. This honors the extraordinary effort of the scientific community and the fantastic and unprecedented team work between national and international scientists, ethical committees, health authorities, insurance companies, editors of scientific journals, health care workers in general and most important the patients, not to mention the governmental institutions that dedicated funding to the upmost limit they could afford. It was an extraordinary time, when everyone was ready to contribute. And the effort payed-off. Global health care organization was a different story.


We were taken by surprise an neglected some research tools, e.g.: postmortem studies (the quickest way to understand a new disease) were somehow banned for protection and basic research facilities were partially closed. Yes, we made some mistakes and quality was sacrificed in the interest of safety and speed, but we learned a lesson for the future: to be prepared.

IdiPAZ is a consolidated research institute and has to move forward. This is only possible if we know where we want to go. In an ever more complicated world, with growing numbers of working groups, new technologies, hubs, alliances, platforms, networks, networks inside networks, funding sources, low grade compulsory quality controls with moving targets, increasing complexity of administrative work and many other hurdles, all in good will intended to facilitate national and international relationships and translational research. Paradoxically, finding the ultimate objective and the way to move forward towards what is real important becomes less clear and one may be confused, if not lost. Where we want to go? what is the aim of a health research institute? how can we measure our value? There could be dozens or even hundreds of answers. I am afraid that what matters are the results of research, rather that the organization, technology, resources, number of activities, certificates, grants, alliances, public funding and the myriad of other valuable assets obtained. These are very important to facilitate and promote research but cannot be considered themselves as a research achievement and should not be confounded with the real target.

IdiPAZ has a strategic plan, the current plan prepared for the period 2020 - 2024, detailed after a thorough review of the institute resources, organization and productivity can be find at he IdiPAZ webpage. Furthermore, the institute External Scientific Committee recommended to: 1/ improve the relationship between basic and clinical groups and 2/ increase the participation in multinational research. Basic research inside a hospital should be linked with the clinical needs and opportunities; should focus on translational research. And clinicians must take advantage of this opportunity. Barriers to research should avoided, but the always limited resources need to focus on basic to clinical translational research. Same for internationalization of research. We have to move forward. We have to foster new and emerging research groups, but the priority must be to support the best fitted for translational and international research. We do not start from scratch, we can grow up and play an ever more relevant role in the scientific community. Do not shy away. Go for it. Do it.

Benchmarking improves quality. Benchmarking (comparing our performance with others) is one of best ways to identify where we are, where we want to go, and always improves quality and performance. Benchmarking is a must for any organization. The question is what to benchmark for and who measures it. There is a myriad of quality parameters and they may be different in national and international agencies and certainly change with time. Like a moving target. For research it is obvious that the number and quality of publications is a major measure but there are others with increasing relevance. They include translation of research to real practice and transmission / feedback from the patients and the general public. The former is the ultimate goal of research and the latter is becoming more and more relevant every day.

IdiPAZ Scientific Publications



IdiPAZ publications progressively increased in spite of the difficulties during COVID times, and the quality was maintained. %Q1: % of publication in the 1st quartile. %D1: % of publications in the 1st decile among the 286 publications related with COVID during the year 2021

1 Introduction

This scientific report follows the recommendations of the ISCiii, and these recommendations are not very different from those of other agencies. The table illustrates the parameters used by one of the international agencies that benchmark international health research institutes using a score with different performance parameters. Explore benchmarking of international health research institutes; you may be surprised. But remember, it is a moving target and the weight given to each indicator is based on common sense and consensus but remains an educated opinion not evidence based; not the best qualification of research (<https://www.scimagoir.com>)

■ Health Research Institutes
 Score indicators

FACTOR	INDICATOR	WEIGHT
Research 50%	Normalized Impact (NI)	13%
	Excellence with Leadership (EwL)	8%
	Output (O)	8%
	Scientific Leadership (L)	5%
	Not Own Journals (NotOJ)	3%
	Own Journals (OJ)	3%
	Excellence (Exc)	2%
	High Quality Publications (Q1)	2%
	International Collaboration (IC)	2%
	Open Access (OA)	2%
Innovation 30%	Scientific Talent Pool (STP)	2%
	Innovative Knowledge (IK)	10%
	Patents (PT)	10%
Societal 20%	Technological Impact (TI)	10%
	Altmetrics (AM)	10%
	Inbound Links (BN)	5%
	Web Size (WS)	5%

variables used for benchmarking international health care research institutes*. Pure research parameters (related to scientific publications) account only for 50% of the punctuation. This score parameters may be different for different agencies and may change with time. Details and definitions for the indicators can be found at: <https://www.scimagoir.com/methodology.php>

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



Dr. Rafael Pérez-Santamarina Feijóo

Managing Director of HULP Chairman of the Board of FIBHULP



Dr. José Luis López-Sendón Henstchel


Scientific Director of IdiPAZ

IdiPaz needs you. There is a lot of challenges and opportunities. The research space and reorganization during the construction of the new hospital, the duplication of facilities and working groups, understanding the intricate role and relationship of Fibhulp, IdiPaz, HULP and UAM - we are missing a lot of opportunities here -, the relationship with our new partners: Getafe University Hospital and European University, finding new alliances at local, national and international levels, how to get closer to the public, update and contents of the webpage, marketing of our research and even more punctual how to amend our weakest points; you name it. We need working groups for specific tasks and people dedicated to solve the problem. We are used to this type of work inside our individual national and international societies. We have to be proud of our institution and it will be impossible without the involvement of the investigators. We need you.

Your opinion is important. Research organization, though not a democratic enterprise, must serve the needs of the investigators, respect the projects of the investigators, help to find funding and other resources and facilitate the administrative work that consumes precious time needed for research activities. It is not leadership by the shake of it, it is constructing leadership with your ideas. At IdiPaz and Fibhulp we need to know your thoughts, what we are doing wrong and what you expect from us. We are public servants. If we don't pay attention to your voice we are useless, if not an extra barrier and then.... It is not only words, I mean it. Please respond the invitation to the survey you have received.

Looking forward
José Luis López-Sendón
 Scientific Director of IdiPAZ

MISSION, VISION & VALUES



■ Mission

To become a research institute that develops multidisciplinary biomedical research in the prioritized areas and with cutting-edge technology. Promoting collaboration with internationally renowned centers, and oriented to the translation of knowledge to clinical practice and the improvement of patients' health.

■ Vision

To become a benchmark in translational biomedical research of excellence both nationally and internationally, committed to the health of patients.

■ Values

- Public engagement
- Continuous improvement through quality fostering
- Orientation towards excellence
- Sense of belonging to the organization
- International vocation
- Leadership in innovation and transfer
- Focus on sustainability
- Encouragement of cooperation and the establishment of alliances.
- Commitment to diversity and equal opportunities

Executive Summary



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



2.1 Global Analysis



2.2 Research Structure



2.3 Training Report and Teaching



2.4 Innovation and Transfer Activities



2.5 Quality Committee



2.6 Clinical Trials



2.7 Platforms



2.8 Scientific Production



2.9 CIBERs and RETICs



2.10 Institutional Projects



2.11 Internationalization



2.12 Dissemination/Divulgateion and Public Engagement



2.13 Responsible Research and Innovation



2.1 Global Analysis

1 Introduction

2 Executive Summary

3 Information Groups by Area


4 Associated Clinicians

2.1.1. SCIENTIFIC ANALYSIS

In 2021, the scientific production of IdiPAZ included more than 1,600 publications, and almost 43% of the publications are IdiPAZ own documents, so the author the first, the last or the corresponding author of the publication is a researcher of the institute. The original articles and reviews articles by IdiPAZ researchers overcome 1,200, more than 45% in the quartile 1 and more than 16% of then published in journal of the first decile of their subject area.

	2021	Total	%Q1	%D1
Publications	1,623		42,51	16,08
Owned Publications	740		45,59	8,65
Un-owned Publications	883		50,06	22,31
Originals	1,242		42,27	15,86
Owned Originals	490		31,63	6,53
Un-owned Originals	752		49,20	21,94
Articles and reviews*	1,255		46,61	17,53
Owned articles and reviews article	488		37,30	7,99
Un-owned articles and reviews article	767		52,54	23,60

* JCR Indexed





IdiPAZ researchers evidenced their participation in national and international scientific networks, with more than 81% of the total documents published in collaboration (81.3%). Regarding collaborative publications, almost 56% were national collaboration and 45% international collaboration, and Intra-institute publications were around 16% of the documents. In addition, collaboration among IdiPAZ research groups is also reflected by the percentage of intramural collaboration, which reached almost 16% for all manuscripts and for originals.

2021	Total	% National Collaboration	% International Collaboration
Collaborative Publications	1,320	55,98	44,02
Owned Collaborative Publications	437	64,76	35,24
Un-owned Collaborative Publications	883	51,64	48,36
Collaborative Originals	1,062	54,71	45,29
Owned Collaborative Originals	310	64,19	35,81
Un-owned Collaborative Originals	752	50,80	49,20
Articles and reviews*	1,094	46,44	53,56
Owned Collaborative articles and reviews article	327	60,86	39,14
Un-owned Collaborative articles and reviews article	767	50,46	49,54

* JCR Indexed

2021	Total	% Intra-Institute Documents
Intra-Institute Publications	267	16,25
Owned Intra-Institute Publications	229	85,77
Un-owned Intra-Institute Publications	38	14,23
Intra-Institute Collaborative Originals	206	16,59
Owned Collaborative Originals	173	83,98
Un-owned Collaborative Originals	33	16,02
Intra-Institute Articles and reviews*	194	15,46
Owned Collaborative articles and reviews article	159	81,96
Un-owned Collaborative articles and reviews article	35	18,04

* JCR Indexed



1 Introduction

2 Executive Summary


3 Information Groups by Area

4 Associated Clinicians




Over the last 5 years, the upward trend in scientific activity conducted by our groups is also reinforced by the analysis of original articles belong to IdiPAZ researchers. In 2021, 490 original articles were published, with a growth of the rates achieved in previous years.


Distribution of publications by quartile 2017-2021




Distribution of originals by quartile 2017-2021



Papers with international collaboration between 2017-2021



Owned originals between 2017-2021



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians




2.1.2. ANNUAL ACCOUNTS


In accordance with the Law 19/2013, of December 9th, of transparency, access to public information and good governance, the Foundation for Biomedical Research of La Paz University Hospital (FIBHULP) makes their information public, with the objective of guaranteeing institutional transparency:

<http://www.idipaz.es/PaginaDinamica.aspx?IdPag=550&Lang=ES>

Economic income 2021



Economic income overhead 2021



	2020	2021
Income	20.630.063,10	20.997.249,40
Grants	7.859.910,06	6.809.626,43
Corporate collaboration agreements and sponsorships	2.055.195,90	1.927.055,72
Grants and other private research projects	2.519.108,86	933.785,31
Scientific research (clinical trials, collaborations...)	8.170.354,07	11.276.496,22
Financial Income	24.240,24	18.089,12
Positive exchange rate differences	313,18	32.196,60
Extraordinary income	940,79	0,00

	20.489.462,95	20.745.095,77
Expenses		
Monetary aid and other	74.414,04	55.037,33
Operating consumption	2.024.659,46	1.486.024,85
Leases and royalties	4.094,10	5.330,70
Repair and maintenance	286,33	593,81
R&D expenses	0	25.875,00
Professional Services	2.412.166,81	2.346.471,84
Other expenses	2.024.968,85	2.612.936,63
Other taxes	2.666,74	4.184,23
Wages and salaries	5.784.745,49	6.412.436,91
Social charges	1.869.504,66	2.032.600,73
Compensations	33.671,27	90.248,50
Amortization of fixed assets	2.302.302,03	1.171.206,76
Provisions (Provision - Excess)	3.423.708,40	4.445.943,15
Financial expenses	473.989,07	37.334,39
Negative exchange differences	19.554,34	4.378,14
Refund of grants, donations and legacies	38.731,36	14.492,80

Surplus for the Year	140.600,15	252.153,63
-----------------------------	-------------------	-------------------

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

In 2021, the foundation –FIBHULP- received a Nominative Transfer of the Consejería de Sanidad de la Comunidad de Madrid in favor of charging the 312D program “Biomedical Research Foundations”, to fund the following items:

- Researchers and personal of support of the I3, I3SNS, Miguel Servet I, Miguel Servet II, Río Hortega, Sara Borrell, Juan de la Cierva, Marie Skłodowska-Curie, and Juan Rodés Programs.
- Intensification Programs of health professionals.
- Activities of promotion and dissemination research and scientific culture.
- Accreditations of the research activity.
- Support to the Technical Units or Platforms for Research and Management of R+D+i

During the year 2021, IdiPAZ has signed with private public entities the number of contracts and agreements detailed below:

- Agreements: 80**
- Service contracts: 52**
- Sponsorship contracts: 20**
- Training contracts: 5**

The main entities with which these contracts have been signed are:

Organization	Nº Agreements
Abbott Laboratories S.A.	4
Abbvie Spain S.L.U.	2
Acuña y Fombona S.A.	1
Alcon Healthcare S.A.	1
Allm Emea GmbH	1
Amgen S.A.	2
Asociación de Cirujanos de Mama de Toledo	1
Asociación Instituto Biodonostia	1
Astrazeneca Farmacéutica Spain S.A.	3
B.Braun Medical S.A.	1
Barcelona Supercomputing Center	1
Bayer Consumer Care AG	1
Bayer Hispania S.L.	1
Boehringer Ingelheim España S.A.	3
Boston Scientific Ibérica S.A.	1
BVBA Nikkiso Belgium	1
CCEIP Lorenzo Luzuriaga	1

Consejo Superior Investigaciones Cientificas	1
Crazy Science & Business S.L.	2
CSL Behring S.A.	2
Ecrin European Clinical Research Inf	3
Ediciones Mayo S.A.	2
EISAI Farmacéutica S.A	1
European Foundation for the Study of Chronic Liver Failure	1
European Spine Study Group Association ESSGA	1
FAES Farma	1
Fundació Clinic Per a la Recerca Biomedica	2
Fundació Eurecat	1
Fundación ACS	2
Fundación Canaria de Investigación Sanitaria	1
Fundación Casa del Corazón	1
Fundación contra la Hipertension Pulmonar	1
Fundación Cris Contra Il Cáncer	3
Fundación de la Sociedad Española de Alergología e Inmunología Clínica	1
Fundación de la Universidad Autónoma de Madrid	1
Fundación Hospital Ramón y Cajal	2
Fundación Hospital Universitario La Princesa	2
Fundación Instituto de Investigación Sanitaria de Santiago de Compostela	2
Fundación Mari Paz Jiménez Casado	1
Fundación para la Investigación Biomédica del Hospital Clínico San Carlos	2
Fundación para la Investigación Biomédica del Hospital Universitario Puerta de Hierro Majadahonda	1
Fundación para la Investigación Biomedica Hospital Universitario La Paz	7
Fundación Profesor Novoa Santos	1
Fundación Vithas	1
Galapagos Biopharma Spain S.L.U	1
Genómica S.A.U	1
Glaxosmithkline S.A.	1
Gmv Soluciones Globales Internet S.A.U	1
Grunenthal Pharma S.A	1
Guangdong Shunde Innovative Designs Institute	1
Hc Hospitales S.L.	1
Hologic Iberia S.L.	1
HSF Pharmaceutica	1

Inmunotek	1
Institut de Recerca Biomedica de Lleida	1
Instituto de Estudios Ciencias Salud Castilla	1
Instituto Investigación Sanitaria Biocruces	2
Instituto Investigación Sanitaria Hospital La Fe	1
Instituto de Investigación Sanitaria Bioaraba	2
IRCCS Sacro Cuore Don Calabria Hospital	1
Janssen-Cilag España S.A.	1
Jazz Pharmaceuticals Iberia S.L.	1
Johnson & Johnson S.A.	1
Laboratorio Menarini S.A.	2
Laboratorios Gebro Pharma S.A.	1
Lilly S.A.	1
Mba Incorporado S.L	1
Medtronic Ibérica S.A.	3
Merck Sharp and Dohme de España S.A.	4
Merck S.L.	2
Montreal Heart Institute	1
Mozo-Grau S.A.	2
Mr Global (Mindray)	1
Nestle España S.A.	1
Neurobotic S.L	1
Novartis Farmaceutica S.A.	3
Novo Nordisk Pharma S.A.	1
Omni Prex S.L	1
ONG Otromundoesposable	11
Opesa Centro de Formación	3
Pfizer S.L.U.	1
Phadia Ab	1
Prim S.A.	1
Promega Corporation	2
Research Triangle Institute / Rti Health Soluciones	1
Roche Farma S.A.	4
Sanofi Aventis S.A	1
Siemens Healthcare S.L.	1
Stem Vision S.L	1
Swedish Orphan Biovitrum S. L	3
Syf Galenus Center S.L	5
Teva Pharma S.L.U.	1
UCB Pharma S.A	3



2.2 Research Structure

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

■ Scientific Director

José Luis López-Sendón Henstchel

■ Scientific Assistant Director

Eduardo López-Collazo

■ Technical Assistant Director

Paloma Gómez Campelo

■ Governing Council

Chairman

Antonio Zapatero Gaviria. *Health Care Vice Councillor and Public Health. CM*

Deputy Chairman

Amaya Mendikoetxea. *Chancellor of UAM*

Members

Rafael Pérez-Santamarina Feijóo. *Chairman of the Board of FIBHULP/HULP Manager*

Rodolfo Álvarez-Sala Walther. *FIBHULP Patron*

Juan José Ríos Blanco. *FIBHULP Patron*

José Luis López-Sendón Henstchel. *Scientific Director IdiPAZ. FIBHULP Patron*

Almudena Castro Conde. *FIBHULP Patron*

Exuperio Díez Tejedor. *FIBHULP Patron*

Alicia Portas Martínez. *Patrono FIBHULP*

Antonio Pérez Martínez. *FIBHULP Patron*

Susana Noval Martín. *HULP Representative*

Francisco García Ríos. *HULP Representative*

Paloma Gómez Campelo. *HULP Representative*

Carlos F. Sánchez Ferrer. *UAM Representative*

José Manuel González Sancho. *UAM Representative*

Esther López García. *UAM Representative*

Miguel Ángel Andrés Molinero. *HUG Manager*

Óscar García López. *Representante UEM*

Secretary

Ana Coloma Zapatero. *Director of FIBHULP*

■ Executive Committee

Chairman

Rafael Pérez-Santamarina Feijóo. *Chairman of the Board of FIBHULP; permanent delegation to Rodolfo Álvarez-Sala Walther.*

Members

José Luis López-Sendón Henstchel. *IdiPAZ Scientific Director*

Francisco García Ríos. *HULP Representative*

Juan José Ríos Blanco. *HULP Representative*

Paloma Gómez Campelo. *IdiPAZ Technical Assistant Director*

Carlos Félix Sánchez Ferrer. *Dean UAM*

Francisco Arnalich Fernández. *UAM Representative*

Miguel Ángel Andrés Molinero. *HUG Manager*

Óscar García López. *UEM Representative*

Rosa Carmen Fernández Lobato. *HUG Representative*

Eduardo López Collazo. *Assistan Scientific Assistant Director and stabilized researcher representative*

Secretary

Ana Coloma Zapatero. *Director of FIBHULP*



■ External Scientific Committee



Juan Tamargo Menéndez. *Professor. Department of Pharmacology and Toxicology, Complutense University of Madrid. Madrid*



Reiner Albert Veitia. *Professor. Université Denis Diderot, Paris VII. Group leader of the Molecular Oncology and Ovarian Pathologies, l'Institut Jacques Monod. Paris*



Joaquín Arribas López. *Director of Research at Parc de Salut Mar (PSMAR) and director of the Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), as well as ICREA research professor at the Vall d'Hebron Institut d'Oncologia (VHIO) Barcelona. Chairman of the Technical Committee on Cancer Screening Health Research Fund (FIS), Institute of Health Carlos III*



Jacinta Cecilia Bustamante. *Associate Lecturer, Cell Biology. Paris Cité University, Laboratory of Human Genetics of Infectious Diseases (INSERM U1163), Imagine Institute. Centre for the Study of Primary Immunodeficiencies, Necker Enfants-Malades Hospital. Paris*



Isabel Fabregat Romero. *Senior Researcher, head of the TGF-beta and Cancer Group. ONCOBELL Programme. Bellvitge Biomedical Research Institute (IDIBELL). Barcelona*



Juan Pedro Bolaños Hernández. *Professor. Department of Biochemistry and Molecular Biology. University of Salamanca. Institute of Functional Biology and Genomics. Salamanca.*



Santiago Rodríguez de Córdoba. *Research Professor. Department of Molecular Biomedicine. Centre for Biological Research- Margarita Salas. CSIC. Madrid*



Pablo Pelegrin Vivancos. *Scientific Assistant Director, Biomedical Research Institute of Murcia (IMIB), University of Murcia. Murcia*



Elisa Martí Gorostiza. *Instituto de Biología Molecular de Barcelona Director. Barcelona*



Stanley Thomas Carmichael. *Professor and Chair and Frances Stark Endowed Chair in the Department of Neurology at the David Geffen School of Medicine at the University of California. Los Ángeles*



María Asuncion Mejías. *Principal investigator in the Center for Vaccines and Immunity at The Research Institute at Nationwide Children's Hospital. Associate Lecturer of Pediatrics at The Ohio State University College. Ohio*



Judith Hochman. *Director of the Cardiovascular Research Institute at New York University Grossman School of Medicine. New York*

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



1
Introduction

2
Executive
Summary

3
Information
Groups
by Area

4
Associated
Clinicians

■ Animal Welfare Organ

Carmen Fernández Criado. *Director of the Veterinary Office of the Faculty of Medicine of the UAM. Specialist in Animal Health and Welfare as an external consultant*

Fernando Carceller Benito. *Deputy Neurosurgery Service HULP as optional and researcher of the "Neurology and Cerebrovascular Disease" from IdiPAZ*

Nuria Vilaboa Díaz. *IdiPAZ's researcher. Internal consultant*

Carlota Largo Aramburu. *Head of the Animal Service HULP Experimental Surgery Specialist in Animal Health and Welfare Center*

■ Technical Secretary

Mercedes Ruiz Balibrea

■ Internal Scientific Committee

Chairman

José Luis López-Sendón Henstchel. *Scientific Director*

Secretary

Nora Butta Coll. *HULP representative*

Members

Eduardo López Collazo. *Scientific Assistant Director and HULP representative*

Paloma Gómez Campelo. *Technical Assistant Director*

Javier de Castro Carpeño. *Innovation Support Unit Coordinator*

José Jonay Ojeda Feo. *Quality Comitee Coordinator*

Bárbara Martínez de Miguel. *Training Comitee Coordinator*

Alejandro Martín Quirós. *Postdoctoral research and HULP representative*

Karla Marina Montalban. *Predocctoral research and HULP representative*





1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Hospital Universitario La Paz's Representative

- Francisco García Río
- Antonio Pérez Martínez
- Jaime Feliu Batlle
- José Luis Merino
- María Gutiérrez Fernández
- Nuria Vilaboa Díaz
- Blanca Fuentes Gimeno
- Inmaculada Ibañez de Cáceres
- María Auxiliadora Bajo

Universidad Autónoma de Madrid's Representative

- María Carmen Sellán Soto
- Esther López García
- Mercedes Salaices Sánchez
- Francisco Arnalich Fernández
- Belén Pérez González

Hospital Universitario de Getafe's Representative

- Javier Sánchez-Rubio Ferrández
- Andrés Maldonado Morillo
- Raquel Herrero Hernández

Universidad Europea de Madrid's Representative

- Óscar García López

FIBHULP

Director

Ana Coloma Zapatero



Human Resources Manager

Head: María Quintanar Jaime
Rocío Mateos Valverde



Private Projects Manager

Head: F. G. G.
Nathalia García Quero



Clinical Trial Manager

Head: Sara Moral Álamo
Desirée Hernández López



Public Projects Manager

Head: Silvia Arce Santamaría
Raquel Carmona del Mazo

Institutional Projects Manager

José Luis Narro Villanueva



European Projects Manager

Head: José Luis Narro Villanueva
Santiago Rello Varona




Contracting and Legal department

Head: Sara Fernández Morata
Irene Montero
Emilia Cerezuela Caravaca
Elena Martínez Fernández



Accountants

Head: Laura López Revuelta
Mónica García López





1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

■ Research Ethics Committee with Medical Products

President

Almudena Castro Conde. *Head of Section of Cardiology Department*

Vicepresident

Jesús Frías Iniesta. *Head of the Clinical Pharmacology Department. Representative of Research Committee*

Members

José Manuel Añón Elizalde. *Head of Section of Intensive Medicine Department*

José Ignacio Bernardino de la Serna. *Assistant Physician-Internal Medicine Department*

Nora Butta Coll. *Head of Research Laboratory of Coagulopathies and Alterations of Haemostasis. Researcher of the IdiPAZ*

Fernando Cabañas González. *Head of Pediatrics and Neonatology. Quirón Salud Madrid University Hospital. Researcher of the IdiPAZ*

Filiberto Chuliá Fernández. *Non-health member. Law Degree. Head of the Legal Advisory Service/Patrimony Unit.*

Mariana Díaz Almiron. *Data analyst. Biostatistics Platform*

María Dolores Diestro Tejeda. *Assistant Physician-Gynaecology and Obstetrics Department*

Jaime Fernández-Bujarrabal Villoslada. *Assistant Physician-Pneumology Department*

María Justa García-Matres Cortés. *Assistant Physician-Urology Department. Representative of Clinical Ethics Committee*

Mercedes Gasior Kabat. *Assistant Physician-Hematology Department*

Pedro Herranz Pinto. *Head of Dermatology Department*

Carlos Lahoz Rallo. *Assistant Physician-Internal Medicine Department*

Nuria Rodríguez Salas. *Assistant Physician-Medical Oncology Department*

Miriam Romero Portales. *Assistant Physician-Digestive System Department*

Filomena Trocoli González. *Nurse. Supervisor of Nephrology Department*

Alejandra Vilanova Sánchez. *Assistant Physician-Pediatric Surgery Department*

Elena Villamañán Bueno. *Assistant Clinical Pharmacist-Pharmacy Department*

Rosa Villanueva Peña. *Assistant Physician-Psychiatry Department*

Members from outside the institution

Evaristo Moliné Jorques. *Layperson and Patient representative*

Eva Prieto Utiel. *Assistant Clinical Pharmacist of Primary Care-Pharmacy Department*



Technical Secretary

Head: Emma Fernández de Uzquiano

Elena García Mendez. *Pharmacist*

Sol de Gracia García. *Administrative Assistant*

María Isabel Arribas Álvarez. *Administrative*

■ Quality Coomittee



Coordinator

José Jonay Ojeda Feo. *HULP Representative*

Members

Blanca Fuentes Gimeno. *HULP Representative*

Alberto Martín Vega. *HULP Representative*

María Luisa Díaz Martínez. *UAM Representative*

Gema Vallés Pérez. *FIBHULP Representative*

Paloma Gómez Campelo. *FIBHULP Representative*

Ana Coloma Zapatero. *FIBHULP Representative*

Aitana López Redondo. *FIBHULP Representative*





1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

■ Unit of Scientific Culture and Innovation Unit

Bárbara Martínez de Miguel
Alejandro Martín Quirós
Paloma Gómez Campelo
Rocío Buendía Domínguez
Gema Vallés Pérez
Lucía Medina Royo
Aitana López Redondo

■ Training Committee



President

Bárbara Martínez de Miguel. *HULP Representative*

Secretary

Mercedes Ruiz Balibrea. *HULP Representative*

Members

Alberto Borobia Pérez. *HULP Representative*
Ana García Redondo. *Researcher R3. UAM Representative*
Paloma Gómez Campelo. *FIBHULP Representative*
María Fernández Velasco. *Researcher R3. FIBHULP Representative*
Alejandro Martín Quirós. *Researcher R4. HULP Representative*
Ana Martínez Virto. *HULP representative*
Julián Nevado Blanco. *Researcher R3. HULP Representative*
Rocío Rosas Alonso. *FIBHULP Representative*
Pilar Sánchez-Corral Gómez. *Researcher R4. Works Council Representative*
Ana Sastre Perona. *Researcher R3. FIBHULP Representative*

■ Equality and Diversity Commission

Members

Eduardo López Collazo. *FIBHULP representative*
María Quintanar Jaime. *FIBHULP representative*
Paloma Gómez Campelo. *FIBHULP representative*
Nuria Vilaboa Díaz. *Employee's representative of FIBHULP*
F. G. G. *Employee's representative of FIBHULP*
Juan Ángel Fresno Vara. *Employee's representative of FIBHULP*

Contact

lgualdadydiversidad@idipaz.es

23th July of 2019, we decided to join as the Equality and Diversity Committee in the Foundation for Biomedical Research of La Paz University Hospital (FIBHULP) because we think it is important to improve equality in the community respecting the differences, and to contribute to their promotion in science.

In a short period, this committee has achieved significant results:

- Prevention and action protocol against discriminatory harassment, moral, sexual harassment and harassment based on sex
- Equality and Diversity Plan

In addition, in December 2019, FIBHULP/IdiPAZ signed the diversity charter, the initiative of the Fundación Diversidad - of the European Institute of Diversity Management and the Alares Foundation with the support of the Spanish Ministry of Equal Opportunities, added at the European diversity Charter.

By signing this document, IdiPAZ/FIBHULP assumes the guidelines of its Decalogue of principles:

1. To sensitize employees in line with the values of equal opportunities and respect for diversity.
2. To advance in the construction of a diverse workforce
3. To promote the inclusion in the workplace
4. To consider policies to promote diversity in the workplace
5. To promote of work-life balance for employees
6. Recognition of the diversity of clients
7. To communicate the compromise around these principles to the employees.
8. To communicate the compromise around these principles to the suppliers.
9. To communicate the compromise around these principles to the public administrations, business organizations, trade unions and other stakeholders.
10. To highlighting activities in support of non-discrimination -and their results- in its Annual Report.





1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

■ Commission for Humanization and Social and Scientific Responsibility

President

Paloma Gómez Campelo. *Technical Assistant Director of IdiPAZ - CSR, SDGs and Agenda 2030 Coordinator of IdiPAZ/FIBHULP*

Vice President

Manuel Arellano Armisen. *Second Vice-President of the Platform of Patients' Organizations, Vice-President of the ALCER National Federation and member of the Board of the European Patients' Forum.*

Members

Ana Coloma Zapatero. *Director of FIBHULP*

María Quintanar Jaime. *FIBHULP Human Resources Department - Head of CSR of IdiPAZ/FIBHULP*

Ana Cristina García Álvarez. *Depty Director of continuity of Care representative of the HULP Humanitization Commission*

Sara Gusi Gil. *Environmental Management Technician. HULP representative*

Gloria García. *District Council representative*

Concepción Velázquez-Gaztelu. *Representative of patient associations. President of NUPA*

Secretary

Aitana López Redondo. *Responsible for SDGs and Agenda 2030 at IdiPAZ/FIBHULP*

Contact

RSC@idipaz.es



IdiPAZ/FIBHULP has the certification of Corporate Social Responsibility through the IQNet SR10 standard, within the Integrated Management System of the Hospital Universitario La Paz.

In addition, we are working on joining the commitment to the Sustainable Development Goals defined by the United Nations, which includes 17 goals and 169 targets, including new areas such as climate change, economic inequality, innovation, sustainable consumption, peace and justice, among other priorities. To this end, we are working to establish a model that includes the SDGs and we have defined a survey to establish those aspects that are most relevant to our institution.

■ Health and Safety Committee

Compostion

Gema Vallés Pérez. *FIBHULP Representative/President*

Sara Fernández Morata. *FIBHULP Representative*

Jesús Mingorance Cruz. *FIBHULP Representative*

Laura Saldaña Quero. *Workers' Representative/Secretary*

Berta Rodés Soldevilla. *Workers' Representative*

F. G. G. *Workers' Representative*

External Prevention Service

Quirón Prevención

Delegate of the External Prevention Service:

Ángel Martínez Blasco

Contact

CSS.FIBHULP@idipaz.es

■ Works Council

Ángel Campos Barros

Juan Ángel Fresno Vara

Rocío López Vacas

Nuría Vilaboa Díaz

F. G. G

Laura Saldaña Quero

Pilar Sánchez-Corral Gómez

Berta Rodés Soldevilla

Contact

comite.empresa.fibhulp@gmail.com





Neurosciences Area

Coordinator

Exuperio Díez Tejedor

Psychiatry and Mental Health

Director: **María Fe Bravo Ortiz**

Neurology and Cerebrovascular Diseases

Director: **Exuperio Díez Tejedor**

Neuroprotective Strategies in Neurodegenerative Diseases

Director: **Antonio Cuadrado Pastor**

Involvement of Glycinergic and Glutamatergic Systems in Central Nervous System Pathologies

Director: **Francisco Zafra Gómez**

Mechanisms and Biomarkers in Neurodegenerative Diseases

Director: **Isabel Lastres Becker**

Research in Multiple Sclerosis Group (HUG)***

Director: **Yolanda Aladro Benito**



Cardiovascular Area

Coordinator

José Luis López-Sendón Henstchel

Invasive and Clinical Cardiology – ICCI-Paz

Director: **José Luis López-Sendón Henstchel**

Cardiovascular Epidemiology and Nutrition****

Director: **Fernando Rodríguez Artalejo**

Coagulopathies and Alterations of Haemostasis


Director: **Víctor Jiménez Yuste**

Vascular Physiology and Pharmacology

Director: **Mercedes Salices Sánchez**

Vascular Pharmacology and Metabolism (FARMAVSM)

Director: **Carlos F. Sánchez Ferrer**



**** The group decided to stop being part of the IdiPAZ structure in March 2022

*** This group became part of IdiPAZ through the signing of a new legal agreement in June 2021

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



Infectious Diseases and Immunity Area

1 Introduction

Coordinator

Eduardo López-Collazo

2 Executive Summary

AIDS and Infectious Diseases

Director: **José Ramón Arribas López**

Molecular Microbiology

Director: **Jesús Mingorance Cruz**

Immuno-Rheumatology

Director: **María Eugenia Miranda Carús**

Innate Immune Response

Director: **Eduardo López-Collazo**

Diagnosis and Treatment of Diseases associated with Abnormalities of the Complement System

Directors: **Margarita López Trascasa**

Pilar Sánchez-Corral Gómez

Lymphocyte Pathophysiology in Immunodeficiencies

Director: **Eduardo López Granados**

Drug Hypersensitivity and Innate Immune Response

Director: **Teresa Bellón Heredia**


Immunomediate Gastrointestinal Diseases and other Digestive Pathologies

Director: **María Dolores Martín Arranz**

3 Information Groups by Area

4 Associated Clinicians





Large System Pathologies Area

Coordinator

Francisco García Río

Internal Medicine and Systemic Diseases

Director: **Francisco Arnalich Fernández**

Organic Dysfunction and Failure in the Aggression

Director: **Abelardo García de Lorenzo y Mateos**

Respiratory Diseases

Director: **Francisco García Río**

Regulation of Gene Expression and by Hypoxia

Director: **Luis del Peso Ovalle**

Nephrology

Director: **Maria Auxiliadora Bajo Rubio**

Aging and Fragility in the Elderly

Director: **Juan Ignacio González Montalvo**

Diagnosis and Treatment of Allergic Diseases

Director: **Santiago Quirce Gancedo**

Gynecologic Oncology*

Director: **Ignacio Zapardiel Gutiérrez**

Patient Blood Management

Director: **Manuel Quintana Díaz**

Urology*

Director: **Luis Martínez-Piñeiro Lorenzo**

Health Care Nurses Research

Director: **Jesús Castro Toro**

Emergency and Critical Pathology

Director: **Alejandro Martín Quirós**

Hospital Pharmacy

Director: **Alicia Herrero Ambrosio**

Translational Hepatology**

Director: **Francisco Javier García-Samaniego Rey**


Fragility and Healthy Aging Research Group (HUG)***

Director: **Leocadio Rodríguez Mañas**

* The External Scientific Committee decided that this group should be removed from the scientific structure on December 2021

** Group recently created, December 2021

*** This group became part of IdiPAZ through the signing of a new legal agreement in June 2021




1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



Cancer and Human Molecular Genetics Area

Coordinator

Gemma Moreno Bueno

INGEMM- Institute of Medical and Molecular Genetics

Director: **Pablo Lapunzina Badía**

Translational Oncology

Director: **Jaime Feliú Battle**

Experimental Therapies and Biomarkers in Cancer

Directors: **Inmaculada Ibáñez de Cáceres**

Javier de Castro Carpeño

Oto-Neurosurgery Research

Director: **Luis Lassaletta Atienza**

Cancer Molecular Pathology and Therapeutic Targets

Director: **David Hardisson Hernández**

Mechanisms of Tumour Progression

Director: **Gemma Moreno Bueno**

Animal and Cell Models for Detection and Characterization of Leukemic Stem Cells

Director: **Carmela Calés Bourguet**

Research and Diagnosis of Inherited Metabolic Diseases


Director: **María Belén Pérez González**

Regulation of Ciliary Structure and Function by Phosphoinositides*

Director: **Francesc García Gonzalo**

Dyslipemias of Genetic Origin and Metabolic Diseases

Sonia Rodríguez Novoa



Surgery, Transplant and Health Technologies Area

Coordinator

Nuria Vilaboa Díaz

Bone Pathophysiology and Biomaterials

Director: **Nuria Vilaboa Díaz**

Cellular Engineering

Director: **María Paz de Miguel González**

Clinical Pharmacology

Director: **Jesús Frías Iniesta**

Osteoarticular Surgery Research – GICOA

Director: **Enrique Gómez Barrena**

Research In Oral and Maxillofacial Surgery

Director: **Juan Luis Cebrián Carretero**


Ana Sastre Perona

Patients Safety and Quality Research

Director: **Elena Ramírez García**

Translational Research and Innovation in General and Digestive Surgery**

Director: **Constantino Fondevila Campo**



1 Introduction


2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

* The External Scientific Committee decided that this group should be removed from the scientific structure on December 2021

** Group recently created, December 2021



Maternal Infant Child and Youth Research Area

Coordinator

Antonio Pérez Martínez
Cristina Calvo Rey

Neonatology

Director: **Adelina Pellicer Martínez**

Molecular Hepatology

Director: **Paloma Jara Vega**

Maternal and Fetal Medicine

Director: **José Luis Bartha Rasero**

Pediatric Respiratory, Systemic and Neurological Infections & Host Immune Response

Director: **Cristina Calvo Rey**

Pediatric Systemic Infections; HIV, tuberculosis, Imported and Emergent Diseases

Director: **Talía Sainz Costa**

Translational Research in Pediatric Oncology, Hematopoietic Transplantation and Cell Therapy

Director: **Antonio Pérez Martínez**

Congenital Malformations and Transplantation**


Director: **Francisco Hernández Oliveros**

Research in Endometriosis**

Director: **Alicia Hernández Gutiérrez**

Pediatric Diseases/Pediatric HIV Group (HUG)***

Director: **Andrés José Alcaraz Romero**



Multidisciplinary Research in Healthy Aging Area



** Group recently created, December 2021

*** This group became part of IdiPAZ through the signing of a new legal agreement in June 2021

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



Public Research Contracts

Ramón y Cajal Stabilisation Contracts (13) - CM

- Karen Elise Heath. *INGEMM - Institute of Medical and Molecular Genetics Group*
- Jesús Mingorance Cruz. *Molecular Microbiology Group*
- Rebeca Pérez de Diego. *Innate Immune Response Group*

Miguel Servet Stabilisation Contracts (12) - ISCIII/ CM

- Teresa Bellón Heredia. *Drug Hypersensitivity and Innate Immune Response Group*
- Juan Ángel Fresno Vara. *Translational Oncology Group*
- Ángel Campos Barros. *INGEMM - Institute of Medical and Molecular Genetics Group*
- María Paz de Miguel González. *Cellular Engineering Group*
- Eduardo López-Collazo. *Innate Immune Response Group*
- Juan Antonio Rey Herranz. *Oto-Neurosurgery research Group*
- Berta Rodés Soldevila. *AIDS and Infectious Diseases Group*
- Pilar Sánchez-Corral Gómez. *Diagnosis and Treatment of Diseases Associated with Abnormalities of the Complement System Group*
- María Rosa Torres Jiménez. *Metabolic-Vascular Unit Group*
- David Vicent López. *Molecular Hepatology Group*
- Nuria Vilaboa Díaz. *Bone Pathophysiology and Biomaterials Group*
- Nora Viviana Butta Coll. *Coagulopathies and Alterations of Haemostasis Group*

- María Inmaculada Ibáñez de Cáceres. *Experimental Therapies and Biomarkers in Cancer Group*
- Rosa María Rodríguez Pérez. *Diagnosis and Treatment of Allergic Diseases Group*
- Laura Saldaña Quero. *Bone Pathophysiology and Biomaterials Group*
- María Fernández Velasco. *Innate Immune Response Group*

Miguel Servet Contracts Type I - ISCIII

- Carolina Cubillos Zapata (MS18/00208). *Respiratory Diseases Group*
- Ana Sastre Perón (MS19/00033). *Experimental Therapies and Biomarkers in Cancer Group*
- Carlos del Fresno Sanchez (CP20/00106). *Innate Immune Response Group*
- Laura Otero Ortega (CP20/00024). *Neurology and Cerebrovascular Diseases Group*

Miguel Servet Contracts Type II - ISCIII

- María Dolores Gutiérrez (MSII20/00002). *Neurology and Cerebrovascular Diseases Group*

Intensification Contracts – ISCIII

- Cristina Calvo (INT19/00009). *Pediatric Respiratory, Systemic and Neurological Infections & Host Immune Response Group*
- Francisco Javier Carcas Sanjuan (INT19/00082). *Clinical Pharmacology Group*
- Alberto M. Borobia Pérez (INT19/00055). *Clinical Pharmacology Group*
- José Ramón Arribas López

(INT20/00041). *AIDS and Infectious Diseases Group*

- Francisco Javier García Río (INT20/00020). *Respiratory Diseases*
- María Alonso de Leciñana Cases (INT21/00017). *Neurology and Cerebrovascular Diseases Group*
- Talía Sainz Costa (INT21/00064). *Pediatric Systemic Infections; HIV, tuberculosis, Imported and Emergent Diseases*

Río Hortega Contracts - ISCIII

- Carmen Busca Arenzana (CM20/00157). *AIDS and Infectious Diseases Group*
- Elisa Alonso López (CM20/00047). *Neurology and Cerebrovascular Diseases Group*
- Clara Isabel Udaondo Gascón (CM21/00012). *Pediatric Respiratory, Systemic and Neurological Infections & Host Immune Response*
- Cristina Marcelo Calvo (CM21/00030). *Associated Clinicians*
- Paula Rodríguez Molino (CM21/00174). *Pediatric Systemic Infections; HIV, tuberculosis, Imported and Emergent Diseases*

Juan Rodés Contracts - ISCIII

- Rocío Rosas Alonso (JR21/00003). *Experimental Therapies and Biomarkers in Cancer Group*

Sara Borrell Contracts - ISCIII

- María Perez Mato (CD19/00033). *Neurology and Cerebrovascular Diseases Group*
- Javier Rodríguez Centeno (CD21/00051). *AIDS and Infectious Diseases Group*
- Francisco Javier Cueto Rodríguez (CD21/00185). *Associated Clinicians*

Marie Skłodowska-Curie Actions - Horizon 2020. European Union

- María Cristina Murano. (CAREIN-TRIALS). *Clinical Pharmacology Group*

Juan de la Cierva Contracts – Ministry of Science, Innovation and Universities

- Elie Dahdouh. (IJC2019-038832-I). *Molecular Microbiology Group*

Predocctoral Fellowship - ISCIII

- Fernando Laso Garcia (FI18/00026). *Neurology and Cerebrovascular Diseases Group*
- Carmen Mestre Duran (FI19/00176). *Translational Research in Pediatric Oncology, Hematopoietic Transplantation and Cell Therapy Group*
- Miranda Burdiel Herencia (FI19/00061). *Experimental Therapies and Biomarkers in Cancer Group*
- Roberto Lozano Rodríguez (FI19/00334). *Innate Immune Response Group*
- Enrique Alfaro García (FI20/00059). *Associated Clinicians*
- Rebeca Gallego Ruiz (FI21/00033). *Neurology and Cerebrovascular Diseases Group*
- Andrea Bueno Sen (21/00259). *Associated Clinicians*

Predocctoral Contract - Ministry of Science, Innovation and Universities

- Francisca Díaz González (FPU17/04055). *Associated Clinicians*

Predocctoral Contract – MINECO

- Miguel Angel Lerma Juarez (PRE2019-090430). *Bone Pathophysiology and Biomaterials*

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

- Elsa Lucas Castro (PRE2021-098PRE2021874). *Associated Clinicians*

Technical Support Stabilisation Contracts - CM

- Francisco Gayá Moreno. *AIDS and Infectious Diseases Group*
- María Teresa Vallejo Cremades. *Associated Clinicians*
- Beatriz Sanz Minguela. *Drug Hypersensitivity and Innate Immune Response Group*

Youth Guarantee Contracts - CM

Graduate

- Lucía María Acero Riaguas (PEJ-2020-AI/BMD-17846). *Experimental Therapies and Biomarkers in Cancer Group*
- María Fuentes Andión (PEJ-2020-AI/BMD-19637). *Associated Clinicians. INGEMM - Institute of Medical and Molecular Genetics Group*
- Paula Cantolla Pablo (PEJ-2020-AI/BMD-18883). *Associated Clinicians. Invasiv and Clinical Cardiology - ICCI - Group*
- Rodrigo Serrano Yamba (PEJ-2020-AI/BMD-17656) *Associated Clinicians. Bone Pathophysiology and Biomaterials Group*

Technical Support

- Virginia Rufo Rabadán (PEJ-2017-TL/BMD-6201). *Associated Clinicians*


Programme	Organisation	Total
Ramón y Cajal Stabilisation Contracts (I3)	CM	3
Miguel Servet Stabilisation Contracts (I2)	ISCI/ CM	16
Technical Support Stabilisation Contracts	CM	3
TOTAL ESTABLISHED		22
Miguel Servet Contracts CP Type 1	ISCI	4
Miguel Servet Contracts CP Type 1I	ISCI	1
Intensification Contracts	ISCI	7
Río Hortega Contracts	ISCI	5
Juan Rodés Contracts	ISCI	1
Marie Skłodowska-Curie Actions	European Union	1
Sara Borrell Contract	ISCI	3
Juan de la Cierva Contracts	Ministry of Science, Innovation and Universities	1
Predocctoral Fellowship	ISCI	7
Predocctoral Contract	Ministry of Science, Innovation and Universities	1
Predocctoral Contract	MINECO	2
Youth Guarantee Contracts	CM	5
TOTAL PROGRAMMES		38
Youth Guarantee Contracts		60
UCICEC	CAIBER	13
FIS Projects	ISCI	9
European Projects	EU	12
Research Network	ISCI	3
Research Network	CM	4
SAF/MAT	MINECO	2
Biobank	ISCI	5
Commercial clinical trials	ISCI	4
Commercial clinical trials	EECC Promoters	22
Private projects	Pharmaceutical Industry	108
In-house Projects	FIBHULP	6
ITEMAS Network	ISCI	3
RETOS	MINECO	1
TOTAL EMPLOYEES DEPENDENT ON P.I.		192
TOTAL STAFF DEPENDENT ON P.I.		189
Technical Unit Staff	FIBHULP	20
TOTAL TECHNICAL UNIT		20
TOTAL		273




Researcher profile

The following graphs show the classification of IdiPAZ researchers according to the EURAXESS regulations proposed by the European Union. In addition, in the following image we can see the evolution of this classification that has occurred in the last year.

Euraxess Researcher Profile



Evolution of the Euraxess Researcher Profile



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



2.3 Training Report and Teaching

Some of the goals of IdiPAZ are to generate knowledge, to train specialists in the biomedical, to promote research and to transfer the knowledge not only to clinical practice but the society too.

2.3.1. DOCTORAL THESES

In 2021, 52 Doctoral Theses have been read and/or supervised by IdiPAZ researchers, and 3 of them was thesis with **International Mention** 

Doctoral Student	Title	Director	University
Aliaño Piña M	Diferencias de género en Anestesiología y Reanimación: desde una perspectiva histórica a la situación española actual	Gilsanz Rodríguez F, Franco Rubio G	UAM
Alonso López E	Vesículas extracelulares y Micro-ARN como biomarcadores de daño, reparación cerebral y recuperación en el infarto cerebral agudo	Gutiérrez Fernández M, Fuentes Gimeno B	UAM
Álvarez Collado L	Prevalencia de factores de riesgo cardiovascular en trabajadores de un hospital terciario y estrategias de promoción de la salud en hospitales de la Comunidad de Madrid	Frías Iniesta JA, Fernández de Bobadilla Osorio J	UAM
Amesty Morello MV	Creación de tejido uretral mediante ingeniería tisular para la reparación de defectos uretrales complejos en un modelo experimental de hipospadias proximal en conejos	López Pereira P, Fossum M	UAM
Arroyo Olivares R	Hábitos de vida y enfermedad cardiovascular en la hipercolesterolemia familiar	Banegas Banegas JR, Mata P	UAM
Barrios Muñoz AL	Plk1, un nuevo regulador de la neurogénesis adulta	Porlan Alonso E	UAM
Bell Fenellos C	Factores predictivos de las alteraciones del desarrollo y las dificultades de aprendizaje en niños menores con síndrome 5P. Aspectos biomédicos, genéticos, cognitivos y conductuales	Sáenz-Rico de Santiago B, Nevado Blanco J	UCM
Bonilla Hernán MG	Enfermedad pulmonar intersticial difusa clínica en pacientes diagnosticados de artritis reumatoide	Balsa Criado A, Álvarez-Sala Walther R	UAM
Bravo Alonso I	Caracterización genética de la acidosis láctica congénita: un ejemplo de análisis integral de una enfermedad rara.	Rodríguez Pombo P, Pérez González MB	UAM
Ceballos Rodríguez MC	Nevus melanocíticos congénitos gigantes: estudio epidemiológico y evaluación clínica, terapéutica, del impacto psicosocial y de la calidad de vida en 153 pacientes	López Gutiérrez JC, Redondo Bellón P	UAM
Corrales Benítez C	Recuperación funcional de la mano quemada tras desbridamiento enzimático	Martínez Méndez JR, González Miranda A	UAM

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Cuenca Martínez F	Evaluación y análisis comparativo de los efectos de los métodos de representación de movimiento en el proceso de aprendizaje motor	La Touche Arbizu R, León Hernández JV	UAM
Dafauce Álvarez-Sala L	Personalidad, ansiedad y depresión como factores predictores del control del asma y de la adherencia al tratamiento en una consulta monográfica de asma grave	Bravo Ortiz MF, Álvarez-Sala Walther R	UAM
del Prado Díaz S	Cambios hemodinámicos y adaptación morfológica y funcional del corazón materno durante la gestación única y gemelar	de la Calle Fernández-Miranda M, Guzmán Martínez G	UAM
Díaz de Terán Velasco FJ	Análisis del fenómeno de sensibilización central y papel de la estimulación del nervio occipital en la cefalea en racimos	Gil-Martínez A, Díez-Tejedor E	UAM
Diekhorst LA	Allogenic adipose mesenchymal stem cell therapy in ischemic stroke with hypertension and hyperglycemia. Experimental animal models	Díez Tejedor E, Gutiérrez Fernández M	UAM
Fernández Félix BM	Investigación clínico-epidemiológica en pronóstico: desarrollos metodológicos y aplicación clínica	Zamora Romero J, García García-Esquinas E	UAM
Gómez Traseira C	Estudio en vida real de las características clínicas, analíticas y de manejo terapéutico de pacientes con angioedema hereditario por déficit del inhibidor de la C1 esterasa (AEH-C1-INH)	Caballero Molina T	UAM
González Amor M	Interferon-stimulated gene 15 (ISG15) and myeloid G protein-coupled receptor kinase 2 (GRK2) are novel mediators of vascular dysfunction induced by hypertension and obesity. International Mention	Briones Alonso AM, García Redondo AB	UAM
González del Portillo E	Evaluación del efecto sinérgico entre radioterapia y moduladores de la autofagia	González Sarmiento R, Pérez Romasanta LA	Universidad de Salamaca
Hernández Aceituno A	Hábitos Saludables y utilización de servicios sanitarios en los adultos mayores	Banegas Banegas JR	UAM
Ibarra Ramírez M	Perfil de expresión de microRNAs en biopsias de testículo de pacientes con Síndrome de Klinefelter.	Martínez de Villarreal LE, González-Peramato Gutiérrez MP	UAM
Jerónimo dos Santos T	An equity-oriented analysis on using diabetes-related technology in children and adolescents with type 1 diabetes mellitus	Argente Oliver J, Rodríguez Artalejo F	UAM
Jiménez Gómez L	Funciones de las subunidades específicas de complejos Polycomb vPRC1, RYBP y YAF2, en el establecimiento y mantenimiento de estados inmortalizados leucémicos	Calés Bourdet C	UAM
Lázaro Perona F	Aplicación de técnicas de qPCR para la cuantificación relativa de enterobacterias	Mingorance Cruz J, García Rodríguez J	UAM
López Cavanillas B	Virus del papiloma humano y citología anómala anal de mujeres en riesgo. Análisis de la prevalencia del virus del papiloma humano y citología anómala anal en mujeres diagnosticadas de neoplasia intraepitelial cervical de alto grado	Hernández Gutiérrez A, Bartha Rasero JL	UAM
Macía Villa CC	Nuevas aportaciones de la ecografía en el estudio de la paratenonitis, entesitis y sinovitis en la artritis psoriásica	de Miguel Mendieta E	UAM
Márquez Expósito L	Papel del ligando no canónico de NOTCH parecido a Delta 1 (DLK1) en el daño renal experimental	Ruiz Ortega M, Rodrigues Díez R	UAM
Miguel Buckley R	Tratamiento antirretroviral guiado por genotipo proviral: ensayo clínico piloto de prueba de concepto ("Art-Pro")	Arribas López JR, Pulido Ortega F	UAM
Monteagudo Vela M	Soporte mecánico circulatorio contemporáneo. De corta a larga duración; una opción real.	García-Guereta Silva L, Aroca Peinado A	UAM
Monzón Manzano E	Estado protrombótico, factores de riesgo cardiovascular y actividad clínica en pacientes con lupus eritematoso sistémico	Butta Coll N, López Longo FJ	UAM
Nanwani Nanwani KL	Estudio del perfil inflamatorio y de la coagulopatía asociada a la hemorragia subaracnoidea aneurismática	Quintana Díaz M, Egea Guerrero JJ	UAM



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Pedraza Sepúlveda L	Caracterización de la hepatitis por medicamentos en la población geriátrica: Programa de farmacovigilancia proactiva por señales de laboratorio	Ramírez García E, Carnicero Carreño JA	UAM
Peña Barreno C	Estudio de la respuesta histopatológica testicular al tratamiento con estrógenos y antiandrógenos a largo plazo y su relación con la disgenesia testicular	González-Peramato Gutiérrez MP, Nistal Martín de Serrano M	UAM
Pérez López C	Estudio volumétrico de adenomas hipofisarios no funcionantes: factores implicados en el grado de resección en cirugía endoscópica endonasal	Isla Guerrero A, Martínez Marín V	UAM
Pesántez Ríos MG	Efectividad del cannabidiol en el tratamiento de las epilepsias refractarias	Pascual Pascual SI	UAM
Piniella Alcalde D	Identificación de nuevas proteínas que interactúan con los transportadores de glutamato y dopamina (GLT-1 y DAT) mediante alteraciones en sus respectivos entornos	Zafra Gómez F, Giménez Martín C	UAM
Prado Vázquez G	Caracterización molecular del melanoma mediante inteligencia artificial: Implicaciones en pacientes tratados con inmunoterapia	Espinosa Arranz E, Gámez Pozo A	UAM
Ramasco Rueda F	Utilidad de la determinación preoperatoria de los niveles séricos de MR-Proadrenomedulina para predecir la necesidad de soporte orgánico postoperatorio en cirugía oncológica abdominal	Gilsanz Rodríguez F, Planas Roca A	UAM
Ríos González E	Calidad de vida y fragilidad en pacientes con cáncer de próstata metastásico o resistente a castración	Martínez-Piñeiro Lorenzo L, Rodríguez de Bethencourt Codes F	UAM
Robles Caballero A	Valoración ecográfica del diámetro de la vaina del nervio óptico, como técnica complementaria, en el diagnóstico de muerte encefálica	Quintana Díaz M, García Olmos LM	UAM
Rodríguez Pardo de Donlebún J	Ictus isquémico por oclusión de gran vaso. Utilidad de una escala para la selección prehospitalaria de pacientes susceptibles de trombectomía mecánica: Madrid-DIRECT	Fuentes Gimeno BE, Díez Tejedor E	UAM
Rodríguez Sánchez I	Dolor crónico, deterioro funcional y enfermedad cardiovascular en las personas mayores	García García-Esquinas E, Rodríguez Artalejo F	UAM
Rosas Alonso R	Desarrollo de un nuevo método para la determinación del biomarcador epigenético MGMT en biopsia líquida y su aplicación en la monitorización de pacientes con glioblastoma	Ibáñez de Cáceres I	UAM
Rubio Aparicio PM	Marcadores tumorales en neuroblastoma: un análisis retrospectivo	Martínez Martínez L	UAM
Rychlik A	Cáncer de endometrio de riesgo intermedio-una entidad clínica heterogénea	Coronado Martín PJ, Zapardiel Gutiérrez I	UAM
San Hipólito Luengo A	Nuevos mecanismos celulares implicados en la inflamación vascular mediada por la interleuquina-1B (1 beta) y la glucosa: Papel del inflamasoma NLRP3 y de las vesículas extracelulares. International Mention 	Peiró Vallejo MC, Sánchez Ferrer C	UAM
Sánchez Casanova S	Hidrogeles fototérmicos con aplicación en ingeniería tisular ósea	Vilaboa Díaz NE	UAM
Suso Martí L	Efectos hipotalgésicos de los métodos de representación de movimiento en el dolor musculoesquelético	La Touche Arbizu R	UAM
Tapia Salinas B	¿Es útil la terapia dirigida por objetivos en pacientes con cirugía reconstructiva de cabeza y cuello con microcirugía de colgajo libre?	Gilsanz Rodríguez F, Alsina Marcos E	UAM
Toledo Negrete JJ	Uso de angiografía por tomografía de coherencia óptica como método diagnóstico de lesiones melanocíticas coroideas	Cajigal Morales D, Asencio Durán M	UAM
Zamarrón de Lucas E	Continuous positive airway pressure effect on albuminuria in patients with diabetic kidney disease and obstructive sleep apnea. International Mention 	García Río F, Álvarez-Sala Walther R	UAM



2.3.2 MASTER THESES

In 2021, 43 Master Theses have been read and/or supervised by IdiPAZ researchers.

Student	Title	Director	University
Boukich El Jouhari N	Effect of Resolvin D2 on the cardiovascular alterations induced by aldosterone	Briones Alonso AM, Rodríguez Díez R	UAM
Arruda Navarro Albuquerque D	Identification of the integrin receptor involved in vascular damage induced by interferon stimulated gene 15	Briones Alonso AM, González Amor M	UAM
Méndez Albiñana P	Efecto de la suplementación con pectina de cítricos sobre biomarcadores del síndrome metabólico en un modelo animal inducido por una dieta rica en grasa.	Blanco Rivero J	UAM
Ayman M	Supplementation with a Carob (Ceratonia siliqua L.) Fruit Improves Endothelial Dysfunction Associated with Metabolic Syndrome in Mice: Possible Role of Hydrogen Sulphide.	García Redondo AB, Blanco Rivero J	UAM
Jiménez Villegas J	Role of NRF2 in C9ORF72 and RNA-related ALS pathology	Rojo Sanchís AI, Cuadrado Pastor A	UAM
Cañizares Moscato L	Preclinical development of P10, a novel small molecule NRF2 activator	Cuadrado Pastor A, García Yagüe AJ	UAM
Lucas Castro E	Role of the transcription factor NRF2 in the regulation of the integrity and function of the blood-brain barrier	Cuadrado Pastor A, Pajares M	UAM
Marty Lobo J	Estudio piloto de las alteraciones del linfocito B en pacientes con hipogammaglobulinemia secundaria post-tratamiento con rituximab.	del Pino Molina L, López Granados E	UCM
Torices Pajares A	Monitorización celular avanzada del trasplante hepático pediátrico	Sánchez Zapardiel E	UCM
Maestre Guillén A	Estudio de las alteraciones del tráfico intracelular del transportador de aminoácidos BAT1 por la acción del virus Sars-COV-2	Zafra Gómez F	UCM
Tirado Melendro P	Estudio de la respuesta al estrés y al daño inflamatorio en células de neuroblastoma. Papel protector del IGF-1	Varela Nieto I, Rodríguez de la Rosa L	UAM
Franco Caspueñas S	Estudio de la senescencia celular como diana terapéutica en células de Schwannomas vestibulares humanos	Jiménez Lara AM, Rodríguez de la Rosa L	UAM
Guerig Rodriguez NE	Bacteriemia por Pseudomonas aeruginosa en niños y adolescentes. Perfil de resistencias a carbapenémicos, datos clínicos y factores de riesgo asociados a mortalidad.	Calvo Rey C, Baquero Artigao F	UCM
Marroquin Castillo C	Estudio retrospectivo de la enfermedad inflamatoria intestinal en el embarazo	Martín Arranz MD	UAM
Ciria Cubas L	Análisis de proteínas de unión a RNA en esclerosis lateral amiotrófica	Lastres-Becker I	UCM
Sierra Puerta T	Percepciones y conocimientos de las enfermeras sobre el dolor de los pacientes	Carmen Sellán Soto M	U. Barcelona-UAM
Hernández de Urrutia MP	Atención por parte de la Enfermera Especializada a mujeres víctimas de agresiones sexuales	Díaz Martínez ML	U. Barcelona-UAM
Catalán Lambán A	Utilidad clínica del análisis del microbioma en el cancer pediátrico	Pérez Martínez A	UNIR
Chávez Castro E	Incidencia de VIH en adolescentes durante periodo 2018-2019 en clínica periférica de la seguridad social de Costa Rica	Sainz Costa T	URJC
Rodríguez Molino P	Profilaxis postexposición frente al VIH en niños, adolescentes y adultos jóvenes	Sainz Costa T	URJC
Nogueira López J	Implementación de las medidas de prevención de la transmisión vertical de VIH en España	Sainz Costa T	URJC

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Gerig Rodríguez N	Bacteriemia por pseudomonas aeruginosa en niños y adolescentes. Perfil de resistencias a carbapenémicos, datos clínicos y factores de riesgo asociados a mortalidad	Baquero Artigao F	UCM
Gómez Aguilar A	Genomic Sequencing of Genes involved in Hereditary Hemorrhagic Telangiectasia (HHT) in patient's DNAs where no mutations were found in their coding regions	Maria Botella LM	UAH
Torres B	Prognostic and predictive role of Gasdermin B in cancer	Moreno Bueno G	UAM
Calderón L	Generation and characterization of hepatic models as a platform for therapeutic development in PMM2-CDG	Pérez González MB	UAM
Díaz Jordan B	Evaluación de las estrategias sociosanitarias instauradas durante la pandemia COVID-19 en pacientes con Hemofilia A moderada/grave con/sin inhibidor en tratamiento profiláctico ambulatorio con emicizumab en la provincia de Ciudad Real-España.	Jiménez-Yuste V	UAH
Ramos de León Y	Análisis farmacoeconómico en hemofilia grave	Álvarez Román MT	UAH
Díez López G	Evaluación mediante modelo mast (model for assesment of telemedicine) de la app y software MYPKFIT® para establecer tratamiento, recogida de datos y seguimiento de pacientes	Álvarez Román MT	UAH
Coll Vallier J	Diátesis hemorrágica: análisis de la variabilidad en los estudios y en los ensayos clínicos	Álvarez Román MT	UAH
Mesa Lorenzo MC	Optimización de recursos y mejora de la calidad de vida en pacientes con hemofilia B	Álvarez Román MT	UAH
Justo Sanz R	Glycosylation pattern and platelet function in patients with primary immune thrombocytopenia	Álvarez Román MT, Butta Col N	UAH
Pozas Mañas MA	Protocolo para el tratamiento del sangrado y cirugía en pacientes con hemofilia A en tratamiento con emicizumab. Revisión de las guías publicadas	Butta Col N	UAH
Dos Santos Ortas A	Impacto de la pandemia de COVID-19 en pacientes con trombocitopenia: estudio descriptivo de una población de pacientes del Hospital Universitario La Paz	Butta Col N	UAH
García Pérez E	Estudio de trombocitopatías en pacientes con síndromes mielodisplásicos	Butta Col N	UAH
Gasior Kabat M	Study of platelet alterations and their relationship with the mutational profile in patients with Essential Thrombocythemia	Butta Col N	UAH
Sarrate García E	Ranges of normality and diagnostic utility of PFA in the pediatric environment	Butta Col N	UAH
Montero Martín L	Usefulness of calibrated automatic thrombography in factor XI deficiency	Butta Col N	UAH
Panizo Echauri I	Study on the feasibility of using techniques laboratory tests (thrombin generation test and Modified APTT) for measurement of effect procoagulant and treatment monitoring with Emicizumab in a model of Hemophilia A Severe in baseline conditions and treatment concomitant with bypass agents	Butta Col N	UAH
Arribas Peña A	Efectos de la antibioterapia en la enfermedad leve o moderada por covid-19 en pacientes ambulatorios del área norte de madrid	González Miranda A	Universidad San Pablo CEU
Reja Ubach M	Toxicidad aguda de hipofraccionamiento en cáncer de pulmón	Manso de Lema A	Universidad Francisco de Vitoria
Garrido Botella MI	Results of radical treatment in locally advanced cervical cancer	Rodríguez Rodríguez I	Universidad Francisco de Vitoria
Rodríguez Roldán M	Single center experience on safety and efficacy of LDR brachytherapy	Alberto Glaría L	Universidad Francisco de Vitoria



2.3.3 FINAL DEGREE THESES

In 2021, 35 Final Degree Theses have been read and/or supervised by IdiPAZ researchers.

Student	Title	Director	University
Tesoro García F	Cuidados de enfermería al paciente con quemaduras	Hernanz Martín R	URJC
Paz Fernandez A	Trastornos del sueño tras un ictus	Hernanz Martín R	URJC
Barahona Borja M	Apnea obstructiva del sueño en tiempos de Covid-19	Hernanz Martín R	URJC
Serrano A	Efecto de la suplementación aguda con monohidrato de creatina para la mejora del rendimiento en el heptatlón femenino	García Redondo AB, Blanco Rivero J	UAM
Rodrigo Huescas N	Estrategias nutricionales para la mejora del rendimiento y recuperación en el fútbol de élite	García Redondo AB, Blanco Rivero J	UAM
Fariñas García S	Vesículas extracelulares en el interactoma hepático en la enfermedad de hígado graso no alcohólico	Martínez Valverde A	UAM
Martín Ortiz B	Mecanismos moleculares asociados al desarrollo de la enfermedad de hígado graso no alcohólico	Angela Martínez Valverde	UAM
Sánchez González L	Metaanálisis de perfiles transcripcionales inducidos por hipoxia	del Peso Ovalle L	UAM
Balsells Alonso MM	Estudio de los mecanismos de liberación de exosomas en células nerviosas en respuesta a isquemia	Zafra Gómez F	UAM
Moreno Esbrí P	Puesta a punto de las herramientas moleculares necesarias para la validación de posibles dianas de fosforilación de Plk1	Porlan Alonso E	UAM
Rodríguez Marrero S	Puesta a punto de modelos celulares de angiosarcoma en 2-3 dimensiones para su uso potencial en el testado farmacológico	Feliu Batllé J	UAM
Pelegriña Sánchez D	Experiencia en implantes cocleares: estudio descriptivo	Lassaletta Atienza L; Morales Puebla JM	UAM
Villar Prieto R	Estudio del potencial papel otoprotector del IGF-1 en respuesta al estrés y al daño celular inducido por cisplatino en la línea celular auditiva HEI-OC1.	Varela Nieto I, García Mato A	UAM
Pardo Díaz M	Estudio in vivo de impresos 3D para la regeneración del estroma corneal	de Miguel González MP	URJC
Navarro Páez F	Towards the development of a biomimetic anterior lamellar corneal layer: Studies based on mesenchymal stem cells and 3D printed collagen scaffolds	de Miguel González MP	Universidad CEU San Pablo
Hernaiz Ferrer AI	¿Es el asma un factor de riesgo en niños para la infección COVID-19?	Calvo Rey C	UAX
Platero Dueñas L	Professionals' knowledge and clinical practice related to pets in transplanted children. Results from an international survey.	Méndez Echevarría A	UAM
Agular Platero E	Mascotas, zoonosis y niños inmunodeprimidos. ¿Qué saben las familias?	Méndez Echevarría A	UAM
Machio Candela N	Tumores malignos de las glándulas salivales: estudio retrospectivo de los pacientes tratados en el Hospital La Paz entre 2008 y 2018	Cebrián Carretero JL	UAM
Cheng K	Actualización sobre cuidados de enfermería frente a las complicaciones derivadas del tratamiento quimioterapéutico en la población pediátrica oncológica	Luna Castaño P	UAM
Sánchez Carreño P	La participación de la familia en el cuidado del paciente pediátrico hospitalizado	Luna Castaño P	UAM

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Crespo Diestro M, Villena Donate A	Cuidados de enfermería en la adaptación psicológica del paciente oncológico pediátrico a la hospitalización	Luna Castaño P	UAM
Ortiz Ramírez A	Eficacia de las terapias de grupo y de la formación en equipos de protección individual durante la pandemia Covid-19	Castro Toro J	Universidad Nebrija
González Moure B	Diagnostico avanzado del retinoblastoma	Escudero López A	UAM
Soria Alcaide E	Ganancia ponderal con los inhibidores de la integrasa	Sainz Costa T	UAM
Rodríguez Escribano P	Efecto de los andrógenos sobre la función vascular en arterias de ratas hipertensas	Ferrer Parra M	UAH
Martínez Siguero MB	Efecto de la testosterona sobre la función vascular. Participación de mediadores celulares	Ferrer Parra M	UAM
Pizarro P	LOXL2 interacts with HuR to promote SOX9 mRNA stability	Portillo Pérez F	UAM
Jiménez Carretero V	Dominios de loxl2 implicados en la interacción proteína-proteína	Portillo Pérez F	UAM
Ramírez O	Analysis of the expression of microRNAs in PMM2-CDG and identification of affected cellular pathways	Pérez González MB	UAM
Chavarri Urraca K	Generación y caracterización de astrocitos derivados de iPSC en Acidemia Propiónica	Richard Rodríguez EM	UAM
Minery Berneguer A	Murine models of phenylketonuria and propionic acidemia: Neurological phenotype and effect of the PKU mutation	Ruiz Desviat ML	UAM
Lillo López P	Estudio de la neurogénesis adulta subependimaria en un modelo murino con inactivación condicional de una quinasa en el ciclo celular	Porlan Alonso E	UAM
Cámara Martínez C	Complicaciones en colgajos fasciocutáneos de diseño subfascial y adelgazados. Comparación de incidencias y complicaciones de los mismos	Bonastre Julia J	UAM
Cid San Miguel A	Monitorización de la perfusión tisular en colgajos fasciocutáneos, diseño subfascial contra diseño adelgazado	Bonastre Julia J	UAM





2.3.2 SCIENTIFIC TRAINING PLAN

The Training Committee established a Training Plan, which specifies the training strategy for the institute's human resources and covers the research training needs of their members. Annually it's developed the training offer with several proposals to make up the plan. Also, it's developed a residents training program have been started for residents doctors of the University Hospital La PAZ.

The own training offer is mainly based on a series of transversal courses in research methodology and courses related of the different lines of research.

The plan is complemented by several activities such as conferences, scientific seminars and other activities linked to these areas.

In addition, The Training Committee established a Residents training program for residents of the University Hospital La Paz.

Members

President

Bárbara Martínez de Miguel

Secretary

Mercedes Ruiz Balibrea

Direction representative

Paloma Gómez Campelo

HULP representative

Julián Nevado Blanco
Alberto Borobia Pérez
Mercedes Ruiz Balibrea

FIBHULP representative

María Fernández Velasco
Rocío Rosas Alonso
Inmaculada Ibáñez de Cáceres

UAM representative

Ana García Redondo

Works Council's representative

Pilar Sánchez-Corral Gómez



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



2.3.4.1. Training Program

Title	Head	Dates	Participants
Técnicas de escritura científica en inglés	María Fernández Velasco	15 th -18 th March	16
Igualdad de género en el ámbito de la investigación	Ana Martín Jiménez	6 th -8 th April	10
Tratamiento y gestión de base de datos	Mercedes Ruiz Balibrea	12 nd -15 th April	14
Ética de la investigación. Puesta en marcha de un estudio de investigación biomédica	Emma Fernández de Uzquiano	25 th -27 th May	8
Introducción a las dimensiones de la investigación e innovación responsable en biomedicina	Santiago Rello Varona	26 th -29 th October	10
Implantación del sistema de responsabilidad social en IdiPAZ en base a la norma IQNet SR10	Sara Gusi Gil	24 th June	10
Bioestadística. Programa con R	María Jiménez González	7 th -10 th June	42
Project Management en investigación clínica	Alberto Borobia	23 rd -30 th November	12
COVID y bioseguridad en laboratorios	Paloma Gómez Campelo	19 th November	14

2.3.4.2. Residents Training Program

The training program has been designed to provide residents at IdiPAZ with scientific tools and skills, which are key for the development of their careers.

Because of the coronavirus situation, in 2021 only a single course was performed:

February-24th | *Taller de Investigación en Simulación* | Head: Manuel Quintana Díaz | Participants: 26

In 2022 we have established the **Research Training Program** for resident doctors to facilitate clinical and translational research opportunities for residents who plan to make research as part of their careers

Title	Head
Elaboración de un proyecto de investigación. Módulo I: ¿Cómo formular una hipótesis en investigación? Módulo II: Metodología básica en investigación	Alejandro Martín Quirós
Lectura crítica	Alejandro Martín Quirós
Bioestadística: 'SPSS'	Rocío Rosas
Jornada para residentes sobre el IdiPAZ	Paloma Gómez Campelo

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



2.3.4.3. Scientific Seminars

IdiPAZ Scientific Seminars program welcomes renowned researchers and clinical investigators to our Institute to share, discuss and debate latest insights, discovery and next directions in oncology with our students, postdocs and senior faculty from our research groups. In this year, Scientific Seminars of IdiPAZ was certified by "Acreditación de Actividades de Formación Continuada de las Profesiones Sanitarias" by the Community of Madrid procedure number nº07-AFOC-00901.4/2020 and 25 seminars were held.

Scientific Coordinators:

- Paloma Gómez Campelo

Secretary:

- Susana García Pérez
- Lucía Medina Royo

Research Area	Date	Speaker	Speaker Photo	Seminar title
 Cancer and Human Molecular Genetics Area	15 th January	Dr. Víctor M. Pérez García Director del laboratorio de Oncología Matemática de la Universidad de Castilla-La Mancha		Biomarcadores y optimización de tratamientos en oncología utilizando modelos matemáticos
 Infectious Diseases and Immunity Area	26 th January	Dr. Pablo Pelegrín Scientific Deputy Director & Principal Investigator BioMedical Research Institute of Murcia (IMIB-Arrixaca)		The role of P2X7 receptor and the NLRP3 inflammasome in the survival during sepsis
 Infectious Diseases and Immunity Area	05 th February	Dr. Carlos del Fresno Miguel Server Researcher Hospital la Paz Institute for Health Research (IdiPAZ)		Innate immunity modulation: implications for fungal infections and cancer immunotherapy
 Neurosciences Area	12 nd February	Dra. Laura Otero Ortega Investigador Miguel Servet Instituto de investigación del hospital universitario la Paz (IdiPAZ)		Papel de las vesículas extracelulares en el tratamiento de la esclerosis múltiple
 Large System Pathologies Area	19 th February	Dra. Emanuela Spagnolo Facultativo Especialista Servicio Ginecología Hospital Universitario "La Paz"		Identificación de factores inmunológicos y moleculares con valor pronóstico en cáncer de ovario asociado a endometriosis e implicados en el potencial de malignización de la endometriosis
 Large System Pathologies Area	05 th March	Dra. María Mittelbrunn Head of Immunometabolism and Inflammation Lab Instituto de Investigación Hospital 12 de Octubre		Inmunometabolismo en envejecimiento y en enfermedades asociadas a la edad
	16 th April	Dra. Cristina Jiménez Núñez Servicio de Farmacia Hospitalaria Hospital Universitario La Paz		Normativa de estudios observacionales con medicamentos. Real Decreto 957/2020, de 3 de noviembre, por el que se regulan los estudios observacionales con medicamentos de uso humano
 Large System Pathologies Area	23 rd April	Dr. Enrique Martín-Gayo Investigador Ramón y Cajal Profesor de la UAM en Medicina		Specific myeloid subsets recruited to the lung are associated with severity of COVID-19
 Infectious Diseases and Immunity Area	30 th April	Dr. Santos Mañes Director Grupo de Investigación Departamento de Inmunología y Oncología del CNB-CSIC		Superoxide dismutase-3: a new regulator for vascular normalization and cancer immunotherapy

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

	Cancer and Human Molecular Genetics Area	07 th May	Dra. Antonia Tomás Jefa del laboratorio de ritmo circadiano y cáncer Instituto Murciano de Investigación Biosanitaria Virgen de la Arrixaca Universidad de Murcia (IMIB-UMU-Arrixaca)		Circadian Rhythm: another way to understand liver cancer
	Infectious Diseases and Immunity Area	14 th May	Dr. Salvador Iborra Departamento de Inmunología, oftalmología y ORL Universidad Complutense de Madrid		Papel de las Células Dendríticas en la regulación de la obesidad
	Infectious Diseases and Immunity Area	21 st May	Dra. Elena Goicoechea de Jorge Departamento de Inmunología, oftalmología y ORL Universidad Complutense de Madrid		Estudio del complemento en vasculitis asociadas con ANCA
	Cancer and Human Molecular Genetics Area	28 th May	Dra. Jacinta Bustamante Université de Paris Institut Imagine, INSERM U-1163 Génétique Humaine des Maladies Infectieuses		Recientes avances en la predisposición genética a micobacterias
		04 th June	Dra. Elena García Méndez Farmacéutica Secretaría Técnica CEIM-Hospital Universitario La Paz		Retos en el consentimiento informado en Investigación Clínica
		11 st June	Dra. Paula Jáuregui Onieva Associate Editor, PLOS Biology, PLOS.		Behind the scenes of scientific publishing
	Cancer and Human Molecular Genetics Area	18 th June	Dra. Teresa López Fernández Facultativo Especialista Servicio Cardiología Hospital Universitario "La Paz"		Carcio-Oncología: Pasado, presente y futuro
	Cancer and Human Molecular Genetics Area	25 th June	Dra. María Casanova Centro Nacional de Investigaciones Oncológicas		Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells
	Surgery, Transplant and Health Technologies Area	01 st October	Dr. Alberto Borobia Facultativo Especialista de Área en Farmacología Clínica, Profesor Asociado de Ciencias de la Salud, Coordinador de la Unidad de Ensayos Clínicos del Hospital La Paz -UICEC		Estudio CombiVacs: Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacs): a multicentre, open-label, randomised, controlled, phase 2 trial
	Infectious Diseases and Immunity Area	08 th October	Dr. Santiago Moreno Guillén Jefe de Servicio de Enfermedades Infecciosas del Hospital Universitario Ramón y Cajal y Catedrático de Medicina en la Universidad de Alcalá		Estrategias para la cura del VIH
	Cardiovascular Area	22 nd October	Dr. Rubén Martínez Barricarte Assistant Professor. Vanderbilt University Medical Center (Nashville, Tennessee, USA), Division of Genetic Medicine, Department of Medicine. Department of Pathology, Microbiology and Immunology		Diseción genética e inmunológica de inmunodeficiencias primarias
		29 th October	Natalia Olivares Consultora Senior RGD, LOPD-GDD y delegada de Protección de Datos en Alaro Avant, S.L.		Protección de datos en investigación e innovación



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

	Infectious Diseases and Immunity Area	05 th November	Dr. Jorge Díaz-Garzón Marco Facultativo especialista en Análisis Clínicos. Hospital Universitario La Paz. Biological Variation Working Group. European Federation of Clinical Chemistry and Laboratory Medicine		PAPER: Working Group on Biological Variation and Task Group for the Biological Variation Database
	Neurosciences Area	12 nd November	Dra. Isabel Lastres Becker Profesora titular de la Universidad Autónoma de Madrid.		CX3CR1-deficient microglia shows impaired signalling of the transcription factor NRF2: Implications in tauopathies
	Infectious Diseases and Immunity Area	19 th November	Irene Gómez Delgado Investigadora predoctoral en IdiPAZ		Las proteínas FHRs del Complemento en la predisposición y evolución de patología renal
	Large System Pathologies Area	03 rd December	Dra. Carolina Cubillos Zapata Investigadora Postdoctoral. Contrato Miguel Servet tipo I. Grupo Enfermedades Respiratorias de IdiPAZ		Soluble PD-L1 is a potential biomarker of cutaneous melanoma aggressiveness and metastasis in obstructive sleep apnoea patients
	Cardiovascular Area	26 th December	Dra. Gabriela Alcaraz García-Tejedor Facultativo Especialista de Anestesiología y Reanimación en el Servicio de Anestesiología Infantil del Hospital . Universitario La Paz		Población de Riesgo de Hipertermia Maligna: Cohorte ambispectiva



Neurosciences Area

The *Cátedra de Neurociencias Clínicas* organizes a series of forums in order to promote teaching and research in the field of Neurosciences

Scientific Coordinators:

- **Exuperio Díez Tejedor**, Jefe de Servicio de Neurología del Hospital Universitario La Paz.
Catedrático del Departamento de Neurología. Facultad de Medicina. Universidad Autónoma de Madrid

Speaker	Talk Title	Date
Milagros Merino Andreu y M^a José de Aguilar-Amat Prior. Unidad de Trastornos Neurológicos del Sueño. Hospital Universitario La Paz.	Curso de Innovaciones clínico terapéuticas en patología neurológica del sueño.	22 nd - 23 rd February
Blanca Fuentes Gimeno. María Alonso de Leciñana. Servicio de Neurología y Centro de Ictus. Hospital Universitario La Paz. Área de Neurociencias del Instituto de Investigación IdiPAZ. Universidad Autónoma de Madrid	Curso de Cambios de paradigma en enfermedades cerebrovasculares.	17 th -18 th March
M^a José de Aguilar-Amat Prior. Pablo Alonso Singer. Servicio de Neurología y Unidad de Epilepsia.	Curso de Innovaciones en el manejo y tratamiento de la epilepsia.	26 th - 27 th April
Ángel Martín Montes. Soledad Serrano López. Ana Frank García. Servicio de Neurología. Unidad Trastornos Cognitivos y del Comportamiento. Hospital Universitario La Paz. Madrid.	Curso de Trastornos cognitivos y del comportamiento: innovaciones en neurodegeneración y daño cerebral.	17 th - 18 th May
Francisco Javier Rodríguez de Rivera Garrido. Exuperio Díez Tejedor. Servicio de Neurología. Hospital Universitario La Paz. Área de Neurociencias del Instituto de Investigación IdiPAZ. Universidad Autónoma de Madrid	Curso de Avances en el diagnóstico y tratamiento en el manejo de las enfermedades neuromusculares y ataxias.	20 th -21 st September



Blanca Fuentes Gimeno. Gerardo Ruiz Ares. María Alonso de Leciana. Servicio de Neurología y Centro de Ictus. Hospital Universitario La Paz. Área de Neurociencias del Instituto de Investigación IdiPAZ. Universidad Autónoma de Madrid	Curso de Actualización en el diagnóstico y tratamiento de la hemorragia cerebral	18 th -19 th October
Antonio Tallón Barranco. Ana Rodríguez Sanz. Servicio de Neurología. Hospital Universitario La Paz. Universidad Autónoma de Madrid.	Curso de Retos en el diagnóstico y tratamiento de la espasticidad.	16 th November
María Gutiérrez Fernández. Laura Otero Ortega. Laboratorio de Ciencias Neurológicas y Cerebrovascular, IdiPAZ.	Curso de Modelos animales para la investigación en ictus.	1 st - 2 nd December

X Symposium Neuroinmunología y Esclerosis Múltiple

Organización: Antonio Tallón Barranco. Inmaculada Puertas Muñoz. Exuperio Díez Tejedor. Servicio de Neurología. Unidad de Neuroinmunología y Esclerosis Múltiple. Hospital Universitario La Paz. Área de Neurociencias del Instituto de Investigación Sanitaria del Hospital Universitario La Paz. Escuela de Ciencias Neurológicas. Cátedra de Neurología. Universidad Autónoma de Madrid. 2nd - 3rd November 2021

Scientific clinical sessions - Hospital Universitario La Paz

Date	Talk Title	Speaker
27 th October 2021	Presentación de la nueva herramienta App de Comunicación, Docencia y Formación del hospital	Speakers: <ul style="list-style-type: none"> • Marta Moro (Subdirección médica SSCC) • Rocío Buendía (Gabinete de comunicación) • Eugenio de Miguel y Beatriz Palacios (Com. Docencia) • Luis Gallego (Comisión de Formación) Coordinators: <ul style="list-style-type: none"> • Esther Rey (Dirección de Enfermería) • Alicia del Pozo (Dirección de RRHH) • Juan José Ríos (Dirección Médica)
3 rd November 2021	Nuevos abordajes en 3 clásicos de la dermatología: dermatitis atópica, vitiligo y alopecia areata	Speakers: <ul style="list-style-type: none"> • Marta Feito Rodríguez (Servicio Dermatología) Coordinators: <ul style="list-style-type: none"> • Pedro Herranz (Servicio Dermatología) • Raúl de Lucas (Servicio Dermatología) • Natalia Hernández Cano (Servicio Dermatología)
10 th November 2021	17 meses de pandemia COVID-19 en el hospital	Speakers: <ul style="list-style-type: none"> • Verónica Pérez Blanco (Servicio Med. Preventiva) • Almudena Quintás (Servicio Med. Preventiva) • Ana Robustillo (Servicio Med. Preventiva) • Concepción Nuñez (Servicio PRL) Coordinators: <ul style="list-style-type: none"> • Ana Robustillo (Servicio Med. Preventiva)
15 th November 2021	LP-IdiPAZ liderando acciones innovadoras para mejorar el pronóstico funcional del recién nacido de alto riesgo	Speakers: <ul style="list-style-type: none"> • Marta Cabrera (Servicio Neonatología) • Bárbara Moreno (Servicio Neonatología) • Adelina Pellicer (Servicio Neonatología) Coordinators: <ul style="list-style-type: none"> • Adelina Pellicer (Servicio Neonatología)

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



1
Introduction

2
Executive Summary

3
Information Groups by Area

4
Associated Clinicians

17 th November 2021	Mujer 48 años con Síndrome de Down y hepatopatía crónica	Speakers: <ul style="list-style-type: none"> • Guillermina Bejarano Redondo (Servicio Urgencias) • Isabel Arenas Berenguer (Servicio Urgencias) • Pablo Puente López (Servicio Anatomía Patológica) Coordinators: <ul style="list-style-type: none"> • Angélica Rivera Núñez (Servicio Urgencias) • María del Carmen González (Servicio A. Patológica)
24 th November 2021	Afrontamiento del sufrimiento ante la muerte. Ley de Eutanasia	Speakers: <ul style="list-style-type: none"> • Alberto Alonso (Unidad Cuidados Paliativos)

■ Another Scientific activities

2nd December 2021: 3rd PhDay IdiPAZ



Best thesis award: first stage clinical research category

- Raquel López González. "Incidencia, mortalidad y supervivencia del cáncer infantil en la Comunidad Autónoma de Madrid"
Directors: Nuria Aragonés Sanz and Marina Pollán Santamaría

Best thesis award: advanced stage clinical research category

- Raquel Díaz Mancebo. "La transición endotelio-mesenquimal, mecanismo clave en el desarrollo de la vasculopatía hialinizante peritoneal"
Directors: María Auxiliadora Bajo Rubio and Gloria del Peso Gilsanz
- Kapil Nanwani. "Systemic inflammation and coagulopathy associated associated to aneurysmal subarachnoid haemorrhage"
Directors: Manuel Quintana-Díaz and Juan-José Egea-Guerrero

Best thesis award: first stage traslational research category

- Ignacio Silva Llanes. "Modulación del envejecimiento y la neurodegeneración por moléculas pequeñas inhibidoras de proteína quinasas"
Director: Isabel Lastres-Becker

Best thesis award: advanced stage traslational research category

- Alfonso Navarro Zapata. "NKG2D CAR-T cells: An innovative therapy for neuroblastoma"
Director: Antonio Pérez Martínez
- Constanza Ballesteros. "Microsomal Prostaglandin E Synthase-1 (mPGES-1): key element in the alterations associated with obesity"
Directors: Ana Briones and Mercedes Salaices

1st December 2021: Presentation Scientific Report 2020





2.3.3 SCIENCE AND SOCIETY-SCIENTIFIC OUTREACH INITIATIVES

The Training Committee established a Training Plan, which specifies the training strategy for the institute's human resources and covers the research training needs of their. The Unit of Scientific Culture and Innovation of IdiPAZ (UCC+i) has the aim of dissemination of science and innovation performed in our institution and as a key service to increase the scientific education and culture, to promote scientific vocations and innovative talent, to communicate researchers' findings, and to foster research among new generations, knowledge the population and patients.

Unit of Scientific Culture and Innovation of IdiPAZ

Members:

- Bárbara Martínez de Miguel
- Alejandro Martín Quirós
- Paloma Gómez Campelo
- Rocío Buendía Domínguez
- Gema Vallés Pérez
- Aitana López Redondo

IdiPAZ took part in the International Day of Women and Girls in Science, the nineteenth edition of the Madrid Science and Innovation Week with twenty one free activities and in the European Researchers' Night with six free activities which allow attendees to get to know first-hand the institution's R+D+I and researchers through talks, workshops, fast meeting, guided tours, etc. Finally, we collaborated in the 4^o ESO+empresa workday, an event which offers the students the opportunity to get to know first-hand the work that healthworkers and Scientifics in a hospital carry out, their motivations and efforts.

11st February 2021: - International Day of Women and Girls in Science



1-14th November 2021– XX Science and Innovation Week

Due to the situation caused by the COVID-19, all the activities that were carried out were online.



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



Activity	Date	Organized by
<p>CULTIVATE: te contamos en qué consiste el cultivo de células humanas y su utilidad en el conocimiento científico de algunas enfermedades respiratorias y tipos de cáncer</p> 	<p>4th November 11st November</p>	<p>Unidad de Cultivos Celulares</p> <ul style="list-style-type: none"> • Gema Vallés Pérez • Carolina Cubillos Zapata • Ana Sastre Perona
<p>Separar el grano de la paja: Cómo encontrar un oasis en el desierto de la información</p>	<p>5th November</p>	<p>Documentalista</p> <ul style="list-style-type: none"> • Raúl Román Cañizares
<p>Luz y color para encontrar las huellas moleculares de intrusos en nuestras células. Visita- taller a la Unidad de Imagen Molecular e Inmunohistoquímica</p>	<p>2nd, 8th November</p>	<p>Laboratorio de Imagen e Inmunohistoquímica</p> <ul style="list-style-type: none"> • Mayte Vallejo Cremades • Onys Camps Ortega
<p>Lo que todo empresario debe saber para establecer una alianza exitosa con un hospital público</p>	<p>11th November</p>	<p>Unidad de Apoyo a la Innovación</p> <ul style="list-style-type: none"> • Estela Sánchez Simón • Lola Pérez Garre
<p>Investigación clínica más allá del COVID. Proyecto ERA4TB. Papel de las enfermeras en la investigación clínica</p>	<p>12nd November</p>	<p>UICEC</p> <ul style="list-style-type: none"> • Alberto Borobia
<p>Mi experiencia con la beca Marie Skłodowska-Curie en la Unidad de Farmacología Clínica</p>	<p>12nd November</p>	<ul style="list-style-type: none"> • María Cristina Murano-Investigadora Marie-Curie
<p>The future needs the best ...biobanqueros!</p> 	<p>10th November</p>	<p>Biobanco de IdiPAZ</p>  <p>PLATAFORMA ISCIII BIOBANCOS Y BIOMODELOS</p> <ul style="list-style-type: none"> • Paloma Gómez Campelo. <i>Directora</i> • Marina Arranz Álvarez. <i>Coordinadora</i> • Yaiza Pedroche. <i>Técnico</i> • Sandra Nieto. <i>Técnico</i>
<p>Visita guiada a la Plataforma de Biobanco</p>	<p>5th November 12th November</p>	<p>Biobanco de IdiPAZ</p>  <p>PLATAFORMA ISCIII BIOBANCOS Y BIOMODELOS</p> <ul style="list-style-type: none"> • Paloma Gómez Campelo. <i>Directora</i> • Marina Arranz Álvarez. <i>Coordinadora</i> • Yaiza Pedroche. <i>Técnico</i> • Sandra Nieto. <i>Técnico</i>

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



2.4 Innovation and Transfer Activities

2.4.1. INNOVATION AND TRANSFER ACTIVITIES

The Innovation Support Unit (or Innovation Unit) of FIBHULP was created in June 2010 within the framework of the ITEMAS Network –currently called ITEMAS Platform- of the Carlos III Institute of Health. Since its creation, the Innovation Support Unit has contributed to promoting and protecting innovative/ground breaking research conducted by IdiPAZ. The Innovation Unit also intends to harness our institute's considerable innovative potential generated, as a step prior to its subsequent transfer to society.

Therefore, one of the main commitments of the Innovation Unit is that researchers and health personnel perceive it as a resource at their service, to provide support and advice in all that relates to the identification, management, protection, transfer, marketing and dissemination of their research results.

Activities

The main aim of the Innovation Support Unit is to identify the potential transferable research results generated within our institute and to accompany and support the researcher throughout the whole innovation process: from the birth of the idea to its placement on the market.

Since the Innovation Unit has been in operation, several projects sponsored by the institute itself have been managed and different collaboration agreements have been signed with important private institutions and organisations to promote innovation.

Our main objectives are:

- Promoting a culture of innovation and entrepreneurship within the institute by fostering the generation of innovative ideas and solutions that meet the needs of patients and society, in general, and supporting their development through various initiatives.
- Actively searching and identifying knowledge and research results emerged within the institute and transferable to the market.
- Fostering and managing the protection and transfer of knowledge and research results to society and promoting the current technology portfolio of the institute while getting an economic return which allows its reinvestment in research and development.
- Promoting the participation of industry in the innovation process acting as a stakeholder actively involved in it.
- Formalising business alliances, including technology companies as well as industrial and financial partners, to develop collaborative projects and to transfer the results to the market.

- Generating resources that achieve the greatest impact on society, enabling a better quality health care and at the same time contributing to the sustainability of the National Health System.
- Boosting a fruitful collaboration among all entities that make up the ITEMAS Platform.

In the last years the UAI has definitely consolidated its presence and visibility in the whole environment Hospital-Institute. Its impact in the Hospital has been strengthened by the creation of both the Innovation Platform and the Innovation Committee as two linked structures within the organisation. The Innovation Platform is an initiative launched from the Hospital's Management Board in order to promote, extend, enhance and stimulate innovation throughout the Hospital. The main mission of the Innovation Platform is to build a culture of innovation among all Hospital and Institute staff. The Innovation Unit is integrated into this platform as its main driver and, as such, it establishes its objectives and marks its lines of action and will be responsible for channelling the entire workload. It also forms part of the Innovation Committee, a decision-making body on the ideas to be supported by FIBHULP.

Among the greatest achievements of the Innovation Support Unit are the following:

- 1. The UAI has become one of IdiPAZ's most in-demand and requested platforms as it is responsible for promoting, supporting and managing all innovation projects.**

At December 31 2021 the UAI had 239 innovation projects or ideas in active state, 24 of which were in the capture phase, 72 in the evaluation phase, 38 in development, 68 in transfer and 37 in the market. According to these data, it follows that 15% of the projects have been successfully exploited and positioned in the market,

1 Introduction

2 Executive Summary


3 Information Groups by Area

4 Associated Clinicians




very positive percentage (although far lower than the aspired figure) given the precariousness of the times we go through and the resources (both human and financial) with which the UAI counts. The analysis of IdiPAZ's technology portfolio according to the type of project show how Health ICT, Bio and Medical Device, and Materials and Devices types stand out above the others, with practically the same number of projects for all three types.

■ UAI portfolio breakdown by project development phase (2021)



■ UAI portfolio breakdown by project type (2021)




2. The UAI has built a wide and diverse technology portfolio. Each year the number of innovation projects managed by the UAI increases with respect to the previous year, also increasing the number of Hospital services, research groups and professionals in general who join IdiPAZ's innovation community.

During 2021 the UAI filed 2 priority patents (Spanish patents), 2 PCT and 4 national or regional phase entry applications (2 at the EPO, 2 at the USPTO), and 1 Spanish patent was granted.

UAI's portfolio of patent families in active state during period 2021 reached the figure of 34 patent families (12 of them with Spanish priority, 9 of them of European priority, 6 of them has US priority and the rest have priority in other countries).


■ Priority of patent families in force during 2021



As for the software, during the period 2021 IdiPAZ had 29 computer applications in use. Special mention should also be made to the UAI trademark portfolio. During the period 2021, 1 European trademark application was filed and 2 European trademarks were granted. The total number of trademark families active and in force during 2021 was 30.

The total tally of Intellectual Property figures in force during 2021 is the following 34 patent families, 29 SW, 30 trademark families, 9 IP Works and 4 know-how.

■ IP legal figures in force during 2021



It is important to note that these trademarks, besides allowing IdiPAZ to distinguish its products or services from competitors' products or services, are associated with the know-how of the institution, know-how that has been transferred along with the distinctive sign in the case of the license agreements signed by the institution in respect of trademarks.

3. The UAI has prepared a catalogue of technology offers -based on specification sheets-, which includes the complete portfolio of exploitable IdiPAZ results.


This catalogue aims to promote the transfer of IdiPAZ's technology portfolio to the industrial sector, generate collaborative projects for technological development and foster the exploitation of research results. Those validated specification sheets are published on IdiPAZ's website. The catalogue is updated as the Institute's technology portfolio grows.



4. The UAI has been, is, and will continue to be the principal architect for the transfer and exploitation of IdiPAZ's technology portfolio.

During 2021, the UAI succeeded in signing 16 license agreements -15 of which related to intellectual property works and 1 to know-how- and the portfolio of licensed or commercially exploited inventions reached the figure of 17 technologies, 5 patents, 1 utility model, 2 SW, 3 trademarks, 3 IP Works and 3 know-how.

■ **Technologies licensed or in commercial exploitation (2021)**



5. Thanks to UAI's support and management it has been possible to create and consolidate the first technology-based company of the Hospital (and also of the region of Madrid) according to the regulations established by the Department of Health of the Community of Madrid.

The spin-off concerned, Biomedical Molecular Medicine, exploits the research results in oncology –specifically, a genomic test to determine whether breast cancer patients should have chemotherapy – designed by some members of IdiPAZ As of 31 December 2021, 4 spin-off projects existed and were being managed by the UAI, 2 of which were expected to be set up in the short-medium term.

6. Through the promotion of a culture of innovation, the UAI has managed to create a large community of innovative professionals.

Over the last year, its promotional activity has consisted in the celebration of several working days, workshops, seminars, etc. Among all the promotional activities organised, the following stand out:

- Workshop "Lo que todo empresario debe saber para establecer una alianza exitosa con un hospital público". XX Semana de la Ciencia y la Innovación 2021, November 2021.
- Webinar "UNE 166002 Sistema de Gestión de la Innovación de IdiPAZ", April 28th, 2021, 13:30-14:30.
- WEBINAR "La protección de datos en investigación: aspectos clave a tener en cuenta". October 29th, 2021. 10:00-11:00h.

Within the framework of this objective of promoting the culture of innovation, IdiPAZ launched on February 25th 2021 the 1st edition of the Call for Aid for the Development of Innovation Projects. With this call IdiPAZ aims to promote the

development of innovation projects, through the granting of an aid, under a regime of publicity, equality, objectivity and competitive concurrence, to carry out the implementation of an innovation project in order to transfer innovative solutions, generating benefits for the community, and at the same time allowing the establishment of partnerships between research entities and companies in the pharmaceutical, biotechnology and medical and health technologies sector. It has been designed as an annual grant that is intended to be perpetuated over time.

This first edition of this Call for Aid was resolved on 12 July 2021 in favour of the project entitled "First biotool for the standardisation of exosomal content in liquid biopsy and its clinical applicability for the stratification and diagnosis of patients with lung cancer (Lucadia)", whose Principal Researcher is Inmaculada Ibañez de Caceres.

In addition, the UAI has collaborated with important institutions and private entities to promote innovation, in particular, it has participated in various forums and round tables organized by various stakeholders of the biomedical sector.

7. The UAI has succeeded in creating a wide-ranging network of contacts. By virtue of its membership in the ITEMAS Platform, the Unit has continued to strengthen ties and creating synergies with the members of this Platform in order to achieve its established objectives.

Apart from the above results, it is important to highlight the increasing amount of innovation projects managed by the Innovation Unit that has been awarded with prestigious awards and aids. The following are some of the projects that won grants or awards during 2021:

(a). Three IdiPAZ projects won awards in the 5th edition of the Healthstart madri+d programme:

Mut4child: project originated at the Institute of Medical and Molecular Genetics (INGEMM) of the Hospital Universitario La Paz and presented by the researcher Adela Escudero. The project works on the development and commercialisation of a genetic diagnostic kit for the optimisation of early diagnosis, prognosis and treatment of childhood cancer. The kit is based on a massive sequencing panel that will allow early detection and improved accuracy in the diagnosis of children with a higher risk of developing cancer, as well as optimising conventional treatment through the use of targeted drugs, in a clear approach to precision medicine.



Promoter team of Mut4child project

Breastfeeding device: project originated in the Paediatric Emergency Department of the Hospital Universitario La Paz and presented by Dr. Patricia Bote Gascón and Mr. Francisco Julián García Rivera. The project has developed a device associated with a mobile application to assess the amount of breast milk



1 Introduction



Promoter team of **Breastfeeding device** project

ingested during breastfeeding, especially in children who are exclusively breastfed. The purpose of the device is not only to quantify the intake but also to reduce the maternal anxiety associated with such a measurement while encouraging breastfeeding.

In addition, the Release project, presented by Cristina Ferreras, a researcher in the Translational research in pediatric oncology, hematopoietic transplantation and cell therapy at IdiPAZ, received the incubation award, a prize consisting of six months in the incubator for scientific-technological companies that the Madrid Science Park Foundation (FPCM) manages

at the Campus of International Excellence. This project, initially presented in the #Vencealvirus hackathon of the Community of Madrid (<https://www.comunidad.madrid/>) launched a year ago, is committed to the creation of a “lympho-library” for immediate use for the treatment by cell therapy of patients infected by SARS-CoV-2 who have COVID-19 disease with a moderate/severe prognosis. The first two projects received €10,000 in services for the maturation and development of the projects.

(b) Project “PLEC2021-008034 Early molecular nanoDIAGnostics of Brain tumors using Immune-PET (DIAGBI)” granted by the Ministry of Science and Innovation in the framework of the R+D+i projects in strategic lines Call for Aid. Principal Investigator: Inmaculada Ibáñez de Cáceres.



2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Organisation



Since its implementation, the Innovation Support Unit has been integrated into the organisational structure of FIBHULP, as one of the Support Platforms for IdiPAZ research.



The Innovation Unit is directed by Dr. Javier de Castro Carpeño, M.D. and Ph.D. in Medicine and he’s a member of the Medical Oncology Department of the La Paz University Hospital, Autonomous University of Madrid and of the Translational Oncology Unit of IdiPAZ.

The Innovation Unit also consists of a team of two experts in fostering innovation and protecting research results and technology transfer:

Estela Sánchez Simón, *Law Graduate*; and
Rocío Jiménez Alonso, *Phd in Neurociences*.

CONTACT

Coordinator

Javier de Castro Carpeño

javier.decastro@salud.madrid.org

Phone: (+34) 91 207 12 34

Members

Estela Sánchez Simón

innovacion.legal@idipaz.es

Phone: (+34) 91 207 12 34

Rocío Jiménez Alonso

rocio.jimenez@idipaz.es

Phone: (+34) 91 207 12 34



2.4.2. PATENTS AND TRADEMARKS



Neurosciences Area

Psychiatry and Mental Health Group

Rodríguez Vega B, authors; FIBHULP, assignee. Brand name: En calma; ESM 3.695.071; 2017 December 12.



Rodríguez Vega B, Mediavilla Torres R, Bravo Ortiz MF, Muñoz San José A, Bayón Pérez C, Lahera Forteza G, Palao Tarrero A, authors; FIBHULP, assignee. Brand name: SocialMind; ESM 3.748.550; 2018 December 17.



Neurology and Cerebrovascular Diseases Group

Valdivieso Amate F, Bullido Gómez-Heras MJ, Martínez García A, inventors; UAM, assignee. Method of identifying compounds that induce or inhibit endoplasmic reticulum stress or oxidative stress. P200702997, PCT/ES2008/000705, EP2221379, US20100304384; 2007 November 13.

Vergés Milano J, García García A, Ruhí Roura R, Montell Bonaventura E, García López M, Aláez Versón CR, Escaich Ferrer J, Egea Maíquez J, Lorrío González S, Negrodo Madrigal P, inventors; BIOIBÉRICA S.A., UAM, assignees. Sulphated disaccharides for the treatment of neurodegenerative and/or neurovascular diseases. P200902399, PCT/EP2010/070613, US20120309707, CA20102785237; 2010 December 22.

Valdivieso Ámate F, Burgos Muñoz JS, Ramírez Moreno C, Sastre Merlín I, inventors; UAM, CSIC, assignees. Method of identifying therapeutic compounds which can be used for the treatment and/or prevention of infections and diseases caused by human herpes viruses. P200400965, PCT/ES2005/000209, EP1769677, US20070218004, AT447321, AU2005235319, CA2562787, JP2007533315; 2004 April 21.

Valdivieso Ámate F, Montoliú JL, Pozueta Larios J, inventors; UAM, CSIC, assignees. Alzheimer's disease animal model, method for obtaining same and uses thereof. P200503002, PCT/ES2006/000673, EP1956091, EP20060841725, US20090222932, CA2638983, JP2009517066; 2005 December 02.

Ballesteros García P, López Larrubia P, Domínguez Mateo L, Marco Contelles JL, Cerdán García-Esteller S, inventors; Universidad Nacional de Educación a Dis-

tancia, CSIC, assignees. Set of magnetic resonance imaging and spectroscopy cell acidity extrinsic indicators comprise polyol derivatives based on alditols. P200300936; 2003 April 23.

Gil Martínez A, author; FIBHULP, assignee. Brand name: Specular Face; ESM 4.022.981; 2019 June 10.



Egea Maíquez FJ, Farré Alins V, Palomino Antolín A, Narros Fernández P, Martins Rosa J, Parada Pérez E, Hernández García BJ, Roda Frade JM, Yus Teruel S, Lagares Gómez-Abascal A, Sánchez Carabias C, Gandía Juan L, inventors; Fundación Hospital La Princesa, FIBHULP, Fundación Hospital 12 de Octubre, UAM, assignees. Method for determining the progression of acute brain damage and pharmaceutical composition for its treatment. P202031194; 2020 November 30.

Neuroprotective Strategies in Neurodegenerative Diseases Group

Cuadrado Pastor A, Innamorato NG, inventors; CSIC, UAM. Use of sulforaphane as supplementary therapy for early-stage neurodegenerative disease. P201231693; 2012 November 06.

León Martínez R, Egea Maíquez J, Buendía Abaitua I, Parada Pérez E, Navarro González de Mesa E, inventors; Fundación para la Investigación Biomédica del Hospital Universitario de La Princesa, UAM, CSIC, DNS NEUROSCIENCE S.A., assignees. Use of 3-(2-isothiocyanatoethyl)-5-methoxy-1H-indole for the treatment of neurodegenerative diseases. P201300667; 2013 July 17.

León Martínez R, Buendía Abaitua I, Navarro González de Mesa E, Michalska P, Gameiro Ros I, López Vivo A, Egea Maíquez J, García López M, García García A, inventors; Fundación para la Investigación Biomédica del Hospital Universitario de La Princesa, UAM, DNS NEUROSCIENCE S.A., assignees. Compounds derived from 3-alkylamine-1H-indolyl acrylate and its use for the treatment of neurodegenerative diseases. P201400810, PCT/ES2015/000139, CA2964309; 2014 October 15.

Mechanisms and Biomarkers in Neurodegenerative Diseases


López-Rodríguez ML, Viso A, Ortega S, Lastres-Becker I, González S, Fernández-Ruiz JJ, Ramos JA, inventors; Universidad Complutense de Madrid, assignees; Nuevos derivados de ácido araquidónico con afinidad por el transportador de anandamide. P200001920. 2020 nov 5

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



Cardiovascular Area

Research on Invasive Clinical Cardiology- ICCI-PAZ Group

Riera del Moral LF, inventor; FIBHULP, assignee. Aortic endoprosthesis for the treatment of aneurysm. P201231638, PCT/ES2013/070712; 2012 October 24.

Figueiras Rama D, López de Sá y Areses E, Millet Roig J, Calvo Saiz CJ, inventors; Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), FIBHULP, Universidad Politécnica de Valencia, assignees. Method of predicting or prognosticating neurological performance in patients who have suffered a cardiac arrest and optionally comatose status due to ventricular fibrillation. PCT/EP2015/076893, EP3020333; 2014 November 17.

Castro Conde A, author; FIBHULP, assignee. Trademark name: RECAR Programa de Rehabilitación Cardíaca; CM 18457042; 2021 April 20.



Vascular Physiology and Pharmacology Group

Pérez Girón JV, Ruiz-Castellanos MJ, de Luis Jiménez O, Pérez Boto V, Sanz González R, Hernández Vélez MC, Mas Gutiérrez JA, Alonso Gordo MJ, Saldañas Sánchez M, Ros Pérez M, Coloma Jerez A, Asenjo Barahona A, Sanz

Montaña JL, Puente Prieto J, Jensen J, inventors; NANOATE, S.L., assignee. Method for producing biosensors. P201031224, PCT/ES2011/070536; 2010 August 05.

Miguel Castro M, López-Alonso Fandiño R, Recio Sánchez MI, Ramos González MM, Aleixandre de Artiñano A, inventors; CSIC, assignee. Bioactive peptides derived from the proteins of egg white by means of enzymatic hydrolysis. P200301829, PCT/ES2004/070059, EP1661913, US8227207, AT388166, DE602004012289, DK1661913, JP2007523045; 2003 July 31.

Miguel Castro M, López-Alonso Fandiño R, Ramos González MM, Aleixandre de Artiñano A, inventors; CSIC, assignee. Production of and antihypertensive properties of peptides derived from egg white proteins. P200501246 PCT/ES2006/070067; 2005 May 23.

Recio Sánchez MI; Quirós del Bosque A, Hernández Ledesma B, Gómez Ruiz JA, Miguel Castro M, Amigo Garrido L, López Expósito I, Ramos González MM, Aleixandre de Artiñano A, (Contreras Gómez M), inventors; CSIC, assignee. Bioactive peptides identified in enzymatic hydrolyzates of milk caseins and method of obtaining same. P200501373, PCT/ES2006/070079, EP1905779, EP2495250, US8354502, AU2006256720, BRP10611729, CA2611416, CN101305017, CN103254278, JP2008545774, KR20080045108, MX2007015528, NO20080103; 2005 June 08.

Garcés Rimón M, Miguel Castro M, López-Alonso Fandiño R, López-Miranda

González V, Uranga Ocio J, inventors; CSIC, Universidad Rey Juan Carlos, assignees; Use of multifunctional bioactive products derived from the enzymatic hydrolysis of egg white proteins for treating metabolic syndrome. P201331767, PCT/ES2014/070880; 2013 December 04.

Miguel Castro M, Garcés Rimón M, López-Alonso Fandiño R, Sandoval Huertas M, inventors; CSIC, Mario Sandoval Huertas, assignees. Healthy food compositions having gel or foam textures and comprising hydrolyzed egg products. P201331886, PCT/ES2014/070902, EP3106042, US9648897, AR098685, JP2015130856, MX2014015135; 2013 December 20.

González-Muñoz R, Pérez de Vega MJ, Miguel M, Balsera-Paredes B, Moreno S, inventors; CSIC, assignee. Triazolyl polyphenols with antioxidant activity and uses thereof; P201531450; 2015 November 08.

González-Muñoz R, Miguel Castro M, Pérez de Vega MJ, Balsera-Paredes B, S Moreno, inventors; CSIC, assignee. Compounds with antioxidant activity and uses thereof. P201630362; 2016 March 29.

León Martínez R, Abril Comesaña S, Duarte Flórez P, Crisman Vigil E, Michalska P, Saldañas Sánchez M, Menéndez Ramos JC, inventors; Fundación para la Investigación Biomédica del Hospital Universitario de la Princesa, UAM, UCM, assignees. Compuestos agonistas nicotínicos y antioxidantes para el tratamiento de enfermedades neurodegenerativas. P201930908. 2019 October 14.

León Martínez R, Abril Comesaña S,

Michalska P, Buendía Abaitua I, Saldañas Sánchez M, Menéndez Ramos JC, García López M; inventors; Fundación para la Investigación Biomédica del Hospital Universitario de la Princesa, UAM, UCM, assignees. Compuestos derivados de 2-iodo-7-(((2-(5-metoxi-1H-indol-3-il)etil)amino)metil)-1-alquil/aryl-6,7,7a,8-tetrahidro-3H-pirrol[2,1-j]quinolina-3,9(5H)-diona como agentes antioxidantes, inductores de NRF2 y moduladores nicotínicos para el tratamiento de enfermedades neurodegenerativas. P201930190. 2019 March 01.

Miguel Castro M, Garcés Rimón M, authors; Miguel Castro M, Garcés Rimón M, assignee. Brand name: leggie. ESM4044711; 2019 November 22.

leggie

Miguel M, Bruna E, Redondo BI, Gómez J, Gómez Sánchez J. inventors : Cárnicas Joselito S.L. assignee. Extracto procedente de la grasa de cerdo, método de obtención, composición alimenticia que lo comprende y usos del mismo. P2021130236. 2021 March 17

Miguel M, Bruna E, Redondo BI, Gómez J, Gómez Sánchez J, Sabater-Muñoz B. inventors: Cárnicas Joselito S.L. assignee. Composición farmacéutica que comprende un extracto procedente de la grasa de jamón de cerdo como principio activo y su uso en medicina para la prevención cardiovascular e inflamación intestinal. P202131111. 2021 november 30

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



Infectious Diseases and Immunity Area

AIDS and Infectious Diseases Group

Romero Gómez M, Solá Lamoglia R, González García JJ, inventors; Servicio Andaluz de Salud, Universidad de Sevilla, Fundació Institut Mar D'Investigacions Mèdiques, FIBHULP, assignees. Kit for decision making in patients with Hepatitis C genotypes 1 and 4. P201330731; 2013 May 21.

Molecular Microbiology Group

Vicente Muñoz M, Mingorance Cruz J, Rueda González MS, inventors; CSIC, assignee. Method for determining state of growth and viability of bacterial FTsZ population, whether natural or cultivated, is based on determining existence of FTsZ rings in actively growing individual cells. P200200370; 2002 February 15.

Mingorance Cruz J, Castán García P, Franco de Sarabia Rosado PM, inventors; BIOTOOLS BIOTECHNOLOGICAL & MEDICAL LABORATORIES S.A., assignee. Composition, method and kit for detecting bacteria by means of sequencing. PCT/ES2009/000507, EP2492352, US2013157265, CA2775273, MX2012004627; 2009 October 22.

Mingorance Cruz J, Castán García P, Franco de Sarabia Rosado PM, inven-

tors; 2B BLACKBIO S.L., assignee. Composition, method and kit for detecting fungi and yeasts by means of sequencing. PCT/ES2010/000248; 2010 June 02.

Immuno-Rheumatology Group

Pascual-Salcedo Pascual MD, Balsa Criado A, Plasencia Rodríguez C, authors; FIBHULP, assignee. Brand name: BioDrug Analysis BIDA. CM 13.808.531, 2015 March 10.



Fernández Luna JL, Martínez Taboada VM, López Hoyos M, Torices del Val S, Muñoz Cacho P, Varela Egocheaga I, Juliá Cano A, Marsal Barril S, Balsa Criado A, inventors; FIBHULP, Fundación Instituto de Investigación Marqués de Valdecilla, Servicio Cántabro de Salud, Universidad de Cantabria, FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA (VHIR), assignees. Method for predicting the clinical response to anti-inflammatory agent therapies. P201600636, PCT/ES2017/000089; 2016 July 26.

Innate Immune Response Group

Llamas Matías MA, López-Collazo E, inventors; FIBHULP, Llamas Matías MA, Empireo S.L., assignees. Method for determine the risk of developing an infectious disease. P201330768, PCT/ES2014/070434, EP3006570; 2013 May 27.

Vela Cuenca M, González Navarro P, Valentín Quiroga J, Escudero López A, Pérez Martínez A, Fernández Casanova L, inventors; FIBHULP, CNIO, assignees. Anti-CXCR4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy. 62/642,313 US Provisional Application; 2018 March 13.

Diagnosis and Treatment of Diseases Associated with Abnormalities of the Complement System Group

López Trascasa M, authors; FIBHULP, assignee. Brand name: COMPLEMENTest; CM 009.658.791; 2011, January 14.



Lymphocyte Pathophysiology in Immunodeficiencies Group

Van Dongen JJM, Orfao de Matos Co-

rreia E Vale JA, Van Der Burg M, Pérez Andrés M, Van Zelm MC, Kalina T, Vlkova M, López Granados E, Blanco Álvarez E, Kienzler AK, inventors; Erasmus University Medical Center Rotterdam, assignee. Reagents, methods, and kits for diagnosing primary immunodeficiencies. PCT/NL2015/050762, US62/072,498; 2014 Oct 30.

Drug Hypersensitivity and Innate Immune Response Group

Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of pyridazine[1',6':1,2]pyrido[3,4-b]indolinium as anti-inflammatory agents. P201331143, PCT/ES2014/070603; 2013 July 25.


Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of piridazine[3,2-b]benzimidazolium as anti-inflammatory agents. P201430411, PCT/ES2014/070603; 2013 July 25.

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



Large System Pathologies Area

Organic Dysfunction and Failure in the Agression Group

Herrero Ambrosio A, Ramírez García E, Ojeda Feo JJ, Pérez Rodríguez J, Asensio Martín MJ, González Sánchez ML, Moro Agud M, Lorente Romeo M, López Nieto M, Gómez Rioja R, authors; FIBHULP, assignee. Brand name: SINOIRES; CM 13.080.056; 2014 July 14



Respiratory Diseases Group

Díaz García E, Laxman Nanwani K, Quintana Díaz M, García Río F, Cubillos-Zapata C, inventors; FIBHULP, CIBER, assignees. Biomarcadores para el pronóstico de pacientes que han sufrido una hemorragia subaracnoidea aneurismática (SAH). P202130180; 2021 March 3

Nephrology Group

Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of pyridazine[1',6':1,2]pyrido[3,4-b]indolinium as anti-inflammatory agents. P201331143, PCT/ES2014/070603; 2013 July 25.

Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso

P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of pyridazine[3,2-b]benzimidazolium as anti-inflammatory agents. P201430411, PCT/ES2014/070603; 2013 July 25.

Aguilera Peralta AI, López-Cabrera M, Selgas Gutiérrez R, Steppan S, Passlickdeetjen J, inventors; Fresenius Medical Care Deutschland GMBH, assignee. Pharmaceutical compositions containing steviosides. EP14191301.2, PCT/EP2015/074955, CN107073022, US10213452; 2014 October 31.

López-Cabrera M, Aguilera Peralta AI, Selgas Gutiérrez R, Passlickdeetjen J, Buechel J, Steppan S, inventors; Fresenius Medical Care AG & Co. KGaA, assignee. Method and kit for diagnosing epithelial to mesenchymal transition of the peritoneum (EMT-Chip). DE102015115158.8, PCT/EP2016/071149, CN108449998B, EP3347715B1, ES2833553T3, JP6869963B2, US2018246098A1; 2015 September 09.

Sánchez Niño MD, Ortiz Arduán A; FIBHULP, Instituto de Investigación Sanitaria Fundación Jiménez Díaz. Pharmaceutical composition and its use in the manufacture of a medicament for treating chronic kidney disease and method for selecting compounds. P201430081, PCT/ES2015/070039; 2014 January 27.

Diagnosis and Treatment of Allergic Diseases Group

Valenta R, Constantin C, Quirce Gancedo, SE, inventors; Phadia AB, assignee. Novel wheat allergens. PCT/SE2008/051377,

EP2225266, US2010305049, AU2008330230, CA2707190, CN101932597, JP2011505134, RU2010126590; 2007 November 30.

Caballero Molina MT, Prior Gómez N, Remor Bitencourt EA, authors, FIBHULP, assignee. Brand name: HAE-QoL HEREDITARY ANGIOEDEMA QUALITY OF LIFE. CM 13.083.068; 2014 July 15.



Sánchez Herreros R, Martínez Fernández J, Castro Morera A, Gasset Vega M, Rodríguez Pérez RM, Pedrosa Delgado M, Quirce Gancedo S, inventors; FIBHULP, CSIC, assignees. Food allergen extracts and methods of producing and using the same. EP16382413.9 (EP3290438); 2016 September 06.

del Pozo Abejón V, Sastre Dominguez J, Rodrigo-Muñoz JM, Sastre Turrión B, Quirce Gancedo S, Cañas Mañas JA, inventors; FIISFJD, Centro de Investigación Biomédica en Red (CIBER), FIBHULP, Fundación Conchita Rábago de Jiménez Díaz, assignees. In vitro method for identifying severity levels in bronchial asthma patients. P201730739, PCT/ES2018/070390, EP3633050; 2017 May 29.

Gynecologic Oncology Group

Zapardiel Gutiérrez I, de Santiago García J, inventors; FIBHULP, assignee. Laparoscopic surgical instrument. P201230950, PCT/ES2013/000139; 2012 June 18.

Zapardiel Gutiérrez I, de Santiago García J, inventors; FIBHULP, assignee. Surgical device. P201330532, PCT/

ES2014/070277; 2013 April, 15.

Urology

Botella Cubells LM, Albiñana Díaz V, Villar Gómez de las Heras K, inventors; CSIC, Alianza Española de Familias de Von Hippel-Lindau-VHL, assignees; Compounds for treating von Hippel-Lindau diseases. P201731019, PCT/EP2018/071220, CA3072389A1, EA202090452A1, EP3664788A1, US2020323798A1; 2017 August 07.

Sánchez-Puelles González-Carvajal JM, Botella Cubells LM, Aguado Sánchez T, Del Río Nechaevsky M, García Martín A, García Díez M, Larcher Laguzzi F, Carretero Trillo M, inventors; CSIC, UC3M, CIEMAT, assignees; Inhibitors of TGF- β 1 and endoglin producers for use in the treatment of epidermolysis bullosa. P201831072, PCT/ES2019/070757; 2018 November 07.

Aguado Sánchez T, Albiñana Díaz V, Botella Cubells LM, Cuesta Martínez A, Sánchez-Puelles González-Carvajal JM, Villar Gómez-de las Heras K, inventors; Alianza Española De Familias De Von Hippel-Lindau-VHL, CSIC, Consorcio Centro de Investigación Biomédica en Red M.P., assignees; Treatment and prevention of glioblastoma. EP18382917A, PCT/EP2019/084822, CA3122640A1; 2018 December 12.

Reyburn HT, Valés-Gómez M, inventors; assignees; Assay for the detection of the Cys-like protease (Mpro) of SARS-CoV-2. EP20382495.8; 2020 August.

Valés-Gómez M, inventors; assignees;

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



Method for the detection and/or quantification of extracellular vesicles in fluid biological samples. EP16411562; 2020 August.

Hospital Pharmacy


Herrero Ambrosio A, Ramírez García E, Ojeda Feo JJ, Pérez Rodríguez J, Asensio Martín MJ, González Sánchez ML, Moro Agud M, Lorente Romeo M, López Nieto M, Gómez Rioja R, authors; FIBHULP, assignee. Brand name: SINOIRES; CM 13.080.056; 2014 July 14



Associated Clinician

de la Oliva Senovilla P, inventor; FIBHULP, Instituto de Salud Carlos III, assignees. Shut-off valve for the interruption technique used in the analysis of respiratory mechanics. PCT/ES2005/000271, EP1897578; 2005 May 16.

Carballo Cardona C; author; FIBHULP, assignee. Trademark name: Diagether. CM15869911, 2016 September 29.



Cancer and Human Molecular Genetics Area


INGEMM- Institute of Medical and Molecular Genetics Group

Friedman S, Li D, Narla G, Martignetti J, Heath K, inventors; Mount Sinai School of Medicine, assignee; Kruppel-like factor 6 (klf6), a tumor suppressor protein, and diagnostics, therapeutics, and screening based on this protein. PCT/US2001/025046, EP1332362, CA2419064, AU8479001, US2005181374, US2011059899; 2000 August 09.

INGEMM, author; FIBHULP, assignee. Brand name: INGEMM INSTITUTO DE GENÉTICA MÉDICA Y MOLECULAR DEL HOSPITAL UNIVERSITARIO LA PAZ; ESM 2.884.849, USM 77.891.143, CM 8.746.869; 2009 July 16, 2009 December 11, 2009 December 10.



INGEMM, author; FIBHULP, assignee. Brand name: KaryoArray; USM 79.078.751, CM8.512.907; 2010 January 07, 2009 August 27.



INGEMM, author; FIBHULP, assignee. Brand name: OverGrowthArray; ESM 2.958.709-3, USM 85.334.932, CM10.009.256; 2010 December 02, 2011 June 01, 2011 May 31.



INGEMM, author; FIBHULP, assignee. Brand name: MetabolArray; ESM 2.958.711-5, USM 85.334.903, CM10.009.348; 2010 December 02, 2011 June 01, 2011 May 31.



Palomares M, Lapunzina P, Nevado J, Vallespin E, Vallcorba I, Melero J, authors; FIBHULP, Hospital Infanta Cristina (Badajoz) Fundesalud, assignees. Brand name: OncoHematoArray; ESM 2.958.703-4, USM 85.334.842, CM10.009.181; 2010 December 02, 2011 June 01, 2011 May 31.



Lapunzina P, Nevado J, Solera J, Vallespin E, Martínez P, Martínez-González V, authors; FIBHULP, assignee. Brand name: ONCOSeq; USM 85.457.843, CM9.969.064; 2011 October 27, 2011 May 16.



INGEMM, author; FIBHULP, assignee. Brand name: OncoArray; ESM 2.962.910, USM 85.363.107, CM10.091.882; 2011 January 05, 2011 July 05, 2011 July 01.



Moreno JC, Moya CM, Vallespin E, Lapunzina P, Nevado J, authors; FIBHULP, assignee. Brand name: ThyroArray; USM 85.686.688, CM10.904.951; 2012 July 25, 2012 May 23.



Lapunzina Badía P, Borobia Pérez AM, Carcas Sanjuán AJ, Tenorio Castaño JA, Arias Lajara P, Lubomirov Jristov R, authors; FIBHULP, UAM, assignees. Brand name: PharmArray; USM 86.004.412, CM11.608.403; 2013 July 08, 2013 February 27.



Palomares Bralo M, Vallespín García E, del Pozo Mate A, Santos Simarro F, authors; FIBHULP, assignee. Brand name: RD-Seq Sequencing Rare Diseases; CM 17.911.029; 2018 May 31.



Lapunzina Badía PD, Borobia Pérez AM, Carcas Sansuán AJ, Tenorio Castaño JA, Arias Lajara P, Frías Iniesta J, Dapia García I, Muñoz M, authors; FIBHULP, UAM, assignees. Brand name: ClinPharmarray. USM87054978, CM15489511; 2016 May 31, 2016 September 07.



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Translational Oncology Group

Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, González Barón M, de Castro Carpeño J, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, assignees. Genomic fingerprint for the prognosis of the evolution of colorectal adenocarcinoma. P200703229, PCT/ES2008/000756, EP2236626; 2007 December 04.

Cejas Guerrero P, González Barón M, Casado Sáenz E, Sánchez Hernández JJ, Perona Abellón R, inventors; FIBHULP, UAM, CSIC, assignees. Use of trefoil factor family 3 (TFF3) in the prognosis of patients diagnosed with colorectal cancer. P200703230, PCT/ES2008/000757, EP2236625; 2007 December 04.

Espinosa Arranz E, Fresno Vara JA, Gámez Pozo A, Sánchez Navarro I, inventors; FIBHULP, assignee. Method for tumor subclassification. P200803509, PCT/ES2009/070533; 2008 December 11.

Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the prediction of a patient's clinical response to an anticancer treatment. P200930400; 2009 July 01.

Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the prediction of a patient's pathological response to an anticancer treatment. P200930438; 2009 July 10.

Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, de Castro Carpeño J, Moreno García V, Burgos Lizalde E, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, Empresa Pública Hospital del Norte, assignees. Genomic fingerprint for predicting the clinical response to an antitumor therapy

in colorectal cancer. P201130863, PCT/ES2012/070379; 2011 May 26.

Moreno Rubio J, Cejas Guerrero P, Feliú Batlle J, Ramírez de Molina AI, Reglero Rada G, Vargas Alonso T, Molina Arranz S, González-Vallinas Garrachón M, inventors; FIBHULP, Fundación Imdea Alimentación, assignees. Methods and kits for the prognosis of colorectal cancer. P201231918, PCT/ES2013/070864; 2012 December 10.

Espinosa Arranz E, Fresno Vara JA, Gámez Pozo A, López Vacas R, Berge Soria J, inventors; FIBHULP, assignee. Method for tumor subclassification. P201430887, 2014 June 09.

Miranda Utrera N, Castellano D, Villacampa Aubá F, Fresno Vara JA, Gámez Pozo A, inventors; FIBHULP, assignees. Prognostic method for determining the risk of relapse in renal cancer patients with a clear cell type of renal carcinoma, stages I and II, and kit for same. P201531360, PCT/EP2016/072723, EP3353322B1, US20180346990, CN108174608, DE3353322, FR3353322, GB3353322; 2015 September 23.

Feliú Battle J, Fernández Martos C, Fresno Vara JA, Ghanem Cañete I, Gámez Pozo A, Trilla Fuertes L, inventors; Biomedica Molecular Medicine SL (BMM), Grupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD), assignees. In vitro method for the prognosis of anal squamous cell carcinoma. EP19382982.7; 2019 November 11.

Experimental Therapies and Biomarkers in Cancer Group

Perona Abellón R, Sánchez Pérez I, Machado Pinilla R, Sastre Garzón L, Murguía Ibáñez JR, inventors; CSIC, UAM, Universidad Politécnica de Valencia, assignees. Sequence of nucleotides and peptides GSE 24.2 of dyskerin, which can induce telomerase activity, method for

obtaining same, therapeutic compositions and applications thereof. P200502511, PCT/ES2006/070152, EP1947175, US20090202503, US2015337022, AT469212, CA2625981, DK1947175, JP2009511036, JP5560398, PT1947175; 2005 October 14.

Perona Abellón R, Sastre Garzón L, Machado Pinilla R, Sánchez Pérez I, inventors; CSIC, UAM, assignees. Use of inductor agents GSE24.2 for producing pharmaceutical compositions for treating illnesses relating to cellular senescence. P200703106, PCT/ES2008/070212, EP2216043, US2011300115, JP2011504483, CA2706467; 2007 November 23.

Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, González Barón M, de Castro Carpeño J, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, assignees. Genomic fingerprint for the prognosis of the evolution of colorectal adenocarcinoma. P200703229, PCT/ES2008/000756, EP2236626; 2007 December 04.

Cejas Guerrero P, González Barón M, Casado Sáenz E, Sánchez Hernández JJ, Perona Abellón R, inventors; FIBHULP, UAM, CSIC, assignees. Use of trefoil factor family 3 (TFF3) in the prognosis of patients diagnosed with colorectal cancer. P200703230, PCT/ES2008/000757, EP2236625; 2007 December 04.

Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, de Castro Carpeño J, Moreno García V, Burgos Lizalde E, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, Empresa Pública Hospital del Norte, assignees. Genomic fingerprint for predicting the clinical response to an antitumor therapy in colorectal cancer. P201130863, PCT/ES2012/070379; 2011 May 26.

Martínez Máñez R, Murguía Ibáñez JR, Perona Abellón R, Agostini A, Mondragón Martínez L, Moreno Torres M,

Manguán García C, Marcos Martínez MD, Soto Camino J, Sancenón Galarza F, inventors; Universidad Politécnica de Valencia, CSIC, Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), assignees. Release of substances into senescent cells. P201231370, PCT/ES2013/070581, EP2893923, JP2015529216, US2015306037; 2012 September 04.

Ibáñez de Cáceres I, Belda Iniesta C, Pernía Arias O, Perona Abellón R, Cortés Sempere M, inventors. FIBHULP, CSIC, UAM, Fundación Hospital de Madrid, assignees. Method for predicting the response to a treatment consisting of radiotherapy combined with cisplatin-based chemotherapy. P201330783, PCT/ES2014/070433, EP3006572, US20160122828, IT1660.13, ES1660.13, FR1660.13, DE1660.13, GB1660.13; 2013 May 29.

Perona Abellón R, Sastre Garzón L, Pintado Berninches L, Carrillo García J, Molina Pachón A, Irradiccio Silva L, Manguán García C, inventors; CSIC, UAM, Advanced Medical Projects, Centro de Investigación Biomédica en Red (CIBER), assignees. Peptides derived from GSE 24.2 for treating diseases caused by oxidative stress and damage to DNA. P201331573, AU2014338820, CA2931429, EP3061815 PCT/ES2014/070803; 2013 October 25.

Ibáñez de Cáceres I, Pernía Arias O, de Castro Carpeño J, Vera Puente O, Jiménez Hernández J, Perona Abellón R, Rojo Todo F, inventors; FIBHULP, CSIC, UAM, Instituto de Investigación Sanitaria FJD, assignees. Determination of methylation and miRNA levels in response to a platinum-based antitumor compound. P201530997, PCT/ES2016/070516; 2015 July 09.

Ibáñez de Cáceres I, de Castro Carpeño J, Vera Puente O, Pernía Arias O, Rodrí-



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

quez Antolín C, González Muñoz VM, Martín Palma ME, Salgado Figueroa AM, inventors; FIBHULP, FIBIOHRC, assignees. MAFG as a potential therapeutic target to restore chemosensitivity in platinum-resistant cancer cells. EP17382610.8 (EP3681515), PCT/EP2018/068156, US16/647,368; 2017 September 15.

Ibáñez de Cáceres I, de Castro Carpeño J, Jiménez Hernández J, Rodríguez Antolín C, Rodríguez Jiménez C, Rosas Alonso R, Cruz Castellanos P, Burdiel Herencia M, Pernía Arias O, Diestro Tejada MD, Esteban Rodríguez MI, inventors; FIBHULP, assignee. miR-151A-3p as an universal endogenous control for exosome cargo normalization. EP19382252.5 (EP3719144), PCT/EP2020/059774 PCT Direct; 2019 April 05.

Ibáñez de Cáceres I, de Castro Carpeño J, Rosas Alonso R, Pernía Arias O, Martínez Marín V, Esteban Rodríguez MI, inventors; FIBHULP, assignee. Method for determining the percentage of methylation of the promoter of the gene O6-methylguanine-DNA methyltransferase (MGMT) in circulating exosomes. EP19382299.6 (EP3725899), PCT/EP2020/060753 PCT Direct; 2019 April 16.

Ibáñez de Cáceres I, de Castro Carpeño J, Jiménez Hernández J, Rodríguez Antolín C, Vera Puente O, Rosas Alonso R, Pernía Arias O, Losantos García I, inventors; FIBHULP, assignee. Method for determining the response to treatment of a patient affected by non-small cell lung carcinoma (NSCLC). EP19382614.6 (Publication Number pending), PCT/EP2020/069659; 2019 July 19.

Oto-Neurosurgery Research Group

Polak M, Roca-Ribas Serdá F, Gavilán Bouzas J, Lassaletta Atienza L, Miró Castillo N, Rodrigo Dacosta J, inventors; MED-EL Elektromedizinische Gerae-

te GmbH, assignee. Hearing treatment in patients with questionable cochlear nerve functionality. US2011275953, PCT/US2011/035312; 2010 May 05.

Cobo Parra P, Varela Nieto I, Murillo-Cuesta S, Navares Zaera R, Martínez Vega R, Cediél Algovia R, inventors; CSIC, UCM, assignees. Anechoic acoustic chamber for evaluating the auditory function in laboratory animals. P201031720; 2010 November 23.

Cobo Parra P, Varela Nieto I, Murillo-Cuesta S, Cediél Algovia R, inventors; CSIC, UCM, assignees. Method for designing a reverberating acoustic chamber for hearing test with animals. Procedimiento para diseñar una cámara acústica reverberante para ensayos auditivos con animales. P200802895, PCT/ES2009/070433; 2008 October 14.

Cancer Molecular Pathology and Therapeutics Targets Group

Redondo Sánchez A, Hardisson Herneáz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the prediction of a patient's clinical response to an anticancer treatment. P200930400; 2009 July 01.

Redondo Sánchez A, Hardisson Herneáz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the prediction of a patient's pathological response to an anticancer treatment. P200930438; 2009 July 10.

Mechanisms of Tumour Progression Group

Matías-Guiu Guía FJ, Dolcet Roca FJ, Reventós Puigjaner J, Colás Ortega E, Prat Díaz de Losada J, Palacios Calvo J, Abal Posada M, López R, Moreno Bueno G, Gil Moreno A, inventors; Institut de Recerca Biomèdica de Lleida Fundació

Doctor Pifarré, Universitat de Lleida, Fundació Hospital Universitari Vall d'Hebron-Institut de Recerca, Fundació Institut de Recerca de la Santa Creu i Sant Pau, Servicio Andaluz de Salud, Servicio Galego de Saúde, Fundación MD Anderson International España, assignees. Method to predict risk of recurrence in endometrial carcinoma. Annexin-A2 as predictor biomarker of recurrent disease in endometrial cancer. EP14155510.2, PCT/EP2015/053387; 2014 February 18.

García García JF, Martín Moreno AM, Roncador G, Martínez Torrecuadra JL, Moreno Bueno G, inventors; Fundación MD Anderson International España, Fundación Centro Nacional de Investigaciones Oncológicas (CNIO), assignees; Method for the diagnosis and/or prognosis of lymphomas. P201231304; 2012 August 14.

Olmeda Casadomé D, Peinado Selgas H, Portillo Pérez F, Nieto Toledano MA, Cano García A, inventors; UAM, assignee. Materials and methods for the depression of the E-cadherin promoter. US20060003956; 2004 March 03.

Olmeda Casadomé D, Moreno Bueno G, Portillo Pérez F, Cano García A, inventors; UAM, CSIC, assignees. Method for the diagnosis and/or prognosis of breast cancer. P200702342, PCT/ES2008/000563; 2007 August 28.

Hergueta Redondo M, Sanz PG, Rojo A, García JF, Moreno-Bueno G, inventors; UAM, CSIC, Fundación MD Anderson International España, assignees; Gasdermin B2 as a new biomarker of malignance and resistance of Trastuzumab inhibitor in Her2+ tumors. P201231560; 2012 October 10.

Animal and Cell Models for Detection and Characterisation of Leukemic Stem Cells Group

Campanero García MR, Molina Priva-

do I, inventors; CSIC, UAM, assignees. Method for identifying patients with sporadic Burkitt's lymphoma, identification method and use of compounds for the treatment of sporadic Burkitt's lymphoma. P200702595, PCT/ES2008/070182; 2007 October 03.

Molina Privado I, Campanero García MR, Rodríguez Martínez M, inventors; CSIC, UAM, assignees; Method for the differential diagnosis between Burkitt lymphoma and diffuse large B-cell lymphoma. P200900651; 2009 March 09.

Zapata Hernández JM, Pérez Chacón G, inventors; CSIC, UAM, assignees; Use of an indolic compound with nucleophilic substituents at C3 and the dimeric variants thereof in the production of a pharmaceutical composition that can be used in the treatment of B-lymphoid neoplasms. P201331397, PCT/ES2014/070726; 2013 September 25.

Research and Diagnosis of Inherited Metabolic Diseases Group

Pérez González B, Ruiz Desviat L, Jorge Finnigan A, Ugarte Pérez M, Martínez Ruiz A, Underhaug J, Barnejee R, inventors; UAM, Universidad de Bergen, Universidad de Michigan, assignees; Compounds useful for the treatment of methylmalonic aciduria. P201330171; 2013 February 11.

Pérez González B, Gámez Abascal MA, Yuste Checa P, Arduim Brasil S, Ugarte Pérez M, Martínez Ruiz A, Underhaug J, inventors; UAM, University of Bergen, assignees; Compounds for treating congenital disorders of glycosylation. EP16382373.5, PCT/EP2017/069147; 2016 July 29.

Dyslipidemias of Genetic Origin and Metabolic Diseases Group

Rodríguez Novoa SM, del Monte Vergara A, Rosas Alonso R, Queiruga Pa-




rada J, Yuste González F, authors; FIBHULP, assignee. Brand name: Pharma Genfinder; CM18332183; 2020 November 05.



Ibáñez de Cáceres I, de Castro Carpeño J, Jiménez Hernández J, Rodríguez Antolín C, Rodríguez Jiménez C, Rosas Alonso R, Cruz Castellanos P, Burdiel Herencia M, Pernía Arias O, Diestro Tejada MD, Esteban Rodríguez MI, inventors; FIBHULP, assignee. miR-151A-3p as an universal endogenous control for exosome cargo normalization. EP19382252.5 (EP3719144), PCT/EP2020/059774 PCT Direct, EP20719957.1 (EP3947733), US17/601,657; 2019 April 05.

Associated Clinician

Glaría Enríquez A, Mañas Rueda A, Velázquez Soto R, inventors; FIBHULP, assignee. Isolation and immobilization device for test animals. P201031519, PCT/ES2011/070709; 2010 October 14.



Surgery, Transplant and Health Technologies Area

Bone Pathophysiology and Biomaterials Group

Vilaboa Díaz NE, González Carrasco JL, Saldaña Quero L, Frutos Torres E, inventors; FIBHULP, CSIC, CIBER-BBN, assignees. Method to obtain a metallic-coated biomaterial; P201030949, PCT/ES2011/070400; 2010 June 21.

Vilaboa Díaz NE, González Carrasco JL, Multigner Domínguez M, Lieblich Rodríguez M, Muñoz Hernández M, Frutos Torres E, Saldaña Quero L, inventors; FIBHULP, CSIC, CIBER-BBN, Universidad Alfonso X El Sabio, assignees. Magnesium/polymer composite biomaterial for biomedical applications; P201030950, PCT/ES2011/070440; 2010 June 21.

Fabiilli M, Wilson C, Padilla F, Martín Saavedra FM, inventors; The regents of the University of Michigan, assignee. Ultrasound-triggerable agents for tissue engineering; PCT/US2013/044817, US2013/0330389; 2012 June 08.

Vilaboa Díaz NE, Calzado Martín A, Crespo García L, Saldaña Quero L, Moreo Calvo P, Alastrué Vera V, inventors; FIBHULP, CIBER-BBN, assignees. Chamber device for dynamic cell culture on biomaterials; P201330040, PCT/ES2013/070819; 2013 January 16.

Martín Saavedra FM, Vilaboa Díaz NE, Cebrían Hernando V, Arruebo Gordo M, Santamaría Ramiro J, Gómez Navascués L, inventors; FIBHULP, CIBER-BBN, Universidad de Zaragoza, assignees. Fibrin hydrogel with plasmonic nanoparticles; P201330894, PCT/ES2014/070484; 2013 June 14.

González Carrasco JL, Benavente Castro R, Cifuentes Cuellar SC, Lieblich Rodríguez M, Olalde Graells B, Atorrastagasti Goyalde G, Argarate Madariaga N, Pacha Olivenza MA, Fernández Calderón MC, Saldaña Quero L, González Martín ML, Pérez Giraldo C, Gallardo Moreno AM, inventors; CSIC, Fundación Tecnalia Research & Innovation, FIBHULP, Universidad de Extremadura, Centro de Investigación Biomédica en Red (CIBER). Moldable, biodegradable, biocompatible and bioresorbable implant material, method for its preparation and uses thereof. P201530683; 2015 May 18.

Voellmy R, Vilaboa Díaz NE, inventors; HSF Pharmaceuticals S.A., assignee. Inhibitors of heat shock factor 1 and uses thereof. US 62/495,501 and US62/499,650, PCT/EP2017/072930, EP3512602; 2016 September 16 and 2017 February 02.

Voellmy R, Vilaboa Díaz NE. Inventors; HSF Pharmaceuticals SA. Assignees. Compounds that induce protein unfolding and a mitigated response thereto, and methods of use thereof. US 62/764,569. 2018 August 08.

Cellular Engineering Group

de Miguel González MP, Arnalich Montiel F, Royuela MM, inventors; FIBHULP, Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal, Universidad de Alcalá, assignees. Corneal endothelium injector; P201131222, PCT/ES2012/070543; 2011 July 18.

Clinical Pharmacology Group

Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee. Brand name: IberoAmerican Journals; ESM 3.063.048; 2013 February 12.



Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee. Brand name: IberoAmerican Journals Plus; ESM 3.063.052; 2013 February 12.



Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee. Brand name: IberoAmerican Journals Clinical Pharmacology; ESM 3.063.053; 2013 February 12.



Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee. Brand name: IberoAmerican Journals Medicine; ESM 3.063.049; 2013 February 12.



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



1
Introduction

2
Executive
Summary

3
Information
Groups
by Area

4
Associated
Clinicians

Lapunzina Badía P, Borobia Pérez AM, Carcas Sansuán AJ, Tenorio Castaño JA, Arias Lajara P, Lubomirov Jristov R, authors; FIBHULP, UAM, assignees. Brand name: PharmArray; USM 86.004.412, CM11.608.403; 2013 July 08, 2013 February 27.



Carcas Sansuán AJ, Borobia Pérez AM, authors; FIBHULP, assignee. Brand name: CRDataX; CM13.681.614; 2015 May 28.



Lapunzina Badía PD, Borobia Pérez AM, Carcas Sansuán AJ, Tenorio Castaño JA, Arias Lajara P, Frías Iniesta J, Dapia García I, Muñoz M, authors; FIBHULP, UAM, assignees. Brand name: ClinPharmarray. USM87054978, CM15489511; 2016 May 31, 2016 September 07.



Osteoarticular Surgery Research-GICOA Group

Arenas Vara MA, Conde del Campo A, De Damborenea González JJ, Matykina E, Esteban Moreno J, Gómez Barrena E, Pérez-Jorge Peremarch C, Pérez Tanoira R, inventors; CSIC, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, assignees. Titanium materials anodised with fluorine. P201030720, PCT/ES2011/070342; 2010 May 14.

Patients Safety and Quality Research Group

Herrero Ambrosio A, Ramírez García E, Ojeda Feo JJ, Pérez Rodríguez J,

Asensio Martín MJ, González Sánchez ML, Moro Agud M, Lorente Romeo M, López Nieto M, Gómez Rioja R, authors; FIBHULP, assignee. Brand name: SINOLRES; CM 13.080.056; 2014 July 14



Associated Clinician

Castell Gómez JT, inventor; FIBHULP, assignee. System of "partial" or "total" openings and buttonholes for patient pyjama or nightgown. P200401758; 2004 July 16.

García Fernández J, inventor; FIBHULP, assignee. Anaesthesia machine simulator. P200702128, PCT/ES2008/070109, US20090044803; 2007 July 30.

de Miguel del Campo E, Posadas Mañanes SJ, Reglero Rada GJ, Largo Aramburu C, García Grande A, Merino Martín JJ, Caz Bonillo V, Fornari Reale T, Rodríguez García-Risco M, Señorans Rodríguez FJ, inventors; FIBHULP, UAM, assignees. Composition for the protection of tissues from the digestive tract and the nervous system of radiotherapy patients; P200931189; 2009 December 17.

Goldman Tarlovky L, inventor; FIBHULP, assignee. System and method to obtain data on a patient's breathing cycle. P201030927, PCT/ES2011/070242; 2010 June 16.

de Miguel del Campo E, Reglero Rada GJ, Largo Aramburu C, Fornari Reale T, Rodríguez García-Risco M, Jaime de Pablo L, Santoyo Díez S, Señorans Rodríguez FJ, García Grande A, Merino Martín J, Caz Bonillo JV, Posadas Mañanes SJ, inventors; FIBHULP, UAM, assignees. Composition for the reduction of symptoms associated with menopause;

P201031225, PCT/ES2011/070586; 2010 August 05.

Castell Gómez JT, inventor; FIBHULP, assignee. Surgical device for interrupted suture. P201031491, PCT/ES2011/002352, EP2626014, US13/878035; 2010 October 07.

Álvarez Gallego M, inventor; FIBHULP, assignee. Device for the extraction of surgical specimens by insufflation and suction. P201031490, PCT/ES2011/002357; 2010 October 07.

de Miguel del Campo E, Largo Aramburu C, Tabernero Urbietta M, Reglero Rada GJ, Marín Martín F, Fornari Reale T, Prodanov Prodanov M, Ruiz Rodríguez A, Ibáñez Ezequiel E, Jaime de Pablo L, Soler Rivas C, Rodríguez García-Risco M, Santoyo Díez S, González Lorente M, Arranz Gutiérrez E, Gil Ramírez A, inventors; FIBHULP, UAM, CSIC, assignees. Functional heart-healthy beverage containing wine and extracts of hops; P201131014, PCT/ES2012/070443; 2011 June 16.

Reglero Rada GJ, de Miguel del Campo E, Marín Martín F, Fornari Reale T, Prodanov Prodanov M, Ruiz Rodríguez A, Largo Aramburu C, Tabernero Urbietta M, Ibáñez Ezequiel E, Jaime de Pablo L, Soler Rivas C, Rodríguez García-Risco M, Santoyo Díez S, González Lorente M, Arranz Gutiérrez E, Gil Ramírez A, inventors; FIBHULP, UAM, CSIC, assignees. Method to obtain extract of hop and the extract obtained. P201230584, PCT/ES2012/070443; 2011 June 16.

Brian Gahan P, Stroun M, García del Olmo D, García Arranz M, Vega Clemente ML, inventors; Peter Brian Gahan, Maurice Stroun, FIBHULP, assignees. Method for blocking tumour growth. EP2808027; 2013 May 29.

Castell Gómez JT, Carrascal Morillo T, inventors; FIBHULP, UNED, assignees.

Synthetic surgical mesh. P201331453, PCT/ES2014/000161; 2013 October 03.

Álvarez Gallego M, Castejón Sisamón C, García Prada JC, Meneses Alonso J, inventors; FIBHULP, UC3M, assignees. Rectoscope. P201630551, PCT/ES2017/070249, EP17788865.8, US20190200853; 2016 April 29.

Froilán Torres C, de María Pallarés P, Díaz Lantada A, Ortego García P, inventors; FIBHULP, UPM, assignees. Endoscopic accessory. P201730569; 2017 March 31.

Azabal Agudo A, Ruiz-Valdepeñas Martín de Almagro S; Julián García Rivera F, de la Quintana Jiménez P, inventors; UP DEVICES AND TECHNOLOGIES, S.L., FIBHULP, assignees. Dispositivo de corte automático de discos de ostomía. P201830718, PCT/ES2019/070492. 2018 July 16.

Ramírez de Molina A, Tabernero Urbietta M, Reglero Rada G, Torres Olivares CF, Largo Aramburu C, Santamaría Ramiro M, Polo Paredes G, Ruiz Pérez D, de Miguel del Campo E, Álvarez Gómez de Segura I, inventors; Fundación IMDEA Alimentación, UAM, FIBHULP, IGENFARMA, assignees. Composición para la reducción del declive metabólico asociado al envejecimiento y/o el tratamiento de trastornos relacionados al metabolismo lipídico. P201830740; 2018 July 20.

Martín Mateos P, Acedo Gallardo P, Jorcano Noval JL, Díaz Ojeda L, Bonastre Juliá J, Martínez Méndez JR, Largo Aramburu C, inventors; UC3M and FIBHULP, assignees. Device for monitoring the perfusion status of skin flaps. P202130486; 2021 May 31.

Salinas Gómez J, García Sanz M; inventors; FIBHULP and DISTRIBUCIONES CLINICAS S.A. (DICLISA), assignees. Two-way probe for flushing and/or draining. U202100070; 2021 February 19.



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Muñoz Caro JM; Azabal Agudo A, Ruiz-Valdepeñas Martín de Almagro S, inventors; FIBHULP and Up Devices and Technologies S.L. assignees. Light diffusing device for photodynamic therapy treatment of anogenital region. U202131773; 2021 September 03.

Gómez Candela C, López Plaza B, Bermejo López L, authors; FIBHULP, assignee. Trademark name: NUTRinvest Grupo de investigación en Nutrición y Alimentos Funcionales; ESM3.649.812-2; 2017 February 02.




De la Quintana Jiménez P, authors; FIBHULP, assignee. Trademark name: #OdeOstomía; CM 016922734; 2017 September 21.



De la Quintana Jiménez P, authors; FIBHULP, assignee. Trademark name: CM 016922858; 2017 September 21.



De la Quintana Jiménez P, authors; FIBHULP, assignee. Trademark name: Ostomía; CM 017131822; 2017 August 22.



Maternal Infant Child and Youth Research Area

Neonatology Group

Segovia Iñigo C, Montes Bueno MT, inventors; Segovia Iñigo C, assignee. Positioning device for neonates (Utility model). U201330102; 2013 January 31.

Pediatric systemic infections; hiv, tuberculosis, imported and emergent diseases Group

Mellado MJ, Piñeiro R, authors; ASOCIACION ESPAÑOLA DE PEDIATRIA (AE-PED), assignee. Trademark name: PEDIAMÉCUM; ESM 3079824; 2013 June 13.



Translational research in pediatric oncology, hematopoietic transplantation and cell therapy Group

Vela Cuenca M, González Navarro P, Valentín Quiroga J, Escudero López A, Pérez Martínez A, Fernández Casanova L, inventors; FIBHULP, CNIO, assignees. Anti-CXCR4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy. 62/642,313 US Provisional Application, IB2019/052042; 2018 March 13.

Pérez Martínez A, Ferreras Puente C,B, inventors; UAM, FIBHULP, Universidad Miguel Hernández de Elche (UMH), Fundación de la Comunitat Valenciana para la gestión del Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), assignees. Memory T cells as adoptive cell therapy for viral infections. EP20382850.4 (EP3974029), PCT/EP2021/076516; 2020 September 25.

Mayán Santos M, Acea Nebriil B, Varela Eirín M, Rodríguez-Candela Mateos M, Díaz Carballa CC, Fonseca Capdevila E, Barrio LC, Escudero López A, inventors; Fundación Profesor Novoa Santos- Instituto de Investigación Biomédica de A Coruña (INIBIC), assignees. Composición para el tratamiento de los efectos secundarios de la radioterapia y/o quimioterapia. PCT/ES2020/070269; 2020 April 27.

Associated Clinician

Hernández Oliveros F, Nana Gómez Mayoral N, Raya González L, Guijarro Fernández E, authors; FIBHULP, HePA, U-TAD, Guijarro Fernández E, assignees. Trademark name: VTR Virtual Transplant Reality; CM18.000.131; 2018 December 14

Other trademarks of IdiPAZ

FIBHULP, author; FIBHULP, assignee. Trademark name: IdiPAZ Instituto de Investigación Hospital Universitario La Paz; USM 85.078.878, CM8.871.873; 2010 July 06, 2010 February 10.




FIBHULP, author; FIBHULP, assignee. Trademark name: CEASEC Centro Avanzado de Simulación y Entrenamiento Clínico; ESM 3.567.901-8; 2015 June 22.



Centro Avanzado de Simulación y Entrenamiento Clínico

FIBHULP, author; FIBHULP, assignee. Trademark name: InnoPAZ Plataforma de Innovación Hospital Universitario La Paz; ESM 3.572.575-3; 2015 July 27.





2.5 Quality Committe

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

IdiPAZ maintains its goal, which is to become a reference centre for multidisciplinary translational biomedical research at national and european level. To achieve this objective, the institution combines its efforts to ensure the quality of all its processes, thus ensuring the provision of the best service, research and teaching.

IdiPAZ is committed to a comprehensive quality model backed by the maturity of the quality management teams of the IdiPAZ institutions. To support and facilitate quality, the institution maintains a Quality Committee.

During 2021, the Quality Committee fostered these principles but also achieved specific goals.

According to the on-going working quality plan the IdiPAZ management system has been maintained once more under the requirements of the ISO 9001:2015 and the UNE 166002:2014 and its scope has been expanded to 2 new platforms/units/committees (<https://www.aenor.com/certificacion/certificado/?codigo=170675>).

Moreover, specific training webinars were developed during the year by the Committee in order to strengthen the competence of IdiPAZ members in quality management, thus ensuring the sharing of best practices among them. These webinars are accessible at IdiPAZ website: <https://idipaz.es/PaginaDinamica.aspx?IdPag=20&Lang=ES>

Finally, considering that IdiPAZ is a continuously evolving organisation, the Quality activities of our institution have been enriched by the different achievements made by its member organizations.

The Hospital Universitario La Paz, despite the ongoing challenges of the COVID-19 pandemic, managed to develop and review several protocols, clinical pathways and clinical practice guidelines. The attached tables show the clinical pathways reviewed in 2021 as well as the protocols developed or updated in the same period. In addition, the staff members continuously collaborate in the improvement of the institution by participating in clinical committees and creating improvement groups, as well as implementing satisfaction surveys for patients and professionals. Also during 2021 hospital departments' quality management have consolidated in an overall management system according to the several national and international ISO standards. The hospital has also several recognitions within the Spanish National Accreditation System for Reference Units and the European Commission's European Reference Networks.

Protocol/Clinical pathway	Status
Abordaje de la Enfermedad Inflamatoria Intestinal de comienzo precoz	New
Actuación ante casos sospechosos o confirmados de gripe en adultos	Updated
Actuación ante casos sospechosos o confirmados de gripe/VRS	Updated
Actuación ante Infecciones de transmisión sexual	Updated
Actuación en la anemia del embarazo, el posparto y en la paciente ginecológica	Updated
Actuación en Urgencias ante un paciente pediátrico portador de trasplante renal	Updated
Actuación y atención en el tromboembolismo pulmonar	Updated
Alosensibilización en el trasplante cardíaco de adultos	New
Alteraciones palpebrales.	Updated
Analgesia epidural para el parto	Updated
Angioedema	New
Antiagregación y anticoagulación	Updated
Antibióticos en endoscopia	New
Atención a la patología completa de la aorta	New
Bacteriemia zero en paciente COVID	Updated
Biopsia hepática	Updated
Cambio de cánula sin sedación en pacientes con Esclerosis Lateral amiotrófica con Ventilación invasiva en domicilio.	Updated
Cáncer y embarazo	Updated
Cataratas congénitas e infantiles.	Updated
Citomegalovirus y embarazo	Updated
Claves para Uso Seguro de gases Medicinales	New
Código Sepsis.	Updated
Colitis isquémica	Updated
Controles analíticos ambulatorios para niños con trasplante renal	Updated
COVID: recomendaciones acompañantes	Updated
COVID: recomendaciones consultas y servicios centrales	Updated
COVID: recomendaciones manejo de pacientes de medicina preventiva	Updated
COVID: recomendaciones obstetricia y ginecología	Updated
COVID: recomendaciones pacientes pediátrico	Updated



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

COVID: recomendaciones pacientes quirúrgico	Updated
Cribado COVID para acompañantes de pacientes hospitalizados	New
Daratumumab: Preparación y análisis de eritrocitos tartados con Daraex	Updated
Derivación de pacientes en consulta anratesia	Updated
Desensibilización de pacientes en programa PATHI de trasplante renal	New
Detección y control de pacientes portadores de microorganismos multirresistentes de transmisión por contacto	Updated
Detección y manejo de muestras lipémicas y con posible contaminación por vía	New
Diabetes-II.	Updated
Diagnóstico ecográfico y manejo del crecimiento intrauterino restringido	Updated
Dilución Fármacos Inotrópicos	New
Dislipemia.	Updated
Divertículo de Zenker	New
ECMO neonatal	Updated
Elución método Elukitt	Updated
Endosponge	New
Enfermedad de Fabry	Updated
Enfermedad del viajero menos prevalentes.	Updated
Enfermedad tromboblógica venosa	Updated
Enfermedades tropicales más prevalentes.	Updated
Enteroscopia balón	New
Enteroscopia PowerSpiral	New
Esclerosis sistémica.	Updated
Esofagitis eosinofílica	Updated
Esófago de Barrett	Updated
Establecimiento de prueba de cribado de porfiria aguda intermitente	New
Estreñimiento crónico refractario	Updated
Estudio de discrepancias serohemáticas	Updated
Evaluación inicial de donante renal vivo de otro centro	New
Evaluación y manejo oftalmológico en pacientes con Stevens-Johnson/ Necroepidermólisis tóxica	New
Fatiga crónica.	Updated
Guía clínica manejo enfermedad tromboembólica venosa.	Updated
Guía clínica manejo insuficiencia cardíaca.	Updated
Guía clínica manejo neumonía.	Updated
Guía de práctica clínica de insuficiencia cardíaca	Updated
Guía de uso de antisépticos hospitalarios	New
Hemovigilancia	Updated
Identificación de Jeringas en Anestesia Pediátrica	New
Inclusión en lista de espera de trasplante renal	Updated
Infección en paciente inmunodeprimido.	Updated
Infección nosocomial.	Updated

Ingesta cáusticos	Updated
Inmunosupresión en pacientes con COVID19	New
Inmunosupresión inicial trasplante renal	Updated
Inmunoterapia oral en niños diagnosticados de alergia persistente a leche de vaca, estratificado por niveles de gravedad	New
Insuficiencia cardíaca comunitaria	Updated
Introducción del estudio del sedimento urinario en el laboratorio de urgencias	New
Limpieza de la Unidad de Aislamiento de Alto Nivel	Updated
Lupus eritematoso y embarazo	Updated
Lupus y síndrome Antifosfolípido.	Updated
Malignidad Cáncer colorrectal	New
Manejo anafilaxia en las consulta de vacunación	New
Manejo anestésico para trasplante pulmonar	Updated
Manejo de contactos de pacientes con tuberculosis	New
Manejo de la alergia a proteína de leche de vaca no IgE mediada	New
Manejo de la anemia en el niño con Enfermedad Inflamatoria Intestinal	New
Manejo de la hiperglucemia en el paciente hospitalizado	Updated
Manejo de los inmunomoduladores	New
Manejo de receptor de donante vivo ABO incompatible	New
Manejo de Vía Aérea Dificil	Updated
Manejo del cáncer de tiroides	Updated
Manejo del hipoparatiroidismo postiroidectomía	Updated
Manejo del suero heterólogo	Updated
Manual de administración de antiinfecciosos parenterales	New
Marcaje del Sitio Quirúrgico	New
Medidas de precaución de la transmisión de microorganismos en el ámbito hospitalario	New
Microftalmía y anoftalmía.	Updated
Monitorización de infección por CMV, VEB y poliomavirus en el trasplante renal pediátrico.	Updated
Obtención y envío de muestras en endoscopia	New
PAAF y biopsia hepática	New
Patología infección VIH.	Updated
Petición pruebas preoperatorias	Updated
pHmetría e impedanciometría	New
Plan de contingencia frente a la infección por Enterobacterias productoras de carbapenemasas	Updated
Plan integral de mejora de la atención sanitaria a los niños con trastorno del espectro autista en la unidad de urgencias pediátricas	New
Preacondicionamiento Farmacológico Preoperatorio en el Paciente Pediátrico con Disfunción Ventricular	New
Prescripción de opioides en dolor crónico en servicios de cirugía	Updated
Profilaxis de la enfermedad tromboembólica en pacientes quirúrgicos	Updated



1 Introduction


2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Profilaxis de osteoporosis en pacientes con trasplante renal	Updated
Profilaxis quirúrgica del recién nacido	Updated
Programa de recuperación intensificada en cirugía colorrectal	Updated
Prono en paciente COVID	Updated
Protocolo asistencial en Unidad de aislamiento de alto nivel.	Updated
Protocolo crioanalgesia para cirugía de Pectus Excavatum	New
Protocolo cuidados de orificio de catéter peritoneal	Updated
Protocolo de actuación del nefrólogo en el acto quirúrgico del trasplante renal	New
Protocolo de actuación frente a posible reacción medicamentosa en planta del Hospital Infantil La Paz	New
Protocolo de asistencia arterio-venosas/ECMO	Updated
Protocolo de atención al paciente hemofílico	New
Protocolo de atención en la Unidad de Urgencias Pediátricas a niños con enfermedades glomerulares complejas.	New
Protocolo de autoadministración de concentrado plasmático de C1INH para adultos	New
Protocolo de cáncer de mama	Updated
Protocolo de cardiopatía isquémica	Updated
Protocolo de derivación de pacientes	New
Protocolo de derivación de pacientes a consulta de disfagia infantil	New
Protocolo de donación cardiaca en asistolia controlada en el paciente pediátrico	New
Protocolo de estudio del candidato a donación renal para receptor pediátrico	Updated
Protocolo de exposición oral controlada a alimentos	New
Protocolo de gestión de la esterilización	New
Protocolo de infección de catéter central permanente en hemodiálisis	Updated
Protocolo de infección peritoneal	Updated
Protocolo de inmunosupresión en el primer trasplante renal de donante vivo y cadáver en pacientes de riesgo inmunológico estándar	Updated
Protocolo de inmunosupresión en el trasplante renal de pacientes de alto riesgo inmunológico	New
Protocolo de inmunosupresión en retrasplante renal	Updated
Protocolo de intoxicación por anestésicos locales	Updated
Protocolo de manejo anestésico en Cirugía Fetal	New
Protocolo de manejo de AEH-nC1INH	Updated
Protocolo de mejora del manejo de pacientes diabéticos hospitalizados	New
Protocolo de normotermia	Updated
Protocolo de preparación de fármacos	Updated
Protocolo de prevención de infección peritoneal	Updated
Protocolo de rechazo agudo celular	New
Protocolo de retirada rápida de esteroides en pacientes de bajo riesgo inmunológico	Updated
Protocolo de sumisión química	Updated

Protocolo de transición pacientes con enfermedades glomerulares complejas	New
Protocolo de trasplante cardíaco	Updated
Protocolo de trombolisis IV con tenecteplasa en el ictus isquémico agudo	New
Protocolo de violencia de género	Updated
Ptois palpebral.	New
Queratoplastias en niños.	Updated
Realización de endoscopias fuera de la Unidad (quirófano, REA/UCI, Infantil)	New
Recomendaciones para la administración de fármacos vía parenteral en el área de pediatría	Updated
Retinopatía diabética en niño	Updated
Sangrías a pacientes en unidades clínicas	Updated
Seguimiento pólipos con Atención Primaria	Updated
Síndrome metabólico	Updated
Stents en endoscopia	Updated
Técnicas de Depuración Extrarrenal	Updated
Test de Hoesch	New
Test de Octeótride	New
Test de péptido C postprandial	New
Transfusión pediátrica	Updated
Tratamiento antibiótico dirigido del recién nacido	Updated
Tratamiento antibiótico empírico del recién nacido	Updated
Tratamiento biológico en el asma	Updated
Tratamiento combinado renal-progenitores hematopoyéticos	New
Tratamiento con Rophylac intramuscular	Updated
Tratamiento de la rinosinusitis crónica con poliposis	New
Tratamiento farmacológico del Ductus arterioso persistente	Updated
Tratamiento rechazo humoral	Updated
Tromboembolismo pulmonar.	Updated
Tromboprofilaxis Pacientes ingresados y ambulantes.	Updated
Trombosis venosa profunda.	Updated
Trombosis venosa superficial.	Updated
Uso de dispositivos de asistencia ventricular de larga duración	Updated
Uso Seguro de Medicamentos en el Bloque Quirúrgico Hospital Infantil	New
Vacunación del paciente con asplenia	New
Vacunación del paciente con hepatopatía crónica	New
Vacunación del paciente con insuficiencia renal crónica	New
Vacunación del paciente con trasplante de progenitores hematopoyéticos	New
Vacunación del paciente con trasplante de órgano sólido	New
Vacunación del paciente con tratamiento inmunosupresor	New
Vasculitis necrotizantes sistémicas.	Updated
Vía clínica de Ictus	Updated
Vía clínica de neoplasias pulmonares	Updated



2.6 Clinical Trials

1 Introduction

In 2021, the number of active clinical trials was 3.711. The number of trials signed in this year was 444.

2 Executive Summary

Martín Arranz, MD. Estudio multicéntrico aleatorizado, doble ciego y controlado con placebo, con tratamiento de mantenimiento durante 52 semanas y una extensión abierta para evaluar la eficacia y la seguridad de Risankizumab en sujetos con Colitis ulcerosa que respondan al tratamiento de inducción en los estudios M16-067 o M16-065.

Type: Clinical Trials, phase III.

Hulp code: Appendix 2 5057 M16-066.

Sponsored by: Abbvie Deutschland GmbH.
Signed date: 25/01/2021

Abdel-Muti Garcia. Estudio prospectivo, aleatorizado, doble ciego, controlado con placebo y multicéntrico para investigar la eficacia y la seguridad de nt 201 en el tratamiento de la espasticidad de la extremidad inferior debido a un ictus o a un traumatismo craneoencefálico en sujetos adultos, seguido de una extensión abierta con o sin tratamiento combinado para la extremidad superior.

Type: Clinical Trials, phase III.

Hulp code: Appendix 1 5336 M602011014.

Sponsored by: Merz Pharmaceuticals GmbH.

Signed date: 12/01/2021

Alcobendas Rueda, RM. Estudio aleatorizado, con enmascaramiento doble y comparativo con un placebo, en el que se evalúan la eficacia, la seguridad y la retirada del tra-

tamiento con baricitinib por vía oral en pacientes con artritis idiopática juvenil de entre 1 y menos de 18 años.

Type: Clinical Trials, phase III.

Hulp code: Appendix 1 5387.

Sponsored by: Lilly, S.A.

Signed date: 21/05/2021

Alcolea Batres, S. Estudio aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y seguridad de ambrisentan en pacientes con COVID-19 severo.

Type: Clinical Trials, phase III.

Hulp code: 5806 N-003-CRD008.

Sponsored by: Noorik Biopharmaceuticals Ag.

Signed date: 05/03/2021

Alcolea Batres, S. Estudio en fase III, prospectivo, multicéntrico, doble ciego, con doble simulación, aleatorizado, controlado con fármaco activo, de grupos paralelos, de grupos secuenciales, adaptativo y basado en acontecimientos para comparar la eficacia, la seguridad y la tolerabilidad de macitentan 75 mg frente a macitentan 10 mg en pacientes con hipertensión arterial pulmonar, seguido de un periodo de tratamiento abierto con macitentan 75 mg.

Type: Clinical Trials, phase III.

Hulp code: Appendix 1 5546.

Sponsored by: Janssen-Cilag España, S.A.

Signed date: 21/05/2021

Alonso Melgar, A. Estudio prospectivo, aleatorizado, abierto, multicéntrico para evaluar los beneficios y riesgos de la conversión de receptores adolescentes de aloinjertoral existente desde 12 años hasta menos de 18 años de edad a un régimen inmunosupresor con belatacept en comparación con la continuación con un régimen con un inhibidor de la calcineurina y su cumplimiento con las medicaciones inmunosupresoras.

Type: Clinical Trials, phase III.

Hulp code: 5787 IM103-402.

Sponsored by: Bristol-Myers Squibb International Corporation (Bmsic).

Signed date: 22/04/2021

Alonso Menchen, D Administración precoz de dexametasona en pacientes hospitalizados por neumonía COVID-19 y alto riesgo de evolución a síndrome de distrés respiratorio agudo.

Type: Clinical Trials, phase III.

Hulp code: 5912 EARLY-DEX COVID 19.

Sponsored by: Fundación Hospital Infanta Leonor.

Signed date: 03/06/2021

Alvarez Escolá, C. Estudio aleatorizado y doble ciego para evaluar la eficacia y la seguridad de cabozantinib (xl184) con dosis de 60 mg/día en comparación con 140 mg/día en pacientes con cáncer medular de tiroides metastásico progresivo.

Type: Clinical Trials, phase IV.

Hulp code: Appendix 1 4351.

Sponsored by: Exelixis, Inc.

Signed date: 28/01/2021

Alvarez Escolá, C. Estudio observacional para la caracterización molecular del carcinoma de tiroides en la población española-proyecto molthy. (spanish observational study for molecular characterization of thyroid carcinoma-molthy project).

Type: Estudios, phase EPA-OD.

Hulp code: PI-4708 TTCC-2020-02.

Sponsored by: Grupo Español de Tratamiento de Tumores de Cabeza y Cuello.

Signed date: 19/04/2021

Álvarez Gallego, M. Resección de tumor rectal mediante dispositivo de acceso transanal multicanal uni-vec.

Type: Estudio Producto Sanitario.

Hulp code: 5774 VEC-PR-1901.

Sponsored by: Vecmedical Spain, S.L.

Signed date: 18/01/2021

Alvarez Gómez, T. Estudio de extensión abierto para investigar la seguridad, tolerabilidad y eficacia a largo plazo de rozozoneixumab en sujetos con trombocitopenia inmune primariapersistente o crónica.

Type: Clinical Trials, phase III.

Hulp code: 5622 TP0004.

Sponsored by: Ucb Biopharma Sprl.

Signed date: 05/03/2021

3 Information Groups by Area

4 Associated Clinicians



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Álvarez Maestro, Mario. Ensayo clínico de fase 3, aleatorizado y controlado con un comparador para estudiar la eficacia y la seguridad de pembrolizumab (mk-3475) en combinación con el bacilo de calmette-guérin (bcg) en participantes con cáncer de vejiga no músculo invasivo (cvnmi) de alto riesgo que es persistente o recurrente tras un tratamiento de inducción con bcg (key-note-676).

Type: Clinical Trials, phase III.
Hulp code: Appendix 1 5493.
Sponsored by: Merck Sharp & Dhome Corp.
Signed date: 17/03/2021

Álvarez Maestro, Mario. Alban: un ensayo de fase III, aleatorizado y abierto, que evalúa la eficacia del atezolizumab administrado de forma concomitante con instilaciones vesicales de bcg (bacilo de calmette-guérin) durante un año en pacientes con cáncer de vejiga sin invasión muscular con alto riesgo de recidiva y que no han sido tratados previamente con bcg.

Type: Clinical Trials, phase III.
Hulp code: 5730 UC 0160/1717 (AFU-GETUG 3).
Sponsored by: Unicancer.
Signed date: 04/06/2021

Álvarez Ortega, CA. Estudio no intervencionista sobre el tratamiento con edoxaban en la práctica clínica habitual para pacientes con fibrilación auricular no valvular. etna-af-europe.

Type: Estudios, phase EPA-SP.
Hulp code: Appendix 1 PI-2559.
Sponsored by: Daiichi-Sankyo Europe GmbH.
Signed date: 02/07/2021

Álvarez Román, MT. Estudio de fase I/II internacional, abierto y multicéntrico de la seguridad y del aumento de dosis de bax 888, un vector de virus adenoasociado de serotipo 8 (vaa8) que expresa un factor VIII

con el dominio b eliminado (b-domain deleted factor VIII, bdd-fvIII) en sujetos con hemofilia A grave administrado como infusión única por vía intravenosa.

Type: Clinical Trials, phase I.
Hulp code: Appendix 1 4930.
Sponsored by: Baxalta Innovations GmbH.
Signed date: 09/02/2021

Álvarez Román, MT. Estudio en fase II, multicéntrico, aleatorizado, doble ciego, controlado con placebo y de dosis paralelas para evaluar la eficacia y la seguridad de skio-703 oral, un inhibidor de quinasa syk, en pacientes con trombocitopenia inmunitaria (tpi) persistente y crónica.

Type: Clinical Trials, phase II.
Hulp code: Appendix 1 5320.
Sponsored by: Oscotec Inc.
Signed date: 10/02/2021

Álvarez Román, MT. Ha-safe: estudio observacional para evaluar la seguridad a largo plazo del tratamiento con damoctocog alfa pegol en práctica habitual en pacientes con hemofilia A tratados previamente.

Type: Estudios, phase EPA-LA.
Hulp code: PI-4627 BAY-DAM-2020-01.
Sponsored by: Bayer Hispania, S.L.
Signed date: 05/05/2021

Álvarez Román, MT. Estudio observacional prospectivo para evaluar la calidad de vida de pacientes con hemofilia A sin inhibidores (hemolife).

Type: Estudios, phase EPA-SP.
Hulp code: Appendix 1 PI-3814.
Sponsored by: Roche Farma, S.A.
Signed date: 11/03/2021

Álvarez Román, MT. Estudio abierto multicéntrico de fase III sobre la seguridad y eficacia a largo plazo del factor de coagulación recombinante intravenoso VIII fc-factor von willebrand-proteína de fusión xten (rfvIIIc-wvf-xten; bivv001) en pacientes previamente tratados con hemofilia A grave.

Type: Clinical Trials, phase III.

Hulp code: 5860 LTS16294.
Sponsored by: Sanofi Aventis S.A.
Signed date: 16/04/2021

Álvarez Román, MT. Experiencia ibérica con afstyla® entresujetos con hemofilia A: un estudio observacional retrospectivo.

Type: Estudios, phase EPA-OD.
Hulp code: PI-4742 CSL627-5004.
Sponsored by: Csl Behring Sa.
Signed date: 31/05/2021

Álvarez Román, MT. Estudio de fase I/II internacional, abierto y multicéntrico de la seguridad y del aumento de dosis de bax 888, un vector de virus adenoasociado de serotipo 8 (vaa8) que expresa un factor VIII con el dominio b eliminado (b-domain deleted factor VIII, bdd-fvIII) en sujetos con hemofilia A grave administrado como infusión única por vía intravenosa.

Type: Clinical Trials, phase I.
Hulp code: Appendix 2 4930.
Sponsored by: Baxalta Innovations GmbH.
Signed date: 23/07/2021

Álvarez Román, MT. Estudio prospectivo, multicéntrico, no intervencional de 24 meses para evaluar la efectividad de elocta en comparación con productos del factor convencional en el tratamiento profiláctico de pacientes con hemofilia A (a-sure).

Type: Estudios, phase EPA-SP.
Hulp code: Appendix 1 PI-2868.
Sponsored by: Swedish Orphan Biovitrum Ab.
Signed date: 25/10/2021

Álvarez Román, MT. Estudio de fase 3, multicéntrico, en doble ciego, aleatorizado y controlado con placebo, para evaluar la eficacia, seguridad y tolerabilidad de rozanolixizumab en adultos con trombocitopenia inmune primaria persistente o crónica.

Type: Clinical Trials, phase III.
Hulp code: 5623 TP0006.
Sponsored by: Ucb Biopharma Sprl.
Signed date: 26/01/2021

Álvarez-Sala Walther, R. Estudio fundamental de 52 semanas de duración, aleatorizado, doble ciego, controlado con placebo en grupos paralelos para evaluar la eficacia, seguridad y tolerabilidad de dupilumab en pacientes con enfermedad pulmonar obstructiva crónica (epoc) de moderada grave con inflamación tipo 2.

Type: Clinical Trials, phase III.
Hulp code: Appendix 1 5539.
Sponsored by: Sanofi-Aventis Recherche & Developpement.
Signed date: 16/07/2021

Amores Hernandez, I. Estudio aleatorizado con control activo para comparar la eficacia y la seguridad de isoflurano inhalado administrado mediante el dispositivo anaconda-s (dispositivo de conservación de anestésico) con midazolam intravenoso para la sedación en pacientes pediátricos con ventilación mecánica de entre 3 y 17 años (menos de 18 años).

Type: Clinical Trials, phase III.
Hulp code: 5607 SED002.
Sponsored by: Sedana Medical.
Signed date: 02/03/2021

Antorrena Miranda, MI. Ensayo de fase III, aleatorizado y doble ciego para evaluar la eficacia y la seguridad de una dosis diaria de 10 mg de empagliflozina en comparación con placebo en pacientes con insuficiencia cardíaca crónica con fracción de eyección preservada (icc-fep).

Type: Clinical Trials, phase III.
Hulp code: Appendix 2 4988.
Sponsored by: Boehringer Ingelheim International GmbH.
Signed date: 16/02/2021

Antorrena Miranda, MI. Ensayo en fase III, aleatorizado y doble ciego para evaluar la eficacia y la seguridad de una dosis diaria de 10 mg de empagliflozina en comparación con el placebo en pacientes con insuficiencia cardíaca crónica con fracción de eyección reducida (icc-fer).



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Type: Clinical Trials, phase III.
Hulp code: Appendix 2 5001.
Sponsored by: Boehringer Ingelheim International GmbH.
Signed date: 20/04/2021

Ares Segura, S. Estudio de fase 3, multicéntrico, aleatorizado, con enmascaramiento parcial y controlado con palivizumab para evaluar la seguridad, la eficacia y la farmacocinética de mk-1654 en lactantes y niños con un riesgo elevado de enfermedad grave por el vrs.

Type: Clinical Trials, phase III.
Hulp code: 5926 MK-1654-007.
Sponsored by: Merck Sharp And Dohme De España, S.A.
Signed date: 11/08/2021

Armada Romero, E. Perfil de ldl-c en pacientes con evento cardiovascular: un estudio multicéntrico retrospectivo en España. estudio heartbeat.

Type: Estudios, phase EPA-OD.
Hulp code: PI-4500 DAI-LDL-2020-01.
Sponsored by: Daiichi Sankyo España.
Signed date: 15/01/2021

Armada Romero, E. Estudio en fase III, aleatorizado, doble ciego y controlado con placebo para evaluar los efectos de dalce-trapib sobre el riesgo cardiovascular (cv) en una población definida genéticamente con síndrome coronario agudo reciente (sca): el ensayo dal-gene.

Type: Clinical Trials, phase III.
Hulp code: Appendix 2 4627.
Sponsored by: Dalcor Pharma Uk Ltd.
Signed date: 03/02/2021

Arribas López, JR. Estudio de fase III, aleatorizado, multicéntrico, con grupos paralelos y de ausencia de inferioridad para evaluar la eficacia, la seguridad y la tolerabilidad del cambio a dolutegravir más lamivudina en adultos infectados por el VIH 1 con supresión virológica.

Type: Clinical Trials, phase III.

Hulp code: Appendix 3 4885 204862.
Sponsored by: Viiv Healthcare Uk Limited.
Signed date: 01/02/2021

Arribas López, JR. Ensayo multicéntrico, adaptativo, randomizado, controlado ciego de seguridad y eficacia de terapias en investigación para pacientes hospitalizados con COVID-19.

Type: Clinical Trials, phase III.
Hulp code: 5669 INSIGHT.
Sponsored by: Regents Of The University Of Minnesota.
Signed date: 12/01/2021

Arribas López, JR. Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, para evaluar la eficacia y la seguridad de AD26.COVID-19 para la prevención de COVID-19 mediada por SARS-CoV-2 en adultos mayores de 18 años.

Type: Clinical Trials, phase III.
Hulp code: Appendix 1 5734 VAC31518COV3009.
Sponsored by: Janssen Cilag International Nv.
Signed date: 16/03/2021

Arribas López, JR. Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, para evaluar la eficacia y la seguridad de ad26.cov2.s para la prevención de COVID-19 mediada por SARS-CoV-2 en adultos mayores de 18 años.

Type: Clinical Trials, phase III.
Hulp code: Appendix 2 5734.
Sponsored by: Janssen Cilag International Nv.
Signed date: 07/04/2021

Arribas López, JR. Virologic outcomes of lamivudine/dolutegravir in virologically suppressed subjects with expected or confirmed resistance to lamivudine (volver study).

Type: Clinical Trials, phase II.
Hulp code: 5851 GESIDA 11820.
Sponsored by: Fundación Seimc-Gesida.
Signed date: 27/04/2021

Arribas López, JR. Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, para evaluar la eficacia y la seguridad de AD26.COVID-19 para la prevención de COVID-19 mediada por SARS-CoV-2 en adultos mayores de 18 años.

Type: Clinical Trials, phase III.
Hulp code: Appendix 3 5734.
Sponsored by: Janssen Cilag International Nv.
Signed date: 04/06/2021

Arribas López, JR. DTG / 3TC frente a BIC/FTC/TAF como terapia de mantenimiento en personas que viven con VIH: Ensayo clínico abierto y aleatorizado.

Type: Clinical Trials, phase IV.
Hulp code: 5799 GESIDA 11720.
Sponsored by: Fundación Seimc-Gesida.
Signed date: 08/06/2021

Arribas López, JR. European discovery for solidarity: an adaptive pandemic and emerging infection platform trial (eu-solidact): efficacy and safety of baricitinib for the treatment of severe COVID-19 (barisolidact).

Type: Clinical Trials, phase II.
Hulp code: 5896 EU-SolidAct.
Sponsored by: Hospital De Oslo.
Signed date: 19/07/2021

Arribas López, JR. Estudio internacional observacional para la caracterización de adultos hospitalizados por las complicaciones de la gripe a pandémica h1n1.

Type: Estudios No EPA.
Hulp code: Appendix 3 3045.
Sponsored by: Copenhagen Hiv Programme.
Signed date: 13/07/2021

Arribas López, JR. Un estudio de no inferioridad de fase IIb, doble ciego, aleatorizado, con control activo, multicéntrico, seguido de un estudio de fase III, de un solo brazo y abierto, para evaluar la inmunogenicidad y la seguridad de una vacuna de refuerzo con un candidato de proteína re-

combinante dimérica de fusión rbd (phh-1v) contra el SARS-CoV-2, en adultos completamente vacunados contra COVID-19.

Type: Clinical Trials, phase II.
Hulp code: 6016 HIPRA-HH-2.
Sponsored by: Hipra Scientific, S.L.U.
Signed date: 03/11/2021

Arribas López, JR. SARS-CoV-2 vaccination strategies in previously hospitalized and recovered COVID-19 patients (vatico).

Type: Clinical Trials, phase IV.
Hulp code: 5970 INSIGHT-016.
Sponsored by: Regents Of The University Of Minnesota.
Signed date: 23/11/2021

Arribas López, JR. Un ensayo clínico aleatorizado, doble ciego, de fase II, controlado con placebo, de un solo centro para evaluar la metformina en comparación con el placebo para la reversión del envejecimiento biológico acelerado en personas que viven con el VIH de 50 años o más y con replicación virológica suprimida.

Type: Clinical Trials, phase II.
Hulp code: 5971 METFORAGING.
Sponsored by: Fundación para la Investigación Biomedica Hospital Universitario La Paz.
Signed date: 02/11/2021

Asencio Duran, M. Estudio observacional retrospectivo multicéntrico para evaluar el impacto del retraso del tratamiento debido a la pandemia de COVID-19 en la agudeza visual de pacientes con degeneración macular asociada a la edad neovascular tratados con terapia anti-veg.

Type: Estudios, phase EPA-OD.
Hulp code: PI-4580 FCB-COVIDTIV-2020-01.
Sponsored by: Fundacio Clinic Per A La Recerca Biomedica.
Signed date: 02/02/2021

Asencio Duran, M. Estudio de fase III, aleatorizado, con comparador activo, con



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

doble enmascaramiento y con grupos paralelos para estudiar la eficacia y la seguridad de CT-P42 en comparación con Eylea en pacientes con edema macular diabético.

Type: Clinical Trials, phase III.
Hulp code: 5763 CT-P42 3.1.
Sponsored by: Academy-Ro Yeonsu-Gu.
Signed date: 09/02/2021

Asencio Duran, M. Proyecto hopes. mejora de la asistencia sanitaria en pacientes crónicos de oftalmología: dmae, emd, ovr y rd.

Type: Estudios, phase EPA-SP.
Hulp code: PI-4150 HOH-COR2020-1.
Sponsored by: Hoh Health Sl.
Signed date: 29/03/2021

Asencio Duran, M. Estudio prospectivo no aleatorizado multicentrico, sobre la eficacia y seguridad de iluvien en pacientes con edema macular diabético y con respuesta insuficiente a terapias disponibles.

Type: Clinical Trials, phase IV.
Hulp code: Appendix 1 4669.
Sponsored by: Ruiz Moreno, Jose Maria.
Signed date: 20/04/2021

Asencio Duran, M. Estudio en fase III, multicéntrico, doble ciego y aleatorizado para evaluar la eficacia y seguridad de opt-302 intravítreo en combinación con aflibercept, en comparación con aflibercept en monoterapia, en participantes con egneración macular asociada a la edad (dmae).

Type: Clinical Trials, phase III.
Hulp code: 5892 OPT-302-1005.
Sponsored by: Opthea Limited.
Signed date: 21/10/2021

Bajo Rubio, MA. Respuesta inmune y seguridad de la vacunación COVID-19 en pacientes con ERC avanzada, en diálisis y trasplantados renales.

Type: Estudios, phase EPA-OD.
Hulp code: PI-4709 SENCOVAC.
Sponsored by: Grupo Español De Estudio De La Nefropatía Diabética.
Signed date: 05/03/2021

Balsa Criado, A. Estudio fase 3, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de deucravacitinib en pacientes con artritis psoriásica activa naive a medicamentos biológicos antirreumáticos modificadores de la enfermedad.

Type: Clinical Trials, phase III.
Hulp code: 5895 IM011-054.
Sponsored by: Bristol-Myers Squibb International Corporation (Bmsic).
Signed date: 15/06/2021

Balsa Criado, A. Estudio aleatorizado, de comparación directa, simpleciego, para evaluar la respuesta al tratamiento con abatacept frente a adalimumab, ambos subcutáneos y con metotrexato de base, en adultos con artritis reumatoide precoz, seropositiva, que tienen alelos de riesgo de clase II del hla para el epitopo compartido y tienen una respuesta insuficiente a metotrexato.

Type: Clinical Trials, phase III.
Hulp code: 5919 IM101863.
Sponsored by: Bristol-Myers Squibb International Corporation (Bmsic).
Signed date: 01/07/2021

Balsa Criado, A. Estudio de fase III, aleatorizado, doble ciego, controlado con placebo para demostrar la eficacia y la seguridad de tildrakizumab en sujetos con artritis psoriásica activa i que habían recibido tratamiento previo con anti-tnf (inspire 1).

Type: Clinical Trials, phase III.
Hulp code: 5756 TILD-19-07.
Sponsored by: Sun Pharma Global Fze.
Signed date: 17/05/2021

Balsa Criado, A. Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo y de 5 años de duración que evalúa la eficacia, seguridad y tolerabilidad de distintas pautas posológicas de Ina043 por vía intraarticular frente a placebo en pacientes con osteoartritis de rodilla sintomática (onwards).

Type: Clinical Trials, phase II.

Hulp code: 5948 CLNA043A12202.
Sponsored by: Novartis Farmaceutica, S.A.
Signed date: 22/10/2021

Balsa Criado, A. Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la seguridad y la eficacia de upadacitinib en sujetos con arteritis de células gigantes.

Type: Clinical Trials, phase III.
Hulp code: 6046 M16-852.
Sponsored by: Abbvie Deutschland Gmbh.
Signed date: 09/12/2021

Balsa Criado, A. Eficacia y seguridad de SAR441344 para el tratamiento del lupus eritematoso sistémico: estudio aleatorizado, doble ciego, controlado con placebo, fase 2, prueba de concepto.

Type: Clinical Trials, phase II.
Hulp code: 6045 ACT17010.
Sponsored by: Sanofi Aventis S.A.
Signed date: 17/11/2021

Baltasar Tello, P. 4341 bo25323/cll14 patricia baltasar.

Type: Clinical Trials, phase III.
Hulp code: Appendix 2 4341.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 29/06/2021

Baltasar Tello, P. Estudio en fase III, abierto y aleatorizado, de loxo-305 en comparación con el tratamiento a elegir por el investigador entre idelalisib en combinación con rituximab o bendamustina en combinación con rituximab en la leucemia linfocítica crónica o linfoma linfocítico de células pequeñas, tratados previamente con inhibidores de la tirosina cinasa de bruton (btk, por sus siglas en inglés) (bruin cll-321).

Type: Clinical Trials, phase III.
Hulp code: 5939 LOXO-BTK-20020.
Sponsored by: Loxo Gmbh.
Signed date: 02/09/2021

Bartha Rasero, JL. Estudio fase 2/3 controlado con placebo, aleatorizado, cegado

para el observador, para evaluar la seguridad, la tolerabilidad y la inmunogenicidad de una vacuna candidata de arn (bnt162b2) del SARS-CoV-2, contra COVID-19 en mujeres embarazadas sanas de 18 años de edad y mayores.

Type: Clinical Trials, phase III.
Hulp code: 5822 C4591015.
Sponsored by: Pfizer, S.L.U.
Signed date: 06/04/2021

Bartha Rasero, JL. Estudio de fase III, doble ciego, aleatorizado y controlado con placebo para evaluar la seguridad, la reatogenicidad y la respuesta inmunitaria de una dosis intramuscular única de la vacuna materna contra el virus respiratorio sincitial (VRS) no potenciada en mujeres embarazadas de alto riesgo de 15 a 49 años y los lactantes nacidos de las madres vacunadas.

Type: Clinical Trials, phase III.
Hulp code: 5888B 214725 (RSV MAT-012).
Sponsored by: Glaxosmithkline, S.A.
Signed date: 03/06/2021

Bartha Rasero, JL. Optimización del manejo prenatal del manejo de las mujeres con amenaza de parto pretérmino mediante modelos de predicción: estudio clínico randomizado multicéntrico abierto (optimpl).

Type: Clinical Trials, phase III.
Hulp code: 5980 OPTIM-PTL.
Sponsored by: Fundacio Clinic Per A La Recerca Biomedica.
Signed date: 09/09/2021

Bartha Rasero, JL. Ensayo en fase III, aleatorizado, doble ciego o con enmascaramiento para el observador, controlado con placebo, para evaluar la eficacia y seguridad de una vacuna de subunidad f prefusión contra el virus respiratorio sincitial (vrs) en lactantes nacidos de mujeres vacunadas durante el embarazo.

Type: Clinical Trials, phase III.
Hulp code: Appendix 1 5526.
Sponsored by: Pfizer, S.L.U.



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Signed date: 25/10/2021

Berbel García, A. Estudio multicéntrico, transversal, nointervencional para evaluar la calidad de vida y el bienestar subjetivo en pacientes con enfermedad de alzheimer temprana (prodrómica y leve). Estudio ALZQOL.

Type: Estudios, phase EPA-OD.

Hulp code: PI-4579 ML42346/ROC-ALZ-2020-0.

Sponsored by: Roche Farma, S.A.

Signed date: 15/03/2021

Bernardino De La Serna, JI. Estudio clínico aleatorizado de fase 3 en participantes infectados por el vih-1 que han recibido varios tratamientos con anterioridad para evaluar la actividad antirretroviral del tratamiento enmascarado con islatravir (isl), doravirina (dor) y doravirina/islatravir (dor/isl), cada uno en comparación con un placebo, y la actividad antirretroviral, la seguridad y la tolerabilidad del tratamiento abierto con dor/isl.

Type: Clinical Trials, phase III.

Hulp code: Appendix 2 5532.

Sponsored by: Merck Sharp And Dohme De España, S.A.

Signed date: 29/04/2021

Bernardino De La Serna, JI. Estudio clínico aleatorizado de fase 3 en participantes infectados por el vih-1 que han recibido varios tratamientos con anterioridad para evaluar la actividad antirretroviral del tratamiento enmascarado con islatravir (isl), doravirina (dor) y doravirina/islatravir (dor/isl), cada uno en comparación con un placebo, y la actividad antirretroviral, la seguridad y la tolerabilidad del tratamiento abierto con dor/isl.

Type: Clinical Trials, phase III.

Hulp code: Appendix 3 5532.

Sponsored by: Merck Sharp And Dohme De España, S.A.

Signed date: 08/09/2021

Bonilla Hernán, MG. Evolucion del lupus eritematoso sistémico en españa.

Type: Estudios No EPA.

Hulp code: Appendix 2 PI-1909.

Sponsored by: Fundación Española De Reumatología.

Signed date: 25/02/2021

Borobia Pérez, A. Ensayo clínico de fase II, comparativo, aleatorizado, adaptativopara evaluar la seguridad e inmunogenicidad de una dosis decominarty@ en sujetos que hayan recibido una dosis devaxzeria.

Type: Clinical Trials, phase II.

Hulp code: 5859 CombiVacS.

Sponsored by: Instituto Salud Carlosiii.

Signed date: 15/04/2021

Borobia Pérez, A. Estudio de fase III, multinacional, observador ciego,aleatorizado, controlado con placebo para demostrar laeficacia de una dosis única de la vacuna en investigaciórsvpref3 oa de gsk en adultos de 60 años o más de edad.

Type: Clinical Trials, phase III.

Hulp code: 5775 212494 (RSV OA=ADJ-006.

Sponsored by: Glaxosmithkline, S.A.

Signed date: 20/05/2021

Borobia Pérez, A. Estudio de fase III, multinacional, observador ciego,aleatorizado, controlado con placebo para demostrar laeficacia de una dosis única de la vacuna en investigaciórsvpref3 oa de gsk en adultos de 60 años o más de edad.

Type: Clinical Trials, phase III.

Hulp code: Appendix 1 5775.

Sponsored by: Glaxosmithkline, S.A.

Signed date: 30/06/2021

Borobia Pérez, A. Estudio fase III, observador-ciego, aleatorizado, internacional para evaluar la consistencia de lotes de la vacuna candidata de gsk para inmunización materna frente al vrs, así como, la respuesta inmune, seguridad y reactogenicidad de esta vacuna candidata de gsk frente al vrs en coadministración con la vacuna tetravalente d-qiv de gsk frente a gripe, en mujeres sanas no embarazadas de 18 a 49 años de edad.

Type: Clinical Trials, phase III.

Hulp code: 5916 214709 (RSV MAT-010).

Sponsored by: Glaxosmithkline, S.A.

Signed date: 28/06/2021

Boto De Los Bueis, A. Registro de infecciones corneales asociadas al uso de lentes de contacto.

Type: Estudios No EPA.

Hulp code: PI-3949 REGINFECOR-LC.

Sponsored by: Sociedad Española De Oftalmología (Seo).

Signed date: 04/02/2021

Bueno Sanchez, D. Un estudio de fase III, abierto, de un solo grupo, multicéntrico de ravulizumab junto al mejor tratamiento sintomático en participantes pediátricos (de 1 mes a <18 años) con microangiopatía trombótica (mat) después de un trasplanta de células madre hematopoyéticas (tcmh).

Type: Clinical Trials, phase III.

Hulp code: 5653 ALXN1210-TMA-314.

Sponsored by: Alexion Pharmaceutical Inc.

Signed date: 09/02/2021

Bueno Sanchez, D. Estudio de fase 2b, abierto y de un solo grupo para evaluar la farmacocinética, la eficacia, la seguridad y la tolerabilidad de letermovir en participantes pediátricos desde el nacimiento hasta menos de 18 años con riesgo de sufrir infección y/o enfermedad por cmv después de un trasplante alogénico de células madre hematopoyéticas (tcmh).

Type: Clinical Trials, phase II.

Hulp code: Appendix 3 5199 MK-8228-030.

Sponsored by: Merck Sharp And Dohme De España, S.A.

Signed date: 26/03/2021

Bueno Sanchez, D. Un estudio de fase III, abierto, de un solo grupo, multicéntrico de ravulizumab junto al mejor tratamiento sintomático en participantes pediátricos (de 1 mes a <18 años) con microangiopatía trombótica (mat) después de un trasplanta de células madre hematopoyéticas (tcmh).

Type: Clinical Trials, phase III.

Hulp code: Appendix 1 5653.

Sponsored by: Alexion Pharmaceutical Inc.

Signed date: 25/11/2021

Bueno Sanchez, D. Estudio observacional retrospectivo de pacientes adultos y pediátricos con microangiopatía trombótica (mat) después de un trasplante de células madre hematopoyéticas (tcmh).

Type: Estudios No EPA.

Hulp code: PI-4902 ALX-TMA-501.

Sponsored by: Alexion Pharmaceutical Inc.

Signed date: 13/10/2021

Bueno Sanchez, D. Estudio de fase 2b, abierto y de un solo grupo para evaluar la farmacocinética, la eficacia, la seguridad y la tolerabilidad de letermovir en participantes pediátricos desde el nacimiento hasta menos de 18 años con riesgo de sufrir infección y/o enfermedad por cmv después de un trasplante alogénico de células madre hematopoyéticas (tcmh).

Type: Clinical Trials, phase II.

Hulp code: Appendix 4 5199 MK-8228-030.

Sponsored by: Merck Sharp And Dohme De España, S.A.

Signed date: 02/12/2021

Caballero Molina, MT. Estudio multicéntrico, prospectivo, nointervencionista de tres años de duración para evaluar laeficacia a largo plazo de lanadelumab en la práctica clínica(enable).

Type: Estudios, phase EPA-OD.

Hulp code: PI-4704 TAK-743(SHP643)-402.

Sponsored by: Takeda Development Center Americas.

Signed date: 28/04/2021

Caballero Molina, MT. Estudio abierto para evaluar la eficacia y la seguridad alargo plazo de lanadelumab para la prevención contra las crisisagudas de angioedema no histaminérgico con inhibidor de c1 (c1-inh) normal.



Type: Clinical Trials, phase III.
Hulp code: 5798 TAK-743-3001.
Sponsored by: Takeda Development Center Americas.
Signed date: 31/05/2021

Caballero Molina, MT. Estudio en fase III, multicéntrico, aleatorizado, controlado con placebo, doble ciego para evaluar la eficacia y la seguridad de lanadelumab para la prevención contra las crisis agudas de angioedema no histamínico con inhibidor de c1 (c1-inh) normal y angioedema adquirido (aea) debido a déficit de c1-inh.

Type: Clinical Trials, phase III.
Hulp code: Appendix 1 5550.
Sponsored by: Dyax Corp.
Signed date: 13/04/2021

Calvo Rey, C. La carga de la infección por vrs en niños pequeños europeos (estudio brice).

Type: Estudios No EPA.
Hulp code: PI-4484 BRICE.
Sponsored by: Julius Clinical Research.
Signed date: 01/03/2021

Calvo Rey, C. Estudio de fase III, doble ciego, aleatorizado y controlado con placebo para evaluar la seguridad, la reactividad y la respuesta inmunitaria de una dosis intramuscular única de la vacuna materna contra el virus respiratorio sincitial (vrs) no potenciada en mujeres embarazadas de alto riesgo de 15 a 49 años y los lactantes nacidos de las madres vacunadas.

Type: Clinical Trials, phase III.
Hulp code: 5888 214725 (RSV MAT-012).
Sponsored by: Glaxosmithkline, S.A.
Signed date: 03/06/2021

Calvo Rey, C. Estudio de fase II, aleatorizado, doble ciego, controlado con placebo y de 2 partes, para evaluar pautas de tratamiento de edp-938 en pacientes de 28 días a 24 meses de edad con infección por el virus respiratorio sincitial (vrs).

Type: Clinical Trials, phase II.

Hulp code: 5717 EDP938-201.
Sponsored by: Enanta Pharmaceuticals, Inc.
Signed date: 05/07/2021

Calvo Rey, C. Estudio en fase IIb abierto para evaluar la seguridad, tolerabilidad e inmunogenicidad de menabcwy en lactantes sanos de 2 y 6 meses.

Type: Clinical Trials, phase IIB.
Hulp code: Appendix 1 5716.
Sponsored by: Pfizer, S.L.U.
Signed date: 01/09/2021

Calvo Rey, C. Ensayo multicéntrico, abierto y con un solo grupo para evaluar la seguridad, la farmacocinética y la actividad antiviral de fostemsavir en combinación con un tratamiento de base optimizado (tbo) en niños y adolescentes infectados por el VIH-1 cuyo tratamiento antirretrovírico combinado (tarv) actual fracasa y que presentan resistencia a antirretrovíricos (arv) de doble o triple clase.

Type: Clinical Trials, phase II.
Hulp code: 5839 PENTA 22/Viiv 212968.
Sponsored by: Fondazione Penta Onlus.
Signed date: 10/08/2021

Canales Albendea, MA. Ensayo de fase Ib/II, abierto, para evaluar la seguridad y la eficacia preliminar de epcoritamab (gen3013; duobody® cd3xcd20) en combinación con otros fármacos en sujetos con linfoma no hodgkin de linfocitos b.

Type: Clinical Trials, phase IIB.
Hulp code: 5667 GCT3013-02.
Sponsored by: Genmab A/S.
Signed date: 19/04/2021

Canales Albendea, MA. Estudio adaptativo de biomarcadores de fase Ib/III, doble ciego, aleatorizado, controlado con principio activo, en 3 etapas de tazemetostat o placebo en combinación con lenalidomida más rituximab en pacientes con linfoma folicular recidivante/resistente al tratamiento.

Type: Clinical Trials, phase I.

Hulp code: Appendix 1 5671.
Sponsored by: Epizyme Inc.
Signed date: 04/03/2021

Canales Albendea, MA. Estudio en fase II, abierto y de dos cohortes debretuximab vedotina y chp (a+chp) en el tratamiento de primera línea de sujetos con linfoma de linfocitos t periféricos (lltp) con menos de un 10% de expresión.

Type: Clinical Trials, phase II.
Hulp code: 5689 SGN35-032.
Sponsored by: Seagen, Inc.
Signed date: 26/05/2021

Canales Albendea, MA. Estudio en fase III multicéntrico, aleatorizado, doble ciego, controlado con placebo y con comparador activo, debretuximab vedotina o placebo en combinación con lenalidomida y rituximab en pacientes con linfoma difuso de células b grandes (ldcbg) recidivante o resistente.

Type: Clinical Trials, phase III.
Hulp code: 5769 SGN35-031.
Sponsored by: Seagen, Inc.
Signed date: 04/06/2021

Canales Albendea, MA. Fase II aleatorizado de loncastuximab tesirina frente a idelalisib en pacientes con linfoma folicular recidivante o resistente (lotis 6).

Type: Clinical Trials, phase II.
Hulp code: 5770 ADCT-402-202.
Sponsored by: Adc Therapeutics Sa.
Signed date: 09/07/2021

Canales Albendea, MA. Estudio controlado de fase Ib/II, abierto, multicéntrico y aleatorizado para investigar la seguridad, tolerabilidad, farmacocinética y eficacia de mosunetuzumab (btct4465a) en combinación con chop o chp-polatuzumab vedotin en pacientes con linfoma no hodgkiniano de linfocitos b.

Type: Clinical Trials, phase I.
Hulp code: Appendix 1 5185.
Sponsored by: F.Hoffmann-La Roche Ltd.

Signed date: 28/07/2021

Canales Albendea, MA. Estudio de fase III aleatorizado, abierto, multicéntrico para evaluar la eficacia y la seguridad de mosunetuzumab combinado con lenalidomida en pacientes con linfoma folicular después de al menos una línea de tratamiento sistémico.

Type: Clinical Trials, phase III.
Hulp code: 5898 GO42909.
Sponsored by: Roche Farma, S.A.
Signed date: 09/09/2021

Canales Albendea, MA. Estudio en fase 3, aleatorizado, de loncastuximab tesirina en combinación con rituximab frente a inmunoterapia en pacientes con linfomadifuso de células b grandes (ldcbg) recidivante o resistente.

Type: Clinical Trials, phase III.
Hulp code: 5848 ADCT 402-311.
Sponsored by: Adc Therapeutics Sa.
Signed date: 02/09/2021

Canales Albendea, MA. Estudio de fase 2 de un solo brazo en monoterapia con tosilitato de valemestostat en sujetos con linfoma periférico de células t en recaída / refractario (valemestostat tosilitato [ds-3201b], un inhibidor dual del potenciador del homólogo zeste [ehz] 1/2 para el linfoma de linfocitos t periférico recidivante/resistente [lltp r/r].

Type: Clinical Trials, phase II.
Hulp code: 5877 DS3201-A-U202.
Sponsored by: Daiichi Sankyo Inc.
Signed date: 08/09/2021

Canales Albendea, MA. Estudio fase 1, multicéntrico, abierto para determinar la seguridad, farmacocinética y eficacia preliminar de una molécula pequeña, cc-99282, disponible para administración oral en monoterapia y en combinación con rituximab en sujetos con linfoma no hodgkin en recaída o refractario (lnh r/r).


Type: Clinical Trials, phase I.
Hulp code: 5852 CC-99282-NHL-001.

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Sponsored by: Celgene Corporation.
Signed date: 07/09/2021

Canales Albendea, MA. Estudio de fase I/II, modular, abierto y multicéntrico, para evaluar azd4573 en combinaciones novedosas con agentes antitumorales en pacientes con neoplasias malignas hematológicas en estadio avanzado.

Type: Clinical Trials, phase I.
Hulp code: 5878 D8230C00002.
Sponsored by: Astrazeneca Ab.
Signed date: 27/09/2021

Canales Albendea, MA. Estudio de fase II, modular, abierto y multicéntrico para evaluar la eficacia y la seguridad del capivasertib en pacientes con linfoma no hodgkin de células b en recidiva o refractario (capital).

Type: Clinical Trials, phase II.
Hulp code: 5880 D361FC00001.
Sponsored by: Astrazeneca Ab.
Signed date: 30/09/2021

Canales Albendea, MA. Estudio fase III abierto, prospectivo, para comparar Polatumumab Vedotin más Rituximab, Ifosfamida, Carboplatino Yetopósido (POLA-R-ICE) y Rituximab, Ifosfamida, Carboplatino Yetopósido (R-ICE) solo como terapia de rescate en pacientes con linfoma difuso de célula b grande (LDCBG) primariamente refractario en recaída.

Type: Clinical Trials, phase III.
Hulp code: 5790 MO40599/ GLA 2017-R2 (Pol).
Sponsored by: Gel-Tamo Grupo Cooperativo Español De Linfoma-Transplante Autonomo De Medula Osea Gel/Tamo.
Signed date: 12/05/2021

Carcas Sansuán, AJ. Four-year effectiveness of COVID-19 vaccines against severe disease and asymptomatic infection: the covidvac@spain study.

Type: Estudios, phase EPA-OD.
Hulp code: PI-4877 COVIDVAC@SPAIN.

Sponsored by: Fundación para la Investigación Biomedica Hospital Universitario La Paz.
Signed date: 08/10/2021

Carpio Segura, CJ. Estudio de fase 3, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia, la seguridad y latolerabilidad de brensocatib administrado una vez al día durante 52 semanas en sujetos con bronquiectasias sin fibrosis quística: estudio aspen.

Type: Clinical Trials, phase III.
Hulp code: 5731 INS 1007-301.
Sponsored by: Insmmed Incorporated.
Signed date: 16/03/2021

Carpio Segura, CJ. Estudio de fase 3, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia, la seguridad y latolerabilidad de brensocatib administrado una vez al día durante 52 semanas en sujetos con bronquiectasias sin fibrosis quística: estudio aspen.

Type: Clinical Trials, phase III.
Hulp code: Appendix 1 5731.
Sponsored by: Insmmed Incorporated.
Signed date: 07/07/2021

Carpio Segura, CJ. Estudio de fase 3, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia, la seguridad y latolerabilidad de brensocatib administrado una vez al día durante 52 semanas en sujetos con bronquiectasias sin fibrosis quística: estudio aspen.

Type: Clinical Trials, phase III.
Hulp code: Appendix 2 5731.
Sponsored by: Insmmed Incorporated.
Signed date: 18/10/2021

Castelo Fernandez, B. Ensayo clínico de fase II, multicéntrico, abierto y de un único brazo para evaluar la seguridad, tolerabilidad, farmacocinética y eficacia de cb-103 en combinación con un inhibidor de aromatasa no esteroideo (iane), anastrozol o letrozol, en pacientes con cáncer de mama

avanzado con receptor hormonal positivo y receptor del factor de crecimiento epidérmico humano 2 (her2) negativo que hayan obtenido beneficio clínico durante un tratamiento previo con un ianei.

Type: Clinical Trials, phase II.
Hulp code: 5691 CAILA (MedOPP319).
Sponsored by: Medica Scientia Innovation Research, S.L.
Signed date: 15/02/2021

Castelo Fernandez, B. Ensayo de fase II abierto, aleatorizado, de bnt113 en combinación con pembrolizumab frente a pembrolizumab en monoterapia como tratamiento de primera línea para pacientes con carcinoma de células escamosas de cabeza y cuello (CCECC) irreseccable, recurrente o metastásico, que es positivo para el genotipo 16 del virus del papiloma humano (VPH16+) y expresa PDL1.

Type: Clinical Trials, phase II.
Hulp code: 5739 BNT113-01.
Sponsored by: Biontech Rna Pharmaceuticals.
Signed date: 02/03/2021

Castelo Fernandez, B. Ensayo internacional fase III, randomizado, doble ciego, multicéntrico, de monalizumab o placebo en combinación con cetuximab en pacientes con carcinoma epidermoide de cabeza y cuello recurrente o metastásico tratado previamente con un inhibidor del punto de control inmunitario.

Type: Clinical Trials, phase III.
Hulp code: 5755 D7310C00001.
Sponsored by: Astrazeneca Farmaceutica Spain, S.A.
Signed date: 18/02/2021

Castelo Fernandez, B. Estudio de fase II, aleatorizado, de dos brazos de tratamiento de abemaciclib en combinación con terapia endocrina (letrozol y fulvestrant) con o sin un ciclo corto de quimioterapia de inducción con paclitaxel como tratamiento de

primera línea en pacientes con cancer de mama hr positivo/her2 negativo localmente avanzado e irreseccable o metastásico con criterios de enfermedad agresiva (abigail).

Type: Clinical Trials, phase II.
Hulp code: 5747 MedOPP321(ABIGAIL).
Sponsored by: Medica Scientia Innovation Research, S.L.
Signed date: 23/04/2021

Castelo Fernandez, B. Estudio en fase III, aleatorizado, doble ciego y controlado con placebo de debio 1143 en combinación con quimioterapia con un derivado del platino y radioterapia de intensidad modulada con fraccionamiento convencional en pacientes con carcinoma escamoso de cabeza y cuello localmente avanzado apto para quimiorradioterapia definitiva (trilynx).

Type: Clinical Trials, phase III.
Hulp code: Appendix 1 5602 Debio 1143-SCCHN.
Sponsored by: Debiopharm, S.A.
Signed date: 29/04/2021

Castelo Fernandez, B. Estudio en fase II de alx148 en combinación con pembrolizumab en pacientes con carcinoma de células escamosas de cabeza y cuello avanzado (aspen-03).

Type: Clinical Trials, phase II.
Hulp code: 5792 AT148003.
Sponsored by: Alx Oncology, Inc.
Signed date: 21/05/2021

Castelo Fernandez, B. Estudio en fase III de alx148 en combinación con pembrolizumab y quimioterapia en pacientes con carcinoma de células escamosas de cabeza y cuello avanzado (aspen-04).

Type: Clinical Trials, phase II.
Hulp code: 5793 AT148004.
Sponsored by: Alx Oncology, Inc.
Signed date: 10/06/2021

Castelo Fernandez, B. El estudio aim-hn y seq-hn: estudio pivotal no comparativo de



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

2 cohortes para evaluar la eficacia de tipifarnib en pacientes con carcinoma de células escamosas de cabeza y cuello (ccec) con mutaciones de hras (aim-hn) y el impacto de las mutaciones de hras en la respuesta a las terapias sistémicas de primera línea para el ccec (seq-hn).

Type: Clinical Trials, phase II.
Hulp code: Appendix 1 5187.
Sponsored by: Kura Oncology, Inc.
Signed date: 02/09/2021

Castelo Fernandez, B. Estudio buran sobre buparlisib (an2025) en combinación con paclitaxel frente a paclitaxel en monoterapia, para pacientes con carcinoma de células escamosas de cabeza y cuello recurrente o metastásico.

Type: Clinical Trials, phase III.
Hulp code: 5884 AN2025H0301.
Sponsored by: Adlai Nortye Usa, Inc.
Signed date: 16/09/2021

Castelo Fernandez, B. Estudio de fase 2 no aleatorizado, abierto, de múltiples cohortes, multicéntrico, para evaluar el beneficio clínico de sar444245 (thor-707) combinado con otras terapias anticancerígenas para el tratamiento de participantes con carcinoma de células escamosas de cabeza y cuello (ccec) (pegasus head and neck 204).

Type: Clinical Trials, phase II.
Hulp code: 6004 ACT16903.
Sponsored by: Sanofi Aventis S.A.
Signed date: 15/09/2021

Castelo Fernandez, B. Ensayo de fase 1b, abierto, con escalado de dosis, para determinar la seguridad y las respuestas inmunitarias dirigidas contra antígenos específicos provocadas por vb.10 neo en combinación con atezolizumab en sujetos con tumores localmente avanzados y metastásicos.

Type: Clinical Trials, phase I.
Hulp code: 5989 VBN-02.
Sponsored by: Vaccibody As.
Signed date: 29/11/2021

Castillo Grau, P. Assure: estudio abierto a largo plazo para evaluar la seguridad y la tolerabilidad de seladelpar en sujetos con colangitis biliar primaria (cbp).

Type: Clinical Trials, phase II.
Hulp code: 5752 CB8025-31731-RE.
Sponsored by: Cymabay Therapeutics, Inc.
Signed date: 25/03/2021

Castillo Grau, P. Estudio de fase 3, aleatorizado y controlado con placebo para evaluar la eficacia y la seguridad de seladelpar en pacientes con colangitis biliar primaria (CBP) y una respuesta insuficiente o intolerancia al ácido ursodesoxicólico.

Type: Clinical Trials, phase III.
Hulp code: 5751 CB8025-32048.
Sponsored by: Cymabay Therapeutics, Inc.
Signed date: 17/03/2021

Castillo Grau, P. Transform: ensayo clínico de fase IIb/III, adaptativo, doble ciego, aleatorizado, controlado con placebo y de 52 semanas de duración de setanaxib con una fase de extensión de 52 semanas en pacientes con colangitis biliar primaria (cbp) y rigidez hepática elevada.

Type: Clinical Trials, phase II.
Hulp code: 6015 GSN000350.
Sponsored by: Genkyotex Suisse Sa.
Signed date: 21/12/2021

Castro Conde, A. Comparación del efecto de tirzepatida frente al de dulaglutida sobre los acontecimientos cardiovasculares mayores en pacientes con diabetes de tipo 2 (surpass-cvot).

Type: Clinical Trials, phase I.
Hulp code: Appendix 1 5484.
Sponsored by: Lilly, S.A.
Signed date: 11/03/2021

Cebrian Carretero, JL. Ensayo clínico aleatorizado, doble ciego, controlado con placebo y con tratamiento activo, para evaluar la eficacia analgésica y la seguridad de una combinación oral de ibuprofeno (arginina)-tramadol hcl administrada a pa-

cientes con dolor moderado a severo tras someterse a cirugía dental.

Type: Clinical Trials, phase III.
Hulp code: 5961 FMLD-IOTRA2-47_FIII.
Sponsored by: Farmalider Sa.
Signed date: 18/10/2021

Custodio Carretero, AB. Ensayo internacional fase III, aleatorizado, doble-ciego, controlado con placebo y multicéntrico, de urvalumab administrado simultáneamente con terapia de quimiorradiación definitiva en pacientes con carcinoma esofágico de células escamosas inoperable, localmente avanzado.

Type: Clinical Trials, phase III.
Hulp code: 5760 D910SC00001.
Sponsored by: Astrazeneca Farmaceutica Spain, S.A.
Signed date: 05/02/2021

Custodio Carretero, AB. Wearables en pacientes con tumores neuroendocrinos gastroenteropancreáticos metastásicos. estudio netfit.

Type: Estudios No EPA.
Hulp code: PI-4592 NETFIT.
Sponsored by: Grupo Español De Tumores Neuroendocrinos Y Endocrinos.
Signed date: 12/02/2021

Custodio Carretero, AB. Estudio en fase III abierto, aleatorizado, multicéntrico, de 2 grupos de trastuzumab deruxtecán en sujetos con adenocarcinoma gástrico o de la unión gastroesofágica (uge) positivo para her2, metastásico y/o no resecable que han progresado durante o después de una pauta que contenía trastuzumab (destiny-gastric04).

Type: Clinical Trials, phase III.
Hulp code: 5847 DS8201-A-U306.
Sponsored by: Daiichi Sankyo Inc.
Signed date: 11/06/2021

Custodio Carretero, AB. Estudio para la validación clínica de un nuevo biomarcador para determinar la predisposición a infec-

ciones en pacientes con infarto agudo de miocardio.

Type: Estudios No EPA.
Hulp code: PI-4835 2020-01.
Sponsored by: Fundación Seom.
Signed date: 17/06/2021

Custodio Carretero, AB. Ensayo en fase 3 aleatorizado, multicéntrico, abierto, comparativo con tratamiento activo para evaluar la eficacia y seguridad de octreotida (cam2029) subcutánea de liberación prolongada frente a octreotida lp o lanreotida atg en pacientes con tumores neuroendocrinos gastroenteropancreáticos.

Type: Clinical Trials, phase III.
Hulp code: 5893 HS-19-657.
Sponsored by: Labcorp Development S.A.U. (Covance Clinical Development, S.A.)
Signed date: 09/08/2021

Custodio Carretero, AB. Ensayo clínico fase II de un único brazo para evaluar la eficacia preliminar de la combinación de 177ludotatato y nivolumab en tumores neuroendocrinos (tne) grado 3 bien diferenciados o carcinomas neuroendocrinos (cne) grado 3 mal diferenciados.

Type: Clinical Trials, phase II.
Hulp code: 5890 HMM008.
Sponsored by: Fundación De Investigación Hm Hospitales.
Signed date: 01/09/2021

Custodio Carretero, AB. Estudio de fase III, multicéntrico y aleatorizado de zanidatamab en combinación con quimioterapia, con o sin tislelizumab, en sujetos con adenocarcinoma gastroesofágico (age) irreseccable, localmente avanzado o metastásico, con her-2 positivo.

Type: Clinical Trials, phase III.
Hulp code: 5938 ZWI-ZW25-301.
Sponsored by: Zymeworks, Inc.
Signed date: 16/09/2021

Custodio Carretero, AB. Estado nutricional de los pacientes con tumor neuroendo-



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

crino gastroenteropancreático en española: nutrigetne.

Type: Estudios No EPA.

Hulp code: PI-4836 GETNE-S2109.

Sponsored by: Grupo Español De Tumores Neuroendocrinos Y Endocrinos.

Signed date: 15/09/2021

De Andres Ares, J. Estudio en fase 1b que investiga la seguridad, latolerabilidad y la eficacia de pp353 en el tratamiento de pacientes condolor lumbar crónico asociado a edema óseo en la placa terminal delcuerpo de la vértebra (modic 1).

Type: Clinical Trials, phase I.

Hulp code: 5871 Persica 002.

Sponsored by: Persica Pharmaceuticals Ltd.

Signed date: 19/07/2021

De Castro Carpeño, J. Estudio observacional para el seguimiento de la actividad de los pacientes con cáncer de pulmón y evaluar su estado funcional mediante dispositivos móviles. LUPA-01.

Type: Estudios No EPA.

Hulp code: 5777 ML42283 ROC-CPN-2020-01.

Sponsored by: Roche Farma, S.A.

Signed date: 20/01/2021

De Castro Carpeño, J. Comparación de la eficacia entre Cobolimab + Dostarlimab + Docetaxel y Dostarlimab + Docetaxel y Docetaxel en monoterapia en participantes con cáncer de pulmón no microcítico avanzado que hayan progresado al tratamiento previo con anti-PD (I) 1 y Quimioterapia.

Type: Clinical Trials, phase II.

Hulp code: 5743 213410.

Sponsored by: Glaxosmithkline, S.A.

Signed date: 19/01/2021

De Castro Carpeño, J. Ensayo clínico plataforma en fase II de inmunooncología de precisión con indicación tumor agnóstica pararamutaciones somáticas específicas (tapistry).

Type: Clinical Trials, phase II.

Hulp code: 5657 BO41932.

Sponsored by: F.Hoffmann-La Roche Ltd.

Signed date: 27/01/2021

De Castro Carpeño, J. Assessment of early resistance mechanisms to first-line osimertinib in egfr-mutant non-small-cell lung cancer (nslc) using spatial transcriptomics.

Type: Estudios, phase EPA-OD.

Hulp code: PI-4620 ESR-20-20709.

Sponsored by: Fundación Oncosur.

Signed date: 11/02/2021

De Castro Carpeño, J. Estudio en paraguas de fase Ib/II, sin enmascaramiento, multicéntrico y aleatorizado para evaluar la eficacia y la seguridad de combinaciones de tratamientos basados en múltiples inmunoterapias en pacientes con carcinoma de pulmón no microcítico metastásico (morphus pulmonar).

Type: Clinical Trials, phase I.

Hulp code: Appendix 1 5591.

Sponsored by: Genentech Inc.

Signed date: 16/02/2021

De Castro Carpeño, J. Estudio internacional multicéntrico de fase III, aleatorizado, doble ciego, controlado con placebo, de medi4736 como tratamiento secuencial en pacientes con cáncer pulmonar de células no pequeñas, localmente avanzado, no resecable (estadio III) que no han progresado después de la terapia de quimiorradiación concurrente definitiva con base de platino (pacific).

Type: Clinical Trials, phase III.

Hulp code: Appendix 2 4235.

Sponsored by: Astrazeneca Ab.

Signed date: 27/04/2021

De Castro Carpeño, J. Ensayo fase III, randomizado, doble ciego, controlado con placebo, multicéntrico, internacional con osimertinib como tratamiento de mantenimiento en pacientes con cáncer de pulmón no microcítico (estadio III) localmente avanzado e irreseccable, con mutación de egfr positiva, cuya enfermedad no ha pro-

gresado después de tratamiento definitivo con quimiorradioterapia basada en platino (laura).

Type: Clinical Trials, phase III.

Hulp code: Appendix 1 5104.

Sponsored by: Astrazeneca Farmaceutica Spain, S.A.

Signed date: 26/04/2021

De Castro Carpeño, J. Estudio en fase II, abierto y de un solo grupo deberzosertib (m6620) en combinación con topotecán en participantes concarcinoma microcítico de pulmón recidivante y resistente al platino.

Type: Clinical Trials, phase II.

Hulp code: 5811 MS201923_0050.

Sponsored by: Merck Healthcare Kga.

Signed date: 26/03/2021

De Castro Carpeño, J. Estudio cesto, abierto, multicéntrico, global, en fase II con entrectinib para el tratamiento de pacientes con tumores sólidos localmente avanzados o metastásicos que albergan reordenaciones en los genes ntrk1/2/3, ros1 o alk.

Type: Clinical Trials, phase II.

Hulp code: Appendix 4 4648.

Sponsored by: F.Hoffmann-La Roche Ltd.

Signed date: 18/03/2021

De Castro Carpeño, J. Estudio en fase II, aleatorizado, doble ciego derelatlimab más nivolumab en combinación con quimioterapia frente anivolumab en combinación con quimioterapia como tratamiento deprimera línea para los participantes con cáncer de pulmón de célulasno pequeñas (cpcnp) en estadio iv o recurrente.

Type: Clinical Trials, phase II.

Hulp code: 5809 CA224104.

Sponsored by: Bristol-Myers Squibb International Corporation (Bmsic).

Signed date: 26/04/2021

De Castro Carpeño, J. Estudio multicéntrico, abierto y de un solo grupo, del perfil molecular de pacientes con cáncer de pulmón no microcítico con mutación del EGFR,

localmente avanzado o metastásico, tratados con Osimertinib.

Type: Clinical Trials, phase II.

Hulp code: Appendix 1 4929.

Sponsored by: Astrazeneca Ab.

Signed date: 27/05/2021

De Castro Carpeño, J. Estudio fase 3, aleatorizado, abierto, para comparar nivolumab más quimiorradioterapia concurrente (qrtc) seguidos por nivolumab más ipilimumab o nivolumab más qrtc seguidos por nivolumab frente a qrtc seguida por durvalumab en el cáncer de pulmón no microcítico localmente avanzado (cpnm la) no tratado previamente.

Type: Clinical Trials, phase III.

Hulp code: Appendix 1 5403.

Sponsored by: Bristol-Myers Squibb International Corporation (Bmsic).

Signed date: 22/06/2021

De Castro Carpeño, J. Estudio de fase II multicéntrico, abierto y con un únicogrupo de tratamiento para evaluar la eficacia y la seguridad de lacombinación de pembrolizumab y lenvatinib en pacientes concarcinoma tímico previamente tratado. pecati.

Type: Clinical Trials, phase II.

Hulp code: 5801 MedOPP341.

Sponsored by: Medica Scientia Innovation Research, S.L.

Signed date: 22/06/2021

De Castro Carpeño, J. Protocolo de acceso ampliado de amg 510 (dci, sotorasib) multicéntrico, abierto y de un solo grupo para el tratamiento desujetos en determinados países europeos con cáncer de pulmón nomicrocítico localmente avanzado e irreseccable o metastásicotratado previamente con la mutación p.g12c en el kras.

Type: Clinical Trials, phase III.

Hulp code: 5881 20190442.

Sponsored by: Amgen, S.A.

Signed date: 01/06/2021

De Castro Carpeño, J. Estudio de fase 3, abierto y aleatorizado para investigarla



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

farmacocinética y la seguridad de pembrolizumab subcutáneo en comparación con pembrolizumab intravenoso, administrado con quimioterapia doble a base de platino, en el tratamiento de primaralínea de participantes con cáncer de pulmón no microcítico epidermoide o no epidermoide metastásico.

Type: Clinical Trials, phase III.
Hulp code: 5857 MK-3475-A86.
Sponsored by: Merck Sharp And Dohme De España, S.A.
Signed date: 18/06/2021

De Castro Carpeño, J. Estudio observacional para describir las características genotípicas y las mutaciones de resistencia en el nsclc alk+.

Type: Estudios No EPA.
Hulp code: PI-4854 ALK-PATHFINDER.
Sponsored by: Fundación Oncosur.
Signed date: 05/07/2021

De Castro Carpeño, J. Estudio de fase 1 para evaluar la seguridad, tolerabilidad y farmacocinética de amg 757 en sujetos con cáncer de pulmón microcítico.

Type: Clinical Trials, phase I.
Hulp code: 5900 20160323.
Sponsored by: Amgen, S.A.
Signed date: 04/08/2021

De Castro Carpeño, J. Estudio de fase 3 abierto, aleatorizado y multicéntrico para comparar la eficacia de tak-788 como tratamiento de primera línea frente a quimioterapia a base de platino en pacientes con cáncer de pulmón no microcítico con mutaciones de egfr por inserción en el exón 20.

Type: Clinical Trials, phase III.
Hulp code: Appendix 1 5454.
Sponsored by: Millennium Pharmaceuticals Inc.
Signed date: 19/07/2021

De Castro Carpeño, J. Ensayo clínico plataforma en fase II de inmunooncología de precisión con indicación tumor agnóstica

paramutaciones somáticas específicas (tapistry).

Type: Clinical Trials, phase II.
Hulp code: Appendix 1 5657.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 02/09/2021

De Castro Carpeño, J. Estudio de fase III aleatorizado y doble ciego de bgba1217, un anticuerpo anti-tigit, en combinación con tislelizumab frente a pembrolizumab en pacientes con cáncer de pulmón no microcítico irreseccable o metastásico no tratado previamente, con expresión de pd-l1 y localmente avanzado.

Type: Clinical Trials, phase III.
Hulp code: 5901 BGB-A317-A1217-302.
Sponsored by: Beigene USA, Inc.
Signed date: 05/08/2021

De Castro Carpeño, J. Ensayo de fase 2 no aleatorizado, abierto, de múltiples cohortes, multicéntrico, para evaluar el beneficio clínico de sar444245(thor-707) combinado con otras terapias anticancerígenas para el tratamiento de participantes con cáncer de pulmón o mesotelioma pleural.

Type: Clinical Trials, phase II.
Hulp code: 5889 ACT16849.
Sponsored by: Sanofi Aventis S.A.
Signed date: 18/06/2021

De Castro Carpeño, J. Estudio en fase III abierto y aleatorizado del tratamiento combinado de amivantamab y lazertinib con quimioterapia basada en platino en comparación con quimioterapia basada en platino en pacientes con cáncer de pulmón no microcítico con mutación del egfr localmente avanzado o metastásico tras el fracaso de osimertinib.

Type: Clinical Trials, phase III.
Hulp code: 5945 61186372NSC3002(MARIPOSA).
Sponsored by: Janssen Cilag International Nv.
Signed date: 16/09/2021

De Castro Carpeño, J. Estudio de fase 2, abierto y multicéntrico de la seguridad y la eficacia de krt-232 en sujetos con cáncer de pulmón microcítico (cpm) recidivante o resistente.

Type: Clinical Trials, phase II.
Hulp code: 5986 KRT-232-112.
Sponsored by: Kartos Therapeutics Inc.
Signed date: 14/10/2021

De Castro Carpeño, J. Estudio fase 3 abierto y aleatorizado de la combinación de la terapia amivantamab y carboplatino-pemetrexed, frente a carboplatino-pemetrexed, en pacientes con cáncer de pulmón no microcítico localmente avanzado o metastásico con egfr mutado por inserciones en el exón 20.

Type: Clinical Trials, phase III.
Hulp code: Appendix 1 5652.
Sponsored by: Janssen Cilag International Nv.
Signed date: 20/10/2021

De Castro Carpeño, J. Estudio aleatorizado de fase III de sitravatinib en combinación con nivolumab frente a docetaxel en pacientes con cáncer de pulmón no microcítico no escamoso avanzado con progresión de la enfermedad durante o después de la quimioterapia con platino y el tratamiento con inhibidor de punto de control (sapphire).

Type: Clinical Trials, phase III.
Hulp code: Appendix 1 5556.
Sponsored by: Mirati Therapeutics, Inc.
Signed date: 30/09/2021

De Castro Carpeño, J. Ensayo de plataforma de fase 2 basado en biomarcadores en pacientes con cáncer de pulmón no microcítico avanzado cuya enfermedad ha progresado durante el tratamiento con osimertinib en primera línea (orchard).

Type: Clinical Trials, phase II.
Hulp code: Appendix 2 5345.
Sponsored by: Astrazeneca Farmaceutica Spain, S.A.

Signed date: 18/10/2021

De Castro Carpeño, J. Estudio multicéntrico de fase 3, aleatorizado, doble ciego, controlado con placebo, para comparar niraparib añadido a pembrolizumab versus placebo añadido a pembrolizumab como terapia de mantenimiento en participantes cuya enfermedad se haya mantenido estable o haya respondido a una primera línea de quimioterapia basada en platino y pembrolizumab en cáncer de pulmón no microcítico estadio IIIb o iv.

Type: Clinical Trials, phase III.
Hulp code: Appendix 1 5665.
Sponsored by: Glaxosmithkline, S.A.
Signed date: 19/07/2021


De Castro Carpeño, J. Estudio abierto, multicéntrico y global para evaluar la eficacia y la seguridad a largo plazo en pacientes que están recibiendo o que han recibido previamente durvalumab en otros protocolos (wave).

Type: Clinical Trials, phase IV.
Hulp code: Appendix 1 5419.
Sponsored by: Astrazeneca Ab.
Signed date: 07/09/2021

De Castro Carpeño, J. Estudio de fase 2, multicéntrico y abierto de sotorasib (amg 510) en sujetos con cpm en estadio iv cuyos tumores presentan mutación del kras-g12c que requieren tratamiento de primera línea (codebreak 201).

Type: Clinical Trials, phase II.
Hulp code: 5924 20190288.
Sponsored by: Amgen, S.A.
Signed date: 26/10/2021

De Castro Carpeño, J. La efectividad del tratamiento antineoplásico sistémico actual en el mundo real en pacientes con carcinoma pulmonar no microcítico (cpnm) avanzado/metastásico con la mutación ex20ins en el receptor del factor de crecimiento epidérmico (es decir, cohorte de control externa); comparación ajustada entre los resulta-



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

dos del mundo real en la cohorte de control externa y los resultados de amivantamab en el ensayo chrysalis.

Type: Estudios, phase EPA-OD.
Hulp code: PI-4921 61186372LUC4002.
Sponsored by: Janssen Pharmaceutica Nv.
Signed date: 11/11/2021

De Lucas Laguna, R. Estudio fase 3, multicéntrico, aleatorizado, doble ciego, controlado con placebo, para evaluar la farmacocinética, la eficacia y la seguridad de bms-986165 en sujetos adolescentes con psoriasis en placas moderada a grave.

Type: Clinical Trials, phase III.
Hulp code: 5803 IM011-126.
Sponsored by: Bristol-Myers Squibb International Corporation (Bmsic).
Signed date: 05/03/2021

De Lucas Laguna, R. Estudio de fase 3, multicéntrico, aleatorizado, comparativo con placebo, con enmascaramiento doble y grupos paralelos, en el que se evalúa la farmacocinética, la eficacia y la seguridad de baricitinib en niños enfermos ambulatorios con dermatitis atópica moderada o grave.

Type: Clinical Trials, phase III.
Hulp code: Appendix 1 5215.
Sponsored by: Lilly, S.A.
Signed date: 27/04/2021

De Lucas Laguna, R. Estudio de fase III, aleatorizado, controlado con placebo y con doble enmascaramiento para evaluar upadacitinib en combinación con corticosteroides tópicos en adolescentes y adultos con dermatitis atópica moderada o grave.

Type: Clinical Trials, phase III.
Hulp code: Appendix 2 5145.
Sponsored by: Abbvie Deutschland Gmbh.
Signed date: 06/05/2021

De Maria Pallares, P. Ensayo clínico doble ciego, controlado con placebo, sobre la eficacia de la ablación antirreflujo de la mucosa del cardias para el tratamiento de la enfermedad por reflujo gastroesofágico.

Type: Estudio Producto Sanitario.
Hulp code: 5828 ECA-HRC-ARMA.
Sponsored by: Fundación Hospital Ramon Y Cajal.
Signed date: 19/05/2021

De Miguel Mendieta, E. Evaluación ecográfica de pacientes con gota que cumplen criterios preliminares de remisión.

Type: Estudios, phase EPA-OD.
Hulp code: PI-4482 MAC-COL-2020-01.
Sponsored by: Andres Collado, Mariano.
Signed date: 09/02/2021

De Paz Arias, R. Ensayo multicéntrico, abierto, de fase Ib/II para evaluar la seguridad y la eficacia de la combinación de bosutinib más atezolizumab en pacientes con leucemia mieloide crónica recién diagnosticada.

Type: Clinical Trials, phase II.
Hulp code: 5715 ZEROLMC-01.
Sponsored by: Fundación Española Para La Curación De La Leucemia Mieloide Crónica.
Signed date: 19/01/2021

De Paz Arias, R. Estudio de fase 1b/2, abierto y multicéntrico para evaluar la seguridad y la eficacia de krt 232 combinado con un inhibidor de la tirosina cinasa (itc) en pacientes con leucemia mieloide crónica (lmc) ph+ recidivante o resistente.

Type: Clinical Trials, phase II.
Hulp code: 5772 KRT-232-117.
Sponsored by: Kartos Therapeutics Inc.
Signed date: 02/02/2021

De Paz Arias, R. Estudio fase III aleatorizado, doble ciego y controlado con placebo de sy1425 más azacitidina en comparación con placebo más azacitidina, en pacientes adultos con reciente diagnóstico de síndrome mielodisplásico de alto riesgo y positivo para rara.

Type: Clinical Trials, phase III.
Hulp code: 5818 SY-1425-301.
Sponsored by: Syros Pharmaceuticals Inc.
Signed date: 07/05/2021

De Paz Arias, R. Enhance: estudio multicéntrico, doble ciego y aleatorizado para comparar magrolimab en combinación con azacitidina frente a azacitidina más placebo en pacientes con síndrome mielodisplásico de alto riesgo sin tratamiento previo.

Type: Clinical Trials, phase III.
Hulp code: 5930 5F9009.
Sponsored by: Gilead Sciences, S.L.
Signed date: 05/07/2021

De Paz Arias, R. Estudio de fase III, multicéntrico, aleatorizado y abierto de asciminib oral frente a un inhibidor de la tirosina quinasa seleccionado por el investigador en pacientes con leucemia mieloide crónica cromosoma filadelfia positivo en fase crónica de nuevo diagnóstico.

Type: Clinical Trials, phase III.
Hulp code: 5967 CABL001J12301.
Sponsored by: Novartis Farmaceutica, S.A.
Signed date: 27/09/2021

Díaz De Terán Velasco, FJ. Estudio de fase 3 multicéntrico, aleatorizado, doble ciego y controlado con placebo de botox (toxina botulínica tipo a) para prevención de migraña en pacientes con migraña episódica.

Type: Clinical Trials, phase III.
Hulp code: 5977 M21-307.
Sponsored by: Abbvie Deutschland Gmbh & Co. Kg.
Signed date: 26/10/2021

Díaz Pollán, B. Ensayo clínico multicéntrico, fase III, aleatorizado, doble ciego para evaluar la eficacia y seguridad de vancomicina oral versus placebo en la prevención de la recidiva de la infección por clostridioides difficile en pacientes que reciben antibioterapia sistémica. (estudio prevan-icd).

Type: Clinical Trials, phase III.
Hulp code: 5525 PREVAN.
Sponsored by: Origüen Sabater, Julia.
Signed date: 17/08/2021

Díez Tejedor, E. Estudio intervencional prospectivo, aleatorizado, multicéntrico in-

ternacional, controlado con tratamiento activo y de 12 meses de duración, en el que se compara el beneficio mantenido de dos paradigmas de tratamiento (erenumab en administración mensual frente a tratamiento profiláctico por vía oral) en pacientes adultos con migraña episódica.

Type: Clinical Trials, phase IV.
Hulp code: Appendix 1 5263.
Sponsored by: Novartis Farmaceutica, S.A.
Signed date: 09/02/2021

Díez Tejedor, E. Estudio multicéntrico, abierto, controlado con placebo externo y de fase III para evaluar la eficacia y la seguridad de ravulizumab en pacientes adultos con trastorno del espectro de neuromielitis óptica (nmosd).

Type: Clinical Trials, phase III.
Hulp code: Appendix 1 5463.
Sponsored by: Alexion Pharmaceutical Inc.
Signed date: 21/05/2021

Dominguez Gadea, L. Evaluación de la captación cardiaca incidental en la gammagrafía ósea.


Type: Estudios No EPA.
Hulp code: PI-4712 B3461086.
Sponsored by: Pfizer, S.L.U.
Signed date: 06/05/2021

Domínguez Ortega, FJ. Prime. estudio observacional prospectivo multicéntrico en varios países sobre patrones de atención de pacientes asmáticos leves.

Type: Estudios, phase EPA-SP.
Hulp code: PI-4591 CHI-SAL-2020-01.
Sponsored by: Chiesi Farmaceutici S.P.A.
Signed date: 20/05/2021

Domínguez Ortega, FJ. Identificación de biomarcadores inmunológicos en pacientes alérgicos.

Type: Estudios No EPA.
Hulp code: PI-4583 LET-INM-2020.
Sponsored by: Laboratorios Leti, S.L.
Signed date: 04/06/2021



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Domínguez Ortega, FJ. Estudio de validación transversal de las versiones adaptadas localmente del cuestionario sobre el deterioro y el riesgo del asma (airq) como herramienta que identifica a pacientes con asma en riesgo de resultados adversos por asma no controlada en Alemania y España.

Type: Estudios, fase EPA-SP.
Hulp code: PI-4846 AIRQ.
Sponsored by: Astrazeneca Farmaceutica Spain, S.A.
Signed date: 20/09/2021

Domínguez Ortega, FJ. Pilot study for validation of the consensus protocol developed by scientific societies (semas, separ, and seaic) in real-life conditions in two Spanish hospitals: the asmanet project.

Type: Estudios No EPA.
Hulp code: PI-5056 ESR-20-20897.
Sponsored by: Instituto De Estudios Ciencias Salud Castilla Instituto De Estudios Ciencias.
Signed date: 22/12/2021

Domínguez Ortega, FJ. Pilot study for validation of the consensus protocol developed by scientific societies (semas, separ, and seaic) in real-life conditions in two Spanish hospitals: the asmanet project.

Type: Estudios No EPA.
Hulp code: PI-5056 ASMANET-ESR-20-2089.
Sponsored by: Instituto De Estudios Ciencias Salud Castilla Instituto De Estudios Ciencias.
Signed date: 22/12/2021

Escobar Cervantes, C. Estudio epidemiológico multinacional transversal de pacientes hipertensos con dislipemia y resultados proporcionados por el paciente.

Type: Estudios, fase EPA-OD.
Hulp code: PI-4893B SNAPSHOT.
Sponsored by: Laboratorios Servier, S.L.
Signed date: 19/10/2021

Espinosa Arranz, E. Estudio observacional descriptivo sobre las características y

evolución del melanoma avanzado y metastásico en España.

Type: Estudios, fase EPA-SP.
Hulp code: Appendix 2 PI-3208.
Sponsored by: Grupo Español Multidisciplinar De Melanoma Gem.
Signed date: 31/03/2021

Espinosa Arranz, E. Encorafenib plus binimetinib in patients with locally advanced, unresectable or metastatic BRAF V600-mutated melanoma treated in real life in Spain: a multi-centric, retrospective and non-interventional study.

Type: Estudios, fase EPA-OD.
Hulp code: PI-4755 GEM-2002.
Sponsored by: Grupo Español Multidisciplinar De Melanoma Gem.
Signed date: 13/03/2021

Espinosa Arranz, E. Multicentric phase II clinical trial to evaluate the activity of encorafenib and binimetinib before local treatment in patients with BRAF mutated melanoma with metastasis to the brain.

Type: Clinical Trials, phase II.
Hulp code: Appendix 1 5225.
Sponsored by: Grupo Español Multidisciplinar De Melanoma Gem.
Signed date: 26/10/2021

Feliú Batlle, J. Estudio de fase III, multicéntrico, en doble ciego y aleatorizado, para investigar la eficacia y la seguridad de CS1003 en combinación con lenvatinib comparados con placebo en combinación con lenvatinib como tratamiento de primera línea en sujetos con carcinoma hepatocelular avanzado.

Type: Clinical Trials, phase III.
Hulp code: 5485 CS1003-305.
Sponsored by: Parexel International (Irl) Limited.
Signed date: 07/04/2021

Feliú Batlle, J. Ensayo randomizado en fase III, abierto, de Napabucasin en combinación con Folfiri y mejor tratamiento de

soporte (BSC) versus Napabucasin más mejor tratamiento de soporte (o solo mejor tratamiento de soporte) en pacientes adultos con cáncer colorrectal metastásico (CCRM).

Type: Clinical Trials, phase III.
Hulp code: 5406 STEMNESS-CRC.
Sponsored by: 1 Globe Health Institute, Llc.
Signed date: 16/09/2021

Feliú Batlle, J. A phase II/III randomized, open-label clinical study of napabucasin in combination with weekly paclitaxel and low-dose gemcitabine in patients with metastatic pancreatic cancer following chemotherapy failure.

Type: Clinical Trials, phase II.
Hulp code: 5598 STEMNESS-PANC.
Sponsored by: 1 Globe Health Institute, Llc.
Signed date: 05/11/2021

Feliú Batlle, J. Estudio en fase I-II, primero en humanos, de CX-2029 en adultos con linfomas difusos de linfocitos B grandes o tumores sólidos no resecables localmente avanzados o metastásicos (proclaim-CX-2029).

Type: Clinical Trials, phase I.
Hulp code: Appendix 2 5153.
Sponsored by: Cytomx Therapeutics, Inc.
Signed date: 22/11/2021

Fernández Capitán, MC. Tratamiento a largo plazo del TEV asociado al cáncer: dosis reducida respecto a dosis completa de apixaban: estudio API-CAT con apixaban en la trombosis del cáncer.

Hulp code: 5443 P170604j.
Sponsored by: Assistance Publique Hopitaux De Paris.
Signed date: 12/10/2021

Fernández Heredero, A. Impacto del hierro intravenoso en el tratamiento preoperatorio de la anemia en pacientes con isquemia crónica de los miembros inferiores.

Type: Clinical Trials, phase IV.
Hulp code: 5854 IRONPAD.
Sponsored by: Fonseca Legrand, Juan Luis.

Signed date: 29/04/2021

Galera Martínez, R. Estudio de la hiperinflación dinámica tras la prueba de la marcha de 6 minutos en los pacientes con asma moderada-grave.

Type: Estudios, fase EPA-OD.
Hulp code: PI-4686 CHI-ASM-2020-01.
Sponsored by: Chiesi España Sa.
Signed date: 07/04/2021

García Barcenilla, S. Estudio observacional para evaluar el impacto y la carga de la enfermedad en hemofilia moderada y grave desde la perspectiva de enfermería y del paciente (estudio nurses-whocare).

Type: Estudios, fase EPA-OD.
Hulp code: PI-4824 ML42270.
Sponsored by: Roche Farma, S.A.
Signed date: 18/06/2021

García Muñoz, A. Ensayo multicéntrico, aleatorizado, controlado y abierto para evaluar la eficacia y seguridad de asunercept en pacientes con enfermedad por COVID-19.

Type: Clinical Trials, phase II.
Hulp code: 5796 APG101_CD_017.
Sponsored by: Apogenix Ag.
Signed date: 12/02/2021

García Río, FJ. Ensayo de fase III, multicéntrico, aleatorizado, doble ciego, de administración crónica, con grupos paralelos y controlado con placebo para evaluar la eficacia y la seguridad de benralizumab 100 mg en pacientes con enfermedad pulmonar obstructiva crónica (EPOC) de moderada a muy grave y con antecedentes de exacerbaciones frecuentes de la EPOC y eosinófilos elevados en sangre periférica (resolute).

Type: Clinical Trials, phase III.
Hulp code: Appendix 1 5421.
Sponsored by: Astrazeneca Farmaceutica Spain, S.A.
Signed date: 19/10/2021

García-Samaniego Rey, J. Estudio de fase 2, aleatorizado, en doble ciego y controlado con placebo de heptacel (fp-02.2 po-



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

tenciada) como vacuna inmunoterapéutica enpacientes con hepatitis b crónica inactiva no tratados previamente.

Type: Clinical Trials, phase II.
Hulp code: 5668 ALT-301-202.
Sponsored by: Altimune Inc.
Signed date: 03/03/2021

García-Samaniego Rey, J. Estudio prospectivo, multicéntrico (b-sure) para evaluar la durabilidad a largo plazo de la respuesta virológica sostenida enparticipantes con hepatitis b crónica tratados y no tratados connucleósidos/nucleótidos, que recibieron gsk3228836 en un estudio detratamiento previo y respondieron a dicho tratamiento.

Type: Clinical Trials, phase II.
Hulp code: 5918 206882.
Sponsored by: Glaxosmithkline Research And Development Limited .
Signed date: 25/10/2021

Gasior Kabat, M. Estudio de fase 3 aleatorizado y abierto para evaluar laeficacia y la seguridad de navitoclax combinado con ruxolitinib encomparación con el mejor tratamiento disponible en pacientes conmielofibrosis en recaída/refractario (transform-2).

Type: Clinical Trials, phase III.
Hulp code: Appendix 1 5714.
Sponsored by: Abbvie Deutschland Gmbh & Co. Kg.
Signed date: 23/02/2021

Gasior Kabat, M. Estudio no intervencionista, decohortes, sobre la evolución clonal de las mutaciones de flt3durante la progresión de la enfermedad en pacientes conleucemia mieloide aguda - clevo.

Type: Estudios, phase EPA-SP.
Hulp code: PI-4372 2215-MA-3297.
Sponsored by: Astellas Pharma Global Development, Inc.
Signed date: 05/07/2021

Gasior Kabat, M. Estudio de fase 3 aleatorizado y abierto para evaluar laeficacia y la seguridad de navitoclax combinado con

ruxolitinib encomparación con el mejor tratamiento disponible en pacientes conmielofibrosis en recaída/refractario (transform-2).

Type: Clinical Trials, phase III.
Hulp code: Appendix 2 5714.
Sponsored by: Abbvie Deutschland Gmbh & Co. Kg.
Signed date: 27/05/2021

Gasior Kabat, M. Estudio de fase 3, aleatorizado y abierto, para evaluar a imetelstat (grn163l) frente al mejor tratamiento disponible en pacientes con mielofibrosis de riesgo intermedio 2 o alto resistente a inhibidores de las cinasas jano.

Type: Clinical Trials, phase III.
Hulp code: 5742 GRN163LMYF3001.
Sponsored by: Geron Corporation.
Signed date: 07/10/2021

Ghanem Cañete, I. Estudio fase II aleatorizado y multicéntrico de Folfox6m + AC monoclonal (Antiegrf o Bevacizumab) solo o en combinación con Quimioembolización hepática (Lifepearls-Irinotecan) en pacientes con cáncer colorrectal y enfermedad metastásica limitada al hígado con criterios de mal pronóstico.

Type: Clinical Trials, phase II.
Hulp code: 5701 LP-IRI-HCPB/ GEMCAD-1802.
Sponsored by: Grupo Español Multidisciplinario En Cáncer Digestivo (Gemcad) Grupo Español Multidisciplinario Del Cáncer Digestivo.
Signed date: 28/01/2021

Ghanem Cañete, I. Estudio para evaluar los efectos del ayuno de corta duracion sobre la toxicidad y eficacia de la quimioterapia.

Type: Estudios No EPA.
Hulp code: PI-3536.
Sponsored by: Fundación Imdea Alimentación.
Signed date: 09/06/2021

Ghanem Cañete, I. Estudio de plataforma en fase Ib/II, sin enmascaramiento y aleato-

rizado para evaluar la seguridad y la eficacia de combinaciones terapéuticas con ab928 enpacientes con cáncer colorrectal metastásico.

Type: Clinical Trials, phase II.
Hulp code: 5776 ARC-9.
Sponsored by: Arcus Biosciences Europe Limited.
Signed date: 16/07/2021

Gil Garay, E. Estudio prospectivo, multicéntrico, no aleatorizado. estudio de resultados clínicos del sistema acetabular r3 en pacientes con enfermedades degenerativas de cadera.

Type: Estudios, phase EPA-SP.
Hulp code: Appendix 2 2929.
Sponsored by: Smith&Nephew Orthopaedics Ag.
Signed date: 12/07/2021

Gómez Carrera, L. Estudio de fase III aleatorizado, doble ciego, controlado por placebo para evaluar la eficacia y seguridad del prm-151 en pacientes con fibrosis pulmonar idiopática.

Type: Clinical Trials, phase III.
Hulp code: 5749 WA42293.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 11/05/2021

Gómez Carrera, L. Estudio de fase III de extensión de etiqueta abierta para evaluar la seguridad y eficacia a largo plazo de prm-151 en pacientes con fibrosis pulmonar idiopática (fpi) estudio de fase III aleatorizado, doble ciego, controlado por placebo para evaluar la eficacia y seguridad del prm-151 en pacientes con fibrosis pulmonar idiopática.

Type: Clinical Trials, phase III.
Hulp code: 5750 WA42294.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 11/05/2021

Gomez De La Riva, A. Bone flap fixation systems for craniotomy procedures.

Type: Estudio Producto Sanitario.
Hulp code: 5782 NEO-LOO-2020-01.

Sponsored by: Neos Surgery S.L.
Signed date: 05/02/2021

Gomez Prieto, P. Estudio fase IIb, aleatorizado, para evaluar la eficacia de la terapia de rescate con brentuximab vedotin-eshap VS eshap enpacientes con Linfoma de Hodgkin clásico refractario o en recaída, seguido de consolidación con Brentuximab Vedotin (en lugar detrasplante autólogo de células madre hematopoyéticas) en aquellos pacientes que alcancen respuesta metabólica completa tras laterapia de rescate.

Type: Clinical Trials, phase II.
Hulp code: 5864 GELTAMO18-HL.
Sponsored by: Gel-Tamo Grupo Cooperativo Español De Linfoma-Transplante Autonomo De Medula Osea Gel/Tamo.
Signed date: 24/05/2021

González Casado, I. Adaptación cultural al español del cuestionario life interference questionnairefor growth hormone deficiency liq-ghd para la valoración de la experiencia conlas inyecciones de hormona de crecimiento.

Type: Estudios No EPA.
Hulp code: PI-4504 MK-ESMODRDL-04-01.
Sponsored by: Pfizer, S.L.U.
Signed date: 05/03/2021

Gonzalez García, JJ. Estudio de fase IIa, aleatorizado, doble ciego y controlado con placebo, de las vacunas contra el vih-1 mva. hti y chadox1.hti, con el agonista de tlr7 vesatolimod (gs-9620), en infección por el vih-1 tratada de forma precoz.

Type: Clinical Trials, phase II.
Hulp code: Appendix 2 5163.
Sponsored by: Aelix Therapeutics S.L.
Signed date: 17/03/2021

Gonzalez García, JJ. Estudio de fase IIb, aleatorizado, con dobleenmascaramiento, de grupos paralelos para evaluar la eficacia, la seguridad, la tolerabilidad y el perfil de



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

resistencia de gsk3640254 en combinación con dolutegravir en comparación con dolutegravir más lamivudina en adultos infectados por el vih-1 sin tratamiento previo.

Type: Clinical Trials, phase II.
Hulp code: 5887 212483.
Sponsored by: Glaxosmithkline Research And Development Limited.
Signed date: 08/07/2021

Gonzalez García, JJ. Bictegravir/ftc/taf para el tratamiento de la infección primaria por hiv (bic-phi trial).

Type: Clinical Trials, phase IV.
Hulp code: 5635 BIC-PHI.
Sponsored by: Fundacio Clinic Per A La Reçerca Biomedica.
Signed date: 12/07/2021

Gonzalez García, JJ. Estudio clínico de fase 3, aleatorizado, doble ciego y controlado con producto activo para evaluar el cambio a doravirina/islatravir (dor/isl) una vez al día en participantes con supresión virológica del vih-1 con bictegravir/emtricitabina/tenofovir alafenamide (bic/ftc/taf).

Type: Clinical Trials, phase III.
Hulp code: Appendix 1 5470.
Sponsored by: Merck Sharp & Dhome Corp.
Signed date: 18/05/2021

Gonzalez García, JJ. Infecciones recientes, agudas y reinfecciones, por vhc en hombres que tienen sexo con hombres con y sin infección por vih. (estudio athens).

Type: Estudios, phase EPA-OD.
Hulp code: PI-4920 GESIDA 12121.
Sponsored by: Fundación Seimc-Gesida.
Signed date: 14/09/2021

Gonzalez García, JJ. Estudio de fase III, aleatorizado, multicéntrico, abierto y de no inferioridad para evaluar la eficacia, la seguridad y la tolerabilidad del cambio de tratamiento a una combinación en dosis fijas de dolutegravir/lamivudina en adultos infectados por el vih-1 con supresión virológica.

Type: Clinical Trials, phase III.
Hulp code: Appendix 2 5354.
Sponsored by: Viiv Healthcare Uk Limited.
Signed date: 26/03/2021

Gonzalez García, JJ. Estudio abierto, multicéntrico y aleatorizado para investigar el tratamiento antirretroviral con inhibidor de la integrasa frente al inhibidor de la proteasa potenciado para pacientes con enfermedad por el vih avanzada. estudio late presenter treatment optimisation (optimización del tratamiento para pacientes con infección avanzada, laptop).

Type: Clinical Trials, phase III.
Hulp code: Appendix 1 5307.
Sponsored by: Neat Id Foundation.
Signed date: 30/06/2021

Gonzalez García, JJ. Estudio clínico de fase 3, aleatorizado, doble ciego y controlado con producto activo para evaluar el cambio a doravirina/islatravir (dor/isl) una vez al día en participantes con supresión virológica del vih-1 con bictegravir/emtricitabina/tenofovir alafenamide (bic/ftc/taf).

Type: Clinical Trials, phase III.
Hulp code: Appendix 2 5470.
Sponsored by: Merck Sharp & Dhome Corp.
Signed date: 20/10/2021

Gonzalez García, JJ. Estudio clínico de continuación, de fase 3, sin enmascaramiento, de doravirina/islatravir (dor/isl) una vez al día para el tratamiento de la infección por el vih-1 en participantes que habían recibido previamente dor/isl en un estudio clínico de fase 2 o fase 3 de dor/isl.

Type: Clinical Trials, phase II.
Hulp code: 6030 MK-8591A-033.
Sponsored by: Merck Sharp And Dohme De España, S.A.
Signed date: 16/12/2021

Gonzalez Martinez, B. Estudio de fase Ib/2 de carfilzomib en combinación con quimioterapia de inducción en niños con

leucemia linfoblástica aguda recurrente o resistente.

Type: Clinical Trials, phase I.
Hulp code: 5745 20140106.
Sponsored by: Amgen, S.A.
Signed date: 04/05/2021

Gonzalez Martinez, B. Ensayo internacional de fase 3 en leucemia linfoblástica aguda positiva para cromosoma filadelfia (Ila ph+) de evaluación del imatinib en combinación con dos diferentes esquemas de quimioterapia citotóxica.

Type: Clinical Trials, phase III.
Hulp code: 5565 EsPhALL2017/COGAALL1631.
Sponsored by: Sociedad Española De Hematología Y Oncología Pediátrica.
Signed date: 02/06/2021

Gonzalez Martinez, B. Ibfm ambi2018 - registro prospectivo sobre leucemia de línea ambigua infantil.

Type: Estudios, phase EPA-SP.
Hulp code: PI-4261 iBFM AMBI2018.
Sponsored by: Sociedad Española De Hematología Y Oncología Pediátrica.
Signed date: 10/11/2021

Gonzalez Martinez, B. Intreall HR 2010 - International study for treatment of high risk childhood relapsed all 2010.

Type: Clinical Trials, phase II.
Hulp code: 4870 IntReALL HR 2010.
Sponsored by: Sociedad Española De Hematología Y Oncología Pediátrica.
Signed date: 15/11/2021

Gonzalez Pizarro, P. Validación del test de aire como método de detección de atelectasias perioperatorias en pediatría: un estudio prospectivo.

Type: Estudios No EPA.
Hulp code: 5518 PEDIATRIC AIT TEST.
Sponsored by: Gonzalez Pizarro, Patricio.
Signed date: 12/07/2021

Grasa Lozano, CD. Estudio de fase 4, abierto y multicéntrico para evaluar la segu-

ridad, la tolerabilidad y la inmunogenicidad de Vaxelis™ en niños sanos que han recibido anteriormente un ciclo infantil devacunación primaria de dos dosis de Vaxelis™ o Hexyon.

Type: Clinical Trials, phase IV.
Hulp code: 6053 V419-016.
Sponsored by: Merck Sharp And Dohme De España, S.A.
Signed date: 04/12/2021

Guerra García, MS. Estudio de fase 1, multicéntrico, abierto, con intensificación de dosis y expansión de cohorte con niraparib y dostarlimab en pacientes pediátricos con tumores sólidos recurrentes o refractarios.

Type: Clinical Trials, phase I.
Hulp code: Appendix 1 5624 213406.
Sponsored by: Glaxosmithkline Research And Development Limited .
Signed date: 22/01/2021

Hernández Gutiérrez, A. Ensayo clínico de fase 2, multicéntrico, abierto, aleatorizado, para evaluar la inhibición de la ovulación de tres dosificaciones de levonorgestrel (Ing) en un sistema de liberación vaginal (slv), que se libera durante 28 días de manera continua, frente a desogestrel (cerazet@).

Type: Clinical Trials, phase II.
Hulp code: 5754 2019-002350-22.
Sponsored by: Chemo Research S.L.
Signed date: 18/03/2021

Herranz Pinto, P. Estudio de fase 3b, aleatorizado, doble ciego, con doble simulación, controlado con principio activo, multicéntrico, para evaluar la eficacia y la seguridad de abrocitinib en comparación con dupilumab en participantes adultos que reciben terapia tópica de base con dermatitis atópica de moderada a grave.

Type: Clinical Trials, phase III.
Hulp code: Appendix 1 5503 B7451050.
Sponsored by: Pfizer, S.L.U.
Signed date: 10/02/2021



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Herranz Pinto, P. Estudio demostrativo preliminar aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad del inhibidor de ripk-1sar443122 en pacientes con lupus eritematoso cutáneo subagudo o discoide/crónico de moderado a grave.

Type: Clinical Trials, phase II.
Hulp code: 5786 ACT16404.
Sponsored by: Sanofi-Aventis Recherche & Developpement.
Signed date: 04/03/2021

Herranz Pinto, P. Caracterización del paciente adulto con dermatitis atópica (da) moderada a grave en unidades de dermatología del ámbito hospitalario en España. estudio dacar.

Type: Estudios No EPA.
Hulp code: PI-4807 NIS-AD-2193.
Sponsored by: Gestió Organització Comunicació S.A.
Signed date: 02/06/2021

Herranz Pinto, P. Ensayo de extensión a largo plazo, multicéntrico, abierto y de un solo brazo, para evaluar la seguridad y eficacia de tralokinumab en pacientes con dermatitis atópica que participaron previamente en ensayos clínicos con tralokinumab - ecztend.

Type: Clinical Trials, phase III.
Hulp code: Appendix 1 5158.
Sponsored by: Leo Pharma A/S.
Signed date: 26/03/2021

Herranz Pinto, P. Estudio de fase 3b, multicéntrico, aleatorizado, en doble ciego, controlado con principio activo de comparación (secukinumab) y de grupos paralelos, para evaluar la eficacia y la seguridad de bimekizumab en adultos con psoriasis (psoriasis) en placas crónica de grado moderado o severo.

Type: Clinical Trials, phase III.
Hulp code: Appendix 2 5109.
Sponsored by: Ucb Biosciences GmbH.
Signed date: 03/03/2021

Herranz Pinto, P. Estudio prospectivo, multicéntrico y a largo plazo para evaluar la seguridad y la eficacia de nemolizumab (cd14152) en sujetos con dermatitis atópica de moderada a grave.

Type: Clinical Trials, phase III.
Hulp code: Appendix 1 5478.
Sponsored by: Galderma S.A.
Signed date: 15/06/2021

Herranz Pinto, P. Estudio prospectivo, multicéntrico y a largo plazo para evaluar la seguridad y la eficacia de nemolizumab (cd14152) en sujetos con dermatitis atópica de moderada a grave.

Type: Clinical Trials, phase III.
Hulp code: Appendix 2 5478.
Sponsored by: Galderma S.A.
Signed date: 05/08/2021

Herranz Pinto, P. Estudio doble ciego, aleatorizado y controlado con placebo para evaluar la eficacia y la seguridad de ctp-543 en pacientes adultos con alopecia areata de moderada a grave.

Type: Clinical Trials, phase III.
Hulp code: 5867 CP543.3002.
Sponsored by: Concert Pharmaceuticals, Inc.
Signed date: 27/08/2021

Herranz Pinto, P. Ensayo fase 2 para evaluar la eficacia y seguridad de los comprimidos de leo 152020 administrados por vía oral en comparación con los comprimidos de placebo durante un período de hasta 16 semanas de tratamiento en adultos con dermatitis atópica de moderada a grave.

Type: Clinical Trials, phase II.
Hulp code: 5835 LP0190-1488.
Sponsored by: Leo Pharma A/S.
Signed date: 20/07/2021

Herranz Pinto, P. Estudio fase 2, aleatorizado, doble ciego, controlado con placebo de 5 grupos paralelos de bms-986166 o branebrutinib para el tratamiento de pacientes con dermatitis atópica de moderada a grave.

Type: Clinical Trials, phase II.
Hulp code: 5943 IM018-005.
Sponsored by: Bristol-Myers Squibb International Corporation (Bmsic).
Signed date: 15/09/2021

Herranz Pinto, P. Estudio en fase III de retirada aleatorizada, doble ciego, controlado con placebo y multicéntrico para investigar la eficacia y la seguridad de pf-04965842 en pacientes de 12 o más años de edad con dermatitis atópica moderada o grave con la opción de un tratamiento de rescate para aquellos pacientes que presenten un empeoramiento de la enfermedad.

Type: Clinical Trials, phase III.
Hulp code: Appendix 3 5089.
Sponsored by: Pfizer, S.L.U.
Signed date: 06/10/2021

Herranz Pinto, P. Estudio aleatorizado, doble ciego y controlado con placebo para evaluar la eficiencia y la seguridad de nemolizumab (cd14152) en sujetos con dermatitis atópica de moderada a grave.

Type: Clinical Trials, phase III.
Hulp code: Appendix 1 5477.
Sponsored by: Galderma S.A.
Signed date: 12/10/2021

Herranz Pinto, P. A randomised, double-blind, placebo-controlled phase 3 clinical trial to assess the efficacy and safety of lebrikizumab in combination with topical corticosteroids in adult and adolescent patients with moderate-to-severe atopic dermatitis that are not adequately controlled with cyclosporine or for whom cyclosporine is not medically advisable.

Type: Clinical Trials, phase III.
Hulp code: 5962 M-17923-30.
Sponsored by: Almirall, Sa.
Signed date: 21/10/2021

Herranz Pinto, P. Estudio aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de nemolizumab en sujetos con dermatitis atópica de

moderada a severa que han tenido una respuesta insuficiente a la ciclosporina a o para los que no es médicamente aconsejable.

Type: Clinical Trials, phase III.
Hulp code: 6007 RD.06.SPR.201591.
Sponsored by: Galderma S.A.
Signed date: 22/12/2021

Hillman Gadea, N. PI-4997 2020-10043.

Type: Estudios No EPA.
Hulp code: PI-4997 2020-10043.
Sponsored by: Lilly, S.A.
Signed date: 02/12/2021

Humala Barbier, KK. Estudio de fase III, abierto, aleatorizado y multicéntrico de ravulizumab en pacientes adultos y adolescentes que presentan microangiopatía trombótica (mat) después de un trasplante de células madre hematopoyéticas (tcmh).

Type: Clinical Trials, phase III.
Hulp code: 5650 ALXN1210-TMA-313.
Sponsored by: Alexion Pharmaceutical Inc.
Signed date: 11/02/2021

Humala Barbier, KK. Agave-201, estudio de fase 2, abierto, aleatorizado y multicéntrico para evaluar la eficacia, la seguridad y la enfermedad del injerto contra el huésped crónica activa recidivante resistente que han recibido al menos 2 líneas de tratamiento sistémico.

Type: Clinical Trials, phase II.
Hulp code: 5891 SNDX-6352-0504.
Sponsored by: Syndax Pharmaceuticals, Inc.
Signed date: 14/05/2021

Humala Barbier, KK. Estudio de fase III, abierto, aleatorizado y multicéntrico de ravulizumab en pacientes adultos y adolescentes que presentan microangiopatía trombótica (mat) después de un trasplante de células madre hematopoyéticas (tcmh).

Type: Clinical Trials, phase III.
Hulp code: Appendix 1 5650.
Sponsored by: Alexion Pharmaceutical Inc.
Signed date: 20/07/2021



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Insauti Pacheco, I. Ensayo fundamental de fase III multicéntrico, aleatorizado, con doble enmascaramiento, controlado con placebo y con dos grupos paralelos para investigar la eficacia y la seguridad de la fosfatasa alcalina recombinante humana para el tratamiento de pacientes con lesión renal aguda asociada a la sepsis.

Type: Clinical Trials, phase III.
Hulp code: Appendix 1 5625.
Sponsored by: Am-Pharma B.V.
Signed date: 22/06/2021

Jiménez Martín, C. Estudio en fase II, abierto, aleatorizado y de varias cohortes para evaluar la eficacia, la seguridad y la farmacocinética preliminares de bivv020 para la prevención y el tratamiento del rechazo mediado por anticuerpos en adultos receptores de trasplante renal.

Type: Clinical Trials, phase II.
Hulp code: 5940 ACT17012.
Sponsored by: Sanofi-Aventis Recherche & Développement.
Signed date: 29/10/2021

Jiménez Valero, S. Ensayo clínico aleatorizado para evaluar el efecto de los betabloqueantes y los antiagregantes plaquetarios en pacientes con disección espontánea de la arteria coronaria.

Type: Clinical Trials, phase IV.
Hulp code: 5960 BA-SCAD.
Sponsored by: Sociedad Española De Cardiología (Sec).
Signed date: 16/08/2021

Jiménez Yuste, VM. Ensayo multinacional, abierto, aleatorizado y controlado para investigar la eficacia y la seguridad de nnc0365-3769 (mim8) en adultos y adolescentes con hemofilia a con o sin inhibidores.

Type: Clinical Trials, phase III.
Hulp code: 5795 NN7769-4514.
Sponsored by: Novo Nordisk A/S-No Valido.
Signed date: 19/04/2021

Jiménez Yuste, VM. Eficacia y seguridad de la administración de concizumab en profilaxis en pacientes con hemofilia a o b sin inhibidores.

Type: Clinical Trials, phase III.
Hulp code: Appendix 3 5401.
Sponsored by: Novo Nordisk Pharma, S.A.
Signed date: 05/05/2021

Jiménez Yuste, VM. Eficacia y seguridad de la administración de concizumab en profilaxis en pacientes con hemofilia a o b sin inhibidores.

Type: Clinical Trials, phase III.
Hulp code: Appendix 2 5400.
Sponsored by: Novo Nordisk A/S.
Signed date: 05/05/2021

Jiménez Yuste, VM. Estudio de fase IV, multicéntrico y abierto para evaluar la salud general, la actividad física y los resultados articulares en participantes de 13 años o más y menos de 70 años con hemofilia a grave o moderada sin inhibidores del fvIII que reciben profilaxis con emicizumab.

Type: Clinical Trials, phase IV.
Hulp code: 5964 MO42623.
Sponsored by: Roche Farma, S.A.
Signed date: 18/10/2021

Labradero De Lera, Carlos. Estudio aleatorizado, multicéntrico, doble ciego, controlado con placebo, de grupos paralelos, basado en acontecimientos y con diseño secuencial por grupos con un periodo de ampliación abierto para evaluar la eficacia y seguridad de selexipag como tratamiento complementario al tratamiento de referencia en niños de ≥ 2 a < 18 años con hipertensión arterial pulmonar.

Type: Clinical Trials, phase III.
Hulp code: Appendix 2 5456.
Sponsored by: Actelion Pharmaceuticals Ltd.
Signed date: 17/05/2021

Lago Núñez, MM. Estudio de fase II en adultos de la unión europea y asia, que evalúa

la inmunogenicidad y la seguridad de la vacuna vyf en investigación en comparación con stamaril®.

Type: Clinical Trials, phase II.
Hulp code: 5819 VYF03.
Sponsored by: Sanofi Aventis S.A.
Signed date: 26/05/2021

Landete Rodriguez, P. Estudio aleatorizado, doble ciego, controlado con placebo, para evaluar la eficacia y seguridad de otilimab intravenoso en pacientes con enfermedad pulmonar grave asociada a COVID-19.

Type: Clinical Trials, phase II.
Hulp code: 5863 214094.
Sponsored by: Glaxosmithkline, S.A.
Signed date: 16/04/2021

Landete Rodriguez, P. Ensayo de fase III multicéntrico, aleatorizado y controlado para determinar la eficacia y la seguridad de dos niveles de dosis de plitidepsin en comparación con el control en pacientes adultos que precisan de hospitalización para el tratamiento médico de la infección moderada por COVID-19.

Type: Clinical Trials, phase III.
Hulp code: 5933 APL-D-003-20.
Sponsored by: Labcorp Development S.A.U. (Covance Clinical Development, S.A).
Signed date: 08/07/2021

Landete Rodriguez, P. Ensayo de fase III multicéntrico, aleatorizado y controlado para determinar la eficacia y la seguridad de dos niveles de dosis de plitidepsin en comparación con el control en pacientes adultos que precisan de hospitalización para el tratamiento médico de la infección moderada por COVID-19.

Type: Clinical Trials, phase III.
Hulp code: Appendix 1 5933.
Sponsored by: Labcorp Development S.A.U. (Covance Clinical Development, S.A).
Signed date: 11/11/2021

Lara Lara, M. Estudio intervencionista, aleatorizado, doble ciego, con grupos para-

lelos y controlado con placebo para evaluar la eficacia y la seguridad de eptinezumab para el tratamiento preventivo de las migrañas en pacientes con un doble diagnóstico de migraña y cefalea por abuso de medicamentos.

Type: Clinical Trials, phase III.
Hulp code: 5680 19139A.
Sponsored by: Lundbeck A/S.
Signed date: 19/01/2021

Lara Lara, M. Estudio intervencionista, aleatorizado, doble ciego, de grupos paralelos y controlado con placebo para evaluar la eficacia y la seguridad de eptinezumab para el tratamiento preventivo de las migrañas.

Type: Clinical Trials, phase III.
Hulp code: 5761 19140A.
Sponsored by: Lundbeck A/S.
Signed date: 02/03/2021

Lara Lara, M. Estudio intervencionista, aleatorizado, doble ciego, con grupos paralelos y controlado con placebo para evaluar la eficacia y la seguridad de eptinezumab para el tratamiento preventivo de las migrañas en pacientes con un doble diagnóstico de migraña y cefalea por abuso de medicamentos.

Type: Clinical Trials, phase III.
Hulp code: Appendix 1 5680.
Sponsored by: Lundbeck A/S.
Signed date: 15/09/2021

Linares Espinós, EE. Estudio aleatorizado, controlado, multicéntrico y abierto para investigar la eficacia y la seguridad de añadirapalutamida a la radioterapia y al agonista de la HLHL en pacientes con cáncer de próstata hormonosensible positivos en PET con PSMA, con un seguimiento observacional de los pacientes negativos en pet con PSMA.

Type: Clinical Trials, phase III.
Hulp code: 5959 56021927PCR3015.
Sponsored by: Janssen Cilag International Nv.
Signed date: 29/09/2021



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Lluch Bernal, MM. Proyecto de colaboración estudio de reactividad cruzada entre cupresáceas y especies relacionadas.

Type: Estudios No EPA.
Hulp code: PI-4783 PI 39/21.
Sponsored by: Alk-Abello, S.A.
Signed date: 20/05/2021

Loeches Yagüe, MB. Ensayo clínico de fase iv-III, con asignación aleatoria, controlado, abierto y multicéntrico, con dos grupos paralelos, para evaluarla eficacia de la combinación de cloxacilina y fosfomicina versus cloxacilina en monoterapia en el tratamiento de la bacteriemia por staphylococcus aureus sensible a la metilicina.

Type: Clinical Trials, phase IV.
Hulp code: 5740 HUB-IDIBELL-SAFO4.3.1.
Sponsored by: Fundación Idibell.
Signed date: 13/04/2021

López Arrieta, JM. Estudio en fase III multicéntrico, aleatorizado, dobleciego y controlado con placebo para evaluar la eficacia, la seguridad y la tolerabilidad de avp-786 (Bromhidrato Dedeudextrometorfano [D6 DM]/Sulfato de Quinidina [q]) para el tratamiento de la agitación en pacientes con demencia de Tipoalzheimer.

Type: Clinical Trials, phase III.
Hulp code: 6000 20-AVP-786-307.
Sponsored by: Avanir Pharmaceuticals, Inc.
Signed date: 06/10/2021

López De La Guía, A. Estudio observacional para valorar la carga de la enfermedad, en términos de calidad de vida relacionada con la salud y costes sanitarios directos, en pacientes con mieloma múltiple de nuevo diagnóstico no candidatos a trasplante autólogo de progenitores hematopoyéticos en España.

Type: Estudios, phase EPA-SP.
Hulp code: Appendix 1 PI-2839.
Sponsored by: Celgene Sl.
Signed date: 14/09/2021

López De Sá Areses, E. Ensayo multicéntrico, adaptativo, aleatorizado y controlado sobre la seguridad y eficacia de las estrategias antitrombóticas en adultos hospitalizados con COVID-19.

Type: Clinical Trials, phase IV.
Hulp code: 5694 ACTIV-4-ACUTE.
Sponsored by: Fundación para la Investigación Biomedica Hospital Universitario La Paz.
Signed date: 15/01/2021

López De Sá Areses, E. Estudio en fase IIb, aleatorizado, doble ciego controlado con placebo, de grupos paralelos para evaluar la eficacia y la seguridad de medi6570 en participantes con infarto de miocardio previo, inflamación persistente y niveles elevados de prohormona n-terminal natriurético cerebral.

Type: Clinical Trials, phase II.
Hulp code: Appendix 1 5637.
Sponsored by: Astrazeneca Ab.
Signed date: 16/03/2021

López De Sá Areses, E. Estudio para la validación clínica de un nuevo biomarcador para determinar la predisposición a infecciones en pacientes con infarto agudo de miocardio.

Type: Estudios No EPA.
Hulp code: pi-4791 BIOMIN-001.
Sponsored by: Crazy Science & Business Sl.
Signed date: 28/06/2021

López De Sá Areses, E. Estudio en fase IIb, aleatorizado, doble ciego controlado con placebo, de grupos paralelos para evaluar la eficacia y la seguridad de medi6570 en participantes con infarto de miocardio previo, inflamación persistente y niveles elevados de prohormona n-terminal natriurético cerebral.

Type: Clinical Trials, phase II.
Hulp code: Appendix 2 5637.
Sponsored by: Astrazeneca Ab.
Signed date: 06/07/2021

López De Sá Areses, E. Estudio clínico-fundamental de fase 3, aleatorizado y controlado con placebo para evaluar la eficacia y la seguridad del estimulador de la gcsveriguat/mk-1242 en adultos con insuficiencia cardíaca crónica con fracción de eyección reducida.

Type: Clinical Trials, phase III.
Hulp code: 5969 MK1242-035.
Sponsored by: Merck Sharp And Dohme De España, S.A.
Signed date: 06/09/2021

López Fernandez, T. Epiq-affiniti ultrasound system study for cardiology.

Type: Estudios No EPA.
Hulp code: Appendix 1 PI-2996.
Sponsored by: Philips Ultrasound Inc.
Signed date: 23/04/2021

López Fernandez, T. Registro de la profilaxis cardioembólica de los pacientes con cáncer en tratamiento oncoespecífico.

Type: Estudios, phase EPA-OD.
Hulp code: PI-4806 PROCECAN 2021.
Sponsored by: Fundación Seth.
Signed date: 07/10/2021

López Gutiérrez, JC. EPIK-P2: Estudio de fase II doble ciego con un periodo inicial aleatorizado, controlado con placebo y de 16 semanas de duración para evaluar la eficacia, la seguridad y la farmacocinética de Alpelisib (BYL719) en pacientes pediátricos y adultos con síndrome de sobrecrecimiento asociado a PIK3CA.

Type: Clinical Trials, phase II.
Hulp code: 5741 CBYL719F12201.
Sponsored by: Novartis Farmaceutica, S.A.
Signed date: 26/01/2021

López Gutiérrez, JC. Estudio de fase II para evaluar la seguridad y la eficacia a largo plazo de alpelisib en pacientes con síndrome de sobrecrecimiento asociado a PIK3CA que hayan participado anteriormente en el estudio CBYL719f12002 (EPIK-p1).

Type: Clinical Trials, phase II.

Hulp code: 6002 CBYL719F12401.
Sponsored by: Novartis Farmaceutica, S.A.
Signed date: 17/11/2021

López Ortega, P. Retrospective cohort safety study of captopril administered for prevention or treatment of heart failure in paediatric patients from birth to 1 year of age.

Type: Estudios, phase EPA-OD.
Hulp code: Appendix 1 PI-3351.
Sponsored by: Proveca Ltd.
Signed date: 27/04/2021

López Plaza, B. Ensayo clínico nutricional para evaluar el efecto del consumo habitual de un probiótico con alta actividad b-galactosidasa sobre los síntomas de la intolerancia a la lactosa en un colectivo de personas con intolerancia a la lactosa.

Type: Estudio Producto Alimentario.
Hulp code: 5758 PROBIOLAC.
Sponsored by: Delafruit, Slu (Go Fruselva).
Signed date: 18/02/2021


López Plaza, B. Ensayo clínico para evaluar el índice glucémico de un suplemento nutricional oral (sno) ipercalórico/ hiperproteico enriquecido en calcio, vitamina d y dha en población adulta sana.

Type: Estudios, phase EPA-OD.
Hulp code: 5921 TERATROFO.
Sponsored by: Fundacio Eurecat.
Signed date: 19/11/2021

Martín Arranz, E. Ensayo multicéntrico fase II con tratamiento de 54 semanas, aleatorizado, doble-ciego, con grupos paralelos, controlado con placebo, para evaluar la eficacia y seguridad de brazikumab en pacientes con colitis ulcerosa activa de olerada agrava (expedition lead-in).

Type: Clinical Trials, phase II.
Hulp code: 5902 D5272C00001.
Sponsored by: Astrazeneca Ab.
Signed date: 22/08/2021

Martín Arranz, MD. Estudio de inducción multicéntrico, aleatorizado, doble ciego



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

y controlado con placebo para evaluar la eficacia y la seguridad de risankizumab en pacientes con colitis ulcerosa activa moderada o grave sin respuesta al tratamiento biológico previo.

Type: Clinical Trials, phase III.
Hulp code: Appendix 2 5058 M16-067.
Sponsored by: Abbvie Spain, S.L.U.
Signed date: 21/01/2021

Martín Arranz, MD. Estudio aleatorizado, doble ciego, controlado con placebo, de 52 semanas de duración para evaluar la eficacia y la seguridad de etrasimod en sujetos con colitis ulcerosa moderadamente activa.

Type: Clinical Trials, phase II.
Hulp code: 5695 APD334-210.
Sponsored by: Arena Pharmaceuticals Inc.
Signed date: 29/01/2021

Martín Arranz, MD. Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo para investigar la eficacia y la seguridad de abbv-323 en pacientes con colitis ulcerosa moderada o grave sin respuesta al tratamiento previo.

Type: Clinical Trials, phase II.
Hulp code: Appendix 3 5246 M15-722.
Sponsored by: Abbvie Deutschland Gmbh & Co. Kg.
Signed date: 19/02/2021

Martín Arranz, MD. Estudio de fase 2b, multicéntrico, aleatorizado, doble ciego, controlado con placebo y de varias dosis para evaluar la eficacia, seguridad y farmacocinética de pf 06480605 en participantes adultos con colitis ulcerosa de moderada a severa.

Type: Clinical Trials, phase II.
Hulp code: Appendix 1 5507.
Sponsored by: Pfizer Inc.
Signed date: 09/03/2021

Martín Arranz, MD. Estudio observacional, prospectivo y multicéntrico para evaluar la calidad de vida relacionada con la salud en pacientes con enfermedad de crohn y

fístulas perianales complejas antes y después del tratamiento: estudio calypso.

Type: Estudios, phase EPA-SP.
Hulp code: PI-4683 TAK-TNF-2019-01/MACS-.
Sponsored by: Takeda Farmaceutica España, S.A. (Antes - Nycomed Pharma S.A.).
Signed date: 16/04/2021

Martín Arranz, MD. Estudio de fase 3, de extensión de seguridad a largo plazo de shp647 en sujetos con colitis ulcerosa de moderada a grave (aida).

Type: Clinical Trials, phase III.
Hulp code: Appendix 3 4965 SHP647-304.
Sponsored by: Shire Human Genetic Therapies, Inc.
Signed date: 06/07/2021

Martín Arranz, MD. Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo para investigar la eficacia y la seguridad de abbv-323 en pacientes con colitis ulcerosa moderada o grave sin respuesta al tratamiento previo.

Type: Clinical Trials, phase II.
Hulp code: Appendix 4 5246.
Sponsored by: Abbvie Deutschland Gmbh & Co. Kg.
Signed date: 22/06/2021

Martín Arranz, MD. Ensayo fase IIb/III, multicéntrico, aleatorizado, doble ciego, controlado con placebo y fármaco activo, con grupos paralelos e ininterrumpido de 52 semanas de duración para evaluar la eficacia y la seguridad de brazikumab en participantes con enfermedad de crohn activa de moderada a grave. (intrepid lead-in).

Type: Clinical Trials, phase III.
Hulp code: 5905 D5271C00001.
Sponsored by: Astrazeneca Ab.
Signed date: 22/08/2021

Martín Arranz, MD. Estudio multicéntrico, aleatorizado, doble ciego y de grupos paralelos para evaluar la eficacia y seguridad

del etrasimod por vía oral como tratamiento de inducción y mantenimiento para la enfermedad de crohn activa de moderada a grave.

Type: Clinical Trials, phase III.
Hulp code: 5808 APD334-202EU.
Sponsored by: Arena Pharmaceuticals Inc.
Signed date: 07/10/2021

Martín Arranz, MD. Ensayo de extensión abierta a largo plazo con brazikumab en pacientes con enfermedad de crohn activa de moderada a grave (intrepid ole).

Type: Clinical Trials, phase III.
Hulp code: 5906 D5271C00002.
Sponsored by: Astrazeneca Farmaceutica Spain, S.A.
Signed date: 13/10/2021

Martín Arranz, MD. Ensayo de extensión de seguridad abierto a largo plazo, fase II con brazikumab en pacientes con colitis ulcerosa activa de moderada a grave (expe-dition ole).

Type: Clinical Trials, phase II.
Hulp code: 5903 D5272C00002.
Sponsored by: Astrazeneca Farmaceutica Spain, S.A.
Signed date: 13/10/2021

Martín Arranz, MD. Ensayo clínico multicéntrico de fase Ib/IIa (prueba de concepto) aleatorizado, con doble ciego y controlado con placebo para evaluar la seguridad, farmacocinética y eficacia del tratamiento oral con ost-122 en pacientes con colitis ulcerosa de moderada a severa.

Type: Clinical Trials, phase I.
Hulp code: Appendix 1 5473.
Sponsored by: Oncostellae S.L.
Signed date: 22/06/2021

Martín Arranz, MD. Estudio aleatorizado, doble ciego, controlado con placebo para evaluar la seguridad y pacientes con Enfermedad de Crohn (EC) activa moderada a grave.

Type: Clinical Trials, phase II.

Hulp code: 5994 M20-371.
Sponsored by: Abbvie Deutschland Gmbh & Co. Kg.
Signed date: 11/11/2021

Martín Arranz, MD. Estudio nacional, de seguimiento postcomercialización, para evaluar en la práctica real la eficacia y seguridad de la granulocitoaféresis y su impacto en la calidad de vida en pacientes en enfermedad inflamatoria intestinal (estudio grace).

Type: Estudio Producto Sanitario.
Hulp code: PI-4918 GRACE.
Sponsored by: AdacYTE Therapeutic SI.
Signed date: 22/10/2021

Martín Arranz, MD. Estudio fase 3, multicéntrico, aleatorizado, con enmascaramiento para los evaluadores de la eficacia de risankizumab en comparación con ustekinumab para el tratamiento de sujetos adultos con enfermedad de crohn de moderada a grave sin respuesta al tratamiento con terapia antitnf.

Type: Clinical Trials, phase III.
Hulp code: Appendix 1 5658.
Sponsored by: Abbvie Deutschland Gmbh & Co. Kg.
Signed date: 01/12/2021

Martín Arranz, MD. Estudio de extensión abierto para evaluar etrasimod cuando se administra a sujetos con colitis ulcerosa activa moderada o grave.

Type: Clinical Trials, phase III.
Hulp code: Appendix 2 5368.
Sponsored by: Arena Pharmaceuticals Inc.
Signed date: 29/11/2021

Martín Carbonero, L. Estudio clínico de fase 3, aleatorizado, abierto y comparativo con tratamiento activo para evaluar el cambio de tratamiento a doravirina/islatravir una vez al día en pacientes infectados por el vih-1 con supresión virológica durante el tratamiento antirretroviral (tar).

Type: Clinical Trials, phase III.
Hulp code: Appendix 2 5471.



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Sponsored by: Merck Sharp & Dhome Corp.

Signed date: 21/01/2021

Martín Quirós, A. Estudio clínico de fase 2/3, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia, la seguridad y la farmacocinética de mk-4482 en adultos no hospitalizados con COVID-19.

Type: Clinical Trials, phase II.

Hulp code: Appendix 1 5693.

Sponsored by: Merck Sharp And Dohme De España, S.A.

Signed date: 16/03/2021

Martín Quirós, A. Estudio de fase II, aleatorizado, doble ciego y controlado con placebo para evaluar la actividad antiviral, la seguridad, la farmacocinética y la eficacia de ro7496998 (at-527) en pacientes adultos no hospitalizados con COVID-19 leve o moderada.

Type: Clinical Trials, phase II.

Hulp code: 5836 WV43042.

Sponsored by: F.Hoffmann-La Roche Ltd.

Signed date: 09/04/2021

Martín Quirós, A. Estudio clínico de fase 2/3, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia, la seguridad y la farmacocinética de mk-4482 en adultos no hospitalizados con COVID-19.

Type: Clinical Trials, phase II.

Hulp code: Appendix 2 5693.

Sponsored by: Merck Sharp And Dohme De España, S.A.

Signed date: 14/07/2021

Martín Quirós, A. Estudio intervencional de fase II/III, doble ciego, de dos grupos para evaluar la eficacia y la seguridad de pf-07321332/ritonavir administrados oralmente y comparado con placebo en pacientes adultos sintomáticos no hospitalizados con COVID-19 que tengan riesgo bajo de progresar a enfermedad severa.

Type: Clinical Trials, phase III.

Hulp code: 5953 C4671002.

Sponsored by: Pfizer, S.L.U.

Signed date: 04/08/2021

Martín Quirós, A. Estudio intervencional de fase II/III, doble ciego, de dos grupos para evaluar la eficacia y la seguridad de pf-07321332/ritonavir administrados oralmente y comparado con placebo en pacientes adultos sintomáticos no hospitalizados con COVID-19 que tengan riesgo elevado de progresar a enfermedad severa.

Type: Clinical Trials, phase III.

Hulp code: 5955 C4671005.

Sponsored by: Pfizer, S.L.U.

Signed date: 04/08/2021

Martín Quirós, A. Estudio de fase II/III, aleatorizado, doble ciego, con doble simulación y controlado con placebo para evaluar la seguridad y eficacia de 2 pautas de pf-07321332/ritonavir administrados oralmente para prevenir los síntomas de la infección por SARS-CoV-2 en adultos que hayan tenido contacto doméstico con personas infectadas por SARS-CoV-2.

Type: Clinical Trials, phase III.

Hulp code: 5954 C4671006.

Sponsored by: Pfizer, S.L.U.

Signed date: 14/09/2021

Martín Quirós, A. Estudio de fase 3, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de mk-4482 en la prevención de la COVID-19 (infección por sarscov-2, confirmada por el laboratorio, con síntomas) en adultos que conviven con una persona con COVID-19.

Type: Clinical Trials, phase III.

Hulp code: 5929 MK-4482-013.

Sponsored by: Merck Sharp And Dohme De España, S.A.

Signed date: 24/08/2021

Martín Salces, M. Ensayo en fase III multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de efgartigimod (argx 113) 10 mg/

kg por vía intravenosa en pacientes adultos con trombocitopenia inmune primaria.

Type: Clinical Trials, phase III.

Hulp code: Appendix 1 5430.

Sponsored by: Argenx Bv (Argenx Bvba).

Signed date: 16/04/2021

Martín Salces, M. Ensayo en fase III multicéntrico, sin enmascaramiento y a largo plazo para evaluar la seguridad y la eficacia de 10 mg/kg de efgartigimod (argx-113) por vía intravenosa en pacientes adultos con trombocitopenia inmunitaria primaria.

Type: Clinical Trials, phase III.

Hulp code: Appendix 1 5480.

Sponsored by: Argenx Bv (Argenx Bvba).

Signed date: 10/05/2021

Martinez Marin, V. Estudio de fase III aleatorizado, multicéntrico, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de trastuzumab emtansina en combinación con atezolizumab o placebo en pacientes con cáncer de mama localmente avanzado o metastásico positivo para her2 y pd-l1 que hayan recibido previamente tratamiento basado en trastuzumab (+/- pertuzumab) y taxanos (kate3).

Type: Clinical Trials, phase III.

Hulp code: 5738 MO42319.

Sponsored by: Roche Farma, S.A.

Signed date: 11/03/2021

Martinez Marin, V. Ensayo clínico de fase III, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad del tratamiento adyuvante con atezolizumab o placebo y trastuzumab emtansina en el cáncer de mama con her2+ y alto riesgo de recidiva después del tratamiento preoperatorio.

Type: Clinical Trials, phase III.

Hulp code: 5744 WO42633.

Sponsored by: Roche Farma, S.A.

Signed date: 01/03/2021

Martinez Marin, V. Análisis observacional del tratamiento con palbociclib en pacien-

tes con cáncer de mama avanzado o metastásico rh+/her2- en primera línea de tratamiento dentro de práctica clínica habitual.

Type: Estudios, phase EPA-OD.

Hulp code: PI-4998 PALBOSPAIN.

Sponsored by: Fundación para la Investigación Biomedica Del Hospital Clínico San Carlos.

Signed date: 15/11/2021

Martinez Marin, V. Ensayo clínico de fase III, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad del tratamiento adyuvante con atezolizumab o placebo y trastuzumab emtansina en el cáncer de mama con her2+ y alto riesgo de recidiva después del tratamiento preoperatorio.

Type: Clinical Trials, phase III.

Hulp code: Appendix 1 5744.

Sponsored by: Roche Farma, S.A.

Signed date: 15/11/2021

Mascias Cadavid, J. Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo para investigar la eficacia y seguridad de fab122 en pacientes con esclerosis lateral amiotrófica.

Type: Clinical Trials, phase III.

Hulp code: 5909 FAB 122-CT-2001.

Sponsored by: Ferrer Internacional, S.A.

Signed date: 15/11/2021

Mascias Cadavid, J. Estudio fase III, prospectivo, multicéntrico randomizado, doble ciego, controlado con placebo y de grupos paralelos para comparar la eficacia y seguridad de masitinib en combinación con riluzol frente a placebo en combinación con riluzol para el tratamiento de pacientes con esclerosis lateral amiotrófica (ela).


Type: Clinical Trials, phase III.

Hulp code: Appendix 1 5412.

Sponsored by: Abscience.

Signed date: 17/11/2021

Mellado Peña, MJ. Ensayo en fase III, aleatorizado, doble ciego para evaluar la



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

seguridad de una vacuna conjugada anti-neumocócica 20-valente en lactantes sanos.

Type: Clinical Trials, phase III.
Hulp code: Appendix 1 5557.
Sponsored by: Pfizer, S.L.U.
Signed date: 24/05/2021

Mendez Echevarria, AM. Estudio multicéntrico, sin enmascaramiento, en el que se evalúa la farmacocinética y la seguridad de baricitinib en pacientes pediátricos (desde 1 año hasta menos de 18 años de edad) hospitalizados con COVID-19.

Type: Clinical Trials, phase III.
Hulp code: 5913 I4V-MC-KHAB.
Sponsored by: Lilly, S.A.
Signed date: 06/09/2021

Mendez Echevarria, AM. Estudio de fase II, abierto, no controlado, de dosis única para evaluar la seguridad, tolerabilidad y farmacocinética, y la aparición de anticuerpos antifármaco para nirsevimab en niños inmunodeprimidos de ≤ 24 meses de edad.

Type: Clinical Trials, phase II.
Hulp code: 5965 D5290C00008.
Sponsored by: Astrazeneca Ab.
Signed date: 13/10/2021

Merino Andreu, M. Estudio en fase I, abierto, de dosis única ascendente para evaluar la farmacocinética y la seguridad de solriamfetol en sujetos pediátricos con narcolepsia.

Type: Clinical Trials, phase I.
Hulp code: 5612 JZP865-101.
Sponsored by: Jazz Pharmaceuticals Ireland Limited.
Signed date: 29/03/2021

Montejano Sánchez, R. Impacto del tratamiento temprano con rdv. experiencia y seguridad con su uso en vida real en pacientes con COVID-19: análisis retrospectivo de la cohorte española.

Type: Estudios, phase EPA-OD.
Hulp code: PI-4839 RDV-RWE.
Sponsored by: Fundación Seimc-Gesida.
Signed date: 23/06/2021

Montes Ramírez, ML. Estudio fase IIIb, aleatorizado, multicéntrico, abierto, de grupos paralelos, de no inferioridad que evalúa la eficacia, seguridad y tolerabilidad de cabotegravir de acción prolongada más rilpivirina de acción prolongada administrados cada 8 semanas o cada 4 semanas en adultos infectados por VIH-1 que presentan supresión virológica.

Type: Clinical Trials, phase IIIb.
Hulp code: Appendix 1 4925.
Sponsored by: Laboratorios Viiv Healthcare, S.L.
Signed date: 11/02/2021

Montesinos Montesinos, MP. Estudio fase IIIb, aleatorizado, multicéntrico, abierto, de grupos paralelos, de no inferioridad que evalúa la eficacia, seguridad y tolerabilidad de cabotegravir de acción prolongada más rilpivirina de acción prolongada administrados cada 8 semanas o cada 4 semanas en adultos infectados por vih-1 que presentan supresión virológica.

Type: Clinical Trials, phase IIIb.
Hulp code: Appendix 2 4925.
Sponsored by: Laboratorios Viiv Healthcare, S.L.
Signed date: 07/10/2021

Mora Rillo, M. Temocilina vs meropenem para el tratamiento de la bacteriemia por enterobacteriales resistentes a cefalosporinas de tercer generación: ensayo aleatorizado y pragmático.

Type: Clinical Trials, phase III.
Hulp code: 5530 ASTARTE.
Sponsored by: Fundación Pública Andaluza Para La Gestión De La Investigación En Salud De Sevilla.
Signed date: 23/02/2021

Morado Arias, M. Estudio de extensión, abierto, multicéntrico de AG-348 en sujetos adultos con deficiencia de piruvato cinasa incluidos previamente en estudios con AG-348.

Type: Clinical Trials, phase III.
Hulp code: Appendix 2 5237.
Sponsored by: Agios Pharmaceuticals, Inc.
Signed date: 16/01/2021

Morado Arias, M. Estudio en fase III, aleatorizado, abierto, comparativo con control activo y multicéntrico, para evaluar la eficacia y la seguridad de crovalimab en comparación con eculizumab en pacientes con hemoglobulina paroxística nocturna (hpn) no tratada previamente con inhibidores del sistema de complemento.

Type: Clinical Trials, phase III.
Hulp code: Appendix 1 5707.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 17/05/2021

Morado Arias, M. Estudio multicéntrico, aleatorizado, controlado con placebo, doble ciego y adaptativo de ft-4202 oral, un activador de la piruvato cinasa en pacientes con anemia drepanocítica.

Type: Clinical Trials, phase II.
Hulp code: 5858 FORMA 4202-HEM-301.
Sponsored by: Forma Therapeutics, Inc.
Signed date: 19/07/2021

Morado Arias, M. estudio de fase 2b, multicéntrico, abierto, para evaluar la eficacia, seguridad y farmacocinética de rilzabrutinib en pacientes con anemia hemolítica autoinmune por anticuerpos calientes.

Type: Clinical Trials, phase II.
Hulp code: 5915 ACT17209.
Sponsored by: Sanofi Aventis S.A.
Signed date: 15/07/2021

Morado Arias, M. Historia natural y resultados de tratamiento de púrpura trombocitopénica trombótica congénita e inmune: estudio de revisión retrospectiva de historial médico del paciente.

Type: Estudios No EPA.
Hulp code: PI-4905 TAK-705-3003.
Sponsored by: Takeda Pharmaceuticals Limited.
Signed date: 15/09/2021

Morado Arias, M. Estudio multicéntrico en fase 3, doble ciego, aleatorizado y controlado con placebo para evaluar la eficacia y seguridad de mitapivat en sujetos con α -o β -talasemia dependiente de transfusiones (energize-t).

Type: Clinical Trials, phase III.
Hulp code: 5856 AG348-C-018.
Sponsored by: Agios Pharmaceuticals, Inc.
Signed date: 28/09/2021

Morado Arias, M. Estudio multicéntrico en fase 3, doble ciego, aleatorizado y controlado con placebo para evaluar la eficacia y seguridad de mitapivat en sujetos con α -o β -talasemia no dependiente de transfusiones (energize).


Type: Clinical Trials, phase III.
Hulp code: 5855 AG348-C-017.
Sponsored by: Agios Pharmaceuticals, Inc.
Signed date: 28/09/2021

Moreno Gómez, JR. Observational study to evaluate the clinical outcome of high-risk patients undergoing percutaneous coronary intervention (pci) with everolimus-eluting stent implantation using intracoronary tools for pci guidance and optimization.

Type: Estudios No EPA.
Hulp code: PI-4898 OPTI-XIENCE.
Sponsored by: Fundación Casa Del Corazón.
Signed date: 30/08/2021

Moreno Gómez, JR. Ensayo clínico controlado aleatorizado para comparar la seguridad y eficacia del stent liberador de sirolimus, ultradelgado con polímero biodegradable (supraflextm cruz), y el stent liberador de everolimus, con polímero biodegradable (synergytm), en el tratamiento de la enfermedad de las arterias coronarias de tres vasos. multivessel talent.

Type: Estudio Producto Sanitario.
Hulp code: 5928 NUIG-2020-002.
Sponsored by: National University Of Ireland, Galway.



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Signed date: 15/09/2021

Moreno Gómez, JR. Estudio aleatorizado paralelo para evaluar la utilidad de la revisión angiográfica rutinaria 6 meses después del intervencionismo percutáneo en el tronco común izquierdo. estudio angeline.

Type: Estudios No EPA.
Hulp code: 5821 EPIC-23.
Sponsored by: Fundación Epic.
Signed date: 05/10/2021

Moreno Gómez, JR. Primera investigación clínica en humanos del catéter para angioplastia coronaria transluminal percutánea recubierto de everolimus de chansu vascular technologies: evaluación clínica en el tratamiento de sujetos con reestenosis intrastent de lesiones de arterias coronarias tratadas previamente.

Type: Estudio Producto Sanitario.
Hulp code: 6029 TP1125.
Sponsored by: Chansu Vascular Technologies, Llc.
Signed date: 18/11/2021

Moreno Gómez, JR. Guía de ultrasonido intravascular para procedimientos complejos indicados como de alto riesgo (ivus chip).

Type: Estudios, phase EPA-OD.
Hulp code: 5979 ECRI 14.
Sponsored by: European Cardiovascular Research Institute (Ecri-14).
Signed date: 30/11/2021

Moreno Gómez, JR. Registro de dispositivos médicos vasculares de abbott (abbott vascular medical deviceregistry av-mdr).

Type: Estudio Producto Sanitario.
Hulp code: PI-5013 CRD-1008/ABT-CIP-10349.
Sponsored by: Sjm International Inc.
Signed date: 01/12/2021

Moreno Gómez, JR. Fractional flow reserve or 3d-quantitative-coronaryangiography based vessel-ffr guided revascularization: fast III trial.

Type: Estudio Producto Sanitario.

Hulp code: 6036 ECRI-15.
Sponsored by: European Cardiovascular Research Institute (Ecri-15).
Signed date: 14/12/2021

Mostaza Prieto, JM. Estudio epidemiológico multinacional transversal de pacientes hipertensos con dislipemia y resultados proporcionados por el paciente.

Type: Estudios, phase EPA-OD.
Hulp code: PI-4893A SNAPSHOT.
Sponsored by: Laboratorios Servier, S.L.
Signed date: 19/10/2021

Mozo Del Castillo, Y. Estudio de fase II, multicéntrico, abierto, de un solo brazo, de ruxolitinib añadido a corticosteroides en sujetos pediátricos con enfermedad de injerto contra huésped crónica moderada y grave tras trasplante alogénico de células madre.

Type: Clinical Trials, phase II.
Hulp code: Appendix 1 5375.
Sponsored by: Novartis Farmaceutica, S.A.
Signed date: 27/04/2021

Navarro Compán, MV. Estudio axioma: axial spondyloarthritis international outcome assessment.

Type: Estudios No EPA.
Hulp code: PI-4601 AXIOMA.
Sponsored by: Maatschap Reumatologie Heelen/Sittard.
Signed date: 08/09/2021

Olveira Martin, A. Estudio de fase 2b, aleatorizado, doble ciego, controlado con placebo, multicéntrico para evaluar la eficacia, seguridad y tolerabilidad de vk2809 administrado durante 52 semanas seguidas de una fase sin medicamento de 4 semanas en sujetos con esteatohepatitis no alcohólica con fibrosis comprobada por biopsia.

Type: Clinical Trials, phase II.
Hulp code: 5766 VK2809-202.
Sponsored by: .
Signed date: 26/04/2021

Olveira Martin, A. Estudio doble ciego, aleatorizado, controlado con placebo y ex-

tensión abierta a largo plazo para evaluar la eficacia y la seguridad de elafibranor 80 mg en pacientes con colangitis biliar primaria con respuesta insuficiente o intolerancia al ácido ursodesoxicólico.

Type: Clinical Trials, phase III.
Hulp code: 5829 GFT505B-319-1.
Sponsored by: Genfit, S.A.
Signed date: 20/04/2021

Olveira Martin, A. Estudio de fase 2a aleatorizado, doble ciego y controlado con placebo de la seguridad, la tolerabilidad, la farmacocinética y la farmacodinamia de dcr-a1at en pacientes con déficit de alfa-1 antitripsina piz.

Type: Clinical Trials, phase II.
Hulp code: 5762 DCR-A1AT-201.
Sponsored by: Medpace Clinical Research, Llc.
Signed date: 13/05/2021

Olveira Martin, A. Estudio de fase II, multicéntrico, aleatorizado, con enmascaramiento doble, con grupos paralelos y controlado con placebo para evaluar la eficacia, la seguridad y la farmacocinética de bfb8488a en comparación con placebo en pacientes con esteatohepatitis no alcohólica.

Type: Clinical Trials, phase II.
Hulp code: 5789 GC41033.
Sponsored by: Genentech Inc.
Signed date: 21/06/2021

Olveira Martin, A. Estudio de fase II, multicéntrico, aleatorizado, con enmascaramiento doble, con grupos paralelos y controlado con placebo para evaluar la eficacia, la seguridad y la farmacocinética de bfb8488a en comparación con placebo en pacientes con esteatohepatitis no alcohólica.

Type: Clinical Trials, phase II.
Hulp code: Appendix 1 5789.
Sponsored by: Genentech Inc.
Signed date: 30/11/2021

Olveira Martin, A. Impacto de la enfermedad de wilson en población española:

un estudio observacional.

Type: Estudios, phase EPA-OD.
Hulp code: PI-4974 HCB/2021/08791.
Sponsored by: Alexion Pharma Spain S.L.
Signed date: 22/10/2021

Pascual Pascual, SI. Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo y multicéntrico para evaluar la eficacia y la seguridad de viltolarsén en niños con distrofia muscular de duchenne (dmd) capaces de caminar.

Type: Clinical Trials, phase III.
Hulp code: Appendix 1 5619.
Sponsored by: Ns Pharma Inc.
Signed date: 14/01/2021

Pascual Pascual, SI. Estudio de continuación, doble ciego, controlado con placebo, aleatorizado, multicéntrico, dividido en dos partes para investigar la seguridad, tolerabilidad, farmacocinética, farmacodinámica y eficacia de ro7034067 en pacientes con atrofia muscular espinal de tipo 2 y 3.

Type: Clinical Trials, phase II.
Hulp code: Appendix 3 4664.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 02/02/2021

Pascual Pascual, SI. Estudio de extensión a largo plazo de nusinersén (bllb058) administrado a dosis más altas en participantes con atrofia muscular espinal que han participado previamente en un estudio de investigación con nusinersén.

Type: Clinical Trials, phase III.
Hulp code: 5764 232SM302.
Sponsored by: Biogen Idec Ltd.
Signed date: 18/03/2021

Pascual Pascual, SI. Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo y multicéntrico para evaluar la eficacia y la seguridad de viltolarsén en niños con distrofia muscular de duchenne (dmd) capaces de caminar.

Type: Clinical Trials, phase III.
Hulp code: Appendix 2 5619.



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Sponsored by: Ns Pharma Inc.
Signed date: 16/03/2021

Pascual Pascual, SI. Estudio de fase 4 de nusinersen (bllb058) en pacientes con atrofia muscular espinal que recibieron onasemogene abeparvovec.

Type: Clinical Trials, phase IV.
Hulp code: 5827 232SM404.

Sponsored by: Biogen Idec Ltd.
Signed date: 01/06/2021

Pascual Pascual, SI. Estudio de extensión de fase 3, multicéntrico y abierto, para evaluar la eficacia y la seguridad de viltolarsén en niños con distrofia muscular de Duchenne (DMD) capaces de caminar.

Type: Clinical Trials, phase III.
Hulp code: 5812 NS-065/NCNP-01-302.

Sponsored by: Ns Pharma Inc.
Signed date: 13/04/2021

Pascual Pascual, SI. Estudio de fase IIIb, multicéntrico, abierto, con una única dosis y un único grupo para evaluar la seguridad, la tolerabilidad y la eficacia de la terapia de sustitución génica con oav101 (avxs-101) por vía intravenosa en pacientes pediátricos con atrofia muscular espinal.

Type: Clinical Trials, phase III.
Hulp code: 5911 COAV101A12306.

Sponsored by: Novartis Farmaceutica, S.A.
Signed date: 12/06/2021

Pascual Pascual, SI. Estudio de extensión abierto para pacientes con atrofia muscular espinal que han participado previamente en estudios experimentales de isis 396443.

Type: Clinical Trials, phase III.
Hulp code: Appendix 2 4577.

Sponsored by: Biogen Idec Research Limited.
Signed date: 07/04/2021

Piteado López, MD. Efficacy, safety and cost-effectiveness of methotrexate, adalimumab, or their combination in non-infectious non-anterior uveitis: a multicenter, randomized, parallel 3 arm, active-controlled,

phase 3 open label with blinded outcome assessment study.

Type: Clinical Trials, phase III.
Hulp code: 5681 CO-THEIA.

Sponsored by: Fundación para la Investigación Biomédica Del Hospital Clínico San Carlos.
Signed date: 15/12/2021

Pérez Martínez, A. Estudio de fase 1/2 multicéntrico para evaluar la seguridad y eficacia de kte-x19 en sujetos pediátricos y adolescentes con leucemia linfoblástica aguda de precursores de linfocitos b recidivante/refractaria o linfoma no Hodgkin de linfocitos b recidivante/refractario (ZUMA-4).

Type: Clinical Trials, phase I.
Hulp code: 5794 KTE-C19-104.

Sponsored by: Kite Pharma, Inc.
Signed date: 21/08/2021

Pinto Marín, A. Estudio de fase III, doble ciego, multicéntrico y aleatorizado de atezolizumab (anticuerpo anti-PD-1) en comparación con un placebo como tratamiento adyuvante en pacientes con cáncer de vejiga con invasión muscular de alto riesgo que tienen niveles de ctDNA positivos tras una citostomía.

Type: Clinical Trials, phase III.
Hulp code: 5748 BO42843.

Sponsored by: F. Hoffmann-La Roche Ltd.
Signed date: 07/01/2021

Pinto Marín, A. Estudio de identificación de biomarcadores en muestras secuenciales de pacientes con cáncer renal.

Type: Estudios No EPA.
Hulp code: PI-4414 SOGUG-2019-IEC(REN)-6.

Sponsored by: Grupo Sogug.
Signed date: 09/02/2021

Pinto Marín, A. Ensayo en fase III abierto, aleatorizado y de no inferioridad de nivolumab subcutáneo frente a nivolumab intravenoso en participantes con carcinoma renal de células claras metastásico o avanzado

que hayan recibido tratamiento sistémico anterior.

Type: Clinical Trials, phase III.
Hulp code: 5805 CA20967T.

Sponsored by: Bristol-Myers Squibb International Corporation (Bmsic).
Signed date: 12/02/2021

Pinto Marín, A. Psmadition: estudio de fase III, prospectivo, aleatorizado, abierto e internacional en el que se compara 177LU-PSMA-617 en combinación con el tratamiento de referencia con el tratamiento de referencia en monoterapia en pacientes varones adultos con cáncer de próstata metastásico sensible a hormonas.

Type: Clinical Trials, phase III.
Hulp code: 5810 CAAA617C12301.

Sponsored by: Novartis Farmaceutica, S.A.
Signed date: 02/03/2021

Pinto Marín, A. Estudio en fase III sobre erdafitinib en comparación con vinflunina, docetaxel o pembrolizumab en sujetos con carcinoma urotelial avanzado y anomalías genéticas seleccionadas en fgfr.

Type: Clinical Trials, phase III.
Hulp code: Appendix 2 4986 42756493BLC3001.

Sponsored by: Janssen Cilag International Nv.
Signed date: 16/02/2021

Pinto Marín, A. Estudio de fase 3, aleatorizado y doble ciego para evaluar pembrolizumab (mk-3475) perioperatorio + quimioterapia neoadyuvante frente a un placebo perioperatorio + quimioterapia neoadyuvante en participantes con cáncer de vejiga con invasión muscular que son aptos para recibir cisplatino (keynote-866).

Type: Clinical Trials, phase III.
Hulp code: Appendix 1 5301.

Sponsored by: Merck Sharp And Dohme De España, S.A.
Signed date: 25/05/2021

Pinto Marín, A. Estudio de fase II abier-

to para evaluar tazemetostat en combinación con enzalutamida o abiraterona/prednisona en pacientes con cáncer de próstata resistente a la castración metastásico, que no han recibido quimioterapia previa.

Type: Clinical Trials, phase II.
Hulp code: 5587 EZH-1101.

Sponsored by: Epizyme Inc.
Signed date: 27/05/2021

Pinto Marín, A. Triton 3: un estudio multicéntrico, aleatorizado, abierto de fase 3 de rucaparib versus elección del médico para pacientes con cáncer de próstata metastásico resistente a la castración asociado con deficiencia de recombinación homóloga.

Type: Clinical Trials, phase III.
Hulp code: Appendix 2 4828.

Sponsored by: Clovis Oncology, Inc.
Signed date: 16/06/2021

Pinto Marín, A. Estudio en fase III aleatorizado, abierto y multicéntrico para determinar la eficacia y la seguridad de durvalumab en combinación con tremelimumab y enfortumab vedotina o durvalumab en combinación con enfortumab vedotina para el tratamiento perioperatorio en pacientes no aptos para cisplatino que se someten a cirugía radical para cáncer de vejiga músculo-invasivo.

Type: Clinical Trials, phase III.
Hulp code: 5876 D910PC00001.

Sponsored by: AstraZeneca Ab.
Signed date: 17/09/2021

Pinto Marín, A. Estudio de fase II, aleatorizado, en doble ciego, controlado con placebo y multicéntrico, para evaluar el tratamiento de mantenimiento con senaparib en pacientes con cáncer de próstata metastásico resistente a la castración y alteraciones genéticas de la vía de reparación por recombinación homóloga tras el tratamiento con docetaxel.

Type: Clinical Trials, phase II.
Hulp code: 5845 IMP4297-202.



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Sponsored by: Impact Therapeutics, Inc.
Signed date: 08/10/2021

Pinto Marín, A. Tinivo-2: estudio en fase III, aleatorizado, controlado, multicéntrico y abierto para comparar tivozanib en combinación con nivolumab con tivozanib en monoterapia en sujetos con carcinoma de células renales que han progresado tras una o dos líneas de tratamiento en las que una línea tiene un inhibidor del punto de control inmunitario.

Type: Clinical Trials, phase III.
Hulp code: 5934 AV-951-20-304.
Sponsored by: Aveo Pharmaceuticals Inc.
Signed date: 14/10/2021

Piqueras Rodríguez, P. Catéter permanente versus inyecciones en el confort del paciente pediátrico durante la administración de heparina de bajopeso molecular: ensayo clínico cruzado.

Type: Estudio Producto Sanitario.
Hulp code: 5283 5283.
Sponsored by: Piqueras Rodríguez, Pedro.
Signed date: 06/07/2021

Plaza López De Sabando, D. Ensayo de fase II, abierto, multicéntrico y no controlado de mk 3475 (pembrolizumab) en niños y adultos jóvenes con linfoma de hodgkin clásico recién diagnosticado y respuesta insuficiente (precoz lenta) a la quimioterapia de primera línea (keynote 667).

Type: Clinical Trials, phase II.
Hulp code: Appendix 2 5346.
Sponsored by: Merck Sharp And Dohme De España, S.A.
Signed date: 15/04/2021

Prados Sánchez, C. Estudio en fase III y abierto para evaluar la seguridad a largo plazo del tratamiento combinado vx-445 en sujetos con fibrosis quística.

Type: Clinical Trials, phase III.
Hulp code: Appendix 1 5383.
Sponsored by: Vertex Pharmaceuticals Incorporated.

Signed date: 08/06/2021

Prieto Nieto, I. Análisis de efectividad de la quimioterapia neoadyuvante en el tratamiento del cáncer de colon localmente avanzado. elecla.

Type: Clinical Trials, phase II.
Hulp code: 5865 ELECLA001.
Sponsored by: Arredondo Chaves, Jorge.
Signed date: 26/04/2021

Prieto Nieto, I. Ensayo clínico multicéntrico fase iv para evaluar la eficacia de la quimioterapia intraoperatoria hipertérmica (hipec) con mitomicina-c tras la citorrducción quirúrgica completa en pacientes con metástasis peritoneales de cáncer de colon.

Type: Clinical Trials, phase IV.
Hulp code: 5814 GECOP-MMC.
Sponsored by: Hospital Universitario De Fuenlabrada.
Signed date: 06/09/2021

Quirce Gancedo, SE. Registro alergodata. **Type:** Estudios, phase EPA-SP.
Hulp code: PI-4784 SEA-OMA-2020-01.
Sponsored by: Fundación De La Sociedad Espanola De Alergología E Inmunología Clínica (Seac).

Signed date: 27/05/2021

Quirce Gancedo, SE. Estudio observacional prospectivo para evaluar la seguridad y la efectividad de la inmunoterapia con un alérgico de polen de olivo y gramíneas en pacientes con asma alérgica estacional. estudio gol.

Type: Estudios, phase EPA-SP.
Hulp code: PI-4707 ALLOLE-2020-01.
Sponsored by: Allergy Therapeutics Iberica Slu.
Signed date: 14/10/2021

Ramos Ramos, JC. Arise - estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo y con tratamiento activo para validar los instrumentos de medida de resultados notificados por el paciente, enpacientes adultos, con infec-

ción pulmonar por micobacterias notuberculosas (mnt) de nuevo diagnostico causada por el complejomycobacterium avium (mac.

Type: Clinical Trials, phase III.
Hulp code: 5708 INS-415.
Sponsored by: Insmed Incorporated.
Signed date: 15/02/2021

Ramos Ramos, JC. Encore - estudio multicéntrico, aleatorizado, dobleciego, controlado con placebo y con tratamiento activo para evaluarla eficacia y seguridad de un régimen basado en la suspensión parainhalación de liposomas de amikacina (alis) en pacientes adultos con infección pulmonar por micobacterias no tuberculosas (mnt) de nuevodiagnostico causada por el complejo mycobacterium avium (mac.

Type: Clinical Trials, phase III.
Hulp code: 5709 INS-416.
Sponsored by: Insmed Incorporated.
Signed date: 15/02/2021

Redondo Sánchez, A. Ensayo fase II, multicéntrico y abierto para evaluar la eficacia y la seguridad del trastuzumab deruxtecan (T-DXD, DS-8201A) para el tratamiento de tumores seleccionados que expresan HER2 .

Type: Clinical Trials, phase II.
Hulp code: 5759 D967VC00001.
Sponsored by: Astrazeneca Farmaceutica Spain, S.A.
Signed date: 18/01/2021

Redondo Sánchez, A. Estudio de fase 3, aleatorizado y doble ciego de pembrolizumab frente a un placebo en combinación con quimioterapia adyuvante con o sin radioterapia para el tratamiento del cáncer de endometrio de alto riesgo recién diagnosticado después de una intervención quirúrgica con intención curativa (keynote-b21 / engot-en11 / gog 3053.

Type: Clinical Trials, phase III.
Hulp code: 5757 MK-3475-B21 / ENGOT-en11.
Sponsored by: Merck Sharp And Dohme

De España, S.A.
Signed date: 02/02/2021

Redondo Sánchez, A. Una comparación en fase III aleatorizada y con doble enmascaramiento de un tratamiento a base de platino con tsr-042 y niraparib frente a la práctica habitual a base de platino como tratamiento de primera línea del cáncer ovárico epitelial no mucinoso en estadios III o iv.

Type: Clinical Trials, phase III.
Hulp code: Appendix 1 5126.
Sponsored by: Tesaro Inc.
Signed date: 04/02/2021

Redondo Sánchez, A. Phase II multicohorttrial of trabectedin and low-dose radiation therapy inadvanced/metastatic sarcomas.

Type: Clinical Trials, phase II.
Hulp code: 5531 GEIS-75.
Sponsored by: Grupo Español De Investigacion En Sarcomas.
Signed date: 23/03/2021

Redondo Sánchez, A. Estudio plataforma, defase II, abierto y multicéntrico para evaluar la eficacia y laseguridad de tratamientos basados en biomarcadores enpacientes con tumores epiteliales de ovario raros persistentes orecurrentes.

Type: Clinical Trials, phase II.
Hulp code: 5817 WO42178.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 26/03/2021

Redondo Sánchez, A. Estudio de fase 1b/2, abierto, para evaluar la seguridad y la eficacia de lucitanib en combinación con nivolumab en pacientes con un tumor sólido metastásico, en estadio avanzado.

Type: Clinical Trials, phase II.
Hulp code: 5721 CO-3810-101.
Sponsored by: Clovis Oncology, Inc.
Signed date: 15/04/2021

Redondo Sánchez, A. Ensayo fase II, multicéntrico y abierto para evaluar laeficacia



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

y la seguridad del trastuzumab deruxtecan (t-dxd, ds-8201a) para el tratamiento de tumores seleccionados que expresan her2(destiny-pantumor02).

Type: Clinical Trials, phase II.

Hulp code: Appendix 1 5759.

Sponsored by: Astrazeneca Farmaceutica Spain, S.A.

Signed date: 02/06/2021

Redondo Sánchez, A. Estudio de fase i/II para evaluar la seguridad, la farmacocinética y la eficacia de la tinostamustina, la primera molécula de fusión alquilante de su clase para la inhibición de la histona deacetilasa (hdac), en pacientes con tumores sólidos avanzados.

Type: Clinical Trials, phase I.

Hulp code: 5771 EDO-S101-1002.

Sponsored by: Mundipharma Research Ltd.

Signed date: 24/05/2021

Redondo Sánchez, A. Un estudio abierto, multicéntrico y de extensión del tratamiento a largo plazo en sujetos que han completado un estudio previo de niraparib patrocinado por glaxosmithkline/tesaro y que el investigador considera que se beneficiará del tratamiento continuo con niraparib (3000-04-003).

Type: Clinical Trials, phase II.

Hulp code: 5698 213409.

Sponsored by: Glaxosmithkline Research And Development Limited.

Signed date: 17/06/2021

Redondo Sánchez, A. Estudio de fase 1b, primero en seres humanos, de aumento escalonado y ampliación de la dosis de xmt-1536 en pacientes con tumores sólidos con probabilidad de expresar napi2b.

Type: Clinical Trials, phase II.

Hulp code: 5574 MER-XMT-1536-1.

Sponsored by: Mersana Therapeutics, Inc.

Signed date: 15/06/2021

Redondo Sánchez, A. Estudio clínico y farmacocinético de fase i/II, multicéntrico

y abierto sobre pm14 en combinación con irinotecán en pacientes pretratados con tumores sólidos avanzados seleccionados.

Type: Clinical Trials, phase II.

Hulp code: 5842 PM14-A-002-20.

Sponsored by: Pharmamar, S.A.

Signed date: 16/06/2021

Redondo Sánchez, A. Estudio abierto en fase i sobre la seguridad, la farmacocinética y la eficacia preliminar de stro-002, un conjugado de anticuerpo y fármaco (caf) dirigido contra el receptor α de folato (folr α), en pacientes con cáncer epitelial de ovario en estadio avanzado (incluido el cáncer de trompas de falopio o el cáncer peritoneal primario) y cánceres de endometrio.

Type: Clinical Trials, phase I.

Hulp code: 5838 STRO-002-GM1.

Sponsored by: Labcorp Drug Development Inc (Covance Inc).

Signed date: 23/07/2021

Redondo Sánchez, A. Estudio aleatorizado, multicéntrico, doble ciego, controlado con placebo, de fase III, de carboplatino y paclitaxel de primera línea en combinación con durvalumab, seguido de durvalumab de mantenimiento con o sin olaparib en pacientes con diagnóstico reciente de cáncer de endometrio avanzado o recurrente (duo-e).

Type: Clinical Trials, phase III.

Hulp code: 5846 D9311C00001.

Sponsored by: Astrazeneca Ab.

Signed date: 21/07/2021

Redondo Sánchez, A. Estudio aleatorizado, abierto, fase 3 de tisotumab vedotina frente a la quimioterapia elegida por el investigador en segunda o tercera línea en el cáncer de cuello uterino recidivante o metastásico.

Type: Clinical Trials, phase III.

Hulp code: 5823 SGNTV-003.

Sponsored by: Seagen, Inc.

Signed date: 14/07/2021

Redondo Sánchez, A. Phase i-II trial of

sunitinib plus nivolumab after standard treatment in advanced soft tissue and bone sarcomas.

Type: Clinical Trials, phase I.

Hulp code: Appendix 2 4854.

Sponsored by: Grupo Español De Investigacion En Sarcomas.

Signed date: 07/09/2021

Redondo Sánchez, A. Estudio de fase III, aleatorizado, doble ciego, adaptativo, controlado con placebo/paclitaxel de avb-56-500 en combinación con paclitaxel en pacientes con cáncer de ovario resistente al platino y recurrente.

Type: Clinical Trials, phase III.

Hulp code: 5897 AVB500-OC-004.

Sponsored by: Aravive Inc.

Signed date: 22/10/2021

Redondo Sánchez, A. Attend ensayo de fase III doble ciego, aleatorizado y controlado con placebo de atezolizumab en combinación con paclitaxel y carboplatino en mujeres con cáncer de endometrio avanzado o recurrente.

Type: Clinical Trials, phase III.

Hulp code: Appendix 1 5123.

Sponsored by: Mango Mario Negri Gynecology Group.

Signed date: 18/10/2021

Redondo Sánchez, A. Una comparación en fase III aleatorizada y con doble enmascaramiento de un tratamiento a base de platino con tsr-042 y niraparib frente a la práctica habitual a base de platino como tratamiento de primera línea del cáncer ovárico epitelial no mucinoso en estadios III o iv.

Type: Clinical Trials, phase III.

Hulp code: Appendix 2 5126.

Sponsored by: Tesaro Inc.

Signed date: 04/11/2021

Redondo Sánchez, A. Estudio de fase 3, aleatorizado y doble ciego de pembrolizumab frente a un placebo en combinación con quimioterapia adyuvante con o sin ra-

dioterapia para el tratamiento del cáncer de endometrio de alto riesgo recién diagnosticado después de una intervención quirúrgica con intención curativa (keynote-b21 / engot-en11 / gog 3053).

Type: Clinical Trials, phase III.

Hulp code: Appendix 1 5757.

Sponsored by: Merck Sharp And Dohme De España, S.A.

Signed date: 13/10/2021

Redondo Sánchez, A. Estudio aleatorizado, multicéntrico, doble ciego, controlado con placebo, de fase III, de carboplatino y paclitaxel de primera línea en combinación con durvalumab, seguido de durvalumab de mantenimiento con o sin olaparib en pacientes con diagnóstico reciente de cáncer de endometrio avanzado o recurrente (duo-e).

Type: Clinical Trials, phase III.

Hulp code: Appendix 1 5846.

Sponsored by: Astrazeneca Ab.

Signed date: 29/11/2021

Redondo Sánchez, A. Estudio de continuación en pacientes que hayan completado un estudio en oncología previo con olaparib y que el investigador considere que van a beneficiarse clínicamente de continuar el tratamiento.

Hulp code: 5833 D0817C00098.

Sponsored by: Astrazeneca Ab.

Signed date: 15/09/2021

Remesal Camba, A. Eficacia, seguridad, tolerabilidad y farmacocinética de tofacitinib para el tratamiento de la artritis idiopática juvenil sistémica (aijs) con características sistémicas activas en niños y adolescentes.

Type: Clinical Trials, phase III.

Hulp code: 5250 A3921165.

Sponsored by: Pfizer Inc.

Signed date: 11/02/2021

Remesal Camba, A. Estudio de fase 3 multicéntrico, doble ciego, aleatorizado, controlado con placebo y de grupos paralelos, seguido de una fase de tratamiento



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

activo para evaluar la eficacia y seguridad de apremilast en niños de 2 a menos de 18 años con úlceras bucales activas asociadas a la enfermedad de behçet (bean).

Type: Clinical Trials, phase III.
Hulp code: Appendix 1 5666.
Sponsored by: Amgen, S.A.
Signed date: 16/03/2021

Remesal Camba, A. Estudio de fase 3 multicéntrico, doble ciego, aleatorizado, controlado con placebo y de grupos paralelos para evaluar la eficacia, seguridad y farmacocinética de apremilast en niños de 5 a menos de 18 años de edad con artritis psoriásica juvenil activa (peapod, por sus siglas en inglés).

Type: Clinical Trials, phase III.
Hulp code: Appendix 1 5673.
Sponsored by: Amgen, S.A.
Signed date: 06/04/2021

Remesal Camba, A. Estudio abierto, multicéntrico, de dos cohortes y un solo grupo para evaluar la eficacia, la seguridad y la tolerabilidad, la farmacocinética y la farmacodinámica de emapalumab en niños y adultos con síndrome de activación de macrófagos (sam) en la enfermedad de still (incluida la artritis idiopática juvenil sistémica y la enfermedad de still del adulto) o con sam en el lupus eritematoso sistémico.

Type: Clinical Trials, phase III.
Hulp code: 5937 NI-0501-14.
Sponsored by: Swedish Orphan Biovitrum Ab, Sobi.
Signed date: 19/09/2021

Remesal Camba, A. Estudio fase II, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia, seguridad y farmacocinética de obinutuzumab en pacientes adolescentes con nefritis lúpica de clase III o IV activa / posterity.

Type: Clinical Trials, phase II.
Hulp code: 5935 WA42985.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 03/09/2021

Rico Nieto, A. Ensayo clínico fase III aleatorizado, controlado y abierto en pacientes con infección recurrente por clostridioides difficile (CD) para evaluar la eficacia y la seguridad de cápsulas de microbiota fecal Liofilizada vs Fidaxomicina.

Type: Clinical Trials, phase III.
Hulp code: 6001 ICD-01.
Sponsored by: Mikrobiomik Healthcare Company, S.L.
Signed date: 13/12/2021

Ríos González, E. Estudio fase II aleatorizado de erdafitinib frente a la selección del investigador de quimioterapia intravesical en sujetos que recibieron el bacilo de Calmette y Guérin (bcg) y presentaron recidiva de cáncer de vejiga no músculo-invasivo (nmIBC) de alto riesgo y mutaciones o fusiones del fgfr.

Type: Clinical Trials, phase II.
Hulp code: Appendix 1 5449.
Sponsored by: Janssen Cilag International Nv.
Signed date: 03/02/2021

Ríos González, E. Estudio de biomarcadores para determinar la frecuencia de defectos en la reparación del ADN en hombres con cáncer de próstata metastásico. estudio prevalence.

Type: Estudios No EPA.
Hulp code: PI-4619 PREVALENCE.
Sponsored by: Janssen Cilag International Nv.
Signed date: 24/02/2021

Ríos González, E. Estudio aleatorizado, doble ciego, controlado con placebo de fase III de niraparib en combinación con acetato de abiraterona y prednisona frente a acetato de abiraterona y prednisona para el tratamiento de participantes con cáncer de próstata metastásico sensible a la castración (cPSCM) con mutaciones deletéreas en la línea germinal o somáticas en los genes de reparación por recombinación homóloga (hrr).

Type: Clinical Trials, phase III.
Hulp code: Appendix 1 5654.
Sponsored by: Janssen Cilag International Nv.
Signed date: 27/05/2021

Ríos González, E. Darol: estudio observacional de darolutamida en pacientes con cáncer de próstata resistente a la castración no metastásico.

Type: Estudios, phase EPA-OD.
Hulp code: PI-4752 BAY-DAR-2021-01.
Sponsored by: Bayer Hispania, S.L.
Signed date: 18/08/2021

Robles Marhuenda, AJ. Estudio abierto, multicéntrico, de dos cohortes y un solo grupo para evaluar la eficacia, la seguridad y la tolerabilidad, la farmacocinética y la farmacodinámica de emapalumab en niños y adultos con síndrome de activación de macrófagos (sam) en la enfermedad de still (incluida la artritis idiopática juvenil sistémica y la enfermedad de still del adulto) o con sam en el lupus eritematoso sistémico.

Type: Clinical Trials, phase III.
Hulp code: 5937B NI-0501-14.
Sponsored by: Swedish Orphan Biovitrum Ab, Sobi.
Signed date: 10/11/2021

Rodríguez De Rivera Garrido, FJ. Estudio de fase III, aleatorizado, abierto y de grupos paralelos para comparar la farmacodinámica, farmacocinética, eficacia, seguridad, tolerabilidad e inmunogenicidad de inyecciones subcutáneas múltiples de efgartigimod PH20 SC con las de infusiones intravenosas múltiples de efgartigimod en pacientes con miastenia grave generalizada.

Type: Clinical Trials, phase III.
Hulp code: 5784 ARGX-113-2001.
Sponsored by: Argenx Bv (Argenx Bvba).
Signed date: 10/02/2021

Rodríguez De Rivera Garrido, FJ. Estudio a largo plazo, en fase III, abierto, multicéntrico y con un solo grupo para evaluar

la seguridad y la tolerabilidad de múltiples inyecciones subcutáneas de efgartigimod ph20 sc en pacientes con miastenia grave generalizada.

Type: Clinical Trials, phase III.
Hulp code: 5785 ARGX-113-2002.
Sponsored by: Argenx Bv (Argenx Bvba).
Signed date: 23/03/2021

Rodríguez De Rivera Garrido, FJ. Estudio fase 3, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos para evaluar la eficacia y seguridad de tolebrutinib (sar442168) en adultos con miastenia grave generalizada.

Type: Clinical Trials, phase III.
Hulp code: 5987 EFC17262.
Sponsored by: Sanofi Aventis S.A.
Signed date: 25/11/2021


Rodríguez Salas, N. Preserve 1: estudio en fase III, aleatorizado, doble ciego de trilaciclib frente a placebo en pacientes que reciben Folfoxiri/Bevacizumab para el cáncer colorrectal metastásico.

Type: Clinical Trials, phase III.
Hulp code: 5699 G1T28-207.
Sponsored by: G1 Therapeutics, Inc.
Signed date: 15/01/2021

Rodríguez Salas, N. Estudio en fase II, multicéntrico, sin enmascaramiento, aleatorizado y controlado para comparar la eficacia de ro7198457 con la estrategia de actitud expectante en pacientes con cáncer colorrectal resecado en estadio II (riesgo elevado) y estadio III que presenten positividad de ADN tumoral circulante (adnct) tras la resección tumoral.

Type: Clinical Trials, phase II.
Hulp code: 5688 BNT122-01.
Sponsored by: Biotech Rna Pharmaceuticals.
Signed date: 10/03/2021

Rodríguez Salas, N. Ensayo en fase III global, multicéntrico, aleatorizado y controlado con placebo para comparar la eficacia y la



seguridad de fruquintinib, más los mejores cuidados paliativos frente a placebo, más los mejores cuidados paliativos en pacientes con cáncer de colorrectal metastásico resistente (fresco2).

Type: Clinical Trials, phase III.

Hulp code: Appendix 1 5592.

Sponsored by: Hutchison Medipharma Limited.

Signed date: 08/03/2021

Rodriguez Salas, N. Estudio epidemiológico para establecer laprevalencia de la expresión de adnct en pacientes con cáncercolorrectal en estadio II (riesgo alto) o en estadio III, despuésde haberse sometido a una intervención quirúrgica conintenciones curativas (r0), seguida por una quimioterapiaantineoplásica posquirúrgica con vigilancia de adnct duranteel seguimiento clínico.

Type: Estudios, phase EPA-SP.

Hulp code: PI-4838 BIO-OXA-2020-01.

Sponsored by: Biontech Rna Pharmaceuticals.

Signed date: 17/06/2021

Rodriguez Salas, N. Estudio abierto, aleatorizado, fase 3 comparando trifluridina/tipiracilo (s95005) en combinación con bevacizumab y capecitabina en combinación con bevacizumab en primera línea de tratamiento de pacientes con cáncer colorrectal metastásico que no son candidatas a terapia intensiva (estudio solstice).

Type: Clinical Trials, phase III.

Hulp code: Appendix 1 4983.

Sponsored by: Laboratorios Servier, S.L.

Signed date: 27/04/2021

Rodriguez Salas, N. Preserve 1: estudio en fase III, aleatorizado, doble ciego de trilaciclib frente a placebo en pacientes que recibenfolfoxiri/bevacizumab para el cáncer colorrectal metastásico.

Type: Clinical Trials, phase III.

Hulp code: Appendix 1 5699.

Sponsored by: G1 Therapeutics, Inc.

Signed date: 11/08/2021

Rodriguez Salas, N. Estudio de fase 3 aleatorizado de mrtx849 en combinación con cetuximab frente a quimioterapia en pacientes con cáncer colorrectal avanzado con mutación de kras g12c con progresión de la enfermedad durante o después del tratamiento de primera línea estándar.

Type: Clinical Trials, phase III.

Hulp code: 5861 849-010.

Sponsored by: Mirati Therapeutics, Inc.

Signed date: 15/09/2021

Rodriguez Salas, N. Observational retrospective study to evaluate realworld effectiveness, safety and tolerability of encorafenib plus cetuximab (ec) in 2nd line treatment of metastatic brafv600e-mutant colorectal cancer in spain.

Type: Estudios, phase EPA-OD.

Hulp code: PI-5017 TTD-21-01.

Sponsored by: Grupo Tratamiento Tumores Digestivos (Geracor).

Signed date: 25/11/2021

Romero Pareja, R. Estrategia de tratamiento precoz con dexametasona a dosis altas frente a dosis estándar enpacientes con neumonía por SARS-CoV-2 (COVID-19). ensayo clínico predexacov.

Type: Clinical Trials, phase III.

Hulp code: 6054 PREDEXACOV.

Sponsored by: Fundación Hospital Infanta Leonor.

Signed date: 01/12/2021

Romero Ribate, D. Estudio de 52 semanas de duración, aleatorizado, doble ciego, con doble simulación, de grupos paralelos, multicéntrico, de no inferioridad, para evaluar la tasa de exacerbación, las mediciones adicionales de control del asma y la seguridad en participantes adultos y adolescentes con asma grave con fenotipo eosinofílico tratados con gsk3511294 en comparación con mepolizumab o benralizumab.

Type: Clinical Trials, phase III.

Hulp code: 5834 206785.

Sponsored by: Glaxosmithkline Research And Development Limited .

Signed date: 06/07/2021

Saenz De Pipaon Marcos, M. Estudio de investigación sobre nutrición: efectos de la alimentación infantil con fórmula de leche de cabra o fórmula de leche de vaca sobre la der-matitis atópica (estudio giraffe).

Type: Estudio Producto Sanitario.

Hulp code: 5649 DGC201911 GIRAFFE.

Sponsored by: Dairy Goat Co-Operative Ltd.

Signed date: 21/04/2021

Sainz Costa, T. A phase IV, single-blind, randomised, controlled, multi-country study to evaluate the immunogenicity and safety of GSK's INFARIX HEXA (DTPA-HBV-IPVHIB) versus MCM vaccine BV's VAXELIS (DTAP5-HBV-IPV-HIB), when administered intramuscularly according to a 2, 4 and 12 month schedule in healthy infants and toddlers.

Type: Clinical Trials, phase IV.

Hulp code: 5753 212645.

Sponsored by: Glaxosmithkline Biologicals S.A.

Signed date: 26/03/2021

Sánchez Azofra, M. Análisis de la efectividad y seguridad del switch de adalimumab original a biosimilar en los pacientes con enfermedad inflamatoria intestinal.

Type: Estudios, phase EPA-OD.

Hulp code: PI-4840 GIS-2021-ADA-SWITCH.

Sponsored by: Perez Gisbert, Javier.

Signed date: 29/06/2021

Santos Simarro, F. Phase 2, open-label, dose-escalation and dose-expansion study of infgratinib, an FGFR 1-3-selective Tyrosine Kinase inhibitor, in children with achondroplasia: Propel 2.

Type: Clinical Trials, phase II.

Hulp code: Appendix 1 5596.

Sponsored by: Qed Therapeutics Inc.

Signed date: 05/10/2021

Soto Abanades, CI. Estudio clínico de fase 3 prospectivo, multicéntrico, doble ciego, aleatorizado, controlado con producto activo, triple simulado, de grupo paralelo, secuencial y adaptativo para comparar la eficacia y seguridad de las monoterapias de macitentan y tadalafilo con la combinación de dosis fija correspondiente en pacientes con hipertensión arterial pulmonar (hap), seguidas de un periodo de tratamiento abierto con una combinación de dosis fija de macitentan y tadalafilo.

Type: Clinical Trials, phase III.

Hulp code: Appendix 2 5319.

Sponsored by: Actelion Pharmaceuticals Ltd.

Signed date: 29/04/2021

Soto Abanades, CI. Estudio en fase III, prospectivo, aleatorizado, doble ciego, multicéntrico, controlado con placebo, de grupos paralelos y flexible con ampliación abierta para evaluar la eficacia y la seguridad de macitentan 75 mg en la hipertensión pulmonar tromboembólica crónica inoperable o persistente/recurrente.

Type: Clinical Trials, phase III.

Hulp code: Appendix 1 5543.

Sponsored by: Actelion Pharmaceuticals Ltd.

Signed date: 26/07/2021

Soto Abanades, CI. Estudio en cesta multicéntrico, aleatorizado, dobleciego (participante e investigador), controlado con placebo y de grupos paralelos para evaluar la seguridad, la tolerabilidad y laeficacia de MHV370 en participantes con síndrome de sjögren o enfermedad mixta del tejido conectivo.

Type: Clinical Trials, phase II.

Hulp code: 5947 CMHV370A12201.

Sponsored by: Novartis Farmaceutica, S.A.

Signed date: 13/09/2021


Spagnolo, E. Ensayo multicéntrico, aleatorizado, doble ciego, de grupos paralelos y abierto para el brazo del comparador acti-

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

vo, de fase IIb para evaluar la eficacia y la seguridad de tres dosis diferentes de un antagonista de p2x3 (bay 1817080) comparado con placebo y elagolix 150mg en mujeres con endometriosis sintomática.

Type: Clinical Trials, phase II.
Hulp code: 5725 BAY 1817080/20584.
Sponsored by: Bayer Ag.
Signed date: 08/02/2021

Spagnolo, E. Estudio de superioridad, multicéntrico, aleatorizado, doble ciego, de tres grupos paralelos en el que se evalúa la eficacia y seguridad de mifepristona (2,5 mg y 5 mg) frente a placebo en el tratamiento de la endometriosis en mujeres en edad fértil durante 24 semanas más un seguimiento de la eficacia y seguridad en pacientes tratadas con 2,5 mg y 5 mg de mifepristona.

Type: Clinical Trials, phase III.
Hulp code: Appendix 1 5280.
Sponsored by: Laboratorios Litaphar.
Signed date: 06/04/2021

Spagnolo, E. Ensayo multicéntrico, aleatorizado, doble ciego, de grupos paralelos y abierto para el brazo del comparador activo, de fase IIb para evaluar la eficacia y la seguridad de tres dosis diferentes de un antagonista de p2x3 (bay 1817080) comparado con placebo y elagolix 150mg en mujeres con endometriosis sintomática.

Type: Clinical Trials, phase II.
Hulp code: Appendix 1 5725.
Sponsored by: Bayer Ag.
Signed date: 07/09/2021

Tirado Requero, P. Estudio multicéntrico, aleatorizado, con enmascaramiento doble, controlado con placebo, de grupos paralelos para comparar la eficacia, la seguridad y la tolerabilidad de la administración subcutánea de fremanezumab, comparado con placebo como tratamiento preventivo de las migrañas episódicas en niños de entre 6 y 17 años.

Type: Clinical Trials, phase III.
Hulp code: Appendix 1 5683.
Sponsored by: Teva Branded Pharmaceutical Products R&D, Inc.
Signed date: 13/07/2021

Tirado Requero, P. Estudio multicéntrico, aleatorizado, con enmascaramiento doble, controlado con placebo, de grupos paralelos para comparar la eficacia, la seguridad y la tolerabilidad de la administración subcutánea de fremanezumab, comparado con placebo como tratamiento preventivo de las migrañas crónicas en niños de entre 6 y 17 años.

Type: Clinical Trials, phase III.
Hulp code: Appendix 1 5682.
Sponsored by: Teva Branded Pharmaceutical Products R&D, Inc.
Signed date: 13/07/2021

Tomás Pérez, M. Ensayo clínico de eficacia y seguridad, prospectivo, multicéntrico, aleatorizado, doble ciego controlado con placebo, con inmunoterapia subcutánea en pacientes con rinitis/rinoconjuntivitis con o sin asma de leve a moderadasensibilizados a gramíneas y cupresáceas.

Type: Clinical Trials, phase II.
Hulp code: 5869 DMV02-SIT-026.
Sponsored by: Immunotek.
Signed date: 29/04/2021

Tomás Pérez, M. Ensayo clínico de eficacia y seguridad, prospectivo, multicéntrico, aleatorizado, doble ciego controlado con placebo, con inmunoterapia subcutánea en pacientes con rinitis/rinoconjuntivitis con o sin asma de leve a moderadasensibilizados a gramíneas y olivo.

Type: Clinical Trials, phase II.
Hulp code: 5883 DMV03-SIT-027.
Sponsored by: Immunotek.
Signed date: 19/05/2021

Tomás Pérez, M. Estudio de fase III, multicéntrico, internacional, aleatorizado, doble ciego, controlado con placebo, de inducción y mantenimiento para evaluar la eficacia y la

seguridad de cc-93538 en sujetos adultos y adolescentes con esofagitis eosinofílica.

Type: Clinical Trials, phase III.
Hulp code: 5832 CC-93538-EE-001.
Sponsored by: Celgene International li -Sarl.
Signed date: 26/04/2021

Torres Santos-Olmo, RM. Estudio de evaluación y manejo de dolor agudo en servicios de urgencias hospitalarios intervención educativa: estudio edurg17.

Type: Estudios, phase EPA-SP.
Hulp code: PI-3022 EDURG17.
Sponsored by: Laboratorio Menarini Sa.
Signed date: 22/07/2021

Trueba Vicente, A. Ensayo clínico que evalúa la tromboprolifaxis óptima y las estrategias anticoagulantes en pacientes con neumonía covid 19.

Type: Clinical Trials, phase III.
Hulp code: 5837B PROTHROMCOVID.
Sponsored by: Fundación Hospital Infanta Leonor.
Signed date: 17/05/2021

Udaondo Gascón, C. Estudio de fase 3 multicéntrico, doble ciego, aleatorizado, controlado con placebo y de grupos paralelos para evaluar la eficacia, seguridad y farmacocinética de apremilast en niños de 5 a menos de 18 años de edad con artritis psoriásica juvenil activa (peapod, por sus siglas en inglés).

Type: Clinical Trials, phase III.
Hulp code: 5673 20190529.
Sponsored by: Amgen, S.A.
Signed date: 18/01/2021

Udaondo Gascón, C. Estudio de fase 3 multicéntrico, doble ciego, aleatorizado, controlado con placebo y de grupos paralelos para evaluar la eficacia, seguridad y farmacocinética de apremilast en niños de 5 a menos de 18 años de edad con artritis psoriásica juvenil activa (peapod, por sus siglas en inglés).

Type: Clinical Trials, phase III.
Hulp code: Appendix 2 5673.
Sponsored by: Amgen, S.A.
Signed date: 21/05/2021

Udaondo Gascón, C. Estudio de fase 3 multicéntrico, doble ciego, aleatorizado, controlado con placebo y de grupos paralelos para evaluar la eficacia, seguridad y farmacocinética de apremilast en niños de 5 a menos de 18 años de edad con artritis psoriásica juvenil activa (peapod, por sus siglas en inglés).

Type: Clinical Trials, phase III.
Hulp code: Appendix 3 5673.
Sponsored by: Amgen, S.A.
Signed date: 14/09/2021

Udaondo Gascón, C. Estudio abierto de dosis múltiples para evaluar la farmacocinética, la seguridad y la tolerabilidad de upadacitinib en pacientes pediátricos con artritis idiopática juvenil de evolución poliarticular.

Type: Clinical Trials, phase III.
Hulp code: Appendix 1 5188.
Sponsored by: Abbvie Deutschland GmbH.
Signed date: 14/07/2021

Urbelz Perez, A. Ensayo clínico que evalúa la tromboprolifaxis óptima y las estrategias anticoagulantes en pacientes con neumonía covid 19.

Type: Clinical Trials, phase III.
Hulp code: 5837 PROTHROMCOVID.
Sponsored by: Fundación Hospital Infanta Leonor.
Signed date: 08/04/2021

Valencia Ortega, E. Ensayo clínico piloto para evaluar la eficacia, seguridad y tolerabilidad del cambio a un tratamiento con bicitegravir/ftc/taf (bictarvy®) más darunavir/cobicistat en pacientes infectados por VIH-1 altamente tratados.

Type: Clinical Trials, phase III.
Hulp code: 5655 BIDA.



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Sponsored by: Asociacion Ris (Red De Investigacion En Sida).
Signed date: 03/02/2021

Valencia Ortega, E. Estudio clínico de fase 3, aleatorizado, doble ciego y comparativo con tratamiento activo para evaluar la actividad antirretroviral, la seguridad y la tolerabilidad de doravirina/islatravir una vez al día en participantes infectados por el vih-1 sin tratamiento previo.

Type: Clinical Trials, phase III.
Hulp code: Appendix 1 5483.

Sponsored by: Merck Sharp & Dhome Corp.
Signed date: 07/10/2021

Vallespín García, E. Estudio observacional retrospectivo para describir la prevalencia de distrofias hereditarias de retina asociadas a la mutación bialélica rpe65 en España: estudio insight-65.

Type: Estudios No EPA.
Hulp code: PI-4813 CLTW888A1ES01.
Sponsored by: Novartis Farmaceutica, S.A.
Signed date: 23/06/2021

Vazquez Colomo, P. Eficacia y tolerabilidad de RD03/2016 (solución oftálmica de levofloxacino; ketorolacotrometamol 0,5 + 0,5% m/v) para el tratamiento de la conjuntivitis bacteriana en adultos: estudio clínico en fase II de no inferioridad, multicéntrico, aleatorizado, enmascarado para el evaluador. Estudio MIRAKLE.

Type: Clinical Trials, phase II.
Hulp code: 5778 LEVOKETO_02-2020.
Sponsored by: Ntc Srl.
Signed date: 30/09/2021

York, EEV. Ensayo clínico aleatorizado controlado y simple ciego en mujeres con cáncer de mama y linfadenectomía axilar, para evaluar la efectividad de hemopatch® en la reducción del drenaje seroso postquirúrgico.

Type: Estudios, fase EPA-OD.
Hulp code: 5944 HVST-HEMO-20.
Sponsored by: Asociación De Cirujanos De Mama De Toledo.



Signed date: 14/10/2021

Zamora Auñón, P. Her2-predict: estudio traslacional de muestras de tumor procedentes de los ensayos DS8201-A-U301, DS8201-A-U302 y DS8201-A-U303.

Type: Clinical Trials, phase II.
Hulp code: 5783 SOLT1-1804.
Sponsored by: Grupo Solti.
Signed date: 23/02/2021

Zamora Auñón, P. SERENA-4: Ensayo de fase III aleatorizado, multicéntrico, doble ciego, de AZD9833 (un SERD, degradador selectivo del RE, oral) más Palbociclib en comparación con anastrozol más palbociclib para el tratamiento de pacientes con cáncer de mama avanzado con receptores estrogénicos positivos y her2 negativo que no han recibido ningún tratamiento sistémico para la enfermedad avanzada.

Type: Clinical Trials, phase III.
Hulp code: 5791 D8532C00001.
Sponsored by: Astrazeneca Ab.
Signed date: 06/04/2021

Zamora Auñón, P. Estudio fase 3, aleatorizado, multicéntrico, doble ciego de sar439859 más palbociclib en comparación

con letrozol más palbociclib para el tratamiento de pacientes con cáncer de mama re(+), her2(-) que no han recibido ningún tratamiento antineoplásico sistémico previo para la enfermedad avanzada.

Type: Clinical Trials, phase III.
Hulp code: Appendix 1 5644.
Sponsored by: Sanofi-Aventis Recherche & Developpement.
Signed date: 02/06/2021

Zamora Auñón, P. Estudio de fase 3, aleatorizado, doble ciego, para comparar la eficacia y seguridad de iraparib frente a placebo en participantes con cáncer de mama her2 negativo conmutación en brca o cáncer de mama triple negativo, con enfermedad molecular basada en la presencia de adn tumoral circulante después de una terapia definitiva (zest).

Type: Clinical Trials, phase III.
Hulp code: 5882 213831.
Sponsored by: Glaxosmithkline, S.A.
Signed date: 25/06/2021

Zamora Auñón, P. Ensayo fase III de trastuzumab deruxtecán (t-dxd) con osin pertuzumab versus taxanos, trastuzumab y pertu-

zumab en primera línea de cáncer de mama metastásico her2 positivo (destiny-breast09).

Type: Clinical Trials, phase III.
Hulp code: 5830 D967UC00001.
Sponsored by: Astrazeneca Ab.
Signed date: 16/07/2021

Zamora Auñón, P. Estudio de fase III, multicéntrico, aleatorizado, abierto y controlado de trastuzumab deruxtecán (t-dxd) frente a trastuzumab emtansina (t-dm1) en pacientes con cáncer de mama primario her2 positivo de alto riesgo que presentan enfermedad invasiva residual en mama o en ganglios linfáticos axilares tras el tratamiento neoadyuvante.

Type: Clinical Trials, phase III.
Hulp code: 5733 DS8201-A-U305 (DESTINY-Br).
Sponsored by: Daiichi Sankyo Inc.
Signed date: 12/07/2021

Zamora Auñón, P. Estudio de fase III, multicéntrico, aleatorizado y abierto para evaluar la eficacia y la seguridad de giredestrant adyuvante en comparación con la monoterapia endocrina adyuvante elegida o el médico en pacientes con cáncer de mama incipiente con receptores estrogénicos positivos y her2 negativo.

Type: Clinical Trials, phase III.
Hulp code: 5957 GO42784.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 22/11/2021

Zamora Auñón, P. Ensayo de fase III aleatorizado de palbociclib con tratamiento endocrino adyuvante estándar frente a monoterapia con tratamiento endocrino adyuvante estándar en cáncer de mama precoz con receptores hormonales positivos (rh+) y her2-negativo.

Type: Clinical Trials, phase III.
Hulp code: 4879 Appendix 1.
Sponsored by: Austrian Breast & Colorectal Cancer Group (AbcsG).
Signed date: 26/10/2021



2.7 Platforms

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

The Scientific Support Platforms are services with the aim of providing a scientific, technical or technological support to research or innovation projects.

They have been created to provide services of advice, methodological support, biostatistical or epidemiological analysis within others and they give the scientific and technical support that researchers need to carry out the research projects.

2.7.1. BIOBANK

The Hospital La Paz Institute for Health Research Biobank (IdiPAZ Biobank) is a platform of support service to the Institute's research, product of the integration of different pre-existing nodes with a long and fruitful research trajectory within the University Hospital La Paz. The IdiPAZ Biobank works to obtain, store, manage and distribute large collections of human biological samples of diseases of interest for researchers.

In 2020, the Biobank increased its capacity with the incorporation of new scientific-technical services, and as result the platform has been renamed as Biobanks and Biomodels platform.

This service is created with the collaboration of the University Hospital La Paz, the Foundation for Biomedical Research of the University Hospital La Paz (FIBHULP) and the Carlos III Health Institute, being integrated into the Network of Hospital Biobanks (RetBioH). The Biobank of the University Hospital La Paz - Institute of Health Research of the University Hospital La Paz - IdiPAZ is registered in the National Biobank Network of the Carlos III Health Institute with the code B.0000684.

The **Platform for Biobanks and Biomodels of IdiPAZ** (PT20/0004) belongs to the **ISCIII Biobanks and Biomodels platform** (<https://www.isciiibiobanksbiomodels.es/>) to support research in Biomedicine and Health Sciences from Strategic Health Action 2017-2023 of the Carlos III Health Institute.



The ISCIII Biobanks and Biomodels Platform has joined the European Biobanking Infrastructure (BBMRI-ERIC) as an observing member, acting as the national node in BBMRI-ERIC, one of the most relevant research platforms in the European Union.



Since 2018, the Biobank of IdiPAZ was certified according to the ISO 9001:2015 quality management system standard within the scope of IQNet Certificate IdiPAZ Number ES-0512/2018.

■ Objectives

The main objective of the IdiPAZ Biobank is to promote biomedical research, which will increase and improve the quality of scientific production in Spain. This is a specialized work in the management of human biological samples and their associated data for biomedical research in accordance with the legislation in force in Spain, Law 14/2007 on Biomedical Research and the RD of Biobanks 1716/2011. This guarantees the confidentiality of the samples and associated data.

The IdiPAZ Biobank provides researchers with an agile channel to access samples, their products and data associated with quality assurances and ethical-legal adaptation.

The obtaining, and if necessary the revocation, of the patient's informed consent is controlled. Special attention is given to guarantee the protection of privacy and the confidential treatment of personal data contained in the IdiPAZ Biobank, clinical data and research results.

Thanks to this, the development of a continuous dynamic of analysis and evaluation of the needs of the users of the Biobank is favored. In addition, the activity of the IdiPAZ Biobank is made known and valued to society and, especially, in the field of patient and affected associations.

The IdiPAZ Biobank will provide benefits at different levels, starting with donors, patients, society in general and the clinicians and researchers involved. It also aims to facilitate communication and cooperation of different groups with common interests both nationally and internationally.

All of this will result in a higher quality of research and an increase in scientific production, without forgetting the strict compliance with the regulations on Data Protection and the Rights to Privacy and Confidentiality of all patients (Organic Law 3/2018 and Regulation General Data Protection 2016/679).

Composition

Scientific Director

Paloma Gómez Campelo (PhD)

Coordinator

Marina Arranz Álvarez

Senior Experts in Pathology and Cytology

Sandra NietoTorrero

Yaiza Pedroche Just

Celia García García

HUB Organoids Manager

Laura Córdoba García

Contact

biobanco.hulp@salud.madrid.org

biobanco@idipaz.es

Phone: Biobank Laboratory (+34) 91 207 11 91

Secretary

Susana García Pérez

Phone: (+34) 91 207 15 12

investigacion.hulp@salud.madrid.org

Scientific Committee

David Hardisson Hernández (MD, PhD)

Francisco Arnalich Fernández (MD, PhD)

Inmaculada Ibáñez de Cáceres (PhD)

Enrique Espinosa Arranz (MD, PhD)

Eduardo López Granados (MD, PhD)


Alicia Hernández Gutiérrez (MD, PhD)



Equipment

- Eight -80°C deep freezers equipped with remote alarm temperature control and a CO2 backup system. Seven of these are equipped with an open door control software
- One tank of liquid nitrogen at its gas phase with an alarm temperature control and a lack of CO2 detector
- W-2D tube system with a data matrix codification for liquids, with a scanner to read col boxes and reader for the identification and the traceability of the tubes
- Combined refrigerator of 4° C y - 20° C
- Cryostat to cut frozen samples
- Microtome y bath/coating to cut paraffin samples
- Laser Microdissector
- Biological safety cabins IIA
- Centrifuge with capacity to process samples in tubes and Eppendorfs
- Automatic platform to manipulate and trace liquids
- One mini coolers to freeze inclined biological samples below 1°C
- Two containers to freeze and transport Isopentane
- One container for the transport of isopentane samples
- Vortex Mixer /agitator
- Spectrophotometer (Nanodrop®)
- Fungibility: basically kits and the necessary products to process and preserve tissues, blood, and cells.
- Printer/photocopier/scanner
- 3 computers and a management computer system
- Label printing system and a bar code reader connected to the management software

Platform for Biobank and Biomodels of IdiPAZ



Portfolio of services

HUB Biobank



Technical and scientific assessment:

- Collection and management of new collection
- Work Methodology/ Methods
- Quality control of DNA/ARN sample treatment
- Expert training to use Biobank management system
- Training and advice on the use of Biobank management software.
- Information to the investigator on the custody, deposit, availability and transfer of samples associated with the biobank.
- Training of trainees (FCTs) of training cycles.

Sample/collection management:

- Coordinating a collection of samples in multiple study/research centers
- Storage of pre-existing collections under LIB 14/2007.
- Storage of preexisting samples in accordance with Spain's Biobank laws LIB 14/2007 and 1716/2011 Royal Decree
- Management and control of Informed Consent (CI) and/or clinic's regarding samples
- Aliquot of blood/salines/plasma/other liquids
- Sample reception and codification

Histology techniques:

- Making paraffin block
- Making frozen tissue blocks
- Paraffin/frozen cuts
- Hematoxylin and eosin stain (H&E)
- Other kinds of stains
- Laser microdissection

Cell techniques:

- Purifying and freezing of mononuclear cells of peripheral blood (PMBCs)

Molecular Techniques:

- DNA and RNA quantification via spectrophotometer (NANODROP)

Researchers who wish to deposit their collections in IdiPAZ' Biobank will have to sign an agreement of sample deposit (in which the terms and conditions under which the Biobank will deposit the samples) and in agreement with the existing legislation on the subject. Also, researchers who wish to use our samples will have to sign a Transfer Agreement (Material Transfer Agreement) in which the terms and conditions under which the Biobank will grant the samples.

HUB Organoids



IdiPAZ's Biobank is working on the establishment of a living biobank of organoid 3D models directly generated from patient biopsies. Patient derived organoids (PDOs) are novel in vitro 3D cell models that preserve the molecular, structural and functional characteristics of their tissues of origin, representing a clinically-relevant alternative to traditional 2D cell lines and an effective tool to study the biology of human tissues in health and disease. Currently we have a comprehensive collection of over 50 highly characterized human intestinal organoids, including rectum and colon, derived from both healthy and colorectal cancer biopsy tissue. This organoid patient-derived collection includes a detailed description of associated patient clinical and pathological data of great value for translational research purposes, as well as histological and molecular characterization of both the tissue of origin and the resulting organoid cultures.


Areas of application:

- Studies of tissue morphogenesis and organ development
- Modelling of infectious, genetic and inflammatory diseases
- Oncology and immuno-oncology
- Identification of diagnostic and prognostic biomarkers
- Drug screening for toxicity and efficacy
- Personalized and precision medicine

Portfolio of services:

- Culture of human healthy intestine organoids derived from donor biopsies
- Culture of human tumoral intestine organoids derived from donor biopsies
- Paraffin/OCT embedding and sectioning
- Hematoxylin and eosin characterization
- Characterization by immunofluorescence and confocal microscopy of organoid sections and 3D organoids
- Cryopreservation and biobanking

■ Biobank's scientific indicators




Publications in 2021 with the mention of IdiPAZ Biobank authorship attribution

Papers	Journal	Impact factor	Cites
1	Biomed Hub	Not indexed	4
1	BioRxiv PREPRINT	Not indexed	0
3	Cancers	6.639	56
1	Clin Epigenet	6.551	2
1	ClinicalMedicine	Not indexed	7
1	Diabetes Res Clin Pract	5.602	1
1	Eur Geriatr Med	1.71	41
1	Front Cell Dev Biol	6.684	19
1	J Infect	6.072	4
1	Microorganisms	4.128	4
1	Mod Pathol	7.842	2
1	Research square PREPRINT	4.064	3
1	Scientific Reports	4.38	1
1	Biomed Hub	Not indexed	4
1	Biomed Hub	Not indexed	4
1	Biomed Hub	Not indexed	4

Finally, the recent emergence of the novel pathogenic SARS-coronavirus 2 (SARS-CoV-2) and its rapid national and international spread pose, have provided the IdiPAZ Biobank the opportunity to have started a COVID-19 Collection.

SARS-CoV-2 Samples



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

2.7.2. BIOSTATISTIC

The objective of the Biostatistics Section is to provide methodological support to the professionals of the "La Paz" University Hospital, in general to the IdiPaz professionals, and to provide technical solutions for the optimization of clinical processes incorporating the necessary technologies for it.

■ Composition

Clinical Biostatistics

Mariana Díaz Almirón

mariana.diaz@idipaz.es

Tel: (+34): 912071791

Itsaso Losantos García

itsaso.losantos@salud.madrid.org

Tel: (+34): 912071791

Bioengineer

Francisco Gayá Moreno

francisco.gaya@salud.madrid.org

Tel: (+34): 912071791

■ Portfolio of services


- Study design
- Creation of data collection systems (such as ms Access)
- Technical support in the development of studies.
- Support for the design and analysis of observational epidemiological studies.
- Assistance in the design, analysis and interpretation of validation studies of diagnostic tests in the clinical hospital context.
- Development of information processing systems (clinical image, readings of measuring devices, implementation of statistical methods ...). Analysis of

results: Multivariate Analysis (Discriminant Analysis, Correspondence Analysis, Factor Analysis, Survival Analysis, Analysis with competitive risks. ..), Generalized Linear Models including Models with Mixed Effects and Generalized Equation Models, development of Risk Models for classification and prediction, construction of Scoring Systems for Risk Assessment, Analysis of Growth Curves, Clinical Trial Methodology, Methods of Sequential Data Analysis, Analysis of High-dimensional Data (Analysis of microarrays). Bicluster Analysis. Resampling Methods (Bootstrap, Jackknife, ...).


- Presentation and dissemination of results
- Realization of training activities

■ Activity Carried Out During 2021


Distribution by Center



Distribution by Research



Distribution by Research Statement



Distribution by Required Support



Pertaining to a Research Line



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

2.7.3. EXPERIMENTAL SURGERY

The Experimental Surgery Section is a support unit for research and teaching. In the research field, the Section develops biomedical research projects and fine-tunes procedures for new diagnostic and therapeutic techniques that use laboratory animals. In the teaching field, the Section organises and supports training courses in surgical, microsurgical, laparoscopic and anaesthetic techniques.

■ Composition

Section Head

Manuel Quintana

manuel.quintana@salud.madrid.org

Phone: (+34) 91 20715 81

Veterinarian

Carlota Largo Aramburu

carlota.largo@salud.madrid.org

Phone: (+34) 91 207 15 81

Secretary

Irene Cuevas Gordo

irene.cuevas@salud.madrid.org

Phone: (+34) 91 727 71 54

Technicians and assistants

Isabel Rodríguez Martín

Mar Varona García

Fernando Gil Villaverde

Pedro Gallego

Sonsoles Jiménez Mediano



bits. The remaining three accommodate rodents (rat, mouse and gerbil). The housing of rodents has controlled ventilation systems (a ventilated rack for mice and another for rats) and conventional systems in shelves. It also has a sealed positive and negative pressure room.

■ Animal facility

The research and teaching at IdiPAZ involving the use of laboratory animals is managed via the animal platform of IdiPAZ, and is overseen by Dr. Carlota Largo Aramburu. In this department we develop biomedical research projects, training courses specific to the various specialties as well as procedures for putting in place new diagnostic techniques or therapies that involve the use of experimental animals. In addition, the animal facility works with the Ethics Committee for Animal Wellbeing, whose authorisations is required for all procedures.

The animal facility is located in basement 2 of the IdiPAZ building within the hospital complex. The facility provides a total of 10 rooms for animal housing, in both breeding and experimental phases, two rooms for animal handling and experimental procedures, a room for washing material, which includes a cage washer, an autoclave and a pressurebased washing system, and several storage rooms for clean materials, feed and wood shavings for cages. In addition, for its proper functioning, the animal facility is connected with the rest of the departments of Experimental Surgery where there is a double operating theatre, a microsurgery room and various additional rooms (dressing areas, offices, and store rooms).

The species typically used include: rodents (rats, mice and gerbils), rabbits, pigs, sheep and goats, and occasionally dogs, cats or guinea pigs. Recently, a fish housing unit has been established (zebra fish). To avoid contamination and permit a good workflow, the rooms for housing of large animals are physically separated from those for the rodents and the rest of the facilities (washing area, store rooms, or the handling room). In addition, all the rooms include an external video camera system to monitor the interior while avoiding the unnecessary entrance of unauthorised personnel.

The cages provide the minimum dimensions required for housing pigs and/or small ruminants. The structure of each cage is includes stainless steel anchored to the wall, with sliding separators that allow the expansion of the space by uniting two cages. The rooms have the slope needed to encourage the elimination of solid residue via a drain located in the rear of the cage. All of the drains are equipped with protection systems to prevent the entrance of rodents or insects.

■ Equipment

The Section consists of two microsurgery rooms, an operating room and an animal facility. The microsurgery room has surgical loupes and microscopes, as well as inhalers anaesthesia systems for rodents. All experimental procedures with rodents are performed in this room. Its layout, with fixed and mobile posts, allows for the implementation of microsurgical and laparoscopic courses with simulators.

The operating room is equipped with double team surgical tables and anaesthesia stations with monitoring equipment, which allow for two surgeries to be performed simultaneously. It is also equipped with laparoscopic, ultrasound and C-Arm X-ray equipment. All procedures performed on large animals are carried out here, along with training courses on surgical, laparoscopic and anaesthetic techniques. The animal facility has a total of five rooms for conventional accommodation of animals, in both the breeding phase and for experimentation. Two of these rooms have modular enclosures for housing large species such as pigs, sheep and rab-

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

For the cleanliness of the room and the animals, there are hot and cold water connections via a hose.

The rabbit room includes modular mobile crate racks of 3, 6 or 9 cages. The rabbits are kept in individual stainless steel cages with plastic grids. They also have a box structure inside that allows the animal to hide or go up to a higher position. The stainless steel feeders and drinking water are located in the cage door. Faeces and urine are collected in an extractible stainless steel tray. This room has a central drain with similar characteristics as those in the large animal room.

The rodent area is separated from the rest of the facility via a gate system (without locking doors) where staff can dress appropriately before entering (boots, robe, gloves, hat and mask). In this area, 5 rooms are located for the housing of rats and mice in both breeding and experimental phases and a room for fish. There is a storeroom for feed and shavings and a room for handling and the performance of procedures.

In addition to two large areas of animals, the animal facility includes:

- A washroom equipped with a cage washer (Hobart), a stainless steel pool and an autoclave. It also has a pressure wash system for cleaning the cages and/or visits that require it.
- A room for handling large animals for the performance of procedures with a table and surgical lamp, surgical cart, monitoring equipment and a C-arm X-Ray.
- Store room (clean material).
- Control room with computers for environmental control.

The animal facility complies with all current legislation and is registered with number ES-280790001941.

■ Animal facility

- Animals for experimentation (own breeding)
- Housing and maintenance of animals
- Leasing of spaces for conducting courses (microsurgery laboratories and operating room)
- Performance of surgical procedures on large animals (leasing space and anaesthesia, does not include surgery)

Applications for animal experimentation projects 2021

- Porcine coronary ischemia/reperfusion model, for testing the cardioprotective effect of molecules involved in acute heart failure. Dr. Carlos Zaragoza
- Development of organoids as a study tool and experimental model of regenerative therapy in intestinal transplantation. Dr. Francisco Hernández Oliveros
- Hydrogels that respond to infrared energy and contain high-capacity adenoviruses. Application in bone regeneration. Dr. Nuria Vllaboa
- Treatment of sepsis due to peritonitis with systemic mesenchymal stem cells. Dr. Isabel Pascual

- Prevention of rejection by adoptive transfer of regulatory T lymphocytes in an experimental model of intestinal transplantation. Dr. Francisco Hernández Oliveros
- Optimization of the survival of the transplanted solid organ to avoid rejection, through the induction of immunological tolerance through hematopoietic mixed chimerism (OneTransplant4Life). Dr. Antonio Perez
- Testing of the Ablaview system to guide chronic vein isolation by irreversible electroporation ablation in a Large White pig model. Dr. David Herranz
- Study of the effect of immunomodulators of the innate immune system on the response to tumors. Dr. Carlos del Fresno
- Stem cells derived from adipose tissue in the treatment of corneal limbal damage. Dra. Paz de Miguel
- Differential regeneration of sensory and motor neurons: Development of bicompartimentalized scaffolds and obtaining different schwann cell phenotypes for the creation of independent molecular environments. Dr. Daniel Gonzalez
- Development of an artificial biohybrid retina based on silk fibroin with human retinal cells to replace damaged tissue in degenerative retinal diseases. Dr. Daniel Gonzalez
- Porcine coronary ischemia/reperfusion model, for testing compounds involved in cardioprotection. Dr. Carlos Zaragoza Sanchez
- Capillary micrograft of follicular units in Sprague Dawley rats with cicatricial alopecia secondary to burns. Carlos Delgado
- Use of epigallocatechin for the prevention and treatment of fetal alcohol syndrome. Experimental and clinical study. Dr. Leopoldo Martinez



2.7.4. DOCUMENTALIST



The documentalist platform is responsible for the analysis, maintenance and dissemination of the scientific production generated by the Institute. This production is collected both in the bibliometric reports that are published on the IdiPAZ website as well as in the Institute's Research Report which is published annually and in which all the research activity of our research groups is collected. Also key is the support of the unit to the scientific management when carrying out internal evaluations of researchers or research groups.

The platform provides support to all IdiPAZ researchers when performing bibliographic searches, managing ORCID, CVN or different researcher profiles, advising on scientific evaluation, advising on quality criteria for scientific publications and any training related to this service.

This platform has also played a key role in publicizing and promoting open access policies, as well as participating in the initiatives carried out by public institutions for the creation of institutional repositories.

Through the documentalist, IdiPAZ members can print the posters that will be used to disseminate the results of their research at the congresses of their specialties.

Since 2018, the Documentalist Platform of IdiPAZ was certified according to the ISO 9001:2015 quality management system standard ES-0512/2018.

■ Composition

Head

Raúl Román Cañizares
documentalista@idipaz.es
Phone: (+34) 91 727 75 76

■ Objectives

The main objectives of the platform are:

- To show society the relevance of scientific research conducted at IdiPAZ.
- Facilitate transparency and maximize the impact of the scientific production of the institute.
- Collaborate in the transmission of knowledge generated in the IdiPAZ environment.

■ Portfolio of services

- Elaboration of Research Report: Design of forms to collect information, bibliographic searches and calculation of bibliometric indicators.
- Collaboration with researchers: Collaboration with research personnel in the search and location of documents useful for their research.
- Elaboration of bibliometric reports: Creation of control tools to keep a record of the Institute's publications.
- Evaluation of researchers: Calculation of bibliometric indicators for decision making in calls where there is a quota of researchers.
- Bibliometric evaluation of research groups: Calculation of bibliometric indicators to determine the scientific production of both established IdiPAZ groups and new groups for their subsequent inclusion in the Institute.
- Advice on bibliographic search tools: Help in the knowledge of the different valid tools for conducting bibliographic searches in specialized databases.
- Advice on the use of bibliometric techniques: Assistance in the knowledge and application of bibliometric indicators to scientific production.
- Poster printing for congresses



2.7.5. UICEC



La Paz Research and Clinical Trials Unit (Unidad de Investigación Clínica y Ensayos Clínicos del Hospital La Paz, HULP-UICEC), is one of the IdiPAZ supported research platforms. Its purpose is to promote and support clinical research at La Paz University Hospital and to establish collaboration links with other investigation centres. Presently HULP-UICEC is the coordinator of the Spanish Clinical Research Network (SCReN), research platform of Instituto de Salud Carlos III.

Its wide portfolio of services provides support to researchers in design, set-up (including IRBs and Competent Authority approvals), management, data analysis and report writing of clinical trials and research projects. As Trials Managers, assists the Principal Investigators in the preparation of feasibility and financial reports, administrative tasks (i.e., investigators coordination, schedule of visits), as well as projects development and research, particularly in the recruitment and follow-up of patients and data collection, assistance in audit, inspections and adverse drug reactions management according to regulatory procedures, among other tasks. We also perform nursing activities and laboratory management, obtaining, processing and shipping the samples to central laboratories. All operations are GCP compliant as needed.

HULP-UICEC also runs a Phase I-II Trial Unit; the facilities and equipment allows harbour early phase clinical trials both in healthy volunteers and patients (children and adults).

■ Composition

Head

Jesús Frías Iniesta (MD, PhD)
jesus.frias@salud.madrid.org

UICEC Manager

Alberto M. Borobia Pérez (MD, PhD)
alberto.borobia@salud.madrid.org
Phone: (+34) 912 071 466

Scientific Coordinator

Antonio J. Carcas Sansuán (MD, PhD)
antonio.carcas@salud.madrid.org

Clinical Pharmacologist

Elena Ramírez García (MD, PhD)
Irene García García (MD)
Alicia Marín Candón (MD)
Javier Queiruga (MD)
Amelia Rodríguez Mariblanca (MD)
Lucía Martínez de Soto (MD)

International Project Manager

Paloma Moraga Alapont (MSc)
Paula Valle Simon (MSc)
Paula Prieto (MSc)

National Project Manager

Rocío Prieto (PhD)

Project Manager Paediatrics Oncology Trials

Pilar Guerra García (MD)
Cristina Blasco (MsC)

Clinical Research Associate

Marina Aparicio Marlasca (PhD)
Francisco Borrel (MsC)
M^a Luisa de Frías (PhD)
Pablo Molina (MsC)

Bioestaticians

María Jiménez González
Vega Rey Mauleón

Technical Secretary of SCReN

Victoria Hernández Rubio
María José Rubira Touriño
Gema del Prado Marugán
Victor Alelú Hernández
Amparo Sánchez Correa

Data Entry

Silvia Llorente
Beatriz Llorente Robledo

Clinical Trials Nurses

Vega Mauleón Martínez (MsC)
Raquel de Madariaga Castell
Laura Vitón Vara (MSc)
Cristina López Crespo (MsC)
Paula de la Rosa Veja (MsC)
Marta Sanz García

Nursing supervisor

Patricia Luna Castaño

Receptionist /Clinical Trials Assistant

Cristina Miragall Roig
Marisol Díaz Guerra
ucicec.hulp@salud.madrid.org
Phone: (+34) 912 071 466

■ Facilities

- 6 Work offices (28 work stations)
- 1 Meeting room (with audiovisual and teleconference systems)
- 1 Archive room
- Phase I/II Clinical Trial Unit:
 - A hospital ward with eight beds and four chairs (children and adults)
 - 1 Doctor's office
 - 1 Central point for sample collection
 - 1 Sitting room
- Carlos III Satellite Unit
 - 1 Work office and doctor's office
 - 1 Laboratory

■ Equipment

- 1 ECG
- 1 Centrifuge (Carlos III Satellite Unit)



- 2 Refrigerated centrifuge
- 1 Refrigerator
- 1 Room temperature chamber (Carlos III Satellite Unit)
- 3 -20°C freezers (1 in Carlos III Satellite Unit)
- 2 -80°C deep freezer
- 4 Vital signs monitors
- Defibrillator
- Temperature recording system
- Digital clocks synchronised by GPS
- 2 medical scales (1 in Carlos III Satellite Unit)
- Digital blood pressure monitors and pulse oximeters
- Digital timers
- Crash trolley
- 2 Cure trolleys
- Video surveillance system
- 11 patient calling devices
- 4 patient surveillance cameras

■ Portfolio of services

The portfolio of services includes more than 80 tasks grouped into:

- Methodologic support
- Clinical trial pre-study activities
- Study development
- Finalization and closure tasks
- Pharmacovigilance
- Statistics and data management
- Medical and nursing tasks

2.7.6. INTERNATIONALISATION

The Internationalisation Platform of IdiPAZ is the office in charge of mobilising, promoting and managing the international projection of the research groups. Our continuous objective is to promote the different research groups that make up the institute at an international level, identifying possible synergies between groups and centres, new partners and sources of funding, as well as the formation of strategic alliances. To this end, we try to maintain an open dialogue not only with our researchers but also with the centres from which the future of research is designed and planned, particularly in the European Union.

Throughout 2021, the Platform has relied on the efforts of:

José Luis Narro Villanueva, MBA

Santi Rello Varona, PhD

Year 2021 watched the take-off of the new EU Framework Programme for Research & Innovation: Horizon Europe (HEU). Every new programme represents an evolution and a sophistication of the funding instruments. New rules, new focus, new templates create challenges for the participation. From the Platform, we have tried to be updated in all the new requirements so we can better assist all of you in your participation.

We have attended 79 events, workshops and information days concerning the new rules and characteristics of HEU. The increased focus on R&I impact, the new rules of funding were, among others, the major items in these sessions.

In 2021, we have participated in 18 proposal for HEU framework programme (and one to the last emergency call of H2020). This represents a significant decrease from the previous year, but a huge step forward in comparison with 2014 (the first year of H2020), when only two proposal were presented. Two of the proposals participated by IdiPAZ (UNDINE, ISIDORE and VACCELERATE) were funded. This will represent an excess of 600.000 € for IdiPAZ in the following years.

Moreover, in 2020 IdiPAZ was the kick-off of RISEinFAMILY, the first EU-funded project in which the institute act as coordinator. This represents a new challenge for the Platform, which has to add the management the efforts of an international coalition of partners to its schedule.

Besides, we also keep doing our job in supporting the institution in get aligned with EU initiatives such us the European Open Science Cloud Association or the Coalition for the Reform of Research Assessment. In addition, we still support the European Reference Network in paediatric transplantation (ERN TransplantChild), coordinated by the HULP.

1
Introduction

2
Executive
Summary

3
Information
Groups
by Area

4
Associated
Clinicians

■ Financed and active international projects- 2021

Finally, throughout 2021 we have managed the following financed and active international projects:

Project	Program	Logo
AIMED Antimicrobial Integrated Methodologies for orthopaedic applications	H2020-MSCA	
CARE Corona Accelerated R&D in Europe	H2020-IMI	
CareInTrials Care in Clinical Trials involving Youth. Exploring Vulnerability through Empirical Philosophy in a Clinical Trials Unit	H2020-MSCA	
CORDIAL Clinical validation of a continuous flow peritoneal dialysis system, with dialysate regeneration	H2020	
EPIC-ALLIANCE Alliance for the Exploration of Pipelines for Inhibitors of Carbapenemases	ERA-NET JPIAMR	
EHRA-PATHS Addressing multimorbidity in elderly atrial fibrillation patients through interdisciplinary, tailored, patient-centred care pathways	H2020	
EJP -RD European Joint Programme on Rare Diseases	H2020	

ERA4TB	European Tuberculosis Regimen Regimen Accelerator	H2020-IMI	
ERICA	European Rare Disease Research Coordination and Support Action	EU Health Programme	
ERN RARE-LIVER	European Reference Network on hepatological diseases	EU Health Programme	
ERN TransplantChild (Coordinado por el HULP)	European Reference Network on transplantation in children	EU Health Programme	
	Integration systems for specific dataset, e-learning and support of ERN Core Services in the ERN TransplantChild	CEF programme	
	PaEdiatric Transplantation European Registry - PETER	EU Health Programme	
EU-RESPONSE	European Research and Preparedness Network for Pandemics and Emerging Infectious Diseases	H2020	
HosmartAI	Hospital Smart development based on AI	H2020	

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians











1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

IMPROVE PD	Identification and Management of Patients at Risk-Outcome and Vascular Events in Peritoneal Dialysis	H2020-MSCA	
NIH-11808SUB	Craniofacial Microsomia: Genetic Causes and Pathway Discovery	NIH-RO1	
ORTHOUnion	ORTHOpedic randomized clinical trial with expanded bone marrow MSC and bioceramics versus autograft in long bone nonUNIONS	H2020	
PHF23776_ES	Enhancing Whole Genome Sequencing (WGS) and/or Reverse Transcription Polymerase Chain Reaction (RT-PCR) national infrastructures and capacities to respond to the Covid-19 pandemic in Spain	ECDC	
R+	Rehab+	EIT-Health	

RESPOND	Improving the Preparedness of Health Systems to Reduce Mental Health and Psychosocial Concerns resulting from the COVID-19 Pandemic	H2020	
RISEinFAMILY	Alliance for Family Integrated Care (FiCare) Implementation in Neonatal Intensive Care Units	H2020-MSCA	
SHARP	Strengthened Health Regulations and Preparedness in EU	EU Health Programme	
VACCELERATE	European Corona Vaccine Trial Accelerator Platform	H2020	
VIRUSCAN	Optomechanics for Virology	H2020	

2.7.7. FLOW CYTOMETER LABORATORY



The Flow Cytometry Core is an integrated facility into the Hospital La Paz Institute for Health Research (IdiPAZ), that provides all its members and external groups access to affordable and high-quality flow cytometry services, along with decisively scientific expertise using this technology in research.

We highlight a wide variety of flow cytometry applications: phenotypic analysis of cellular subpopulations using extracellular and intracellular staining, preliminary studies for subsequent clinical application, complex multicolor flow cytometry analysis, etc. This technology is an indispensable biomedicine tool, promoting symbiosis between clinical and basic researchers, as well as cooperation with external institutions.

The services provided include:

- Theoretical seminars and hands-on workshops in flow cytometry.
- Scientific and technical support.
- Experimental design, data analysis and interpretation assistance.
- Development of novel multicolor flow cytometry techniques assistance.

■ Composition

Head

Kilian Gutiérrez Viñas

kilian.Gutiérrez@idipaz.es

Phone: (+34) 91 727 00 00 (ext. 441021)

Secretary

Susana García Pérez

investigacion.hulp@salud.madrid.org

Phone: (+34) 912 071

■ Equipment

Currently, the unit has four analyzers:

- One Beckman Coulter Navios™ cytometer analyzer:
A clinical system that delivers analytical excellence by coupling extraordinary sensitivity, resolution and dynamic range with high-speed data collection. With superior detection capabilities, Navios Cytometer provides accurate measurements, especially for rare events, which are critical to clinical diagnosis and monitoring.
This analyzer has three lasers: Blue solid state Diode (5 detectors), Red solid state Diode (3 detectors) and Violet solid state Diode (2 detectors), with which Navios can analyse ten colors simultaneously.
- Two Becton Dickinson FACSCalibur™ cytometer analyzers:
A system that supports a wide variety of research and clinical applications and is complemented by a broad suite of intuitive software solutions to streamline analy-

sis for a wide range of applications including enumeration of lymphocyte subsets, stem cells, residual white blood cells, and reticulocytes.

Each analyser has two lasers: Blue argon laser (3 detectors), and Red solid state Diode (1 detector), with which FACSCalibur™ can analyse four colors simultaneously.

- One Becton Dickinson FACSCelesta™ cytometer analyzer:


It is designed to make multicolored flow cytometry more accessible and allow researchers to benefit from new equipment and reagent technological innovations. These optical and reagent technology parallel advances allow multi-laser equipment to complement with new bright fluorochromes, providing a deeper and more powerful insight into cell analysis.

This analyzer has three lasers: Blue solid state Diode (4 detectors), Violet solid state Diode (6 detectors), and Ultra Violet solid state Diode (2 detectors), with which FACSCelesta™ can analyse twelve colors simultaneously.


These support a wide range of flow cytometry applications, and the possibility of developing new ones responding to facility needs and/or upon users demand. Also during 2021, the Flow Cytometry Core endured quality levels required according to ISO 9001:2015 standard.

■ Indicators


Cytometry Core Activity




Cytometers Activity Distribution



Groups Activity (%)



Cytometers Activity





2.7.8. CELL CULTURE LABORATORY

The Cell Culture Unit has been established as a core support division integrated and supported by Hospital La Paz Institute for Health Research (IdiPAZ) and La Paz University Hospital.

This unit facilitates the establishment and management of in vitro model systems and the performance of experimental-related techniques for different applications and purposes. Among others, these include the elucidation of molecular and cellular mechanisms involved in a biological process, the prediction of cellular and tissue responses to a specific microenvironment and/or the identification and development of novel drugs, compounds and/or therapeutic targets. Therefore, this platform provides a fundamental basis for the development of research initiatives in the field of Biomedical and Pharmacological Research and Health Sciences.

■ Composition

Coordinator

Gema Vallés Pérez (PhD)

gema.valles@salud.madrid.org

Phone: (+34) 917277000 (ext. 1576)

Technician

Beatriz Sanz Minguela

Phone: (+34) 917277000 (ext. 2142)

Secretary

Susana García Pérez

investigacion.hulp@salud.madrid.org

Phone: (+34) 91 207 15 12

■ Objectives

The Cell Culture Unit accomplishes its mission by providing users with assistance and support at scientific, technical and instrumental level through access to knowledge, equipment, material and human resources. According to IdiPAZ strategic plan and other institutional guidelines, this division contributes to the translation of biomedical research by fostering the synergies and cooperation between clinic- and basic- oriented research groups belonging to IdiPAZ as well as to external institutions. It also provides a dynamic and shared operational environment offering a convenient basis for the exchange and dissemination of the scientific knowledge, innovation and creativity as well as the creation of collaborations and alliances between researchers of various categories and disciplines. Moreover, the association and proximity with other core facilities such as the Molecular Imaging and Immunohistochemistry Unit, the Flow Cytometry Unit or the BSL2-Virology laboratory, enable users to develop complementary techniques, to explore and upgrade research hypotheses and to extend and/or improve their objectives.

■ Equipment and facilities

The Cell Culture Unit consists of an experimentation laboratory, a cryopreservation room and a warehouse. All facilities are located in the IdiPAZ building.

The experimentation laboratory is fitted with the following equipment:

Cabinets

4 Telstar Bio-II-A biological safety cabinets

1 Telstar Bio-II Advanced 3 biological safety cabinets

2 Nuaire NU-437-400E biological safety cabinets

1 Heraeus HS-12 biological safety cabinets

1 Faster BH-EN 2004 biological safety cabinet

1 Gelaire BSB 4A biological safety cabinet

1 Esco Class II BSC biological safety cabinet

2 Faster BIO 48 vertical laminar flow cabinets

1 Faster TWO 30 vertical laminar flow cabinet

Incubators

3 Thermo Forma Scientific incubators

2 HERAcell incubators

1 Biotech Galaxy S incubators

3 Nuaire Autoflow incubators

1 Sanyo O2/CO2 incubator

This equipment is complemented with a centralized and alarmed gas system, which guarantees a constant and controlled supply of CO₂ and N₂.

Microscopes

1 Nikon DIAPHOT TMD inverted light microscope connected to a Nikon D80 digital camera.

1 Leica DMIL inverted light microscope connected to a Canon Powershot S70 digital camera.

1 Optika inverted light microscope

1 Motic AE2000 inverted light microscope connected to an automatic counter Celeromics

1 Lan Optics inverted light microscope

Centrifuges

- 2 Eppendorf 5810R refrigerated centrifuges
- 2 Eppendorf 5804 centrifuge
- 1 Hettich Universal 32R refrigerated centrifuge
- 1 Kubota 2010 centrifuge

Cell Separation System

- 1 Milteny Biotec autoMACS cell separation system

Freezing systems

- 2 Liebherr refrigerator (4°C and -20°C)
- 1 Balay refrigerator (4°C and -20°C)
- 1 Whirlpool refrigerator (4°C and -20°C)
- 1 Beko refrigerator (4°C and -20°C)

Other equipment

- 1 Presoclave 75 P-Selecta autoclave
- 1 Millipore water purification system
- 1 Heidolph Reax 2000 vortex
- 1 Raypa thermostatic waterbath
- 1 Memmert thermostatic waterbath
- 2 Precistern thermostatic waterbath
- 1 Grant JB Aqua 12 Plus thermostatic waterbath
- Vacuum pumps, pipettes, counters, automatic pipettors, freezing containers, cell counting cameras, etc

The cryopreservation room is equipped with

- 2 Statebourne Biorack 3000 liquid nitrogen tank
- 1 Thermo Locator 6 Plus liquid nitrogen tank
- 1 10 K Taylor Wharton liquid nitrogen tank
- 1 MVE cryosystem 4000 liquid nitrogen tank
- 1 Cryo Diffusion B2016 liquid nitrogen tank
- 1 Cryo diffusion B2048 liquid nitrogen tank
- 1 Cryo Diffusion B2011 liquid nitrogen tank
- 1 SEO GT40 liquid nitrogen tank
- 1 MVE XLC 511 liquid nitrogen tank

The infrastructure for cryopreservation is completed with a liquid nitrogen transfer device and an alarmed Oxygen O2 detector coupled to a mechanical ventilation system.

Portfolio of services


In general, this Division offers support for experimental approaches on an extensive range of matters including cell experimentation, consumables and reagents, equipment and laboratory area, technical assistance, training and research.

The main aspects of this support includes:

- Scientific and technical advice, personalized support and consultation: guidance in experimental setup and design, study planning, optimization of techniques and protocols, reagents and material acquisition, cells supply, troubleshooting, analysis and interpretation of results...
- Basic training and hands-on experiments (implementation of the self-service mode) according to biosafety, waste disposal and good laboratory practice guidelines.
- Access to specific facilities including instrumentation, equipment, materials and reagents.
- Preparation and supply of certain materials, reagents and sterile solutions.
- Management and general supervision including good laboratory practices and work habits, cleaning and waste disposal and operation and maintenance of the equipment.
- Performance of experimental procedures: cell separation, cell isolation for cultivation, maintenance and propagation of cell lines and primary cultures, cryopreservation and resuscitation, viability and proliferation, etc...
- Control and maintenance of cryopreserved stock cells.
- Elaboration and management of protocols and guidelines, operating procedures, reports and other required mandatory documentation.
- Detection, identification and treatment of contaminations in cell cultures.


The Cell Culture Unit was certified according to the ISO 9001:2015 quality management system standard within the scope of IQNet Certificate INSTITUTO DE INVESTIGACIÓN SANITARIA DEL HOSPITAL UNIVERSITARIO LA PAZ Number ES-0512/2018.

The personnel associated to the Unit are indebted to the users and other joint staff who directly and indirectly has contributed to this highlight.




Cell Culture Unit's scientific indicators


USERS: Distribution according to academic profil



USERS: Distribution according to IdiPAZ research areas



Projects according to Research Area



COLLABORATIONS: Networks & CIBER



International collaborations



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

2.7.9. MOLECULAR IMAGING AND IMMUNOHISTOCHEMISTRY



The Molecular Imaging and Immunohistochemistry Unit is one of the shared research laboratories offered by IdiPaz to carry out basic clinical and translational research. The Unit's mission is to provide a centralized service equipped with the highest quality histology, immunohistochemistry and imaging equipment, as well as scientific and technical support for researchers. The activities of the Unit are framed in the improvement of management, continuous training and the promotion of innovation established in the strategic plan of IdiPaz. The objectives are approached with criteria of technical quality and innovation for the improvement of laboratory facilities and processes and also promoting the application of Bioimaging techniques in clinical research and basic health sciences.

The Unit, located in the IdiPaz building of the La Paz University Hospital, consists of two sections, the Immunohistochemistry and Microscopy laboratories. The immunohistochemistry laboratory, located on the first floor of the IdiPaz building, offers protocols and equipment that allow performing cytopspins, fixation techniques (paraffin or frozen), tissue sectioning (microtomes and cryostats) and classic or advanced immunostaining (Dako Autostainer). The Microscopy Laboratory is on floor -1 and houses conventional, fluorescence and confocal microscopes and a Nanosight microscope with nanoparticle tracking system. These microscopes allow the acquisition of images of fixed or in vivo samples, for studies of proliferation, apoptosis, size, shape and cell viability. In addition, the lab offers image analysis programs (NIS Elements AR, Nanosight 3.1, LASAF, Image ProPlus and ImageJ).

■ Composition

Head

María Teresa Vallejo Cremades (PhD)

tvallejo.hulp@salud.madrid.org

Phone: (+34) 917277526

Technician

Onys Camps Ortega

onys.camps.ortega@idipaz.es

ext. 42148

Secretary

Susana García Pérez

investigacion.hulp@salud.madrid.org

Phone: (+34) 91 207 15 12

■ Resources, Equipment and Management of the Laboratory

The services of the ImageM_IHQ core facility are available to all scientists in different models; collaboration, Do-It-Yourself (DiY) or in a fee (in this case, it must be consulted the head of the laboratory, the lab will support the service depending on staff availability). DiY users are allowed to access the facilities ONLY after training by the lab staff, training sessions can be scheduled at any time of the year. In addition, the lab provides fee-for-service model of use to external institutions and private companies. Access to the Immunohistochemistry Lab is free but access to the Microscopy requires the magnetic individual identification card.

The laboratory staff will give the basic rules to new users for good practices and safety work in the laboratory. Users should not use the equipment until the laboratory personnel have checked their correct training. Users must schedule the time of work in any equipment and booking reserve it is mandatory in all the facility.

Equipment of Molecular Image and Immunohistochemistry Unit

Immunohistochemistry Laboratory:

- Tissue processor providing efficient, reliable and timely processing of paraffin wax (Leica TP1020)
- Embedding unit for high quality paraffin blocking (Leica EG1160)
- Selecta Wax dispenser, paraffin wax dispenser with adjustable temperature from ambient to 100 °C
- 2 microtomes for specimen sectioning Leica RM2255
- 1 microtome for specimen sectioning Shandon AS325
- Leica EG 1150C Cold plate
- 2 thermostatic water Leica HI 1210 baths
- 1 thermostatic water Selecta Thermofn bath
- Automated Immunohistochemistry autostainer (Autostainer Plus DAKO)
- 2 Cryostat for frozen sectioning (Leica CM 3050S and Leica CM1950)
- PTLINK DAKO
- Crison pH meter
- Liebherr upright freezer (-20°C and 4°C)
- Liebherr economy freezer (-20°C)
- Shandon Cytospin 2
- Memmert BE 500 and UN30 oven.
- Selecta Agimatic-E magnetic stirrer with heating
- Olympus CH microscope, for practical laboratory applications
- Gilson pipette sets
- NUAIRE laboratory fume hood.

Staining area with manual options for Do-It-Yourself staining and cover slipping.

The laboratory is equipped with shared facilities from Translational Oncology and Anatomopathology Breast and Gynecological Cancer groups that use them for diagnostic



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

and clinical research purpose (ESCO fume hood and Crison Microtome). Permission to use must be asked to the head of these laboratories.

The Microscopy laboratory equipment includes:

- Leica TCS SPE inverted confocal. Leica DMI4000B inverted microscope; Illumination source, Lasers diode 405, Lasers diode 488, Lasers diode 532 and Lasers diode 635; Dishes, Standard microscope slides.
- NIKON microscope ECIPSE IT to conventional and fluorescence microscopy, in vivo imaging and High Content (equipped with incubation chamber)
 - Camera IMAGING SOURCE
 - Lauda Ecoline Star incubator edition 003
 - Hotplate (OKO LAB)
 - D gas (Okolab)
 - Microscope culture plates adapter
- Leica DMI6000B inverted microscope. Filter cubes: A4(UV), L5 (green), N3 (red) and Y5 (far red)
- Olympus BX41 (Bright field) upright microscope with an attached Digital camera
- Zeiss Axioplan 2 upright microscope with five objectives from 5x to 100x, phase contrast and fluorescent capabilities
- Zeiss Axio Lab.AI microscope five objectives from 5x to 100x. ERC5S Axocan camera.
- Nanosight LM10 viewing unit measures nanoparticles, exosomes, vesicles' size based on the scattering of light, includes a microscope, a LM10 viewing unit, a Marlin camera, an objective x20 and is connected to a image analysis software.
- Digital microscopy (photography with a Leica DFC 350 FXR2 digital camera attached)
- Image ProPlus 5.0 image analysis software
- Leica LAS AF image analysis software
- Analysis work station with Huygens deconvolution software, Image J, LASAF Lite programme and related image analysis software.
- Nanosight NTA 3.1 analytical software.

The laboratory is equipped with shared facility from Neuroscience group (Leica TCS SPE inverted confocal).

■ Service Portfolio

- Collection and processing for fixing and decalcification of samples.
- Sample processing in paraffin by hand or automatic.
 - Complete paraffin embedding processing.
 - Serial cut in microtome and tissue assembly.
- Antibodies' validation.
- Buffer preparation and distribution of consumables.

- Sample processing frozen.
 - Preparation of freeze blocks.
 - Serial sections of blocks freeze and cuts collected on slides or floating.
- Staining.
 - Hematoxylin - eosin.
 - Masson trichrome.
 - PAS.
 - Cytochemical and immunohistochemical techniques.
 - Decalcification of samples required.
 - Dewaxing cuts, performing staining.
 - Immunohistochemical staining automated system Autostainer.
 - Protocols for Immunofluorescence in frozen tissue and paraffin.
 - Dehydration and slide assembly.
- Image acquisition. Viewing and digital format acquisition.
 - Light microscopy.
 - Light microscopy with phase contrast.
 - Epifluorescence.
 - Confocal microscopy.
 - Advanced Microscopy in living cell.
- Fluorescence colocalization by confocal microscopy.
- 3D reconstruction.
- In vivo image acquisition of biological samples (incubation system for the temperature and CO₂).
- Morphometry in biological samples.
- Large images acquisitions (scanning the entire slide) for bright field and fluorescence.
- Collaboration for sample processing protocols for microscopy (fastening, staining, marking, etc.) and advice for planning projects that could require the use of microscopy.



■ Research Highlights

In 2021, Image unit collaborate with the groups belonging to the research areas of IdiPAZ; Neurosciences, Infectious disease and immunity, Cancer and human molecular genetics, Cardiovascular, Organ system pathologies and Surgery, transplant and health technologies. The collaboration are reflected in scientific dissemination as congress presentations and international publications.

Graft infusion of adipose-derived mesenchymal stromal cells to prevent rejection in experimental intestinal transplantation: A feasibility study. Andres AM, Stringa P, Talayero P, Santamaria M, García-Arranz M, García Gómez-Heras S, Largo-Aramburu C, Aras-López RM, Vallejo-Cremades MT, Guerra Pastrían L, Vega L, Encinas JL, Ló-

pez-Santamaria M, Hernández-Oliveros F. Clin Transplant. 2021 Apr;35(4):e14226. doi: 10.1111/ctr.14226. Epub 2021 Feb 5..

■ Equipment usage ratio



After the special circumstances experienced during 2020, the activity level of the unit has almost doubled during 2021.

In 2021, the unit increased the number of users. As observed in previous years, the most of inner users are interested in both Microscopy and Immunohistochemistry labs. This year, the Unit has had almost equal external users in the Microscopy and the Immunohistochemistry lab

In 2021, the Unit maintained the certified scope of quality by AENOR referring to its processes according to the guidelines of the UNE-EN ISO 9001: 2015 Standard, its membership to the Spanish Network of Advanced Optical Microscopy (REMOA) and participation in the XXI Science Week organized by the CAM with the workshop entitled “Luz y color para encontrar las huellas moleculares de intrusos en nuestras células. Visita- taller a la Unidad de Imagen Molecular e Inmunohistoquímica” allows us to disseminate the scientific activity carried out in our platform.

And finally, IdiPaz has obtained in 2021 funding to equip the unit with a state-of-the-art microscope. The application presented by IdiPaz, coordinated by Dr. López Collazo and with the advice and participation of the Molecular Image and Immunohistochemistry unit, was selected by ISCIII to be financed according to the IFCS21 Singular Infrastructures call.



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

2.7.10. RADIOISOTOPE

The radioisotope laboratory of IdiPAZ is a second category radioactive facility authorized by the Nuclear Safety Council for the use of non-encapsulated radioactive sources. The radioisotopes authorized at the facility are: 3H, 33P, 32P, 125I, 14C, 51Cr.

The laboratory, in addition to the beta counter, has equipment and working space for the performance of molecular biology and biochemical procedures and experiments with cell cultures. Currently the most common procedures are cell proliferation tests with tritiated thymidine.

The use of the facility both by staff of the institution and by external users requires prior authorization by those responsible for the facility that approves both the technical suitability of the users to work with radioactivity, and the procedures to be employed. The HULP Radiation Protection Service is responsible for control of the facility and of the radioactive wastes generated.

■ Composition

Head laboratory

Nuria Vilaboa Díaz

nuria.vilaboa@salud.madrid.org

Phone: (+34) 912 071 034

David Vicent López

david.vicent@salud.madrid.org

Phone: (+34) 91 207 10 30

Secretary

Susana García Pérez

investigacion.hulp@salud.madrid.org

Phone: (+34) 91 207 15 12

2.7.11. BSL2-VIROLOGY LABORATORY



The BSL2-Virology laboratory is an IdiPAZ platform created in September 2019 to support the Institute's research. Many are the research groups that have benefited from the platform to conduct their research safely, since working with samples infected with a certain type of pathogen requires facilities with an adequate level of biosafety. The BSL2-Virology laboratory was certified according to ISO 9001 quality management standard within the scope of IQNet.

■ Composition

Coordinator

Berta Rodés Soldevila

berta.rodés@salud.madrid.org

Phone: (+34) 912 071 022

Secretary

Susana García Pérez

Investigación.hulp@salud.madrid.org

Phone: (+34) 912 071 512

■ Objectives

The BSL2-virology laboratory has been adapted to work with human samples infected with the HIV, HBV and HCV viruses; as well as GMOs of risk group 1 and 2. It also allows developing certain experimental processes with other viral pathogens that require a biosafety level 2. The laboratory provides researchers with the necessary equipment to perform their own experimental processing and analysis, as well as training and assistance.

■ Resources

The BSL2-Virology Laboratory consists of an experimental laboratory and a compartment with a watertight door. All facilities are located in the IdiPAZ building.

The experimental laboratory is equipped with the following equipment:

Type II Biological Safety Cabinets (BSC)

- 1 BSC Telstar BIO-II-A/D
- 2 BSC Telstar BIO-II-A/P
- 1 BSC Neuroaire CSB120

CO2 incubators

- 2 HERAEUS BB-6220 incubators

Centrifuges

- 1 HERAEUS Biofuge primor refrigerated centrifuge
- 1 Hettich Universal 320 non-refrigerated centrifuge

Microscope

- 1 NIKON Eclipse TS100 Inverted Optical Microscope

Refrigeration systems

- 1 Liebherr upright freezer (-20°C)
- 1 Liebherr profi line fridge (4°C)

Other equipment

- 1 P-Selecta Precistern thermostatic waterbath
- 1 Inteliwasher 3D-IW8 BIOSAN


Permitted techniques

- Processing of different types of blood cells.
- Preparation of samples from HIV+ patients for cytometry.
- Studies of cellular polyfunctionality in the immune response against HIV.
- Handling and experimental processes of cell cultures.
- Measurement of the impact of antiretroviral drugs on mitochondrial function in PBMCs.
- Construction of viral protein expression vectors in eukaryotic expression vectors.
- ELISA techniques.
- In May 2020 the laboratory was authorized for the use of blood samples from patients with covid-19 and certain related processes.




BSL2-virology laboratory management indicators


Persons taking a biosafety course/capacity-building



n° new and unsubscribed users per month



n° new and unsubscribed users per month



2.7.12. SEQUENCING PLATFORM



The research support activity is one of the basic pillars of the institute and our laboratory is proud to participate in this strategic line. There was a need for a service in the genomics area that would allow connecting research into the genomic area to the institute's precision medicine research lines. The laboratory also supports the different diagnostic units of the hospital that have incorporated the advances obtained in research. Thus, we have always been characterized as a clear example of translational research.

Our laboratory has the necessary equipment and infrastructure to perform tasks such as conventional sequencing (Sanger method), marker DNA genotyping and other molecular biology techniques based on capillary electrophoresis. The equipment can use up to five simultaneous colours on the same sample when it migrates to the genetic analyzers. Therefore, we are able to detect more than 30 polymorphic markers per sample. The knowledge of the staff allows us to offer design, protocol development, and data analysis support and task training in genomic techniques.

Since last year, collaboration/synergy has been maintained with the Genomic Analysis platform to offer new services in Next Generation Sequencing techniques to the institute's research lines, and new synergies are currently being created to offer researchers the necessary support.

During the last year, the close interaction with research groups at different levels has resulted in the co-authorship of three articles in international journals, and the contribution to more than thirty articles in which the facility has contributed its resources.

The close working relationship with the research lines allows the laboratory staff to participate as a collaborating researcher in one of the FIS projects awarded to the institute. The laboratory is committed to quality work by maintaining ISO 9001:2015 certification, obtained in 2018. In addition, lab participate in international external quality controls annual evaluations (EMQN).

■ Composition

Person in charge

María del Rocío Mena de la Cruz

mariarocio.mena@salud.madrid.org

Phone: +34 912071214

Conventional sequencing

Person in charge

María del Rocío Mena de la Cruz

mariarocio.mena@salud.madrid.org

Phone: +34 912071214

Technical Staff

María Fernández Elvira

mfelvira@salud.madrid.org

Ruth Rodríguez García

mruth.rodriquez@salud.madrid.org

Genomic Analysis

Person in charge

Rebeca Pérez de Diego

rebeca.perez@idipaz.es

Phone: +34 91 207 10 32

Technical Staff

Ana María Van Den Rym Mayoral

■ Equipment

- Eppendorf 5415D Centrifuge.
- Veriti Termocycler (Applied Biosystems).
- Genetics Analyzers 3130xl y 3730xl (Applied Biosystems-Life Technologies).

Software

- Sequencing Analysis v5.3.1
- Sequence Scanner v1.0
- GeneMapper v4.0
- Peak Scanner v1.0
- Variant report v1.0

■ Portofolio Service

Conventional sequencing


- Nucleic Acid quantitation (Tecan, Nanodrop).
- PCR purification for Sanger sequencing (Exosap).
- Sanger Sequencing.
- Migration Sanger samples.

• Fragments Analysis:

- STRs analysis
- QF-PCR.
- MLPAs (multiplex ligation-dependent probe amplification).
- Microsatellite instability (MSI).
- AZF.
- SnapShot.
- TP-PCR
- ARMS

Genomic Analysis

- Genetic analysis from annotated variants of PID Sequencing Panel.
- Genetic analysis from annotated whole exome sequencing (WES) variants.
- Genetic analysis from annotated whole genome sequencing (WGS) variants.
- Genetic analysis from raw data in FASQ format from PID Sequencing Panel.
- Genetic analysis from raw data in whole exome sequencing (WES) FASQ format.




2021 Facility Activity


Conventional sequencing

Research Area	Genotyping Products		Sanger Sequencing Products		Sanger Sequencing		Total samples
Infectious diseases and immunity	424	3,31%	2969	9,71%	36	1,96%	3429
Cardiovascular	-	-	212	0,69%	-	-	212
Organ system pathologies	7	0,05%	3042	9,95%	-	-	3049
Cancer and human molecular genetics	12374	96,62%	24348	79,64%	1803	97,94%	38525
Total	12807		30573		1841		45221

Research areas




Services



Genomic Analysis

Research Area	Genetic analysis from annotated variants of PID Sequencing Panel	Genetic analysis from annotated whole exome sequencing (WES) variants	Genetic analysis from annotated whole genome sequencing (WGS) variants	Total samples
External researches	2	89	1	92



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



Publications

1. Rapidly Progressing to ESRD in an Individual with Coexisting ADPKD and Masked Klinefelter and Gitelman Syndromes.

Peces R, Peces C, Mena R, Cuesta E, García-Santiago FA, Ossorio M, Afonso S, Lapunzina P, Nevado J.

Genes (Basel). 2022 Feb 23;13(3):394. doi: 10.3390/genes13030394.

PMID: 35327948 Free PMC article.

2. Historical and geographical distribution of the founder mutation c.610G>A; p.Ala204Thr in the CLCNKB gene linked to Bartter syndrome type III in Spain.

Peces R, Mena R, Peces C, Barruz P, Trujillo H, Carreño A, Espinosa L, Selgas R, Lapunzina P, Nevado J.

Clin Kidney J. 2021 Apr 28;14(8):1990-1993. doi: 10.1093/ckj/sfab083. eCollection 2021 Aug.

PMID: 34345425 Free PMC article. No abstract available.

3. Mosaic Variegated Aneuploidy syndrome 2 caused by biallelic variants in CEP57, two new cases and review of the phenotype.

Santos-Simarro F, Pacio M, Cueto-González AM, Mansilla E, Valenzuela-Palafoll MI, López-Grondona F, Lledín MD, Schuffelmann C, Del Pozo Á, Solis M, Vallcorba P, Lapunzina P, Menéndez Suso JJ, Siccha SM, Montejo JM, Mena R, Jiménez-Rodríguez C, García-Miñaur S, Palomares-Bralo M.

Eur J Med Genet. 2021 Nov;64(11):104338. doi: 10.1016/j.ejmg.2021.104338. Epub 2021 Sep 7.

PMID: 34500087 Review.

4. Birth of two healthy girls following preimplantation genetic diagnosis and gestational surrogacy in a rapidly progressive autosomal dominant polycystic kidney disease case using tolvaptan.

Peces R, Mena R, Peces C, Cuesta E, Lapunzina P, Selgas R, Nevado J.

Clin Kidney J. 2021 Apr 25;14(8):1987-1989. doi: 10.1093/ckj/sfab082. eCollection 2021 Aug.

PMID: 34345424 Free PMC article. No abstract available.

5. Respiratory viral infections in otherwise healthy humans with inherited IRF7 deficiency.

Campbell TM, Liu Z, Zhang Q, Moncada-Velez M, Covill LE, Zhang P, Alavi Darazam I, Bastard P, Bizien L, Bucciol G, Lind Enoksson S, Jouanguy E, Karabela ŞN, Khan T, Kendir-Demirkol Y, Arias AA, Mansouri D, Marits P, Marr N, Migeotte I, Moens L, Ozcelik T, Pellier I, Sendel A, Shahrooei M, Smith CIE, Vandernoot I, Willekens K; COVID Human Genetic Effort, Bergman P, Abel L, Cobat A, Casanova JL, Meyts I, Bryceson YT.

J Exp Med. 2022 Jul 4;219(7):e20220202. doi: 10.1084/jem.20220202. Epub 2022 Jun 7. PMID: 35670811 Free PMC article.

6. Clinical and Immunological Features of Human BCL10 Deficiency.

García-Solis B, Van Den Rym A, Pérez-Caraballo JJ, Al-Ayoubi A, Alazami AM, Lorenzo L, Cubillos-Zapata C, López-Collazo E, Pérez-Martínez A, Allende LM, Markle J, Fernández-Arquero M, Sánchez-Ramón S, Recio MJ, Casanova JL, Mohammed R, Martínez-Barricarte R, Pérez de Diego R.

Front Immunol. 2021 Nov 12;12:786572. doi: 10.3389/fimmu.2021.786572. eCollection 2021. PMID: 34868072 Free PMC article.

7. From Your Nose to Your Toes: A Review of Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic-Associated Pernio.


Arkin LM, Moon JJ, Tran JM, Asgari S, O'Farrelly C, Casanova JL, Cowen EW, Mays JW, Singh AM, Drolet BA; COVID Human Genetic Effort.

J Invest Dermatol. 2021 Dec;141(12):2791-2796. Doi: 10.1016/j.jid.2021.05.024. Epub 2021 Jul 15. PMID: 34561087 Free PMC article. Review.

8. SARS-CoV-2-related MIS-C: A key to the viral and genetic causes of Kawasaki disease?

Sancho-Shimizu V, Brodin P, Cobat A, Biggs CM, Toubiana J, Lucas CL, Henrickson SE, Belot A; MIS-C@CHGE, Tangye SG, Milner JD, Levin M, Abel L, Bogunovic D, Casanova JL, Zhang SY.

J Exp Med. 2021 Jun 7;218(6):e20210446. doi: 10.1084/jem.20210446. PMID: 33904890 Free PMC article. Review.



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



2.7.13. BIOINFORMATICS SERVICE

The research support activity is one of the basic pillars of the institute and our laboratory is proud to participate in this strategic line. There was a need for a service in the Research bioinformatic support platform whose main objective is to promote the development of any DNA / RNA study on a massive scale, either in humans or in other organisms. The activity of the platform is aimed at advising scientists and researchers on the possibilities and benefits obtained from the application of computational biology techniques in their research. In addition, researchers will be supported in the analysis and interpretation of data obtained using high-throughput experimental techniques.

■ Composition

Coordinator

Alejandro Pascual Iglesias

Alejandro.pascual.iglesias@idipaz.es

Phone: +34 207 15 12

■ Services

1. Experimental design. Advice to decide the sample size, the design of the study and the planning of the methodology.
2. Data analysis. The bioinformatic processing of the data obtained is carried out in various high-performance technological platforms used in the field of genomics. These analyzes include normalization, statistical analysis, and representation of the results. The most common analyzes are:
 - I. Differential expression of genes, miRNAs or lncRNAs. The technology of origin of the experiments can be microarrays (Affymetrix, Agilent) or RNA-seq (Illumina, Ion Torrent).
 - II. Protein-DNA interactions from immunoprecipitation and microarray (ChIP-chip) or sequencing (ChIP-seq) experiments.
 - III. Helps to interpret results. Once the genes of interest have been selected, biological-functional assignment studies are carried out, such as the study of functional enrichment of gene / protein lists.
 - IV. Design, implementation and administration of databases (eg of patients, samples, etc.).
 - V. Individualized training activities: Training for users (scientific / technical) in the main theoretical and practical foundations for handling results and their interpretation.

■ Functioning

The procedure to follow is as follows:

- Fill in the "Job Application" form and send it to carolina.rubio.martin@idipaz.es. Fill in what you want to do by means of a short memory in which the primary objective of the study and the secondary objectives, if any, are clearly specified.
- Meeting with the Bioinformatics Platform to share questions such as the sample size with which it is going to work, the statistical power to be obtained and the variables to be analyzed.
- Preparation and delivery of the data to be analyzed in the format previously agreed between both parties.
- Carrying out the analysis.
- Delivery of results in the pertinent formats.

■ Equipment

- High technical computer
- Intel Core i9 9900K
- Gigabyte Z390 D ATX 1151 1
- MEMORY HYPERX FURY 16GB

■ Activity in 2021



All the projects based on the work of bioinformatic platform are actually resulting in several research papers:

- Prior SARS-CoV-2 infection balances immune responses triggered by four EMA-approved COVID-19 vaccines: An observational studyThe immune checkpoints storm in COVID-19: role as severity markers at emergency department admission
- Differential Immune Checkpoint and Ig-like V-Type Receptor Profiles in COVID-19: Associations with Severity and Treatment.

Also, during 2021, the platform offered help in other projects such as the "Programa Mentor", helping clinical researchers to develop and present their projects:

- Desarrollo de modelos 3D in vitro de Cáncer de Colon para el desarrollo de nuevas Terapias
- Impacto de los viajes internacionales sobre la prevalencia de la colonización intestinal por enterobacterias resistentes y la microbiota y su repercusión clínica tras el viaje: Estudio MERIT
- Precision medicine in bladder carcinoma (premlac). molecular management of periperative treatments.
- Descifrando las causas de baja visión en la infancia: abordaje clínico y genético
- Fibrosis miocárdica en transposición de grandes vasos y ventrículo derecho sistémico: caracterización con biomarcadores moleculares y de imagen y asociación con eventos adversos
- Efecto del sellado tisular durante la linfadenectomía inguinofemoral en cáncer de vulva
- Predicting effectiveness of drugs used for treating cardiovascular conditions in new-born infants
- Estudio de factores químicos medioambientales mediante cromatografía líquida y espectrometría de masas y su influencia en el perfil epigenético mediante técnicas de análisis masivo en el Glioblastoma multiforme, nueva aproximación a la identificación de factores de riesgo prevenibles.
- Paving the Way for Personalized Medicine in neonatal and pediatric Intensive Care Units.
- Un paso más hacia la medicina personalizada: Biomarcadores PREdictores de respuesta óptima a biológicos o inhibidores de JAK en pacientes con Artritis Reumatoide (estudio PREBIORA).
- Bacteriemias por gramnegativos resistentes a carbapenémicos en Pediatría. Epidemiología, característi-

- cas clínicas, estrategias de tratamiento y predictores de mortalidad en España.
- Desarrollo de un modelo predictivo del pronóstico de los pacientes con ictus agudo basado en la toma de decisiones



- Personalización de las maniobras de reclutamiento pulmonar en paciente pediátrico mediante test de aire y pulsioximetría: estudio prospectivo doble ciego
- Estabilización del aneurisma de Aorta Abdominal con células Troncales: Ensayo clínico controlado con cohortes históricas

- Mining Artificial intelligence for Anal Cancer Screening (MARACAS): a randomized controlled clinical trial.

Counselling services in different researching projects for example modelling of predictive algorithm in "Desarrollo de un modelo predictivo del pronóstico de los pacientes con ictus agudo basado en la toma de decisiones".

Students in the platform:

This year, we are hosting the *Master on Bioinformatics applied to Personalized Medicine and Health* degree student with the Project called "Predictive software development and application in childhood kidney transplant failure: an immunological approach to side effects and rejection."

The student will be supervised by Alejandro Pascual as TFM tutor and Eduardo López-Collazo.

2.7.14. PAIN PLATFORM

The Early-Stage Researcher Support Platform (Plataforma de Apoyo al Investigador Novel) from IdiPAZ is a platform that aims to promote the design and development of research projects in health areas. Focused in our early-stage professional researchers, training and research development will be encouraged to achieve our clinicians a better performance in competitive calls.

■ Composition

Head

Paloma Gómez Campelo

Staff

Daniel Quijada Alcón

mentor@idipaz.es

Phone: (+34) 91 207 17 40

■ Portfolio of services

- Methodological and epidemiological support to the study design of the professionals in early-stage research.
- Technical and methodological support in developing a research protocol for a study.
- Analysis of the grounds for refusal of rejected projects.
- Methodological support to write grant proposals to access all available funding programs.
- Technical support in writing other scientific documents.
- Mentor Program

■ Mentor Program

IdiPAZ, with the support of La Paz University Hospital, in 2021 has implemented the 1st Mentor Program with the purpose of supporting our clinical early career researchers in the achievement of competitive projects, mainly from the main national call for health research projects: "Acción Estratégica en Salud (AES)", granted by Instituto de Salud Carlos III.

The Mentor Program plans a scientific and technical support in the preparation and tracking of research proposals. Furthermore, it take into account the experience and scientific knowledge from our senior researchers to help our earlystage researchers from the beginning of their research career.

The objectives of the program are:

- Increasing the number of clinical research in IdiPAZ.
- Avoiding a generational leap of clinical researchers.
- Strengthening the research profile of our clinical staff.
- Becoming IdiPAZ a clinical research model, as the same level that IdiPAZ is in the clinical trials.
- Performing an internal cultural change in clinical research

2.7.15. FOOD, NUTRITION AND HEALTH

The IdiPAZ Food, Nutrition and Health Platform (NUTRinvest) is a structure created to provide scientific-technical service and support in Human Research and Specialized Advice in Nutrition and Food issues.

The Platform provide service of Specialized Advice in Nutrition and Food at 3 levels:

1. Industries (agro-food or pharmaceutical sector) interesting in the new products development with an improved nutritional profile.
2. Companies interested in creating new technological tools to facilitate the acquisition of guidelines and healthy habits (web, app, etc.) and healthy habits.
3. Individual interested in knowing their nutritional status through a precision and individualized nutritional assessment.

■ Composition

Principal Researcher

Bricia López Plaza, PhD, MSc.
bricia.plaza@idipaz.es

Project manager

Samara Palma Milla, PhD, MD.
samara.palma@salud.madrid.org

Clinical Research Associate

Edwin Fernández Cruz, PhD.
edwin.fernandez.cruz@idipaz.es

Marlhyn Valero Pérez (Nutricionist).
marlhyn.valero@idipaz.es

Natalia García Vázquez (Pharmacist)
ngarcia.hulp@salud.madrid.org

Marina Morato Martínez (Nutricionist)
marina.morato@salud.madrid.org

Lucía Arcos Castellanos (Nutricionist)
larcosc Castellanos@gmail.com

Laura Mola Reyes (Endocrinologist)
lmola@salud.madrid.org

Rosa María García Moreno (Endocrinologist)
jmartinh2@salud.madrid.org

■ Main sectors

- Agri-food/pharmaceutical industries interested in designing or validating the effectiveness of new products.
- Institutions/government agencies with an interest in expanding knowledge in the area of nutrition for the generation/implementation of political measures in Public Health.
- Public or private institutions that want to develop

computer applications, or information or communication programs in the field of Nutrition of interest to health professionals, consumers or patients.

- Researchers with interest in the inclusion of nutritional variables in their research projects.
- Individuals interested in obtain information about their nutritional health and who wish to receive precision and individualized nutrition through detailed analysis.

■ Portfolio of services

- Scientific advice to improve nutritional profiles of foods or nutritional formulas.
- Scientific-technical support in the area of Human Nutrition research:
 - Create well designed Project Plan for Clinical Trials and other human studies.
 - Management and Submission of applications to the Ethics Committee: The platform prepares and management all the documents required by obtain the approval of the Ethics Committee (Informed consent form, Letters from ethics committees. Study questionnaire (copies of any questionnaires or draft questionnaires), Case Record Forms (CRFs), Budget details, etc.)
 - Field work execution (all activities are carried out by members of the platform team with consolidated qualifications in the area):
 - Individualized ietary studies: through the use of validated tools (Food records (24h, 3-7 days), Food Frequency Questionnaires, Weighted food records, DIAL software, calorimetry ...)
 - Diagnostic and screening nutritional studies:

using validated methodology (Subjective Global Assessment (SGA), Nutritional Status Assessment (NSA), Malnutrition Universal Screening Tool (MUST), Mini Nutrition Assessment (MNA).

- Anthropometric studies: Weight, Height, Circumferences, Folds, Bioelectrical Impedance, DXA...
- Biochemical studies (blood, urine, feces): measurements of health markers related to the area of nutrition (glucose metabolism parameters, curves for calculating the glycemic index, lipid metabolism, inflammation, oxidation and hormonal biomarkers...)
- Physical activity studies: through the use of validated questionnaires (IPAQ, MINNESOTA...).
- Evaluate the use of sensors, control devices and monitoring support (blood glucose, weight, eating disorders, food photographs, physical activity, etc.).
- Evaluate the use of specific nutrient modules, oral nutritional supplements and highly specialized artificial nutrition (enteral and parenteral).
- Functional capacity studies: through dynamometry and validated questionnaires.
- Sensory perception studies: through the use of validated questionnaires
- Satiety control studies: using biochemical markers and handling of validated questionnaires
- Quality of life studies: through the use of validated questionnaires.
- Tolerance Studies: through the use of validated questionnaires.
- Nutrigenetics and Metabolic Studies with our collaborating centers.
- Production of scientific and technical report



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

- Development of computer applications for websites or mobile apps in the nutrition/food area.
- Individual nutritional status evaluations and proposals for individualized nutrition intervention programs.
- To contribute and design components for nutrition education strategies and programs

■ Equipment

- Dual-energy x-ray absorptiometry (DXA)
- Bioelectric Impedance System (BIA) for body composition measurement through Inbody device.
- Ultrasound machine for advanced high resolution diagnosis.
- Holtain Skinfold Calipers
- Tanita digital healthcare scales
- Executive Diameter Tape
- Indirect calorimetry
- Accelerometers

■ Activity indicators

Articles:

- Fernández Cruz E, López Plaza B, Santurino C, Gómez Candela C. Nutritional composition and nutritional claims of Canary Islands banana. *Nutr Hosp.* 2021 Dec 9;38(6):1248-1256. doi: 10.20960/nh.03614. PMID: 34649457
- Morato-Martínez M, Santurino C, López-Plaza B, Arcos-Castellanos L, Clavero-Fraile M, Valero-Pérez M, Palma Milla S, Valero M, Gómez Candela C. A standardized, integral nutritional intervention and physical activity program reduces body weight in women newly diagnosed with breast cancer. *Nutr Hosp.* 2021 Jun 10;38(3):575-584. doi: 10.20960/nh.03409. PMID: 33813835
- Morales D, Shetty SA, López-Plaza B, Gómez-Candela C, Smidt H, Marín FR, Soler-Rivas C. Modulation of human intestinal microbiota in a clinical trial by consumption of a β-D-glucan-enriched extract obtained from *Lentinula edodes*. *Eur J Nutr.* 2021 Sep;60(6):3249-3265. doi: 10.1007/s00394-021-02504-4. PMID: 3358029
- Loria Kohen V, Campos Del Portillo R, Valero Pérez M, Mories Álvarez MT, Castro Alija MJ, Matía-Martín MP, Gómez Candela C. Nutritional education protocol in the treatment of eating disorders in the clinical and care

settings. *Nutr Hosp.* 2021 Jul 29;38(4):857-870. doi: 10.20960/nh.03617. PMID: 34126747

- Rojo-Tirado MA, Benito PJ, Ruiz JR, Ortega FB, Romero-Moraleda B, Butragueño J, Bermejo LM, Castro EA, Gómez-Candela C. Body Composition Changes after a Weight Loss Intervention: A 3-Year Follow-Up Study. *Nutrients.* 2021 Jan 7;13(1):164. doi: 10.3390/nu13010164. PMID: 33430216
- Wanden-Berghe C, Virgili Casas N, Cuerda Compés C, Ramos Boluda E, Pereira Cunill JL, Maíz Jiménez MI, Burgos Peláez R, Gómez Candela C, Penacho Lázaro MÁ, Sánchez Martos EÁ, de Luis DA, Zugasti Murillo A, Martínez Faedo C, Álvarez Hernández J, Campos Martín C, Rioja-Vázquez R, Irlés Rocamora JA, Díaz Guardiola P, Sanz Paris A, Matía Martín P, Carabaña Pérez F, Martín Folgueras T, Chinchetru M^ªJ, Luengo Pérez LM, Martínez Costa C, Tejera Pérez C, Arraiza Irigoyen C, Sánchez-Vilar Burdiel O, García Delgado Y, Ponce González MÁ, Mauri Roca S, García Zafra MV, Germán Díaz M, Morán López JM, Molina Baeza B, Gonzalo Marín M, Sánchez Sánchez R, Calañas Continente A, Garde Orbaiz C, Martínez Olmos MÁ, Joaquín Ortiz C, Suárez Llanos JP, Forga Visa MT, Gil Martínez M^ªC, Carrera Santaliestra MJ, Padín López S, Lobo G, Apezetxea Celaya A, Ballesta Sánchez C, Bonada Sanjaume A, Cánovas Gaillemín B, Cardona Pera D, García Puente I, Higuera Pulgar I, Miserachs Aranda N, Del Olmo García MD, Palma Milla S, Parés Marimón RM, Pintor de la Maza B, Sánchez Martos EÁ. Home and Ambulatory Artificial Nutrition (NADYA) Group report: home parenteral nutrition in Spain, 2019]. *Nutr Hosp.* 2021 Dec 9;38(6):1304-1309. doi: 10.20960/nh.03720. PMID: 34670394
- Gómez Candela C, Palma Milla S, Carrillo Lozano E, Di Martino M, González Alcolea N, Olivar Roldán J, Suárez de la Rica A, Pestaña Lagunas D. Immunonutrition in fast-track surgical patients - Evidence review and adapted algorithm. *Nutr Hosp.* 2021 Jun 10;38(3):601-6021. doi: 10.20960/nh.03405. PMID: 33878885

Projects:

- Ensayo clínico para evaluar el efecto del consumo habitual de un microorganismo con actividad probiótica sobre la mejoría de síntomas en personas con alteraciones gastrointestinales transitorias leves no asociadas a enfermedad. Código HULP 6010.
- Proyecto para comprobar la factibilidad de la aplicación de la ecografía nutricional en el diagnóstico y seguimiento de pacientes con riesgo nutricional al alta

hospitalaria: estudio y función de composición corporal. Estudio DRECO. FIM-DRECO-2021-01.

- Estudio clínico nutricional longitudinal prospectivo para evaluar el efecto del consumo de un suplemento nutricional oral sobre la masa muscular medida con ecografía en pacientes con desnutrición. Código HULP 4829.
- Efecto del consumo habitual de una dieta completa hiperproteica e hipercalórica parcialmente hidrolizada rica en omega 3 y fibra soluble sobre el estado nutricional y la función gastrointestinal de pacientes desnutridos sometidos a cirugía pancreática oncológica. Código HULP 6149.
- Estudio observacional prospectivo para evaluar la adherencia y tolerancia de un suplemento nutricional oral (SNO) hiperproteico con fibra en pacientes hospitalizados con desnutrición. Código HULP 4422.

External users

Food industry

1. AB Biotics, S.A.
2. Nutricia S.R.L.
3. Go Fruselva, S.L.
4. Persán Distribuciones Farmacéuticas S.R.L.
5. Adventia Pharma, S.L.
6. Asociación Nacional de Fabricantes de Conservas de Pescados y Mariscos y Centro Técnico Nacional de Conservación de Productos de la pesca (ANFACO-CECOPESCA).
7. Alga Energy S.A.

Pharmaceutical laboratories

1. Abbott Laboratories S.A
2. Baxter S.L.
3. B. Braun Medical S.A.
4. Nestlé España S.A.
5. Cantabria Lab Nutrición Médica S.L.
6. Nutricia S.R.L.
7. Persán Distribuciones Farmacéuticas S.R.L.

To implement clinical trials or epidemiological studies well designed in the area of human nutrition, in order to validate the activity and efficacy of bioactive compounds, nutrients, foods, dietary patterns or artificial nutrition, on different parameters related to the health promotion, the disease prevention or its therapeutic activity.

2.7.16. SIMULATION PLATFORM (CEASEC)

The IdiPAZ/FIBHULP Simulation Centre offers professionals from various fields the following possibilities:

- Learning and training on the approach for patients in critical clinical conditions: cardiopulmonary resuscitation, shock of various origins, acute respiratory failure of various aetiologies, multiple trauma, arrhythmias, complicated births, difficult airways, safety, and leadership.
- Ongoing training of teams who treat patients in critical conditions: ICU, anaesthesia, emergency department, surgery.
- Learning and training on managing patients with technology-dependent conditions: mechanical ventilation, extracorporeal membrane oxygenation, dialysis, haemodialysis and haemofiltration and external ventricular assistance.
- Learning and training on managing technology for diagnostic and therapeutic use: echocardiography, abdominal ultrasonography, catheterisation, laparoscopic surgery, bronchoscopy, laryngoscopy, endoscopy and colonoscopy.
- Learning the use of invasive techniques: arterial and central venous cannulation, nasogastric and vesical catheterisation, suturing, thoracocentesis, paracentesis, tracheostomy, nerve blocks.
- Learning to perform a correct medical history review and physical examination and communicating and contacting patients, using actors and advanced simulators.

■ Composition

Governing Council

Dr. Javier Cobas Gamallo
D^a. Ana Coloma Zapatero
Dra. Carlota Largo Aramburu
D^a Elena Martín de Castro
D^a. Alicia Portas Martínez
Dr. Manuel Quintana Díaz
Dr. Pedro de la Oliva Senovilla
Dr. Ramón Cantero Cid
Dra. Ana M^a Sánchez Torres

D^a. Estela Sánchez Simón
Dra. Emilia Guash Arévalo
Dr. Esteban López de Sá y Areses
D^a. Irene Cuevas Gordo
Dr. Ignacio Zapadiel Gutiérrez
Dra. Esther Rey Cuevas
Dr. Juan José Ríos Blanco
Dra. Dolores Elorza
Dra. Marta Cortés León

Chairman Governing Council

Dr. Manuel Quintana Díaz

Secretary Governing Council

D^a Ana Coloma Zapatero
D^a Estela Sánchez Simón

Contact

Dña. Irene Cuevas
 irene.cuevas@salud.madrid.org
 Phone: (+34) 91 207 71 54

Clinical Simulation Technician

Javier Rubio Bolívar

■ Innovation projects in new technologies

The CEASEC collaborates with the Polytechnic University of Madrid in the development of new clinical training devices. During 2021, technological projects were carried out to train the technical skills of different medical specialties to address pathologies of various kinds: stroke, pulmonary ultrasound, hemorrhagic trauma, tracheotomies, intubation and lumbar punctures, and monitoring for the traceability of a transplant system organs, among others.

During this period, 7 biomedical engineering students have carried out their curricular internships and TFG and TFG work tutored by the Center's staff. All of them were clinically validated with great acceptance and projection for patents and publications to be developed in 2022.

■ Intubation simulator



■ Intubation simulator



■ Activity of CEASEC

CEASEC is the Advanced Clinical Training and Simulation Center. During 2021, the CEASEC activity has highly increased compared to 2020. The platform has provided assistance and support for research and teaching in more than 50 courses. Some of them: Advanced Course for Instructors in Clinical Simulation, Initial Assistance to Pediatric Trauma, Donation Simulation Conference in Asystole, Action in a neonatal crisis situation, Master's degree in critical illness and emergencies, SVB, SVI, SVA, CRM, Initial management of the patient with critical traumatic hemorrhage in urgencies and emergencies, simulation workshop for less invasive administration of surfactant, etc.



2.7.17. TISSUE ENGINEERING AND 3D PRINTING PLATFORM

The Tissue Engineering and 3D Printing Platform purpose is to promote the development of biomedical research and clinical applications based on tissue engineering and bioprinting and offer different services as 3D printing technologies, computer imaging, virtual planning and computer aided design to the professionals of HULP an IDIPAZ.

Research and activity areas of the platform are:

- Establishment of a patient-derived organoid biobank
- Bioprinting of tissues and organs > development of a skin and colon model
- Lab on a Chip (LOC) and Organ on a Chip (OOC) devices
- Tissue engineering approaches to develop tissue models and organs
- Development of new medical devices (biomodels, surgical guides, prosthesis and implants) based on emerging technologies as 3D printing
- Computer imaging, virtual planning and 3D printing to plan surgeries

During this year, and in collaboration with the IdiPaz Biobank platform, the tissue engineering and 3D printing platform has generated a living biobank of intestinal organoids from patient biopsies. Organoids are three-dimensional structures developed in the laboratory from stem cells, which self-organize, self-renew, and recapitulate the function and structure of the equivalent organ in vivo, representing a clinically relevant alternative to traditional 2D cell lines and a valuable tool for basic and translational research. Tissue Engineering and 3D Printing in collaboration with Idipaz Biobank has produced a collection of cultures of human intestinal organoids, including the rectum and colon, derived from patients with colorectal cancer (CRC) in three-dimensional extracellular matrices. We have also verified the functionality of the proposed methodology through the morphological and cellular characterization of the organoids generated, confirming that they retain the molecular, structural and functional characteristics of their tissues of origin, constituting an invaluable tool for the development of personalized therapies against CRC.

■ Composition

Director

Ramón Cantero Cid

Scientific advisor

Maria P. De Miguel González

Contact

PITI3D@idipaz.es


Phone: (+34) 91 207 15 12 (ext 2484)

■ Equipment

- Bioprinter Unit (V1 REGEMAT 3D) for thermoplastics, microextrusion, UV curing, temperature control and injection of cell laden biomaterials
- Fused deposition modelling (FDM) 3D printer for prototyping
- A Bioreactor to mature tissues based on mechanical excitation

■ Portfolio of services

- Bioprinting of meshes structures with or without cells
- 3D cell cultures
- Cell viability and proliferation assays to assess biocompatibility of reactives and materials
- Development of biofabrication processes
- Development of Lab on a Chip (LOC) and Organ on a Chip (OOC) devices
- Computer imaging and tissue segmentation from TAC and MRI
- 3D virtual planning
- Computer Aided Design (CAD)
- 3D printing of biomodels, surgical guides, prosthesis and implants in polymers and metals
- Biomaterials processing and manufacturing
- Education and training in the areas of activities





2.8 Scientific Production

2.8.1. JOURNAL ANALYSIS

The journals whose titles are in bold type belong to the first decile of their category

Journal	ISSN	Impact Factor	Total of documents	Quartile
Access Microbiology	2516-8290	Not Indexed	Not Indexed	Not Indexed
Acs Chemical Neuroscience	1948-7193	5,78	1	Q1
Acta Dermato-Venereológica	0001-5555	3,875	2	Q2
Acta Neuropatológica Comunicaciones	2051-5960	7,578	1	Q1
Acta Otorrinolaringológica Española	2173-5735	Not Indexed	Not Indexed	Not Indexed
Acta Paediatrica	0803-5253	4,056	2	Q1
Acta Physiologica	1748-1708	7,523	1	Q1
Actas Dermo-Sifiliográficas	0001-7310	Not Indexed	Not Indexed	Not Indexed
Actas Urológicas Españolas	0210-4806	0,887	10	Q4
Advanced Biology	2701-0198	Not Indexed	Not Indexed	Not Indexed
Advances in Skin & Wound Care	1527-7941	2,373	1	Q2
Advances in Therapy	0741-238X	4,07	2	Q2
Age and Ageing	0002-0729	12,782	4	Q1
Aging Clinical and Experimental Research	1594-0667	4,481	1	Q2
Aging-Us	1945-4589	5,955	1	Q2
AIDS	0269-9370	4,632	2	Q2
AIDS Research and Human Retroviruses	0889-2229	1,723	1	Q4
Alcohol	0741-8329	2,558	1	Q3
Alimentary Pharmacology & Therapeutics	0269-2813	9,524	2	Q1
Allergologia et Immunopathologia	0301-0546	2,094	1	Q4
Allergy	0105-4538	14,71	5	Q1

Allergy Asthma and Clinical Immunology	1710-1492	3,373	2	Q3
American Heart Journal	0002-8703	5,099	1	Q2
American Journal of Cardiology	0002-9149	3,133	1	Q3
American Journal of Clinical Nutrition	0002-9165	8,472	2	Q1
American Journal of Dermatopathology	0193-1091	1,319	1	Q4
American Journal of Emergency Medicine	0735-6757	4,093	1	Q1
American Journal of Human Genetics	0002-9297	11,043	1	Q1
American Journal of Hypertension	0895-7061	3,08	1	Q3
American Journal of Kidney Diseases	0272-6386	11,072	1	Q1
American Journal of Medical Genetics Part A	1552-4825	2,578	2	Q3
American Journal of Medical Genetics Part C-Seminars in Medical Genetics	1552-4868	3,359	1	Q3
American Journal of Obstetrics and Gynecology	0002-9378	10,693	1	Q1
American Journal of Physiology-Heart and Circulatory Physiology	0363-6135	5,125	1	Q1
American Journal of Preventive Medicine	0749-3797	6,604	1	Q1
American Journal of Public Health	0090-0036	11,561	1	Q1
American Journal of Stem Cells	2160-4150	Not Indexed	Not Indexed	Not Indexed

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

American Journal of Transplantation	1600-6135	9,369	4	Q1
American Journal of Tropical Medicine and Hygiene	0002-9637	3,707	1	Q2
American Surgeon	0003-1348	1,002	1	Q4
Anaesthesia	0003-2409	12,893	2	Q1
Anaesthesia Critical Care & Pain Medicine	2352-5568	7,025	1	Q1
Anales de Pediatría	1695-4033	2,377	15	Q3
Anales del Sistema Sanitario de Navarra	1137-6627	0,892	1	Q4
Analytica Chimica Acta	0003-2670	6,911	1	Q1
Andrología	0303-4569	2,532	1	Q3
Anesthesia and Analgesia	0003-2999	6,627	1	Q1
Anesthesiology	0003-3022	8,986	1	Q1
Angiology	0003-3197	3,299	1	Q3
Annals of Allergy Asthma & Immunology	1081-1206	6,248	1	Q2
Annals of Diagnostic Pathology	1092-9134	2,134	1	Q3
Annals of Hematology	0939-5555	4,03	2	Q2
Annals of Intensive Care	2110-5820	10,318	1	Q1
Annals of Internal Medicine	0003-4819	51,598	2	Q1
Annals of Oncology	0923-7534	51,769	1	Q1
Annals of the Rheumatic Diseases	0003-4967	27,973	1	Q1
Annals of Vascular Surgery	0890-5096	1,607	3	Q4
Antibiotics-Basel	2079-6382	5,222	3	Q1
Antimicrobial Agents and Chemotherapy	0066-4804	5,938	4	Q1
Antioxidants	2076-3921	7,675	2	Q1
Antiviral Research	0166-3542	10,103	1	Q1
Apoptosis	1360-8185	5,561	1	Q2
Applied Artificial Intelligence	0883-9514	2,777	1	Q2
Applied Catalysis A-General	0926-860X	5,723	1	Q2
Applied Sciences-Basel	2076-3417	2,838	1	Q2
Arab Journal of Urology	2090-598X	Not Indexed	Not Indexed	Not Indexed
Archives de Pediatría	0929-693X	1,82	1	Q4
Archives of Biochemistry and Biophysics	0003-9861	4,114	1	Q2
Archives of Bone and Joint Surgery-Abjs	2345-4644	Not Indexed	Not Indexed	Not Indexed
Archives of Disease in Childhood	0003-9888	4,92	2	Q1

Archives of Disease in Childhood-Fetal and Neonatal Edition	1359-2998	6,643	1	Q1
Archives of Oral Biology	0003-9969	2,64	1	Q3
Archives of Osteoporosis	1862-3522	2,879	1	Q2
Archives of Pathology & Laboratory Medicine	0003-9985	5,686	1	Q1
Archivos de Bronconeumología	0300-2896	6,333	16	Q1
Archivos de Cardiología de México	1405-9940	Not Indexed	Not Indexed	Not Indexed
Archivos de la Sociedad Española de Oftalmología	2173-5794	Not Indexed	Not Indexed	Not Indexed
Archivos Españoles de Urología	0004-0614	0,43	9	Q4
Arteriosclerosis Thrombosis and Vascular Biology	1079-5642	10,514	1	Q1
Arthritis & Rheumatology	2326-5191	15,483	1	Q1
Arthritis Care & Research	2151-464X	5,178	2	Q2
Arthritis Research & Therapy	1478-6354	5,606	1	Q1
Arthroscopy Techniques	2212-6287	Not Indexed	Not Indexed	Not Indexed
Artificial Organs	0160-564X	2,663	1	Q3
Atención Primaria	0212-6567	2,206	6	Q3
Atherosclerosis	0021-9150	6,847	1	Q1
Atherosclerosis Plus	2667-0895	Not Indexed	Not Indexed	Not Indexed
Audiology and Neuro-Otology	1420-3030	2,213	1	Q3
Autophagy	1554-8627	13,391	1	Q1
Balkan Medical Journal	2146-3123	3,57	1	Q2
Biochemical Society Transactions	0300-5127	4,919	1	Q2
Biochimica et Biophysica Acta-Molecular Basis of Disease	0925-4439	6,633	1	Q1
Biochimica et Biophysica Acta-Reviews on Cancer	0304-419X	11,414	1	Q1
Biology-Basel	2079-7737	5,168	2	Q1
Biomedicine & Pharmacotherapy	0753-3322	7,419	3	Q1
Biomedicine Hub	2296-6870	Not Indexed	Not Indexed	Not Indexed
Biomedicines	2227-9059	4,757	7	Q2
Biomolecules	2218-273X	6,064	1	Q2
BJS Open	2474-9842	3,875	1	Q1
BJU International	1464-4096	5,969	2	Q1
Blood	0006-4971	25,476	1	Q1
Blood Advances	2473-9529	7,637	2	Q1
Blood Cancer Journal	2044-5385	9,812	4	Q1
Blood Cells Molecules and Diseases	1079-9796	2,372	3	Q4



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Blood Coagulation & Fibrinolysis	0957-5235	1,061	1	Q4
Blood Reviews	0268-960X	10,626	1	Q1
BMC Health Services Research	1472-6963	2,908	1	Q3
BMC Infectious Diseases	1471-2334	3,67	1	Q3
BMC Medicine	1741-7015	11,15	1	Q1
BMC Pediatrics	1471-2431	2,567	1	Q3
BMC Pregnancy and Childbirth	1471-2393	3,105	2	Q2
BMC Psychology	2050-7283	2,588	1	Q2
BMC Public Health	1471-2458	4,135	1	Q2
BMC Rheumatology	2520-1026	Not Indexed	Not Indexed	Not Indexed
BMC Womens Health	1472-6874	2,742	1	Q3
BMJ Case Reports	1757-790X	Not Indexed	Not Indexed	Not Indexed
BMJ Open	2044-6055	3,006	7	Q2
BMJ Open Respiratory Research	2052-4439	5,059	1	Q2
BMJ Supportive & Palliative Care	2045-435X	4,633	1	Q1
Boletín de Pediatría	0214-2597	Not Indexed	Not Indexed	Not Indexed
Bone & Joint Journal	2049-4394	5,385	1	Q1
Bone & Joint Research	2046-3758	4,41	1	Q1
Bone Marrow Transplantation	0268-3369	5,174	1	Q2
Brain	0006-8950	15,255	1	Q1
Brain Sciences	2076-3425	3,333	3	Q3
Brazilian Journal of Anesthesiology	0104-0014	Not Indexed	Not Indexed	Not Indexed
Brazilian Journal of Physical Therapy	1413-3555	4,762	1	Q1
British Journal of Cancer	0007-0920	9,075	1	Q1
British Journal of Haematology	0007-1048	8,615	1	Q1
British Journal of Nutrition	0007-1145	4,125	1	Q3
British Journal of Ophthalmology	0007-1161	5,908	1	Q1
British Journal of Pharmacology	0007-1188	9,473	1	Q1
British Journal of Surgery	0007-1323	11,122	3	Q1
Burns	0305-4179	2,609	1	Q2
Burns & Trauma	2321-3868	5,711	1	Q1
Canadian Journal of Psychiatry- Revue Canadienne de Psychiatrie	0706-7437	5,321	1	Q2
Cancer	0008-543X	6,921	1	Q1
Cancer Cell International	1475-2867	6,436	1	Q2
Cancer Chemotherapy and Pharmacology	0344-5704	3,288	2	Q3
Cancer Immunology Immunotherapy	0340-7004	6,63	1	Q1
Cancer Investigation	0735-7907	2,368	1	Q4

Cancer Management and Research	1179-1322	3,602	1	Q3
Cancer Research	0008-5472	13,312	2	Q1
Cancer Treatment Reviews	0305-7372	13,608	2	Q1
Cancers	2072-6694	6,575	27	Q2
Cardiology Journal	1897-5593	3,487	1	Q2
Cardiovascular & Hematológico Disorders Drug Targets	2212-4063	Not Indexed	Not Indexed	Not Indexed
Cardiovascular Diabetology	1475-2840	8,949	2	Q1
Cardiovascular Drugs and Therapy	0920-3206	3,947	1	Q2
Cardiovascular Revascularization Medicine	1553-8389	Not Indexed	Not Indexed	Not Indexed
Case Reports in Urology	2090-696X	Not Indexed	Not Indexed	Not Indexed
Catheterization and Cardiovascular Interventions	1522-1946	2,585	2	Q3
Cell Reports	2211-1247	9,995	1	Q1
Cells	2073-4409	7,666	7	Q2
Cellular and Molecular Life Sciences	1420-682X	9,207	1	Q1
Chest	0012-3692	10,262	1	Q1
Children-Basel	2227-9067	2,835	6	Q2
Childs Nervous System	0256-7040	1,532	1	Q4
Circulation	0009-7322	39,918	8	Q1
Circulation-Cardiovascular Interventions	1941-7640	7,514	2	Q1
Circulation-Genomic and Precision Medicine	2574-8300	7,465	1	Q1
Cirugía Cardiovascular	1134-0096	Not Indexed	Not Indexed	Not Indexed
Cirugía Española	0009-739X	2,242	5	Q3
Cirugía Pediátrica	2445-2807	Not Indexed	Not Indexed	Not Indexed
Cirugía y Cirujanos	0009-7411	0,416	1	Q4
Clinica Chimica Acta	0009-8981	6,314	1	Q1
Clínica e Investigación en Arteriosclerosis	0214-9168	Not Indexed	Not Indexed	Not Indexed
Clínica e Investigación en Ginecología y Obstetricia	0210-573X	Not Indexed	Not Indexed	Not Indexed
Clinical & Translational Oncology	1699-048X	3,34	17	Q3
Clinical Advances in Hematology & Oncology	1543-0790	Not Indexed	Not Indexed	Not Indexed
Clinical and Experimental Allergy	0954-7894	5,401	1	Q2
Clinical and Experimental Immunology	0009-9104	5,732	1	Q2
Clinical and Experimental Medicine	1591-8890	5,057	1	Q2



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Clinical and Experimental Rheumatology	0392-856X	4,862	1	Q2
Clinical and Translational Allergy	2045-7022	5,657	1	Q2
Clinical and Translational Medicine	2001-1326	8,554	3	Q1
Clinical Cancer Research	1078-0432	13,801	2	Q1
Clinical Case Reports	2050-0904	Not Indexed	Not Indexed	Not Indexed
Clinical Chemistry	0009-9147	12,167	2	Q1
Clinical Chemistry and Laboratory Medicine	1434-6621	8,49	3	Q1
Clinical Drug Investigation	1173-2563	3,58	1	Q3
Clinical Endocrinology	0300-0664	3,523	1	Q3
Clinical Epigenetics	1868-7075	7,259	2	Q1
Clinical Genetics	0009-9163	4,296	4	Q2
Clinical Immunology	1521-6616	10,19	1	Q1
Clinical Infectious Diseases	1058-4838	20,999	3	Q1
Clinical Kidney Journal	2048-8505	5,86	6	Q1
Clinical Lymphoma Myeloma & Leukemia	2152-2650	2,822	2	Q3
Clinical Microbiology and Infection	1198-743X	13,31	12	Q1
Clinical Neurology and Neurosurgery	0303-8467	1,885	1	Q3
Clinical Nutrition	0261-5614	7,643	3	Q1
Clinical Orthopaedics and Related Research	0009-921X	4,755	1	Q1
Clinical Research in Cardiology	1861-0684	6,138	1	Q2
Clinical Reviews in Allergy & Immunology	1080-0549	10,817	2	Q1
Clinical Rheumatology	0770-3198	3,65	4	Q3
Clinical Science	0143-5221	6,876	2	Q1
Clinical Therapeutics	0149-2918	3,637	1	Q2
Clinical Transplantation	0902-0063	3,456	3	Q2
Clinics and Research in Hepatology and Gastroenterology	2210-7401	3,189	1	Q3
Cochrane Database of Systematic Reviews	1469-493X	12,008	1	Q1
Communications Biology	2399-3642	6,548	1	Q1
Communications in Nonlinear Science and Numerical Simulation	1007-5704	4,186	2	Q1
Comprehensive Psychiatry	0010-440X	7,211	1	Q1
Computer Methods and Programs in Biomedicine	0169-2607	7,027	1	Q1
Contact Dermatitis	0105-1873	6,419	1	Q1

Cornea	0277-3740	3,152	1	Q2
Coronary Artery Disease	0954-6928	1,717	2	Q4
Critical Care	1364-8535	19,334	1	Q1
Critical Care Medicine	0090-3493	9,296	2	Q1
Critical Reviews in Food Science and Nutrition	1040-8398	11,208	1	Q1
Cts-Clinical and Translational Science	1752-8054	4,438	1	Q2
Cureus	2168-8184	Not Indexed	Not Indexed	Not Indexed
Current Atherosclerosis Reports	1523-3804	5,967	1	Q1
Current Medical Research and Opinion	0300-7995	2,705	1	Q3
Current Opinion in Anesthesiology	0952-7907	2,733	1	Q3
Current Opinion in Clinical Nutrition and Metabolic Care	1363-1950	3,62	1	Q3
Current Opinion in Obstetrics & Gynecology	1040-872X	2,211	1	Q4
Current Opinion in Pulmonary Medicine	1070-5287	2,868	1	Q4
Current Opinion in Urology	0963-0643	2,808	1	Q3
Current Pediatrics Reports	2167-4841	Not Indexed	Not Indexed	Not Indexed
Current Treatment Options in Allergy	2196-3053	Not Indexed	Not Indexed	Not Indexed
Current Treatment Options in Oncology	1527-2729	5,08	2	Q2
Cytometry Part B-Clinical Cytometry	1552-4949	3,248	1	Q2
De Medio Aevo	2255-5889	Not Indexed	Not Indexed	Not Indexed
Dermatologic Surgery	1076-0512	2,914	1	Q2
Dermatologic Therapy	1396-0296	3,858	2	Q2
Dermatology and Therapy	2193-8210	3,661	3	Q2
Diabetes Research and Clinical Practice	0168-8227	8,18	2	Q1
Diabetic Medicine	0742-3071	4,213	1	Q2
Diagnostic Microbiology and Infectious Disease	0732-8893	2,983	2	Q3
Diagnostics	2075-4418	3,992	2	Q2
Digestive Diseases	0257-2753	3,421	1	Q3
Drugs	0012-6667	11,431	1	Q1
Ear and Hearing	0196-0202	3,562	1	Q1
Early Human Development	0378-3782	2,699	1	Q2
Ebiomedicine	2352-3964	11,205	2	Q1
Eclinicalmedicine	2589-5370	17,033	2	Q1



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Educatio Siglo Xxi	1699-2105	Not Indexed	Not Indexed	Not Indexed
Efort Open Reviews	2396-7544	4,775	7	Q1
Electronic Journal of Linear Algebra	1537-9582	0,882	1	Q3
Elife	2050-084X	8,713	1	Q1
Embo Molecular Medicine	1757-4676	14,26	1	Q1
Emergencias	1137-6821	5,345	6	Q1
Emergency Medicine Journal	1472-0205	3,814	1	Q2
Emerging Infectious Diseases	1080-6040	16,126	4	Q1
Endocrine	1355-008X	3,925	2	Q3
Endocrine-Related Cancer	1351-0088	5,9	1	Q1
Endocrinología Diabetes y Nutrición	2530-0180	1,833	3	Q4
Enfermedades Infecciosas y Microbiología Clínica	0213-005X	1,994	14	Q4
Enfermería Clínica	1130-8621	Not Indexed	Not Indexed	Not Indexed
Enfermería Intensiva	1130-2399	Not Indexed	Not Indexed	Not Indexed
Engineering	2095-8099	12,834	1	Q1
Environmental Pollution	0269-7491	9,988	1	Q1
Epidemiology and Infection	0950-2688	4,434	1	Q2
Epilepsia	0013-9580	6,74	4	Q1
ESMO Open	2059-7029	6,883	3	Q1
Eurasian Journal of Medicine and Oncology	2587-196X	Not Indexed	Not Indexed	Not Indexed
Eurointervention	1774-024X	7,728	3	Q1
Europace	1099-5129	5,486	4	Q2
European Annals of Allergy and Clinical Immunology	1764-1489	Not Indexed	Not Indexed	Not Indexed
European Archives of Oto-Rhino-Laryngology	0937-4477	3,236	1	Q2
European Cardiology Review	1758-3756	Not Indexed	Not Indexed	Not Indexed
European Geriatric Medicine	1878-7649	3,269	1	Q3
European Heart Journal	0195-668X	35,855	1	Q1
European Heart Journal-Acute Cardiovascular Care	2048-8726	4,766	1	Q2
European Heart Journal-Cardiovascular Imaging	2047-2404	9,13	1	Q1
European Heart Journal-Cardiovascular Pharmacotherapy	2055-6837	11,177	1	Q1
European Heart Journal-Case Reports	2514-2119	Not Indexed	Not Indexed	Not Indexed
European Heart Journal-Quality of Care and Clinical Outcomes	2058-5225	7,064	1	Q1

European Journal of Cancer	0959-8049	10,002	1	Q1
European Journal of Cardio-Thoracic Surgery	1010-7940	4,534	2	Q1
European Journal of Clinical Investigation	0014-2972	5,722	1	Q1
European Journal of Clinical Microbiology & Infectious Diseases	0934-9723	5,103	2	Q2
European Journal of Endocrinology	0804-4643	6,558	1	Q1
European Journal of Gynaecological Oncology	0392-2936	0,255	1	Q4
European Journal of Haematology	0902-4441	3,674	4	Q3
European Journal of Heart Failure	1388-9842	17,349	1	Q1
European Journal of Hospital Pharmacy	2047-9956	2,537	2	Q3
European Journal of Human Genetics	1018-4813	5,351	1	Q1
European Journal of Immunology	0014-2980	6,688	1	Q2
European Journal of Internal Medicine	0953-6205	7,749	2	Q1
European Journal of Medical Genetics	1769-7212	2,465	4	Q3
European Journal of Medical Research	0949-2321	4,981	1	Q2
European Journal of Medicinal Chemistry	0223-5234	7,088	1	Q1
European Journal of Neurology	1351-5101	6,288	3	Q1
European Journal of Nutrition	1436-6215	4,865	2	Q2
European Journal of Obstetrics & Gynecology and Reproductive Biology	0301-2115	2,831	1	Q3
European Journal of Ophthalmology	1120-6721	1,922	3	Q4
European Journal of Paediatric Neurology	1090-3798	3,692	1	Q2
European Journal of Pain	1090-3801	3,651	1	Q2
European Journal of Pediatric Surgery	0939-7248	1,794	2	Q3
European Journal of Pediatric Surgery Reports	2194-7619	Not Indexed	Not Indexed	Not Indexed
European Journal of Pediatrics	0340-6199	3,86	7	Q1
European Journal of Preventive Cardiology	2047-4873	8,526	1	Q1
European Journal of Protistology	0932-4739	3,471	1	Q3



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

European Journal of Public Health	1101-1262	4,424	1	Q2
European Journal of Rheumatology	2147-9720	Not Indexed	Not Indexed	Not Indexed
European Journal of Trauma and Emergency Surgery	1863-9933	2,374	1	Q3
European Journal of Vascular and Endovascular Surgery	1078-5884	6,427	1	Q1
European Respiratory Journal	0903-1936	33,795	2	Q1
European Spine Journal	0940-6719	2,721	3	Q2
European Stroke Journal	2396-9873	5,894	1	Q1
European Urology	0302-2838	24,267	3	Q1
European Urology Oncology	2588-9311	8,208	1	Q1
Eurosurveillance	1025-496X	21,286	4	Q1
Excli Journal	1611-2156	4,022	2	Q2
Experimental Dermatology	0906-6705	4,511	1	Q1
Experimental Eye Research	0014-4835	3,77	1	Q2
Experimental Gerontology	0531-5565	4,253	1	Q2
Expert Opinion on Biología Therapy	1471-2598	5,589	1	Q1
Expert Opinion on Drug Metabolism & Toxicology	1742-5255	4,936	1	Q1
Expert Opinion on Drug Safety	1474-0338	4,011	1	Q2
Expert Review of Clinical Pharmacology	1751-2433	4,108	1	Q2
Expert Review of Hematology	1747-4086	2,819	7	Q3
Expert Review of Medical Devices	1743-4440	3,439	1	Q3
Expert Review of Ophthalmology	1746-9899	Not Indexed	Not Indexed	Not Indexed
Family Practice	0263-2136	2,29	1	Q3
Farmacia Hospitalaria	1130-6343	Not Indexed	Not Indexed	Not Indexed
Faseb Journal	0892-6638	5,834	1	Q1
Fertility and Sterility	0015-0282	7,49	1	Q1
Fetal Diagnosis and Therapy	1015-3837	2,208	3	Q4
Food and Waterborne Parasitology	2405-6766	Not Indexed	Not Indexed	Not Indexed
Food Chemistry	0308-8146	9,231	1	Q1
Food Control	0956-7135	6,652	1	Q1
Free Radical Biology and Medicine	0891-5849	8,101	1	Q1
Frontiers in Aging Neuroscience	1663-4365	5,702	2	Q1
Frontiers in Bioscience-Landmark	2768-6701	3,115	1	Q3
Frontiers in Cardiovascular Medicine	2297-055X	5,846	2	Q2
Frontiers in Cell and Developmental Biology	2296-634X	6,081	4	Q1

Frontiers in Cellular Neuroscience	1662-5102	6,147	1	Q1
Frontiers in Endocrinology	1664-2392	6,055	3	Q1
Frontiers in Genetics	1664-8021	4,772	2	Q1
Frontiers in Immunology	1664-3224	8,786	18	Q1
Frontiers in Marine Science	2296-7745	5,247	1	Q1
Frontiers in Medicine	2296-858X	5,058	11	Q2
Frontiers in Molecular Neuroscience	1662-5099	6,261	1	Q1
Frontiers in Neurology	1664-2295	4,086	9	Q2
Frontiers in Oncology	2234-943X	5,738	3	Q2
Frontiers in Pediatrics	2296-2360	3,569	10	Q2
Frontiers in Pharmacology	1663-9812	5,988	4	Q1
Frontiers in Physiology	1664-042X	4,755	4	Q1
Frontiers in Psychiatry	1664-0640	5,435	1	Q2
Future Cardiology	1479-6678	Not Indexed	Not Indexed	Not Indexed
Future Microbiology	1746-0913	3,553	1	Q3
Future Oncology	1479-6694	3,674	2	Q3
Gaceta Sanitaria	0213-9111	2,479	3	Q3
Gastric Cancer	1436-3291	7,701	1	Q1
Gastroenterología y Hepatología	0210-5705	5,867	3	Q2
Genes	2073-4425	4,141	4	Q2
Genetics in Medicine	1098-3600	8,864	3	Q1
Genome Biology	1474-760X	17,906	3	Q1
Global & Regional Health Technology Assessment	2284-2403	Not Indexed	Not Indexed	Not Indexed
Global Heart	2211-8160	3,218	1	Q3
Gynecologic Oncology	0090-8258	5,304	3	Q1
Haematologica	0390-6078	11,047	1	Q1
Haemophilia	1351-8216	4,263	11	Q2
Head and Neck-Journal For the Sciences and Specialties of the Head and Neck	1043-3074	3,821	1	Q1
Health & Place	1353-8292	4,931	3	Q1
Hearing Research	0378-5955	3,672	1	Q1
Heart	1355-6037	7,365	2	Q1
Heart Failure Reviews	1382-4147	4,654	1	Q2
Heart Rhythm	1547-5271	6,779	1	Q2
Heliyon	2405-8440	3,776	1	Q2
Hellenic Journal of Cardiology	1109-9666	5,795	1	Q2
Hemasphere	2572-9241	8,3	1	Q1



Hepatology	0270-9139	17,298	2	Q1
Hip International	1120-7000	1,756	2	Q3
Hipertensión y Riesgo Vascular	1889-1837	Not Indexed	Not Indexed	Not Indexed
HIV Medicine	1464-2662	3,094	2	Q3
Hormone and Metabolic Research	0018-5043	2,788	1	Q4
Hormone Molecular Biology and Clinical Investigation	1868-1883	Not Indexed	Not Indexed	Not Indexed
Hormones-International Journal of Endocrinology and Metabolism	1109-3099	3,419	2	Q3
Hypertension	0194-911X	9,897	2	Q1
Infection	0300-8126	7,455	1	Q1
Inflammatory Bowel Diseases	1078-0998	7,29	2	Q1
Injury-International Journal of the Care of the Injured	0020-1383	2,687	3	Q2
Intensive and Critical Care Nursing	0964-3397	4,235	1	Q1
Intensive Care Medicine	0342-4642	41,787	1	Q1
Internal and Emergency Medicine	1828-0447	5,472	1	Q2
Internal Medicine Journal	1444-0903	2,611	1	Q3
International Archives of Allergy and Immunology	1018-2438	3,767	2	Q3
International Journal of Antimicrobial Agents	0924-8579	15,441	1	Q1
International Journal of Behavioral Nutrition and Physical Activity	1479-5868	8,925	1	Q1
International Journal of Cardiology	0167-5273	4,039	2	Q2
International Journal of Chronic Obstructive Pulmonary Disease	1178-2005	2,893	1	Q4
International Journal of Clinical Pharmacy	2210-7703	2,305	1	Q4
International Journal of Clinical Practice	1368-5031	3,149	1	Q2
International Journal of Dermatology	0011-9059	3,204	2	Q2
International Journal of Environmental Research and Public Health	1660-4601	4,614	12	Q1
International Journal of Epidemiology	0300-5771	9,685	2	Q1
International Journal of Gynecological Cancer	1048-891X	4,661	5	Q1
International Journal of Hematology	0925-5710	2,319	1	Q4
International Journal of Molecular Sciences	1422-0067	6,208	18	Q1

International Journal of Oncology	1019-6439	5,884	1	Q2
International Journal of Rheumatic Diseases	1756-1841	2,558	2	Q4
International Journal of Spine Surgery	2211-4599	Not Indexed	Not Indexed	Not Indexed
International Journal of Stroke	1747-4930	6,948	1	Q1
International Journal of Surgical Pathology	1066-8969	1,358	1	Q4
International Orthopaedics	0341-2695	3,479	1	Q2
International Urology and Nephrology	0301-1623	2,266	1	Q3
Investigational New Drugs	0167-6997	3,651	1	Q2
Iscience	2589-0042	6,107	1	Q1
JAAD Case Reports	2352-5126	Not Indexed	Not Indexed	Not Indexed
JACC. Cardiovascular Imaging	1876-7591	16,051	1	Q1
JAIDS-Journal of Acquired Immune Deficiency Syndromes	1525-4135	3,771	2	Q3
JAMA Cardiology	2380-6583	30,154	2	Q1
JAMA Neurology	2168-6149	29,907	1	Q1
JAMA Oncology	2374-2437	33,006	1	Q1
JAMA Otolaryngology-Head & Neck Surgery	2168-6181	8,961	1	Q1
JAMA Pediatrics	2168-6203	26,796	3	Q1
JCR-Journal of Clinical Rheumatology	1076-1608	3,902	1	Q3
JIMD Reports	2192-8304	Not Indexed	Not Indexed	Not Indexed
JMIR Public Health and Surveillance	2369-2960	14,557	1	Q1
Joint Bone Spine	1297-319X	5,263	3	Q2
Journal for Immunotherapy of Cancer	2051-1426	12,487	3	Q1
Journal of Aapos	1091-8531	1,325	1	Q4
Journal of Affective Disorders	0165-0327	6,533	1	Q1
Journal of Allergy and Clinical Immunology	0091-6749	14,29	3	Q1
Journal of Allergy and Clinical Immunology-In Practice	2213-2198	11,022	7	Q1
Journal of Antimicrobial Chemotherapy	0305-7453	5,758	6	Q1
Journal of Arthroplasty	0883-5403	4,435	1	Q1
Journal of Biological Chemistry	1083-351X	5,486	1	Q2

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



Journal of Biomedical Science	1021-7770	12,771	1	Q1
Journal of Bone and Joint Surgery-American Volume	0021-9355	6,558	1	Q1
Journal of Cancer Research and Therapeutics	0973-1482	1,331	1	Q4
Journal of Cancer Survivorship	1932-2259	4,062	1	Q1
Journal of Cardiovascular Echography	2211-4122	Not Indexed	Not Indexed	Not Indexed
Journal of Cardiovascular Pharmacology	0160-2446	3,271	1	Q3
Journal of Cellular and Molecular Medicine	1582-1838	5,295	1	Q2
Journal of Cellular Physiology	0021-9541	6,513	1	Q1
Journal of Childrens Orthopaedics	1863-2521	1,917	1	Q3
Journal of Clinical and Experimental Dentistry	1989-5488	Not Indexed	Not Indexed	Not Indexed
Journal of Clinical Apheresis	0733-2459	2,605	1	Q4
Journal of Clinical Endocrinology & Metabolism	0021-972X	6,134	1	Q1
Journal of Clinical Epidemiology	0895-4356	7,407	1	Q1
Journal of Clinical Ethics	1046-7890	0,471	1	Q3
Journal of Clinical Immunology	0271-9142	8,542	2	Q1
Journal of Clinical Medicine	2077-0383	4,964	36	Q2
Journal of Clinical Oncology	0732-183X	50,717	3	Q1
Journal of Clinical Psychiatry	0160-6689	5,906	1	Q1
Journal of Clinical Virology	1386-6532	14,481	2	Q1
Journal of Crohns & Colitis	1873-9946	10,02	2	Q1
Journal of Electrocardiology	0022-0736	1,38	1	Q4
Journal of Emergency Medicine	0736-4679	1,473	2	Q4
Journal of Endocrinológica Investigation	0391-4097	5,467	1	Q2
Journal of Epidemiology and Community Health	0143-005X	6,286	1	Q1
Journal of Experimental & Clinical Cancer Research	1756-9966	12,658	1	Q1
Journal of Extracellular Vesicles	2001-3078	17,337	1	Q1
Journal of Fungi	2309-608X	5,724	1	Q1
Journal of Gastrointestinal Surgery	1091-255X	3,267	1	Q2
Journal of General Internal Medicine	0884-8734	6,473	2	Q1
Journal of Geriatric Oncology	1879-4068	3,929	1	Q3
Journal of Global Antimicrobial Resistance	2213-7165	4,349	1	Q2

Journal of Gynecologic Oncology	2005-0380	4,756	3	Q1
Journal of Gynecology Obstetrics and Human Reproduction	2468-7847	2,156	1	Q4
Journal of Hand Surgery-European Volume	1753-1934	2,206	1	Q3
Journal of Headache and Pain	1129-2369	8,588	1	Q1
Journal of Healthcare Quality Research	2603-6479	Not Indexed	Not Indexed	Not Indexed
Journal of Hematology & Oncology	1756-8722	23,168	3	Q1
Journal of Hepatology	0168-8278	30,083	2	Q1
Journal of Hospital Medicine	1553-5592	2,899	1	Q3
Journal of Human Lactation	0890-3344	2,665	1	Q1
Journal of Hypertension	0263-6352	4,776	1	Q2
Journal of Immunology	0022-1767	5,426	1	Q2
Journal of Infection	0163-4453	38,637	7	Q1
Journal of Infectious Diseases	0022-1899	7,759	2	Q1
Journal of Inflammation Research	1178-7031	4,631	2	Q3
Journal of Intensive Care Medicine	0885-0666	2,889	1	Q3
Journal of International Medical Research	0300-0605	1,573	1	Q4
Journal of Invasive Cardiology	1042-3931	1,711	1	Q4
Journal of Investigational Allergology and Clinical Immunology	1018-9068	8,185	15	Q1
Journal of Laparoendoscopic & Advanced Surgical Techniques	1092-6429	1,766	1	Q3
Journal of Laryngology and Otology	1748-5460	2,187	1	Q3
Journal of Maternal-Fetal & Neonatal Medicine	1476-7058	2,323	2	Q3
Journal of Medical Internet Research	1438-8871	7,076	1	Q1
Journal of Medical Systems	0148-5598	4,92	1	Q1
Journal of Medical Virology	0146-6615	20,693	1	Q1
Journal of Minimally Invasive Gynecology	1553-4650	4,314	2	Q1
Journal of Neurointerventional Surgery	1759-8478	8,572	1	Q1
Journal of Neurology	0340-5354	6,682	1	Q1
Journal of Neurology Neurosurgery and Psychiatry	0022-3050	13,654	2	Q1
Journal of Neurosurgery-Pediatrics	1933-0707	2,713	1	Q2

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Journal of Nutrition	0022-3166	4,687	1	Q2
Journal of Obstetrics and Gynaecology	0144-3615	1,226	2	Q4
Journal of Obstetrics and Gynaecology Research	1341-8076	1,697	2	Q4
Journal of Ovarian Research	1757-2215	5,506	1	Q1
Journal of Paediatrics and Child Health	1034-4810	1,929	1	Q3
Journal of Pain Research	1178-7090	2,832	2	Q3
Journal of Pediatric Surgery	0022-3468	2,549	2	Q2
Journal of Pediatric Surgery Case Reports	2213-5766	Not Indexed	Not Indexed	Not Indexed
Journal of Pediatrics	0022-3476	6,314	5	Q1
Journal of Personalized Medicine	2075-4426	3,508	4	Q2
Journal of Plastic Reconstructive and Aesthetic Surgery	1748-6815	3,022	1	Q2
Journal of Proteome Research	1535-3893	5,37	1	Q1
Journal of Psychiatric Research	0022-3956	5,25	3	Q2
Journal of Public Health	1741-3842	5,058	1	Q1
Journal of Rehabilitation Medicine	1650-1977	3,959	1	Q1
Journal of Rheumatology	0315-162X	5,346	3	Q2
Journal of Science and Medicine in Sport	1440-2440	4,597	1	Q1
Journal of Shoulder and Elbow Surgery	1058-2746	3,507	1	Q2
Journal of the American Academy of Dermatology	0190-9622	15,487	3	Q1
Journal of the American College of Cardiology	0735-1097	27,203	4	Q1
Journal of the American College of Emergency Physicians Open	2688-1152	Not Indexed	Not Indexed	Not Indexed
Journal of the American Heart Association	2047-9980	6,106	3	Q2
Journal of the European Academy of Dermatology and Venereology	0926-9959	9,228	3	Q1
Journal of the International AIDS Society	1758-2652	6,707	1	Q1
Journal of the Science of Food and Agriculture	0022-5142	4,125	1	Q1
Journal of Thrombosis and Haemostasis	1538-7933	16,036	3	Q1
Journal of Travel Medicine	1195-1982	39,194	2	Q1

Journal of Tropical Pediatrics	0142-6338	1,794	1	Q3
Journal of Ultrasound	1971-3495	Not Indexed	Not Indexed	Not Indexed
Journal of Ultrasound in Medicine	0278-4297	2,754	1	Q2
Journal of Urology	0022-5347	7,6	2	Q1
Journal of Vascular Surgery-Venous and Lymphatic Disorders	2213-333X	4,19	1	Q1
Journal of Virology	0022-538X	6,549	2	Q2
Journals of Gerontology Series A-Biological Sciences and Medical Sciences	1079-5006	6,591	5	Q1
Kidney International	0085-2538	18,998	1	Q1
Kidney International Reports	2468-0249	6,234	1	Q1
Lancet	0140-6736	202,731	3	Q1
Lancet Child & Adolescent Health	2352-4642	37,746	1	Q1
Lancet Global Health	2214-109X	38,927	1	Q1
Lancet HIV	2352-3018	16,07	2	Q1
Lancet Infectious Diseases	1473-3099	71,421	1	Q1
Lancet Neurology	1474-4422	59,935	1	Q1
Lancet Oncology	1470-2045	54,433	3	Q1
Lancet Regional Health-Europe	2666-7762	Not Indexed	Not Indexed	Not Indexed
Lancet Respiratory Medicine	2213-2600	102,642	2	Q1
Langenbecks Archives of Surgery	1435-2443	2,895	1	Q2
Leukemia	0887-6924	12,883	2	Q1
Leukemia & Lymphoma	1042-8194	2,996	1	Q3
Life Science Alliance	2575-1077	5,781	1	Q1
Liver International	1478-3223	8,754	2	Q1
Lung	0341-2040	3,777	1	Q3
Macromolecular Chemistry and Physics	1022-1352	2,996	1	Q2
Materials Today Communications	2352-4928	3,662	1	Q3
Medical Dosimetry	0958-3947	1,531	1	Q4
Medical Mycology	1369-3786	3,747	1	Q1
Medical Physics	0094-2405	4,506	1	Q2
Medical Teacher	0142-159X	4,277	2	Q1
Medicina Clinica	0025-7753	3,2	15	Q2
Medicina de Familia-SEMERGEN	1138-3593	Not Indexed	Not Indexed	Not Indexed
Medicina Intensiva	0210-5691	2,799	8	Q3
Medicina Oral Patología Oral y Cirugía Bucal	1698-6946	2,883	4	Q2
Medicina-Lithuania	1010-660X	2,948	1	Q3



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Medicine	0025-7974	1,817	4	Q3
Meta Gene	2214-5400	Not Indexed	Not Indexed	Not Indexed
Methods and Protocols	2409-9279	Not Indexed	Not Indexed	Not Indexed
Microbiologyopen	2045-8827	3,904	1	Q3
Microlife	2633-6693	Not Indexed	Not Indexed	Not Indexed
Microorganisms	2076-2607	4,926	3	Q2
Microporous and Mesoporous Materials	1387-1811	5,876	1	Q1
Minerva Anestesiológica	0375-9393	3,396	2	Q3
Minerva Obstetrics and Gynecology	2724-606X	Not Indexed	Not Indexed	Not Indexed
Minerva Urology and Nephrology	2724-6051	5,214	5	Q1
Modern Rheumatology Case Reports	2472-5625	Not Indexed	Not Indexed	Not Indexed
Molecular and Cellular Endocrinology	0303-7207	4,369	1	Q2
Molecular Biology Reports	0301-4851	2,742	1	Q4
Molecular Genetics & Genomic Medicine	2324-9269	2,473	1	Q3
Molecular Genetics and Metabolism Reports	2214-4269	2,082	1	Q4
Molecular Neurobiology	0893-7648	5,682	1	Q1
Molecular Psychiatry	1359-4184	13,437	2	Q1
Molecular Syndromology	1661-8769	1,494	1	Q4
Molecules	1420-3049	4,927	1	Q2
Movement Disorders	0885-3185	9,698	1	Q1
Muscle & Nerve	0148-639X	3,852	1	Q2
Nature	0028-0836	69,504	2	Q1
Nature and Science of Sleep	1179-1608	3,384	1	Q3
Nature Cancer	2662-1347	23,177	1	Q1
Nature Communications	2041-1723	17,694	5	Q1
Nefrología	0211-6995	3,084	9	Q2
Nephrology Dialysis Transplantation	0931-0509	7,186	1	Q1
Neurochemistry International	0197-0186	4,297	1	Q2
Neuroendocrinology	0028-3835	5,135	1	Q2
Neurología	0213-4853	5,486	7	Q1
Neurological Sciences	1590-1874	3,83	2	Q2
Neurologist	1074-7931	1,524	1	Q4
Neurology	0028-3878	11,8	2	Q1
Neurology-Clinical Practice	2163-0402	Not Indexed	Not Indexed	Not Indexed
Neuromuscular Disorders	0960-8966	3,538	2	Q2

Neuropharmacology	0028-3908	5,273	2	Q1
Neurospine	2586-6583	3,374	2	Q2
New England Journal of Medicine	0028-4793	176,079	9	Q1
New Microbes and New Infections	2052-2975	Not Indexed	Not Indexed	Not Indexed
NPJ Breast Cancer	2374-4677	7,519	1	Q1
Nucleic Acids Research	0305-1048	19,16	1	Q1
Nutrición Hospitalaria	1699-5198	1,169	8	Q4
Nutrients	2072-6643	6,706	13	Q1
Nutritional Metabolism and Cardiovascular Diseases	0939-4753	4,666	1	Q2
Nutritional Care of Preterm Infants: Scientific Basis and Practical Guidelines, 2Nd Edition	0084-2230	0,256	1	Q4
Obesity Research & Clinical Practice	1871-403X	5,214	1	Q2
Obstetric Medicine	1753-495X	Not Indexed	Not Indexed	Not Indexed
Ocular Immunology and Inflammation	0927-3948	3,728	3	Q2
Oncologist	1083-7159	5,837	3	Q2
Oncology Research and Treatment	2296-5270	2,844	1	Q4
Open Forum Infectious Diseases	2328-8957	4,423	4	Q2
Orphanet Journal of Rare Diseases	1750-1172	4,307	4	Q2
Orthopaedics & Traumatology-Surgery & Research	1877-0568	2,425	1	Q3
Osteoporosis International	0937-941X	5,071	2	Q2
Otolaryngology-Head and Neck Surgery	0194-5998	5,591	2	Q1
PACE-Pacing and Clinical Electrophysiology	0147-8389	1,912	1	Q4
Pain Medicine	1526-2375	3,637	2	Q2
Pain Physician	1533-3159	4,396	1	Q2
Pancreatology	1424-3903	3,977	1	Q3
Pathogens	2076-0817	4,531	3	Q2
Pediatric Allergy and Immunology	0905-6157	5,464	3	Q1
Pediatric and Developmental Pathology	1093-5266	2,266	1	Q3
Pediatric Blood & Cancer	1545-5009	3,838	1	Q1
Pediatric Critical Care Medicine	1529-7535	3,971	2	Q1
Pediatric Dermatology	0736-8046	1,997	4	Q3
Pediatric Drugs	1174-5878	3,93	1	Q1
Pediatric Emergency Care	0749-5161	1,602	2	Q3



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Pediatric Hematology and Oncology	0888-0018	2,07	2	Q3
Pediatric Infectious Disease Journal	0891-3668	3,806	12	Q1
Pediatric Neurology	0887-8994	4,21	1	Q1
Pediatric Pulmonology	8755-6863	4,09	2	Q1
Pediatric Research	0031-3998	3,953	1	Q1
Pediatric Rheumatology	1546-0096	3,413	1	Q2
Pediatrics	0031-4005	9,703	3	Q1
PEERJ	2167-8359	3,061	1	Q2
Pharmaceutics	1999-4923	6,525	4	Q1
Pharmacogenetics and Genomics	1744-6872	2	1	Q4
Pharmacological Research	1043-6618	10,334	1	Q1
Physica Medica-European Journal of Medical Physics	1120-1797	3,119	1	Q3
Plastic and Reconstructive Surgery	0032-1052	5,169	2	Q1
Plastic and Reconstructive Surgery-Global Open	2169-7574	Not Indexed	Not Indexed	Not Indexed
Platelets	0953-7104	4,236	1	Q2
Plos Neglected Tropical Diseases	1935-2735	4,781	1	Q1
Plos One	1932-6203	3,752	11	Q2
Polymer Testing	0142-9418	4,931	1	Q1
Polymers	2073-4360	4,967	1	Q1
Proceedings of the National Academy of Sciences of the United States of America	0027-8424	12,779	1	Q1
Prostaglandins & Other Lipid Mediators	1098-8823	3,813	1	Q3
Protist	1434-4610	2,656	1	Q4
Psicothema	0214-9915	4,104	2	Q1
Psychiatric Rehabilitation Journal	1095-158X	2,809	1	Q1
Psychiatric Services	1075-2730	4,157	1	Q1
Psychological Medicine	0033-2917	10,592	1	Q1
Pulmonary Pharmacology & Therapeutics	1094-5539	3,282	1	Q3
Pulmonology	2531-0437	9,216	1	Q1
Radiología	0033-8338	Not Indexed	Not Indexed	Not Indexed
Reactive Oxygen Species: Network Pharmacology and Therapeutic Applications	0171-2004	Not Indexed	Not Indexed	Not Indexed
Redox Biology	2213-2317	10,787	1	Q1
Reproductive Sciences	1933-7191	2,924	1	Q3
Respiratory Medicine	0954-6111	4,582	1	Q2

Reumatología Clínica	1699-258X	Not Indexed	Not Indexed	Not Indexed
Revista Clínica Española	0014-2565	3,064	2	Q2
Revista Cubana de Estomatología	1561-297X	Not Indexed	Not Indexed	Not Indexed
Revista de Neurología	0210-0010	1,235	3	Q4
Revista de Osteoporosis y Metabolismo Mineral	1889-836X	Not Indexed	Not Indexed	Not Indexed
Revista de Psiquiatría Y Salud Mental	1888-9891	6,795	3	Q1
Revista Española de Anestesiología y Reanimación	0034-9356	Not Indexed	Not Indexed	Not Indexed
Revista Española de Cardiología	0300-8932	6,975	15	Q1
Revista Española de Cirugía Oral y Maxilofacial	2173-9161	Not Indexed	Not Indexed	Not Indexed
Revista Española de Cirugía Ortopédica y Traumatología	2173-576X	Not Indexed	Not Indexed	Not Indexed
Revista Española de Enfermedades Digestivas	1130-0108	2,389	8	Q4
Revista Española de Geriátria y Gerontología	1578-1747	Not Indexed	Not Indexed	Not Indexed
Revista Española de Medicina Nuclear e Imagen Molecular	2253-654X	1,247	2	Q4
Revista Española de Nutrición Humana y Dietética	2173-1292	Not Indexed	Not Indexed	Not Indexed
Revista Española de Patología	1988-561X	Not Indexed	Not Indexed	Not Indexed
Revista Española de Quimioterapia	0214-3429	2,515	8	Q3
Revista Española de Salud Pública	1135-5727	1,333	5	Q4
Revista Iberoamericana de Micología	1130-1406	1,385	2	Q4
Revista Rol de Enfermería	0210-5020	Not Indexed	Not Indexed	Not Indexed
Revue Francaise D'Allergologie	1877-0320	0,254	1	Q4
Rheumatology	1462-0324	7,046	3	Q1
Rheumatology Advances in Practice	2514-1775	Not Indexed	Not Indexed	Not Indexed
Rheumatology and Therapy	2198-6576	4,081	1	Q3
RMD Open	2056-5933	5,806	6	Q1
Salud Colectiva	1669-2381	0,727	1	Q4
Scandinavian Journal of Clinical & Laboratory Investigation	0036-5513	2,209	1	Q4
Scandinavian Journal of Medicine & Science in Sports	0905-7188	4,645	1	Q1
Science Immunology	2470-9468	30,63	1	Q1
Science Translational Medicine	1946-6234	19,319	2	Q1
Scientific Reports	2045-2322	4,996	23	Q2



Seizure-European Journal of Epilepsy	1059-1311	3,414	2	Q3
Seminars in Arthritis and Rheumatism	0049-0172	5,431	6	Q2
Seminars in Cancer Biology	1044-579X	17,012	1	Q1
Seminars in Thrombosis and Hemostasis	0094-6176	6,398	1	Q1
Sensors	1424-8220	3,847	1	Q2
Skin Research and Technology	0909-752X	2,24	1	Q3
Sleep Medicine	1389-9457	4,842	2	Q2
SN Comprehensive Clinical Medicine	2523-8973	Not Indexed	Not Indexed	Not Indexed
Somatosensory and Motor Research	0899-0220	1,126	1	Q4
Spine	0362-2436	3,241	1	Q2
Spine Deformity	2212-134X	Not Indexed	Not Indexed	Not Indexed
Stata Journal	1536-867X	4,45	1	Q1
Stroke	0039-2499	10,17	3	Q1
Stroke and Vascular Neurology	2059-8688	9,893	1	Q1
Surgical and Radiologic Anatomy	0930-1038	1,354	2	Q3
Surgical Infections	1096-2964	1,853	1	Q3
Surgical Innovation	1553-3506	1,785	1	Q3
Surgical Oncology-Oxford	0960-7404	2,388	1	Q3
Therapeutic Advances in Medical Oncology	1758-8340	5,485	1	Q2
Therapeutic Advances in Musculoskeletal Disease	1759-720X	3,625	3	Q3
Therapeutic Advances in Neurological Disorders	1756-2856	6,43	1	Q1
Therapeutic Drug Monitoring	0163-4356	3,118	1	Q2
Thorax	0040-6376	9,102	1	Q1
Thrombosis and Haemostasis	0340-6245	6,681	1	Q1
Thrombosis Research	0049-3848	10,407	2	Q1
Transactions of the Royal Society of Tropical Medicine and Hygiene	0035-9203	2,455	1	Q3
Transfusion	0041-1132	3,337	1	Q3

Transfusion and Apheresis Science	1473-0502	2,596	1	Q4
Translational Psychiatry	2158-3188	7,989	1	Q1
Translational Research	1931-5244	10,171	1	Q1
Transplant Infectious Disease	1398-2273	Not Indexed	Not Indexed	Not Indexed
Transplant International	0934-0874	3,842	2	Q1
Transplantation and Cellular Therapy	2666-6375	Not Indexed	Not Indexed	Not Indexed
Transplantation Direct	2373-8731	Not Indexed	Not Indexed	Not Indexed
Transplantation Proceedings	0041-1345	1,014	1	Q4
Travel Medicine and Infectious Disease	1477-8939	20,441	3	Q1
Trials	1745-6215	2,728	4	Q4
Turkish Neurosurgery	1019-5149	0,972	1	Q4
Ultraschall in Der Medizin	0172-4614	5,445	1	Q1
Ultrasound in Obstetrics & Gynecology	0960-7692	8,678	2	Q1
Urologic Oncology-Seminars and Original Investigations	1078-1439	2,954	2	Q3
Urology	0090-4295	2,633	1	Q3
Vaccine	0264-410X	4,169	1	Q3
Vaccines	2076-393X	4,961	1	Q2
Vascular Medicine	1358-863X	4,739	1	Q2
Virchows Archiv	0945-6317	4,535	1	Q2
Virulence	2150-5594	5,428	1	Q2
Viruses-Basel	1999-4915	5,818	7	Q2
World Journal of Clinical Oncology	2218-4333	Not Indexed	Not Indexed	Not Indexed
World Journal of Clinical Pediatrics	2219-2808	Not Indexed	Not Indexed	Not Indexed
World Journal of Emergency Surgery	1749-7922	8,165	2	Q1
World Journal of Gastroenterology	1007-9327	5,374	1	Q2
World Journal of Orthopedics	2218-5836	Not Indexed	Not Indexed	Not Indexed
World Journal of Pediatrics	1708-8569	9,186	2	Q1
World Neurosurgery	1878-8750	2,21	1	Q3
World Review of Nutrition and Dietetics	0084-2230	0,256	1	Q4

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

2.8.2. HIGH IMPACT PUBLICATIONS



Neurosciences Area


Fuentes B, de Leciñana MA, García-Madrona S, Díaz-Otero F, Aguirre C, Calleja P, Egido JA, Carneado-Ruiz J, Ruiz-Ares G, Rodríguez-Pardo J, Rodríguez-López A, Ximénez-Carrillo A, de Felipe A, Ostos F, González-Ortega G, Simal P, Escalonilla CIG, Gómez-Porro-Sánchez P, Desanvicente Z, Reig G, Gil-Núñez A, Masjuán J, **Díez-Tejedor E**. Stroke acute management and outcomes during the COVID-19 outbreak a cohort study from the madrid stroke network. *Stroke*. 2021; 52(2): 552-62. Article. IF: 10.17; D1

Llorente P, Mejías V, Sastre I, Recuero M, Aldudo J, **Bullido MJ**. Matrix metalloproteinase 14 regulates HSV-1 infection in neuroblastoma cells. *Antivir Res*. 2021; 192: 105116. Article. IF: 10.103; Q1.NO

de Leciñana MA, Castellanos M, Ayo-Martín O, Morales A. Stroke care during the COVID-19 outbreak in Spain: the experience of Spanish stroke units. *Stroke Vasc Neurol*. 2021; 6(2): 267-73. Article. IF: 9.893; D1

Piniella D, Martínez-Blanco E, Bartolomé-Martín D, Sanz-Martos AB, **Zafra F**. Identification by proximity labeling of novel lipidic and proteinaceous potential partners of the dopamine transporter. *Cell Mol Life Sci*. 2021; 78(23): 7733-56. Article. IF: 9.207; Q1

Jiménez-Villegas J, Ferraiuolo L, Mead RJ, Shaw PJ, Cuadrado A, **Rojo AI**. NRF2 as a therapeutic opportunity to impact in the molecular roadmap of ALS. *Free Radical Bio Med*. 2021; 173: 125-41. Article. IF: 8.101; Q1



Cardiovascular Area

Caro-Codón J, Rey JR, Buño A, Iñiesta AM, Rosillo SO, Castrejón-Castrejón S, Rodríguez-Sotelo L, Martínez LA, Marco I, Merino C, Martín-Polo L, García-Veas

JM, Martínez-Cossiani M, González-Valle L, Herrero A, López-de-Sa E, **Merino JL**. Characterization of NT-proBNP in a large cohort of COVID-19 patients. *Eur J Heart Fail*. 2021; 23(3): 456-64. Article. IF: 17.349; D1

Hermenegildo-López Y, Sandoval-Insauti H, Donat-Vargas C, Banegas JR, Rodríguez-Artalejo F, **Guallar-Castillon P**. General and central obesity operate differently as predictors of falls requiring medical care in older women: a population-based cohort study in Spain. *Age Ageing*. 2021; 50(1): 213-9. Article. IF: 12.782; D1

Carballo-Casla A, Ortola R, García-Esquinas E, Oliveira A, Sotos-Prieto M, Lopes C, López-García E, **Rodríguez-Artalejo F**. The southern european atlantic diet and all-cause mortality in older adults. *BMC Med*. 2021; 19(1): 36. Article. IF: 11.15; Q1

García-Esquinas E, Carrasco-Ríos M, Ortola R, Prieto MS, Pérez-Gómez B, Gutiérrez-González E, Banegas JR, Queipo R, Olmedo P, Gil F, Téllez-Plaza M, Navas-Acién A, Pastor-Barriuso R, **Rodríguez-Artalejo F**. Selenium and impaired physical function in US and Spanish older adults. *Redox Biol*. 2021; 38: 101819. Article. IF: 10.787; D1

García-Esquinas E, Téllez-Plaza M, Pastor-Barriuso R, Ortola R, Olmedo P, Gil F, López-García E, Navas-Acién A, **Rodríguez-Artalejo F**. Blood cadmium and physical function limitations in older adults. *Environ Pollut*. 2021; 276: 116748. Article. IF: 9.988; Q1



Infectious Diseases and Immunity Area

Pérez-Latorre L, Berenguer J, Micán R, Montero M, Cifuentes C, Puig T, Sanz J, Ferrero OL, de la Fuente B, Rodríguez C, Reus S, Hernández-Quero J, Gaspar G, Pérez-Martínez L, García C, Force L, Veloso S, de Miguel M, Jarrín I, **González-García J**. HIV/HBV coinfection: temporal trends and patient characteristics, Spain, 2002 to 2018. *Euro Surveill*. 2021; 26(25): 2000236. Article. IF: 21.286; D1

Carrero A, Berenguer J, Hontañón V, Guardiola JM, Navarro J, von Wichmann MA, Téllez MJ, Quereda C, Santos I, Sanz J, Galindo MJ, Hernández-Quero J, Jiménez-Sousa MA, Pérez-Latorre L, Bellón JM, Resino S, Esteban H, Martínez E, **González-García J**. Effects of hepatitis C virus (HCV) eradication on bone mineral

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians


1 Introduction

density in human immunodeficiency virus/HCV-coinfected patients. *Clin Infect Dis.* 2021;73(7): E2026-33. Article. IF: 20.999; D1

Olender SA, Pérez KK, Go AS, Balani B, Price-Haywood EG, Shah NS, Wang S, Walunas TL, Swaminathan S, Slim J, Chin B, De Wit S, Ali SM, Viladomiu AS, Robinson P, Gottlieb RL, Tsang TYO, Lee IH, Hu H, Haubrich RH, Chokkalingam AP, Lin LJ, Zhong LJ, Bekele BN, Mera-Giler R, Phulpin C, Edgar H, Gallant J, Díaz-Cuervo H, Smith LE, Osinusi AO, Brainard DM, **Bernardino JI**. Remdesivir for severe coronavirus disease 2019 (COVID-19) versus a cohort receiving standard of care. *Clin Infect Dis.* 2021; 73(11): E4166-74. Article. IF: 20.999; D1

Esteban-Cantos A, Rodríguez-Centeno J, Barruz P, Alejos B, Saiz-Medrano G, Nevado J, Martín A, Gaya F, de Miguel R, Bernardino JI, Montejano R, Mena-Garay B, Cadinanos J, Florence E, Mulcahy F, Banhegyi D, Antinori A, Pozniak A, Wallet C, Raffi F, Rodés B, **Arribas JR**. Epigenetic age acceleration changes 2 years after antiretroviral therapy initiation in adults with HIV: a substudy of the NEAT001/ANRS143 randomised trial. *Lancet Hiv.* 2021; 8(4): e197-205. Article. IF: 16.07; D1

Lazaro-Perona F, Rodríguez-Tejedor M, Ruiz-Carrascoso G, Díaz-Pollan B, Loeches B, Ramos-Ramos JC, **Mingorance J**. Intestinal loads of OXA-48-producing *Klebsiella pneumoniae* in colonized patients determined from surveillance rectal swabs. *Clin Microbiol Infect.* 2021; 27(8): 1169.e7-e12. Article. IF: 13.31; D1



Large System Pathologies Area

Couto M, Bernard A, Delgado L, Drobic F, Kurowski M, Moreira A, Rodrigues-Alves R, Rukhadze M, Seys S, Wiszniewska M, **Quirce S**. Health effects of exposure to chlorination by-products in swimming pools. *Allergy.* 2021; 76(11): 3257-75. Article. IF: 14.71; D1


Loli-Ausejo D, López-Lera A, Drouet C, Lluncor M, Phillips-Angles E, Pedrosa M, Cabañas R, **Caballero T**. In search of an association between genotype and phenotype in hereditary angioedema due to C1-INH deficiency. *Clin Rev Allerg Immun.* 2021; 61(1): 1-14. Article. IF: 10.817; Q1

Forjaz MJ, Ayala A, Caminoa M, Prior N, Pérez-Fernández E, **Caballero T**. HAE-AS: A specific disease activity scale for hereditary angioedema with C1-inhibitor deficiency. *J Invest Allerg Clin.* 2021; 31(3): 246-52. Article. IF: 8.185; Q1

Salinero-Fort MA, Gómez-Campelo P, Cardenas-Valladolid J, San Andrés-Rebollo

FJ, de Miguel-Yanes JM, **de Burgos-Lunar C**. Effect of depression on mortality in type 2 diabetes mellitus after 8 years of follow-up. The DIADEMA study. *Diabetes Res Clin Pract.* 2021; 176: 108863. Article. IF: 8.18; Q1

Pérez-Torres A, García MEG, Ossorio-González M, García LA, Bajo MA, del Peso G, Plaza AC, **Selgas R**. The effect of nutritional interventions on long-term patient survival in advanced chronic kidney disease. *Nutrients.* 2021; 13(2): 621. Article. IF: 6.706; Q1



Cancer and Human Molecular Genetics Area

Cejas P, Xie YT, Font-Tello A, Lim K, Syamala S, Qiu XT, Tewari AK, Shah N, Nguyen HM, Patel RA, Brown L, Coleman I, Hackeng WM, Brosens L, Dreijerink KMA, Ellis L, Abou Alaiwi S, Seo JH, Baca S, Beltran H, Khani F, Pomerantz M, Dall'Agnese A, Crowdis J, Van Allen EM, Bellmunt J, Morrissey C, Nelson PS, DeCaprio J, Farago A, Dyson N, Drapkin B, Liu XS, Freedman M, Haffner MC, Corey E, Brown M, Long HW. Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer. *Nat Commun.* 2021; 12(1): 5775. Article. IF: 17.694; D1

López-Menéndez C, Vázquez-Naharro A, Santos V, Dubus P, Santamaría PG, Martínez-Ramírez A, Portillo F, Moreno-Bueno G, Faraldo MM, **Cano A**. E2A modulates stemness, metastasis, and therapeutic resistance of breast cancer. *Cancer Res.* 2021; 81(17): 4529-44. Article. IF: 13.312; D1


Horn D, Fernández-Núñez E, Gómez-Carmona R, Rivera-Barahona A, Nevado J, Schwartzmann S, Ehmke N, Lapunzina P, Otaify GA, Temtamy S, Aglan M, Boschann F, **Ruiz-Pérez VL**. Biallelic truncating variants in MAPKAPK5 cause a new developmental disorder involving neurological, cardiac, and facial anomalies combined with synpolydactyly. *Genet Med.* 2021; 23(4): 679-88. Article. IF: 8.864; D1

Perez-Chacon G, Zapata JM. The Traf2DNxBCL2-tg mouse model of chronic lymphocytic leukemia/small lymphocytic lymphoma recapitulates the biased IGHV gene usage, stereotypy, and antigen-specific HCDR3 selection of its human counterpart. *Front Immunol.* 2021; 12: 627602. Article. IF: 8.786; Q1

Bermúdez-Muñoz JM, Celaya AM, García-Mato A, Muñoz-Espin D, Rodríguez-de la Rosa L, Serrano M, **Varela-Nieto I**. Dual-specificity phosphatase 1 (DUSP1) has a central role in redox homeostasis and inflammation in the mouse cochlea. *Antioxidants.* 2021; 10(9): 1351. Article. IF: 7,675; D1

3 Information Groups by Area

4 Associated Clinicians



Surgery, Transplant and Health Technologies Area


Borobia AM, Carcas AJ, Pérez-Olmeda M, Castaño L, Bertrán MJ, García-Pérez J, Campins M, Portoles A, González-Pérez M, Morales MTG, Arana-Arri E, Aldea M, Díez-Fuertes F, Fuentes I, Ascaso A, Lora D, Imaz-Ayo N, Barón-Mira LE, Agustí A, Pérez-Ingidua C, de la Camara AG, Arribas JR, Ochando J, Alcamí J, Belda-Iniesta C, **Frías J**. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. *Lancet*. 2021; 398(10295): 121-30. Article. IF: 202.731; D1

Borobia AM, García-García I, Díaz-García L, Rodríguez-Mariblanca A, de Soto LM, Villatoro JM, Meseguer ES, González JJ, Iniesta JF, García ER, Arribas JR, **Carcas-Sansuan AJ**. Health care workers' reasons for choosing between two different COVID-19 prophylaxis trials in an acute pandemic context: Single-center questionnaire study. *J Med Internet Res*. 2021; 23(2): e23441. Article. IF: 7.076; D1

Tapia, B; Garrido, E; Cebrián, JL; del Castillo, JL; Gonzalez, J; Losantos, I; **Gilsanz, F**. Impact of goal directed therapy in head and neck oncological surgery with micro-surgical reconstruction: Free flap viability and complications. *Cancers (Basel)*. 2021; 13(7): 1545. Article. IF: 6.575; Q2

Cadenas-Martín M, Moratilla A, Fernández-Delgado J, Arnalich-Montiel F, **de Miguel MP**. Improvement of an effective protocol for directed differentiation of human adipose tissue-derived adult mesenchymal stem cells to corneal endothelial cells. *Int J Mol Sci*. 2021; 22(21): 11982. Article. IF: 6.208; Q1

Pedraza L, Laosa O, Rodríguez-Mañas L, Gutiérrez-Romero DF, Frías J, Carnicero JA, **Ramírez E**. Drug induced liver injury in geriatric patients detected by a two-hospital prospective pharmacovigilance program: A comprehensive analysis using the Roussel Uclaf causality assessment method. *Front Pharmacol*. 2021; 11: 600255. Article. IF: 5.988; Q1



Maternal Infant Child and Youth Research Area

Ara-Montojo MF, Bustamante J, **Sainz T**, Pérez S, Jiménez-Moreno B, Ruiz-Carrascoso G, Rodríguez-Molino P, Villota J, García-López-Hortenano M, **Mellado-Peña MJ**. Intestinal giardiasis in children: Five years experience in a reference unit. *Travel Med Infect Dis*. 2021; 42: 102082. Article. IF: 20.441; D1

Pérez-Martínez A, Mora-Rillo M, Ferreras C, Guerra-García P, Pascual-Miguel B, Mestre-Durán C, Borobia AM, Carcas AJ, Queiruga-Parada J, García I, Sánchez-Zapardiel E, Gasior M, De Paz R, Marcos A, Vicario JL, Balas A, Moreno MA, Eguizabal C, Solano C, Arribas JR, Buckley RD, Montejano R, Soria B. Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE). *Eclinicalmedicine*. 2021; 39: 101086. Article. IF: 17.033; D1

Goldman DL, Aldrich ML, Hagmann SHF, Bamford A, Camacho-González A, Lapadula G, Lee P, Bonfanti P, Carter CC, Zhao Y, Telep L, Pikora C, Naik S, Marshall N, Katsarolis I, Das M, DeZure A, Desai P, Cao HY, Chokkalingam AP, Osinusi A, Brainard DM, **Méndez-Echevarría A**. Compassionate use of remdesivir in children with severe COVID-19. *Pediatrics*. 2021; 147(5): e2020047803. Article. IF: 9.703; D1

García LS, Gómez-Torres N, Cabañas F, González-Sánchez R, López-Azorín M, Moral-Pumarega MT, Escuder-Vieco D, Cabanes-Alonso E, Castro I, Alba C, Gómez JMR, **Pellicer A**. Immediate pre-partum SARS-CoV-2 status and immune profiling of breastmilk: A case-control Study. *Front Immunol*. 2021; 12: 720716. Article. IF: 8.786; Q1

Alonso L, **Méndez-Echevarría A**, Rudilla F, Mozo Y, Soler-Palacín P, Sisinni L, Bueno D, Riviere J, de Paz R, Sánchez-Zapardiel E, Querol S, Rodríguez-Pena R, López-Granados E, Gimeno R, de Heredia CD, **Pérez-Martínez A**. Failure of viral-specific T cells administered in pre-transplant settings in children with inborn errors of immunity. *J Clin Immunol*. 2021; 41(4): 748-55. Article. IF: 8.542; Q1

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

2.8.3. MOST RELEVANT PUBLICATIONS IN 2021

■ 2021 – Best International Collaboration Publication

Esteban-Cantos A, Rodríguez-Centeno J, Barruz P, Alejos B, Saiz-Medrano G, Nevado J, Martín A, Gaya F, de Miguel R, Bernardino JI, Montejano R, Mena-Garay B, Cadinanos J, Florence E, Mulcahy F, Banhegyi D, Antinori A, Pozniak A, Wallet C, Raffi F, Rodés B, **Arribas JR**. Epigenetic age acceleration changes 2 years after antiretroviral therapy initiation in adults with HIV: a substudy of the NEAT001/ANRS143 randomised trial. *Lancet Hiv*. 2021; 8(4): e197-205. Article. D1

■ 2021- Best Publication in Open Acces

Borobia AM, Carcas AJ, Pérez-Olmeda M, Castaño L, Bertrán MJ, García-Pérez J, Campins M, Portoles A, González-Pérez M, Morales MTG, Arana-Arri E, Aldea M, Díez-Fuertes F, Fuentes I, Ascaso A, Lora D, Imaz-Ayo N, Barón-Mira LE, Agustí A, Pérez-Ingidua C, de la Camara AG, Arribas JR, Ochando J, Alcami J, Belda-Iniesta C, **Frías J**. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. *Lancet*. 2021; 398(10295): 121-30. Article. D1

■ 2021 – Best Publication of the Research Area

■ 2021 – Best Publication of the Neuroscience Area

Fuentes B, de Leciñana MA, García-Madrona S, Díaz-Otero F, Aguirre C, Calleja P, Egidio JA, Carneado-Ruiz J, Ruiz-Ares G, Rodríguez-Pardo J, Rodríguez-López A, Ximénez-Carrillo A, de Felipe A, Ostos F, González-Ortega G, Simal P, Escalonilla CIG, Gómez-Porro-Sánchez P, Desanvicente Z, Reig G, Gil-Núñez A, Masjuán J, **Díez-Tejedor E**. Stroke acute management and outcomes during the COVID-19 outbreak a cohort study from the madrid stroke network. *Stroke*. 2021; 52(2): 552-62. Article. D1

■ 2021 – Best Publication of the Cardiovascular Area

Caro-Codón J, Rey JR, Buño A, Iniesta AM, Rosillo SO, Castrejón-Castrejón S, Rodríguez-Sotelo L, Martínez LA, Marco I, Merino C, Martín-Polo L, García-Veas JM, Martínez-Cossiani M, González-Valle L, Herrero A, López-de-Sa E, **Merino JL**. Characterization of NT-proBNP in a large cohort of COVID-19 patients. *Eur J Heart Fail*. 2021; 23(3): 456-64. Article. D1

■ 2021 – Best Publication of the Infectious Diseases and Immunity Area

Esteban-Cantos A, Rodríguez-Centeno J, Barruz P, Alejos B, Saiz-Medrano G, Nevado J, Martín A, Gaya F, de Miguel R, Bernardino JI, Montejano R, Mena-Garay B, Cadinanos J, Florence E, Mulcahy F, Banhegyi D, Antinori A, Pozniak A, Wallet C, Raffi F, Rodés B, **Arribas JR**. Epigenetic age acceleration changes 2 years after antiretroviral therapy initiation in adults with HIV: a substudy of the NEAT001/ANRS143 randomised trial. *Lancet Hiv*. 2021; 8(4): e197-205. Article. D1

■ 2021 – Best Publication of the Large System Pathologies Area

Forjaz MJ, Ayala A, Caminoa M, Prior N, Pérez-Fernández E, **Caballero T**. HAE-AS: A specific disease activity scale for hereditary angioedema with C1-inhibitor deficiency. *J Invest Allerg Clin*. 2021; 31(3): 246-52. Article. Q1

■ 2021 – Best Publication of the Cancer and Human Molecular Genetics Area

Cejas P, Xie YT, Font-Tello A, Lim K, Syamala S, Qiu XT, Tewari AK, Shah N, Nguyen HM, Patel RA, Brown L, Coleman I, Hackeng WM, Brosens L, Dreijerink KMA, Ellis L, Abou Alaiwi S, Seo JH, Baca S, Beltran H, Khani F, Pomerantz M, Dall'Agnese A, Crowdis J, Van Allen EM, Bellmunt J, Morrissey C, Nelson PS, DeCaprio J, Farago A, Dyson N, Drapkin B, Liu XS, Freedman M, Haffner MC, Corey E, Brown M, Long HW. Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer. *Nat Commun*. 2021; 12(1): 5775. Article. D1

■ 2021 – Best Publication of the Surgery, Transplant and Health Technologies Area

Borobia AM, Carcas AJ, Pérez-Olmeda M, Castaño L, Bertrán MJ, García-Pérez J, Campins M, Portoles A, González-Pérez M, Morales MTG, Arana-Arri E, Aldea M, Díez-Fuertes F, Fuentes I, Ascaso A, Lora D, Imaz-Ayo N, Barón-Mira LE, Agustí A, Pérez-Ingidua C, de la Camara AG, Arribas JR, Ochando J, Alcami J, Belda-Iniesta C, **Frías J**. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. *Lancet*. 2021; 398(10295): 121-30. Article. D1

■ 2021 – Best Publication of the Maternity and Pediatric Area

Pérez-Martínez A, Mora-Rillo M, Ferreras C, Guerra-García P, Pascual-Miguel B, Mestre-Durán C, Borobia AM, Carcas AJ, Queiruga-Parada J, García I, Sánchez-Zapardiel E, Gasior M, De Paz R, Marcos A, Vicario JL, Balas A, Moreno MA, Eguzabal C, Solano C, Arribas JR, Buckley RD, Montejano R, Soria B. Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE). *Eclinicalmedicine*. 2021; 39: 101086. Article. D1

■ 2021 – Best Publication in Collaboration with Primary Health Care

Gutiérrez-Misis A, Queipo R, Castell MV, Alarcón T, Menéndez-Colino R, Ojeda-Thies C, Puime AO, González-Montalvo JI. Mortality among older Spanish people with hip fractures: a population-based matched cohort study. *Aging Clinical and Experimental Research*. 2021; 33(11): 3141-3. Q2



2.9 CIBERs and RETICs

1 Introduction


2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

2.9.1. CIBER- BIOMEDICAL RESEARCH NETWORKING CENTERS

Throughout 2021, IdiPAZ has participated in the following thematic networks and research consortiums legally recognized by the Carlos III Health Institute.

Project	Acronym	CIBER	Funding Organisation	Principal Researcher	IdiPAZ Group	End Date
CB06/05/0007	 CIBERNED	Networked Biomedical Research Center for Neurodegenerative Diseases	Carlos III Health Institute	Bullido Gómez-Heras, María Jesús	Neurology and cerebrovascular diseases	31/12/2022
CB06/05/0010	 ciberNed	Networked Biomedical Research Center for Neurodegenerative Diseases	Carlos III Health Institute	Cuadrado Pastor, Antonio	Neuroprotective Strategies in Neurodegenerative Diseases	31/12/2022
CB07/08/0033	 CIBERDEM	Networked thematic area of Diabetes and Associated Metabolic Diseases	Carlos III Health Institute	Martínez Valverde, Ángela María	Neuroprotective Strategies in Neurodegenerative Diseases	31/12/2022
CB15/00037	 CIBERES	Networked Biomedical Research Center for Respiratory Diseases	Carlos III Health Institute	García Río, Francisco	Respiratory Diseases	31/12/2021
CB06/01/0008	 CIBER-BBN	Networked Biomedical Research Center for Bio-engineering, Biomaterials and Nanomedicine	Carlos III Health Institute	Vilaboa Díaz, Nuria Elda	Bone Pathophysiology and biomaterials	31/12/2023
CB06/04/0083	 CIBEREHD	Networked Biomedical Research Center for Hepatic and Digestive Diseases	Carlos III Health Institute	García-Samaniego Rey, Javier	Translational Hepatology	31/12/2023
CB06/04/0011				Fondevila Campo, Constantino	Translacional Research and Innovation in general and Digestive Surgery	31/12/2023



1 Introduction

2 Executive Summary

3 Information Groups of Area

4 Associated Clinicians

CB06/07/1033		Carlos III Health Institute	Caballero Molina, María Teresa	Diagnosis and Treatment of Allergic Diseases	31/12/2023
CB06/07/1005	 CIBERER Networked Biomedical Research Center for Rare Diseases	Carlos III Health Institute	Lapunzina Badía, Pablo	INGEMM Institute of Medical and Molecular Genetics	31/12/2023
CB06/07/0004		Carlos III Health Institute	Pérez González, María Belén	Research and Diagnosis of Inherited Metabolic Diseases	31/12/2023
CB06/07/1021		Carlos III Health Institute	Varela Nieto, María Isabel	Oto-Neurosurgery Research	31/12/2022
CB06/07/0038		Carlos III Health Institute	Botella Cubells, Luisa María	Urology	31/12/2021
CB19/07/00042		Carlos III Health Institute	López Granados, Eduardo	Lymphocyte Pathophysiology in Immunodeficiencies	31/12/2023
CB06/02/0001	 CIBERESP Networked Biomedical Research Center for Public Health and Epidemiology	Carlos III Health Institute	Rodríguez Artalejo, Fernando	Cardiovascular Epidemiology and Nutrition	31/12/2023
CB16/11/00286		Carlos III Health Institute	Salaices Sánchez, Mercedes	Vascular Physiology and Pharmacology	31/12/2022
CB16/12/00295	 CIBERONC Networked Biomedical Research Center for Cancer	Carlos III Health Institute	Moreno Bueno, Gema	Mechanisms of Tumour Progression	31/12/2022
CB16/12/00273		Carlos III Health Institute	Muñoz Terol, Alberto	Mechanisms of Tumour Progression	31/12/2022
CB16/12/00398		Carlos III Health Institute	Feliú Batlle, Jaime	Trasnlational Oncology	31/12/2022

2.9.2. NETWORKS AND PLATFORMS

IdiPAZ is also part of the following Platforms and Networks for Cooperative Research in Health are organisational structures which seek to conduct cooperative research projects of transversal character.

Project	Acronym	Network	Funding Organisation	Principal Researcher	IdiPAZ Group	End Date
PT20/00002	 ITEMAS Plataforma de Innovación en Tecnologías Médicas y Sanitarias	Plataforma ITEMAS	Carlos III Health Institute	de Castro Carpeño, Javier	Experimental Therapies and Biomarkers in Cancer	31/12/2023
PT17/0005/0025						28/02/2021
PT20/00004	 RNBB Red de Biobancos	Red de Biobancos	Carlos III Health Institute	Gómez Campelo, Paloma	Aging and Fragility in the Elderly	31/12/2023
PT17/0015/0025						28/02/2021



PT20/00036	 SCReN Spanish Clinical Research Network ISCIII	Plataforma de Unidades de Investigación Clínica y Ensayos Clínicos	Carlos III Health Institute	Frías Iniesta, Jesús	Clinical Pharmacology	31/12/2023
PT17/0015/0025						28/02/2021
RD16/0019/0005	 INVICTUS PLUS	Vascular and Cerebral Diseases Network	Carlos III Health Institute	Díez Tejedor, Exuperio	Neurology and Cerebrovascular Diseases	31/12/2022
RD16/0025/0018	 RIS Red Española de Investigación en SIDA	Research Network for AIDS	Carlos III Health Institute	González García, Juan	AIDS and Infectious Diseases	30/06/2022
RD16/0027/0002	 RICET	Tropical Disease Cooperative Research Network	Carlos III Health Institute	Díaz Menéndez, Marta	AIDS and infectious diseases	31/12/2022
RD16/0012/0012	 RIER	Investigational Network in Inflammation and Rheumatic Diseases	Carlos III Health Institute	Miranda Carús, María Eugenia	Immuno-Rheumatology	31/12/2022
RD16/0022/0004	 SAMID	Research Network for Maternal and Child Health and Development	Carlos III Health Institute	Cabañas González, Fernando	Neonatology	31/12/2022
RD16/0022/0006				Martínez Martínez, Leopoldo	Associated Clinician	31/12/2022
RD16/0009/0008	 REDINREN	Inflamación e inmunopatología de órganos y sistemas	Carlos III Health Institute	Bajo Rubio, María Auxiliadora	Nephrology	31/12/2022
RD16/0006/0033	 ARADYAL	Asthma, Adverse and Allergic Reactions	Carlos III Health Institute	Laguna Martínez, José Julio	Associated Clinician	31/12/2022
	 NuRCaMein	Spanish Nuclear Receptor Research Network	Ministerio de Investigación, Ciencia y Universidades	Muñoz Terol, Alberto	Mechanisms of Tumour Progression	31/12/2022

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians










1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

		ECLip The European Consortium of Lipodystrophies (ECLip)	European Network	López Trascasa, Margarita	Diagnosis and Treatment of Diseases Associated with Abnormalities of the Complement System	31/12/2022
CA19117		ReMO Researcher Mental Health Observatory	Horizon Europe COST Action	Gómez Campelo, Paloma	Aging and Fragility in the Elderly	31/12/2024
CA18211		DEVOTION Perinatal Mental Health and Birth-Related Trauma	Horizon Europe COST Action	Bravo Laguna, María Carmen	Psychiatry and Mental Health	31/12/2023
		eUROGEN ERN Urogenital Diseases	ERN European Reference Network	López Pereira, Pedro	Urology	31/12/2021
		RARE-LIVER ERN Hepatological diseases	ERN European Reference Network	Hierro Llanillo L	Molecular Hepatology	31/12/2023
		TRANSPLANTCHILD ERN Paediatric Transplants	ERN European Reference Network	Jara Vega, Paloma	Molecular Hepatology	31/12/2023
		EATRIS European Infrastructure for Translational Medicine	EATRIS European Infrastructure	Ibáñez de Cáceres Inmaculada	Experimental Therapies and Biomarkers in Cancer	31/12/2023
		ECRIN European Clinical Research Infrastructure Network	ERIN European Research Infrastructure Consortium	Frías Iniesta, Jesús	Clinical Pharmacology	31/12/2023



2.10 Institutional Projects

2.10.1. MENTOR PROGRAM

In 2021, IdiPAZ, with the support of La Paz University Hospital, has implemented the 1st Mentor Program with the purpose of supporting our clinical early career researchers in the achievement of competitive projects, mainly from the main national call for health research projects: "Acción Estratégica en Salud (AES)", granted by Instituto de Salud Carlos III.

The Mentor Program plans a scientific and technical support in the preparation and tracking of research proposals. Furthermore, it takes into account the experience and scientific knowledge from our senior researchers to help our early stage researchers from the beginning of their research career.

The objectives of the program are:

- Increasing the number of clinical research in IdiPAZ.
- Avoiding a generational leap of clinical researchers.
- Strengthening the research profile of our clinical staff.
- Becoming IdiPAZ a clinical research model, as the same level that IdiPAZ is in the clinical trials.
- Performing an internal cultural change in clinical research

1st Mentor Program included different action plans have been implemented: to update the standardized curriculum for researchers, enable synergies to create research groups, support from the different platforms of IdiPAZ, services of medical writing and stand out the impact and the strategic priorities of the projects for the National Health System.

Criteria for participation in the program were:

- Under 50 years old.

- Have a doctoral degree.
- Have applied for an Acción Estratégica en Salud research project in the last 5 years.
- To have publications as corresponding author related with the research lines of the project.

In the **1st Mentor Program** 67 participants were included:

Researcher	Service
María Pedrosa Delgado	Alergología
Javier Domínguez Ortega	Alergología
Leticia de las Vecillas Sánchez	Alergología
María Mercedes López Martínez	Anestesia y Reanimación General
Elena Gredilla Díaz	Anestesia y Reanimación General
Blanca Beatriz Martínez Serrano	Anestesia y Reanimación General
Patricio González Pizarro	Anestesia y Reanimación Infantil
Luis Riera del Moral	Angiología y Cirugía Vasculard
María Dolores Martín Arranz	Aparato Digestivo
Esther Pérez David	Cardiología
Juan Caro Codón	Cardiología
Sandra Ofelia Rosillo Rodríguez	Cardiología
Sergio Castrejón Castrejón	Cardiología
Raúl Sánchez Pérez	Cirugía Cardíaca Infantil
Ramón Cantero Cid	Cirugía General y del Aparato Digestivo
Amelia J. Hessheimer	Cirugía General y del Aparato Digestivo
Mario Álvarez Gallego	Cirugía General y del Aparato Digestivo

Isabel Pascual Migueláñez	Cirugía General y del Aparato Digestivo
José Luis del Castillo Pardo de Vera	Cirugía Maxilofacial
Luis Landín Jarillo	Cirugía Plástica
Cristina Verdú Sánchez	Cuidados Intensivos Pediátricos
Elena Sendagorta Cudós	Dermatología
Marta Feito Rodríguez	Dermatología
Samara Palma Milla	Endocrinología
Patricia Luna Castaño	Enfermería - UCI Pediátrico
Carmen Sobrino Jiménez	Farmacia
Patricia Ysabel Condorhuamán Alvarado	Geriatría
Raquel Ramírez Martín	Geriatría
Rocío Menéndez Colino	Geriatría
Ángelo Gámez Pozo	FIBHULP
Marta Mendiola Sabio	FIBHULP
Elena Vallespin García	INGEMM
María Palomares Bralo	INGEMM
Pilar Nozal Aranda	Inmunología
Manuel Quintana Díaz	Medicina Intensiva
Marta Díaz Menéndez	Medicina Interna
Marta Mora Rillo	Medicina Interna
Rocío Montejano Sánchez	Medicina Interna
Gloria del Peso Gilsanz	Nefrología
María Carmen Bravo Laguna	Neonatología
Raquel Casitas Mateo	Neumología
Elisabet Martínez Cerón	Neumología
Carlos Javier Carpio Segura	Neumología

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Ester Zamarrón de Lucas	Neumología
Raúl Galera Martínez	Neumología
María Luisa Gandía González	Neurocirugía
Beatriz Mansilla Fernández	Neurocirugía
Víctor Rodríguez Domínguez	Neurocirugía
Fco. Javier Díaz de Terán Velasco	Neurología
Jorge Rodríguez Pardo de Donlebún	Neurología
Ignacio Zapardiel Gutiérrez	Obstetricia y Ginecología
María de la Calle Fernández-Miranda	Obstetricia y Ginecología
Emanuela Spagnolo	Obstetricia y Ginecología
Covadonga Martí Álvarez	Obstetricia y Ginecología
Marcos Javier Cuerva González	Obstetricia y Ginecología
Álvaro Pinto Marín	Oncología Médica
Rosa Morera López	Oncología Radioterápica
Elisabet González del Portillo	Oncología Radioterápica
Ana Méndez Echevarría	Pediatría
Teresa del Rosal Rabés	Pediatría
Luis Escosa García	Pediatría
Ángela Palao Tarrero	Psiquiatría y Psicología Clínica
Eduardo Fernández Jiménez	Psiquiatría y Psicología Clínica
Pedro Navía Álvarez	Radiodiagnóstico
Chamaida Plasencia Rodríguez	Reumatología
Angélica Rivera Núñez	Urgencias
Rosario Torres Santos-Olmos	Urgencias

The program was in collaboration with a network of seniors mentors:

Rebeca Pérez de Diego
Eduardo López Collazo
Jesús Mingorance Cruz
Karen Elise Heath
Inmaculada Ibañez de Cáceres
José Luis López Sendón
Alejandro Martín Quirós
Eduardo López Granados
Teresa Bellón Heredia
María Gutiérrez Fernández
Laura Saldaña Quero
María Auxiliadora Bajo Rubio
Francisco García Río
Beatriz Rodríguez Vega
María Eugenia Miranda Carús
Carlos del Fresno Sánchez
Ana Sastre Perona
Adellina Pellicer Martínez
Alberto Borobia Perez
Santiago Rello Varona
Cristina Calvo Rey
Víctor Jiménez Yuste
Constantino Fondevila Campo
María Josefa Mellado Peña



Webinar	Speaker	Date
Impacto esperado del proyecto y plan de difusión	Daniel Quijada	21/10/2021
Cómo preparar un buen presupuesto	Silvia Arce y Sara Fernández	18/11/2021
CVN e identificador ORCID	Raúl Román y Lucía Medina	16/12/2021
Interés estratégico del proyecto para la convocatoria	Daniel Quijada	13/01/2022
Planificación metodológica para proyectos de Ensayos Clínicos en la AES	Alberto Borobia	20/01/2022
Plan de gestión de datos científicos. Protección de datos	Daniel Quijada, Estela Sánchez y Dolores Pérez	03/02/2022
Novedades de la convocatoria AES 2022	Mercedes Ruiz	16/02/2022

2.10.2. TRANSVERSAL RESEARCH PROJECT

IdiPAZ's Strategic Plan has, among its prioritized lines of action, the promotion of research of excellence through the consolidation of the research areas and groups that make up the scientific structure. For this, the model of interrelation between the research areas and groups of the Institute is key and directly impacts the generation of synergies and the development of joint collaborative projects.

The main objective of the Transversal Research Projects is to strengthen the configuration of multidisciplinary research teams, participated by IdiPAZ research groups (both excellent, consolidated and emerging as young researchers).

Two Transversal Research Projects have been implemented:

- **Study of pathogen-host interaction: implementation of a logistic for the development of infectious disease projects.** At the IdiPAZ facilities, construction has begun on a biological containment laboratory that will allow the handling of pathogens classified as biosafety levels 2 and 3. This means the possibility of carrying out studies in a controlled environment with infectious agents whose risk of transmission and health risk is moderate (level 2) and with those that present a high risk of transmission, for example, by aerosols and that can generate serious diseases (level 3). This facility is equipped with safety systems such as hoods for handling biological agents, controlled access, exclusions and specific showers, as well as to control the exit of materials under safe conditions. This facility represents a leap in quality for IdiPAZ as it will provide the facilities required to meet the new infectious challenges that society is facing
- **Biomodels for the study of multiple diseases: a tool for the development and implementation of therapies.** During this year, construction work began on a SPF (Specific Pathogen Free) animal facility. This is an area where strict microbiological control is maintained to ensure that the experimental animals housed do not suffer unwanted infections. Access to this area is controlled by a system of locks and

quarantines. Similarly, all incoming materials must be previously sterilized by means of the autoclaves and sterilization systems present at the entrance to the facility. This type of animal facility allows the development of experiments with immunosuppressed animals, very useful experimental models since they allow working with human cells, which is extremely important for a health research institute such as IdiPAZ..

Approach of these Transversal Research Projects included:

- Translational vision, interrelation between the scientific areas of IdiPAZ and orientation to the clinical practice setting.
- Participatory research projects in which collaboration between research groups from different Areas is promoted.
- Projects coordinated by a person in charge who encourages participation and collaboration between groups for the development of projects.
- Evaluation with monitoring indicators based on standards of excellence, focused on obtaining funding, scientific production and / or results in clinical practice.



1
Introduction

2
Executive
Summary

3
Information
Groups
by Area

4
Associated
Clinicians


2.10.3. TRANSPLANTCHILD

During this year we face the fifth year of the coordination of the European Reference Network (ERN) TransplantChild (www.transplant-child.eu). ERN TransplantChild tackles a low prevalence complex procedure and condition that is the paediatric transplantation of all kind of solid organ (kidney, liver, heart, intestine and lung) and hematopoietic stem cell transplantation (HSCT).

The involvement of the multidisciplinary team working at IdiPAZ and La Paz University Hospital, makes possible the development of important activities focused on topics related to paediatric transplantation working together with excellence centres across Europe.

During the 11th Board of the Network, organised in Paris (France) during May 2022 there was an specific welcome for the healthcare providers that joined the network as of 1st January 2022. This increased the reach of the ERN to over 120 paediatric transplantation programmes at 40 healthcare providers located in 21 European countries.

Following this growth there were 4 operational areas created from the coordination team located at IdiPaz-La Paz University Hospital to aid in the objectives of the network and increase the efficiency of operations. These 4 operational areas comprise European countries that transplantation-wise are alike in terms of operations and management of paediatric patients.



Following the initially founded objectives of ERN TransplantChild of knowledge spreading and education of professionals, a third workshop was organised regarding the topics of Tolerance in paediatric transplantation and Transition to adulthood, focusing on the preparation of the young adult to transit from the paediatric care to

the adult care, taking into consideration the training and self-conscious of the young adult and a smooth transfer to the professionals in adult care. In this workshop not only we aim to tackle healthcare professionals but also include patients and families, following the main aim of ERN TransplantChild.

We continued the pilot from last year and are on the verge of releasing the first open release of the PETER registry, the first European Paediatric Transplantation Registry. With this registry, open to all healthcare providers in Europe, we aim to put together both clinical data and patient outcome to better understand and improve their care and take over research projects.

The results of one of the studies carried out in TransplantChild have been published as well:

- "Cold Ischemia Time and Graft Fibrosis Are Associated with Autoantibodies after Paediatric Liver Transplantation: A Retrospective Cohort Study of the European Reference Network TransplantChild" (DOI: 10.3390/children9020275)

The ERN TransplantChild continues having patients as the core of its aims and as so has collaborate with the advocates patients groups in the study of the social resources available for patients and families among Europe and are working on a consensus document with minimum resources recommendations.

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



2.11 Internationalization

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

- Argentina
- Australia
- Austria
- Belgium
- Brazil
- Bulgaria
- Canada
- Chile
- China
- Colombia
- Cuba
- Denmark
- Ecuador
- Finlandia
- France
- Germany
- Greece
- Hungary
- Iceland
- India
- Iran
- Israel
- Italy
- Japón
- Líbano
- Lithuania
- Macedonia
- Mexico
- Netherlands
- Norway
- Pakistan
- Peru
- Poland
- Portugal
- Puerto Rico
- Romania
- Russia
- Saudi Arabia
- Singapore
- Slovenia
- South Korea
- Suiza
- Sweden
- Switzerland
- Taiwan
- Thailand
- Turkey
- Ukraine
- United Arab Emirates
- United Kingdom
- United States of America





2.12 Dissemination/Divulgence and Public Engagement

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

The scientific communications have as main objective the dissemination of the research carried out by IdiPAZ's scientists and the strengthening of the bonds with both other institutions and the general public. IdiPAZ uses its tool to carry out this task, the newsletter "IdiPAZ Informa", in 2021, **247 newsletters** were sent to our researchers.

During 2021, **61 news** have been issued by IdiPAZ, including press releases, highlighting the scientific achievements by IdiPAZ researchers. Also, **three numbers** of our scientific newsletters "IdiPAZ News" were published.

We have noticed a steady increase in the media coverage of our research and activities, with a significant rise of the appearances in press as well as in social media. This increase is due to the involvement of many of IdiPAZ's researchers. In our website, "IdiPAZ in the media" is included a coverage of **157 digital press mentions** along this year: <https://www.idipaz.es/PaginaDinamica.aspx?IdPag=671&Lang=ES>

About our website, the total number of **visits was 56,476**. April being the month with the most visits, with a total of 7,134 visits. IdiPAZ is also very active on the major social networks, with a community of **almost 3,000 followers on Twitter**. By other way, news that includes the work of our researchers and other news of interest to the public, are

published in the main social networks. Our Twitter account, @IdiPAZscience, has the largest number of followers among the institutes of the community of Madrid.

In addition to these actions, in 2021 we began to work on the dissemination of small training pills on Sustainable Development Goals and Responsible Research and Innovation, **15 formative pills** were sent them to our researchers.

With the great collaboration of the centre's scientists, IdiPAZ has been able to participate in activities such as the European Researcher's Night, the Science and Innovation Week or the celebration of the International Day of Women and Girls in Science. The centre has also made guided visits for high school students, some face-to-face and some virtual, talks and workshops for kids and schools.

We would like to acknowledge the collaboration and support of the Communication Office of the Hospital Universitario La Paz.

Communication manager

Lucía Medina

comunicacion@idipaz.es

Phone: (+34) 91 727 75 76 ext 442978

2.12.1. SELECTED MEDIA APPEARANCES

		17/12/2021 El Hospital La Paz pone en marcha una Unidad de Hospitalización a Domicilio Pediátrica (HADA)			10/12/2021 La Paz prueba la viabilidad y seguridad de la inmunoterapia como tratamiento contra la COVID-19
		17/12/2021 Díaz Ayuso presenta en La Paz el primer sistema de radioterapia de precisión molecular guiada por resonancia magnética para tratar tumores			03/12/2021 La Paz, referente en el tratamiento de preservación de fertilidad en pacientes con cáncer genital
		16/12/2021 Pediatria del Hospital La Paz se consolida como referente nacional en investigación			02/12/2021 El Hospital La Paz estrena nuevas instalaciones para los pacientes de Hemato-Oncología Pediátrica



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

		01/12/2021 El Instituto de Investigación de La Paz supera los 8.500 puntos de factor impacto
		29/11/2021 La Consejería de Sanidad otorga a la FIBHULP la Subvención Nominativa
		29/11/2021 La doctora Patricia Condorhuamán recibe dos premios en el XII Congreso de la Sociedad Española de Fracturas Osteoporóticas
		23/11/2021 El Hospital La Paz lidera el grupo español de un estudio internacional sobre diálisis peritoneal
		18/11/2021 Investigadores del Hospital La Paz prueban que la inmunidad innata entrenada protegé frente al COVID
		18/11/2021 El investigador del IdiPAZ Gonzalo Martínez-Ales ha sido premiado por su tesis doctoral
		15/11/2021 El Hospital La Paz se compromete con los Objetivos de Desarrollo Sostenible
		11/11/2021 La Unidad de Enfermedades Infecciosas Pediátricas de La Paz, referente nacional en investigación
		10/11/2021 El Hospital La Paz clausura el curso de "Gestión Integral Hospitalaria", centrado en la COVID-19
		25/10/2021 Una aplicación creada por el Hospital La Paz facilita la vida de los pacientes con hemofilia
		22/10/2021 Premio a la Mejor Publicación Nacional 2021 de la Sociedad Madrileña de Neumología y Cirugía Torácica

		23/09/2021 El Hospital La Paz acoge un curso europeo sobre manejo quirúrgico del cáncer de cuello uterino
		22/09/2021 El Hospital La Paz analiza el impacto de la pandemia de COVID-19 en los profesionales sanitarios
		13/09/2021 Investigadores del IdiPAZ lideran un gran proyecto internacional para desarrollar nuevos tratamientos contra la tuberculosis
		20/07/2021 El Sistema de calidad del Hospital Universitario La Paz cuenta con más de 40 servicios y seis normas certificadas
		14/07/2021 El Dr. Jorge Díaz-Garzón premiado por la European Federation of Laboratory Medicine (EFLM)
		14/07/2021 El Hospital La Paz recertifica su Sistema de Gestión Integrado
		07/07/2021 La Paz acoge una iniciativa para mejorar la estancia hospitalaria de los niños con cáncer
		30/06/2021 Premio Castroviejo-Santén para Celia Fernández
		17/06/2021 La Paz ilustra áreas de Hematología y Farmacia para mejorar la experiencia de sus pacientes
		17/06/2021 El Hospital La Paz recertifica su Sistema de Gestión Integrado
		15/06/2021 La Paz recibe una beca para un proyecto de diagnóstico genético de la Hipertensión Pulmonar
		10/06/2021 El Hospital La Paz reconoce el trabajo de los finalistas del concurso del Nuevo Hospital



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

		07/06/2021 La Paz recibe la acreditación internacional JACIE en trasplante de progenitores hematopoyéticos			08/04/2021 El Hospital La Paz muestra que los antirretrovirales revierten el envejecimiento biológico por VIH
		04/06/2021 José Ramón Arribas, nuevo presidente de Gesida			26/03/2021 IdiPAZ consigue el sello Human Resources Excellence in Research (HRS4R)
		21/05/2021 La Paz, pionero en ofrecer la terapia por hidroablación en hiperplasia benigna de próstata			24/03/2021 Aprobamos el proyecto definitivo para la reforma integral del Hospital La Paz
		20/05/2021 La Paz realiza el diagnóstico genético de más de 2.000 displasias esqueléticas cada día			18/03/2021 La Paz realiza la implantación de electrodos profundos cerebrales gracias a una novedosa técnica
		01/06/2021 IdiPAZ comprometido con los Objetivos de Desarrollo Sostenible			15/03/2021 El Hospital La Paz realiza el primer proceso de donación con el programa ECMO móvil infantil
		18/05/2021 La Paz participa en el documental "Impredicibles" sobre el agiograma hereditario (AEH)			08/03/2021 La Paz-IdiPAZ coordina una red europea para luchar contra resistencias bacterianas a antibióticos
		14/05/2021 La Paz adapta sus actividades a los pacientes ingresados en el Hospital Infantil, pese a la pandemia			05/03/2021 El Hospital Universitario La Paz-IdiPAZ participa en el proyecto 'HosmartAI'
		29/04/2021 La Paz, el único hospital de España que ofrece la crioblación a pacientes con cáncer de mama			26/02/2021 La Paz encabeza un proyecto europeo para investigar variantes y desarrollar vacunas para COVID-19
		26/04/2021 El Hospital Universitario La Paz supera el centenar de trasplantes cardiacos			22/02/2021 El doctor Landín, nuevo presidente de la Comisión Permanente del Consejo Nacional de Especialidades en Ciencias
		12/04/2021 La Paz inicia el ensayo de una terapia oncológica en niños con anomalías vasculares raras			17/02/2021 La Paz, pionero en la atención integral a los niños con cáncer en su propia habitación
		09/04/2021 La Paz impulsa la iniciativa "Entorno Amigo para las Personas Mayores"			15/02/2021 La Paz recibe el certificado del Índice de Humanización de Hospitales Infantiles de AENOR



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians


		15/02/2021 La Unidad de Terapias Avanzadas de La Paz prueba un fármaco experimental en fibrosarcoma infantil
		11/02/2021 Día Internacional de la Mujer y la Niña en la Ciencia 2021
		29/01/2021 Reconocimiento de Excelencia a la Unidad de Atención Integral a pacientes con EII de La Paz

		28/01/2021 El Hospital La Paz, a la cabeza en el número de trasplantes infantiles realizados en España
		26/01/2021 Un estudio de La Paz y Atención Primaria revela alteraciones en la lengua como síntoma de COVID-19
		26/01/2021 El Hospital La Paz lidera las donaciones de sangre de la Comunidad de Madrid en 2020

2.12.2. IDIPAZ NEWS



2.12.3. WEBSITE



2.12.4. SOCIAL NETWORKS

Platform	Handle	Followers	Publications
Twitter	@IdipazScience	2,890	1433
LinkedIn	https://es.linkedin.com/company/fibhulp	1,486	24
Instagram	@Idipaz	1008	387
Facebook	facebook.com/IdiPAZ	478	434
YouTube	youtube.com/IdiPAZ	14	25

Highlighted tweets	Impressions	Engagements
	24,502	1,234

	7,758	252
--	-------	-----



1 Introduction
















2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

	6,288	208		5,607	234
	5,838	577		5,077	200

2.12.5. FORMATIVE PILLS ABOUT GOALS AND RRI

	Training pills presentation		ODS 11. Sustainable cities and communities		Campaign #Responsible Consumption		Digital Transformtion		Conduct code
	GOAL 3. Good health and well-being		Introduction to the RRI in Biomedicine		GOAL 5. Gender equality		GOAL ODS 13. #ForTheClimate		ODS 17. Partnerships for the goals
	GOAL 9. Industry, innovation and infrastructure		10 tips for sustainability		Data protection		#25N International Day for the Elimination of Violence against women		ODS 12. Responsible consumption and production

2.12.6. OTHER ACTIVITIES





2.13 Responsible Research and Innovation

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Responsible Research and Innovation (RRI) is the Science with and for Society framework that encompasses all key actions aimed to anticipate and assess potential implications and societal expectations with regard to research and innovation, with the aim to Foster the design of inclusive and sustainable research and innovation. Based on RRI principles, IdiPAZ is growing to imply societal actors to work together for the research process in order to align both the process and its outcomes with the values, needs and expectations of society. IdiPAZ has continued and development new several RRI actions:

■ Ethics and Research Integrity



- Human Resources Strategy for Researchers- HRS4R: endorsed the Charter and Code principles, gap analysis, OTM-R and action Plan design. In 2020, the European Commission awarded the 'HR Excellence in Research Award' to the institution.
- Own Ethic Committee: Research Ethics Committee with Medical Products and Animal Welfare Organ.
- International Organisation for Standardisation (ISO) 9001 Certification for Committees and Platforms of IdiPAZ.
- Good Practice Recommendations Guidelines.

■ Ethics and Research Integrity

- Own Open access Guideline of IdiPAZ.
- To encourage researchers to participate in the institutional Open-Access Repositories with papers and research data: as Repisalud of the Institute of Health Carlos III, Institutional Repository of the Regional Health System of the Community of Madrid, and Biblos-e Archivo of the Autonomous University of Madrid.
- Scientific Seminar, with online video recording to connect to the scientific community and the society.
- Since 2020, IdiPAZ participates as a member of the European Open Science Cloud (EOSC) Association (<https://eosc.eu>) to accelerate the creation of open knowledge, increase the re-use of research databases by the larger community, inspire ways for ways to share medical data that ensures respect to privacy of



personal information, promote education in Open Science practices, spur innovation and foster new jobs aimed to sustain openness and curation of research.

- Workshop to promote and create the ORCID code used between IdiPAZ researchers (03/11/2020).
- Workshop to create the normalised curriculum in CVN format (05/02/2021).
- Workshop of the Institutional Repository of the Regional Health System of the Community of Madrid to promote the use between IdiPAZ researchers (15/03/2021) to collect, preserve and make available to any interested person the scientific production generated by the professionals of all the centres and services of the Ministry of Health as result of their assistance, research and teaching activity, thus guaranteeing their conservation and open access and promoting their visibility and dissemination.
- Act 19/2013, of December 9, 2013, on transparency, access to public information and good governance. In accordance with the provisions of Article 66 paragraphs 1 and 2 of Law 10/2019 of April 10, 2009, and Article 2.1 of Law 10/2019 of April 10, 2009, and with the aim of publicising our entity and the relevant information about it, the FIBHULP is registered in the Transparency Register of the Community of Madrid since March 4, 2021 with registration number 202100170.
- **European Union Transparency Register.** The Interinstitutional Agreement between the European Parliament and the European Commission sets out the rules and principles on which the Transparency Register is based. The first Agreement (signed in June 2011) was reviewed after two years. The revised Agreement was adopted in April 2014. FIBHULP is currently listed in the **European Union Register** as of May 10, 2021 under registration number 86699642652-90.
- The following training and conferences related to Open Science and RRI have been held:
 - 10/03/2021- Training Day RIs in Biomedical Science

- 22/04/2021- Institutional Repository Presentation Conference
- 29/06/2021- Open Science Workshop for Health Research Institutes.
- 24/06/2021- Training Day "Social Responsibility in IdiPAZ".
- In addition, information notes about our Open Science Policy have been sent through our communication channel.

■ Science Education

- Scientific divulgation activities: At IdiPAZ we have a communication plan focused on planning the Institute's communication actions, both internal and external.
 - International Day of Women and Girls in Science.
 - Science and Innovation Week.
 - European Researchers' Night.
 - "4° ESO+empresa" Day.
 - Science on the street.



- Scientific Culture and Innovation Unit of IdiPAZ.

■ Public engagement

- Current information about Clinical Trials research studies in different phases for Patients.
- The society has the opportunity to collaborate with IdiPAZ via sponsorship and our Patronage Strategy - Pazito: colabora.
- IdiPAZ+i News is an information bulletin focus to translated the society that the hospital is not only a place to treat the patients, otherwise the researchers try to improve the health and wellbeing of our population with the research and innovation projects.

■ Governance

- IdiPAZ is a participating member of the Assemblies for a EU Coalition for Reforming Research Assessment. The Coalition will help all kinds of research performing organisations to abandon or reposition uninformative metrics (Journal Impact Factor, h-index, Shanghai rankings etc.) towards a more comprehensive system of scientific quality evaluation, aligned with DORA and HRS4R.



2.13 Responsible Research and Innovation




- Participative Governance: European Reference Network on paediatric transplantation (ERN TransplantChild), coordinated by our institution, TransplantChild Patients Committee.
- Research Ethics Committee with Medical Products.
- Commission for Humanization and Social and Scientific Responsibility of IdiPAZ: This commission aims to ensure compliance with the principles of Responsible Research and Innovation (RRI) and Open Science, following the recommendations of the European Commission. It is also committed to promoting the social and scientific responsibility of our researchers, aimed at promoting research and innovation for society. Through this committee we have launched a process of integration of the Sustainable Development Goals and Agenda 2030. The members of the commission include representatives of patients' associations, representatives of the district council, the hospital and FIBHULP/IdiPAZ.

■ Gender Equality

- Design of the **II Equality and Diversity Plan**, registered with REGCON (*Registro y Depósito de Convenios Colectivos, acuerdos colectivos de trabajo y Planes de Igualdad*)- Code 28109182112021.
- Creation of the Equality and Diversity Committee.
- Protocol for the prevention of and action against discriminatory harassment, moral and sexual harassment and harassment based on gender which has been developed by IdiPAZ's Commission for Equality and Diversity, to recognize, prevent, and if necessary, eradicate all those behaviors and organizational factors that reveal violent behavior in the workplace and promote a healthy work environment and climate, both physically and psychologically.
- Human Resources Strategy for Researchers- HRS4R: endorsed the Charter and Code principles, gap analysis, OTM-R and action Plan design.
- Participation in the International Day of Women and Girls in Science.

■ Social Responsibility

In 2020, IdiPAZ/FIBHULP get the international certification thought IQ-Net SR10, as a mark of confidence to shareholders and other stakeholders that reliable, recognized and value focus management practices are in place.



A commitment to the sustainable development goals and the 2030 agenda and a corporate social responsibility policy have been developed, which sets out the activities and guidelines that are carried out to fulfill this commitment.



Goals to Transform Our World

In line with Social Responsibility Strategy, IdiPAZ began to work in Sustainable Development Goals proposed by the 2030 Agenda for Sustainable Development, adopted by all United Nations Member States. It provides a shared blueprint for peace and prosperity for people and the planet, now and into the future, and 17 Sustainable Development Goals (SDGs) were proposed.

A materiality study was performed through a process of questionnaire sent to all the researchers, identifying and mapping all of the research lines and projects of the Institute. As a result of the analysis, IdiPAZ prioritised four Sustainable Development Goals that were included in their Strategic research and innovation Plan as follows:

Strategic ODS:

3. Good Health
5. Gender Equality
8. Decent work and Economic Growth
9. Innovation and Infrastructure
10. Reduced inequalities
12. Responsible consumption and production
17. Partnerships for the goals

Relevant ODS:

4. Quality education
7. Affordable and clean energy
13. Climate action
16. Peace, justice and strong institutions




In the next years, IdiPAZ will contribute to the implementation of the SDGs through its work on the seven strategic goals and targets. The prioritised SDGs have been aligned and integrated with the objectives and axes of the Strategic Plan for Research and Innovation 2020-2024. In addition, we have drawn up a Sustainability Report 2021, which covers the entire process of implementing the SDGs in the institute and the actions to be developed in the coming years. The goals we are going to work on in the short and long term are the following:



- 3.3** By 2030, end the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases and combat hepatitis, water-borne diseases and other communicable diseases.
- 3.4** By 2030, reduce by one third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being.
- 3.5** Strengthen the prevention and treatment of substance abuse, including narcotic drug abuse and harmful use of alcohol.
- 3.A** Strengthen the implementation of the World Health Organisation Framework Convention on Tobacco Control in all countries, as appropriate.
- 3.B** Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all.
- 3.C** Substantially increase health financing and the recruitment, development, training and retention of the health workforce in developing countries, especially in least developed countries and small island developing States.



- 5.1** End all forms of discrimination against all women and girls everywhere
- 5.2** Eliminate all forms of violence against all women and girls in the public and private spheres, including trafficking and sexual and other types of exploitation
- 5.4** Recognize and value unpaid care and domestic work through the provision of public services, infrastructure and social protection policies and the promotion of shared responsibility within the household and the family as nationally appropriate
- 5.5** Ensure women's full and effective participation and equal opportunities for leadership at all levels of decision making in political, economic and public life
- 5.B** Enhance the use of enabling technology, in particular information and communications technology, to promote the empowerment of women
- 5.C** Adopt and strengthen sound policies and enforceable legislation for the promotion of gender equality and the empowerment of all women and girls at all levels



- 8.3** Promote development-oriented policies that support productive activities, decent job creation, entrepreneurship, creativity and innovation, and encourage the formalisation and growth of micro-, small- and medium-sized enterprises, including through access to financial services
- 8.5** By 2030, achieve full and productive employment and decent work for all women and men, including for young people and persons with disabilities, and equal pay for work of equal value
- 8.6** By 2020, substantially reduce the proportion of youth not in employment, education or training
- 8.7** Take immediate and effective measures to eradicate forced labour, end modern slavery and human trafficking and secure the prohibition and elimination of the worst forms of child labour, including recruitment and use of child soldiers, and by 2025 end child labour in all its forms
- 8.8** Protect labour rights and promote safe and secure working environments for all workers, including migrant workers, in particular women migrants, and those in precarious employment



2.13 Responsible Research and Innovation



- 9.1** Develop quality, reliable, sustainable and resilient infrastructure, including regional and transborder infrastructure, to support economic development and human well-being, with a focus on affordable and equitable access for all
- 9.2** Promote inclusive and sustainable industrialization and, by 2030, significantly increase the contribution of industry to employment and gross domestic product, in accordance with national circumstances, and double that contribution in the least developed countries.
- 9.3** Increase access of small industries and other enterprises, particularly in developing countries, to financial services, including affordable credit, and their integration into value chains and markets.
- 9.5** Enhance scientific research, upgrade the technological capabilities of industrial sectors in all countries, in particular developing countries, including, by 2030, encouraging innovation and substantially increasing the number of research and development workers per 1 million people and public and private research and development spending



- 10.2** By 2030, empower and promote the social, economic and political inclusion of all, irrespective of age, sex, disability, race, ethnicity, origin, religion or economic or other status
- 10.3** Ensure equal opportunity and reduce inequalities of outcome, including by eliminating discriminatory laws, policies and practices and promoting appropriate legislation, policies and action in this regard
- 10.4** Adopt policies, especially fiscal, wage and social protection policies, and progressively achieve greater equality



- 12.2** By 2030, achieve the sustainable management and efficient use of natural resources
- 12.4** By 2020, achieve the environmentally sound management of chemicals and all wastes throughout their life cycle, in accordance with agreed international frameworks, and significantly reduce their release to air, water and soil in order to minimise their adverse impacts on human health and the environment
- 12.5** By 2030, substantially reduce waste generation through prevention, reduction, recycling and reuse
- 12.8** By 2030, ensure that people everywhere have the relevant information and awareness for sustainable development and lifestyles in harmony with nature



- 17.6** Enhance North-South, South-South and triangular regional and international cooperation on and access to science, technology and innovation and enhance knowledge sharing on mutually agreed terms, including through improved coordination among existing mechanisms, in particular at the United Nations level, and through a global technology facilitation mechanism
- 17.17** Encourage and promote effective public, public-private and civil society partnerships, building on the experience and resourcing strategies of partnerships.



2.13 Responsible Research and Innovation

In 2021, we published the **IdiPAZ Sustainability Report**. In it we can find our sustainability management and the implementation of the Sustainable Development Goals in our institute as well as all the action plans that will be carried out in the coming years. In order to support this initiative to which we are committed, a working group for sustainable development and agenda 2030 has been created.

In relation to our commitment to the SDGs, we have developed a series of campaigns that favour their achievement and support environmental and social improvement in our environment. Some of the campaigns we have carried out or collaborated in have been:



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Information Groups by Area

-  Neurosciences Area
-  Cardiovascular Area
-  Infectious Diseases and Immunity Area
-  Large System Pathologies Area
-  Cancer and Human Molecular Genetics Area
-  Surgery, Transplant and Health Technologies Area
-  Maternal Infant Child and Youth Research Area
-  Multidisciplinary Research in Healthy Aging



1
Introduction

2
Executive Summary

3
Information Groups by Area


4
Associated Clinicians

Information Groups by Area



Neurosciences Area

Documents: 129
 Originals: 108
 D1: 18 Q1: 70



Cancer and Human Molecular Genetics Area

Documents: 232
 Originals: 170
 D1: 45 Q1: 109



Cardiovascular Area

Documents: 234
 Originals: 179
 D1: 52 Q1: 126




Surgery, Transplant and Health Technologies Area

Documents: 205
 Originals: 155
 D1: 15 Q1: 53



Infectious Diseases and Immunity Area

Documents: 299
 Originals: 237
 D1: 60 Q1: 126



Maternal Infant Child and Youth Research Area

Documents: 269
 Originals: 211
 D1: 45 Q1: 116



Large System Pathologies Area


Documents: 354
 Originals: 262
 D1: 52 Q1: 152



Multidisciplinary Research in Healthy Aging Area

Under construction

Information Groups by Area



One of the objectives of the IdiPAZ Institute is that the research groups and areas are in permanent contact and collaborate in their work. To this end, area coordination meetings are usually held in which the directors present the main advances and work carried out by their team. The last one was held on 23 June and was entitled "Nuevos horizontes y sinergias".





Neurosciences Area

3.1

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Exuperio Díez Tejedor

Documents: 129

Originals: 108

D1: 19 Q1: 70

- 3.1.1 Psychiatry and Mental Health Group
- 3.1.2 Neurology and Cerebrovascular Diseases Group
- 3.1.3 Neuroprotective Strategies in Neurodegenerative Diseases Group
- 3.1.4 Involvement of Glycinergic and Glutamatergic Systems in Central Nervous System Pathologies Group
- 3.1.5 Mechanisms and Biomarkers in Neurodegenerative Diseases Group
- 3.1.6 Research in Multiple Sclerosis Group (HUG)





Neurosciences Area



1 Introduction


2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Strategic Objectives	Development forecast for the coming years
<p>Neuroscience Area is composed of 5 research groups and has as general objectives the promotion of teaching, research and dissemination of knowledge in the field of neurosciences and neurological diseases, particularly in relation to clinical neurosciences.</p>	<p>Cohesion between different disciplines (biomedical research, engineering).</p> <p>Encourage and promote research among the healthcare staff who sometimes perceive research as something negative.</p>
	<p>Innovation and technology transfer.</p>

Actions
<p>Performing annual workshops and seminars science.</p>
<p>Training in research methodology in specialized health personnel and in training.</p>
<p>Innovation promotion program that involves health organizations, research institutions and companies.</p>





3.1.1 Psychiatry and Mental Health Group

Publications: 28

Q1: 19

COMPOSITION



■ **María Fe Bravo Ortiz.** Jefe de Servicio de Psiquiatría. Hospital Universitario La Paz. Profesora Asociada. Facultad de Medicina. Universidad Autónoma de Madrid

Blanca Amador Sastre. Facultativo Especialista de Área en Psicología Clínica. Hospital Universitario La Paz

Jorge Andreo Jover. Investigador Predoctoral. FIBHULP

Carmen Bayón Pérez. Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz. Profesora

Asociada. Facultad de Medicina. Universidad Autónoma de Madrid

Susana Cebolla Lorenzo. Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz

Consuelo de Dios Perrino. Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz

Eduardo Fernández Jiménez. Psicólogo Interno Residente. Hospital Universitario La Paz

Nieves González Suárez. Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz

Ana Hospital Moreno. Facultativo Especialista de Área en Psicología Clínica. Hospital Universitario La Paz

Eduardo Jiménez Sola. Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz

Jesús Martí Esquitino. Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz

Gonzalo Martínez-Ales García. Investigador Postdoctoral. Universidad de Columbia

Roberto Mediavilla Torres. Investigador Postdoctoral. Universidad Autónoma de Madrid

Ainoa Muñoz San José. Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz

Óscar Pajares González-Gallego. Enfermero Especialista en Salud Mental CSM Fuencarral. Hospital Universitario La Paz

Ángela Palao Tarrero. Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz

Pau Pérez Sales. Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz

Cristina Rocamora González. Psicóloga. Residencia Asistida San Camilo

Beatriz Rodríguez Vega. Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz. Profesora Asociada. Facultad de Medicina. Universidad Autónoma de Madrid

María Paz Vidal Villegas. Investigadora predoctoral. Hospital Universitario La Paz

Rosa Villanueva Peña. Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz

STRATEGIC OBJECTIVE

The group focuses its objectives on evaluating the efficacy of psychotherapeutic techniques as a complement to other specific treatments in mental disorders and other medical illnesses, as well as on the evaluation of mental health services. Of special interest is the

evaluation of the efficacy of suicide prevention interventions.

It also focuses on the investigation of the interaction of genetic and environmental factors in the etiology and evolution of mental disorders, especially psychosis.

In addition, the group is involved in the evaluation of new treatments or new indications in mental illnesses through participation in clinical trials.

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

RESEARCH LINES

- Psychotherapeutic interventions in mental disorders
- Suicide prevention

- Psychological and social impact of the COVID-19 pandemic
- e-Health interventions
- Mindfulness-based interventions

RESEARCH ACTIVITY

■ Doctoral theses

Dafaue Álvarez-Sala L. Personalidad, ansiedad y depresión como factores predictores del control del asma y de la adherencia al tratamiento en una consulta monográfica de asma grave [dissertation]. Madrid: UAM: 2021(03/06/2021).

Directors: Bravo Ortiz MF
Álvarez Sala R.

■ Publications

- Ayuso-Mateos JL, Mediavilla R, McGreevy KR, Bravo-Ortiz MF. Informing the response to COVID-19 in Spain: priorities for mental health research. *Rev Psiquiatr Salud Ment.* 2021; 14(2): 79-82. Editorial Material. IF: 6.795; Q1
- Bouza C, Martínez-Alés G, López-Cuadrado T. Recent trends of invasive mechanical ventilation in older adults: a nationwide population-based study. *Age Ageing.* 2021; 50(5): 1607-15. Article. IF: 12.782; D1
- Cegla-Schvartzman F, Ovejero S, López-Castro-ma J, Palomar-Ciria N, Migoya-Borja M, Bello H, Martínez-Ales G, Baca-García E. Diagnostic stability in bipolar disorder: A follow-up study in 130,000 patient-years. *J Clin Psychiat.* 2021; 82(6): 20m13764. Article. IF: 5.906; Q1
- Fernández-Jiménez E, Muñoz-Sanjose A, Mediavilla R, Martínez-Ales G, Louzao II, Andreo J, Cebolla S, Bravo-Ortiz MF, Bayón C. Prospective analysis between neutrophil-to-lymphocyte ratio on admission and development of delirium among older hospitalized patients with COVID-19. *Front Aging Neurosci.* 2021; 13: 764334. Article. IF: 5.702; Q1

- Gimbrone C, Rutherford C, Kandula S, Martínez-Ales G, Shaman J, Olfson M, Gould MS, Pei S, Galanti M, Keyes KM. Associations between COVID-19 mobility restrictions and economic, mental health, and suicide-related concerns in the US using cellular phone GPS and Google search volume data. *Plos One.* 2021; 16(12): e0260931. Article. IF: 3.752; Q2
- González-Pinto A, Balanza-Martínez V, Hernández AB, Gutiérrez-Rojas L, Montes JM, Perrino CD, Sola VP, González ALM, Palomo AG, Crespo JM. Expert consensus on information sheet proposals for patients under treatment with lithium. *Rev Psiquiatr Salud Ment.* 2021; 14(1): 27-39. Article. IF: 6.795; Q1
- Gutiérrez-Gutiérrez B, del Toro MD, Borobia AM, Carcas A, Jarrin I, Yllescas M, Ryan P, Pachón J, Carratala J, Berenguer J, Arribas JR, Rodríguez-Bano J (Martínez-Alés G). Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study. *Lancet Infect Dis.* 2021; 21(6): 783-92. Article. IF: 71.421; D1
- Gutiérrez-Gutiérrez B, Pérez-Nadales E, Pérez-Galera S, Fernández-Ruiz M, Carratala J, Oriol I, Cordero E, Lepe JA, Tan BH, Corbella L, Paul M, Natera AM, David MD, Montejo M, Iyer RN, Pierrotti LC, Merino E, Steinke SM, Rana MM, Muñoz P, Mularoni A, van Delden C, Grossi PA, Seminari EM, Gunseren F, Lease ED, Roilides E, Fortun J, Arslan H, Coussement J, Tufan ZK, Pilmis B, Rizzi M, Loeches B, Eriksson BM, Abdala E, Soldani F, Lowman W, Clemente WT, Bodro M, Farinas MC, Kazak E, Martínez-Martínez L, Aguado JM, Torre-Cisneros J, Pascual A, Rodríguez-Bano J, (Martínez-Alés G). Propensity score and desirability of outcome ranking analysis of ertapenem for treatment of nonsevere bacteremic urinary tract infections due to

extended-spectrum-beta-lactamase-producing enterobacteriales in kidney transplant recipients. *Antimicrob Agents Ch.* 2021; 65(11): e01102-21. Article. IF: 5.938; Q1

- Izquierdo A, Cabello M, Leal I, Ayora M, Rodríguez-Jiménez R, Ibáñez A, Díaz-Marsa M, Bravo-Ortiz MF, Baca-García E, Madrigal JLM, Fares-Otero NE, Díaz-Caneja CM, Arango C, Mateos JLA. How does neighbourhood socioeconomic status affect the interrelationships between functioning dimensions in first episode of psychosis? A network analysis approach. *Health Place.* 2021; 69: 102555. Article. IF: 4.931; Q1
- Izquierdo A, Cabello M, Leal I, Mellor-Marsa B, Ayora M, Bravo-Ortiz MF, Rodríguez-Jiménez R, Ibáñez A, MacDowell KS, Malpica N, Díaz-Marsa M, Baca-García E, Fares-Otero NE, Meleiro H, López-García P, Díaz-Caneja CM, Arango C, Ayuso-Mateos JL. The interplay between functioning problems and symptoms in first episode of psychosis: An approach from network analysis. *J Psychiatr Res.* 2021; 136: 265-73. Article. IF: 5.25; Q2
- Keyes KM, Kandula S, Olfson M, Gould MS, Martínez-Alés G, Rutherford C, Shaman J. Suicide and the agent-host-environment triad: leveraging surveillance sources to inform prevention. *Psychol Med.* 2021; 51(4): 529-37. Editorial Material. IF: 10.592; D1
- Lahera G, Reboreda A, Vallespi A, Vidal C, López V, Aznar A, Fernández P, Escolar M, Martínez-Ales G, Rodríguez-Jiménez R, Halverson T, Frommann N, Wolwer W, Penn DL. Social cognition and interaction training (SCIT) versus training in affect recognition (TAR) in patients with schizophrenia: A randomized controlled trial. *J Psychiatr Res.* 2021; 142: 101-9. Article. IF: 5.25; Q2
- Martínez-Alés G, Barrigón ML, López-Castro-

mán J, Baca-García E. Editorial: Suicide and related behaviour. *Front Psychiatry.* 2021; 12: 676487. Editorial Material. IF: 5.435; Q2

- Martínez-Alés G, Domingo-Reloso A, Arribas JR, Quintana-Díaz M, Hernan MA. Critical care requirements under uncontrolled transmission of SARS-CoV-2. *Am J Public Health.* 2021; 111(5): 923-6. Article. IF: 11.561; D1
- Martínez-Ales G, Gimbrone C, Rutherford C, Kandula S, Olfson M, Gould MS, Shaman J, Keyes KM. Role of firearm ownership on 2001-2016 trends in US firearm suicide rates. *Am J Prev Med.* 2021; 61(6): 795-803. Article. IF: 6.604; D1
- Martínez-Alés G, Pamplin JR, Rutherford C, Gimbrone C, Kandula S, Olfson M, Gould MS, Shaman J, Keyes KM. Age, period, and cohort effects on suicide death in the United States from 1999 to 2018: moderation by sex, race, and firearm involvement. *Mol Psychiatr.* 2021; 26(7): 3374-82. Article. IF: 13.437; D1
- Martínez-Alés G, Rodríguez JBC, Lázaro P, Domingo-Reloso A, Barrigón ML, Angora R, Rodríguez-Vega B, Jiménez-Sola E, Sánchez-Castro P, Román-Mazuecos E, Villoria L, Ortega AJ, Navio M, Stanley B, Rosenheck R, Baca-García E, Bravo-Ortiz MF. Cost-effectiveness of a contact intervention and a psychotherapeutic program for post-discharge suicide prevention: Rentabilité d'une intervention de contact et d'un programme de psychothérapie pour la prevention du suicide apres le conge de l'hopital. *Can J Psychiat.* 2021; 66(8): 737-46. Article. IF: 5.321; Q2
- Mascayano F, van der Ven E, Martínez-Ales G, Henao AR, Zambrano J, Jones N, Cabassa LJ, Smith TE, Yang LH, Susser E, Dixon LB. Disengagement from early intervention services for psychosis: A systematic review. *Psychiatr Serv.* 2021; 72(1): 49-60. Review. IF: 4.157; Q1

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

- Mediavilla R, Fernández-Jiménez E, Martínez-Ales G, Moreno-Kustner B, Martínez-Morata I, Jaramillo F, Moran-Sánchez I, Minue S, Torres-Cantero A, Alvarado R, Ayuso-Mateos JL, Mascayano F, Susser E, Bravo-Ortiz MF. Role of access to personal protective equipment, treatment prioritization decisions, and changes in job functions on health workers' mental health outcomes during the initial outbreak of the COVID-19 pandemic. *J Affect Disorders*. 2021; 295: 405-9. Article. IF: 6.533; Q1
- Mediavilla R, López-Arroyo M, Gómez-Arnau J, Wiesepape C, Lysaker PH, Lahera G. Autobiographical memory in schizophrenia: The role of metacognition. *Compr Psychiat*. 2021; 109: 152254. Article. IF: 7.211; Q1
- Mediavilla R, Muñoz-Sanjose A, Rodríguez-Vega B, Lahera G, Palao A, Bayón C, Vidal-Villegas MP, Chadwick P, Bravo-Ortiz MF. People with psychosis improve affective social cognition and self-care after a mindfulness-based social cognition training program (SocialMIND). *Psychiatr Rehabil J*. 2021; 44(4): 391-5. Article. IF: 2.809; Q1
- Navarro LN, Osorio VLD, Ortiz MFB, Liria AF. Mental health and human rights: The experience of professionals in training with the use of mechanical restraints in Madrid, Spain. *Salud Colect*. 2021; 17: e3045. Article. IF: 0.727; Q4
- Orosa-Duarte A, Mediavilla R, Bayón C. Response to Ms. Babu. *Med Teach*. 2021; 43(12): 1460. Letter. IF: 4.277; Q1
- Orosa-Duarte A, Mediavilla R, Muñoz-Sanjose A, Palao A, Garde J, López-Herrero V, Bravo-Ortiz MF, Bayón C, Rodríguez-Vega B. Mindfulness-based mobile app reduces anxiety and increases self-compassion in healthcare students: A randomised controlled trial. *Med Teach*. 2021; 43(6): 686-93. Article. IF: 4,277; Q1
- Pérez-Sales P, González-Rubio R, Mellor-Marsa B, Martínez-Alés G. Beyond torture checklists: an exploratory study of the reliability and construct validity of the Torturing Environment Scale (TES). *BMC Public Health*. 2021; 21(1): 372. Article. IF: 4.135; Q2

- Ramírez-Cervantes KL, Romero-Pardo V, Pérez-Tovar C, Martínez-Ales G, Quintana-Díaz M. A medicalized hotel as a public health resource for the containment of Covid-19: more than a place for quarantining. *J Public Health-Uk*. 2021; 43(1): 89-97. Article. IF: 5.058; Q1
- Stanley B, Martínez-Alés G, Gratch I, Rizk M, Galfalvy H, Choo TH, Mann JJ. Coping strategies that reduce suicidal ideation: An ecological momentary assessment study. *J Psychiatr Res*. 2021; 133: 32-7. Article. IF: 5.25; Q2
- Torrijos-Zarcelo M, Mediavilla R, Rodríguez-Vega B, Del Río-Diéguez M, López-Álvarez I, Rocamora-González C, Palao-Tarrero A. Mindful self-compassion program for chronic pain patients: A randomized controlled trial. *Eur J Pain*. 2021; 25(4): 930-44. Article. IF: 3.651; Q2

■ Research projects

Bravo Ortiz MF. Impacto de la pandemia de COVID-19 en la salud mental de trabajadores en dispositivos sanitarios. Estudio internacional multicéntrico. The covid-19 heroes study (COV20/00988). ISCIII. 2020-2021.

Management centre: FIBHULP

Bravo Ortiz MF. Intervenciones basadas en mindfulness para mejorar la cognición social en pacientes con un primer episodio psicótico (2021). ISCIII. 2018-2021.

Management centre: FIBHULP

Bravo Ortiz MF. Ambiente y genes en esquizofrenia (S2017/BMD-3740 AGES-CM 2-CM). CM. 2018-2021.

Management centre: FIBHULP

Bravo Ortiz MF. Impacto de lapandemia de COVID-19 en la salud mental de trabajadores en dispositivos sanitarios.

Estudio internacional multicéntrico: the COVID-19 Heroes Study (PI-4099-BRAVO ORTIZ). Sociedad Española de Psiquiatría. 2020-Ongoing.

Management centre: FIBHULP

Bravo Ortiz MF. Improving the Preparedness of Health Systems to Reduce Mental Health and Psychosocial Concerns resulting from the COVID-19 Pandemic (RESPOND). UE. 2020-2023.

Management centre: FIBHULP

Bravo Ortiz MF. Estudio longitudinal de una cohorte representativa: superando la heterogeneidad clínica y biológica en primeros episodios psicóticos (PI20/01113). ISCIII. 2021-2023.

Management centre: FIBHULP

de Dios Perrino C. Regulación epigenética del sistema oxitocina-vasopresina y prosociabilidad en la manía bipolar (PI-1946 GRUPOS EMERGENTES 2014). FIBHULP. 2015-Ongoing.

Management centre: FIBHULP

Rodríguez Vega B. Prevención e intervención en suicidio (SURVIVE): estudio de cohorte y ensayos clínicos controlados anidados de programas de prevención secundaria para intentos de suicidio (PI19/00941). ISCIII. 2020-2022.

Management centre: FIBHULP

Rodríguez Vega B. Comparación de dos estrategias de intervención para el tratamiento de los trastornos depresivos en pacientes oncológicos (). Lundbeck España S. A. 2007-Ongoing.

Management centre: FIBHULP

Rodríguez Vega B. Traducción y validación de los instrumentos reflective functioning questionnaire e inventory of personality organization (). Fundación Vasca de Innovación e Investigación Sanitarias. 2018-Ongoing.

Management centre: FIBHULP

■ Patents and trademarks

Rodríguez Vega B, authors; FIBHULP, assignee. Brand name: En calma; ESM 3.695.071; 2017 December 12.



Rodríguez Vega B, Mediavilla Torres R, Bravo Ortiz MF, Muñoz San José A, Bayón Pérez C, Lahera Forteza G, Palao Tarrero A. authors; FIBHULP, assignee. Brand name: SocialMind; ESM 3.748.550; 2018 December 17.;





3.1.2 Neurology and Cerebrovascular Diseases Group

Publications: 43

Q1: 22

COMPOSITION



■ **Exuperio Díez Tejedor.** Catedrático del Departamento de Neurología. Facultad de Medicina. Universidad Autónoma de Madrid

María José Aguilar-Amat Prior. Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz

María Alonso de Leciñana Cases. Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz

Elisa Alonso López. Contrato Río Hortega. Hospital Universitario La Paz

Francisco Javier Arpa Gutiérrez. Profesor Asociado Facultad de Medicina. Universidad Autónoma de Madrid

María Jesús Bullido Gómez-Heras. Profesor Titular. Departamento de Biología Molecular. Facultad de Ciencias. CBM "Severo Ochoa"

Fernando Carceller Benito. Facultativo Especialista de Área en Neurocirugía. Hospital Universitario La Paz

Elena de Celis Ruiz. Investigadora Predoctoral. Hospital Universitario La Paz

Sebastián Cerdán García-Esteller. Investigador Postdoctoral. Laboratorio de Imagen y Espectroscopia por Resonancia Magnética. IIB "Alberto Sols"

María Delia Chaverri Rada. Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz

Jorge Eduardo Collazos Castro. Jefe de Laboratorio de Reparación Neural y Biomateriales. Hospital Nacional de Parapléjicos de Toledo

Francisco Javier Díaz de Terán Velasco. Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz

Josué Fernández Carnero. Profesor e Investigador Postdoctoral. Centro Superior de Estudios Universitarios La Salle

Andrés Francisco Fernández Prieto. Facultativo Especialista de Área en Radiología. Hospital Universitario La Paz

Mireya Fernández-Fournier Fernández. Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz

Raúl Ferrer Peña. Profesor Titular. Centro Superior de Estudios Universitarios La Salle

Ana Frank García. Jefe de Sección en Servicio de Neurología. Hospital Universitario La Paz. Profesora Titular de Neurología. Facultad de Medicina. Universidad Autónoma de Madrid

Remedios Frutos Martínez. Facultativo Especialista de Área en Radiología. Hospital Universitario La Paz

Blanca Fuentes Gimeno. Jefa de Sección en Neurología. Hospital Universitario La Paz

Rebeca Gallego Ruiz. Investigadora Predoctoral. FIBHULP

María Luisa Gandía González. Facultativa Especialista de Área en Neurocirugía. Hospital Universitario La Paz

Iván García Suárez. Facultativo Especialista de Área en Urgencias. Hospital Universitario San Agustín

Alfonso Gil Martínez. Fisioterapeuta. Hospital Universitario La Paz

María del Carmen Gómez de Frutos. Investigadora Predoctoral. Hospital Universitario La Paz

Ana Cristina Guadaño Ferraz. Científico Titular. Departamento de Fisiopatología Endocrina y del Sistema Nervioso. IIB "Alberto Sols"

María Dolores Gutiérrez Fernández. Investigadora Postdoctoral. Contrato Miguel Servet tipo I. Labora-

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

torio de Neurociencias y Enfermedades Cerebrovasculares. Hospital Universitario La Paz

María Hernández Barral. Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz

David Hernández Herrero. Facultativo Especialista de Área en Rehabilitación y Medicina Física. Hospital Universitario La Paz

Vicente Iváñez Mora. Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz

Roy La Touche Arbizu. Profesor Titular. Centro Superior de Estudios Universitarios La Salle

Laura Lacruz Ballester. Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz

Manuel Lara Lara. Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz

Fernando Laso García. Investigador Predoctoral. Hospital Universitario La Paz

Jesús María López Arrieta. Jefe de Sección de Geriátrica. Hospital de Cantoblanco – Hospital Universitario La Paz. Profesor Asociado de Prácticas. Facultad de Psicología. Universidad Autónoma de Madrid

María Pilar López Larrubia. Científica Titular. CSIC. IBB “Alberto Sols”

David López Martín. Investigador Predoctoral. FIBHULP

Ibai López de Uralde Villanueva. Investigador Predoctoral. Centro Superior de Estudios Universitarios La Salle

Begoña Marín Aguilera. Facultativo Especialista de Área en Radiología. Hospital Universitario La Paz

Juan Andrés Martín Gonzalo. Profesor Titular. Escuela Universitaria de Fisioterapia de la ONCE

Ángel Martín Montes. Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz

Arturo Martínez Arroyo. Técnico de Laboratorio. Hospital Universitario La Paz

Mercedes Martínez Moreno. Facultativo Especialista de Área en Medicina Física y Rehabilitación. Hospital Universitario La Paz

Susana Moraleda Pérez. Jefe de Sección de Medicina Física y Rehabilitación. Hospital Universitario La Paz

Pedro Navía Álvarez. Facultativo Especialista de Área en Radiología. Hospital Universitario La Paz

Pilar Negrodo Madrigal. Profesor Interino. Departamento de Anatomía, Histología y Neurociencia. Universidad Autónoma de Madrid

Susana Noval Martín. Facultativo Especialista de Área en Oftalmología. Hospital Universitario La Paz

Jesús Oliván Palacios. Facultativo Especialista de Área en Neurofisiología Clínica. Hospital Carlos III - Hospital Universitario La Paz

Laura Otero Ortega. Investigadora Postdoctoral. Contrato Juan de la Cierva. Hospital Universitario La Paz

Joaquín Pardo Montero. Profesor Titular. Centro Superior de Estudios Universitarios La Salle

Alba París Alemany. Profesora. Investigadora Predoctoral. Centro Superior de Estudios Universitarios La Salle

Samuel Ignacio Pascual Pascual. Jefe de Sección de Neurología Pediátrica. Hospital Universitario La Paz. Profesor Asociado. Facultad de Medicina. Universidad Autónoma de Madrid

José Francisco Paz Solís. Facultativo Especialista de Área en Neurocirugía. Hospital Universitario La Paz

Dolores Piniella Alcalde. Investigadora Postdoctoral. FIBHULP

Javier Pozo Novoa. Investigador Predoctoral. FIBHULP

Inmaculada Puertas Muñoz. Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz

Estrella Rausell Tamayo. Catedrática. Departamento de Anatomía, Histología y Neurociencias. Facultad de Medicina. Universidad Autónoma de Madrid

Ricardo Jaime Rigual Bobillo. Facultativo Especialista de Área de Neurología. Hospital Universitario La Paz

José María Roda Frade. Jefe de Servicio de Neurocirugía. Hospital Universitario La Paz

Irene Rodríguez Andonaegui. Profesor Ayudante. Escuela Universitaria de Fisioterapia de la ONCE

Jorge Rodríguez de Pardo de Donlebún. Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz

Francisco Javier Rodríguez de Rivera Garrido. Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz

Ana Rodríguez Sanz. Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz

Aranzazu Royo Orejas. Jefe de Sección de Radiología. Hospital Universitario La Paz

Gerardo Ruiz Ares. Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz

María Teresa Salas Campos. Técnico Superior Psicología. Servicio de Neurología. Hospital Universitario La Paz

Susana Santiago Pérez. Facultativo Especialista de Área en Neurofisiología. Hospital Universitario La Paz

Soledad Serrano López. Facultativa Especialista de Área en Neurología. Hospital Universitario La Paz

Antonio Tallón Barranco. Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz

Gabriel Torres Iglesias. Médico Adjunto en el Servicio de Neurología. FIBHULP

Gema Torrijos Barbero. Especialista en Neuropsicología. Unidad de Memoria y Demencias. Hospital de Cantoblanco-Hospital Universitario La Paz

Arturo Ugalde Canitrot. Facultativo Especialista de Área en Neurofisiología Clínica. Hospital Universitario La Paz

Francisco Vivancos Matellano. Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz

STRATEGIC OBJECTIVE

■ CEREBROVASCULAR

- Development of translational research studies (both animal and clinical studies) in cerebrovascular diseases, with the objectives of increasing the understanding of the

pathogenesis of both cerebral infarction (with cortical and subcortical affectation) and cerebral hemorrhage. To analyze the influence of hyperglycemia, diabetes and glycemic variability in the evolution of stroke. To identify prognostic biomarkers and therapeutic targets mainly aimed at the promotion of brain protection and repair, with a special interest on the development of cell therapy as well as in trophic fac-



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

tors, extracellular vesicles and remyelinating drugs. To analyze the contribution of comorbidities in the mechanisms that occur after stroke, and the effect of therapies (protective, reparative .) in animal models of stroke associated with hypertension and hyperglycemia.

- Clinical trials of cell therapy in acute cerebral infarction (clinical trial AMASCIS and European Consortium RESSTORE-H2020).
- Development of innovative strategies in the diagnosis and treatment of ischemic stroke, through the development of an independent operator-ultrasound device for brain visualization and for enhancement by ultrasound of drug therapies (BDNF, exosomes) in the ischemic area.
- Evaluation of the benefit of the implementation of prehospital clinical scales able to identify of patients of cerebral artery occlusion susceptible to mechanical thrombectomy in order to shorten treatment delay and improve the prognosis of patients.
- Study of the clinical (neurological and neuropsychological) and anthropological factors influencing functional recovery and reintegration of stroke patients as well as the compliance with the recommendations for secondary stroke prevention.
- To analyze the recovery of post-stroke aphasia through a dubbing tool for television series and the development of a communication app. To evaluate the use of virtual reality in the recovery of motor and cognitive sequelae post-stroke, as well as the computational analysis of movement.
- To evaluate the effectiveness of keeping oral or parenteral anticoagulation in the acute phase of cardioembolic ischemic stroke.
- To discover factors anticipating the development of atrial fibrillation through EKG and echocardiographic abnormalities in cryptogenic stroke.
- Impact of COVID-19 pandemic in stroke care and in stroke outcomes.

■ HEADACHES AND NEUROPATHIC PAIN

- Analysis of the expression of the phenomenon central painful awareness in different primary and secondary headaches.
- Central Sensitization and pain perception in patients with cluster headache.
- Features and outcome of migraine in patients with fibromyalgia.
- Response to OnabotulinumtoxinA in High Frequency Episodic Migraine.
- Refractory migraine database.
- Short Term Prophylaxis of Cluster Headache: A Comparative Study.
- Study of neuropathic and chronic craniofacial pain.
- Photophobia management using greater occipital nerve blocks in migraine patients.
- CGRP-pathway drugs in patients with refractory migraine and medication overuse headache.
- CGRP-pathway drugs in patients with refractory migraine and autoimmune diseases.
- CGRP-pathway drugs in elderly patients with refractory migraine.
- Multicentric collaboration in post-COVID related headache investigation.

- Features and outcome of chronic refractory cluster headache treated with greater occipital nerve stimulation.

■ NEURODEGENERATIVE DISEASES

Alzheimer's disease

- Study of the lysosomal pathway involvement in a model of neurodegeneration and cholesterol dysregulation in Alzheimer's disease.
- Study of genetic polymorphism related with PSP in the context of a multicentre Genome Wide Association study (GWAS).

Parkinson's disease

- Tremor as a negative predictive factor in developing dementia associated with Parkinson's disease.
- Evaluation of the benefits and risks of continuous infusion of intraduodenal levodopa in idiopathic Parkinson's disease.

Hereditary ataxias

- Assessment of therapeutic response to Frenkel training exercises enhanced by Wii game console in patients with cerebellar ataxia.
- Participation in the Registry of the European Consortium EFACTS (European Friedreich's Ataxia Consortium for Translational Studies) aimed at improve the knowledge of the epigenetic mechanisms related to silencing the expression of frataxin and the pathogenesis of the disease, identification of biomarkers and genes modifying the clinical expression of the disease, development of new therapies as well as cellular and animal models for the study of Friedreich's Ataxia.

■ NEUROIMMUNOLOGY/NEUROINFLAMMATION

Multiple sclerosis

- Analysis of extracellular vesicles as biomarkers in multiple sclerosis patients.
- Analysis of molecular and neuroimaging biomarkers of brain damage and repair in Multiple Sclerosis.
- Search for biomarkers associated with damage, progression and response to treatment in Multiple Sclerosis.
- Development of an automatic tool to assess disability progression in Multiple Sclerosis patients.
- Identification of cognitive factors and depressive symptoms that may contribute to information processing speed in Multiple Sclerosis patients.

Autoimmune encephalitis and other autoimmune neurological diseases

- Neurological syndromes associated to antiGAD antibodies.
- Identification of biomarkers in Paraneoplastic syndromes and other neurological diseases associated to antibodies.



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Infectious diseases

- Study of neurological symptoms after COVID19 recovery in patients refer to specific consultation.
- Analysis of brain volumetry in patients with cognitive symptoms after COVID19.
- COVID-19 associated encephalopathy. Risk factors and outcomes.

■ **AUTONOMIC NERVOUS SYSTEM**

- Evaluation of the Autonomic Nervous System in movement disorders.
- Evaluation of the Autonomic Nervous System in focal autonomic neuropathies and in Fabry disease.

■ **NEUROMUSCULAR DISEASES**

- Observational study of the clinical course of patients with Charcot-Marie-Tooth disease. Identification of prognostic factors.
- Efficacy of evaluation of Eslicarbazepine acetate in neuropathic pain in patients with peripheral neuropathies.
- Develop a hand thermography tool for the diagnosis of fine fiber neuropathy.

Amyotrophic Lateral Sclerosis (ALS)

- Analysis of the different profiles of cognitive impairment in ALS patients. Adaptation and validation of cognitive ALS specific scales for Spanish patients .Study of cognitive potentials for identification of possible specific EEG endophenotypes in ALS patients.
- Study of biomarkers in ALS and other motor neuron diseases. Genetic,metabolomic and proteomic profiling combined with clinical parameters .
- Participation In Project MinE: International program analyzing the genoma of 15000 patients and controls by the same genotyping platform.
- Functional study of Autonomic Nervous System in Amyotrophic Lateral Sclerosis. Identification of differential patterns of the disease presentation and their impact on clinical outcome.

■ **SLEEP**

- Development and evaluation of intervention protocols in childhood insomnia treatment.
- Analysis of sleep microstructure in newborns with Prader Willi Syndrome.
- Study on the efficacy of child insomnia treatment with oral iron supplements against placebo.

■ **EPILEPSY**

- Analysis of factors influencing the recurrence of seizures, tolerance and adherences to drugs, during the first monotherapy in patients with epilepsy.

- Analysis of neuropsychological disorders in the primary generalized epilepsy.
- Obstructive sleep apnea in Epilepsy.
- Impact of perampanel in patients with epileptic encephalopathies. A multicentric study.
- Approach to refractory status epilepticus. Analysis of the different anesthetic agents commonly used in an intensive care unit
- Epilepsy in the elderly patient: peculiarities and treatment alternatives, with a special focus in refractory cases.

■ **DIGITAL TECHNOLOGIES APPLIED TO NEUROLOGICAL DISEASES**

- Objective assessment of motor or other functional deficits (stroke, movement disorders, multiple sclerosis)
- Environmental enrichment to promote early stroke recovery
- Virtual reality in promoting cognitive and motor recovery
- New applications of ultrasound for diagnosis and research in neurological diseases

■ **NEUROSTIMULATION**

- Neurostimulation in brain and spinal cord injuries

■ **BRAIN DEVELOPMENT DISORDERS**

- Study and functional classification of the gait of pediatric patients with cerebral palsy.
- Study and functional classification of the gait of patients with familial spastic paraparesis.
- Gait analysis as a tool for the differential diagnosis between child cerebral palsy and PEF in paediatric patients.

RESEARCH LINES

- Cerebrovascular diseases.
- Headache and neuropathic pain.
- Neurodegenerative diseases: cognitive disorders, movement disorders and spinocerebellar ataxias.
- Neuroimmunology. Multiple sclerosis.
- Neuromuscular diseases. Motor neuron diseases Amyotrophic lateral sclerosis.
- Digital Technologies applied to neurological diseases
- Neurostimulation in brain and spinal cord injuries
- Developmental disorders and neurological maturation (TRADESMA).

RESEARCH ACTIVITY

■ Doctoral theses

Alonso López E. Vesículas extracelulares y Micro-ARN como biomarcadores de daño, reparación cerebral y recuperación en el infarto cerebral agudo[dissertation]. Madrid: UAM: 2021(24/06/2021).

Directors: Gutiérrez Fernández M, Fuentes Gimeno B.

Cuenca Martínez F. Evaluación y análisis comparativo de los efectos de los métodos de representación de movimiento en el proceso de aprendizaje motor[dissertation]. Madrid: UAM: 2021(17/05/2021).

Directors: La Touche Arbizu R, León Hernández JV.

Díaz de Terán Velasco FJ. Análisis del fenómeno de sensibilización central y papel de la estimulación del nervio occipital en la cefalea en racimos[dissertation]. Madrid: UAM: 2021(01/12/2021).

Directors: Gil-Martínez A, Díez-Tejedor E.

Diekhorst LA. Allogenic adipose mesenchymal stem cell therapy in ischemic stroke with hypertension and hyperglycemia. Experimental animal models[dissertation]. Madrid: UAM: 2021(18/05/2021).

Directors: Díez Tejedor E, Gutiérrez Fernández M.

Pesántez Ríos MG. Efectividad del canabidiol en el tratamiento de las epilepsias refractarias[dissertation]. Madrid: UAM: 2021(27/10/2021).

Director: Pascual Pascual SI.

Rodríguez Pardo de Donlebún J. Ictus isquémico por oclusión de gran vaso. Utilidad de una escala para la selección prehospitalaria de pacientes susceptibles de trombectomía mecánica: Madrid-DIRECT[dissertation]. Madrid: UAM: 2021(20/05/2021).

Directors: Fuentes Gimeno B, Díez Tejedor E.

Suso Martí L. Efectos hipalgésicos de los métodos de representación de movimiento en el dolor musculoesquelético[dissertation]. Madrid: UAM: 2021(01/06/2021).

Director: La Touche Arbizu R.

■ Publications

- Abboud H, Probasco J, Irani SR, Ances B, Benavides DR, Bradshaw M, Christo PP, Dale RC, Fernández-Fournier M, Flanagan EP, Gadoth A, George P, Grebenciucova E, Jammoul A, Lee ST, Li YB, Matiello M, Morse AM, Rae-Grant A, Rojas G, Rossman I, Schmitt S, Venkatesan A, Vernino S, Pittock SJ, Titulaer M. Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management. *J Neurol Neurosurg Ps.* 2021; 92(8): 897-907. Review. IF: 13.654; D1
- Abboud H, Probasco JC, Irani S, Ances B, Benavides DR, Bradshaw M, Christo PP, Dale RC, Fernández-Fournier M, Flanagan EP, Gadoth A, George P, Grebenciucova E, Jammoul A, Lee ST, Li YB, Matiello M, Morse AM, Rae-Grant A, Rojas G, Rossman I, Schmitt S, Venkatesan A, Vernino S, Pittock SJ, Titulaer MJ. Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management. *J Neurol Neurosurg Ps.* 2021; 92(7): 757-68. Review. IF: 13.654; D1
- de Antonio LAR, Castañón IG, Prior MJAA, Puertas I, Suárez IG, Guevara CO. Non-inflammatory causes of emergency consultation in patients with multiple sclerosis. *Neurologia.* 2021; 36(6): 403-11. Article. IF: 5.486; Q1

- de Celis-Ruiz E, Fuentes B, Moniche F, Montaner J, Borobia AM, Gutiérrez-Fernández M, Díez-Tejedor E. Allogenic adipose tissue-derived mesenchymal stem cells in ischaemic stroke (AMASCIS-02): a phase IIb, multicentre, double-blind, placebo-controlled clinical trial protocol. *BMJ Open.* 2021; 11(8): e051790. Article. IF: 3.006; Q2
- de Rojas I, Hernández I, Montreal L, Quintela I, Calero M, Royo JL, Vilas RH, González-Pérez A, Franco-Macias E, Macías J, Menéndez-González M, Frank-García A, Díez-Fairen M, Lage C, García-Madróna S, Aguilera N, García-González P, Puerta R, Sotolongo-Grau O, Alonso-Lana S, Rabano A, Pastor AA, Pastor AB, Corma-Gómez A, Montes AM, Rodríguez CM, Buiza-Rueda D, Perinan MT, Rodríguez-Rodríguez E, Álvarez I, Allende IR, Pineda JAA, Sánchez-Arjona MB, Fernández-Fuertes M, Mendoza S, del Ser T, García-Ribas G, Sánchez-Juan P, Pastor P, Bullido MJ, Álvarez V, Real LMM, Mir P, Pinol-Ripoll G, García-Alberca JM, Medina M, Orellana A, Butler CRR, Marquie M, Sáez ME, Carracedo A, Tarraga L, Boada M, Ruiz A. Genomic characterization of host factors related to SARS-CoV-2 infection in people with dementia and control populations: The GR@ACE/DEGESCO Study. *J Pers Med.* 2021; 11(12): 1318. Article. IF: 3.508; Q2
- de Rojas I, Moreno-Grau S, Tesi N, Grenier-Boley B, Andrade V, Jansen IE, Pedersen NL, Stringa N, Zettergren A, Hernández I, Montreal L, Antunez C, Antonell A, Tankard RM, Bis JC, Sims R, Bellenguez C, Quintela I, González-Pérez A, Calero M, Franco-Macias E, Macías J, Blesa R, Cervera-Carles L, Menéndez-González M, Frank-García A, Royo JL, Moreno F, Vilas RH, Baquero M, Díez-Fairen M, Lage C, Squassina A, de Mendonca A, Pastor AA, Kok AAL, Meggy A, Pastor AB, Espinosa A, Corma-Gómez A, Martín Montes A, Sanabria A, DeStefano AL, Schneider A, Haapasalo A, Stahlbom AK, Tybjaerg-Hansen A, Hartmann AM, Spottke A, Corbaton-Anchuelo A, Rongve A, Borroni B,

- Arosio B, Nacmias B, Nordestgaard BG, Kunkle BW, Charbonnier C, Abdelnour C, Masullo C, Martínez Rodríguez C, Muñoz-Fernández C, Dufouil C, Graff C, Ferreira CB, Chillotti C, Reynolds CA, Fenoglio C, Van Broeckhoven C, Clark C, Pisanu C, Satizabal CL, Holmes C, Buiza-Rueda D, Aarsland D, Rujescu D, Alcolea D, Galimberti D, Wallon D, Seripa D, Grunblatt E, Dardiotis E, Duzel E, Scarpini E, Conti E, Rubino E, Gelpi E, Rodríguez-Rodríguez E, Duron E, Boerwinkle E, Ferri E, Tagliavini F, Kucukali F, Pasquier F, Sánchez-García F, Mangialasche F, Jessen F, Nicolas G, Selbaek G, Ortega G, Chene G, Hadjigeorgiou G, Rossi G, Spalletta G, Giaccone G, Grande G, Binetti G, Papanberg G, Hampel H, Bailly H, Zetterberg H, Soininen H, Karlsson IK, Álvarez I, Appollonio I, Giegling I, Skoog I, Saltvedt I, Rainero I, Allende IR, Hort J, Diehl-Schmid J, Van Dongen J, Vidal JS, Lehtisalo J, Wiltfang J, Thomassen JQ, Kornhuber J, Haines JL, Vogelgsang J, Pineda JA, Fortea J, Popp J, Deckert J, Buerger K, Morgan K, Fließbach K, Slegers K, Molina-Porcel L, Kilander L, Weinhold L, Farrer LA, Wang LS, Kleiheidam L, Farotti L, Parnetti L, Tremolizzo L, Hausner L, Benussi L, Froelich L, Ikram MA, Deniz-Naranjo MC, Tsolaki M, Rosende-Roca M, Lowenmark M, Hulsman M, Spallazzi M, Pericak-Vance MA, Esiri M, Sánchez-Arjona MB, Dalmaso MC, Martínez-Larrad MT, Arcaio M, Nothen MM, Fernández-Fuertes M, Dichgans M, Ingelsson M, Herrmann MJ, Scherer M, Vyhnalek M, Kosmidis MH, Yannakouli M, Schmid M, Ewers M, Heneka MT, Wagner M, Scamosci M, Kivipelto M, Hiltunen M, Zulaica M, Alegret M, Fornage M, Roberto N, van Schoor NM, Seidu NM, Banaj N, Armstrong NJ, Scarmeas N, Scherbaum N, Goldhardt O, Hanon O, Peters O, Skrobot OA, Quenez O, Lerch O, Bossu P, Caffarra P, Rossi PD, Sakka P, Hoffmann P, Holmans PA, Fischer P, Riederer P, Yang Q, Mars-hall R, Kalaria RN, Mayeux R, Vandenbergh R, Cecchetti R, Ghidoni R, Frikke-Schmidt R, Sorbi S, Hagg S, Engelborghs S, Helisalmi S, Sando SB, Kern S, Archetti S, Boschi S, Fostinelli S, Gil S, Mendoza S, Mead S, Ciccone S, Djurovic S, Heilmann-Heimbach S, Riedel-Heller S, Kuulasmaa T, del Ser T, Lebouvier T, Polak T, Ngandu T, Grimmer T, Bessi V, Escott-Price V, Giedraitis

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

V, Deramecourt V, Maier W, Jian XQ, Pijnenburg YAL, Smith AD, Abdelnour C, Adames-Gómez AD, Macleod C, Jansen IE, Kehoe PG, García-Ribas G, Sánchez-Juan P, Pastor P, Pérez-Tur J, Pinol-Ripoll G, de Munain AL, García-Alberca JM, Bullido MJ, Álvarez V, Lleo A, Real LM, Mir P, Medina M, Scheltens P, Holstege H, Marquie M, Saez ME, Carracedo A, Amouyel P, Schellenberg GD, Williams J, Seshadri S, van Duijn CM, Mather KA, Sánchez-Valle R, Serrano-Rios M, Orellana A, Tarraga L, Blennow K, Huisman M, Andreassen OA, Posthuma D, Clarimon J, Boada M, van der Flier WM, Ramirez A, Lambert JC, van der Lee SJ, Ruiz A. Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. *Nat Commun*. 2021; 12(1): 3417. Article. IF: 17.694; D1

• Diaz-de-Teran J, Membrilla JA, Paz-Solís J, de Lorenzo I, Roa J, Lara-Lara M, Gil-Martínez A, Díez-Tejedor E. Occipital nerve stimulation for pain modulation in drug-resistant chronic cluster headache. *Brain Sci*. 2021; 11(2): 236. Article. IF: 3.333; Q3

• Farre-Alins V, Palomino-Antolín A, Narros-Fernández P, López-Rodríguez AB, Decouty-Pérez C, Muñoz-Montero A, Zamorano-Fernández J, Mansilla-Fernández B, Giner-García J, García-Feijoo P, Sáez-Alegre M, Palpan-Flores AJ, Roda-Frade JM, Carabias CS, Rosa JM, Civantos-Martín B, Yus-Teruel S, Gandía L, Lagares A, Hernández-García BJ, Egea J. Serum amyloid A1/toll-like receptor-4 axis, an important link between inflammation and outcome of TBI patients. *Biomedicines*. 2021; 9(6): 599. Article. IF: 4.757; Q2

• Fernández-Alcalde C, Nieves-Moreno M, Noval S, Peralta JM, Montano VEE, del Pozo A, Santos-Simarro F, Vallespin E. Molecular and genetic mechanism of non-syndromic congenital cataracts. Mutation screening in spanish families. *Genes (Basel)*. 2021; 12(4): 580. Article. IF: 4.141; Q2

• Fuentes B, Amaro S, de Leciñana MA, Arenillas JF, Ayo-Martín O, Castellanos M, Freijo M, García-Pastor A, Gomis M, Choco MG, López-Cancio E, Sánchez PM, Morales A, Palacio-Portilla EJ, Rodríguez-Yáñez M, Roquer J, Segura T, Serena J, Vivancos-Mora J. Stroke prevention in patients with type 2 diabetes or prediabetes. Recommendations from the Cerebrovascular Diseases Study Group, Spanish Society of Neu-

rology. *Neurologia*. 2021; 36(4): 305-23. Article. IF: 5.486; Q1

• Fuentes B, de Leciñana MA, García-Madrona S, Díaz-Otero F, Aguirre C, Calleja P, Egido JA, Carneado-Ruiz J, Ruiz-Ares G, Rodríguez-Pardo J, Rodríguez-López A, Ximenez-Carrillo A, de Felipe A, Ostos F, González-Ortega G, Simal P, Escalonilla CIG, Gómez-Porro-Sánchez P, Desanvicente Z, Reig G, Gil-Núñez A, Masjuan J, Díez-Tejedor E. Stroke acute management and outcomes during the COVID-19 outbreak: a cohort study from the Madrid stroke network. *Stroke*. 2021; 52(2): 552-62. Article. IF: 10.17; D1

• Fuentes B, de Leciñana MA, Rigual R, García-Madrona S, Díaz-Otero F, Aguirre C, Calleja P, Egido-Herrero JA, Carneado-Ruiz J, Ruiz-Ares G, Rodríguez-Pardo J, Rodríguez-López A, Ximenez-Carrillo A, de Felipe A, Ostos F, González-Ortega G, Simal P, Escalonilla CGI, Gómez-Porro-Sánchez P, Cabal-Paz B, Reig G, Gil-Núñez A, Masjuan J, Tejedor ED. Fewer COVID-19-associated strokes and reduced severity during the second COVID-19 wave: The Madrid Stroke Network. *Eur J Neurol*. 2021; 28(12): 4078-89. Article. IF: 6.288; Q1

• Fuentes B, Ntaios G, Putaala J. Editorial: Current challenges in cardioembolic stroke. *Front Neurol*. 2021; 12: 688371. Editorial Material. IF: 4.086; Q2

• García Feijoo P, Carceller Benito FE, Kalra N, Paucar Cardenas G, Saez Alegre M, Vivancos Sánchez C, Rodríguez Dominguez V, Roda Frade JM. Seven microaneurysms: description of an experimental rodent model for neurovascular training. *Turk Neurosurg*. 2021; 31(2): 217-22. Article. IF: 0.972; Q4

• Gómez-de Frutos MC, García-Suárez I, Laso-García F, Diekhorst L, Otero-Ortega L, de Leciñana MA, Fuentes B, Gutiérrez-Fernández M, Díez-Tejedor E, Ruiz-Ares G. B-Mode ultrasound, a reliable tool for monitoring experimental intracerebral hemorrhage. *Front Neurol*. 2021; 12: 771402. Article. IF: 4.086; Q2

• Gómez-de Frutos MC, Laso-García F, García-Suárez I, Diekhorst L, Otero-Ortega L, de Leciñana MA, Fuentes B, Piniella D, Ruiz-Ares G, Díez-Tejedor E, Gutiérrez-Fernández M. The Role of ultrasound as a diagnostic and therapeutic tool in experimental animal models of stroke: A review. *Biomedicines*. 2021; 9(11): 1609. Review. IF: 4.757; Q2

• Gutiérrez-Fernández M, de la Cuesta F, Tallón A, Cuesta I, Fernández-Fournier M, Laso-García F, Gómez-de Frutos MC, Díez-Tejedor E, Otero-Ortega L. Potential roles of extracellular vesicles as biomarkers and a novel treatment approach in multiple sclerosis. *Int J Mol Sci*. 2021; 22(16): 9011. Review. IF: 6.208; Q1

• Haro-Martínez A, Pérez-Araujo CM, Sánchez-Caro JM, Fuentes B, Díez-Tejedor E. Melodic intonation therapy for post-stroke non-fluent aphasia: Systematic review and meta-analysis. *Front Neurol*. 2021; 12: 700115. Review. IF: 4.086; Q2

• Kristen H, Sastre I, Aljama S, Fuentes M, Recuero M, Frank-García A, Martín A, Sánchez-Juan P, Lage C, Bullido MJ, Aldudo J. LAMP2 deficiency attenuates the neurodegeneration markers induced by HSV-1 infection. *Neurochem Int*. 2021; 146: 105032. Article. IF: 4.297; Q2

• Lastres-Becker I, Porras G, Arribas-Blázquez M, Maestro I, Borrego-Hernández D, Boya P, Cerdán S, García-Redondo A, Martínez A, Martín-Requero A. Molecular alterations in sporadic and SOD1-ALS immortalized lymphocytes: Towards a personalized therapy. *Int J Mol Sci*. 2021; 22(6): 3007. Article. IF: 6.208; Q1

• Llorente P, Mejias V, Sastre I, Recuero M, Aldudo J, Bullido MJ. Matrix metalloproteinase 14 regulates HSV-1 infection in neuroblastoma cells. *Antivir Res*. 2021; 192: 105116. Article. IF: 10.103; Q1

• Mantegazza R, Wolfe GI, Muppidi S, Wiendl H, Fujita KP, O'Brien FL, Booth HDE, Howard JF. Post-intervention status in patients with refractory myasthenia gravis treated with eculizumab during REGAIN and its open-label extension. *Neurology*. 2021; 96(4): E610-18. Article. IF: 11.8; D1

• Miranda-Barrios J, Bravo-Queipo-de-Llano B, Baquero-Artigao F, Granados-Fernández M, Noval S, Rabanal I, Méndez-Echevarría A, del Rosal T, Sainz T, Aracil J, Calvo C. Preseptal versus orbital cellulitis in children: An observational study. *Pediatr Infect Dis J*. 2021; 40(11): 969-74. Article. IF: 3.806; Q1

• Miranda-Herrero MC, Vázquez-López M, Barredo-Valderrama E, de Castro PD, Chacón-Pascual A, Pascual-Pascual SI. Visuospatial functions in preterm schoolchildren without cognitive delay: Using Pascual's Graphomotor test as a screening method. *Early Hum Dev*.

2021; 161: 105454. Article. IF: 2.699; Q2

• Mora JS, Bradley WG, Chaverri D, Hernández-Barral M, Mascias J, Gámez J, Gargiulo-Monachelli GM, Moussy A, Mansfield CD, Hermine O, Ludolph AC. Long-term survival analysis of masitinib in amyotrophic lateral sclerosis. *Ther Adv Neurol Disord*. 2021; 14: 17562864211030400. Article. IF: 6.43; Q1

• Moreno-Grau S, Fernández MV, de Rojas I, García-González P, Fernández I, Farias F, Budde JP, Quintela I, Madrid L, González-Pérez A, Montreal L, Alarcon-Martín E, Alegret M, Maronas O, Pineda JA, Macías J, Marquie M, Valero S, Benaque A, Clarimon J, Bullido MJ, García-Ribas G, Pastor P, Sánchez-Juan P, Álvarez V, Pinol-Ripoll G, García-Alberca JM, Royo JL, Franco-Macias E, Mir P, Calero M, Medina M, Rabano A, Avila J, Antunex C, Real LM, Orellana A, Carracedo A, Saez ME, Tarraga L, Boada M, Cruchaga C, Ruiz A. Long runs of homozygosity are associated with Alzheimer's disease. *Transl Psychiat*. 2021; 11(1): 142. Article. IF: 7.989; Q1

• Natera-de Benito D, Aguilera-Albesa S, Costa-Comellas L, García-Romero M, Miranda-Herrero MC, Olives JR, García-Campos O, del Val EM, García MJM, Martínez IM, Cancho-Candela R, Fernández-García MA, Pascual-Pascual SI, Gómez-Andres D, Nascimento A. COVID-19 in children with neuromuscular disorders. *J Neurol*. 2021; 268(9): 3081-5. Article. IF: 6.682; Q1

• Nieves-Moreno M, Noval S, Peralta J, Palomares-Bralo M, del Pozo A, García-Miñaur S, Santos-Simarro F, Vallespin E. Expanding the phenotypic spectrum of PAX6 mutations: From congenital cataracts to nystagmus. *Genes (Basel)*. 2021; 12(5): 707. Article. IF: 4.141; Q2

• Nogueira RG, Abdalkader M, Qureshi MM, Frankel MR, Mansour OY, Yamagami H, Qiu ZM, Farhoudi M, Siegler JE, Yaghi S, Raz E, Sakai N, Ohara N, Piotin M, Mechtouff L, Eker O, Chalumeau V, Kleinig TJ, Pop R, Liu JM, Winters HS, Shang XJ, Vasquez AR, Blasco J, Arenillas JF, Martínez-Galdamez M, Brehm A, Psychogios MN, Lylyk P, Haussen DC, Al-Bayati AR, Mohamadden MH, Fonseca L, Silva ML, Montalverne F, Renieri L, Mangiafico S, Fischer U, Gralla J, Frei D, Chugh C, Mehta BP, Nagel S, Mohlenbruch M, Ortega-Gutiérrez S, Farooqui M, Hassan AE, Taylor A, Lapergue B, Consoli A, Campbell BCV, Sharma M, Walker M, Van Horn N, Fiehler J, Nguyen HT, Nguyen QT, Watanabe

1 Introduction

2 Executive Summary


3 Information Groups by Area

4 Associated Clinicians

D, Zhang H, Le HV, Nguyen VQ, Shah R, Devlin T, Khandelwal P, Linfante I, Izzath W, Lavados PM, Olavarria VV, Silva GS, Sousa AVD, Kirmani J, Bendzus M, Amano T, Yamamoto R, Doijiri R, Tokuda N, Yamada T, Terasaki T, Yazawa Y, Morris JG, Griffin E, Thornton J, Lavoie P, Matouk C, Hill MD, Demchuk AM, Killer-Oberpfalzer M, Nahab F, Altschul D, Ramos-Pachon A, de la Ossa NP, Kikano R, Boisseau W, Walker G, Cordina SM, Puri A, Kuhn AL, Gandhi D, Ramakrishnan P, Novakovic-White R, Chebl A, Kargiotis O, Czap A, Zha A, Masoud HE, López C, Ozretic D, Al-Mufti F, Zie WJ, Duan ZH, Yuan ZZ, Huang WG, Hao YG, Luo J, Kalousek V, Bourcier R, Guile R, Hetts S, Al-Jehani HM, AlHazzani A, Sadeghi-Hokmabadi E, Teleb M, Payne J, Lee JS, Hong JM, Sohn SI, Hwang YH, Shin DH, Roh HG, Edgell R, Khatri R, Smith A, Malik A, Liebeskind D, Herial N, Jabbour P, Magalhaes P, Ozdemir AO, Aykac O, Uwatoko T, Dembo T, Shimizu H, Sugiura Y, Miyashita F, Fukuda H, Miyake K, Shimbo J, Sugimura Y, Beer-Furlan A, Joshi K, Catanese L, Abud DG, Neto OP, Mehrpour M, Al Hashmi A, Saqqur M, Mostafa A, Fifi JT, Hussain S, John S, Gupta R, Sivan-Hoffmann R, Reznik A, Sani AF, Geyik S, Akil ECR, Churojana A, Ghoreishi A, Saadatnia M, Sharifpour E, Ma A, Faulder K, Wu T, Leung L, Malek A, Voetsch B, Wakhloo A, Rivera R, Iman DMB, Pikula A, Lioutas VA, Thomalla G, Birnbaum L, Machi P, Bernava G, McDermott M, Kleindorfer D, Wong K, Patterson MS, Fiorot JA, Huded V, Mack W, Tenser M, Eskey C, Multani S, Kelly M, Janardhan V, Cornett O, Singh V, Murayama Y, Mokin M, Yang PF, Zhang XX, Yin CG, Han HX, Peng Y, Chen WH, Crosa R, Frudit ME, Pandian JD, Kulkarni A, Yagita Y, Takenobu Y, Matsumaru Y, Yamada S, Kono R, Kanamaru T, Yamazaki H, Sakaguchi M, Todo K, Yamamoto N, Sonoda K, Yoshida T, Hashimoto H, Nakahara I, Cora E, Volders D, Ducroux C, Shoamanesh A, Ospel J, Kaliaev A, Ahmed S, Rashid U, Rebello LC, Pereira VM, Fahed R, Chen M, Sheth SA, Palaodimou L, Tsvigoulis G, Chandra R, Koefman F, Leung T, Khosravani H, Dharmadhikari S, Frisullo G, Calabresi P, Tsiskaridze A, Lobjanidze N, Grigoryan M, Czlonkowska A, de Sousa DA, Demeestere J, Liang C, Sangha N, Lutsep HL, Ayo-Martin O, Cruz-Culebras A, Tran AD, Young CY, Cordonnier C, Caparros F, De Leciñana MA, Fuentes B, Yavagal D, Jovin T, Spelle L, Moret J, Khatri P, Zaidat O, Raymond J, Martins S, Ngu-

yen T. Global impact of COVID-19 on stroke care. *Int J Stroke*. 2021; 16(5): 573-84. Article. IF: 6.948; Q1

- Otero-Ortega L, Alonso-López E, Pérez-Mato M, Laso-García F, Gómez-de Frutos MC, Diekhorst L, García-Bermejo ML, Conde-Moreno E, Fuentes B, de Leciñana MA, Armada E, Buiza-Palomino L, Díez-Tejedor E, Gutiérrez-Fernández M. Similarities and differences in extracellular vesicle profiles between ischaemic stroke and Mmocardial infarction. *Biomedicines*. 2021 ;9(1): 8. Article. IF: 4.757; Q2
- Otero-Ortega L, Alonso-López E, Pérez-Mato M, Laso-García F, Gómez-de Frutos MC, Diekhorst L, García-Bermejo ML, Conde-Moreno E, Fuentes B, de Leciñana MA, Bravo SB, Díez-Tejedor E, Gutiérrez-Fernández M. Circulating extracellular vesicle proteins and microRNA profiles in subcortical and cortical-subcortical ischaemic stroke. *Biomedicines*. 2021; 9(7): 786. Article. IF: 4.757; Q2
- Otero-Ortega L, Gutiérrez-Fernández M, Díez-Tejedor E. Recovery after stroke: New insight to promote brain plasticity. *Front Neurol*. 2021; 12: 768958. Editorial Material. IF: 4.086; Q2
- Pastor AG, Martínez ELC, Rodríguez-Yáñez M, de Leciñana MA, Amaro S, Arenillas JF, Ayo-Martin O, Castellanos M, Fuentes B, Freijo MM, Gomis M, Choco MG, Sánchez PM, Morales A, Palacio-Portilla EJ, Segura T, Serena J, Vivancos-Mora J, Roquer J. Recommendations of the Spanish Society of Neurology for the prevention of stroke. Interventions on lifestyle and air pollution. *Neurologia*. 2021; 36(5): 377-87. Article. IF: 5.486; Q1
- Pastor S, de Celis E, García IL, de Leciñana MA, Fuentes B, Díez-Tejedor E. Development of the Madrid stroke programme: Milestones and changes in stroke trends and mortality from 1997 to 2017. *Neuroepidemiology*. 2021; 55(2): 135-40. Article. IF: 5.393; Q1
- Rodríguez-Yáñez M, Gómez-Choco M, López-Cancio E, Amaro S, de Leciñana MA, Arenillas JF, Ayo-Martin O, Castellanos M, Freijo MM, García-Pastor A, Gomis M, Sánchez PM, Morales A, Palacio-Portilla EJ, Roquer J, Segura T,



1
Introduction

2
Executive
Summary

3
Information
Groups
by Area

4
Associated
Clinicians

- Serena J, Vivancos-Mora J, Fuentes B. Stroke prevention in patients with arterial hypertension: Recommendations of the Spanish Society of Neurology's Stroke Study Group. *Neurologia*. 2021; 36(6): 462-71. Article. IF: 5.486; Q1
- Ruiz-Ares G, Fuentes B, de Donlebur JRP, de Leciñana MA, Gutiérrez-Zúñiga R, Rigual R, Díez-Tejedor E. Usefulness of orbital colour Doppler ultrasound in vascular-related monocular vision loss. *Vasc Med*. 2021; 26(3): 302-9. Article. IF: 4.739; Q2
 - Ruiz-Ares G, Jiménez-Valero S, Fernández-Prieto A, Arbas-Redondo E, Díaz-Pollán B, Navia P, Meras P, de Leciñana MA, de Donebur JRP, Rigual R, Fuentes B, Díez-Tejedor E. Concurrent stroke and myocardial infarction after Mild COVID-19 infection. *Neurologist*. 2021; 26(3): 86-9. Article. IF: 1.524; Q4
 - Siddiqi ZA, Nowak RJ, Mozaffar T, O'Brien F, Yountz M, Patti F. Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study. *Muscle Nerve*. 2021; 64(6): 662-9. Article. IF: 3.852; Q2
 - Sivera R, Lupo V, Frasquet M, Argente-Escrib H, Alonso-Pérez J, Díaz-Manera J, Querol L, García-Romero MD, Pascual SI, García-Sobrino T, Paradas C, Vázquez-Costa JF, Muelas N, Millet E, Vilchez JJ, Espinos C, Sevilla T. Charcot-Marie-Tooth disease due to MORC2 mutations in Spain. *Eur J Neurol*. 2021; 28(9): 3001-11. Article. IF: 6.288; Q1
 - Soto-Anari M, López N, Rivera-Fernández C, Belón-Hercilla V, Fernández-Guinea S. Literacy level and executive control in healthy older peruvian adults. *Front Neurol*. 2021; 12: 629048. Article. IF: 4.086; Q2
 - Steiner T, Dichgans M, Norrving B, Aamodt AH, Berge E, Christensen H, Fuentes B, Khatri P, Korpoki E, Marti-Fabregas J, Quinn T, Toni D, Zedde M, Sacco S, Turc G. European Stroke Organisation (ESO) standard operating procedure for the preparation and publishing of guidelines. *Eur Stroke J*. 2021; 6(3): 122-34. Article. IF: 5.894; Q1
 - Treder MS, Charest I, Michelmann S, Martín-Buro MC, Roux F, Carceller-Benito F, Ugalde-Cantrot A, Rollings DT, Sawlani V, Chelvarajah R, Wimber M, Hanslmayr S, Staresina BP. The hippocampus as the switchboard between perception and memory. *P Natl Acad Sci USA*. 2021;

- 118(50): e2114171118. Article. IF: 12.779; Q1
- Zúñiga RG, de Leciñana MA, Díez A, Iglesias GT, Pascual A, Higashi A, Pardo JR, Herrero DH, Fuentes B, Tejedor ED. A new software for quantifying motor deficit after stroke: A case-control feasibility pilot study. *Front Neurol*. 2021; 12: 603619. Article. IF: 4.086; Q2

■ Research projects

Aguilar-Amat Prior MJ. Registro de pacientes en una clinica de primera crisis epileptica. Laboratorios Bial S.A. 2016-Ongoing.

Management centre: FIBHULP

Alonso de Leciñana Cases M. Exosomas circulantes y mecanismos de reparación en ictus hemorrágico. Estudio traslacional (PI17/01922). ISCIII. 2018-2022.

Management centre: FIBHULP

Alonso de Leciñana Cases M. Identificación de proteínas implicadas en la neuroreparación tras la isquemia cerebral. estudio clínico-experimental. Fundacion Hospital Ramon y Cajal. 2016-Ongoing.

Management centre: FIBHULP

Alonso López E. Contrato Rio Hortega (CM20/00047). ISCIII. 2020-2023.

Management centre: FIBHULP

Carceller Benito F. Imagen multimodal de la respuesta terapeutica a estrategias multidiana en enfermedades neurológicas (MULTI-TARGET&VIEW-CM) (S2017/BMD-3688). CM. 2018-2022.

Management centre: FIBHULP

Chaverri Rada MD. Recogida y envío de muestras de adn genómico de pacientes con ela para su estudio dentro del proyecto mine. Fundela. 2020-Ongoing.

Management centre: FIBHULP

Díaz De Teran Velasco FJ. Influencia del

estres como factor precipitante de la crisis en pacientes con epilepsia. UCB Pharma S.A. 2015-Ongoing.

Management centre: FIBHULP

Díaz de Terán Velasco FJ. Sensibilización central y percepción del dolor en pacientes con cefalea en racimos. Allergan S.A. 2019-Ongoing.

Management centre: FIBHULP

Díez Tejedor E. Actualización y renovación de la actividad en neurología crónica hospitalaria registro de anticoagulación en ictus. Boehringer Ingelheim España S.A. 2007-Ongoing.

Management centre: FIBHULP

Díez Tejedor E. AMASCIS-02. Alogenic adipose tissue-derived mesenchymal stem cells in ischemic stroke. A phase IIB multicenter double blind placebo controlled clinical trial (PIC18/00016). ISCIII. 2019-2022.

Management centre: FIBHULP

Díez Tejedor E. Analysis of the protective effect of olmesartan administrated pre or post-cerebral infarction in an animal model Pfizer S.L.U. 2011-Ongoing.

Management centre: FIBHULP

Díez Tejedor E. Aplicación de nano partículas lipídicas biomodales sectorizadas hacia la zona de preinfarto en la reparación mediada por citocolina en el tratamiento de la isquemia cerebral. modelo en ratas. Ferrer Farma S.A. 2009-Ongoing.

Management centre: FIBHULP

Díez Tejedor E. Brain repair therapy with exosomes derived mesenchymal stem cells in experimental intracerebral hemorrhage model. Roche Farma S.A. 2016-Ongoing.

Management centre: FIBHULP

Díez Tejedor E. Efecto de los factores tróficos (cerebrolisina) y terapia con células madre en isquemia cerebral focal. Estudio experimental en ratas ii Ever Neuro Pharma GmbH. 2010-Ongoing.

Management centre: FIBHULP

Díez Tejedor E. Informatización de la gestión de pacientes. Unidad de neuroinmunología y esclerosis múltiple en el Hospital Universitario La Paz. Sanofi Aventis S.A. 2014-Ongoing.

Management centre: FIBHULP

Díez Tejedor E. Pacientes con esclerosis múltiple: análisis de la respuesta a tratamientos biológicos Fundación Biogen Idec. 2013-Ongoing.

Management centre: FIBHULP

Díez Tejedor E. Pacientes con esclerosis múltiple: análisis de la respuesta al natalizumab Schering España, S.A. Schering España S.A. 2011-Ongoing.

Management centre: FIBHULP

Díez Tejedor E. Registro clínico para el seguimiento de tratamiento anticoagulante en prevención secundaria tras un ictus cardioembólico Boehringer Ingelheim España S.A. 2011-Ongoing.

Management centre: FIBHULP

Díez Tejedor E. Se formará en proyectos de inmunología para la unidad de esclerosis múltiple, implantación del modelo eae, desarrolló técnicas para determinar las células reguladoras y analisis de marcadores biológicos en pacientes con em que estén en tratamiento con natalizumab. Biogen Idec Ltd. 2008-Ongoing.

Management centre: FIBHULP

Frank García A. Análisis antropológico de la sobrecarga del cuidador principal de personas con demencia. Estrategias

1
Introduction

2
Executive
Summary

3
Information
Groups
by Area

4
Associated
Clinicians

de comunicación. Varios. 2018-Ongoing.

Managment centre: FIBHULP

Frank García A. Evaluacion de la satisfaccion e impacto de los talleres formativo-informativos sobre ictus realizados por el servicios de neurologia y centro de ictus del Hospital Universitario La Paz. Varios. 2018-Ongoing.

Managment centre: FIBHULP

Frank García A. Effect of early and adult-life stress on the brain epigenome: relevance for the occurrence of Alzheimer's disease (AC17/00120). ISCIII. 2018-2021.

Managment centre: FIBHULP

Fuentes Gimeno B. Ensayo clínico piloto dulcinea (dubbing language-therapy cinemabased in aphasia post-stroke. A feasibility cross-over pilot-trial (HR18/0026). Fundacion Bancaria Caixa D'Estalvis i Pensions de Barcelona La Caixa. 2019-Ongoing.

Managment centre: FIBHULP

Fuentes Gimeno B. Variabilidad glucémica: impacto pronóstico en el infarto cerebral agudo e influencia del tratamiento corrector de la hiperglucemia. Estudio GLIAS-3 (PI18/00991). ISCIII. 2019-2022.

Managment centre: FIBHULP

Gandia González ML. Estudio multicéntrico del interactoma metabólico y genético en gliomas humanos. Implicaciones Diagnósticas y Pronósticas. (PI17/00361). ISCIII. 2018-2021.

Managment centre: FIBHULP

Gil Martínez A. Efectividad de un programa de ejercicios en pacientes con enfermedad de covid-19 ingresados en planta del Hospital Universitario La Paz. Colegio Oficial de Fisioterapeutas de la Comunidad de Madrid. 2020-Ongoing.

Managment centre: FIBHULP

Gil Martínez A. Face mirror. FIPSE. 2018-Ongoing.

Managment centre: FIBHULP

Gil Martínez A. Sistema de interaccion natural para analisis y rehabilitacion de los trastornos de la marcha en la enfermedad de Parkinson (MOBEEZE). Fundación I+D Del Software Libre. 2016-Ongoing.

Managment centre: FIBHULP

Gómez de Frutos MC. Contrato predoctoral (FI17/00188). ISCIII. 2018-2021.

Managment centre: FIBHULP

Gutiérrez Fernández MD, Alonso de Leciñana Cases M. Descifrando el papel de las vesículas extracelulares como moduladores de la respuesta inmunológica para promover la recuperación funcional tras la hemorragia cerebral. Estudio traslacional. (PI20/00243). ISCIII. 2020-2023.

Managment centre: FIBHULP

Gutiérrez Fernández MD. Exosomes as predictive biomarkers in acute ischemic stroke patients: a translational research approach (CPII20/00002). ISCIII. 2020-2024.

Managment centre: FIBHULP

Laso García F. Contrato predoctoral (FI18/00026). ISCIII. 2019-2023.

Managment centre: FIBHULP

Martínez Moreno M. Puesta en marcha del estudio de título provisional: estudio en pacientes con atrofia muscular espinal de inicio tardío ml43472. Roche Farma S.A. 2020-Ongoing.

Managment centre: FIBHULP

Moraleda Perez S. Pacientes con parálisis facia periférica: registro de características clínicas antes y después del tra-

tamiento con toxina botulínica tipo a y reeducación neuromuscular facial. Merz Pharma España S.L. 2014-Ongoing.

Managment centre: FIBHULP

Noval Martín S. Estudio multicéntrico de tres años de duración para evaluar la tomografía de coherencia óptica como medida de valoración en pacientes con esclerosis múltiple Novartis Farmaceutica S.A. 2012-Ongoing.

Managment centre: FIBHULP

Otero Ortega L. Contrato Miguel Servet (CP20/00024). ISCIII. 2020-2025.

Managment centre: FIBHULP

Otero Ortega L. Treatment choice matters in multiple sclerosis: The role of extracellular vesicles in predicting treatment response (CP20/00024). ISCIII. 2020-2023.

Managment centre: FIBHULP

Pascual Pascual SI. Longitudinal data collection from patients with spinal muscular atrophy in Spain a nationwide registry-cuidame. Fundación Sant Joan de Deu. 2020-Ongoing.

Managment centre: FIBHULP

Pascual Pascual SI. PI-713 estudio de la eficacia de la toxina botulínica en el pie equino espástico de la parálisis cerebral y de los factores que influyen en la misma. Allergan S.A. 2008-Ongoing.

Managment centre: FIBHULP

Pascual Pascual SI. Safety evaluation on the use of botulinum toxin type a for the treatment of spasticity in children after 20 years of experience 1996-2015. A retrospective monocenter observacional study based on a data base containing over 1000 children. Ipsen Innovation. 2017-Ongoing.

Managment centre: FIBHULP

Pérez Mato M. Contrato Sara Borrell (CD19/00033). ISCIII. 2020-2023.

Managment centre: FIBHULP

Rigual Bobillo RJ. Continuación del tratamiento anticoagulante en la fase aguda infarto cerebral carioembolico. Estudio Coala-IC. Daiichi Sankyo España. 2020-Ongoing.

Managment centre: FIBHULP

Roda Frade JM. Estudio multicéntrico del interactoma metabólico y genético en gliomas humanos. Implicaciones diagnósticas y pronósticas (PI17/00361). ISCIII. 2018-2022.

Managment centre: FIBHULP

Roda Frade JM. Imagen multimodal de la respuesta terapeutica a estrategias multidiana en enfermedades neurológicas (S2017/BMD-3688). CM. 2018-2021.

Managment centre: FIBHULP

Roda Frade JM. Programa de formación de un becario para el estudio del paciente diagnosticado con dolor cronico y/o trastornos del movimiento candidato a tratamiento con neuromodulación Médular y cerebral. Boston Scientific Iberica S.A. 2017-Ongoing.

Managment centre: FIBHULP

Rodríguez de Rivera Garrido FJ. Consorcio europeo de ataxia de friedreich para la realizacion de estudios traslacionales. Varios. 2015-Ongoing.

Managment centre: FIBHULP

Rodríguez de Rivera Garrido FJ. Estudio doble ciego, controlado con placebo, de grupos paralelos, aleatorizado, multicéntrico de la eficacia y seguridad de nicotinamida en pacientes con ataxia de Friedreich (AC16/00082). ISCIII. 2017-2021.

Managment centre: FIBHULP

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Ruíz Ares G. Influencia de factores clínicos, bioquímicos y ultrasonográficos asociados al pronóstico de la hemorragia intracerebral parenquimatosa. Estudio traslacional (PI16/01052). ISCIII. 2017-2021.

Managment centre: FIBHULP

Tallón Barranco A. Programa fellowship en investigación. Merck S.L. 2020-On-going.

Managment centre: FIBHULP

Vivancos Matellano F. Proyecto de desarrollo para la mejora clínico-asistencial de pacientes con enfermedad de parkinson avanzada tras el confinamiento. Abbvie Spain S.L.U. 2020-Ongoing.

Managment centre: FIBHULP

■ Cibers and Retics

Bullido Gómez-Heras MJ. Centro de Investigación en Red de Enfermedades neurodegenerativas (CB06/05/0007). ISCIII. (31/12/2022).

Managment centre: FIBHULP

Díez Tejedor E. Vascular and Cerebral Diseases Network. (RD16/0019/0005). ISCIII. (31/12/2022).

Managment centre: FIBHULP

■ Clinical trials

Díaz De Terán Velasco, FJ. Estudio de fase 3 multicentro, aleatorizado, doble ciego y controlado con placebo de botox (toxina botulínica tipo a) para prevención de migraña en pacientes con migraña episódica.

Type: Clinical Trials, phase III.
HULP code: 5977 M21-307.

Sponsored by: Abbvie Deutschland

Gmbh & Co. Kg.

Signed date: 26/10/2021

Díez Tejedor, E. Estudio intervencional prospectivo, aleatorizado, multicéntrico internacional, controlado con tratamiento activo y de 12 meses de duración, en el que se compara el beneficio mantenido de dos paradigmas de tratamiento (erenumab en administración mensual frente a tratamiento profiláctico por vía oral) en pacientes adultos con migraña episódica.

Type: Clinical Trials, phase IV.

HULP code: Appendix 1 5263.

Sponsored by: Novartis Farmaceutica, S.A.

Signed date: 09/02/2021

Díez Tejedor, E. Estudio multicéntrico, abierto, controlado con placebo externo y de fase III para evaluar la eficacia y la seguridad de ravulizumab en pacientes adultos con trastorno del espectro de neuromielitis óptica (nmosd).

Type: Clinical Trials, phase III.

HULP code: Appendix 1 5463.

Sponsored by: Alexion Pharmaceutical Inc.

Signed date: 21/05/2021

Lara Lara, M. Estudio intervencionista, aleatorizado, doble ciego, congrupos paralelos y controlado con placebo para evaluar la eficacia y la seguridad de eptinezumab para el tratamiento preventivo de las migrañas en pacientes con un doble diagnóstico de migraña y cefalea por abuso de medicamentos.

Type: Clinical Trials, phase III.

HULP code: 5680 19139A.

Sponsored by: Lundbeck A/S.

Signed date: 19/01/2021

Lara Lara, M. Estudio intervencionista, aleatorizado, doble ciego, de grupos pa-

ralelos y controlado con placebo para evaluar la eficacia y la seguridad de eptinezumab para el tratamiento preventivo de la migraña.

Type: Clinical Trials, phase III.

HULP code: 5761 19140A.

Sponsored by: Lundbeck A/S.

Signed date: 02/03/2021

Lara Lara, M. Estudio intervencionista, aleatorizado, doble ciego, congrupos paralelos y controlado con placebo para evaluar la eficacia y la seguridad de eptinezumab para el tratamiento preventivo de las migrañas en pacientes con un doble diagnóstico de migraña y cefalea por abuso de medicamentos.

Type: Clinical Trials, phase III.

HULP code: Appendix 1 5680.

Sponsored by: Lundbeck A/S.

Signed date: 15/09/2021

López Arrieta, JM. Estudio en fase III multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia, la seguridad y la tolerabilidad de avp-786 (Bromhidrato Dedeudextrometorfano [D6 DM]/Sulfato de Quinidina [q]) para el tratamiento de la agitación en pacientes con demencia de Tipo Alzheimer.

Type: Clinical Trials, phase III.

HULP code: 6000 20-AVP-786-307.

Sponsored by: Avanir Pharmaceuticals, Inc.

Signed date: 06/10/2021

Pascual Pascual, SI. Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo y multicéntrico para evaluar la eficacia y la seguridad de viltolarsén en niños con distrofia muscular de Duchenne (dmd) capaces de caminar.

Type: Clinical Trials, phase III.

HULP code: Appendix 1 5619.

Sponsored by: Ns Pharma Inc.

Signed date: 14/01/2021

Pascual Pascual, SI. Estudio de continuación, doble ciego, controlado con placebo, aleatorizado, multicéntrico, dividido en dos partes para investigar la seguridad, tolerabilidad, farmacocinética, farmacodinámica y eficacia de ro7034067 en pacientes con atrofia muscular espinal de tipo 2 y 3.

Type: Clinical Trials, phase II.

HULP code: Appendix 3 4664.

Sponsored by: F.Hoffmann-La Roche Ltd.

Signed date: 02/02/2021

Pascual Pascual, SI. Estudio de extensión a largo plazo de nusinersén (bllb058) administrado a dosis más altas en participantes con atrofia muscular espinal que han participado previamente en un estudio de investigación con nusinersén.

Type: Clinical Trials, phase III.

HULP code: 5764 232SM302.

Sponsored by: Biogen Idec Ltd.

Signed date: 18/03/2021

Pascual Pascual, SI. Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo y multicéntrico para evaluar la eficacia y la seguridad de viltolarsén en niños con distrofia muscular de Duchenne (dmd) capaces de caminar.

Type: Clinical Trials, phase III.

HULP code: Appendix 2 5619.

Sponsored by: Ns Pharma Inc.

Signed date: 16/03/2021

Pascual Pascual, SI. Estudio de fase 4 de nusinersén (bllb058) en pacientes con atrofia muscular espinal que recibieron onasemnogene ABEPRAVOVEC.

Type: Clinical Trials, phase IV.

HULP code: 5827 232SM404.

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Sponsored by: Biogen Idec Ltd.
Signed date: 01/06/2021

Pascual Pascual, SI. Estudio de extensión de fase 3, multicéntrico y abierto, para evaluar la eficacia y la seguridad de viltolarsén en niños con distrofia muscular de Duchenne (DMD) capaces de caminar.

Type: Clinical Trials, phase III.
HULP code: 5812 NS-065/NCNP-01-302.

Sponsored by: Ns Pharma Inc.
Signed date: 13/04/2021

Pascual Pascual, SI. Estudio de fase IIIb, multicéntrico, abierto, con un único dosis y un único grupo para evaluar la seguridad, la tolerabilidad y la eficacia de la terapia de sustitución génica con oav101 (avxs-101) por vía intravenosa en pacientes pediátricos con atrofia muscular espinal.

Type: Clinical Trials, phase III.
HULP code: 5911 COAV101A12306.
Sponsored by: Novartis Farmaceutica, S.A.

Signed date: 12/06/2021

Pascual Pascual, SI. Estudio de extensión abierto para pacientes con atrofia muscular espinal que han participado previamente en estudios experimentales de isis 396443.

Type: Clinical Trials, phase III.
HULP code: Appendix 2 4577.
Sponsored by: Biogen Idec Research Limited.

Signed date: 07/04/2021

Rodríguez De Rivera Garrido, FJ. Estudio de fase III, aleatorizado, abierto y de grupos paralelos para comparar la farmacodinámica, farmacocinética, eficacia, seguridad, tolerabilidad e inmunogenicidad de inyecciones subcutáneas múltiples de efgartigimod PH20 SC con las de infusiones intravenosas múltiples de efgartigimod en pacientes con miastenia grave generalizada.

Type: Clinical Trials, phase III.
HULP code: 5784 ARGX-113-2001.

Sponsored by: Argenx Bv (Argenx Bvba).
Signed date: 10/02/2021

Rodríguez De Rivera Garrido, FJ. Estudio a largo plazo, en fase III, abierto, multicéntrico y con un solo grupo para evaluar la seguridad y la tolerabilidad de múltiples inyecciones subcutáneas de efgartigimod ph20 sc en pacientes con miastenia grave generalizada.

Type: Clinical Trials, phase III.
HULP code: 5785 ARGX-113-2002.

Sponsored by: Argenx Bv (Argenx Bvba).
Signed date: 23/03/2021

Rodríguez De Rivera Garrido, FJ. Estudio fase 3, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos para evaluar la eficacia y seguridad de tolebrutinib (sar442168) en adultos con miastenia gravis generalizada.

Type: Clinical Trials, phase III.
HULP code: 5987 EFC17262.

Sponsored by: Sanofi Aventis S.A.
Signed date: 25/11/2021

Patents and trademarks

Ballesteros García P, López Larrubia P, Domínguez Mateo L, Marco Contelles JL, Cerdán García-Esteller S, inventors; Universidad Nacional de Educación a Distancia, CSIC, assignees. Set of magnetic resonance imaging and spectroscopy cell acidity extrinsic indicators comprise polyol derivatives based on alditols. P200300936; 2003 April 23.

Valdivieso Amate F, Bullido Gómez-Heras MJ, Martínez García A, inventors; UAM, assignee. Method of identifying compounds that induce or inhibit endoplasmic reticulum stress or oxidative stress. P200702997, PCT/ES2008/000705, EP2221379, US20100304384; 2007 November 13.

Valdivieso Ámate F, Burgos Muñoz JS, Ramírez Moreno C, Sastre Merlín I, inventors; UAM, CSIC, assignees. Method of identifying therapeutic compounds which can be used for the treatment and/or prevention of infections and diseases caused by human herpes viruses. P200400965, PCT/ES2005/000209, EP1769677, US20070218004, AT447321, AU2005235319, CA2562787, JP2007533315; 2004 April 21.

Valdivieso Ámate F, Montoliú JL, Pozueta Larios J, inventors; UAM, CSIC, assignees. Alzheimer's disease animal model, method for obtaining

same and uses thereof. P200503002, PCT/ES2006/000673, EP1956091, EP20060841725, US20090222932, CA2638983, JP2009517066; 2005 December 02.

Vergés Milano J, García García A, Ruhí Roura R, Montell Bonaventura E, García López M, Aláez Versón CR, Escaich Ferrer J, Egea Máiquez J, Lorrío González S, Negrodo Madrigal P, inventors; BIOIBÉRICA S.A., UAM, assignees. Sulphated disaccharides for the treatment of neurodegenerative and/or neurovascular diseases. P200902399, PCT/EP2010/070613, US20120309707, CA20102785237; 2010 December 22.

Gil-Martínez A, inventors; FIBHULP, assignees. Specular Face. 4022981/5. 2019 December 10



Egea Máiquez FJ, Farré Alins V, Palomino Antolín A, Narros Fernández P, Martins Rosa J, Parada Pérez E, Hernández García BJ, Roda Frade JM, Yuste Teruel S, Lagares Gómez-Abascal A, Sánchez Carabias C, Gandía Juan L, inventors; Fundación Hospital La Princesa, FIBHULP, Fundación Hospital 12 de Octubre, UAM, assignees. Method for determining the progression of acute brain damage and pharmaceutical composition for its treatment. P202031194, PCT/ES2021/070856; 2020 November 30.



3.1.3 Neuroprotective Strategies in Neurodegenerative Diseases Group

Publications: 8

Q1: 4



COMPOSITION

■ **Antonio Cuadrado Pastor.** Catedrático.

Facultad de Medicina. Universidad Autónoma de Madrid

María Antón Valadés. Investigadora Predoctoral.
Universidad Autónoma de Madrid

María Isabel Escoll Guerrero. Investigadora
Postdoctoral. Universidad Autónoma de Madrid

Raquel Fernández Ginés. Investigadora Predoctoral.
Universidad Autónoma de Madrid

Ángel Juan García Yagüe. Investigador Postdoctoral.
CIBERNED

Nadia Giselle Innamorato. Investigadora Predoctoral.

Universidad Autónoma de Madrid

Diego Lastra Martínez. Investigador Predoctoral.
Universidad Autónoma de Madrid

Ángela Martínez Valverde. Investigadora
Postdoctoral. CSIC. IIB "Alberto Sols"

Patricia Rada Llano. Investigadora Postdoctoral. IIB
"Alberto Sols"

Natalia Robledinos Antón. Investigador Predoctoral.
Universidad Autónoma de Madrid

Ana Isabel Rojo Sanchís. Profesora Ayudante
Doctor. Universidad Autónoma de Madrid

STRATEGIC OBJECTIVE

Oxidative stress is a key element in the aetiopathogenesis of neurodegenerative diseases and their comorbidities. Our laboratory studies the antioxidant protection mechanisms activated by extracellular signals and how this response could be regulated pharmacologically to provide a therapeutic benefit in these diseases.

To meet these two objectives, we are studying signalling pathways that regulate antioxidant metabolism and provide a general protective response. An important finding of this group was the observation that the PI3K/AKT/GSK-3 survival pathway regulates the transcription factor NRF2, guardian of cellular redox homeostasis, that provides protection against oxidative, inflammatory and proteotoxic stress.

For the past year we have been working on the validation this transcription factor as a new therapeutic target to modify progression of Parkinson's and Alzheimer's disease as well as co-morbid retinopathy and type II diabetes.

RESEARCH LINES

- Role of oxidative stress in neuronal death and neuroinflammation in neurodegenerative diseases.
- The transcription factor NRF2 as a new therapeutic target in Parkinson's and Alzheimer's disease
- Molecular basis of the role of NRF2 in type 2 diabetes and its complications (diabetic retinopathy and nephropathy).

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

RESEARCH ACTIVITY

■ Doctoral theses

Master Theses

Jiménez Villegas J. Role of NRF2 in C9ORF72 and RNA-related ALS pathology[dissertation]. Madrid: UAM: 2021(18/06/2022).

Directors: Rojo Sanchís AI, Cuadrado Pastor A.

Cañazares Moscato L. Preclinical development of P10, a novel small molecule NRF2 activator[dissertation]. Madrid: UAM: 2021(04/07/2022).

Directors: Cuadrado Pastor A, García Yagüe AJ.

Lucas Castro E. Role of the transcription factor NRF2 in the regulation of the integrity and function of the blood-brain barrier[dissertation]. Madrid: UAM: 2021(28/06/2022).

Directors: Cuadrado Pastor A, Pajares M

Final Degree Theses

Fariñas García S. Vesículas extracelulares en el interactoma hepático en la enfermedad de hígado graso no alcohólico[dissertation]. Madrid: UCM: 2021(07/06/2022).

Director: Martínez Valverde A.

Martín Ortiz B. Mecanismos moleculares asociados al desarrollo de la enfermedad de hígado graso no alcohólico[dissertation]. Madrid: UCM: 2021(07/06/2022).

Director: Martínez Valverde A.

■ Publications

- Duarte P, Cuadrado A, Leon R. Monoamine oxidase inhibitors: From classic to new clinical approaches. *Handb Exp Pharmacol.* 2021; 264: 229-59. Article. Not Indexed
- García-Yagüe AJ, Lastres-Becker I, Stefanis L, Vassilatis DK, Cuadrado A. alpha-Synuclein Induces the GSK-3-Mediated Phosphorylation and Degradation of NURR1 and Loss of Dopaminergic Hallmarks. *Mol Neurobiol.* 2021; 58(12): 6697-711. Article. IF: 5.682; Q1
- Jiménez-Villegas J, Ferraiuolo L, Mead RJ, Shaw PJ, Cuadrado A, Rojo AI. NRF2 as a therapeutic opportunity to impact in the molecular roadmap of ALS. *Free Radical Bio Med.* 2021; 173: 125-41. Article. IF: 8.101; Q1
- Klionsky DJ, Abdel-Aziz AK, Abdelfatah S, Abdellatif M, Abdoli A, Abel S, Abdeliovich H, Abildgaard MH, Abudu YP, (et al) Yakhine-Diop SMS. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). *Autophagy.* 2021; 17(1): 1-382. Review. IF: 13,391; Q1
- Lastra D, Fernández-Ginés R, Manda G, Cuadrado A. Perspectives on the clinical development of NRF2-targeting drugs. *Handb Exp Pharmacol.* 2021; 264: 93-141. Article. Not Indexed
- Milanese E, Cucos Catalina A, Matías-Guiu JA, Pinol-Ripoll G, Manda G, Dobre M, Cuadrado A. Reduced blood RGS2 expression in mild cognitive impairment patients. *Front Aging Neurosci.* 2021; 13: 738244. Article. IF: 5.702; Q1
- Milanese E, Dobre M, Cucos CA, Rojo AI, Jiménez-Villegas J, Capetillo-Zarate E, Matute C, Pinol-Ripoll G, Manda G, Cuadrado A. Whole blood expression pattern of inflammation and redox genes in mild Alzheimer's disease. *J Inflamm Res.* 2021; 14: 6085-102. Article. IF: 4.631; Q3
- Milanese E, Manda G, Dobre M, Codrici E, Neagoe IV, Popescu BO, Bajenaru OA, Spiru L, Tudose C, Prada GI, Davidescu EI, Pinol-Ripoll G, Cuadrado A. Distinctive under-expression profile of inflammatory and redox genes in the blood of elderly patients with cardiovascular di-

sease. *J Inflamm Res.* 2021; 14: 429-42. Article. IF: 4,631; Q3

■ Research projects

Cuadrado A; Lastres-Becker I. Papel de NRF2 en la función y el destino del cerebro con Alzheimer (SAF2016-76520-R). MICINN. 2017-2020.

Management centre: UAM

Cuadrado Pastor A, Rojo Sanchís AI. El factor de transcripción NRF2 en la fisiología de la enfermedad de Alzheimer (1004020167). MICINN. 2020-2023.

Management centre: UAM

Cuadrado Pastor A. Desarrollo de fármacos activadores de NRF2 para terapias innovadoras de la enfermedad de Alzheimer - GT2 (2018/00050/001). CAM. 2018-2022.

Management centre: UAM

Cuadrado Pastor A. Investigación traslacional sobre la regulación farmacológica NRF2 en enfermedades no transmisibles (10.2J.01.03). MICINN. 2020-2022.

Management centre: UAM

Martínez Valverde A. Extending the knowledge of the cellular and molecular mediators in the progression and treatment of non-alcoholic fatty liver disease linked to obesity (FATLiV). (RTI2018-094052-B-I00). MICINN. 2019-2022.

Management centre: CISC

Martínez Valverde A. Extracelular vesicles: new insights into their role in liver-pancreas interactome in T2D. European Association for the Study of Diabetes. 2021-2023.

Management centre: CIBER

Martínez Valverde A. Identification of metabolic biomarkers for chronic diseases and treatments/Identificación de biomarcadores metabólicos para enfermedades crónicas y sus tratamientos (EIN2020-112263). MICINN. 2021-2022.

Management centre: CISC

Martínez Valverde A. Mecanismos moleculares y comunicación intertisular en la resistencia a la insulina (B2017/BMD-3684 MOIR2-CM). CAM. 2018-2022.

Management centre: CISC

Martínez Valverde A. New messengers in the interactome of hepatic and extra-hepatic cells in non-alcoholic fatty liver disease with diagnostic value. Fundación Ramón Areces. 2019-2022.

Management centre: CISC

Martínez Valverde A. Training European Network:Metabolic Dysfunctions associated with Pharmacological Treatment of Schizophrenia (ITN-TREATMENT Grant Agreement 721236.). EU. 2017-2021.

Management centre: CISC

Rojo Sanchís AI. NRF2: Biomarcador y evaluación como diana terapéutica para la esclerosis lateral amiotrófica (10.04.02.0149). Fundación Tatiana. 2019-2021.

Management centre: UAM

■ Cibers and Retics

Cuadrado Pastor A. Networked Biomedical Research Center for Neurodegenerative Diseases. (CB06/05/0010). ISCIII. (2022).

1
Introduction

2
Executive Summary

3
Information Groups by Area

4
Associated Clinicians

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Management centre: UAM

Martínez Valverde AM. Networked Biomedical Research Center for Diabetes and Associated Metabolic Diseases. (CB07/08/0033). ISCIII. (2022). IIBm Alberto Sols-UAM, CSIC.

Management centre: IIBm Alberto Sols-UAM, CSIC

■ Patents and trademarks

Cuadrado Pastor A, Innamorato NG, inventors: CSIC, UAM. Use of sulfoaphane as supplementary therapy for early-stage neurodegenerative disease. P201231693; 2012 November 06.

León Martínez R, Egea Maíquez J, Buendía Abaitua I, Parada Pérez E, Navarro González de Mesa E, inventors; Fundación para la Investigación Biomédica del Hospital Universitario de La Princesa, UAM, CSIC, DNS NEUROSCIENCE S.A., assignees. Use of 3-(2-isothiocyanatoethyl)-5-methoxy-1H-indole for the treatment of neurodegenerative diseases. P201300667; 2013 July 17.

León Martínez R, Buendía Abaitua I, Navarro González de Mesa E, Michalska P, Gameiro Ros I, López Vivo A, Egea Maíquez J, García López M, García García A, inventors; Fundación para la Investigación Biomédica del Hospital Universitario de La Princesa, UAM, DNS NEUROSCIENCE S.A., assignees. Compounds derived from 3-alkylamine-1H-indolyl acrylate and its use for the treatment of neurodegenerative diseases. P201400810, PCT/ES2015/000139, CA2964309; 2014 October 15.





3.1.4 Involvement of Glycinergic and Glutamatergic Systems in Central Nervous System Pathologies Group

Publications: 6
Q1: 6

COMPOSITION



■ **Francisco Zafra Gómez.** Catedrático. Facultad de Ciencias. Universidad Autónoma de Madrid
María del Carmen Aragón Rueda. Catedrática. Facultad de Ciencias. Universidad Autónoma de Madrid
Beatriz Fuensanta López Corcuera. Catedrática. Facultad de Ciencias Universidad Autónoma de Madrid
Enrique Núñez Balbuena. Investigador Postdoctoral. Universidad Autónoma de Madrid
Eva María Porlan Alonso. Profesor Contratado Doctor. Universidad Autónoma de Madrid

STRATEGIC OBJECTIVE

Role of glutamate and glycine transporters in physiological and pathological aspects of glutamatergic and glycinergic neurotransmission.

Involvement of glutamate transporters in excitotoxicity, ischemia and traumatic brain injury

Pathologies of glycinergic neurotransmission such as hyperekplexia and pain

Role of the adult neurogenesis in neurorepair.

Role of microRNAs in ischemic tolerance

RESEARCH LINES

- 1- Physiological and pathological aspects of glutamate fluxes in brain as potential targets to prevent excitotoxicity, associated with brain disfunctions like ischemia, or traumatic brain injury, with special interest in intracellular traffic and characterization of interactomes of transporters and receptors of glutamatergic synapses.
- 2- Glycinergic neurotransmission. Identification and characterization of new GlyT2 mutations (SLC6A5 gene) associated to human hyperekplexia. Effects of the mutations on transporter structure, function, proteostasis and glycinergic neurotransmission. Role

1
Introduction

2
Executive
Summary

3
Information
Groups
by Area

4
Associated
Clinicians

in presynaptic hyperekplexia of different genes related to GlyT2 trafficking, interactoma, posttranslational modifications. Rescue interventions.

3- Study of plastic adaptations affecting glycine transporters in physiological and pathological nociception. Regulation of GlyTs by receptors modulating nociceptive signaling (P2XR, P2YR, mACh, nACh, α_2 adrenergic, 5-HT). Signaling pathways.

4- Neuron-glia crosstalk through microRNAs and exosomes
5- Physiological and pathological aspects of Neuronal reparation by adult neurogenesis:

- A) Identification of novel regulatory mechanisms of adult neurogenesis by kinases.
- B) Identification of novel regulatory mechanisms of adult neurogenesis by microRNAs and other non-coding RNAs.

RESEARCH ACTIVITY

■ Doctoral theses

Piniella Alcalde D. Identificación de nuevas proteínas que interactúan con los transportadores de glutamato y dopamina (GLT-1 y DAT) mediante alteraciones en sus respectivos entornos [dissertation]. Madrid: UAM: 2021(16/04/2021).

Director: Zafra Gómez F.

Barrios Muñoz AL. Plk1, un nuevo regulador de la neurogénesis adulta [dissertation]. Madrid: UAM: 2021 (28/09/2021).

Director: Porlan Alonso E

■ Master Theses

Maestre Guillén A. Estudio de las alteraciones del tráfico intracelular del transportador de aminoácidos b^{at}1 por la acción del virus Sars-Cov-2 [dissertation]. Madrid: UCM: 2021(16/09/2021).

Director: Zafra Gómez F.

■ Final Degree Theses

Balsells Alonso MM. Estudio de los mecanismos de liberación de exosomas en células nerviosas en respuesta a isquemia [dissertation]. Madrid: UAM: 2021(14/06/2021).

Director: Zafra Gómez F.

Moreno Esbrí P. Puesta a punto de las herramientas moleculares necesarias para la validación de posibles dianas de fosforilación de Plk1 [dissertation]. Madrid: UAM: 2021(14/06/2021).

Director: Porlan Alonso E

Lillo López P. Estudio de la neurogénesis adulta subependimaria en un modelo murino con inactivación condicional de una quinasa en el ciclo celular [dissertation]. Madrid: UAM: 2022(15/06/2021).

Director: Porlan Alonso E

■ Publications

• Arribas-Blázquez M, Piniella D, Olivios-Ore LA,

Bartolomé-Martín D, Leite C, Giménez C, Ardalejo AR, Zafra F. Regulation of the voltage-dependent sodium channel Na(V)1.1 by AKT1. *Neuropharmacology*. 2021; 197: 108745. Article. IF: 5.273; Q1

• Benito-Muñoz C, Perona A, Felipe R, Pérez-Siles G, Núñez E, Aragón C, López-Corcuera B. Structural determinants of the neuronal glycine transporter 2 for the selective inhibitors ALX1393 and ORG25543. *ACS Chem Neurosci*. 2021; 12(11): 1860-72. Article. IF: 5.78; Q1

• de la Rocha-Muñoz A, Melgarejo E, Aragón C, López-Corcuera B. Rescue of two trafficking-defective variants of the neuronal glycine transporter GlyT2 associated to hyperekplexia. *Neuropharmacology*. 2021; 189: 08543. Article. IF: 5.273; Q1

• De la Rocha-Muñoz A, Núñez E, Vishwanath AA, Gómez-López S, Dhanasobhon D, Rebola N, López-Corcuera B, de Juan-Sanz J, Aragón C. The presynaptic glycine transporter GlyT2 is regulated by the Hedgehog pathway in vitro and in vivo. *Commun Biol*. 2021; 4(1): 1197. Article. IF: 6.548. Q1

• García-Magro N, Martín YB, Negro P, Zafra F, Avendaño C. Microglia and inhibitory circuitry in the medullary dorsal horn: Laminar and time-dependent changes in a trigeminal model

of neuropathic pain. *Int J Mol Sci*. 2021; 22(9): 4564. Article. IF: 6.208; Q1

• Piniella D, Martínez-Blanco E, Bartolomé-Martín D, Sanz-Martos AB, Zafra F. Identification by proximity labeling of novel lipidic and proteinaceous potential partners of the dopamine transporter. *Cell Mol Life Sci*. 2021; 78(23): 7733-56. Article. IF: 9.207; Q1

■ Research projects

Zafra Gómez F. Papel de los microRNAs y los exosomas en la inducción de la tolerancia isquémica en el cerebro (RTI2018-098712-B-I00). Ministerio de Economía, Industria y Competitividad. 2019-2021.

Management centre: UAM

Porlan Alonso E. Nuevos reguladores farmacológicos de la neurogénesis adulta y la reprogramación directa (PID2019-104763RB-I00). Ministerio de Economía, Industria y Competitividad. 2020-2023.

Management centre: UAM



3.1.5 Mechanisms and Biomarkers in Neurodegenerative Diseases Group

Publications:	6
Q1:	5

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



COMPOSITION

- **Isabel Lastres Becker.** Profesora Titular. Universidad Autónoma de Madrid
- **Marina Arribas Blázquez.** Profesora Ayudante Doctor. Universidad Complutense de Madrid
- **Silvia Constanza Contreras Jurado.** Titulado Superior de Actividades Técnicas y Profesional. CSIC
- **Ignacio Silva Llanes.** Investigador Predoctoral. CSIC

STRATEGIC OBJECTIVE

The aging of the population poses a growing burden in society. This is associated with the increase in disability and diseases that have a high impact on health care, on patients and their families. Likewise, aging is associated with the appearance of different neurodegenerative diseases, among which include Alzheimer's disease (AD), Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS). Therefore, the development of advanced biological markers, new drugs and appropriate technology is the key to establishing a treatment for these diseases, which is currently an important social challenge. In our laboratory we study the molecular basis of neurodegeneration. The research projects we develop have a multidisciplinary approach that combines basic and translational research, using cell culture techniques, murine models and postmortem samples from patients with AD, PD and ALS.



1 Introduction

2 Executive
Summary

3 Information
Groups
by Area

4 Associated
Clinicians

Amyotrophic lateral sclerosis (ALS): Design and development of innovative drugs for the treatment of ALS

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that affects motor neurons in the spinal cord and cerebral cortex. Patients have a loss of muscle strength and coordination that progressively progresses, preventing the performance of daily activities. Until now there is no treatment that cures ALS, and for this reason in our laboratory we are developing several lines of research that aim to address this challenge by designing and developing new therapies for the treatment of ALS. In collaboration with several laboratories in a project funded by the Community of Madrid (ELA_Madrid S2017/BMD-3813) we have generated and functionally and biochemically characterized cell models (lymphoblasts) based on human samples. In addition, we are developing new compounds that modulate the TDP-43 and NRF2 signaling pathways, respectively, validating them in cellular and mouse models of ALS. In this context, in a project funded by the Ministry of Science, Innovation and Universities (PID2019-105600RB-I00) we are also investigating the modulation of aging and neurodegeneration by small molecule protein kinase inhibitors, in collaboration with Dr. Ana Martínez. On the other hand, one of the main characteristics of ALS is that there are alterations in mRNA metabolism and deregulated axonal transport. For this reason, in a project financed by FUNDELA, we are determining if the TDP-43 aggregates kidnap the RNA-binding proteins, and do not let them carry out their function, in such a way that the mRNAs do not reach the synaptic connections and cannot be translated, causing there to be no connection between the neuron and the muscle, which ultimately leads to loss of muscle function. So we are looking at RNA granule transport and protein translation in situ in ALS, determining the involvement of STAUFEN and TDP-43 proteins.

Tauopathies: new biomarkers and targets against neurodegeneration

The TAU protein is the main component of the intracellular filamentous deposits that define a series of neurodegenerative diseases called tauopathies. In general, tauopathies are characterized by alterations in synaptic plasticity, cell death, proteinopathy, and neuroinflammation. Despite enormous efforts to find a cure for these diseases, there is still no effective treatment. That is why in my laboratory we face this challenge with two different approaches. In our laboratory we have shown in vitro and in vivo that neurons

with accumulation of TAU induce the expression of the cannabinoid receptor CB2, which enhances neurodegeneration. Therefore, in a first approach we focus on the study of the pharmacological modulation of the CB2 receptor and its effects on TAU-induced neurodegeneration, with a project funded by the Fundación Tatiana Pérez de Guzmán el Bueno (2021-2024). There are currently no specific biomarkers for tauopathies that allow a prognosis/diagnosis of these diseases. For this reason, we are interested in the analysis of miR-142 as a biomarker in tauopathies and its implication in new therapeutic strategies.

Implication of alterations at the mitochondrial level and mitophagy in Parkinson's disease

In collaboration with Dr. Patricia Boya, from the "Margarita Salas" Biological Research Center, we are interested in elucidating the molecular aspects that underlie Parkinson's Disease (PD). PD is the second most common multisystem neurodegenerative disorder associated with aging. Most cases of PD are sporadic and of unknown aetiology, but mutations in genes such as PARKIN and PINK1 have been associated with familial forms of the disease. Mitochondrial impairment is a well-established pathological hallmark of PD, but whether mitophagy is impaired in this disease remains a subject of intense debate. Therefore, in this research project we are determining the role of mitophagy and whether the different mechanisms of mitophagy are altered in PD.

RESEARCH LINES

- Implication of alterations at the mitochondrial and mitophagy level in Parkinson's Disease
- New therapeutic strategies for diseases with alterations in the TAU protein, such as Alzheimer's disease. We have two different approaches to this:
 - Modulation at the epigenetic level: miRNAs
 - Involvement of the cannabinoid system: CB2 receptor
- Development of new therapeutic strategies for amyotrophic lateral sclerosis. We have three different approaches:
 - Design of new drugs
 - Analysis of RNA metabolism and stress granule formation
 - Implication of the kinases RIPK1 and SGK1 in the pathology

RESEARCH ACTIVITY

■ Doctoral theses

Ciria Cubas L. Análisis de proteínas de unión a RNA en esclerosis lateral amiotrófica [dissertation]. Madrid: UCM; 2021(08/07/2021).

Director: Lastres-Becker I.

■ Publications

- Galán-Ganga M, Rodríguez-Cueto C, Merchán-Rubira J, Hernández F, Ávila J, Posada-Ayala M, Lanciego JL, Luengo E, López MG, Rabano A, Fernández-Ruiz J, Lastres-Becker I. Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration. *Acta Neuropathol Commun.* 2021; 9(1): 90. Article. IF: 7.578; Q1
- García-Yagüe AJ, Lastres-Becker I, Stefanis L, Vassilatis DK, Cuadrado A. Alpha-Synuclein induces the GSK-3-mediated phosphorylation and degradation of NURR1 and loss of dopaminergic hallmarks. *Mol Neurobiol.* 2021; 58(12): 6697-711. Article. IF: 5.682; Q1
- Klionsky DJ, Abdel-Aziz AK, Abdelfatah S, Abdellatif M, Abdoli A, Abel S, Abeliovich H, Abildgaard MH, Abudu YP, Acevedo-Arozena A, , Yakhine-Diop (et al) SMS. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). *Autophagy.* 2021; 17(1): 1-382. Review. IF: 13.391; Q1
- Lastres-Becker I, Porras G, Arribas-Blázquez M, Maestro I, Borrego-Hernández D, Boya P, Cerdán S, García-Redondo A, Martínez A, Martín-Requero A. Molecular alterations in sporadic and SOD1-ALS immortalized lymphocytes: Towards a personalized therapy. *Int J Mol Sci.* 2021; 22(6): 3007. Article. IF: 6.208; Q1
- Lastres-Becker I. Editorial: Tau Protein: Mechanisms from health to degeneration. *Front Mol Neurosci.* 2021; 14: 743986. Editorial Material. IF: 6.261; Q1
- Lastres-Becker I. Special issue role of NRF2 in disease: Novel molecular mechanisms and therapeutic approaches. *Biomolecules .* 2021; 11(2): 202. Editorial Material. IF: 6.064; Q2

■ Research projects

Martínez A; Lastres-Becker I. Diseño y desarrollo de fármacos innovadores para el tratamiento de la esclerosis lateral amiotrófica (B2017/BMD-3813 ELA-Madrid). CM. 2018-2022.

Management centre: CSIC-UAM

Lastres-Becker I. Análisis del transporte de gránulos de RNA y traducción de proteínas in situ en ELA: ¿implicación de SATUFEN y TDP-43? (2019/00325/001). FUNDELA. 2019-2021.

Management centre: UAM

Martínez A; Lastres-Becker I. Aging and neurodegeneration targeting by protein kinase small molecules inhibitors (PID2019-105600RB-I00). Ministerio de Ciencia e Innovación. 2020-2023.

Management centre: CSIC

Lastres-Becker I. Modulación del receptor cannabinoide CB2 como nueva estrategia terapéutica para proteger contra la neurodegeneración inducida por TAU (2021/00072/001). Fundación Tatiana Pérez de Guzmán el Bueno. 2021-2024.

Management centre: UAM

■ Patents and trademarks

López-Rodríguez ML, Viso A, Ortega S, Lastres-Becker I, González S, Fernández-Ruiz JJ, Ramos JA, inventors; Universidad Complutense de Madrid, assignees; Nuevos derivados de ácido araquidónico con afinidad por el transportador de anandamide. P200001920. 2020 nov 5

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians





3.1.6 Research in Multiple Sclerosis Group (HUG)*

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



■ **Yolanda Aladro Benito.** Médico Adjunto Neurología. Profesor Asociado de la Universidad Europea de Madrid

STRATEGIC OBJECTIVE


Assess progression in Multiple sclerosis through gait analysis using wearable inertial sensors to find more objective, sensitive and reliable measures to detect and monitor clinical progression in progressive MS.

To validate selected measures provided by inertial sensors to monitor gait impairment in a prospective cohort of MS patients in the early stages of PMS (primary and secondary MS).

RESEARCH LINES

- Estudio de la marcha con biosensores en pacientes con esclerosis múltiple.
- Covid-19 en esclerosis múltiple
- Esclerosis múltiple de inicio tardío
- Utilización de sensores de movimiento en el temblor esencial

* This group became part of IdiPAZ through the signing of a new legal agreement in June 2021



Cardiovascular Area

3.2

José Luis López-Sendón Henstchel

Documents:	234	
Originals:	179	
D1:	52	Q1: 126


- 3.2.1 Invasive Clinical Cardiology – ICCI-Paz Group
- 3.2.2 Cardiovascular Epidemiology and Nutrition Group
- 3.2.3 Coagulopathies and Alterations of Haemostasis Group
- 3.2.4 Vascular Physiology and Pharmacology Group
- 3.2.5 Vascular Pharmacology and Metabolism Group (FARMAVSM)

1 Introduction


2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



Cardiovascular Area



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



Strategic Objectives	Development forecast for the coming years	Actions
<p>Cardiovascular Area is composed of 6 groups that carry out basic, experimental and clinical research in the fields of cardiology and cardiovascular risk factors. The area has an important activity in the performance of international clinical trials of wide impact and applicability. The scientific production of the cardiovascular area is supported by a high impact factor. The groups also have extensive experience in training researchers.</p>	<p>To merge the groups by research lines in order to avoid the duplicities that make the group lose strength and competitiveness and to bet on being more competitive and to take better advantage of the resources.</p>	<p>Foster and support translational research lines.</p>
	<p>The area should be focused on consolidated and multidisciplinary research lines rather than structured by pathologies. The collaboration with research groups from other organizations should be the norm.</p>	<p>Establish relationships/ collaboration/alliances with other IdiPAZ research groups and with groups from other institutions and maintain those already started.</p>
	<p>Resources should be focused on priorities established by the researchers themselves, or directly by IdiPAZ after analyzing the scientific production of each group.</p>	<p>Analyze the scientific production of each group.</p>
	<p>Clinical research through the resources it provides (clinical trials) should guide basic research projects in order to offer the ideal field for translational medicine. This type of research also provides a stronger link between international research groups.</p>	<p>Encourage participation in clinical trials of researchers.</p>



3.2.1 Invasive Clinical Cardiology - ICCI-PAZ Group

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Publications: 72

Q1: 43

COMPOSITION



■ **José Luis López-Sendón Henstchel.**

Director Científico de IdiPAZ. Hospital Universitario La Paz.

Isabel Antorrena Miranda. Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz

Eduardo Armada Romero. Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz

Almudena Castro Conde. Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz

Carlos Escobar Cervantes. Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz

Regina Dalmau González-Gallarza. Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz

Francisco Javier Domínguez Melcón. Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz

Jaime Fernández de Bobadilla Osorio. Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz

Javier Fuertes Beneítez . Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz

Guillermo Galeote García. Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz

Elvira Ana González García. Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz

Teresa González Gallego. Investigadora Senior (Contrato Ramón y Cajal). IIB "Alberto Sols"

Gabriela Guzmán Martínez. Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz

Ángel Manuel Iniesta Manjavacas. Facultativo Especialista de Área en Cardiología . Hospital Universitario La Paz

Santiago Jiménez Valero. Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz

Teresa López Fernández. Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz

Esteban López de Sá y Areses. Jefe de Sección de Cuidados Intensivos Cardiológicos. Hospital Universitario La Paz

José Luis Merino Llorens. Facultativo Especialista de Área en Cardiología. Director Unidad Investigación en Arritmias/Electrofisiología Robótica. Hospital Universitario La Paz

José Raúl Moreno Gómez. Jefe de Sección de Hemodinámica. Hospital Universitario La Paz

María del Mar Moreno Yangüela. Jefe de Sección de Imagen Cardíaca. Hospital Universitario La Paz

Rafael Peinado Peinado. Jefe de Sección de Arritmias y Electrofisiología. Hospital Universitario La Paz

Esther Pérez David. Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz

Juan Ramón Rey Blas. Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz

Luis Riera del Moral. Facultativo Especialista de Área en Angiología y Cirugía Vascul. Hospital Universitario La Paz. Profesor Asociado Departamento de Cirugía. Universidad Autónoma de Madrid

Inmaculada Roldán Rabadán. Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz

José Ruiz Cantador. Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz

Silvia Cayetana Valbuena López. Médico Interno Residente en Cardiología. Hospital Universitario La Paz



1
Introduction

2
Executive
Summary

3
Information
Groups
by Area

4
Associated
Clinicians

STRATEGIC OBJECTIVE

The group consists of various healthcare units of the Department of Cardiology at Hospital La Paz: Clinic/Coronary Unit, interventional cardiology, cardiac imaging, electrophysiology, rehabilitation and adult congenital heart disease.

The main research lines focus on providing clinical responses, with local research protocols and direct participation in clinical trials and international multicentre registries. Moreover, clinical translational potential is reinforced through an institutional relationship with the CNIC.

RESEARCH LINES

- Myocardial ischaemia. Acute and chronic. Diagnosis, prognosis and treatment.
- Cardiac arrhythmias. Catheter navigation systems.
- Diagnosis and treatment. Post cardiac arrest hypothermia.
- Heart Failure. Diagnosis and treatment. Cardiotoxicity of antineoplastic agents.
- Cardiac diagnostic imaging.
- Aortic stenosis. Diagnosis and treatment.
- Adult congenital heart diseases.
- Endovascular therapy and new cellular therapies in peripheral vascular disease.

RESEARCH ACTIVITY

■ Doctoral theses

del Prado Díaz S. Cambios hemodinámicos y adaptación morfológica y funcional del corazón materno durante la gestación única y gemelar[dissertation]. Madrid: UAM: 2021(17/05/2021).

Directors: de la Calle Fernández-Miranda M, Guzmán Martínez S.

■ Publications

- Alfonso F, Cuesta J, del Blanco BG, Bosa F, de Prado AP, Masotti M, Trillo R, Rumoroso JR, Moreno R, Cequier A, Gutiérrez H, Touchard AG, López-Minguez JR, Zueco J, Serra A, Velázquez M, Moris C, Bastante T, García-Guimaraes M, Rivero F, Fernández-Pérez C. Scoring balloon predilation before bioresorbable vascular scaffold implantation in patients with in-stent restenosis: the RIBS VI 'scoring' study. *Coronary Artery Dis.* 2021; 32(2): 96-104. Article. IF: 1.717; Q4
- Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure-Valenzuela E, Giannetti N, Gómez-Mesa JE, Janssens S, Januzzi JL, González-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Pina IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vine-

reanu D, Zhang J, Carson P, Lam CSP, Marx N, Zeller C, Sattar N, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M, (López-Sendón JL). Empagliflozin in heart failure with a preserved ejection fraction. *New Engl J Med.* 2021; 385(16): 1451-61. Article. IF: 176.079; D1

- Anker SD, Butler J, Filippatos G, Khan MS, Marx N, Lam CSP, Schnaidt S, Ofstad AP, Brueckmann M, Jamal W, Bocchi EA, Ponikowski P, Perrone SV, Januzzi JL, Verma S, Bohm M, Ferreira JP, Pocock SJ, Zannad F, Packer M. Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status results from the EMPEROR-Reduced Trial. *Circulation.* 2021; 143(4): 337-49. Article. IF: 39.918; D1
- Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Inzucchi SE, Kosiborod MN, Cherney DZI, Dwyer JP, Scirica BM, Bailey CJ, Diaz R, Ray KK, Udell JA, Lopes RD, Lapuerta P, Steg PG, (López-Sendón JL). Sotagliflozin in patients with diabetes and chronic kidney disease. *New Engl J Med.* 2021; 384(2): 129-39. Article. IF: 176.079; D1
- Briongos-Figuero S, García-Alberola A, Rubio J, Segura JM, Rodríguez A, Peinado R, Alzueta J, Martínez-Ferrer JB, Vinolas X, de la Concha JF, Anguera I, Martín M, Cerda L, Pérez L. Long-term outcomes among a nationwide cohort of patients using an implantable cardioverter-defibrillator: UMBRELLA Study Final Results. *J Am Heart Assoc.* 2021; 10(1): e018108. Article. IF: 6.106; Q2

• Caro-Codón J, Lip GYH, Rey JR, Iñiesta AM, Rosillo SO, Castrejón-Castrejón S, Rodríguez-Sotelo L, García-Veas JM, Marco I, Martínez LA, Martín-Polo L, Merino C, Martínez-Cossiani M, Buno A, González-Valle L, Herrero A, López-de-Sa E, Merino JL. Prediction of thromboembolic events and mortality by the CHADS(2) and the CHA(2) DS(2)-VASc in COVID-19. *Europace.* 2021; 23(6): 937-47. Article. IF: 5.486; Q2

• Caro-Codón J, Rey JR, Buño A, Iñiesta AM, Rosillo SO, Castrejón-Castrejón S, Merino C, Marco I, Martínez LA, García-Veas JM, Martín-Polo L, Rodríguez-Sotelo L, Martínez-Cossiani M, González-Valle L, Herrero A, López-de-Sa E, Merino JL. Characterization of myocardial injury in a cohort of patients with SARS-CoV-2 infection. *Med Clin-Barcelona.* 2021; 157(6): 274-80. Article. IF: 3.2; Q2

• Caro-Codón J, Rey JR, Buño A, Iñiesta AM, Rosillo SO, Castrejón-Castrejón S, Rodríguez-Sotelo L, Martínez LA, Marco I, Merino C, Martín-Polo L, García-Veas JM, Martínez-Cossiani M, González-Valle L, Herrero A, López-de-Sa E, Merino JL. Characterization of NT-proBNP in a large cohort of COVID-19 patients. *Eur J Heart Fail.* 2021; 23(3): 456-64. Article. IF: 17.349; D1

• Chieffo A, Tarantini G, Naber CK, Barbato E, Roffi M, Stefanini GG, Buchanan GL, Buszman P, Moreno R, Zawislak B, Cayla G, Danenberg H, Da Silveira JAB, Nef H, James SK, Ferre JM, Voskuil M, Witt N, Windecker S, Baumbach A, Dudek D. Performing elective cardiac invasive procedures during the COVID-19 outbreak: a position state-

ment from the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eurointervention.* 2021; 16(14): 1177-86. Article. IF: 7.728; Q1

• de Groot JR, Weiss TW, Kelly P, Monteiro P, Deharo JC, de Asmundis C, López-de-Sa E, Waltenberger J, Steffel J, Levy P, Bakhai A, Zierhut W, Laeis P, Manu MC, Reimitz PE, De Caterina R, Kirchhof P. Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study. *Eur Heart J Cardiovasc Pharmacother.* 2021; 7(F11): F30-9. Article. IF: 11.177; D1

• De Luca G, Debel N, Cercek M, Jensen LO, Vavlukis M, Calmac L, Johnson T, Ferrer GR, Ganjukov V, Wojakowski W, Kinnaird T, von Birgelen C, Cottin Y, Jsselmuiden A, Tuccillo B, Versaci F, Royaards KJ, ten Berg J, Laine M, Dirksen M, Siviglia M, Casella G, Kala P, Gil JLD, Banning A, Becerra V, De Simone C, Santucci L, Carrillo X, Scoccia A, Amoroso G, van't Hof AW, Kovarnik T, Tsigkas G, Mehili J, Gabrielli G, Rios XF, Bakracski N, Levesque S, Cirrincione G, Guiducci V, Kidawa M, Spedicato L, Marinucci L, Ludman P, Zilio F, Galasso G, Fabris E, Menichelli M, García-Touchard A, Manzo S, Caiazzo G, Moreu J, Fores JS, Donazzan L, Vignali L, Teles R, Benit E, Agostoni P, Ojeda FB, Lehtola H, Camacho-Freiere S, Kraaijeveld A, Antti Y, Bocalatte M, Deharo P, Martínez-Luengas IL, Scheller B, Varytimiadi E, Moreno R, Uccello G, Faurie B, Barrios AG, Milewski M, Bruwiere E, Smits P, Wilbert B, Di



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Uccio FS, Parodi G, Kedhi E, Verdoia M. Impact of SARS-CoV-2 positivity on clinical outcome among STEMI patients undergoing mechanical reperfusion: Insights from the ISACS STEMI COVID 19 registry. *Atherosclerosis*. 2021; 332: 48-54. Article. IF: 6.847; Q1

- Delgado J, Cepeda JM, Llorens P, Jacob J, Comin J, Montero M, Miro O, de Sa EL, Manzano L, Martín-Sánchez FJ, Formiga F, Masip J, Pérez-Calvo JI, Herrero-Puente P, Manito N. Consensus on improving the comprehensive care of patients with acute heart failure. *Rev Clin Esp*. 2021; 221(3): 163-8. Article. IF: 3.064; Q2
- Demchuk AM, Yue P, Zotova E, Nakamya J, Xu LZ, Milling TJ, Ohara T, Goldstein JN, Middeldorp S, Verhamme P, López-Sendón JL, Conley PB, Curnutte JT, Eikelboom JW, Crowther M, Connolly SJ. Hemostatic efficacy and anti-FXa (Factor Xa) reversal with andexanet alfa in intracranial hemorrhage ANNEXA-4 Substudy. *Stroke*. 2021; 52(6): 2096-105. Article. IF: 10.17; D1
- Dube MP, Legault MA, Lemacon A, Perreault LPL, Foudjio R, Waters DD, Kouz S, Pinto FJ, Maggioni AP, Diaz R, Berry C, Koenig W, López-Sendón J, Garcia H, Kiwan GS, Asselin G, Provost S, Barhdadi A, Sun ME, Cossette M, Blondeau L, Mongrain I, Dubois A, Rhainds D, Bouabdallaoui N, Samuel M, de Denus S, L'Allier PL, Guertin MC, Roubille F, Tardif JC. Pharmacogenomics of the efficacy and safety of colchicine in COLCOT. *Circ Genom Precis Med*. 2021; 14(2): 223-9. Article. IF: 7.465; D1
- Fabritz L, Crijns HJGM, Guasch E, Goette A, Hausler KG, Kotecha D, Lewalter T, Meyer C, Potpara TS, Rienstra M, Schnabel RB, Willems S, Breithardt G, Camm AJ, Chan A, Chua W, de Melis M, Dimopoulou C, Dobrev D, Easter C, Eckardt L, Haase D, Hatem S, Healey JS, Heijman J, Hohnloser SH, Huebner T, Ilyas BS, Isaacs A, Kutschka I, Leclercq C, Lip GH, Marinelli EA, Merino JL, Mont L, Nabauer M, Oldgren J, Purerfellner H, Ravens U, Savelieva I, Sinner MF, Sitch A, Smolnik R, Steffel J, Stein K, Stoll M, Svennberg E, Thomas D, Van Gelder IC, Vardar B, Wakili R, Wieloch M, Zeemering S, Ziegler PD, Heidbuchel H, Hindricks G, Schotten U, Kirchhof P. Dynamic risk assessment to improve quality of care in patients with atrial fibrillation: the 7th AF-NET/EHRA Consensus Conference. *Europace*. 2021; 23(3): 329-44. Article. IF: 5.486; Q2
- Faroux L, Lhermusier T, Vincent F, Nombela-Franco L, Tchetché D, Barbanti M, Abdel-Wahab M, Windecker S, Auffret V, Campanha-Borges DC, Fischer Q, Muñoz-García E, Trillo-Nouche R, Jorgensen T, Serra V, Toggweiler S, Tarantini G,

Saia F, Durand E, Donaint P, Gutiérrez-Ibanes E, Wijeyesundera HC, Veiga G, Patti G, D'Ascenzo F, Moreno R, Hengstenberg C, Chamandi C, Asmarats L, Hernández-Antolin R, Gómez-Hospital JA, Córdoba-Soriano JG, Landes U, Jiménez-Díaz VA, Cruz-González I, Nejiri M, Roubille F, Van Belle E, Armijo G, Siddiqui S, Costa G, Elsaify S, Pilgrim T, le Breton H, Urena M, Muñoz-García AJ, Sondergaard L, Bach-Oller M, Fraccaro C, Eltchaninoff H, Metz D, Tamargo M, Fradejas-Sastre V, Rognoni A, Bruno F, Goliash G, Santalo-Corcoy M, Jiménez-Mazuecos J, Webb JG, Muntane-Carol G, Paradis JM, Mangieri A, Ribeiro HB, Campelo-Parada F, Rodes-Cabau J. ST-Segment elevation myocardial infarction following transcatheter aortic valve replacement. *J Am Coll Cardiol*. 2021; 77(17): 2187-99. Article. IF: 27.203; D1

- Fiolet ATL, Opstal TSJ, Mosterd A, Eikelboom JW, Jolly SS, Keech AC, Kelly P, Tong DC, Lalyand J, Nidorf SM, Thompson PL, Budgeon C, Tijssen JGP, Cornel JH, (López-Sendón JL). Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. *Eur Heart J*. 2021; 42(28): 2765-75. Review. IF: 35.855; D1
- Gao C, Kogame N, Sharif F, Smits PC, Tonino P, Hofma S, Moreno R, Choudhury A, Petrov I, Ceguier A, Colombo A, Kaul U, Zaman A, de Winter RJ, Onuma Y, Serruys PW. Prospective multicenter randomized all-comers trial to assess the safety and effectiveness of the ultra-thin strut sirolimus-eluting coronary stent supraflex two-year outcomes of the TALENT Trial. *Circ Cardiovasc Inte*. 2021; 14(3): e010312. Letter. IF: 7.514; Q1
- García-Escobar A, Jiménez-Valero S, Galeote G, Jurado-Román A, García-Rodríguez J, Moreno R. The soluble catalytic ectodomain of ACE2 a biomarker of cardiac remodeling: new insights for heart failure and COVID19. *Heart Fail Rev*. 2021; 26(4): 961-71. Article. IF: 4.654; Q2
- García-Escobar A, Jurado-Román A, Jiménez-Valero S, Galeote G, Moreno R. Clinical outcomes of drug-eluting balloon for treatment of small coronary artery in patients with acute myocardial infarction: comment. *Intern Emerg Med*. 2021; 16(4): 1099-100. Letter. IF: 5.472; Q2
- García-Guimaraes M, Bastante T, Macaya F, Roura G, Sanz R, Alvarado JCB, Tizon H, Flores-Ríos X, Moreu J, Ojeda S, Nogales JM, Veiga G, Masotti M, Camacho-Freire SJ, Jiménez-Valero S, Jiménez-Kockar M, Lozano I, González-Ferreiro R, Velazquez M, Avanzas P, Rivero F, Alfonso F. Spontaneous coronary artery dissection in Spain: clinical and angiographic characteristics, man-

agement, and in-hospital events. *Rev Esp Cardiol*. 2021; 74(1): 15-23. Article. IF: 6.975; Q1

- Goligher EC, Bradbury CA, McVerry BJ, Lawler PR, Berger JS, Gong MN, Carrier M, Reynolds HR, Kumar A, Turgeon AF, Kornblith LZ, Kahn SR, Marshall JC, Kim KS, Houston BL, Derde LPG, Cushman M, Tritschler T, Angus DC, Godoy LC, McQuilten Z, Kirwan BA, Farkouh ME, Brooks MM, Lewis RJ, Berry LR, Lorenzi E, Gordon AC, Berry SM, McArthur CJ, Neal MD, Hochman JS, Webb SA, Zarychanski R, Ahuja T, Al-Beidh F, Annane D, Arabi YM, Aryal D, Kreuziger LB, Beane A, Bhimani Z, Bihari S, Billett HH, Bond L, Bonten M, Brunkhorst F, Buxton M, Buzgau A, Castellucci LA, Chekuri S, Chen JT, Cheng AC, Chkhikvadze T, Coiffard B, Contreras A, Costantini TW, de Brouwer S, Detry MA, Duggal A, Dzavik V, Efron MB, Eng HF, Escobedo J, Estcourt LJ, Everett BM, Fergusson DA, Fitzgerald M, Fowler RA, Froese JD, Fu ZX, Galanaud JP, Galen BT, Gandotra S, Girard TD, Goodman AL, Goossens H, Green C, Greenstein YY, Gross PL, Haniffa R, Hegde SM, Hendrickson CM, Higgins AM, Hindenburg AA, Hope AA, Horowitz JM, Horvat CM, Huang DT, Hudock K, Hunt BJ, Husain M, Hyzy RC, Jacobson JR, Jayakumar D, Keller NM, Khan A, Kim Y, Kindzelski A, King AJ, Kornblith AE, Kutcher ME, Laffan MA, Lamontagne F, Le Gal G, Leeper CM, Leifer ES, Lim G, Lima FG, Linstrum K, Litton E, López-Sendón J, Lother SA, Marten N, Marinéz AS, Martínez M, García EM, Mavromichalis S, McAuley DF, McDonald EG, McGlothlin A, McGuinness SP, Middeldorp S, Montgomery SK, Mouncey PR, Murthy S, Nair GB, Nair R, Nichol AD, Nicolau JC, Nunez-García B, Park JJ, Park PK, Parke RL, Parker JC, Parnia S, Paul JD, Pompilio M, Quigley JG, Rosenson RS, Rost NS, Rowan K, Santos FO, Santos M, Santos MO, Satterwhite L, Saunders CT, Schreiber J, Schutgens REG, Seymour CW, Siegal DM, Silva DG, Singhal AB, Slutsky AS, Solvason D, Turner AM, Van Bentum-Puijk W, van de Veerdonk FL, van Diepen S, Vázquez-Grande G, Wahid L, Wareham V, Widmer RJ, Wilson JG, Yuriditsky E, Zhong YQ. Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. *New Engl J Med*. 2021; 385(9): 777-89. Article. IF: 176.079; D1
- Gonzalo N, Salazar CH, Pérez-Vizcayno MJ, Gómez-Polo JC, Jiménez-Quevedo P, Jiménez-Valero S, Masotti M, Romaguera R, Fernández-Ortiz A, Escaned J, Alfonso F, Macaya C. Influence of neoatherosclerosis on prognosis and treatment response in patients with in-stent restenosis. *Rev Esp Cardiol*. 2021; 74(5): 427-35.

Article. IF: 6.975; Q1

- González-García A, Jiménez-Valero S, Jurado-Román A, Galeote G, Moreno R. Transcatheter aortic valve implantation during COVID-19 pandemic: The device also matters. *Cardiovasc Revasc Med*. 2021; 26: 66-7. Letter. Not Indexed
- Grand J, Miger K, Sajadieh A, Kober L, Torp-Pedersen C, Ertl G, López-Sendón J, Maggioni AP, Teerlink JR, Sato N, Gimpelewicz C, Metra M, Holbro T, Nielsen OW. Systolic blood pressure and outcome in patients admitted with acute heart failure: An analysis of individual patient data from 4 randomized clinical trials. *J Am Heart Assoc*. 2021; 10(18): e022288. Article. IF: 6.106; Q2
- Gutiérrez E, Gómez-Lara J, Moreno R. Importance of nonobstructive atheromatosis in patients with acute myocardial infarction. *Rev Esp Cardiol*. 2021; 74(11): 901-4. Editorial Material. IF: 6.975; Q1
- Hernández JMDT, Otaegui I, Subinas A, Gómez-Menchero A, Moreno R, Rondan J, Muñoz-García E, Sainz-Laso F, del Blanco BG, Rumoroso JR, Díaz JF, Berenguer A, Gómez-Lara J, Zueco J. First-in-man evaluation of a sirolimus-eluting stent with abluminal fluoropolymer/triflusal coating with ultrathin struts by OCT at 9 months' follow-up: The PROMETHEUS Study. *Cardiovasc Revasc Med*. 2021; 32: 18-24. Article. Not Indexed
- Jurado-Román A, González A, Jiménez-Valero S, Galeote G, Moreno R, de Sa EL. What have we learnt from the use of papyrus covered stent in France and Spain?. *Catheter Cardio Inte*. 2021; 98(2): 410. Letter. IF: 2.585; Q3
- Jurado-Román A, Jiménez-Valero S, Galeote G, Moreno R. Traveling wire after chronic total occlusion percutaneous coronary intervention. *J Invasive Cardiol*. 2021; 33(7): E578-9. Editorial Material. IF: 1.711; Q4
- Jurado-Román A, Rodríguez O, Amat I, Romani SA, García-Touchard A, Cruz-González I, Benito-González T, Fernández-Cisnal A, Córdoba-Soriano JG, Subinas A, Hernández-Antolin R, Bayón J, García-Tejada J, Salinas P, Cortés C, Lozano F, Bastante T, Núñez-Gil IJ, Moreno R, López-Sendón JL. Clinical outcomes after implantation of polyurethane-covered cobalt-chromium stents: Insights from the papyrus-Spain registry. *Cardiovasc Revasc Med*. 2021; 29: 22-8. Article. Not Indexed
- Lam CSP, Giczewska A, Sliwa K, Edelmann F, Refsgaard J, Bocchi E, Ezekowitz JA, Hernández AF, O'Connor CM, Roessig L, Patel MJ, Pieske B, Anstrom KJ, Armstrong PW, (López-Sendón JL). Clinical outcomes and response to vericiguat ac-




1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



ording to index heart failure event insights from the VICTORIA Trial. *JAMA Cardiol.* 2021; 6(6): 706-12. Article. IF: 30.154; D1

- Lawler PR, Golighe EC, Berge JS, Neal MD, McVerry BJ, Nicolau JC, Gong MN, Carrier M, Rosenson RS, Reynolds HR, Turgeon AF, Escobedo J, Huang DT, Bradbury CA, Houston BL, Kornblith LZ, Kumar A, Kah NSR, Cushman M, McQuilten Z, Slutsky AS, Kim KS, Gordon AC, Kirwan BA, Brooks MM, Higgins AM, Lewis RJ, Lorenzi E, Berry SM, Berry LR, Angus DC, McArthur CJ, Webb SA, Farkouh ME, Hochman JS, Zarychanski R, Aday AW, Al-Beidh F, Annane D, Arabi YM, Aryal D, Kreuziger LB, Beane A, Bhimani Z, Bihari S, Billett HH, Bond L, Bonten M, Brunkhorst F, Buxton M, Buzgau A, Castellucci LA, Chekuri S, Chen JT, Cheng AC, Chkhikvadzw T, Coiffard B, Costantini TW, de Brouwer S, Derde LPG, Detry MA, Duggal A, Dzavik V, Efron MB, Estcourt LJ, Everett BM, Fergusson DA, Fitzgerald M, Fowler RA, Galanaud JP, Galen BT, Gandotra S, García-Madróna S, Girard TD, Godoy LC, Goodman AL, Goossens H, Green C, Greenstein YY, Gross PL, Hamburg NM, Haniffa R, Hanna G, Hanna N, Hegde SM, Hendrickson CM, Hite RD, Hindenburg AA, Hope AA, Horowitz JM, Horvat CM, Hudock K, Hunt BJ, Husain M, Hyzy RC, Iyer VN, Jacobson JR, Jayakumar D, Keller NM, Khan A, Kim Y, Kindzelski AL, Kin AJ, Knudson MM, Kornblith AE, Krishnan V, Kutcher ME, Laffan MA, Lamontagne F, Le Gal G, Leeper CM, Leifer ES, Lim G, Lima FG, Linstrum K, Litton E, López-Sendón J, Moreno JLLS, Lothar SA, Malhotra S, Marcos M, Marinez AS, Marshall JC, Marten N, Matthey MA, McAuley DF, McDonald EG, McGlothlin A, McGuinness SP, Middeldorp S, Montgomery SK, Moore SC, Guerreor RM, Mouncey PR, Murthy S, Nair GB, Nair R, Nichol AD, Núñez-García B, Pandey A, Park PK, Parke RL, Parker JC, Parnia S, Paul JD, González YSP, Pompilio M, Prekker ME, Quigley JG, Rost NS, Rowan K, Santos FO, Santos M, Santos MO, Satterwhite L, Saunders CT, Schutgens REG, Seymour CW, Siegal DM, Silva DG, Shankar-Hari M, Sheehan JP, Singhal AB, Solvaso D, Stanworth SJ, Tritschler T, Turner AM, Van Bentum-Puijk W, van de Veerdonk FL, van Diepen S, Vázquez-Grande G, Wahid L, Wareham V, Wells BJ, Widmer RJ, Wilson JG, Yuriditsky E, Zampieri FG. Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. *New Engl J Med.* 2021; 385(9): 790-802. Article. IF: 176.079; D1
- López-de-Sa E. Acute coronary occlusion in non-STEMI: If you change the way you look at things, the things you look at change. *Int J Cardiol.* 2021; 322: 49-50. Editorial Material. IF: 4.039; Q2



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

- López-Sendón J, Moreno R, Tamargo J. ISCHEMIA trial: key questions and answers. *Eur Cardiol.* 2021; 16: e34. Article. Not Indexed
- Magnani G, Ardissino D, Im K, Budaj A, Storey RF, Steg PG, Bhatt DL, Cohen M, Ophius TO, Goudev A, Parkhomenko A, Kamensky G, Angiolillo DJ, López-Sendón J, Johanson P, Braunwald E, Sabatine MS, Bonaca MP. Predictors, type, and impact of bleeding on the net clinical benefit of long-term ticagrelor in stable patients with prior myocardial infarction. *J Am Heart Assoc.* 2021; 10(4): e017008. Article. IF: 6.106; Q2
- Mancini G BJ, Leipsic J, Budoff MJ, Hague CJ, Min JK, Stevens SR, Reynolds HR, O'Brien SM, Shaw LJ, Manjunath CN, Mavromatis K, Demkow M, López-Sendón JL, Chernavskiy AM, Gosselin G, Schuchlenz H, Devlin GP, Chauhan A, Bangalore S, Hochman JS, Maron DJ. CT angiography followed by invasive angiography in patients with moderate or severe ischemia-insights from the ISCHEMIA Trial. *JACC Cardiovasc Imaging.* 2021; 14(7): 1384-93. Article. IF: 16.051; D1
- Manolis AJ, Boden WE, Collins P, Dechend R, Kallistratos MS, Sendón JL, Poulimenes LE, Ambrosio G, Rosano G. State of the art approach to managing angina and ischemia: tailoring treatment to the evidence. *Eur J Intern Med.* 2021; 92: 40-7. Review. IF: 7.749; Q1
- Melón NMM, Valero SJ, González-Trevilla AA, Martín MTV. Intraplaque hemorrhage: Can OCT identify this elusive pathological substrate? *Cardiovasc Revasc Med.* 2021; 30: 89-90. Editorial Material. Not Indexed
- Merino-Caviedes S, Gutiérrez LK, Alfonso-Almazán JM, Sanz-Estebánez S, Cordero-Grande L, Quintanilla JG, Sánchez-González J, Marina-Breyse M, Galán-Arriola C, Enriquez-Vázquez D, Torres C, Pizarro G, Ibáñez B, Peinado R, Merino JL, Pérez-Villacastín J, Jalife J, López-Yunta M, Vázquez M, Aguado-Sierra J, González-Ferrer JJ, Pérez-Castellano N, Martín-Fernández M, Albelola-López C, Filgueiras-Rama D. Time-efficient three-dimensional transmural scar assessment provides relevant substrate characterization for ventricular tachycardia features and long-term recurrences in ischemic cardiomyopathy. *Sci Rep-Uk.* 2021; 11(1): 18722. Article. IF: 4.996; Q2
- Mesnier J, Ducrocq G, Danchin N, Ferrari R, Ford I, Tardif JC, Tendra M, Fox KM, Steg PG, (López-Sendón JL). International observational analysis of evolution and outcomes of chronic stable angina the multinational CLARIFY study. *Circulation.* 2021; 144(7): 512-23. Article. IF: 39.918; D1
- Miller AB, Januzzi JL, O'Neill BJ, Gundapaneni B, Patterson TA, Sultan MB, López-Sendón J. Causes of cardiovascular hospitalization and death in patients with transthyretin amyloid cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]). *Am J Cardiol.* 2021; 148: 146-50. Article. IF: 3.133; Q3
- Monreal E, de la Maza SS, Gullón P, Natera-Villalba E, Chico-García JL, Beltrán-Corbellini A, Martínez-Sanz J, García-Barragán N, Buisan J, Toledano R, Alonso-Canovas A, Pérez-Torre P, Matute-Lozano MC, López-Sendón JL, García-Ribas G, Corral I, Fortun J, Montero-Erasquin B, Manzano L, Maiz-Carro L, Costa-Frossard L, Masjuan J. Non-severe immunosuppression might be associated with a lower risk of moderate-severe acute respiratory distress syndrome in COVID-19: A pilot study. *J Med Virol.* 2021; 93(4): 2243-51. Article. IF: 20.693; D1
- Moreno R, Alonso JJ, Caballero R, del Corral E, Elizaga J, Asenjo RM, Mena MJ, Alfonso F, Fernández-Ortiz A, Goicolea FJ, Botas J, Navarro F, Alegria-Barrero E, Ansele JC, de Sa EL, López-Sendón JL. Age and gender influence on time of arrival for STEMI patients during Covid-19 pandemic. *Am J Emerg Med.* 2021; 42: 244-5. Letter. IF: 4.093; Q1
- Moreno R, Baz JA, Moreu J, Berenguer A, González-García A, Galeote G, Hernández U, Canton T, Jiménez-Valero S, Jurado-Román A, Moya H, Lazaro E. Transcatheter aortic valve implantation for degenerated aortic valves: Experience with a new supra-annular device. The Spanish Allegra valve-in-valve (SAVIV) registry. *Cather Cardio Inte.* 2021; 98(2): 365-70. Article. IF: 2.585; Q3
- Moreno R, Díez JL, Diarte JA, Salinas P, Hernández JMD, Andrés-Cordón JF, Trillo R, Briales JA, Amat-Santos I, Romaguera R, Díaz JF, Vaquerizo B, Ojeda S, Cruz-González I, Morena-Salas D, de Prado AP, Sarmago F, Portero P, Gutiérrez-Barrios A, Alfonso F, Bosch E, Pinar E, Ruiz-Arroyo JR, Ruiz-Quevedo V, Jiménez-Mazuecos J, Lozano F, Rumoroso JR, Novo E, Irazusta FJ, Del Blanco BG, Moreu J, Ballesteros-Pradas SM, Frutos A, Villa M, Alegria-Barrero E, Lazaro R, Paredes E. Impact of diabetes in patients waiting for invasive cardiac procedures during COVID-19 pandemic. *Cardiovasc Diabetol.* 2021; 20(1): 69. Article. IF: 8.949; Q1
- Moreno R, Unverdorben M, Jurado-Roman A, Galeote G, Jiménez-Valero S, Arroyo-Ucar E, Thiele H. The risk of valve thrombosis is higher with intra-annular versus supra-annular transcatheter aortic valve prosthesis. A meta-analysis from randomized controlled trials. *Clin Res Cardiol.* 2021; 110(12): 2007-9. Letter. IF: 6.138; Q2
- Moreno R. After TAVI, aspirin vs. aspirin plus clopidogrel for 3 mo reduced bleeding and a composite of bleeding and thrombotic events at 1 y. *Ann Intern Med.* 2021; 174(2): JC21. Editorial Material. IF: 51.598; D1
- Ntaios G, Huisman MV, Diener HC, Halperin JL, Teutsch C, Marler S, Gurusamy VK, Thompson M, Lip GYH, Olshansky B, (López-Sendón JL). Anticoagulant selection in relation to the SAME-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry. *Hell J Cardiol.* 2021; 62(2): 152-7. Article. IF: 5.795; Q2
- Oliver JM, Gallego P, González AE, Ávila P, Alonso A, Garcia-Hamilton D, Peinado R, Dos-Subira L, Pijuan-Domenech A, Rueda J, Rodríguez-Puras MJ, García-Orta R, Martínez-Quintana E, Dantino T, Fernández-Aviles F, Bermejo J. Predicting sudden cardiac death in adults with congenital heart disease. *Heart.* 2021; 107(1): 67-75. Article. IF: 7.365; Q1
- Oliver-Ruiz JM, Peinado-Peinado R. Preventing ventricular arrhythmias and sudden cardiac death in adults with repaired tetralogy of Fallot: a never-ending story? *Rev Esp Cardiol.* 2021; 74(11): 905-8. Editorial Material. IF: 6.975; Q1
- Packer M, Anker SD, Butler J, Filippatos G, Ferrera JP, Pocock SJ, Sattar N, Brueckmann M, Jamal W, Cotton D, Iwata T, Zannad F. Empagliflozin in patients with heart failure, reduced ejection fraction, and volume overload. *J Am Coll Cardiol.* 2021; 77(11): 1381-92. Article. IF: 27.203; D1
- Packer M, Butler J, Zannad F, Filippatos G, Ferrera JP, Pocock SJ, Carson P, Anand I, Doehner W, Haass M, Komajda M, Miller A, Pehrson S, Teerlink JR, Schnaidt S, Zeller C, Schnee JM, Anker SD, (López-Sendón JL). Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction EMPEROR-Preserved Trial. *Circulation.* 2021; 144(16): 1284-94. Article. IF: 39.918; D1
- Pascual-Tejerina V, Sánchez-Recalde A, Gutiérrez-Laraya F, Ruiz-Cantador J, Rodríguez-Padial L, Zamorano JL. Transcatheter closure of a vertical vein in a patient with total anomalous pulmonary venous drainage decompressing the left atrium with an AFR device. *Rev Esp Cardiol.* 2021; 74(11): 990-1. Letter. IF: 6.975; Q1
- Peinado RP. Adherence to optimal ICD programming: an unresolved issue. *Rev Esp Cardiol.* 2021; 74(4): 286-9. Editorial Material. IF: 6.975; Q1
- Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM, (López-Sendón JL). Cardiovascular events with finerenone in kidney disease and type 2 Diabetes. *New Engl J Med.* 2021; 385(24): 2252-63. Article. IF: 176.079; D1
- Reynolds HR, Picard MH, Spertus JA, Peteiro J, Sendón JLL, Senior R, El-Hajjar MC, Celutkienė J, Shapiro MD, Pellikka PA, Kunichoff DF, Anthonopolos R, Alfakih K, Abdul-Nour K, Khouri M, Bershtein L, De Belder M, Poh KK, Beltrame JF, Min JMK, Fleg JL, Li Y, Maron DJ, Hochman JS. Natural history of patients with ischemia and no obstructive coronary artery disease The CIAO-ISCHEMIA Study. *Circulation.* 2021; 144(13): 1008-23. Article. IF: 39.918; D1
- Roca RF, Salado JCS, Fernández MC, Acuna JMG, Serrano AL, de Sa EL, Ramírez JR. Management of temperature control in post-cardiac arrest care: an expert report. *Med Intensiva.* 2021; 45(3): 164-74. Article. IF: 2.799; Q3
- Rodríguez-Leor O, Cid-Álvarez B, de Prado AP, Rossello X, Ojeda S, Serrador A, López-Palop R, Martín-Moreiras J, Rumoroso JR, Cequier A, Ibáñez B, Cruz-González I, Romaguera R, Moreno R. In-hospital outcomes of COVID-19 ST-elevation myocardial infarction patients. *Eurointervention.* 2021; 16(17): 1426-33. Article. IF: 7.728; Q1
- Romaguera R, Ojeda S, Cruz-González I, Moreno R. Spanish cardiac catheterization and coronary intervention registry. 30th Official Report of the Interventional Cardiology Association of the Spanish Society of Cardiology (1990-2020) in the year of the COVID-19 pandemic. *Rev Esp Cardiol.* 2021; 74(12): 1096-106. Article. IF: 6.975; Q1
- Rubio-Alarcón M, Camara-Checa A, Dago M, Crespo-García T, Nieto-Marín P, Marín M, Merino JL, Toquero J, Salguero-Bodes R, Tamargo J, Cebrián J, Delpón E, Caballero R, Invest. Zfhx3 transcription factor represses the expression of SCN5A gene and decreases sodium current density (I-Na). *Int J Mol Sci.* 2021; 22(23): 13031. Article. IF: 6.208; Q1
- RuiPérez-Campillo S, Castrejón S, Martínez M, Cervigón R, Meste O, Merino JL, Millet J, Castells F. Non-invasive characterisation of macroentrant atrial tachycardia types from a vectorcardiographic approach with the slow conduction region as the cornerstone. *Comput Meth Prog Bio.* 2021; 200: 105932. Article. IF: 7.027; D1
- Sabate M, Okkels-Jensen L, Tilsted HH, Moreno R, del Blanco BG, Macaya C, de Prado AP, Cequier A, Pérez-Fuentes P, Schutte D, Costa R, Stoll HP, Lassen JF. Thin- versus thick-strut polymer-free biolimus-eluting stents: the BioFreedom QCA randomised trial. *Eurointervention.* 2021; 17(3): 233-9. Article. IF: 7.728; Q1
- Salamanca J, García-Guimaraes M, Camacho-



1
Introduction

2
Executive
Summary

3
Information
Groups
by Area

4
Associated
Clinicians

Freire SJ, Ojeda S, Veiga G, Jiménez-Valero S, Hernández-Antolin R, Trillo R, Velazquez M, Cortes C, Gutiérrez-Barríos A, Franco-Pelaez JA, Lezcano-Pertejo C, Diez-Delhoyo F, Gamarra A, Aguilar R, Diez-Villanueva P, Bastante T, Alfonso F. Spontaneous coronary artery dissection and Takotsubo syndrome: comparison of baseline clinical and angiographic characteristics and in-hospital outcomes. *Coronary Artery Dis.* 2021;32(6):509-516. Article. IF: 1,717; Q4

- Salinas P, Gonzalo N, Moreno VH, Fuentes M, Santos-Martínez S, Fernández-Díaz JA, Amat-Santos IJ, Ojeda FB, Borrego JC, Cuesta J, Hernández JMD, Diego-Nieto A, Dubois D, Galeote G, Goicolea J, Gutiérrez A, Jiménez-Fernández M, Jiménez-Mazuecos J, Jurado A, Lacunza J, Lee DH, López M, Lozano F, Martín-Moreiras J, Martín-Yuste V, Millán R, Minana G, Mohandes M, Morales-Ponce FJ, Nunez J, Ojeda S, Pan M, Rivero F, Robles J, Rodríguez-Leiras S, Rojas S, Rondán J, Rumiz E, Sabate M, Sanchis J, Vaquerizo B, Escaned J. Choice of CTO scores to predict procedural success in clinical practice. A comparison of 4 different CTO PCI scores in a comprehensive national registry including expert and learning CTO operators. *Plos One.* 2021; 16(4): e0245898. Article. IF: 3.752; Q2
- Samuel M, Tardif JC, Khairy P, Roubille F, Waters DD, Gregoire JC, Pinto FJ, Maggioni AP, Diaz R, Berry C, Koenig W, Ostadal P, López-Sendón J, Gamra H, Kiwan GS, Dube MP, Provencher M, Orfanos A, Blondeau L, Kouz S, L'Allier PL, Ibrahim R, Bouabdallaoui N, Mitchell D, Guertin MC, Leloir J. Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). *Eur Heart J Qual Care Clin Outcomes.* 2021; 7(5): 486-95. Article. IF: 7.064; Q1
- Tamargo J, López-Sendón J. Ranolazine: a better understanding of pathophysiology and patient profile to guide treatment of chronic stable angina. *Future Cardiol.* 2021; 18(3): 235-51. Review. Not Indexed
- Tardif JC, Bouabdallaoui N, L'Allier PL, Gaudet D, Shah BI, Pillinger MH, López-Sendón J, da Luz P, Verret L, Audet S, Dupuis J, Denault A, Pellerier M, Tessier PA, Samson S, Fortin D, Tardif JD, Busseuil D, Goulet E, Lacoste C, Dubois A, Joshi AY, Waters DD, Hsue P, Lepor NE, Lesage F, Sain-turet N, Roy-Clavel E, Bassevitch Z, Orfanos A, Stamatescu G, Gregoire JC, Busque L, Lavallee C, Hetu PO, Paquette JS, Deftereos SG, Levesque S, Cossette M, Nozza A, Chabot-Blanchet M, Dube MP, Guertin MC, Boivin G. Colchicine for community-treated patients with COVID-19

(COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. *Lancet Respir Med.* 2021; 9(8): 924-32. Article. IF: 102.642; D1

- Testa L, Agnifili M, Van Mieghem NM, Tchetché D, Asgar AW, De Backer O, Latib A, Reimers B, Stefanini G, Trani C, Colombo A, Giannini F, Bartorelli A, Wojakowski W, Dabrowski M, Jagielak D, Banning AP, Kharbanda R, Moreno R, Scholer J, van Royen N, Pinto D, Serra A, Segev A, Giordano A, Brambilla N, Rubbio AP, Casenghi M, Oreglia J, De Marco F, Tanja R, McCabe JM, Abizaid A, Voskuil M, Teles R, Zoccai GB, Bianchi G, Sondergaard L, Bedogni F. Transcatheter aortic valve replacement for degenerated transcatheter aortic valves The TRANSIT International Project. *Circ-Cardiovasc Inte.* 2021; 14(6): 628-38. Article. IF: 7.514; Q1
- Trejo-Velasco B, Tello-Montoliu A, Cruz-González I, Moreno R, Baz-Alonso JA, Salvadores PJ, Romaguera R, Molina-Navarro E, Paredes-Galán E, Fernández-Barbeira S, Ortiz-Saez A, Bastos-Fernández G, de Miguel-Castro A, Figueiras-Guzman A, Íñiguez-Romo A, Jiménez-Díaz VA. Impact of comorbidities and antiplatelet regimen on platelet reactivity levels in patients undergoing transcatheter aortic valve implantation. *J Cardiovasc Pharm.* 2021; 78(3): 463-73. Article. IF: 3.271; Q3
- Vega JDS, Salinas GLA, Flórez JMV, Sole AA, de Sa EL, Ruiz RS, Palacios VB, Raposeiras-Roubin S, Varela SG, Sanchis J, Melchor LS, Martínez-Seara X, López LM, Gómez JLZ, Fernández MS. Temporal trends in postinfarction ventricular septal rupture: the CIVIAM Registry. *Rev Esp Cardiol.* 2021; 74(9): 757-64. Article. IF: 6.975; Q1
- Vehmeijer JT, Koyak Z, Leerink JM, Zwinderman AH, Harris L, Peinado R, Oechslin EN, Robbers-Visser DE, Groenink M, Boekholdt SM, De Winter RJ, Oliver JM, Bouma BJ, Buuts W, Van Gelder IC, Mulder BJM, de Groot JR. Identification of patients at risk of sudden cardiac death in congenital heart disease: The PRospective study on implanTable cardioverter defibrillator therapy and sudden cardiac death in Adults with Congenital Heart Disease (PREVENTION-ACHD). *Heart Rhythm.* 2021; 18(5): 785-92. Article. IF: 6.779; Q2
- White HD, O'Brien SM, Alexander KP, Boden WE, Bangalore S, Li JH, Manjunath CN, López-Sendón JL, Petteiro J, Gosselin G, Berger JS, Maggioni AP, Reynolds HR, Hochman JS, Maron DJ. Comparison of days alive out of hospital with initial invasive vs conservative management a prespecified analysis of the ISCHEMIA Trial. *JAMA Cardiol.* 2021; 6(9): 1023-31. Article. IF: 30.154; D1

■ Research projects

Antorrena Miranda MI. International study of comparative health effectiveness with medical and invasive approaches - estudio internacional comparativo de la eficacia sanitaria con enfoques médicos e invasivos. New York University School Of Medicine. 2013-Ongoing.

Management centre: FIBHULP

Galeote García G. Aterectomia rotacional electiva vs de rescate en pacientes con lesiones coronarias calcificadas graves e insuficiencia renal crónica. Medtronic Ibérica S.A. 2020-Ongoing.

Management centre: FIBHULP

Guzmán Martínez G. Inmunidad en sars-cov-2 y riesgo cardiovascular. Cohorte prospectiva. FIBHULP. 2020-Ongoing.

Management centre: FIBHULP

Guzmán Martínez G. Marcadores precoces de disfunción ventricular derecha y alteraciones de la circulación pulmonar en pacientes afectos de hipertensión pulmonar. Siemens Healthcare S.L. 2018-Ongoing.

Management centre: FIBHULP

Jiménez Valero S. Análisis de correlación entre los marcadores de inflamación y morfología de placas coronarias mediante tomografía de coherencia óptica y tec multicorte: estudio IVI. Abbott Laboratories S.A. 2009-Ongoing.

Management centre: FIBHULP

Jiménez Valero S. Estudio en modelo porcino para evaluar la utilidad de la tomografía de coherencia óptica en el análisis de las lesiones endocárdicas producidas por radiofrecuencia. Medlumics S.L. 2015-Ongoing.

Management centre: FIBHULP

López de Sá y Areses E. Investigación

traslacional en arritmias cardíacas hereditarias (S2017/BMD-3738). CM. 2018-2021.

Management centre: FIBHULP

López-Sendón Henstchel JL. Biomarcadores en la cardiotoxicidad por agentes antineoplás: rendimiento diagnóstico. Boehringer Ingelheim España S.A. 2015-Ongoing.

Management centre: FIBHULP

López-Sendón Henstchel JL. Colchicine cardiovascular outcome trial_COLCOT. Montreal Heart Institute. 2017-Ongoing.

Management centre: FIBHULP

López-Sendón Henstchel JL. Colchicine coronavirus sars-cov2 trial (COCORONA-Covid-19). Montreal Heart Institute. 2020-Ongoing.

Management centre: FIBHULP

López-Sendón Henstchel JL, Borobia Pérez AM. A multicentre, adaptative, randomize controlled platform trial of the safety and efficacy of antithrombotic and additional strategies in hospitalized adult with COVID-19. National Institute of Health. 2020-Ongoing.

Management centre: FIBHULP

Merino Llorens JL. Addressing multimorbidity in elderly atrial fibrillation patients through interdisciplinary, tailored, patient-centred care pathways (EHRA-PATHS). UE. 2020-2026.

Management centre: FIBHULP

Merino Llorens JL. El vectorcardiograma como herramienta de caracterización no invasiva de la dinámica de activación y de la presencia y localización de zonas de conducción lenta en los circuitos de flutter auricular atípico izquierdo mediante vectorcardiograma. Arrhythmia Network Technology S.L. 2018-Ongoing.

Management centre: FIBHULP



1
Introduction

2
Executive
Summary

3
Information
Groups
by Area

4
Associated
Clinicians

Merino Llorens JL. Formación en investigación en electrofisiología cardiaca. European Society Of Cardiology. 2015-Ongoing.

Managment centre: FIBHULP

Merino Llorens JL. High radiofrecuency power for faster and safer pulmonary veins ablation trial (Power FAST II) (PI18/01522). ISCI. 2019-2021.

Managment centre: FIBHULP

Merino Llorens JL. High radiofrequency power for faste and safe pulmonary veins ablation-a pilot observational study (Power Fast I). Arrhythmia Network Trechnology S.L. 2018-Ongoing.

Managment centre: FIBHULP

Merino Llorens JL. Hospital Smart development based on AI (HosmartAI). UE. 2020-2024.

Managment centre: FIBHULP

Merino Llorens JL. Registro retrospectivo de identificación de factores cardiovasculares de mal pronóstico en pacientes covid-19 (CARD-COVID). Medtronic Ibérica S.A. 2020-Ongoing.

Managment centre: FIBHULP

Moreno Gómez JR. Evaluación clínica y seguimiento de los pacientes con cardiopatía estructural sometidos a procedimientos de tratamiento percutáneo. Abbott Laboratories S.A. 2011-Ongoing.

Managment centre: FIBHULP

Peinado Peinado R. Comparación de un cateter multielectrodo frente a un cateter de ablación de punta irrigada para crear mapas de voltaje y activación en pacientes con taquicardias auriculares macroreentrantes. Medtronic Iberica S.A. 2019-Ongoing.

Managment centre: FIBHULP

Peinado Peinado R. Influencia del remodelado eléctrico del miocardio auricular en la recurrencia de fibrilación auricular tras el aislamiento eléctrico de las venas pulmonares por fibrilación auricular paroxística. Abbott Medical España S.A. 2009-Ongoing.

Managment centre: FIBHULP

Peinado Peinado R. Papel de los receptores del sistema inmune innato en el desarrollo y evolución de la fibrilación auricular. Medtronic Iberica S.A. 2021-Ongoing.

Managment centre: FIBHULP

Peinado Peinado R. PI-719 síndrome de apneas-hipopneas obstructivas del sueño y arritmias ventriculares en pacientes con disfunción ventricular sistólica portadores de DAI. Fundación Casa del Corazón. 2008-Ongoing.

Managment centre: FIBHULP

Peinado Peinado R. Registro de pacientes con cardiopatía congénita del adulto portadores de un sistema de terapia de resincronización cardiaca (RETRACCA). Abbott Medical España S.A. 2017-Ongoing.

Managment centre: FIBHULP

Peinado Peinado R. Utilidad de los algoritmos de diagnostico diferencial electrocardiografico de las taquicardias regulares de QRS ancho en pacientes con cardiopatías congénitas de adulto. Medtronic Iberica S.A. 2019-Ongoing.

Managment centre: FIBHULP

Riera del Moral LF. Tratamiento celular de los aneurismas de aorta abdominal en un modelo murino. Jotec Cardiovascular S.L. 2017-Ongoing.

Managment centre: FIBHULP

■ Clinical trials

Antorrena Miranda, MI. Ensayo de fase III, aleatorizado y doble ciego para evaluar la eficacia y la seguridad de una dosis diaria de 10 mg de empaglifozina en comparación con placebo en pacientes con insuficiencia cardíaca crónica con fracción de eyección preservada (icc-fep).

Type: Clinical Trials, phase III.

HULP code: Appendix 2 4988.

Sponsored by: Boehringer Ingelheim International GmbH.

Signed date: 16/02/2021

Antorrena Miranda, MI. Ensayo en fase III, aleatorizado y doble ciego para evaluar la eficacia y la seguridad de una dosis diaria de 10 mg de empaglifozina en comparación con el placebo en pacientes con insuficiencia cardíaca crónica con fracción de eyección reducida (icc-fer).

Type: Clinical Trials, phase III.

HULP code: Appendix 2 5001.

Sponsored by: Boehringer Ingelheim International GmbH.

Signed date: 20/04/2021

Armada Romero, E. Perfil de ldl-c en pacientes con evento cardiovascular: un estudio multicentrico retrospectivo en España. estudio heartbeat.

Type: Estudios, phase EPA-OD.

HULP code: PI-4500 DAI-LDL-2020-01.

Sponsored by: Daiichi Sankyo España.

Signed date: 15/01/2021

Armada Romero, E. Estudio en fase III, aleatorizado, doble ciego y controlado con placebo para evaluar los efectos de dalcetrapib sobre el riesgo cardiovascular (cv) en una población definida genéticamente con síndrome coronario agudo reciente (sca): el ensayo dal-gene.

Type: Clinical Trials, phase III.

HULP code: Appendix 2 4627.

Sponsored by: Dalcor Pharma Uk Ltd.
Signed date: 03/02/2021

Castro Conde, A. Comparación del efecto de tirzepatida frente al de dulaglutida sobre los acontecimientos cardiovasculares mayores en pacientes con diabetes de tipo 2 (surpass-cvot).

Type: Clinical Trials, phase I.

HULP code: Appendix 1 5484.

Sponsored by: Lilly, S.A.

Signed date: 11/03/2021

Escobar Cervantes, C. Estudio epidemiológico multinacional transversal de pacientes hipertensos con dislipemia y resultados proporcionados por el paciente.

Type: Estudios, phase EPA-OD.

HULP code: PI-4893B SNAPSHOT.

Sponsored by: Laboratorios Servier, S.L.

Signed date: 19/10/2021

Jiménez Valero, S. Ensayo clínico aleatorizado para evaluar el efecto de los betabloqueantes y los antiagregantes plaquetarios en pacientes con disección espontánea de la arteria coronaria.

Type: Clinical Trials, phase IV.

HULP code: 5960 BA-SCAD.

Sponsored by: Sociedad Española De Cardiología (Sec).

Signed date: 16/08/2021

López De Sá Areses, E. Ensayo multicéntrico, adaptativo, aleatorizado y controlado sobre la seguridad y eficacia de las estrategias antitrombóticas en adultos hospitalizados con COVID-19.

Type: Clinical Trials, phase IV.

HULP code: 5694 ACTIV-4-ACUTE.

Sponsored by: Fundacion Para La Investigacion Biomedica Hospital Universitario La Paz.

Signed date: 15/01/2021

López De Sá Areses, E. Estudio en fase IIb, aleatorizado, doble ciego contro-



lado con placebo, de grupos paralelos para evaluar la eficacia y la seguridad de medi6570 en participantes con infarto de miocardio previo, inflamación persistente y niveles elevados de prohormona n-terminal natriurético cerebral.

Type: Clinical Trials, phase II.
HULP code: Appendix 1 5637.
Sponsored by: Astrazeneca Ab.
Signed date: 16/03/2021

López De Sá Areses, E. Estudio para la validación clínica de un nuevo biomarcador para determinar la predisposición a infecciones en pacientes con infarto agudo de miocardio.

Type: Estudios No EPA.
HULP code: pi-4791 BIOMIN-001.
Sponsored by: Crazy Science & Business Sl.
Signed date: 28/06/2021

López De Sá Areses, E. Estudio en fase IIb, aleatorizado, doble ciego controlado con placebo, de grupos paralelos para evaluar la eficacia y la seguridad de medi6570 en participantes con infarto de miocardio previo, inflamación persistente y niveles elevados de prohormona n-terminal natriurético cerebral.

Type: Clinical Trials, phase II.
HULP code: Appendix 2 5637.
Sponsored by: Astrazeneca Ab.
Signed date: 06/07/2021

López De Sá Areses, E. Estudio clínico fundamental de fase 3, aleatorizado y controlado con placebo para evaluar la eficacia y la seguridad del estimulador de la gcsvericiguat/mk-1242 en adultos con insuficiencia cardíaca crónica con fracción de eyección reducida.

Type: Clinical Trials, phase III.
HULP code: 5969 MK1242-035.
Sponsored by: Merck Sharp And Doh-

me De España, S.A.
Signed date: 06/09/2021

López Fernández, T. Epiq-affiniti ultrasound system study for cardiology.

Type: Estudios No EPA.
HULP code: Appendix 1 PI-2996.
Sponsored by: Philips Ultrasound Inc.
Signed date: 23/04/2021

López Fernández, T. Registro de la profilaxis cardioembólica de los pacientes con cáncer en tratamiento oncoespecífico.

Type: Estudios, phase EPA-OD.
HULP code: PI-4806 PROCECAN 2021.
Sponsored by: Fundacion Seth.
Signed date: 07/10/2021

Moreno Gómez, JR. Observational study to evaluate the clinical outcome of high-risk patients undergoing percutaneous coronary intervention (pci) with everolimus-eluting stent implantation using intracoronary tools for pci guidance and optimization.

Type: Estudios No EPA.
HULP code: PI-4898 OPTI-XIENCE.
Sponsored by: Fundación Casa Del Corazón.
Signed date: 30/08/2021

Moreno Gómez, JR. Ensayo clínico controlado aleatorizado para comparar la seguridad y eficacia del stent liberador de sirolimus, ultradelgado con polímero biodegradable (supraflextm cruz), y el stent liberador de everolimus, con polímero biodegradable (synergym), en el tratamiento de la enfermedad de las arterias coronarias de tres vasos. multivessel talent.

Type: Estudio Producto Sanitario.
HULP code: 5928 NUIG-2020-002.
Sponsored by: National University Of Ireland, Galway.
Signed date: 15/09/2021

Moreno Gómez, JR. Estudio aleatorizado paralelo para evaluar la utilidad de la revisión angiográfica rutinaria 6 meses después del intervencionismo percutáneo en el tronco común izquierdo. estudio angeline.

Type: Estudios No EPA.
HULP code: 5821 EPIC-23.
Sponsored by: Fundación Epic.
Signed date: 05/10/2021

Moreno Gómez, JR. Primera investigación clínica en humanos del catéter para angioplastia coronaria transluminal percutánea recubierto de everolimus de chansu vascular technologies: evaluación clínica en el tratamiento de sujetos con reestenosis intrastent de lesiones de arterias coronarias tratadas previamente.

Type: Estudio Producto Sanitario.
HULP code: 6029 TP1125.
Sponsored by: Chansu Vascular Technologies, Llc.
Signed date: 18/11/2021

Moreno Gómez, JR. Guía de ultrasonido intravascular para procedimientos complejos indicados como de alto riesgo (ivus chip).

Type: Estudios, phase EPA-OD.
HULP code: 5979 ECRI 14.
Sponsored by: European Cardiovascular Research Institute (Ecri-14).
Signed date: 30/11/2021

Moreno Gómez, JR. Registro de dispositivos médicos vasculares de abbott (abbott vascular medical device registry av-mdr).

Type: Estudio Producto Sanitario.
HULP code: PI-5013 CRD-1008/ABT-CIP-10349.
Sponsored by: Sjm International Inc.
Signed date: 01/12/2021

Moreno Gómez, JR. Fractional flow re-

serve or 3d-quantitative-coronaryangiography based vessel-ffr guided revascularization: fast III trial.

Type: Estudio Producto Sanitario.
HULP code: 6036 ECRI-15.
Sponsored by: European Cardiovascular Research Institute (Ecri-15).
Signed date: 14/12/2021".

Patents and trademarks

Figueiras Rama D, López de Sá y Areses E, Millet Roig J, Calvo Saiz CJ, inventors; Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), FIBHULP, Universidad Politécnica de Valencia, assignees. Method of predicting or prognosticating neurological performance in patients who have suffered a cardiac arrest and optionally comatose status due to ventricular fibrillation. PCT/EP2015/076893, EP3020333; 2014 November 17.

Riera del Moral LF, inventor; FIBHULP, assignee. Aortic endoprosthesis for the treatment of aneurysm. P201231638, PCT/ES2013/070712; 2012 October 24.

Castro Conde A, author; FIBHULP, assignee. Trademark name: RECAR Programa de Rehabilitación Cardíaca; CM 18457042; 2021 April 20.



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



3.2.2 Cardiovascular Epidemiology and Nutrition Group*

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Publications: 42

Q1: 26

COMPOSITION



Fernando Rodríguez Artalejo. Catedrático de Medicina Preventiva y Salud Pública. Facultad de Medicina. Universidad Autónoma de Madrid

José Ramón Banegas Banegas. Catedrático de Medicina Preventiva y Salud Pública. Facultad de Medicina. Universidad Autónoma de Madrid

Auxiliadora Graciani Pérez-Regadera. Profesora Contratada de Medicina Preventiva y Salud Pública. Facultad de Medicina. Universidad Autónoma de Madrid

Pilar Guallar Castillón. Profesora Titular de Medicina Preventiva y Salud Pública. Facultad de Medicina. Universidad Autónoma de Madrid

Juan Luis Gutiérrez Fisac. Profesor Asociado de Medicina Preventiva y Salud Pública. Facultad de Medicina. Universidad Autónoma de Madrid

Esther López García. Profesora Contratada. Doctora de Medicina Preventiva y Salud Pública. Facultad de Medicina. Universidad Autónoma de Madrid

STRATEGIC OBJECTIVE

Our strategic objective is to produce relevant information to support clinical and population-based policies aimed at controlling CVD. The results of our studies have been explicitly incorporated into the National Strategy for Ischemic Heart Disease Control and into the National Strategy for Obesity Prevention and Control, elaborated by the Ministry of Health.

Moreover, our research results have also supported the develop-

ment of clinical guidelines in this field; specifically, the guidelines of the Spanish Society for Arterial Hypertension, and guidelines of the Spanish Society of Family Medicine, the leading society devoted to primary health care in Spain.

RESEARCH LINES

- Cardiovascular and nutritional epidemiology

* The group decided to stop being part of the IdiPAZ structure in March 2022



RESEARCH ACTIVITY

■ Doctoral theses

Arroyo Olivares R. Hábitos de vida y enfermedad cardiovascular en la hipercolesterolemia familiar[dissertation]. Madrid: UAM: 2021(29/06/2021).

Directors: Banegas Banegas JR, Mata P.

Fernández Félix BM. Investigación clínico-epidemiológica en pronóstico: desarrollos metodológicos y aplicación clínica[dissertation]. Madrid: UAM: 2021(13/07/2021).

Directors: Zamora Romero J, García García-Esquinas E.

Hernández Aceituno A. Hábitos Saludables y Utilización de Servicios Sanitarios en los Adultos Mayores[dissertation]. Madrid: UAM: 2021(14/12/2021).

Director: Banegas Banegas JR.

Jeronimo dos Santos T. An equity-oriented analysis on using diabetes-related technology in children and adolescents with type 1 diabetes mellitus[dissertation]. Madrid: UAM: 2021(04/11/2021).

Directors: Argente Oliver J, Rodríguez Artalejo F.

Rodríguez Sánchez I. Dolor crónico, deterioro funcional y enfermedad cardiovascular en las personas mayores[dissertation]. Madrid: UAM: 2021(24/06/2021).

Directors: García García-Esquinas E, Rodríguez Artalejo F.

■ Publications

• Arias-Fernández L, Smith-Plaza AM, Barrera-Castillo M, Prado-Suárez J, López-García E,

Rodríguez-Artalejo F, Lana A. Sleep patterns and physical function in older adults attending primary health care. *Fam Pract.* 2021; 38(2): 147-53. Article. IF: 2.29; Q3

• Caballero FF, Struijk EA, Buño A, Rodríguez-Artalejo F, López-García E. Plasma ceramides and risk of impaired lower-extremity function in older adults: A nested case-control Study. *J Gerontol A-Biol.* 2021; 76(7): 1280-7. Article. IF: 6.591; Q1

• Caballero FF, Struijk EA, Lana A, Buño A, Rodríguez-Artalejo F, López-García E. Plasma acylcarnitines and risk of lower-extremity functional impairment in older adults: a nested case-control study. *Sci Rep-Uk.* 2021; 11(1): 3350. Article. IF: 4.996; Q2

• Cabañas-Sánchez V, Esteban-Cornejo I, García-Esquinas E, Ortola R, Ara I, Rodríguez-Gómez I, Chastin SFM, Rodríguez-Artalejo F, Martínez-Gómez D. Cross-sectional and prospective associations of sleep, sedentary and active behaviors with mental health in older people: a compositional data analysis from the Seniors-ENRICA-2 study. *Int J Behav Nutr Phy.* 2021; 18(1): 124. Article. IF: 8.925; Q1

• Canton R, Ramos PD, García-Botella A, García-Lledo A, Gómez-Pavón J, del Castillo JG, Hernández-Sampelayo T, Martín-Delgado MC, Sánchez FJM, Martínez-Selles M, García JMM, Guillen SM, Rodríguez-Artalejo F, Ruiz-Galiana J, Bouza E. New variants of SARS-CoV-2. *Rev Esp Quim.* 2021; 34(5): 419-28. Review. IF: 2.515; Q3

• Carballo-Casla A, García-Esquinas E, López-García E, Sotos-Prieto M, Struijk EA, Caballero FF, Rodríguez-Artalejo F, Ortola R. Consumption of food fried in olive oil and unhealthy aging in a Mediterranean country. *Clin Nutr.* 2021; 40(1): 277-85. Article. IF: 7.643; Q1

• Carballo-Casla A, Ortola R, García-Esquinas E, Oliveira A, Sotos-Prieto M, Lopes C, López-García E, Rodríguez-Artalejo F. The southern European atlantic diet and all-cause mortality in older adults. *BMC Med.* 2021; 19(1): 36. Article. IF: 11.15; Q1

• Chambón C, Neyraud E, Sayd T, Bros P, Di Biagio R, Hyvriér F, Fear C, Andre P, Rodríguez-Artalejo F, López-García E, García-Esquinas E, Gómez-Cabrero D, Proctor G, Morzel M. The salivary proteome reflects some traits of dietary habits in diabetic and non-diabetic older adults. *Eur J Nutr.* 2021; 60(8): 4331-44. Article. IF: 4.865; Q2

• Chaparro M, Garre A, Ortiz AN, Palomares MTDL, Rodríguez C, Riestra S, Vela M, Benítez

JM, Salgado EF, Rodríguez ES, Hernández V, Ferreira-Iglesias R, Diaz AP, Barrio J, Huguet JM, Sicilia B, Martín-Arranz MD, Calvet X, Ginard D, Alonso-Abreu I, Fernández-Salazar L, Trastoy PV, Rivero M, Vera-Mendoza I, Vega P, Navarro P, Sierra M, Cabriada JL, Aguas M, Vicente R, Navarro-Llavat M, Echarrí A, Gomollon F, del Rio EG, Pínero C, Casanova MJ, Spicakova K, de Zarate JO, Cortes ET, Gutiérrez A, Alonso-Galan H, Hernández-Martínez A, Marrero JM, Poyatos RL, Calafat M, Romero LM, Robledo P, Bosch O, Jiménez N, Comas ME, Duque JM, Coronel AMF, Sampedro MJ, Abizanda ES, Martínez BH, Pozzati L, Rosaenz HF, Suárez BC, Serrano PL, Lucendo AJ, Vicente MM, Bermejo F, Palanca JJR, Menacho M, Carmona A, Camargo R, Alsina ST, Maroto N, de la Puerta JN, Castro E, Marín-Jiménez I, Botella B, Sapina A, Cruz N, Forcelledo JLF, Bouhmidí A, Castano-Milla C, Opio V, Nicolas I, Kutz M, Bechiarelli AA, Gordillo J, Ber Y, Domínguez YT, Duran MTN, Mondejar SR, Martínez-Cerezo FJ, Kolle L, Sabat M, Ledezma C, Iyo E, Roncero O, Irisarri R, Lluís L, Gómez IB, Zapata EM, Alcalá MJ, Pascual CM, Montealegre M, Mata L, Monrobel A, Camba AH, Hernández L, Tejada M, Mir A, Galve ML, Soler M, Hervias D, Gómez-Valero JA, Barreiro-de Acosta M, Rodríguez-Artalejo F, García-Esquinas E, Gisbert JP. Incidence, clinical characteristics and management of inflammatory bowel disease in Spain: Large-scale epidemiological study. *J Clin Med.* 2021; 10(13): 2885. Article. IF: 4.964; Q2

• Christophi CA, Sotos-Prieto M, Lan FY, Delgado-Velandia M, Efthymiou V, Gaviola GC, Hadjivasilis A, Hsu YT, Kyprianos A, Lidoriki I, Wei CF, Rodríguez-Artalejo F, Kales SN. Ambient temperature and subsequent COVID-19 mortality in the OECD countries and individual United States. *Sci Rep-Uk.* 2021; 11(1): 8710. Article. IF: 4.996; Q2

• Díaz-Alonso J, Bueno-Pérez A, Torano-Ladero L, Caballero FF, López-García E, Rodríguez-Artalejo F, Lana A. Limitación auditiva y fragilidad social en hombres y mujeres mayores. *Gac Sanit.* 2021; 35(5): 425-31. Article. IF: 2.479; Q3

• Donat-Vargas C, Sandoval-Insusti H, Rey-García J, Banegas JR, Rodríguez-Artalejo F, Guallar-Castillón P. Five-color Nutri-Score labeling and mortality risk in a nationwide, population-based cohort in Spain: the Study on Nutrition and Cardiovascular Risk in Spain (ENRICA). *Am J Clin Nutr.* 2021; 113(5): 1301-11. Article. IF: 8,472; D1

• Donat-Vargas C, Sandoval-Insusti H, Rey-García J, Moreno-Franco B, Akesson A, Banegas JR, Rodríguez-Artalejo F, Guallar-Castillón P. High consumption of ultra-processed food is associated with incident dyslipidemia: A prospective study of older adults. *J Nutr.* 2021; 151(8): 2390-8. Article. IF: 4.687; Q2

• Dos Santos TJ, Campos JDD, Argente J, Rodríguez-Artalejo F. Effectiveness and equity of continuous subcutaneous insulin infusions in pediatric type 1 diabetes: A systematic review and meta-analysis of the literature. *Diabetes Res Clin Pr.* 2021; 172: 108643. Review. IF: 8,18; Q1

• Estrada-deLeon DB, Struijk EA, Caballero FF, Prieto MS, Rodríguez-Artalejo F, López-García E. Prolonged nightly fasting and lower-extremity functioning in community-dwelling older adults. *Brit J Nutr.* 2021; 126(9): 1347-54. Article. IF: 4.125; Q3

• García-Esquinas E, Carrasco-Ríos M, Ortola R, Prieto MS, Pérez-Gómez B, Gutiérrez-González E, Banegas JR, Queipo R, Olmedo P, Gil F, Téllez-Plaza M, Navas-Acien A, Pastor-Barriuso R, Rodríguez-Artalejo F. Selenium and impaired physical function in US and Spanish older adults. *Redox Biol.* 2021; 38: 101819. Article. IF: 10.787; D1

• García-Esquinas E, Ortola R, Gine-Vázquez I, Carnicero JA, Manas A, Lara E, Álvarez-Bustos A, Vicente-Rodríguez G, Sotos-Prieto M, Olaya B, García-García FJ, Gusi N, Banegas JR, Rodríguez-Gómez I, Struijk EA, Martínez-Gómez D, Lana A, Haro JM, Ayuso-Mateos JL, Rodríguez-Mañas L, Ara I, Miret M, Rodríguez-Artalejo F. Changes in health behaviors, mental and physical health among older adults under severe lockdown restrictions during the COVID-19 pandemic in Spain. *Int J Env Res Pub He.* 2021; 18(13): 7067. Article. IF: 4.614; Q1

• García-Esquinas E, Ortola R, Martínez-Gómez D, Damián J, Prina M, Rodríguez-Artalejo F, Pastor-Barriuso R. Causal effects of physical activity and sedentary behaviour on health deficits accumulation in older adults. *Int J Epidemiol.* 2021; 50(3): 852-65. Article. IF: 9.685; D1

• García-Esquinas E, Téllez-Plaza M, Pastor-Barriuso R, Ortola R, Olmedo P, Gil F, López-García E, Navas-Acien A, Rodríguez-Artalejo F. Blood cadmium and physical function limitations in older adults. *Environ Pollut.* 2021; 276: 116748. Article. IF: 9.988; Q1

• Hermenegildo-López Y, Donat-Vargas C, Sandoval-Insusti H, Moreno-Franco B, Rodríguez-

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Ayala M, Rey-García J, Banegas JR, Rodríguez-Artalejo F, Guallar-Castillón P. A higher intake of energy at dinner is associated with incident metabolic syndrome: A prospective cohort study in older adults. *Nutrients*. 2021; 13(9): 3035. Article. IF: 6.706; Q1

• Hermenegildo-López Y, Sandoval-Insauti H, Donat-Vargas C, Banegas JR, Rodríguez-Artalejo F, Guallar-Castillón P. General and central obesity operate differently as predictors of falls requiring medical care in older women: a population-based cohort study in Spain. *Age Ageing*. 2021; 50(1): 213-9. Article. IF: 12.782; D1

• Iurilli MLC, Zhou B, Bennett JE, Carrillo-Larco RM, Sophia MK, Rodríguez-Martínez A, Bixby H, Solomon BD, (et al) . Heterogeneous contributions of change in population distribution of body mass index to change in obesity and underweight NCD Risk Factor Collaboration (NCD-RisC). *Elife*. 2021; 10: e60060. Article. IF: 8,713; D1

• León-González R, Rodríguez-Artalejo F, Ortola R, López-García E, García-Esquinas E. Social network and risk of poor sleep outcomes in older adults: Results from a Spanish prospective cohort study. *Nat Sci Sleep*. 2021; 13: 399-409. Article. IF: 3.384; Q3

• Machado-Fragua MD, Struijk EA, Yévenes-Briones H, Rodríguez-Artalejo F, López-García E. Coffee consumption and risk of hearing impairment in men and women. *Clin Nutr*. 2021; 40(5): 3429-35. Article. IF: 7.643; Q1

• Martín-Calvo N, Bes-Rastrollo M, Gómez-Donoso C, Rodríguez-Artalejo F, Vioque J, Royo-Bordonada MA, Bueno-Cavanillas A, Ruiz-Canela M, Martínez-González MA. Reduction of red and processed meats in the Spanish population: What is its impact on total and cardiovascular mortality? *Aten Prim*. 2021; 53(2): 101950. Article. IF: 2.206; Q3

• Martínez-Pérez C, San-Cristóbal R, Guallar-Castillón P, Martínez-González MA, Salas-Salvado J, Corella D, Castaner O, Martínez JA, Alonso-Gómez AM, Warnberg J, Vioque J, Romaguera D, López-Miranda J, Estruch R, Tinahones FJ, Lapetra J, Serra-Majem L, Bueno-Cavanillas A, Tur JA, Sánchez VM, Pinto X, Gaforio JJ, Matia-Martin P, Vidal J, Vázquez C, Ros E, Bes-Rastrollo M, Babio N, Sorli JV, Lassale C, Pérez-Sanz B, Vaquero-Luna J, Bazan MJA, Barcelo-Iglesias MC, Konieczna J, Rios AG, Bernal-López MR, Santos-Lozano JM, Toledo E, Becerra-Tomas N, Portoles

O, Zomeno MD, Abete I, Moreno-Rodríguez A, Lecea-Juarez O, Nishi SK, Muñoz-Martínez J, Ordovas JM, Daimiel L. Use of different food classification systems to assess the association between ultra-processed food consumption and cardiometabolic health in an elderly population with metabolic syndrome (PREDIMED-Plus Cohort). *Nutrients*. 2021; 13(7): 2471. Article. IF: 6.706; Q1

• Monroy-Parada DX, Prieto-Castillo L, Ordaz-Castillo E, Bosqued MJ, Rodríguez-Artalejo F, Royo-Bordonada MA. Map of school nutritional policies in Spain. *Gac Sanit*. 2021; 35(2): 123-9. Article. IF: 2.479; Q3

• Moreno-Franco B, Rodríguez-Ayala M, Donat-Vargas C, Sandoval-Insauti H, Rey-García J, López-García E, Banegas JR, Rodríguez-Artalejo F, Guallar-Castillón P. Association of cooking patterns with inflammatory and cardio-metabolic risk biomarkers. *Nutrients*. 2021; 13(2): 633. Article. IF: 6.706; Q1

• Muñoz-Cabrejas A, Laclaustra M, Guallar-Castillón P, Casasnovas JA, Jaraúta E, Sandoval-Insauti H, Donat-Vargas C, Moreno-Franco B. High-quality intake of carbohydrates is associated with lower prevalence of subclinical atherosclerosis in femoral arteries: The AWHS study. *Clin Nutr*. 2021; 40(6): 3883-9. Article. IF: 7.643; Q1

• Ortola R, García-Esquinas E, Buño-Soto A, Sotos-Prieto M, Struijk EA, Caballero FF, López-García E, Banegas JR, Rodríguez-Artalejo F. Healthy dietary patterns are associated with lower concentrations of growth differentiation factor 15 in older adults. *Am J Clin Nutr*. 2021; 113(6): 1619-26. Article. IF: 8.472; D1

• Ortola R, García-Esquinas E, Cabañas-Sánchez V, Migueles JH, Martínez-Gómez D, Rodríguez-Artalejo F. Association of physical activity, sedentary behavior, and sleep with unhealthy aging: Consistent results for device-measured and self-reported behaviors using isotemporal substitution models. *J Gerontol A-Biol*. 2021; 76(1): 85-94. Article. IF: 6.591; Q1

• Padrón-Monedero A, Rodríguez-Artalejo F, López-García E. Dietary micronutrients intake and plasma fibrinogen levels in the general adult population. *Sci Rep-Uk*. 2021; 11(1): 3843. Article. IF: 4.996; Q2

• Pérez-Lasierra JL, Laclaustra M, Guallar-Castillón P, Casasnovas JA, Casajus JA, Jaraúta E, González-Aguero A, Moreno-Franco B. Daily sitting

for long periods increases the odds for subclinical atheroma plaques. *J Clin Med*. 2021; 10(6): 1229. Article. IF: 4.964; Q2

• Rey-García J, Donat-Vargas C, Sandoval-Insauti H, Bayan-Bravo A, Moreno-Franco B, Banegas JR, Rodríguez-Artalejo F, Guallar-Castillón P. Ultra-processed food consumption is associated with renal function decline in older adults: A prospective cohort study. *Nutrients*. 2021;13(2): 428. Article. IF: 6.706; Q1

• Rodríguez-Artalejo F, García-Esquinas E. Joy is short-lived in the house of the poor. *J Epidemiol Commun H*. 2021; 75(7): 608-9. Editorial Material. IF: 6.286; Q1

• Ruiz-Galiana J, Cantón R, Ramos PD, García-Botella A, García-Lledo A, Gómez-Pavón J, del Castillo JG, Hernández Sampelayo T, Martín-Delgado MC, Sánchez FJM, Martínez-Selles M, García JMM, Guillen SM, Rodríguez-Artalejo F, Bouza E. COVID-19 vaccination: the reality after clinical trials. *Rev Esp Quim*. 2021; 34(5): 408-18. Review. IF: 2.515; Q3

• Sánchez-Niubo A, Forero CG, Wu YT, Gine-Vázquez I, Prina M, de la Fuente J, Daskalopoulou C, Critselis E, de la Torre-Luque A, Panagiotakos D, Arndt H, Ayuso-Mateos JL, Bayes-Marin I, Bickenbach J, Bobak M, Caballero FF, Chatterji S, Egea-Cortes L, García-Esquinas E, Leonardi M, Koskinen S, Koupil I, Mellor-Marsa B, Olaya B, Pajak A, Prince M, Raggi A, Rodríguez-Artalejo F, Sanderson W, Scherbov S, Tamosiunas A, Tobias-Adamczyk B, Tyrovolas S, Haro JM. Development of a common scale for measuring healthy ageing across the world: results from the ATHLOS consortium. *Int J Epidemiol*. 2021; 50(3): 880-2. Article. IF: 9.685; D1

• Sotos-Prieto M, Ortola R, López-García E, Rodríguez-Artalejo F, García-Esquinas E. Adherence to the Mediterranean diet and physical resilience in older adults: The seniors-ENRICA Cohort. *J Gerontol A-Biol*. 2021; 76(3): 505-12. Article. IF: 6.591; Q1

• Sotos-Prieto M, Ortola R, Ruiz-Canela M, García-Esquinas E, Martínez-Gómez D, López-García E, Martínez-González MA, Rodríguez-Artalejo F. Association between the Mediterranean lifestyle, metabolic syndrome and mortality: a whole-country cohort in Spain. *Cardiovasc Diabetol*. 2021; 20(1): 5. Article. IF: 8.949; Q1

• Sotos-Prieto M, Zhao SZ, Kline D, Brock G, Gooding H, Mattei J, Rodríguez-Artalejo F, Min YI,

Rimm EB, Tucker KL, Joseph JJ. Application of a lifestyle-based score to predict cardiovascular risk in African Americans: The Jackson Heart Study. *J Clin Med*. 2021; 10(11): 2252. Article. IF: 4.964; Q2

• Yévenes-Briones H, Caballero FF, Struijk EA, Rey-Martínez J, Montes-Jovellar L, Graciani A, Rodríguez-Artalejo F, López-García E. Association between hearing loss and impaired physical function, frailty, and disability in older adults a cross-sectional study. *JAMA Otolaryngol*. 2021; 147(11): 951-8. Article. IF: 8.961; D1

• Zhou B, Carrillo-Larco RM, Danaei G, Riley LM, Paciorek CJ, Stevens GA, Gregg EW, Bennett JE, Solomon B, (et al) Cisneros JZ. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. *Lancet*. 2021; 398(10304): 957-80. Article. IF: 202.731; D1

■ Research projects

Rodríguez Artalejo F. Patrones dietéticos, composición corporal, deterioro físico y cognitivo en los ancianos españoles. CIBEResp. 2016-Ongoing.

Management centre: FIBHULP

Rodríguez Artalejo F. El síndrome de fragilidad y los factores psicosociales en la trayectorias de envejecimiento saludable: una cohorte comunicativa de adultos mayores en España. CIBEResp. 2018-Ongoing.

Management centre: FIBHULP

■ Cibers and Retics

Rodríguez Artalejo F. Networked Biomedical Research Center for Public Health and Epidemiology. (CB06/02/0001). ISCIII. (31/12/2021).

Management centre: UAM



3.2.3 Coagulopathies and Alterations of Haemostasis Group

Publications: 34

Q1: 12



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

COMPOSITION

Víctor Manuel Jiménez Yuste. Jefe de Servicio de Hematología. Hospital Universitario La Paz. Profesor Asociado de la Universidad Autónoma de Madrid

María Teresa Álvarez Román. Jefa de Sección de Coagulopatías. Hospital Universitario La Paz

Nora Viviana Butta Coll. Investigadora Senior (Contrato Miguel Servet - Tipo 2). Jefa de Laboratorio. Hospital Universitario La Paz

Raquel Fernández Morata. Técnico de Laboratorio. Hospital Universitario La Paz

Elena García Arias-Salgado. Investigadora asociada. Advanced Medical Projects Madrid

Sara García Barcenilla. Coordinadora de Estudios. Hospital Universitario La Paz

Mónica Martín Salces. Facultativo Especialista de Área en Hematología y Hemoterapia. Hospital Universitario La Paz

Isabel Rivas Pollmar. Médico Adjunto en Hematología. Hospital Universitario La Paz

STRATEGIC OBJECTIVE

This group's research activities address various relevant questions in the area of haematology and focus on the characterisation of the genetic and molecular basis of coagulation and haemostatic function. Our group investigates physiological processes such as coagulation, haemostasis, innate immunity, inflammation, cell adhesion and migration, and cell signalling, with special emphasis on their relevance to pathological processes.

In addition, we perform epidemiological studies to facilitate patient data analysis and therapeutic treatment.

RESEARCH LINES

• **Haemophilia A and B:**

- Genetic and molecular studies in patients with haemophilia A and B

- Risk factors for the development of factor FVIII/FIX inhibitors in patients with haemophilia A and B. Individualised treatment adaptation based on the nature of antigenic epitopes
- Epidemiological studies of congenital haemophilia A and B, acquired haemophilia A and von Willebrand's disease
- **Haemostasis disorders:**
 - Haemostasis in thrombocytopenic diseases (immune thrombocytopenic purpura and myelodysplastic syndromes)
 - Haemostasis in inflammatory diseases
- **Cardiovascular and nutritional epidemiology**

RESEARCH ACTIVITY

■ Doctoral theses

Monzón Manzano E. Estado protrombótico, factores de riesgo cardiovascular y actividad clínica en pacientes con lupus eritematoso sistémico[dissertation]. Madrid: UAM: 2021(16/06/2021).

Directors: Butta Coll N,
López Longo FJ

■ Master Theses

Díaz Jordan B. Evaluación de las estrategias sociosanitarias instauradas durante la pandemia COVID-19 en pacientes con Hemofilia A moderada/grave con/sin inhibidor en tratamiento profiláctico ambulatorio con emicizumab en la provincia de Ciudad Real-España.[dissertation]. Alcalá de Henares: UAH: 2021(10/03/2021).

Director: Jiménez-Yuste V.

Ramos de León Y. Análisis farmacoeconómico en hemofilia grave[dissertation]. Alcalá de Henares: UAH: 2021(10/03/2021).

Director: Álvarez Román MT.

Díez López G. Evaluación mediante modelo mast (model for assesment of telemedicine) de la app y software MYPKFIT® para establecer tratamiento, recogida de datos y seguimiento de

pacientes[dissertation]. Alcalá de Henares: UAH: 2021(10/03/2021).

Director: Álvarez Román MT.

Coll Vallier J. Diátesis hemorrágica: análisis de la variabilidad en los estudios y en los ensayos clínicos [dissertation]. Alcalá de Henares: UAH: 2021(10/03/2021).

Director: Álvarez Román MT.

Mesa Lorenzo MC. Optimización de recursos y mejora de la calidad de vida en pacientes con hemofilia B[dissertation]. Alcalá de Henares: UAH: 2021(10/03/2021).

Director: Álvarez Román MT.

Justo Sanz R. Glycosylation pattern and platelet function in patients with primary immune thrombocytopenia [dissertation]. Alcalá de Henares: UAH: 2021(10/03/2021).

Directors: Álvarez Román MT,
Butta Coll N

Pozas Mañas MA. Protocolo para el tratamiento del sangrado y cirugía en pacientes con hemofilia A en tratamiento con emicizumab. Revisión de las guías publicadas[dissertation]. Alcalá de Henares: UAH: 2021(10/03/2021).

Director: Butta Coll N

Dos Santos Ortas A. Impacto de la pandemia de COVID-19 en pacientes con trombocitopenia: estudio descriptivo de una población de pacientes del Hospital Universitario La Paz[dissertation]. Alcalá de Henares: UAH: 2021(10/03/2021).

Director: Butta Coll N

García Pérez E. Estudio de trombotopatías en pacientes con síndromes mielodisplásicos[dissertation]. Alcalá de Henares: UAH: 2021(10/03/2021).

Director: Butta Coll N.

Gasior Kabat M. Study of platelet alterations and their relationship with the mutational profile in patients with Essential Thrombocythemia[dissertation]. Alcalá de Henares: UAH: 2021(10/03/2021).

Director: Butta Coll N.

Sarrate García E. Ranges of normality and diagnostic utility of PFA in the pediatric environment[dissertation]. Alcalá de Henares: UAH: 2021(10/03/2021).

Director: Butta Coll N.

Montero Martín L. Usefulness of calibrated automatic thrombography in factor XI deficiency[dissertation]. Alcalá de Henares: UAH: 2021(10/03/2021).

Director: Butta Coll N.

Panizo Echauri I. Study on the feasibility of using techniques laboratory tests (thrombin generation test and Modified APTT) for measurement of effect procoagulant and treatment monitoring with Emicizumab in a model of Hemophilia A Severe in baseline conditions and treatment concomitant with bypass agents[dissertation]. Alcalá de Henares: UAH: 2021(10/03/2021).

Director: Butta Coll N.

■ Publications

- Álvarez-Román, MT; de la Corte-Rodríguez, H; Rodríguez-Merchán, EC; Martín-Salces, M; Rivas-Pollmar, MI; Butta, NV; García-Barcelona, S; Acuna, P; Cebanu, T; González, E; Monzón-Manzano, ME; Jiménez-Yuste, V. COVID-19 and telemedicine in haemophilia in a patient with severe haemophilia a and orthopaedic surgery. Haemophilia. 2021; 27(1): E137-9. Letter. IF: 4.263; Q2
- Álvarez-Román, MT; Kurnik, K. Care for children with haemophilia during COVID-19: Data of the PedNet study group. Haemophilia. 2021; 27(4): E537-9. Letter. IF: 4.263; Q2
- Callaghan, MU; Negrier, C; Paz-Priel, I; Chang, T; Chebon, S; Lehle, M; Mahlangu, J; Young, G; Kruse-Jarres, R; Mancuso, ME; Niggli, M; Howard, M; Bienz, NS; Shima, M; Jiménez-Yuste, V; Schmitt, C; Asikanius, E; Levy, GG; Pipe, SW; Oldenburg, J. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

- studies. *Blood*. 2021; 137(16): 2231-42. Article. IF: 25.476; D1
- Carcao, M; Mancuso, ME; Young, G; Jiménez-Yuste, V. Key questions in the new hemophilia era: update on concomitant use of FVIII and emicizumab in hemophilia A patients with inhibitors. *Expert Rev Hematol*. 2021; 14(2): 143-8. Review. IF: 2.819; Q3
 - de la Corte-Rodríguez, H; Rodríguez-Merchán, EC; Álvarez-Román, MT; Jiménez-Yuste, V. Applying world health organization 2020 guidelines on physical activity and sedentary behavior to people with hemophilia. *Expert Rev Hematol*. 2021; 14(5): 429-36. Review. IF: 2.819; Q3
 - de la Cruz-benito, B; Rivas-Pollmar, MI; Román, MTA; Trelles-Martínez, R; Martín-Salces, M; Lázar-del Campo, P; Ramírez-López, A; García-Barcenilla, S; Cebanu, T; Acuña-Butta, P; Monzón-Manzano, E; González-Zorrilla, E; Jiménez-Yuste, V; Butta, NV. Paradoxical effect of SARS-CoV-2 infection in patients with immune thrombocytopenia. *Brit J Haematol*. 2021; 19 2(6): 973-7. Article. IF: 8.615; Q1
 - del Campo, PL; López, AR; Benito, BD; Arias, RD; Álvarez, TD; Vadillo, IS; Barbier, KH; Pérez, EG; Ortas, AD; de la Guía, AL; Kabat, MG; Tello, PB; Yuste, VJ; Albendea, MC. Hematopoietic cell transplantation during COVID-19 pandemic: experience from a tertiary hospital in Madrid. *Expert Rev Hematol*. 2021; 14(1): 1-5. Editorial Material. IF: 2.819; Q3
 - Dolan, G; Benson, G; Bowyer, A; Eichler, H; Hermans, C; Jiménez-Yuste, V; Ljung, R; Pollard, D; Santagostino, E; Salek, SZ. Principles of care for acquired hemophilia. *Eur J Haematol*. 2021; 106(6): 762-73. Article. IF: 3.674; Q3
 - Feito-Rodríguez, M; Mayor-Ibarguren, A; Camara-Hijon, C; Montero-Vega, D; Servera-Negre, G; Ruiz-Bravo, E; Nozal, P; Rodríguez-Peralto, JL; Enguita, AB; Bravo-Gallego, LY; Granados-Fernández, M; Fernández-Alcalde, C; Fernández-Herederó, A; Alonso-Riano, M; Jiménez-Yuste, V; Nuno-González, A; De Lucas-Laguna, R; López-Granados, E; Herranz-Pinto, P. Chilblain-like lesions and COVID-19 infection: A prospective observational study at Spain's ground zero. *J Am Acad Dermatol*. 2021; 84(2): 507-9. Letter. IF: 15.487; D1
 - Freixer, G; Zekri-Nechar, K; Zamorano-Leon, JJ; Hugo-Martínez, C; Butta, NV; Monzón, E; Recio, MJ; Giner, M; López-Farre, A. Pro-apoptotic properties and mitochondrial functionality in platelet-like-particles generated from low Aspirin-incubated Meg-01 cells. *Platelets*. 2021; 32(8): 1063-72. Article. IF: 4.236; Q2
 - Gálvez, E; Vallespín, E; Arias-Salgado, EG; Sánchez-Valdepeñas, C; Giménez, Y; Navarro, S; Río, P; Bogliolo, M; Pujol, R; Peiro, M; Nevado, J; Zubicaray, J; Sebastian, E; Catala, A; Beléndez, C; de Heredia, CD; Galera, A; Badell, I; Madero, L; Perona, R; Sastre, L; Surrallés, J; Bueren, J; Lapunzina, P; Sevilla, J. Next-generation sequencing in bone marrow failure syndromes and isolated cytopenias: Experience of the spanish network on bone marrow failure syndromes. *Hemasphere*. 2021; 5(4): e539 . Article. IF: 8.3; Q1
 - Gasior, M; Ferreras, C; de Paz, R; Bueno, D; Mozo, Y; Sisinni, L; Canzales, JT; González, B; Olivas-Mazón, R; Marcos, A; Romero, AB; Constanto, A; Mirones, I; Fernández-Arroyo, A; Balas, A; Vicario, JL; Escudero, A; Yuste, VJ; Perez-Martínez, A. The role of early natural killer cell adoptive infusion before engraftment in protecting against human herpesvirus-6B encephalitis after naive T-cell-depleted allogeneic stem cell transplantation. *Transfusion*. 2021; 61(5): 1505-17. Article. IF: 3.337; Q3
 - Jiménez-Yuste, V; Auerswald, G; Benson, G; Dolan, G; Hermans, C; Lambert, T; Ljung, R; Morfini, M; Santagostino, E; Salek, SZ. Practical considerations for nonfactor-replacement therapies in the treatment of haemophilia with inhibitors. *Haemophilia*. 2021; 27(3): 340-50. Review. IF: 4.263; Q2
 - Jiménez-Yuste, V; de la Corte-Rodríguez, H; Álvarez-Román, MT; Martín-Salces, M; Querol, F; Bonanad, S; Mingot-Castellano, ME; Fernández-Mosteirin, N; Canaro, M; Santamaría, A; Núñez, R; García-Frade, LJ; Martinoli, C; Kim, HK. Ultrasound evaluation of joint damage and disease activity in adult patients with severe haemophilia A using the HEAD-US system. *Haemophilia*. 2021; 27(3): 479-87. Article. IF: 4.263; Q2
 - Jiménez-Yuste, V; Rodríguez-Merchán, EC; Matsushita, T; Holme, PA. Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery. *Haemophilia*. 2021; 27(4): 519-30. Review. IF: 4.263; Q2
 - Kabat, MG; Bueno, D; Sisinni, L; de Paz, R; Mozo, Y; Perona, R; Arias-Salgado, EG; Rosich, B; Marcos, A; Romero, AB; Constanto, A; Jiménez-Yuste, V; Perez-Martínez, A. Selective T-cell depletion targeting CD45RA as a novel approach for HLA-mismatched hematopoietic stem cell transplantation in pediatric nonmalignant hematological diseases. *Int J Hematol*. 2021; 114(1): 116-23. Article. IF: 2.319; Q4
 - Liesner, RJ; Abraham, A; Altisent, C; Belletrutti, MJ; Carcao, M; Carvalho, M; Chambost, H; Chan, AKC; Dubey, L; Ducore, J; Gattens, M; Gresele, P; Gruel, Y; Guillet, B; Jiménez-Yuste, V; Kitanovski, L; Klukowska, A; Lohade, S; Mancuso, ME; Oldenburg, J; Pavlova, A; Pollio, B; Sigaud, M; Vdovin, V; Vilchevska, K; Wu, JKM; Jansen, M; Belyanskaya, L; Walter, O; Knaub, S; Neufeld, EJ. Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study. *Thromb Haemostasis*. 2021; 121(11): 1400-8. Article. IF: 6.681; Q1
 - Lozano, ML; Segu-Verges, C; Coma, M; Álvarez-Román, MT; González-Porras, JR; Gutiérrez, L; Valcarcel, D; Butta, N. Elucidating the mechanism of action of the attributed immunomodulatory role of eltrombopag in primary immune thrombocytopenia: An in silico approach. *Int J Mol Sci*. 2021; 22(13): 6907. Article. IF: 6.208; Q1
 - Merino, A; Hoogduijn, MJ; Molina-Molina, M; Arias-Salgado, EG; Korevaar, SS; Baan, CC; Montes-Worboys, A. Membrane particles from mesenchymal stromal cells reduce the expression of fibrotic markers on pulmonary cells. *Plos One*. 2021; 16(3): e0248415. Article. IF: 3.752; Q2
 - Miesbach, W; Chowdary, P; Coppens, M; Hart, DP; Jiménez-Yuste, V; Klamroth, R; Makris, M; Noone, D; Peyvandi, F. Delivery of AAV-based gene therapy through haemophilia centres-A need for re-evaluation of infrastructure and comprehensive care: A Joint publication of EAHAD and EHC. *Haemophilia*. 2021; 27(6): 967-73. Article. IF: 4.263; Q2
 - Mingot-Castellano, ME; Pardos-Gea, J; Haya, S; Bastida-Bermejo, JM; Tassies, D; Marco-Rico, A; Núñez, R; García-Candel, F; de Mora, MCFS; Soto, I; Álvarez-Román, MT; Asenjo, S; Carrasco, M; Lluch-García, R; Martín-Antorán, JM; Rodríguez-Alen, A; Rosello, E; Torres-Minana, L; Marcellini-Antonio, S; Moreto-Quinana, A; Rodríguez-García, JA; Aguinaco-Culebras, R; Alonso-Escobar, N; Cervero-Santiago, C; Fernández-Mosteirin, N; Martínez-Badas, MP; Pérez-Sánchez, M; Pérez-Montes, R; Rodríguez-González, R; Uribe-Barrientos, M; Caparros-Miranda, IS; Iglesias-Fernández, M; Baena, A; Rodríguez-López, M; Sebrango-Sandia, A; Vázquez-Fernández, I; Marco, P. Management of acquired hemophilia A: results from the Spanish registry. *Blood Adv*. 2021; 5(19): 3821-9. Article. IF: 7.637; Q1
 - Oldenburg, J; Tran, H; Peyvandi, F; Núñez, R; Trask, P; Chebon, S; Mahlangu, JN; Lehle, M; Jiménez-Yuste, V; von Mackensen, S. Health-related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors-A non-interventional study. *Haemophilia*. 2021; 27(3): 398-407. Article. IF: 4.263; Q2
 - Parnes, A; Mahlangu, JN; Pipe, SW; Paz-Priel, I; Lehle, M; Trask, PC; Jiménez-Yuste, V. Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies. *Haemophilia*. 2021; 27(6): E772-5. Letter. IF: 4.263; Q2
 - Pérez-Rodríguez, A; Battle, J; Pinto, JC; Corrales, I; Borrás, N; García-Martínez, I; Cid, AR; Bonanad, S; Parra, R; Mingot-Castellano, ME; Navarro, N; Altisent, C; Pérez-Montes, R; Moreto, A; Herrero, S; Soto, I; Mosteirín, NF; Jiménez-Yuste, V; Jacob, AD; Fontanes, E; Mateo, J; Quismondo, NC; Battle, F; Vidal, F; López-Fernández, MF. Type 2N VWD: Conclusions from the Spanish PCM-EVW-ES project. *Haemophilia*. 2021; 27(6): 1007-21. Article. IF: 4.263; Q2
 - Peyvandi, F; Auerswald, G; Austin, SK; Liesner, R; Kavakli, K; Román, MTA; Millar, CM. Diagnosis, therapeutic advances, and key recommendations for the management of factor X deficiency. *Blood Rev*. 2021; 50: 100833. Review. IF: 10.626; Q1
 - Pintado-Berninches, L; Montes-Worboys, A; Manguan-García, C; Arias-Salgado, EG; Serrano, A; Fernández-Varas, B; Guerrero-López, R; Iarriccio, L; Planas, L; Guenecheta, G; Eguisaguierre, SP; Hernández, RM; Igartua, M; Pedraz, JL; Cortijo, J; Sastre, L; Molina-Molina, M; Perona, R. GSE4-loaded nanoparticles a potential therapy for lung fibrosis that enhances pneumocyte growth, reduces apoptosis and DNA damage. *Faseb J*. 2021; 35(3): e21422. Article. IF: 5.834; Q1
 - Planas-Cerezales, L; Arias-Salgado, EG; Berastegui, C; Montes-Worboys, A; González-Montelongo, R; Lorenzo-Salazar, JM; Vicens-Zygmunt, V; García-Moyano, M; Dorca, J; Flores, C; Perona, R; Román, A; Molina-Molina, M. Lung transplant improves survival and quality of life regardless of telomere dysfunction. *Front Med (Lausanne)*. 2021; 8: 695919. Article. IF: 5.058; Q2
 - Ramírez-López, A; Román, MTA; Manzano, EM; Acuña, P; Arias-Salgado, EG; Salces, MM; Pollmar, MIR; Yuste, VJ; Sanz, RJ; Barcenilla, SG; Cebanu, T; Zorrilla, EG; Butta, NV. The importance of platelet glycoside residues in the haemostasis of patients with immune thrombocytopenia. *J Clin Med*. 2021; 10(8): 1661. Article. IF: 4.964; Q2
 - Román, MTA; Benítez, O; Canaro, MI; Fernández, MFL; Jaime, FLJ; Arranz, JM; Núñez, R; López, MR; Aisa, CS; Jiménez-Yuste, V. Expert opinion paper on the treatment of hemophilia B with albutrepenonacog alfa. *Expert Opin Biol Ther*.



1
Introduction

2
Executive
Summary

3
Information
Groups
by Area

4
Associated
Clinicians

2021; 21(9): 1165-71. Article. IF: 5.589; Q1

- Román, MTA; Rodríguez, HD; Boix, SB; Mingot-Castellano, ME; Mosteirín, NF. The factor VIII treatment history of non-severe hemophilia A: COMMENT. Joint damage in adult patients with mild or moderate hemophilia A evaluated with the HEAD-US system. *J Thromb Haemost.* 2021; 19(10): 2638-41. Letter. IF: 16.036; D1
- Román, MTA; Yuste, VJ; Barcenilla, SG; López, AR; Manzano, EM; Benito, BD; Butta, PA; Pollmar, MIR; Martínez, RT; Zorrilla, EG; Salces, MM; Cebanu, T; Butta, NV. Impact of COVID-19 pandemic on patients with immune thrombocytopenia. *Med Lith.* 2021; 57(3): 219. Article. IF: 2.948; Q3
- Sanabria, M; Román, MTA; Castaman, G; Janbain, M; Matsushita, T; Meijer, K; Oldenburg, J; Friedl, S; Reding, MT. Design of the HEM-POWR study: a prospective, observational study of real-world treatment with damococog alfa pegol in patients with haemophilia A. *BMJ Open.* 2021; 11(9): e044997. Article. IF: 3.006; Q2
- Skinner, MW; Negrier, C; Paz-Priel, I; Chebon, S; Jiménez-Yuste, V; Callaghan, MU; Lehle, M; Niggli, M; Mahlangu, J; Shapiro, A; Shima, M; Campinha-Bacote, A; Levy, GG; Oldenburg, J; von Mackensen, S; Pipe, SW. The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies. *Haemophilia.* 2021; 27(5): 854-5. Article. IF: 4.263; Q2
- Tiede, A; Karim, FA; Jiménez-Yuste, V; Klamroth, R; Lejniec, S; Suzuki, T; Groth, A; Santagostino, E. Factor VIII activity and bleeding risk during prophylaxis for severe hemophilia A: a population pharmacokinetic model. *Haematologica.* 2021; 106(7): 1902-9. Article. IF: 11.047; Q1

■ Research projects

Álvarez Román MT. Analisis descriptivo de los resultados del tratamiento en el mundo real con damococog alfa pegol en comparación con el tratamiento anterior (dacopri). Bayer Consumer Care AG. 2021-Ongoing.

Managment centre: FIBHULP

Álvarez Román MT. Experiencias reales en la práctica clínica con elocta. Swedish

Orphan Biovitrum Ab Sobi. 2019-Ongoing.

Managment centre: FIBHULP

Álvarez Román MT. Hemolition: estudio observacional ambispectivo para evaluar la efectividad y seguridad del tratamiento con emicizumab de pacientes con hemofilia a en condiciones de practica clinica habitual ml41684. Roche Losada, Olga. 2019-Ongoing.

Managment centre: FIBHULP

Álvarez Román MT. Implementacion de las aplicaciones moviles florio y florio-kids en pacientes con hemofilia a y b en tratamiento profiláctico. Swedish Orphan Biovitrum S.L. 2021-Ongoing.

Managment centre: FIBHULP

Álvarez Román MT. Programa del tratamiento multidisciplinario del paciente con hemofilia. Omnix Pharma S.L. 2017-Ongoing.

Managment centre: FIBHULP

Álvarez Román MT. Puesta en marcha y realización del estudio clínico "ml40944. hemolife: un estudio observacional de calidad de vida en personas con hemofilia a y cuidadores (no definitivo)" y el estudio: "hemolition: estudio observacional ambispectivo para evaluar la eficacia y seguridad del tratamiento en emicizumab de pacientes con hemofilia a en condiciones práctica clinica habitual (no definitivo)". Roche Farma S.A. 2018-Ongoing.

Managment centre: FIBHULP

Butta Coll N. Desarrollo de nanosistemas para eliminar la respuesta inmune contra el factor viii en ratones con hemofilia grave e inhibidores: un estudio de prueba de concepto para el diseño de nuevos protocolos de tolerancia inmune en pacien-

tes con hemofilia. Real Fundacion Victoria Eugenia. 2018-Ongoing.

Managment centre: FIBHULP

Butta Coll N. Determinación de los niveles y actividad de tfpi en el plasma de pacientes con alteración hemostática no filiada. Novo Nordisk Pharma S.A. 2020-Ongoing.

Managment centre: FIBHULP

Butta Coll N. Development of nanosystems to delete immune responses against factor VIII in mice with severe hemophilia A and inhibitors: a proof of concept study to erase inhibitors in patients with hemophilia (PROEX 130/18). Takeda. 2020-2023.

Managment centre: FIBHULP

Butta Coll N. Estudio de la hemostasia en la enfermedad de behçet. Baxter, S.L. 2011-Ongoing.

Managment centre: FIBHULP

Butta Coll N. Evaluación del efecto procoagulante in vitro de concentrados de factor ix en pacientes en profilaxis con emicizumab. C S.L. Behring S.A. 2021-Ongoing.

Managment centre: FIBHULP

Butta Coll N. Role of platelet glycosylation on platelet function and immune response in immune thrombocytopenia patients (PI19/00772). ISCI. 2020-2022.

Managment centre: FIBHULP

García Barcenilla S. Puesta en marcha del estudio clinico con codigo:ml42270: "estudio observacional para evaluar las estrategias de afrontamiento del dolor crónico en pacientes con hemofilia a desde el punto de vista de enfermería (no definitivo)". Roche Farma S.A. 2020-Ongoing.

Managment centre: FIBHULP

Jiménez Yuste V. Case-control pilot study of the immune modulating effect of feiba on patients with haemophilia a and inhibitors. Baxter Healthcare Corporation. 2013-Ongoing.

Managment centre: FIBHULP

Jiménez Yuste V. Desarrollo de un nuevo método de laboratorio de alta sensibilidad para la detección cuantitativa de anticuerpos contra el factor VIII. Pfizer S.L.U. 2012-Ongoing.

Managment centre: FIBHULP

Jiménez Yuste V. Estudio de efecto procoagulante del emicizumab y de su combinación con concentrados de factor para el tratamiento de sangrados en pacientes con hemofilia A grave. (PI19/00631). ISCI. 2020-2022.

Managment centre: FIBHULP

Jiménez Yuste V. Estudio del papel de los biomarcadores de daño endotelial, hepatocelular y fibrosis hepática y la elastografía de transición en el diagnóstico del síndrome de obstrucción sinusoidal. Jazz Pharmaceuticals Iberia S.L. 2015-Ongoing.

Managment centre: FIBHULP

Jiménez Yuste V. Estudio in vitro del efecto procoagulante de factor VII recombinante activado y vatreptacog alfa en sangre de pacientes con hemofilia grave mediante tromboelastografía y test de generación de tromina. Novo Nordisk A/S. 2012-Ongoing.

Managment centre: FIBHULP

Jiménez Yuste V. Estudio in vitro del efecto procoagulante de feibar en pacientes en profilaxis con emicizumab. Takeda Pharmaceutical International AG. 2020-Ongoing.

Managment centre: FIBHULP

Jiménez Yuste V. Field study to evaluate the activity a site specific of b-domain deleted (bdd) pegylated recombinant fviii protein (bay 94-9024) in plasma samples measured with both chromogenic and one stage assays used in clinical laboratories. Bayer Hispania S.L. 2015-Ongoing.

Managment centre: FIBHULP

Jiménez Yuste V. Head-us mobile app: desingn and implementation. Pfizer Inc. 2017-Ongoing.

Managment centre: FIBHULP

Jiménez Yuste V. Individualización de la profilaxis: estudio de los

niveles valles mediante técnicas globales e impacto de la actividad fisica. World Federation Of Hemophilia. 2015-Ongoing.

Managment centre: FIBHULP

Jiménez Yuste V. Iniciativas confihe: profilaxis personalizada: estudios prospectivos de la influencia de los parámetros farmacocinéticos individuales, test globales de la coagulación y actividad deportiva en la eficacia de la profilaxis. Mk Media S.L. 2017-Ongoing.

Managment centre: FIBHULP

Jiménez Yuste V. Monitorización del tratamiento con agentes "bypass", en pacientes con hemofilia e inhibidor mediante tres métodos de evaluación global de la hemostasia. Sanofi Aventis S.A. 2007-Ongoing.

Managment centre: FIBHULP

Jiménez Yuste V. One-year training and research scholarship programme in haemophilia and other haemostatic disorders. Novo Nordiks Health Care AG. 2015-Ongoing.

Managment centre: FIBHULP

Jiménez Yuste V. Sinovitis post-hemartros. estudio clínico, biológico y ecográfico. Post-hemarthrosis sinovitis markers on patients with haemophilia on prophylaxis. clinical, biological and ultrasonographic study. Pfizer S.L.U. 2012-Ongoing.

Managment centre: FIBHULP

Jiménez Yuste V. Tailoring prophylaxis in children with severe haemophilia: impact of the trough procoagulant state on

the incidence of breakthrough bleeding. Novo Nordiks Health Care Ag. 2015-Ongoing.

Managment centre: FIBHULP

Rivas Pollmar MI. Evaluacion de la carga asistencial de enfermería durante el uso de bombas de infusión intravenosa programables para la administración frecuente de bolos de rfviii. Novo Nordisk Pharma S.A. 2020-Ongoing.

Managment centre: FIBHULP

Rivas Pollmar MI. Individualización de la profilaxis en pacientes pediátricos con hemofilia a grave mediante estudio farmacocinético y farmacodinámico en tratamiento con productos de vida media estándar y vida media extendida. Swedish Orphan Biovitrum S.L. 2020-Ongoing.

Managment centre: FIBHULP

■ Clinical trials

Álvarez Román, MT. Estudio de fase i/II internacional, abierto y multicéntrico de la seguridad y del aumento de dosis de bax 888, un vector de virus adenoasociado de serotipo 8 (vaa8) que expresa un factor vIII con el dominio b eliminado (b-domain deleted factor vIII, bdd-fvIII) en sujetos con hemofilia a grave administrado como infusión única por vía intravenosa.

Type: Clinical Trials, phase I.

HULP code: Appendix 1 4930.

Sponsored by: Baxalta Innovations GmbH.

Signed date: 09/02/2021

Álvarez Román, MT. Estudio en fase II, multicéntrico, aleatorizado, doble ciego, controlado con placebo y de dosis paralelas para evaluar la eficacia y la seguridad



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

de ski-o-703 oral, un inhibidor de quinasa syk, en pacientes con trombocitopenia inmunitaria (tpi) persistente y crónica.

Type: Clinical Trials, phase II.
HULP code: Appendix 1 5320.
Sponsored by: Oscotec Inc.
Signed date: 10/02/2021

Álvarez Román, MT. Ha-safe: estudio observacional para evaluar la seguridad a largo plazo del tratamiento con damoctocog alfa pegol en práctica habitual en pacientes con hemofilia A tratados previamente.

Type: Estudios, phase EPA-LA.
HULP code: PI-4627 BAY-DAM-2020-01.
Sponsored by: Bayer Hispania, S.L.
Signed date: 05/05/2021

Álvarez Román, MT. Estudio observacional prospectivo para evaluar la calidad de vida de pacientes con hemofilia A sin inhibidores (hemolife).

Type: Estudios, phase EPA-SP.
HULP code: Appendix 1 PI-3814.
Sponsored by: Roche Farma, S.A.
Signed date: 11/03/2021

Álvarez Román, MT. Estudio abierto multicéntrico de fase III sobre la seguridad y eficacia a largo plazo del factor de coagulación recombinante intravenoso VIII fc-factor von willebrand-proteína de fusión xten (rfvIIIc-vwf-xten; bivv001) en pacientes previamente tratados con hemofilia grave.

Type: Clinical Trials, phase III.
HULP code: 5860 LTS16294.
Sponsored by: Sanofi Aventis S.A.
Signed date: 16/04/2021

Álvarez Román, MT. Experiencia ibérica

con afstyla® entresujetos con hemofilia A: un estudio observacional retrospectivo.

Type: Estudios, phase EPA-OD.
HULP code: PI-4742 CSL627-5004.
Sponsored by: Csl Behring Sa.
Signed date: 31/05/2021

Álvarez Román, MT. Estudio de fase I/II internacional, abierto y multicéntrico de la seguridad y del aumento de dosis de bax 888, un vector de virus adenoasociado de serotipo 8 (vaa8) que expresa un factor VIII con el dominio B eliminado (b-domain deleted factor VIII, bdd-fvIII) en sujetos con hemofilia A grave administrado como infusión única por vía intravenosa.

Type: Clinical Trials, phase I.
HULP code: Appendix 2 4930.
Sponsored by: Baxalta Innovations GmbH.
Signed date: 23/07/2021

Álvarez Román, MT. Estudio prospectivo, multicéntrico, no intervencional de 24 meses para evaluar la efectividad de elocta en comparación con productos del factor convencional en el tratamiento profiláctico de pacientes con hemofilia A (a-sure).

Type: Estudios, phase EPA-SP.
HULP code: Appendix 1 PI-2868.
Sponsored by: Swedish Orphan Biovitrum Ab.
Signed date: 25/10/2021

Álvarez Román, MT. Estudio de fase 3, multicéntrico, en doble ciego, aleatorizado y controlado con placebo, para evaluar la eficacia, seguridad y tolerabilidad de rozanolixizumab en adultos con trombocitopenia inmune primaria persistente o crónica.

Type: Clinical Trials, phase III.
HULP code: 5623 TP0006.
Sponsored by: Ucb Biopharma Sprl.
Signed date: 26/01/2021

García Barcenilla, S. Estudio observacional para evaluar el impacto y la carga de la enfermedad en hemofilia moderada y grave desde la perspectiva de enfermería y del paciente (estudio nurses-whocare).

Type: Estudios, phase EPA-OD.
HULP code: PI-4824 ML42270.
Sponsored by: Roche Farma, S.A.
Signed date: 18/06/2021

Jiménez Yuste, VM. Ensayo multinacional, abierto, aleatorizado y controlado para investigar la eficacia y la seguridad de nnc0365-3769 (mim8) en adultos y adolescentes con hemofilia A con o sin inhibidores.

Type: Clinical Trials, phase III.
HULP code: 5795 NN7769-4514.
Sponsored by: Novo Nordisk A/S-No Valido.
Signed date: 19/04/2021

Jiménez Yuste, VM. Eficacia y seguridad de la administración de concizumab en profilaxis en pacientes con hemofilia A o B con inhibidores.

Type: Clinical Trials, phase III.
HULP code: Appendix 3 5401.
Sponsored by: Novo Nordisk Pharma, S.A.
Signed date: 05/05/2021

Jiménez Yuste, VM. Eficacia y seguridad de la administración de concizumab en profilaxis en pacientes con hemofilia A o B sin inhibidores.

Type: Clinical Trials, phase III.
HULP code: Appendix 2 5400.

Sponsored by: Novo Nordisk A/S.
Signed date: 05/05/2021

Jiménez Yuste, VM. Estudio de fase IV, multicéntrico y abierto para evaluar la salud general, la actividad física y los resultados articulares en participantes de 13 años o más y menos de 70 años con hemofilia A grave o moderada sin inhibidores del fvIII que reciben profilaxis con emicizumab.

Type: Clinical Trials, phase IV.
HULP code: 5964 MO42623.
Sponsored by: Roche Farma, S.A.
Signed date: 18/10/2021

Martín Salces, M. Ensayo en fase III multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de efgartigimod (argx 113) 10 mg/kg por vía intravenosa en pacientes adultos con trombocitopenia inmune primaria.

Type: Clinical Trials, phase III.
HULP code: Appendix 1 5430.
Sponsored by: Argenx Bv (Argenx Bvba).
Signed date: 16/04/2021

Martín Salces, M. Ensayo en fase III multicéntrico, sin enmascaramiento y a largo plazo para evaluar la seguridad y la eficacia de 10 mg/kg de efgartigimod (argx-113) por vía intravenosa en pacientes adultos con trombocitopenia inmunitaria primaria.

Type: Clinical Trials, phase III.
HULP code: Appendix 1 5480.
Sponsored by: Argenx Bv (Argenx Bvba).
Signed date: 10/05/2021



3.2.4 Vascular Physiology and Pharmacology Group

Publications: 14
Q1: 14

COMPOSITION



■ **Mercedes Salaces Sánchez.** Catedrática. Departamento de Farmacología. Facultad de Medicina. Universidad Autónoma de Madrid

María Jesús Alonso Gordo. Catedrática. Departamento de Ciencias Básicas de la Salud. Facultad de Ciencias de la Salud. Universidad Rey Juan Carlos

Constanza Ballesteros Martínez. Investigadora Predoctoral. Universidad Autónoma de Madrid

María Teresa Barrús Ortiz. Profesora Contratada Doctor. Departamento de Ciencias Básicas de la Salud. Facultad de Ciencias de la Salud. Universidad Rey Juan Carlos

Javier Blanco Rivero. Profesor Contratado Doctor. Departamento de Fisiología. Facultad de Medicina. Universidad Autónoma de Madrid

Ana María Briones Alonso. Profesora Titular. Departamento de Farmacología. Facultad de Medicina. Universidad Autónoma de Madrid

Ana Belén García Redondo. Profesora Ayudante Doctor. Departamento de Fisiología. Facultad de Medicina. Universidad Autónoma de Madrid

María González Amor. Investigadora Predoctoral. Universidad Autónoma de Madrid

Zoe González Carnicero. Investigadora Predoctoral. Universidad Rey Juan Carlos

Raquel Hernanz Martín. Profesora Titular. Departamento de Ciencias Básicas de la Salud. Facultad de Ciencias de la Salud. Universidad Rey Juan Carlos

Ángela Martín Cortes. Profesora Contratada Doctor. Departamento de Ciencias de la Salud. Facultad de Ciencias de la Salud. Universidad Rey Juan Carlos

Marta Martínez Casales. Investigadora Predoctoral. Universidad Rey Juan Carlos

Marta Miguel Castro. Investigador Científico. Instituto de Investigación en Ciencias de la Alimentación. Consejo Superior de Investigaciones Científicas

Roberto Palacios Ramírez. Investigador Posdoctoral. Universidad Rey Juan Carlos

Raquel Rodríguez Díez. Investigadora Postdoctoral. Universidad Autónoma de Madrid

Lucía Serrano Díaz del Campo. Investigadora Predoctoral. Universidad Autónoma de Madrid

STRATEGIC OBJECTIVE

Our group is a well-established research group with more than 30 years of experience in the study of the mechanisms involved in the functional, structural and mechanical alterations of the vasculature in

various cardiovascular pathologies such as ageing, diabetes and, in particular, hypertension.

The group is located at the Faculty of Medicine (UAM) and maintains research collaborations with investigators at various universities in Spain and in other countries. Our main objective is to gain further

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

insight into the physiological and molecular mechanisms involved in alterations of resistance and conductance arteries in cardiovascular pathologies. To conduct our research, we generally use various experimental approaches including in vivo animal models, ex vivo experiments and in vitro cellbased studies combined with physiological, pharmacological and molecular biology techniques.

In addition, we have begun to translate this knowledge into human studies. In terms of the mediators involved, we have a particular interest in the role of prostanoids derived from the inducible isoform of cyclooxygenase (COX-2) and reactive oxygen species (and their interaction among each other or with other mediators such as nitric oxide) in inflammatory conditions that resemble those found in cardiovascular pathologies. This research is important given the essential role these mediators play in the control of vascular smooth muscle tone and vascular structure.

RESEARCH LINES

- Inflammation and vascular function and remodelling. Changes with hypertension and other cardiovascular pathologies.
- Adipose tissue and vascular alterations in cardiovascular pathologies.
- Neural control of vascular tone.
- Cardiovascular effects of heavy metals.
- Antioxidant and antihypertensive properties of food bioactive compounds.
- Resolution of inflammation as a therapeutic approach for cardiovascular diseases

RESEARCH ACTIVITY

■ Doctoral theses

González Amor M. Interferon-stimulated gene 15 (ISG15) and myeloid G protein-coupled receptor kinase 2 (GRK2) are novel mediators of vascular dysfunction induced by hypertension and obesity[dissertation]. Madrid: UAM: 2021(09/07/2021).

Directors: Briones Alonso AM, García Redondo AB.

International Mention 

■ Master Theses

Boukich El Jouhari N. Effect of Resolvin D2 on the cardiovascular alterations induced by aldosterone[dissertation]. Madrid: UAM: 2021(06/09/2021).

Directors: Briones Alonso AM, Rodrigues Díez R

Arruda Navarro Albuquerque D. Identification of the integrin receptor involved in vascular damage induced by interferon stimulated gene 15[dissertation]. Madrid: UAM: 2021(06/09/2021).

Directors: Briones Alonso AM, González Amor M

Méndez Albiñana P. Efecto de la suplementación con pectina de cítricos sobre biomarcadores del síndrome metabólico en un modelo animal inducido por una dieta rica en grasa.[dissertation]. Madrid: UAM: 2021(06/09/2021).

Director: Blanco Rivero J.

Ayman M. Supplementation with a Carob (Ceratonia siliqua L.) Fruit Improves Endothelial Dysfunction Associated with Metabolic Syndrome in Mice: Possible Role of Hydrogen Sulphide.[dissertation]. MADRID: UAM: 2021(06/09/2021)

Directors: García Redondo AB, Blanco Rivero J.

■ Final Degree Theses

Tesoro García F. Cuidados de enfermería al paciente con quemaduras[dissertation]. Alcorcón: URJC: 2021(16/06/2021).

Director: Hernanz Martín R.

Paz Fernández A. Trastornos del sueño tras un ictus[dissertation]. Alcorcón: URJC: 2021(16/06/2021).

Director: Hernanz Martín R.

Barahona Borja M. Apnea obstructiva del sueño en tiempos de Covid-19[dissertation]. Alcorcón: URJC: 2021(16/06/2021).

Director: Hernanz Martín R.

Serrano A. Efecto de la suplementación aguda con monohidrato de creatina para

la mejora del rendimiento en el heptatlón femenino[dissertation]. Madrid: UAM: 2021(16/06/2021).

Directors: García Redondo AB, Blanco Rivero J.

Rodrigo Huescas N. Estrategias nutricionales para la mejora del rendimiento y recuperación en el fútbol de élite[dissertation]. Madrid: UAM: 2021(16/06/2021).

Directors: García Redondo AB, Blanco Rivero J.

■ Publications

- Beck L, Pinilla E, Arcanjo DDR, Hernanz R, Prater-Duran J, Petersen AG, Kohler R, Sheykhzade M, Comerma-Steffensen S, Simonsen U. Pifendone is a vasodilator: Involvement of KV7 channels in the effect on endothelium-dependent vasodilation in type-2 diabetic mice. Front Pharmacol. 2021, 11: 619152. Article. IF: 5.988, Q1



1
Introduction

2
Executive
Summary

3
Information
Groups
by Area

4
Associated
Clinicians

- Blanco-Rivero J Couto GK Paula SM Fontes MT Rossoni LV. Enhanced sympathetic neurotransduction in the superior mesenteric artery in a rat model of heart failure: role of noradrenaline and ATP. *Am J Physiol-Heart C*. 2021, 320(2): H563-74. Article. IF: 5.125, Q1
- Briones A Fernández-Alfonso M. Report on the 24th meeting of the ECCR 8th-9th October 2021. *Clin Sci (Lond)*. 2021, 135(S1): 1. Article. IF: 6.876, Q1
- Canes L, Martí-Pamies I, Ballester-Servera C, Alonso J, Serrano E, Briones AM, Rodríguez C, Martínez-González J. High NOR-1 (Neuron-Derived Orphan Receptor 1) expression strengthens the vascular wall response to angiotensin II leading to aneurysm formation in mice. *Hypertension*. 2021, 77(2): 557-70. Article. IF: 9.897, Q1
- Cros-Brunso L, Camacho-Rodríguez L, Martínez-González A, Llevenes P, Salaices M, García-Redondo AB, Blanco-Rivero J. A blunted sympathetic function and an enhanced nitrgic activity contribute to reduce mesenteric resistance in hyperthyroidism. *Int J Mol Sci*. 2021, 22(2): 570. Article. IF: 6.208, Q1
- Davel AP, Blanco-Rivero J, Rossoni LV. Editorial: Vascular adjustments in cardiovascular disorders. *Front Physiol*. 2021, 12: 777488. Editorial Material. IF: 4.755, Q1
- López-Moreno M, Garcés-Rimón M, Miguel M, López MTI. Adherence to mediterranean diet alcohol consumption and emotional eating in spanish university students. *Nutrients*. 2021, 13(9): 3174. Article. IF: 6.706, Q1
- Martínez-Casales M, Hernanz R, Alonso MJ. Vascular and macrophage heme oxygenase-1 in hypertension: A mini-review. *Front Physiol*. 2021, 12: 643435. Review. IF: 4.755, Q1
- Mas-Bargues C Alique M Barrus-Ortiz MT Borrás C Rodríguez-Díez R. Exploring new kingdoms: The role of extracellular vesicles in oxi-inflammaging related to cardiorenal syndrome. *Antioxidants*. 2022, 11(1): 78. Review. IF: 7.675, D1
- Morales D, Miguel M, Garcés-Rimón M. Pseudocereals: a novel source of biologically active peptides. *Crit Rev Food Sci*. 2021, 61(9): 1537-44. Review. IF: 11.208, D1
- Naya-Catala F, Wiggers GAA, Piazzon MC, López-Martínez MI, Estensoro I, Caldach-Giner JAA, Martínez-Cuesta MC, Requena T, Sitja-Bobadilla A, Miguel M, Pérez-Sánchez J. Modulation of Gilthead sea bream gut microbiota by

a bioactive egg white hydrolysate: Interactions between bacteria and host lipid metabolism. *Front Mar Sci*. 2021, 8: 698484. Article. IF: 5.247, D1

- Olivencia MA Martínez-Casales M Peraza DA García-Redondo AB Mondéjar-Parreno G Hernanz R Salaices M Cogolludo A Pennington MW Valenzuela C Briones AM. KV1.3 channels are novel determinants of macrophage-dependent endothelial dysfunction in a mouse model with angiotensin II-induced hypertension. *Brit J Pharmacol*. 2021, 178(8): 1836-54. Article. IF: 9.473, D1
- Oller J, Gabande-Rodríguez E, Ruiz-Rodríguez MJ, Desdin-Mico G, Aranda JF, Rodrigues-Diez R, Ballesteros-Martínez C, Blanco EM, Roldan-Montero R, Acuna P, Gil AF, Martín-López CE, Nistal JF, Cárdenas CLL, Lindsay ME, Martín-Ventura JL, Briones AM, Redondo JM, Mittelbrunn M. Extracellular tuning of mitochondrial respiration leads to aortic aneurysm. *Circulation*. 2021, 143(21): 2091-109. Article. IF: 39.918, D1
- Simoes MR, Azevedo BF, Alonso MJ, Salaices M, Vassallo DV. Chronic low-level lead exposure increases mesenteric vascular reactivity: role of cyclooxygenase-2-derived prostanoids. *Front Physiol*. 2021, 11: 590308. Article. IF: 4.755, Q1

■ Research projects

Briones Alonso AM (UAM). General Coordinator: Thomas Unger (University of Maastricht). Mechanistic Integration of vascular and endocrine pathways for Subtyping Hypertension: an Innovative network approach for Future generation research Training-MINDSHIFT (Grant agreement 954798). Marie Skłodowska-Curie actions. Innovative Training Networks (ITN)-European Joint Doctorates. 2021-2024.

Management centre: UAM

Briones Alonso AM. Deciphering the role of novel inflammatory mediators derived from interferon and the inefficient resolution of inflammation in the cardio-

vascular damage associated to hypertension (PID2020-116498RB-I00). AEI. 2021-2024.

Management centre: UAM

Briones Alonso AM. Interferon stimulated gene 15 (ISG15) as a novel mediator of cardiovascular damage. Bayer Grants-4Targets. 2020-2021.

Management centre: UAM

García-Redondo AB. Interferon stimulated gene 15 (ISG15) as a new mediator of aortic aneurysms (SI1-PJI-2019-321). CAM. 2020-2022.

Management centre: UAM

Miguel Castro M. Hidrólisis de proteínas vegetales de alto valor biológico: obtención de péptidos antioxidantes y nuevas texturas culinarias para la elaboración de productos sin gluten (AGL-2017-89213). MINECO. 2018-2021.

Management centre: CSIC

Miguel Castro M. Hidrolizado de clara de huevo y salud cardiovascular. Estudio del efecto antihipertensivo y de los mecanismos de acción en ratas DOCA-sal. (COOPA20453). CSIC. 2021-2022.

Management centre: CIAL (CSIC)

Rodríguez Díez R. Contrato Juan de la Cierva (IJCI-2017-31399). MINECO. 2019-2021.

Management centre: UAM

Salaices Sánchez M, Briones Alonso AM. Novel inflammatory mechanisms of vascular damage in hypertension and obesity. Role of pro-resolving lipid mediators as possible therapeutic strategy. (SAF2016-80305-P). MINECO. 2017-2021.

Management centre: UAM

Salaices Sánchez M. Mediadores y mecanismos moleculares de patologías aórticas y valvulares (B2017/BMD-3676). CAM. 2018-2021.

Management centre: UAM.

■ Cibers and Retics

Salaices Sánchez M. Networked Biomedical Research Center for Cardiovascular Diseases. (CB16/11/00286). IISCIII. (31/12/2022).

Management centre: UAM.

■ Patents and trademarks

González-Muñiz R, Pérez de Vega MJ, Miguel M, Balsara-Paredes B, Moreno S, inventors; CSIC, assignee. Triazolyl polyphenols with antioxidant activity and uses thereof; P201531450; 2015 November 08.

León Martínez R, Abril Comesaña S, Duarte Flórez P, Crisman Vigil E, Michalska P, Salaices Sánchez M, Menéndez Ramos JC, inventors; Fundación para la Investigación Biomédica del Hospital Universitario de la Princesa, UAM, UCM, assignees. Compuestos agonistas nicotínicos y antioxidantes para el tratamiento de enfermedades neurodegenerativas. P201930908. 2019 October 14.

León Martínez R, Abril Comesaña S, Michalska P, Buendía Abaitua I, Salaices Sánchez M, Menéndez Ramos JC, García López M; inventors; Fundación para la Investigación Biomédica del Hospital



1 Introduction

Universitario de la Princesa, UAM, UCM, assignees. Compuestos derivados de 2-iodo-7-(((2-(5-metoxi-1H-indol-3-il)etil) amino)metil)-1-alkuil/aryl-6,7,7a,8-tetrahidro-3H-pirrololo[2,1-j]quinolina-3,9(5H)-diona como agentes antioxidantes, inductores de NRF2 y moduladores nicotínicos para el tratamiento de enfermedades neurodegenerativas. P201930190. 2019 March 01 .

Miguel Castro M, Garcés Rimón M, López-Alonso Fandiño R, Sandoval Huertas M, inventors; CSIC, Mario Sandoval Huertas, assignees. Healthy food compositions having gel or foam textures and comprising hydrolyzed egg products. P201331886, PCT/ES2014/070902, EP3106042, US9648897, AR098685, JP2015130856, MX2014015135; 2013 December 20.

Miguel Castro M, López-Alonso Fandiño R, Ramos González MM, Aleixandre de Artiñano A, inventors; CSIC, assignee. Production of and antihypertensive properties of peptides derived from egg white proteins. P200501246 PCT/ES2006/070067; 2005 May 23.

Miguel Castro M, López-Alonso Fandiño R, Recio Sánchez MI, Ramos González MM, Aleixandre de Artiñano A, inventors; CSIC, assignee. Bioactive peptides derived from the proteins of egg white by means of enzymatic hydrolysis. P200301829, PCT/ES2004/070059, EP1661913, US8227207, AT388166, DE602004012289, DK1661913,

JP2007523045; 2003 July 31.

Miguel Castro M, Garcés Rimón M, authors; Miguel Castro M, Garcés Rimón M, assignee. Brand name: leggie. ESM4044711; 2019 November 22.

Leggie

Pérez Girón JV, Ruiz-Castellanos MJ, de Luis Jiménez O, Pérez Boto V, Sanz González R, Hernández Vélez MC, Mas Gutiérrez JA, Alonso Gordo MJ, Sallaices Sánchez M, Ros Pérez M, Coloma Jerez A, Asenjo Barahona A, Sanz Montaña JL, Puente Prieto J, Jensen J, inventors; NANOATE, S.L., assignee. Method for producing biosensors. P201031224, PCT/ES2011/070536; 2010 August 05.

Recio Sánchez MI; Quirós del Bosque A, Hernández Ledesma B, Gómez Ruiz JA, Miguel Castro M, Amigo Garrido L, López Expósito I, Ramos González MM, Aleixandre de Artiñano A, (Contreras Gómez M), inventors; CSIC, assignee. Bioactive peptides identified in enzymatic hydrolyzates of milk caseins and method of obtaining same. P200501373, PCT/ES2006/070079, EP1905779, EP2495250, US8354502, AU2006256720, BRPI0611729, CA2611416, CN101305017, CN103254278, JP2008545774, KR20080045108, MX2007015528, NO20080103; 2005 June 08.

Miguel M, Bruna E, Redondo BI, Gómez J, Gómez Sánchez J. inventors: : Cárnicas Joselito S.L: assigne. Extracto procedente de la grasa de cerdo, método de obtención, composición alimenticia que lo comprende y usos del mismo. P2021130236. 2021 March 17

Miguel M, Bruna E, Redondo BI, Gómez J, Gómez Sánchez J, Sabater-Muñoz B. inventors: Cárnicas Joselito S.L. assignee. Composición farmacéutica que comprende un extracto procedente de la grasa de jamón de cerdo como principio activo y su uso en medicina para la prevención cardiovascular e inflamación intestinal. P202131111. 2021 november 30




2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



3.2.5 Vascular Pharmacology and Metabolism Group (FARMAVSM)



Publications: **3**
Q1: **3**

COMPOSITION

■ **Carlos Félix Sánchez Ferrer.** Catedrático de Farmacología. Universidad Autónoma de Madrid

Elena Cercas Alonso. Técnico Especialista en Análisis Clínico. Universidad Autónoma de Madrid

Fernando de la Cuesta Marina. Investigador Postdoctoral. Universidad Autónoma de Madrid

Pilar Dongil Sánchez. Ayudante de Investigación. Universidad Autónoma de Madrid

Jorge Francisco Gómez Cerezo. Jefe de Servicio de Medicina Interna. Hospital Universitario Infanta Sofía

Marta Menéndez Ribes. Investigadora Predoctoral. Universidad Autónoma de Madrid

Concepción Peiró Vallejo. Catedrática de Farmacología. Universidad Autónoma de Madrid

Álvaro San Hipólito Luengo. Investigador Predoctoral. Universidad Autónoma de Madrid

Lucía Shamoon. Investigadora Predoctoral. Universidad Autónoma de Madrid

Inés Valencia Fernández. Investigador Predoctoral. Universidad Autónoma de Madrid

STRATEGIC OBJECTIVE

Understanding vascular ageing, both in healthy and pathological conditions, like obesity and diabetes mellitus.

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



1
Introduction

2
Executive
Summary

3
Information
Groups
by Area

4
Associated
Clinicians

RESEARCH LINES

- Mechanisms of human vascular ageing
- Mechanisms for vascular damage in diabetes mellitus
- Obesity, adipokines, insulin resistance, and vascular dysfunction
- Role for the angiotensin-(1-7)/Mas receptor axis on vascular function and inflammation
- Development of novel extracellular vesicle-based therapies for cardiovascular diseases

RESEARCH ACTIVITY

■ Doctoral theses

San Hipólito Luengo A. Nuevos mecanismos celulares implicados en la inflamación vascular mediada por la interleuquina 1b y la glucosa. Papel del inflamasoma NLRP3 y de las vesículas extracelulares[dissertation]. Madrid: UAM: 2021(16/04/2021).

Directors: Peiró Vallejo C,
Sánchez Ferrer CF.

International Mention 

■ Publications

• Olivares-Silva F, de Gregorio N, Espitia-Corredor J, Espinoza C, Vivar R, Silva D, Osorio JM, Lavandero S, Peiró C, Sánchez-Ferrer C, Díaz-Araya G. Resolvin-D1 attenuation of angiotensin II-induced cardiac inflammation in mice is associated with prevention of cardiac remodeling and hypertension. *BBA-Mol Basis Dis.* 2021; 1867(12): 166241. Article. IF: 6.633; Q1

- Salas-Hernández A, Ruz-Cortés F, Bruggendieck F, Espinoza-Pérez C, Espitia-Corredor J, Varela NM, Quiñones LA, Sánchez-Ferrer C, Peiró C, Díaz-Araya G. Resolvin D1 reduces expression and secretion of cytokines and monocyte adhesion triggered by Angiotensin II, in rat cardiac fibroblasts. *Biomed Pharmacother.* 2021; 141: 111947. Article. IF: 7.419; D1
- Salas-Hernández A, Espinoza-Pérez C, Vivar R, Espitia-Corredor J, Lillo J, Parra-Flores P, Sánchez-Ferrer CF, Peiró C, Díaz-Araya G. Resolvin D1 and E1 promote resolution of inflammation in rat cardiac fibroblast in vitro. *Mol Biol Rep.* 2021; 48(1): 66. Article. IF: 2.742; Q4

■ Research projects

de la Cuesta Marina F. Developing novel nanotherapies for atherosclerosis by delivering senolytics to the plaque using mesenchymal stem cell-derived extracellular vesicles (2019-T1/IND-13794). CM. 2020-2024.

Managment centre: UAM

Peiró Vallejo C, Sánchez Ferrer CF. Adipoquinas: nuevas dianas farmacológicas para prevenir el envejecimiento vascular (SAF2017-84776-R). MINECO. 2018-2021.

Managment centre: UAM

Sánchez Ferrer CF. Citómetro Separador Sorter. (EQC2018-005059-P). Ministerio de Ciencia, Innovación y Universidades. 2019-2020.

Managment centre: UAM

Peiró Vallejo C, Lorenzo González O. Viral S protein-ACE2 interactions: cell damage, protection and prognosis in the cardiovascular complications of COVID-19 (SPACE2-CV-COVID-CM). CM/EU. 2020-2022.

Managment centre: UAM



Infectious Diseases and Immunity Area



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Eduardo López-Collazo

Documents:	299	
Originals:	237	
D1:	60	Q1: 126

- 3.3.1 AIDS and Infectious Diseases Group
- 3.3.2 Molecular Microbiology Group
- 3.3.3 Immuno-Rheumatology Group
- 3.3.4 Innate Immune Response Group
- 3.3.5 Diagnosis and Treatment of Diseases associated with Abnormalities of the Complement System Group
- 3.3.6 Lymphocyte Pathophysiology in Immunodeficiencies Group
- 3.3.7 Drug Hypersensibility and Innate Immune Response Group
- 3.3.8 Immunommediate Gastrointestinal Diseases and other Digestive Pathologies Group



Infectious Diseases and Immunity Area



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Strategic Objectives	Development forecast for the coming years	Actions
<p>Infectious Diseases and Immunity Area is composed of 11 groups focused on the study of diseases related to the immune system such as HIV, autoimmune diseases, cancer, etc., as well as the molecular mechanisms that explain the phenomena associated with these pathologies.</p>	<p>To identify priority research topics in our area and if necessary expand some of them.</p>	<p>Promote the priority research line identified.</p>
	<p>To generate and develop scientific research projects that allow the production of knowledge in the biomedical area.</p>	<p>Obtain national and international scientific research projects in biomedical area.</p>
	<p>To generate a significant number of research products/ results, such as publications in nationally and internationally indexed journals, journals that contribute to the social appropriation of knowledge.</p>	<p>Improve the annual number of publications in the first quartile and decile, and total impact factor of the area.</p>
	<p>To socialize the research results by presenting papers at national and international events.</p>	<p>Increase the presence of area researchers in national and international events.</p>
	<p>To establish agreements and strategic alliances with other communities of knowledge that allow academic discussion and project development.</p>	<p>Search for synergies with other groups with similar and complement research lines.</p>
	<p>To promote the training of young researchers and undergraduate and graduate students.</p>	<p>Training in research methodology undergraduate, predoctoral and postdoctoral personal.</p>
<p>To develop a good system of applied research so that everything studied in the laboratory has repercussions on both our patients and our entities.</p>	<p>Promote the synergies of translational researchers and clinical researchers, and their incorporation into groups.</p>	





3.3.1 AIDS and Infectious Diseases Group

Publications: 46

Q1: 26

COMPOSITION



José Ramón Arribas López. Facultativo Especialista de Área en Medicina Interna (Contrato de Intensificación). Unidad de VIH. Hospital Universitario La Paz. Profesor Asociado. Universidad Autónoma de Madrid

Marta Arsuaga Vicente. Médico Adjunto en Medicina Interna. Hospital Carlos III - Hospital Universitario La Paz

José Ignacio Bernardino de la Serna. Facultativo Especialista de Área en Medicina Interna. Unidad VIH. Hospital Universitario La Paz

Carmen Busca Arenzana. Contrato Río Hortega. Hospital Universitario La Paz

Julén Cadiñanos Loidi. Contrato Río Hortega. Hospital Universitario La Paz

Fernando de la Calle Prieto. Médico adjunto en Medicina Interna. Unidad de Medicina Tropical. Hospital Carlos III - Hospital Universitario La Paz. Profesor Colaborador. Universidad Autónoma de Madrid

Rosa de Miguel Buckley. Facultativo Especialista Adjunto en Medicina Interna. Hospital Universitarios La Paz

Marta Díaz Menéndez. Médico adjunto en Medicina Interna. Unidad de Medicina Tropical. Hospital Universitario La Paz

Beatriz Díaz Pollán. Facultativo Especialista de Área en Medicina Interna. Unidad de Enfermedades Infecciosas y Microbiología Clínica. Hospital Universitario La Paz

Andrés Esteban Cantos. Investigador Predoctoral. Hospital Universitario La Paz

Marta Gálvez Charro. Enfermera. Unidad de VIH. Hospital Universitario La Paz

Francisco Gayá Moreno. Investigador Predoctoral (Contrato de Estabilización de Técnicos de Apoyo). Hospital Universitario La Paz

Juan Julián González García. Facultativo Especialista de Área en Medicina Interna. Unidad de VIH. Hospital Universitario La Paz

Pedro Herranz Pinto. Facultativo Especialista de Área en Dermatología. Jefe de Sección. Hospital Universitario La Paz

Víctor Hontañón Antoñana. Investigador predoctoral. Hospital Universitario La Paz

María Jiménez González. Bioestadística. FIBHULP
María Concepción Ladrón de Guevara García. Facultativo Especialista de Área en Microbiología y Parasitología. Hospital Carlos III - Hospital Universitario La Paz

María del Mar Lago Núñez. Facultativo Especialista de Área en Medicina Interna. Unidad de Medicina Tropical. Hospital Carlos III - Hospital Universitario La Paz

Luz Martín Carbonero. Facultativo Especialista de Área. Hospital Universitario La Paz

Patricia Martínez Martín. Médico Adjunto en Medicina Interna. Hospital Universitario La Paz

Mario Mayoral Muñoz. Enfermero. Hospital Universitario La Paz

Beatriz Mena Garay. Técnico de Grado Superior. Hospital Universitario La Paz

Juan José Miguel Castro. Enfermero. Hospital Universitario La Paz

Rocío Montejano Sánchez. Investigadora Predoctoral (Contrato Río Hortega). Hospital Universitario La Paz

María Luisa Montes Ramírez. Facultativo Especialista de Área de Medicina Interna. Unidad de VIH. Hospital Universitario La Paz


Marta Mora Rillo. Facultativo Especialista de Área de Medicina Interna. Unidad de Enfermedades Infecciosas y Microbiología Clínica. Hospital Universitario La Paz

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Francisco Moreno Ramos. Farmacéutico. Hospital Universitario La Paz

José María Peña Sánchez de Rivera. Jefe de Sección de Plaza Vinculada. Hospital Universitario La Paz. Catedrático. Universidad Autónoma de Madrid

Berta Rodés Soldevila. Investigadora Senior (Contrato Miguel Servet- I2). Hospital Universitario La Paz

Juan Carlos Ramos Ramos. Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz

Javier Rodríguez Centeno. Investigador postdoctoral. Hospital Universitario La Paz

Gabriel Saiz Medrano. Técnico de Grado Superior. FIBHULP

Elena Sendagorta Cudós. Facultativo Especialista de Área de Dermatología. Hospital Universitario La Paz

Lucía Serrano Morago. Investigadora predoctoral. Hospital Universitario La Paz

Eulalia Valencia Ortega. Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz

STRATEGIC OBJECTIVE

Although great progress has been made, HIV infection remains an incurable disease. Even under the best circumstances, HIV-infected patients who receive current antiretroviral therapy have a survival disadvantage compared with the general non-infected population, which is estimated to be a life expectancy of 15 years less than the general population.

HIV infection is highly prevalent in Spain. Among western European countries, Spain has the second highest prevalence. An important local characteristic of the HIV-infected population in Spain is the high prevalence of hepatitis C coinfection.

This research line covers four main topics of research in HIV infection: antiretroviral treatment, HIV-HCV coinfection, metabolic complications and HIV-resistance to antiretroviral drugs. In addition, we are planning to start another research project on infections other than HIV.

The group has started a new research line regarding the aging and HIV Infection.

Tropical diseases are increasing as a consequence of global travel. These diseases continue to be relatively rare however, and therefore, often sub-optimal treated if managed by non-specialists. Furthermore, every year an increasing amount of special travelers (pregnants,

comorbidities, immunosuppressed) travel abroad, adding complexity in terms of a timely and effective diagnosis and management. The Tropical and Travel Medicine Unit provide both pre and posttravel assistance in imported infectious diseases. The aim of this Unit is to provide efficient and effective specialist care with proven or suspected tropical disease and a specific preventative travel advice, together with international vaccines recommended for the trip.

RESEARCH LINES

- Antiretroviral therapy & resistance.
- Metabolic complications of antiretroviral therapy.
- Liver disease.
- Neurocognitive impairment.
- Paediatric HIV infection and MTCT.
- Epigenetic and cellular factors related to HIV progression
- Optimisation of antibiotic therapy (ID no HIV)
- Tropical diseases
- Emerging and re-emerging virus
- Molecular and cellular biomarkers of aging

RESEARCH ACTIVITY

■ Doctoral theses

Miguel Buckley R. Tratamiento antirretroviral guiado por genotipo proviral: ensayo clínico piloto de prueba de concepto ("Art-Pro")[dissertation]. Madrid: UAM: 2021(28/06/2021).

Directors: Arribas López JR, Pulido Ortega F.

■ Publications

• Arenzana CB, Castanedo LO, Fernández CC, Rodríguez DN, Pinto PH, Hierro ABD, Martín AO, Ramírez MLM. Psoriasis and liver damage in HIV-

infected patients. *Cells*. 2021; 10(5): 1099. Article. IF: 7.666; Q2

• Berenguer J, Borobia AM, Ryan P, Rodríguez-Baño J, Bellón JM, Jarrin I, Carratala J, Pachón J, Carcas AJ, Yllescas M, Arribas JR. Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score. *Thorax*. 2021; 76(9): 920-9. Article. IF: 9.102; Q1

• Berenguer J, Díez C, Martín-Vicente M, Mican R, Pérez-Eliás MJ, García-Fraile LJ, Vidal F, Suárez-García I, Podzamczar D, del Romero J, Pulido F, Iribarren JA, Gutiérrez F, Poveda E, Galera C, Izquierdo R, Asensi V, Portilla J, López JC, Arribas JR, Moreno S, González-García J, Resino S, Jarrin I. Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort. *Clin Microbiol Infect*.



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

- 2021; 27(11): 1678-84. Article. IF: 13.31; D1
- Borobia AM, Carcas AJ, Pérez-Olmeda M, Castano L, Bertrán MJ, García-Pérez J, Campins M, Portoles A, González-Pérez M, Morales MTG, Arana-Arri E, Aldea M, Díez-Fuertes F, Fuentes I, Ascaso A, Lora D, Imaz-Ayo N, Baron-Mira LE, Agustí A, Pérez-Inguidua C, de la Cámara AG, Arribas JR, Ochando J, Alcamí J, Belda-Iniesta C, Frías J. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. *Lancet*. 2021; 398(10295): 121-30. Article. IF: 202.731; D1
 - Borobia AM, García-García I, Díaz-García L, Rodríguez-Mariablanca A, de Soto LM, Villatoro JM, Meseguer ES, González JJ, Iniesta JF, García ER, Arribas JR, Carcas-Sansuan AJ. Health care workers' reasons for choosing between two different COVID-19 prophylaxis trials in an acute pandemic context: Single-center questionnaire study. *J Med Internet Res*. 2021; 23(2): e23441. Article. IF: 7.076; D1
 - Brochado O, Martínez I, Berenguer J, Medrano L, González-García J, Jiménez-Sousa MA, Carrero A, Hontañón V, Navarro J, Guardiola JM, Fernández-Rodríguez A, Resino S. HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients. *J Biomed Sci*. 2021; 28(1): 23. Article. IF: 12.771; D1
 - Brochado-Kith O, Martínez I, Berenguer J, González-García J, Salguero S, Sepulveda-Crespo D, Díez C, Hontañón V, Ibáñez-Samaniego L, Pérez-Latorre L, Fernández-Rodríguez A, Jiménez-Sousa MA, Resino S. HCV cure with direct-acting antivirals improves liver and immunological markers in HIV/HCV-coinfected patients. *Front Immunol*. 2021; 12: 723196. Article. IF: 8.786; Q1
 - Buckley RD, Díaz-Menéndez M. Go to gate: COVID-19 imported cases in Madrid and the potential role of airport transmissions. *T Roy Soc Trop Med H*. 2021; 115(7): 731-2. Editorial Material. IF: 2.455; Q3
 - Busto-Leis JM, Servera-Negre G, Mayor-Ibarguren A, Sendagorta-Cudós E, Feito-Rodríguez M, Nuno-González A, Montero-Vega MD, Herranz-Pinto P. Pityriasis rosea, COVID-19 and vaccination: new keys to understand an old acquaintance. *J Eur Acad Dermatol*. 2021; 35(8): E489-91. Letter. IF: 9.228; D1
 - Cadiñanos J, Montejano R, Buckley RD, Marcelo C, Arribas JR. Risks and benefits of reducing the number of drugs to treat HIV-1 infection. *Expert Opin Drug Saf*. 2021; 20(4): 397-409. Review. IF: 4.011; Q2
 - Carrero A, Berenguer J, Hontañón V, Guardiola JM, Navarro J, von Wichmann MA, Téllez MJ, Quereda C, Santos I, Sanz J, Galindo MJ, Hernández-Quero J, Jiménez-Sousa MA, Pérez-Latorre L, Bellón JM, Resino S, Esteban H, Martínez E, González-García J. Effects of hepatitis C virus (HCV) eradication on bone mineral density in human immunodeficiency virus/HCV-coinfected patients. *Clin Infect Dis*. 2021; 73(7): E2026-33. Article. IF: 20.999; D1
 - Castanedo LQ, Fernández CC, Cudós ES. Neutrophilic dermatosis on the dorsal hands. *Actas Dermosifiliogr*. 2021; 112(7): 661-2. Editorial Material. Not Indexed
 - Condes E, Arribas JR. Impact of COVID-19 on Madrid hospital system. *Enferm Infecc Microbiol Clin*. 2021; 39(5): 256-7. Letter. IF: 1.994; Q4
 - de Ory SJ, Beltrán-Páez C, Gutiérrez-López M, Santos MD, Prieto L, Sainz T, Guillén S, Aguilera-Alonso D, Díez C, Bernardino JI, Mellado MJ, Ramos JT, Holguin A, Navarro M. Prevalence of M184V and K65R in proviral DNA from PBMCs in HIV-infected youths with lamivudine/emtricitabine exposure. *J Antimicrob Chemother*. 2021; 76(7): 1886-92. Article. IF: 5.758; Q1
 - del Amo J, Polo R, Moreno S, Díaz A, Martínez E, Arribas JR, Jarrin I, Hernan MA. Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy RESPONSE. *Ann Intern Med*. 2021; 174(4): 581-2. Letter. IF: 51.598; D1
 - Díaz-Menéndez M, Arsuaga M. Pre-travel consultation: The exciting new mission for James Bond. *Travel Med Infect Dis*. 2021; 44: 102203. Editorial Material. IF: 20.441; D1
 - Díaz-Menéndez M, Malmierca E. Reply to: Integral management of COVID-19 in Madrid: Turning things around during the second wave. *Lancet Reg Health Eur*. 2021; 3: 100068. Letter. Not Indexed
 - Díaz-Menéndez M, Trigo E, Borobia AM, Arsuaga M, de la Calle-Prieto Fernando, Buckley RD, Lago M, Arribas JR. Presenting characteristics and outcomes of migrants in a cohort of hospitalized patients with COVID-19: Does the origin matter? *Travel Med Infect Dis*. 2021; 42: 102027. Letter. IF: 20.441; D1
 - Díez C, del Romero-Raposo J, Mican R, López JC, Blanco JR, Calzado S, Sampérez G, Portilla J, García-Fraile LJ, Gutiérrez F, Gómez-Sirvent JL, Suarez-García I, Amador C, Novella M, Arribas JR, Moreno S, González-García J, Jarrin I, Berenguer J. COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study. *HIV Med*. 2021; 22(9): 867-76. Article. IF: 3.094; Q3
 - Esteban-Cantos A, Rodríguez-Centeno J, Baruz P, Alejos B, Saiz-Medrano G, Nevado J, Martín A, Gaya F, de Miguel R, Bernardino JI, Montejano R, Mena-Garay B, Cadiñanos J, Florence E, Mulcahy F, Banhegyi D, Antinori A, Pozniak A, Wallet C, Raffi F, Rodés B, Arribas JR. Epigenetic age acceleration changes 2 years after antiretroviral therapy initiation in adults with HIV: a substudy of the NEAT001/ANRS143 randomised trial. *Lancet HIV*. 2021; 8(4): e197-205. Article. IF: 16.07; D1
 - Feito-Rodríguez M, Mayor-Ibarguren A, Camara-Hijón C, Montero-Vega D, Servera-Negre G, Ruiz-Bravo E, Nozal P, Rodríguez-Peralto JL, Enguita AB, Bravo-Gallego LY, Granados-Fernández M, Fernández-Alcalde C, Fernández-Heredero A, Alonso-Riano M, Jiménez-Yuste V, Nuno-González A, de Lucas-Laguna R, López-Granados E, Herranz-Pinto P. Chilblain-like lesions and COVID-19 infection: A prospective observational study at Spain's ground zero. *J Am Acad Dermatol*. 2021; 84(2): 507-9. Letter. IF: 15.487; D1
 - Fernández MG, Villamañán E, Jiménez-Nacher I, Moreno F, Plasencia C, Gaya F, Herrero A, Balsa A. Cost evaluation of biological drugs in rheumatoid arthritis patients in a tertiary hospital: Influential factors on price. *Rheumatol Clin*. 2021; 17(6): 335-42. Article. Not Indexed
 - González AN, Magaletskyy K, Carrillo PM, Masdemont BL, Ibarguren AM, Rodríguez MF, Pinto PH. Are oral mucosal changes a sign of COVID-19? A cross-sectional study at a field hospital. *Actas Dermosifiliogr*. 2021; 112(7): 640-44. Article. Not Indexed
 - Grillo S, Cuervo G, Carratala J, San-Juan R, Aguado JM, Morata L, Gómez-Zorrilla S, López-Contreras J, Gasch O, Gomila-Grange A, Iftimie S, García-Pardo G, Calbo E, Boix-Palop L, Orío I, Jover-Sáenz A, López-Cortés LE, Euba G, Aguirregabiria M, García-País MJ, Gioia F, Paño JR, Pedro-Botet ML, Benítez RM, Pérez-Rodríguez MT, Meije Y, Loeches-Yagüe MB, Horna G, Berbel D, Domínguez MA, Padullas A, Cobo S, Hereu P, Videla S, Tebe C, Pallares N, Miro JM, Pujol M. Multicentre, randomised, open-label, phase IV-III study to evaluate the efficacy of cloxacillin plus fosfomycin versus cloxacillin alone in adult patients with methicillin-susceptible *Staphylococcus aureus* bacteraemia: study protocol for the SAFO trial. *BMJ Open*. 2021; 11(8): e051208. Article. IF: 3.006; Q2
 - Gutiérrez-Gutiérrez B, del Toro MD, Borobia AM, Carcas A, Jarrin I, Yllescas M, Ryan P, Pachón J, Carratala J, Berenguer J, Arribas JR, Rodríguez-Baño J. Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study. *Lancet Infect Dis*. 2021; 21(6): 783-92. Article. IF: 71.421; D1
 - Kayi I, Madran B, Keske S, Karanfíl O, Arribas JR, Pshenichnaya N, Petrosillo N, Gonen M, Ergonul O. The seroprevalence of SARS-CoV-2 antibodies among health care workers before the era of vaccination: a systematic review and meta-analysis. *Clin Microbiol Infect*. 2021; 27(9): 1242-9. Review. IF: 13.31; D1
 - López-Cavanillas B, Benítez CG, Serrano M, Sendagorta E, Hernández A, Bartha JL. Analysis of the prevalence of human papillomavirus and abnormal anal cytology in women at risk. *J Obstet Gynaecol*. 2021; 41(7): 1139-44. Article. IF: 1.226; Q4
 - Martínez-Ales G, Domingo-Reloso A, Arribas JR, Quintana-Díaz M, Hernan MA. Critical care requirements under uncontrolled transmission of SARS-CoV-2. *Am J Public Health*. 2021; 111(5): 923-26. Article. IF: 11.561; D1
 - Medrano LM, Berenguer J, Salguero S, González-García J, Díez C, Hontañón V, García-Broncano P, Ibáñez-Samaniego L, Bellón JM, Jiménez-Sousa MA, Resino S. Successful HCV therapy reduces liver disease severity and inflammation biomarkers in HIV/HCV-coinfected patients with advanced cirrhosis: A Cohort Study. *Front Med (Lausanne)*. 2021; 8: 615342. Article. IF: 5.058; Q2
 - Micán R, Arenzana CB, Vásquez J, Daroca G, Pérez-Valero I, Martín-Carbonero L. Hepatitis B reactivation after tenofovir withdrawal in an HIV-infected patient with history of cured hepatitis B virus infection and poor immunological status. *AIDS*. 2021; 35(10): 1707-8. Letter. IF: 4.632; Q2
 - Montejano R, Domínguez-Domínguez L, de Miguel R, Rial-Crestelo D, Esteban-Cantos A, Aranguren-Rivas P, García-Álvarez M, Alejos B, Bisbal O, Santacreu-Guerrero M, Hernando A, Bermejo-Plaza L, Cadiñanos J, Mayoral M, Castro JM, Moreno V, Martín-Carbonero L, Rodés B, Delgado R, Rubio R, Pulido F, Arribas JR. Detection of archived lamivudine-associated resistance mutations in virologically suppressed, lamivudine-experienced HIV-infected adults by different genotyping techniques (GEN-PRO study). *J Antimicrob Chemother*. 2021; 76(12): 3263-71. Article. IF: 5.758; Q1
 - Nuno-González A, Magaletskyy K, Rodríguez MF, Ibarguren AM, Beato MJ, Bravo ER, Pinto PH.

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

- Palmoplantar erythrodysesthesia: a diagnostic sign of COVID-19. *J Eur Acad Dermatol.* 2021; 35(4): E247-9. Letter. IF: 9.228; D1
- Olender SA, Pérez KK, Go AS, Balani B, Price-Haywood EG, Shah NS, Wang S, Walunas TL, Swaminathan S, Slim J, Chin B, De Wit S, Ali SM, Viladomiu AS, Robinson P, Gottlieb RL, Tsang TYO, Lee IH, Hu H, Haubrich RH, Chokkalingam AP, Lin LJ, Zhong LJ, Bekele BN, Mera-Giler R, Phulpin C, Edgar H, Gallant J, Díaz-Cuervo H, Smith LE, Osinusi AO, Brainard DM, Bernardino JI. Remdesivir for severe coronavirus disease 2019 (COVID-19) versus a cohort receiving standard of care. *Clin Infect Dis.* 2021; 73(11): E4166-74. Article. IF: 20.999; D1
 - Orkin C, Oka S, Philibert P, Brinson C, Bassa A, Gusev D, Degen O, García JG, Morell EB, Tan DHS, D'Amico R, Dorey D, Griffith S, Thiagarajah S, St Clair M, Van Solingen-Ristea R, Crauwels H, Ford SL, Patel P, Chounta V, Vanveggel S, Cutrell A, Van Eygen V, Vandermeulen K, Margolis DA, Smith KY, Spreen WR. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study. *Lancet HIV.* 2021; 8(4): e185-96. Article. IF: 16.07; D1
 - Pardo AA, Palomino MM, Jiménez-Nacher I, Moreno F, Fernández MAG, González-García J, Ambrosio AH. Real-world experience with two-drug regimens in HIV-1-infected patients beyond the indication of clinical trials: 48 weeks' results. *AIDS Res Hum Retrov.* 2021; 37(10): 761-767. Article. IF: 1.723; Q4
 - Pérez-Latorre L, Berenguer J, Micán R, Montero M, Cifuentes C, Puig T, Sanz J, Ferrero OL, de la Fuente B, Rodríguez C, Reus S, Hernández-Queiro J, Gaspar G, Pérez-Martínez L, García C, Force L, Veloso S, de Miguel M, Jarrín I, González-García J. HIV/HBV coinfection: temporal trends and patient characteristics, Spain, 2002 to 2018. *Euro Surveill.* 2021; 26(25): 2000236. Article. IF: 21,286; D1
 - Pérez-Martínez A, Mora-Rillo M, Ferreras C, Guerra-García P, Pascual-Miguel B, Mestre-Durán C, Borobia AM, Carcas AJ, Queiruga-Parada J, García I, Sánchez-Zapardiel E, Gasior M, de Paz R, Marcos A, Vicario JL, Balas A, Moreno MA, Eguizabal C, Solano C, Arribas JR, Buckley RD, Montejano R, Soria B. Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE). *Eclinicalmedicine.* 2021; 39: 101086. Article. IF: 17.033; Q1
 - Pérez-Valero I, Llibre JM, Castagna A, Pulido F,

- Molina JM, Esser S, Margot N, Shao YW, Temme L, Piontkowsky D, McNicholl IR, Haubrich R. Switching to Eelvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in adults with HIV and M184V/I mutation. *JAIDS-J Acq Imm Def.* 2021; 86(4): 490-5. Article. IF: 3.771; Q3
- Quintana-Castanedo L, Mayor-Ibarguren A, Tarín-Vicente E, Herranz-Pinto P. Ibrutinib-induced leg ulcer successfully treated with platelet-rich plasma. *Dermatol Ther.* 2021; 34(2): 14874. Letter. IF: 3.858; Q2
- Quintana-Castanedo L, Sánchez-Orta A, Nuno-González A, Herranz-Pinto P. Usefulness of cutaneous ultrasound in the management of Parry Romberg syndrome. *Skin Res Technol.* 2021; 27(4): 644-5. Letter. IF: 2.24; Q3
- Rial-Crestelo D, de Miguel R, Montejano R, Domínguez-Domínguez L, Aranguren-Rivas P, Esteban-Cantos A, Bisbal O, Santacreu-Guerrero M, García-Álvarez M, Alejos B, Hernando A, Bermejo-Plaza L, Cadinanos J, Mayoral M, Castro JM, Moreno V, Martín-Carbonero L, Delgado R, Rubio R, Pulido F, Arribas JR. Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study. *J Antimicrob Chemother.* 2021; 76(3): 738-42. Article. IF: 5.758; Q1
- Rodríguez-Baño J, Pachón O, Carratala J, Ryan P, Jarrín I, Yllescas M, Arribas JR, Berenguer J. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19). *Clin Microbiol Infect.* 2021; 27(2): 244-52. Article. IF: 13.31; D1
- Salvador F, Lucas-Dato A, Roure S, Arsuaga M, Pérez-Jacoite A, García-Rodríguez M, Pérez-Molina JA, Buonfrate D, Saugar JM, Molina I. Effectiveness and safety of a single-dose ivermectin treatment for uncomplicated strongyloidiasis in immunosuppressed patients (ImmunoStrong Study): The Study Protocol. *Pathogens.* 2021; 10(7): 812. Article. IF: 4.531; Q2
- Sánchez-Azofra M, Fernández I, García-Buey ML, Domínguez-Domínguez L, Fernández-Rodríguez CM, Mancebo A, Bonet L, Ryan P, Gea F, Díaz-Sánchez A, García-Mayor M, Martín-Carbonero L, Castillo P, Manzano ML, González-Moreno L, Pulido F, Gutiérrez ML, Moreno JM, García-Amengual IM, Cuevas G, Guerrero A, Rivero-Fernández M, Portales ME, Montes ML, Oliveira A. Hepatocellular carcinoma risk in hepatitis C stage-3 fibrosis after sustained virological response with direct-acting antivirals. *Liver Int.*

- 2021; 41(12): 2885-91. Article. IF: 8.754; Q1
- Sendagorta E, Servera G, Nuno A, Gil R, Pérez-España L, Herranz P. Direct-to-patient teledermatology during COVID-19 lockdown in a health district in Madrid, Spain: The EVIDE-19 Pilot Study. *Actas Dermosifiliogr.* 2021; 112(4): 345-53. Article. Not Indexed
- Whitlock GG, Protopoulos K, Bernardino JI, Imaz A, Curran A, Stingone C, Shivasankar S, Edwards S, Herbert S, Thomas K, Mican R, Prieto P, García JN, Andreoni M, Hill S, Okhai H, Stuart D, Bourne A, Conway K. Chems4EU: chemsex use and its impacts across four European countries in HIV-positive men who have sex with men attending HIV services. *HIV Med.* 2021; 22(10): 944-57. Article. IF: 3.094; Q3

■ Research projects

Andrés Esteban EM. Valores pronósticos. Recursos consumidos y coste hospitalario de pacientes ingresados por infección Sars-Cov-2 según su fragilidad (COV20/00519). ISCIII. 2020-2021.

Management centre: FIBHULP

Arribas López JR. Ensayo clínico aleatorizado para evaluar la eficacia de diferentes tratamientos en paciente con COVID que requieren hospitalización (COV20/00023). ISCIII. 2020-2021.

Management centre: FIBHULP

Arribas López JR. Estudio de longitud telomérica en pacientes infectados por el VIH expuestos a dos estrategias de tratamiento atirretroviral diferente. Telomere Length Substudy. The European Treatment Network For Hiv, Hepatitis and Global Infectious Diseases. 2016-Ongoing.

Management centre: FIBHULP

Arribas López JR. EU-RESPONSE. UE. 2020-2025.

Management centre: FIBHULP

Arribas López JR. Impacto de abacavir y

tenofovir en la recuperación a largo plazo del estado de inmunosenescencia en una cohorte prospectiva de adultos de avirémicos infectados por el VIH (P119/00294). ISCIII. 2020-2022.

Management centre: FIBHULP

Bernardino de la Serna JI. Biological age and cardiovascular ischemic events or diabetes in HIV-infected patients. Gilead Sciences S. L. 2017-Ongoing.

Management centre: FIBHULP

Bernardino de la Serna JI. Enfermedad coronaria obstruida asintomática en pacientes VIH. Papel de la metilación del ADN y la activación monocitaria en la progresión de la aterosclerosis coronaria (P118/01327). ISCIII. 2019-2021.

Management centre: FIBHULP

Bernardino de la Serna JI. Programa de actualización sobre investigación en pacientes infectados por el VIH ¿qué hay de nuevo? nuevos pacientes, nuevos retos, nuevos investigadores. Gilead Sciences S. L. 2018-Ongoing.

Management centre: FIBHULP

Cadiñanos Loidi J. Contrato Río Hortega (CM19/00059). ISCIII. 2020-2021.

Management centre: FIBHULP


Díaz Menéndez M. Evaluación de la patología adquirida por viajeros de riesgo durante un viaje internacional: estudio prospectivo en un centro de referencia. International Society of Travel Medicine. 2017-Ongoing.

Management centre: FIBHULP

Esteban Cantos A. Contrato predoctoral (F117/00194). ISCIII. 2018-2021.

Management centre: FIBHULP

Gayá Moreno F. Contrato técnico de



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

apoyo a estabilizado (ECA07/013). CM. 2008-2025.

Managment centre: FIBHULP

González García JJ. Morbilidad y mortalidad a largo plazo tras la erradicación del VHC en pacientes coinfectados por VIH/VHC con fibrosis hepática avanzada/cirrosis (PI17/00903). ISCIII. 2018-2022.

Managment centre: FIBHULP

Herranz Pinto P. Formación específica de dermatólogos y reumatólogos sobre el manejo de la psoriasis y artitis psoriásica con el fin de contribuir a la mejora holística de la patología. Amgen S. A. 2021-Ongoing.

Managment centre: FIBHULP

Montejano Sánchez R. Contrato Juan Rodés (JR18/00039). ISCIII. 2019-2022.

Managment centre: FIBHULP

Montes Ramírez ML. Estudio de hepatopatías en pacientes infectados por VIH sin hepatitis víricas que reciben tratamiento antirretroviral. Abbvie Spain S. L. U. 2016-Ongoing.

Managment centre: FIBHULP

Montes Ramírez ML. Estudio de la enfermedad hepática no vírica en pacientes con infección por VIH. Impacto de la esteatohepatitis no alcohólica y su relación con la microbiótica y el microbioma intestinal local (PI17/01218). ISCIII. 2018-2021.

Managment centre: FIBHULP

Rodés Soldevila B. Contrato garantía juvenil técnico laboratorio (PEJ2019_TL/BMD_12514). CM. 2020-2021.

Managment centre: FIBHULP

Rodés Soldevila B. Contrato Miguel Servet Categoría A (CES11/021). ISCIII. 2007-2025.

Managment centre: FIBHULP

Rodés Soldevila B. Convenio Marco: prácticas de María de Frrutos del Pozo: Máster Microbiología. 450 horas totales. Universidad Complutense de Madrid. 2016-Ongoing.

Managment centre: FIBHULP

Rodés Soldevila B. Estrategias de tratamiento antirretroviral y su efecto en la edad epigenética en pacientes VIH positivos con supresión virológica (PI18/00569). ISCIII. 2019-2021.

Managment centre: FIBHULP

Arribas López JR. Metformina vs placebo para la reversión de la aceleración de la edad biológica en personas de 50 años o mayores que viven con el VIH y con replicación viral suprimida (ICI20/00043). ISCIII. 2021-2024.

Managment centre: FIBHULP

Arribas López JR. Contrato de intensificación (INT20/00041). ISCIII-MICINN. 2021-2022.

Managment centre: FIBHULP

Busca Arenzana C. Contrato Rio Horte-ga (CM20/00157). ISCIII-MICINN. 2020-2021.

Managment centre: Hospital Universitario La Paz

González García JJ. Infecciones Agudas/ Recientes y Reinfecciones por VHC en Hombres que tienen Sexo con Hombres con y sin VIH (PI20/00507). ISCIII. 2021-2023.

Managment centre: FIBHULP

Arribas López JR. Puesta en marcha del ensayo clinico mk-7110-009-estudio clinico de fase 3 aleatorizado, doble ciego y controlado con placebo para evaluar

la eficacia y al seguridad de mk-7110 en participantes hospitalizados con covid-19 moderada o grave. Merck Sharp and Dohme de España S.A. 2021-Ongoing.

Managment centre: FIBHULP

Arsuaga Vicente M. Filling key research gaps with clinical implications in mansonellosis and schistosomiasis. a network approach. IRCCS Sacro Cuore Don Calabria Hospital. 2021-Ongoing.

Managment centre: FIBHULP

Herranz Pinto P. Preceptorship del servicio de dermatologia del hospital universitario la paz dirigido a dermatologos. Novartis Argentina S.A. 2017-Ongoing.

Managment centre: FIBHULP

■ Cibers & Retics

González García J. Research Network for AIDS. (RD16/0025/0018). ISCIII. (31/12/2022)

Díaz Menendez M. Tropical Disease Cooperative Research Network. (RD16/0027/0002). ISCIII. (31/12/20221).

■ Clinical trials

Arribas López JR. Estudio de fase III, aleatorizado, multicéntrico, con grupos paralelos y de ausencia de inferioridad para evaluar la eficacia, la seguridad y la tolerabilidad del cambio a dolutegravir más lamivudina en adultos infectados por el vih 1 con supresión virológica.

Type: Clinical Trials, phase III.

HULP code: Appendix 3 4885 204862.

Sponsored by: Viiv Healthcare Uk Limited.

Signed date: 01/02/2021

Arribas López JR. Ensayo multicéntrico, adaptativo, randomizado, controlado ciego de seguridad y eficacia de terapias en investigación para pacientes hospitalizados con COVID-19.

Type: Clinical Trials, phase III.

HULP code: 5669 INSIGHT.

Sponsored by: Regents Of The University Of Minnesota.

Signed date: 12/01/2021

Arribas López JR. Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, para evaluarla eficacia y la seguridad de AD26.COVID.S para la prevención de COVID-19 mediada por SARS-CoV-2 en adultos mayores de 18 años.

Type: Clinical Trials, phase III.

HULP code: Appendix 1 5734 VAC-31518COV3009.

Sponsored by: Janssen Cilag International Nv.

Signed date: 16/03/2021

Arribas López JR. Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, para evaluarla eficacia y la seguridad de ad26.cov2.s para la prevención de COVID-19 mediada por SARS-CoV-2 en adultos mayores de 18 años.

Type: Clinical Trials, phase III.

HULP code: Appendix 2 5734.

Sponsored by: Janssen Cilag International Nv.

Signed date: 07/04/2021

Arribas López JR. Virologic outcomes of lamivudine/dolutegravir virologically suppressed subjects with expected or confirmed resistance to lamivudine (volver study).



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Type: Clinical Trials, phase II.
HULP code: 5851 GESIDA 11820.
Sponsored by: Fundacion Seimc-Gesida.
Signed date: 27/04/2021

Arribas López JR. Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, para evaluarla eficacia y la seguridad de AD26.COVS para la prevención de COVID-19 mediada por SARS-CoV-2 en adultos mayores de 18 años.

Type: Clinical Trials, phase III.
HULP code: Appendix 3 5734.
Sponsored by: Janssen Cilag International Nv.
Signed date: 04/06/2021

Arribas López JR. DTG / 3TC frente a BIC/FTC/TAF como terapia de mantenimiento en personas que viven con VIH: Ensayo clínico abierto y aleatorizado.

Type: Clinical Trials, phase IV.
HULP code: 5799 GESIDA 11720.
Sponsored by: Fundacion Seimc-Gesida.
Signed date: 08/06/2021

Arribas López JR. European discovery for solidarity: an adaptive pandemic and emerging infection platform trial (eu-solidact): efficacy and safety of baricitinib for the treatment of severe COVID-19 (barisolidact).

Type: Clinical Trials, phase II.
HULP code: 5896 EU-SolidAct.
Sponsored by: Hospital De Oslo.
Signed date: 19/07/2021

Arribas López JR. Estudio internacional observacional para la caracterización de adultos hospitalizados por las complicaciones de la gripe pandémica h1n1.

Type: Estudios No EPA.
HULP code: Appendix 3 3045.
Sponsored by: Copenhagen Hiv Programme.
Signed date: 13/07/2021

Arribas López JR. Un estudio de no inferioridad de fase IIb, doble ciego, aleatorizado, con control activo, multicéntrico, seguido de un estudio de fase III, de un solo brazo y abierto, para evaluar la inmunogenicidad y la seguridad de una vacuna de refuerzo con un candidato de proteína recombinante dimerica de fusión rbd (phh-1v) contra el SARS-CoV-2, en adultos completamente vacunados contra COVID-19.

Type: Clinical Trials, phase II.
HULP code: 6016 HIPRA-HH-2.
Sponsored by: Hipra Scientific, S.L.U.
Signed date: 03/11/2021

Arribas López JR. SARS-CoV-2 vaccination strategies in previously hospitalized and recovered COVID-19 patients (vatico).

Type: Clinical Trials, phase IV.
HULP code: 5970 INSIGHT-016.
Sponsored by: Regents Of The University Of Minnesota.
Signed date: 23/11/2021

Arribas López JR. Un ensayo clínico aleatorizado, doble ciego, de fase II, controlado con placebo, de un solo centro para evaluar la metformina en comparación con el placebo para la reversión del envejecimiento biológico acelerado en personas que viven con el VIH de 50 años o más y con replicación virológica suprimida.

Type: Clinical Trials, phase II.
HULP code: 5971 METFORAGING.
Sponsored by: Fundacion Para La Investigacion Biomedica Hospital

Universitario La Paz.
Signed date: 02/11/2021

Bernardino De La Serna, JI. Estudio clínico aleatorizado de fase 3 en participantes infectados por el VIH-1 que han recibido varios tratamientos con anterioridad para evaluar la actividad antirretroviral del tratamiento enmascarado con islatravir (isl), doravirina (dor) y doravirina/islatravir (dor/isl), cada uno en comparación con un placebo, y la actividad antirretroviral, la seguridad y la tolerabilidad del tratamiento abierto con dor/isl.

Type: Clinical Trials, phase III.
HULP code: Appendix 2 5532.
Sponsored by: Merck Sharp And Dohme De España, S.A.
Signed date: 29/04/2021

Bernardino De La Serna, JI. Estudio clínico aleatorizado de fase 3 en participantes infectados por el VIH-1 que han recibido varios tratamientos con anterioridad para evaluar la actividad antirretroviral del tratamiento enmascarado con islatravir (isl), doravirina (dor) y doravirina/islatravir (dor/isl), cada uno en comparación con un placebo, y la actividad antirretroviral, la seguridad y la tolerabilidad del tratamiento abierto con dor/isl.

Type: Clinical Trials, phase III.
HULP code: Appendix 3 5532.
Sponsored by: Merck Sharp And Dohme De España, S.A.
Signed date: 08/09/2021

Díaz Pollán, B. Ensayo clínico multicéntrico, fase III, aleatorizado, doble ciego para evaluar la eficacia y seguridad de vancomicina oral versus placebo en la prevención de la recidiva de la infección por clostridioides difficile en pacientes que reciben antibioterapia sistémica".

(estudio prevan-icd).

Type: Clinical Trials, phase III.
HULP code: 5525 PREVAN.
Sponsored by: Origüen Sabater, Julia.
Signed date: 17/08/2021

González García, JJ. Estudio de fase IIa, aleatorizado, doble ciego y controlado con placebo, de las vacunas contra el VIH-1 mva.hti y chadox1.hti, con el agonista de TLR7 vesatolimod (gs-9620), en infección por el VIH-1 tratada de forma precoz.

Type: Clinical Trials, phase II.
HULP code: Appendix 2 5163.
Sponsored by: Aelix Therapeutics S.L.
Signed date: 17/03/2021

González García, JJ. Estudio de fase IIb, aleatorizado, con doble enmascaramiento, de grupos paralelos para evaluar la eficacia, la seguridad, la tolerabilidad y el perfil de resistencia de gsk3640254 en combinación con dolutegravir en comparación con dolutegravir más lamivudina en adultos infectados por el VIH-1 sin tratamiento previo.

Type: Clinical Trials, phase II.
HULP code: 5887 212483.
Sponsored by: Glaxosmithkline Research And Development Limited.
Signed date: 08/07/2021

González García, JJ. Bictegravir/ftc/taf para el tratamiento de la infección primaria por HIV (bic-phi trial).

Type: Clinical Trials, phase IV.
HULP code: 5635 BIC-PHI.
Sponsored by: Fundacio Clinic Per A La Recerca Biomedica.
Signed date: 12/07/2021

González García, JJ. Estudio clínico de fase 3, aleatorizado, doble ciego y controlado con producto activo para evaluar

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

el cambio a doravirina/islatravir (dor/isl) una vez al día en participantes con supresión virológica del vih-1 con bictegravir/emtricitabina/tenofovir alafenamide (bic/ftc/taf).

Type: Clinical Trials, phase III.

HULP code: Appendix 1 5470.

Sponsored by: Merck Sharp & Dhome Corp.

Signed date: 18/05/2021

González García, JJ. Infecciones recientes, agudas y reinfecciones, por vhc en hombres que tienen sexo con hombres con y sin infección por vih. (estudio athens).

Type: Estudios, phase EPA-OD.

HULP code: PI-4920 GESIDA 12121.

Sponsored by: Fundacion Seimc-Gesida.

Signed date: 14/09/2021

González García, JJ. Estudio de fase III, aleatorizado, multicéntrico, abierto y de no-inferioridad para evaluar la eficacia, la seguridad y la tolerabilidad del cambio de tratamiento a una combinación en dosis fijas de dolutegravir/lamivudina en adultos infectados por el vih-1 con supresión virológica.

Type: Clinical Trials, phase III.

HULP code: Appendix 2 5354.

Sponsored by: Viiv Healthcare Uk Limited.

Signed date: 26/03/2021

González García, JJ. Estudio abierto, multicéntrico y aleatorizado para investigar el tratamiento antirretroviral con inhibidor de la integrasa frente al inhibidor de la proteasa potenciado para pacientes con enfermedad por el vih avanzada. estudio late presenter treatment optimisation (optimización del tratamiento

para pacientes con infección avanzada, laptop.

Type: Clinical Trials, phase III.

HULP code: Appendix 1 5307.

Sponsored by: Neat Id Foundation.

Signed date: 30/06/2021

González García, JJ. Estudio clínico de fase 3, aleatorizado, doble ciego y controlado con producto activo para evaluar el cambio a doravirina/islatravir (dor/isl) una vez al día en participantes con supresión virológica del vih-1 con bictegravir/emtricitabina/tenofovir alafenamide (bic/ftc/taf).

Type: Clinical Trials, phase III.

HULP code: Appendix 2 5470.

Sponsored by: Merck Sharp & Dhome Corp.

Signed date: 20/10/2021

González García, JJ.

Estudio clínico de continuación, de fase 3, sin enmascaramiento, de doravirina/islatravir (dor/isl) una vez al día para el tratamiento de la infección por el vih-1 en participantes que habían recibido previamente dor/isl en un estudio clínico de fase 2 o fase 3 de dor/isl.

Type: Clinical Trials, phase II.

HULP code: 6030 MK-8591A-033.

Sponsored by: Merck Sharp And Dhome De España, S.A.

Signed date: 16/12/2021

Herranz Pinto, P. Estudio de fase 3b, aleatorizado, doble ciego, con doble simulación, controlado con principio activo, multicéntrico, para evaluar la eficacia y la seguridad de abrocitinib en comparación con dupilumab en participantes adultos que reciben terapia tópica de base con dermatitis atópica de moderada a grave.

Type: Clinical Trials, phase III.

HULP code: Appendix 1 5503 B7451050.

Sponsored by: Pfizer, S.L.U.

Signed date: 10/02/2021

Herranz Pinto, P. Estudio demostrativo preliminar aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad del inhibidor de ripk1sar443122 en pacientes con lupus eritematoso cutáneo subagudo o discoide/crónico de moderado a grave.


Type: Clinical Trials, phase II.


HULP code: 5786

ACT16404.

Sponsored by:

Sanofi-Aventis





1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Recherche & Développement.
Signed date: 04/03/2021

Herranz Pinto, P. Caracterización del paciente adulto con dermatitis atópica (da) moderada a grave en unidades de dermatología del ámbito hospitalario en España. estudio dacar.

Type: Estudios No EPA.
HULP code: PI-4807 NIS-AD-2193.
Sponsored by: Gestió Organització Comunicació S.A.
Signed date: 02/06/2021

Herranz Pinto, P. Ensayo de extensión a largo plazo, multicéntrico, abierto y de un solo brazo, para evaluar la seguridad y eficacia de tralokinumab en pacientes con dermatitis atópica que participaron previamente en ensayos clínicos con tralokinumab - ecztend.

Type: Clinical Trials, phase III.
HULP code: Appendix 1 5158.
Sponsored by: Leo Pharma A/S.
Signed date: 26/03/2021

Herranz Pinto, P. Estudio de fase 3b, multicéntrico, aleatorizado, en doble ciego, controlado con principio activo de comparación (secukinumab) y de grupos paralelos, para evaluar la eficacia y la seguridad de bimekizumab en adultos con psoriasis (ps) en placas crónica de grado moderado o severo.

Type: Clinical Trials, phase III.
HULP code: Appendix 2 5109.
Sponsored by: Ucb Biosciencias GmbH.
Signed date: 03/03/2021

Herranz Pinto, P. Estudio prospectivo, multicéntrico y a largo plazo para evaluar la seguridad y la eficacia de nemolizumab (cd14152) en sujetos con dermatitis atópica de moderada a grave.

Type: Clinical Trials, phase III.
HULP code: Appendix 1 5478.
Sponsored by: Galderma S.A.
Signed date: 15/06/2021

Herranz Pinto, P. Estudio prospectivo, multicéntrico y a largo plazo para evaluar la seguridad y la eficacia de nemolizumab (cd14152) en sujetos con dermatitis atópica de moderada a grave.

Type: Clinical Trials, phase III.
HULP code: Appendix 2 5478.
Sponsored by: Galderma S.A.
Signed date: 05/08/2021

Herranz Pinto, P. Estudio doble ciego, aleatorizado y controlado con placebo para evaluar la eficacia y la seguridad de ctp-543 en pacientes adultos con alopecia areata de moderada a grave.

Type: Clinical Trials, phase III.
HULP code: 5867 CP543.3002.
Sponsored by: Concert Pharmaceuticals, Inc.
Signed date: 27/08/2021

Herranz Pinto, P. Ensayo fase 2 para evaluar la eficacia y seguridad de los comprimidos de leo 152020 administrados por vía oral en comparación con los comprimidos de placebo durante un período de hasta 16 semanas de tratamiento en adultos con dermatitis atópica de moderada a grave.

Type: Clinical Trials, phase II.
HULP code: 5835 LP0190-1488.
Sponsored by: Leo Pharma A/S.
Signed date: 20/07/2021

Herranz Pinto, P. Estudio fase 2, aleatorizado, doble ciego, controlado con placebo de 5 grupos paralelos de bms-986166 o branebrutinib para el tratamiento de pacientes con dermatitis atópica de moderada a grave.

pica de moderada a grave.

Type: Clinical Trials, phase II.
HULP code: 5943 IM018-005.
Sponsored by: Bristol-Myers Squibb International Corporation (Bmsic).
Signed date: 15/09/2021

Herranz Pinto, P. Estudio en fase III de retirada aleatorizada, doble ciego, controlado con placebo y multicéntrico para investigar la eficacia y la seguridad de pf-04965842 en pacientes de 12 o más años de edad con dermatitis atópica moderada o grave con la opción de un tratamiento de rescate para aquellos pacientes que presenten un empeoramiento de la enfermedad.

Type: Clinical Trials, phase III.
HULP code: Appendix 3 5089.
Sponsored by: Pfizer, S.L.U.
Signed date: 06/10/2021

Herranz Pinto, P. Estudio aleatorizado, doble ciego y controlado con placebo para evaluar la eficiencia y la seguridad de nemolizumab (cd14152) en sujetos con dermatitis atópica de moderada a grave.

Type: Clinical Trials, phase III.
HULP code: Appendix 1 5477.
Sponsored by: Galderma S.A.
Signed date: 12/10/2021

Herranz Pinto, P. A randomised, double-blind, placebo-controlled phase 3 clinical trial to assess the efficacy and safety of lebrikizumab in combination with topical corticosteroids in adult and adolescent patients with moderate-to-severe atopic dermatitis that are not adequately controlled with cyclosporine or for whom cyclosporine is not medically advisable.

Type: Clinical Trials, phase III.
HULP code: 5962 M-17923-30.

Sponsored by: Almirall, Sa.
Signed date: 21/10/2021

Herranz Pinto, P. Estudio aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de nemolizumab en sujetos con dermatitis atópica de moderada a severa que han tenido una respuesta insuficiente a la ciclosporina a o para los que no es médicamente aconsejable.

Type: Clinical Trials, phase III.
HULP code: 6007 RD.06.SPR.201591.
Sponsored by: Galderma S.A.
Signed date: 22/12/2021

Lago Núñez, MM. Estudio de fase II en adultos de la unión europea y asia, que evalúa la inmunogenicidad y la seguridad de la vacuna vif en investigación en comparación con stamaril®.

Type: Clinical Trials, phase II.
HULP code: 5819 VYF03.
Sponsored by: Sanofi Aventis S.A.
Signed date: 26/05/2021

Martín Carbonero, L. Estudio clínico de fase 3, aleatorizado, abierto y comparativo con tratamiento activo para evaluar el cambio de tratamiento a doravirina/islatravir una vez al día en pacientes infectados por el VIH-1 con supresión virológica durante el tratamiento antirretroviral (tar).

Type: Clinical Trials, phase III.
HULP code: Appendix 2 5471.
Sponsored by: Merck Sharp & Dhome Corp.
Signed date: 21/01/2021

Montejano Sánchez, R. Impacto del tratamiento temprano con rdv. experiencia y seguridad con su uso en vida real en pacientes con COVID-19: análisis retrospectivo de la cohorte española.

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Type: Estudios, phase EPA-OD.
HULP code: PI-4839 RDV-RWE.
Sponsored by: Fundacion Seimc-Gesida.
Signed date: 23/06/2021

Montes Ramírez, ML. Estudio fase IIIb, aleatorizado, multicéntrico, abierto, de grupos paralelos, de no inferioridad que evalúa la eficacia, seguridad y tolerabilidad de cabotegravir de acción prolongada más rilpivirina de acción prolongada administrados cada 8 semanas o cada 4 semanas en adultos infectados por VIH-1 que presentan supresión virológica.

Type: Clinical Trials, phase IIIb.
HULP code: Appendix 1 4925.
Sponsored by: Laboratorios Viiv Healthcare, S.L.
Signed date: 11/02/2021

Mora Rillo, M. Temocilina vs meropenem para el tratamiento de la bacteriemia por enterobacteriales resistentes a cefalosporinas de tercer generación: ensayo aleatorizado y pragmático.

Type: Clinical Trials, phase III.
HULP code: 5530 ASTARTE.
Sponsored by: Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla.
Signed date: 23/02/2021

Ramos Ramos, JC. Arise - estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo y con tratamiento activo para validar los instrumentos de medida de resultados notificados por el paciente, en pacientes adultos, con infección pulmonar por micobacterias no tuberculosas (mnt) de nuevo diagnóstico causada por el complejo *Mycobacterium avium* (mac).

Type: Clinical Trials, phase III.
HULP code: 5708 INS-415.
Sponsored by: Insmad Incorporated.
Signed date: 15/02/2021

Ramos Ramos, JC. Encore - estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo y con tratamiento activo para evaluar la eficacia y seguridad

de un régimen basado en la suspensión parainhalación de liposomas de amikacina (alis) en pacientes adultos con infección pulmonar por micobacterias no tuberculosas (mnt) de nuevo diagnóstico causada por el complejo *Mycobacterium avium* (mac).

Type: Clinical Trials, phase III.
HULP code: 5709 INS-416.
Sponsored by: Insmad Incorporated.
Signed date: 15/02/2021

Valencia Ortega, E. Ensayo clínico piloto para evaluar la eficacia, seguridad y tolerabilidad del cambio a un tratamiento con bictegravir/ftc/taf (bictarvy®) más darunavir/cobicistat en pacientes infectados por VIH-1 altamente tratados.

Type: Clinical Trials, phase III.
HULP code: 5655 BIDA.
Sponsored by: Asociación Ris (Red de Investigación en Sida).
Signed date: 03/02/2021

Valencia Ortega, E. Estudio clínico de fase 3, aleatorizado, doble ciego y com-

parativo con tratamiento activo para evaluar la actividad antirretroviral, la seguridad y la tolerabilidad de doravirina/islatravir una vez al día en participantes infectados por el VIH-1 sin tratamiento previo.

Type: Clinical Trials, phase III.
HULP code: Appendix 1 5483.
Sponsored by: Merck Sharp & Dhome Corp.
Signed date: 07/10/2021

Patents and trademarks

Romero Gómez M, Solá Lamoglia R, González García JJ, inventors; Servicio Andaluz de Salud, Universidad de Sevilla, Fundació Institut Mar D'Investigacions Mèdiques, FIBHULP, assignees. Kit for decision making in patients with Hepatitis C genotypes 1 and 4. P201330731; 2013 May 21.






3.3.2 Molecular Microbiology Group

Publications: 25

Q1: 18



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

COMPOSITION

■ **Jesús Mingorance Cruz.** Investigador Senior (Contrato Ramón y Cajal - I3). Hospital Universitario La Paz

Emilio Cendejas Bueno. Investigador Postdoctoral (Contrato Juan Rodes). Hospital Universitario La Paz

María Teresa Corcuera Pindado. Técnico Grado Superior. Hospital Universitario La Paz

Elias Dahdouh. Investigador Postdoctoral Marie Curie. Hospital Universitario La Paz

Manuela de Pablos Gómez. Facultativo Especialista de Área en Microbiología. Hospital Universitario La Paz

Silvia García Bujalance. Facultativo Especialista de Área en Microbiología. Hospital Universitario La Paz

María Jesús García García. Catedrática del Departamento de Medicina Preventiva y Salud Pública y Microbiología. Facultad de Medicina. Universidad Autónoma de Madrid

Julio García Rodríguez. Jefe de Servicio de Microbiología. Hospital Universitario La Paz

Paulino Gómez Puertas. Científico Titular CSIC. Profesor Honorario. CBM "Severo Ochoa". Universidad Autónoma de Madrid

María Rosa Gómez-Gil Mira. Facultativo Especialista de Área en Microbiología. Hospital Universitario La Paz

Sonia Jiménez Rodríguez. Técnico de Laboratorio. Hospital Universitario La Paz

Fernando Lázaro Perona. Facultativo Especialista de Área en Microbiología. Hospital Universitario La Paz

Dolores Montero Vega. Facultativo Especialista de Área en Microbiología. Hospital Universitario La Paz

María Belén Loeches Yagüe. Médico Adjunto. Unidad de Enfermedades Infecciosas. Hospital Universitario La Paz

Carmen Menéndez Gómez. Profesora Contratada Doctora del Departamento de Medicina Preventiva y Salud Pública y Microbiología. Facultad de Medicina. Universidad Autónoma de Madrid

Arturo Noguero Asensio. Jefe de Servicio de Medicina Interna. Hospital de Cantoblanco-Hospital Universitario La Paz

Verónica Pérez Blanco. Facultativo Especialista de Área en Medicina Preventiva. Hospital Universitario La Paz

Rafael Carlos Prados Rosales. Profesor Contratado Doctor del Departamento de Medicina Preventiva y Salud Pública y Microbiología. Facultad de Medicina. Universidad Autónoma de Madrid

María Inmaculada Quiles Melero. Facultativo Especialista de Área en Microbiología. Hospital Universitario La Paz

Alicia Rico Nieto. Facultativo Especialista de Área en Microbiología. Hospital Universitario La Paz

María Pilar Romero Gómez. Facultativo Especialista de Área en Microbiología. Hospital Universitario La Paz

Guillermo Ruiz Carrascoso. Facultativo Especialista de Área en Microbiología. Hospital Universitario La Paz

Carlos Toro Rueda. Facultativo Especialista de Área en Microbiología. Hospital Carlos III-Hospital Universitario La Paz

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

STRATEGIC OBJECTIVE

The Molecular Microbiology research group is integrated into the Department of Microbiology at Hospital La Paz, and a significant number of its members are physicians in the department devoted to microbiological diagnostic work. This integration determines the group's strategic approach and therefore, the different lines of research revolve around several aspects of clinical microbiology and infectious diseases.

An important line of activity (Clinical Microbiology) is the result of the routine activities provided by the department, but goes further and deeper into the methodological, epidemiological and pathological challenges encountered in the daily routine.

One research line derived from the former is the development of methods for the molecular characterisation of pathogenic microorganisms, including microbiological diagnosis and epidemiological analysis, and more recently, microbial genomics.

Another line focuses on the study of the evolution of pathogenic microorganisms. As a model of opportunistic pathogens, we study *Escherichia coli*, a microorganism that is well characterised at the

genetic level and that is clinically relevant as the primary cause of urinary tract infections and one of the most frequently involved in bacteraemia.

As a model of viral pathogens, we study the dynamics of HIV viral populations over time and in terms of the response to antiretroviral treatment.

The taxonomy of the Mycobacteria and the study of *Mycobacterium tuberculosis* persistence are research lines developed jointly by the UAM and Hospital members of the group.

The Group includes a CSIC research scientist specialized in biocomputing and molecular dynamics.

RESEARCH LINES

- Molecular epidemiology and evolution of pathogens
- Molecular methods for diagnostics of infectious diseases
- Microbial genomics
- Tuberculosis and other Mycobacteria
- Clinical Microbiology

RESEARCH ACTIVITY

■ Doctoral theses

Lázaro Perona F. Aplicación de técnicas de qPCR para la cuantificación relativa de enterobacterias [dissertation]. Madrid: UAM: 2021(22/06/2022).

Directors: Mingorance Cruz J, García Rodríguez J.

■ Publications

• Ara-Montojo MF, Escosa-García L, Alguacil-Guillén M, Seara N, Zozaya C, Plaza D, Schuffelmann-Gutiérrez C, de la Vega A, Fernández-Cambor C, Ramos-Boluda E, Romero-Gómez MP, Ruiz-Carrascoso G, Losantos-García I, Mellado-Pena MJ, Gómez-Gil R. Predictors of mortality and clinical characteristics among carbapenem-resistant or carbapenemase-producing Enterobacteriaceae bloodstream infections in

Spanish children. *J Antimicrob Chemother.* 2021; 76(1): 220-5. Article. IF: 5.758; Q1


- Arroyo BG, Bueno EC, Romero-Gómez MP. Gemella haemolysans meningitis. *Med Clin-Barcelona.* 2021; 157(12): E347-8. Letter. IF: 3.2; Q2
- Bretón-Martínez JR, Alcolea A, Quintero-García D, Méndez-Echevarría A, Ramos E, Bueno F, Colomina J, Mari-López J, Crehuela-Gaudiza E, García-Rodríguez J, Martínez-Costa C. Non-wild-type cryptococcosis in a child with multivisceral organ transplant who owned bird pets. *Transpl Infect Dis.* 2021; 23(3): e13558. Article. Not Indexed
- Cendejas-Bueno E, Falces-Romero I, Laplaza-González M, Escosa-García L, Schuffelmann-Gutiérrez C, Romero-Gómez MP, Verdu-Sánchez C, Calderón-Llopis B, Amores-Hernández I, Peman J, Gómez-Zamora A, Río-García M, Menéndez-Suso JJ, Rodríguez-Álvarez D, Durán-Lorenzo I, Pérez-Acosta E, Rubio MR, Álvarez-Rojas E, Martínez-Romillo PD, Goded-Rambla F, de Lorenzo AG, Maseda E, Mingorance J, de la Oлива P, García-Rodríguez J. Candidemia diagnosis

with T2 nuclear magnetic resonance in a PICU: A new approach. *Pediatr Crit Care Me.* 2021; 22(2): E109-14. Article. IF: 3.971; Q1

- Cendejas-Bueno E, Peinado H, Baquero-Artigao F, Falces-Romero I, Calvo-Rey C, La Banda-Montalvo L, García-Rodríguez J. Off-label use of T2Candida (R) test in vitreous humor for diagnosing invasive candidiasis: a clinical report. *Future Microbiol.* 2021; 16(9): 619-21. Article. IF: 3.553; Q3
- Cendejas-Bueno E, Romero-Gómez MP, Escosa-García L, Jiménez-Rodríguez S, Mingorance J, García-Rodríguez J. Lower nasopharyngeal viral loads in pediatric population. The missing piece to understand SARS-CoV-2 infection in children? *J Infection.* 2021; 83(2): E18-9. Letter. IF: 38.637; D1
- Colino RM, de Miguel AM, Argentina F, Marques MB, Jiménez BC, Hernández PL, Bueno SJ, Vega MDM, Rodríguez JG, Simo BF, Fernández MAN, del Toro TR, Alarcón TA, Peromingo FJM, González-Montalvo JI. Evolution of COVID-19 at nursing homes from the second wave to vaccina-

tion. Description of a coordination program between Primary Care, Geriatrics and Public Health. *Rev Esp Salud Publica.* 2021; 95: e1-11. Article. IF: 1.333; Q4

- Dahdouh E, Díaz-Pollán B, Falces-Romero I, Mingorance J, Gómez-Gil R. Characterization of an osteomyelitis case caused by dalbavancin, ceftaroline, and vancomycin non-susceptible methicillin-resistant *Staphylococcus aureus*. *Eur J Clin Microbiol.* 2021; 40(9): 2029-32. Article. IF: 5.103; Q2
- Dahdouh E, Lázaro-Perona F, Romero-Gómez MP, Mingorance J, García-Rodríguez J, Montero MD, Toro-Rueda C, García-Bujalance S, Ruiz-Carrascoso G, Cendejas-Bueno E, Falces-Romero I, Ruiz-Bastián M, Gutiérrez-Arroyo A, de Velasco-Sada PG, Gómez-Arroyo B, García-Sánchez C, Guédez-López V, Bloise I, Alguacil-Guillén M, Liras-Hernández MG, Sánchez-Castellano M, García-Clemente P, González-Donapetry P, San Jose-Villar S, de Pablos M, Gómez-Gil R, Corcuera M, Rico-Nieto A, Loeches B. C-t values from SARS-CoV-2 diagnostic PCR assays should not be



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

used as direct estimates of viral load. *J Infection*. 2021; 82(3): 426-8. Letter. IF: 38.637; D1

- Dahdouh E, Lázaro-Perona F, Ruiz-Carrascoso G, García LS, de Pipaón MS, Mingorance J. Intestinal dominance by *Serratia marcescens* and *Serratia ureilytica* among neonates in the setting of an outbreak. *Microorganisms*. 2021; 9(11): 2271. Article. IF: 4.926; Q2
- de Ceano-Vivas M, García ML, Velázquez A, del Valle FM, Menasalvas A, Cilla A, Epalza C, Romero MP, Cabrero M, Calvo C. Neurodevelopmental outcomes of infants younger than 90 days old following enterovirus and parechovirus infections of the central nervous system. *Front Pediatr*. 2021; 9: 719119. Article. IF: 3.569; Q2
- de la Oliva P, Rodríguez-Rubio M, García-Rodríguez J. Scientific ambiguity in the time of coronavirus disease 2019. *JAMA Pediatr*. 2021; 175(3): 318. Letter. IF: 26.796; D1
- Díaz-García J, Arendrup MC, CAntón R, García-Rodríguez J, de la Pedrosa EGG, Parisi G, Peman J, Postero B, Sanguinetti M, Da Matta DA, Colombo AL, Muñoz P, Sánchez-Carrillo C, Guinea J, Escribano P. Lack of relationship between genotype and virulence in *Candida* species. *Rev Iberoam Micol*. 2021; 38(1): 9-11. Article. IF: 1.385; Q4
- Falces-Romero I, Mingorance J, García-Rodríguez J, Cendejas-Bueno E. A new application of MALDI biotyper for a potential use in therapeutic drug monitoring of voriconazole. *Antimicrob Agents Ch*. 2021; 65(8): e02458-20. Article. IF: 5.938; Q1
- Falces-Romero I, Romero-Gómez MP, Moreno-Ramos F, Mingorance J, García-Rodríguez J, Cendejas-Bueno E. Epidemiology of bloodstream *Candida* species in a Spanish tertiary care hospital as a guide for implementation of T2MR (T2CANDIDA (R)) for rapid diagnosis of candidemia. *Med Mycol*. 2021; 59(4): 350-4. Article. IF: 3.747; D1
- García-Escobar A, Jiménez-Valero S, Galeote G, Jurado-Román A, García-Rodríguez J, Moreno R. The soluble catalytic ectodomain of ACE2 a biomarker of cardiac remodeling: new insights for heart failure and COVID19. *Heart Fail Rev*. 2021; 26(4): 961-71. Article. IF: 4.654; Q2
- Gómez-Junyent J, Lora-Tamayo J, Baraia-Etxaburu J, Sánchez-Somolinos M, Iribarren JA, Rodríguez-Pardo D, Praena-Segovia J, Sorli L, Bahamonde A, Riera M, Rico A, del Toro MD, Morata L, Cobo J, Falgueras L, Benito N, Munez E, Jover-Saenz A, Pigrau C, Ariza J, Murillo O. Implant removal in the management of prosthetic joint infection by staphylococcus aureus: Outcome and predictors of failure in a large retrospective multicenter study. *Antibiotics (Basel)*. 2021; 10(2): 118. Article. IF: 5.222; Q1
- González-Donapetry P, García-Clemente P, Bloise I, García-Sánchez C, Castellano MAS, Romero MP, Arroyo AG, Mingorance J, La Calle MDV, García-Rodríguez J. Think of the children evaluation of SARS-CoV-2 rapid antigen test in pediatric population. *Pediatr Infect Dis J*. 2021; 40(5): 385-8. Article. IF: 3.806; Q1
- Jiménez-García R, Nogueira J, Retuerta-Oliva A, Sainz T, Cano-Fernández J, Flores-Pérez P, Méndez-Echevarría A, Villalobos-Pinto E, Calleja-Gero L, Sanz-Santaeufemia FJ, Romero MP, del Rosal T, Baquero-Artigao F, Grasa C, Calvo C. Pneumonia in hospitalized children during SARS-CoV-2 pandemic. Is it All COVID-19? Comparison between COVID and non-COVID pneumonia. *Pediatr Infect Dis J*. 2021; 40(3): E111-3. Article. IF: 3.806; Q1
- Jomehzadeh N, Koolivand Z, Dahdouh E, Akbari A, Zahedi A, Chamkouri N. Investigating in-vitro antimicrobial activity, biosynthesis, and characterization of silver nanoparticles, zinc oxide nanoparticles, and silver-zinc oxide nanocomposites using *Pistacia Atlantica* Resin. *Mater Today Commun*. 2021; 27: 102457. Article. IF: 3.662; Q3
- Lázaro-Perona F, Rodríguez-Antolín C, Alguacil-Guillén M, Gutiérrez-Arroyo A, Mingorance J, García-Rodríguez J. Evaluation of two automated low-cost RNA extraction protocols for SARS-CoV-2 detection. *Plos One*. 2021; 16(2): e0246302. Article. IF: 3.752; Q2
- Lázaro-Perona F, Rodríguez-Tejedor M, Ruiz-Carrascoso G, Díaz-Pollán B, Loeches B, Ramos-Ramos JC, Mingorance J. Intestinal loads of OXA-48-producing *Klebsiella pneumoniae* in colonized patients determined from surveillance rectal swabs. *Clin Microbiol Infect*. 2021; 27(8):-. Article. IF: 13.31; D1
- Martínez-López N, Muñoz-Almagro C, Launes C, Navascués A, Imaz-Pérez M, Reina J, Romero MP, Calvo C, Ruiz-García M, Megias G, Valencia-Ramos J, Otero A, Cabrero M. Surveillance for enteroviruses associated with hand, foot, and mouth disease, and other mucocutaneous symptoms in Spain, 2006-2020. *Viruses-Basel*. 2021; 13(5): 781. Article. IF: 5.818; Q2
- Medina N, Soto-Debrán JC, Seidel D, Akyar I, Badali H, Barac A, Bretagne S, Cag Y, Cassagne C, Castro C, Chakrabarti A, Dannaoui E, Cardozo C, García-Rodríguez J, Guillard J, Hamal P, Hoenigl M, Jagielski T, Khodavaisy S, Lo Cas-

cio G, Martínez-Rubio MC, Meletiadi S, Muñoz P, Ochman E, Pelaez T, Balzola APA, Prattes J, Roilides E, de Pipaón MRP, Stauf R, Steinmann J, Suarez-Barrechea AI, Tejero R, Trovato L, Vinuela L, Wongsuk T, Zak I, Zarrinfar H, Lass-Flörl C, Arian-Akdagli S, Alastruey-Izquierdo A. *MixInYeast*: A multicenter study on mixed yeast infections. *J Fungi (Basel)*. 2021; 7(1): 13. Article. IF: 5.724; Q1
- Moreno-García E, Puerta-Alcalde P, Gariup G, Fernández-Ruiz M, Cortés LEL, Cuervo G, Salavert M, Merino P, Machado M, Guinea J, García-Rodríguez J, Garnacho-Montero J, Cardozo C, Peman J, Montejo M, Fortún J, Almirante B, Castro C, Rodríguez-Bano J, Aguado JM, Martínez JA, Carratala J, Soriano A, García-Vidal C. Early stepdown from echinocandin to fluconazole treatment in candidemia: A post hoc analysis of three cohort studies. *Open Forum Infect Dis*. 2021; 8(6): ofab250. Article. IF: 4.423; Q2
- Navarro-Carrera P, García-Rodríguez J, Cendejas-Bueno E. Detection of *Neisseria meningitidis* in a patient receiving ravulizumab by the FilmArray (R) Meningitis/Encephalitis panel- A case report. *J Infection*. 2021; 82(6): E22-3. Letter. IF: 38.637; D1
- Pérez-Nadales E, Alastruey-Izquierdo A, Linares-Sicilia MJ, Soto-Debrán JC, Abdala E, García-Rodríguez J, Montejo M, Muñoz P, Lletí MS, Rezusta A, de Pipaón MRP, Yáñez L, Merino E, Campos-Herrero MI, Costa-Mateo JM, Fortun J, García-Lozano T, García-Vidal C, Fernández-Ruiz M, Sánchez-Reus F, Castro-Méndez C, Guerrero-Lozano I, Soler-Palacin P, Aguado JM, Martínez-Martínez L, Torre-Cisneros J, Nucci M. Invasive fusariosis in nonneutropenic patients, Spain, 2000-2015. *Emerg Infect Dis*. 2021; 27(1): 26-35. Article. IF: 16.126; D1
- Quiles-Melero I, García-Rodríguez J. Systemic antifungal drugs. *Rev Iberoam Micol*. 2021; 38(2): 42-6. Article. IF: 1.385; Q4
- Romero-Gómez MP, Gómez-Sebastián S, Cendejas-Bueno E, Montero-Vega MD. Ct value is not enough to discriminate patients harbouring infective virus. *J Infection*. 2021; 82(3): E35-7. Letter. IF: 38.637; D1
- Ruiz-Bastián M, Falces-Romero I, Ramos-Ramos JC, de Pablos M, García-Rodríguez J. Bacterial co-infections in COVID-19 pneumonia in a tertiary care hospital: Surfing the first wave. *Diagn Microb Infect Dis*. 2021; 101(3): 115477. Article. IF: 2.983; Q3
- Salinas P, Gonzalo N, Moreno VH, Fuentes M, Santos-Martínez S, Fernández-Díaz JA, Amat-

Santos IJ, Ojeda FB, Borrego JC, Cuesta J, Hernández JMD, Diego-Nieto A, Dubois D, Galeote G, Goicolea J, Gutiérrez A, Jiménez-Fernández M, Jiménez-Mazuecos J, Jurado A, Lacunza J, Lee DH, López M, Lozano F, Martín-Moreiras J, Martín-Yuste V, Millán R, Minana G, Mohandes M, Morales-Ponce FJ, Nunez J, Ojeda S, Pan M, Rivero F, Robles J, Rodríguez-Leiras S, Rojas S, Rondan J, Rumiz E, Sabate M, Sanchis J, Vaquerizo B, Escaned J. Choice of CTO scores to predict procedural success in clinical practice. A comparison of 4 different CTO PCI scores in a comprehensive national registry including expert and learning CTO operators. *Plos One*. 2021; 16(4): e0245898. Article. IF: 3.752; Q2
- Viedma E, Dahdouh E, González-Alba JM, González-Bodi S, Martínez-García L, Lázaro-Perona F, Recio R, Rodríguez-Tejedor M, Figueira MD, CAntón R, Delgado R, García-Rodríguez J, Galán JC, Mingorance J, Muñoz-Gallego I, Villa J, Martín-Higuera MD, Meléndez MA, Reyes CA, Rolo M, Rivas G, Sigcha MA, Gómez-Herrador A, Montero-Vega MD, Romero MP, García-Bujalance S, Bueno EC, Toro-Rueda C, Ruiz-Carrascoso G, Perona FL, Falces-Romero I, Gutiérrez-Arroyo A, de Velasco-Sada PG, Ruiz-Bastian M, Alguacil-Guillén M, González-Donapetry P, Guédez-López GV, García-Clemente P, Hernández MGL, García-Sánchez C, Sánchez-Castellano M, San Jose-Villar S, Rodríguez-Domínguez M, Romero-Hernández B, Abreu M, Marcos D, Marinovich J, Becerra F, López-Pintor JM. Genomic epidemiology of SARS-CoV-2 in Madrid, Spain, during the first wave of the pandemic: Fast spread and early dominance by D614G variants. *Microorganisms*. 2021; 9(2): 454. Article. IF: 4.926; Q2
- Vilchez HH, Escudero-Sánchez R, Fernández-Sampedro M, Murillo O, Auñón A, Rodríguez-Pardo D, Jover-Saenz A, del Toro MD, Rico A, Falgueras L, Praena-Segovia J, Guio L, Iribarren JA, Lora-Tamayo J, Benito N, Morata L, Ramírez A, Riera M. Prosthetic shoulder joint infection by cutibacterium acnes: Does rifampin improve prognosis? A retrospective, multicenter, observational study. *Antibiotics (Basel)*. 2021; 10(5): 475. Article. IF: 5.222; Q1
- Villaverde S, Domínguez-Rodríguez S, Sabrido G, Pérez-Jorge C, Plata M, Romero MP, Grasa CD, Jiménez AB, Heras E, Broncano A, Nunez MD, Illan M, Merino P, Soto B, Molina-Arana D, Bermejo A, Mendoza P, Gijón M, Pérez-Moneo B, Moraleda C, Tagarro A. Diagnostic accuracy of the panbio severe acute respiratory syndrome coronavirus 2 antigen rapid test compared with reverse-transcriptase polymerase chain reaction



testing of nasopharyngeal samples in the pediatric population. *J Pediatr-Us.* 2021; 232: 287-9. Article. IF: 6.314; D1

- Villaverde S, Merino-Amador P, Mendoza P, Molina-Arana D, Romero MP, Moraleda C, Tagarro A. Diagnostic performance of antigen testing for severe acute respiratory syndrome coronavirus 2 Reply. *J Pediatr-Us.* 2021; 233: 283-4. Letter. IF: 6.314; D1

■ Research projects

Cendejas Bueno E. Desarrollo y validación de métodos para la detección y cuantificación de antifúngicos sistémicos en suero mediante MALDI-TOF (PI17/01444). ISCI. 2018-2022.

Management centre: FIBHULP

Dahdouh E. Alianza para la exploración de inhibidores de carbapenemasas (AC20/00012). ISCI. 2021-2022.

Management centre: FIBHULP

Dahdouh E. Contrato Juan de la Cierva (IJC2019-038832-I.). MICIIN. 2021-2023.

Management centre: FIBHULP

Falces Romero I. Contrato Río Hortega (CM19/00115). ISCI. 2020-2021.

Management centre: FIBHULP

García Bujalance S. Evaluación del rendimiento del ensayo aptima HIV-1 quant para la detección y cuantificación del HIV-1 en muestras de plasma. Hologic Deutschland GmbH. 2016-Ongoing.

Management centre: FIBHULP

García Rodríguez J. Evaluación infecciosas panel en cobas e801. Roche Diagnostics S.L. 2017-Ongoing.

Management centre: FIBHULP

Gómez-Gil Mira MR. In vitro activities of ceftaroline, daptomycin, linezolid, and vancomycin against bacteremic methicillin-resistant staphylococcus aureus isolates. Astrazeneca Farmaceutica Spain S.A. 2013-Ongoing.

Management centre: FIBHULP

Mingorance Cruz J. Análisis cuantitativo de la colonización intestinal por enterobacterias productoras de carbapenemasas (PI16/01209). ISCI. 2017-2020.

Management centre: FIBHULP

Mingorance Cruz J. Aplicación de los métodos de tipado genómico y molecular a la elaboración del mapa microbiológico del Hospital Universitario La Paz. Genómica S.A.U. 2012-Ongoing.

Management centre: FIBHULP

Mingorance Cruz J. Colaboración para el desarrollo de proyectos específicos entre el grupo de investigación de microbiología molecular del idipaz en concreto: el desarrollo de soluciones en el ámbito de la microbiología molecular para atención en el punto de necesidad basadas en genedrive. Epistem Ltd. 2016-Ongoing.

Management centre: FIBHULP

Mingorance Cruz J. Contrato garantía juvenil técnico laboratorio (PEJ-2017-TL/BMD-6939). CM. 2018-2021.

Management centre: FIBHULP

Mingorance Cruz J. Contrato I3 Estabilizado (CESI311). CM. 2011-2025.

Management centre: FIBHULP

Mingorance Cruz J. Mecanismos moleculares de la heteroresistencia y la heterogénea susceptibilidad a carbapenémicos

en enterobacterias productoras de carbapenemasas (PI19/01356). ISCI. 2020-2022.

Management centre: FIBHULP

Ruiz Carrascoso G. Evaluación y validación del sistema de inteligencia analítica biwer analytics como herramienta de mejora en el seguimiento de brotes por sars-cov-2. Werfen España S.A.U. 2020-Ongoing.

Management centre: FIBHULP

Toro Rueda C. Evaluación del rendimiento de una prueba en el punto de atención de QPCR para diagnóstico biológico. Epistem Ltd. 2012-Ongoing.

Management centre: FIBHULP

Toro Rueda C. Evaluación del rendimiento de una prueba en el punto de atención de QPCR para el diagnóstico microbiológico. Epistem Ltd. 2012-Ongoing.

Management centre: FIBHULP

■ Clinical trials

Loeches Yagüe, MB. Ensayo clínico de fase iv-III, con asignación aleatoria, controlado, abierto y multicéntrico, con dos grupos paralelos, para evaluar la eficacia de la combinación de cloxacilina y fosfomicina versus cloxacilina en monoterapia en el tratamiento de la bacteriemia por staphylococcus aureus sensible a la meticilina.

Type: Clinical Trials, phase IV.

HULP code: 5740 HUB-IDIBELL-SA-FO4.3.1.

Sponsored by: Fundación Idibell.

Signed date: 13/04/2021

Rico Nieto, A. Ensayo clínico fase III aleatorizado, controlado y abierto en pacientes con infección recurrente por clostridioides difficile (CD) para evaluar la eficacia y la seguridad de cápsulas de microbiota fecal liofilizada vs Fidaxomicina.

Type: Clinical Trials, phase III.

HULP code: 6001 ICD-01.

Sponsored by: Mikrobiomik Healthcare Company, S.L.

Signed date: 13/12/2021

■ Patents and trademarks

Mingorance Cruz J, Castán García P, Franco de Sarabia Rosado PM, inventors; 2B BLACKBIO S.L., assignee. Composition, method and kit for detecting fungi and yeasts by means of sequencing. PCT/ES2010/000248; 2010 June 02.

Mingorance Cruz J, Castán García P, Franco de Sarabia Rosado PM, inventors; BIOTOOLS BIOTECHNOLOGICAL & MEDICAL LABORATORIES S.A., assignee. Composition, method and kit for detecting bacteria by means of sequencing. PCT/ES2009/000507, EP2492352, US2013157265, CA2775273, MX2012004627; 2009 October 22.

Vicente Muñoz M, Mingorance Cruz J, Rueda González MS, inventors; CSIC, assignee. Method for determining state of growth and viability of bacterial FTsZ population, whether natural or cultivated, is based on determining existence of FTsZ rings in actively growing individual cells. P200200370; 2002 February 15.

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



3.3.3 Immuno-Rheumatology Group

Publications: 46

Q1: 12

COMPOSITION



■ **María Eugenia Miranda Carús.** Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz

Pilar Aguado Acín. Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz

Alejandro Balsa Criado. Jefe de Servicio de Reumatología. Hospital Universitario La Paz. Profesor Asociado. Facultad de Medicina. Universidad Autónoma de Madrid

María Gema Bonilla Hernán. Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz

Ana Castilla Plaza. Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz

Eugenio de Miguel Mendieta. Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz

Francisco de Borja Hernández de Breijo. Investigador Postdoctoral. Hospital Universitario La Paz

Paula Fortea Gordo. Investigadora Predoctoral. Hospital Universitario La Paz

Sara García Carazo. Facultativo Especialista de Área

en Reumatología. Hospital Universitario La Paz

Emilio Martín Mola. Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz

Ana Martínez Feito. Investigadora Postdoctoral. Hospital Universitario La Paz

Irene Monjo Henry. Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz

María Victoria Navarro Compán. Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz

Laura Nuño Nuño. Médico Adjunto Interino en Reumatología. Hospital Universitario La Paz

María Dora Pascual-Salcedo Pascual. Químico Adjunto en Inmunología. Hospital Universitario La Paz

Chamaida Plasencia Rodríguez. Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz

Diana Peiteado López. Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz

Alejandro Villalba Yllán. Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz

STRATEGIC OBJECTIVE

Our objective is to investigate the pathogenesis and evolution of rheumatic diseases, specifically focusing on imaging, genetics, metabolic pathways and immunopathogenesis.

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

RESEARCH LINES

- Immunopathogenesis, genetic, evolution, prognosis and biomarkers of inflammatory and autoimmune arthritis
- Imaging of inflammatory and autoimmune arthritis
- Immunopathogenesis and genetics of osteoporosis
- Immunogenicity of biological therapies with monoclonal antibodies
- Immunopathogenesis, evolution, prognosis and biomarkers of ocular inflammatory pathology
- Classification and Clinical outcomes of patients with inflammatory and autoimmune arthritis

RESEARCH ACTIVITY

■ Doctoral theses

Macía Villa CC. Nuevas aportaciones de la ecografía en el estudio de la paratenonitis, entesitis y sinovitis en la artritis psoriásica [dissertation]. Madrid: UAM: 2021(06/04/2021).

Director: de Miguel Mendieta E.

Bonilla Hernán MG. Enfermedad pulmonar intersticial difusa clínica en pacientes diagnosticados de artritis reumatoide. [dissertation]. Madrid: UAM: 2021(15/12/2021).

Directors: Balsa Criado A, Álvarez-Sala Walther R

■ Publications

- Almodóvar R, Canete JD, de Miguel E, Pinto JA, Queiro R. Definition of remission and disease activity assessment in psoriatic arthritis: evidence and expert-based recommendations. *Reumatol Clin.* 2021; 17(6): 343-50. Article. Not Indexed
- Almodóvar R, Joven B, Almaraz ER, Melchor S, Rabadan E, Villaverde V, Navio T, Méndez LC, Oliveira LL, Prada A, González L, Martos AG, Navarro-Compán V, Loza E, Zarco P. Comparative results of the implementation in daily practice of an evaluation checklist for patients with axial spondyloarthritis and psoriatic arthritis. *Reumatol Clin.* 2021; 17(7): 392-6. Article. Not Indexed
- Álvarez-Rivas N, Sang-Park H, del Campo PD, Fernández-Castro M, Corominas H, Andreu JL,


Navarro-Compán V. Efficacy of belimumab in Primary Sjogren's syndrome: A systematic review. *Reumatol Clin.* 2021; 17(3): 170-4. Review. Not Indexed

- Benavent D, Fernández-Luque L, Navarro-Compán V, Balsa A, Plasencia C. Comment on: Telemedicine in the management of rheumatoid arthritis: maintaining disease control with less health-care utilization. *Rheumatol Adv Pract.* 2021; 5(2): rkab032. Letter. Not Indexed
- Benavent D, Peiteado D, Martínez-Huedo MA, Hernández-Hurtado M, Balsa A, de Miguel E. Healthcare-related impact of gout in hospitalized patients in Spain. *SCI Rep-Uk.* 2021; 11(1): 13287. Article. IF: 4.996; Q2
- Benavent D, Plasencia C, Poddubnyy D, Kishimoto M, Proft F, Sawada H, López-Medina C, Dougados M, Navarro-Compán V. Unveiling axial involvement in psoriatic arthritis: An ancillary analysis of the ASAS-perSpA study. *Semin Arthritis Rheu.* 2021; 51(4): 766-74. Article. IF: 5.431; Q2
- Boel A, Navarro-Compán V, Boonen A, Mease P, Kiltz U, Dougados M, Landewe R, van der Heijde D. Domains to be considered for the core outcome set of axial spondyloarthritis: results from a 3-round delphi survey. *J Rheumatol.* 2021; 48(12): 1810-14. Article. IF: 5.346; Q2
- Boel A, Navarro-Compán V, Landewe R, van der Heijde D. Two different invitation approaches for consecutive rounds of a Delphi survey led to comparable final outcome. *J Clin Epidemiol.* 2021; 129: 31-9. Article. IF: 7.407; D1
- Bogas P, Plasencia-Rodríguez C, Navarro-Compán V, Tornero C, Novella-Navarro M, Nuño L, Martínez-Feito A, Hernández-Breijo B, Balsa A. Comparison of long-term efficacy between biological agents following tumor necrosis factor

inhibitor failure in patients with rheumatoid arthritis: a prospective cohort study. *Ther Adv Musculoskelet Dis.* 2021; 13: 1759720X211060910. Article. IF: 3.625; Q3

- Calderón-Goercke M, Castaneda S, Aldasoro V, Villa I, Moriano C, Romero-Yuste S, Narváez J, Gómez-Arango C, Pérez-Pampin E, Melero R, Becerra-Fernández E, Revenga M, Álvarez-Rivas N, Galisteo C, Sivera F, De Miguel E, Prieto-Pena D, González-Gay MA, Hernández JL, Blanco R. Tocilizumab in refractory giant cell arteritis. Monotherapy versus combined therapy with conventional immunosuppressive drugs. Observational multicenter study of 134 patients. *Semin Arthritis Rheu.* 2021; 51(2): 387-94. Article. IF: 5.431; Q2
- Christiansen SN, Filippou G, Scire CA, Balint PV, Bruyn GAW, Dalbeth N, Dejaco C, Delle Sedie A, Filippucci E, Hammer HB, Iagnocco A, Keen HI, Kissin EY, Koski J, Mandl P, Martín J, De Miguel E, Moller I, Naredo E, Pineda C, Schmidt WA, Stewart S, D'Agostino MA, Terslev L. Consensus-based semi-quantitative ultrasound scoring system for gout lesions: Results of an OMERACT Delphi process and web-reliability exercise. *Semin Arthritis Rheu.* 2021; 51(3): 644-9. Article. IF: 5.431; Q2
- Collada JM, Macía-Villa C, Plasencia C, Álvarez-Gracia JM, de Miguel E. Doppler enthesitis: a potential useful outcome in the assessment of axial spondyloarthritis and psoriatic arthritis. *Clin Rheumatol.* 2021; 40(5): 2013-20. Article. IF: 3.65; Q3
- Coronel L, Rodríguez-Pardo J, Monjo I, de Miguel E. Prevalence and significance of ischemic cerebrovascular events in giant cell arteritis. *Med Clin-Barcelona.* 2021; 157(2): 53-7. Article. IF: 3.2; Q2

- Deodhar A, Mease P, Marzo-Ortega H, Hunter T, Sandoval D, Kronbergs A, Lauzon S, Leung A, Navarro-Compán V. Ixekizumab improves sleep and work productivity in patients with non-radiographic axial spondyloarthritis: results from the COAST-X trial at 52 weeks. *BMC Rheumatol.* 2021; 5(1): 50. Article. Not Indexed
- Deodhar AA, Mease PJ, Rahman P, Navarro-Compán V, Strand V, Hunter T, Bolce R, Leon L, Lauzon S, Marzo-Ortega H. Ixekizumab improves spinal pain, function, fatigue, stiffness, and sleep in radiographic axial Spondyloarthritis: COAST-VW 52-week results. *Bmc Rheumatol.* 2021; 5(1): 35. Article. Not Indexed
- Fernández MG, Villamañán E, Jiménez-Nacher I, Moreno F, Plasencia C, Gaya F, Herrero A, Balsa A. Cost evolution of biological drugs in rheumatoid arthritis patients in a tertiary hospital: Influential factors on price. *Reumatol Clin.* 2021; 17(6): 335-42. Article. Not Indexed
- Ferraz-Amaro I, Rueda-Gotor J, Genre F, Corrales A, Blanco R, Portilla V, Mazón IG, Llorca J, Expósito R, Vicente EF, Quevedo-Abeledo JC, Rodríguez-Lozano C, Ortega-Castro R, Ladehesa-Pineda ML, Fernández-Carballido C, Martínez-Vidal MP, Castro-Corredor D, Anino-Fernández J, Vivar MLG, Galíndez-Agirregoikoa E, Peiteado D, Plasencia-Rodríguez C, Pérez EM, Díaz CF, Castaneda S, González-Gay MA. Potential relation of cardiovascular risk factors to disease activity in patients with axial spondyloarthritis. *Ther Adv Musculoskelet Dis.* 2021; 13: 1759720X211033755. Article. IF: 3.625; Q3
- Fuentelsaz-Romero S, Barrio-Alonso C, Campos RG, Torresano MT, Muller IB, Triguero-Martínez A, Nuño L, Villalba A, García-Vicuna R, Jansen G, Miranda-Carús ME, González-Alvaró I, Puig-Kroger A. The macrophage reprogramming ability



of antifolates reveals soluble CD14 as a potential biomarker for methotrexate response in rheumatoid arthritis. *Front Immunol.* 2021; 12: 776879. Article. IF: 8.786; Q1

- Garrido-Cumbrera M, Bundy C, Navarro-Compañ V, Makri S, Sanz-Gómez S, Christen L, Mahapatra R, Delgado-Domínguez CJ, Poddubnyy D. Patient-reported impact of axial spondyloarthritis on working life: results from the european map of axial spondyloarthritis survey. *Arthrit Care Res.* 2021; 73(12): 1826-33. Article. IF: 5.178; Q2
- Garrido-Cumbrera M, Gálvez-Ruiz D, Delgado-Domínguez CJ, Poddubnyy D, Navarro-Compañ V, Christen L, Mahapatra R, Makri S, Bundy C. Impact of axial spondyloarthritis on mental health in Europe: results from the EMAS study. *RMD Open.* 2021; 7(3): e001769. Article. IF: 5.806; Q1
- Garrido-Cumbrera M, Gratacos J, Collantes-Estévez E, Zarco-Montejo P, Sastre C, Christen L, Sanz-Gómez S, Correa-Fernández J, Navarro-Compañ V. A benchmarking study evaluating axial spondyloarthritis burden in Spain and other European countries. results from the Spanish atlas and the European map of axial spondyloarthritis (EMAS) studies. *Int J Rheum Dis.* 2021; 24(9): 1127-36. Article. IF: 2.558; Q4
- Garrido-Cumbrera M, Marzo-Ortega H, Christen L, Plazuelo-Ramos P, Webb D, Jacklin C, Irwin S, Grange L, Makri S, Mateus EF, Mingolla S, Antónopoulou K, Sanz-Gómez S, Correa-Fernández J, Carmona L, Navarro-Compañ V. Assessment of impact of the COVID-19 pandemic from the perspective of patients with rheumatic and musculoskeletal diseases in Europe: results from the REUMAVID study (phase 1). *RMD Open.* 2021; 7(1): e001546. Article. IF: 5.806; Q1
- Garrido-Cumbrera M, Poddubnyy D, Gossec L, Mahapatra R, Bundy C, Makri S, Sanz-Gómez S, Christen L, Delgado-Domínguez CJ, Navarro-Compañ V. Gender differences in patient journey to diagnosis and disease outcomes: results from the European Map of Axial Spondyloarthritis (EMAS). *Clin Rheumatol.* 2021; 40(7): 2753-61. Article. IF: 3.65; Q3
- Gottlieb AB, Mease PJ, Kirkham B, Nash P, Balsa AC, Combe B, Rech J, Zhu X, James D, Martín R, Ligozio G, Abrams K, Pricop L. Secukinumab efficacy in psoriatic arthritis machine learning and meta-analysis of four phase 3 trials. *JCR-J Clin Rheumatol.* 2021; 27(6): 239-47. Article. IF: 3.902; Q3
- Gracia JMA, Sánchez-Piedra C, Manero J, Ruiz-Lucea ME, López-Vives L, Bohórquez C, Martínez-Barrio J, Bonilla G, Vela P, García-Villanueva MJ, Navio-Marco MT, Pavia M, Galindo M,

Erausquin C, González-Gay MA, Rua-Figueroa I, Pego-Reigosa JM, Castrejon I, Sánchez-Costa JT, González-Davila E, Díaz-González F. Role of targeted therapies in rheumatic patients on COVID-19 outcomes: results from the COVIDSER study. *RMD Open.* 2021; 7(3): e001925. Article. IF: 5.806; Q1

- Hernández MAA, Andreu JL, Criado AB, Díaz-González F, Muelas JMV, Silva RQ, Gómez-Reino JJ. Update of the position paper of the Spanish society of rheumatology on biosimilar drugs. *Reumatol Clin.* 2021; 17(3): 160-9. Article. Not Indexed
- Hernández-Breijo B, Brenis CM, Plasencia-Rodríguez C, Martínez-Feito A, Novella-Navarro M, Pascual-Salcedo D, Balsa A. Methotrexate reduces the probability of discontinuation of TNF inhibitors in seropositive patients with rheumatoid arthritis. a real-world data analysis. *Front Med (Lausanne).* 2021; 8: 692557. Article. IF: 5.058; Q2
- Hernández-Breijo B, Navarro-Compañ V, Plasencia-Rodríguez C, Parodis I, Gehin JE, Martínez-Feito A, Novella-Navarro M, Mezcuca A, Warren DJ, Nozal P, Pascual-Salcedo D, Balsa A. BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors. *SCI Rep-Uk.* 2021; 11(1): 11632. Article. IF: 4.996; Q2
- Hernández-Breijo B, Plasencia-Rodríguez C, Navarro-Compañ V, García-Hoz C, Nieto-Ganan I, Sobrino C, Bachiller-Corral J, Díaz-Almirón M, Martínez-Feito A, Jurado T, Lapuente-Suáñez P, Bonilla G, Pijoan-Moratalla C, Roy G, Vázquez-Díaz M, Balsa A, Villar LM, Pascual-Salcedo D, Rodríguez-Martín E. Remission induced by TNF inhibitors plus methotrexate is associated with changes in peripheral naive B cells in patients with rheumatoid arthritis. *Front Med (Lausanne).* 2021; 8: 683990. Article. IF: 5.058; Q2
- López-Medina C, Molto A, Sieper J, Duruoz T, Kiltz U, Elzorkany B, Hajjaj-Hassouni N, Burgos-Vargas R, Maldonado-Cocco J, Ziade N, Gavali M, Navarro-Compañ V, Luo SF, Monti S, Tae-Jong K, Kishimoto M, Pimentel-Santos FM, Gu JR, Schiott R, van Gaalen FA, Geher P, Magrey M, Vodnizza SEI, Bautista-Molano W, Maksymowicz W, Machado PM, Landew R, van der Heijde D, Dougados M. Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study. *RMD Open.* 2021; 7(1): e001450. Article. IF: 5.806; Q1
- Macía-Villa C, Valenciano AC, de Miguel E. Enthesis lesions are associated with X-ray pro-

gression in psoriatic arthritis. *Int J Rheum Dis.* 2021; 24(6): 828-33. Article. IF: 2.558; Q4

- Martín-Martínez MA, Castaneda S, Sánchez-Alonso F, García-Gómez C, González-Juanatey C, Sánchez-Costa JT, Belmonte-López MA, Tornero-Molina J, Santos-Rey J, González COS, Quesada E, Moreno-Gil MP, Cobo-Ibáñez T, Pinto-Tasnde JA, Babio-Herraez J, Bonilla G, Juan-Mas A, Manero-Ruiz FJ, Romera-Baures M, Bachiller-Corral J, Chamizo-Carmona E, Uriarte-Ecenarro M, Barbadillo C, Fernández-Carballido C, Aurrecochea E, Moller-Parrera I, Llorca J, González-Gay MA. Cardiovascular mortality and cardiovascular event rates in patients with inflammatory rheumatic diseases in the CARDIOvascular in rheuMATology (CARMA) prospective study- results at 5 years of follow-up. *Rheumatology.* 2021; 60(6): 2906-15. Article. IF: 7.046; Q1
- Mayor Ibaguren A, Espinosa Arranz E, Peiteado López D, Custodio A, Herranz Pinto P. Apremilast for immune checkpoint inhibitor-induced psoriasis: A case series. *JAAD Case Rep.* 2021; 11: 84-9. Article. Not Indexed
- Navarro-Compañ V, Sepriano A, El-Zorkany B, van der Heijde D. Axial spondyloarthritis. *Ann Rheum Dis.* 2021; 80(12): 1511-21. Review. IF: 27.973; D1
- Novella-Navarro M, Plasencia-Rodríguez C, Nuño L, Balsa A. Risk factors for developing rheumatoid arthritis in patients with undifferentiated arthritis and inflammatory arthralgia. *Front Med (Lausanne).* 2021; 8: 668898. Review. IF: 5.058; Q2
- Prada PAZ, Laurin CLU, Astete CAG, Caltelblanco SK, Navarro-Compañ V. Influence of smoking and obesity on treatment response in patients with axial spondyloarthritis: a systematic literature review. *Clin Rheumatol.* 2021; 40(5): 1673-86. Review. IF: 3.65; Q3
- Regueiro C, Casares-Marfil D, Lundberg K, Knevel R, Acosta-Herrera M, Rodríguez-Rodríguez L, López-Mejías R, Pérez-Pampin E, Triguero-Martínez A, Nuño L, Ferraz-Amaro I, Rodríguez-Carrio J, López-Pedreira R, Robustillo-Villarino M, Castaneda S, Remuzgo-Martínez S, Alperi M, Alegre-Sancho JJ, Balsa A, González-Álvoro I, Mera A, Fernández-Gutiérrez B, González-Gay MA, Trouw LA, Gronwall C, Padyukov L, Martín J, González A. HLA-B*08 identified as the most prominently associated major histocompatibility complex locus for anti-carbamylated protein antibody-positive/anti-cyclic citrullinated peptide-negative rheumatoid arthritis. *Arthritis Rheumatol.* 2021; 73(6): 963-9. Article. IF: 15.483; Q1
- Regueiro C, Nuño L, Triguero-Martínez A, Ortiz

AM, Villalba A, Boveda MD, Martínez-Feito A, Conde C, Balsa A, González-Alvaro I, González A. Increased disease activity in early arthritis patients with anti-carbamylated protein antibodies. *SCI Rep-Uk.* 2021; 11(1): 9945. Article. IF: 4.996; Q2

- Remuzgo-Martínez S, Atienza-Mateo B, Ocejovinyals JG, Genre F, Pulito-Cueto V, Mora-Cuesta VM, Iturbe-Fernández D, Lera-Gómez L, Pérez-Fernández R, Prieto-Pena D, Irure J, Romero-Bueno F, Sánchez-Pernaute O, Alonso-Moralejo R, Nuño L, Bonilla G, Vicente-Rabaneda EF, Grafía I, Prieto-González S, Narvaez J, Trallero-Araguas E, Selva-O'Callaghan A, Gualillo O, Cavagna L, Cifrián JM, Renzoni EA, Castaneda S, López-Mejías R, González-Gay MA, Ortego-Centeno N, Pérez-Gómez N, Mera A, Martínez-Barrio J, Moriano C, Díez E, Calvo-Alen J, Balsa A. Role of MUC1 rs4072037 polymorphism and serum KL-6 levels in patients with antisynthetase syndrome. *SCI Rep-Uk.* 2021; 11(1): 22574. Article. IF: 4.996; Q2
- Remuzgo-Martínez S, Atienza-Mateo B, Ocejovinyals JG, Pulito-Cueto V, Prieto-Pena D, Genre F, Marquez A, Llorca J, Cuesta VMM, Fernández DI, Riesco L, Ortego-Centeno N, Gómez NP, Mera A, Martínez-Barrio J, López-Longo FJ, Lera-Gómez L, Moriano C, Díez E, Tomero E, Calvo-Alen J, Romero-Bueno F, Sánchez-Pernaute O, Nuño L, Bonilla G, Grafía I, Prieto-González S, Narvaez J, Trallero-Araguas E, Selva-O'Callaghan A, Gualillo O, Martín J, Cavagna L, Castaneda S, Cifrián JM, Renzoni EA, López-Mejías R, González-Gay MA. HLA association with the susceptibility to anti-synthetase syndrome. *Joint Bone Spine.* 2021; 88(3): 105115. Article. IF: 5.263; Q2
- Rueda-Gotor J, López-Mejías R, Remuzgo-Martínez S, Pulito-Cueto V, Corrales A, Lera-Gómez L, Portilla V, González-Mazon I, Blanco R, Exposito R, Mata C, Llorca J, Hernández-Hernández V, Rodríguez-Lozano C, Barbarroja N, Castro RO, Vicente E, Fernández-Carballido C, Martínez-Vidal MP, Castro-Corredor D, Anino-Fernández J, Peiteado D, Plasencia-Rodríguez C, Galindez-Agirregoikoa E, García-Vivar ML, Gualillo O, Quevedo-Abeledo JC, Castaneda S, Ferraz-Amaro I, González-Gay MA, Genre F. Vaspin in atherosclerotic disease and cardiovascular risk in axial spondyloarthritis: a genetic and serological study. *Arthritis Res Ther.* 2021; 23(1): 111. Article. IF: 5.606; Q1
- Salvarani C, Sebastiani M, Dieude P, García M, Deberdt W, Rogai V, de la Torre I, Inciarte-Mundo J, Balsa A. Baricitinib and the Risk of Incident Interstitial Lung Disease: A Descriptive Clinical

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Case Report from Clinical Trials. *Rheumatol Ther.* 2021; 8(3): 1435-41. Article. IF: 4.081; Q3

- Schafer VS, Chrysidis S, Schmidt WA, Duftner C, Iagnocco A, Bruyn GA, Carrara G, De Miguel E, Diamantopoulos AP, Nielsen BD, Fredberg U, Hartung W, Hanova P, Hansen IT, Hocevar A, Juche A, Kermani TA, Lorenzen T, Macchioni P, Milchert M, Dohn UM, Mukhtyar C, Monti S, Ponte C, Seitz L, Scire CA, Terslev L, Dasgupta B, Keen HI, Pineda C, Dejaco C. OMERACT definition and reliability assessment of chronic ultrasound lesions of the axillary artery in giant cell arteritis. *Semin Arthritis Rheu.* 2021; 51(4): 951-6. Article. IF: 5.431; Q2
- Segura BT, González IA, Rua-Figueroa I, Veiga NP, Pérez VD, Olive-Marques A, Galindo M, Calvo J, Ovalles-Bonilla JG, Fernández-Nebro A, Menor-Almagro R, Tomero E, del Amo ND, Isacelaya EU, Martínez-Taboada VM, Andreu JL, Boteanu A, Narvaez J, Movasat A, Montilla C, Gallego JMS, Hernández-Cruz B, Andres M, Salgado E, Freire M, Garcia SM, Moriano C, Expósito L, Velasquez CP, Velloso-Feijoo ML, Cacheda AP, Lozano-Rivas N, Bonilla G, Arévalo M, Jiménez I, Quevedo-Vila V, Manero-Ruiz FJ, Lefebvre PGD, Vázquez-Rodríguez TR, Ibanez-Rua J, Cobo-Ibáñez T, Pego-Reigosa JM. Relevance of gastrointestinal manifestations in a large Spanish cohort of patients with systemic lupus erythematosus: what do we know? *Rheumatology.* 2021; 60(11): 5329-36. Article. IF: 7.046; Q1
- Shephard JLV, Rodríguez CP, Ferrer CS, López DP, Criado AB, López-Granados E, García-Morato MB. Colitis expands the phenotype of PAAND patients: new case report and review of the literature. *Rheumatology.* 2021; 60(9): E316-7. Letter. IF: 7.046; Q1
- Taylor PC, Atzeni F, Balsa A, Gossec L, Muller-Ladner U, Pope J. The key comorbidities in patients with rheumatoid arthritis: a narrative review. *J Clin Med.* 2021; 10(3): 509. Review. IF: 4.964; Q2

■ Research projects

Aguado Acín P. Caracterización e historia natural de la hipofosfatasa en pacientes adultos con confirmación genética frente a pacientes con fosfatasa alcalina baja y test genético negativo. Hipofosfatasa del adulto. Alexion Pharmaceutical Inc. 2017-Ongoing.

Managment centre: FIBHULP

Balsa Criado A. Actualización en patologías autoinmunes, análisis de implantación en telemedicina y adaptación de nuevas medidas y criterios de derivación adecuados en estas patologías. Roche Farma S. A. 2021-2021.

Managment centre: FIBHULP

Balsa Criado A. Desarrollo de biochips para monitorización de infliximab y la presencia de anticuerpos frente a infliximab en sangre. IMG Pharma Biotech. 2017-Ongoing.

Managment centre: FIBHULP

Balsa Criado A. Estudio de las comorbilidades en la artritis reumatoide. Roche Farma S. A. 2011-Ongoing.

Managment centre: FIBHULP

Balsa Criado A. Estudio para determinar la correlación entre la calprotectina sérica y la actividad de la artritis reumatoide. Arepaz. 2010-Ongoing.

Managment centre: FIBHULP

Balsa Criado A. Mejora de herramientas y procedimientos para facilitar la consulta virtual en pacientes con enfermedad inflamatoria. Abbvie Spain S.L.U. 2021-Ongoing.

Managment centre: FIBHULP

Balsa Criado A. Relación entre los niveles de fármaco circulante, la aparición de anticuerpos anti idiotipo y la respuesta clínica, en pacientes con enfermedades articulares inflamatorias (artritis reumatoide, artritis idiopática juvenil, artritis psoriática, enfermedad de Still y espondiloartropatías) que reciben tratamiento biológico. Pfizer S. L. U. 2011-Ongoing.

Managment centre: FIBHULP

Bonilla Hernán MG. Specific biomarkers of the interstitial lung disease associated with rheumatoid arthritis (PI-3886). ISCIII. 2019-Ongoing.

Managment centre: SERGAS

de Miguel Mendieta E. Analisis de imagenes ecograficas para el diagnostico de arteritis de celulas gigantes mediante tecnicas de deep learning. Roche Farma S.A. 2021-Ongoing.

Managment centre: FIBHULP

De Miguel Mendieta E. Factores de riesgo de progresión radiográfica en columna de pacientes con espondilitis anquilosante. Influencia de los tratamientos actuales (PI17/01840). ISCIII. 2018-2022.

Managment centre: FIBHULP

del Cerro Marín MJ. Incidencia y evolución en la hipertensión pulmonar en prematuros que desarrollan displasia broncopulmonar. Pfizer S. A. 2009-Ongoing.

Managment centre: FIBHULP

Martínez Feito A. Relevancia de la presencia y titulo de autoanticuerpos (factor reumatoide y antipéptido citrulinado ciclico) en los niveles de farmacos anti-tnf en pacientes con artritis reumatoide. UCB Pharma S.A. 2021-Ongoing.

Managment centre: FIBHULP

Miranda Carús ME. Células T helper foliculares (Tfh), T foliculares reguladoras (Tfr) y T helper periféricas (Tph) en Artritis Reumatoide preclínica, temprana y establecida: herramientas para la medicina personalizada (PI20/00141). ISCIII. 2021-2023.

Managment centre: FIBHULP

Miranda Carús ME. Efecto del metotrexato en la frecuencia y función de las células T helper foliculares; implicaciones

patogénicas y pronósticas. Laboratorios Gebro Pharma S. A. 2020-Ongoing.

Managment centre: FIBHULP

Miranda Carús ME. Frecuencia y función de las células T helper foliculares circulantes y plasmablastos en pacientes con artritis reumatoide, y su relación con los niveles de autoanticuerpos: odificaciones asociadas con el bloqueo de la coestimulación por Abatacept. Bristol Myers Squibb S. A. U. 2016-Ongoing.

Managment centre: FIBHULP

Miranda Carús ME. Frecuencia, fenotipo y función de las células B reguladoras (BREG) en pacientes con artritis reumatoide preclínica, temprana y establecida (PI16/01189). ISCIII. 2017-2021.

Managment centre: FIBHULP

Navarro Compán MV. Resonancia magnética de sacroilíacas y desarrollo de un cuestionario para identificar espondiloartritis axial precoz en pacientes con dolor lumbar crónico remitidos a otros especialistas distintos al reumatólogo. Novartis Farmaceutica S.A. 2021-Ongoing.

Managment centre: FIBHULP


Navarro Compán MV. Towards a definition of early axial and peripheral spondyloarthritis. Assessment In Spondyloarthritis International Society. 2021-2023.

Managment centre: FIBHULP

Pascual-Salcedo Pascual MD, Herranz Pinto P. Identificación precoz de buenos respondedores primarios a las terapias biológicas en la psoriasis moderada a grave. Laboratorios Leo Pharma S. A. 2014-Ongoing.

Managment centre: FIBHULP

Plasencia Rodríguez C, Benavent D. Estudio de viabilidad de soluciones digi-



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

tales para la el seguimiento y apoyo a pacientes con enfermedades reumatológicas inmuno-mediadas(PI4519). Sociedad Española de Reumatología. 2020-Ongoing.

Managment centre: FIBHULP

Plasencia Rodríguez C. Identificación precoz de respuesta clínica a la terapia anti-TNF en la artritis reumatoide (PI16/00474). ISCIII. 2017-2021.

Managment centre: FIBHULP

Plasencia Rodríguez C. Identificación precoz de respuesta clínica a la terapia anti-TNF en la artritis reumatoide (PI479). Sociedad de Reumatología de la Comunidad de Madrid. 2018-Ongoing.

Managment centre: FIBHULP

■ Cibers & Retics

Miranda Carús, ME. Investigational Network in Inflammation and Rheumatic Diseases. (RIER). (RD16/0012/0012) Carlos III Health Institute. (31/12/2022).

■ Clinical trials

Balsa Criado, A. Estudio fase 3, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad del deucravacitinib en pacientes con artritis psoriásica activa naive a medicamentos biológicos antirreumáticos modificadores de la enfermedad".

Type: Clinical Trials, phase III.

HULP code: 5895 IM011-054.

Sponsored by: Bristol-Myers Squibb International Corporation (Bmsic).

Signed date: 15/06/2021

Balsa Criado, A. Estudio aleatorizado,

de comparación directa, simpleciego, para evaluar la respuesta al tratamiento con abatacept frente a adalimumab, ambos subcutáneos y con metotrexato de base, en adultos con artritis reumatoide precoz, seropositiva, que tienen alelos de riesgo de clase II del hla para el "epitopo compartido" y tienen una respuesta insuficiente a metotrexato.

Type: Clinical Trials, phase III.

HULP code: 5919 IM101863.

Sponsored by: Bristol-Myers Squibb International Corporation (Bmsic).

Signed date: 01/07/2021

Balsa Criado, A. Estudio de fase III, aleatorizado, doble ciego, controlado con placebo para demostrar la eficacia y la seguridad de tildrakizumab en sujetos con artritis psoriásica activa i que habían recibido tratamiento previo con anti-tnf (inspire 1).

Type: Clinical Trials, phase III.

HULP code: 5756 TILD-19-07.

Sponsored by: Sun Pharma Global Fze.

Signed date: 17/05/2021

Balsa Criado, A. Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo y de 5 años de duración que evalúa la eficacia, seguridad y tolerabilidad de distintas pautas posológicas de Ina043 por vía intraarticular frente a placebo en pacientes con osteoartritis de rodilla sintomática (onwards).

Type: Clinical Trials, phase II.

HULP code: 5948 CLNA043A12202.

Sponsored by: Novartis Farmaceutica, S.A.

Signed date: 22/10/2021

Balsa Criado, A. Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la seguridad y

la eficacia de upadacitinib en sujetos con arteritis de células gigantes.

Type: Clinical Trials, phase III.

HULP code: 6046 M16-852.

Sponsored by: Abbvie Deutschland GmbH.

Signed date: 09/12/2021

Balsa Criado, A. Eficacia y seguridad de SAR441344 para el tratamiento del lupus eritematoso sistémico: estudio aleatorizado, doble ciego, controlado con placebo, fase 2, prueba de concepto.

Type: Clinical Trials, phase II.

HULP code: 6045 ACT17010.

Sponsored by: Sanofi Aventis S.A.

Signed date: 17/11/2021

Bonilla Hernán, MG. Evolucion del lupus eritematoso sistemico en españa.

Type: Estudios No EPA.

HULP code: Appendix 2 PI-1909.

Sponsored by: Fundacion Española De Reumatologia.

Signed date: 25/02/2021

De Miguel Mendieta, E. Evaluación ecográfica de pacientes con gota que cumplen criterios preliminares de remisión.

Type: Estudios, phase EPA-OD.

HULP code: PI-4482 MAC-COL-2020-01.

Sponsored by: Andres Collado, Maria-no.

Signed date: 09/02/2021

Navarro Compán, MV. Estudio axioma: axial spondyloarthritis international outcome assessment.

Type: Estudios No EPA.

HULP code: PI-4601 AXIOMA.

Sponsored by: Maatschap Reumatologie Heelen/Sittard.

Signed date: 08/09/2021

Peiteado López, MD. Efficacy, safety and costeffectiveness of methotrexate, adalimumab, or their combination in non infectious non anterior uveitis: a multicenter, randomized, parallel 3 arm, active-controlled, phase 3 open label with blinded outcome assessment study.

Type: Clinical Trials, phase III.

HULP code: 5681 CO-THEIA.

Sponsored by: Fundacion Para La Investigacion Biomedica Del Hospital Clinico San Carlos.

Signed date: 15/12/2021"

■ Patents and trademarks

Pascual-Salcedo Pascual MD, Balsa Criado A, Plasencia Rodríguez C, authors; FIBHULP, assignee. Brand name: BioDrug Analysis BIDA. CM 13.808.531, 2015 March 10.



Fernández Luna JL, Martínez Taboada VM, López Hoyos M, Torices del Val S, Muñoz Cacho P, Varela Egocheaga I, Juliá Cano A, Marsal Barril S, Balsa Criado A, inventors; FIBHULP, Fundación Instituto de Investigación Marqués de Valdecilla, Servicio Cántabro de Salud, Universidad de Cantabria, Fundación Hospital Universitari Vall D'Hebron - Institut de Recerca (VHIR), assignees. Method for predicting the clinical response to anti-inflammatory agent therapies. P201600636, PCT/ES2017/000089; 2016 July 26.

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

3.3.4 Innate Immune Response Group

Publications: 26
Q1: 13

COMPOSITION



Eduardo Manuel López-Collazo. Subdirector Científico de IdiPAZ. Investigador Senior (Contrato Miguel Servet - I2). Jefe de Laboratorio. Hospital Universitario La Paz

Luis Augusto Aguirre Pérez. Investigador Postdoctoral. Hospital Universitario La Paz

Susana Alemany de la Peña. Investigadora Senior. Jefe de Laboratorio. IIB "Alberto Sols

Jose Avendaño Ortiz. Ayudante de Investigación. Hospital Universitario La Paz

Gloria Cristina Bonel Pérez. Ayudante de investigación. Hospital Universitario La Paz

Lisardo Boscá Gomar. Investigador Senior. Jefe de Laboratorio. IIB "Alberto Sols

Jose Carlos Casavilla Dueñas. Técnico de Apoyo. FIBHULP

Antonio Castrillo Viguera. Investigador Senior. Jefe de Laboratorio. IIB "Alberto Sols

Laura Córdoba García. Responsable HUB - Organoides. Biobanco de IdiPAZ. FIBHULP

Jesús Espada Regalado. Investigador Senior. FIBHULP

Carlos del Fresno Sánchez. Investigador Postdoctoral (Contrato Miguel Servet - Tipo I). FIBHULP

María Fernández Velasco. Investigadora Senior (Contrato Miguel Servet - Tipo I). Hospital Universitario La Paz

Santiago Gómez Ruiz. Profesor Titular. Universidad Rey Juan Carlos

María Susana Guerra García. Investigadora Postdoctoral. Universidad Autónoma de Madrid

Kilián Jesús Gutiérrez Viñas. Responsable de laboratorio de Citometría de Flujo. FIBHULP

Roberto Lozano Rodríguez. Investigador Predoctoral. Hospital Universitario La Paz

Charbel Antonio Maroun Eid. Facultativo Especialista de Área en Urgencias. Hospital del Norte

Paloma Martín Sanz. Investigadora Senior. Jefe de Laboratorio. IIB "Alberto Sols

Karla Marina Montalbán Hernández. Investigadora Predoctoral. Hospital Universitario La Paz

Alejandro Pascual Iglesias. Bioinformático. FIBHULP

Rebeca Pérez de Diego. Investigadora Senior (Contrato Ramón y Cajal). Hospital Universitario La Paz

Sanjiv Prashar. Profesor Titular. Universidad Rey Juan Carlos

Elisa Pulido Lucas. Técnico de laboratorio. Hospital Universitario La Paz

Carolina Rubio Marín. Bioinformática. Hospital Universitario La Paz

Verónica Terrón Arcos. Técnico de Laboratorio. Hospital Universitario La Paz

Jaime Valentín Quiroga. Investigador Predoctoral. FIBHULP

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

STRATEGIC OBJECTIVE

This group focuses on the study of the reprogramming of the innate immune response in the context of inflammatory diseases (e.g., sepsis, cystic fibrosis, acute coronary syndrome, lung cancer) using the description of the various molecular mechanisms that underlie the reprogramming of monocytes/macrophages during refractory states. The innate immune response is activated in various clinical contexts that can be modelled *in vitro*. The initial reaction of the Innate Immune System is marked by an inflammatory response that is similar in different contexts.

However, after the initial response, a “deviation” is produced towards an “alternative” response that may, in many cases, lead to refractory states such as endotoxin and tumour tolerance. These refractory states may have undesirable clinical consequences and their study is the objective of our research.

RESEARCH ACTIVITY

■ Publications

- Asano T, Boisson B, Onodi F, Matuozzo D, Moncada-Velez M, Renkilaraj MRLM, Zhang P, Meerens L, Bolze A, Materna M, Korniotis S, Gervais A, Talouarn E, Bigio B, Seeleuthner Y, Bilguvar K, Zhang Y, Neehus AL, Ogishi M, Pelham SJ, Le Voyer T, Rosain J, Philippot Q, Soler-Palacin P, Colobran R, Martín-Nalda A, Riviere JG, Tandjaoui-Lambiotte Y, Chaibi K, Shahrooei M, Darazam IA, Olyaei NA, Mansouri D, Palabiyik F, Ozcelik T, Novelli G, Novelli A, Casari G, Aiuti A, Carrera P, Bondesan S, Barzaghi F, Rovere-Querini P, Tresoldi C, Franco JL, Rojas J, Reyes LF, Bustos IG, Arias AA, Morelle G, Kyheng C, Troya J, Planas-Serra L, Schluter A, Gut M, Pujol A, Allende LM, Rodríguez-Gallego C, Flores C, Cabrera-Marante O, Pleguezuelo DE, de Diego RP, Keles S, Aytekin G, Akcan OM, Bryceson YT, Bergman P, Brodin P, Smole D, Smith CIE, Norlin AC, Campbell TM, Covill LE, Hammarstrom L, Pan-Hammarstrom Q, Abolhassani H, Mane S, Marr N, Ata M, Al Ali F, Khan T, Spaan AN, Dalgard CL, Bonfanti P, Biondi A, Tubiana S, Burdet C, Nussbaum R, Kahn-Kirby A, Snow AL, Bustamante J, Puel A, Boisson-Dupuis S, Zhang SY, Beziat V, Lifton RP, Bastard P, Notarangelo LD, Abel L, Su HC, Jouanguy E, Amara A, Soume-

- lis V, Cobat A, Zhang Q, Casanova JL. X-linked recessive TLR7 deficiency in similar to 1% of men under 60 years old with life-threatening COVID-19. *Sci Immunol*. 2021; 6(62): eabl4348. Article. IF: 30.63; D1
- Avendaño-Ortiz J, Lozano-Rodríguez R, Martín-Quirós A, Maroun-Eid C, Terrón-Arcos V, Montalbán-Hernández K, Valentín J, del Val EM, García-Garrido MA, del Balzo-Castillo A, Casavilla-Dueñas JC, Peinado M, Gómez L, Herrero-Benito C, Rubio C, Cubillos-Zapata C, Pascual-Iglesias A, del Fresno C, Aguirre LA, López-Collazo E. SARS-CoV-2 proteins induce endotoxin tolerance hallmarks: a demonstration in patients with COVID-19. *J Immunol*. 2021; 207(1): 162-74. Article. IF: 5.426; Q2
- Avendaño-Ortiz J, Lozano-Rodríguez R, Martín-Quirós A, Terrón V, Maroun-Eid C, Montalbán-Hernández K, Valentín-Quiruga J, García-Garrido MA, del Val EM, del Balzo-Castillo A, Peinado M, Gómez L, Herrero-Benito C, Rubio C, Casavilla-Dueñas JC, Gómez-Campelo P, Pascual-Iglesias A, del Fresno C, Aguirre LA, López-Collazo E. The immune checkpoints storm in COVID-19: Role as severity markers at emergency department admission. *Clin Transl Med*. 2021; 11(10): e573. Letter. IF: 8.554; Q1
- Brea R, Valdecantos P, Rada P, Alen R, García-

- Monzon C, Bosca L, Fuertes-Agudo M, Casado M, Martín-Sanz P, Valverde AM. Chronic treatment with acetaminophen protects against liver aging by targeting inflammation and oxidative stress. *Aging-Us*. 2021; 13(6): 7800-27. Article. IF: 5.955; Q2
- Calvo PA, Martínez-Jiménez MI, Díaz M, Stojkovic G, Kasho K, Guerra S, Wanrooij S, Méndez J, Blanco L. Motif WFYY of human PrimPol is crucial to stabilize the incoming 3' nucleotide during replication fork restart. *Nucleic Acids Res*. 2021; 49(14): 8199-13. Article. IF: 19.16; D1
- Carbo JM, Leon TE, Font-Díaz J, De la Rosa JV, Castrillo A, Picard FR, Staudenraus D, Huber M, Cedo L, Escola-Gil JC, Campos L, Bakiri L, Wagner EF, Caelles C, Stratmann T, Van Ginderachter JA, Valledor AF. Pharmacologic activation of Ixr alters the expression profile of tumor-associated macrophages and the abundance of regulatory T cells in the tumor microenvironment. *Cancer Res*. 2021; 81(4): 968-85. Article. IF: 13.312; D1
- Chen MJ, Sun XC, Wei W, Cucarella C, Martín-Sanz P, Casado M, Pi LY, Ren B, Cao Q. Hepatic COX-2 expression protects mice from an alcohol-high fat diet-induced metabolic disorder by involving protein acetylation related energy metabolism. *Alcohol*. 2021; 92: 41-52. Article. IF: 2.558; Q3

- Díaz-García E, García-Tovar S, Casitas R, Jau-reguizar A, Zamarrón E, Sánchez-Sánchez B, Sastre-Perona A, López-Collazo E, García-Río F, Cubillos-Zapata C. Intermittent hypoxia mediates paraspeckle protein-1 upregulation in sleep apnea. *Cancers (Basel)*. 2021; 13(15): 3888. Article. IF: 6.575; Q2
- Díaz-Sánchez M, Renones P, Mena-Palomo I, López-Collazo E, Fresno F, Oropeza FE, Prashar S, O'Shea VAD, Gómez-Ruiz S. Ionic liquid-assisted synthesis of F-doped titanium dioxide nanomaterials with high surface area for multi-functional catalytic and photocatalytic applications. *Appl Catal A-Gen*. 2021; 613: 118029. Article. IF: 5.723; Q2
- Fernández-García V, González-Ramos S, Martín-Sanz P, García-del Portillo F, Laparra JM, Bosca L. NOD1 in the interplay between microbiota and gastrointestinal immune adaptations. *Pharmacol Res*. 2021; 171: 105775. Review. IF: 10.334; D1
- Fernández-García V, González-Ramos S, Martín-Sanz P, Laparra JM, Bosca L. Beyond classic concepts in thyroid homeostasis: Immune system and microbiota. *Mol Cell Endocrinol*. 2021; 533: 111333. Article. IF: 4.369; Q2
- Fernández-García V, González-Ramos S, Martín-Sanz P, Laparra JM, Bosca L. NOD1-targeted immunonutrition approaches: on the way from

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

- disease to health. *Biomedicines*. 2021; 9(5): 519. Review. IF: 4.757; Q2
- Font-Díaz J, Jiménez-Panizo A, Caelles C, Vivanco MD, Pérez P, Aranda A, Estebáñez-Perpina E, Castrillo A, Ricote M, Valledor AF. Nuclear receptors: Lipid and hormone sensors with essential roles in the control of cancer development. *Semin Cancer Biol*. 2021; 73: 58-75. Article. IF: 17.012; D1
 - García-Penas A, Wang Y, Mena-Palomo I, López-Collazo E, Díaz-García D, Gómez-Ruiz S, Stadler FJ. Preparation, thermoresponsive behavior, and preliminary biological study of functionalized poly(N-isopropylacrylamide-co-dopamine methacrylamide) copolymers with an organotin(IV) compound. *Polym Test*. 2021; 94: 107046. Article. IF: 4.931; D1
 - García-Solis B, van den Rym A, Pérez-Caraballo JJ, Al-Ayoubi A, Alazami AM, Lorenzo L, Cubillos-Zapata C, López-Collazo E, Pérez-Martínez A, Allende LM, Markle J, Fernández-Arquero M, Sánchez-Ramón S, Recio MJ, Casanova JL, Mohammed R, Martínez-Barricarte R, de Diego RP. Clinical and immunological features of human BCL10 deficiency. *Front Immunol*. 2021; 12: 786572. Article. IF: 8.786; Q1
 - Gómez CE, Perdiguero B, Falqui M, Marín MQ, Becares M, Sorzano COS, García-Arriaza J, Esteban M, Guerra S. Enhancement of HIV-1 envelope-specific CD8 T cell responses using interferon-stimulated gene 15 as an immune adjuvant. *J Virol*. 2021; 95(2): e01155-20. Article. IF: 6.549; Q2
 - Guevara-Hoyer K, Fuentes-Antras J, de la Fuente-Munoz E, de la Peña AR, Vinuela M, Cabello-Clotet N, Estrada V, Culebras E, Delgado-Iribarren A, Martínez-Novillo M, Torrejon MJ, de Diego RP, Fernández-Arquero M, Ocana A, Pérez-Segura P, Sánchez-Ramón S. Serological tests in the detection of SARS-CoV-2 antibodies. *Diagnostics (Basel)*. 2021; 11(4): 678. Article. IF: 3.992; Q2
 - Jaen RI, Sánchez-García S, Fernández-Velasco M, Boscá L, Prieto P. Resolution-based therapies: The potential of lipoxins to treat human diseases. *Front Immunol*. 2021; 12: 658840. Review. IF: 8.786; Q1
 - Martínez PT, García PD, Salas MR, Sánchez RR, Avendaño-Ortiz J, Guerrero-Monjo S, García F, Llamas MA, López-Collazo E, Saz-Leal P, del Fresno C. SARS-CoV-2 IgG seropositivity in a cohort of 449 non-hospitalized individuals during Spanish COVID-19 lockdown. *SCI Rep-Uk*. 2021; 11(1): 21612. Article. IF: 4.996; Q2
 - Montalbán-Hernández K, Cantero-Cid R, Lozano-Rodríguez R, Pascual-Iglesias A, Avendaño-Ortiz

- J, Casavilla-Dueñas JC, Pérez GCB, Guevara J, Marcano C, Barragan C, Valentin J, del Fresno C, Aguirre LA, Collazo EL. Soluble SIGLEC5: A new prognosis marker in colorectal cancer patients. *Cancers (Basel)*. 2021; 13(15): 3896. Article. IF: 6.575; Q2
- Navarro-García JA, González-Lafuente L, Fernández-Velasco M, Ruilope LM, Ruiz-Hurtado G. Fibroblast growth factor-23-klotho axis in cardiovascular syndrome: mediators and potential therapeutic targets. *Front Physiol*. 2021; 12: 775029. Review. IF: 4.755; Q1
- Oleaga-Quintas C, de Oliveira EB, Rosain J, Rapaport F, Deswarte C, Guerin A, Sajjath SM, Zhou YJ, Marot S, Lozano C, Branco L, Fernández-Hidalgo N, Lew DB, Brunel AS, Thomas C, Launay E, Arias AA, Cuffel A, Monjo VC, Neehus AL, Marques L, Roynard M, Moncada-Velez M, Gerceker B, Colobran R, Vigue MG, López-Herrera G, Berrón-Ruiz L, Méndez NHS, Romanillos PO, Le Voyer T, Puel A, Bellanne-Chantelot C, Ramirez KA, Lorenzo-Díaz L, Alejo NR, de Diego RP, Condino-Neto A, Mellouli F, Rodríguez-Gallego C, Witte T, Restrepo JF, Jobim M, Boisson-Dupuis S, Jeziorski E, Fieschi C, Vogt G, Donadieu J, Pasquet M, Vasconcelos J, Ardeniz FO, Martínez-Gallo M, Campos RA, Jobim LF, Martínez-Barricarte R, Liu K, Cobat A, Abel L, Casanova JL, Bustamante J. Inherited GATA2 deficiency is dominant by haploinsufficiency and displays incomplete clinical penetrance. *J Clin Immunol*. 2021; 41(3): 639-57. Article. IF: 8.542; Q1
- Povo-Retana A, Mojena M, Boscá A, Pedros J, Peraza DA, Valenzuela C, Laparra JM, Calle F, Bosca L. Graphene particles interfere with pro-inflammatory polarization of human macrophages: functional and electrophysiological evidence. *Adv Biol (Weinh)*. 2021; 5(11): 2100882. Article. Not Indexed
- Ramírez CM, Torrecilla-Parra M, Pardo-Marqués V, de-Frutos MF, Pérez-García A, Tabraue C, de la Rosa JV, Martín-Rodríguez P, Díaz-Sarmiento M, Núñez U, Orizaola MC, Traves PG, Camps M, Boscá L, Castrillo A. Crosstalk between LXR and caveolin-1 signaling supports cholesterol efflux and anti-inflammatory pathways in macrophages. *Front Endocrinol (Lausanne)*. 2021; 12: 635923. Article. IF: 6.055; Q1
- Rubio-Garrido M, Avendaño-Ortiz J, Ndarabu A, Rubio C, Reina G, López-Collazo E, Holguin A. Dried blood specimens as an alternative specimen for immune response monitoring during HIV infection: a proof of concept and simple method in a pediatric cohort. *Front Med (Lausanne)*. 2021; 8: 678850. Article. IF: 5.058; Q2

- Val-Blasco A, Gil-Fernández M, Rueda A, Pereira L, Delgado C, Smani T, Hurtado GR, Fernández-Velasco M. Ca²⁺ mishandling in heart failure: Potential targets. *Acta Physiol*. 2021; 232(3): e13691. Review. IF: 7.523; D1

Research projects

Aguirre Pérez LA. La metástasis del cáncer de ovario en la niñez y la adolescencia: un abordaje inmunológico para su erradicación. Fundación Familia Alonso. 2020-Ongoing.

Management centre: FIBHULP

Cantero Cid R. Contrato garantía juvenil técnico laboratorio (PEJ2019_TL/BMD_13082). CM. 2020-2021.

Management centre: FIBHULP

Cantero Cid R. Fabricación inteligente de materiales avanzados para el transporte, la energía y la salud (S2018/NMT-4381). CM. 2019-2022.

Management centre: FIBHULP

Casavilla Dueñas JC. Contrato garantía juvenil (PEJ2019_TL/BMD_13082). CM. 2020-2021.

Management centre: FIBHULP

Fernández Velasco M. Determinación de nuevos mediadores del sistema inmune innato como biomarcadores de daño cardiaco en el infarto agudo de miocardio. Sociedad Española de Cardiología. 2019-Ongoing.

Management centre: FIBHULP

Fernández Velasco M. New inflammatory targets for atrial myopathy associated with heart failure (PI20/01482). ISCIII. 2021-2023.

Management centre: FIBHULP

Fernández Velasco M. NOD 1, una nueva diana terapéutica en el tratamiento del

infarto agudo de miocardio (PI17/01344). ISCIII. 2018-2022.


Management centre: FIBHULP


López Collazo EM. Análisis de muestras del proyecto ensayo clínico para la realización de la investigación clínica sobre una nueva técnica diagnóstica basada en PCR a tiempo real, para determinar la predisposición a infecciones en pacientes con infarto de miocardio, necesario para su aprobación regulatoria. Crazy Science & Business S.L. 2021-Ongoing.

Management centre: FIBHULP

López Collazo EM. Caracterización de la inmunidad innata en niños nacidos de madres portadoras de VIH. Fundación Familia Alonso. 2019-Ongoing.

Management centre: FIBHULP





1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

López Collazo EM. Contrato Miguel Serret Categoría A (CES08/002). CM. 2009-2025.

Managment centre: FIBHULP

López Collazo EM. Contribución de las células híbridas tumorales a la metástasis del cáncer de pulmón: estudio exhaustivo en modelos animales y pacientes con metástasis avanzada. FIBHULP. 2018-Ongoing.

Managment centre: FIBHULP

López Collazo EM. Convocatoria interna Jesús Antolín Garcarena 2018. Contrato Roberto Lozano Rodríguez. FIBHULP. 2018-Ongoing.

Managment centre: FIBHULP

López Collazo EM. Desarrollo de modelos experimentales para el tratamiento personalizado del cáncer de páncreas. Hospital Universitario de Fuenlabrada. 2017-Ongoing.

Managment centre: FIBHULP

López Collazo EM. Detection of prometastatic hybrids in primary tumour, peripheral blood and metastasis from patients with cancer: a strategy for its deactivation. Siemens Gamesa Renewable Energy S. A. 2020-Ongoing.

Managment centre: FIBHULP

López Collazo EM. El desarrollo de biomodelos partiendo de animales genéticamente transformados, biopsias, piezas de cirugía, células madres y vesículas extracelulares contribuirá al estudio e implantación de nuevas terapias y de una medicina personalizada (). FIBHULP. 2020-Ongoing.

Managment centre: FIBHULP

López Collazo EM. Estudio de la interacción entre las células troncales de cáncer colorrectal y el sistema inmune innato.

Roche Farma S. A. 2015-Ongoing.

Managment centre: FIBHULP

López Collazo EM. Estudio del sistema inmune infiltrado en el cáncer de pulmón y búsqueda de marcadores pronósticos en células circulantes de pacientes que sufren esta enfermedad. Immunostep S. L. 2014-Ongoing.

Managment centre: FIBHULP

López Collazo EM. Fallo en trasplante renal infantil: un abordaje inmunológico para los efectos secundarios y el rechazo. Fundación Familia Alonso. 2020-Ongoing.

Managment centre: FIBHULP

López Collazo EM. Formación del personal investigador en colaboración con instituciones públicas y privadas que dirigen sus actividades a este campo. Syf Galenus Center S. L. 2018-Ongoing.

Managment centre: FIBHULP

López Collazo EM. Inmune checkpoint en pacientes con COVID-19: una propuesta para la estratificación y la terapia dirigida al huésped. Encinar Rodríguez, Jesus. 2020-Ongoing.

Managment centre: FIBHULP

López Collazo EM. La metástasis tumoral infantil: una propuesta para eliminarla. Fundación Familia Alonso. 2018-Ongoing.

Managment centre: FIBHULP

López Collazo EM. Los inmune-checkpoints en la sepsis: un abordaje para el diagnóstico y la terapia (PI18/00148). ISCIII. 2019-2021.

Managment centre: FIBHULP

López Collazo EM. Plataforma de citometría de flujo del IdiPAZ. Lyposmol Biotech S.L. 2019-Ongoing.

Managment centre: FIBHULP

López Collazo EM. Plataforma de citometría espectral del IdiPAZ. FIBHULP. 2021-Ongoing.

Managment centre: FIBHULP

López Collazo EM. The risk of infections in several pathologies: a thorough study with clinical tools development for personalised medicine (PIE15/00065). ISCIII. 2016-2021.

Managment centre: FIBHULP

López Collazo EM. Transplantation (SOT & HSCT) in children transchild. CM. 2016-Ongoing.

Managment centre: FIBHULP

Lozano Rodríguez R. Contrato predoctoral (FI19/00334). ISCIII. 2020-2023.

Managment centre: FIBHULP

Montalbán Hernández KM. INPHINIT_ The risk of infection in several pathologies: a thorough study with clinical tools for personalised medicine (INPHINIT_Montalban). Fundación La Caixa. 2018-2021.

Managment centre: FIBHULP

Pérez de Diego R. Contrato predoctoral (PEJD2019_PRE/BMD_16556). CM. 2020-2021.

Managment centre: FIBHULP

Pérez de Diego R. Errores congénitos de la inmunidad y predisposición a la infección por Sars-Cov-2 y a la gravedad del COVID-19. Acción coordinada internacional de secuenciación exómica completa (COV20/01333). ISCIII. 2020-2021.

Managment centre: FIBHULP

Pérez de Diego R. Medicina de precisión en inmunodeficiencias primarias: desde la identificación y caracterización de nuevas etiologías genéticas hasta la edición

génica (PI17/00543). ISCIII. 2018-2022.

Managment centre: FIBHULP

Pérez de Diego R. Medicina de precisión en inmunodeficiencias primarias: desentrañando nuevas etiologías genéticas mediante aproximaciones ómicas. Esid 2021 juniors bridge grant. European Society For Immunodeficiencies. 2021-Ongoing.

Managment centre: FIBHULP

Clinical trials

Guerra García, MS. Estudio de fase 1, multicéntrico, abierto, con intensificación de dosis y expansión de cohorte con niraparib y dostarlimab en pacientes pediátricos con tumores sólidos recurrentes o refractarios.

Type: Clinical Trials, phase I.

HULP code: Appendix 1 5624 213406.

Sponsored by: Glaxosmithkline Research And Development Limited.

Signed date: 22/01/2021

Patents and trademarks

Llamas Matías MA, López-Collazo E, inventors; FIBHULP, Llamas Matías MA, Empireo S.L., assignees. Method for determine the risk of developing an infectious disease. P201330768, PCT/ES2014/070434, EP3006570; 2013 May 27.

Vela Cuenca M, González Navarro P, Valentín Quiroga J, Escudero López A, Pérez Martínez A, Fernández Casanova L, inventors; FIBHULP, CNIO, assignees. Anti-CXCR4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy. 62/642,313 US Provisional Application; 2018 March 13.



3.3.5 Diagnosis and Treatment of Diseases Associated with Abnormalities of the Complement System Group

Publications: 12

Q1: 9

COMPOSITION



■ **Margarita López Trascasa.** Investigadora "ad honorem" IdiPAZ. Profesora Asociada UAM. Hospital Universitario La Paz. Universidad Autónoma de Madrid

■ **Pilar Sánchez Corral Gómez.** Investigadora Senior (Contrato Miguel Servet - I2). Jefe de Laboratorio. Hospital Universitario La Paz

Fernando Corvillo Rodríguez. Investigador Postdoctoral. Contratado CIBERER. Hospital Universitario La Paz

Laura Espinosa Román. Jefa de Servicio Nefrología Pediátrica. Hospital Universitario La Paz

Irene Gómez Delgado. Investigadora predoctoral. Hospital Universitario La Paz

Laura González Sánchez. Investigador Postdoctoral. Contratado CIBERER. Hospital Universitario La Paz

Alberto López Lera. Investigador Postdoctoral. Contratado CIBERER. Hospital Universitario La Paz

Marta Melgosa Hijosa. Facultativo Especialista de Área en Nefrología Infantil. Hospital Universitario La Paz

Pilar Nozal Aranda. Facultativo Especialista de Área en Inmunología. Investigadora postdoctoral. Hospital Universitario La Paz

STRATEGIC OBJECTIVE

This is a national reference group for the study of primary or acquired defects in the complement system.

The main aim is to gain an understanding of the molecular mechanisms underlying in complement deficiency or dysregulation in se-

veral human diseases, the majority of which are classified as rare diseases.

In this context, the group implements and applies various methodological strategies (immunological, biochemical, proteomic and genetic) to detect clinically relevant deficiencies or functional defects in complement components. By following a clearly translational

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

approach, the group also develops new diagnostic tests which are implemented in the clinical practice, especially for treatment adjustment and patient follow-up.

The research lines could be classified as: screening and characterization of genetic or acquired complement defects that cause renal pathology (I), functional and molecular diagnosis of deficiencies affecting individual components of the complement system (II), diagnosis and molecular studies in Hereditary Angioedema and screening for disease modifying genes (III), study of pathogenic mechanisms in acquired lipodystrophies (IV).

RESEARCH LINES

- Screening and characterization of genetic and acquired Complement defects in renal disease.
- Biochemical and molecular diagnosis of isolated Complement deficiencies.
- Screening and molecular characterization of disease modifying genes in Hereditary Angioedema.
- Genetic and immunological mechanisms associated with Complement dysregulation in partial lipodystrophy.
- Characterization of autoantibodies in acquired generalized lipodystrophy.

RESEARCH ACTIVITY

■ Publications

- Amesty MV, Vilanova A, Melgosa M, Parrón M, Rivas-Vila S, Lobato R, López-Pereira P, Martínez-Urrutia MJ. Successful living-donor kidney transplantation after vena cava flow obstruction in a small recipient. *J Pediatr Surg Case Rep.* 2021;64(0):-101683. Article. IF: Not Indexed; Not Indexed.NO
- Antón-Gamero M, Melgosa-Hijosa M. Reporting inherited kidney diseases: pick up the gauntlet. *Clin Kidney J.* 2021; 14(10): 2276-7. Letter. IF: 5.86; Q1
- Caravaca-Fontán F, Trujillo H, Alonso M, Díaz-Encarnacion M, Cabello V, Ariceta G, Quintana LF, Marco H, Barros X, Ramos N, Rodríguez-Mendiola N, Cruz S, Fernández-Juaáez G, Rodríguez E, de la Cerda F, de Jose AP, López I, Fernández L, Gómez VP, Ávila A, Bravo L, Lumbreras J, Allende N, de la Nieta MDS, Olea T, Melgosa M, Huerta A, Miquel R, Mon C, Fraga G, de Lorenzo A, Draibe J, González F, Shabaka A, Illescas ML, Calvo C, Oviedo V, Da Silva I, de Jorge EG, Caravaca F, Praga M. Validation of a histologic scoring Index for C3 Glomerulopathy. *Am J Kidney Dis.* 2021; 77(5): 684-95. Article. IF: 11.072; D1
- Corvillo F, González-Sánchez L, López-Lera A, Arjona E, Ceccarini G, Santini F, Araujo-Vilar D, Brown RJ, Villarroya J, Villarroya F, de Córdoba SR, Caballero T, Nozal P, López-Trascasa M. Complement factor D (adipsin) levels are elevated in acquired partial lipodystrophy (Barraquer-Simons syndrome). *Int J Mol Sci.* 2021; 22(12): 6608. Article. IF: 6.208; Q1
- Delgado IG, Corvillo F, Nozal P, Arjona E, Madrid A, Melgosa M, Bravo J, Szilagyi A, Csuka D, Veszeli N, Prohaszka Z, Sánchez-Corral P. Complement Genetic Variants and FH Desialylation in *S. pneumoniae*-Haemolytic Uraemic Syndrome. *Front Immunol.* 2021;12(0):-641656. Article. IF: 8,786; Q1
- Delgado IG, Gutiérrez-Tenorio J, Rodríguez GMF, Caverio T, Arjona E, Sánchez-Corral P. Low factor H-related 5 levels contribute to infection-triggered haemolytic uraemic syndrome and membranoproliferative glomerulonephritis. *Clin Kidney J.* 2021; 14(2) :707-9. Article. IF: 5.86; Q1
- Lera AL. Pathophysiology and underlying mechanisms in hereditary angioedema. *Balk Med J.* 2021; 38(2): 82-8. Review. IF: 3.57; Q2
- Loli-Ausejo D, López-Lera A, Drouet C, Lluncor M, Phillips-Angles E, Pedrosa M, Cabañas R, Caballero T. In Search of an association between genotype and phenotype in hereditary angioedema due to C1-INH deficiency. *Clin Rev Allerg Immun.* 2021; 61(1): 1-14. Article. IF: 10,817; Q1.
- López-Gálvez R, de la Morena-Barrio ME, Minano A, Pathak M, Marcos C, Emsley J, Caballero T, López-Trascasa M, Vicente V, Corral J, López-Lera A. Thrombin in the activation of the fluid contact phase in patients with hereditary angioedema carrying the F12 P.Thr309Lys Variant. *Clin Rev Allerg Immun.* 2021; 60(3): 357-88. Article. IF: 10,817. Q1
- López-Trascasa M, Alonso-Melgar A, Melgosa-

- Hijosa M, Espinosa-Román L, Lledin-Barbancho MD, García-Fernández E, de Córdoba SR, Sánchez-Corral P. Case report: combined liver-kidney transplantation to correct a mutation in complement factor b in an atypical hemolytic uremic syndrome patient. *Front Immunol.* 2021; 12: 751093. Article. IF: 8.786; Q1
- Marcos-Jiménez A, Sánchez-Alonso S, Alcaraz-Serna A, Esparcia L, López-Sanz C, Sampedro-Núñez M, Mateu-Albero T, Sánchez-Cerrillo I, Martínez-Fleta P, Gabriele L, Guerola LD, Rodríguez-Frade JM, Casasnovas JM, Reyburn HT, Vales-Gómez M, López-Trascasa M, Martín-Gayo E, Calzada MJ, Castaneda S, de la Fuente H, González-Alvaro I, Sánchez-Madrid F, Muñoz-Calleja C, Alfranca A. Deregulated cellular circuits driving immunoglobulins and complement consumption associate with the severity of COVID-19 patients. *Eur J Immunol.* 2021;51(3):634-647. Article. IF: 6,688; Q2.
- Pérez-Martínez A, Guerra-García P, Melgosa M, Frauca E, Fernández-Cambor C, Remesal A, Calvo C. Clinical outcome of SARS-CoV-2 infection in immunosuppressed children in Spain. *Eur J Pediatr.* 2021; 180(3): 967-71. Article. IF: 3,86; Q1

■ Research projects

García-Giménez JL, Sánchez-Corral Gómez P. Validación de biomarcadores para el diagnóstico y el pronóstico de la sep-

sis neonatal (ACCI2018-09). ISCIII. 2019-2021.

Management centre: CIBERER

López Lera A. Angioedema hereditario sin deficiencia de C1-Inhibidor: nuevas aproximaciones diagnósticas y pronósticas. Modelo para el estudio de FXII, una molécula pleiotrópica (ACCI2018-04). ISCIII. 2019-2021.

Management centre: CIBERER

López Trascasa M. Complementest. Déficits y alteraciones del sistema del complemento en patología humana . 2011-Ongoing.

Management centre: FIBHULP

Nozal Aranda P, Corvillo Rodríguez F. Detección y caracterización de autoanticuerpos en pacientes con lipodistrofia generalizada adquirida (síndrome de Lawrence). Asociación de Familiares y Afectados de Lipodistrofia (AELIP). 2019-Ongoing.

Management centre: CIBERER

Sánchez-Corral Gómez P. Contrato Mi-

guel Servet Categoría A (CES07/030).
CM. 2008-2025.

Managment centre: FIBHULP

Sánchez-Corral Gómez P. Contribución de variantes de las proteínas FHRS (factor H-Retaled) del complemento en patología renal. Fundación SENEPRO. 2018-On-going.

Managment centre: FIBHULP

Sánchez-Corral Gómez P. El sistema del complemento en salud y enfermedad (Complemento II-CM) (S2017/BMD-3673). CM. 2018-2021.

Managment centre: FIBHULP

Sánchez-Corral Gómez P. Perfiles cuantitativos de las proteínas FH/FHRS del complemento como biomarcadores de predisposición y pronóstico en el síndrome hemolítico-urémico primario y secundario (PI19/00970). ISCIII. 2020-2022.

Managment centre: FIBHULP

■ Cibers & Retics

Sánchez-Corral Gómez P. Networked Biomedical Research Center for Rare Diseases. (CB06/07/1033). ISCIII. (31/12/2021).

López Trascasa M. European consortium on lipodystrophies. (ECLIp). UE. (31/12/2021).

■ Patents and trademarks

López Trascasa M, authors; FIBHULP, assignee. Brand name: COMPLEMENTest; CM 009.658.791; 2011, January 14.



1 Introduction

2 Executive Summary


3 Information Groups by Area

4 Associated Clinicians



3.3.6 Lymphocyte Pathophysiology in Immunodeficiencies Group

Publications: 29
 Q1: 14



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

COMPOSITION

Eduardo López Granados. Coordinador de Inmunología. Hospital Universitario La Paz

Luz Yadira Bravo Gallego. Facultativo Especialista de Área en Inmunología. Hospital Universitario La Paz

María Bravo García-Morato. Facultativo Especialista de Área en Inmunología. Hospital Universitario La Paz

Carmen Cámara Hijón. Facultativo Especialista de Área en Inmunología. Hospital Universitario La Paz

María Coronel Díaz. Técnico de Laboratorio. Hospital Universitario La Paz

Lucía del Pino Molina. Investigadora Postdoctoral. Hospital Universitario La Paz

Carla Cecilia Gianelli. Facultativo Especialista de Área en Inmunología. Hospital Universitario La Paz

Diego Plaza López de Sabando. Facultativo Especialista de Área en Hemato-Oncología Pediátrica. Hospital Universitario La Paz

Keren Reche Yebra. Técnico de Laboratorio. FIBHULP

Ángel Julián Robles Marhuenda. Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz

Rebeca Rodríguez Pena. Facultativo Especialista de Área en Inmunología. Hospital Universitario La Paz

María Carmen Salcedo Moreno. Técnico de Laboratorio. Hospital Universitario La Paz

Elena Sánchez Zapardiel. Facultativo Especialista de Área en Inmunología. Hospital Universitario La Paz

Ana Sastre Urguelles. Facultativo Especialista de Área en Hemato-Oncología Pediátrica. Hospital Universitario La Paz

Juan Manuel Torres Canizales. Médico Inmunólogo. Hospital Universitario La Paz

Yolanda Soto Serrano. Investigadora Predoctoral. Hospital Universitario La Paz

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

STRATEGIC OBJECTIVE

Our group attempts to unravel the molecular bases of primary immunodeficiencies (PIDs), a large group of rare conditions (more than 400 types described so far) that virtually affect any cell type of the immune system and increase the risk of infections, autoimmunity and cancer in patients. We take a multidisciplinary clinical, anatomic, genetic, epigenetic and functional approach. By correlating clinical and experimental data, we aim to achieve a better understanding of these rare diseases and lay the grounds for, repurposed or new, more effective treatments.

Taking advantage of the knowledge and resources developed to dissect the immune system in PIDs, we are developing new schemes for immune monitoring of transplanted patients, to better estimate immunosuppression and tolerance, and early detection of severe complications as infections and rejection. Finally, we explore novel approaches for monitoring, and fine tuning of immunotherapies.

RESEARCH LINES

- To define the anatomical, cellular, molecular and (epi)genetic bases of immunological dysfunction in patients diagnosed with primary immunodeficiency in our clinic.
- The maturation and functional specialization of human B lymphocytes, and its pathophysiology in primary and secondary antibody immunodeficiencies.
- The analysis of the immunological reconstitution after haemopoietic stem cell transplantation, and the discovery and clinical validation of immunological biomarkers for immunosuppression and tolerance in solid organ transplantation.
- The development and clinical implementation of patient-tailored monitoring schemes of immunotherapies in wide clinical use.

RESEARCH ACTIVITY

■ Doctoral theses

Master Theses

Marty Lobo J. Estudio piloto de las alteraciones del linfocito B en pacientes con hipogammaglobulinemia secundaria post-tratamiento con rituximab.[dissertation]. Madrid: UCM: 2021(01/07/2021).

Directors: del Pino Molina L, López Granados E

Torices Pajares A. Monitorización celular avanzada del trasplante hepático pediátrico[dissertation]. Madrid: UCM: 2021(01/07/2021).

Director: Sánchez Zapardiel E.

■ Publications

- Alonso L, Méndez-Echevarría A, Rudilla F, Mozo

Y, Soler-Palacín P, Sisinni L, Bueno D, Riviere J, de Paz R, Sánchez-Zapardiel E, Querol S, Rodríguez-Pena R, López-Granados E, Gimeno R, de Heredia CD, Pérez-Martínez A. Failure of viral-specific T cells administered in pre-transplant settings in children with inborn errors of immunity. *J Clin Immunol.* 2021; 41(4): 748-55. Article. IF: 8.542; Q1


- Alonso-Espias M, Martínez-Sánchez N, Robles-Marhuenda A, Martín-Boado ME, Regojo-Zapata RM, Bartha JL. Diagnosis of amyopathic dermatomyositis after two intrauterine fetal deaths. *Obstet Med.* 2021; 14(2): 109-12. Article. Not Indexed
- Baker A, Remacha EF, Canzales JT, Bravo-Gallego LY, Fitzpatrick E, Melgar AA, Bartolo GM, Guereta LG, Boluda ER, Mozo Y, Broniszczak D, Jarmuzek W, Kalicinski P, Maecker-Kolhoff B, Carlens J, Baumann U, Roy C, Chardot C, Benetti E, Cananzi M, Calore E, Dello Strologo L, Candusso M, Lopes MF, Brito MJ, Goncalves C, Do Carmo C, Stephenne X, Wennberg L, Stone R, Rascon J, Lindemans C, Turkiewicz D, Giraldi E, Nicastro E, D'Antiga L, Ackermann O, Vega PJ. Current Practices on diagnosis, prevention and treatment of post-transplant lymphoproliferative

disorder in pediatric patients after solid organ transplantation: results of an international multicenter healthcare working group survey. *Children (Basel).* 2021; 8(8): 661. Article. IF: 2.835; Q2

- Berenguer J, Borobia AM, Ryan P, Rodríguez-Bano J, Bellón JM, Jarrín I, Carratala J, Pachon J, Carcas AJ, Yllescas M, Arribas JR. Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score. *Thorax.* 2021; 76(9): 920-9. Article. IF: 9.102; Q1
- Canzales JT, Ferreras C, Pascual A, Alonso L, Regueiro A, Plaza M, Hurtado JMP, Benito A, Couso JM, Fuster JL, Díaz-Almiron M, Bueno D, Mozo Y, López AG, Vicario JL, Balas A, Sisinni L, de Heredia CD, Pérez-Martínez A. Haploidentical transplantation in pediatric non-malignant diseases: A retrospective analysis on behalf of the Spanish Group for Hematopoietic Transplantation (GETH). *Eur J Haematol.* 2021; 106(2): 196-204. Article. IF: 3.674; Q3
- Colmenero-Velázquez A, Esteso G, del Rosal T, Apalategui AC, Reyburn H, López-Granados E. Marked changes in innate immunity associated with a mild course of COVID-19 in identical twins with athymia and absent circulating T cells. *J*

Allergy Clin Immun. 2021; 147(2): 567-8. Letter. IF: 14.29; D1

- del Pino-Molina L, Canzales JMT, Rodríguez-Pena R, López-Granados E. Evaluation of B-cell intracellular signaling by monitoring the PI3K-Akt axis in patients with common variable immunodeficiency and activated phosphoinositide 3-kinase delta syndrome. *Cytom Part B-Clin Cy.* 2021; 100(4): 460-6. Article. IF: 3.248; Q2
- del Pino-Molina L, López-Granados E, Lecevisse Q, Canzales JT, Pérez-Andrés M, Blanco E, Wentink M, Bonroy C, Nechvatalova J, Milota T, Kienzler AK, Philippe J, Sousa AE, van der Burg M, Kalina T, van Dongen JJM, Orfao A. Dissection of the pre-germinal center B-cell maturation pathway in common variable immunodeficiency based on standardized flow cytometric euroflow tools. *Front Immunol.* 2021; 11: 603972. Article. IF: 8.786; Q1
- Espinosa G, Galindo-Izquierdo M, Puig BM, Caro MC, Beltran PD, López JAM, Sánchez NM, Robles-Marhuenda A, Almaraz ER, Saez-Comet L, Ugarte A, Vela-Casasempere P, Bartha JL, Ruiz-Irastorza G, Martínez-Taboada VM. Pregnancy control in patients with systemic lupus erythematosus and antiphospholipid syndrome. Part 1:



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Infertility, ovarian preservation and preconception assessment. Consensus Document of the Spanish Society of Gynaecology and Obstetrics (SEGO), the Spanish Society of Internal Medicine (SEMI) and the Spanish Society of Rheumatology (SER). *Reumatol Clin.* 2021; 17(2): 61-6. Article. Not Indexed

- Feito-Rodríguez M, Mayor-Ibarguren A, Camara-Hijón C, Montero-Vega D, Servera-Negre G, Ruiz-Bravo E, Nozal P, Rodríguez-Peralto JL, Enguita AB, Bravo-Gallego LY, Granados-Fernández M, Fernández-Alcalde C, Fernández-Heredero A, Alonso-Riano M, Jiménez-Yuste V, Nuno-González A, De Lucas-Laguna R, López-Granados E, Herranz-Pinto P. Chilblain-like lesions and COVID-19 infection: A prospective observational study at Spain's ground zero. *J Am Acad Dermatol.* 2021; 84(2): 507-9. Letter. IF: 15.487; D1
- Fernández L, Polo LC, García-Morato MB, Valls ABE, Ruiz-Bravo E, Muñoz-Cabello P, Ibanez K, Rodríguez-Laguna L, Martín-Arenas R, Ortega M, Palomares-Bralo M, del Pozo A, García-Guereña L, García-Minaur S, Lapunzina P, Vallespin E. Molecular and histologic insights on early onset cardiomyopathy in Danon disease females. *Clin Genet.* 2021; 99(3): 481-3. Letter. IF: 4.296; Q2
- Gutiérrez-Gutiérrez B, del Toro MD, Borobia AM, Carcas A, Jarrín I, Yllescas M, Ryan P, Pachon J, Carratala J, Berenguer J, Arribas JR, Rodríguez-Bano J. Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study. *Lancet Infect Dis.* 2021; 21(6): 783-92. Article. IF: 71.421; D1
- Li J, Ohmura S, Marchetto A, Orth MF, Imle R, Dallmayer M, Musa J, Knott MML, Holting TLB, Stein S, Funk CM, Sastre A, Alonso J, Bestvater F, Kasan M, Romero-Pérez L, Hartmann W, Ranft A, Banito A, Dirksen U, Kirchner T, Cidre-Aranaz F, Grunewald TGP. Therapeutic targeting of the PLK1-PRC1-axis triggers cell death in genomically silent childhood cancer. *Nat Commun.* 2021; 12(1): 5356. Article. IF: 17.694; D1
- López-Nevado M, Docampo-Cordeiro J, Ramos JT, Rodríguez-Pena R, Gil-López C, Sánchez-Ramon S, Gil-Herrera J, Díaz-Madronero MJ, Delgado-Martín MA, Morales-Pérez P, Paz-Artal E, Magerus A, Rieux-Laucat F, Allende LM. Next generation sequencing for detecting somatic FAS mutations in patients with autoimmune lymphoproliferative syndrome. *Front Immunol.* 2021; 12: 656356. Article. IF: 8.786; Q1
- López-Nevado M, González-Granado LI, Ruiz-García R, Pleguezuelo D, Cabrera-Marante O, Salmón N, Blanco-Lobo P, Domínguez-Pinilla N, Rodríguez-Pena R, Sebastian E, Cruz-Rojo J, Olbrich P, Ruiz-Contreras J, Paz-Artal E, Neth O, Allende LM. Primary immune regulatory disorders with an autoimmune lymphoproliferative syndrome-like phenotype: immunologic evaluation, early diagnosis and management. *Front Immunol.* 2021; 12: 671755. Article. IF: 8.786; Q1
- Lozano-Ojalvo D, Cámara C, López-Granados E, Nozal P, Del Pino-Molina L, Bravo-Gallego LY, Paz-Artal E, Pion M, Correa-Rocha R, Ortiz A, López-Hoyos M, Iribarren ME, Portoles J, Rojo-Portoles MP, Ojeda G, Cervera I, González-Pérez M, Bodega-Mayor I, Montes-Casado M, Portoles P, Pérez-Olmeda M, Oteo J, Sánchez-Tarjuelo R, Pothula V, Schwarz M, Brahmachary M, Tan AT, Le Bert N, Berin C, Bertoletti A, Guccione E, Ochando J. Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals. *Cell Rep.* 2021; 36(8): 109570. Article. IF: 9.995; Q1
- Marhuenda AR, Collada JM, Fernández FA. Yellow nails syndrome. *Rev Clin Esp.* 2021; 221(8): 491-2. Editorial Material. IF: 3.064; Q2
- Markiewicz-Kijewska M, Kalicinski P, Canzales JT, Di Giorgio A, Baumann U, Jorns C, Baker A, Lopes MF, Remacha EF, López-Granados E, Vega PJ, Basso MS, Kowalewski G, Kaminska D, Ferreira S, Liccardo D, Pietrobbattista A, Spada M. ABOincompatible liver transplantation in children: a 20 year experience from centres in the transplantchild european reference network. *Children (Basel).* 2021; 8(9): 760. Article. IF: 2.835; Q2
- Martínez-Sánchez N, Marhuenda AR, Fernández-Miranda MD, Bartha JL. First trimester combined screening test for aneuploidies in anti-Ro carriers pregnant women. *Clin Rheumatol.* 2021; 40(7): 2699-705. Article. IF: 3.65; Q3
- Méndez-Echevarría A, Camino MB, del Rosal T, Casas I, Pozo F, Pascual-Pascual SI, García-Romero M, Camara C, Calvo C. The role of respiratory viruses in children with ataxia-telangiectasia. *Viruses-Basel.* 2021; 13(5): 867. Article. IF: 5.818; Q2
- Meyts I, Bucciol G, Quinti I, Neven B, Fischer A, Seoane E, López-Grandos E, Gianelli C, Robles-Marhuenda A, Jeandel PY, Paillard C, Sankaran VG, Demirdag YY, Lougaris V, Aiuti A, Plebani A, Milito C, Dalm VASH, Guevara-Hoyer K, Sánchez-Ramon S, Bezrodnik L, Barzagli F, González-Granado LI, Hayman GR, Uzel G, Men-

donca LO, Agostini C, Spadaro G, Badolato R, Soresina A, Vermeulen F, Bosteels C, Lambrecht BN, Keller M, Mustillo PJ, Abraham RS, Gupta S, Ozen A, Karakoc-Aydiner E, Baris S, Freeman AF, Yamazaki-Nakashimada M, Scheffler-Mendoza S, Espinosa-Padilla S, Gennery AR, Jolles S, Espinosa Y, Poli MC, Fieschi C, Hauck F, Cunningham-Rundles C, Mahlaoui N, Warnatz K, Sullivan KE, Tangye SG. Coronavirus disease 2019 in patients with inborn errors of immunity: An international study. *J Allergy Clin Immunol.* 2021; 147(2): 520-31. Article. IF: 14.29; D1

- Molina LD, Canzales JMT, Pernia O, Pena RR, de Cáceres II, Granados EL. Defective Bcl-2 expression in memory B cells from common variable immunodeficiency patients. *Clin Exp Immunol.* 2021; 203(3): 341-50. Article. IF: 5.732; Q2
- Murillo-Sanjuan L, González-Vicent M, Aparicio BA, Serra IB, Villa AR, Oficialdegui MLU, López-Duarte M, Belendez-Bieler C, Urgelles AS, Navarro JS, Diaz-de-Heredia C. Survival and toxicity outcomes of hematopoietic stem cell transplantation for pediatric patients with Fanconi anemia: a unified multicentric national study from the Spanish Working Group for Bone Marrow Transplantation in Children. *Bone Marrow Transpl.* 2021; 56(5): 1213-6. Article. IF: 5.174; Q2
- Pérez EM, Shephard JLV, García-Morato MB, Marhuenda AR, Nodal EMO, Bozano GP, Casado IG, Fresno LS, Echevarría AM, Rabes TD, Martínez LA, López-Granados E, Pena RR. Variants in CASP10, a diagnostic challenge: Single center experience and review of the literature. *Clin Immunol.* 2021; 230: 108812. Review. IF: 10.19; Q1
- Pérez-Martínez A, Mora-Rillo M, Ferreras C, Guerra-García P, Pascual-Miguel Q, Mestre-Duran C, Borobia AM, Carcas AJ, Queiruga-Parada J, García I, Sánchez-Zapardiel E, Gasior M, De Paz R, Marcos A, Vicario JL, Balas A, Moreno MA, Eguizabal C, Solano C, Arribas JR, Buckley RD, Montejano R, Soria B. Phase I dose-escalation single center clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE). *Eclinicalmedicine.* 2021; 39: 101086. Article. IF: 17.033; Q1
- Ramos-Ruperto L, Busca-Arenzana C, Valdivieso J, López-Granados E, Robles-Marhuenda A. COVID-19 and pembrolizumab-induced secondary hemophagocytic lymphohistiocytosis: a case report. *SN Compr Clin Med.* 2021; 3(6): 1412-5. Article. Not Indexed
- Roos D, van Leeuwen K, Hsu AP, Priel DL, Begtrup A, Brandon R, Stasia MJ, Bakri FG, Koker N, Koker MY, Madkaika M, de Boer M, García-

Morato MB, Shephard JLV, Roesler J, Kanegane H, Kawai T, Di Matteo G, Shahrooei M, Bustamante J, Rawat A, Vignesh P, Mortaz E, Fayezi A, Cagdas D, Tezcan I, Kitcharoensakul M, Dinauer MC, Meyts I, Wolach B, Condino-Neto A, Zerbe CS, Holland SM, Malech HL, Gallin JI, Kuhns DB. Hematologically important mutations: X-linked chronic granulomatous disease (fourth update). *Blood Cell Mol Dis.* 2021; 90: 102587. Article. IF: 2.372; Q4

- Sánchez MDC, Gómez VG, Urgelles AS, de Sabando DPL, Aparicio PR, Martínez LM, Gamarra EA, Kreiling JJP, Zapata RMR, Gutiérrez JCL, Alvarado EA, Martín FG, Torres AMS, Manzano EM, del Valle LG, Pérez-Martínez A. Treatment of infantile fibrosarcoma associated to an abdominal aortic aneurysm with larotrectinib: a case report. *Pediatr Hemat Oncol.* 2021; 38(5): 504-9. Article. IF: 2.07; Q3
- Shephard JLV, Rodríguez CP, Ferrer CS, López DP, Criado AB, López-Granados E, García-Morato MB. Colitis expands the phenotype of PAAND patients: new case report and review of the literature. *Rheumatology.* 2021; 60(9): E316-7. Letter. IF: 7.046; Q1

■ Research projects

López Granados E. Contrato predoctoral (PEJD2019_PRE/BMD_15188). CM. 2020-2021.

Management centre: FIBHULP

López Granados E. Desregulación de la expresión génica del linfocito B en la inmunodeficiencia común variable: papel de la epigenética y los microRNAs (PI16/01605). ISCI. 2017-2020.

Management centre: FIBHULP

Sánchez Zapardiel E. Validación de nuevas técnicas de estimación de la inmunosupresión y detección del rechazo en trasplante hepático pediátrico (PI19/01311). ISCI. 2020-2022.

Management centre: FIBHULP

López Granados E. Estudio exploratorio sistemático de la competencia en la res-

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

puesta linfocitaria al Sars-Cov-2, en diversas situaciones del huésped y según severidad de la COVID-19 (InmunoCOVID). Cytognos. 2021-Ongoing.

Managment centre: FIBHULP

López Granados E. European Rare Disease Coordination and support action (ERICA). UE. 2020-2024.

Managment centre: FIBHULP

López Granados E. Un esfuerzo integral para intentar descifrar las bases (epi) genéticas, fenotípicas y funcionales de la desregulación del linfocito B en deficiencias de anticuerpos, para un mejor pronóstico y tratamiento de los pacientes. (PI20/01371). ISCIII. 2021-2023.

Managment centre: FIBHULP

López Granados E. Actualización y renovación de la actividad en el servicio de inmunología del Hospital Universitario La Paz. Octapharma S.A. 2012-Ongoing.

Managment centre: FIBHULP

López Granados E. Síndrome inflamatorio multisistémico asociado a covid-19 en niños (mis-c): bases genéticas, epigenéticas e inmunopatogénicas. Fundació Marató Tv3. 2021-Ongoing.

Managment centre: FIBHULP

López Granados E. Evento de formación sobre la celiaquía y Evento de formación sobre las conectivopatías. Thermo Fisher Diagnostics S.L.U. 2021-Ongoing.

Managment centre: FIBHULP

■ Cibers & Retics

López Granados E. Centro de Investigación Biomédica en Red de Enfermedades Raras. (CB19/07/00042). ISCIII. (31/12/2021).

Managment centre: FIBHULP

■ Clinical trials

Plaza López De Sabando, D. Ensayo de fase II, abierto, multicéntrico y no controlado de mk 3475 (pembrolizumab) en niños y adultos jóvenes con linfoma de hodgkin clásico recién diagnosticado y respuesta insuficiente (precoz lenta) a la quimioterapia de primera línea (keynote 667).

Type: Clinical Trials, phase II.

HULP code: Appendix 2 5346.

Sponsored by: Merck Sharp And Dohme De España, S.A.

Signed date: 15/04/2021

Robles Marhuenda, AJ. Estudio abierto, multicéntrico, de dos cohortes y un solo grupo para evaluar la eficacia, la seguridad y la tolerabilidad, la farmacocinética y la farmacodinámica de emapalumab en niños y adultos con síndrome de activación de macrófagos (SAM) en la enfermedad de still (incluida la artritis idiopática juvenil sistémica y la enfermedad de still del adulto) o con sam en el lupus eritematoso sistémico.

Type: Clinical Trials, phase III.


HULP code: 5937B NI-0501-14.

Sponsored by: Swedish Orphan Biovitrum Ab, Sobi.

Signed date: 10/11/2021

■ Patents and trademarks

Van Dongen JJM, Orfao de Matos Correia E Vale JA, Van Der Burg M, Pérez Andrés M, Van Zelm MC, Kalina T, Vlkova M, López Granados E, Blanco Álvarez E, Kienzler AK, inventors; Erasmus University Medical Center Rotterdam, assignee. Reagents, methods, and kits for diagnosing primary immunodeficiencies. PCT/NL2015/050762, US62/072,498; 2014 Oct 30.





3.3.7 Drug Hypersensitivity and Innate Immune Response Group

Publications: 12

Q1: 4

COMPOSITION



Teresa Bellón Heredia. Investigadora Senior (Contrato Miguel Servet -I2). Jefa de laboratorio. Hospital Universitario La Paz

María del Rosario Cabañas Moreno. Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz

Jessica González Ramos. Médico Interno Residente en Dermatología. Hospital Universitario La Paz

Celia Martínez Prieto. Técnico de Grado Superior. Hospital Universitario La Paz

Aranzazú Isabel Rodríguez Sanz. Investigadora Postdoctoral. Hospital Universitario La Paz

Gastón Roustán Gullón. Facultativo Especialista de Área en Dermatología. Hospital Universitario Puerta de Hierro. Profesor Asociado. Facultad de Medicina. Universidad Autónoma de Madrid

Beatriz Sanz Minguela. Técnico de Grado Superior. Hospital Universitario La Paz

STRATEGIC OBJECTIVE

Cutaneous adverse drug reactions are unpredictable and represent a plethora of skin diseases with various degrees of severity. The spectrum ranges from mild to potentially fatal multisystem maladies. Those of most concern are usually referred to as severe cutaneous adverse reactions (SCARs), and include acute generalized exanthematous pustulosis (AGEP), drug reaction with eosinophilia and systemic symptoms (DRESS), also known as drug induced hypersensitivity syndrome or hypersensitivity syndrome (DIHS/HSS), Stevens-Johnson's syndrome (SJS), and toxic epidermal necrolysis (TEN). Among them, SJS and TEN are


the most severe clinical entities and are nowadays considered as variants of the same disease characterized by keratinocyte necrosis and epidermal detachment with the formation of subepidermal bullae. From the immunopathogenic point of view, SCARs are T-cell mediated type IV hypersensitivity reactions. However, T cells can orchestrate different types of immune responses and this functional heterogeneity has led to a further sub-classification into type IVa-IVd hypersensitivity that considers the distinct cytokine production pattern by T cell subpopulations, and emphasizes the participation of different effector cells causing inflammation and tissue damage. Current knowledge supports the active participation of cytotoxic lymphocytes in different clinical entities.

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



1 Introduction

Our project aims to a better understanding of the immune mechanisms underlying the etiopathogenesis of these diseases. The study is performed in the framework of the consortium PIELenRed (Plataforma interdisciplinaria para el estudio de reacciones cutáneas graves en red) integrated by researchers belonging to different hospitals in Madrid. Reactivation of latent herpesvirus has been described during the development of some of the previously mentioned clinical entities. In order to improve our understanding of the behaviour of the immune system during viral replication, collaboration has been established with the Kidney Transplant Unit (Nephrology Service, HULP). Kidney transplant recipients are being followed immediately before and after transplant in order to identify patients with active CMV replication.

General objectives for the next 5 years

The main objectives are:

- 1) Biobanking of samples of severe cutaneous adverse reactions to medications (DRESS, AGEP and SJS/TEN) associated to the registry PIELenRed, and integrated in the international registry RegiSCAR.
- 2) To investigate in vitro test for drug causality assessment.
- 3) To explore the involvement of the innate immune response (in particular natural cytotoxic activity) during the development of SCARs.
- 4) Identification of biomarkers of susceptibility.
- 5) To find biomarkers for disease and response to treatments.

- 6) To explore the potential of microRNAs in SJS/TEN as biomarkers of disease and of response to treatments, as well as their relationship with pathogenic mechanisms.
- 7) To analyze the evolution of the cytotoxic response in patients with CMV replication.
- 8) Compare the innate immune response in patients with CMV replication after kidney transplant and in patients with SCARs.

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

RESEARCH LINES

- Biobanking of biological samples from patients with severe cutaneous adverse reactions to medications (DRESS, AGEP and SJS/TEN).
- Development and evaluation of in vitro tests for drug causality assessment.
- Identification of biomarkers of susceptibility.
- Involvement of NK receptors in the etiopathogenesis of Stevens-Johnson syndrome /Toxic epidermal necrolysis (SJS/TEN).
- Differential analysis of the cytokine pattern involved in different SCARs (AGEP, DRESS and SJS/TEN).
- Analysis of miRNAs as biomarkers of disease and response to treatments.
- Identification of biomarkers of response to immunomodulatory treatments

RESEARCH ACTIVITY

Publications

- Alfageme F, Wortsman X, Catalano O, Roustan G, Crisan M, Crisan D, Gaitini DE, Cerezo E, Badea R. European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB) position statement on dermatologic ultrasound. *Ultraschall Med.* 2021; 42(1): 39-47. Article. IF: 5,445; D1
- Benavent MP, Fernández IS, Negrete EL, Gullón GR, Roldan FA. Double nail of the second toe: A case report with sonographic and radiological correlation. *Pediatr Dermatol.* 2021; 38(6): 1588-9. Article. IF: 1.997; Q3
- Cabañas R, Ramírez E, Bellón T. Identifying the culprit drug in severe cutaneous adverse reactions (SCARs). *Curr Treat Options Allergy.* 2021; 8(3): 194-209. Article. Not Indexed
- Cantero-Navarro E, Rayego-Mateos S, Orejudo M, Tejedor-Santamaria L, Tejera-Munoz A, Sanz AB, Márquez-Expósito L, Marchant V, Santos-Sánchez L, Egido J, Ortiz A, Bellón T, Rodríguez-Díez RR, Ruiz-Ortega M. Role of macrophages and related cytokines in kidney disease. *Front Med (Lausanne).* 2021; 8: 688060. Review. IF: 5.058; Q2
- Fernández IS, Marti LP, Botello LN, Gullon GR. Clinical and histologic features of multiple primary melanoma in a series of 31 patients. *Actas Dermosifiliogr.* 2021; 112(1): 52-8. Article. Not Indexed
- Guilarte M, Sala-Cunill A, Baeza ML, Cabañas R, Hernández MD, Ibáñez E, de Larramendi CH, Leonart R, Lobera T, Marques L, Pedro BSD, Botha J, Andresen I, Caballero T. Hereditary angioedema due to C1 inhibitor deficiency: real-world experience from the Icatibant Outcome Survey in Spain. *Allergy Asthma Clin Immunol.* 2021; 17(1): 137. Article. IF: 3.373; Q3
- Loli-Ausejo D, de Abreu JMG, Fiandor A, Cabañas R, Domínguez-Ortega F, Caballero ML, Lluch-Bernal M, García-Panto CR, Nunez MC, Quirce S. Allergic reactions after administration of pfizer-biontech covid-19 vaccine to health care workers at a tertiary hospital. *J Invest Allerg Clin.* 2021; 31(6): 507-8. Editorial Material. IF: 8.185; Q1
- Loli-Ausejo D, López-Lera A, Drouet C, Lluncor M, Phillips-Angles E, Pedrosa M, Cabañas R, Caballero T. In search of an association between genotype and phenotype in hereditary angioedema due to c1-inh deficiency. *Clin Rev Allerg Immunol.* 2021; 61(1): 1-14. Article. IF: 10,817; Q1
- Loli-Ausejo D, Vílchez-Sánchez F, Cabañas R, Fiandor A, Lluch-Bernal M, González-Munoz M, Domínguez-Ortega J. Basophil activation test in the diagnosis of hypersensitivity reactions to quinolones in a real-life setting. *Clin Exp Allergy.* 2021; 51(3): 503-7. Letter. IF: 5.401; Q2
- Marqués-Mejías MA, Entrala A, Cabañas R, Caballero T. Mediastinal angioedema: A rare manifestation of hereditary angioedema. *J Allergy Clin Immunol Pract.* 2021; 9(1): 477-8. Editorial Material. IF: 11,022; Q1

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

- Salguero I, Roustan G, Requena L, Suarez D, García-Fresnadillo D, Redondo JI, Najera L. Immunophenotypic differences in tumor-infiltrating lymphocytes and neovascularization between primary cutaneous melanoma with and without metastasis: an immunohistochemical study of 80 cases. *Am J Dermatopath.* 2021; 43(11): 811-8. Article. IF: 1.319; Q4
- Torre-Castro J, Moya-Martínez C, Mendoza-Cembranos MD, Macías-del-Toro E, Díaz-Recuero JL, Machan S, Rodríguez-Pinilla M, Córdoba R, Alfageme F, Roustan G, Najera-Botello L, Requena L. Sonographic appearance of primary cutaneous B-cell lymphomas. *Int J Dermatol.* 2021; 60(9): 1156-8. Letter. IF: 3.204; Q2

■ Research projects

Bellón Heredia T. Contrato Miguel Servet Categoría B (CES06/016). ISCIII. 2007-2025.

Managment centre: FIBHULP

Bellón Heredia T. Impacto de los inhibidores de calcineurina sobre linfocitos efectores citotóxicos en síndrome de Stevens-Johnson/ necrolisis epidérmica tóxica de análisis de il-15 como biomarcador (PI18/00718). ISCIII. 2019-2021.

Managment centre: FIBHULP

Sanz Minguela B. Contrato técnico de apoyo estabilizado (ECA07/008). ISCIII. 2008-2025.

Managment centre: FIBHULP

Bellón Heredia T. Creación de un centro de referencia para el estudio de los mecanismos implicados en las reacciones de hipersensibilidad a las membranas de hemodiálisis basadas en polysulfona (PI-3009). Nipro Euope NV. 2017-Ongoing.

Managment centre: FIBHULP

■ Patents and trademarks

Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of pyridazine[1',6':1,2]pyrido[3,4-b]indolinium as anti-inflammatory agents. P201331143, PCT/ES2014/070603; 2013 July 25.

Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of piridazine[3,2-b]benzimidazolium as anti-inflammatory agents. P201430411, PCT/ES2014/070603; 2013 July 25.





1
Introduction

2
Executive
Summary

3
Information
Groups
by Area

4
Associated
Clinicians



3.3.8 Immunomediante Gastrointestinal Diseases and other Digestive Pathologies Group

Publications: 18

Q1: 6

COMPOSITION

María Dolores Martín Arranz. Jefa de Sección de Aparato Digestivo. Hospital Universitario La Paz. Profesora Asociada. Unidad Autónoma de Madrid

Laura García Ramírez. Investigadora Predoctoral. FIBHULP

Eduardo Martín Arranz. Facultativo Especialista de Área en Aparato Digestivo. Hospital Universitario La Paz

Jesús Noci Belda. Enfermero. Hospital Universitario La Paz

Joaquín Poza Cordón. Facultativo Especialista de Área en Aparato Digestivo. Hospital Universitario La Paz

José Luis Rueda García. Facultativo Especialista de Área en Aparato Digestivo. Hospital Universitario La Paz

María Sánchez Azofra. Facultativo Especialista de Área en Aparato Digestivo. Hospital Universitario La Paz

Cristina Julia Suárez Ferrer. Facultativo Especialista de Área en Aparato Digestivo. Hospital Universitario La Paz

Tamara Verges Martínez-Meco. Investigadora Predoctoral. FIBHULP

STRATEGIC OBJECTIVE

Our work focuses on diseases of the Digestive System with special dedication to Inflammatory Bowel Disease (IBD) and other immune-mediated diseases.

The group is formed by gastroenterologists, biologists, pharmacists and nurses; all of them are part of a multidisciplinary working group. In addition to promoting our own research projects in our area, we participate in numerous clinical trials of molecules in development.

Our objectives are to optimize existing treatments, promote measures to improve the quality of life and translational research in search

of precision medicine, incorporating new technologies to the management of our patients.

RESEARCH LINES

- Correlation of drug levels with therapeutic response
- Intestinal ultrasound
- Dysplasia detection techniques in IBD
- Hypercoagulability studies in IBD
- Immunological basis of inflammatory bowel disease: changes in cellular and inflammatory mediator expression with different therapies

RESEARCH ACTIVITY

■ Doctoral theses


Master Theses

Marroquin Castillo C. Estudio retrospectivo de la enfermedad inflamatoria intestinal en el embarazo[disertation]. Madrid: UAM: 2021(01/06/2021).

Director: Martín Arranz MD.

■ Publications

- Chaparro M, Garre A, Mesonero F, Rodríguez C, Barreiro-de Acosta M, Martínez-Cadilla J, Arroyo MT, Mancenido N, Sierra-Ausin M, Vera-Mendoza I, Casanova MJ, Nos P, González-Munoz C, Martínez T, Bosca-Watts M, Calafat M, Busquets D, Girona E, Llao J, Martín-Arranz MD, Piqueras M, Ramos L, Suris G, Bermejo F, Carbajo AY, Casas-Deza D, Fernández-Clotet A, García MJ, Ginard D, Gutiérrez-Casbas A, Hernández L, Lucendo AJ, Márquez L, Merino-Ochoa O, Rancel FJ, Taxonera C, Sanromán AL, Rubio S, Domenech E, Gisbert JP. Tofacitinib in ulcerative colitis: Real-world evidence from the ENEIDA registry. *J Crohns Colitis.* 2021; 15(1): 35-42. Article. IF: 10.02; Q1
- Chaparro M, Garre A, Ortiz AN, Palomares MTDL, Rodríguez C, Riestra S, Vela M, Benítez JM, Salgado EF, Rodríguez ES, Hernández V, Ferreiro-Iglesias R, Díaz AP, Barrio J, Huguet JM, Sicilia B, Martín-Arranz MD, Calvet X, Ginard D, Alonso-Abreu I, Fernández-Salazar L, Trastoy PV, Rivero M, Vera-Mendoza I, Vega P, Navarro P, Sierra M, Cabriada JL, Aguas M, Vicente R, Navarro-Llavat M, Echarri A, Gomollón F, del Río EG, Pínero C, Casanova MJ, Spicakova K, de Zarate JO, Cortes ET, Gutiérrez A, Alonso-Galán H, Hernández-Martínez A, Marrero JM, Poyatos RL, Calafat M, Romero LM, Robledo P, Bosch O, Jiménez N, Comas ME, Duque JM, Coronel AMF, Sampedro MJ, Abizanda ES, Martínez BH, Pozzati L, Rosaenz HF, Suarez BC, Serrano PL, Lucendo AJ, Vicente MM, Bermejo F, Palanca JJR, Mena-chó M, Carmona A, Camargo R, Alsina ST, Maroto N, de la Puerta JN, Castro E, Marín-Jiménez I, Botella B, Sapina A, Cruz N, Forcelledo JLF, Bouhmidí A, Castano-Milla C, Opio V, Nicolás I, Kutz M, Bechiarelli AA, Gordillo J, Ber Y, Domínguez YT, Duran MTN, Mondéjar SR, Martínez-Cerezo FJ, Kolle L, Sabat M, Ledezma C, Iyo E, Roncero O, Irisarri R, Lluís L, Gómez IB, Zapata EM, Alcalá MJ, Pascual CM, Montealegre M, Mata L, Monrobel A, Camba AH, Hernández L, Tejada M, Mir A, Galve ML, Soler M, Hervías D, Gómez-Valero JA, Barreiro-de Acosta M, Rodríguez-Artalejo F, García-Esquinas E, Gisbert JP. Incidence, clinical characteristics and management of inflammatory bowel disease in Spain: large-scale epidemiological study. *J Clin Med.* 2021; 10(13): 2885. Article. IF: 4.964; Q2
- de las Casas SG, Álvarez-Gallego M, Martínez JAG, Alcolea NG, Serrano CB, Jiménez AU, Arranz MDM, Martín JLM, Migueláñez IP. Management of perianal fistula in inflammatory bowel disease: identification of prognostic factors associated with surgery. *Langenbeck Arch Surg.* 2021; 406(4): 1181-8. Article. IF: 2.895; Q2
- Ferrer CS, Cerdón JP, Anguita OC, Delgado PM, García JLR, Arranz EM, Azofra MS, Belda JN, Ramírez LG, Martín-Arranz MD. Prognostic value of ultrasound activity and parietal healing in patients with Crohn's disease. *Rev Esp Enferm Dig.* 2021; 113(7): 494-9. Article. IF: 2.389; Q4
- Ferrer CS, Robles TP, Martín-Arranz MD. Adherence to intravenous biological treatment in inflammatory bowel disease patients during the COVID-19 pandemic. *Rev Esp Enferm Dig.* 2021; 113(2): 154. Letter. IF: 2.389; Q4
- García JLR, Suárez-Ferrer C, Cerdón JP, Martín-Arranz E, Azofra MS, Ramírez LG, Noci J, Martín-Arranz MD. Doppler activity and ultrasonographic detection of intra-abdominal fistulas are predictors of surgery in Crohn's disease. *Digest Dis.* 2021; 39(3): 204-10. Article. IF: 3.421; Q3
- García MJ, Rivero M, Miranda-Bautista J, Bastón-Rey I, Mesonero F, Leo-Carnerero E, Casas-Deza D, Fernández CC, Martín-Cardona A, El Hajra I, Hernández-Aretxabaleta N, Pérez-Martínez I, Fuentes-Valenzuela E, Jiménez N, de Celix CR, Gutiérrez A, Ferrer CS, Huguet JM, Fernández-Clotet A, González-Vivo M, Del Val B, Castro-Poceiro J, Melcarne L, Dueñas C, Izquierdo M, Monfort D, Bouhmidí A, De la Piscina PR, Romero E, Molina G, Zorrilla J, Calvino-Suarez C, Sánchez E, Núñez A, Sierra O, Castro B, Zabana Y, González-Partida I, De la Maza S, Castano A, Najera-Munoz R, Sánchez-Guillen L, Castro MR, Rueda JL, Benítez JM, Delgado-Guillena P, Tar-




1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

dillo C, Pena E, Frago-Larramona S, Rodríguez-Grau MC, Plaza R, Pérez-Galindo P, Martínez-Cadilla J, Menchen L, Barreiro-De Acosta M, Sánchez-Aldehuelo R, De la Cruz MD, Lamuela LJ, Marín I, Nieto-García L, López-San Román A, Herrera JM, Chaparro M, Gisbert JP. Impact of biological agents on postsurgical complications in inflammatory bowel disease: a multicentre study of GETECCU. *J Clin Med.* 2021; 10(19): 4402. Article. IF: 4.964; Q2

- Gómez A, Pato ML, Bujanda L, Sala N, Companioni O, Cosme A, Tufano M, Hanly DJ, García N, Sanz-Anquela JM, Gisbert JP, López C, Elizalde JI, Cuatrecasas M, Andreu V, Paules MJ, Martín-Arranz MD, Ortega L, Poves E, Barrio J, Torres MA, Muñoz G, Ferrández A, Ramirez-Lazaro MJ, Lario S, González CA, Esteller M, Berdasco M. Follow-up study confirms the presence of gastric cancer dna methylation hallmarks in high-risk precursor lesions. *Cancers (Basel).* 2021; 13(11): 2760. Article. IF: 6.575; Q2
- Guijarro LG, Cano-Martínez D, Toledo-Lobo MV, Salinas PS, Chaparro M, Gómez-Lahoz AM, Zoullas S, Rodríguez-Torres R, Roman ID, Monasor LS, Ruiz-Llorente L, Boyano-Adán MD, Guerra I, Iborra M, Cabriada JL, Bujanda L, Taxonera C, García-Sánchez V, Marín-Jiéñez I, Barreiro-de Acosta M, Vera I, Martín-Arranz MD, Mesonero F, Sempere L, Gomollon F, Hinojosa J, Álvarez-Mon M, Gisbert JP, Ortega MA, Hernández-Breijo B. Relationship between IGF-1 and body weight in inflammatory bowel diseases: Cellular and molecular mechanisms involved. *Biomed Pharmacother.* 2021; 144: 112239. Article. IF: 7.419; D1
- Oliveira-Martín A, Yebra-Carmona J, Amaral-González C, Tejedor M, Eiras P, Hernández-Pérez M, Suárez-Cabredo C, Spigarelli-de Rabago I, Suárez-Ferrer C, Morales-Arreaez D, Chico I, Diaz-Flores F, Rodríguez R, Llorente S, Molina-Pérez E, de Aguilar MNHG. Retrieval and treatment of patients with primary biliary cholangitis who are lost in the health system. *Rev Esp Enferm Dig.* 2021; 113(11): 776-9. Article. IF: 2.389; Q4
- Ramos JL, Ferrer CS, Córdón JP, Azofra MS, García JLR, Arranz EM, Carmona JY, García IA, Arranz MDM. Optimization of azathioprine dose in combined treatment with anti-TNF-alpha in inflammatory bowel disease. *Gastroent Hepat-Barc.* 2021; 44(5): 337-45. Article. IF: 5.867; Q2
- Ripolles T, Poza J, Ferrer CS, Martínez-Pérez MJ, Martín-Algibez A, Páez BD. Evaluation of Crohn's disease activity: development of an ultrasound score in a multicenter study. *Inflamm Bowel Dis.* 2021; 27(1): 145-54. Article. IF: 7.29; Q1

- Roig CA, Córdón JP, Gallego MA, Pastrán LG. Ileal endometriosis in a patient with Crohn's disease: a diagnostic challenge. *Rev Esp Enferm Dig.* 2021; 113(12): 847. Letter. IF: 2.389; Q4
- Sainz E, Zabana Y, Miguel I, Fernández-Clotet A, Beltran B, Núñez L, García MJ, Martín-Arranz MD, Iglesias E, Canete F, Gutiérrez A, Piqueras M, Pérez-Martínez I, Bujanda L, Rodríguez-Lago I, Casanova MJ, Navarro P, Vicente R, Merino O, Algaba A, Rodríguez C, Huguet JM, Fernández-Baneres F, Domenech E, Esteve M. Clinical features, therapeutic requirements and evolution of patients with Crohn's disease and upper gastrointestinal involvement (CROHNEX study). *Aliment Pharm Ther.* 2021; 54(8): 1041-51. Article. IF: 9.524; D1
- Sánchez-Azofra M, Fernández I, García-Buey ML, Domínguez-Domínguez L, Fernández-Rodríguez CM, Mancebo A, Bonet L, Ryan P, Gea F, Díaz-Sánchez A, García-Mayor M, Martín-Carbonero L, Castillo P, Manzano ML, González-Moreno L, Pulido F, Gutiérrez ML, Moreno JM, García-Amengual IM, Cuevas G, Guerrero A, Rivero-Fernández M, Portales ME, Montes ML, Olveira A. Hepatocellular carcinoma risk in hepatitis C stage-3 fibrosis after sustained virological response with direct-acting antivirals. *Liver Int.* 2021; 41(12): 2885-91. Article. IF: 8.754; Q1
- Shephard JLV, Rodríguez CP, Ferrer CS, López DP, Criado AB, López-Granados E, García-Morato MB. Colitis expands the phenotype of PAAND patients: new case report and review of the literature. *Rheumatology.* 2021; 60(9): E316-7. Letter. IF: 7.046; Q1
- Soto YZ, Ferrer CS, Cordon JP, Arranz EM, Anguita OC, García JLR, Azofra MS, Ramírez LG, Arranz MDM. Is the degree of i2a recurrence in Crohn's disease secondary to ischemic phenomena? *Rev Esp Enferm Dig.* 2021; 113(4): 246-50. Article. IF: 2.389; Q4
- Tello ED, Suárez JA, Catalán EB, Maldonado CB, Manso MCH, Morales AJ, Marín-Jiménez I, Martín-Arranz MD, García-Merino A, Etesam JP, Rodríguez-Sagrado MA, de Salazar JRG, Martín ET, Salgado-Boquete L. Multidisciplinary management of the adverse effects of apremilast. *Actas Dermosifiliogr.* 2021; 112(2): 134-41. Article. Not Indexed

■ Research projects

Martín Arranz MD. Efecto terapeutico de la administración colonoscópica de

células madre mesenquimales derivadas de tejido adiposo humano de diferentes donantes (HASC) en un modelo de colitis de rata por enema de TNBS. *Abbvie Spain S.L.U.* 2010-2025.

Managment centre: FIBHULP

Martín Arranz MD. Efecto terapeutico de la administración colonoscópica de células madre mesenquimales derivadas de tejido adiposo humano de diferentes donantes (HASC) en un modelo de colitis de rata por enema de TNBS. *Abbvie Spain S.L.U.* 2021-2021.

Managment centre: FIBHULP

■ Clinical trials

Martín Arranz, E. Ensayo multicéntrico fase II con tratamiento de 54semanas, aleatorizado, doble-ciego, con grupos paralelos, controlado con placebo, para evaluar la eficacia y seguridad de brazikumab en pacientes con colitis ulcerosa activa de oederada agrave (expedition lead-in).

Type: Clinical Trials, phase II.

HULP code: 5902 D5272C00001.

Sponsored by: Astrazeneca Ab.

Signed date: 22/08/2021

Martín Arranz, MD. Ensayo clínico multicéntrico de fase Ib/IIa (prueba de concepto)aleatorizado, con doble ciego y controlado con placebo para evaluar la seguridad, farmacocinética y eficacia del tratamiento oral con ost-122 en pacientes con colitis ulcerosa de moderada a severa.

Type: Clinical Trials, phase I.

HULP code: Appendix 1 5473.

Sponsored by: Oncostellae S.L.

Signed date: 22/06/2021

Martín Arranz, MD. Ensayo de extensión abierta a largo plazo con brazikumab en pacientes con enfermedad de crohn activa de moderada a grave (intrepid ole).

Type: Clinical Trials, phase III.

HULP code: 5906 D5271C00002.

Sponsored by: Astrazeneca Farmaceutica Spain, S.A.

Signed date: 13/10/2021

Martín Arranz, MD. Ensayo de extensión de seguridad abierto a largo plazo, fase II con brazikumab en pacientes con colitis ulcerosa activa de moderada a grave (expedition ole).

Type: Clinical Trials, phase II.

HULP code: 5903 D5272C00002.

Sponsored by: Astrazeneca Farmaceutica Spain, S.A.

Signed date: 13/10/2021

Martín Arranz, MD. Ensayo fase IIb/III, multicéntrico, aleatorizado, dobleciego, controlado con placebo y fármaco activo, con gruposparalelos e ininterrumpido de 52 semanas de duración para evaluar laeficacia y la seguridad de brazikumab en participantes conenfermedad de crohn activa de moderada a grave. (intrepid lead-in).

Type: Clinical Trials, phase III.

HULP code: 5905 D5271C00001.

Sponsored by: Astrazeneca Ab.


Signed date: 22/08/2021

Martín Arranz, MD. Estudio aleatorizado, doble ciego, controlado con placebo para evaluar la seguridad y pacientes con Enfermedad de Crohn (EC) activa moderada a grave.

Type: Clinical Trials, phase II.

HULP code: 5994 M20-371.

Sponsored by: Abbvie Deutschland GmbH & Co. Kg.



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Signed date: 11/11/2021

Martín Arranz, MD. Estudio aleatorizado, doble ciego, controlado con placebo, de 52 semanas de duración para evaluar la eficacia y la seguridad de etrasimod en sujetos con colitis ulcerosa moderadamente activa.

Type: Clinical Trials, phase II.

HULP code: 5695 APD334-210.

Sponsored by: Arena Pharmaceuticals Inc.

Signed date: 29/01/2021

Martín Arranz, MD. Estudio de extensión abierto para evaluar etrasimod cuando se administra a sujetos con colitis ulcerosa activa moderada o grave.

Type: Clinical Trials, phase III.

HULP code: Appendix 2 5368.

Sponsored by: Arena Pharmaceuticals Inc.

Signed date: 29/11/2021

Martín Arranz, MD. Estudio de fase 2b, multicéntrico, aleatorizado, doble ciego, controlado con placebo y de varias dosis para evaluar la eficacia, seguridad y farmacocinética de pf 06480605 en participantes adultos con colitis ulcerosa de moderada a severa.

Type: Clinical Trials, phase II.

HULP code: Appendix 1 5507.

Sponsored by: Pfizer Inc.

Signed date: 09/03/2021

Martín Arranz, MD. Estudio de fase 3, de extensión de seguridad a largo plazo de shp647 en sujetos con colitis ulcerosa de moderada a grave (aida).

Type: Clinical Trials, phase III.

HULP code: Appendix 3 4965 SHP647-304.

Sponsored by: Shire Human Genetic Therapies, Inc.

Signed date: 06/07/2021

Martín Arranz, MD. Estudio de inducción multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de risankizumab en pacientes con colitis ulcerosa activa moderada o grave sin respuesta al tratamiento biológico previo.

Type: Clinical Trials, phase III.

HULP code: Appendix 2 5058 M16-067.

Sponsored by: Abbvie Spain, S.L.U.

Signed date: 21/01/2021

Martín Arranz, MD. Estudio fase 3, multicéntrico, aleatorizado, con enmascaramiento para los evaluadores de la eficacia de risankizumab en comparación con ustekinumab para el tratamiento de sujetos adultos con enfermedad de crohn de moderada a grave sin respuesta al tratamiento con terapia anti-tnf.

Type: Clinical Trials, phase III.

HULP code: Appendix 1 5658.

Sponsored by: Abbvie Deutschland Gmbh & Co. Kg.

Signed date: 01/12/2021

Martín Arranz, MD. Estudio multicéntrico aleatorizado, doble ciego y controlado con placebo, con tratamiento de mantenimiento durante 52 semanas y una extensión abierta para evaluar la eficacia y la seguridad de Risankizumab en sujetos con Colitis ulcerosa que respondan al tratamiento de inducción en los estudios M16-067 o M16-065.

Type: Clinical Trials, phase III.

HULP code: Appendix 2 5057 M16-066.

Sponsored by: Abbvie Deutschland Gmbh.

Signed date: 25/01/2021

Martín Arranz, MD. Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo para investigar la eficacia y la seguridad de abbv-323 en pacientes con colitis ulcerosa moderada o grave sin respuesta al tratamiento previo.

Type: Clinical Trials, phase II.

HULP code: Appendix 3 5246 M15-722.

Sponsored by: Abbvie Deutschland Gmbh & Co. Kg.

Signed date: 19/02/2021

Martín Arranz, MD. Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo para investigar la eficacia y la seguridad de abbv-323 en pacientes con colitis ulcerosa moderada o grave sin respuesta al tratamiento previo.

Type: Clinical Trials, phase II.

HULP code: Appendix 4 5246.

Sponsored by: Abbvie Deutschland Gmbh & Co. Kg.

Signed date: 22/06/2021

Martín Arranz, MD. Estudio multicéntrico, aleatorizado, doble ciego y de grupos paralelos para evaluar la eficacia y seguridad del etrasimod por vía oral como tratamiento de inducción y mantenimiento para la enfermedad de crohn activa de moderada a grave.

Type: Clinical Trials, phase III.

HULP code: 5808 APD334-202EU.

Sponsored by: Arena Pharmaceuticals Inc.

Signed date: 07/10/2021

Martín Arranz, MD. Estudio nacional, de seguimiento postcomercialización, para evaluar en la práctica real la eficacia y seguridad de la granulocitoaféresis y su impacto en la calidad de vida en pacientes en enfermedad inflamatoria intestinal (estudio grace).

Type: Estudio Producto Sanitario.

HULP code: PI-4918 GRACE.

Sponsored by: Adacyte Therapeutic Sl.

Signed date: 22/10/2021

Martín Arranz, MD. Estudio observacional, prospectivo y multicéntrico para evaluar la calidad de vida relacionada con la salud en pacientes con enfermedad de crohn y fistulas perianales complejas antes y después del tratamiento: estudio calypso.

Type: Estudios, phase EPA-SP.

HULP code: PI-4683 TAK-TNF-2019-01/MACS-.

Sponsored by: Takeda Farmaceutica España, S.A. (Antes - Nycomed Pharma S.A.).

Signed date: 16/04/2021


Sánchez Azofra, M. Análisis de la efectividad y seguridad del switch de adalimumab original a biosimilar en los pacientes con enfermedad inflamatoria intestinal.

Type: Estudios, phase EPA-OD.

HULP code: PI-4840 GIS-2021-ADA-SWITCH.

Sponsored by: Perez Gisbert, Javier.

Signed date: 29/06/2021



Large System Pathologies Area


Francisco García Río

Documents: 354

Originals: 262

D1: 52 Q1: 152

- 3.4.1 Internal Medicine and Systemic Diseases Group
- 3.4.2 Organic Dysfunction and Failure in the Aggression Group
- 3.4.3 Respiratory Diseases Group
- 3.4.4 Regulation of Gene Expression and by Hypoxia Group
- 3.4.5 Nephrology Group
- 3.4.6 Aging and Fragility in the Elderly Group
- 3.4.7 Diagnosis and Treatment of Allergic Diseases Group
- 3.4.8 Gynecologic Oncology Group
- 3.4.9 Patient Blood Management Group
- 3.4.10 Urology Group
- 3.4.11 Health Care Nurses Research Group
- 3.4.12 Emergency and Critical Pathology Group
- 3.4.13 Hospital Pharmacy Group
- 3.4.14 Translational Hepatology Group
- 3.4.15 Fragility and Healthy Aging Research Group (HUG)




1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



Large System Pathologies Area

3.4




- 1 Introduction
- 2 Executive Summary
- 3 Information Groups by Area
- 4 Associated Clinicians



Strategic Objectives	Development forecast for the coming years
<p>Includes 16 research groups that focus their interest on the study of pathogenic mechanisms and therapeutic options in some of the most prevalent diseases in our environment: respiratory, allergological, renal, digestive, gynaecological, and ophthalmological and paediatric, both in stable phase and at different levels of severity. In addition, we maintain interest in their involvement in the different phases of development, analyzing both the neonatal phase and old age.</p>	<p>Redefinition of the area with a more transversal character. Although this proposal requires a greater elaboration and consensus of all the groups in the area, the reformulation of the area is proposed as a new one focused, for example, on inflammation and hypoxia.</p>
	<p>Incorporation of related groups from other areas (immunorheumatology, hepatology, among others) and consolidation of some emerging groups.</p>
	<p>To ensure that 50% of the publications are in the first quartile of each thematic area.</p>
	<p>To promote intramural collaborations between groups.</p>

Actions

- Conduct seminars and coordination meetings among groups of different areas.
- Promote work and synergies with other research groups of the institute with a deeper trajectory.
- Improve the annual number of publications in the first quartile.
- Promote work and synergies with other research groups of the institute with a deeper trajectory.




3.4.1 Internal Medicine and Systemic Diseases Group

Publications: 34

Q1: 16

COMPOSITION



Francisco Arnalich Fernández. Jefe Servicio de Medicina Interna. Hospital Universitario La Paz. Catedrático. Facultad de Medicina. Universidad Autónoma de Madrid

José Luis Cedillo Mireles. Investigador Predoctoral (contrato FPU). Universidad Autónoma de Madrid

María del Carmen Fernández Capitán. Jefa de Sección de Medicina Interna. Hospital Universitario La Paz

Carmen Montiel López. Catedrática. Facultad de Medicina. Universidad Autónoma de Madrid

María Angustias Quesada Simón. Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz. Profesora Honoraria. Universidad Autónoma de Madrid

Juan José Ríos Blanco. Subdirector Médico. Hospital Universitario La Paz

STRATEGIC OBJECTIVE

In the setting of the systemic response frequently found in patients attended in Internal Medicine wards, our group has studied some regulatory mechanisms of the innate immune response in patients with sepsis and other inflammatory states such as acute coronary syndromes (ACS), cystic fibrosis and cancer.

The first line of our research is the link between the parasympathetic and innate immune systems, that is the molecular mechanisms by which acetylcholine can influence the immune system via the "cholinergic anti-inflammatory pathway".

This pathway is mediated by the vagus nerve which releases acetylcholine to interact with the $\alpha 7$ subunit of the nicotinic acetylcholine receptor ($\alpha 7nAChR$).


We firstly reported that the neuronal $\alpha 7$ nicotinic receptor subunit gene (CHRNA7) is partially duplicated in the human genome forming a hybrid gene (CHRFAM7A) with the novel FAM7A gene, and provided experimental data showing that $\text{dup}\alpha 7$ could modulate $\alpha 7$ receptor-mediated synaptic transmission and cholinergic anti-inflammatory response (J Biol Chem 2011). The Toll-like receptor (TLR) plays an important role in the induction of the hyperinflammatory response and tissue injury in sepsis. We found that the $\alpha 7$ gene ex-

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



1
Introduction

2
Executive
Summary

3
Information
Groups
by Area

4
Associated
Clinicians

pression level in septic patients' peripheral blood mononuclear cells (PBMC) is a clinically relevant marker to assess the magnitude of the patient's inflammatory state, disease severity, and clinical outcome (J Infect Dis 2015).

Another exciting line of our research is the involvement of the $\alpha 7$ -nicotinic receptor and its endogenous modulator dup $\alpha 7$ in human smoking-related tumors, and particularly their involvement in tobacco carcinogen-induced tumor development and chemotherapy resistance. This topic has attracted a grant from the Ministerio de Economía y Competitividad from 2014-2017. Besides, professor Jaime Renart who works in our team group, is doing new research on the molecular mechanisms of podoplanin, a type I transmembrane mucin widely known as a marker for lymphatic endothelial cells that has a critical role during development of the heart, lungs and lymphatic endothelial system. The expression of podoplanin is significantly enhanced during tissue remodeling processes and in several types of human cancer, including squamous cell carcinomas.

RESEARCH LINES

- Molecular mechanisms involved in the innate immune response.
- Link between the parasympathetic and innate immune systems.

Collaborative research line:

- Adaptive immune response in human immunodeficiency virus (HIV) infection.
- Multicentric group: RIETE group (Registro Español de Enfermedad Trombo-Embólica).
- Molecular mechanisms of podoplanin during tissue remodeling processes and in several types of human cancer.
- Mechanisms and clinical features of systemic autoimmune diseases.
- Lines of study framed in basic research projects:
- Study of the pathophysiological role of nicotinic $\alpha 7$ and dup- $\alpha 7$ receptors expressed in human macrophages, neurons and lung carcinoma cells.
- Identification of signalling pathways connecting nicotinic $\alpha 7$ receptors and negative regulators of TLR-mediated inflammation in human macrophages.

RESEARCH ACTIVITY

■ Doctoral theses

Alonso López E. Vesículas extracelulares y Micro-ARN como biomarcadores de daño, reparación cerebral y recuperación en el infarto cerebral agudo [dissertation]. Madrid: UAM: 2021(24/06/2021).

Directors: Gutiérrez Fernández M, Fuentes Gimeno B.


■ Publications

- Arévalo-Lorido JC, Carretero-Gómez J, Gómez-Huelgas R, Llacer P, Manzano L, Simon MAQ, Villanueva BR, Franco AG, Cepeda JM, Pérez-Barquero MM. Comorbidities and their implications in patients with and without type 2 diabetes mellitus and heart failure with preserved ejection fraction. Findings from the rica registry. *Int J Clin Pract.* 2021;75(1):-e13661. Article. IF: 3,149; Q2

- Berenguer J, Borobia AM, Ryan P, Rodríguez-Bano J, Bellón JM, Jarrín I, Carratala J, Pachón J, Carcas AJ, Yllescas M, Arribas JR. Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score. *Thorax.* 2021; 76(9): 920-29. Article. IF: 9.102; Q1
- Blondon M, Jiménez D, Robert-Ebadi H, Del Toro J, López-Jiménez L, Falga C, Skride A, Font L, Vázquez FJ, Bounameaux H, Monreal M. Comparative clinical prognosis of massive and non-massive pulmonary embolism: A registry-based cohort study. *J Thromb Haemost.* 2021; 19(2): 408-16. Article. IF: 16.036; D1
- Brochado O, Martínez I, Berenguer J, Medrano L, González-García J, Jiménez-Sousa MA, Carrero A, Hontañón V, Navarro J, Guardiola JM, Fernández-Rodríguez A, Resino S. HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients. *J Biomed Sci.* 2021; 28(1): 23. Article. IF: 12.771; D1
- Calderón-Parra J, Muino-Míguez A, Bendala-

- Estrada AD, Ramos-Martínez A, Munez-Rubio E, Carracedo EF, Montes JT, Rubio-Rivas M, Arnalich-Fernández F, Beato Pérez JL, Brunen JMG, Beamonte ED, Fontan PMP, Carmona MD, Martínez RFM, García AG, Mosteiro CS, de Almeida CT, Moraleja JG, Deodati F, Escalante MDM, Tomas MLA, Huelgas RG, Rojo JMC, Núñez-Cortés JM. Inappropriate antibiotic use in the COVID-19 era: Factors associated with inappropriate prescribing and secondary complications. Analysis of the registry SEMI-COVID. *Plos One.* 2021; 16(5): e0251340. Article. IF: 3.752; Q2
- Camporese G, Simioni P, Di Micco P, Fernández-Capitan C, Rivas A, Font C, Sahuquillo JC, Villares P, Prandoni P, Monreal M. Edoxaban for the long-term therapy of venous thromboembolism: should the criteria for dose reduction be revised? *CTS Clin Transl Sci.* 2021; 14(1): 335-42. Article. IF: 4.438; Q2
- Carrero A, Berenguer J, Hontañón V, Guardiola JM, Navarro J, von Wichmann M, Téllez MJ, Quereda C, Santos I, Sanz J, Galindo MJ, Hernández-Quero J, Jiménez-Sousa MA, Pérez-La-

- torre L, Bellón JM, Resino S, Esteban H, Martínez E, González-García J. Effects of hepatitis C virus (HCV) eradication on bone mineral density in human immunodeficiency virus/HCV-coinfected patients. *Clin Infect Dis.* 2021; 73(7): E2026-33. Article. IF: 20.999; D1
- Demelo-Rodríguez P, Farfán-Sedano AI, Pedrajas JM, Llamas P, Sigüenza P, Jaras MJ, Quintana-Díaz M, Fernández-Capitan C, Bikdeli B, Jiménez D, Monreal M. Bleeding risk in hospitalized patients with COVID-19 receiving intermediate or therapeutic doses of thromboprophylaxis. *J Thromb Haemost.* 2021; 19(8): 1981-9. Article. IF: 16.036; D1
- Díaz-Simón R, Lalueza A, Lora-Tamayo J, Rubio-Rivas M, Mendo CL, Martínez MLT, Méndez CA, Fontán PMP, Cruz AF, Cabrera JLR, Rodríguez BC, Rubio AE, de Ávila VSR, García GMG, Osorio LC, González-Fernández M, Noya AG, Wittel MB, Fernández FA, Sempere VM, Artero A, Loureiro-Amigo J, Huelgas RG, Santos JMA, Lumbreras C. Clinical characteristics and risk factors of respiratory failure in a cohort of young



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

patients requiring hospital admission with sars-cov2 infection in Spain: results of the multicenter SEMI-COVID-19 Registry. *J Gen Intern Med.* 2021;36(10):3080-3087. Article. IF: 6,473; Q1

- Díez C, Del Romero-Raposo J, Micán R, López JC, Blanco JR, Calzado S, Samperiz G, Portilla J, García-Fraile LJ, Gutiérrez F, Gómez-Sirvent JL, Suárez-García I, Amador C, Novella M, Arribas JR, Moreno S, González-García J, Jarrin I, Berenguer J. COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study. *Hiv Med.* 2021;22(9):867-876. Article. IF: 3,094; Q3
- Estrada ADB, Parra JC, Carracedo EF, Míguez AM, Martínez AR, Rubio EM, Rubio-Rivas M, Agudo P, Fernández FA, Pérez VE, Martínez MLT, Vieitez AC, Fontan PMP, Bustamante M, Freire SJ, Oriol-Bermudez I, Artero A, Sierra JO, Manrique MA, Carrasco-Sánchez HFJ, Vento VC, García GMG, Cubero-Morais P, Casas-Rojo JM, Núñez-Cortes JM. Inadequate use of antibiotics in the covid-19 era: effectiveness of antibiotic therapy. *BMC Infect Dis.* 2021; 21(1): 1144. Article. IF: 3.67; Q3
- Expósito-Ruiz M, Arcelus JI, Caprini JA, López-Espada C, Bura-Riviere A, Amado C, Loring M, Mastroiacovo D, Monreal M. Timing and characteristics of venous thromboembolism after noncancer surgery. *J Vasc Surg Venous Lymphat Disord.* 2021; 9(4): 859-67. Article. IF: 4.19; Q1
- Fernández-Capitán C, Barba R, Díaz-Pedroche MD, Siguenza P, Demelo-Rodríguez P, Siniscalchi C, Pedrajas JM, Farfan-Sedano AI, Olivera PE, Gómez-Cuervo C, Llamas P, Villares P, Sánchez O, López-Reyes R, Catella J, Bikdeli B, Weinberg I, Tafur AJ, Jiménez D, Monreal M. Presenting characteristics, treatment patterns, and outcomes among patients with venous thromboembolism during hospitalization for COVID-19. *Semin Thromb Hemost.* 2021; 47(4): 351-61. Article. IF: 6.398; Q1
- García-Cervera C, Giner-Galván V, Wikman-Jorgensen P, Laureiro J, Rubio-Rivas M, Arena AG, Arnalich-Fernández F, Pérez JLB, Núñez JAV, Igual JJG, Díez-Manglano J, Bailón MM, Blanco MJG, Castro SJF, Lobo JA, Manzano L, Gamboa JOM, Pérez LA, Moraleja JG, Hernaiz RC, Alegria JG, Noya AG, Huelgas RG, Bermejo CL, Santos JMA. Estimation of admission d-dimer cut-off value to predict venous thrombotic events in hospitalized covid-19 patients: analysis of the SEMI-COVID-19 registry. *J Gen Intern Med.* 2021; 36(11): 3478-86. Article. IF: 6.473; Q1
- González MM, Gonzalo ES, López IC, Fernández FA, Pérez JLB, Monge DM, Núñez JAV, Fenoll RG, Fernández CS, Castro SJF, Bailon MM, Fraile

IP, Madrazo M, Fontan PMP, Gamboa JOM, García AG, Vieitez AC, Aizpuru EMF, Arostegui AA, Erdozain AC, Cilleros CM, Amigo JL, Epelde F, Bermejo CL, Santos JMA. The prognostic value of eosinophil recovery in covid-19: a multicentre, retrospective cohort study on patients hospitalized in Spanish hospitals. *J Clin Med.* 2021; 10(2): 305. Article. IF: 4.964; Q2

- Gutiérrez MDA, Rubio-Rivas M, Gómez CR, Sáez AM, de Pedro IP, Homs N, García BA, Carvajal CC, Fernández FA, Pérez JLB, Núñez JAV, Gimenez LL, Fernández CS, Bailon MM, de Almeida CT, Moraleja JG, García-Monge MD, Amezua CH, Montero MDF, Galván VG, Sánchez RG, Sáenz JC, Boixeda R, Rincón JMR, Huelgas RG. Autoimmune diseases and COVID-19 as risk factors for poor outcomes: Data on 13,940 hospitalized patients from the Spanish nationwide SEMI-COVID-19 registry. *J Clin Med.* 2021; 10(9): 1844. Article. IF: 4.964; Q2
- Gutiérrez-Gutiérrez B, del Toro MD, Borobia AM, Carcas A, Jarrín I, Yllescas M, Ryan P, Pachón J, Carratala J, Berenguer J, Arribas JR, Rodríguez-Bano J. Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study. *Lancet Infect Dis.* 2021; 21(6): 783-92. Article. IF: 71.421; D1
- Josa-Laorden C, Crestelo-Vieitez A, Andreu MDG, Rubio-Rivas M, Sánchez M, Samaniego NT, Fernández FA, Bermudez RI, Aizpuru EMF, Núñez JAV, Fontan PMP, Ballesteros JS, Castro SJF, Fernández MP, García AV, Rodríguez VN, Giner-Galván V, Sánchez FJC, Milian AH, Cobos-Siles M, Lecumberri JVN, García VH, Pérez MDP, Núñez-Cortes JM, Rojo JMC. Gender-based differences by age range in patients hospitalized with COVID-19: A Spanish observational cohort study. *J Clin Med.* 2021; 10(5): 899. Article. IF: 4.964; Q2
- Lora-Tamayo J, Maestro G, Lalueza A, Rubio-Rivas M, Paul GV, Fernández FA, Pérez JLB, Núñez JAV, Barrio ML, Bermejo CL. Early Lopinavir/ritonavir does not reduce mortality in COVID-19 patients: Results of a large multicenter study. *J Infection.* 2021; 82(6): 293-8. Letter. IF: 38.637; D1
- Marhuenda AR, Collada JM, Fernández FA. Yellow nails syndrome. *Rev Clin Esp.* 2021; 221(8): 491-2. Editorial Material. IF: 3.064; Q2
- Martínez-Lacalzada M, Viteri-Noel A, Manzano L, Fabregate M, Rubio-Rivas M, García SL, Arnalich-Fernández F, Beato-Pérez JL, Vargas-Núñez JA, Salvo-Manuel E, Espino-Álvarez AC, Freire-Castro SJ, Loureiro-Amigo J, Fontán PMP, Pina A, Suárez AMA, Silva-Asiain A, García-López

B, del Pino JL, Sanz-Canovas J, Chazarra-Pérez P, García-García GM, Núñez-Cortes JM, Casas-Rojo JM, Gómez-Huelgas R. Predicting critical illness on initial diagnosis of COVID-19 based on easily obtained clinical variables: development and validation of the PRIORITY model. *Clin Microbiol Infect.* 2021; 27(12): 1838-44. Article. IF: 13.31; D1

- Pérez-Latorre L, Berenguer J, Micán R, Montero M, Cifuentes C, Puig T, Sanz J, Ferrero OL, de la Fuente B, Rodríguez C, Reus S, Hernández-Queiro J, Gaspar G, Pérez-Martínez L, García C, Force L, Veloso S, De Miguel M, Jarrin I, González-García J. HIV/HBV coinfection: temporal trends and patient characteristics, Spain, 2002 to 2018. *Euro Surveill.* 2021; 26(25): 2000236. Article. IF: 21.286; D1
- Ramos-Martínez A, Parra-Ramírez LM, Morras I, Carnevali M, Jiménez-Ibáñez L, Rubio-Rivas M, Arnalich F, Beato JL, Monge D, Asin U, Suárez C, Freire SJ, Méndez-Bailón M, Perales I, Loureiro-Amigo J, Gómez-Belda AB, Pesqueira PM, Gómez-Huelgas R, Mella C, Díez-García LF, Fernández-Sola J, González-Ferrer R, Aroza M, Anton-Santos JM, Bermejo CL. Frequency, risk factors, and outcomes of hospital readmissions of COVID-19 patients. *Sci Rep-Uk.* 2021; 11(1): 13733. Article. IF: 4.996; Q2
- Ramos-Rincón JM, Buonaiuto V, Ricci M, Martín-Carmona J, Paredes-Ruiz D, Calderon-Moreno M, Rubio-Rivas M, Beato-Pérez JL, Arnalich-Fernández F, Monge-Monge D, Vargas-Núñez JA, Acebes-Repiso G, Méndez-Bailón M, Perales-Fraile I, García-García GM, Guisado-Vasco P, Abdelhady-Kishita A, Pascual-Pérez MDLR, Rodríguez-Fernández-Viagas C, Montano-Martínez A, López-Ruiz A, González-Juárez MJ, Pérez-García C, Casas-Rojo JM, Gómez-Huelgas R. Clinical characteristics and risk factors for mortality in very old patients hospitalized with COVID-19 in Spain. *J Gerontol A-Biol.* 2021; 76(3): E28-37. Article. IF: 6.591; Q1
- Ramos-Ruperto L, Busca-Arenzana C, Boto-de los Bueis A, Schlincker A, Arnalich-Fernández F, Robles-Marhuenda A. Cancer-associated retinopathy and treatment with intravenous immunoglobulin therapy. a seldom used approach? *Ocul Immunol Inflamm.* 2021; 29(2): 399-402. Letter. IF: 3.728; Q2
- Roy-Vallejo E, Purificación AS, Pena JDT, Moreno BS, Arnalich F, Blanco MJG, Miranda JL, Romero-Cabrera JL, Gil CRH, Bascuñana J, Rubio-Rivas M, Otero SP, Sempere VM, Rodríguez-Solis JB, Sánchez RG, del Pino JL, Noya AG, Navas-Alcantara MS, Rodríguez BC, Alcalá JN, Suárez-Lombrana

A, Soler JA, Gómez-Huelgas R, Casas-Rojo JM, Núñez-Cortes JM. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers withdrawal is associated with higher mortality in hospitalized patients with COVID-19. *J Clin Med.* 2021; 10(12): 2642. Article. IF: 4.964; Q2

- Rubio-Rivas M, Corbella X, Formiga F, Fernández EM, Escalante MDM, Fernández IB, Fernández FA, del Corral-Beamonte E, Lalueza A, Virto AP, Vallejo ER, Loureiro-Amigo J, Suárez AMA, Abadía-Otero J, de la Chica MN, González RE, Milián AH, Manrique MA, Encinar JCB, Noya AG, Ferrer RG, Aguilera MP, Sánchez RG, Núñez-Cortes JM, Casas-Rojo JM. Risk categories in COVID-19 based on degrees of inflammation: data on more than 17,000 patients from the Spanish SEMI-COVID-19 Registry. *J Clin Med.* 2021; 10(10): 2214. Article. IF: 4.964; Q2
- Sánchez-Purificación A, Castellano A, Gutiérrez B, Galvez M, Díaz B, Pérez T, Arnalich F. Reduction of agalsidase beta infusion time in patients with fabry disease: A case series report and suggested protocol. *Mol Genet Metab Rep.* 2021; 27: 100755. Letter. IF: 2.082; Q4
- Suárez-García I, Alejos B, Pérez-Eliás MJ, Iribarren JA, Hernando A, Ramírez M, Tasiais M, Pascual M, Jarrin I, Hernando V. How do women living with HIV experience menopause? Menopausal symptoms, anxiety and depression according to reproductive age in a multicenter cohort. *BMC Womens Health.* 2021; 21(1): 223. Article. IF: 2.742; Q3
- Suárez-García I, Perales-Fraile I, González-García A, Munoz-Blanco A, Manzano L, Fabregate MA, Díez-Manglano J, Aizpuru EF, Fernández FA, García AG, Gómez-Huelgas R, Ramos-Rincon JM. In-hospital mortality among immunosuppressed patients with COVID-19: Analysis from a national cohort in Spain. *Plos One.* 2021; 16(8): e0255524. Article. IF: 3.752; Q2
- Tong HY, Borobia AM, Quintana-Díaz M, Fabra S, González-Vinolis M, Fernández-Capitán C, Rodríguez-Davila MA, Lorenzo A, López-Parra AM, Ruiz-Gimenez N, Abad-Santos F, Suárez C, Madridano O, Gómez-Cerezo JF, Llamas P, Baeza-Richer C, Arroyo-Pardo E, Carcas AJ. Acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolism: a randomised clinical trial. *J Clin Med.* 2021; 10(13): 2949. Article. IF: 4.964; Q2
- Torres-Pena JD, Pérez-Belmonte LM, Fuentes-Jiménez F, Carmona MDL, Pérez-Martínez P, López-Miranda J, Sánchez FJC, Núñez JAV, Beaumont ED, Gamboa JOM, García AG, Moraleja JG, Troncoso AC, Martínez MLT, Montero MDD,

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



Ripol JMS, Sánchez RG, González DA, Boixeda R, Rodríguez BC, Ena J, García GMG, Esteve AV, Rincon JMR, Gómez-Huelgas R. Prior treatment with statins is associated with improved outcomes of patients with COVID-19: Data from the SEMI-COVID-19 Registry. *Drugs*. 2021; 81(6): 685-95. Article. IF: 11.431; D1

- Tung-Chen Y, Pizarro I, Rivera-Núñez MA, Martínez-Virto AM, Lorenzo-Hernández A, Sancho-Bueso T, Salgueiro G, Fernández-Capitán C. Sonographic evolution of the superficial vein thrombosis of the lower extremity. *J Ultrasound*. 2021; 24(3): 253-9. Article. Not Indexed
- Zhou ZE, Jardine MJ, Li Q, Neuen BL, Cannon CP, de Zeeuw D, Edwards R, Levin A, Mahaffey KW, Perkovic V, Neal B, Lindley RI. Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease results from the CRE-DENCE trial and meta-analysis. *Stroke*. 2021; 52(5): 1545-56. Article. IF: 10.17; D1

■ Research projects

Montiel López C, Arnalich Fernández F. Resistencia a quimioterapia y a terapia dirigida a EGFR inducida por consumo de tabaco a través de receptores nicotínicos en cáncer de pulmón no microcítico: estudio in vitro, in vivo y en pacientes. (SAF2017-82689-R). CM. 2018-2021.

Management centre: UAM

Ríos Blanco JJ. Estudio de hipertensión pulmonar en la cohorte de pacientes con infección VIH del Hospital La Paz. Glaxosmithkline S.A. 2010-Ongoing.

Management centre: FIBHULP

Ríos Blanco JJ. Estudio de la relación entre la rigidez arterial y la función endotelial en pacientes con hipertensión de bata blanca. Menarini Diagnósticos S. A. 2009-Ongoing.

Management centre: FIBHULP

Ríos Blanco JJ. Formación de personal investigador en colaboración con instituciones públicas y privadas. Varios. 2013-Ongoing.

Management centre: FIBHULP


■ Clinical trials

Fernández Capitán, MC. Tratamiento a largo plazo del tev asociado al cáncer: dosis reducida respecto a dosis completa de apixaban: estudio api-cat con apixaban en la trombosis del cáncer.

HULP code: 5443 P170604j.

Sponsored by: Assistance Publique Hopitaux De Paris.

Signed date: 12/10/2021



3.4.2 Organic Dysfunction and Failure in the Aggression Group

Publications: 27
Q1: 14

COMPOSITION



■ **Abelardo García de Lorenzo y Mateos.** Jefe de Servicio de Medicina Intensiva. Hospital Universitario La Paz. Profesor Titular. Facultad de Medicina. Universidad Autónoma de Madrid

José Luis Cedillo Mireles. Investigador Predoctoral (contrato FPU). Universidad Autónoma de Madrid

Jose Manuel Añon Elizalde. Jefe de Sección en Medicina Intensiva. Hospital Universitario La Paz

Alejandro Agrifoglio Rotaeché. Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz

María Antonia Arce Mendiburu. Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz

María José Asensio Martín. Jefe de Sección de Medicina Intensiva. Hospital Universitario La Paz

Lucía Cachafeiro Fuciños. Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz

Belén Civantos Martín. Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz

María Belén Estebáñez Montiel. Facultativo Especialista de Área en Medicina Intensiva. Coordinador de Tránsito. Hospital Universitario La Paz

Juan Carlos Figueira Iglesias. Jefe de Sección de Medicina Intensiva. Hospital Universitario La Paz

Eva Mercedes Flores Cabeza. Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz

Ricardo García Hernández. Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz

Mónica Hernández Bernal. Médico Adjunto Especialista en Unidad de Cuidados Intensivos. Hospital Universitario La Paz

Eva Herrero de Lucas. Facultativo Especialista de Área en Medicina Intensiva. Facultativo Especialista de Área en Medicina Intensiva

Jesús Javier Manzanares Gómez. Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz

Eva Perales Ferrera. Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz

Itziar Pozuelo Echegaray. Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz

Montserrat Aránzazu Rodríguez Aguirregaviria. Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario Infanta Leonor

Santos Manuel Sánchez Sánchez. Jefe de Sección de Medicina Intensiva. Hospital Universitario La Paz


Santiago Yus Teruel. Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

STRATEGIC OBJECTIVE

The global objective of the investigation team on DYSFUNCTION AND ORGAN FAILURE IN AGGRESSION is the optimization of the patient management in the really critical ill patients who can develop Organ Dysfunction or Organ Failure. Multiorgan Dysfunction & Multiorgan Failure Syndrome (MOF-MOD Syndrome) are correlated with bad prognostic and high mortality rates.

D-FMO Syndrome is correlated both with the disease severity and the therapeutic efforts. The therapeutic management of the patient must be early and directed to specific objectives.

Otherwise, the support measures must be directed to the specific situations (like sepsis, trauma...) and to the Organs or Systems in Dysfunction or Failure (coagulation, haemodynamic, respiratory or

renal...) Finally, the detection of D-FMO Syndrome employing not only single markers (clinic) but early and organ specific biomarkers (basic or advanced biochemical markers, molecular markers...) can bring a higher efficacy and better results

Finally, the detection of D-FMO Syndrome employing not only single markers (clinic) but early and organ specific biomarkers (basic or advanced biochemical markers, molecular markers...) can bring a higher efficacy and better results.

RESEARCH LINES

- Biomarkers
- Resuscitation income
- Therapeutic support

RESEARCH ACTIVITY


Publications

- Amer M, Kamel AM, Bawazeer M, Maghrabi K, Butt A, Dahhan T, Kseibi E, Khurshid SM, Abujazar M, Alghunaim R, Rabee M, Abualkhair M, Al-Janoubi A, AlFirm AT, Gajic O, Walkey AJ, Mosier JM, Zabolotskikh IB, Gavidia OY, Yus-Teruel S, Bernstein MA, Boman K, Kumar VK, Bansal V, Kashyap R. Clinical characteristics and outcomes of critically ill mechanically ventilated COVID-19 patients receiving interleukin-6 receptor antagonists and corticosteroid therapy: a preliminary report from a multinational registry. *Eur J Med Res.* 2021; 26(1): 117. Article. IF: 4.981; Q2
- Anón JM, Arellano MS, Pérez-Márquez M, Díaz-Alvarino C, Márquez-Alonso JA, Rodríguez-Peláez J, Nanwani-Nanwani K, Martín-Pellicer A, Civantos B, López-Fernández A, Seises I, García-Nerin J, Figueira JC, Casero H, Vejo J, Agrifoglio A, Cachafeiro L, Díaz-Almirón M, Villar J. The role of routine FIBERoptic bronchoscopy monitoring during percutaneous dilatational TRACHEostomy (FIBERTRACH): a study protocol for a randomized, controlled clinical trial. *Trials.* 2021; 22(1): 423. Article. IF: 2.728; Q4
- Anón JM, Villar J. Ten reasons why corticosteroid therapy reduces mortality in severe COVID-19. *Intens Care Med.* 2021; 47(3): 355-6. Letter. IF: 41.787; D1

- Augusto DE, Soba FM, de la Calle B, Blanco AP, Estebáñez B, Velasco J, Sánchez-Carretero MJ, Pont T, Villares JMP, Masnou N, Delgado MCM, Coll E, Perojo D, Urunuela D, Dominguez-Gil B. Cuidados intensivos orientados a la donación de órganos. Recomendaciones ONT-SEMICYUC. *Med Intensiva.* 2021; 45(4): 234-42. Article. IF: 2.799; Q3
- Avidan A, Sprung CL, Schefold JC, Ricou B, Hartog CS, Nates JL, Jaschinski U, Lobo SM, Joynt GM, Lesieur O, Weiss M, Antonelli M, Bulow HH, Bocci MG, Robertsén A, Anstey MH, Estebáñez-Montiel B, Lautrette A, Gruber A, Estella A, Mullick S, Sreedharan R, Michalsen A, Feldman C, Tislijar K, Posch M, Ovu S, Tamowicz B, Demoule A, Ganz FD, Pargger H, Noto A, Metnitz P, Zubeck L, de la Guardia V, Danbury CM, Szucs O, Protti A, Filipe M, Simpson SQ, Green C, Giannini AM, Soliman IW, Piras C, Caser EB, Hache-Marliere M, Mentzelopoulos SD. variations in end-of-life practices in intensive care units worldwide (Ethicus-2): a prospective observational study. *Lancet Respir Med.* 2021; 9(10): 1101-10. Article. IF: 102.642; D1
- Balandín B, Ballesteros D, de Luna RR, López-Vergara L, Pintado V, Sancho-González M, Soriano-Cuesta C, Pérez-Pedrero MJ, Asensio-Martín MJ, Fernández-Simon I, Rodríguez-Serrano D, Silva A, Chicot M, Iranzo R, Martínez-Sagasti F, Royuela A. Multicenter study of ceftolozane/ta-

- zobactam for treatment of Pseudomonas aeruginosa infections in critically ill patients. *Int J Antimicrob Ag.* 2021; 57(3): 106270. Article. IF: 15441; D1
- Berenguer J, Borobia AM, Ryan P, Rodríguez-Bano J, Bellón JM, Jarrín I, Carratala J, Pachón J, Carcas AJ, Yllescas M, Arribas JR. Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score. *Thorax.* 2021; 76(9): 920-9. Article. IF: 9.102; Q1
- Bier-Laning C, Cramer JD, Roy S, Palmieri PA, Amin A, Anon JM, Bonilla-Asalde CA, Bradley PJ, Chaturvedi P, Cognetti DM, Dias F, Di Stadio A, Fagan JJ, Feller-Kopman DJ, Hao SP, Kim KH, Koivunen P, Loh WS, Mansour J, Naunheim MR, Schultz MJ, Shang Y, Sirjani DB, St John MA, Tay JK, Vergez S, Weinreich HM, Wong EWY, Zenk J, Rassekh CH, Brenner MJ. Tracheostomy during the covid-19 pandemic: comparison of international perioperative care protocols and practices in 26 countries. *Otolaryng Head Neck.* 2021; 164(6): 1136-47. Review. IF: 5.591; D1
- Cendejas-Bueno E, Falces-Romero I, Laplaza-González M, Escosa-García L, Schuffelmann-Gutiérrez C, Romero-Gómez MP, Verdu-Sánchez C, Calderón-Llopis B, Amores-Hernández I, Peman J, Gómez-Zamora A, Río-García M, Menéndez-Suso JJ, Rodríguez-Álvarez D, Durán-Lorenzo I, Pérez-Acosta E, Rubio MR, Álvarez-Rojas E,

- Martínez-Romillo PD, Goded-Rambaud F, de Lorenzo AG, Maseda E, Mingorance J, de la Oliva P, García-Rodríguez J. Candidemia diagnosis with t2 nuclear magnetic resonance in a picu: a new approach. *Pediatr Crit Care Me.* 2021; 22(2): E109-14. Article. IF: 3.971; Q1
- de la Fuente IS, de la Fuente JS, Collado ZM, Alves SC, Griffith MSB, de Aledo ALG, Mendoza JB, Riera JASI, de Lorenzo AG, González JCM. Combination of arterial lactate levels and Cv-aCO2/Da-vO2 ratio to predict early allograft dysfunction after liver transplantation. *Clin Transplant.* 2021; 35(12): e14482. Article. IF: 3.456; Q2
- Farre-Alins V, Palomino-Antolin A, Narros-Fernández P, López-Rodríguez AB, Decouty-Pérez C, Muñoz-Montero A, Zamorano-Fernández J, Mansilla-Fernández B, Giner-García J, García-Feijoo P, Sáez-Alegre M, Palpan-Flores AJ, Roda-Frade JM, Carabias CS, Rosa JM, Civantos-Martín B, Yus-Teruel S, Gandía L, Lagares A, Hernández-García BJ, Egea J. Serum amyloid A1/toll-like receptor-4 Axis, an important Link between Inflammation and Outcome of TBI Patients. *Biomedicine.* 2021; 9(6): 599. Article. IF: 4.757; Q2
- Franco RF, de Lorenzo AG, Castro AG. Diabulimia: An updated perspective. *Enferm Clin.* 2021;31(6): 396-397. Letter. Not Indexed



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

- García-Cunchillos I, Estebáñez B, Lado C. New Approach to the ultrastructure of the capillitium in the order trichiales (myxomycetes, amoebzoa) and its phylogenetic implications. *Protist*. 2021; 172(2): 125805. Article. IF: 2.656; Q4
- García-Cunchillos I, Estebáñez B, Lado C. Spore ultrastructural features and significance of their diverse ornamental elements in the evolutionary history of the order Trichiales (Myxomycetes, Amoebozoa). *Eur J Protistol*. 2021; 81: 125839. Article. IF: 3.471; Q3
- García-de-Lorenzo A, Jiménez V, Feliú J, Asensio MJ, Civantos B, Anon JM. Multidisciplinary rounds in oncology and hematology: Are they superior to rapid response teams? *Med Intensiva*. 2021; 45(2): 127-8. Letter. IF: 2.799; Q3
- Glas GJ, Horn J, Hollmann MW, Preckel B, Colpaert K, Malbrain M, Neto AS, Asehnoune K, de Abreu MG, Martin-Loeches I, Pelosi P, Sjoberg F, Binnekade JM, Cleffken B, Juffermans NP, Knape P, Loef BG, Mackie DP, Enkhbaatar P, Depetris N, Perner A, Herrero E, Cachafeiro L, Jeschke M, Lipman J, Legrand M, Horter J, Lavrentieva A, Kazemi A, Guttormsen AB, Huss F, Kol M, Wong H, Starr T, De Crop L, de Oliveira W, Silva JM, Grion CMC, Burnett M, Mondrup F, Ravat F, Fontaine M, Le Floch R, Jeanne M, Bacus M, Chaussard M, Lehnhardt M, Mikhail BD, Gille J, Sharkey A, Trommel N, Reidinga AC, Vieleers N, Tilsley A, Onarheim H, Bouza MT, Agrifoglio A, Freden F, Palmieri T, Painting LE, Schultz MJ. Ventilation practices in burn patients-an international prospective observational cohort study. *Burns Trauma*. 2021; 9: tkab034. Article. IF: 5.711; D1
- González J, Benítez ID, Carmona P, Santistevé S, Monge A, Moncusi-Moix A, Gort-Paniello C, Pinilla L, Carratala A, Zuñil M, Ferrer R, Ceccato A, Fernández L, Motos A, Riera J, Menendez R, García-Gasulla D, Penuelas O, Bermejo-Martín JF, Labarca G, Caballero J, Torres G, De Gonzalo-Calvo D, Torres A, Barbe F. Pulmonary function and radiologic features in survivors of critical covid-19 a 3-month prospective cohort. *Chest*. 2021; 160(1): 187-98. Article. IF: 10.262; D1
- Gutiérrez-Gutiérrez B, del Toro MD, Borobia AM,

- Carcas A, Jarrín I, Yllescas M, Ryan P, Pachón J, Carratala J, Berenguer J, Arribas JR, Rodríguez-Bano J. Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study. *Lancet Infect Dis*. 2021; 21(6): 783-92. Article. IF: 71.421; D1
- Hernández-Beeftink T, Guillén-Guio B, Rodríguez-Pérez H, Marcelino-Rodríguez I, Lorenzo-Salazar JM, Corrales A, Prieto-González M, Rodríguez-Pérez A, Carriodo D, Blanco J, Ambros A, González-Higueras E, Casanova NG, González-Garay M, Espinosa E, Muriel A, Domínguez D, de Lorenzo AG, Anón JM, Soro M, Belda J, García JGN, Villar J, Flores C. Whole-blood mitochondrial dna copies are associated with the prognosis of acute respiratory distress syndrome after sepsis. *Front Immunol*. 2021; 12: 737369. Article. IF: 8.786; Q1
- Marx G, Zacharowski K, Ichai C, Asehnoune K, Cerny V, Dembinski R, Roca RF, Fries D, Molnar Z, Rosenberger P, Sánchez-Sánchez M, Schurholz T, Dehnhardt T, Schmier S, von Kleist E, Brauer U, Simon TP. Efficacy and safety of early target-controlled plasma volume replacement with a balanced gelatine solution versus a balanced electrolyte solution in patients with severe sepsis/septic shock: study protocol, design, and rationale of a prospective, randomized, controlled, double-blind, multicentric, international clinical trial: GENIUS-Gelatine use in ICU and sepsis. *Trials*. 2021; 22(1): 376. Article. IF: 2.728; Q4
- Nanwani-Nanwani KL, Civantos-Martín B, Flores-Cabeza E. How much surface can be debrided with bromelain safely? *Burns*. 2021; 47(4): 981-2. Letter. IF: 2.609; Q2
- Padilla M, Coll E, Fernández-Pérez C, Pont T, Ruiz A, Pérez-Redondo M, Oliver E, Atutxa L, Mancino JM, Daga D, Miñambres E, Moya J, Vidal B, Dueñas-Jurado JM, Mosteiro F, Rodríguez-Salgado A, Fernández-García E, Lara R, Hernández-Marrero D, Estebáñez B, Rodríguez-Ferrero ML, Barber M, García-López F, Andrés A, Santiago C, Zapatero A, Badenes R, Carrizosa F, Blanco JJ, Bernal JL, Elola FJ, Vidal C, Terron C, Castro P, Comas J, Domínguez-Gil B. Improved short-term outcomes of kidney transplants in contro-

- lled donation after the circulatory determination of death with the use of normothermic regional perfusion. *Am J Transplant*. 2021; 21(11): 3618-28. Article. IF: 9.369; D1
- Penuelas O, del Campo-Albendea L, de Aledo ALG, Anón JM, Rodríguez-Solis C, Mancebo J, Vera P, Ballesteros D, Jiménez J, Maseda E, Figueira JC, Franco N, Algaba A, Aviles JP, Díaz R, Abad B, Canabal A, Abella A, Gordo F, García J, Suárez JG, Cedeno J, Martínez-Palacios B, Mantega E, Martínez O, Blancas R, Bardi T, Pestana D, Lorente JA, Muriel A, Esteban A, Frutos-Vivar F. Long-term survival of mechanically ventilated patients with severe COVID-19: an observational cohort study. *Ann Intensive Care*. 2021; 11(1): 143. Article. IF: 10.318; Q1
- Rotaèche AA, Fucinos LC, Bernal MH, Mateos AGDY. Critically ill patients infected with HIV: 15 years of experience. *Med Intensiva*. 2021; 45(7): 442-3. Letter. IF: 2.799; Q3
- Soriano A, Montejano R, Sanz-Moreno J, Figueira JC, Grau S, Guerri-Fernández R, Castro-Gómez A, Pérez-Román I, Hidalgo-Vega A, González-Domínguez A. Impact of remdesivir on the treatment of covid-19 during the first wave in Spain. *Adv Ther*. 2021; 38(7): 4057-69. Article. IF: 4.07; Q2
- Torres A, Motos A, Riera J, Fernández-Barat L, Ceccato A, Pérez-Arnal R, García-Gasulla D, Penuelas O, Lorente JA, Rodríguez A, de Gonzalo-Calvo D, Almansa R, Gabarrus A, Menendez R, Bermejo-Martín JF, Ferrer R, Villar RA, Anon JM, Barbera C, Barberan J, Ortiz AB, Bustamante-Munguira E, Caballero J, Carbajales C, Carbonell N, Catalán-González M, Galbán C, Gumucio-Sanguino VD, de la Torre MD, Díaz E, Estella A, Gallego E, Garmendia JLG, Garnacho-Montero J, Gómez JM, Huerta A, García RNJ, Loza-Vázquez A, Marín-Corral J, de la Gandara AM, Varela IM, Messa JL, Albaiceta GM, Novo MA, Penasco Y, Pozo-Laderas JC, Ricart P, Salvador-Ade I, Sánchez-Mirallas A, chinesta SS, Socias L, Sole-Violan J, Sipmann FS, Lomas LT, Trenado J, Barbe F. The evolution of the ventilatory ratio is a prognostic factor in mechanically ventilated COVID-19 ARDS patients. *Crit Care*. 2021; 25(1): 331. Article. IF: 19.334; Q1

- Villar J, González-Martín JM, Ambros A, Mosteiro F, Martínez D, Fernández L, Soler JA, Parra L, Solano R, Soro M, Del Campo R, González-Luengo RI, Civantos B, Montiel R, Pita-García L, Vidal A, Anón JM, Ferrando C, Díaz-Domínguez FJ, Mora-Ordóñez JM, Fernández MM, Fernández C, Fernández RL, Rodríguez-Suárez P, Steyerberg EW, Kacmarek RM. Stratification for identification of prognostic categories in the acute respiratory distress syndrome (SPIRES) score. *Crit Care Med*. 2021; 49(10): E920-30. Article. IF: 9.296; Q1

Research projects



Estébanez Montiel B. Formación en donación y trasplante para profesionales de unidades generadoras de potenciales donantes pediátricos (ONT2020). MISAN. 2021-2021.

Managment centre: FIBHULP

Patents and trademarks

Herrero Ambrosio A, Ramírez García E, Ojeda Feo JJ, Pérez Rodríguez J, Asensio Martín MJ, González Sánchez ML, Moro Agud M, Lorente Romeo M, López Nieto M, Gómez Rioja R, authors; FIBHULP, assignee. Trademark name: SINOIRES; CM 13.080.056; 2014 July 14.





3.4.3 Respiratory Diseases Group

Publications: 29

Q1: 14

COMPOSITION



■ **Francisco José García Río.** Jefe de Sección de Neumología (Contrato de Intensificación). Facultad de Medicina. Hospital Universitario La Paz. Catedrático. Universidad Autónoma de Madrid

Sergio Alcolea Batres. Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz

Rodolfo Álvarez-Sala Walther. Jefe de Servicio de Neumología. Hospital Universitario La Paz. Catedrático. Facultad de Medicina. Universidad Autónoma de Madrid

Juan José Cabanillas Martín. Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz

Carlos Javier Carpio Segura. Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz

Raquel Casitas Mateo. Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz

Carolina Cubillos Zapata. Investigadora Postdoctoral. Contrato Miguel Servet tipo I. Hospital Universitario La Paz

Raúl Galera Martínez. Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz

Luis Gómez Carrera. Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz

Elena Díaz García. Investigador Predoctoral. CIBERER
María Antonia Gómez Mendieta. Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz

Ana Jaureguizar Oriol. Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz

Elisabet Martínez Cerón. Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz

Concepción Prados Sánchez. Jefe de Sección de Neumología. Hospital Universitario La Paz

David Romero Ribate. Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz

Ana Santiago Recuerda. Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz

Carlos Villasante Fernández-Montes. Jefe de Sección de Neumología. Hospital Universitario La Paz

Ester Zamarrón de Lucas. Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz

STRATEGIC OBJECTIVE

Our group studies the molecular mechanisms of cardiovascular morbidity associated with sleep breathing disorders, in particular, the sleep apnoeahypopnea syndrome(SAHS).

We also provide evidence for making clinical decisions on patients with these disorders. We conduct studies to evaluate the mecha-

nisms involved in the development of arterial hypertension, arrhythmias, heart failure, ischaemic heart disease, pulmonary hypertension, pulmonary embolism, and carbohydrate metabolism disorders.


In terms of the pathogenesis of airflow limitations, several of our projects have focused on small airway function, bronchial hyperresponsiveness and exercise adaptation in a number of obstructive diseases, particularly COPD, asthma and cystic fibrosis. We also evaluate the

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



1 Introduction

objective measurement of daily physical activity in these patients and contribute to the best definition of its determinants and its clinical and prognostic usefulness. We collaborate with other research groups to study the contribution of the innate immune system to the evolution of these diseases and the relationship between the response to hypoxia and the clinical expression of COPD and SAHS.

Finally, in the field of the systematisation of lung function testing, we create reference values for various population groups and define

the methodological aspects of the measurement of exhaled breath condensate and nitric oxide.

RESEARCH LINES

- Morbidity of sleep-disordered breathing
- Pathogenesis of airflow limitation
- Systematization of lung function testing

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

RESEARCH ACTIVITY

■ Doctoral theses

Zamarrón de Lucas E. Continuous positive airway pressure effect on albuminuria in patients with diabetic kidney disease and obstructive sleep apnea[dissertation]. Madrid: UAM: 2021(24/11/2021).

Directors: García Río F, Álvarez-Sala R.

Dafauce Álvarez-Sala L. Personalidad, ansiedad y depresión como factores predictores del control del asma y de la adherencia al tratamiento en una consulta monográfica de asma grave[dissertation]. Madrid: UAM: 2021(03/06/2021).

Director: Bravo Ortiz MF, Álvarez Sala R.

Bonilla Hernán MG. Enfermedad pulmonar intersticial difusa clínica en pacientes diagnosticados de artritis reumatoide. [dissertation]. Madrid: UAM: 2021(15/12/2021).

Directors: Balsa Criado A, Álvarez-Sala Walther R

■ Publications

• Aguilar PM, Carrera LG, Segura CC, Sánchez MIT, Pena MFV, Hernán GB, Rodríguez IE, Za-

pata RMR, De Lucas EZ, Álvarez PDA, Bueno EV, Sánchez CP, Walther RAS. Relationship between air pollution levels in Madrid and the natural history of idiopathic pulmonary fibrosis: severity and mortality. *J Int Med Res.* 2021; 49(7): 3000605211029060. Article. IF: 1.573; Q4

• Alcazar-Navarrete B, García-Río F, Sánchez G, Mariscal E, García A, Cuesta M, Uria E, Miravittles M. Burden of disease among exacerbating patients with copd treated with triple therapy in Spain. *Int J Chron Obstruct Pulmon Dis.* 2021; 16: 2149-61. Article. IF: 2.893; Q4

• Alonso-Fernández A, Quetglas CR, Mochales AH, De Larrinaga AAR, Barón AS, Rodríguez PR, Gómez AVG, Martínez CP, Marín JPC, Nicolau MB, Moncadas MC, Marcet MC, Bravo MD, Benasar AB, Coma AI, Morell-García D, Zarza JAP, Carrero MPG, Cantolla JD, Trigo JMM, Cebrian MCP, Soriano JB, García-Río F. Influence of obstructive sleep apnea on systemic inflammation in pregnancy. *Front Med (Lausanne).* 2021; 8: 674997. Article. IF: 5.058; Q2

• Cáceres LD, Moreno RMG, Castillo EG, Sanz MTP, Oliveira C, Clemente MG, Royo RN, Sánchez CP, Sánchez PC, Serrano MJO, Galo AP, Tomas EN, Peris AE, Velilla MF, Torres MI, Bermudez JA. Effect of sex differences on computed tomography findings in adults with cystic fibrosis: a multicenter study. *Arch Bronconeumol.* 2021; 57(4): 256-63. Article. IF: 6.333; Q1

• Dafauce L, Romero D, Carpio C, Barga P, Quirce S, Villasante C, Bravo MF, Álvarez-Sala R. Psychodemographic profile in severe asthma and effect of emotional mood disorders and hyperventilation syndrome on quality of life. *BMC Psychol.* 2021; 9(1): 3. Article. IF: 2.588; Q2

• Díaz-García E, García-Tovar S, Casitas R, Jaureguizar A, Zamarrón E, Sánchez-Sánchez B,

Sastre-Perona A, López-Collazo E, García-Río F, Cubillos-Zapata C. Intermittent hypoxia mediates paraspeckle protein-1 upregulation in sleep apnea. *Cancers (Basel).* 2021; 13(15): 3888. Article. IF: 6.575; Q2

• Galera R, Casitas R, Martínez-Cerón E, Rodríguez-Fraga O, Utrilla C, Torres I, Cubillos-Zapata C, García-Río F. Effect of dynamic hyperinflation on cardiac response to exercise of patients with chronic obstructive pulmonary disease. *Arch Bronconeumol.* 2021; 57(6): 406-14. Article. IF: 6.333; Q1

• García-Quero C, García-Río F. Smoking-induced small airway dysfunction. An early marker of future Copd?. *Arch Bronconeumol.* 2021; 57(1): 3-4. Editorial Material. IF: 6.333; Q1

• García-Río F, Alonso-Arroyo A, de-Granda-Orive JI, Castello-Cogollos L, Alexandre-Benavent R. Worldwide production on sleep apnea from 2009-2018. Analysis of the ability to secure funding and international collaboration networks. *Resp Med.* 2021; 185: 106486. Article. IF: 4.582; Q2

• Khalyfa A, Trzepizur W, Gileles-Hillel A, Qiao ZH, Sanz-Rubio D, Marín JM, Martínez-García MA, Campos-Rodríguez F, Almendros I, Farre R, Sánchez-de-la-Torre M, García-Río F, Gozal D. Heterogeneity of melanoma cell responses to sleep apnea-derived plasma exosomes and to intermittent hypoxia. *Cancers (Basel).* 2021; 13(19): 4781. Article. IF: 6.575; Q2

• López-Campos JL, Rubio MC, Alonso JLI, Fernández-Villar A, Abascal-Bolado B, Alcázar B, García-Río F, Peces-Barba G, Batlles JS, Garceran JMM, Miranda JAR, Figueira-Goncalves JM, Soler-Cataluna JJ, Tramporno M, Ruiz FO, Pérez SS, Martínez CJA. Forum COPD working group consensus on the diagnosis, treatment and

follow-up of COPD. *Arch Bronconeumol.* 2021; 57(9): 596-9. Letter. IF: 6.333; Q1

• López-Padilla D, García-Río F, Alonso-Arroyo A, Valls NA, Lajas AC, Blanco MC, González VG, Flores ML, Redondo MM, Gisbert NM, Castillejo EO, Bernáldez MP, Gallán MP, Ribera VP, Maestu LP, Moreno BR, Jimeno ER, Azofra AS, Segrelles-Calvo G, Tinedo JRT, Reyes PV, de Granda-Orive JI. Errare humanum est, though a lucky mistake, indeed! *Arch Bronconeumol.* 2021; 57(2): 146-7. Letter. IF: 6.333; Q1

• López-Padilla D, García-Río F, Alonso-Arroyo A, Valls NA, Lajas AC, Blanco MC, González VG, Flores ML, Redondo MM, Gisbert NM, Castillejo EO, Bernáldez MP, Gallán MP, Ribera VP, Maestu LP, Moreno BR, Jimeno ER, Azofra AS, Segrelles-Calvo G, Tinedo JRT, Reyes PV, de Granda-Orive JI. Gender differences in original archives de bronconeumologia publications, 2001-2018. *Arch Bronconeumol.* 2021; 57(2): 107-14. Article. IF: 6.333; Q1

• Martínez-Cerón E, Casitas R, Galera R, Sánchez-Sánchez B, Zamarrón E, García-Sánchez A, Jaureguizar A, Cubillos-Zapata C, García-Río F. Contribution of sleep characteristics to the association between obstructive sleep apnea and dyslipidemia. *Sleep Med.* 2021; 84: 63-72. Article. IF: 4.842; Q2

• Martínez-García MA, Oscullo G, Posadas T, Zaldivar E, Villa C, Dobarganes Y, Girón R, Oliveira C, Maiz L, García-Clemente M, Sibila O, Golpe R, Rodríguez J, Barreiro E, Rodríguez JL, Feced-Olmos L, Prados C, Muriel A, de la Rosa D. Pseudomonas aeruginosa and lung function decline in patients with bronchiectasis. *Clin Microbiol Infect.* 2021; 27(3): 428-34. Article. IF: 13.31; D1

• Martínez-García MA, Villa C, Dobarganes Y, Girón R, Maiz L, García-Clemente M, Sibila O,



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Golpe R, Rodríguez J, Barreiro E, Rodríguez JL, Menéndez R, Prados C, de la Rosa D, Olveira C. RIBRON: The Spanish online bronchiectasis registry. Characterization of the first 1912 patients. *Arch Bronconeumol.* 2021; 57(1): 28-35. Article. IF: 6.333; Q1

• Méndez-Echevarría A, Sainz T, de Felipe B, Alcolea S, Olbrich P, Goycochea-Valdivia WA, Escosa-García L, Cobo L, Calvo C, Neth O. High rates of SARS-CoV-2 family transmission in children of healthcare workers during the first pandemic wave in Madrid, Spain serologic study. *Pediatr Infect Dis J.* 2021; 40(5): E185-8. Article. IF: 3.806; Q1

• Navarro-Soriano C, Martínez-García MA, Torres G, Barbe F, Sánchez-de-la-Torre M, Caballero-Eraso C, Lloberes P, Cambriles TD, Somoza M, Masa JF, González M, Manas E, de la Pena M, García-Río F, Montserrat JM, Muriel A, Oscullo G, García-Ortega A, Posadas T, Campos-Rodríguez F. Long-term effect of CPAP treatment on cardiovascular events in patients with resistant hypertension and sleep apnea. Data From the HIPARCO-2 Study. *Arch Bronconeumol.* 2021; 57(3): 165-71. Article. IF: 6.333; Q1

• Navarro-Soriano C, Torres G, Barbe F, Sánchez-de-la-Torre M, Manas P, Lloberes P, Cambriles TD, Somoza M, Masa JF, González M, Manas E, de la Pena M, García-Río F, Montserrat JM, Muriel A, Oscullo G, García-Ortega A, Posadas T, Campos-Rodríguez F, Martínez-García MA. The HIPARCO-2 study: long-term effect of continuous positive airway pressure on blood pressure in patients with resistant hypertension: a multicenter prospective study. *J Hypertens.* 2021; 39(2): 302-9. Article. IF: 4.776; Q2

• Núñez-Fernández M, Ramos-Hernández C, García-Río F, Torres-Duran M, Nodar-Germinas A, Tilve-Gómez A, Rodríguez-Fernández P, Valverde-Pérez D, Ruano-Ravina A, Fernández-Villar A. Alterations in respiratory function test three months after hospitalisation for covid-19 pneumonia: value of determining nitric oxide diffusion. *J Clin Med.* 2021; 10(10): 2119. Article. IF: 4.964; Q2

• Olaguibel JM, Alobid I, Puebla A, Crespo-Lessmann A, Ortega D, García-Río F, Izquierdo-Domínguez A, Mullol J, Plaza V, Quirce S, Rojas-Lechuga MJ, Valverde-Monge M, Sastre J. Functional examination of the upper and lower airways in asthma and respiratory allergic diseases: considerations in the post-SARS-CoV-2 era. *J Invest Allerg Clin.* 2021; 31(1): 17-35. Review. IF: 8.185; Q1

• Puente-Maestu L, Ortega F, de Pedro JG, Rodríguez-Nieto MJ, Gómez-Seco J, Galdiz B, Ojanguren I, Muñoz X, Blanco I, Burgos F, Rodríguez-Chiaradia DA, Gea J, García-Río F. Prediction equations for maximal aerobic capacity on cycle ergometer for the Spanish adult population. *Arch Bronconeumol.* 2021; 57(7): 471-8. Article. IF: 6.333; Q1

• Salvador ML, Loaiza CAQ, Padial LR, Barbera JA, López-Meseguer M, López-Reyes R, Sala-Llinas E, Alcolea S, Blanco I, Escribano-Subias P. Portopulmonary hypertension: prognosis and management in the current treatment era - results from the REHAP registry. *Intern Med J.* 2021; 51(3): 355-65. Article. IF: 2.611; Q3

• Soriano JB, Alfageme I, Miravittles M, de Lucas P, Soler-Cataluña JJ, García-Río F, Casanova C, González-Moro JMR, Cosío B, Sánchez G, Ancohea J. Prevalence and determinants of COPD in Spain: EPISCAN II. *Arch Bronconeumol.* 2021; 57(1): 61-9. Article. IF: 6.333; Q1

• Villamañán E, Sobrino C, Bilbao C, Fernández J, Herrero A, Calle M, Álvaro D, Segura M, Picazo G, Rodríguez JM, Baldominos G, Ramírez MT, Larrubia Y, Llorente J, Martínez A, Álvarez-Sala R. Off-label use of inhaled bronchodilators in hospitalised patients in Spain: a multicentre observational study. *Eur J Hosp Pharm-S P.* 2021; 28(E1): E23-8. Article. IF: 2.537; Q3

• Villamañán E, Sobrino C, Carpio C, Moreno M, Arancón A, Lara C, Pérez E, Jiménez C, Zamarrón E, Jiménez-Nacher I, Herrero A, Álvarez-Sala R. Inhaled bronchodilators use and clinical course of adult inpatients with Covid-19 pneumonia in Spain: A retrospective cohort study. *Pulm Pharmacol Ther.* 2021; 69: 102007. Article. IF: 3.282; Q3

• Wang XJ, Villa C, Dobarganes Y, Olveira C, Girón R, García-Clemente M, Maiz L, Sibila O, Golpe R, Menéndez R, Rodríguez-López J, Prados C, Martínez-García MA, Rodríguez JL, de la Rosa D, Durán X, Barreiro E. Differences in nutritional status and inflammatory biomarkers between female and male patients with bronchiectasis: a large-cohort study. *Biomedicines.* 2021; 9(8): 905. Article. IF: 4.757; Q2

• Wang XJ, Villa C, Dobarganes Y, Olveira C, Girón R, García-Clemente M, Maiz L, Sibila O, Golpe R, Menéndez R, Rodríguez-López J, Prados C, Martínez-García MA, Rodríguez JL, de la Rosa D, Durán X, García-Ojalvo J, Barreiro E. Phenotypic clustering in non-cystic fibrosis bronchiectasis patients: the role of eosinophils in disease severity. *Int J Env Res Pub He.* 2021; 18(16): 8431. Article. IF: 4.614; Q1

• Zamarrón E, Jaureguizar A, García-Sánchez A, Díaz-Cambriles T, Alonso-Fernández A, Lores V, Mediano O, Rodríguez-Rodríguez P, Cabello-Pelegrin S, Morales-Ruiz E, Ramírez-Prieto MT, Valiente-Díaz MI, Gómez-García T, García-Río F. Obstructive sleep apnea is associated with impaired renal function in patients with diabetic kidney disease. *Sci Rep-Uk.* 2021; 11(1): 5675. Article. IF: 4.996; Q2

Research projects

Cubillos Zapata C. El papel del inflammasoma en el progreso de las comorbilidades en pacientes con apnea obstructiva del sueño (CP18/00028). ISCIII. 2019-2022.

Management centre: FIBHULP

Cubillos Zapata C. Estudio de la respuesta inmune en casos anidados en una cohorte para evaluar el efecto de los antiretrovirales en la evolución de la infección por el coronavirus Sars-Cov-2 (COV20/00207). ISCIII. 2020-2021.

Management centre: FIBHULP

Cubillos Zapata C. Identificación del riesgo de cáncer en pacientes con apnea obstructiva del sueño con la detección de inmunocheckpoints (PI19/01363). ISCIII. 2020-2022.

Management centre: FIBHULP

García Río FJ. Análisis de la actividad del sistema inmune innato en pacientes con síndrome de apneas-hipopneas del sueño grave. Roche Farma S. A. 2014-Ongoing.

Management centre: FIBHULP

García Río FJ. Contrato de intensificación (INT20/00020). ISCIII-MICINN. 2021-2022.

Management centre: FIBHULP

García Río FJ. Contribución de las alte-

raciones de la percepción de la disnea al diagnóstico de asma ficticio en obesos. Astrazeneca Farmacéutica Spain S. A. 2009-Ongoing.

Management centre: FIBHULP

García Río FJ. Efecto de la CPAP nasal sobre la reducción de la albuminuria en pacientes con nefropatía diabética y apnea obstructiva del sueño (PI16/00201). ISCIII. 2017-2021.

Management centre: FIBHULP

García Río FJ. Relación entre la actividad física cotidiana de pacientes con EPOC y la actividad de su sistema inmune innato y adaptativo. Identificación de biomarcadores pronósticos (PI19/01612). ISCIII. 2020-2022.

Management centre: FIBHULP

Gómez Carrera L. Auditoría clínica sobre manejo de fibrosis pulmonar idiopática en el área sanitaria del Hospital La Paz. Boehringer Ingelheim España S. A. 2016-Ongoing.

Management centre: FIBHULP

Gómez Carrera L. Avances en enfermedad pulmonar intersticial difusa. Boehringer Ingelheim España S.A. 2021-Ongoing.

Management centre: FIBHULP


Jaureguizar Oriol AS. Contrato Rio Horteaga (CM20/00057). ISCIII-MICINN. 2021-2022.

Management centre: Hospital Universitario La Paz

Cibers & Retics

García Río F. CIBER de Enfermedades Respiratorias. (CB15/00037). ISCIII. (31/12/2021).

Management centre: FIBHULP



1
Introduction

2
Executive
Summary

3
Information
Groups
by Area

4
Associated
Clinicians

■ Clinical trials

Alcolea Batres, S. Estudio aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y seguridad de ambrientan en pacientes con COVID-19 severo.

Type: Clinical Trials, phase III.

HULP code: 5806 N-003-CRD008.

Sponsored by: Noorik Biopharmaceuticals Ag.

Signed date: 05/03/2021

Alcolea Batres, S. Estudio en fase III, prospectivo, multicéntrico, doble ciego, con doble simulación, aleatorizado, controlado con fármaco activo, de grupos paralelos, de grupos secuenciales, adaptativo y basado en acontecimientos para comparar la eficacia, la seguridad y latolerabilidad de macitentán 75 mg frente a macitentán 10 mg en pacientes con hipertensión arterial pulmonar, seguido de un periodo de tratamiento abierto con macitentán 75 mg.

Type: Clinical Trials, phase III.

HULP code: Appendix 1 5546.

Sponsored by: Janssen-Cilag España, S.A.

Signed date: 21/05/2021

Álvarez-Sala Walther, R. Estudio fundamental de 52 semanas de duración, aleatorizado, doble ciego, controlado con placebo en grupos paralelos para evaluar la eficacia, seguridad y tolerabilidad de dupilumab en pacientes con enfermedad pulmonar obstructiva crónica (epoc) de moderada grave con inflamación tipo 2.

Type: Clinical Trials, phase III.

HULP code: Appendix 1 5539.

Sponsored by: Sanofi-Aventis Recherche & Développement.

Signed date: 16/07/2021

Carpio Segura, C.J. Estudio de fase 3, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia, la seguridad y latolerabilidad de brensocatib administrado una vez al día durante 52 semanas en sujetos con bronquiectasias sin fibrosis quística: estudio aspen.

Type: Clinical Trials, phase III.

HULP code: 5731 INS 1007-301.

Sponsored by: Inmed Incorporated.

Signed date: 16/03/2021

Carpio Segura, C.J. Estudio de fase 3, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia, la seguridad y latolerabilidad de brensocatib administrado una vez al día durante 52 semanas en sujetos con bronquiectasias sin fibrosis quística: estudio aspen.

Type: Clinical Trials, phase III.

HULP code: Appendix 1 5731.

Sponsored by: Inmed Incorporated.

Signed date: 07/07/2021

Carpio Segura, C.J. Estudio de fase 3, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia, la seguridad y latolerabilidad de brensocatib administrado una vez al día durante 52 semanas en sujetos con bronquiectasias sin fibrosis quística: estudio aspen.

Type: Clinical Trials, phase III.

HULP code: Appendix 2 5731.

Sponsored by: Inmed Incorporated.

Signed date: 18/10/2021

Galera Martínez, R. Estudio de la hiperinsuflación dinámica tras la prueba de la marcha de 6 minutos en los pacientes con asma moderada-grave.

Type: Estudios, phase EPA-OD.

HULP code: PI-4686 CHI-ASM-2020-01.

Sponsored by: Chiesi España Sa.

Signed date: 07/04/2021

García Río, F.J. Ensayo de fase III, multicéntrico, aleatorizado, doble ciego, de administración crónica, con grupos paralelos y controlado con placebo para evaluar la eficacia y la seguridad de benralizumab 100 mg en pacientes con enfermedad pulmonar obstructiva crónica (epoc) de moderada a muy grave y con antecedentes de exacerbaciones frecuentes de la epoc y eosinófilos elevados en sangre periférica (resolutive).

Type: Clinical Trials, phase III.

HULP code: Appendix 1 5421.

Sponsored by: Astrazeneca Farmaceutica Spain, S.A.

Signed date: 19/10/2021

Gómez Carrera, L. Estudio de fase III aleatorizado, doble ciego, controlado por placebo para evaluar la eficacia y seguridad del prm-151 en pacientes con fibrosis pulmonar idiopática.

Type: Clinical Trials, phase III.

HULP code: 5749 WA42293.

Sponsored by: F.Hoffmann-La Roche Ltd.

Signed date: 11/05/2021

Gómez Carrera, L. Estudio de fase III de extensión de etiqueta abierta para evaluar la seguridad y eficacia a largo plazo de prm-151 en pacientes con fibrosis pulmonar idiopática (fpi) estudio de fase III aleatorizado, doble ciego, controlado por placebo para evaluar la eficacia y seguridad del prm-151 en pacientes con fibrosis pulmonar idiopática.

Type: Clinical Trials, phase III.

HULP code: 5750 WA42294.

Sponsored by: F.Hoffmann-La Roche Ltd.

Signed date: 11/05/2021

Prados Sánchez, C. Estudio en fase III y abierto para evaluar la seguridad a largo plazo del tratamiento combinado vx-445 en sujetos con fibrosis quística.

Type: Clinical Trials, phase III.

HULP code: Appendix 1 5383.

Sponsored by: Vertex Pharmaceuticals Incorporated.

Signed date: 08/06/2021

Romero Ribate, D. Estudio de 52 semanas de duración, aleatorizado, doble ciego, con doble simulación, de grupos paralelos, multicéntrico, de no inferioridad, para evaluar la tasa de exacerbación, las mediciones adicionales de control del asma y la seguridad en participantes adultos y adolescentes con asma grave con fenotipo eosinofílico tratados con gsk3511294 en comparación con mepolizumab o benralizumab.

Type: Clinical Trials, phase III.


HULP code: 5834 206785.

Sponsored by: Glaxosmithkline Research And Development Limited .,

Signed date: 06/07/2021"

■ Patents and trademarks

Díaz García E, Laxman Nanwani K, Quintana Díaz M, García Río F, Cubillos-Zapata C, inventors; FIHULP, CIBER, assignees. Biomarcadores para el pronóstico de pacientes que han sufrido una hemorragia subaracnoidea aneurismática (SAH). P202130180; 2021 March 3



1 Introduction

2 Executive
Summary

3 Information
Groups
by Area

4 Associated
Clinicians



3.4.4 Regulation of Gene Expression and by Hypoxia Group

Publications: 29

Q1: 14



COMPOSITION

■ **Luis del Peso Ovalle.** Profesor Titular. Departamento de Bioquímica. Facultad de Medicina. Universidad Autónoma de Madrid

Benilde Jiménez Cuenca. Profesor Titular. Departamento de Bioquímica Facultad de Medicina. Universidad Autónoma de Madrid

STRATEGIC OBJECTIVE

Oxygen homeostasis, central to physiology, is altered in high-incidence pathologies such as cardiovascular disease and cancer. Therefore, the elucidation of cellular and molecular adaptive responses to hypoxia is an important topic of biomedical research. Hypoxia-inducible transcription factors (HIFs) play a key role in this response by controlling the expression of most of the genes involved in adaptation to hypoxia. The aim of our group is to contribute to the understanding of the transcriptional response to hypoxia and the cellular and molecular mechanisms underlying adaptive responses such as the induction of angiogenesis. Our long-term goal is to exploit this knowledge to improve the clinical management of pathologies in which the development of tissue hypoxia is a common feature.

RESEARCH LINES

- Characterisation of molecular mechanisms responsible for the transcriptional response to hypoxia
- Identification of polymorphisms affecting HIF binding sites and characterisation of their functional effect
- Cellular and molecular mechanism of angiogenesis regulation by hypoxia
- Hypoxia regulation of metabolism and role of HIF in metabolic diseases

RESEARCH ACTIVITY

■ Doctoral theses

Final Degree Theses

Sánchez González L. Metaanálisis de perfiles transcripcionales inducidos por hipoxia[dissertation]. Madrid: UAM: 2021 (17/06/2021). Director: del Peso Ovalle).

Director: del Peso Ovalle L.

■ Research projects

del Peso Ovalle L. Implementación de procedimientos para análisis de datos derivados de técnicas de secuenciación de alto rendimiento (IND2019/BMD-17134). CM. 2021-2023.

Management centre: UAM

del Peso Ovalle L. Contribución de BHLHE40 a la respuesta transcripcional a la hipoxia y su implicación en patologías metabólicas y respiratorias (PID2020-118821RB-I00). MI-CINN. 2021-2024.

Management centre: UAM



1 Introduction

2 Executive Summary

3 Information Groups by Area


4 Associated Clinicians



3.4.5 Nephrology Group

Publications: 28

Q1: 15



COMPOSITION

■ **María Auxiliadora Bajo Rubio.** Jefe de Sección de Nefrología. Hospital Universitario La Paz. Profesora Asociada. Facultad de Medicina. Universidad Autónoma de Madrid

María José Castro Notario. Enfermera. Hospital Universitario La Paz

Olga Costero Fernández. Facultativo Especialista de Área en Nefrología. Hospital Universitario La Paz

Gloria del Peso Gilsanz. Facultativo Especialista de Área en Nefrología. Hospital Universitario La Paz

María José Fernández Reyes. Facultativo Especialista de Área en Nefrología. Hospital de Segovia

Helena García LLana. Psicóloga Investigadora. Hospital Universitario La Paz

María Elena González García. Facultativo Especialista de Área en Nefrología. Hospital Universitario La Paz

Guadalupe González Mateo. Investigadora Postdoctoral. Hospital Universitario La Paz

Carlos Jiménez Martín. Jefe de Sección de Nefrología. Hospital Universitario La Paz

María Ovidia López Oliva. Facultativo Especialista de Área en Nefrología. Hospital Universitario La Paz

Teresa Olea Tejero. Facultativo Especialista de Área en Nefrología. Hospital Universitario La Paz

Almudena Pérez Torres. Dietista-Nutricionista. Hospital Universitario Santa Cristina

Begoña Rivas Becerra. Facultativo Especialista de Área en Nefrología. Hospital Universitario La Paz


Rafael Jesús Sánchez Villanueva. Facultativo Especialista de Área en Nefrología. Hospital Universitario La Paz

Rafael Selgas Gutiérrez. Jefe de Servicio de Nefrología. Hospital Universitario La Paz

STRATEGIC OBJECTIVE

The strategic objective of this care-research group is to enable, by developing a deep understanding of the various components that make up nephrology (kidney diseases in initial stages, progression of kidney disease, particular and general complications of dialysis and

kidney transplantation), access by affected patients to the best diagnostic and therapeutic interventions available at any time. Each of the areas must ensure a minimum level of research and development activity representing the innovation in these areas. The lines of research are at times cross-sectional to the four components indicated for overall nephrology.



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

RESEARCH LINES

The lines of research are occasionally cross-sectional to the four components indicated for nephrology as a whole.

A) Incipient nephropathies and kidney disease progression:

- Glomerular and tubular nephropathies. New diagnostic markers and interventions.
- Organisational Research (computerisation, organisation of generational change in the department and network).
- Morbidity, mortality and progression of Diabetic Nephropathy and other glomerular nephropathies.
- Autosomal Dominant Polycystic Kidney Disease. Family Studies and treatment approaches with Tolvaptan.
- Association of cardiovascular disease with the progress of nephropathies (NEFRONA multicenter study, REDinREN).
- Incorporation of a psychologist into the department of nephrology: criteria and process. Issues on monitoring therapeutic adherence, in particular among transplanted patients
- Occult Hepatitis C virus in different kidney disease situations.

B) Complications of dialysis

- Establishment of normal peritoneal function in humans. Implications for patient survival and long-term treatment. New dialysis fluids. Aquaporin 1 (AQP1) and its genetic polymorphisms: relationship with peritoneal transport of water. Multicentre European study.

- The alternatively activated macrophage in peritoneal effluent (AAM): its relationship with defence and peritoneal fibrosis. CCL18 as a chemokine of AAM and a mediator of peritoneal fibrosis.
- Peritoneal biopsy for the complete evaluation of the peritoneal membrane. A correspondence study with cell and component findings in peritoneal effluent during kidney transplantation is ongoing (Multicenter).
- Cardiovascular risk in patients with advanced kidney disease and on dialysis. Endocrine aspects. The abdominal adipocyte and adipocytokines. FABP antagonists as blockers of the adipocyte-macrophage response. Nonthyroidal diseases, influence on CKD patients. FGF 21 role in uremic insulin resistance.
- Mouse model for peritoneal dialysis: exploration of the effects of dialysis fluids, pharmacological interventions and genetic manipulation (KO, transgenic).
- Allergic reactions to hemodialysis membranes: mechanisms and alternatives.

C) Complications of kidney transplantation:

- Toxicity due to immunosuppressants. Ultrasound contrast in the analysis of renal microvasculature in kidney transplantation and complications.
- The involvement of CMV in the renal graft response: anticipated diagnosis.

RESEARCH ACTIVITY

■ Doctoral theses

Márquez Expósito L. Papel del ligando no canónico de NOTCH parecido a Delta 1 (DLK1) en el daño renal experimental [dissertation]. Madrid: UAM: 2021(09/07/2021).

Directors: Ruiz Ortega M, Rodrigues Díez R.

■ Publications

• Alonso-Pérez E, Fome C, Soro M, Valls M, Manzanelli AG, Valdivielso JM. Health care costs in

patients with and without secondary hyperparathyroidism in Spain. *Adv Ther.* 2021; 38(10): 5333-44. Article. IF: 4.07; Q2


- Ávila-Carrasco L, García-Mayorga EA, Díaz-Ávila DL, Garza-Veloz I, Martínez-Fierro ML, González-Mateo GT. Potential therapeutic effects of natural plant compounds in kidney disease. *Molecules.* 2021; 26(20): 6096. Review. IF: 4.927; Q2
- Bermúdez-López M, Perpín H, Amigo N, Castro E, Alonso N, Mauricio D, Fernández E, Valdivielso JM. Advanced lipoprotein parameters could better explain atheromatosis in non-diabetic chronic kidney disease patients. *Clin Kidney J.* 2021; 14(12): 2591-9. Article. IF: 5.86; Q1
- Buxeda A, Arias-Cabrales C, Pérez-Saez MJ, Cacho J, Pelegrín SC, Melilli E, Aladren MJ, Galea-

no C, Lorenzo I, Mazuecos A, Saura IM, Franco A, Ruiz-Fuentes MD, Sánchez-Camara LA, Siverio O, Martín ML, González-García E, López V, Martín-Moreno PL, Moína I, Berrio EM, Moreso F, Portoles JM, Santana-Estupinan R, Zarraga S, Canal C, Sánchez-Álvarez E, Pascual J, Crespo M. Use and safety of remdesivir in kidney transplant recipients with COVID-19. *Kidney Int Rep.* 2021; 6(9): 2305-15. Article. IF: 6.234; Q1

- Caravaca-Fontán F, Trujillo H, Alonso M, Díaz-Encarnación M, Cabello V, Ariceta G, Quintana LF, Marco H, Barros X, Ramos N, Rodríguez-Mendiola N, Cruz S, Fernández-Juárez G, Rodríguez E, de la Cerda F, de Jose AP, López I, Fernández L, Gómez VP, Ávila A, Bravo L, Lumberas J, Allende N, de la Nieta MDS, Olea T, Melgosa M,

Huerta A, Miquel R, Mon C, Fraga G, de Lorenzo A, Draibe J, González F, Shabaka A, Illescas ML, Calvo C, Oviedo V, Da Silva I, de Jorge EG, Caravaca F, Praga M. Validation of a histologic scoring index for C3 glomerulopathy. *Am J Kidney Dis.* 2021; 77(5): 684-95. Article. IF: 11,072; D1

- Coll E, Fernández-Ruiz M, Sánchez-Álvarez JE, Martínez-Fernández JR, Crespo M, Gayoso J, Bada-Bosch T, Oppenheimer F, Moreso F, López-Oliva MO, Melilli E, Rodríguez-Ferrero ML, Bravo C, Burgos E, Facundo C, Lorenzo I, Yáñez I, Galeano C, Roca A, Cabello M, Gómez-Bueno M, García-Cosío MD, Graus J, Llado L, de Pablo A, Loinaz C, Aguado B, Hernández D, Domínguez-Gil B. COVID-19 in transplant recipients: The Spanish experience. *Am J Transplant.* 2021;



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

21(5): 1825-37. Article. IF: 9.369; D1

- Fernández LM, Sánchez-Álvarez JE, de la Tassa CM, Fernández JJB, María V, Fernández E, Valdiviuelso JM, Betriú A. Risk factors associated with valvular calcification in patients with chronic kidney disease. Analysis of NEFRONA study. *Nefrología*. 2021; 41(3): 337-46. Article. IF: 3.084; Q2
- Fernández-Juárez G, Rojas-Rivera J, van de Logt AE, Justino J, Sevillano A, Caravaca-Fontan F, Ávila A, Rabasco C, Cabello V, Varela A, Díez M, Martín-Reyes G, Díezhandino MG, Quintana LF, Agraz I, Gómez-Martino JR, Cao M, Rodríguez-Moreno A, Rivas B, Galeano C, Bonet J, Romero A, Shabaka A, Plaisier E, Espinosa M, Egido J, Segarra A, Lambeau G, Ronco P, Wetzels J, Praga M. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. *Kidney Int*. 2021; 99(4): 986-98. Article. IF: 18.998; D1
- González-Parra E, Bover J, Herrero J, Sánchez E, Molina P, Martín-Malo A, Rubio MAB, Lloret S, Navarro J, Arenas MD. Control of phosphorus and prevention of fractures in the kidney patient. *Nefrología*. 2021; 41(1): 7-14. Review. IF: 3.084; Q2
- Heras Benito M, Fernández-Reyes Luis MJ, Martín Varas C, Urzola Rodríguez G. Clinical characteristics of chronic kidney disease (no dialysis) in nonagenarians. *Rev Esp Geriatr Gerontol*. 2021; 56(2): 119-20. Article. Not Indexed
- Herzog R, Sacnun JM, González-Mateo G, Bartosova M, Bialas K, Wagner A, Unterwurzacher M, Sobieszek IJ, Daniel-Fischer L, Rusai K, Pascual-Anton L, Kaczirek K, Vyhytil A, Schmitt CP, López-Cabrera M, Alper SL, Aufricht C, Kratochwill K. Lithium preserves peritoneal membrane integrity by suppressing mesothelial cell alpha B-crystallin. *Sci Transl Med*. 2021; 13(608): eaaz9705. Article. IF: 19.319; D1
- Leon LM, García EG, López MO, Afonso S, Santana MJ, Jiménez C. Immunosuppressive drugs and transplantation protocols. *Arch Esp Urol*. 2021; 74(10): 1002-12. Article. IF: 0.43; Q4
- Maldonado M, Ossorio M, Del Peso G, Santos C, Álvarez L, Sánchez-Villanueva R, Rivas B, Vega C, Selgas R, Bajo MA. COVID-19 incidence and outcomes in a home dialysis unit in Madrid (Spain) at the height of the pandemic. *Nefrología*. 2021; 41(3): 329-36. Article. IF: 3.084; Q2
- Martín-Moreno PL, Sánchez-Fructuoso AI, Mazuecos A, Mir M, López-López I, González-Rinne A, Coca A, Valero R, Galiano AV, Ridaó N, Toa-

- panta-Gaibor NG, Fernández-Tagarro E, Cruzado-Vega L, Pérez-Mir M, Jiménez C. Paternal safety of the use of mycophenolic acid in kidney transplant recipients. Results of the EMVARON study. *Clin Transplant*. 2021; 35(5): e14256. Article. IF: 3.456; Q2
- Morelle J, Marechal C, Yu ZZ, Debaix H, Corre T, Lambie M, Verduijn M, Dekker F, Bovy P, Evenepoel P, Bammens B, Selgas R, Bajo MA, Coester AM, Sow A, Hautem N, Struijk DG, Krediet RT, Balligand JL, Goffin I, Crott R, Ripoché P, Davies S, Devuyt O. AQP1 promoter variant, water transport, and outcomes in peritoneal dialysis. *New Engl J Med*. 2021; 385(17): 1570-80. Article. IF: 176.079; D1
- Paez-Vega A, Cantisan S, Aguera ML, Suner M, Facundo C, Yuste JR, Fernández-Ruiz M, Montejo M, Redondo-Pachón D, López-Oliva MO, Fernández-Rodríguez A, Farinas MC, Hernández D, Len O, Muñoz P, Valle-Arroyo J, Rodelo-Haad C, Cordero E, Torre-Cisneros J. Pretransplant CMV-specific T-cell immunity but not dose of antithymocyte globulin is associated with recovery of specific immunity after kidney transplantation. *J Infect Dis*. 2021; 223(7): 1205-13. Article. IF: 7.759; Q1
- Peces R, Mena R, Peces C, Barruz P, Trujillo H, Carreno A, Espinosa L, Selgas R, Lapunzina P, Nevado J. Historical and geographical distribution of the founder mutation c.610G > A; p.Ala204Thr in the CLCNKB gene linked to Bartter syndrome type III in Spain. *Clin Kidney J*. 2021; 14(8): 1990-3. Letter. IF: 5.86; Q1
- Peces R, Mena R, Peces C, Cuesta E, Lapunzina P, Selgas R, Nevado J. Birth of two healthy girls following preimplantation genetic diagnosis and gestational surrogacy in a rapidly progressive autosomal dominant polycystic kidney disease case using tolvaptan. *Clin Kidney J*. 2021; 14(8): 1987-9. Letter. IF: 5.86; Q1
- Pérez-Torres A, García MEG, Ossorio-González M, García LA, Bajo MA, del Peso G, Plaza AC, Selgas R. The effect of nutritional interventions on long-term patient survival in advanced chronic kidney disease. *Nutrients*. 2021; 13(2): 621. Article. IF: 6.706; Q1
- Pérez-Torres A, Muñoz AC, Arnal LML, Paris AS, Peracho CV, Catalá JL, Villanueva RS, Guldrić SC, González FT, Pérez AN, Amado AS, García MEG, Cuadrado GB. Multidisciplinary nutritional consensus on assessment and nutritional dietary treatment in patients with chronic kidney disease and SARS-CoV-2 infection. *Nefrología*. 2021; 41(4): 453-60. Article. IF: 3.084; Q2

- Portoles J, Vega A, Lacoba E, López-Sánchez P, Botella M, Yuste C, Cleary CM, Ballesteros SS, Sanchidrián SG, García LS, Carreno A, Bajo MA, Janeiro D, Tato A, Molano B, Cleary CM, Escribano A, Vian J, Ballesteros SS, Vega A, Martínez A, Campos J, Bajo MA, del Peso G, Palomares JRR, Carreno A, Felipe C, Perpen A, Hernández MJ, Moreno F, García LS, Gorrín MR, Burguera A, Fernández-Reyes MJ, Rodríguez A, Hevia C, Lorenzo M, Paraiso V, Sanchidrián SG, Tornero F, Hernández E, Ortega M, Gutiérrez BC, Benito J, Ortega O, Herrero JC, Pizarro MS. Is peritoneal dialysis suitable technique CKD patients over 65 years? A prospective multicenter study. *Nefrología*. 2021; 41(5): 529-38. Article. IF: 3.084; Q2
- Portoles JM, Jiménez C, Janeiro D, López-Oliva MO, Ortega-Carrion A, Blanquez D, Arribas L, Gómez C, Díez T, Pascual J, Portero I. The immunobiogram, a novel in vitro assay to evaluate treatment resistance in patients receiving immunosuppressive therapy. *Front Immunol*. 2021; 11: 618202. Article. IF: 8.786; Q1
- Rodríguez-Diez RR, Tejera-Muñoz A, Orejudo M, Márquez-Expósito L, Santos L, Rayego-Mateos S, Cantero-Navarro E, Tejedor-Santamaría L, Marchant V, Ortiz A, Egido J, Mezzano S, Selgas R, Navarro-González JF, Valdiviuelso JM, Lavoz C, Ruiz-Ortega M. Interleukin-17A: Potential mediator and therapeutic target in hypertension. *Nefrología*. 2021; 41(3): 244-57. Review. IF: 3.084; Q2
- Ruiz-Ruigómez M, Fernández-Ruiz M, Silva JT, Vidal E, Origen J, Calvo-Cano A, Luna-Huerta E, Merino E, Hernández D, Jironda-Gallegos C, Escudero-Sánchez R, Gioia F, Moreno A, Roca C, Cordero E, Janeiro D, Sánchez-Sobrinho B, Montero MM, Redondo D, Candel FJ, Pérez-Flores I, Arminanzas C, González-Rico C, Farinas MC, Rodrigo E, Loeches B, López-Oliva MO, Montejo M, Lauzurica R, Horcajada JP, Pascual J, Andres A, Aguado JM, López-Medrano F. Efficacy and safety of oral fosfomycin for asymptomatic bacteriuria in kidney transplant recipients: results from a spanish multicenter cohort. *Antimicrob Agents Ch*. 2021; 65(5): e02267-20. Article. IF: 5.938; Q1
- Solache-Berrocal G, Rolle-Sonora V, Martín-Fernández N, Cambay S, Valdiviuelso JM, Rodríguez I. CYP2A1 and KL polymorphisms are associated with the extent of vascular calcification but do not improve prediction of cardiovascular events. *Nephrol Dial Transpl*. 2021; 36(11): 2076-83. Article. IF: 7.186; Q1
- van Gelder MK, Vollenbroek JC, Lentferink BH,

- Hazenbrink DHM, Besseling PJ, Simonis F, Giovannella S, Ligabue G, Rubio MBA, Cappelli G, Joles JA, Verhaar MC, Gerritsen KGF. Safety of electrooxidation for urea removal in a wearable artificial kidney is compromised by formation of glucose degradation products. *Artif Organs*. 2021; 45(11): 1422-28. Article. IF: 2.663; Q3
- Villanego F, Mazuecos A, Pérez-Flores IM, Moroso F, Andres A, Jiménez-Martín C, Molina M, Canal C, Sánchez-Camara LA, Zarraza S, Ruiz-Fuentes MD, Aladren MJ, Melilli E, López V, Sánchez-Álvarez E, Crespo M, Pascual J. Predictors of severe COVID-19 in kidney transplant recipients in the different epidemic waves: Analysis of the Spanish Registry. *Am J Transplant*. 2021; 21(7): 2573-82. Article. IF: 9.369; D1
- Zamarrón E, Jaureguizar A, García-Sánchez A, Díaz-Cambriles T, Alonso-Fernández A, Lores V, Mediano O, Rodríguez-Rodríguez P, Cabello-Pelegrin S, Morales-Ruiz E, Ramirez-Prieto MT, Valiente-Díaz MI, Gómez-García T, García-Río F. Obstructive sleep apnea is associated with impaired renal function in patients with diabetic kidney disease. *Sci Rep-Uk*. 2021; 11(1): 5675. Article. IF: 4.996; Q2

■ Research projects

Bajo Rubio MA. Abordaje nutricional en pacientes con enfermedad renal. Frese-nius Kabi España S.A.U. 2021-Ongoing.

Management centre: FIBHULP

Bajo Rubio MA. Biopsia líquida en diálisis peritoneal: correlación biopsia / efluente peritoneal (PI18/00882). ISCIII. 2019-2023.

Management centre: FIBHULP

Bajo Rubio MA. Clinical validation of a continuous flow peritoneal dialysis system, with dialysate regeneration (COR-DIAL). UE. 2020-2024.

Management centre: FIBHULP

Bajo Rubio MA. Las células mesoteliales del efluente crecidas ex vivo reflejan las alteraciones peritoneales encontradas en la biopsia peritoneal. Oportuni-



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

dades adicionales para biomarcadores en el efluente. Fundación SENEPRO. 2016-Ongoing.

Managment centre: FIBHULP

Jiménez Martín C. Desarrollo y aplicación de un programa grupal de atención psicológica basada en las preferencias y valores con el objetivo de mejora de resultados en salud en el paciente con trasplante renal. Astellas Pharma S.A. 2018-Ongoing.

Managment centre: FIBHULP

Jiménez Martín C. Evaluación de la microcirculación cortical (MCC) del trasplante renal a largo plazo medida por ecografía con contraste (EC) y su correlación histopatológica por biopsia renal. Sociedad Madrileña de Trasplantes. 2019-Ongoing.

Managment centre: FIBHULP

Sánchez Villanueva R. Creación de un centro de referencia para el estudio de los mecanismos implicados en las reacciones de hipersensibilidad a las membranas de hemodialisis basadas en polysulfona. Nipro Europe Nv. 2017-Ongoing.

Managment centre: FIBHULP

■ Cibers & Retics

Bajo Rubio MA. Red de Investigación Renal. (RD16/0009/0008). ISCIII. (31/12/2022).

Managment centre: FIBHULP

Bajo Rubio MA. Red de Investigación Renal. (RD21/0005/0018). ISCIII. (31/12/2024).

Managment centre: FIBHULP

■ Clinical trials

Bajo Rubio, MA. Respuesta inmune y seguridad de la vacunación COVID-19 en pacientes con ERC avanzada, en diálisis y trasplantados renales.

Type: Estudios, phase EPA-OD.

HULP code: PI-4709 SENCOVAC.

Sponsored by: Grupo Español De Estudio De La Nefropatía Diabética.

Signed date: 05/03/2021

Jiménez Martín, C. Estudio en fase II, abierto, aleatorizado y de varias cohortes para evaluar la eficacia, la seguridad y la farmacocinética preliminares de bivv020 para la prevención y el tratamiento del rechazo mediado por anticuerpos en adul-

tos receptores de trasplante renal.

Type: Clinical Trials, phase II.

HULP code 5940 ACT17012.

Sponsored by: Sanofi-Aventis Recherche & Developpement.

Signed date: 29/10/2021

■ Patents and trademarks



Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of pyridazine[1',6':1,2]pyrido[3,4-b]indolinium as anti-inflammatory agents. P201331143, PCT/ES2014/070603; 2013 July 25.

Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of piridazine[3,2-b]benzimidazolium as anti-inflammatory agents. P201430411, PCT/ES2014/070603; 2013 July 25.

Aguilera Peralta AI, López-Cabrera M, Selgas Gutiérrez R, Steppan S, Passlickdeetjen J, inventors; Fresenius Medical Care Deutschland GMBH, assignee. Pharmaceutical compositions containing steviosides. EP14191301.2, PCT/EP2015/074955, CN107073022, US10213452; 2014 October 31.

López-Cabrera M, Aguilera Peralta AI, Selgas Gutiérrez R, Passlickdeetjen J, Buechel J, Steppan S, inventors; Fresenius Medical Care AG & Co. KGaA, assignee. Method and kit for diagnosing epithelial to mesenchymal transition of the peritoneum (EMT-Chip). DE102015115158.8, PCT/EP2016/071149, CN108449998B, EP3347715B1, ES2833553T3, JP6869963B2, US2018246098A1; 2015 September 09.

Sánchez Niño MD, Ortiz Arduán A; FIBHULP, Instituto de Investigación Sanitaria Fundación Jiménez Díaz. Pharmaceutical composition and its use in the manufacture of a medicament for treating chronic kidney disease and method for selecting compounds. P201430081, PCT/ES2015/070039; 2014 January 27.



3.4.6 Aging and Fragility in the Elderly Group

Publications: 12
Q1: 2

COMPOSITION



■ **Juan Ignacio González Montalvo.**

Jefe de Servicio de Geriátria. Hospital Universitario La Paz. Profesor Asociado. Universidad Autónoma de Madrid

Juan Carlos Abánades Herranz. Subdirector Médico. Responsable de la Unidad de Formación e Investigación. Atención Primaria

María Teresa Alarcón Alarcón. Jefe de Sección de Geriátria. Hospital Universitario La Paz

Juan Cárdenas Valladolid. Técnico de la Gerencia Adjunta de Planificación y Calidad de Atención Primaria. Atención Primaria

María Victoria Castell Alcalá. Facultativo Especialista de Área en Medicina Familiar y Comunitaria. Atención Primaria

Patricia Ysabel Condorhuamán Alvarado. Facultativo Especialista de Área en Geriátria. Hospital Universitario La Paz

Carmen de Burgos Lunar. Facultativo Especialista de Área en Medicina Preventiva. Hospital Universitario La Paz

Macarena Díaz de Bustamante de Ussía. Médico Interno Residente. Hospital Universitario La Paz

Araceli Garrido Barral. Facultativo Especialista de Área en Medicina Familiar y Comunitaria. Atención Primaria

Paloma Gómez Campelo. Subdirectora Científica de IdiPAZ. Investigador Postdoctoral. FIBHULP

Pilar Gotor Pérez. Enfermera. Unidad de Valoración Geriátrica y Orto geriátria. Hospital Universitario La Paz

Alicia Gutiérrez Misis. Profesor ayudante Doctor. Universidad Autónoma de Madrid

Rosa Julián Viñals. Facultativo Especialista de Área en Medicina Familiar y Comunitaria. Centro de Salud Raúl de Castroviejo. Atención Primaria

Rocío Menéndez Colino. Facultativo Especialista de Área en Geriátria. Hospital de Cantoblanco - Hospital Universitario La Paz

Débora Moral Cuesta. Médico Interno Residente en Geriátria. Hospital Universitario La Paz

Ángel Otero Puime. Profesor Emérito de Medicina Preventiva y Salud Pública. Universidad Autónoma de Madrid.

Rocío Queipo Matas. Investigadora Predoctoral. Universidad Autónoma de Madrid

Raquel Ramírez Martín. Médico Interno Residente. Hospital Universitario La Paz

Peggy Paola Ríos Germán. Médico Interno Residente en Geriátria. Hospital Universitario La Paz

Ana María Rosas Hernández. Investigadora Predoctoral. Universidad Autónoma de Madrid

María del Pilar Sáez López. Facultativo Especialista de Área en Geriátria. Complejo Asistencial de Ávila

Miguel Ángel Salinero Fort. Gerente Adjunto de Planificación y Calidad. Atención Primaria


Mercedes Sánchez Martínez. Profesor Asociado. Universidad Autónoma de Madrid

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

STRATEGIC OBJECTIVE

o promote and improve the quality of research in the field of Primary Health Care and Geriatrics in the area of influence of IdiPAZ.

Progress in the epidemiological study of frailty in the elderly.

To consolidate clinical studies related to hip fracture and acute and chronic diseases in the elderly.

RESEARCH LINES

- Coordination of the National Registry of Hip Fractures: a multi-center observational study including patients from 75 Spanish hospitals with an acute fragility hip fracture. The registry collects

data from the acute hospital phase and a one-month follow-up from about 80 Spanish hospitals.

- Study of the influence of frailty in the implantation of transcatheter aortic valve. Multicenter project that includes data from five Spanish hospitals
- Cross-specificity Geriatrics: Co-management of old patients diagnosed of cancer in collaboration with the General Surgery, Medical and Radioterapeutic Oncology, Urology and Vascular Surgery Departments of the La Paz Hospital.
- Observational study of the evolution of old patients affected of a traumatic intracranial hemorrhage, in collaboration with the Neurosurgery Department of the La Paz Hospital.

RESEARCH ACTIVITY

■ Publications

- Castell-Alcala MV, Prieto-Aldana M, Gutiérrez-Misis A, Julián Vinals R, Schwarz C, Gálvez-Fernández M, Rodríguez-Barrientos R, Polentinos-Castro E. Quality of life and physical activity in prefrail individuals over 70 years in primary care. *Rev Esp Salud Publica.* 2021; 95: e202110160. Article. IF: 1.333; Q4
- Castellón P, Núñez JH, Mori-Gamarra F, Ojeda-Thies C, Sáez-López P, Salvador J, Angles F, González-Montalvo JI. Hip fractures in Spain: are we on the right track? Statistically significant differences in hip fracture management between Autonomous Communities in Spain. *Arch Osteoporos.* 2021; 16(1): 40. Article. IF: 2.879; Q2
- Colino RM, de Miguel AM, Argentina F, Marqués MB, Jiménez BC, Hernández PL, Bueno SJ, Vega MDM, Rodríguez JG, Simo BF, Fernández MAN, del Toro TR, Alarcón TA, Peromingo FJM, González-Montalvo JI. Evolution of COVID-19 at nursing homes from the second wave to vaccination. Description of a coordination program between Primary Care, Geriatrics and Public Health. *Rev Esp Salud Publica.* 2021; 95: e1-11. Article. IF: 1.333; Q4
- de Villambrosia CG, López PS, de Diego IM, Martín CL, Santa Teresa MC, Alarcón T, Thies CO, Matas RQ, González-Montalvo JI. Predictive model of gait recovery at one month after

hip fracture from a national cohort of 25,607 patients: the hip fracture prognosis (hf-prognosis) tool. *Int J Env Res Pub He.* 2021; 18(7): 3809. Article. IF: 4.614; Q1

- Feliú J, Pinto A, Basterretxea L, López-San Vicente B, Paredero I, Llabres E, Jiménez-Munárriz B, Antonio-Rebollo M, Losada B, Espinosa E, Girones R, Custodio AB, Muñoz MD, Díaz-Almirón M, Gómez-Mediavilla J, Torregrosa MD, Soler G, Cruz P, Higuera O, González-Montalvo JI, Molina-Garrido MJ. Development and validation of an early mortality risk score for older patients treated with chemotherapy for cancer. *J Clin Med.* 2021; 10(8): 1615. Article. IF: 4.964; Q2
- Gutiérrez-Misis A, Queipo R, Castell MV, Alarcón T, Menéndez-Colino R, Ojeda-Thies C, Puime AO, González-Montalvo JI. Mortality among older Spanish people with hip fractures: a population-based matched cohort study. *Aging Clin Exp Res.* 2021; 33(11): 3141-3. Letter. IF: 4.481; Q2
- Herbolzheimer F, Ungar N, Portegijs E, Dallmeier D, Schaap L, Smith T, Stubbs B, Deeg D, Peter R, Castell MV, Otero A, Edwards M, Siviero P, Limongi F, Dennison E, van Schoor N, Veronese N, Timmermans EJ, van der Pas S. Neighborhood environment, social participation, and physical activity in older adults with lower limb osteoarthritis: A mediation analysis. *Health Place.* 2021; 68: 102513. Article. IF: 4.931; Q1
- Menéndez-Colino R, Argentina F, de Miguel AM,

Barcons Marques M, Chaparro Jiménez B, Figueroa Poblete C, Alarcón T, Martínez Peromingo FJ, González-Montalvo JI. Liaison geriatrics with nursing homes in COVID time. A new coordination model arrived to stay. *Rev Esp Geriatr Gerontol.* 2021; 56(3): 157-65. Article. Not Indexed

- Menéndez-Colino R, Misis AG, Alarcón T, Díez-Sebastián J, de Bustamante MD, Queipo R, Otero A, González-Montalvo JI. Development of a new comprehensive preoperative risk score for predicting 1-year mortality in patients with hip fracture: the HULP-HF score. Comparison with 3 other risk prediction models. *Hip Int.* 2021; 31(6): 804-11. Article. IF: 1.756; Q3
- Puime AO, Gutiérrez-Misis A, Toledo-Bartolomé D, Saez-López P, Gómez-Campelo P, Ojeda-Thies C, Matzucchelli R, González-Montalvo JI. The Spanish National Hip Fractures Registry (RNFC) and the Minimum Basic Data Set (CMBD) are useful for research on hip fractures: comparison of two registries. *Rev Esp Salud Publica.* 2021; 95: e202111195. Article. IF: 1.333; Q4
- Ríos-Germán PP, Gutiérrez-Misis A, Queipo R, Ojeda-Thies C, Sáez-López P, Alarcón T, Puime AO, Gómez-Campelo P, Navarro-Castellanos L, González-Montalvo JI. Differences in the baseline characteristics, management and outcomes of patients with hip fractures depending on their pre-fracture place of residence: the Spanish National Hip Fracture Registry (RNFC) cohort. *Eur*

Geriatr. Med. 2021; 12(5): 1021-9. Article. IF: 3.269; Q3

- Siviero P, Limongi F, Gesmundo A, Zambon S, Cooper C, Dennison EM, Edwards MH, van der Pas S, Timmermans EJ, van Schoor NM, Schaap LA, Dallmeier D, Denking MD, Peter R, Castell MV, Otero A, Pedersen NL, Deeg DJH, Maggi S. Factors associated with functional decline in hand and hip/knee osteoarthritis after one year: data from a population-based study. *Arthrit Care Res.* 2021; 73(9): 1343-53. Article. IF: 5.178; Q2

■ Research projects


Gómez Campelo P. Nodo científico Biobanco HULP. Instituto Salud Carlos III. 2014-Ongoing.

Management centre: FIBHULP

González Montalvo JI, Gómez Campelo P. Registro nacional de fracturas de cadera estudio RNFC. Fundación Mutua Madrileña. 2018-Ongoing.

Management centre: FIBHULP

González Montalvo JI. Geriatria transversal: detección y manejo de la fragili-



1
Introduction

2
Executive
Summary

3
Information
Groups
by Area

4
Associated
Clinicians

dad en pacientes adultos mayores con patología quirúrgica. Varios. 2019-Ongoing.

Managment centre: FIBHULP

González Montalvo JI. Prevención secundaria de fracturas por fragilidad: descripción del tipo de pacientes y del funcionamiento de una fracture liaison service en pacientes con fractura de cadera tratados en un Servicios de Ortopediátrica. Amgen S. A. 2018-Ongoing.

Managment centre: FIBHULP

González Montalvo JI. Proyecto del registro nacional de fracturas de cadera por fragilidad en el anciano. Amgen S. A. 2017-Ongoing.

Managment centre: FIBHULP

Menéndez Colino R. Impacto de una intervención multidisciplinaria en el pronóstico de pacientes frágiles con estenosis aórtica severa sintomática: ensayo randomizado. (PI19/01010). ISCIII. 2020-2022.

Managment centre: FIBHULP

■ Cibers & Retics

Gómez Campelo P. Plataforma Red de Biobancos. (PT17/0015/0025). ISCIII. (28/02/2021).

Managment centre: FIBHULP



Gómez Campelo P. Plataforma de biobanco y biomodelos (organoides) del Instituto de Investigación sanitaria del Hospital Universitario la Paz. (PT20/00004). ISCIII. (31/12/2023).

Managment centre: FIBHULP

Gómez Campelo P. Researcher Mental Health. (CA19117). EU. (31/12/2024).

Managment centre: FIBHULP





3.4.7 Diagnosis and Treatment of Allergic Diseases Group

Publications: 49

Q1: 32

COMPOSITION



■ **Santiago Eugenio Quirce Gancedo.** Jefe de Servicio de Alergología. Hospital Universitario La Paz

María Luisa Caballero Soto. Facultativo Especialista de Área en Inmunología. Hospital Universitario La Paz

María Pilar Encarnación Barranco Sanz. Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz

María Teresa Caballero Molina. Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz

Francisco Javier Contreras Porta. Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz

Leticia de las Vecillas Sánchez. Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz

Francisco Javier Domínguez Ortega. Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz

Ana María del Carmen Fiandor Román. Jefe de Sección de Alergología. Hospital Universitario La Paz
Carmen Gómez Traseira. Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz

Juan Alberto Luna Porta. Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz

María Magdalena Lluch Bernal. Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz

María Pedrosa Delgado. Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz

Elsa Phillips Angles. Facultativo Especialista de Área en Alergología Pediátrica. Hospital Universitario La Paz

Mónica Rodríguez Álvarez. Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz

María Rosa Rodríguez Pérez. Investigadora Senior (Contrato Miguel Servet- Tipo 2). Hospital Universitario La Paz

Margarita Tomás Pérez. Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz

Ana María Umpiérrez Rodríguez. Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz

STRATEGIC OBJECTIVE

These group members are specialists in various areas of allergic diseases, which enable them to perform clinical studies and basic research on the main allergic diseases (food allergies, asthma and rhini-

tis, urticaria/ angiooedema and drug allergies). The group's strategic research objectives include:


- The development of new techniques to improve the diagnosis of food allergies by determining the molecular sensitisation profile

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

- The study of hyperresponsiveness and airway inflammation in asthma, as well as the role of allergen exposure and comorbidities in this disease
- The study of the pathogenesis and treatment of eosinophilic diseases of the airways (eosinophilic bronchitis) and the gastrointestinal tract (eosinophilic oesophagitis)
- The characterisation of various types of angioedema caused by Bradykinin (hereditary and acquired) and improvements in their diagnosis and treatment
- Research on the epidemiology and pathomechanisms of severe adverse reactions caused by immune hypersensitivity reactions to drugs.

- Studies on bronchial hyperresponsiveness to direct and indirect agents and airway inflammation
- Eosinophilic diseases of the respiratory tract (eosinophilic bronchitis) and digestive system (eosinophilic esophagitis)
- Persistent and difficult to control asthma: study on the influence of common and occupational allergens, comorbidities and new therapies
- Aspirin-exacerbated respiratory disease (AERD): inflammatory markers and desensitisation protocol
- Adverse immunologic reactions to drugs: study on the cellular and molecular mechanisms involved
- Molecular basis of allergy: characterization of allergens and modulating factors of allergenicity. Novel allergy biomarkers: microRNAs and mRNAs. Seeking the differences of specific IgE between allergic patients and asymptomatic individuals.
- Study of hypersensitivity reactions due to excipients present in the formulation of drugs, vaccines and cosmetics

RESEARCH LINES

- Food allergy (milk, egg, fruit, cereals): molecular diagnosis (by allergenic components) and treatment with oral desensitisation
- Epidemiology, physiopathology, diagnosis and treatment of angioedema and urticaria

RESEARCH ACTIVITY

■ Doctoral theses

Gómez Traseira C. Estudio en viuda real de las características clínicas, analíticas y de manejo terapéutico de pacientes con angioedema hereditario por déficit del inhibidor de la C1 esterasa (AEH-C1-INH) [dissertation]. Madrid: UAM: 2021(19/09/2021).

Director: Caballero Molina MT.

■ Publications

- Almonacid C, Blanco-Aparicio M, Domínguez-Ortega J, Giner J, Molina J, Plaza V. Teleconsultation in the follow-up of the asthma patient. Lessons after COVID-19. Arch Bronconeumol. 2021; 57: 13-4. Editorial Material. IF: 6.333; Q1
- Barranco P, Palao P, Ruiz I, Domínguez-Ortega J, Vila-Nadal G, Pola B, Quirce S. Relationship between IGE-mediated sensitization to staphylo-


coccus aureus enterotoxin B, asthma severity, and atopy. J Invest Allerg Clin. 2021; 31(2): 170-3. Editorial Material. IF: 8.185; Q1

- Bernstein JA, Bouillet L, Caballero T, Staevska M. Hormonal effects on urticaria and angioedema conditions. J Allergy Clin Immunol Pract. 2021; 9(6): 2209-19. Review. IF: 11.022; Q1
- Betancourt A, Zapatero A, Pola-Bibian B, Domínguez-Ortega J. Impact of short-term exposure to below recommended PM10 pollution levels on asthma exacerbations. J Invest Allerg Clin. 2021; 31(5): 439-40. Editorial Material. IF: 8.185; Q1
- Bork K, Anderson JT, Caballero T, Craig T, Johnston DT, Li HH, Longhurst HJ, Radojicic C, Riedl MA. Assessment and management of disease burden and quality of life in patients with hereditary angioedema: a consensus report. Allergy Asthma Clin Immunol. 2021; 17(1): 40. Review. IF: 3.373; Q3
- Brix ATH, Boysen HB, Weller K, Caballero T, Bygum A. Patient-reported outcome measures for angioedema: A literature review. Acta Derm-Venerol. 2021; 101: adv00456. Review. IF: 3.875; Q2

- Caballero ML, Domínguez-Ortega J, Nin-Valencia AR, Sánchez-Ocando H, Barranco P. Eosinophil count could be more sensitive in induced sputum than in peripheral blood for phenotyping of patients with severe eosinophilic asthma. J Invest Allerg Clin. 2021; 31(4): 360-1. Letter. IF: 8.185; Q1
- Caballero ML, Krantz MS, Quirce S, Phillips EJ, Stone CA. Hidden dangers: recognizing excipients as potential causes of drug and vaccine hypersensitivity reactions. J Allergy Clin Immunol Pract. 2021; 9(8): 2968-82. Review. IF: 11.022; Q1
- Caballero ML, Quirce S. Excipients as potential agents of anaphylaxis in vaccines: analyzing the formulations of currently authorized COVID-19 vaccines. J Invest Allerg Clin. 2021; 31(1): 92-3. Letter. IF: 8.185; Q1
- Caballero T. Treatment of hereditary angioedema. J Invest Allerg Clin. 2021; 31(1): 1-16. Review. IF: 8.185; Q1
- Corvillo F, González-Sánchez L, López-Lera A, Arjona E, Ceccarini G, Santini F, Araujo-Vilar D, Brown RJ, Villarroya J, Villarroya F, de Cordo-

ba SR, Caballero T, Nozal P, López-Trascasa M. Complement factor D (adipsin) levels are elevated in acquired partial lipodystrophy (Barraquer-Simons syndrome). Int J Mol Sci. 2021; 22(12): 6608. Article. IF: 6.208; Q1

- Couto M, Bernard A, Delgado L, Drobnic F, Kurowski M, Moreira A, Rodrigues-Alves R, Rukhadze M, Seys S, Wiszniewska M, Quirce S. Health effects of exposure to chlorination by-products in swimming pools. Allergy. 2021; 76(11): 3257-75. Article. IF: 14.71; D1
- Dafaue L, Romero D, Carpio C, Barga P, Quirce S, Villasante C, Bravo MF, Álvarez-Sala R. Psychodemographic profile in severe asthma and effect of emotional mood disorders and hyperventilation syndrome on quality of life. BMC Psychol. 2021; 9(1): 3. Article. IF: 2.588; Q2
- de Llano LAP, Gancedo SQ, Moral VP. Treatment of moderate-severe asthma: an alternative strategy to the guidelines recommendations. Arch Bronconeumol. 2021; 57(4): 243-5. Editorial Material. IF: 6.333; Q1
- de Llano LP, Davila I, Martínez-Moragon E, Domínguez-Ortega J, Almonacid C, Colas C,



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

- García-Rivero JL, Carmona L, de Yébenes MJG, Cosío BG. Development of a tool to measure the clinical response to biologic therapy in uncontrolled severe asthma: the FEV1, exacerbations, oral corticosteroids, symptoms score. *J Allergy Clin Immunol Pract.* 2021; 9(7): 2725-31. Article. IF: 11.022; Q1
- Delgado J, Dávila IJ, Domínguez-Ortega J. Clinical recommendations for the management of biological treatments in severe asthma patients: a consensus statement. *J Invest Allerg Clin.* 2021; 31(1): 36-43. Review. IF: 8.185; Q1
 - Esteban-Gorgojo I, Gorgojo MP, Sastre J, Quirce S. Food allergy as an asthma comorbidity in children and adolescents: a practical approach through a real-world study. *Allergol Immunopath.* 2021; 49(1): 68-78. Article. IF: 2.094; Q4
 - Farkas H, Reshef A, Caballero T, López MCO, Kessel A, Vardi M, Hao JM, Aberer W. Continued icatibant use across recurrent attacks in adolescents with hereditary angioedema. *Pediatr Allerg Immun-Uk.* 2021; 32(6): 1392-96. Letter. IF: 5.464; D1
 - Forjaz MJ, Ayala A, Caminoa M, Prior N, Pérez-Fernández E, Caballero T. HAE-AS: A specific disease activity scale for hereditary angioedema with c1-inhibitor deficiency. *J Invest Allerg Clin.* 2021; 31(3): 246-52. Article. IF: 8.185; Q1
 - Guilarte M, Sala-Cunill A, Baeza ML, Cabañas R, Hernández MD, Ibanez E, de Larramendi CH, Leonart R, Lobera T, Marques L, Pedro BSD, Botha J, Andresen I, Caballero T. Hereditary angioedema due to C1 inhibitor deficiency: real-world experience from the Icatibant Outcome Survey in Spain. *Allergy Asthma Clin Immunol.* 2021; 17(1): 137. Article. IF: 3.373; Q3
 - Lee EY, Hsieh J, Borici-Mazi R, Caballero T, Kananí A, Lacuesta G, McCusker C, Wasserman S, Betschel S. Quality of life in patients with hereditary angioedema in Canada. *Ann Allerg Asthma Im.* 2021; 126(4): 394-400 Article. IF: 6.248; Q2
 - Loli-Ausejo D, de Abreu JMG, Fiandor A, Cabañas R, Domínguez-Ortega F, Caballero ML, Lluch-Bernal M, García-Panto CR, Núñez MC, Quirce S. Allergic reactions after administration of Pfizer-BioNTech COVID-19 vaccine to health care workers at a tertiary hospital. *J Invest Allerg Clin.* 2021; 31(6): 507-8. Editorial Material. IF: 8.185; Q1
 - Loli-Ausejo D, López-Lera A, Drouet C, Llluncor M, Phillips-Angles E, Pedrosa M, Cabanas R, Caballero T. In search of an association between genotype and phenotype in hereditary angioedema due to C1-INH deficiency. *Clin Rev Allerg Immu.* 2021; 61(1): 1-14. Article. IF: 10.817; Q1
 - Loli-Ausejo D, Pedrosa M, Rodríguez-Pérez R, Hurtado JL, Pérez-Tavarez R, Gasset M. Fish transformations and allergenicity. *Rev Esp Nutr Hum Diet.* 2021; 25: 61-2. Article. Not Indexed
 - Loli-Ausejo D, Vilchez-Sánchez F, Cabanas R, Fiandor A, Lluch-Bernal M, González-Munoz M, Domínguez-Ortega J. Basophil activation test in the diagnosis of hypersensitivity reactions to quinolones in a real-life setting. *Clin Exp Allergy.* 2021; 51(3): 503-7. Letter. IF: 5.401; Q2
 - López-Gálvez R, de la Morena-Barrio ME, Minano A, Pathak M, Marcos C, Emsley J, Caballero T, López-Trascasa M, Vicente V, Corral J, López-Lera A. Thrombin in the activation of the fluid contact phase in patients with hereditary angioedema carrying the F12 P.Thr309Lys variant. *Clin Rev Allerg Immu.* 2021; 60(3): 357-68. Article. IF: 10.817; Q1
 - Lumry WR, Zuraw B, Cicardi M, Craig T, Anderson J, Banerji A, Bernstein JA, Caballero T, Farkas H, Gower RG, Keith PK, Levy DS, Li HH, Magerl M, Manning M, Riedl MA, Lawo JP, Prusty S, Machnig T, Longhurst H. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study. *Orphanet J Rare Dis.* 2021; 16(1): 86. Article. IF: 4.307; Q2
 - Marqués-Mejías MA, Entrala A, Cabanas R, Caballero T. Mediastinal angioedema: A rare manifestation of hereditary angioedema. *J Allergy Clin Immunol Pract.* 2021; 9(1): 477-8. Editorial Material. IF: 11.022; Q1
 - Maurer M, Aygören-Pursun E, Banerji A, Bernstein JA, Boysen HB, Busse PJ, Bygum A, Caballero T, Castaldo AJ, Christiansen SC, Craig T, Farkas H, Grumach AS, Hide M, Katelaris CH, Li HH, Longhurst H, Lumry WR, Magerl M, Martínez-Saguer I, Riedl MA, Zhi YX, Zuraw B. Consensus on treatment goals in hereditary angioedema: A global Delphi initiative. *J Allergy Clin Immunol.* 2021; 148(6): 1526-32. Article. IF: 14.29; D1
 - Maurer M, Caballero T, Aberer W, Zanichelli A, Bouillet L, Bygum A, Grumach AS, Botha J, Andresen I, Longhurst HJ. Variability of disease activity in patients with hereditary angioedema type 1/2: longitudinal data from the Icatibant Outcome Survey. *J Eur Acad Dermatol.* 2021; 35(12): 2421-30. Article. IF: 9.228; D1
 - Migueles N, Vandenplas O, Suojalehto H, Walusiak-Skorupa J, Muñoz X, Sastre J, Merget R, Moscato G, Quirce S, Meyer N, Godet J, de Bloy F. Phenotypes of occupational asthma defined with induced sputum after specific inhalation challenge. *Rev Fr Allergol.* 2021; 61(4): 223-5. Article. IF: 0.254; Q4
 - Molina-París J, Trigueros JA, Gómez-Sáenz JT, Puente-Maestu L, Julia B, Domínguez-Ortega J. Perceptions of family doctors, pulmonologists and allergists on the approach to patients with chronic cough. Results of an anonymous survey. *Semergen.* 2021; 47(6): 376-84. Article. Not Indexed
 - Nunes FL, Ferriani MPL, Moreno AS, Langer SS, Maia LSM, Ferraro MF, Sarti W, de Bessa J, Cunha D, Suffritti C, Dias MM, Januario YC, da-Silva LLP, Aragon DC, Caballero T, Arruda LK. Decreasing attacks and improving quality of life through a systematic management program for patients with hereditary angioedema. *Int Arch Allergy Imm.* 2021; 182(8): 697-708. Article. IF: 3.767; Q3
 - Olaguibel JM, Alobod I, Puebla A, Crespo-Lessmann A, Ortega D, García-Río F, Izquierdo-Domínguez A, Mulla J, Plaza V, Quirce S, Rojas-Lechuga MJ, Valverde-Monge M, Sastre J. Functional examination of the upper and lower airways in asthma and respiratory allergic diseases: considerations in the post-SARS-CoV-2 era. *J Invest Allerg Clin.* 2021; 31(1): 17-35. Review. IF: 8.185; Q1
 - Pedrosa M, Loli-Ausejo D, García-Lozano JR, Fiandor A, Lluch-Bernal M, Hurtado JL, Domínguez-Ortega J, Quirce S, Gasset M, Rodríguez-Pérez R. The burden of allergens in surimi-based products diminishes with industrial processing. *J Invest Allerg Clin.* 2021; 31(5): 443-5. Editorial Material. IF: 8.185; Q1
 - Pérez-Tavárez R, Moreno HM, Borderias J, Loli-Ausejo D, Pedrosa M, Hurtado JL, Rodríguez-Pérez R, Gasset M. Fish muscle processing into seafood products reduces f3-parvalbumin allergenicity. *Food Chem.* 2021; 364: 130308. Article. IF: 9.231; D1
 - Pfeiffer S, Sandler P, Raith M, Pascal M, Muñoz-Cano RM, San Bartolome C, Nobauer K, Quirce S, Razzazi-Fazeli E, Focke-Tejkl M, Sterflinger K, Swoboda I. Identification of Ulocladium chartarum as an important indoor allergen source. *Allergy.* 2021; 76(10): 3202-6. Letter. IF: 14.71; D1
 - Plaza V, Trigueros JA, Cisneros C, Domínguez-Ortega J, Cimbalsek S, Fernández S, Hernández J, López JD, Ojanguren I, Padilla A, Pallares A, Sánchez-Toril FJ, Torrego A, Urrutia I, Quirce S. The importance of small airway dysfunction in asthma: The GEMA-FORUM III task force. *J Invest Allerg Clin.* 2021; 31(5): 433-6. Editorial Material. IF: 8.185; Q1
 - Puente-Maestu L, Molina-París J, Trigueros JA, Gómez-Sáenz JT, Cea-Calvo L, Fernández S, Sánchez-Jareno M, Domínguez-Ortega J. A Survey of physicians' perception of the use and effectiveness of diagnostic and therapeutic procedures in chronic cough patients. *Lung.* 2021; 199(5): 507-15. Article. IF: 3.777; Q3
 - Quirce S, Domínguez-Ortega J, Luna JA. Novel approaches in occupational asthma diagnosis and management. *Curr Opin Pulm Med.* 2021; 27(1): 9-14. Review. IF: 2.868; Q4
 - Rial MJ, Álvarez-Puebla MJ, Arismendi E, Caballero ML, Canas JA, Cruz MJ, González-Barcala FJ, Luna JA, Martínez-Rivera C, Mulla J, Muñoz X, Olaguibel JM, Picado C, Plaza V, Quirce S, Romero-Mesones C, Salgado FJ, Sastre B, Soto-Retes L, Valero A, Valverde M, Sastre J, del Pozo V. Clinical and inflammatory characteristics of patients with asthma in the Spanish MEGA project cohort. *Clin Transl Allergy.* 2021; 11(1): e12001. Article. IF: 5.657; Q2
 - Rial MJ, Valverde M, del Pozo V, González-Barcala FJ, Martínez-Rivera C, Muñoz X, Olaguibel JM, Plaza V, Curto E, Quirce S, Barranco P, Domínguez-Ortega J, Mulla J, Picado C, Valero A, Bobolea I, Arismendi E, Ribo P, Sastre J. Clinical characteristics in 545 patients with severe asthma on biological treatment during the COVID-19 outbreak. *J Allergy Clin Immunol Pract.* 2021; 9(1): 487-9. Letter. IF: 11.022; Q1
 - Sánchez CA, Moreno CM, Gancedo SQ, Sánchez-Herrero MG, Gutiérrez FJA, Conejero DB, Cardona V, Soriano JB. PAGE Study: Summary of a study protocol to estimate the prevalence of severe asthma in Spain using big data methods. *J Invest Allerg Clin.* 2021; 31(4): 308-15. Article. IF: 8.185; Q1
 - Sastre J, Santiago V, Lacomba M, Quirce S, Pan V, González D, Rivera JMO, Jaen MJT, Vázquez R, Amerigo A, Fernández O. SEIC specialty forum: analysis of the current situation of allergology in Spain and outlook for the future. *J Invest Allerg Clin.* 2021; 31(2): 120-31. Review. IF: 8.185; Q1
 - Sigurdardottir ST, Jonasson K, Clausen M, Bjornsdottir KL, Sigurdardottir SE, Roberts G, Grimshaw K, Papadopoulos NG, Xepapadakis P, Fiandor A, Quirce S, Sprickelmann AB, Hulshof L, Kowalski ML, Kurowski M, Dubakiene R, Rudzeviciene O, Bellach J, Yurek S, Reich A, Erhard SM, Couch P, Rivas MF, van Ree R, Mills C, Grabenhenrich L, Be-



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

yer K, Keil T. Prevalence and early-life risk factors of school-age allergic multimorbidity: The Euro-Prevall-iFAAM birth cohort. *Allergy*. 2021; 76(9): 2855-65. Article. IF: 14.71; D1

- Tabar AI, Delgado J, González-Mancebo E, Arroabarren E, Retes LS, Domínguez-Ortega J. Recent advances in allergen-specific immunotherapy as treatment for allergic asthma: a practical overview. *Int Arch Allergy Imm*. 2021; 182(6): 496-514. Review. IF: 3.767; Q3
- Vila-Nadal G, Román AF, Revuelto RH, Hernández-Maraver D, Fuentes AEK, García ER, Moreno RC. Efficacy of therapeutic plasma exchange in severe immune hemolytic anemia induced by a carboplatin desensitization procedure. *J Invest Allerg Clin*. 2021; 31(2): 178-9. Editorial Material. IF: 8.185; Q1
- Vilchez-Sánchez F, Tomas-Pérez M, Sánchez-Jareño M, Loli-Ausejo D, Quirce S, Domínguez-Ortega J. Allergic sensitization profiles among the foreign-born population in the north of Madrid. *Eur Ann Allergy Clin Immunol*. 2021; 53(1): 23-28. Article. Not Indexed
- Wiszniewska M, Dellis P, van Kampen V, Suojalehto H, Munoz X, Walusiak-Skorupa J, Lindstrom I, Merget R, Romero-Mesones C, Sastre J, Quirce S, Mason P, Riffart C, Godet J, de Blay F, Vandenplas O. Characterization of occupational eosinophilic bronchitis in a multicenter cohort of subjects with work-related asthma symptoms. *J Allergy Clin Immunol Pract*. 2021; 9(2): 937-44. Article. IF: 11.022; Q1

■ Research projects

Caballero Molina MT. Development and trans-cultural validation of an international specific questionnaire (IHAE-QOL) for assessment of health related quality of life in adult patients with hereditary angioedema due to c1 inhibitor deficiency (HAE) and quality of life study (DTV-IHAE-QOL). *Hereditary Angio-Edema In*. 2009-Ongoing.

Managment centre: FIBHULP

Caballero Molina MT. Estudio de las características clínicas y fisiopatológicas del angioedema sin habones (PI19/O1434). *ISCIII*. 2020-2022.

Managment centre: FIBHULP

Caballero Molina MT. Impacto humanístico y económico del angioedema hereditario en España. *Estudio Impactaeh*. Shire International GmbH. 2021-Ongoing.

Managment centre: FIBHULP

Domínguez Ortega FJ. Asesoramiento para el diseño del estudio clínico Ensayo clínico prospectivo multicéntrico aleatorizado de doble simulación controlado con placebo de búsqueda de la dosis más eficaz para el tratamiento de rinitis/rinconjuntivitis por alergia frente al polen gramíneas. *Inmunotek*. 2015-Ongoing.

Managment centre: FIBHULP

Domínguez Ortega FJ. Estudio de coste-efectividad de mepolizumab en pacientes con asma grave no controlada en condiciones de vida-real. *Glaxosmithkline S. A.* 2021-Ongoing.

Managment centre: FIBHULP

Quirce Gancedo SE. Relación entre asma y obesidad en la población española mayor o igual a 18 años. *Novartis Farmacéutica S. A.* 2009-Ongoing.

Managment centre: FIBHULP

Rodríguez Pérez MR. Contrato garantía juvenil técnico laboratorio (PEJ2019_TL/BMD_12199). *CM*. 2020-2021.

Managment centre: FIBHULP

Rodríguez Pérez MR. Evaluación de la capacidad alérgica de productos alimentarios mediante test de activación de basófilos y sensibilización cutánea con alimentos. *Angulas Aguinaga S. A. U.* 2018-Ongoing.

Managment centre: FIBHULP

Tomás Pérez M. Efectividad de la inmunoterapia sublingual de ltp (slit meloco-

ton) en pacientes con alergia a melocoton y otros vegetales por sensibilización a ltp en condiciones de práctica clínica habitual. *Alk-Abello S.A.* 2020-Ongoing.

Managment centre: FIBHULP

■ Cibers & Retics

Caballero Molina MT. Centro de Investigación Biomédica en Red de Enfermedades Raras. (CB06/07/1033). *ISCIII*. (31/12/2022).

Managment centre: FIBHULP

■ Clinical trials

Caballero Molina, MT. Estudio abierto para evaluar la eficacia y la seguridad a largo plazo de lanadelumab para la prevención contra las crisis agudas de angioedema no histaminérgico con inhibidor de c1 (c1-inh) normal.

Type: Clinical Trials, phase III.

HULP code: 5798 TAK-743-3001.

Sponsored by: Takeda Development Center Americas.

Signed date: 31/05/2021

Caballero Molina, MT. Estudio en fase III, multicéntrico, aleatorizado, controlado con placebo, doble ciego para evaluar la eficacia y la seguridad de lanadelumab para la prevención contra las crisis agudas de angioedema no histaminérgico con inhibidor de c1 (c1-inh) normal y angioedema adquirido (aea) debido a déficit de c1-inh.

Type: Clinical Trials, phase III.

HULP code: Appendix 1 5550.

Sponsored by: Dyax Corp.

Signed date: 13/04/2021

Caballero Molina, MT. Estudio multicén-

trico, prospectivo, nointervencionista de tres años de duración para evaluar la eficacia a largo plazo de lanadelumab en la práctica clínica (enable).

Type: Estudios, phase EPA-OD.

HULP code: PI-4704 TAK-743(SHP643)-402.

Sponsored by: Takeda Development Center Americas.

Signed date: 28/04/2021

Domínguez Ortega, FJ. Estudio de validación transversal de las versiones adaptadas localmente del cuestionario sobre el deterioro y el riesgo del asma (airq) como herramienta que identifica a pacientes con asma en riesgo de resultados adversos por asma no controlada en Alemania y España.

Type: Estudios, phase EPA-SP.

HULP code: PI-4846 AIRQ.

Sponsored by: Astrazeneca Farmacéutica Spain, S.A.

Signed date: 20/09/2021

Domínguez Ortega, FJ. Identificación de biomarcadores inmunológicos en pacientes alérgicos.

Type: Estudios No EPA.

HULP code: PI-4583 LET-INM-2020.

Sponsored by: Laboratorios Leti, S.L.


Signed date: 04/06/2021

Domínguez Ortega, FJ. Pilot study for validation of the consensus protocol developed by scientific societies (semas, separ, and seaic) in real-life conditions in two Spanish hospitals: the asmanet project.

Type: Estudios No EPA.

HULP code: PI-5056 ESR-20-20897.

Sponsored by: Instituto De Estudios Ciencias Salud Castilla Instituto De Estudios Ciencias.



1 Introduction

2 Executive
Summary

3 Information
Groups
by Area

4 Associated
Clinicians

Signed date: 22/12/2021

Domínguez Ortega, FJ. Pilot study for validation of the consensus protocol developed by scientific societies (semas, se-par, and seaic) in real-life conditions in two spanish hospitals:the asmanet project.

Type: Estudios No EPA.

HULP code: PI-5056 ASMANET- ESR-20-2089.

Sponsored by: Instituto De Estudios Ciencias Salud Castilla Instituto De Estudios Ciencias.

Signed date: 22/12/2021

Domínguez Ortega, FJ. Prime. estudio observacionalprospectivo multicéntrico en varios países sobre patrones deatención de pacientes asmáticos leves.

Type: Estudios, phase EPA-SP.

HULP code: PI-4591 CHI-SAL-2020-01.

Sponsored by: Chiesi Farmaceutici S.P.A.

Signed date: 20/05/2021

Lluch Bernal, MM. Proyecto de colaboración estudio de reactividad cruzada entre cupresáceas y especies relacionadas.

Type: Estudios No EPA.

HULP code: PI-4783 PI 39/21.

Sponsored by: Alk-Abello, S.A.

Signed date: 20/05/2021

Quirce Gancedo, SE. Estudio observa-

cional prospectivo para evaluar la seguridad y la efectividad de la inmunoterapia con un alergoide de polen de olivo y gramíneas en pacientes con asma alérgica estacional. estudio gol.

Type: Estudios, phase EPA-SP.

HULP code: PI-4707 ALLOLE-2020-01.

Sponsored by: Allergy Therapeutics Iberica Slu.

Signed date: 14/10/2021

Quirce Gancedo, SE. Registro alergodata.

Type: Estudios, phase EPA-SP.

HULP code: PI-4784 SEA-OMA-2020-01.

Sponsored by: Fundacion De La Sociedad Espanola De Alergologia E Inmunologia Clínica (Seac).

Signed date: 27/05/2021

Tomás Pérez, M. Ensayo clínico de eficacia y seguridad, prospectivo, multicéntrico, aleatorizado, doble ciego controlado con placebo, con inmunoterapia subcutánea en pacientes con rinitis/rinoconjuntivitis con o sin asma de leve a moderada-sensibilizados a gramíneas y cupresáceas.

Type: Clinical Trials, phase II.

HULP code: 5869 DMV02-SIT-026.

Sponsored by: Immunotek.

Signed date: 29/04/2021

Tomás Pérez, M. Ensayo clínico de eficacia

y seguridad, prospectivo,multicéntrico, aleatorizado, doble ciego controlado con placebo,con inmunoterapia subcutánea en pacientes conrinitis/rinoconjuntivitis con o sin asma de leve a moderadasensibilizados a gramíneas y olivo.

Type: Clinical Trials, phase II.

HULP code: 5883 DMV03-SIT-027.

Sponsored by: Immunotek.

Signed date: 19/05/2021

Tomás Pérez, M. Estudio d efase III, multicéntrico, internacional, aleatorizado, doble ciego, controlado con lacebo, de inducción y mnatenimientopara evaluar la eficacia y la seguridad de cc-93538 en sujetos adultosy adolescentes con esofagitis eosinofílica.

Type: Clinical Trials, phase III.

HULP code: 5832 CC-93538-EE-001.

Sponsored by: Celgene International li -Sarl.

Signed date: 26/04/2021c

Patents and trademarks

Valenta R, Constantin C, Quirce Gancedo, SE, inventors; Phadia AB, assignee. Novel wheat allergens. PCT/SE2008/051377, EP2225266, US2010305049, AU2008330230,


CA2707190, CN101932597, JP2011505134, RU2010126590; 2007 November 30.

Caballero Molina MT, Prior Gómez N, Remor Bitencourt EA, authors, FIBHULP, assignee. Brand name: HAE-QoL HEREDITARY ANGIOEDEMA QUALITY OF LIFE. CM 13.083.068; 2014 July 15.

HAE-QoL
HEREDITARY ANGIOEDEMA QUALITY OF LIFE

Sánchez Herreros R, Martínez Fernández J, Castro Morera A, Gasset Vega M, Rodríguez Pérez RM, Pedrosa Delgado M, Quirce Gancedo S, inventors; FIBHULP, CSIC, assignees. Food allergen extracts and methods of producing and using the same. EP16382413.9 (Publication Number pending); 2016 September 06.

del Pozo Abejón V, Sastre Dominguez J, Rodrigo-Muñoz JM, Sastre Turrión B, Quirce Gancedo S, Cañas Mañas JA, inventors; FIISFJD, Centro de Investigación Biomédica en Red (CIBER), FIBHULP, Fundación Conchita Rábago de Jiménez Díaz, assignees. In vitro method for identifying severity levels in bronchial asthma patients. P201730739; 2017 May 29.



3.4.8 Gynecologic Oncology Group*

Publications: 18

Q1: 12

COMPOSITION



Ignacio Zapardiel Gutiérrez. Facultativo Especialista de Área en Ginecología y Obstetricia. Unidad de Ginecología Oncológica. Hospital Universitario La Paz. Profesor Asociado Facultad de Medicina. Universidad Autónoma de Madrid

Diana Alecsandru Danceanu. Médico Especialista en Inmunología. IVI Madrid

María Cerrillo Martínez. Ginecóloga Especialista en Reproducción Humana. IVI Madrid

María Dolores Diestro Tejada. Facultativo Especialista de Área en Ginecología y Obstetricia. Unidad de Ginecología Oncológica. Hospital Universitario La Paz

Cristina González Benítez. Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz

Juan Antonio García Velasco. Profesor Titular. Universidad Rey Juan Carlos

María Josefa Herrera de la Muela. Facultativo Especialista de Área en Ginecología y Obstetricia. Unidad de Patología Mamaria. Hospital Universitario La Paz

Israel Ortega Sánchez. Coordinador del Departamento Internacional. IVI Madrid

Margarita Sánchez-Pastor Ruiz. Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz. Profesor Asociado Facultad de Medicina. Universidad Autónoma de Madrid

María Serrano Velasco. Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz

María Elisa Varela Sanz. Investigadora Postdoctoral. Centro Nacional de Investigaciones Oncológicas

STRATEGIC OBJECTIVE

The main objective of our group is to study all aspects related to gynaecologic malignancies. It includes from diagnosis to treatment and follow-up. For the next years we will focus our research on the malignancies affecting female uterus, including cervical and endometrial cancer as well as uterine sarcomas.

We will develop at least two stable and comprehensive specific research lines trying to pay attention to molecular aspects as well as clinical features of the Gynaecological cancers. But we will support the rest of aspects of the subspecialty.

RESEARCH LINES

- Evaluation, treatment and surgery of oncologic diseases in gynecology.
- Pelvic floor reconstructive surgery.
- Molecular disorders in preeclampsia, placenta and other obstetrical diseases.


* The External Scientific Committee decided that this group would have to be reformulated at the December 2021 meeting

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



RESEARCH ACTIVITY

Publications

- Ángeles MA, Cabarrou B, Gil-Moreno A, Pérez-Benavente A, Spagnolo E, Rychlik A, Martínez-Gómez C, Guyon F, Zapardiel I, Querleu D, Illac C, Migliorelli F, Betrian S, Ferrón G, Hernández A, Martínez A. Effect of tumor burden and radical surgery on survival difference between upfront, early interval or delayed cytoreductive surgery in ovarian cancer. *J Gynecol Oncol.* 2021; 32(6): e78. Article. IF: 4.756; Q1
- Antolín E, Herrero B, Rodríguez R, Illescas T, Duyos I, Gimeno A, Sotillo L, Abascal A, Orensanz I, Hernández A, Bartha JL. How to organize a Fetal Medicine Unit in the context of COVID-19 pandemic. Safe measures for obstetric scans and equipment cleaning. *Clin Invest Ginecol Obstet.* 2021; 48(1): 3-13. Article. Not Indexed
- Cibula D, Borcinova M, Marnitz S, Jarkovsky J, Klat J, Piika R, Torne A, Zapardiel I, Petiz A, Lay L, Sehnal B, Ponce J, Felsing M, Arencibia-Sánchez O, Kascak P, Zalewski K, Presl J, Palop-Moscardo A, Tingulstad S, Vergote I, Redecha M, Fruhauf F, Kohler C, Kocian R. Lower-limb lymphedema after sentinel lymph node biopsy in cervical cancer patients. *Cancers (Basel).* 2021; 13(10): 2360. Article. IF: 6.575; Q2
- Cibula D, Dostalek L, Jarkovsky J, Mom CH, López A, Falconer H, Fagotti A, Ayhan A, Kim SH, Ortiz DI, Klat J, Obermair A, Landoni F, Rodríguez J, Manchanda R, Kostun J, dos Reis R, Meydanli MM, Odetto D, Laky R, Zapardiel I, Weinberger V, Benesova K, Borcinova M, Pari D, Salehi S, Bizzarri N, Akilli H, Abu-Rustum NR, Salcedo-Hernández RA, Javurkova V, Slama J, van Lonkhuijzen LRCW. The annual recurrence risk model for tailored surveillance strategy in patients with cervical cancer. *Eur J Cancer.* 2021; 158: 111-22. Article. IF: 10.002; Q1
- Concin N, Planchamp F, Abu-Rustum NR, Atasev B, Cibula D, Fagotti A, Fotopoulou C, Knapp P, Marth C, Morice P, Querleu D, Sehouli J, Stepanyan A, Taskiran C, Vergote I, Wimberger P, Zapardiel I, Persson J. European Society of Gynaecological Oncology quality indicators for the surgical treatment of endometrial carcinoma. *Int J Gynecol Cancer.* 2021; 31(12): 1508-29. Article. IF: 4.661; Q1
- Cristóbal I, Boado EM, Magdaleno F, Antolín E, Bartha JL, De la Calle M. Brain astrocytomas and pregnancy: an obstetric challenge. *Clin Invest Ginecol Obstet.* 2021; 48(3): 100664. Article. Not Indexed
- Dajti I, Valenzuela JI, Boccalatte LA, Gemelli NA, Smith DE, Dudi-Venkata NN, Kroon HM, Sammour T, Roberts M, Mitchell D, Lah K, Pearce A, (et al) Fernández-López AJ. Machine learning risk prediction of mortality for patients undergoing surgery with perioperative SARS-CoV-2: the COVIDSurg mortality score. *Brit J Surg.* 2021; 108(11): 1274-92. Article. IF: 11.122; D1
- Delgado-Sánchez E, Peay-Pinacho JA, Hernández Gutiérrez A, Álvarez Bernardi J, Zapardiel I. Role of single-site and mini-laparoscopy in gynecologic surgery. *Minerva Obstet Gynecol.* 2021; 73(2): 166-78. Review. Not Indexed
- Diestro MD, Berjón A, Zapardiel I, Yébenes L, Ruiz I, Lekuona A, Rezola M, Jaunarena I, Siegrist J, Sánchez-Pastor M, Cuadra M, Sagasta A, Guerra I, Lete LI, Roldan F, Marta CB, Boillos M, Cardiel M, López-de la Manzanara C, Relea F, Coronado P, Pascual A, Román M, Peiro G, Matute L, Montero B, Muruzabal J, Guarch R, Zorrero C, Calatrava A, Ribot L, Costa I, Hernández A, Hardisson D. One-step nucleic acid amplification (OSNA) of sentinel lymph node in early-stage endometrial cancer: Spanish multicenter study (ENDO-OSNA). *Cancers (Basel).* 2021; 13(17): 4465. Article. IF: 6,575; Q2
- Ghoniem K, Larish AM, Dinoui G, Zhou XC, Alhilli M, Wallace S, Wohlmuth C, Baiocchi G, Tokgozoglu N, Raspagliesi F, Buda A, Zanagnolo V, Zapardiel I, Jagasia N, Giuntoli R, Glickman A, Peiretti M, Lanner M, Chacon E, Di Guilmi J, Pereira A, Laas E, Fishman A, Nitschmann CC, Parker S, Joehlin-Price A, Lees B, Covens A, De Brot L, Taskiran C, Bogani G, Paniga C, Multinu F, Hernández-Gutiérrez A, Weaver AL, McGree ME, Mariani A. Oncologic outcomes of endometrial cancer in patients with low-volume metastasis in the sentinel lymph nodes: An international multi-institutional study. *Gynecol Oncol.* 2021; 162(3): 590-8. Article. IF: 5.304; Q1
- Glasbey JC, Ademuyiwa A, Adisa A, AlAmeer E, Arnaud AP, Ayasra F, Azevedo J, Bravo AM, Costas-Chavarri A, Edwards J, Correia J, (et al). Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study. *Lancet Oncol.* 2021; 22(11): 1507-17. Article. IF: 54.433; D1

hort study. *Lancet Oncol.* 2021; 22(11): 1507-17. Article. IF: 54.433; D1

- Glasbey JC, Omar O, Nepogodiev D, Minaya-Bravo A, Bankhead-Kendall BK, Fiore M, Futaba K, Gabre-Kidan A, Gujjuri RR, Isik A, Kaafarani HMA, Luke L. (et al). Preoperative nasopharyngeal swab testing and postoperative pulmonary complications in patients undergoing elective surgery during the SARS-CoV-2 pandemic. *Brit J Surg.* 2021; 108(1): 88-96. Article. IF: 11.122; D1
- Pineda VG, Zapardiel I, Gracia M, Siegrist J, Diestro MD, Alonso M, Hernández A. Avoiding full lymphadenectomies in intermediate- and high-risk endometrial cancer by sentinel lymph node biopsy implementation. *Front Oncol.* 2021; 11: 654285. Article. IF: 5.738; Q2
- Rodríguez J, Rauh-Hain JA, Sáenz J, Isla DO, Pereira GJR, Odetto D, Martinelli F, Villoslada V, Zapardiel I, Trujillo LM, Pérez M, Hernández M, Saadi JM, Raspagliesi F, Valdivia H, Siegrist J, Fu SS, Nava MH, Echeverry L, Noll F, Ditto A, López A, Hernández A, Pareja R. Oncological outcomes of laparoscopic radical hysterectomy versus radical abdominal hysterectomy in patients with early-stage cervical cancer: a multicenter analysis. *Int J Gynecol Cancer.* 2021; 31(4): 504-11. Article. IF: 4.661; Q1
- Tabiri S, Kamarajah SK, Nepogodiev D, Li E, Simoes J, Sravanam S, Owusu SA, Mahama H, Agyeman YN, Arthur J, Fernández JD (et al). Impact of bacillus calmette-guerin (BCG) vaccination on postoperative mortality in patients with perioperative SARS-CoV-2 infection. *BJS Open.* 2021; 5(6): zrab131. Letter. IF: 3.875; Q1
- Zapardiel I, Boria F, Halaska MJ, De Santiago J. Laparoscopic power morcellation: Techniques to avoid tumoral spread. *J Minim Invas Gyn.* 2021; 28(8): 1442-3. Editorial Material. IF: 4.314; Q1
- Zapardiel I, Coronado PJ. Author's response to letter to editor on VULCAN study. *Int J Gynecol Cancer.* 2021; 31(1): 158. Letter. IF: 4.661; Q1
- Zapardiel I, Kocian R, Kohler C, Klat J, Germanova A, Jacob A, Bajsova S, Bohmer G, Lay L, Gilbáñez B, Havelka P, Kipp B, Szewczyk G, Toth R, Staringer JC, De Santiago J, Coronado PJ, Poka R, Laky R, Luyckx M, Fastrez M, Dusek L, Hernández A, Cibula D. Voiding recovery after radical parametrectomy in cervical cancer patients: An international prospective multicentre trial - SEN-

TIX. *Gynecol Oncol.* 2021; 160(3): 729-34. Article. IF: 5.304; Q1

Research projects

Herrera de la Muela MJ. Calidad de vida y satisfacción con la cirugía en mujeres con cáncer de mama con reconstrucción postmastectomía: Estudio BRECAR (Breast Cancer Reconstruction Study). FIBHULP. 2015-Ongoing.

Management centre: FIBHULP

Zapardiel Gutiérrez I. Evaluación del antígeno epididimal humano -HE4 - en el diagnóstico diferencial y seguimiento de la endometriosis superficial y profunda. Abboott Laboratories S.A. 2012-Ongoing.

Management centre: FIBHULP

Zapardiel Gutiérrez I. Ultraestadificación molecular ganblio centinela en cáncer de cérvix: mRNA e6/e7 hpv (). Secuvita S. L. 2013-Ongoing.

Management centre: FIBHULP

Patents and trademarks

Zapardiel Gutiérrez I, de Santiago García J, inventors; FIBHULP, assignee. Laparoscopic surgical instrument. P201230950, PCT/ES2013/000139; 2012 June 18.


Zapardiel Gutiérrez I, de Santiago García J, inventors; FIBHULP, assignee. Surgical device. P201330532, PCT/ES2014/070277; 2013 April, 15.

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



3.4.9 Patient Blood Management Group

Publications: 24
Q1: 11

COMPOSITION

■ **Manuel Quintana Díaz.** Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz. Profesor Asociado Facultad de Medicina. Universidad Autónoma de Madrid

María José Alcaide Martín. Facultativo Especialista de Área en Análisis Clínicos. Tutora de residentes de Análisis Clínicos. Hospital Universitario La Paz

Eva María Andrés Esteban. Epidemióloga. Hospital Universitario La Paz

Sara Fabra Cadenas. Facultativo Especialista de Área en Medicina Familiar y Comunitaria. Hospital Universitario La Paz

Pilar Fernández Calle. Facultativo Especialista de Área en Análisis Clínicos. Coordinadora de Calidad de Análisis Clínicos. Hospital Universitario La Paz

José Antonio García Erce. Facultativo Especialista de Área en Hematología. Hospital San Jorge de Huesca

Raúl Juárez Vela. Profesor Titular de Universidad. Universidad de La Rioja

Milagros Martí de Gracia. Facultativo Especialista de Área en Radiodiagnóstico. Jefe de Sección de Radiología de Urgencias. Hospital Universitario La Paz

Ana María Martínez Virto. Facultativo Especialista de Área en Medicina Familiar y Comunitaria. Coordinadora Adjunta de Urgencias. Hospital Universitario La Paz

Paloma Oliver Sáez. Facultativo Especialista de Área en Análisis Clínicos. Tutora de residentes de Análisis Clínicos. Hospital Universitario La Paz

María Inmaculada Pinilla Fernández. Facultativo Especialista de Área en Radiodiagnóstico. Hospital Universitario La Paz

María Angélica Rivera Núñez. Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz

Marcelino Sánchez Casado. Facultativo Especialista de Área en Medicina Intensiva. Hospital Virgen de la Salud

STRATEGIC OBJECTIVE


Stratifying risk in the critically ill patient.

- Stratify pulmonary thromboembolism risk
- Try to diagnose the potentially ill politraumatized patient at the emergency room Enhance the use of blood products

- Critically ill patient coagulopathy
- Early diagnose of anemia at the emergency room
- Intravenous iron usage

Anticoagulation Reserval.

Patient Blood Mangement Implementation.



RESEARCH LINES

- Critical Bleeding
- Anticoagulation reversal

- Frailty
- COVID19
- Interrelation in Cardiovascular Diseases and Cares

RESEARCH ACTIVITY

■ Doctoral theses

Nanwani Nanwani KL. Estudio del perfil inflamatorio y de la coagulopatía asociada a la hemorragia subaracnoidea aneurismática [dissertation]. Madrid: UAM: 202102/12/2021).

Directors: Quintana Díaz M, Egea Guerrero JJ.

Robles Caballero A. Valoración ecográfica del diámetro de la vaina del nervio óptico, como técnica complementaria, en el diagnóstico de muerte encefálica [dissertation]. Madrid: UAM: 2021(21/04/2021).

Directors: Quintana Díaz M, García Olmos LM.

■ Publications

- Álvarez-Troncoso J, Ramos-Ruperto L, Fernández-Cidón P, Trigo-Esteban E, Tung-Chen Y, Busca-Arenzana C, Quintana-Díaz M, Buño-Soto A, Arnalich-Fernández F, Fernández-Capitán C. Screening protocol and prevalence of venous thromboembolic disease in hospitalized patients with COVID-19. *J Ultras Med.* 2022; 41(7): 1689-98. Article. IF: 2.754; Q2
- Andrés-Esteban EM, Quintana-Díaz M, Ramírez-Cervantes KL, Benayas-Pena I, Silva-Obregon A, Magallón-Botaya R, Santolalla-Arnedo I, Juárez-Vela R, Gea-Caballero V. Outcomes of hospitalized patients with COVID-19 according to level of frailty. *PEERJ.* 2021; 9: e11260. Article. IF: 3.061; Q2
- Avendaño-Sola C, de la Cámara R, Castellanos

M, Ezpeleta D, García-Azorín D, Martínez CI, Lecumberri R, de Gracia MM, Marguello ER, Rovira A, Sancho-López A, Garrido P. Diagnostic and treatment recommendations from the FACME ad-hoc expert working group on the management of cerebral venous sinus thrombosis associated with COVID-19 vaccination. *Neurologia.* 2021; 36(6): 451-61. Article. IF: 5.486; Q1

- Beverina I, Jerico C, Quintana-Díaz M, García-Erce JA. Therapeutic alternative to transfusion in nonpregnant women with iron deficiency anemia caused by uterine blood loss. *J Emerg Med.* 2021; 60(4): 565-6. Letter. IF: 1.473; Q4
- Chico-Fernández M, Barea-Mendoza JA, Pérez-Barcena J, García-Saez I, Quintana-Díaz M, Marina L, Mayor-García DM, Servia-Goixart L, Jiménez-Moragas JM, Llopart-Pou JA. Concomitant traumatic brain injury and hemorrhagic shock: outcomes using the spanish trauma icu registry (RETRAUCI). *Am Surgeon.* 2021; 87(3): 370-5. Article. IF: 1.002; Q4
- Chico-Fernández M, Barea-Mendoza JA, Servia-Goixart L, Ormazabal-Zabala T, Quintana-Díaz M, González-Robledo J, Iglesias-Santiago A, Sánchez-Arguiano MJ, Pérez-Barcena J, Llopart-Pou JA. Factors associated with death due to trauma in patients with a Glasgow Coma Scale score of 3 and bilateral fixed dilated pupils. *Emergencias.* 2021; 33(2): 121-7. Article. IF: 5.345; Q1
- Demelo-Rodríguez P, Farfán-Sedano AI, Pedrajas JM, Llamas P, Siguenza P, Jaras MJ, Quintana-Díaz M, Fernández-Capitán C, Bikdeli B, Jiménez D, Montreal M. Bleeding risk in hospitalized patients with COVID-19 receiving intermediate or therapeutic doses of thromboprophylaxis. *J Thromb Haemost.* 2021; 19(8): 1981-89. Article. IF: 16.036; D1
- Díaz E, Menéndez RA, Cortes PV, Escapa MG, Suberviola B, Lazaro AS, Neira PM, Díaz MQ, González MC. Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS)

and the Working Groups in Transfusions and Blood Products (GTTH). *Med Intensiva.* 2021; 45(2): 104-21. Review. IF: 2.799; Q3

- García-Erce JA, Romón-Alonso I, Jerico C, Domingo-Morera JM, Arroyo-Rodríguez JL, Sola-Lapena C, Bueno-Cabrera JL, Juárez-Vela R, Zalba-Marcos S, Abad-Motos A, Gea-Caballero V, Santolalla-Arnedo I, Quintana-Díaz M. Blood donations and transfusions during the covid-19 pandemic in Spain: impact according to autonomous communities and hospitals. *Int J Env Res Pub He.* 2021; 18(7): 3480. Article. IF: 4.614; Q1
- Gómez-Soria I, Esteban EMA, Brutón AG, Peralta-Marrupe P. Long-term effect analysis of a cognitive stimulation program in mild cognitive impairment elderly in Primary Care: A randomized controlled trial. *Aten Prim.* 2021; 53(7): 102053. Article. IF: 2.206; Q3
- Gutiérrez-Gutiérrez B, del Toro MD, Borobia AM, Carcas A, Jarrín I, Yllescas M, Ryan P, Pachón J, Carratala J, Berenguer J, Arribas JR, Rodríguez-Bano J. Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicenter cohort study. *Lancet Infect Dis.* 2021; 21(6): 783-92. Article. IF: 71.421; D1
- Jiménez CS, Romero-Garrido JA, García-Martín A, Quintana-Díaz M, Jiménez-Vicente C, González-Del Valle L, Ambrosio AH, Benedi-González J. Safety and effectiveness of a four-factor prothrombin complex concentrate for vitamin K antagonist reversal following a fixed-dose strategy. *Eur J Hosp Pharm-S P.* 2021; 28(E1): E66-71. Article. IF: 2.537; Q3
- Larraga-García B, López LC, Bolívar FJR, Quintana-Díaz M, Gutiérrez A. Design and development of an interactive web-based simulator for trauma training: a pilot study. *J Med Syst.* 2021; 45(11): 96. Article. IF: 4.92; Q1
- Larraga-García B, Pérez-Jiménez A, Ros-Dópicos S, Rubio-Bolívar J, Quintana-Díaz M, Gutiérrez A. Design and development of a hemorrhagic trauma simulator for lower limbs: a pilot study.

Sensors-Basel. 2021; 21(11): 3816. Article. IF: 3.847; Q2


- Llau J V, Ferrandis R, Sierra P, Hidalgo F, Cassinello C, Gómez-Luque A, Quintana M, Amezcaga R, Gerol M, Serrano A, Marcos P. SEDAR-SEMI-CYUC consensus on the management of haemostasis disorders in severe COVID-19 patients. *Med Intensiva (Engl Ed).* 2021; 45(9): 567-8. Letter. Not Indexed
- López-Martín I, Esteban EA, García-Martínez FJ. Relationship between MMR vaccination and severity of Covid-19 infection. Survey among primary care physicians. *Med Clin-Barcelona.* 2021; 156(3): 140-1. Letter. IF: 3.2; Q2
- Magallón-Botaya R, Oliván-Blázquez B, Ramírez-Cervantes KL, Méndez-López-de-la-Manzanara F, Aguilar-Palacio I, Casajuana-Closas M, Andrés-Esteban E. Geographic factors associated with poorer outcomes in patients diagnosed with covid-19 in primary health care. *Int J Env Res Pub He.* 2021; 18(7): 3842. Article. IF: 4.614; Q1
- Martínez-Ales G, Domingo-Relloso A, Arribas JR, Quintana-Díaz M, Hernán MA. Critical care requirements under uncontrolled transmission of SARS-CoV-2. *Am J Public Health.* 2021; 111(5): 923-6. Article. IF: 11.561; D1
- Raasveldt SJ, Delnoij TSR, Broman LM, Lansink-Hartgring AO, Hermans G, De Troy E, Taccone FS, Diaz MQ, van der Velde F, Miranda DD, Scholten E, Vlaar APJ. Extracorporeal membrane oxygenation in patients with covid-19: an international multicenter cohort study. *J Intensive Care Med.* 2021; 36(8): 910-7. Article. IF: 2.889; Q3
- Ramírez-Cervantes KL, Romero-Pardo V, Pérez-Tovar C, Martínez-Ales G, Quintana-Díaz M. A medicalized hotel as a public health resource for the containment of Covid-19: more than a place for quarantining. *J Public Health-Uk.* 2021; 43(1): 89-97. Article. IF: 5.058; Q1
- Salvador JFS, Giménez-Arnau AM, de la Fuente EG, del Castillo JG, Virto AMM, Blanco IM, Serra-Baldrich E, Llorens P. Managing urticaria in

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

the emergency department: recommendations of a multidisciplinary expert panel. *Emergencias*. 2021; 33(4): 299-308. Article. IF: 5.345; Q1

- Salvador JFS, Giménez-Arnau AM, de la Fuente EG, del Castillo JG, Virtos AMM, Blanco IM, Serra-Baldrich E, Llorens P. Urticaria in the emergency department: the view of allergy and immunology specialists Reply. *Emergencias*. 2021; 33(4): 325-6. Letter. IF: 5.345; Q1
- Tong HY, Borobia AM, Quintana-Díaz M, Fabra S, González-Vinolis M, Fernández-Capitan C, Rodríguez-Dávila MA, Lorenzo A, López-Parra AM, Ruiz-Giménez N, Abad-Santos F, Suárez C, Madridano O, Gómez-Cerezo JF, Llamas P, Baeza-Richer C, Arroyo-Pardo E, Carcas AJ. Acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolism: a randomised clinical trial. *J Clin Med*. 2021; 10(13): 2949. Article. IF: 4.964; Q2
- Tung-Chen YL, Algora-Martón A, Llamas-Fuentes R, Rodríguez-Fuertes P, Virto AMM, Sanz-Rodríguez E, Alonso-Martínez B, Núñez MAR. Point-of-care ultrasonography in the initial characterization of patients with COVID-19. *Med Clin-Barcelona*. 2021; 156(10): 477-84. Article. IF: 3.2; Q2

Research projects

Andrés Esteban EA. Variables pronósticos. Recursos consumidos y coste hospitalario (COV20/00519). ISCIII. 2020-2021.

Management centre: FIBHULP

Martí de Gracia M. Mejora de la adecuación en la solicitud de pruebas de imagen con radiación ionizante (TC y RX) en los servicios de urgencias hospitalarios. proyecto MAPAC-IMAGEN II (P116/01828). ISCIII. 2017-2021.

Management centre: FIBHULP

Martínez Virto AM. Epidemiología del angioedema en los servicios de urgencias. Shire International GMBH. 2020-Ongoing.

Management centre: FIBHULP

Oliver Sáez P. Estudio de gasometría en el lugar de asistencia. Beneficio para el paciente. Asociación Española de Farmacéuticos Analistas. 2012-Ongoing.

Management centre: FIBHULP

Quintana Díaz M. Estudio de la coagulopatía y de los perfiles de inflamación sistémica asociados a la hemorragia subaracnoidea aneurismática. FIBHULP. 2020-Ongoing.

Management centre: FIBHULP

Quintana Díaz M. Estudio de monitorización de heparinas de bajo peso molecular como profilaxis en un Servicio de Urgencias. Bayer Hispania S. L. 2011-Ongoing.

Management centre: FIBHULP

Quintana Díaz M. Identificación de factores de gravedad en el paciente con traumatismo potencialmente grave. FIBHULP. 2013-Ongoing.

Management centre: FIBHULP

Quintana Díaz M. Manejo inicial del paciente con hemorragia crítica traumática en urgencias y emergencias. Varios Financiadores. 2021-Ongoing.

Management centre: FIBHULP

Quintana Díaz M. Traumatismo y transfusión ¿una asociación necesaria?. Fundación Mutua Madrileña. 2019-Ongoing.

Management centre: FIBHULP





3.4.10 Urology Group*

Publications: 37
Q1: 12

COMPOSITION



Luis Martínez-Piñeiro Lorenzo. Jefe de Servicio en Urología. Hospital Universitario La Paz
Alfredo Aguilera Bazán. Facultativo Especialista de Área en Urología. Hospital Universitario La Paz
José María Alonso Dorrego. Facultativo Especialista de Área en Urología. Hospital Universitario La Paz
Luisa María Botella Cubells. Investigadora Científica CSIC. Centro de Investigaciones Biológicas Margarita Salas

Mario Álvarez Maestro. Facultativo Especialista de Área en Urología. Hospital Universitario La Paz
José Ramón Cansino Alcaide. Facultativo Especialista de Área en Urología. Hospital Universitario La Paz
Cristina de Castro Guerin. Facultativo Especialista de Área en Urología. Hospital Universitario La Paz
Esaú Fernández Pascual. Facultativo Especialista de Área en Urología. Hospital Universitario La Paz
Mercedes Ferrer Parra. Catedrática. Departamento de Fisiología, Facultad de Medicina, UAM.
Eugenia García Fernández. Facultativo Especialista de Área en Anatomía Patológica. Hospital Universitario La Paz
María Justa García Matres y Cortés. Facultativo Especialista de Área en Urología. Hospital Universitario La Paz
Estefanía Esperanza Linares Espinos. Facultativo Especialista de Área en Urología. Hospital Universitario La Paz

José Miguel Gómez de Vicente. Facultativo Especialista de Área en Urología. Hospital Universitario La Paz
Asier Leivar Tamayo. Facultativo Especialista de Área en Urología. Hospital Universitario La Paz
Pedro López Pereira. Jefe de Servicio de Urología Pediátrica. Hospital Universitario La Paz
Nuría Malats Riera. Investigadora Senior. Centro Nacional de Investigaciones Oncológicas
José Antonio Moreno Valle. Facultativo Especialista de Área en Urología. Hospital Universitario La Paz
José Ramón Pérez-Carral García. Médico Adjunto en Urología. Hospital Universitario La Paz
Francisco Real Arribas. Investigador Senior. Centro Nacional de Investigaciones Oncológicas
Emilio Ríos González. Médico Adjunto en Urología. Hospital Universitario Infanta Sofía
María Carmen Valés Gómez. Investigadora Científica CSIC. Centro de Investigaciones Biológicas Margarita Salas

STRATEGIC OBJECTIVE

We aim to consolidate a strong research group into:

- Urologic Oncology
- Reconstructive surgery
- Endurologic and minimally invasive surgery
- Lithiasis

- Incontinence / Neuro-urology
- Andrology / Reproduction

Through basic and experimental research, clinical research, translational research and clinical trials.

The results of this projects should be translated into doctoral theses, publications in high impact journals and visibility factor, as to finally achieve patents and trademarks.


* The External Scientific Committee decided that this group would have to be reformulated at the December 2021 meeting

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

RESEARCH LINES

Urological Oncology

The group's efforts will focus on the following fields of research:

BLADDER CANCER

- Immunological response in patients with bladder cancer treated with BCG.
- Urinary markers in diagnosis and prediction of response in patients with bladder cancer.
- New immunomodulatory treatments in bladder cancer.
- New imaging methods for the diagnosis of bladder cancer.
- Efficacy of combined chemo and immunotherapy hyperthermia in bladder cancer.

PROSTATE CANCER

- Castration resistant prostate carcinoma, immune response, and evaluation of predictive markers of therapeutic response.
- Medical treatment of locally advanced and metastatic prostate cancer.
- Development of new surgical minimally invasive techniques for localized prostate cancer.

KIDNEY CANCER

- Development of new surgical minimally invasive techniques for localized kidney cancer.

- Research of new therapeutic lines in hereditary renal cancer.
- Medical treatment

Reconstructive surgery

- Development and improvement of new reconstructive surgery techniques for complex urethral strictures, genitourinary congenital malformations and genitourinary fistulas.
- Development of a Regenerative Medicine Unit and Tissue Bioengineering applied to reconstructive urologic surgery.

Endurologic and minimally invasive surgery

- Development of new endourological surgery techniques for minimally invasive treatment of benign prostatic hyperplasia and urinary lithiasis.
- Development of a learning program in laparoscopy and other minimally invasive surgeries.

Lithiasis

- Study of new inhibitors of crystallization of urine solutes as prevention of lithogenesis.
- Metabolic study of renal lithiasis.

Incontinence and Neuro-urology

- Study and treatment of chronic pelvic pain.
- Development and improvement of new systems for urinary incontinence

RESEARCH ACTIVITY

■ Doctoral theses

Martínez Sigüero MB. Efecto de la testosterona sobre la función vascular. Participación de mediadores celulares[dissertation]. Madrid: UAM: 2021(16/06/2021).

Director: Ferrer Parra M.

■ Master Theses

Gómez Aguilar A. Genomic Sequencing of Genes involved in Hereditary Hemorrhagic Telangiectasia (HHT) in patient's DNAs where no mutations were found in their coding regions[dissertation]. Ma-

drid: UAH: 2021(09/06/2021).

Director: María Botella LM.

■ Final Degree Theses

Rodríguez Escribano P. Efecto de los andrógenos sobre la función vascular en arterias de ratas hipertensas[dissertation]. Madrid: UAH: 2021(16/06/2021).

Director: Ferrer Parra M.

■ Publications

• Álvarez-Maestro M, Eguibar A, Chanca P, Klett-Mingo M, Rivas JG, Buño-Soto A, de Bethencourt FR, Ferrer M. Androgen deprivation therapy in patients with prostate cancer increases

serum levels of thromboxane a(2): cardiovascular implications. *Front Cardiovasc Med* . 2021; 8: 653126. Article. IF: 5.846; Q2

• Álvarez-Maestro M, Guerrero-Ramos F, Rodríguez-Faba O, Domínguez-Escrig JL, Fernández-Gómez JM. Current treatments for BCG failure in non-muscle invasive bladder cancer (NMIBC). *Actas Urol Esp*. 2021; 45(2): 93-102. Review. IF: 0.887; Q4

• Álvarez-Maestro M, Rivas JG, Moschini M. Surgery for oligometastatic prostate cancer: Where are we going? *Actas Urol Esp*. 2021; 45(7): 479-80. Editorial Material. IF: 0.887; Q4

• Ballesteros Ruiz C, Álvarez-Maestro M, Alonso Dorrego JM, de Castro Guerin C, Cansino Alcaide R, Carrión DM, Gómez de Vicente JM, Aguilera Bazán A, Martínez Piñeiro L. Kidney transplant urinary complications. Diagnosis and treatment. *Arch Esp Urol*. 2021; 74(10): 1029-39.


Review. IF: 0.43; Q4

• Bazán AA, Carrión DM, Rivas JG, Quesada-Olarte J, Quintana LM, Álvarez-Maestro M, Martínez-Piñeiro L. Active surveillance in renal tumors: Clinical and oncological outcomes. *J Cancer Res Ther*. 2021; 17(2): 414-9. Article. IF: 1.331; Q4

• Carrión DM, Rivas JG, Bazán AA, Ruiz CB, Álvarez-Maestro V, González ER, Martínez-Piñeiro L. The benefit of a neoadjuvant instillation of chemotherapy in non-muscle invasive bladder cancer: interim analysis of the precave randomized clinical trial. *Arch Esp Urol*. 2021; 74(9): 883-93. Article. IF: 0.43; Q4

• Counago F, Álvarez-Maestro M. Are we at the end of adjuvant radiotherapy for prostate cancer?. *Actas Urol Esp*. 2021; 45(8): 521-3. Editorial Material. IF: 0.887; Q4

• de Rojas-P I, Albiñana V, Taranets L, Recio-Poveda L, Cuesta AM, Popov N, Kronenberger T, Bo-



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

tella LM. The endothelial landscape and its role in Von Hippel-Lindau disease. *Cells*. 2021; 10(9): 2313. Article. IF: 7.666; Q2

- Di Mauro M, Tonioni C, Cocci A, Kluth LA, Russo GI, Rivas JG, Cacciamani G, Cito G, Morelli G, Polloni G, di Maida F, Giunti D. Penile length and circumference dimensions: A large study in young Italian men. *Andrologia*. 2021; 53(6): e14053. Article. IF: 2.532; Q3
- Gacci M, Marchioni M, De Francesco P, Natoli C, Calabro F, Losanno T, Gianmartin C, Serni S, Doni L, De Nunzio C, De Tursi M, Valeriani M, Giacinti S, Álvarez-Maestro M, Scarzia M, Ludovico GM, Del Bene G, Simone G, Ferriero M, Tuderti G, Bove P, Laudisi A, Carrieri G, Cormio L, Verze P, La Rocca R, Falsaperla M, Frantelluzzi V, Greco F, Di Nicola M, Schips L, Cindolo L. Enzalutamide in patients with castration-resistant prostate cancer: retrospective, multicenter, real life study. *Minerva Urol Nephrol*. 2021; 73(4): 489-97. Article. IF: 5.214; Q1
- Hevia Palacios M, Álvarez-Maestro M, Gómez Rivas J, Aguilera Bazán A, Martínez-Piñero L. Zinner syndrome with ectopic ureter emptying into seminal vesicle. *Case Rep Urol*. 2021; 2021: 8834127. Article. Not Indexed
- Isidoro-García L, Villalpando DM, Ferrer M. Vasomotor action of androgens in the mesenteric artery of hypertensive rats. Role of perivascular innervation. *Plos One*. 2021; 16(2): e0246254. Article. IF: 3.752; Q2
- Mantica G, Carrion DM, Pang KH, Fiori C, Rivas JG, Esperto F. European Society of Residents in Urology (ESRU) and Minerva Urology Nephrology (MUN) reviews project: update after 3 years of collaboration. *Minerva Urol Nephrol*. 2021; 73(2): 269-71. Letter. IF: 5.214; Q1
- Marchioni M, Cheaib JG, Takagi T, Pavan N, Antonelli A, Everaerts W, Heck M, Rha KH, Mottrie A, Kaouk J, Capitanio U, Lima E, Veccia A, Crivellaro S, Linares E, Celia A, Porpiglia F, Autorino R, Di Nicola M, Schips L, Pierorazio PM, Mir MC. Active surveillance for small renal masses in elderly patients does not increase overall mortality rates compared to primary intervention: a propensity score weighted analysis. *Minerva Urol Nephrol*. 2021; 73(6): 781-8. Article. IF: 5.214; Q1
- Marchioni M, Kriegmair M, Heck M, Amiel T, Porpiglia F, Ceccucci E, Campi R, Minervini A, Mari A, Van Bruwaene S, Linares E, Hevia V, Musquera M, D'Anna M, Derweesh I, Bradshaw A, Autorino R, Guruli G, Veccia A, Roussel E, Albersen M, Pavan N, Claps F, Antonelli A, Palumbo C, Klatte T, Erdem S, Mir MC. Development of a novel risk score to select the optimal candidate for cytoreductive nephrectomy among patients

with metastatic renal cell carcinoma. Results from a multi-institutional registry (REMARCC). *Eur Urol Oncol*. 2021; 4(2): 256-63. Article. IF: 8.208; Q1

- Marchioni M, Sountoulides P, Furlan M, Mir MC, Aretano L, Rubio-Briones J, Álvarez-Maestro M, Di Nicola M, Bazán AA, Antonelli A, Simeone C, Schips L. Management of local recurrence after radical nephrectomy: surgical removal with or without systemic treatment is still the gold standard. Results from a multicenter international cohort. *Int Urol Nephrol*. 2021; 53(11): 2273-80. Article. IF: 2.266; Q3
- Marcos S, Albiñana V, Recio-Poveda L, Tarazona B, Verde-González MP, Ojeda-Fernández L, Botella LM. SARS-CoV-2 infection in hereditary hemorrhagic telangiectasia patients suggests less clinical impact than in the general population. *J Clin Med*. 2021; 10(9): 1884. Article. IF: 4.964; Q2
- Marcos S, Botella LM, Albiñana V, Arbia A, de Rosales AM. Sclerotherapy on demand with polidocanol to treat HHT nosebleeds. *J Clin Med*. 2021; 10(17): 3845. Article. IF: 4.964; Q2
- Martini A, Afferi L, Zamboni S, Schultz JG, Lonati C, Mattei A, Karnes RJ, Soligo M, Stabile A, Di Trapani E, De Cobelli O, Simone G, Simeone C, Álvarez-Maestro M, Gandaglia G, Gallina A, Colombo R, Briganti A, Montorsi F, Xylinas E, Shariat SF, Moschini M. Oncologic surveillance for variant histology bladder cancer after radical cystectomy. *J Urology*. 2021; 206(4): 885-93. Article. IF: 7.6; Q1
- Mori K, Miura N, Comperat E, Nikles S, Pang KH, Misrai V, Gómez Rivas J, Papalia R, Shariat SF, Esperto F, Pradere B. A systematic review and meta-analysis of prognostic impact of different Gleason patterns in ISUP grade group 4. *Minerva Urol Nephrol*. 2021; 73(1): 42-9. Review. IF: 5.214; Q1
- Morozov A, Barret E, Veneziano D, Grigoryan V, Salomón G, Fokin I, Taratkin M, Poddubskaya E, Gómez Rivas J, Puljatti S, Okhunov Z, Cacciamani GE, Checcucci E, Marengo Jiménez JL, Enikeev D. A systematic review of nerve-sparing surgery for high-risk prostate cancer. *Minerva Urol Nephrol*. 2021; 73(3): 283-91. Review. IF: 5.214; Q1
- Nowak L, Krajewski W, Moschini M, Chorbinska J, Poletajew S, Tukiendorf A, Muilwijk T, Joniau S, Tafuri A, Antonelli A, Orlando R, Di Trapani E, Álvarez-Maestro M, Simone G, Zamboni S, Simeone C, Marconi MC, Mastroianni R, Piszczek R, Xylinas E, Zdrojow R. Assessment of the oncological outcomes of three different bacillus Calmette-Guerin strains in patients with high-grade T1 non-muscle-invasive bladder cancer. *Arab J Urol*

. 2021; 19(1): 78-85. Article. Not Indexed

- Paglialonga A, Gaetano R, Robert L, Hurard M, Botella LM, Barr N, Jondeau G, Pini A. eHealth for patients with rare diseases: the eHealth Working Group of the European Reference Network on Rare Multisystemic Vascular Diseases (VAS-CERN). *Orphanet J Rare Dis*. 2021; 16(1): 164. Article. IF: 4.307; Q2
- Pinto A, Álvarez-Maestro M. Adjuvant immunotherapy in muscle-invasive bladder cancer: Closer than it seems? *Actas Urol Esp*. 2021; 45(9): 567-8. Editorial Material. IF: 0.887; Q4
- Plata A, Guerrero-Ramos F, García C, González-Díaz A, González-Valcarcel I, de la Morena JM, Diaz-Goizueta FJ, del Álamo JF, Gonzalo V, Montero J, Sousa-Escandon A, Leon J, Pontones JL, Delgado F, Adriaola M, Pascual A, Calleja J, Ruano A, Martínez-Piñero L, Angulo JC. Long-term experience with hyperthermic chemotherapy (HIVEC) using mitomycin-c in patients with non-muscle invasive bladder cancer in Spain. *J Clin Med*. 2021; 10(21): 5105. Article. IF: 4.964; Q2
- Pozo-Agundo A, Villaescusa N, Martorell-Marugan J, Soriano O, Leyva S, Jodar-Reyes AB, Botella LM, Carmona-Sáez P, Blanco FJ. Identification of exosomal microRNA signature by liquid biopsy in hereditary hemorrhagic telangiectasia patients. *Int J Mol Sci*. 2021; 22(17): 9450. Article. IF: 6.208; Q1
- Rivas JG, Carrion DM, Chandrasekar T, Álvarez-Maestro M, Enikeev D, Martínez-Piñero L, Barret E. The role of multiparametric magnetic resonance imaging in the selection and follow-up of patients undergoing active surveillance for prostate cancer. An European Section of Uro-Technology (ESUT) review. *Actas Urol Esp*. 2021; 45(3): 188-97. Review. IF: 0.887; Q4
- Rivas JG, Toribio-Vázquez C, Taratkin M, Marengo JL, Grossmann R. Autonomous robots: a new reality in healthcare? A project by european association of urology-young academic urologist group. *Curr Opin Urol*. 2021; 31(2): 155-9. Review. IF: 2.808; Q3
- Rivas JG, Vázquez CT, Ruiz CB, Taratkin M, Marengo JL, Cacciamani GE, Checcucci E, Okhunov Z, Enikeev D, Esperto F, Grossmann R, Somani B, Veneziano D. Artificial intelligence and simulation in urology. *Actas Urol Esp*. 2021; 45(8): 524-9. Review. IF: 0.887; Q4
- Rodríguez-Serrano A, Carrion DM, Rivas JG, Álvarez-Maestro M, Sánchez S, de Bethencourt FR, Bazán AA, Martínez-Piñero L. Prognostic value of urinary cytology for detecting urothelial carcinoma recurrence after radical cystectomy. *Actas Urol Esp*. 2021; 45(6): 466-72. Article. IF: 0.887; Q4
- Rojas MM, Villalpando DM, Alexander-Aguilera


- Ferrer M, García HS. Effect of CLA supplementation on factors related to vascular dysfunction in arteries of orchidectomized rats. *Prostag Oth Lipid M*. 2021; 157: 106586. Article. IF: 3.813; Q3
- Ruiz CB, Álvarez-Maestro M, Dorrego JMA, Guerin CD, Alcaide RC, Monsalve DC, de Vicente JMG, Bazán AA, Piñero LM. Urinary complications of renal transplantation. Diagnosis and treatment. *Arch Esp Urol*. 2021; 74(10): 1029-39. Article. IF: 0.43; Q4
- Ruiz CB, Martínez-Piñero L. Re: Observation vs. early drainage for grade IV blunt renal trauma: a multicenter study. *Eur Urol*. 2021; 80(5): 671-2. Editorial Material. IF: 24.267; D1
- Taratkin M, Álvarez-Maestro M, Rivas JG. The need of avoiding unnecessary biopsies in active surveillance for prostate cancer. *Actas Urol Esp*. 2021; 45(6): 417-8. Editorial Material. IF: 0.887; Q4
- Trelles CR, Martínez-Piñero L. Re: The role of cytoreductive radical prostatectomy in the treatment of newly diagnosed low-volume metastatic prostate cancer. results from the local treatment of metastatic prostate cancer (LoMP) registry. *Eur Urol*. 2021; 80(6): 764-5. Editorial Material. IF: 24.267; D1
- Tubaro A, Speakman M, de la Taille A, Martínez-Piñero L, Berges R, Patel A, Bjartell A, Caris C, Witjes W. A European registry evaluating symptomatic effectiveness of pharmacologically treated patients with lower urinary tract symptoms due to benign prostatic enlargement: lessons learned. *J Urology*. 2021; 205(4): 1145-51. Article. IF: 7.6; Q1
- Witjes JA, Bruins HM, Cathomas R, Comperat EM, Cowan NC, Gakis G, Hernández V, Espinos EL, Lorch A, Neuzillet Y, Rouanne M, Thalmann GN, Veskimäe E, Ribal MJ, van der Heijden AG. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. *Eur Urol*. 2021; 79(1): 82-104. Review. IF: 24.267; D1

■ Research projects

Botella Cubells LM. Bases moleculares, diagnóstico genético y búsqueda de terapias de 2 enfermedades raras con afectación vascular: HHT y VHL (SAF2017-83351R). MiCINN. 2018-2021.

Management centre: Centro de Investigaciones Biológicas Margarita Salas

Botella Cubells LM. El genoma de HHT (PIE-201820E973). CSIC. 2018-2021.



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Management centre: Centro de Investigaciones Biológicas Margarita Salas

Botella Cubells LM. Translational Research in rare diseases of vascular origin: pathological models and molecular bases of therapies. (PID2020-115371RB-I00). MICINN. 2021-2024.

Management centre: Centro de Investigaciones Biológicas Margarita Salas

Ferrer Parra M. Acción no genómica de 5β-dihidrotestosterona. Utilización terapéutica en el tratamiento de las alteraciones vasculares asociadas a déficit androgénico. (PI19/01282). ISCIII. 2020-2022.

Management centre: UAM

Linares Espinós EE. Análisis de biomarcadores en exosomas de plasma y orina de pacientes con cáncer de próstata resistente a la castración. Astellas Pharma S.A. 2017-Ongoing.

Management centre: FIBHULP

López Pereira P. Utilización de constructos de mucosa urotelial autóloga obtenidos mediante ingeniería tisular para la realización uretroplastias reconstructivas en un modelo experimental de hipospadias proximal en conejos. Fundación para la Investigación en Urología. 2016-Ongoing.

Management centre: FIBHULP

Martínez-Piñeiro Lorenzo L. Immunothercan-CM: Inmunidad tumoral e inmunoterapia del cáncer (S2017/BMD-3733). CM. 2018-2021.

Management centre: FIBHULP

Martínez-Piñeiro Lorenzo L. Polish Spanish uro-onco scientific forum exchange 2018. ICP Group. 2018-Ongoing.

Management centre: FIBHULP

Valés Gómez MM. Mejora del tratamiento del cáncer de vejiga por Baciloterapia (RTC-2017-6379-1). MINECO. 2018-2022.

Management centre: CNB

Valés Gómez MM. Modulación de la respuesta Natural Killer en el reconocimiento y evasión tumoral (MoNKTuRE) (RTI2018-093569-B-I00). MINECO. 2019-2021.

Management centre: CNB

Valés Gómez MM. Red traslacional para la aplicación clínica de vesículas extracelulares (RED2018-102411-T). MINECO. 2020-2021.

Management centre: UAM

■ Cibers & Retics

Botella Cubells LM. Centro de Investigación Biomédica en Red de Enfermedades Raras. (CIBERer). ISCIII. (31/12/2021).

Management centre: CSIC

López Pereira P. Red Europea de enfermedades urológicas raras. (e UROGEN). EU. (31/12/2021).

Management centre: FIBHULP

■ Clinical trials

Linares Espinós, EE. Estudio aleatorizado, controlado, multicéntrico yabierto para investigar la eficacia y la seguridad de añadirapalutamida a la radioterapia y al agonista de la HLHL en pacientes con cáncer de próstata hormonosensible positivos en PET con PSMA, con un seguimiento observacional de los pacientes negativos en petcon PSMA.

Type: Clinical Trials, phase III.

HULP code: 5959 56021927PCR3015.

Sponsored by: Janssen Cilag International Nv.

Signed date: 29/09/2021

Ríos González, E. Estudio fase II aleatorizado de erdafitinib frente a la selección del investigador de quimioterapia intravesical en sujetos que recibieron el bacilo de calmette y guérin (bcg) y presentaron

recidiva de cáncer de vejiga no músculo-invasivo (nmibc) de alto riesgo y mutaciones o fusiones del fgfr.

Type: Clinical Trials, phase II.

HULP code: Appendix 1 5449.

Sponsored by: Janssen Cilag International Nv.

Signed date: 03/02/2021

Ríos González, E. Estudio de biomarcadores para determinar la frecuencia de defectos en la reparación del ADN en hombres con cáncer de próstata metastásico. estudio prevalencia.

Type: Estudios No EPA.

HULP code: PI-4619 PREVALENCE.

Sponsored by: Janssen Cilag International Nv.

Signed date: 24/02/2021

Ríos González, E. Estudio aleatorizado, doble ciego, controlado con placebo de fase III de niraparib en combinación con acetato de abiraterona y prednisona frente a acetato de abiraterona y prednisona para el tratamiento de participantes con cáncer de próstata metastásico sensible a la castración (cpscm) con mutaciones deletéreas en la línea germinal o somáticas en los genes de reparación por recombinación homóloga (hrr).

Type: Clinical Trials, phase III.

HULP code: Appendix 1 5654.

Sponsored by: Janssen Cilag International Nv.

Signed date: 27/05/2021

Ríos González, E. Darol: estudio observacional de darolutamida en pacientes con cáncer de próstata resistente a la castración no metastásico.

Type: Estudios, phase EPA-OD.

HULP code: PI-4752 BAY-DAR-2021-01.

Sponsored by: Bayer Hispania, S.L.

Signed date: 18/08/2021

■ Patents and trademarks


Botella Cubells LM, Albiñana Díaz V, Villar Gómez de las Heras K, inventors; CSIC, Alianza Española de Familias de Von Hippel-Lindau-VHL, assignees; Compounds for treating von Hippel-Lindau diseases. P201731019, PCT/EP2018/071220, CA3072389A1, EA202090452A1, EP3664788A1, US2020323798A1; 2017 August 07.

Sánchez-Puelles González-Carvajal JM, Botella Cubells LM, Aguado Sánchez T, Del Río Nechaevsky M, García Martín A, García Díez M, Larcher Laguzzi F, Carrero Trillo M, inventors; CSIC, UC3M, CIEMAT, assignees; Inhibitors of TGF-β1 and endoglin producers for use in the treatment of epidermolysis bullosa

Aguado Sánchez T, Albiñana Díaz V, Botella Cubells LM, Cuesta Martínez A, Sánchez-Puelles González-Carvajal JM, Villar Gómez-de las Heras K, inventors; Alianza Española De Familias De Von Hippel-Lindau-VHL, CSIC, Consorcio Centro de Investigación Biomédica en Red M.P., assignees; Treatment and prevention of glioblastoma. EP18382917A, PCT/EP2019/084822, CA3122640A1; 2018 December 12.

Reyburn HT, Valés-Gómez M, inventors; assignees; Assay for the detection of the Cys-like protease (Mpro) of SARS-CoV-2. EP20382495.8; 2020 August.

Valés-Gómez M, inventors; assignees; Method for the detection and/or quantification of extracellular vesicles in fluid biological samples. EP16411562; 2020 August.



3.4.11 Health Care Nurses Research Group

Publications: 5

Q1: 1

COMPOSITION



Patricia Luna Castaño. Supervisora Unidad Apoyo a la Investigación en Cuidados. Hospital Universitario La Paz

Laura Alonso Recio. Profesora Contratada. Universidad de Educación a Distancia

Jesús Castro Toro. Supervisor de Área Funcional. Hospital Universitario La Paz

Víctor Manuel Cornejo del Río. Supervisor de Unidad Quirúrgica. Hospital Carlos III- Hospital Universitario La Paz

María Ricardina Delgado Sandoval. Enfermera en Servicio de Consultas Externas. Hospital Universitario La Paz

María Luisa Díaz Martínez. Profesora Contratada. Universidad Autónoma de Madrid

María Durán Agüí. Enfermera en Servicio de Medicina Interna. Hospital Universitario La Paz

Salomé Herrero Cereceda. Enfermera Unidad Quirúrgica. Hospital Cantoblanco-Hospital Universitario La Paz

Pedro Piqueras Rodríguez. Supervisor de Enfermería en Unidad de Neonatología. Hospital Universitario La Paz

Ana Ramos Cruz. Supervisor de Enfermería en Reanimación Maternidad. Hospital Universitario La Paz. Profesora Asociada de Grado de Enfermería. Centro Universitario de Ciencias de la Salud San Rafael-Nebrija

María del Carmen Sellán Soto. Profesora Contratada. Universidad Autónoma de Madrid

Gema Tapia Serrano. Enfermera de Cuidados Intensivos Pediátricos. Hospital Universitario La Paz

STRATEGIC OBJECTIVE

Care is an indispensable activity for survival, since humanity exists. Care has been relevant as a primary function to promote and develop all those activities that make people live.

This research group aims to collaborate on growing clinical evidence on health care. The real gap between what generates scientific knowledge and the decisions that are made in the day to day is ethically unacceptable. Between 30 and 40% of patients do not receive care consistent with the results of the research and around 20-25% of care may be unnecessary or potentially harmful. Evidence-Based Practice (PBE) or Evidence is based on the fact that greater knowled-

ge and use of research results in clinical practice will contribute to improving the health of the population. Today, it is well known that the implementation of the best scientific evidence available in the clinical practice improves quality of care and clinical outcomes.

In addition, decision-makers based on available evidence tend to be more satisfied with their role and focus on improving the quality of care given to patients.

Finally, it should be noted that using evidence in daily practice can achieve health goals at a minimum cost. Cost-effectiveness studies have been conducted in which evidence-based care is linked to a reduction in health costs compared to traditional care.


At the same time, society is facing new economic, political, demo-

1
Introduction

2
Executive
Summary

3
Information
Groups
by Area

4
Associated
Clinicians



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

graphic, social and cultural challenges that require health services capable of meeting the growing health needs of the population. It is necessary to investigate in clinical practice the most advanced care in order to achieve the full development of care and ensure the achievement of the best results in terms of overall health and quality of life of patients, Effectiveness of interventions, greater cohesion of health care teams, and of course, all contribute to the sustainability of the health system and user satisfaction.

RESEARCH LINES

- Vital Processes and complex care
- Technological innovation and its application in health care
- Management of care and results of professional practice

RESEARCH ACTIVITY

■ Doctoral theses

Master Theses

Sierra Puerta TT. Percepciones y conocimientos de las enfermeras sobre el dolor de los pacientes[dissertation]. Madrid: Universitat de Barcelona-Universidad Autónoma de Madrid: 2021(16/06/2021).
Director: Carmen Sellán Soto M.

Hernández de Urrutia MP. Atención por parte de la Enfermera Especializada a mujeres víctimas de agresiones sexuales[dissertation]. Madrid: Universitat de Barcelona-Universidad Autónoma de Madrid: 2021(18/06/2021).
Director: Díaz Martínez ML.

Final Degree Theses

Cheng K. Actualización sobre cuidados de enfermería frente a las complicaciones derivadas del tratamiento quimioterapéutico en la población pediátrica oncológica[dissertation]. Madrid: Universidad Autónoma de Madrid: 2021(21/06/2021).
Director: Luna Castaño P.

Sánchez Carreño P. La participación de la familia en el cuidado del paciente pediátrico hospitalizado[dissertation]. Ma-

drid: Universidad Autónoma de Madrid: 2021(22/06/2021).

Director: Luna Castaño P.

Crespo Diestro M, Villena Donate A. Cuidados de enfermería en la adaptación psicológica del paciente oncológico pediátrico a la hospitalización[dissertation]. Madrid: Universidad Autónoma de Madrid: 2021(21/06/2021).
Director: Luna Castaño P.

Ortiz Ramírez A. Eficacia de las terapias de grupo y de la formación en equipos de protección individual durante la pandemia Covid-19[dissertation]. Madrid: Universidad Nebrija: 2021(03/06/2021).
Director: Castro Toro J.

■ Publications

- Bosch-Alcaraz A, Alcolea-Monge S, Lorenzo RF, Luna-Castaño P, Belda-Hofheinz S, Pegueroles AF, Piqueras-Rodríguez P, Molina-Gallego I, Potes-Rojas C, Gesti-Senar S, Orozco-Gómez R, Tercero-Cano MC, Saz-Roy MA, Jordán I, García-Soler P, Tamame-San Antonio M. Grade of sedation in the critically ill paediatric patient and its correlation with sociodemographic and clinical variables. Multicentre COSAIP study. *Enferm Intensiva.* 2021; 32(4): 189-97. Article. Not Indexed
- Bosch-Alcaraz A, Luna-Castaño P, García-Soler P, Tamame-San Antonio M, Falco-Pegueroles A, Alcolea-Monge S, Lorenzo RF, Piqueras-Rodríguez P, Molina-Gallego I, Potes-Rojas C, Gesti-Senar S, Orozco-Gómez R, Tercero-Cano MC, Saz-Roy MA,

Jordan I, Belda-Hofheinz S. Level of discomfort in critically ill paediatric patients and its correlation with sociodemographic and clinical variables, analgosedation and withdrawal syndrome. *CO-SAIP multicentre study (Phase 2).* *An Pediatr.* 2021; 95(6): 397-405. Article. IF: 2.377; Q3

- González-Gil MT, Alcolea-Cosin MT, Pérez-García S, Luna-Castano P, Torrent-Vela S, Piqueras-Rodríguez P, Gil-Dominguez S, Alonso-Lloret F, Belda-Hofheinz S, Sánchez-Díaz JI, Espinosa-Bayal MA. Children's visits to the paediatric intensive care unit from the nurses' experience. *Enferm Intensiva.* 2021; 32(3): 133-44. Article. Not Indexed
- González-Gil MT, González-Blázquez C, Parro-Moreno AI, Pedraz-Marcos A, Palmar-Santos A, Otero-García L, Navarta-Sánchez MV, Alcolea-Cosin MT, Arguello-López MT, Canalejas-Pérez C, Carrillo-Camacho ME, Casillas-Santana ML, Díaz-Martínez ML, García-González A, García-Perea E, Martínez-Marcos M, Martínez-Martín ML, Palazuelos-Puerta MD, Sellan-Soto C, Oter-Quintana C. Nurses' perceptions and demands regarding COVID-19 care delivery in critical care units and hospital emergency services. *Intensive Crit Care Nurs.* 2021; 62: 102966. Article. IF: 4.235; D1
- Mateo-Martínez G, Sellán-Soto MC, Vázquez-Sellán A. The construction of contemporary nursing identity from narrative accounts of practice and professional life. *Heliyon.* 2021; 7(5): e06942. Article. IF: 3.776; Q2

■ Research projects

Castro Toro J. Efectividad de la aplicación móvil -Vivir con EPOC- para mejorar la adherencia al tratamiento y la calidad de vida en pacientes con enfermedades

pulmonar obstructiva crónica. Fundación Vodafone España. 2018-Ongoing.

Managment centre: FIBHULP

Piqueras Rodríguez P. Catéter permanente versus inyecciones en el confort del paciente pediátrico durante la administración de heparina de bajo peso molecular: ensayo clínico cruzado. Piqueras Rodríguez P. 2021-Ongoing.

Managment centre: FIBHULP

Sellán Soto MC. Efectividad del masaje terapéutico para aliviar el malestar de niños y niñas con bronquiolitis. CODEM. 2019-Ongoing.

Managment centre: Red Internacional de Enfermería en Salud infantil

■ Clinical trials


Piqueras Rodríguez, P. Catéter permanente versus inyecciones en el confort del paciente pediátrico durante la administración de heparina de bajopeso molecular: ensayo clínico cruzado.

Type: Estudio Producto Sanitario.

HULP code: 5283 5283.

Sponsored by: Piqueras Rodríguez, Pedro.

Signed date: 06/07/2021



3.4.12 Emergency and Critical Pathology Group

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Publications: 21
Q1: 10



COMPOSITION

■ **Alejandro Martín Quirós.** Facultativo Especialista de Área en Urgencias. Hospital Universitario La Paz

Gillermína Bejarano Redondo. Médico Adjunto en Urgencias. Hospital Universitario La Paz

Labna Dani Ben Abdel-lah. Facultativo Especialista de Área en Urgencias. Hospital Universitario La Paz

María Elena Calvín García. Facultativo Especialista de Área en Urgencias. Hospital Universitario La Paz

Julio Cobo Mora. Jefe de la Unidad de Urgencias. Hospital Universitario La Paz

María de los Ángeles García Martín. Facultativo Especialista de Área especialista en Farmacia Hospitalaria. Hospital Universitario La Paz

Olga González Peña. Facultativo Especialista de Área en Medicina Familiar y Comunitaria. Hospital Universitario La Paz

Manuel Jesús González Viñolis. Facultativo Especialista de Área en Urgencias. Hospital Universitario La Paz

Macarena Lerín Baratas. Facultativo Especialista de Área en Urgencias. Hospital Universitario La Paz

María Lorena López Corcuera. Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz

Mikel Rico Briñas. Facultativo Especialista de Área en Urgencias. Hospital Universitario La Paz

Paloma Isabel Romero Gallego-Acho. Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz

María José Simón Merlo. Facultativo Especialista de Área en Radiología. Hospital Universitario La Paz

Yaletung Chen. Facultativo Especialista de Área en Urgencias. Hospital Universitario La Paz


STRATEGIC OBJECTIVE

We collaborate with other research groups, to study clinical and prognostic usefulness tests in cardiology, to develop new strategies for the treatment and diagnosis of infectious diseases, and to investigate new antibiotics with the pneumology group.

We develop a new and pioneering line of imagingdiagnostic, with

the line of emergency ultrasound, being national referents in research in this field, in which we have the active support of private enterprise.

We will investigate the possibility of supporting us in new technologies that help the clinician in the decisión making in the field of the treatment of the diabetes, impelling global initiatives both at the hospital and the population level.



1
Introduction

RESEARCH LINES

- Integral management of the treatment and follow-up of the diabetic patient.
- Emergency ultrasound.
- Sepsis

- SARS-CoV-2 and COVID19 acute management
- Care of infectious diseases in the emergency room.
- Optimization of the management of the acute intoxicated patient and use of chemical substances for terrorist purposes.
- Attention to cardiovascular pathology of emergencies.
- Attention to respiratory pathology.

2
Executive
Summary

3
Information
Groups
by Area

4
Associated
Clinicians

RESEARCH ACTIVITY

■ Publications

- Abdukahil SA, Abe R, Abel L, Absil L, Acker A, Adachi S, Adam E, Adriaño D, Ainscough K, Hsain AA, Zucman D. (et al). COVID-19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospective multinational observational study. *Infection*. 2021; 49(5): 889-905. Article. IF: 7.455; Q1
- Avendaño-Ortiz J, Lozano-Rodríguez R, Martín-Quirós A, Maroun-Eid C, Terron-Arcos V, Montalbán-Hernández K, Valentin J, del Val EM, García-Garrido MA, del Balzo-Castillo A, Casalvilla-Duenas JC, Peinado M, Gómez L, Herrero-Benito C, Rubio C, Cubillos-Zapata C, Pascual-Iglesias A, del Fresno C, Aguirre LA, López-Collazo E. SARS-CoV-2 proteins induce endotoxin tolerance hallmarks: a demonstration in patients with COVID-19. *J Immunol*. 2021; 207(1): 162-74. Article. IF: 5.426; Q2
- Avendaño-Ortiz J, Lozano-Rodríguez R, Martín-Quirós A, Terron V, Maroun-Eid C, Montalbán-Hernández K, Valentin-Quiroga J, García-Garrido MA, del Val EM, del Balzo-Castillo A, Peinado M, Gómez L, Herrero-Benito C, Rubio C, Casalvilla-Duenas JC, Gómez-Campelo P, Pascual-Iglesias A, del Fresno C, Aguirre LA, López-Collazo E. The immune checkpoints storm in COVID-19: Role as severity markers at emergency department admission. *Clin Transl Med*. 2021; 11(10): e573. Letter. IF: 8.554; Q1
- Berenguer J, Borobia AM, Ryan P, Rodríguez-Bañó J, Bellón JM, Jarrín I, Carratala J, Pachón J, Carcas AJ, Yllescas M, Arribas JR. Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score. *Thorax*. 2021; 76(9): 920-9. Article. IF: 9.102; Q1
- Chen YT, Fuentes PR, Saez PO, Villegas TV, Soto AB, Calle PF, Cardona CC, Mora JC, Ca-

nadas MJ, Tong HY, Borobia AM. Efficacy of a fast-track pathway for managing uncomplicated renal or ureteral colic in a hospital emergency department: the STONE randomized clinical trial of Sonography and Testing of a Nephrolithiasis Episode. *Emergencias*. 2021; 33(1): 23-8. Article. IF: 5.345; Q1

- Cogliati C, Bosch F, Tung-Chen Y, Smallwood N, Torres-Macho J. NNLung ultrasound in COVID-19: Insights from the frontline and research experiences. *Eur J Intern Med*. 2021; 90: 19-24. Article. IF: 7.749; Q1
- COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-19. *Nature*. 2021; 600(7889): 472-7. Article. IF: 69.504; D1
- Dopico LR, Tung-Chen Y, Barco MP, García AM. Monitoring of the rehabilitation therapy of COVID-19 effort dyspnea. *Enferm Infecc Microb Cl*. 2021; 39(5): 258-9. Letter. IF: 1.994; Q4
- Gómez-Junyent J, Lora-Tamayo J, Baraia-Etxaburu J, Sánchez-Somolinos M, Iribarren JA, Rodríguez-Pardo D, Praena-Segovia J, Sorli L, Bahamonde A, Riera M, Rico A, del Toro MD, Morata L, Cobo J, Falgueras L, Benito N, Munez E, Jover-Saenz A, Pigrau C, Ariza J, Murillo O. Implant removal in the management of prosthetic joint infection by staphylococcus aureus: outcome and predictors of failure in a large retrospective multicenter study. *Antibiotics (Basel)*. 2021; 10(2): 118. Article. IF: 5.222; Q1
- Gutiérrez-Gutiérrez B, del Toro MD, Borobia AM, Carcas A, Jarrín I, Yllescas M, Ryan P, Pachón J, Carratala J, Berenguer J, Arribas JR, Rodríguez-Bano J. Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study. *Lancet Infect Dis*. 2021; 21(6): 783-92. Article. IF: 71.421; D1
- Hernández-Piriz A, Tung-Chen Y, Jiménez-Vi-

rumbrales D, Ayala-Larranaga I, Barba-Martín R, Canora-Lebrato J, Zapatero-Gaviria A, De Casasola-Sánchez GG. Importance of lung ultrasound follow-up in patients who had recovered from coronavirus disease 2019: Results from a prospective study. *J Clin Med*. 2021; 10(14): 3196. Article. IF: 4.964; Q2


- Martín-Quirós A, Maroun-Eid C, Avendaño-Ortiz J, Lozano-Rodríguez R, Valentin Quiroga J, Terrón V, Montalbán-Hernández K, García-Garrido MA, Muñoz del Val E, del Balzo-Castillo A, Rubio C, Cubillos-Zapata C, Aguirre LA, López-Collazo E. Potential role of the galectin-9/tim-3 axis in the disparate progression of sars-cov-2 in a married couple: a case report. *Biomed Hub*. 2021; 6(1): 48-58-. Article. Not Indexed
- May L, Quirós AM, Ten Oever J, Hoogerwerf J, Schoffelen T, Schouten J. Antimicrobial stewardship in the emergency department: characteristics and evidence for effectiveness of interventions. *Clin Microbiol Infecc*. 2021; 27(2): 204-9. Review. IF: 13.31; D1
- Schoffelen T, Schouten J, Hoogerwerf J, Quirós AM, May L, Ten Oever J, Hulscher M. Quality indicators for appropriate antimicrobial therapy in the emergency department: a pragmatic Delphi procedure. *Clin Microbiol Infecc*. 2021; 27(2): 210-4. Article. IF: 13.31; D1
- Tong HY, Borobia AM, Quintana-Díaz M, Fabra S, González-Vinolis M, Fernández-Capitan C, Rodríguez-Dávila MA, Lorenzo A, López-Parra AM, Ruiz-Giménez N, Abad-Santos F, Suárez C, Madridano O, Gómez-Cerezo JF, Llamas P, Baeza-Richer C, Arroyo-Pardo E, Carcas AJ. Acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolism: a randomised clinical trial. *J Clin Med*. 2021; 10(13): 2949. Article. IF: 4.964; Q2
- Torres-Macho J, Sánchez-Fernández M, Arnanz-González I, Tung-Chen Y, Franco-Moreno AI,

Duffort-Falco M, Beltran-Romero L, Rodríguez-Suárez S, Bernabeu-Wittel M, Urbano E, Méndez-Bailon M, Roque-Rojas F, García-Guijarro E, García-Casasola G. Prediction accuracy of serial lung ultrasound in covid-19 hospitalized patients (Pred-Echovid Study). *J Clin Med*. 2021; 10(21): 4818. Article. IF: 4.964; Q2

- Tung-Chen Y, Algora-Martín A, Rodríguez-Roca S, de Santiago AD. COVID-19 multisystemic inflammatory syndrome in adults: a not to be missed diagnosis. *BMJ Case Rep*. 2021; 14(4): e241696. Article. Not Indexed
- Tung-Chen Y, Alonso-González B, Arroyo-Rico I. Lung ultrasonography unmasking the asymptomatic SARS-CoV-2 carrier. *Med Clin-Barcelona*. 2021; 156(4): 196-7. Letter. IF: 3.2; Q2
- Tung-Chen Y, González-Vinolis M, Santos-Olmo RMT. Tele-ultrasound guided through WhatsApp. *Med Clin-Barcelona*. 2021; 157(11): E343-4. Letter. IF: 3.2; Q2
- Tung-Chen YL, Algora-Martín A, Llamas-Fuentes R, Rodríguez-Fuertes P, Virto AMM, Sanz-Rodríguez E, Alonso-Martínez B, Núñez MAR. Point-of-care ultrasonography in the initial characterization of patients with COVID-19. *Med Clin-Barcelona*. 2021; 156(10): 477-44. Article. IF: 3.2; Q2
- Tung-Chen YL, Marín-Baselga R, Soriano-Arroyo R, Muñoz-del Val E. Time course of lung changes on thoracic ultrasound of mild COVID-19 patients. *Enferm Infecc Microb Cl*. 2021; 39(1): 46-8. Letter. IF: 1.994; Q4

■ Research projects

Martín Quirós A. Impacto del retraso en el inicio de la antibioterapia e identificación de biomarcadores pronósticos en la



evolución de pacientes con sepsis a shock séptico (PI20/01589). ISCIII. 2021-2023.

Management centre: FIBHULP

Martín Quirós A. Development of robust and innovative vaccine effectiveness (DRI-VE). EU. 2020-2021.

Management centre: FIBHULP

■ Clinical trials

López Ortego, P. Retrospective cohort safety study of captopril administered for prevention or treatment of heart failure in paediatric patients from birth to 1 year of age.

Type: Estudios, phase EPA-OD.

HULP code: Appendix 1 PI-3351.

Sponsored by: Proveca Ltd.

Signed date: 27/04/2021

Martín Quirós, A. Estudio clínico de fase 2/3, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia, la seguridad y la farmacocinética de mk-4482 en adultos no hospitalizados con COVID-19.

Type: Clinical Trials, phase II.

HULP code: Appendix 1 5693.

Sponsored by: Merck Sharp And Dohme De España, S.A.

Signed date: 16/03/2021

Martín Quirós, A. Estudio de fase II, aleatorizado, doble ciego y controlado con placebo para evaluar la actividad antiviral, la seguridad, la farmacocinética y la eficacia de ro7496998 (at-527) en pacientes adultos no hospitalizados con COVID-19 leve o moderada.

Type: Clinical Trials, phase II.

HULP code: 5836 WV43042.

Sponsored by: F.Hoffmann-La Roche Ltd.

Signed date: 09/04/2021

Martín Quirós, A. Estudio clínico de fase 2/3, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia, la seguridad y la farmacocinética de mk-4482 en adultos no hospitalizados con COVID-19.

Type: Clinical Trials, phase II.

HULP code: Appendix 2 5693.

Sponsored by: Merck Sharp And Dohme De España, S.A.

Signed date: 14/07/2021

Martín Quirós, A. Estudio intervencional de fase II/III, doble ciego, de dos grupos para evaluar la eficacia y la seguridad de pf-07321332/ritonavir administrados oralmente y comparado con placebo en pacientes adultos sintomáticos no hospitalizados con COVID-19 que tengan riesgo bajo de progresar a enfermedad severa.

Type: Clinical Trials, phase III.

HULP code: 5953 C4671002.

Sponsored by: Pfizer, S.L.U.

Signed date: 04/08/2021

Martín Quirós, A. Estudio intervencional de fase II/III, doble ciego, de dos grupos para evaluar la eficacia y la seguridad de pf-07321332/ritonavir administrados oralmente y comparado con placebo en pacientes adultos sintomáticos no hospitalizados con COVID-19 que tengan riesgo elevado de progresar a enfermedad severa.

Type: Clinical Trials, phase III.

HULP code: 5955 C4671005.

Sponsored by: Pfizer, S.L.U.

Signed date: 04/08/2021

Martín Quirós, A. Estudio de fase II/

III, aleatorizado, doble ciego, con doble simulación y controlado con placebo para evaluar la seguridad y eficacia de 2 pautas de pf-07321332/ritonavir administrados oralmente para prevenir los síntomas de la infección por SARS-CoV-2 en adultos que hayan tenido contacto doméstico con personas infectadas por SARS-CoV-2.

Type: Clinical Trials, phase III.

HULP code: 5954 C4671006.

Sponsored by: Pfizer, S.L.U.

Signed date: 14/09/2021

Martín Quirós, A. Estudio de fase 3, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de mk-4482 en la prevención de la COVID-19 (infección por sarscov-2, confirmada por el laboratorio, con síntomas) en adultos que conviven con una persona con COVID-19.

Type: Clinical Trials, phase III.

HULP code: 5929 MK-4482-013.

Sponsored by: Merck Sharp And Dohme De España, S.A.

Signed date: 24/08/2021

1
Introduction

2
Executive
Summary

3
Information
Groups
by Area

4
Associated
Clinicians



3.4.13 Hospital Pharmacy Group

Publications: 12
Q1: 1

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



COMPOSITION

■ **Alicia Herrero Ambrosio.** Jefa de Servicio de Farmacia Hospitalaria. Hospital Universitario La Paz. Profesora Asociada. Universidad Complutense De Madrid

Susana Andrés Morera. Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz

Cristina Bilbao Gómez-Martino. Facultativo Especialista de Área en Farmacia Hospitalaria. FIBHULP

Nuria Blázquez Ramos. Farmacéutica. FIBHULP

Cristina Cárdenas Serralde. Farmacéutico Especialista en Farmacia Hospitalaria. FIBHULP

María Gema Casado Abad. Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz

María del Río Durango. Farmacéutico Especialista en Farmacia Hospitalaria. FIBHULP

Luis González del Valle. Jefe de Sección de Farmacia Hospitalaria. Hospital Universitario La Paz

María Ángeles González Fernández. Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz

Inmaculada Jiménez Nacher. Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz

Catalina Lara Cátedra. Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz

Marta Moro Agud. Farmacéutico Especialista en Farmacia Hospitalaria. Hospital Universitario La Paz

Tamara Pérez Robles. Facultativo Especialista de Área en Farmacia Hospitalaria. FIBHULP

Elena María Rodríguez Martín. Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz

José Antonio Romero Garrido. Farmacéutico Adjunto. Hospital Universitario La Paz

Rosario Fátima Ros Catellar. Farmacéutico Especialista en Farmacia Hospitalaria. Hospital Universitario La Paz


Margarita Ruano Encinar. Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz

Luis Sánchez-Rubio Fernández. Facultativo Especialista de Área en Farmacia Hospitalaria. FIBHULP

Carmen Sobrino Jiménez. Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz

María Luisa Testillano Tarrero. Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz

Elena Villamañán Bueno. Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

STRATEGIC OBJECTIVE

The Hospital Pharmacy group aims to investigations on pharmacotherapy focused on both, researches on treatments and innovation technology related to the medication use process in order to optimize clinical practice.

RESEARCH LINES

1. Evaluation of Drugs - Real World Outcomes, especially those associated with high economic impact or with limited clinical evidence. In this regard, our target is to investigate on the following fields:

- Coagulopathies
- Oncology
- Biologic therapies
- Infectious diseases
- Rare diseases
- Gene therapy
- Link between the parasympathetic and innate immune systems

2. Investigation on strategies for early detection and prevention of medication errors either in patients with critical illness and patients with complex chronic conditions.

3. Analysis of the impact on medication adherence and health outcomes of innovation in new technologies applied to the medication use process:

- Telepharmacy programs including or not medications home delivery. Evaluation of their impact on medication adherence and health outcomes in different pathologies such as migraine, multiple sclerosis, prostate cancer and asthma
- Development and evaluation of digital health tools applied to congenital coagulopathies and its impact in terms of adherence and treatment cost-effectiveness improvement
- Research on the effect of predictive analytics and big data on clinical decision making and pharmaceutical outcomes optimization
- Identification of signalling pathways connecting nicotinic alpha7 receptors and negative regulators of TLR-mediated inflammation in human macrophages

4. Development of new drugs: Advanced therapies

RESEARCH ACTIVITY


■ Publications

- Aguilar PM, Carrera LG, Segura CC, Sánchez MIT, Peña MFV, Hernán GB, Rodríguez IE, Zapata RMR, De Lucas EZ, Álvarez PDA, Bueno EV, Sánchez CP, Walther RAS. Relationship between air pollution levels in Madrid and the natural history of idiopathic pulmonary fibrosis: severity and mortality. *J Int Med Res.* 2021; 49(7): 3000605211029060. Article. IF: 1.573; Q4
- Caro-Codón J, Lip GYH, Rey JR, Iniesta AM, Rosillo SO, Castrejón-Castrejón S, Rodríguez-Sotelo L, García-Veas JM, Marco I, Martínez LA, Martín-Polo L, Merino C, Martínez-Cossiani M, Buño A, González-Valle L, Herrero A, López-de-Sa E, Merino JL. Prediction of thromboembolic events and mortality by the CHADS(2) and the CHA(2) DS(2)-VASc in COVID-19. *Europace.* 2021; 23(6): 937-47. Article. IF: 5.486; Q2
- Caro-Codón J, Rey JR, Buño A, Iniesta AM, Rosillo SO, Castrejón-Castrejón S, Merino C, Marco

- I, Martínez LA, García-Veas JM, Martín-Polo L, Rodríguez-Sotelo L, Martínez-Cossiani M, González-Valle L, Herrero A, López-de-Sa E, Merino JL. Characterization of myocardial injury in a cohort of patients with SARS-CoV-2 infection. *Med Clin-Barcelona.* 2021; 157(6): 274-80. Article. IF: 3.2; Q2
- Caro-Codón J, Rey JR, Buño A, Iniesta AM, Rosillo SO, Castrejón-Castrejón S, Rodríguez-Sotelo L, Martínez LA, Marco I, Merino C, Martín-Polo L, García-Veas JM, Martínez-Cossiani M, González-Valle L, Herrero A, López-de-Sa E, Merino JL. Characterization of NT-proBNP in a large cohort of COVID-19 patients. *Eur J Heart Fail.* 2021; 23(3): 456-64. Article. IF: 17.349; D1
- Fernández A, Navarro-Zapata A, Escudero A, Matamala N, Ruz-Caracuel B, Mirones I, Pernas A, Cobo M, Casado G, Lanzarot D, Rodríguez-Antolín C, Vela M, Ferreras C, Mestre C, Viejo A, Leivas A, Martínez J, Fernández L, Pérez-Martínez A. Optimizing the procedure to manufacture

- clinical-grade nk cells for adoptive immunotherapy. *Cancers (Basel).* 2021; 13(3): 577. Article. IF: 6.575; Q2
- Fernández MG, Villamañan E, Jiménez-Nacher I, Moreno F, Plasencia C, Gaya F, Herrero A, Balsa A. Cost evolution of biological drugs in rheumatoid arthritis patients in a tertiary hospital: Influential factors on price. *Reumatol Clin.* 2021; 17(6): 335-42. Article. Not Indexed
- González-Fernández MA, Jiménez-Nacher I, Villamañan-A-Bueno E, García-Trevijano M, Herrero A. The role of the pharmacist within an immune-mediated inflammatory disease unit: Results of a survey of healthcare providers and patients. *Farm Hosp.* 2021; 45(6): 305-16. Article. Not Indexed
- Jiménez CS, Romero-Garrido JA, García-Martín A, Quintana-Díaz M, Jiménez-Vicente C, González-Del Valle L, Ambrosio AH, Benedi-González J. Safety and effectiveness of a four-factor prothrombin complex concentrate for vitamin K

- antagonist reversal following a fixed-dose strategy. *Eur J Hosp Pharm-S P.* 2021; 28(E1): E66-71. Article. IF: 2.537; Q3
- Pardo AA, Palomino MM, Jiménez-Nacher I, Moreno F, Fernández MAG, González-García J, Ambrosio AH. Real-world experience with two-drug regimens in hiv-1-infected patients beyond the indication of clinical trials: 48 weeks' results. *AIDS Res Hum Retrov.* 2021; 37(10): 761-7. Article. IF: 1.723; Q4
- Sánchez MDC, Gómez VG, Urgelles AS, de Sabando DPL, Aparicio PR, Martínez LM, Gamarra EA, Kreiling JJP, Zapata RMR, Gutiérrez JCL, Alvarado EA, Martín FG, Torres AMS, Manzano EM, del Valle LG, Pérez-Martínez A. Treatment of infantile fibrosarcoma associated to an abdominal aortic aneurysm with larotrectinib: a case report. *Pediatr Hemat Oncol.* 2021; 38(5): 504-9. Article. IF: 2.07; Q3
- Villamañan E, Sobrino C, Bilbao C, Fernández J, Herrero A, Calle M, Álvaro D, Segura M, Picazo



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

G, Rodríguez JM, Baldominos G, Ramírez MT, Larrubia Y, Llorente J, Martínez A, Álvarez-Sala R. Off-label use of inhaled bronchodilators in hospitalised patients in Spain: a multicentre observational study. *Eur J Hosp Pharm-S P*. 2021; 28(E1): E23-8. Article. IF: 2.537; Q3

- Villamañan E, Sobrino C, Carpio C, Moreno M, Arancón A, Lara C, Pérez E, Jiménez C, Zamarrón E, Jiménez-Nacher I, Herrero A, Álvarez-Sala R. Inhaled bronchodilators use and clinical course of adult inpatients with Covid-19 pneumonia in Spain: A retrospective cohort study. *Pulm Pharmacol Ther*. 2021; 69: 102007. Article. IF: 3.282; Q3

■ Research projects

Herrero Ambrosio A. Actualización y promoción de la actividad investigadora en el servicio de farmacia del Hospital Universitario La Paz. Vifor Pharma España S.L. 2016-Ongoing.

Management centre: FIBHULP

Herrero Ambrosio A. Desarrollo de un sistema de gestión de medicamentos en investigación. Sanofi Aventis S.A. 2008-Ongoing.

Management centre: FIBHULP

Herrero Ambrosio A. Estudio de evalua-

ción del servicio de telefarmacia y entrega no presencial de medicación desde la farmacia hospitalaria a partir de la pandemia covid-19. Amgen S.A. 2020-Ongoing.

Management centre: FIBHULP

Herrero Ambrosio A. Evaluación de la notificación de alergias a fármacos en pacientes hospitalizados. utilidad de la prescripción electrónica en la prevención de errores de medicación. Amgen S.A. 2012-Ongoing.

Management centre: FIBHULP

Herrero Ambrosio A. Implantación del módulo epase en la elaboración de anti-neoplásicos. Amgen S.A. 2013-Ongoing.

Management centre: FIBHULP

Herrero Ambrosio A. Informatización y optimización de procesos en la unidad de ensayos clínicos del servicio de farmacia. Vifor Pharma España S.L. 2015-Ongoing.

Management centre: FIBHULP

Herrero Ambrosio A. XVI Jornadas farmaceuticas de investigación sobre el tratamiento del paciente hemofílico y complicaciones asociadas. Roche Farma S.A. 2019-Ongoing.

Management centre: FIBHULP

Moro Agud M. Evaluación de la implantación de una plataforma de gestión del conocimiento para la comunicación, formación y docencia en el Hospital Universitario La Paz. Pfizer S.L.U. 2020-Ongoing.

Management centre: FIBHULP

Romero Garrido JA. Estudio de adherencia al tratamiento de los pacientes en profilaxis con factores de la coagulación y su relación con los episodios de sangrado. Amgen S.A. 2014-Ongoing.

Management centre: FIBHULP

Romero Garrido JA. Estudio de adherencia al tratamiento sustitutivo con factores de la coagulación en pacientes diagnosticados de hemofilia grave en régimen de demanda y profilaxis y su relación con episodios de sangrado. Pfizer S.L.U. 2016-Ongoing.

Management centre: FIBHULP

Villamañan Bueno E. Búsqueda de marcadores genéticos en el tratamiento de la fibrosis pulmonar idiopática con pirfenidona y nintedanib. Fundación Española de Farmacia Hospitalaria (FEFH).

2020-Ongoing.

Management centre: FIBHULP


Villamañan Bueno E. Evaluación de las objeciones alegadas por un comité ético de investigación clínica a los consentimientos informados de los estudios clínicos. Amgen S.A. 2016-Ongoing.

Management centre: FIBHULP

■ Patents and trademarks

Herrero Ambrosio A, Ramírez García E, Ojeda Feo JJ, Pérez Rodríguez J, Asensio Martín MJ, González Sánchez ML, Moro Agud M, Lorente Romeo M, López Nieto M, Gómez Rioja R, authors; FIBHULP, assignee. Trademark name: SINOIRES; CM 13.080.056; 2014 July 14.






1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

3.4.14 Translational Hepatology Group*



COMPOSITION

■ **Francisco Javier García-Samaniego Rey.** Jefe de Sección en Hepatología. Profesor Titular. Universidad Complutense de Madrid

Antonio Madejón Seiz. Investigador Senior. FIBHULP

STRATEGIC OBJECTIVE

The research group conducted by Dr. García-Samaniego has extensive experience in the study of liver diseases, focusing its research activity, in both, clinical and basic aspects. In recent years the group has developed its activity preferentially in the study of viral hepatitis. The expertise areas of the research group are the study of infections caused by the hepatitis viruses [hepatitis viruses B (HBV), C (HCV) and delta (HDV)] and the chronic liver disease related to HBV, HCV and HDV at a time in which highly efficient antiviral systems against HBV, and especially against HCV has been developed.

In addition to complete the research lines, the global strategy of the group will be focused in maintaining the high level of collaboration, both with CIBERehd research groups and with external groups, as well as to increase of the cooperation ways with private enterprise.

RESEARCH LINES

Main research lines:

- Study of the epidemiological situation and optimization of the cascade of care for patients with infection by the hepatitis del-

ta virus (HDV). Project in collaboration with the Hospital Clinic of Barcelona and Infanta Leonor of Madrid, and funded by the HDV DESCRIBE program sponsored by Gilead Scientific, S.A.

- Development of HCV micro-elimination strategies through the optimization and implementation of HCV detection and quantification systems at diagnostic points.
- Analysis of the role of epigenetic modifications induced by infection by hepatotropic viruses in the evolution of liver disease and the development of liver cancer, before and after antiviral treatment. Project performed in collaboration with the Department of Biochemistry of the Faculty of Medicine of the UAM and the Virology laboratory of the Molecular Biology Center "Severo Ochoa".
- Study of liver fibrosis progression factors in patients with metabolic hepatic steatosis.

Alternative lines of work:

- Study of the role of the intestinal microbiota as a prognostic factor for adverse effects in biological cancer therapy. Project developed in collaboration with the Department of Biochemistry of the Faculty of Medicine of the UAM.
- Study of the influence of pre-existing liver disease on the evolution of COVID.

* Group recently created, december 2021

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



3.4.15 Fragility and Healthy Aging Research Group (HUG)*



COMPOSITION

■ **Leocadio Rodríguez Mañas.** Jefe de Servicio de Geriátria. Hospital Universitario de Getafe

STRATEGIC OBJECTIVE

The central interest of our line of research is the evaluation of vascular damage, particularly endothelial dysfunction and its underlying mechanisms, in the presence of aging and diabetes. In addition to evaluating the role of visceral fat in the generation of vascular damage in two situations where visceral fat is increased: obesity and the aging process itself.


In recent years we have expanded our focus of interest to three fields closely related to the clinical aspects of frailty: 1) its diagnosis by comparing different instruments and creating a new one (Frailty Trait Score) with features that improve some of the problems that existed in the current instruments and studying the role of biomarkers (laboratory and imaging), 2) its clinical rela-

tionship with sarcopenia, generating frailty phenotypes by virtue of the presence/absence of sarcopenia (sarcopenic and non-sarcopenic frailty), with different prognostic and therapeutic implications, 3) the approach to frailty in clinical settings and, closely related to this, 4) the validation of interventions in frail/prefrail subjects in general and with diabetes in particular. These aspects have been developed through different projects, both national and European.

RESEARCH LINES

- Endothelial dysfunction associated with aging, diabetes and obesity
- Clinical aspects of frailty

* This group became part of IdiPAZ through the signing of a new legal agreement in June 2021



Cancer and Human Molecular Genetics Area



1 Introduction

2 Executive Summary


3 Information Groups by Area

4 Associated Clinicians

Gema Moreno Bueno

Documents:	232		
Originals:	170		
D1:	45	Q1:	109

- 3.5.1 INGEMM- Institute of Medical and Molecular Genetics Group
- 3.5.2 Translational Oncology Group
- 3.5.3 Experimental Therapies and Biomarkers in Cancer Group
- 3.5.4 Oto-Neurosurgery Research Group
- 3.5.5 Cancer Molecular Pathology and Therapeutic Targets Group
- 3.5.6 Mechanisms of Tumour Progression Group
- 3.5.7 Animal and Cell Models for Detection and Characterization of Leukemic Stem Cells Group
- 3.5.8 Research and Diagnosis of Inherited Metabolic Diseases Group
- 3.5.9 Dyslipidemias of Genetic Origin and Metabolic Diseases Group



Cancer and Human Molecular Genetics Area



1 Introduction



2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



Strategic Objectives	Development forecast for the coming years	Actions
<p>Cancer and Medical Genetics area is made up of 10 groups and its objective is to deepen its knowledge in all aspects related to neoplastic disease, including the biology of the tumour, identification of therapeutic targets, development of new treatments, analysis of the efficacy of available treatments, identification of biomarkers and carrying out studies aimed at prevention and early diagnosis. In relation to human and molecular genetics, the aim is to identify genetic alterations related to human diseases in order to make an early diagnosis and prevent the development of pathologies.</p>	<p>Research in the area of cancer and genetics is expanding, both in terms of basic and translational research and clinical research. It is foreseeable that collaboration between groups in the area will continue to increase but also the collaboration with external organisations.</p>	<p>Facilitate the application request for European projects through the IdiPAZ Internalization Platform.</p>
	<p>In order to facilitate its development, it will be necessary for the Institution to provide sufficient space and adequate common infrastructures.</p>	<p>Support researchers to continue being a reference in the international area.</p>
	<p>It is foreseeable that this expansion will lead to the possibility of applying for European projects and leading consortiums, where once again the support of the Foundation will be essential for their application and management.</p>	<p>Promote at international level the different research groups of the area, identifying possible synergies between groups and centers, new partners and funding sources, as well as to forge strategic alliances.</p>



3.5.1 INGEMM - Institute of Medical and Molecular Genetics (Instituto de Genética Médica y Molecular) Group

Publications: 27

Q1: 10

COMPOSITION



Pablo Daniel Lapunzina Badía. Facultativo Especialista de Área en Genética. Hospital Universitario La Paz

Cinthia Amiñoso Carbonero. Técnico de Laboratorio. Hospital Universitario La Paz

Pedro Arias Lajara. Técnico de Laboratorio. Hospital Universitario La Paz

Sara Benito Sanz. Investigadora Postdoctoral. Hospital Universitario La Paz

Ángel Campos Barros. Investigador Senior (Contrato Miguel Servet- I2). Jefe de Laboratorio. Hospital Universitario La Paz

Ángela del Pozo Mate. Técnico Informático. Hospital Universitario La Paz

Begoña Ezquieta Zubicaray. Bioquímico Adjunto. Hospital Universitario La Paz

Luis Fernández García-Moya. Biólogo. Hospital Universitario La Paz

Blanca Nieves Fernández Martínez. Técnico de Laboratorio. Hospital Universitario La Paz

María Victoria Fernández Montaña. Técnico de Laboratorio. Hospital Universitario La Paz

Amparo García Cardenal. Técnico de Laboratorio. Hospital Universitario La Paz

Fe Amalia García Santiago. Bióloga. Hospital Universitario La Paz

Sixto García-Miñaur Rica. Genetista. Hospital Universitario La Paz

Isabel Gómez Nieto. Técnico de Laboratorio. Hospital Universitario La Paz

Karen Elise Heath. Investigadora Senior (Contrato Ramón y Cajal- I3). Jefe de Laboratorio. Hospital Universitario La Paz

Teresa López Timénez. Técnico de Laboratorio. Hospital Universitario La Paz

Alicia Llorente Alonso. Técnico de Laboratorio. Hospital Universitario La Paz

María Elena Mansilla Aparicio. Genetista. Hospital Universitario La Paz

Pilar Martínez González. Bióloga. Hospital Universitario La Paz

Víctor Manuel Martínez González. Investigador Postdoctoral. Hospital Universitario La Paz

María Cruz Martínez Martínez. Técnico de Laboratorio. Hospital Universitario La Paz

José Carlos Moreno Navarro. Facultativo Especialista de Área en Genética. Hospital Universitario La Paz

María Ángeles Mori Álvarez. Bioquímico Adjunto. Hospital Universitario La Paz


Julián Nevado Blanco. Biólogo. Hospital Universitario La Paz

1
Introduction

2
Executive Summary

3
Information Groups by Area

4
Associated Clinicians



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

María Palomares Bralo. Bióloga. Hospital Universitario La Paz

María Sol Pérez Coto. Técnico de Laboratorio. Hospital Universitario La Paz

Víctor Luis Ruiz Pérez. Investigador Científico de OPls. Jefe de laboratorio. IIB "Alberto Sols"

Carmen Sánchez Gómez. Técnico de Laboratorio. Hospital Universitario La Paz

Fernando Santos Simarro. Médico Adjunto de Pediatría. Hospital Universitario La Paz

Jesús Solera García. Facultativo Especialista de Área en Análisis Bioquímicos. Hospital Universitario La Paz

Mario Solís López. Bioinformático. Hospital Universitario La Paz

Elena Vallespín García. Jefa de Grupo de la Sección de Ofalmogenética Molecular. Hospital Universitario La Paz

STRATEGIC OBJECTIVE

This is a clinical and basic research team that conducts several lines of research into early diagnosis, disease mechanisms and new therapeutic strategies for genetic diseases, developmental disorders and congenital defects. It is a heterogeneous group consisting of physicians, pharmacists, molecular biologists, bioinformaticians, technicians and administrative officers.

RESEARCH LINES

- Subtelomeric rearrangements in patients with idiopathic mental retardation.
- Genetic and functional analysis of the SHOX and SHOX2 genes in human growth.
- Overgrowth syndromes. Clinical and molecular analysis.
- Genetic determinants of syndromic and non-syndromic proportional short stature
- Genetic determinants of disglycaemia: hypoglycaemia, diabetes mellitus and hyperinsulinism
- SNPs arrays in pharmacogenetics, HIV patients and genetic associations.

- Genetic determinants of congenital hypopituitarism
- CGH arrays and genomic rearrangements in patients with congenital malformations, intellectual disability and tumores.
- Molecular genetics of hypertrophic cardiomyopathy.
- Functional analysis of CLCN1 mutations in congenital myotonia.
- Molecular study of endothelial dysfunction in diabetes and ageing.
- Molecular characterization of the 22q11.2 región by MLPA, microsatélites and FISH.
- Pharmacogenetics and pharmacogenomics.
- Autosomal recessive osteogenesis imperfecta.
- Genomic tools for diagnosis: oligos and SNP arrays.
- Macrocephaly-capillary malformations and syndromes with macrocephaly.
- Next generation sequencing as a new tool in the diagnosis of genetic diseases.
- Classification and Ontologies of Diseases
- Primary Pulmonary hypertension
- Análisis genómico global en el Síndrome de invdup(15) [idic(15) syndrome]
- Molecular characterization of inv dup del (8p) by Karyotype, SNP arrays and FISH

RESEARCH ACTIVITY

■ Doctoral theses

Bell Fenellos, C. Factores predictivos de las alteraciones del desarrollo y las dificultades de aprendizaje en niños menores con síndrome 5P-. Aspectos biomédicos, genéticos, cognitivos y conductuales [dissertation]. Madrid: UCM: 2021(23/03/2021).

Directors: Sáenz-Rico de Santiago B, Nevado Blanco, Julián.


■ Publications

- Baldassarri M, Picchiotti N, Fava F, Fallerini C, Benetti E, Daga S, Valentino F, Doddato G, Furini S, Giliberti A, Tita R, Amitrano S, Bruttini M, Croci S, Meloni I, Pinto AM, Iuso N, Gabbi C, Sciarra F, Venneri MA, Gori M, Sanarico M, Crawley FP,

- Pagotto U, Fanelli F, Mezzullo M, Dominguez-Garrido E, Planas-Serra L, Schluter A, Colobran R, Soler-Palacin P, Lapunzina P, Tenorio J, Pujol A, Castagna MG, Marcelli M, Isidori AM, Renieri A, Frullanti E, Mari F. Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males. *Ebiomedicine*. 2021; 65: 103246. Article. IF: 11.205; Q1
- Bonilla-Fornes S, Galan-Ledesma L, Pérez PM, Modamio-Hoybjor S, Carbonell-Pérez JM, Parron-Pajares M, Heath KE, Galan-Gómez E. Early

clinical and radiological improvement in a young boy with metaphyseal anadysplasia type 2. *Eur J Med Genet*. 2021; 64(10): 104307. Article. IF: 2.465; Q3

- Candelo E, Sanz AM, Ramírez-Montano D, Díaz-Ordóñez L, Granados AM, Rosso F, Nevado J, Lapunzina P, Pachajoa H. A possible association between zika virus infection and cdk5rap2 mutation. *Front Genet*. 2021; 12: 530028. Article. IF: 4.772; Q1
- Carrera IA, Fernández-Burriel M, Lapunzina P,



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Tenorio JA, Navas VDG, Isidro EM. TBL1XR1 associated intellectual disability, a new missense variant with dysmorphic features plus autism: Expanding the phenotypic spectrum. *Clin Genet.* 2021; 99(6): 812-7. Article. IF: 4.296; Q2

- del Pino M, Sánchez-Soler MJ, Parrón-Pajares M, Aza-Carmona M, Heath KE, Fano V. Description of four patients with TRIP11 variants expand the clinical spectrum of odontochondroplasia (ODCD) and demonstrate the existence of common variants. *Eur J Med Genet.* 2021; 64(5): 104198. Article. IF: 2.465; Q3
- Esteban-Cantos A, Rodríguez-Centeno J, Barruz P, Alejos B, Saiz-Medrano G, Nevado J, Martín A, Gaya F, De Miguel R, Bernardino JI, Montejano R, Mena-Garay B, Cadinanos J, Florence E, Mulcahy F, Banhegyi D, Antinori A, Pozniak A, Wallet C, Raffi F, Rodes B, Arribas JR. Epigenetic age acceleration changes 2 years after antiretroviral therapy initiation in adults with HIV: a substudy of the NEAT001/ANRS143 randomised trial. *Lancet HIV.* 2021; 8(4): e197-205. Article. IF: 16.07; D1
- Fernández-Alcalde C, Nieves-Moreno M, Noval S, Peralta JM, Montano VEE, del Pozo A, Santos-Simarro F, Vallespin E. Molecular and genetic mechanism of non-syndromic congenital cataracts. mutation screening in spanish families. *Genes (Basel).* 2021; 12(4): 580. Article. IF: 4.141; Q2
- Gallego N, Cruz-Utrilla A, Guillén I, Bonora AM, Ochoa N, Arias P, Lapunzina P, Escribano-Subias P, Nevado J, Tenorio-Castano J. Expanding the evidence of a semi-dominant inheritance in *gdf2* associated with pulmonary arterial hypertension. *Cells.* 2021; 10(11): 3178. Article. IF: 7.666; Q2
- Gálvez E, Vallespin E, Arias-Salgado EG, Sánchez-Valdepenas C, Gimenez Y, Navarro S, Rio P, Bogliolo M, Pujol R, Peiro M, Nevado J, Zubizaray J, Sebastian E, Catala A, Belendez C, de Heredia CD, Galera A, Badell I, Madero L, Perona R, Sastre L, Surrallés J, Bueren J, Lapunzina P, Sevilla J. Next-generation sequencing in bone marrow failure syndromes and isolated cytopenias: experience of the spanish network on bone marrow failure syndromes. *Hemasphere.* 2021; 5(4): e539. Article. IF: 8.3; Q1
- García-Santiago FA, Martínez-Payo C, Mansilla E, Santos-Simarro F, Ballesteros MRD, Mori MA, Alvarado EA, Nieto Y, Vallcorba I, Tenorio J, Nevado J, Lapunzina P. Prenatal ultrasound findings in Koolen-de Vries fetuses: Central nervous system anomalies are frequent markers of this syndrome. *Mol Genet Genomic Med.* 2021; 9(5): e1649. Article. IF: 2.473; Q3
- Gong BS, Li D, Kusko R, Novorodovskaya N,

Zhang YF, Wang SZ, Pabon-Pena C, Zhang ZH, Lai K, Cai WS, LoCoco JS, (et al). Cross-oncology panel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions. *Genome Biol.* 2021; 22(1): 109. Article. IF: 17.906; D1

- Hernández-González I, Tenorio-Castaño J, Ochoa-Parra N, Gallego N, Pérez-Olivares C, Lago-Docampo M, Doza JP, Valverde D, Lapunzina P, Escribano-Subias P. Novel genetic and molecular pathways in pulmonary arterial hypertension associated with connective tissue disease. *Cells.* 2021; 10(6): 1488. Article. IF: 7.666; Q2
- Horn D, Fernández-Núñez E, Gómez-Carmona R, Rivera-Barahona A, Nevado J, Schwartzmann S, Ehmke N, Lapunzina P, Otaify GA, Temtamy S, Aglan M, Boschann F, Ruiz-Pérez VL. Biallelic truncating variants in *MAPKAPK5* cause a new developmental disorder involving neurological, cardiac, and facial anomalies combined with synpolydactyly. *Genet Med.* 2021; 23(4): 679-88. Article. IF: 8.864; D1
- Lacasta-Plasin C, Martínez-Glez V, Rodríguez-Laguna L, Cervantes-Pardo A, Martínez-Menchón T, Sánchez-Jiménez R, Campos-Domínguez M. *KRAS* mutation identified in a patient with melorheostosis and extended lymphangiomatosis treated with sirolimus and trametinib. *Clin Genet.* 2021; 100(4): 484-5. Letter. IF: 4.296; Q2
- Lapunzina P, Tenorio-Castaño J, Nevado J, Barros AC, Pachajoa H, Ruiz-Pérez VL, Castilla EE. The portrayal of dwarfism without skeletal dysplasia in art: Proportionate short stature due to growth hormone deficiency and other disorders. *Am J Med Genet C.* 2021; 187(2): 186-91. Article. IF: 3.359; Q3
- Luce L, Abelleiro MM, Carcione M, Mazzanti C, Rossetti L, Radic P, Szijan I, Menazzi S, Francipane L, Nevado J, Lapunzina P, De Brasi C, Giliberto F. Analysis of complex structural variants in the *DMD* gene in one family. *Neuromuscular Disord.* 2021; 31(3): 253-63. Article. IF: 3.538; Q2
- Nevado J, Bel-Fenellos C, Sandoval-Talamantes AK, Hernández A, Biencinto-López C, Martínez-Fernández ML, Barruz P, Santos-Simarro F, Mori-Álvarez MA, Mansilla E, García-Santiago FA, Valcorba I, Saenz-Rico B, Martínez-Frias ML, Lapunzina P. Deep phenotyping and genetic characterization of a cohort of 70 individuals with 5p minus syndrome. *Front Genet.* 2021; 12: 645595. Article. IF: 4.772; Q1
- Nieves-Moreno M, Noval S, Peralta J, Palomares-Bralo M, del Pozo A, García-Minaur S, Santos-Simarro F, Vallespin E. Expanding the phenotypic

spectrum of *pax6* mutations: from congenital cataracts to nystagmus. *Genes (Basel).* 2021; 12(5): 707. Article. IF: 4.141; Q2

- Núñez MP, Charterina SA, Pérez-Olivares C, Ostolaza YR, Ruiz RM, Valls ABE, Tenorio JA, Zazo NG, Gafas AD, Lapunzina P, Chaverri AR, Subias PE. Radiological findings in multidetector computed tomography (mdct) of hereditary and sporadic pulmonary veno-occlusive disease: certainties and uncertainties. *Diagnostics (Basel).* 2021; 11(1): 141. Article. IF: 3.992; Q2
- Peces R, Mena R, Peces C, Barruz P, Trujillo H, Carrero A, Espinosa L, Selgas R, Lapunzina P, Nevado J. Historical and geographical distribution of the founder mutation c.610G > A; p.Ala204Thr in the *CLCNKB* gene linked to Bartter syndrome type III in Spain. *Clin Kidney J.* 2021; 14(8): 1990-3. Letter. IF: 5.86; Q1
- Peces R, Mena R, Peces C, Cuesta E, Lapunzina P, Selgas R, Nevado J. Birth of two healthy girls following preimplantation genetic diagnosis and gestational surrogacy in a rapidly progressive autosomal dominant polycystic kidney disease case using tolvaptan. *Clin Kidney J.* 2021; 14(8): 1987-9. Letter. IF: 5.86; Q1
- Pienkos S, Gallego N, Condón DF, Cruz-Utrilla A, Ochoa N, Nevado J, Arias P, Agarwal S, Patel H, Chakraborty A, Lapunzina P, Escribano P, Tenorio-Castano J, Pérez VDA. Novel *TNIP2* and *TRAF2* variants are implicated in the pathogenesis of pulmonary arterial hypertension. *Front Med (Lausanne).* 2021; 8: 625763. Article. IF: 5.058; Q2
- Santos-Simarro F, Pacio M, Cueto-González AM, Mansilla E, Valenzuela-Palafoll MI, López-Gronadona F, Lledin MD, Schuffelmann C, del Pozo A, Solís M, Vallcorba P, Lapunzina P, Suso JJM, Siccha SM, Montejo JM, Mena R, Jiménez-Rodríguez C, García-Miñaur S, Palomares-Bralo M. Mosaic variegated aneuploidy syndrome 2 caused by biallelic variants in *cep57*, two new cases and review of the phenotype. *Eur J Med Genet.* 2021; 64(11): 104338. Review. IF: 2.465; Q3
- Sentchordi-Montane L, Benito-Sanz S, Aza-Carmona M, Díaz-González F, Modamio-Hoybjor S, de la Torre C, Nevado J, Ruiz-Ocana P, Bezanilla-López C, Prieto P, Bahillo-Curienes P, Carcavilla A, Mulero-Collantes I, Barreda-Bonis AC, Cruz-Rojas J, Ramírez-Fernández J, de la Vega JAB, Travessa AM, Amigo JGD, Del Pozo A, Vallespin E, Solís M, Goetz C, Campos-Barros A, Santos-Simarro F, González-Casado I, Ros-Pérez P, Parrón-Pajares M, Heath KE. High prevalence of variants in skeletal dysplasia associated genes in individuals with short stature and minor skeletal

anomalies. *Eur J Endocrinol.* 2021; 185(5): 691-705. Article. IF: 6.558; Q1

- Tenorio-Castaño J, Morte B, Nevado J, Martínez-Glez V, Santos-Simarro F, García-Miñaur S, Palomares-Bralo M, Pacio-Miguez M, Gómez B, Arias P, Alcoceba A, Carrion J, Arias P, Almoguera B, López-Gronadona F, Llorda-Sánchez I, Galán-Gómez E, Valenzuela I, Pérez MPM, Cusco I, Barros F, Pie J, Ramos S, Ramos FJ, Kuechler A, Tizzano E, Ayuso C, Kaiser FJ, Pérez-Jurado LA, Carracedo A, Lapunzina P. Schuurs-Hoeijmakers Syndrome (PACS1 Neurodevelopmental Disorder): Seven novel patients and a review. *Genes (Basel).* 2021; 12(5): 738. Review. IF: 4.141; Q2
- Tenorio-Castaño JA, Arias P, Fernández-Jaen A, Lay-Son G, Bueno-Lozano G, Bayat A, Faivre L, Gallego N, Ramos S, Butler KM, Morel C, Hadjiyannakis S, Lespinasse J, Tran-Mau-Them F, Santos-Simarro F, Pinson L, Martínez-Monseny AF, Cord MDO, Álvarez S, Stolerman ES, Washington C, Ramos FJ, Lapunzina P. Tenorio syndrome: Description of 14 novel cases and review of the clinical and molecular features. *Clin Genet.* 2021; 100(4): 405-11. Review. IF: 4.296; Q2
- Trilla-Fuertes L, Gámez-Pozo A, Maurel J, García-Carbonero R, Capdevila J, G-Pastrián L, Mendiola M, Pena C, López-Vacas R, Cuatrecasas M, García-Alfonso P, Ramos-Ruiz R, Llorens C, Ghanem I, Conill C, Heredia-Soto V, Campos-Barros A, Vara JAF, Feliú J. Description of the genetic variants identified in a cohort of patients diagnosed with localized anal squamous cell carcinoma and treated with panitumumab. *Sci Rep-Uk.* 2021; 11(1): 7402. Article. IF: 4.996; Q2

■ Research projects


Campos Barros A. Contrato Miguel Servet Categoría B (CES06/019). ISCIII. 2008-2025.

Management centre: FIBHULP

Campos Barros A. Descifrando la complejidad genética del hipopituitarismo congénito (P118/00402). ISCIII. 2019-2021.

Management centre: FIBHULP

García-Miñaur Rica S. Manejo clínico perinatal y evolución y pronóstico en el síndrome de selección 22q11. The In-



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

ternational 22Q11.2 Foundation Inc. 2019-Ongoing.

Managment centre: FIBHULP

Heath KE. Análisis genético y funcional de las displasias esqueléticas (PID2020-116263RB-100). MICIIN. 2021-.

Managment centre: FIBHULP

Heath KE. Contrato I3 Estabilizado (CESI308/003). ISCIII. 2009-2025.

Managment centre: FIBHULP

Heath KE. Estudio comprensivo de la genética de las displasias esqueléticas: 1) Caracterización de la regulación de SHOX en la placa de crecimiento humano, y 2) análisis genético de las displasias esqueléticas mediante ACGH y NGS. Acuña y Fombona S. A. 2012-Ongoing.

Managment centre: FIBHULP

Heath KE. Identificación y estudio funcional de nuevos defectos moleculares en displasias esqueléticas (SAF2017-84646-R). MINECO. 2018-2021.

Managment centre: FIBHULP

Lapunzina Badía PD, Feliú Batlle J, Hardisson Hernández D. Determinación



genómica de muestras del biomarcador del gen KRAS y NRAS. Amgen S. A. 2014-Ongoing.

Managment centre: FIBHULP

Lapunzina Badía PD. An omnigenic view of genetic susceptibility to severe covid19. Fundació Marató Tv3. 2021-Ongoing.

Managment centre: FIBHULP

Lapunzina Badía PD. Análisis genético y genómico en pacientes afectados por la enfermedad de Gorham-Stout y por anomalías generales. The Lymphatic Malformation Institute. 2012-Ongoing.

Managment centre: FIBHULP

Lapunzina Badía PD. Análisis genómico global en el síndrome de Invdup 15 syndrome: evaluación de la dosis genómica

mediante microarrays personalizados de SNPS y estudio de genes candidatos del fenotipo. Fundación Inversión Duplicación del Cromosoma 15. 2017-Ongoing.

Managment centre: FIBHULP

Lapunzina Badía PD. Análisis genómico global en el síndrome de invdupdel 8P: evaluación de la dosis genómica mediante microarrays personalizados de SNPS y estudio de genes candidatos del fenotipo. La Asociación Síndrome Duplicidad Inversión Deleción del Brazo Corto del Cromosoma 8. 2015-Ongoing.

Managment centre: FIBHULP

Lapunzina Badía PD. Aplicación de técnicas genómicas (genoma completo y 4C-Seq para TDA) en pacientes con síndromes de sobrecrecimiento (PI20/01053). ISCIII. 2021-2023.

Managment centre: FIBHULP

Lapunzina Badía PD. Búsqueda de mutaciones en el gen Cripak y otros modificadores en pacientes con hipertensión arterial pulmonar. Fundación contra la Hipertensión Pulmonar. 2018-Ongoing.

Managment centre: FIBHULP


Lapunzina Badía PD. Contrato predoctoral (PEJD2019_PRE/BMD_15054). CM. 2020-2021.

Managment centre: FIBHULP

Lapunzina Badía PD. Craniofacial microsomia> genetic causes and pathway discovery. Seattle Children-S Hospital Research Foundation. 2017-Ongoing.

Managment centre: FIBHULP

Lapunzina Badía PD. Desarrollo de las tareas de análisis de variantes y alteraciones genéticas en genes específicos necesarios para el desarrollo del estudio "ERC-Avatar" del Hospital Universitario



1
Introduction

2
Executive
Summary

3
Information
Groups
by Area

4
Associated
Clinicians

de Fuenlabrada. Hospital Universitario de Fuenlabrada. 2019-Ongoing.

Managment centre: FIBHULP

Lapunzina Badía PD. Estudio clínico molecular en pacientes con síndrome de sobrecrecimiento. Estudio de los genes NSD1, NIZP1, HRAS, CDKN1C, GLP, y de las regiones cromosómicas 5q35, xq26 y 11p en pacientes con SSC. Efficie Servicios para la Investigación S. L. 2005-Ongoing.

Managment centre: FIBHULP

Lapunzina Badía PD. Estudio genético-molecular de genes candidatos en pacientes con hipertensión pulmonar idiopática. Actelion Pharmaceuticals España. 2011-Ongoing.

Managment centre: FIBHULP

Lapunzina Badía PD. Evaluación genómica en el síndrome de wolf-hirschhorn [síndrome 4p]: microarrays personalizados de snps y estudio de genes candidatos. Asociación Española Del Síndrome De Wolf Hirschhorn. 2017-.

Managment centre: FIBHULP

Lapunzina Badía PD. Evaluación psicométrica en pacientes con síndrome de Phelan-M Dermid Síndrome de microdelección 22q13. Oryzon Genomics S. A. 2020-Ongoing.

Managment centre: FIBHULP

Lapunzina Badía PD. Exomas baleares y extremadura. Sanidad Publica de la Comunidad Autónoma de Extremadura. 2018-Ongoing.

Managment centre: FIBHULP

Lapunzina Badía PD. Inteligencia artificial y machine learning en enfermedades humanas. Fundación Ramón Areces. 2019-Ongoing.

Managment centre: FIBHULP

Lapunzina Badía PD. Proyecto piloto para la mejora del diagnóstico genético de personas y familias afectadas con enfermedades raras de base genética. MSCBS. 2018-2021.

Managment centre: FIBHULP

Lapunzina Badía PD. Screening of high-risk pediatric population using an epilepsy gene panel for early diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2) disease. Biomarin International Limited. 2017-Ongoing.

Managment centre: FIBHULP

Martínez González VM. En búsqueda del diagnóstico genético en pacientes con espectro Pros. Fundación Bancaria Caixa D'Estalvis I Pensions de Barcelona la Caixa. 2019-Ongoing.

Managment centre: FIBHULP

Martínez González VM. Estudio genético y funcional en pacientes con enfermedades de Gorham-Stout (GSD) y anomalías linfáticas generalizadas. Comunidad de Madrid. 2018-Ongoing.

Managment centre: FIBHULP

Moreno Navarro JC. Disección genética de la narcolepsia y otras hipersomnias centrales. Merino Andreu, Milagros. 2019-Ongoing.

Managment centre: FIBHULP

Moreno Navarro JC. Disrupción tiroidea gestacional por xenobióticos fenólicos halogenados: efectos tiroideos, cerebrales y hepáticos en el modelo murino dehal1(-/-) y en mujeres embarazadas (PI16/00830). ISCIII. 2017-2021.

Managment centre: FIBHULP

Moreno Navarro JC. Síndrome de res-

tistencia a las hormonas tiroideas. Estudio genético-molecular en población española. Moreno Navarro, José Carlos. 2013-Ongoing.

Managment centre: FIBHULP

Nevado Blanco J, Lapunzina Badía PD. Evaluación genómica en el síndrome de Wolf-Hirschhorn [Síndrome 4P]: microarrays personalizados de SNPS y estudio de genes candidatos. Asociación Española del Síndrome de Wolf Hirschhorn. 2017-Ongoing.

Managment centre: FIBHULP

Nevado Blanco J. Aproximación genómica en el síndrome de Phelanmc Dermid [Síndrome de microdelección 22q13]: microarrays personalizados de SNPS y evaluación de los genes candidatos. La Asociación Síndrome Phelan-Mcdermid. 2017-Ongoing.

Managment centre: FIBHULP

Nevado Blanco J. Evaluación genómica en el s. de Wolf-Hirschhorn; microarrays personalizados de SNPS y genes candidatos: aproximación a las alteraciones dentales y a una epilepsia compleja (PI18/01433). ISCIII. 2019-2021.

Managment centre: FIBHULP

Palomares Bralo M. Contrato garantía laboratorio (PEJ-2017-TL/BMD-6201). CM. 2018-2021.

Managment centre: FIBHULP

Palomares Bralo M. Red de recursos genómicos, funcionales, clínicos y terapéuticos para el estudio de las enfermedades raras neurológicas (S2017/BMD-3721). CM. 2018-2021.

Managment centre: FIBHULP

Palomares Bralo M. Secuenciación rápida del exoma, utilidad/aplicación en

pacientes pediátricos ingresados en edades de críticos o de alta complejidad (PI19/01681). ISCIII. 2020-2022.

Managment centre: FIBHULP

Solera García J. Estudio de microRNAs en pacientes con glucogenosis tipo II (enfermedad de Pompe) como marcadores de diagnóstico, progresión de la enfermedad y respuesta al tratamiento. Fundación Genzyme. 2013-Ongoing.

Managment centre: FIBHULP

Solís López M. Contrato de apoyo bioinformático (CA18/00033). ISCIII. 2019-2021.

Managment centre: FIBHULP

Tenorio Castaño JA. Pasión hp-genética de la hipertensión pulmonar. Fundación Contra La Hipertensión Pulmonar (Fchp). 2020-Ongoing.

Managment centre: FIBHULP

Vallespín García E. Desarrollo e implementación de un protocolo integral combinado con la búsqueda de nuevos genes de cataratas congénitas bilaterales no sindrómicas. Grupo Social ONCE. 2020-2021.

Managment centre: FIBHULP


Vallespín García E. Miopía magna de inicio precoz (<10 años) con o sin Nistagmo: estudio clínico y genético (PI18/01234). ISCIII. 2019-2021.

Managment centre: FIBHULP

■ Cibers & Retics

Lapunzina Badía P. CIBER Enfermedades Raras. (CB06/07/1033). Lapunzina Badía P. (31/12/2021).

Managment centre: FIBHULP



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Clinical trials

Santos Simarro, F. Phase 2, open-label, dose-escalation and dose-expansion study of infigratinib, an FGFR 1-3-selective Tyrosine Kinase inhibitor, in children with achondroplasia: Propel 2.

Type: Clinical Trials, phase II.

HULP code: Appendix 1 5596.

Sponsored by: Qed Therapeutics Inc.

Signed date: 05/10/2021

Vallespín García, E. Estudio observacional retrospectivo paradescribir la prevalencia de distrofias hereditarias de retinaasociadas a la mutación bialélica rpe65 en españa: estudioinsight-65.

Type: Estudios No EPA.

HULP code: PI-4813 CLTW888A1ES01.

Sponsored by: Novartis Farmaceutica, S.A.

Signed date: 23/06/2021

Patents and trademarks


Friedman S, Li D, Narla G, Martignetti J, Heath K, inventors; Mount Sinai School of Medicine, assignee; Kruppel-like factor 6 (klf6), a tumor suppressor protein, and diagnostics, therapeutics, and screening based on this protein. PCT/US2001/025046, EP1332362, US2005181374, US2011059899, AU8479001, CA2419064; 2000 August 09.

INGEMM, author; FIBHULP, assignee. Brand name: INGEMM INSTITUTO DE GENÉTICA MÉDICA Y MOLECULAR DEL HOSPITAL UNIVERSITARIO LA PAZ;

ESM 2.884.849, USM 77.891.143, CM 8.746.869; 2009 July 16, 2009 December 11, 2009 December 10.



INGEMM, author; FIBHULP, assignee. Brand name: KaryoArray; USM 79.078.751, CM 8.512.907; 2010 January 07, 2009 August 27.



INGEMM, author; FIBHULP, assignee. Brand name: OverGrowthArray; ESM 2.958.709-3, USM 85.334.932, CM 10.009.256; 2010 December 02, 2011 June 01, 2011 May 31.



INGEMM, author; FIBHULP, assignee. Brand name: MetabolArray; ESM 2.958.711-5, USM 85.334.903, CM 10.009.348; 2010 December 02, 2011 June 01, 2011 May 31.



Palomares M, Lapunzina P, Nevado J, Vallespín E, Vallcorba I, Melero J,

authors; FIBHULP, Hospital Infanta Cristina (Badajoz) Fundesalud, assignees. Brand name: OncoHematoArray; ESM 2.958.703-4, USM 85.334.842, CM 10.009.181; 2010 December 02, 2011 June 01, 2011 May 31.



INGEMM, author; FIBHULP, assignee. Brand name: OncoArray; ESM 2.962.910, USM 85.363.107, CM 10.091.882; 2011 January 05, 2011 July 05, 2011 July 01.



Lapunzina P, Nevado J, Solera J, Vallespín E, Martínez P, Martínez-González V, authors; FIBHULP, assignee. Brand name: ONCOSeq; USM 85.457.843, CM 9.969.064; 2011 October 27, 2011 May 16.



Moreno JC, Moya CM, Vallespín E, Lapunzina P, Nevado J, authors; FIBHULP, assignee. Brand name: ThyroArray; USM 85.686.688, CM 10.904.951; 2012 July 25, 2012 May 23.



Lapunzina Badía P, Borobia Pérez AM, Carcas Sansuán AJ, Tenorio Castaño JA, Arias Lajara P, Lubomirov Jristov R, authors; FIBHULP, UAM, assignees. Brand name: PharmArray; USM 86.004.412, CM 11.608.403; 2013 July 08, 2013 February 27.





Lapunzina Badía PD, Borobia Pérez AM, Carcas Sansuán AJ, Tenorio Castaño JA, Arias Lajara P, Frías Iniesta J, Dapia García I, Muñoz M, authors; FIBHULP, UAM, assignees. Brand name: ClinPharmarray., CM15489511; 2016 May 31, 2016 September 07.



Palomares Bralo M, Vallespín García E, del Pozo Mate A, Santos Simarro F, authors; FIBHULP, assignee. Brand name: RD-Seq Sequencing Rare Diseases; CM 17.911.029; 2018 May 31.





3.5.2 Translational Oncology Group

Publications: 43

Q1: 21

COMPOSITION



Jaime Feliú Batlle. Jefe de Servicio de Oncología Médica. Hospital Universitario La Paz. Profesor Titular de Oncología. Universidad Autónoma de Madrid

Jorge Barriuso Feijóo. Facultativo Especialista de Área en Oncología. Hospital Universitario La Paz

Borja Belandía Gómez. Científico Titular. IIB "Alberto Sols"

Beatriz Castelo Fernández. Facultativo Especialista de Área en Oncología. Hospital Universitario La Paz

Enrique Espinosa Arranz. Facultativo Especialista de Área en Oncología. Hospital Universitario La Paz. Profesor Asociado. Universidad Autónoma de Madrid

Paloma Cejas Guerrero. Investigadora Postdoctoral. Hospital Universitario La Paz

Roberto Crespo San Pedro. Técnico Superior en Anatomía Patológica. Hospital Universitario La Paz

Ana Belén Custodio Carretero. Facultativo Especialista de Área en Oncología. Hospital Universitario La Paz

Juan Ángel Fresno Vara. Investigador Senior (Contrato Miguel Servet - I2). Jefe de Laboratorio. Hospital Universitario La Paz

Alejandro Gallego Martínez. Facultativo Especialista de Área en Oncología. Hospital Universitario La Paz

Ángelo Gámez Pozo. Investigador Postdoctoral (Contrato Técnico de Apoyo). Hospital Universitario La Paz

Laura García Acebedo. Médico Interno Residente. Coordinadora del Registro de Tumores. Hospital Universitario La Paz

Ismael Ghanem Cañete. Facultativo Especialista de Área en Oncología. Hospital Universitario La Paz

Juan Carlos Lacal Sanjuán. Profesor de Investigación. IIB "Alberto Sols"

Victoria María Heredia Soto. Investigadora Postdoctoral. Hospital Universitario La Paz

Rocío López Vacas. Técnico de Laboratorio (Contrato Técnico de Apoyo). Hospital Universitario La Paz

Virginia Martínez Marín. Facultativo Especialista de Área en Oncología. Hospital Universitario La Paz

Ignacio Palmero Rodríguez. Científico Titular. IIB "Alberto Sols"

Álvaro Pinto Marín. Facultativo Especialista de Área en Oncología. Hospital Universitario La Paz

Andrés Redondo Sánchez. Facultativo Especialista de Área en Oncología. Hospital Universitario La Paz. Profesor Asociado. Universidad Autónoma de Madrid

Nuria Rodríguez Salas. Facultativo Especialista de Área en Oncología. Hospital Universitario La Paz

Lucía Trilla Fuertes. Investigadora Predoctoral. Biomedica Molecular Medicine S.L.


Pilar Zamora Auñón. Facultativo Especialista de Área en Oncología. Hospital Universitario La Paz. Profesor Asociado. Universidad Autónoma de Madrid

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

STRATEGIC OBJECTIVE

The aim of cancer research is to improve understanding of all aspects of the disease, including deepening our understanding of the biology of the tumour, developing new treatments, analysing the efficacy of diagnostic tests and performing studies aimed at prevention and early diagnosis.

The Translational Oncology group's objective is to conduct highly scientific applied research in such a way that basic research can be rapidly translated to clinical practice. In other words, cancer patients at La Paz University Hospital benefit almost immediately from the results of research conducted by their own physicians.

Although important advances have been made in recent years in our understanding of the origin and evolution of cancer, their implementation in healthcare takes too much time. The Translational Oncology Unit (TOU) was established with the objective of facilitating the incorporation into clinical practice of new advances in molecular biology and the technology developed in this field.

The main lines of study are based on tumours with the greatest incidence and impact on survival, such as lung, colorectal, breast and ovarian cancer, although other types of neoplasms have been incorporated such as gastric and renal cancer. A series of fundamental objectives have been established for these neoplasms that can be summarised as early diagnosis, molecular classification for therapeutic goals and the search for individualised treatments. The majority of TOU projects have as their primary objective the search for predictors of susceptibility or resistance to anticancer agents and the search for prognostic factors related to the evolution of the tumour.

RESEARCH LINES

- Identification of prognostic factors Clinical Genomic Proteomic.
- Identification of mechanisms of resistance to drugs.
- Efficacy and toxicity of antineoplastic therapies.
- Palliative care and supportive treatments.

RESEARCH ACTIVITY

■ Doctoral theses

Pérez López C. Estudio volumétrico de adenomas hipofisarios no funcionantes: factores implicados en el grado de resección en cirugía endoscópica endonasal [dissertation]. Madrid: UAM: 2021(18/03/2021).

Directors: Isla Guerrero A, Martínez Marín V.

Prado Vázquez G. Caracterización molecular del melanoma mediante inteligencia artificial: Implicaciones en pacientes tratados con inmunoterapia [dissertation]. Madrid: UAM: 2021(416/04/2021).

Directors: Espinosa Arranz E, Gámez Pozo A.

■ Final Degree Theses

Rodríguez Marrero S. Puesta a punto de

modelos celulares de angiosarcoma en 2-3 dimensiones para su uso potencial en el testado farmacológico [dissertation]. Madrid: UAM: 2021(13/06/2021).

Director: Feliu Batllé J.

■ Publications


- Bockorny B, Macarulla T, Semenisty V, Borazanci E, Feliú J, Ponz-Sarvisé M, Abad DG, Oberstein P, Alistar A, Muñoz A, Geva R, Guillen-Ponce C, Fernández MS, Peled A, Chaney M, Gliko-Kabir I, Shemesh-Darvish I, Ickowicz D, Sorani E, Kadosh S, Vainstein-Haras A, Hidalgo M. Motixafortide and pembrolizumab combined to nanoliposomal irinotecan, fluorouracil, and folinic acid in metastatic pancreatic cancer: The COMBAT/KEYNOTE-202 Trial. *Clin Cancer Res.* 2021; 27(18): 5020-27. Article. IF: 13.801; D1
- Calderón C, Gómez D, Carmona-Bayonas A, Hernández R, Ghanem I, Raga MG, García LO, Carrasco MG, de Ceballos MHL, Ferreira E, Jiménez-Fonseca P. Social support, coping strategies and sociodemographic factors in women

with breast cancer. *Clin Transl Oncol.* 2021; 23(9): 1955-60. Article. IF: 3.34; Q3

- Calderón C, Jiménez-Fonseca P, Hernández R, Muñoz MD, de Castro EM, Higuera O, Ghanem I, Castelo B, Rogado J, Carmona-Bayonas A. Prospective study comparing clinicians' and cancer patients' estimates of risk of relapse and toxicity with adjuvant chemotherapy. *Cancer Invest.* 2021; 39(8): 589-96. Article. IF: 2.368; Q4
- Carmona-Bayonas A, Calderón C, Hernández R, Montes AF, Castelo B, Ciria-Suárez L, Antonanzas M, Rogado J, Pacheco-Barcia V, Martínez EA, Ivars A, de la Pena FA, Jiménez-Fonseca P. Prediction of quality of life in early breast cancer upon completion of adjuvant chemotherapy. *NPJ Breast Cancer.* 2021; 7(1): 92. Article. IF: 7.519; Q1
- Cejas P, Xie YT, Font-Tello A, Lim K, Syamala S, Qiu XT, Tewari AK, Shah N, Nguyen HM, Patel RA, Brown L, Coleman I, Hackeng WM, Brosens L, Dreijerink KMA, Ellis L, Abou Alaiwi S, Seo JH, Baca S, Beltran H, Khani F, Pomerantz M, Dall'Agnese A, Crowdis J, Van Allen EM, Bellmunt J, Morrissey C, Nelson PS, DeCaprio J, Farago A, Dyson N, Drapkin B, Liu XS, Freedman M, Haffner MC, Corey E, Brown M, Long HW. Subtype he-

terogeneity and epigenetic convergence in neuroendocrine prostate cancer. *Nat Commun.* 2021; 12(1): 5775. Article. IF: 17.694; D1

- Ciria-Suárez L, Jiménez-Fonseca P, Palacin-Lois M, Antonanzas-Basa M, Fernández-Montes A, Manzano-Fernández A, Castelo B, Asensio-Martínez E, Hernando-Polo S, Calderón C. Breast cancer patient experiences through a journey map: A qualitative study. *Plos One.* 2021; 16(9): e0257680. Article. IF: 3.752; Q2
- Coleman RL, Lorusso D, Gennigens C, González-Martin A, Randall L, Cibula D, Lund B, Woelber L, Pignata S, Forget F, Redondo A, Vindelov SD, Chen MH, Harris JR, Smith M, Nicacio LV, Teng MSL, Laenen A, Rangwala R, Manso L, Mirza M, Monk BJ, Vergote I. Efficacy and safety of tisu-tumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. *Lancet Oncol.* 2021; 22(5): 609-19. Article. IF: 54.433; D1
- Escudero J, Heredia-Soto V, Wang YY, Ruiz P, Hu YY, Gallego A, Pozo-Kreilinger JJ, Martínez-Marrín V, Berjon A, Ortiz-Cruz E, Bernabeu D, Feliú J, Tang J, Redondo A, Mendiola M. Eribulin activity in soft tissue sarcoma monolayer and three-



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

dimensional cell line models: could the combination with other drugs improve its antitumoral effect? *Cancer Cell Int.* 2021; 21(1): 646. Article. IF: 6.436; Q2

- Esteban E, Expósito F, Crespo G, Lambea J, Pinto A, Puente J, Arranz JA, Redrado M, Rodríguez-Antona C, de Andrea C, López-Brea M, Redin E, Rodríguez A, Serrano D, García J, Grande E, Castellano D, Calvo A. Circulating levels of the interferon-gamma-regulated chemokines cxc10/cxc11, il-6 and hgf predict outcome in metastatic renal cell carcinoma patients treated with antiangiogenic therapy. *Cancers (Basel)*. 2021; 13(11): 2849. Article. IF: 6.575; Q2
- Feliú J, Espinosa E, Basterretxea L, Paredero I, Llabres E, Jiménez-Munarriz B, Antonio-Rebollo M, Losada B, Pinto A, Girones R, Custodio AB, Muñoz MD, Gómez-Mediavilla J, Torregrosa MD, Soler G, Cruz P, Higuera O, Molina-Garrido MJ. Undertreatment and overtreatment in older patients treated with chemotherapy. *J Geriatr Oncol.* 2021; 12(3): 381-7. Article. IF: 3.929; Q3
- Feliú J, Espinosa E, Basterretxea L, Paredero I, Llabres E, Jiménez-Munarriz B, Losada B, Pinto A, Custodio AB, Muñoz MD, Gómez-Mediavilla J, Torregrosa MD, Cruz P, Higuera O, Molina-Garrido MJ. Prediction of unplanned hospitalizations in older patients treated with chemotherapy. *Cancers (Basel)*. 2021; 13(6): 1437. Article. IF: 6.575; Q2
- Feliú J, Fernández MJ, Macarulla T, Massuti B, Albero A, González JFG, Quintero-Aldana G, Delgado-Mingorance JI, Montes AF, Piernavieja CG, Valladares-Ayerbes M, Muñoz AML, Solís RM, Vicente P, González EC, Cebrian IG, López-Rivanco G. Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study. *Cancer Chemoth Pharm.* 2021; 87(4): 543-53. Article. IF: 3.288; Q3
- Feliú J, Pinto A, Basterretxea L, López-San Vicente B, Paredero I, Llabres E, Jiménez-Munarriz B, Antonio-Rebollo M, Losada B, Espinosa E, Girones R, Custodio AB, Muñoz MD, Díaz-Almirón M, Gómez-Mediavilla J, Torregrosa MD, Soler G, Cruz P, Higuera O, González-Montalvo JI, Molina-Garrido MJ. Development and validation of an early mortality risk score for older patients treated with chemotherapy for cancer. *J Clin Med.* 2021; 10(8): 1615. Article. IF: 4.964; Q2
- Gallego A, Garrido D, Yébenes L, Mendiola M, Castelo B, Redondo A. Long-term response to olaparib in BRCA1-related ovarian cancer with brain metastases. *Int J Gynecol Cancer.* 2021;

31(9): 1292-6. Article. IF: 4.661; Q1


- Gallego A, Martínez B, Ghanem I, Cantero JM, Espinosa E, Castelo B, Zamora P, Ruiz-Gimenez L, Redondo A, Feliú J. Cancer survivors referred to a long-term survivorship outpatient service within academic medical oncology: descriptive study. *J Cancer Surviv.* 2021; 15(6): 811-7. Article. IF: 4.062; Q1
- García-de-Lorenzo A, Jiménez V, Feliú J, Asensio MJ, Civantos B, Anon JM. Multidisciplinary rounds in oncology and hematology: Are they superior to rapid response teams?. *Med Intensiva.* 2021; 45(2): 127-8. Letter. IF: 2.799; Q3
- Gómez-España MA, Montes AF, García-Carbonero R, Mercade TM, Maurel J, Martín AM, Pazo-Cid R, Vera R, Carrato A, Feliú J. SEOM clinical guidelines for pancreatic and biliary tract cancer (2020). *Clin Transl Oncol.* 2021; 23(5): 988-1000. Article. IF: 3.34; Q3
- González-Cao M, Casas CM, Oramas J, Berciano-Guerrero MA, de la Cruz L, Cerezuela P, Arance A, Muñoz-Couselo E, Espinosa E, Puertolas T, Beveridge RD, Ochendusko S, Villanueva MJ, Basterretxea L, Bellido L, Rodríguez D, Campos B, Montagut C, Drozdowskyj A, Molina MA, López-Martín JA, Berrocal A. Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial. *Nat Commun.* 2021; 12(1): 7008. Article. IF: 17.694; D1
- González-Cao M, Puertolas T, Riveiro M, Muñoz-Couselo E, Ortiz C, Paredes R, Podzamczar D, Manzano JL, Molto J, Revollo B, Carrera C, Mateu L, Fancelli S, Espinosa E, Clotet B, Martínez-Picado J, Cerezuela P, Soria A, Márquez I, Mandala M, Berrocal A. Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM). *J Immunother Cancer.* 2021; 9(3): e001664. Article. IF: 12.487; Q1
- Gutiérrez-Sainz L, Vinal D, Villamayor J, Martínez-Pérez D, García-Cuesta JA, Ghanem I, Custodio A, Feliú J. Prognostic factors in advanced pancreatic ductal adenocarcinoma patients-receiving second-line treatment: a single institution experience. *Clin Transl Oncol.* 2021; 23(9): 1838-46. Article. IF: 3.34; Q3
- Heredia-Soto V, Rodríguez-Salas N, Feliú J. Liquid biopsy in pancreatic cancer: are we ready to apply it in the clinical practice? *Cancers (Basel)*. 2021; 13(8): 1986. Review. IF: 6.575; Q2
- Lacal JC, Zimmerman T, Campos JM. Choline kinase: an unexpected journey for a precision medicine strategy in human diseases. *Pharmaceutics.* 2021; 13(6): 788. Review. IF: 6.525; Q1
- Lee CH, Shah AY, Rasco D, Rao AR, Taylor HM,

Di Simone C, Hsieh JJ, Pinto A, Shaffer RD, Sarrío RG, Cohn AL, Vogelzang JN, Bilén MA, Ribe SG, Goksel M, Tennoe OK, Richards D, Sweis FR, Courtright J, Heinrich D, Jain S, Wu J, Schmidt VE, Perini FR, Kubiak P, Okpara EC, Smith DA, Motzer JR. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. *Lancet Oncol.* 2021; 22(7): 946-58. Article. IF: 54.433; D1

- Llombart-Cussac A, Pérez-García JM, Bellet M, Dalenc F, Gil-Gil M, Ruiz-Borrego M, Gavila J, Sampayo-Cordero M, Aguirre E, Schmid P, Marme F, Di Cosimo S, Gligorov J, Schneeweiss A, Albanell J, Zamora P, Wheatley D, Martínez-de Dueñas E, Amillano K, Malfettone A, Cortes J. Fulvestrant-palbociclib vs. letrozole-palbociclib as initial therapy for endocrine-sensitive, hormone receptor-positive, erbb2-negative advanced breast cancer: a randomized clinical trial. *JAMA Oncol.* 2021; 7(12): 1791-9. Article. IF: 33.006; D1
- López-Janeiro A, Ruz-Caracuel I, Ramón-Patino JL, De los Ríos V, Esparza MV, Berjon A, Yébenes L, Hernández A, Masetto I, Kadioglu E, Goubert V, Heredia-Soto V, Barderas R, Casal JI, de Andrea CE, Redondo A, Mendiola M, Pelaez-García A, Hardisson D. Proteomic analysis of low-grade, early-stage endometrial carcinoma reveals new dysregulated pathways associated with cell death and cell signaling. *Cancers (Basel)*. 2021; 13(4): 794. Article. IF: 6.575; Q2
- Majem M, Manzano JL, Marquez-Rodas I, Mújika K, Muñoz-Couselo E, Pérez-Ruiz E, de la Cruz-Merino L, Espinosa E, González-Cao M, Berrocal A. SEOM clinical guideline for the management of cutaneous melanoma (2020). *Clin Transl Oncol.* 2021; 23(5): 948-60. Article. IF: 3.34; Q3
- Maroto P, del Muro XG, Valverde C, Pinto A, Sánchez A, Guma J, Alonso T, del Prado PM, Vázquez S, Mellado B, Aparicio J, Fernández-Aramburo A, Girones R, Terrasa J. Incidence and clinical pattern of contralateral synchronous and metachronous germ cell testicular cancer. *Urol Oncol-Semin Ori.* 2021; 39(2): 135. Article. IF: 2.954; Q3
- Martínez-Pérez D, Vinal D, Solares I, Espinosa E, Feliú J. Gp-100 as a novel therapeutic target in uveal melanoma. *Cancers (Basel)*. 2021; 13(23): 5968. Review. IF: 6.575; Q2
- Martínez-Trufero J, Jurado JC, Gómez-Mateo MC, Bernabeu D, Floria LJ, Lavernia J, Sebío A, del Muro XG, Álvarez R, Correa R, Hernández-Leon CN, Marquina G, Hindi N, Redondo A, Martínez V, Asencio JM, Mata C, Morales CMV, Martín-Broto J. Uncommon and peculiar soft

tissue sarcomas: Multidisciplinary review and practical recommendations for diagnosis and treatment. Spanish group for Sarcoma research (GEIS - GROUP). Part I. *Cancer Treat Rev.* 2021; 99: 102259. Review. IF: 13.608; D1

- Martínez-Trufero J, Jurado JC, Hernández-Leon CN, Correa R, Asencio JM, Bernabeu D, Álvarez R, Hindi N, Mata C, Marquina G, Martínez V, Redondo A, Floria LJ, Gómez-Mateo MC, Lavernia J, Sebío A, del Muro XG, Martín-Broto J, Valverde-Morales C. Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations. Spanish Group for Sarcoma research (GEIS -GROUP). Part II. *Cancer Treat Rev.* 2021; 99(0): 102260. Review. IF: 13.608; D1
- Ostios-García L, Villamayor J, García-Lorenzo E, Vinal D, Feliú J. Understanding the immune response and the current landscape of immunotherapy in pancreatic cancer. *World J Gastroenterol.* 2021; 27(40): 6775-93. Review. IF: 5.374; Q2
- Pérez-Fidalgo JA, Cortes A, Guerra E, García Y, Iglesias M, Sarmiento UB, García EC, Sánchez LM, Santaballa A, Oaknin A, Redondo A, Rubio MJ, González-Martín A. Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study). *ESMO Open.* 2021; 6(4): 100212. Article. IF: 6.883; Q1
- Pinto A, Álvarez-Maestro M. Adjuvant immunotherapy in muscle-invasive bladder cancer: Closer than it seems? *Actas Urol Esp.* 2021; 45(9): 567-8. Editorial Material. IF: 0.887; Q4
- Piulats JM, Espinosa E, de la Cruz-Merino L, Varela M, Carrion LA, Martín-Algarra S, Castro RL, Curiel T, Rodríguez-Abreu D, Redrado M, Goma M, Rullan AJ, González AC, Berrocal-Jaime A. Nivolumabplus ipilimumab for treatment-naive metastatic uveal melanoma: an open-label, multicenter, phase II trial by the spanish multidisciplinary melanoma group (GEM-1402). *J Clin Oncol.* 2021; 39(6): 586-98. Article. IF: 50.717; D1
- Povedano E, Gamella M, Torrente-Rodríguez RM, Montiel VRV, Montero-Calle A, Solís-Fernández G, Navarro-Villoslada F, Pelaez-García A, Mendiola M, Hardisson D, Feliú J, Barderas R, Pingarrón JM, Campuzano S. Multiplexed magnetic beads-assisted amperometric bioplayers for global detection of methylations in nucleic acids. *Anal Chem Acta.* 2021; 1182: 338946. Article. IF: 6.911; Q1
- Redondo A, Guerra E, Manso L, Martín-Lorente C, Martínez-García J, Pérez-Fidalgo JA, Varela MQ, Rubio MJ, Barretina-Ginesta MP, González-Martín A. SEOM clinical guideline in ovarian can-



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

cer (2020). *Clin Transl Oncol.* 2021; 23(5): 961-8. Article. IF: 3.34; Q3

- Redondo A, Oaknin A, Rubio MJ, Barretina-Ginesta MP, de Juan A, Manso L, Romero I, Martín-Lorente C, Poveda A, González-Martín A. Management of advanced ovarian cancer in Spain: an expert Delphi consensus. *J Ovarian Res.* 2021; 14(1): 72. Article. IF: 5.506; Q1
- Rosas-Alonso R, Colmenarejo-Fernández J, Perinía O, Rodríguez-Antolín C, Esteban I, Ghanem I, Sánchez-Cabrero D, Losantos-García I, Palacios-Zambrano S, Moreno-Bueno G, de Castro J, Martínez-Marín V, Ibáñez-de-Cáceres I. Clinical validation of a novel quantitative assay for the detection of MGMT methylation in glioblastoma patients. *Clin Epigenetics.* 2021; 13(1): 52. Article. IF: 7.259; Q1
- Ruz-Caracuel I, López-Janeiro A, Heredia-Soto V, Ramon-Patino JL, Yébenes L, Berjon A, Hernández A, Gallego A, Ruiz P, Redondo A, Pelaez-García A, Mendiola M, Hardisson D. Clinicopathological features and prognostic significance of CTNNB1 mutation in low-grade, early-stage endometrial endometrioid carcinoma. *Virchows Arch.* 2021; 479(6): 1167-76. Article. IF: 4.535; Q2
- Solaresy I, Vinal D, Morales-Conejo M, Rodríguez-Salas N, Feliú J. Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review. *ESMO Open.* 2021; 6(4): 100223. Review. IF: 6.883; Q1
- Trilla-Fuertes L, Gámez-Pozo A, Maurel J, García-Carbonero R, Capdevila J, G-Pastrian L, Mendiola M, Pena C, López-Vacas R, Cuatrecasas M, García-Alfonso P, Ramos-Ruiz R, Llorens C, Ghanem I, Conill C, Heredia-Soto V, Campos-Barros A, Vara JAF, Feliú J. Description of the genetic variants identified in a cohort of patients diagnosed with localized anal squamous cell carcinoma and treated with panitumumab. *Sci Rep-Uk.* 2021; 11(1): 7402. Article. IF: 4.996; Q2
- Velasco-Ruiz A, Núñez-Torres R, Pita G, Wildiers H, Lambrechts D, Hatse S, Delombaerde D, Van Brussel T, Alonso MR, Álvarez N, Herraes B, Vulsteke C, Zamora P, López-Fernández T, González-Neira A. POLRMT as a novel susceptibility gene for cardiotoxicity in epirubicin treatment of breast cancer patients. *Pharmaceutics.* 2021; 13(11): 1942. Article. IF: 6.525; Q1
- Watt AC, Cejas P, de Cristo MJ, Metzger O, Lam EYN, Qiu XT, BrinJones H, Kesten N, Coulson R, Font-Tello A, Lim K, Vadhi R, Daniels VW, Montero J, Taing L, Meyer CA, Gilan O, Bell CC, Korthauer KD, Giambartolomei C, Pasanici B, Seo

JH, Freedman ML, Ma CT, Ellis MJ, Krop I, Winer E, Letai A, Brown M, Dawson MA, Long HW, Zhao JJ, Goel S. CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity. *Nat Cancer.* 2021; 2(1): 34-48. Article. IF: 23.177; D1

Research projects

Cejas Guerrero P. Análisis dinámico de la cromatina en el adenocarcinoma de páncreas mediante análisis fit-seq de la marca de histona H3K4ME2 (P118/01604). ISCI. 2019-2021.

Management centre: FIBHULP

Custodio Carretero AB. Implicación de los cambios dinámicos de la cromatina en la progresión tumoral y la predicción de respuesta a quimioterapia neoadyuvante en adenocarcinoma gástrico localmente avanzado (P116/01646). ISCI. 2017-2021.

Management centre: FIBHULP

Espinosa Arranz E. Antitumor effects of anti PD-L1 immunotherapy atezolizumab plus metformin and chemotherapy in triple negative breast cancer. Roche Farma S. A. 2021-Ongoing.

Management centre: FIBHULP

Espinosa Arranz E. Desarrollo y validación de un predictor molecular con valor pronóstico en melanoma en estadios localizados para mejorar el seguimiento y el uso de terapia adyuvante (IND2017/BMD-7783). CM. 2018-2021.

Management centre: FIBHULP

Feliú Batlle J. Estudio de biomarcadores pronósticos y predictivos en adenocarcinoma de páncreas. Varios. 2015-Ongoing.

Management centre: FIBHULP

Feliú Batlle J. Estudio de factores predictivos de toxicidad grave (grado 3-4) en anciano. Fundación Pfizer. 2012-Ongoing.

Management centre: FIBHULP

Feliú Batlle J. Identificación de una huela genética para el pronóstico en pacientes con cáncer de colon en estado II operados con intención curativa. Varios. 2013-Ongoing.

Management centre: FIBHULP

Feliú Batlle J. Proyecto desarrollo de consulta de psicooncología en el Hospital Universitario La Paz. Merck S. L. 2012-Ongoing.

Management centre: FIBHULP

Feliú Batlle J. Reanima-CM (S2017/BMD-3875). CM. 2018-2021.

Management centre: FIBHULP

Feliú Batlle J. Utilidad de la determinación del DNA circulante para monitorizar la respuesta al tratamiento neoadyuvante en los pacientes con cáncer de recto localmente avanzado. Fundación SEOM. 2014-Ongoing.

Management centre: FIBHULP

Feliú Batlle J. Validation of biomarkers to predict response to anti-egfr therapy identified by shotgun proteomics. FIBHULP. 2018-Ongoing.

Management centre: FIBHULP

Fresno Vara JA. Caracterización molecular del cáncer de mama mediante TaqMan Low Density Arrays: Aplicación al diagnóstico. FUAM. 2014-Ongoing.

Management centre: FIBHULP

Fresno Vara JA. Contrato Miguel Servet Categoría A (CES11/020). ISCI. 2012-2025.

Management centre: FIBHULP

Fresno Vara JA. Convocatoria interna Jesús Antolín Garcíarena 2018. Contrato Andrea Zapater Moros. CM. 2018-Ongoing.

Management centre: FIBHULP

Fresno Vara JA. Desarrollo de test moleculares predictivos, basados en el análisis del metaboloma, de la respuesta a neoadyuvancia en cáncer de mama (IND2018/BMD-9262). CM. 2019-2021.

Management centre: FIBHULP

Ghanem Cañete I. Alteraciones genómicas en carcinoma escamoso de ano. Secuenciación del exoma completo. Roche Farma S. A. 2019-Ongoing.

Management centre: FIBHULP

Martínez Marín V. Estudio perfil mutacional e inmunohistoquímico en GIST: búsqueda de factores pronósticos y predictivos. Pfizer S. L. U. 2013-Ongoing.

Management centre: FIBHULP

Pinto Marín A. Evaluación del metaboloma sanguíneo como fuente de biomarcadores para el manejo del paciente con cáncer: el caso del cáncer de prostata metastásico. Varios. 2015-Ongoing.

Management centre: FIBHULP

Pinto Marín A. Validación del test con valor pronóstico BIO-MIRCC. Biomédica Molecular Medicine S. L. 2020-Ongoing.


Management centre: FIBHULP

Redondo Sánchez A. Mendiola Sabio M. Identificación de marcadores de HRD y predicción de la respuesta a inhibidores de PARP en líneas celulares establecidas y organoides derivados de pacientes con cáncer de ovario. Grupo Español de Investigación Cáncer de Ovario. 2021-Ongoing.

Management centre: FIBHULP

Redondo Sánchez A. Análisis de expresión de miRNAs relacionados con el proceso angiogénico en cáncer mama. Roche Farma S. A. 2014-Ongoing.

Management centre: FIBHULP



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Redondo Sánchez A. Cáncer de mama y angiogénesis: estudio de perfiles de expresión génica en muestras parafinadas. Roche Farma S. A. 2009-Ongoing.

Managment centre: FIBHULP

Redondo Sánchez A. Caracterización de la acción de trabectedina y análogos, lurbinedina y análogos y PM60184 en modelos celulares en dos y tres dimensiones de carcinoma de ovario. Pharmamar S. A. 2016-Ongoing.

Managment centre: FIBHULP

Redondo Sánchez A. Caracterización in vitro del efecto antitumoral de eribulina (en monoterapia y en combinación con otros fármacos) en líneas celulares de liposarcoma y leiomiomasarcoma. Eisai Farmacéutica S. A. 2018-Ongoing.

Managment centre: FIBHULP

Redondo Sánchez A. Caracterización molecular y estudio de biomarcadores de inmunomodulación en el cáncer de endometrio. Subestudio: Estudio in vitro de modelos de cocultivo entre células tumorales de cáncer de ovario y fibroblastos. Grupo Español de Investigación Cáncer de Ovario. 2019-Ongoing.

Managment centre: FIBHULP

Redondo Sánchez A. Estudio in vitro de modelos en tres dimensiones de cáncer de ovario: interacción entre las células tumorales y células del microambiente tumoral. Roche Farma S. A. 2017-Ongoing.

Managment centre: FIBHULP

Redondo Sánchez A. International sarcoma científica meeting. EISAI Farmacéutica S. A. 2017-Ongoing.

Managment centre: FIBHULP

Rodríguez Salas N. Cáncer colorrectal en población joven. Estudio farmacogenómico en organoides y efectos del

microambiente tumoral (ICI20/00057). ISCI. 2021-2024.

Managment centre: FIBHULP

Zamora Auñón P. Metabólica y modelización del metabolismo celular del cáncer para la detección de enfermedad mínima residual en pacientes con cáncer de mama. Roche Farma S. A. 2018-Ongoing.

Managment centre: FIBHULP

■ Cibers & Retics

Feliú Batlle J. Networked Biomedical Research Center for Cancer. (CB16/12/00398). ISCI. (31/12/2022).

Managment centre: FIBHULP

■ Clinical trials

Castelo Fernández, B. Ensayo clínico de fase II, multicéntrico, abierto y de un único brazo para evaluar la seguridad, tolerabilidad, farmacocinética y eficacia de cb-103 en combinación con un inhibidor de aromatasa no esteroideo (iane), anastrozol o letrozol, en pacientes con cáncer de mama avanzado con receptor hormonal positivo y receptor del factor de crecimiento epidérmico humano 2 (her2) negativo que hayan obtenido beneficio clínico durante un tratamiento previo con un ianei.

Type: Clinical Trials, phase II.

HULP code: 5691 CAILA (MedOPP319).

Sponsored by: Medica Scientia Innovation Research, S.L.

Signed date: 15/02/2021

Castelo Fernández, B. Ensayo de fase II abierto, aleatorizado, de bnt113 en combinación con pembrolizumab frente a pembrolizumab en monoterapia como tratamiento de primera línea para pacientes con carcinoma de células escamosas de cabeza y cuello (CCECC) irreseccable,

recurrente o metastásico, que es positivo para el genotipo 16 del virus del papiloma humano (VPH16+) y expresa PDL1.

Type: Clinical Trials, phase II.

HULP code: 5739 BNT113-01.

Sponsored by: Biontech Rna Pharmaceuticals.

Signed date: 02/03/2021

Castelo Fernández, B. Ensayo internacional fase III, randomizado, doble ciego, multicéntrico, de monalizumab o placebo en combinación con cetuximab en pacientes con carcinoma epidermoide de cabeza y cuello recurrente o metastásico tratado previamente con un inhibidor del punto de control inmunitario.

Type: Clinical Trials, phase III.

HULP code: 5755 D7310C00001.

Sponsored by: Astrazeneca Farmacéutica Spain, S.A.

Signed date: 18/02/2021

Castelo Fernández, B. Estudio de fase II, aleatorizado, de dos brazos de tratamiento de abemaciclib en combinación con terapia endocrina (letrozol y fulvestrant) con o sin un ciclo corto de quimioterapia de inducción con paclitaxel como tratamiento de primera línea en pacientes con cáncer de mama hr positivo/her2 negativo localmente avanzado e irreseccable o metastásico con criterios de enfermedad agresiva (abigail).

Type: Clinical Trials, phase II.

HULP code: 5747

MedOPP321(ABIGAIL).

Sponsored by: Medica Scientia Innovation Research, S.L.

Signed date: 23/04/2021

Castelo Fernández, B. Estudio en fase III, aleatorizado, doble ciego y controlado con placebo de debio 1143 en combinación con quimioterapia con un derivado del platino y radioterapia de intensidad

modulada con fraccionamiento convencional en pacientes con carcinoma escamoso de cabeza y cuello localmente avanzado apto para quimiorradioterapia definitiva (trilyn).

Type: Clinical Trials, phase III.

HULP code: Appendix 1 5602 Debio 1143-SCCHN.

Sponsored by: Debiopharm, S.A. Debiopharm, S.A.

Signed date: 29/04/2021

Castelo Fernández, B. Estudio en fase II de alx148 en combinación con pembrolizumab en pacientes con carcinoma de células escamosas de cabeza y cuello avanzado (aspen-03).

Type: Clinical Trials, phase II.

HULP code: 5792 AT148003.

Sponsored by: Alx Oncology, Inc.

Signed date: 21/05/2021

Castelo Fernández, B. Estudio en fase III de alx148 en combinación con pembrolizumab y quimioterapia en pacientes con carcinoma de células escamosas de cabeza y cuello avanzado (aspen-04).

Type: Clinical Trials, phase II.

HULP code: 5793 AT148004.

Sponsored by: Alx Oncology, Inc.

Signed date: 10/06/2021


Castelo Fernández, B. El estudio aim-hn y seq-hn: estudio pivotal no comparativo de 2 cohortes para evaluar la eficacia de tipifarnib en pacientes con carcinoma de células escamosas de cabeza y cuello (ccec) con mutaciones de hras (aim-hn) y el impacto de las mutaciones de hras en la respuesta a las terapias sistémicas de primera línea para el ccec (seq-hn).

Type: Clinical Trials, phase II.

HULP code: Appendix 1 5187.

Sponsored by: Kura Oncology, Inc.

Signed date: 02/09/2021



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



Castelo Fernández, B. Estudio buran sobre buparlisib (an2025) en combinación con paclitaxel frente a paclitaxel en monoterapia, para pacientes con carcinoma de células escamosas de cabeza y cuello recurrente o metastásico.

Type: Clinical Trials, phase III.
HULP code: 5884 AN2025H0301.
Sponsored by: Adlai Nortye Usa, Inc.
Signed date: 16/09/2021

Castelo Fernández, B. Estudio de fase 2 no aleatorizado, abierto, de múltiples cohortes, multicéntrico, para evaluar el beneficio clínico de sar444245 (thor-707) combinado con otras terapias anticancerígenas para el tratamiento de participantes con carcinoma de células escamosas de cabeza y cuello (ccec) (pegasus head and neck 204.

Type: Clinical Trials, phase II.
HULP code: 6004 ACT16903.
Sponsored by: Sanofi Aventis S.A.
Signed date: 15/09/2021

Castelo Fernández, B. Ensayo de fase 1b, abierto, con escalado de dosis, para determinar la seguridad y las respuestas inmunitarias dirigidas contra antígenos específicos provocadas por vb.10 neo en combinación con atezolizumab en sujetos con tumores localmente avanzados y metastásicos.

Type: Clinical Trials, phase I.
HULP code: 5989 VBN-02.
Sponsored by: Vaccibody As.
Signed date: 29/11/2021

Custodio Carretero, AB. Ensayo internacional fase III, aleatorizado, doble-cego, controlado con placebo y multicéntrico, de urvalumab administrado simultáneamente con terapia de quimiorradiación

definitiva en pacientes con carcinoma esofágico de células escamosas inoperable, localmente avanzado.

Type: Clinical Trials, phase III.
HULP code: 5760 D910SC00001.
Sponsored by: Astrazeneca Farmaceutica Spain, S.A.
Signed date: 05/02/2021

Custodio Carretero, AB. Wearables en pacientes con tumores neuroendocrinos gastroenteropancreáticos metastásicos. estudio netfit.

Type: Estudios No EPA.
HULP code: PI-4592 NETFIT.
Sponsored by: Grupo Español De Tumores Neuroendocrinos Y Endocrinos.
Signed date: 12/02/2021

Custodio Carretero, AB. Estudio en fase III abierto, aleatorizado, multicéntrico, de 2 grupos de trastuzumab deruxtecán en sujetos con adenocarcinoma gástrico o de la unión gastroesofágica (uge) positivo-para her2, metastásico y/o no resecable que han progresado durante o después de una pauta que contenía trastuzumab (destiny-gastric04).

Type: Clinical Trials, phase III.
HULP code: 5847 DS8201-A-U306.
Sponsored by: Daiichi Sankyo Inc.
Signed date: 11/06/2021

Custodio Carretero, AB. Estudio para la validación clínica de un nuevo biomarcador para determinar la predisposición a infecciones en pacientes con infarto agudo de miocardio.

Type: Estudios No EPA.
HULP code: PI-4835 2020-01.
Sponsored by: Fundacion Seom.
Signed date: 17/06/2021

Custodio Carretero, AB. Ensayo en fase 3

aleatorizado, multicéntrico, abierto, comparativo con tratamiento activo para evaluar la eficacia y seguridad de octreotida (cam2029) subcutánea de liberación prolongada frente a octreotida Ip o lanreotida atg en pacientes con tumores neuroendocrinos gastroenteropancreáticos.

Type: Clinical Trials, phase III.
HULP code: 5893 HS-19-657.
Sponsored by: Labcorp Development S.A.U. (Covance Clinical Development, S.A).
Signed date: 09/08/2021

Custodio Carretero, AB. Ensayo clínico fase II de un único brazo para evaluar la eficacia preliminar de la combinación de 177ludotatato y nivolumab en tumores neuroendocrinos (tne) grado 3 bien diferenciados o carcinomas neuroendocrinos (cne) grado 3 mal diferenciados.


Type: Clinical Trials, phase II.
HULP code: 5890 HMH008.
Sponsored by: Fundacion De Investigación Hm Hospitales.
Signed date: 01/09/2021

Custodio Carretero, AB. Estudio de fase III, multicéntrico y aleatorizado de zanidatamab en combinación con quimioterapia, con o sin tislelizumab, en sujetos con adenocarcinoma gastroesofágico (age) irresecable, localmente avanzado o metastásico, con her-2 positivo.

Type: Clinical Trials, phase III.
HULP code: 5938 ZWI-ZW25-301.
Sponsored by: Zymeworks, Inc.
Signed date: 16/09/2021

Custodio Carretero, AB. Estado nutricional de los pacientes con tumor neuroendocrino gastroenteropancreático en España: nutrigetne.

Type: Estudios No EPA.
HULP code: PI-4836 GETNE-S2109.



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Sponsored by: Grupo Español De Tumores Neuroendocrinos Y Endocrinos.
Signed date: 15/09/2021

Espinosa Arranz, E. Estudio observacional descriptivo sobre las características y evolución del melanoma avanzado y metastásico en España.

Type: Estudios, phase EPA-SP.
HULP code: Appendix 2 PI-3208.
Sponsored by: Grupo Español Multidisciplinar De Melanoma Gem.
Signed date: 31/03/2021

Espinosa Arranz, E. Encorafenib plus binimetinib in patients with locally advanced, unresectable or metastatic BRAF V600-mutated melanoma treated in real life in Spain: a multi-centric, retrospective and non-interventional study.

Type: Estudios, phase EPA-OD.
HULP code: PI-4755 GEM-2002.
Sponsored by: Grupo Español Multidisciplinar De Melanoma Gem.
Signed date: 13/03/2021

Espinosa Arranz, E. Multicentric phase II clinical trial to evaluate the activity of encorafenib and binimetinib before local treatment in patients with BRAF mutated melanoma with metastasis to the brain.

Type: Clinical Trials, phase II.
HULP code: Appendix 1 5225.
Sponsored by: Grupo Español Multidisciplinar De Melanoma Gem.
Signed date: 26/10/2021

Feliú Batlle, J. Estudio de fase III, multicéntrico, en doble ciego y aleatorizado, para investigar la eficacia y la seguridad de CS1003 en combinación con lenvatinib comparados con placebo en combinación con lenvatinib como tratamiento de primera línea en sujetos con carcinoma hepatocelular avanzado.

Type: Clinical Trials, phase III.
HULP code: 5485 CS1003-305.
Sponsored by: Parexel International (Irl) Limited.
Signed date: 07/04/2021

Feliú Batlle, J. Ensayo randomizado en fase III, abierto, de Napabucasin en combinación con Folfiri y mejor tratamiento de soporte (BSC) versus Napabucasin más mejor tratamiento de soporte (o solo mejor tratamiento de soporte) en pacientes adultos con cáncer colorrectal metastásico (CCRM).

Type: Clinical Trials, phase III.
HULP code: 5406 STEMNESS-CRC.
Sponsored by: 1 Globe Health Institute, Llc.
Signed date: 16/09/2021

Feliú Batlle, J. A phase II/III randomized, open-label clinical study of napabucasin in combination with weekly paclitaxel and low-dose gemcitabine in patients with metastatic pancreatic cancer following chemotherapy failure.

Type: Clinical Trials, phase II.
HULP code: 5598 STEMNESS-PANC.
Sponsored by: 1 Globe Health Institute, Llc.
Signed date: 05/11/2021

Feliú Batlle, J. Estudio en fase I-II, primero en humanos, de CX-2029 en adultos con linfomas difusos de linfocitos B grandes o tumores sólidos no resecables localmente avanzados o metastásicos (proclaim-CX-2029).

Type: Clinical Trials, phase I.
HULP code: Appendix 2 5153.
Sponsored by: Cytomx Therapeutics, Inc.
Signed date: 22/11/2021

Ghanem Cañete, I. Estudio fase II aleatorizado y multicéntrico de Folfox6m + AC monoclonal (Antiegrif o Bevacizumab) solo o en combinación con Quimioembolización hepática (Lifepearls-Irinotecan) en pacientes con cáncer colorrectal y enfermedad metastásica limitada al hígado con criterios de mal pronóstico.

Type: Clinical Trials, phase II.
HULP code: 5701 LP-IRI-HCPB/GEM-CAD-1802.
Sponsored by: Grupo Español Multidisciplinario En Cáncer Digestivo (Gemcad) Grupo Español Multidisciplinario Del Cáncer Digestivo.
Signed date: 28/01/2021

Ghanem Cañete, I. Estudio para evaluar los efectos del ayuno de corta duración sobre la toxicidad y eficacia de la quimioterapia.

Type: Estudios No EPA.
HULP code: PI-3536.
Sponsored by: Fundación Imdea Alimentación.
Signed date: 09/06/2021

Ghanem Cañete, I. Estudio de plataforma en fase Ib/II, sin enmascaramiento y aleatorizado para evaluar la seguridad y la eficacia de combinaciones terapéuticas con AB928 en pacientes con cáncer colorrectal metastásico.

Type: Clinical Trials, phase II.
HULP code: 5776 ARC-9.
Sponsored by: Arcus Biosciences Europe Limited,
Signed date: 16/07/2021

Martínez Marin, V. Estudio de fase III aleatorizado, multicéntrico, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de trastuzumab o placebo y trastuzumab emtansina en combinación con atezolizumab o placebo en pacientes con cáncer de mama localmente avanzado ome-

tastásico positivo para her2 y pd-11 que hayan recibido previamente tratamiento basado en trastuzumab (+/- pertuzumab) y taxanos(kate3).

Type: Clinical Trials, phase III.
HULP code: 5738 MO42319.
Sponsored by: Roche Farma, S.A.
Signed date: 11/03/2021

Martínez Marin, V. Ensayo clínico de fase III, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad del tratamiento adyuvante con atezolizumab o placebo y trastuzumab emtansina en el cáncer de mama con her2+ y alto riesgo de recidiva después del tratamiento preoperatorio.


Type: Clinical Trials, phase III.
HULP code: 5744 WO42633.
Sponsored by: Roche Farma, S.A.
Signed date: 01/03/2021

Martínez Marin, V. Análisis observacional del tratamiento con palbociclib en pacientes con cáncer de mama avanzado o metastásico rh+/her2- en primera línea de tratamiento dentro de práctica clínica habitual.

Type: Estudios, phase EPA-OD.
HULP code: PI-4998 PALBOSPAIN.
Sponsored by: Fundación Para La Investigación Biomedica Del Hospital Clínico San Carlos.
Signed date: 15/11/2021

Martínez Marin, V. Ensayo clínico de fase III, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad del tratamiento adyuvante con atezolizumab o placebo y trastuzumab emtansina en el cáncer de mama con her2+ y alto riesgo de recidiva después del tratamiento preoperatorio.

Type: Clinical Trials, phase III.



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

HULP code: Appendix 1 5744.

Sponsored by: Roche Farma, S.A.

Signed date: 15/11/2021

Pinto Marín, A. Estudio de fase III, doble ciego, multicéntrico y aleatorizado de atezolizumab (anticuerpo anti-pd-l1) en comparación con un placebo como tratamiento adyuvante en pacientes con cáncer de vejiga con invasión muscular de alto riesgo que tienen niveles de ctd-na positivos tras una cistectomía.

Type: Clinical Trials, phase III.

HULP code: 5748 BO42843.

Sponsored by: F.Hoffmann-La Roche Ltd.

Signed date: 07/01/2021

Pinto Marín, A. Estudio de identificación de biomarcadores en muestras secuenciales de pacientes con cáncer renal.

Type: Estudios No EPA.

HULP code: PI-4414 SOGUG-2019-IEC(REN)-6.

Sponsored by: Grupo Sogug.

Signed date: 09/02/2021

Pinto Marín, A. Ensayo en fase III abierto, aleatorizado y de noinferioridad de nivolumab subcutáneo frente a nivolumab intravenoso en participantes con carcinoma renal de células claras metastásico o avanzado que hayan recibido tratamiento sistémico anterior.

Type: Clinical Trials, phase III.

HULP code: 5805 CA20967T.

Sponsored by: Bristol-Myers Squibb International Corporation (Bmsic).

Signed date: 12/02/2021

Pinto Marín, A. Psmaddition: estudio de fase III, prospectivo, aleatorizado, abierto e internacional en el que se compara 177LU-PSMA-617 en combinación con el tratamiento de referencia con el tratamiento de referencia en monoterapia en pacientes

varones adultos con cáncer de próstata metastásico sensible a hormonas.

Type: Clinical Trials, phase III.

HULP code: 5810 CAAA617C12301.

Sponsored by: Novartis Farmaceutica, S.A.

Signed date: 02/03/2021

Pinto Marín, A. Estudio en fase III sobre erdafitinib en comparación con vinflunina, docetaxel o pembrolizumab en sujetos con carcinoma urotelial avanzado y anomalías genéticas seleccionadas en fgfr.

Type: Clinical Trials, phase III.

HULP code: Appendix 2 4986 42756493BLC3001.

Sponsored by: Janssen Cilag International Nv.

Signed date: 16/02/2021

Pinto Marín, A. Estudio de fase 3, aleatorizado y doble ciego para evaluar pembrolizumab (mk-3475) perioperatorio + quimioterapia neoadyuvante frente a un placebo perioperatorio + quimioterapia neoadyuvante en participantes con cáncer de vejiga con invasión muscular que son aptos para recibir cisplatino (keynote-866).

Type: Clinical Trials, phase III.

HULP code: Appendix 1 5301.

Sponsored by: Merck Sharp And Dohme De España, S.A.

Signed date: 25/05/2021

Pinto Marín, A. Estudio de fase Ib/II abierto para evaluar tazemetostat en combinación con enzalutamida o abiraterona/prednisona en pacientes con cáncer de próstata resistente a la castración metastásico, que no han recibido quimioterapia previa.

Type: Clinical Trials, phase II.

HULP code: 5587 EZH-1101.

Sponsored by: Epizyme Inc.

Signed date: 27/05/2021

Pinto Marín, A. Triton 3: un estudio multicéntrico, aleatorizado, abierto de fase 3 de rucaparib versus elección del médico para pacientes con cáncer de próstata metastásico resistente a la castración asociado con deficiencia de recombinación homóloga.

Type: Clinical Trials, phase III.

HULP code: Appendix 2 4828.

Sponsored by: Clovis Oncology, Inc.

Signed date: 16/06/2021

Pinto Marín, A. Estudio en fase III aleatorizado, abierto y multicéntrico para determinar la eficacia y la seguridad de durvalumab en combinación con tremelimumab y enfortumab vedotina o durvalumab en combinación con enfortumab vedotina para el tratamiento perioperatorio en pacientes no aptos para cisplatino que se someten a cistectomía radical para cáncer de vejiga músculo-invasivo.

Type: Clinical Trials, phase III.

HULP code: 5876 D910PC00001.

Sponsored by: Astrazeneca Ab.

Signed date: 17/09/2021

Pinto Marín, A. Estudio de fase II, aleatorizado, en doble ciego, controlado con placebo y multicéntrico, para evaluar el tratamiento de mantenimiento con senaparib en pacientes con cáncer de próstata metastásico resistente a la castración y alteraciones génicas de la vía de reparación por recombinación homóloga tras el tratamiento con docetaxel.

Type: Clinical Trials, phase II.

HULP code: 5845 IMP4297-202.

Sponsored by: Impact Therapeutics, Inc.

Signed date: 08/10/2021

Pinto Marín, A. Tinivo-2: estudio en fase III, aleatorizado, controlado, multicéntrico y abierto para comparar tivozanib en combinación con nivolumab con tivoza-

nib en monoterapia en sujetos con carcinoma de células renales que han progresado tras una o dos líneas de tratamiento en las que una línea tiene un inhibidor del punto de control inmunitario.

Type: Clinical Trials, phase III.

HULP code: 5934 AV-951-20-304.

Sponsored by: Aveo Pharmaceuticals Inc.

Signed date: 14/10/2021

Redondo Sánchez, A. Ensayo fase II, multicéntrico y abierto para evaluar la eficacia y la seguridad del trastuzumab deruxtecan (T-DXD, DS-8201A) para el tratamiento de tumores seleccionados que expresan HER2.

Type: Clinical Trials, phase II.

HULP code: 5759 D967VC00001.

Sponsored by: Astrazeneca Farmaceutica Spain, S.A.

Signed date: 18/01/2021

Redondo Sánchez, A. Estudio de fase 3, aleatorizado y doble ciego de pembrolizumab frente a un placebo en combinación con quimioterapia adyuvante con o sin radioterapia para el tratamiento del cáncer de endometrio de alto riesgo recién diagnosticado después de una intervención quirúrgica con intención curativa (keynote-b21 / engot-en11 / gog 3053).


Type: Clinical Trials, phase III.

HULP code: 5757 MK-3475-B21 / ENGOT-en11.

Sponsored by: Merck Sharp And Dohme De España, S.A.

Signed date: 02/02/2021

Redondo Sánchez, A. Una comparación en fase III aleatorizada y con doble enmascaramiento de un tratamiento a base de platino con tsr-042 y niraparib frente a la práctica habitual a base de platino como tratamiento de primera línea del



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

cáncer ovárico epitelial no mucinoso en estadios III o iv.

Type: Clinical Trials, phase III.
HULP code: Appendix 1 5126.
Sponsored by: Tesaro Inc.
Signed date: 04/02/2021

Redondo Sánchez, A. Phase II multicohort trial of trabectedin and low-dose radiation therapy in advanced/metastatic sarcomas.

Type: Clinical Trials, phase II.
HULP code: 5531 GEIS-75.
Sponsored by: Grupo Español De Investigacion En Sarcomas.
Signed date: 23/03/2021

Redondo Sánchez, A. Estudio plataforma, defase II, abierto y multicéntrico para evaluar la eficacia y la seguridad de tratamientos basados en biomarcadores en pacientes con tumores epiteliales de ovario raros persistentes o recurrentes.

Type: Clinical Trials, phase II.
HULP code: 5817 WO42178.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 26/03/2021

Redondo Sánchez, A. Estudio de fase 1b/2, abierto, para evaluar la seguridad y la eficacia de lucitanib en combinación con nivolumab en pacientes con un tumor sólido metastásico, en estadio avanzado.

Type: Clinical Trials, phase II.
HULP code: 5721 CO-3810-101.
Sponsored by: Clovis Oncology, Inc.
Signed date: 15/04/2021

Redondo Sánchez, A. Ensayo fase II, multicéntrico y abierto para evaluar la eficacia y la seguridad del trastuzumab deruxtecan (t-dxd, ds-8201a) para el tratamiento de tumores seleccionados que expresan her2 (destiny-pantumor02).

Type: Clinical Trials, phase II.

HULP code: Appendix 1 5759.
Sponsored by: Astrazeneca Farmaceutica Spain, S.A.
Signed date: 02/06/2021

Redondo Sánchez, A. Estudio de fase i/II para evaluar la seguridad, la farmacocinética y la eficacia de la tinostamustina, la primeramolécula de fusión alquilante de su clase para la inhibición de la histona deacetilasa (ihdac), en pacientes con tumores sólidos avanzados.

Type: Clinical Trials, phase I.
HULP code: 5771 EDO-S101-1002.
Sponsored by: Mundipharma Research Ltd.
Signed date: 24/05/2021

Redondo Sánchez, A. Un estudio abierto, multicéntrico y de extensión del tratamiento a largo plazo en sujetos que han completado un estudio previo de niraparib patrocinado por glaxosmithkline/tesaro y que el investigador considera que se beneficiarán del tratamiento continuo con niraparib (3000-04-003).

Type: Clinical Trials, phase II.
HULP code: 5698 213409.
Sponsored by: Glaxosmithkline Research And Development Limited.
Signed date: 17/06/2021

Redondo Sánchez, A. Estudio de fase 1b, primero en seres humanos, de aumento escalonado y ampliación de la dosis de xmt-1536 en pacientes con tumores sólidos con probabilidad de expresar npi2b.

Type: Clinical Trials, phase II.
HULP code: 5574 MER-XMT-1536-1.
Sponsored by: Mersana Therapeutics, Inc.
Signed date: 15/06/2021

Redondo Sánchez, A. Estudio clínico y

farmacocinético de fase i/II, multicéntrico y abierto sobre pm14 en combinación con irinotecán en pacientes pretratados con tumores sólidos avanzados seleccionados.

Type: Clinical Trials, phase II.
HULP code: 5842 PM14-A-002-20.
Sponsored by: Pharmamar, S.A.
Signed date: 16/06/2021

Redondo Sánchez, A. Estudio abierto en fase i sobre la seguridad, la farmacocinética y la eficacia preliminar de stro-002, un conjugado de anticuerpo y fármaco (caf) dirigido contra el receptor α de folato (folra), en pacientes con cáncer epitelial de ovario en estadio avanzado (incluido el cáncer de trompas de falopio o el cáncer peritoneal primario) y cánceres de endometrio.

Type: Clinical Trials, phase I.
HULP code: 5838 STRO-002-GM1.
Sponsored by: Labcorp Drug Development Inc (Covance Inc).
Signed date: 23/07/2021

Redondo Sánchez, A. Estudio aleatorizado, multicéntrico, doble ciego, controlado con placebo, de fase III, de carboplatino y paclitaxel de primera línea en combinación con durvalumab, seguido de durvalumab de mantenimiento con o sin olaparib en pacientes con diagnóstico reciente de cáncer de endometrio avanzado o recurrente (duo-e).

Type: Clinical Trials, phase III.
HULP code: 5846 D9311C00001.
Sponsored by: Astrazeneca Ab.
Signed date: 21/07/2021

Redondo Sánchez, A. Estudio aleatorizado, abierto, fase 3 de isotumab vedotina frente a la quimioterapia elegida por el investigador en segunda o tercera línea en el cáncer de cuello uterino recidivante

ometastásico.

Type: Clinical Trials, phase III.
HULP code: 5823 SGNV-003.
Sponsored by: Seagen, Inc.
Signed date: 14/07/2021

Redondo Sánchez, A. Phase i-II trial of sunitinib plus nivolumab after standard treatment in advanced soft tissue and bone sarcomas.

Type: Clinical Trials, phase I.
HULP code: Appendix 2 4854.
Sponsored by: Grupo Español De Investigacion En Sarcomas.
Signed date: 07/09/2021


Redondo Sánchez, A. Estudio de fase III, aleatorizado, doble ciego, adaptativo, controlado con placebo/paclitaxel de avb-s6-500 en combinación con paclitaxel en pacientes con cáncer de ovario resistente al platino y recurrente.

Type: Clinical Trials, phase III.
HULP code: 5897 AVB500-OC-004.
Sponsored by: Aravive Inc.
Signed date: 22/10/2021

Redondo Sánchez, A. Attend ensayo de fase III doble ciego, aleatorizado y controlado con placebo de atezolizumab en combinación con paclitaxel y carboplatino en mujeres con cáncer de endometrio avanzado o recurrente.

Type: Clinical Trials, phase III.
HULP code: Appendix 1 5123.
Sponsored by: Mango Mario Negri Gynecology Group.
Signed date: 18/10/2021

Redondo Sánchez, A. Una comparación en fase III aleatorizada y con doble enmascaramiento de un tratamiento a base de platino con tsr-042 y niraparib frente a la práctica habitual a base de platino como tratamiento de primera línea del



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

cáncer ovárico epitelial no mucinoso en estadios III o IV.

Type: Clinical Trials, phase III.
HULP code: Appendix 2 5126.
Sponsored by: Tesaro Inc.
Signed date: 04/11/2021

Redondo Sánchez, A. Estudio de fase 3, aleatorizado y doble ciego de pembrolizumab frente a un placebo en combinación con quimioterapia adyuvante con o sin radioterapia para el tratamiento del cáncer de endometrio de alto riesgo recién diagnosticado después de una intervención quirúrgica con intención curativa (keynote-b21 / engot-en11 / gog 3053).

Type: Clinical Trials, phase III.
HULP code: Appendix 1 5757.
Sponsored by: Merck Sharp And Dohme De España, S.A.
Signed date: 13/10/2021

Redondo Sánchez, A. Estudio aleatorizado, multicéntrico, doble ciego, controlado con placebo, de fase III, de carboplatino y paclitaxel de primera línea en combinación con durvalumab, seguido de durvalumab de mantenimiento con o sin olaparib en pacientes con diagnóstico reciente de cáncer de endometrio avanzado o recurrente (duo-e).

Type: Clinical Trials, phase III.
HULP code: Appendix 1 5846.
Sponsored by: Astrazeneca Ab.
Signed date: 29/11/2021

Redondo Sánchez, A. Estudio de continuación en pacientes que hayan completado un estudio en oncología previo con olaparib y que el investigador considere que van a beneficiarse clínicamente de continuar el tratamiento.

HULP code: 5833 D0817C00098.
Sponsored by: Astrazeneca Ab.

Signed date: 15/09/2021

Rodríguez Salas, N. Preserve 1: estudio en fase III, aleatorizado, doble ciego de trilaciclib frente a placebo en pacientes que reciben Folfoxiri/Bevacizumab para el cáncer colorrectal metastásico.

Type: Clinical Trials, phase III.
HULP code: 5699 G1T28-207.
Sponsored by: G1 Therapeutics, Inc.
Signed date: 15/01/2021

Rodríguez Salas, N. Estudio en fase II, multicéntrico, sin enmascaramiento, aleatorizado y controlado para comparar la eficacia de ro7198457 con la estrategia de actitud expectante en pacientes con cáncer colorrectal reseccionado en estadio II (riesgo elevado) y estadio III que presenten positividad de ADN tumoral circulante (adnct) tras la resección tumoral.

Type: Clinical Trials, phase II.
HULP code: 5688 BNT122-01.
Sponsored by: Biontech Rna Pharmaceuticals.
Signed date: 10/03/2021

Rodríguez Salas, N. Ensayo en fase III global, multicéntrico, aleatorizado y controlado con placebo para comparar la eficacia y la seguridad de fruquintinib, más los mejores cuidados paliativos frente a placebo, más los mejores cuidados paliativos en pacientes con cáncer de colorrectal metastásico resistente (fresco2).

Type: Clinical Trials, phase III.
HULP code: Appendix 1 5592.
Sponsored by: Hutchison Medipharma Limited.
Signed date: 08/03/2021

Rodríguez Salas, N. Estudio epidemiológico para establecer la prevalencia de la expresión de adnct en pacientes con cáncer colorrectal en estadio II (riesgo

alto) o en estadio III, después de haberse sometido a una intervención quirúrgica con intenciones curativas (r0), seguida por una quimioterapia antineoplásica posquirúrgica con vigilancia de adnct durante el seguimiento clínico.

Type: Estudios, phase EPA-SP.
HULP code: PI-4838 BIO-OXA-2020-01.
Sponsored by: Biontech Rna Pharmaceuticals.
Signed date: 17/06/2021

Rodríguez Salas, N. Estudio abierto, aleatorizado, fase 3 comparando trifluridina/tipiracilo (s95005) en combinación con bevacizumab y capecitabina en combinación con bevacizumab en primera línea de tratamiento de pacientes con cáncer colorrectal metastásico que no son candidatos a terapia intensiva (estudio solstice).

Type: Clinical Trials, phase III.
HULP code: Appendix 1 4983.
Sponsored by: Laboratorios Servier, S.L.
Signed date: 27/04/2021

Rodríguez Salas, N. Preserve 1: estudio en fase III, aleatorizado, doble ciego de trilaciclib frente a placebo en pacientes que reciben folfoxiri/bevacizumab para el cáncer colorrectal metastásico.

Type: Clinical Trials, phase III.
HULP code: Appendix 1 5699.
Sponsored by: G1 Therapeutics, Inc.
Signed date: 11/08/2021

Rodríguez Salas, N. Estudio de fase 3 aleatorizado de mrx849 en combinación con cetuximab frente a quimioterapia avanzada con mutación de kras g12c con progresión de la enfermedad durante o después del tratamiento de primera línea estándar.

Type: Clinical Trials, phase III.
HULP code: 5861 849-010.
Sponsored by: Mirati Therapeutics, Inc.
Signed date: 15/09/2021

Rodríguez Salas, N. Observational retrospective study to evaluate realworld effectiveness, safety and tolerability of encorafenib plus cetuximab (ec) in 2nd line treatment of metastatic BRAFV600E-mutant colorectal cancer in Spain.

Type: Estudios, phase EPA-OD.
HULP code: PI-5017 TTD-21-01.
Sponsored by: Grupo Tratamiento Tumores Digestivos (Gercor).
Signed date: 25/11/2021


Zamora Auñón, P. Her2-predict: estudio traslacional de muestras de tumor procedentes de los ensayos DS8201-A-U301, DS8201-A-U302 y DS8201-A-U303.

Type: Clinical Trials, phase II.
HULP code: 5783 SOLT1-1804.
Sponsored by: Grupo Solti.
Signed date: 23/02/2021

Zamora Auñón, P. SERENA-4: Ensayo de fase III aleatorizado, multicéntrico, doble ciego, de AZD9833 (un SERD, degradador selectivo del RE, oral) más Palbociclib en comparación con anastrozol más palbociclib para el tratamiento de pacientes con cáncer de mama avanzado con receptores estrogénicos positivos y her2 negativo que no han recibido ningún tratamiento sistémico para la enfermedad avanzada.

Type: Clinical Trials, phase III.
HULP code: 5791 D8532C00001.
Sponsored by: Astrazeneca Ab.
Signed date: 06/04/2021

Zamora Auñón, P. Estudio fase 3, aleatorizado, multicéntrico, doble ciego de sar439859 más palbociclib en compara-



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

ción con letrozol más palbociclib para el tratamiento de pacientes con cáncer de mama re(+), her2(-) que no han recibido ningún tratamiento antineoplásico sistémico previo para la enfermedad avanzada.

Type: Clinical Trials, phase III.

HULP code: Appendix 1 5644.

Sponsored by: Sanofi-Aventis Recherche & Développement.

Signed date: 02/06/2021

Zamora Auñón, P. Estudio de fase 3, aleatorizado, doble ciego, para comparar la eficacia y seguridad de iraparib frente a placebo en participantes con cáncer de mama her2 negativo conmutación en brca o cáncer de mama triple negativo, con enfermedad molecular basada en la presencia de adh tumoral circulante después de una terapia definitiva (zest).

Type: Clinical Trials, phase III.

HULP code: 5882 213831.

Sponsored by: Glaxosmithkline, S.A.

Signed date: 25/06/2021

Zamora Auñón, P. Ensayo fase III de trastuzumab deruxtecan (t-dxd) con osin pertuzumab versus taxanos, trastuzumab y pertuzumab en primera línea de cáncer de mama metastásico her2 positivo (destiny-breast09).

Type: Clinical Trials, phase III.

HULP code: 5830 D967UC00001.

Sponsored by: Astrazeneca Ab.

Signed date: 16/07/2021

Zamora Auñón, P. Estudio de fase III, multicéntrico, aleatorizado, abierto y controlado de trastuzumab deruxtecan (t-dxd) frente a trastuzumab emtansina (t-dm1) en pacientes con cáncer de mama primario her2 positivo de alto riesgo que

presentan enfermedad invasiva residual en mama o en ganglios linfáticos axilares tras el tratamiento neoadyuvante.

Type: Clinical Trials, phase III.

HULP code: 5733 DS8201-A-U305 (DESTINY-Br).

Sponsored by: Daiichi Sankyo Inc.

Signed date: 12/07/2021

Zamora Auñón, P. Estudio de fase III, multicéntrico, aleatorizado y abierto para evaluar la eficacia y la seguridad de giredestrant adyuvante en comparación con la monoterapia endocrina adyuvante elegida o el médico en pacientes con cáncer de mama incipiente con receptores estrogénicos positivos y her2 negativo.

Type: Clinical Trials, phase III.

HULP code: 5957 GO42784.

Sponsored by: F.Hoffmann-La Roche Ltd.

Signed date: 22/11/2021

Zamora Auñón, P. Ensayo de fase III aleatorizado de palbociclib con tratamiento endocrino adyuvante estándar frente a monoterapia con tratamiento endocrino adyuvante estándar en cáncer de mama precoz con receptores hormonales positivos (rh+) y her2-negativo.

Type: Clinical Trials, phase III.

HULP code: 4879 Appendix 1.

Sponsored by: Austrian Breast & Colorectal Cancer Group (Abcsrg).

Signed date: 26/10/2021

■ Patents and trademarks

Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, de Castro Carpeño J, Moreno García V, Burgos Lizalde E,

Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, Empresa Pública Hospital del Norte, assignees. Genomic fingerprint for predicting the clinical response to an antitumor therapy in colorectal cancer. P201130863, PCT/ES2012/070379; 2011 May 26.

Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, González Barón M, de Castro Carpeño J, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, assignees. Genomic fingerprint for the prognosis of the evolution of colorectal adenocarcinoma. P200703229, PCT/ES2008/000756, EP2236626; 2007 December 04.

Cejas Guerrero P, González Barón M, Casado Sáenz E, Sánchez Hernández JJ, Perona Abellón R, inventors; FIBHULP, UAM, CSIC, assignees. Use of trefoil factor family 3 (TFF3) in the prognosis of patients diagnosed with colorectal cancer. P200703230, PCT/ES2008/000757, EP2236625; 2007 December 04.

Espinosa Arranz E, Fresno Vara JA, Gámez Pozo A, López Vacas R, Berges Soria J, inventors; FIBHULP, assignee. Method for tumor subclassification. P201430887, 2014 June 09.

Espinosa Arranz E, Fresno Vara JA, Gámez Pozo A, Sánchez Navarro I, inventors; FIBHULP, assignee. Method for tumor subclassification. P200803509, PCT/ES2009/070533; 2008 December 11.

Miranda Utrera N, Castellano D, Villacampa Aubá F, Fresno Vara JA, Gámez Pozo A, inventors; FIBH120, FIBHULP, assignees. Prognostic method for deter-



mining the risk of relapse in renal cancer patients with a clear cell type of renal carcinoma, stages I and II, and kit for same. P201531360, PCT/EP2016/072723, EP3353322B1, US20180346990, CN108174608, DE3353322, FR3353322, GB3353322; 2015 September 23.

Moreno Rubio J, Cejas Guerrero P, Feliú Batlle J, Ramírez de Molina AI, Reglero Rada G, Vargas Alonso T, Molina Arranz S, González-Vallinas Garrachón M, inventors; FIBHULP, Fundación Imdea Alimentación, assignees. Methods and kits for the prognosis of colorectal cancer. P201231918, PCT/ES2013/070864; 2012 December 10.

Redondo Sánchez A, Hardisson Herández D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the prediction of a patient's clinical response to an anticancer treatment. P200930400; 2009 July 01.

Redondo Sánchez A, Hardisson Herández D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the prediction of a patient's pathological response to an anticancer treatment. P200930438; 2009 July 10.

Feliú Battle, J, Fernández Martos C, Fresno Vara JA, Ghanem Cañete I, Gámez Pozo A, Trilla Fuertes L, inventors; Biomedica Molecular Medicine SL (BMM), Grupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD), assignees. In vitro method for the prognosis of anal squamous cell carcinoma. EP1938298.7; 2019 November 11.



3.5.3 Experimental Therapies and Biomarkers in Cancer Group

Publications: 31
Q1: 13

COMPOSITION



■ **María Inmaculada Ibáñez de Cáceres.** Investigadora Principal (Contrato Miguel Servet-Tipo 2). Jefe de Laboratorio. FIBHULP

■ **Javier de Castro Carpeño.** Jefe de Sección de Oncología. Hospital Universitario La Paz. Profesor Asociado. Universidad Autónoma de Madrid

Lucía Acero Riaguas. Investigadora Predoctoral. Universidad Autónoma de Madrid

Miranda Burdiel Herencia. Investigadora Predoctoral. FIBHULP

Julián Colmenarejo Fernández. Investigador Predoctoral. FIBHULP

Patricia Cruz Castellanos. Facultativo Especialista de Área en Oncología Médica. Hospital Universitario La Paz

Álvaro García Guede. Investigador Predoctoral. FIBHULP

María Isabel Esteban Rodríguez. Facultativo Especialista de Área en Anatomía Patológica. Hospital Universitario La Paz

Ana Belén Griso Acevedo. Investigadora Predoctoral. FIBHULP

Julia Jiménez Hernández. Investigadora Predoctoral. FIBHULP

Cristina Manguán García. Técnico de Laboratorio. IIB "Alberto Sols"

Olga Pernía Arias. Técnico de Laboratorio (Contrato PTA). FIBHULP

Garcilaso Riesco Eizaguirre. Facultativo Especialista de Área en Endocrinología y Nutrición. FIBHULP

Carlos Rodríguez Antolín. Bioinformático Contratado. FIBHULP

Rocío Rosas Alonso. Investigadora Joan Rodés. Hospital Universitario La Paz

STRATEGIC OBJECTIVE

Our research is focused on the study of the genetic and epigenetic mechanisms involved in the tumor initiation, progression and resistance to chemo & immunotherapy.


We have used various strategies to approach this problem, such as identifying new targets involved in drug responses and studying their alterations in human samples. In addition, we have identified genetic and epigenetic changes in tumour suppressor genes, miRNAs and lncRNAs with associated clinical use in early diagnosis, prognosis and

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



drug response prediction in solid tumors and in liquid biopsy. Some of these targets present a strong potential role as therapeutic target in lung, ovarian and head and neck cancer treatment.

RESEARCH LINES

- Identification of predictive epigenetic biomarkers in the appearance of resistance to treatment in solid tumors.
- Study of the molecular mechanisms underlying simultaneous resis-

tance to platinum in cancer, through the epigenetic regulation of regulatory non-coding RNAs in lung cancer.

- Identification of new therapeutic targets. In recent years we have also identified the direct regulation of the MAFG gene through miR-7 in our experimental models in lung and EPOC.
- Identification of biomarkers in exosomes such as liquid biopsy in patients with lung and ovarian cancer.
- Fine-tuning of high performance techniques available internationally and to the National Health System (NHS). (NGS and Characterization of DNA methylation status).

1
Introduction

2
Executive
Summary

3
Information
Groups
by Area

4
Associated
Clinicians

RESEARCH ACTIVITY

■ Doctoral theses

Rosas Alonso R. Desarrollo de un nuevo método para la determinación del biomarcador epigenético MGMT en biopsia líquida y su aplicación en la monitorización de pacientes con glioblastoma[dissertation]. Madrid: UAM: 2021(16/07/2021).

Director: Ibáñez de Cáceres I.

■ Publications

- Álvarez YE, Carpeño JD, Bell D, Drago A, Franceschetti A. Prevention of chemotherapy-induced nausea and vomiting in the real-world setting in Spain. *Clin Transl Oncol.* 2021; 23(10): 2155-62. Article. IF: 3.34; Q3
- Campelo MRG, Arriola E, Balea BC, López-Brea M, Fuentes-Pradera J, Carpeño JD, Aguado C, Parente DP, Pulido FD, Ruiz-Gracia P, Rodríguez-Abreu D. PD-L1 inhibitors as monotherapy for the first-line treatment of non-small-cell lung cancer in pd-1 positive patients: a safety data network meta-analysis. *J Clin Med.* 2021; 10(19): 4583. Review. IF: 4.964; Q2
- Casanova-Acebes M, Dalla E, Leader AM, LeBerichel J, Nikolic J, Morales BM, Brown M, Chang C, Troncoso L, Chen ST, Sastre-Perona A, Park MD, Tabachnikova A, Dhainaut M, Hamon P, Maier B, Sawai CM, Agullo-Pascual E, Schober M, Brown BD, Reizis B, Marron T, Kenigsberg


E, Mousson C, Benaroch P, Aguirre-Ghiso JA, Merad M. Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells. *Nature.* 2021; 595(7868): 578-584. Article. IF: 69.504; D1

- Casarrubios M, Cruz-Bermúdez A, Nadal E, Insa A, Campelo MDG, Lazaro M, Domine M, Majem M, Rodríguez-Abreu D, Martínez-Martí A, de Castro-Carpeño J, Cobo M, López-Vivanco G, Del Barco E, Caro RB, Vinolas N, Aranda IB, Viteri S, Massuti B, Barquin M, Laza-Briviesca R, Sierra-Rodero B, Parra ER, Sánchez-Espiridion B, Rocha P, Kadara H, Wistuba II, Romero A, Calvo V, Provencio M. Pretreatment tissue tcr repertoire evenness is associated with complete pathologic response in patients with nscl receiving neoadjuvant chemoimmunotherapy. *Clin Cancer Res.* 2021; 27(21): 5878-90. Article. IF: 13.801; D1
- Cruz Castellanos P, Gutiérrez Sainz L, Esteban MI, de Castro J. Pulmonary adenocarcinoma with double mutation EGFR: L858R and G719X. *Rev Esp Patol.* 2021; 54(3): 211-4. Article. Not Indexed
- Cruz Castellanos P, Sánchez Cabrero D, Esteban MI, de Castro J. Retrospective study of lung carcinoma: experience in a third level Spanish hospital. *Rev Esp Patol.* 2021; 54(2): 85-91-. Article. Not Indexed
- Díaz-García E, García-Tovar S, Casitas R, Jau-reguizar A, Zamarron E, Sánchez-Sánchez B, Sastre-Perona A, López-Collazo E, García-Río F, Cubillos-Zapata C. Intermittent hypoxia mediates paraspeckle protein-1 upregulation in sleep apnea. *Cancers (Basel).* 2021; 13(15): 3888. Article. IF: 6.575; Q2

- Escobar-Álvarez Y, de Castro-Carpeño J, Feyjoo M, Martín-Algarra S. Evaluation of patient quality care in Spain in prevention of nausea and vomiting induced by chemotherapy. *J Healthc Qual Res.* 2021; 36(3): 142-9. Article. Not Indexed
- Foox J, Nordlund J, Lalancette C, Gong T, Lacey M, Lent S, Langhorst BW, Ponnaluri VKC, Williams L, Padmanabhan KR, Cavalcante R, Lundmark A, Butler D, Mozsary C, Gurvitch J, Grealley JM, Suzuki M, Menor M, Nasu M, Alonso A, Sheridan C, Scherer A, Bruinsma S, Golda G, Muszynska A, Labaj PP, Campbell MA, Wos F, Raine A, Liljedahl U, Axelsson T, Wang C, Chen Z, Yang ZW, Li J, Yang XP, Wang HW, Melnick A, Guo S, Blume A, Franke V, de Cáceres II, Rodríguez-Antolín C, Rosas R, Davis JW, Ishii J, Megherbi DB, Xiao WM, Liao W, Xu J, Hong HX, Ning BT, Tong WD, Akalin A, Wang YL, Deng YP, Mason CE. The SEQC2 epigenomics quality control (EpiQC) study. *Genome Biol.* 2021; 22(1): 332. Article. IF: 17.906; D1
- Gálvez E, Vallespin E, Arias-Salgado EG, Sánchez-Valdepenas C, Giménez Y, Navarro S, Río P, Bogliolo M, Pujol R, Peiro M, Nevado J, Zubizaray J, Sebastian E, Catala A, Belendez C, de Heredia CD, Galera A, Badell I, Madero L, Perona R, Sastre L, Surrallés J, Bueren J, Lapunzina P, Sevilla J. Next-generation sequencing in bone marrow failure syndromes and isolated cytopenias: experience of the spanish network on bone marrow failure syndromes. *Hemasphere.* 2021; 5(4): e539. Article. IF: 8.3; Q1
- Gómez-González C, Rosas-Alonso R, Rodríguez-Antolín C, García-Guede A, Ibáñez de Cáceres I, Sanguino J, Pascual SI, Esteban I, del Pozo A, Mori MA, Torres RJ, Prior C. Symptomatic hete-

rozygous X-Linked myotubular myopathy female patient with a large deletion at Xq28 and decreased expression of normal allele. *Eur J Med Genet.* 2021; 64(4): 104170. Article. IF: 2.465; Q3

- Gutiérrez-Sainz L, Cruz P, Martínez-Recio S, Higuera O, Esteban-Rodríguez MI, Arias-Lotto F, González RA, De Castro-Carpeño J. Malignant pleural mesothelioma: clinical experience and prognostic value of derived neutrophil-to-lymphocyte ratio and PD-L1 expression. *Clin Transl Oncol.* 2021; 23(10): 2030-5. Article. IF: 3.34; Q3
- Gutiérrez-Sainz L, Cruz-Castellanos P, Higuera O, De Castro-Carpeño J. Neoadjuvant chemoimmunotherapy in patients with resectable non-small cell lung cancer. *Curr Treat Option On.* 2021; 22(10): 91. Review. IF: 5.08; Q2
- Hurtado FK, de Braud F, Carpeño JD, Luken MJD, Wang D, Scott J, Lau YY, McCulloch T, Mau-Sorensen M. Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug-drug interaction study in patients with ALK plus advanced tumors. *Cancer Chemoth Pharm.* 2021; 87(4): 475-86. Article. IF: 3.288; Q3
- Jantus-Lewintre E, Sureda BM, Larriba JLG, Rodríguez-Abreu D, Juan O, Blasco A, Domine M, Pullá MP, Garde J, Álvarez R, Maestu I, de Carrion RP, Artal A, Rolfo C, de Castro J, Guillot M, Oramas J, de las Peñas R, Ferrera L, Martínez N, Serra O, Rosell R, Camps C. Prospective exploratory analysis of angiogenic biomarkers in peripheral blood in advanced nscl patients treated with bevacizumab plus chemotherapy: The ANGIOMET Study. *Front Oncol.* 2021; 11: 695038. Article. IF: 5.738; Q2
- Kabat MG, Bueno D, Sisinni L, de Paz R, Mozo



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Y, Perona R, Arias-Salgado EG, Rosich B, Marcos A, Romero AB, Constanzo A, Jiménez-Yuste V, Pérez-Martínez A. Selective T-cell depletion targeting CD45RA as a novel approach for HLA-mismatched hematopoietic stem cell transplantation in pediatric nonmalignant hematological diseases. *Int J Hematol.* 2021; 114(1): 116-23. Article. IF: 2.319; Q4

• Laza-Briviesca R, Cruz-Bermúdez A, Nadal E, Insa A, García-Campelo MD, Huidobro G, Domine M, Majem M, Rodríguez-Abreu D, Martínez-Martí A, Carpeño JD, Cobo M, Vivanco GL, Del Barco E, Caro RB, Vinolas N, Aranda IB, Viteri S, Massuti B, Casarrubios M, Sierra-Rodero B, Tarín C, García-Grande A, Haymaker C, Wistuba II, Romero A, Franco F, Provencio M. Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemotherapy included in NADIM clinical trial. *Clin Transl Med.* 2021; 11(7): e491. Article. IF: 8.554; Q1

• Liu SV, Reck M, Mansfield AS, Mok T, Scherpereel A, Reinmuth N, Garassino MC, Carpeño JD, Califano R, Nishio M, Orlandi F, Alatorre-Alexander J, Leal T, Cheng Y, Lee JS, Lam S, McClelland M, Deng Y, Phan S, Horn L. Updated overall survival and pd-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). *J Clin Oncol.* 2021; 39(6): 619-30. Article. IF: 50.717; D1

• López-Fernández T, Carpeño JD. Cancer and acute cardiovascular diseases: team work to transform the clinical practice. *Eur Heart J Acute Cardiovasc Care.* 2021; 10(8): 840-2. Editorial Material. IF: 4.766; Q2

• Mielgo-Rubio X, Martín M, Remón J, Higuera O, Calvo V, Jarabo JR, Conde E, Luna J, Provencio M, de Castro J, López-Ríos F, Hernando-Trancho F, Counago F. Targeted therapy moves to earlier stages of non-small-cell lung cancer: emerging evidence, controversies and future challenges. *Future Oncol.* 2021; 17(30): 4011-25. Review. IF: 3.674; Q3

• Molina LD, Canizales JMT, Pernia O, Pena RR, de Cáceres II, Granados EL. Defective Bcl-2 expression in memory B cells from common variable immunodeficiency patients. *Clin Exp Immunol.* 2021; 203(3): 341-50. Article. IF: 5.732; Q2

• Nadal E, Bosch-Barrera J, Cedres S, Coves J, García-Campelo R, Guirado M, López-Castro R, Ortega AL, Vicente D, de Castro-Carpeño J. SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020). *Clin Transl Oncol.* 2021; 23(5): 980-7. Article. IF: 3.34; Q3

• Pintado-Berninches L, Montes-Worboys A, Manuguán-García C, Arias-Salgado EG, Serrano A, Fernández-Varas B, Guerrero-López R, Iarriccio L, Planas L, Guenechea G, Egusquiaguirre SP, Hernández RM, Igartua M, Pedraz JL, Cortijo J, Sastre L, Molina-Molina M, Perona R. GSE4-loaded nanoparticles a potential therapy for lung fibrosis that enhances pneumocyte growth, reduces apoptosis and DNA damage. *Faseb J.* 2021; 35(3): e21422. Article. IF: 5.834; Q1

• Planas-Cerezales L, Arias-Salgado EG, Berastegui C, Montes-Worboys A, González-Montelongo R, Lorenzo-Salazar JM, Vicens-Zygmunt V, García-Moyano M, Dorca J, Flores C, Perona R, Román A, Molina-Molina M. Lung transplant improves survival and quality of life regardless of telomere dysfunction. *Front Med (Lausanne).* 2021; 8: 695919. Article. IF: 5.058; Q2

• Rodríguez-Antolín C, Rosas-Alonso R, Cruz P, Higuera O, Sánchez-Cabrero D, Esteban-Rodríguez I, Peláez-García A, Montano VEF, Rodríguez-Jiménez C, de Cáceres II, de Castro J. Novel SLC12A2-ROS1 fusion in non-small cell lung cancer with a significant response to crizotinib: the importance of choosing the appropriate next-generation sequencing assay. *Oncologist.* 2021; 26(6): E908-12. Article. IF: 5.837; Q2

• Rosas-Alonso R, Colmenarejo-Fernández J, Pernia O, Rodríguez-Antolín C, Esteban I, Ghanem I, Sánchez-Cabrero D, Losantos-García I, Palacios-Zambrano S, Moreno-Bueno G, de Castro J, Martínez-Marin V, Ibáñez-de-Cáceres I. Clinical validation of a novel quantitative assay for the detection of MGMT methylation in glioblastoma patients. *Clin Epigenetics.* 2021; 13(1): 52. Article. IF: 7.259; Q1

• Sierra-Rodero B, Cruz-Bermúdez A, Nadal E, Garitaonandia Y, Insa A, Mosquera J, Casal-Rubio J, Domine M, Majem M, Rodríguez-Abreu D, Martínez-Martí A, Carpeño JD, Cobo M, Vivanco GL, Del Barco E, Caro RB, Vinolas N, Aranda IB, Viteri S, Massuti B, Laza-Briviesca R, Casarrubios M, García-Grande A, Romero A, Franco F, Provencio M. Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial. *J Immunother Cancer.* 2021; 9(8): e002804. Article. IF: 12.487; Q1

• Soo R, Han JY, Dimopoulou G, Cho BC, Yeo CM, Nadal E, Carcereny E, de Castro J, Sala MA, Bernabe R, Coate L, Provencio M, Campelo RG, Cuffe S, Hashemi S, Fruh M, Ruepp B, Roschitzki-Voser H, Stahel R, Peters S. VP3-2021: A randomized phase II study of second-line osimertinib

(Osi) and bevacizumab (Bev) versus Osi in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial. *Ann Oncol.* 2021; 32(7): 942-44. Editorial Material. IF: 51.769; D1

• Soto JA, Rodríguez-Antolín C, Vera O, Pernia O, Esteban-Rodríguez I, Diestro MD, Benítez J, Sánchez-Cabo F, Álvarez R, de Castro J, de Cáceres II. Transcriptional epigenetic regulation of Fkbp1/Pax9 genes is associated with impaired sensitivity to platinum treatment in ovarian cancer. *Clin Epigenetics.* 2021; 13(1): 167. Article. IF: 7.259; Q1

• Tao YB, Wang F, Shen XP, Zhu GW, Liu RY, Viola D, Elisei R, Puxeddu E, Fugazzola L, Colombo C, Jarzab B, Czarniecka A, Lam AK, Mian C, Vianello F, Yip L, Riesco-Eizaguirre G, Santisteban P, O'Neill CJ, Sywak MS, Clifton-Bligh R, Bendlova B, Sykorova V, Zhao SH, Wang YG, Xing MZ. BRAF V600E status sharply differentiates lymph node metastasis-associated mortality risk in papillary thyroid cancer. *J Clin Endocr Metab.* 2021; 106(11): 3228-38. Article. IF: 6.134; Q1

• Vinal D, Martínez D, Higuera O, de Castro J. Genomic profiling in non-small-cell lung cancer in young patients. A systematic review. *Esmo Open.* 2021; 6(1): 100045. Review. IF: 6.883; Q1

Research projects

Burdiel Herencia M. Contrato predoctoral (F119/00061). ISCIII-MICINN. 2021-2023.

Management centre: FIBHULP

Cruz Castellanos P. App respira. Boehringer Ingelheim España, S.A. 2019-Ongoing.

Management centre: FIBHULP

de Castro Carpeño J. Comité de gestión de programa: diseño, mediante inteligencia artificial, de algoritmos predictivos para la identificación de individuos en riesgo de desarrollar sobrepeso/obesidad y sus patologías asociadas: aportación del análisis genético (S2017/BMD-3773). CM. 2018-2021.

Management centre: FIBHULP

de Castro Carpeño J. Desarrollo de las tareas necesarias para la puesta en marcha del estudio clínico m40221 título: "estudio de práctica clínica en condiciones reales para evaluarla toma de decisiones en el tratamiento de segunda línea conforme a las normas asistenciales y basado en los perfiles de foundation medicine en pacientes con cáncer de pulmón no microcítico (cpnm) localmente avanzado o metastásico con histología de adenocarcinoma en España". Roche Farma S. A. 2018-Ongoing.

Management centre: FIBHULP


de Castro Carpeño J. Determinación mediante inmunohistoquímica de la expresión de PDL-1 en carcinoma de célula no pequeña de pulmón. Fundación ECO. 2016-Ongoing.

Management centre: FIBHULP

de Castro Carpeño J. Eluxa 2: estudio de fase III, abierto, aleatorizado y controlado con producto activo, multicéntrico e internacional, para evaluar la eficacia de B11482694 frente a un doblete de quimioterapia estándar que incluye platino en pacientes con cáncer de pulmón no microcítico localmente avanzado o metastásico, con la mutación T790 M, cuya enfermedad ha progresado con el tratamiento previo con un inhibidor de la tirosina cinasa del receptor del factor de crecimiento epidérmico (EGFR-TKI). Parexel International (Irl) Limited. 2016-Ongoing.

Management centre: FIBHULP

de Castro Carpeño J. Prestación de servicios para el desarrollo de las tareas necesarias en el estudio Estudio observacional de alectinib en pacientes con CPNM ALK+ en el programa de acceso precoz en España. Roche Farma S. A. 2018-Ongoing.



1
Introduction

2
Executive
Summary

3
Information
Groups
by Area

4
Associated
Clinicians

Managment centre: FIBHULP

Esteban Rodríguez MI. Proyecto para la evaluación retrospectiva de muestras pareadas de biopsia y citología para la detección de reordenamientos de alk y expresión de pd-I1 en cpcnp. Roche Farma S. A. 2017-Ongoing.

Managment centre: FIBHULP

Ibáñez De Cáceres MI. Early molecular nanoDIAGnostics of brain tumors using Immune-PET (DIAGBI) (PLEC2021-008034). MICIIN. 2021-2024.

Managment centre: FIBHULP

Ibáñez De Cáceres MI. Estudio de la Plasticidad Tumoral Epigenética a través de la carcinogénesis y progresión del CPNM en biopsia líquida . SETuP (PI21/00145). ISCIII. 2021-Ongoing.

Managment centre: FIBHULP

Ibáñez De Cáceres MI. Estudio de los mecanismos moleculares y celulares responsables de la aparición de resistencia a quimioterapia mediados MOR MAFG y su implicación como nueva diana diagnóstica y terapéutica en cancer de pulmón no microcítico (PI18/00050). ISCIII. 2019-2021.

Managment centre: FIBHULP

Ibáñez De Cáceres MI. Evaluación y puesta a punto del biomarcador epigenético MGMT en biopsia líquida como prueba no invasiva de seguimiento, en pacientes con gliomas. Cuesta Barrio, Juan. 2017-Ongoing.

Managment centre: FIBHULP

Ibáñez De Cáceres MI. First bio-tool for exosomal normalization in liquid biopsy and its clinical applicability for lung cancer patients stratification. Fundación

Bancaria Caixa D'Estalvis I Pensions de Barcelona la Caixa. 2020-2022.

Managment centre: FIBHULP

Ibáñez De Cáceres MI. Identificación de marcadores epigenéticos para diagnóstico no invasivo en resistencia a platinos y su implicación en el uso de terapias individualizadas. ISCIII. 2013-Ongoing.

Managment centre: FIBHULP

Ibáñez De Cáceres MI. Identificación y uso de microRNAs como marcadores epigenéticos de sensibilidad a cisplatino en cáncer de pulmón no microcítico: implicación en terapias individualizadas. Roche Farma S. A. 2014-Ongoing.

Managment centre: FIBHULP

Ibáñez De Cáceres MI. Papel de los exosomas en la inducción de resistencia a platino en un modelo experimental de líneas celulares de cáncer de pulmón. Roche Farma S. A. 2017-Ongoing.

Managment centre: FIBHULP

Ibáñez De Cáceres MI. Plataforma del grupo de investigación de terapias experimentales y biomarcadores en cáncer (tebc). Helicon Medical Sl. 2021-Ongoing.

Managment centre: FIBHULP

Ibáñez De Cáceres MI. Prediapt: desarrollo de un sistema predictivo de respuesta al tratamiento con derivados del platino en cáncer de pulmón basado en aptámeros (RTC-2019-007229-1). MICIU. 2020-2023.

Managment centre: FIBHULP

Ibáñez De Cáceres MI. Validación clínica del Epigen kit: un nuevo test para predecir la respuesta al tratamiento del cáncer de pulmón no microcítico (CPNM).

Epigen-kit (RTC-2016-5314-1). MINECO. 2016-2020.

Managment centre: FIBHULP

Ibáñez De Cáceres MI. Validación del biomarcador epigenético MGMT en biopsia líquida como prueba no invasiva en pacientes con gliomas (DTS20/00029). ISCIII. 2021-2023.

Managment centre: FIBHULP

Ibáñez De Cáceres MI. Validación preclínica de diferentes biomarcadores epigenéticos con potencial uso diagnóstico y predictivo, en tumores sólidos tratados con derivados del platino. Nuevos retos clínicos asociados al estudio molecular de las biopsias líquidas en cáncer (PI15/00186). ISCIII. 2016-2020.

Managment centre: FIBHULP

Rodríguez Antolín C. Implementación diagnóstica del análisis de metilación dirigida en plataformas de secuenciación masiva de cáncer. Roche Farma S. A. 2019-Ongoing.

Managment centre: FIBHULP

Rosas Alonso R. Contrato Río Hortega (CM19/00100). ISCIII. 2020-2021.

Managment centre: FIBHULP

Sastre Perona A. Beca Lúis Álvarez. FIBHULP. 2022-2022.

Managment centre: FIBHULP

Sastre Perona A. Contrato garantía juvenil Ayudante de Investigación (PEJ-2020-AI/BMD-17846). CM. 2020-2023.

Managment centre: FIBHULP

Sastre Perona A. Contrato garantía juvenil Técnico (PEJ-2021-TL/BMD-21631). ISCIII. 2022-2024.

Managment centre: FIBHULP

Sastre Perona A. Contrato Miguel Servet tipo I (CP19/00063). ISCIII. 2020-2024.

Managment centre: FIBHULP

Sastre Perona A. Desarrollo de herramientas predictivas y terapéuticas para combatir la resistencia a cisplatino en carcinomas escamosos de cabeza y cuello (PI20/00329). ISCIII. 2020-2023.

Managment centre: FIBHULPi

■ Cibers & Retics

de Castro Carpeño J. Plataforma de Innovación. (PT17/0005/0025). ISCIII. (31/12/2023).

Managment centre: FIBHULP

de Castro Carpeño J. Dinamización e innovación de las capacidades industriales del SNS y su transferencia al sector productivo. (PT20/00002). ISCIII. (31/12/2023).

Managment centre: FIBHULP

Ibáñez de Cáceres I. European Infrastructure for Translational Medicine. EU. (31/12/2023).

Managment centre: FIBHULP

■ Clinical trials

de Castro Carpeño, J. Estudio observacional para el seguimiento de la actividad de los pacientes con cáncer de pulmón y evaluar su estado funcional mediante dispositivos móviles. LUPA-01.


Type: Estudios No EPA.

HULP code: 5777 ML42283 ROC-CPN-2020-01.

Sponsored by: Roche Farma, S.A.

Signed date: 20/01/2021

de Castro Carpeño, J. Comparación de



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

la eficacia entre Cobolimab + Dostarlimab + Docetaxel y Dostarlimab + Docetaxel y Docetaxel en monoterapia en participantes con cáncer de pulmón no microcítico avanzado que hayan progresado al tratamiento previo con anti-PD (l) 1 y Quimioterapia.

Type: Clinical Trials, phase II.

HULP code: 5743 213410.

Sponsored by: Glaxosmithkline, S.A.

Signed date: 19/01/2021

de Castro Carpeño, J. Ensayo clínico plataforma en fase II de inmunooncología de precisión con indicación tumor agnóstica paramutaciones somáticas específicas (tapistry).

Type: Clinical Trials, phase II.

HULP code: 5657 BO41932.

Sponsored by: F.Hoffmann-La Roche Ltd.

Signed date: 27/01/2021

de Castro Carpeño, J. Assessment of early resistance mechanisms to first-line osimertinib in egfr-mutant non-small-cell lung cancer (nscl) using spatial transcriptomics.

Type: Estudios, phase EPA-OD.

HULP code: PI-4620 ESR-20-20709.

Sponsored by: Fundacion Oncosur.

Signed date: 11/02/2021

de Castro Carpeño, J. Estudio en paraguas de fase Ib/II, sin enmascaramiento, multicéntrico y aleatorizado para evaluar la eficacia y la seguridad de combinaciones de tratamientos basados en múltiples inmunoterapias en pacientes con carcinoma de pulmón no microcítico metastásico (morpheus pulmonar).

Type: Clinical Trials, phase I.

HULP code: Appendix 1 5591.

Sponsored by: Genentech Inc.



Signed date: 16/02/2021

de Castro Carpeño, J. Estudio internacional multicéntrico de fase III, aleatorizado, doble ciego, controlado con placebo, de medi4736 como tratamiento secuencial en pacientes con cáncer pulmonar de células no pequeñas, localmente avanzado, no resecable (estadio III) que no han progresado después de la terapia de quimiorradiación concurrente definitiva con

base de platino (pacific).

Type: Clinical Trials, phase III.

HULP code: Appendix 2 4235.

Sponsored by: Astrazeneca Ab.

Signed date: 27/04/2021


de Castro Carpeño, J. Ensayo fase III, randomizado, doble ciego, controlado con placebo, multicéntrico, internacional con osimertinib como tratamiento de mantenimiento en pacientes con cáncer

de pulmón no microcítico (estadio III) localmente avanzado e irreseccable, con mutación de egfr positiva, cuya enfermedad no ha progresado después de tratamiento definitivo con quimiorradioterapia basada en platino (laura).

Type: Clinical Trials, phase III.

HULP code: Appendix 1 5104.

Sponsored by: Astrazeneca Farmaceutica Spain, S.A.



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Signed date: 26/04/2021

de Castro Carpeño, J. Estudio en fase II, abierto y de un solo grupo de bevacizumab (m6620) en combinación con topotecán en participantes con carcinoma microcítico de pulmón recidivante y resistente al platino.

Type: Clinical Trials, phase II.
HULP code: 5811 MS201923_0050.
Sponsored by: Merck Healthcare KgaA.
Signed date: 26/03/2021

de Castro Carpeño, J. Estudio ceto, abierto, multicéntrico, global, en fase II con entrectinib para el tratamiento de pacientes con tumores sólidos localmente avanzados o metastásicos que albergan reordenaciones en los genes ntrk1/2/3, rs1 o alk.

Type: Clinical Trials, phase II.
HULP code: Appendix 4 4648.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 18/03/2021

de Castro Carpeño, J. Estudio en fase II, aleatorizado, doble ciego de relatimab más nivolumab en combinación con quimioterapia frente a nivolumab en combinación con quimioterapia como tratamiento de primera línea para los participantes con cáncer de pulmón de células pequeñas (cpcnp) en estadio iv o recurrente.

Type: Clinical Trials, phase II.
HULP code: 5809 CA224104.
Sponsored by: Bristol-Myers Squibb International Corporation (Bmsic).
Signed date: 26/04/2021

de Castro Carpeño, J. Estudio multicéntrico, abierto y de un solo grupo, del perfil molecular de pacientes con cáncer de pulmón no microcítico con mutación del

EGFR, localmente avanzado o metastásico, tratados con Osimertinib.

Type: Clinical Trials, phase II.
HULP code: Appendix 1 4929.
Sponsored by: Astrazeneca Ab.
Signed date: 27/05/2021

de Castro Carpeño, J. Estudio fase 3, aleatorizado, abierto, para comparar nivolumab más quimiorradioterapia concurrente (qrtc) seguidos por nivolumab más ipilimumab o nivolumab más qrtc seguidos por nivolumab frente a qrtc seguida por durvalumab en el cáncer de pulmón no microcítico localmente avanzado (cpnm la) no tratado previamente.

Type: Clinical Trials, phase III.
HULP code: Appendix 1 5403.
Sponsored by: Bristol-Myers Squibb International Corporation (Bmsic).
Signed date: 22/06/2021

de Castro Carpeño, J. Estudio de fase II multicéntrico, abierto y con un único grupo de tratamiento para evaluar la eficacia y la seguridad de la combinación de pembrolizumab y lenvatinib en pacientes con carcinoma tímico previamente tratado. pecati.

Type: Clinical Trials, phase II.
HULP code: 5801 MedOPP341.
Sponsored by: Medica Scientia Innovation Research, S.L.
Signed date: 22/06/2021

de Castro Carpeño, J. Protocolo de acceso ampliado de amg 510 (dci, sotorasib) multicéntrico, abierto y de un solo grupo para el tratamiento de sujetos en determinados países europeos con cáncer de pulmón no microcítico localmente avanzado e irreseccable o metastásico tratado previamente con la mutación p.g12c en el kras.

Type: Clinical Trials, phase III.
HULP code: 5881 20190442.
Sponsored by: Amgen, S.A.
Signed date: 01/06/2021

de Castro Carpeño, J. Estudio de fase 3, abierto y aleatorizado para investigar la farmacocinética y la seguridad de pembrolizumab subcutáneo en comparación con pembrolizumab intravenoso, administrado con quimioterapia doble a base de platino, en el tratamiento de primera línea de participantes con cáncer de pulmón no microcítico epidermoide o no epidermoide metastásico.

Type: Clinical Trials, phase III.
HULP code: 5857 MK-3475-A86.
Sponsored by: Merck Sharp And Dohme De España, S.A.
Signed date: 18/06/2021

de Castro Carpeño, J. Estudio observacional para describir las características genotípicas y las mutaciones de resistencia en el nscL alk+.

Type: Estudios No EPA.
HULP code: PI-4854 ALK-PATHFINDER.
Sponsored by: Fundacion Oncosur.
Signed date: 05/07/2021

de Castro Carpeño, J. Estudio de fase 1 para evaluar la seguridad, tolerabilidad y farmacocinética de amg 757 en sujetos con cáncer de pulmón microcítico.

Type: Clinical Trials, phase I.
HULP code: 5900 20160323.
Sponsored by: Amgen, S.A.
Signed date: 04/08/2021

de Castro Carpeño, J. Estudio de fase 3 abierto, aleatorizado y multicéntrico para comparar la eficacia de tak-788 como tratamiento de primera línea frente a quimioterapia a base de platino en pacientes con cáncer de pulmón no microcítico

con mutaciones de egfr por inserción en el exón 20.

Type: Clinical Trials, phase III.
HULP code: Appendix 1 5454.
Sponsored by: Millennium Pharmaceuticals Inc.
Signed date: 19/07/2021

de Castro Carpeño, J. Ensayo clínico plataforma en fase II de inmunooncología de precisión con indicación tumor agnóstica paramutaciones somáticas específicas (tapistry).


Type: Clinical Trials, phase II.
HULP code: Appendix 1 5657.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 02/09/2021

de Castro Carpeño, J. Estudio de fase III aleatorizado y doble ciego de bgba1217, un anticuerpo anti-tigit, en combinación con tislelizumab frente a pembrolizumab en pacientes con cáncer de pulmón no microcítico irreseccable o metastásico no tratado previamente, con expresión de pd-l1 y localmente avanzado.

Type: Clinical Trials, phase III.
HULP code: 5901 BGB-A317-A1217-302.
Sponsored by: Beigene Usa, Inc.
Signed date: 05/08/2021

de Castro Carpeño, J. Ensayo de fase 2 no aleatorizado, abierto, de múltiples cohortes, multicéntrico, para evaluar el beneficio clínico de sar444245 (thor-707) combinado con otras terapias anticancerígenas para el tratamiento de participantes con cáncer de pulmón o mesotelioma pleural.

Type: Clinical Trials, phase II.
HULP code: 5889 ACT16849.



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Sponsored by: Sanofi Aventis S.A.
Signed date: 18/06/2021

de Castro Carpeño, J. Estudio en fase III abierto y aleatorizado del tratamiento combinado de amivantamab y lazertinib con quimioterapia basada en platino en comparación con quimioterapia basada en platino en pacientes con cáncer de pulmón no microcítico con mutación del egfr localmente avanzado o metastásico tras el fracaso de osimertinib.

Type: Clinical Trials, phase III.
HULP code: 5945
61186372NSC3002(MARIPOSA).
Sponsored by: Janssen Cilag International Nv.
Signed date: 16/09/2021

de Castro Carpeño, J. Estudio de fase 2, abierto y multicéntrico de la seguridad y la eficacia de krt-232 en sujetos con cáncer de pulmón microcítico (cpm) recidivante o resistente.

Type: Clinical Trials, phase II.
HULP code: 5986 KRT-232-112.
Sponsored by: Kartos Therapeutics Inc.
Signed date: 14/10/2021

de Castro Carpeño, J. Estudio fase 3 abierto y aleatorizado de la combinación de la terapia amivantamab y carboplatino-pemetrexed, frente a carboplatino-pemetrexed, en pacientes con cáncer de pulmón no microcítico localmente avanzado o metastásico con egfr mutado por inserciones en el exon 20.

Type: Clinical Trials, phase III.
HULP code: Appendix 1 5652.
Sponsored by: Janssen Cilag International Nv.
Signed date: 20/10/2021

de Castro Carpeño, J. Estudio aleatorizado de fase III de sitravatinib en combi-

nación con nivolumab frente a docetaxel en pacientes con cáncer de pulmón no microcítico no escamoso avanzado con progresión de la enfermedad durante o después de la quimioterapia con platino y el tratamiento con inhibidor de punto de control (sapphire).

Type: Clinical Trials, phase III.
HULP code: Appendix 1 5556.
Sponsored by: Mirati Therapeutics, Inc.
Signed date: 30/09/2021

de Castro Carpeño, J. Ensayo de plataforma de fase 2 basado en biomarcadores en pacientes con cáncer de pulmón no microcítico avanzado cuya enfermedad ha progresado durante el tratamiento con osimertinib en primera línea (orchard).

Type: Clinical Trials, phase II.
HULP code: Appendix 2 5345.
Sponsored by: Astrazeneca Farmaceutica Spain, S.A.
Signed date: 18/10/2021

de Castro Carpeño, J. Estudio multicéntrico de fase 3, aleatorizado, doble ciego, controlado con placebo, para comparar niraparib añadido a pembrolizumab versus placebo añadido a pembrolizumab como terapia de mantenimiento en participantes cuya enfermedad se haya mantenido estable o haya respondido a una primera línea de quimioterapia basada en platino y pembrolizumab en cáncer de pulmón no microcítico estadio IIIb o iv.

Type: Clinical Trials, phase III.
HULP code: Appendix 1 5665.
Sponsored by: Glaxosmithkline, S.A.
Signed date: 19/07/2021

de Castro Carpeño, J. Estudio abierto, multicéntrico y global para evaluar la eficacia y la seguridad a largo plazo en pacientes que están recibiendo o que

han recibido previamente durvalumab en otros protocolos (wave).

Type: Clinical Trials, phase IV.
HULP code: Appendix 1 5419.
Sponsored by: Astrazeneca Ab.
Signed date: 07/09/2021

de Castro Carpeño, J. Estudio de fase 2, multicéntrico y abierto de sotorasib (amg 510) en sujetos con cpm en estadio iv cuyos tumores presentan mutación del krasg12c que requieren tratamiento de primera línea (codebreak 201).

Type: Clinical Trials, phase II.
HULP code: 5924 20190288.
Sponsored by: Amgen, S.A.
Signed date: 26/10/2021

de Castro Carpeño, J. La efectividad del tratamiento antineoplásico sistémico actual en el mundo real en pacientes con carcinoma pulmonar no microcítico (cpnm) avanzado/metastásico con la mutación ex20ins en el receptor del factor de crecimiento epidérmico (es decir, cohorte de control externa); comparación ajustada entre los resultados del mundo real en la cohorte de control externa y los resultados de amivantamab en el ensayo chrysalis.

Type: Estudios, phase EPA-OD.
HULP code: PI-4921
61186372LUC4002.
Sponsored by: Janssen Pharmaceutica Nv.
Signed date: 11/11/2021

Patents and trademarks

Perona Abellón R, Sánchez Pérez I, Machado Pinilla R, Sastre Garzón L, Murguía Ibáñez JR, inventors; CSIC, UAM,


Universidad Politécnica de Valencia, assignees. Sequence of nucleotides and peptides GSE 24.2 of dyskerin, which can induce telomerase activity, method for obtaining same, therapeutic compositions and applications thereof. P200502511, PCT/ES2006/070152, EP1947175, US20090202503, US2015337022, AT469212, CA2625981, DK1947175, JP2009511036, JP5560398, PT1947175; 2005 October 14.

Perona Abellón R, Sastre Garzón L, Machado Pinilla R, Sánchez Pérez I, inventors; CSIC, UAM, assignees. Use of inductor agents GSE24.2 for producing pharmaceutical compositions for treating illnesses relating to cellular senescence. P200703106, PCT/ES2008/070212, EP2216043, US2011300115, JP2011504483, CA2706467; 2007 November 23.

Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, González Barón M, de Castro Carpeño J, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, assignees. Genomic fingerprint for the prognosis of the evolution of colorectal adenocarcinoma. P200703229, PCT/ES2008/000756, EP2236626; 2007 December 04.

Cejas Guerrero P, González Barón M, Casado Sáenz E, Sánchez Hernández JJ, Perona Abellón R, inventors; FIBHULP, UAM, CSIC, assignees. Use of trefoil factor family 3 (TFF3) in the prognosis of patients diagnosed with colorectal cancer. P200703230, PCT/ES2008/000757, EP2236625; 2007 December 04.

Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, de Castro Carpeño J,



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Moreno García V, Burgos Lizalde E, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, Empresa Pública Hospital del Norte, assignees. Genomic fingerprint for predicting the clinical response to an antitumor therapy in colorectal cancer. P201130863, PCT/ES2012/070379; 2011 May 26.

Martínez Máñez R, Murguía Ibáñez JR, Perona Abellón R, Agostini A, Mondragón Martínez L, Moreno Torres M, Manguán García C, Marcos Martínez MD, Soto Camino J, Sancenón Galarza F, inventors; Universidad Politécnica de Valencia, CSIC, Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), assignees. Release of substances into senescent cells. P201231370, PCT/ES2013/070581, EP2893923, JP2015529216, US2015306037; 2012 September 04.

Ibáñez de Cáceres I, Belda Iniesta C,

Pernía Arias O, Perona Abellón R, Cortés Sempere M; inventors. FIBHULP, CSIC, UAM, Fundación Hospital de Madrid, assignees. Method for predicting the response to a treatment consisting of radiotherapy combined with cisplatin-based chemotherapy. P201330783, PCT/ES2014/070433, EP3006572, US20160122828, IT1660.13, ES1660.13, FR1660.13, DE1660.13, GB1660.13; 2013 May 29.

Perona Abellón R, Sastre Garzón L, Pintado Berninches L, Carrillo García J, Molina Pachón A, Irradiccio Silva L, Manguán García C, inventors; CSIC, UAM, Advanced Medical Projects, Centro de Investigación Biomédica en Red (CIBER), assignees. Peptides derived from GSE 24.2 for treating diseases caused by oxidative stress and damage to DNA. P201331573, AU2014338820, CA2931429, EP3061815 PCT/ES2014/070803; 2013 October 25.

Ibáñez de Cáceres I, Pernía Arias O, de Castro Carpeño J, Vera Puente O, Jiménez Hernández J, Perona Abe-

llón R, Rojo Todo F, inventors; FIBHULP, CSIC, UAM, Instituto de Investigación Sanitaria FJD, assignees. Determination of methylation and miRNA levels in response to a platinum-based antitumor compound. P201530997, PCT/ES2016/070516; 2015 July 09.



Ibáñez de Cáceres I, de Castro Carpeño J, Vera Puente O, Pernía Arias O, Rodríguez Antolín C, González Muñoz VM, Martín Palma ME, Salgado Figueroa AM, inventors; FIBHULP, FIBIOHRC, assignees. MAFG as a potential therapeutic target to restore chemosensitivity in platinum-resistant cancer cells. EP17382610.8 (EP3681515), PCT/EP2018/068156, US16/647,368; 2017 September 15.

Ibáñez de Cáceres I, de Castro Carpeño J, Jiménez Hernández J, Rodríguez Antolín C, Rodríguez Jiménez C, Rosas Alonso R, Cruz Castellanos P, Burdiel Herencia M, Pernía Arias O, Diestro Tejada MD, Esteban Rodríguez MI, inventors; FIBHULP, assignee. miR-151A-3p as an universal endogenous control for exo-

some cargo normalization. EP19382252.5 (EP3719144), PCT/EP2020/059774 PCT Direct, EP20719957.1 (EP3947733), US17/601,657; 2019 April 05.

Ibáñez de Cáceres I, de Castro Carpeño J, Rosas Alonso R, Pernía Arias O, Martínez Marín V, Esteban Rodríguez MI, inventors; FIBHULP, assignee. Method for determining the percentage of methylation of the promoter of the gene O6-methylguanine-DNA methyltransferase (MGMT) in circulating exosomes. EP19382299.6 (EP3725899), PCT/EP2020/060753 PCT Direct, EP20723998.9 (EP3956475), US17/604,172; 2019 April 16.

Ibáñez de Cáceres I, de Castro Carpeño J, Jiménez Hernández J, Rodríguez Antolín C, Vera Puente O, Rosas Alonso R, Pernía Arias O, Losantos García I, inventors; FIBHULP, assignee. Method for determining the response to treatment of a patient affected by non-small cell lung carcinoma (NSCLC). EP19382614.6 (EP3999664), PCT/EP2020/069659; 2019 July 19.



3.5.4 Oto-Neurosurgery Research Group

Publications: 21

Q1: 11

COMPOSITION



■ **Luis Lassaletta Atienza.** Jefe de Sección de Otorrinolaringología. Hospital Universitario La Paz

Carolina Alfonso Carrillo. Facultativo Especialista de Área en Otorrinolaringología. Hospital Universitario La Paz

Miryam Calvino Fernández. Investigadora Postdoctoral. Universidad Autónoma de Madrid

Alejandro Castro Calvo. Facultativo Especialista de Área en Otorrinolaringología. Hospital Universitario La Paz

Isabel García López. Facultativo Especialista de Área en Otorrinolaringología. Hospital Universitario La Paz

Javier Gavilán Bouzas. Jefe de Servicio de Otorrinolaringología. Facultad de Medicina. Hospital Universitario La Paz. Catedrático. Departamento de Cirugía. Universidad Autónoma de Madrid

Teresa González Otero. Facultativo Especialista de Área en Cirugía Maxilofacial. Hospital Universitario La Paz

José Manuel Morales Puebla. Facultativo Especialista de Área en Otorrinolaringología. Hospital Universitario La Paz

Silvia Murillo Cuesta. Investigadora Postdoctoral. IIB "Alberto Sols"

María Fernanda Pedrero Escalas. Facultativo Especialista de Área en Otorrinolaringología. Hospital Universitario La Paz

Carolina Peña Granero. Técnico de Laboratorio (Contrato PTA). Hospital Universitario La Paz

Rosa María Pérez Mora. Facultativo Especialista de Área en Otorrinolaringología. Hospital Universitario La Paz

Juan Antonio Rey Herranz. Investigador Senior (Contrato Mlguel Servet - I2). Jefe de Laboratorio. Hospital Universitario La Paz

Laura del Río Arroyo. Facultativo Especialista de Área en Otorrinolaringología. Hospital Universitario La Paz

Lourdes Rodríguez de la Rosa. Investigadora Postdoctoral. IIB "Alberto Sols"

Isabel Pilar Sánchez Cuadrado. Facultativo Especialista de Área en Otorrinolaringología. Hospital Universitario La Paz

Miguel Torres Martín. Investigador Postdoctoral. Hospital Universitario La Paz

María Isabel Varela Nieto. Profesor de Investigación. IIB "Alberto Sols"

Antonio Villalobo Polo. Profesor de Investigación. IIB "Alberto Sols"

STRATEGIC OBJECTIVE

The systematic use of magnetic resonance imaging (MRI) has dramatically increased the diagnosis of patients with vestibular schwannoma (VS). The majority of patients with VS complain of hypoacusis or tinnitus, and very few present more debilitating symptoms. The-


efore, the approach with a patient with VS is complex because the treatment of the tumour is directed towards avoiding complications arising from its growth and not necessarily towards improving the patient's quality of life. Currently, there are no factors that allow us to predict the growth of vestibular schwannoma.

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



1
Introduction

2
Executive
Summary

3
Information
Groups
by Area

4
Associated
Clinicians



Recent advances in the field of oncogenetics have allowed us to better understand the development of VS.

The study of the correlation between clinical variables related to the biological behaviour of VS and its genetic and epigenetic disorders aims to find the factors that predict the behaviour of VS. This will help us identify patients who need active treatment of the tumour and avoid the morbidity associated with the treatment in those who do not need it.

The cochlear implant (CI) is currently the only solution for relieving the condition in patients with severe or profound hypoacusis who do not benefit from a prosthetic adaptation with a conventional hearing aid. It is estimated that there are currently 120,000 adults in Spain with profound sensorineural hypoacusis. In recent years, new hearing implants have been developed including osseointegrated implants and active middle ear implants. It's excellent and often spectacular results and its low rate of complications have transformed CI from an innovative technology in the experimental phase to a routine, safe and effective procedure, capable of returning deaf individuals to the hearing world and ending their isolation, increasing their quality of life. Over the past decade the relationship between hearing loss and cognitive decline in the older population has become the subject of research. We also explore the relationships between the cognitive function and the audiometric performances in patients wearing a CI.


Moderate to severe hypoacusis is one of the most prevalent medical problems. Ciliated sensory cells and neurons do not regenerate in mammals, which is the main cause of sensorineural hearing loss (SNHL). Mutations altering the levels of Insulin like growth factor type 1 (IGF-1) cause SNHL in humans and mice. IGF-1 is an essential factor in the postnatal development of mammals, and its level decreases with ageing. We are studying the participation of IGF-1 in the pathophysiology of SNHL, as well as the molecular signalling networks conferring specificity in the otic cellular response to IGF-1. We are studying the signals that regulate otic damage with the objective of identifying the key factors implicated in functional repair and regeneration of inner ear cells. In short, our work contributes to the study of auditory pathophysiology, with the ultimate objective of

investigating the potential clinical usefulness of IGF-1 and downstream signalling in human sensorineural deafness.

Bell's palsy is the most common diagnosis associated with facial nerve weakness or paralysis. However, not all patients with facial paresis/paralysis have Bell's palsy. Other common causes include treatment of vestibular schwannoma, head and neck tumors, iatrogenic injuries, Herpes zoster, or trauma. The approach to each of these conditions varies widely, The addition of adjunctive major or minor facial procedures in the context of a multidisciplinary Facial Paralysis Unit improves the final facial outcome.

RESEARCH LINES

- Tumors of the CNS: vestibular schwannoma, meningiomas, gliomas, and other: surgery, oncogenetics, quality of life, etc.
- Auditory implants: cochlear implants, middle ear implants, bone-conduction implants: surgical aspects, telephone use, quality of life, perception of music, cognitive decline, anatomy based fitting, etc.
- IGF-I deficiency: a rare syndromic human deafness.
- Neurobiology of hearing: molecular and cellular bases of hearing loss of different aetiology (genetic, noise exposure, malnutrition, and ototoxic drugs). Identification of transcriptional networks.
- Development of experimental models of deafness (genetic, noise exposure, malnutrition, ototoxic drugs and surgery associated trauma) for pre-clinical studies with potential therapeutic molecules, thus identifying possible therapeutic targets, potential markers for diagnosis and generation of vital guidelines.
- Head and Neck tumors and voice pathology.
- The role of cellular senescence in the development of the inner ear and the auditory pathology.
- Studies on three systems implicated in the development of tumor metastasis: the tyrosine kinase receptors EGFR/ ErbB2; the non-receptor tyrosine kinase c-Src; and the adaptor protein Grb7.
- Facial paralysis: evaluation, diagnosis and surgery



RESEARCH ACTIVITY

■ Doctoral theses

Master Theses

Tirado Melendro P. Estudio de la respuesta al estrés y al daño inflamatorio en células de neuroblastoma. Papel protector del IGF-1[dissertation]. Madrid: UAM: 2021(01/09/2021).

Directors: Varela Nieto I,
Rodríguez de la Rosa L

Franco Caspueñas S. Estudio de la senescencia celular como diana terapéutica en células de Schwannomas vestibulares humanos[dissertation]. Madrid: UAM: 2021(01/09/2021).

Directors: Jiménez Lara AM,
Rodríguez de la Rosa L.

Final Degree Theses

Pelegrina Sánchez D. Experiencia en implantes cocleares: estudio descriptivo [dissertation]. Madrid: UAM: 2021(01/06/2021).

Directors: Lassaletta Atienza L,
Morales Puebla JM

Villar Prieto R. Estudio del potencial papel otoprotector del IGF-1 en respuesta al estrés y al daño celular inducido por cisplatino en la línea celular auditiva HEI-OC1. [dissertation]. Madrid: UAM: 2021(01/06/2021).

Directors: Varela Nieto I,
García Mato A.

■ Publications

• Abdelli F, Jellali K, Anguita E, González-Muñoz M, Villalobo E, Madronal I, Alcalde J, Ben Ali M, Elloumi-Mseddi J, Jemel I, Tebar F, Enrich C, Aifa S, Villalobo A. The role of the calmodulin-

binding and calmodulin-like domains of the epidermal growth factor receptor in tyrosine kinase activation. *J Cell Physiol.* 2021; 236(7): 4997-5011. Article. IF: 6.513; Q1

• Alcalde J, Munk M, González-Muñoz M, Panina S, Berchtold MW, Villalobo A. Calmodulin down-regulation in conditional knockout HeLa cells inhibits cell migration. *Arch Biochem Biophys.* 2021; 697: 108680. Article. IF: 4.114; Q2

• Bermúdez-Muñoz JM, Celaya AM, García-Mato A, Muñoz-Espin D, Rodríguez-de la Rosa L, Serrano M, Varela-Nieto I. Dual-specificity phosphatase 1 (dusp1) has a central role in redox homeostasis and inflammation in the mouse cochlea. *Antioxidants.* 2021; 10(9): 1351. Article. IF: 7.675; D1

• Celaya AM, Rodríguez-De la Rosa L, Bermúdez-Muñoz JM, Zubeldia JM, Roma-Mateo C, Avendaño C, Pallardo FV, Varela-Nieto I. IGF-1 Haploinsufficiency causes age-related chronic cochlear inflammation and increases noise-induced hearing loss. *Cells.* 2021; 10(7): 1686. Article. IF: 7.666; Q2

• COVIDSurg Collaborative GlobalSurg Collaborative (Lassaletta Atienza L). SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study. *Br J Surg.* 2021; 108(9): 1056-63. Article. IF: 11.122; D1

• COVIDSurg Collaborative, GlobalSurg Collaborative (Lassaletta Atienza L). Effects of pre-operative isolation on postoperative pulmonary complications after elective surgery: an international prospective cohort study. *Anaesthesia.* 2021; 76(11): 1454-64. Article. IF: 12.893; D1

• COVIDSurg Collaborative, GlobalSurg Collaborative (Lassaletta Atienza L). Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study. *Anaesthesia.* 2021; 76(6): 748-58. Article. IF: 12.893; D1

• de la Rosa J, Urdiciain A, Zelaya MV, Zazpe I, Meléndez B, Rey JA, Idoate MA, Castresana JS. APR-246 combined with 3-deazaneplanocin A, panobinostat or temozolomide reduces clonogenicity and induces apoptosis in glioblastoma cells. *Int J Oncol.* 2021; 58(3): 312-30. Article. IF: 5.884; Q2

• Fumero MJ, Eustaquio-Martín A, Gorospe JM, López RP, Revilla MAG, Lassaletta L, Schätzer R, Nopp P, Stohl JS, López-Poveda EA. A state-of-the-art implementation of a binaural cochlear-implant sound coding strategy inspired by the

medial olivocochlear reflex. *Hearing Res.* 2021; 409: 108320. Article. IF: 3.672; Q1

• García-Mato A, Cervantes B, Murillo-Cuesta S, de la Rosa L, Varela-Nieto I. Insulin-like growth factor 1 signaling in mammalian hearing. *Genes (Basel).* 2021; 12(10): 1553. Review. IF: 4.141; Q2

• Lassaletta L, Ruiz-Bravo E, García-Raya P, Fernández-Zubillaga A, González-Otero T, Gavilán J. Fibrovascular tumor-like lesions of the facial nerve. *Audiol Neuro-Otol.* 2021; 26(1): 27-34. Article. IF: 2.213; Q3

• Leon Y, Magarinos M, Varela-Nieto I. Ceramide kinase inhibition blocks igf-1-mediated survival of otic neurosensory progenitors by impairing akt phosphorylation. *Front Cell Dev Biol.* 2021; 9: 678760. Article. IF: 6.081; Q1

• Mateos-Serrano B, García-López I, Toledano A, Gavilán J. Subjective voice analysis in patients with muscular tension dysphonia: comparison between clinician and patient evaluation. *J Laryngol Otol.* 2021; 135(5): 458-63. Article. IF: 2.187; Q3

• Mertens G, Andries E, Claes AJ, Topsakal V, Van de Heyning P, Van Rompaey V, Calvino M, Cuadrado IS, Muñoz E, Gavilán J, Bienkowska K, Swierniak W, Skarzynski PH, Skarzynski H, Tapper L, Killan C, Ridgwell J, McGowan J, Raine C, Tavora-Vieira D, Marino R, Acharya A, Lassaletta L. Cognitive improvement after cochlear implantation in older adults with severe or profound hearing impairment: a prospective, longitudinal, controlled, multicenter study. *Ear Hearing.* 2021; 42(3): 606-4. Article. IF: 3.562; Q1

• Morales Puebla JM, López Juanes N, Varo Alonso M, Sánchez Cuadrado I, Gavilán Bouzas J, Lassaletta Atienza L. Clinical-radiological correlation in temporal bone fractures. *Acta Otorrinolaringol Esp.* 2021; 72(5): 295-304. Article. Not Indexed

• Morales-Puebla JM, González-Otero T, Moraleda S, Santiago S, Gavilán J, Lassaletta L. Combined Sequential Bilateral Hypoglossal-to-facial and Masseter-to-facial Transfers for Bilateral Facial Paralysis. *Plast Reconstr Surg Glob Open.* 2021; 9(7): -e3689. Article. IF: Not Indexed; Not Indexed.NO

• Murillo-Cuesta S, Celaya AM, Cervantes B, Bermúdez-Muñoz JM, Rodríguez-de la Rosa L, Contreras J, Sánchez-Perez I, Varela-Nieto I. Therapeutic efficiency of the APAF-1 antagonist LPT99 in a rat model of cisplatin-induced hearing loss. *Clin Transl Med.* 2021; 11(4): e363. Letter.

IF: 8.554; Q1

• Sánchez-Cuadrado I, Calvino M, Morales-Puebla JM, Gavilán J, Mato T, Penarrocha J, Prim MP, Lassaletta L. Quality of life following cochlear implantation in patients with meniere's disease. *Front Neurol.* 2021; 12: -670137. Article. IF: 4.086; Q2

• Urdiciain A, Erasquin E, Zelaya MV, Zazpe I, Lanciego JL, Meléndez B, Rey JA, Idoate MA, Riobo-Del Galdo NA, Castresana JS. Silencing of histone deacetylase 6 decreases cellular malignancy and contributes to primary cilium restoration, epithelial-to-mesenchymal transition reversion, and autophagy inhibition in glioblastoma cell lines. *Biology (Basel).* 2021; 10(6): 467. Article. IF: 5.168; Q1

• van de Heyning P, Mertens G, Topsakal V, de Brito R, Wimmer W, Caversaccio MD, Dazert S, Volkenstein S, Zernotti M, Parnes LS, Staecker H, Bruce IA, Rajan G, Atlas M, Friedland P, Skarzynski PH, Sugarova S, Kuzovkov V, Hagr A, Mlynski R, Schmutzhard J, Usami SI, Lassaletta L, Gavilán J, Godey B, Raine CH, Hagen R, Sprinzl GM, Brown K, Baumgartner WD, Karltorp E. Two-phase survey on the frequency of use and safety of MRI for hearing implant recipients. *Eur Arch Oto-Rhino-L.* 2021; 278(11): 4225-33. Article. IF: 3.236; Q2

• Varela-Nieto I, Murillo-Cuesta S, Rodríguez-de la Rosa L, Oset-Gasque MJ, Marco-Contelles J. Use of radical oxygen species scavenger nitrones to treat oxidative stress-mediated hearing loss: state of the art and challenges. *Front Cell Neurosci.* 2021; 15(5): 711269. Review. IF: 6.147; Q1

■ Research projects

García-López I. Parálisis bilateral de las cuerdas vocales: epidemiología y posibilidades terapéuticas aplicadas (PI-3780). Med-El Elektromedizinische Geräte Gesellschaft M. B. H. 2019-Ongoing.

Managment centre: FIBHULP

Lassaletta Atienza L. Empleo de un clip de fijación en la implantación coclear. Varios financiadores. 2020-2021.


Managment centre: FIBHULP

1
Introduction

2
Executive
Summary

3
Information
Groups
by Area

4
Associated
Clinicians



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Lassaletta Atienza L. Implantes cocleares y función cognitiva en mayores de 55 años. Confederación Española de Familias de Personas Sordas. 2021-2021.

Managment centre: FIBHULP

Lassaletta Atienza L. Implantes cocleares y función cognitiva. Medidas de resultados auditivos, calidad de vida y calidad del sonido (PI16/00079). ISCIII. 2017-2021.

Managment centre: FIBHULP

Lassaletta Atienza L. Leespq en niños con implante coclear en español (PI-4725). Med-El Elektromedizinische Gerate GmbH. 2021-Ongoing.

Managment centre: FIBHULP

Lassaletta Atienza L. Parálisis facial periférica aguda en el contexto de la pandemia por SARS-CoV-2 (PI-4632). Varios financiadores. 2021-2023.

Managment centre: FIBHULP

Lassaletta Atienza L. Programación Remota para implante coclear MED-EL durante la pandemia por la COVID-19 (PI-4985). Med-El Elektromedizinische Gerate GMBH. 2021-2022.

Managment centre: FIBHULP

Murillo Cuesta S. Delivery of Antisense RNA Therapeutics (CA17103). COST Action (EU). 2018-2022.

Managment centre: Biocruces Bizkaia Health Research Institute

Murillo Cuesta S. Grupo de Trabajo Modelos murinos para el estudio de enfermedades raras (ERP1PDI761). CIBERER. 2020-2022.

Managment centre: CIBERER

Rey Herranz JA. Contrato Miguel Servet Categoría A (CES05/027). ISCIII. 2006-2025.

Managment centre: FIBHULP

Rodríguez de la Rosa L. Grupo de Trabajo Edición Genómica y Terapia Génica (ERP1PDI755). CIBERER. 2020-2022.

Managment centre: CIBERER

Sánchez Cuadrado IP. Validación al español de la escala de valoración clínica eFACE y del SunnyBrook Facial Grading System (PI20/01032). ISCIII. 2020-2023.

Managment centre: FIBHULP

Varela Nieto I, Murillo Cuesta S. Bases genéticas y moleculares de la sordera neurosensorial y del daño auditivo: exploración de nuevas dianas y estrategias terapéuticas (T-HEARPY) (PID2020-115274RB-I00). MCIN/AEI/10.13039/501100011033. 2021-2024.

Managment centre: CSIC

Varela Nieto I, Murillo Cuesta S. Scientific research and development services in the field of hearing loss (ERP17PE12). SPIRAL Therapeutix. 2017-2021.

Managment centre: CIBERER

Varela Nieto I. A sound proteome for a sound body: targeting proteolysis for proteome remodeling (ProteoCure) (CA20113). COST. EU Framework Programme Horizon 2020. 2021-2025.

Managment centre: Centro de Investigación Príncipe Felipe

Varela Nieto I. Ayuda para la realización de doctorado industrial para la Agencia

Estatal Consejo Superior de Investigaciones Científicas y la empresa Alodia Farmaceutica S.L (IND2020/BMD-17454). Agencia Estatal CSIC. Aloda Farmacéutica S.L. 2020-2023.

Managment centre: CSIC

Varela Nieto I. Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases (BenBedPhar) (CA20121). COST. EU Framework Programme Horizon 2020. 2021-2025.

Managment centre: UAM

Varela Nieto I. Grupo de Trabajo Desarrollo de nuevas herramientas terapéuticas basadas en RNA para el tratamiento de enfermedades raras (ERP1PDI756). CIBERER. 2020-2022.

Managment centre: CIBERER

Varela Nieto I. Imagen multimodal de la respuesta terapéutica a estrategias multidiana en enfermedades neurológicas (MULTITARGET&VIEWCM) (B2017/BMD-3688). CAM. 2018-2022.

Managment centre: IIB Alberto Sols

Varela Nieto I. Prueba de concepto para determinar el efecto de la Colesteronitrona F2 en el tratamiento de la Presbiacusia (NITROPROHEAR). (0551_PSL_6_E). EU Framework programme Horizon 2020. 2020-2021.

Managment centre: CSIC

Varela Nieto I. Senescencia celular: mecanismos y terapias (SENESTHERAPY) (RED2018-102698-T). Ministerio de Ciencia, Innovación y Universidades. 2018-2022.

Managment centre: Fundacio Institut de Recerca Biomedica

■ Cibers & Retics

Varela Nieto I. Centro de Investigación en Red de Enfermedades Raras. (CB06/07/1021). ISCIII. (31/12/2021).



Managment centre: FIBHULP

■ Patents and trademarks

Polak M, Roca-Ribas Serdá F, Gavilán Bouzas J, Lassaletta Atienza L, Miró Castillo N, Rodrigo Dacosta J, inventors; MED-EL Elektromedizinische Gerate GmbH, assignee. Hearing treatment in patients with questionable cochlear nerve functionality. US2011275953, PCT/US2011/035312; 2010 May 05.


Cobo Parra P, Varela Nieto I, Murillo-Cuesta S, Navares Zaera R, Martínez Vega R, Cediél Algovia R, inventors; CSIC, UCM, assignees. Anechoic acoustic chamber for evaluating the auditory function in laboratory animals. P201031720; 2010 November 23.

Cobo Parra P, Varela Nieto I, Murillo-Cuesta S, Cediél Algovia R, inventors; CSIC, UCM, assignees. Method for designing a reverberating acoustic chamber for hearing test with animals. Procedimiento para diseñar una cámara acústica reverberante para ensayos auditivos con animales. P200802895, PCT/ES2009/070433; 2008 October 14.



3.5.5 Cancer Molecular Pathology and Therapeutic Targets Group

Publications: 23
Q1: 9



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

COMPOSITION

■ **David Hardisson Hernández.** Jefe de Servicio de Anatomía Patológica. Hospital Universitario La Paz. Catedrático. Facultad de Medicina. Universidad Autónoma de Madrid

Alberto Berjón García. Médico Adjunto Especialista de Área en Anatomía Patológica. Hospital Universitario La Paz

Javier de Santiago García. Jefe de Servicio de Ginecológica Oncológica. Hospital Universitario La Paz. Profesor Asociado. Facultad de Medicina. Universidad Autónoma de Madrid

Laura Guerra Pastrán. Médico Adjunto Especialista de Área en Anatomía Patológica. Hospital Universitario La Paz

José Juan Pozo Kreilinger. Facultativo Especialista de Área en Anatomía Patológica. Hospital Universitario La Paz

Jorge Martín Pérez. Investigador Científico IIB "Alberto Sols"

Marta Mendiola Sabio. Investigadora Postdoctoral. Hospital Universitario La Paz

María Miguel Martín. Técnico de Laboratorio. Hospital Universitario La Paz

Alberto Peláez García. Investigador Postdoctoral. Hospital Universitario La Paz

Elia Pérez Fernández. Investigadora Predoctoral. Hospital Universitario La Paz


José Ignacio Sánchez Méndez. Jefe de Sección de Ginecología y Obstetricia. Hospital Universitario La Paz. Profesor Asociado. Facultad de Medicina. Universidad Autónoma de Madrid

Laura Yébenes Gregorio. Médico Adjunto Especialista de Área en Anatomía Patológica. Hospital Universitario La Paz

STRATEGIC OBJECTIVE

The fundamental interest of our research group is centered in the

study of molecular biomarkers that have a direct implication in the handling of the cancer patients with the last aim to identify and to validate therapeutic targets.



1
Introduction

2
Executive
Summary

3
Information
Groups
by Area

4
Associated
Clinicians

Ovarian cancer Research Line

The ovarian carcinoma is the main cause of gynecological cancer mortality in the western societies. Nevertheless, the classic parameters are imperfect predictors for patients outcome, partly due to the complexity of the molecular genetic events that sublie these tumors and to the fact that they are not totally known. Research on this field could identify more precise markers to correctly stratify the patients according to their probability to recur and response to treatments.

Angiogenesis, epithelial to mesenchymal transition and hypoxia are processes demonstrated to have an important role in the development of these tumors. The main objective of this line of investigation, therefore, is to identify discrete markers or gene expression profiles related to these events, with predictive and prognostic value for ovarian cáncer patients.


Endometrial cancer Research Line

Endometrial carcinoma is the fourth most common cancer in women in the developed world. Histomorphologic criteria are not strongly enough tools to distinguish more aggressive tumors. Based on molecular characterization, risk stratification systems could be useful for decision making.

The main objective of this line of investigation, therefore, is to identify molecular markers with predictive and prognostic value for endometrial cancer patients.

Breast cancer Research Line

C-Src is sobreexpressed and/or hyperactive in breast carcinoma biopsies and their implication in the tumorigenesis has been proved in murine models.



Our studies on genetically modified human breast cancer cells and mice can establish the relevance of the function of scaffolding of SFKs in breast cancer. In addition, our work can lead to the development of new prognosis and therapeutic tools to improve the treatment of the breast cancer.

Angiogenesis and breast cancer. Angiogenesis is a key process in tumor development. Our group has been working for years on the search of biomarkers related to this process. Specifically on breast cancer, it is important to identify patients that will benefit of evacizumab containing regimes.

Sarcomas Research Line

Bone and Soft tissue sarcomas includes a group of heterogeneous pathologies that were traditionally treated in the same way. The clinical investigation has allowed the identification of sub-groups with different response to treatments. The objective of this line of work is to find biomarkers for the best stratification of the patients, as well as to get a better knowledge of the molecular mechanisms for the development of these tumors.

Neuroendocrine tumors Research Line.


The neuroendocrine tumors (NET) include heterogeneous neoplasias, regarding morphologic and functionally features. They constitute a challenge for the medical management, mainly regarding diagnose and handling. Although we have improve the knowledge of molecular events related to their development in the last decade, we need to better known this tumors, in order to establish an early detection, that it improves the rates of survival.

In vitro 2- and 3D cell culture models for functional studies.

The identification of potential markers in different pathologies might be complemented by functional studies, focused on the characterization of cancer and estromal cell features, important for tumor development that it improves the rates of survival.

RESEARCH LINES

- Ovarian and endometrial cancer
- Breast cancer
- Sarcomas
- Neuroendocrine tumors
- New in vitro models of disease



RESEARCH ACTIVITY

1
Introduction

2
Executive
Summary

3
Information
Groups
by Area

4
Associated
Clinicians



■ Publications


- Ahmad H, Vilanova-Sánchez A, Amengual I, Guerra-Pastrián L, Garrido-Pontnou M, Montalvo C, Bueno A, Langer J, Woods RJ, Levitt MA. Skip segment hirschsprung disease managed by pull-through of the right colon. *European J Pediatr Surg Rep.* 2021; 9(1): E28-32. Article. Not Indexed
- Andrés AM, Stringa P, Talayero P, Santamaria M, García-Arranz M, Gómez-Heras SG, Largo-Aramburu C, Aras-López RM, Vallejo-Cremades MT, Pastríán LG, Vega L, Encinas JL, López-Santamaria M, Hernández-Oliveros F. Graft infusion of adipose-derived mesenchymal stromal cells to prevent rejection in experimental intestinal transplantation: A feasibility study. *Clin Transplant.* 2021; 35(4): e14226. Article. IF: 3.456; Q2
- Dajti I, Valenzuela JI, Boccalatte LA, Gemelli NA, Smith DE, Dudi-Venkata NN, Kroon HM, Sammour T, Roberts M, Mitchell D, Lah K, Pearce A, Carrasco-Prats M, Gimenez-Francois C, Ruiz-Marin M, Fernández-López AJ (et al). Machine learning risk prediction of mortality for patients undergoing surgery with perioperative SARS-CoV-2: the COVIDSurg mortality score. *Brit J Surg.* 2021; 108(11): 1274-92. Article. IF: 11.122; D1

- Diestro MD, Berjón A, Zapardiel I, Yébenes L, Ruiz I, Lekuona A, Rezola M, Jaunarena I, Siegrist J, Sánchez-Pastor M, Cuadra M, Sagasta A, Guerra I, Lete LI, Roldán F, Marta CB, Boillos M, Cardiel M, López-de la Manzanara C, Relea F, Coronado P, Pascual A, Román M, Peiro G, Matute L, Montero B, Muruzabal J, Guarch R, Zorrero C, Calatrava A, Ribot L, Costa I, Hernández A, Hardisson D. One-step nucleic acid amplification (osna) of sentinel lymph node in early-stage endometrial cancer: spanish multicenter study (ENDO-OSNA). *Cancers (Basel).* 2021; 13(17): 4465. Article. IF: 6.575; Q2
- Escudero A, Ruz-Caracuel B, Bueno D, Martínez M, Rubio P, Regojo RM, Antolin E, Ybarra M, Martínez L, Pozo-Kreiling JJ, Elorza MD, Pellicer A, Omeñaça F, Pérez-Martínez A. Genetic predisposition to fetal and neonatal cancer. *Clin Transl Oncol.* 2021; 23(6): 1179-84. Article. IF: 3.34; Q3
- Escudero J, Heredia-Soto V, Wang YY, Ruiz P, Hu YY, Gallego A, Pozo-Kreiling JJ, Martínez-Marin V, Berjón A, Ortiz-Cruz E, Bernabéu D, Felú J, Tang J, Redondo A, Mendiola M. Eribulin activity in soft tissue sarcoma monolayer and three-dimensional cell line models: could the combi-

- Diestro MD, Berjón A, Zapardiel I, Yébenes L, Ruiz I, Lekuona A, Rezola M, Jaunarena I, Siegrist J, Sánchez-Pastor M, Cuadra M, Sagasta A, Guerra I, Lete LI, Roldán F, Marta CB, Boillos M, Cardiel M, López-de la Manzanara C, Relea F, Coronado P, Pascual A, Román M, Peiro G, Matute L, Montero B, Muruzabal J, Guarch R, Zorrero C, Calatrava A, Ribot L, Costa I, Hernández A, Hardisson D. One-step nucleic acid amplification (osna) of sentinel lymph node in early-stage endometrial cancer: spanish multicenter study (ENDO-OSNA). *Cancers (Basel).* 2021; 21(1): 646. Article. IF: 6.436; Q2
- Fernández-Acenero MJ, Barderas R, García AP, Martínez-Useros J, Díez-Valladares L, Pérez-Aguirre, Medina LO, Esteban SD, García-Botella S, del Arco CD, Galindo C. Aryl hydrocarbon receptor interacting protein (AIP) significantly influences prognosis of pancreatic carcinoma. *Ann Diagn Pathol.* 2021; 53: 151742. Article. IF: 2.134; Q3
- Gallego A, Garrido D, Yébenes L, Mendiola M, Castelo B, Redondo A. Long-term response to olaparib in BRCA1-related ovarian cancer with brain metastases. *Int J Gynecol Cancer.* 2021; 31(9): 1292-6. Article. IF: 4.661; Q1
- Gil-Moreno A, Alonso-Alconada L, Díaz-Feijoo B, Domingo S, Vilar A, Hernández A, Gilbert J, Lluca A, Torne A, de Santiago J, Carbonell-Socias M, Lago V, Arias E, Sampayo V, Siegrist J, Chipirliu A, Sánchez-Iglesias JL, Pérez-Benavente A, Padilla-Iserte P, Santacana M, Matias-Guiu X, Abal M, López-López R. M-TRAP: Safety and performance of metastatic tumor cell trap device in advanced ovarian cancer patients. *Gynecol Oncol.* 2021; 161(3): 681-6. Article. IF: 5.304; Q1
- Glasbey JC, Omar O, Nepogodiev D, Minaya-Bravo A, Bankhead-Kendall BK, Fiore M, Futaba K, Gabre-Kidan A, Gujjuri RR, Isik A, Kaafarani HMA, (et al) Lamb B, Liu S, Luke L. Preoperative

nasopharyngeal swab testing and postoperative pulmonary complications in patients undergoing elective surgery during the SARS-CoV-2 pandemic. *Brit J Surg.* 2021; 108(1): 88-96. Article. IF: 11.122; D1

- López-Janeiro A, Ruz-Caracuel I, Ramón-Patino JL, de los Ríos V, Esparza MV, Berjón A, Yébenes L, Hernández A, Masetto I, Kadioglu E, Goubert V, Heredia-Soto V, Barderas R, Casal JI, de Andrea CE, Redondo A, Mendiola M, Pelaez-García A, Hardisson D. Proteomic analysis of low-grade, early-stage endometrial carcinoma reveals new dysregulated pathways associated with cell death and cell signaling. *Cancers (Basel).* 2021; 13(4): 794. Article. IF: 6.575; Q2
- Marti C, Sánchez-Méndez JI. The present and future of neoadjuvant endocrine therapy for breast cancer treatment. *Cancers (Basel).* 2021; 13(11): 2538. Review. IF: 6.575; Q2
- Mayoral-Varo V, Sánchez-Bailón MP, Calcabrini A, García-Hernández M, Frezza V, Martín ME, González VM, Martín-Pérez J. The Relevance of the SH2 domain for c-src functionality in triple-negative breast cancer cells. *Cancers (Basel).* 2021; 13(3): 462. Article. IF: 6.575; Q2
- Povedano E, Gamella M, Torrente-Rodríguez RM, Montiel VRV, Montero-Calle A, Solís-Fernández G, Navarro-Villoslada F, Peláez-García A, Mendiola M, Hardisson D, Feliú J, Barderas R, Pingarrón JM, Campuzano S. Multiplexed magnetic beads-assisted amperometric bioplatforams for global detection of methylations in nucleic acids. *Anal Chim Acta.* 2021; 1182: 338946. Article. IF: 6.911; Q1
- Rodríguez-Antolíñ C, Rosas-Alonso R, Cruz P, Higuera O, Sánchez-Cabrero D, Esteban-Rodríguez I, Peláez-García A, Montano VEF, Rodríguez-Jiménez C, de Caceres II, de Castro J. Novel SLC12A2-ROS1 fusion in non-small cell lung cancer with a significant response to crizotinib: the importance of choosing the appropriate next-generation sequencing assay. *Oncologist.* 2021; 26(6): E908-12. Article. IF: 5.837; Q2
- Roig CA, Cordón JP, Gallego MA, Pastríán LG. Ileal endometriosis in a patient with Crohn's disease: a diagnostic challenge. *Rev Esp Enferm Dig.* 2021; 113(12): 847. Letter. IF: 2.389; Q4
- Ruz-Caracuel I, López-Janeiro A, Heredia-Soto V, Ramón-Patino JL, Yébenes L, Berjón A, Hernández A, Gallego A, Ruiz P, Redondo A, Peláez-García A, Mendiola M, Hardisson D. Cli-



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

nicopathological features and prognostic significance of CTNNB1 mutation in low-grade, early-stage endometrial endometrioid carcinoma. *Virchows Arch.* 2021; 479(6): 1167-76. Article. IF: 4.535; Q2

- San Segundo-Acosta P, Montero-Calle A, Jernbom-Falk A, Alonso-Navarro M, Pin E, Andersson E, Hellstrom C, Sánchez-Martínez M, Rabano A, Solís-Fernández G, Peláez-García A, Martínez-Useros J, Fernández-Acenero MJ, Manberg A, Nilsson P, Barderas R. Multiomics profiling of alzheimer's disease serum for the identification of autoantibody biomarkers. *J Proteome Res.* 2021; 20(11): 5115-30. Article. IF: 5.37; Q1
- Sánchez MDC, Gómez VG, Urgelles AS, de Sábando DPL, Aparicio PR, Martínez LM, Gamarra EA, Kreilinger JJP, Zapata RMR, Gutiérrez JCL, Alvarado EA, Martín FG, Torres AMS, Manzano EM, del Valle LG, Pérez-Martínez A. Treatment of infantile fibrosarcoma associated to an abdominal aortic aneurysm with larotrectinib: a case report. *Pediatr Hemat Oncol.* 2021; 38(5): 504-9. Article. IF: 2.07; Q3
- Tabiri S, Kamarajah SK, Nepogodiev D, Li E, Simoes J, Sravanam S, Owusu SA, Mahama H, Agyeman YN, Arthur J, Kunfah SM, Fernández-Candela A, Curtis-Martínez C, Soler-Silva A, Oller A, Triguero-Canovas D, Bosch-Ramírez M, Lillo C, Lario S, Arroyo A, Segura-Illa ME, Aniceto GS, Castano-Leon AM, Jiménez-Roldan L, Fernández JD (et al). Impact of Bacillus Calmette-Guerin (BCG) vaccination on postoperative mortality in patients with perioperative SARS-CoV-2 infection. *BJS Open.* 2021; 5(6): zrab131. Letter. IF: 3.875; Q1
- Trilla-Fuertes L, Gámez-Pozo A, Maurel J, García-Carbonero R, Capdevila J, G-Pastrían L, Mendiola M, Pena C, López-Vacas R, Cuatrecasas M, García-Alfonso P, Ramos-Ruiz R, Llorens C, Ghanem I, Conill C, Heredia-Soto V, Campos-Barros A, Vara JAF, Feliú J. Description of the genetic variants identified in a cohort of patients diagnosed with localized anal squamous cell carcinoma

and treated with panitumumab. *Sci Rep-Uk.* 2021; 11(1): 7402. Article. IF: 4.996; Q2

- Zapardiel I, Boria F, Halaska MJ, de Santiago J. Laparoscopic power morcellation: techniques to avoid tumoral spread. *J Minim Invas Gyn.* 2021; 28(8): 1442-3. Editorial Material. IF: 4.314; Q1
- Zapardiel I, Kocian R, Kohler C, Klat J, Germanova A, Jacob A, Bajsova S, Bohmer G, Lay L, Gil-Ibanez B, Havelka P, Kipp B, Szweczyk G, Toth R, Staringer JC, de Santiago J, Coronado PJ, Poka R, Laky R, Luyckx M, Fastrez M, Dusek L, Hernández A, Cibula D. Voiding recovery after radical parametrectomy in cervical cancer patients: An international prospective multicentre trial - SENTIX. *Gynecol Oncol.* 2021; 160(3): 729-34. Article. IF: 5.304; Q1

Research projects

Guerra Pastrían L. Desarrollo de tareas de revisión patológica nacional del ensayo clínico Paediatric Hepatic International Tumour Trial (PHITT). Fundación para la Investigación Biomédica de Córdoba Fibioc. 2019-Ongoing.

Management centre: FIBHULP

Hardisson Hernández D. Aplicabilidad de la proteogenómica en la progresión del carcinoma endometriode de endometrio diagnosticado en estadios iniciales (P117/01723). ISCIII. 2018-2021.

Management centre: FIBHULP

Hardisson Hernández D. Riesgo de recaída en pacientes con carcinoma de mama primario HER2 negativo y receptores esrogénicos positivos: estudio compara-

tivo de dos perfiles de expresión génica (Mammaprint® y Endopredict®). Fundación Sociedad Española de Anatomía Patológica. 2019-Ongoing.

Management centre: FIBHULP

Mendiola Sabio M. Hardisson Hernández D. Identificación de biomarcadores en cáncer de pulmón no microcítico. AstraZeneca Farmacéutica Spain S. A. 2020-Ongoing.

Management centre: FIBHULP

Mendiola Sabio M. Exploration of 2 and 3d models of angiosarcoma and their farcological sdreening. Grupo Español de Investigación en Sarcomas. 2019-Ongoing.

Management centre: FIBHULP

Mendiola Sabio M. Identificación de perfiles de expresión génica diferencial relacionados con la angiogénesis entre el carcinoma de ovario primario y sus metástasis. Ortomedimatec. 2012-Ongoing.

Management centre: FIBHULP

Mendiola Sabio M. Papel de RANKL en el sarcoma de Ewing: un estudio in vitro para la confirmación de una nueva diana terapéutica. Grupo Español de Investigación en Sarcomas. 2012-Ongoing.

Management centre: FIBHULP

Mendiola Sabio M. Realización de técnicas de detección de expresión proteica el

IGTP. Construcción de matrices tisulares y tinciones con anticuerpos específicos. Fundacio Institut Dínvestigació én Ciéncies de la S. A.lut Germans Trias I Pujol. 2015-Ongoing.

Management centre: FIBHULP


Mendiola Sabio M. Identificación de marcadores de HRD y predicción de la respuesta a inhibidores dePARP en líneas celulares establecidas y organoides derivados de pacientes con cancer de ovario. Grupo Español de Investigacion Cancer de Ovario (GEICO). 2021-Ongoing.

Management centre: FIBHULP

Patents and trademarks

Redondo Sánchez A, Hardisson Hernández D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the prediction of a patient's clinical response to an anticancer treatment. P200930400; 2009 July 01.


Redondo Sánchez A, Hardisson Hernández D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the prediction of a patient's pathological response to an anticancer treatment. P200930438; 2009 July 10.



3.5.6 Mechanisms of Tumour Progression Group

Publications: 11

Q1: 7



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

COMPOSITION

Gema Moreno Bueno. Profesora Titular. Universidad Autónoma de Madrid

David Albandea Rodríguez. Investigador Predoctoral. IIB "Alberto Sols"

Antonio Barbachano Becerril. Investigador Postdoctoral. IIB "Alberto Sols"

Pilar de la Paz Bustamante Madrid. Investigadora Predoctoral. IIB "Alberto Sols"

Alba Costales Carrera. Investigador Predoctoral. IIB "Alberto Sols"

Patricia Carrasco Ramírez. Investigadora Predoctoral. IIB "Alberto Sols"

Eva Díaz Martín. Investigador Predoctoral. Fundación MD Anderson International España

Gemma Domínguez Muñoz. Profesora contratada. Universidad Autónoma de Madrid

Asunción Fernández Barral. Investigadora Postdoctoral. IIB "Alberto Sols"

Gemma Ferrer Mayorga. Investigadora Postdoctoral. IIB "Alberto Sols"

Alfredo Floristán Muruzábal. Investigador Predoctoral. IIB "Alberto Sols"

Pablo García Sanz. Investigador Postdoctoral. IIB "Alberto Sols"

José Manuel González Sancho. Profesor Titular. Universidad Autónoma de Madrid

Patricia González Santamaría. Investigadora Postdoctoral. Universidad Autónoma de Madrid

Marta Hergueta Redondo. Investigadora Predoctoral. Universidad Autónoma de Madrid

María Jesús Larriba Muñoz. Científica Titular. IIB "Alberto Sols"

Ester Martín Villar. Investigadora Postdoctoral. IIB "Alberto Sols"

Saleta Morales Dolores. Técnico de Laboratorio. Universidad Autónoma de Madrid

Alba Mota Jiménez. Investigadora Predoctoral. IIB "Alberto Sols"

Alberto Muñoz Terol. Profesor de Investigación. IIB "Alberto Sols"

Eva Pérez Cuevas. Investigadora Postdoctoral. IIB "Alberto Sols"

Sara Oltra Sanchís. Investigador Postdoctoral. Universidad Autónoma de Madrid

Francisco Portillo Pérez. Catedrático. Departamento de Bioquímica. Facultad de Medicina. Universidad Autónoma de Madrid


Miguel Quintanilla Ávila. Profesor de Investigación. IIB "Alberto Sols"

Carmen Ramos Nebot. Investigadora Predoctoral. Universidad Autónoma de Madrid

José David Sarrío López. Investigador Postdoctoral. IIB "Alberto Sols"

Laura Sin Diz. Investigadora Postdoctoral. Fundación MD Anderson International España

Alberto Vázquez Naharro. Investigador Predoctoral. Universidad Autónoma de Madrid



1
Introduction

STRATEGIC OBJECTIVE

Study of novel resistance mechanisms.

Analysis of tumor invasion and metastasis mechanisms in solid tumors.

Caracterización de nuevos biomarcadores en carcinomas de mama y ginecológicos.

Design of new targeted therapies to biomarkers formerly characterized by the group.

Characterization of EMT processes in tumor metastasis.

Characterize vitamin D action in stem cells and tumor microenvironment in colorectal cancer.

RESEARCH LINES

- Characterization of new resistance mechanism in breast tumors (HER2+).
- Intratumor heterogeneity study in different types of tumors.
- Cell plasticity and tumor metastasis.
- Study of vitamin D effects on patient-derived colon normal and cancer-associated fibroblasts and organoids.
- Identificación de marcadores de diagnóstico precoz en biopsia líquida en cáncer colorrectal.

2
Executive
Summary

RESEARCH ACTIVITY

■ Doctoral theses

Master Theses

Torres B. Prognostic and predictive role of Gasdermin B in cancer[dissertation]. Madrid: UAM: 2021(16/09/2021).

Director: Moreno Bueno G.

Final Degree Theses

Pizarro P. LOXL2 interacts with HuR to promote SOX9 mRNA stability[dissertation]. Madrid: UAM: 2021(15/06/2021).

Director: Portillo Pérez F

Jiménez Carretero V. Dominios de loxl2 implicados en la interacción proteína-proteína[dissertation]. Madrid: UAM: 2021(23/05/2021).

Director: Portillo Pérez F.

■ Publications

- Barbachano A, Fernández-Barral A, Bustamante-Madrid P, Prieto I, Rodríguez-Salas N, Larriba MJ, Muñoz A. Organoids and colorectal cancer. *Cancers (Basel)*. 2021; 13(11): 2657. Review. IF: 6.575; Q2

- García-Estévez L, Calvo I, Pérez S, Gallegos I, Díaz E, Sampayo-Cordero M, Oltra SS, Moreno-Bueno G. Predictive role of leptin receptor (OB-R) overexpression in patients with early breast cancer receiving neoadjuvant systemic treatment. *Cancers (Basel)*. 2021; 13(13): 3269. Article. IF: 6.575; Q2
- García-Estévez L, Cortés J, Pérez S, Calvo I, Gallegos I, Gema B. Obesity and breast cancer: a paradoxical and controversial relationship influenced by menopausal status. *Front Oncol*. 2021; 11: 705911. Review. IF: 5.738; Q2
- García-Estévez L, González-Martínez S, Moreno-Bueno G. The leptin axis and its association with the adaptive immune system in breast cancer. *Front Immunol*. 2021; 12: 784823. Review. IF: 8.786; Q1
- López-Menéndez C, Vázquez-Naharro A, Santos V, Dubus P, Santamaría PG, Martínez-Ramírez A, Portillo F, Moreno-Bueno G, Faraldo MM, Cano A. E2A modulates stemness, metastasis, and therapeutic resistance of breast cancer. *Cancer Res*. 2021; 81(17): 4529-44. Article. IF: 13.312; D1
- Rodríguez-Cobos J, Vinal D, Poves C, Fernández-Acenero MJ, Peinado H, Pastor-Morate D, Prieto MI, Barderas R, Rodríguez-Salas N, Domínguez G. Delta Np73, TAp73 and delta 133p53 extracellular vesicle cargo as early diagnosis markers in colorectal cancer. *Cancers (Basel)*. 2021; 13(9): 2240. Article. IF: 6.575; Q2
- Rosas-Alonso R, Colmenarejo-Fernández J, Perriera O, Rodríguez-Antolín C, Esteban I, Ghanem I, Sánchez-Cabrero D, Losantos-García I, Palacios-Zambrano S, Moreno-Bueno G, de Castro J,

Martínez-Marín V, Ibáñez-de-Cáceres I. Clinical validation of a novel quantitative assay for the detection of MGMT methylation in glioblastoma patients. *Clin Epigenetics*. 2021; 13(1): 52. Article. IF: 7.259; Q1

- Royo F, Azkargorta M, Lavín JL, Clos-García M, Cortazar AR, González-López M, Barcena L, del Portillo HA, Yáñez-Mo M, Marcilla A, Borrás FE, Peinado H, Guerrero I, Vales-Gómez M, Cereijo U, Sardon T, Aransay AM, Elortza F, Falcon-Pérez JM. Extracellular vesicles from liver progenitor cells downregulates fibroblast metabolic activity and increase the expression of immune-response related molecules. *Front Cell Dev Biol*. 2021; 8: 613583. Article. IF: 6.081; Q1
- Sarrio D, Martínez-Val J, Molina-Crespo A, Sánchez L, Moreno-Bueno G. The multifaceted roles of gasdermins in cancer biology and oncologic therapies. *Bba-Rev Cancer*. 2021; 1876(2): 188635. Review. IF: 11.414; D1
- Suárez H, Andréu Z, Mazzeo C, Toribio V, Pérez-Rivera AE, López-Martín S, García-Silva S, Hurtado B, Morato E, Pelaez L, Arribas EA, Tolentino-Cortez T, Barreda-Gómez G, Marina AI, Peinado H, Yanez-Mo M. CD9 inhibition reveals a functional connection of extracellular vesicle secretion with mitophagy in melanoma cells. *J Extracell Vesicles*. 2021; 10(7): e12082. Article. IF: 17.337; D1
- Zamudio-Martínez E, Herrera-Campos AB, Muñoz A, Rodríguez-Vargas JM, Oliver FJ. Tankyrases as modulators of pro-tumoral functions: molecular insights and therapeutic opportunities. *J Exp Clin Canc Res*. 2021; 40(1): 144. Review. IF: 1.658; D1

■ Research projects

Moreno Bueno G, Matías-Guiu X. Targeting the most aggressive type of endometrial carcinoma. (GCTRA18014MATI). AECC. 2018-2024.

Management centre: FMDA-UAM

Moreno Bueno G. Molecular characterization of Gasdermin B cytotoxic activity and its potential application for the treatment of cancer (GB-citoTOX). (PID2019-104644RB-I00). MICINN. 2020-2023.

Management centre: UAM


Moreno Bueno G. Targeting Gasdermin-B overexpression as a new therapeutic approach in Her2+ cancers. (AECCINVEST-2019GMB). AECC. 2019-2022.

Management centre: UAM

Domínguez Muñoz G. Identificación de los mecanismos implicados en la diseminación peritoneal del cáncer colorrectal. Papel de Deltanp73: implicaciones diagnósticas, pronósticas y terapéuticas (PI18/00473). ISCIII. 2019-2021.

3
Information
Groups
by Area

4
Associated
Clinicians



1
Introduction

2
Executive
Summary

3
Information
Groups
by Area

4
Associated
Clinicians

Managment centre: FIBHULP

Muñoz Terol A, Larriba Muñoz MJ. Estudio de los efectos de la vitamina D en la fisiología y patología del colon humano usando organoides y cultivos primarios de fibroblastos derivados de pacientes (PID2019-104867RB-I00). MICINN. 2020-2023.

Managment centre: CSIC

Rodríguez Salas N, Muñoz Terol A. Cáncer colorrectal en población joven. Estudio farmacogenómico en organoides y efectos del microambiente tumoral (ICI20/00057). ISCIII. 2021-2024.

Managment centre: FIBHULP

Portillo Pérez F. LOXL2 y LOXL3: Descubriendo nuevas vulnerabilidades terapéuticas en la progresión tumoral (PID2019-111052RB-I00). MICINN. 2020-2023.

Managment centre: UAM

■ Cibers & Retics

Cano García A, Moreno Bueno G. Networked Biomedical Research Center for Cancer (CIBERonc). ISCIII. (31/12/2022).

Managment centre: FIBHULP

Muñoz Terol A. Networked Biomedical Research Center for Cancer (CIBERonc). ISCIII. (31/12/2022).

Managment centre: FIBHULP

Muñoz Terol A. Red Temática de Receptores Nucleares en Cáncer, Metabolismo e Inflamación. (NuRCaMeIn). Ministerio de Ciencia, Innovación y Universidades (31/12/2020).

Managment centre: FIBHULP

■ Patents and trademarks

García García JF, Martín Moreno AM, Roncador G, Martínez Torrecuadra JL, Moreno Bueno G, inventors; Fundación MD Anderson International España, Fundación Centro Nacional de Investigaciones Oncológicas (CNIO), assignees; Method for the diagnosis and/or prognosis of lymphomas. P201231304; 2012 August 14.

Hergueta Redondo M, Sanz PG, Rojo A, García JF, Moreno-Bueno G, inventors; UAM, CSIC, Fundación MD Anderson International España, assignees; Gasdermin B2 as a new biomarker of malignance and resistance of Trastuzumab inhibitor in Her2+ tumors. P201231560; 2012 October 10.

Matías-Guiu Guía FJ, Dolcet Roca FJ, Reventós Puigjaner J, Colás Ortega E, Prat Díaz de Losada J, Palacios Calvo J, Abal Posada M, López López R, Moreno Bueno G, Gil Moreno A, inventors; Institut de Recerca Biomèdica de Lleida Fundació Doctor Pi-farré, Universitat deLleida, Fundació Hospital Universitari Vall d'Hebron-Institut de Recerca, Fundació Institut de Recerca de L'Hospital de la Santa Creu i Sant Pau, Servicio Andaluz de



Salud, Servizo Galego de Saúde, Fundación MD Anderson International España, assignees. Method to predict risk of recurrence in endometrial carcinoma. Annexin-A2 as predictor biomarker of recurrent disease in endometrial cancer. EP14155510.2, PCT/EP2015/053387; 2014 February 18.

Olmeda Casadomé D, Moreno Bueno G, Portillo Pérez F, Cano García

A, inventors; UAM, CSIC, assignees. Method for the diagnosis and/or prognosis of breast cancer. P200702342, PCT/ES2008/000563; 2007 August 28.

Olmeda Casadomé D, Peinado Selgas H, Portillo Pérez F, Nieto Toledano MA, Cano García A, inventors; UAM, assignee. Materials and methods for the derepression of the Ecadherin promoter. US20060003956; 2004 March 03.






3.5.7 Animal and Cell Models for Detection and Characterisation of Leukemic Stem Cells Group

Publications: 18

Q1: 9



COMPOSITION

■ **Carmela Calés Bourdet.** Catedrática, Departamento de Bioquímica. Facultad de Medicina. Universidad Autónoma de Madrid

Mónica Bravo Madrigal. Investigadora Predoctoral. Universidad Autónoma de Madrid

Miguel Ramón Campanero García. Investigador Científico. Centro de Biología Molecular "Severo Ochoa2"

Miguel Ángel Canales Albendea. Jefe de Sección de Hematología. Hospital Universitario La Paz

Raquel de Paz Arias. Facultativo Especialista de Área en Hematología. Hospital Universitario La Paz

Bárbara Fernández Morales. Investigadora Predoctoral. Universidad Autónoma de Madrid

Dolores Hernández Maraver. Facultativo Especialista de Área en Hematología. Hospital Universitario La Paz

Ana Kerguelen Fuentes. Facultativo Especialista de Área en Hematología. Hospital Universitario La Paz

Yenny Montenegro Medina. Investigadora Postdoctoral. Universidad Autónoma de Madrid

Marta Morado Arias. Técnico de Laboratorio. Hospital Universitario La Paz

Gema Pérez Chacón. Investigadora Postdoctoral. IIB "Alberto Sols"

Juan Manuel Zapata Hernández. Científico Titular. IIB "Alberto Sols"

STRATEGIC OBJECTIVE

Proper homeostasis of stem cells and pluripotent progenitor is pivotal to the development of haematopoietic proliferative disorders such as myelodysplastic or myeloproliferative syndromes, leukaemia and lymphoma. It is well known that alterations in transcriptional programs lead to transformed phenotypes, which are at the basis of the insidious acquisition of stem-like phenotypes of immature cells. Our group is interested in the role of transcriptional regulators, global regulators such as c-myc, c-myb, E2F and epigenetic controllers such

as PcG factors in limiting the self-renewal capacity of common myeloid and lymphoid progenitors.


Our group has two main activities: basic research aimed to unravel the molecular mechanisms responsible for the acquisition of malignant haematological phenotypes (mouse models as well as ex vivo cell models to approach the questions outlined above); and research aimed to document clinical parameters and molecular markers that may be of use to a better understanding of the progression and outcome of haematological diseases, mainly myelodysplasia, lymphoma and multiple myeloma.

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



RESEARCH LINES

- Role of epigenetic and transcriptional regulators in myelodysplasia: cellular and animal models

- Molecular and cellular basis of lymphoid neoplasias: non Hodgkin lymphomas and chronic lymphocytic leukaemia.
- Molecular markers of haematological malignancies

RESEARCH ACTIVITY

■ Doctoral theses

Jiménez Gómez L. Funciones de las subunidades específicas de complejos Polycomb vPRC1, RYBP y YAF2, en el establecimiento y mantenimiento de estados inmortalizados leucémicos [dissertation]. Madrid: UAM: 2021(02/06/2021).

Director: Calés Bourdet C.

■ Publications

- Alonso L, Méndez-Echevarría A, Rudilla F, Mozo Y, Soler-Palacin P, Sisinni L, Bueno D, Riviere J, de Paz R, Sánchez-Zapardiel E, Querol S, Rodríguez-Pena R, López-Granados E, Gimeno R, de Heredia CD, Pérez-Martínez A. Failure of viral-specific T cells administered in pre-transplant settings in children with inborn errors of immunity. *J Clin Immunol.* 2021; 41(4): 748-55. Article. IF: 8.542; Q1
- Arguello-Marina M, López-Rubio M, Morado M. SARS-CoV-2 infection in patients with sickle cell disease. *Med Clin-Barcelona.* 2021; 157(7): 345-6. Letter. IF: 3.2; Q2
- Balzarotti M, Magagnoli M, Canales MA, Corradini P, Grande C, Sancho JM, Zaja F, Quinson AM, Belsack V, Maier D, Carlo-Stella C. A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma. *Invest New Drug.* 2021; 39(4): 1028-35. Article. IF: 3.651; Q2
- Campanero MR, Redondo JM. Letter by Campanero and Redondo regarding article, jugular vein injection of high-titer lentiviral vectors does not transduce the aorta. *Arterioscler Thromb Vas.* 2021; 41(4): e238-9. Letter. IF: 10.514; D1
- de la Fuente-Alonso A, Toral M, Alfayate A, Ruiz-Rodríguez MJ, Bonzon-Kulichenko E, Teixido-

Tura G, Martínez-Martínez S, Méndez-Olivares MJ, López-Maderuelo D, González-Valdés I, García-Izquierdo E, Mingo S, Martín CE, Muino-Mosquera L, de Backer J, Nistal JF, Forteza A, Evangelista A, Vázquez J, Campanero MR, Redondo JM. Aortic disease in Marfan syndrome is caused by overactivation of sGC-PRKG signaling by NO. *Nat Commun.* 2021; 12(1): 2628. Article. IF: 17.694; D1

- del Puerto A, Pose-Utrilla J, Simón-García A, López-Menéndez C, Jiménez AJ, Porlán E, Pajuelo LSM, Cano-García G, Martí-Prado B, Sebastián-Serrano A, Sánchez-Carralero MP, Cesca F, Schiavo G, Ferrer I, Farinas I, Campanero MR, Iglesias T. Kidins220 deficiency causes ventriculomegaly via SNX27-retromer-dependent AQP4 degradation. *Mol Psychiatr.* 2021; 26(11): 6411-26. Article. IF: 13.437; D1
- Ferreras C, Pascual-Miguel B, Mestre-Durán C, Navarro-Zapata A, Clares-Villa L, Martín-Cortázar C, de Paz R, Marcos A, Vicario JL, Balas A, García-Sánchez F, Eguizabal C, Solano C, Mora-Rillo M, Soria B, Pérez-Martínez A. SARS-CoV-2-specific memory T lymphocytes from covid-19 convalescent donors: identification, biobanking, and large-scale production for adoptive cell therapy. *Front Cell Dev Biol.* 2021; 9: 620730. Article. IF: 6.081; Q1
- García LMG, Escudero A, Mestre C, Soler JLF, Martínez AP, Valero JMV, Vela M, Ruz B, Navarro A, Fernández L, Fernández A, Leivas A, Martínez-López J, Ferreras C, de Paz R, Blanquer M, Galan V, González B, Corral D, Sisinni L, Mirones I, Balas A, Vicario JL, Valle P, Borobia AM, Pérez-Martínez A. Phase 2 clinical trial of infusing haploidentical k562-mb15-41bbl-activated and expanded natural killer cells as consolidation therapy for pediatric acute myeloblastic leukemia. *Clin Lymph Myelom Leuk.* 2021; 21(5): 328-37. Article. IF: 3.822; Q3
- García-Gutiérrez V, Luna A, Alonso-Domínguez JM, Estrada N, Boque C, Xicoy B, Giraldo P, Angona A, Álvarez-Larrán A, Sánchez-Guijo F, Ramírez MJ, Mora E, Vélez P, Rosell A, Araujo-

MC, Cuevas B, Sagues M, Cortés M, Encinas MP, Montero LFC, Vega MM, Serrano L, Gómez V, García-Hernández C, Lakhwani S, Coll AP, de Paz R, Suárez-Varela S, Fernández-Ruiz A, López RP, Ortiz-Fernández A, Jiménez-Velasco A, Steegmann-Olmedillas JL, Hernández-Boluda JC. Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice. *Blood Cancer J.* 2021; 11(2): 16. Letter. IF: 9.812; Q1

- Gasior M, Ferreras C, de Paz R, Bueno D, Mozo Y, Sisinni L, Canizales JT, González B, Olivares-Mazon R, Marcos A, Romero AB, Constanzo A, Mirones I, Fernández-Arroyo A, Balas A, Vicario JL, Escudero A, Yuste VJ, Pérez-Martínez A. The role of early natural killer cell adoptive infusion before engraftment in protecting against human herpesvirus-6B encephalitis after naive T-cell-depleted allogeneic stem cell transplantation. *Transfusion.* 2021; 61(5): 1505-17. Article. IF: 3.337; Q3
- Janusz K, Izquierdo MM, Cadenas FL, Ramos F, Sánchez JMH, Lumberras E, Robledo C, del Real JS, Caballero JC, Collado R, Bernal T, Pedro C, Insunza A, de Paz R, Xicoy B, Salido E, García JS, Minguez SS, García CM, Muñoz AMS, Barba MS, Rivas JMH, Abaigar M, Campelo MD. Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients. *Ann Hematol.* 2021; 100(8): 1995-2004. Article. IF: 4.03; Q2
- Kabat MG, Bueno D, Sisinni L, De Paz R, Mozo Y, Perona R, Arias-Salgado EG, Rosich B, Marcos A, Romero AB, Constanzo A, Jiménez-Yuste V, Pérez-Martínez A. Selective T-cell depletion targeting CD45RA as a novel approach for HLA-mismatched hematopoietic stem cell transplantation in pediatric nonmalignant hematological diseases. *Int J Hematol.* 2021; 114(1): 116-23. Article. IF: 2.319; Q4
- Maerevoet M, Zijlstra JM, Follows G, Casasnovas RO, Vermaat JSP, Kalakonda N, Goy A, Choquet S, Van den Neste E, Hill B, Thieblemont C, Cavallo F, De la Cruz F, Kuruvilla J, Hamad N, Jae-

ger U, Caimi P, Gurion R, Warzocha K, Bakhshi S, Sancho JM, Schuster M, Egyed M, Offner F, Vasiliakopoulos TP, Samal P, Ku MT, Ma XW, Corona K, Chamoun K, Shah J, Shacham S, Kauffman MG, Canales M. Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study. *J Hematol Oncol.* 2021; 14(1): 111. Letter. IF: 23.168; D1


- Morado M, Villegas AM, de la Iglesia S, Martínez-Nieto J, Barreto RD, Beneitez D, Salido E. Consensus document for the diagnosis and treatment of pyruvate kinase deficiency. *Med Clin-Barcelona.* 2021; 157(5): 253. Article. IF: 3.2; Q2
- Morales-Ortega A, de Tena JG, Frutos-Pérez B, Jaenes-Barrios B, Farfan-Sedano AI, Canales-Albendea MA, Bernal-Bello D. COVID-19 in patients with hematological malignancies: Considering the role of tyrosine kinase inhibitors. *Cancer-Am Cancer Soc.* 2021; 127(11): 1937-8. Letter. IF: 6.921; Q1
- Pérez-Martínez A, Mora-Rillo M, Ferreras C, Guerra-García P, Pascual-Miguel B, Mestre-Durán C, Borobia AM, Carcas AJ, Queiruga-Parada J, García I, Sánchez-Zapardiel E, Gasior M, de Paz R, Marcos A, Vicario JL, Balas A, Moreno MA, Eguizabal C, Solano C, Arribas JR, Buckley RD, Montejano R, Soria B. Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE). *Eclinicalmedicine.* 2021; 39: 101086. Article. IF: 17.033; D1
- Ramírez-López A, del Campo PL, Humala K, Benito BD, Sánchez-Vadillo I, de la Guía AL, Arias RD, Jiménez-Yuste V, Canales M. Lessons learned for successful treatment of AML in the second wave of COVID-19 outbreak. *Leukemia Lymphoma.* 2021; 62(8): 2034-6. Letter. IF: 2.996; Q3
- Shah J, Shacham S, Kauffman M, Daniele P, Tomaras D, Tremblay G, Casasnovas RO, Maerevoet M, Zijlstra J, Follows G, Vermaat JSP, Kalakonda N, Goy AH, Choquet S, Van den Neste

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

E, Hill BT, Thieblemont C, Cavallo F, de la Cruz F, Kuruvilla J, Hamad N, Bouabdallah R, Jager U, Caimi P, Gurion R, Warzocha K, Bakhshi S, Sancho JM, Schuster M, Egyed M, Offner F, Vasilakopoulos TP, Samal P, Nagy A, Ku M, Alben-dea MA. Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma. *Future Oncol.* 2021; 17(11): 1295-310. Article. IF: 3.674; Q3

■ Research projects

Canales Albendea MA. Preceptorship. Derribando fronteras en el manejo de los procesos linfoproliferativos indolentes. Dendrita Health Marketing S. A. 2020-Ongoing.

Managment centre: FIBHULP

Canales Albendea MA. Programa para la investigación en neoplasias linfoides. Astellas Pharma S. A. 2008-Ongoing.

Managment centre: FIBHULP

■ Clinical trials

Canales Albendea, MA. Ensayo de fase Ib/II, abierto, para evaluar la seguridad y la eficacia preliminar de eporitamab (gen3013; duobody® cd3xcd20) en combinación con otros fármacos en sujetos con linfoma no hodgkin de linfocitos b.

Type: Clinical Trials, phase IIB.
HULP code: 5667 GCT3013-02.
Sponsored by: Genmab A/S.
Signed date: 19/04/2021

Canales Albendea, MA. Estudio adaptativo de biomarcadores de fase Ib/III, doble ciego, aleatorizado, controlado con principio activo, en 3 etapas de taze-metostat o placebo en combinación con lenalidomida más rituximab en pacientes con linfoma folicular recidivante/resistente al tratamiento.

Type: Clinical Trials, phase I.
HULP code: Appendix 1 5671.
Sponsored by: Epizyme Inc.
Signed date: 04/03/2021

Canales Albendea, MA. Estudio en fase II, abierto y de dos cohortes debretuximab vedotina y chp (a+chp) en el tratamiento de primera línea de sujetos con linfoma de linfocitos t periféricos (lItp) con menos de un 10% de expresión.

Type: Clinical Trials, phase II.
HULP code: 5689 SGN35-032.
Sponsored by: Seagen, Inc.
Signed date: 26/05/2021

Canales Albendea, MA. Estudio en fase III multicéntrico, aleatorizado, doblecie-go, controlado con placebo y con comparador activo, debrentuximab vedotina o placebo en combinación con lenalidomida yrituximab en pacientes con linfoma difuso de células b grandes (ldcbg) recidivante o resistente.

Type: Clinical Trials, phase III.
HULP code: 5769 SGN35-031.
Sponsored by: Seagen, Inc.
Signed date: 04/06/2021

Canales Albendea, MA. Fase II aleatorizado de loncastuximab tesirina frente a idelalisib en pacientes con linfoma folicular recidivante o resistente (lotis 6).

Type: Clinical Trials, phase II.
HULP code: 5770 ADCT-402-202.
Sponsored by: Adc Therapeutics Sa.
Signed date: 09/07/2021

Canales Albendea, MA. Estudio controlado de fase Ib/II, abierto, multicéntrico y aleatorizado para investigar la seguridad, tolerabilidad, farmacocinética y eficacia de mosunetuzumab (btct4465a) en combinación con chop o chp-polatuzumab vedotin en pacientes con linfoma no hod-

gkiniano de linfocitos b.

Type: Clinical Trials, phase I.
HULP code: Appendix 1 5185.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 28/07/2021

Canales Albendea, MA. Estudio de fase III aleatorizado, abierto, multicéntrico para evaluar la eficacia y la seguridad de mosunetuzumab combinado con lenalidomida en pacientes con linfoma folicular después de al menos una línea de tratamiento sistémico.

Type: Clinical Trials, phase III.
HULP code: 5898 GO42909.
Sponsored by: Roche Farma, S.A.
Signed date: 09/09/2021

Canales Albendea, MA. Estudio en fase 3, aleatorizado, de loncastuximab tesirina en combinación con rituximab frente a inmunoterapia en pacientes con linfomadifuso de células b grandes (ldcbg) recidivante o resistente.

Type: Clinical Trials, phase III.
HULP code: 5848 ADCT 402-311.
Sponsored by: Adc Therapeutics Sa.
Signed date: 02/09/2021

Canales Albendea, MA. Estudio de fase 2 de un solo brazo en monoterapia con tosilito de valemestostat en sujetos con linfoma periférico decélulas t en recaída / refractario (valemestostat tosilito [ds-3201b], uninhibidor dual del potenciador del homólogo zeste [ezh] 1/2 para ellinfoma de linfocitos t periférico recidivante/resistente [lItp r/r.

Type: Clinical Trials, phase II.
HULP code: 5877 DS3201-A-U202.
Sponsored by: Daiichi Sankyo Inc.
Signed date: 08/09/2021

Canales Albendea, MA. Estudio fase 1, multicéntrico, abierto paradeterminar la seguridad, farmacocinética y eficacia preliminar de una molécula pequeña, cc-99282, disponible para administración oral en monoterapia y en combinación con rituximab en sujetos con linfoma no hodgkin en recaída o refractario (lnh r/r.

Type: Clinical Trials, phase I.
HULP code: 5852 CC-99282-NHL-001.
Sponsored by: Celgene Corporation.
Signed date: 07/09/2021


Canales Albendea, MA. Estudio de fase i/II, modular, abierto y multicéntrico, para evaluar azd4573 en combinaciones novedosas con agentes antitumorales en pacientes con neoplasias malignas hematológicas en estadio avanzado.

Type: Clinical Trials, phase I.
HULP code: 5878 D8230C00002.
Sponsored by: Astrazeneca Ab.
Signed date: 27/09/2021

Canales Albendea, MA. Estudio de fase II, modular, abierto y multicéntrico para evaluar la eficacia y la seguridad del capivasertib en pacientes con linfoma no hodgkin de células b en recidiva o refractario (capital).

Type: Clinical Trials, phase II.
HULP code: 5880 D361FC00001.
Sponsored by: Astrazeneca Ab.
Signed date: 30/09/2021

Canales Albendea, MA. Estudio fase III abierto, prospectivo, para comparar Polatuzumab Vedotin más Rituximab, Ifosfamida, Carboplatino Yetopósido (POLA-R-ICE) y Rituximab, Ifosfamida, Carboplatino Yetopósido (R-ICE) solo como terapia de rescate en pacientes con linfoma difuso de célula b grande (LDCBG) primariamente refractario en recaída.



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Type: Clinical Trials, phase III.
HULP code: 5790 MO40599/ GLA 2017-R2 (Pol).

Sponsored by: Gel-Tamo Grupo Cooperativo Español De Linfoma- Trasplante Autonomo De Médula Osea Gel/Tamo.

Signed date: 12/05/2021

De Paz Arias, R. Ensayo multicéntrico, abierto, de fase Ib/II para evaluar la seguridad y la eficacia de la combinación de bosutinib más atezolizumab en pacientes con leucemia mieloide crónica recién diagnosticada.

Type: Clinical Trials, phase II.

HULP code: 5715 ZEROLMC-01.

Sponsored by: Fundación Española Para La Curación De La Leucemia Mieloide Crónica.

Signed date: 19/01/2021

De Paz Arias, R. Estudio de fase 1b/2, abierto y multicéntrico para evaluar la seguridad y la eficacia de krt 232 combinado con un inhibidor de la tirosina cinasa (itc) en pacientes con leucemia mieloide crónica (lmc) ph+ recidivante o resistente.

Type: Clinical Trials, phase II.

HULP code: 5772 KRT-232-117.

Sponsored by: Kartos Therapeutics Inc.

Signed date: 02/02/2021

De Paz Arias, R. Estudio fase III aleatorizado, doble ciego y controlado con placebo de sy1425 más azacitidina en comparación con placebo más azacitidina, en pacientes adultos con reciente diagnóstico desíndrome mielodisplásico de alto riesgo y positivos para rara.

Type: Clinical Trials, phase III.

HULP code: 5818 SY-1425-301.

Sponsored by: Syros Pharmaceuticals Inc.

Signed date: 07/05/2021

De Paz Arias, R. Enhance: estudio multicéntrico, doble ciego y aleatorizado para comparar magrolimab en combinación con azacitidina frente a azacitidina más placebo en pacientes con síndrome mielodisplásico de alto riesgo sin tratamiento previo.

Type: Clinical Trials, phase III.

HULP code: 5930 5F9009.

Sponsored by: Gilead Sciences, S.L.

Signed date: 05/07/2021

De Paz Arias, R. Estudio de fase III, multicéntrico, aleatorizado y abierto de ascimnib oral frente a un inhibidor de la tirosina quinasa seleccionado por el investigador en pacientes con leucemia mieloide crónica cromosoma filadelfia positivo en fase crónica de nuevo diagnóstico.

Type: Clinical Trials, phase III.

HULP code: 5967 CABL001J12301.

Sponsored by: Novartis Farmaceutica, S.A.

Signed date: 27/09/2021

Morado Arias, M. Estudio de extensión, abierto, multicéntrico de AG-348 en sujetos adultos con deficiencia de piruvato cinasa incluidos previamente en estudios con AG-348.

Type: Clinical Trials, phase III.

HULP code: Appendix 2 5237.

Sponsored by: Agios Pharmaceuticals, Inc.

Signed date: 16/01/2021

Morado Arias, M. Estudio en fase III, aleatorizado, abierto, comparativo con

control activo y multicéntrico, para evaluar la eficacia y la seguridad de crovalimab en comparación con eculizumab en pacientes con hemoglobulina paroxística nocturna (hpn) no tratada previamente con inhibidores del sistema de complemento.

Type: Clinical Trials, phase III.

HULP code: Appendix 1 5707.

Sponsored by: F.Hoffmann-La Roche Ltd.

Signed date: 17/05/2021

Morado Arias, M. Estudio multicéntrico, aleatorizado, controlado con placebo, doble ciego y adaptativo de ft-4202 oral, un activador de la piruvato cinasa en pacientes con anemia drepanocítica.

Type: Clinical Trials, phase II.

HULP code: 5858 FORMA 4202-HEM-301.

Sponsored by: Forma Therapeutics, Inc.

Signed date: 19/07/2021

Morado Arias, M. estudio de fase 2b, multicéntrico, abierto, para evaluar la eficacia, seguridad y farmacocinética de rilzabrutinib en pacientes con anemia hemolítica autoinmune por anticuerpos calientes.

Type: Clinical Trials, phase II.

HULP code: 5915 ACT17209.

Sponsored by: Sanofi Aventis S.A.

Signed date: 15/07/2021

Morado Arias, M. Historia natural y resultados de tratamiento de púrpura trombocitopénica trombótica congénita e inmune: estudio de revisión retrospectiva de historial médico del paciente.

Type: Estudios No EPA.

HULP code: PI-4905 TAK-705-3003.

Sponsored by: Takeda Pharmaceuticals Limited.

Signed date: 15/09/2021

Morado Arias, M. Estudio multicéntrico en fase 3, doble ciego, aleatorizado y controlado con placebo para evaluar la eficacia y seguridad de mitapivat en sujetos con α - o β -talasemia dependiente de transfusiones (energize-t).

Type: Clinical Trials, phase III.

HULP code: 5856 AG348-C-018.

Sponsored by: Agios Pharmaceuticals, Inc.

Signed date: 28/09/2021

Morado Arias, M. Estudio multicéntrico en fase 3, doble ciego, aleatorizado y controlado con placebo para evaluar la eficacia y seguridad de mitapivat en sujetos con α - o β -talasemia no dependiente de transfusiones (energize).

Type: Clinical Trials, phase III.



HULP code: 5855 AG348-C-017.

Sponsored by: Agios Pharmaceuticals, Inc.

Signed date: 28/09/2021

Patents and trademarks

Zapata Hernández JM, Pérez Chacón G, inventors; CSIC, UAM, assignees. Use of an indolic compound with nucleophilic substituents at C3 and the dimeric variants thereof in the production of a pharmaceutical composition that can be used in the treatment of B-lymphoid neoplasms. P201331397, PCT/ES2014/070726; 2013 September 25.



3.5.8 Research and Diagnosis of Inherited Metabolic Diseases Group

Publications: 9

Q1: 4

COMPOSITION



■ **María Belén Pérez González.** Profesora Titular. Universidad Autónoma de Madrid. CBM "Severo Ochoa"

Patricia Alcaide Alonso. Investigadora Postdoctoral. CEDEM

Margarita Castro Reguera. Investigadora Predoctoral. CEDEM

Magdalena de Ugarte Pérez. Directora del CEDEM. CEDEM

Isaac Ferrer López. Técnico de Laboratorio. CEDEM

María Alejandra Gámez Abascal. Investigadora Senior (Contrato Ramón y Cajal). CBM "Severo Ochoa"

Fernando García Muñoz. Técnico de Laboratorio. CEDEM

Fátima Leal Pérez. Técnico de Laboratorio. CIBERER

Rosa María Navarrete López de Soria. Técnico de Laboratorio. CIBERER

Eva María Richard Rodríguez. Profesora Titular. Universidad Autónoma de Madrid. CBM "Severo Ochoa"

María Pilar Rodríguez Pombo. Profesora Titular. Universidad Autónoma de Madrid. CBM "Severo Ochoa"

María Lourdes Ruiz Desviat. Profesora Titular. Universidad Autónoma de Madrid. CBM "Severo Ochoa"

Pedro Ruiz Sala. Investigador Postdoctoral. CEDEM

STRATEGIC OBJECTIVE

- Development of genomic and metabolomic techniques aimed at improving the diagnosis of hereditary metabolic diseases.
- Study of mitochondrial dysfunction and oxidative stress as a modifier of the clinical phenotype and as a potential therapeutic target in organic acidurias.
- Development of novel therapeutic strategies: antisense therapy and pharmacological chaperone.

- Development of animal and cellular models.
- Registry of patients with hereditary metabolic diseases.

RESEARCH LINES


- Improved diagnosis of congenital defects of glycosylation and mitochondrial defects through the application of genomic techniques (RNAseq and DNAseq of exoma and genome) and metabolomics.

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

- Identification of deep intronic mutations in metabolic disorders gene by transcriptional analysis. Functional validation in cellular splicing systems.
- Development of antisense therapy and pharmacological chaperones as therapeutic approaches transverse and applicable to numerous EMH.
- Study of oxidative stress and evaluation of common signatures of neuropathogenicity and cardiotoxicity in congenital defects of glycosylation, organic acidemias and mitochondrial diseases.
- Evaluation of drugs aimed at the recovery of mitochondrial function and biogenesis.

- Search for biomarkers as predictors of severity and as systems for the evaluation of pharmacological therapies.
- Characterization of pathophysiology in a murine model of propionic acidemia.
- Identification of dysregulated miRNA in propionic acidemia and characterization of its association with pathology and its usefulness as biomarkers.
- Generation of iPSC from patient-derived fibroblast with organic acidemia and congenital defects of glycosylation. Differentiation to hepatocytes, neural progenitors or cardiomyocytes.

RESEARCH ACTIVITY

■ Doctoral theses

Bravo Alonso, I. Caracterización genética de la acidosis láctica congénita: un ejemplo de análisis integral de una enfermedad rara.[dissertation]. Madrid: UAM: 2021(10/09/2021).

Directors: Pérez González MB, Rodríguez Pombo

■ Master Theses

Calderón L. Generation and characterization of hepatic models as a platform for therapeutic development in PMM2-CDG[dissertation]. Madrid: UAM: 2022(19/06/2021).

Director: Pérez González MB

■ Final Degree Theses

Bravo Alonso, I. Ramírez O. Analysis of the expression of microRNAs in PMM2-CDG and identification of affected cellular pathways [dissertation]. Madrid: UAM: 2022(30/05/2021).

Director: Pérez González MB

Chavarrí Urraca K. Generación y caracterización de astrocitos derivados de

iPSC en Acidemia Propiónica [dissertation]. Madrid: UAM: 2022(30/05/2021).

Director: Richard Rodríguez EM

Minery Berneguer A. Murine models of phenylketonuria and propionic acidemia: Neurological phenotype and effect of the PKU mutation[dissertation]. Madrid: UAM: 2022(29/05/2021).

Director: Ruiz Desviat ML

■ Publications

- Alonso-Barroso E, Pérez B, Desviat LR, Richard E. Cardiomyocytes derived from induced pluripotent stem cells as a disease model for propionic acidemia. *Int J Mol Sci.* 2021; 22(3): 1161. Article. IF: 6.208; Q1
- Hammond SM, Aartsma-Rus A, Alves S, Borgos SE, Buijsen RAM, Collin RWJ, Covello G, Denti MA, Desviat LR, Echevarría L, Foged C, Gaina G, Garanto A, Goyenvallé AT, Guzowska M, Holodnuka I, Jones DR, Krause S, Lehto T, Montolio M, Van Roon-Mom W, Arechavala-Gómeza V. Delivery of oligonucleotide-based therapeutics: challenges and opportunities. *EMBO Mol Med.* 2021; 13(4): e13243. Review. IF: 14.26; D1
- Jabato FM, Córdoba-Caballero J, Rojano E, Roma-Mateo C, Sanz P, Pérez B, Gallego D, Seoane P, Ranea JAG, Perkins JR. Gene expression analysis method integration and co-expression module detection applied to rare glucide metabo-

lism disorders using ExpHunterSuite. *Sci Rep-Uk.* 2021; 11(1): 15062. Article. IF: 4.996; Q2

- Papazoglu GM, Cubilla M, Pereyra M, de Kremer RD, Pérez B, Sturiale L, Asteggiano CG. Mass spectrometry glycophenotype characterization of ALG2-CDG in Argentinean patients with a new genetic variant in homozygosis. *Glycoconjugate J.* 2021; 38(2): 191-200. Article. IF: 3.009; Q3
- Pico S, Perras A, Santos-Galindo M, Pose-Utrilla J, Castro M, Fraga E, Hernández IH, Elorza A, Anta H, Wang N, Marti-Sánchez L, Belloc E, García-Esparcia P, Garrido JJ, Ferrer I, Macías-García D, Mir P, Artuch R, Pérez B, Hernández F, Navarro P, López-Sendón JL, Iglesias T, Yang XW, Méndez R, Lucas JJ. CPEB alteration and aberrant transcriptome-polyadenylation lead to a treatable SLC19A3 deficiency in Huntington's disease. *Sci Transl Med.* 2021; 13(613): eabe7104. Article. IF: 19.319; D1
- Rojano E, Córdoba-Caballero J, Jabato FM, Gallego D, Serrano M, Pérez B, Pares-Aguilar A, Perkins JR, Ranea JAG, Seoane-Zonjic P. Evaluating, filtering and clustering genetic disease cohorts based on human phenotype ontology data with cohort analyzer. *J Pers Med.* 2021; 11(8): 730. Article. IF: 3.508; Q2
- Ruiz-Sala P, Peña-Quintana L. Biochemical markers for the diagnosis of mitochondrial fatty acid oxidation diseases. *J Clin Med.* 2021; 10(21): 4855. Review. IF: 4.964; Q2
- Salsench EM, Maroofian R, Deng RZ, Lanko K, Nikoncuk A, Pérez B, Sánchez-Lijarcio O, Ibáñez-Mico S, Wojcik A, Vargas M, Al-Sanna NA, Girgis MY, Silveira TRD, Bauer P, Schroeder A, Fong CT, Begtrup A, Babaei M, Toosi MB, Ashrafzadeh

F, Imannezhad S, Doosti M, Ahangari N, Torbati PN, Karimiani EG, Murphy D, Cali E, Kaya IH, AlMuhaizea M, Colak D, Cardona-Londono KJ, Arold ST, Houlden H, Bertoli-Avella A, Kaya N, Barakat TS. Expanding the mutational landscape and clinical phenotype of the Y1F1B related brain disorder. *Brain.* 2021; 144(10): e85. Letter. IF: 15.255; D1


- Stanescu S, Belanger-Quintana A, Fernández-Félix BM, Arrieta F, Quintero V, Maldonado MS, Alcaide P, Martínez-Pardo M. Severe anemia in patients with Propionic acidemia is associated with branched-chain amino acid imbalance. *Orphanet J Rare Dis.* 2021; 16(1): 226. Letter. IF: 4.307; Q2

■ Research projects

Pérez González MB. Bases moleculares de las enfermedades neurometabólicas y desarrollo de terapias específicas de mutación. Fundación Isabel Gemio. 2016-2021.

Management centre: Fundación Severo Ochoa

Pérez González MB. Enfoque cross-ómico para el descubrimiento de la base genética de errores innatos del metabolismo y para una intervención terapéutica



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

personalizada (PI19/01155). ISCIII. 2020-2022.

Managment centre: UAM

Pérez González MB. Raregenomicscm (B2017/BMD3721). CAM. 2018-2021.

Managment centre: UAM

Richard Rodríguez EM. Academia pro-
piónica: impacto en el epigenoma y el
proteoma en relación con el fenotipo car-
diaco y neurológico. Fundación Ramón
Arecas. 2021-2023.

Managment centre: Fundación Severo
Ochoa

Ruiz Desviat LM. Delivery of RNA the-
rapy. European cooperation in Science
and Technology (COST) (CA17103). EU.
2018-2022.

Managment centre: UAM

Pérez González MB. Desarrollo de tera-
pias con chaperonas farmacológicas para
el defecto congénito de glicosilación
PMM2-CDG. CIBERer-ISCIII. 2018-2021.

Managment centre: UAM


Pérez González MB, Palau F. Medicina
de sistemas aplicada a la identificación
de nuevas dianas terapéuticas en enfer-
medades raras de base genética. Funda-
ción Ramón Arecas. 2019-2021.

Managment centre: UAM

Pérez González MB, Palau F. GenNatal,
un proyecto piloto sobre secuenciación ge-
nómica en medicina neonatal y salud públi-
ca. Fundación Ramón Arecas. 2019-2021.

Managment centre: UAM

Ruiz Desviat LM. Mecanismos respon-
sables del fenotipo patológico en enfer-
medades neurometabólicas raras y apro-
ximaciones terapéuticas personalizadas
(PID2019-105344RB-I00). MCINN. 2020-
2023.



Managment centre: UAM

Pérez González MB. Estudio observacio-
nal: ESTUDIO α -REVEAL. Chiese Thera-
peutics. 2021-2022.

Managment centre: UAM

Pérez González MB. Identificación y
diagnóstico de la deficiencia AADC. PTC
Therapeutics. 2021-2022.

Managment centre: UAM

■ Cibers & Retics



Pérez González MB. Centro de Investi-
gación en Red de Enfermedades Raras
(CB06/07/0004). ISCIII. (31/12/2021).

Managment centre: UAM

■ Patents and trademarks

**Pérez González B, Ruiz Desviat L, Jor-
ge Finnigan A, Ugarte Pérez M, Martí-
nez Ruiz A, Underhaug J, Barnejee R,**
inventors; UAM, Universidad de Bergen,
Universidad de Michigan, assignees;
Compounds useful for the treatment of
methylmalonic aciduria. P201330171;
2013 February 11.

**Pérez González B, Gámez Abascal MA,
Yuste Checa P, Arduim Brasil S, Ugarte
Pérez M, Martínez Ruiz A, Underhaug J,**
inventors; UAM, University of Bergen, assign-
ees; Compounds for treating congenital
disorders of glycosylation. EP16382373.5,
PCT/EP2017/069147; 2016 July 29.



3.5.9 Regulation of Ciliary Structure and Function by Phosphoinositides Group*

Publications: 3

Q1: 2

COMPOSITION



Francesc García Gonzalo. Investigador Ramón y Cajal. Universidad Autónoma de Madrid

Pablo Barberito González. Investigador Postdoctoral. Universidad Autónoma de Madrid

Raquel Martín Morales. Investigadora Predoctoral. Universidad Autónoma de Madrid

María Belén Sierra Rodero. Investigadora Predoctoral. Universidad Autónoma de Madrid

STRATEGIC OBJECTIVE

Cilia play important roles in human health and disease. Our goal is to better understand cilia structure and function, and how they can be manipulated to promote human health.

But what are cilia and why are they important for our health? Cilia are cell membrane protrusions with an endoskeleton consisting of nine microtubule doublets. This basic architecture, shared by both cilia and flagella, is conserved from unicellular organisms to humans.

There are two kinds of cilia: motile and immotile (a.k.a. primary). Motile cilia resemble oars, displacing extracellular fluids. This is how we expel mucus from our bronchi and how sperm swim. Instead, primary cilia behave like antennae, detecting optical, mechanical or chemical signals. Our vision, hearing and smell depend on immotile cilia. Primary cilia also monitor urine flow in the kidney, act as sensors for hunger-controlling hormones in the brain, and control limb and nervous system patterning in the embryo, among many other functions.

Congenital ciliary defects cause ciliopathies, genetically and clinically.


* The External Scientific Committee decided that this group would have to be reformulated at the December 2021 meeting

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



1
Introduction

lly diverse illnesses whose most common symptoms include mental retardation, retinal degeneration, kidney cysts, polydactyly, obesity, sterility, respiratory infections, and skeletal, heart and brain malformations. Many ciliopathies are rare syndromes (Meckel, Joubert, Bardet-Biedl, Kartagener, etc.), whereas others are more common and affect a single organ (polycystic kidney disease, retinitis pigmentosa). Ciliopathies are not the only diseases cilia are involved in. Several cancer types, like medulloblastoma and basal cell carcinoma, arise from abnormal activation of Hedgehog signaling, a ciliary pathway essential for embryonic development and adult stem cell function.

2
Executive
Summary

3
Information
Groups
by Area

4
Associated
Clinicians



On the other hand, increasing evidence suggests that cilia modulate the progression of other diseases, such as diabetes and Alzheimer's. Given that ciliary function is critically dependent on their composition, our main strategy consists in understanding the molecular mechanisms underlying: (1) ciliary accumulation of the receptors and transducers that sensitize cilia to external stimuli, and (2) the changes in cilia composition whereby ciliary signals are relayed to the rest of the cell.


RESEARCH LINES

- Ciliary targeting of G protein-coupled receptors (GPCRs)
- Ciliary targeting of INPP5E, a ciliopathy-associated phosphoinositide phosphatase
- Regulation of ciliary ectocytosis and disassembly by INPP5E
- Roles of B9 ciliopathy proteins at the ciliary transition zone
- Cell-based assays to test the effects of ciliopathy mutations
- Regulation of ciliogenesis and Hedgehog signaling by the transcription factor NRF2

RESEARCH ACTIVITY

■ Publications

- García-Gonzalo FR, Soares H, Lopes SS, Inoue T. Editorial: The cytoskeleton and cellular compartmentation: cilia as specialized cellular domains. *Front Cell Dev Biol.* 2021; 9: 777758. Editorial Material. IF: 6.081; Q1
- Barbeito P, Tachibana Y, Martín-Morales R, Moreno P, Mykytyn K, Kobayashi T, García-Gonzalo FR. HTR6 and SSTR3 ciliary targeting relies on both IC3 loops and C-terminal tails. *Life Sci Alliance.* 2021; 4(3): e202000746. Article. IF: 5.781; Q1
- Barbeito P, García-Gonzalo FR. HTR6 and SSTR3 targeting to primary cilia. *Biochem Soc T.* 2021; 49(1): 79-91. Review. IF: 4.919; Q2



1
Introduction

2
Executive
Summary

3
Information
Groups
by Area

4
Associated
Clinicians

3.5.10 Dyslipidemias of Genetic Origin and Metabolic Diseases Group



Publications: 6

Q1: 1



COMPOSITION

■ **Sonia María Rodríguez Novoa.** Facultativo Especialista de Área. Responsable del Laboratorio de Genética de Enfermedades Metabólicas. Hospital Universitario La Paz

■ **Álvaro del Monte Vergara.** Investigador Predoctoral. Hospital Universitario La Paz

■ **Amanda Herranz Cecilia.** Investigadora Predoctoral. Hospital Universitario La Paz

■ **Ana Carazo Álvarez.** Técnico de Laboratorio. Hospital Universitario La Paz

■ **Carmen Rodríguez Jiménez.** Especialista en Bioquímica Clínica. Hospital Universitario La Paz


■ **Elena Sevilla Alonso.** Investigadora Predoctoral. Hospital Universitario La Paz

■ **Javier Sanguino Otero.** Investigador Posdoctoral. Hospital Universitario La Paz

STRATEGIC OBJECTIVE

Our research is especially focused on the molecular diagnosis of dyslipidemias of genetic origin. Among dyslipidemias, Familial Hypercholesterolemia (FH) stands out for its impact on health. FH is an important risk factor in the development of early cardiovascular disease. Patients with pathogenic variants in the main genes involved in FH (LDLR, APOB, PCSK9, and LDLRAP1) are at high risk of premature coronary disease. The autosomal dominant hypercholesterolemia is

caused by pathogenic variants at LDLR, APOB or PCSK9 genes. Patients with FH have a 50% of having a child with the condition. In this context, early detection of genetic alterations in patient's relatives is essential in order to establish an early treatment. Genetic studies of the family have proven to be cost-effective. The massively parallel sequencing technology (NGS) provide an useful tool to carry out this type of studies. However, it is important not only the detection of new variants but the characterization of them to determine their impact or pathogenicity. For this purpose, our research group has deve-



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

loped and validated functional in vitro studies for the characterization of genetic variants in the main genes associated with FH.

An important percentage of patients with hypercholesterolemia do not present pathogenic variants in the most frequent genes. Our group has a line of research focused on the search for new candidate genes and epigenetic causes related with altered lipid metabolism. We have developed in vitro studies to determine the impact of microRNAs on the expression of LDLR and PCSK9.

In addition to FH, we also study other genetic dyslipidemias such as familial hypertriglyceridemia and other "rare" dyslipidemias that are often not diagnosed with the usual diagnostic tools.

RESEARCH LINES

- Molecular diagnosis of familial hypercholesterolemia by massive sequencing of a panel of genes. Study of the exome to detect new candidate genes.
- Functional studies of genetic variants in LDLR, PCSK9 and APOB in cellular model.
- Study of microRNAs as modulators of cholesterol regulation and their impact on familial hypercholesterolemia.
- Molecular diagnosis of hypertriglyceridemia and other "rare" dyslipidemia.
- Genetic diagnosis of metabolic diseases.

RESEARCH ACTIVITY

■ Publications

- Gómez-González C, Rosas-Alonso R, Rodríguez-Antolín C, García-Guede A, Ibáñez de Cáceres I, Sanguino J, Pascual SI, Esteban I, del Pozo A, Mori MA, Torres RJ, Prior C. Symptomatic heterozygous X-Linked myotubular myopathy female patient with a large deletion at Xq28 and decrease expression of normal allele. *Eur J Med Genet.* 2021; 64(4): 104170. Article. IF: 2.465; Q3
- Mazo MA, Sanguino J, Martín-Gullón I, Rubio J. Formation of carbon nanofibers with Ni catalyst supported on a micro-mesoporous glass. *Micropor Mesopor Mat.* 2021; 323: 111168. Article. IF: 5.876; Q1
- Rodríguez-Antolín C, Rosas-Alonso R, Cruz P, Higuera O, Sánchez-Cabrero D, Esteban-Rodríguez I, Peláez-García A, Montano VEF, Rodríguez-Jiménez C, de Cáceres II, de Castro J. Novel SLC12A2-ROS1 fusion in non-small cell lung cancer with a significant response to crizotinib: the importance of choosing the appropriate next-generation sequencing assay. *Oncologist.* 2021; 26(6): E908-12. Article. IF: 5.837; Q2
- Rosas-Alonso R, Queiruga J, Arias P, del Monte A, Yuste F, Rodríguez-Antolín C, Losantos-García I, Borobia AM, Rodríguez-Novoa S. Analytical validation of a laboratory-development multi-gene pharmacogenetic assay. *Pharmacogenet Genom.* 2021; 31(8): 177-84. Article. IF: 2; Q4
- Santos-Simarro F, Pacio M, Cueto-González AM,

Mansilla E, Valenzuela-Palafoll MI, López-Grondona F, Lledin MD, Schuffelmann C, del Pozo A, Solis M, Vallcorba P, Lapunzina P, Suso JJM, Siccha SM, Montejo JM, Mena R, Jiménez-Rodríguez C, García-Miñaur S, Palomares-Bralo M. Mosaic variegated aneuploidy syndrome 2 caused by biallelic variants in CEP57, two new cases and review of the phenotype. *Eur J Med Genet.* 2021; 64(11): 104338. Review. IF: 2.465; Q3

- Siccha SM, Cueto AM, Parrón-Pajares M, González-Morán G, Pacio-Míguez M, del Pozo A, Solis M, Rodríguez-Jiménez C, Caino S, Fano V, Heath KE, García-Miñaur S, Palomares-Bralo M, Santos-Simarro F. Delineation of the clinical and radiological features of Stuve-Wiedemann syndrome childhood survivors, four new cases and review of the literature. *Am J Med Genet A.* 2021; 185(3): 856-65. Review. IF: 2.578; Q3

■ Research projects

Rodríguez Novoa SM. Diagnóstico genético de la hipercolesterolemia familiar mediante secuenciación masiva. Estudio funcional de nuevas variantes y detección de mosaicismos. Estudio de miRNAs (PI18/00917). ISCIII. 2019-2021.

Management centre: FIBHULP

Rodríguez Novoa SM. Renal tubular and markers of bone turnover in hbv mono-infected patients during long term treatment with entecavir or tenofovir. Bristol-Myers Squibb International Corporation. 2011-Ongoing.

Management centre: FIBHULP


■ Patents and trademarks


Rodríguez Novoa SM, del Monte Vergara A, Rosas Alonso R, Queiruga Parada J, Yuste González F, authors; FIBHULP, assignee. Trademark name: Pharma Genfinder; CM18332183; 2020 November 05.



Ibáñez de Cáceres I, de Castro Carpeño J, Jiménez Hernández J, Rodríguez

Antolín C, Rodríguez Jiménez C, Rosas Alonso R, Cruz Castellanos P, Burdiel Herencia M, Pernía Arias O, Diestro Tejada MD, Esteban Rodríguez MI, inventors; FIBHULP, assignee. miR-151A-3p as a universal endogenous control for exosome cargo normalization. EP19382252.5 (EP3719144), PCT/EP2020/059774 PCT Direct, EP20719957.1 (EP3947733), US17/601,657; 2019 April 05.





Surgery, Transplant and Health Technologies Area

3.6

Nuria Vilaboa Díaz

Documents:	205		
Originals:	155		
D1:	15	Q1:	53

- 3.6.1 Bone Pathophysiology and Biomaterials Group
- 3.6.2 Cellular Engineering Group
- 3.6.3 Clinical Pharmacology Group
- 3.6.4 Osteoarticular Surgery Research – GICOA Group
- 3.6.5 Research in Oral and Maxillofacial Surgery Group
- 3.6.6 Patients Safety and Quality Research Group
- 3.6.7 Translational Research and Innovation in General and Digestive Surgery Group




1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



Surgery, Transplant and Health Technologies Area

3.6



- 1 Introduction
- 2 Executive Summary
- 3 Information Groups by Area
- 4 Associated Clinicians



Strategic Objectives	Development forecast for the coming years
<p>Surgery, Transplant and Health Technologies Area is composed of 10 very heterogeneous groups and the absence of common activities between them make the general objectives equivalent to the sum of the research lines of each of the groups. The main objective of the area is to locate points where synergies between groups can be established.</p>	<p>Cellular and organ engineering, underdeveloped.</p>
	<p>Stem and precursor cells. This is one of the most successful lines and the one that has motivated more collaborations between them. It is certainly one of the possibilities for the future.</p>
	<p>Animal models. Cellular models. They require personnel trained in cell culture techniques and who masters animal models of human diseases.</p>
	<p>Minimally invasive surgery: one of the most important translational fields in recent years, a permanent demand from the population and an indicator of the quality of healthcare systems</p>

Actions

- Support researchers to continue being a reference in the national area.
- Identify and promote at international level the new research lines identifying as innovative and competitive.



3.6.1 Bone Pathophysiology and Biomaterials Group

Publications: 7
Q1: 4

COMPOSITION



Nuria Elda Vilaboa Díaz. Investigadora Senior (Contrato Miguel Servet - I2). Jefe de Laboratorio. FIBHULP

Fátima Bensiamar Hadia. Técnico de Laboratorio. FIBHULP

Clara Escudero Duch. Investigadora Postdoctoral. FIBHULP

Marcos de Mesa Cáceres. Técnico de Laboratorio. FIBHULP

Mabel Falguera Uceda. Investigadora Predoctoral. Hospital Universitario La Paz

Eduardo García Cimbreló. Doctor Emérito. Hospital Universitario La Paz. Universidad Autónoma de Madrid

Enrique Gil Garay. Jefe de Servicio de Cirugía Ortopédica y Traumatología. Hospital Universitario La Paz. Profesor Titular. Departamento de Cirugía. Facultad de Medicina. Universidad Autónoma de Madrid

Miguel Ángel Lerma Juárez. Investigador Predoctoral. FIBHULP

Leila Maestro Paramio. Investigadora Predoctoral. FIBHULP

Carmen Martín Hervás. Facultativo Especialista de Área en Radiodiagnóstico. Hospital Universitario La Paz. Profesora Asociada. Facultad de Medicina. Universidad Autónoma de Madrid

Alonso Carlos Moreno García. Facultativo Especialista de Área en Cirugía Ortopédica y Traumatología. Hospital Universitario La Paz

Laura Saldaña Quero. Investigadora Senior (Contrato Miguel Servet-Tipo I). Jefe de Laboratorio. FIBHULP

Silvia Sánchez Casanova. Investigador Predoctoral. FIBHULP

Gema Vallés Pérez. Investigadora Senior. Responsables de Cultivos Celulares y de los Laboratorios Comunes de IdiPAZ. FIBHULP

STRATEGIC OBJECTIVE

The Bone Physiopathology and Biomaterials group includes basic and clinical researchers from IdiPAZ. The group has broad experience in clinical and basic research on biomaterials for orthopaedic implants and bone tissue engineering. The principal goal of the group

is to improve the clinical outcome of orthopaedic surgery through research on implants and biomaterials used for manufacturing prosthetic device.


The group is also interested in bone tissue engineering applications, developing surgical procedures that make use of allotransplants, evaluating scaffolds manufactured by collaborative partners, develo-

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

ping novel gene therapy strategies aimed to heal bone defects and studying the interactions of the immune and skeletal systems. Specific areas of clinical research on implants include follow-up studies on various devices in use for orthoarticular surgery.

The main areas of interest in basic research on the biocompatibility of materials include:

- understanding the influence of the surface biomaterial properties on the behaviour of bone-related cells
- the study of cell reactions occurring in the vicinity of implanted materials caused by wear particles
- the deliberate manipulation of cell responses after exposure to nanoparticles designed for gene delivery and optical hyperthermia applications.

The team is also interested in the development of transcriptional tar-

geting strategies to ensure tight control of the expression of therapeutic proteins and their potential application in inducing an orchestrated expression of growth factors involved in bone healing.

RESEARCH LINES

- Clinical research in implants for bone repair
- Biocompatibility of new materials for potential use in implants for bone repair: cell and surface interactions, cell and particle interactions
- Study of the interactions between the immune and skeletal systems
- Control of the expression of therapeutic genes using gene circuits
- Study of the physiopathology of bone diseases

RESEARCH ACTIVITY

■ Doctoral theses

Sánchez Casanova S. Hidrogeles foto-térmicos con aplicación en ingeniería tisular ósea [dissertation]. Madrid: UAM: 2021(04/06/2021).

Director: Vilaboa Díaz N.

■ Publications

- Cifuentes SC, Saldaña L, González-Carrasco JL, Benavente R, García-Penas A. Effect of thermal processing on the dynamic/isothermal crystallization and cytocompatibility of polylactic acid for biomedical applications. *Macromol Chem Phys.* 2021; 222(23): 2100274. Article. IF: 2.996; Q2
- Aguado M, Saldaña L, del Río EP, Guasch J, Pareira M, Córdoba A, Seras-Franzoso J, Cano-Garrido O, Vazquez E, Villaverde A, Veciana J, Ratera I, Vilaboa N, Ventosa N. Polylactide, processed by a foaming method using compressed freon r134a, for tissue engineering. *Polymers-Basel.* 2021; 13(20): -3453. Article. IF: 4,967; Q1
- Maestro-Paramio L, García-Rey E, Bensiamar F, Saldana L. Osteoblast function in patients with idiopathic osteonecrosis of the femoral head implications for a possible novel therapy. *Bone Joint*

Res. 2021; 10(9): 619-28. Article. IF: 4.41; Q1

- García-Rey E, Saldaña L, García-Cimbrelo E. Impaction bone grafting in hip re-revision surgery bone stock restoration and radiological migration of the acetabular component. *Bone Joint J.* 2021; 103B(3): 492-9. Article. IF: 5.385; D1
- García-Rey E, Bizot P, García-Cimbrelo E. Ceramic-on-ceramic cementless total hip arthroplasty in patients aged 40 years or under: Do preoperative conditions affect long-term results? *Orthop Traumatol-Sur.* 2021; 107(1): 102763. Article. IF: 2.425; Q3
- Fernández-Villa D, Asensio G, Silva M, Ramírez-Jiménez RA, Saldaña L, Vilaboa N, Leite-Oliveira A, San Román J, Vázquez-Lasa B, Rojo L. Vitamin B9 derivatives as carriers of bioactive cations for musculoskeletal regeneration applications: Synthesis, characterization and biological evaluation. *Eur J Med Chem.* 2021; 212: 113152. Article. IF: 7.088; D1
- Valles G, García-Rey E, Saldaña L, García-Cimbrelo E, Vilaboa N. Wear of hip prostheses increases serum IGFBP-1 levels in patients with aseptic loosening. *Sci Rep-Uk.* 2021; 11(1): 576. Article. IF: 4.996; Q2

■ Research projects

Huarte Sebastián C. Contrato garantía

juvenil (PEJ-2020-AI/BMD-17656). CAM. 2021-2021.

Managment centre: FIBHULP

Lerma Juarez MA. Contrato predoctoral (PRE2019-090430). MICIU. 2020-2024.

Managment centre: FIBHULP

Ortega Ponce D. Nanotecnología en hipertermia traslacional (RED2018-102626-T). MICIU. 2020-2022.

Managment centre: Fundacion IMDEA Nanociencia

Saldaña Quero L. Identificación de factores moleculares implicados en la osteonecrosis idiopática: análisis del transcrito del tejido óseo (PI18/00643). ISCIII. 2019-2023.

Managment centre: FIBHULP

Serrano Yamba RF. Contrato garantía juvenil (PEJ-2020-AI/BMD-17656). CAM. 2021-2023.

Managment centre: FIBHULP

Vilaboa Díaz NE, Saldaña Quero L. Desarrollo de fluidos que potencien o favorezcan la osteointegración de los implantes ante distintas situaciones. Mozo-Grau S. A. 2017-Ongoing.

Managment centre: FIBHULP

Vilaboa Díaz NE. Contrato Miguel Serret Categoría A (CES07/031). CM. 2007-2025.

Managment centre: FIBHULP

Vilaboa Díaz NE. Detección de activación de HSF parte II. HSF Pharmaceutica. 2004-Ongoing.

Managment centre: FIBHULP

Vilaboa Díaz NE. Hidrogeles que responden a energía infrarroja y contienen adenovirus de alta capacidad. Aplicación en regeneración ósea (RTI2018-095159-B-I00). MICIU. 2019-2022.

Managment centre: FIBHULP



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

■ Cibers & Retics

Vilaboa Díaz NE. Networked Biomedical Research Center for Bio-engineering, Biomaterials and Nanomedicine (CB06/01/0008). Carlos III Health Institute. (31/12/2022).

Management centre: FIBHULP

■ Patents and trademarks

Vilaboa Díaz NE, González Carrasco JL, Saldaña Quero L, Frutos Torres E. inventors; FIBHULP, CSIC, CIBER-BBN, assignees. Method to obtain a metallic-coated biomaterial; P201030949, PCT/ES2011/070400; 2010 June 21.

Vilaboa Díaz NE, González Carrasco JL, Multigner Domínguez M, Lieblich Rodríguez M, Muñoz Hernández M, Frutos Torres E, Saldaña Quero L, inventors; FIBHULP, CSIC, CIBER-BBN, Universidad Alfonso X El Sabio, assignees. Magnesium/polymer composite biomaterial for biomedical applications; P201030950, PCT/ES2011/070440; 2010 June 21.

Fabiilli M, Wilson C, Padilla F, Martín Saavedra FM, inventors; The regents of the University of Michigan, assignee. Ultrasound-triggerable agents for tissue engineering; PCT/US2013/044817, US2013/0330389; 2012 June 08.

Vilaboa Díaz NE, Calzado Martín A, Crespo García L, Saldaña Quero L, Moreo Calvo P, Alastrué Vera V, inventors; FIBHULP, CIBER-BBN, assignees. Chamber device for dynamic cell culture on biomaterials; P201330040, PCT/ES2013/070819; 2013 January 16.



Martín Saavedra FM, Vilaboa Díaz NE, Cebrián Hernando V, Arruebo Gordo M, Santamaría Ramiro J, Gómez Navascués L, inventors; FIBHULP, CIBER-BBN, Universidad de Zaragoza, assignees. Fibrin hydrogel with plasmonic nanoparticles; P201330894, PCT/ES2014/070484; 2013 June 14.

González Carrasco JL, Benavente Castro R, Cifuentes Cuellar SC, Lieblich Rodríguez M, Olalde Graells B, Atorrastagasti Goyalde G, Argarate Madariaga N, Pacha Olivenza MA, Fernández Calderón MC, Saldaña Quero L, González Martín ML, Pérez Giraldo C, Gallardo Moreno AM, inventors; CSIC, Fundación Tecnalia Research & Innovation, FIBHULP, Universidad de Extremadura, Centro de

Investigación Biomédica en Red (CIBER). Moldable, biodegradable, biocompatible and bioresorbable implant material, method for its preparation and uses thereof. P201530683; 2015 May 18.

Voellmy R, Vilaboa Díaz NE, inventors; HSF Pharmaceuticals S.A., assignee. Inhibitors of heat shock factor I and uses thereof. US 62/495,501 and US62/499,650, PCT/EP2017/072930, EP3512602; 2016 September 16 and 2017 February 02.

Voellmy R, Vilaboa Díaz NE. Inventors; HSF Pharmaceuticals SA. Assignees. Compounds that induce protein unfolding and a mitigated response thereto, and methods of use thereof. US 62/764,569. 2018 August 08

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



3.6.2 Cellular Engineering Group

Publications: 9

Q1: 1

COMPOSITION



■ **María Paz de Miguel González.** Investigadora Senior (Contrato Miguel Servet - I2). Jefe de Laboratorio. Hospital Universitario La Paz

■ **María Pilar González-Peramato Gutiérrez.** Facultativo Especialista de Área en Anatomía Patológica. Hospital Universitario La Paz

■ **Manuel Nistal Martín de Serrano.** Catedrático Departamento de Histología y Neurociencia. Facultativo de Medicina. Universidad Autónoma de Madrid

■ **Javier Francisco Regadera González.** Catedrático. Departamento de Histología y Neurociencia. Facultad de Medicina. Universidad Autónoma de Madrid


STRATEGIC OBJECTIVE

To ascertain the mechanisms responsible for converting a differentiated cell into a pluripotent cell and at the same time how these establish a relationship between cellular reprogramming and oncogenic transformation, in order to use divergent pathways governing these processes as clinical early diagnostic tools and therapeutic targets for clinical intervention.

To develop new cell therapy approaches in diverse organs transplants.

RESEARCH LINES

- Molecular mechanisms of cellular reprogramming in normal and neoplastic environments.
- New techniques and therapies in transplants.



RESEARCH ACTIVITY

■ Doctoral theses

Peña Barreno C. Estudio de la respuesta histopatológica testicular al tratamiento con estrógenos y antiandrógenos a largo plazo y su relación con la disgenesia testicular[dissertation]. Madrid: UAM: 2021(30/04/2021).

Directors: González-Peramato Gutiérrez MP,
Nistal Martín de Serrano M.

Ibarra Ramírez M. Perfil de expresión de microRNAs en biopsias de testículo de pacientes con Síndrome de Klinefelter.[dissertation]. Madrid: UAM: 2021(19/02/2021).

Directors: Martínez de Villarreal LE,
González-Peramato
Gutiérrez MP.

Final Degree Theses

Pardo Díaz M. Estudio in vivo de impresos 3D para la regeneración del estroma corneal[dissertation]. Madrid: Universidad Rey Juan Carlos: 2021(01/07/2021).

Director: de Miguel González MP

Navarro Páez F. Towards the develop-

ment of a biomimetic anterior lamellar corneal layer: Studies based on mesenchymal stem cells and 3D printed collagen scaffolds[dissertation]. Madrid: Universidad CEU San Pablo: 2021(01/07/2021).

Director: de Miguel González MP

■ Publications

- Cadenas-Martín M, Moratilla A, Fernández-Delgado J, Arnalich-Montiel F, de Miguel MP. Improvement of an effective protocol for directed differentiation of human adipose tissue-derived adult mesenchymal stem cells to corneal endothelial cells. *Int J Mol Sci.* 2021; 22(21): 11982. Article. IF: 6.208; Q1
- de la Parra I, Serrano A, Vives R, Hermida J, Díez-Valladares LI, Barrera J, Cortés JA, González-Peramato P, Gómez A, Moreno J. Sarcomatoid transformation of chromophobe renal cell carcinoma: an unusual pathology. our experience, definition of therapeutic guidelines and review of literature. *Eurasian J Med Oncol.* 2021; 5(4): 361-7. Review. Not Indexed
- del Barrio JLA, Arnalich-Montiel F, de Miguel MP, El Zarif M, Alio JL. Corneal stroma regeneration: Preclinical studies. *Exp Eye Res.* 2021; 202: 108314. Article. IF: 3.77; Q2
- El Zarif M, Alio JL, del Barrio JLA, De Miguel MP, Jawad KA, Makdissy N. Corneal stromal regeneration: a review of human clinical studies in keratoconus treatment. *Front Med (Lausanne).* 2021; 8: 650724. Review. IF: 5.058; Q2
- El Zarif M, Alio JL, del Barrio JLA, Jawad KA, Palazon-Bru A, Jawad ZA, De Miguel MP, Mak-

dissy N. Corneal stromal regeneration therapy for advanced keratoconus: long-term outcomes at 3 years. *Cornea.* 2021; 40(6): 741-54. Article. IF: 3.152; Q2

- Martín J, Serrano A, Barrera J, Cortese JA, González-Peramato P, Sierra JM. Abnormal calcifications in chromophobic cell renal tumors: description of a clinical case and review of the literature. *Arch Esp Urol.* 2021; 74(3): 355-9. Review. IF: 0.43; Q4
- Moratilla A, de la Maza DS, Martín MC, López-Iglesias P, González-Peramato P, De Miguel MP. Inhibition of pkc epsilon induces primordial germ cell reprogramming into pluripotency by hif1&2 upregulation and histone acetylation. *Am J Stem Cells.* 2021; 10(1): 1-17. Article. Not Indexed
- Nieto-Nicolau N, Martínez-Conesa EM, Fuentes-Julián S, Arnalich-Montiel F, García-Tuñón I, de Miguel MP, Casaroli-Marano RP. Priming human adipose-derived mesenchymal stem cells for corneal surface regeneration. *J Cell Mol Med.* 2021; 25(11): 5124-37. Article. IF: 5.295; Q2
- Padilla-Ansala C, García-Fernández E, González-Peramato P. Histopathological subtypes and PD-L1 expression in primary urethral adenocarcinoma: A series of 5 cases. *Int J Surg Pathol.* 2021; 29(5): 488-95. Article. IF: 1.358; Q4

■ Research projects

Cadenas Martín M. Contrato predoctoral (PEJD-2018-PRE/BMD-8878). CM. 2019-2021.

Managment centre: FIBHULP

de Miguel González MP. Contrato Miguel Servet Categoría A (CP03/0007). ISCIII. 2010-2025.

Managment centre: FIBHULP

de Miguel González MP. Contribución de la modificación metabólica a la reprogramación celular y la transformación oncogénica (). Fundación Domingo Martínez. 2017-Ongoing.

Managment centre: FIBHULP

de Miguel González MP. Generación de estroma corneal bio-mimético por impresión 3D de colágeno y células madre mesenquimales (). Stem Vision S. L. 2021-Ongoing.

Managment centre: FIBHULP

■ Patents and trademarks

de Miguel González MP, Arnalich Montiel F, Royuela MM, inventors; FIBHULP, Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal, Universidad de Alcalá, assignees. Corneal endothelium injector; P201131222, PCT/ES2012/070543; 2011 July 18.

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



3.6.3 Clinical Pharmacology Group

Publications: 21

Q1: 11

COMPOSITION



■ **Jesús Frías Iniesta.** Jefe de Servicio de Farmacología Clínica. Hospital Universitario La Paz. Catedrático. Facultad de Medicina. Universidad Autónoma de Madrid

Pilar Ayllón García. Técnico de laboratorio. Universidad Autónoma de Madrid

Alberto Borobia Pérez. Facultativo Especialista de Área en Farmacología Clínica. Hospital Universitario La Paz

Antonio Javier Carcas Sansuán. Facultativo Especialista de Área en Farmacología Clínica. Hospital Universitario La Paz. Profesor Titular. Facultad de Medicina. Universidad Autónoma de Madrid

Laura Díaz García. Facultativo Especialista de Área en Farmacología Clínica. Hospital Universitario La Paz

Blanca Duque Bascuñana. Responsable de Calidad. Universidad Autónoma de Madrid

Alberto García Bartolomé. Investigador Postdoctoral. Hospital Universitario La Paz

Irene García García. Facultativo Especialista de Área en Farmacología Clínica. Hospital Universitario La Paz

José Carlos Martínez Ávila. Investigador Postdoctoral. Hospital Universitario La Paz

Lucía Martínez de Soto. Coordinadora de Ensayos Clínicos. FIBHULP

Pablo Molina Benítez. Investigador Predoctoral. FIBHULP

Paloma Moraga Alapont. Gestora de proyectos SCReN (Spanish Clinical Research Network). FIBHULP

María Cristina Murano Murano. Investigador Postdoctoral. FIBHULP

Paula Prieto Correa. Monitora de Ensayos Clínicos. FIBHULP

Rocío Prieto Pérez. Gestora de proyectos SCReN (Spanish Clinical Research Network). FIBHULP

Hoi Yan Tong. Responsable de Farmacovigilancia. Hospital Universitario La Paz


STRATEGIC OBJECTIVE

Clinical pharmacology, as a scientific and professional discipline, has the objective of achieving an effective, efficacious and efficient use of drugs, at both the individual and group level. This means that Clinical Pharmacology is a cross-sectional discipline that must establish collaborations with numerous other disciplines and health professionals.

In this context and in the field of clinical research, the interests of our

group are focused on two fundamental aspects:

1. Customisation of drug treatments: research and development of techniques and methods that individualise the use of drugs, improve their efficacy and reduce their risks.
2. The improvement of treatment by obtaining high quality evidence on the efficacy of clinical trials, strategies of identification, evaluation and prevention of adverse reactions to medication (pharmacovigilance programmes) and evaluation of the suitability of their use and effectiveness (studies on the use of medication).



RESEARCH LINES

- Therapeutic drug monitoring (TDM) – Development of individualised therapeutic drug monitoring programmes and pharmacogenetics.
- Getting quality evidences for the establishment of drug efficacy, safety and adequate use of medicines in humans.

RESEARCH ACTIVITY

■ Doctoral theses

Álvarez Collado L. Prevalencia de factores de riesgo cardiovascular en trabajadores de un hospital terciario y estrategias de promoción de la salud en hospitales de la Comunidad de Madrid [dissertation]. Madrid: UAM: 2021(09/04/2021).

Directors: Frías Iniesta J,
Fernández de Bobadilla
Osorio J

■ Publications

- García-García I, Dapia I, Montserrat J, de Soto LM, Bueno D, Díaz L, Queiruga J, Mariblanca AR, Guerra-García P, Ramírez E, Frías J, Martínez AP, Carcas-Sansuán AJ, Borobia AM. Experience of a strategy including cyp2c19 preemptive genotyping followed by therapeutic drug monitoring of voriconazole in patients undergoing allogeneic hematopoietic stem cell transplantation. *Front Pharmacol.* 2021; 12: 717932. Article. IF: 5.988; Q1
- García-García I, Guerra-García P, Ferreras C, Borobia AM, Carcas AJ, Queiruga-Parada J, Vicario JL, Mirones I, Solano C, Eguizabal C, Soria B, Pérez-Martínez A. A phase I/II dose-escalation multi-center study to evaluate the safety of infusion of natural killer cells or memory T cells as adoptive therapy in coronavirus pneumonia and/or lymphopenia: RELEASE study protocol. *Trials.* 2021; 22(1): 674. Article. IF: 2.728; Q4
- Delgado A, Stewart S, Urroz M, Rrodríguez A, Borobia AM, Akatbach-Bousaid I, González-Munoz R, Ramírez E. Characterisation of drug-induced liver injury in patients with COVID-19 detected by a proactive pharmacovigilance program from laboratory signals. *J Clin Med.* 2021; 10(19): 4432. Article. IF: 4.964; Q2

- Rosas-Alonso R, Queiruga J, Arias P, del Monte A, Yuste F, Rrodríguez-Antolin C, Losantos-García I, Borobia AM, Rrodríguez-Novoa S. Analytical validation of a laboratory-development multigene pharmacogenetic assay. *Pharmacogenet Genom.* 2021; 31(8): 177-84. Article. IF: 2; Q4
- Berenguer J, Borobia AM, Ryan P, Rrodríguez-Baño J, Bellón JM, Jarrín I, Carratala J, Pachón J, Carcas AJ, Yllescas M, Arribas JR. Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score. *Thorax.* 2021; 76(9): 920-9. Article. IF: 9.102; Q1
- Saiz-Rodríguez M, Váldez-Acosta S, Borobia AM, Burqueño M, Gálvez-Múgica MA, Acero J, Cabaleiro T, Muñoz-Guerra MF, Puerro M, Llanos L, Martínez-Pérez D, Ochoa D, Carcas AJ, Abad-Santos F. Influence of genetic polymorphisms on the response to tramadol, ibuprofen, and the combination in patients with moderate to severe pain after dental surgery. *Clin Ther.* 2021; 43(5): E86-102. Article. IF: 3.637; Q2
- Pérez-Martínez A, Mora-Rillo M, Ferreras C, Guerra-García P, Pascual-Miguel B, Mestre-Durán C, Borobia AM, Carcas AJ, Queiruga-Parada J, García I, Sánchez-Zapardiel E, Gasior M, De Paz R, Marcos A, Vicario JL, Balas A, Moreno MA, Eguizabal C, Solano C, Arribas JR, Buckley RD, Montejano R, Soria B. Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE). *Eclinicalmedicine.* 2021; 39: 101086. Article. IF: 17.033; D1
- Borobia AM, Carcas AJ, Pérez-Olmeda M, Castaño L, Bertrán MJ, García-Pérez J, Campins M, Portoles A, González-Pérez M, Morales MTG, Arana-Arri E, Aldea M, Díez-Fuentes F, Fuentes I, Ascaso A, Lora D, Imaz-Ayo N, Barón-Mira LE, Agustí A, Pérez-Inguidua C, de la Cámara AG, Arribas JR, Ochando J, Alcamí J, Belda-Iniesta C, Frías J. Immunogenicity and reactivity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label,

randomised, controlled, phase 2 trial. *Lancet.* 2021; 398(10295): 121-30. Article. IF: 202,731; D1


- Tong HY, Borobia AM, Quintana-Díaz M, Fabra S, González-Vinolis M, Fernández-Capitán C, Rodríguez-Dávila MA, Lorenzo A, López-Parra AM, Ruiz-Giménez N, Abad-Santos F, Suárez C, Madridano O, Gómez-Cerezo JF, Llamas P, Baeza-Richer C, Arroyo-Pardo E, Carcas AJ. Acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolism: a randomised clinical trial. *J Clin Med.* 2021; 10(13): 2949. Article. IF: 4.964; Q2
- Gutiérrez-Gutiérrez B, del Toro MD, Borobia AM, Carcas A, Jarrín I, Yllescas M, Ryan P, Pachón J, Carratala J, Berenguer J, Arribas JR, Rodríguez-Bano J. Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study. *Lancet Infect Dis.* 2021; 21(6): 783-92. Article. IF: 71.421; D1
- Díaz-Menéndez M, Trigo E, Borobia AM, Arsuaiga M, de la Calle-Prieto Fernando, Buckley RD, Lago M, Arribas JR. Presenting characteristics and outcomes of migrants in a cohort of hospitalized patients with COVID-19: Does the origin matter? *Travel Med Infect Dis.* 2021; 42: 102027. Letter. IF: 20.441; D1
- Prieto-Escolar M, Torrado JJ, Álvarez C, Ruiz-Picazo A, Simón-Vázquez M, Govantes C, Frías J, García-Arieta A, González-Álvarez I, Bermejo M. One and two-step in vitro-in vivo correlations based on usp iv dynamic dissolution applied to four sodium montelukast products. *Pharmaceutics.* 2021; 13(5): 690. Article. IF: 6.525; Q1
- García LMG, Escudero A, Mestre C, Soler JLF, Martínez AP, Valero JMV, Vela M, Ruz B, Navarro A, Fernández L, Fernández A, Leivas A, Martínez-López J, Ferreras C, de Paz R, Blanquer M, Galán V, González B, Corral D, Sisinni L, Mirones I, Balas A, Vicario JL, Valle P, Borobia AM, Pérez-Martínez A. Phase 2 clinical trial of infusing haploidentical k562-mb15-41bblactivated and expanded natural killer cells as consolidation therapy for pediatric acute myeloblastic leukemia. *Clin Lymph Myelom Leuk.* 2021; 21(5): 328-37. Article. IF: 2.822; Q3
- Meseguer ES, Elizalde MU, Borobia AM, Ramirez E. Valproic acid-induced liver injury: a case-control study from a prospective pharmacovigilance program in a tertiary hospital. *J Clin Med.* 2021; 10(6): 1153. Article. IF: 4.964; Q2
- Borobia AM, García-García I, Díaz-García L, Rodríguez-Mariblanca A, de Soto LM, Villatoro JM, Meseguer ES, González JJ, Iniesta JF, García ER, Arribas JR, Carcas-Sansuan AJ. Healthcare workers' reasons for choosing between two different covid-19 prophylaxis trials in an acute pandemic context: single-center questionnaire study. *J Med Internet Res.* 2021; 23(2): e23441. Article. IF: 7.076; D1
- García-García I, Borobia AM. Current approaches and future strategies for the implementation of pharmacogenomics in the clinical use of azole antifungal drugs. *Expert Opin Drug Met.* 2021; 17(5): 509-14. Editorial Material. IF: 4.936; Q1
- Pedraza L, Laosa O, Rrodríguez-Mañas L, Gutiérrez-Romero DF, Frías J, Carnicero JA, Ramírez E. Drug induced liver injury in geriatric patients detected by a two-hospital prospective pharmacovigilance program: a comprehensive analysis using the rousell uclaf causality assessment method. *Front Pharmacol.* 2021; 11: 600255. Article. IF: 5.988; Q1
- Borobia A, Canogar R. Nonsparse companion hessenberg matrices. *Electron J Linear Al.* 2021; 37: 193-210. Article. IF: 0.882; Q3
- Chen YT, Fuentes PR, Saez PO, Villegas TV, Soto AB, Calle PF, Cardona CC, Mora JC, Canadas MJ, Tong HY, Borobia AM. Efficacy of a fast-track pathway for managing uncomplicated renal or ureteral colic in a hospital emergency department: the STONE randomized clinical trial of Sonography and Testing of a Nephrolithiasis Episode. *Emergencias.* 2021; 33(1): 23-8. Article. IF: 5.345; Q1

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

- de Celis-Ruiz E, Fuentes B, Moniche F, Montaner J, Borobia AM, Gutiérrez-Fernández M, Díez-Tejedor E. Allogeneic adipose tissue-derived mesenchymal stem cells in ischaemic stroke (AMASCIS-02): a phase IIb, multicentre, double-blind, placebo-controlled clinical trial protocol. *BMJ Open*. 2021; 11(8): e051790. Article. IF: 3.006; Q2
- Fabbri A, Borobia AM, Ricard-Hibon A, Coffey F, Caumont-Prim A, Montestruc F, Soldi A, Lulgilde ST, Dickerson S. Low-dose methoxyflurane versus standard of care analgesics for emergency trauma pain: a systematic review and meta-analysis of pooled data. *J Pain Res*. 2021; 14: 93-105. Review. IF: 2.832; Q3

■ Research projects

Borobia Pérez A. Contrato de intensificación (INT19/00055). ISCIII. 2020-2021.

Management centre: FIBHULP

Borobia Pérez A. Coordinación del ensayo clínico Ensayo multicéntrico, adaptativo, aleatorizado y controlado sobre la seguridad y eficacia de las estrategias antitrombóticas en adultos hospitalizados con COVID-19 (). New York University School of Medicine. 2020-Ongoing.

Management centre: FIBHULP

Borobia Pérez A. Corona Accelerated R&D in Europe (H2020-JTI-IMI2-2020-21-single-stage). UE. 2020-2025.

Management centre: FIBHULP

Borobia Pérez A. Ensayo clínico aleatorizado y multicéntrico para evaluar la efectividad y la eficiencia de una estrategia de genotipado anticipado de voriconazol en pacientes con riesgo de aspergilosis (PI18/01322). ISCIII. 2019-2021.

Management centre: FIBHULP

Borobia Pérez A. European Regimen Accelerator for Tuberculosis - ERA4TB (H2020-JTI-IMI2-2018-15). UE. 2019-Ongoing.

Management centre: FIBHULP

Borobia Pérez A. Marie Skłodowska-Curie Actions - Individual Fellow (CareInTrials). UE. 2019-2023.

Management centre: FIBHULP

Borobia Pérez A. Puesta en marcha del estudio A randomized, double-blind, placebo-controlled, parallel-group, multicentre study of the efficacy and safety of nicotinamide in patients with Friedreich's ataxia (NICOFA) (). ECRIN European Clinical Research Inf. 2020-Ongoing.

Management centre: FIBHULP

Borobia Pérez A. Puesta en marcha y realización del ensayo clínico. Proyecto Acanto y proyecto Facet. Fundación para la Investig Biomédica Hospital Universitario de Getafe. 2018-Ongoing.

Management centre: FIBHULP

Borobia Pérez A. Registro de pacientes atendidos en la unidad de farmacoge-

nética del Hospital La Paz y análisis de la actividad realizada desde su creación. Varios. 2017-Ongoing.

Management centre: FIBHULP

Borobia Pérez A. Tareas necesarias para la puesta en marcha y realización del ensayo clínico Treatment of high grade non-muscle invasive urothelial carcinoma of the bladder by standard number and dose of intravesical BCG instillations versus reduced number of intravesical instillations with standard dose of BCG, a european association of urology research foundation randomised phase iii clinical trial- nimbus. Fundación para la Investigación de la Asociación Europea de Urología. 2017-Ongoing.

Management centre: FIBHULP

Borobia Pérez A. Tareas necesarias para la puesta en marcha y realización del estudio observacional Estudio de evaluación y manejo del dolor agudo en Servicios de Urgencias hospitalarias e intervención educativa: estudio Edurg17. Laboratorio Menarini S. A. 2018-Ongoing.

Management centre: FIBHULP

Borobia Pérez AM, López-Sendón Henstchel JL. A multicentre, adaptative, randomize controlled platform trial of the safety and efficacy of antithrombotic and adicional strategies in hospitalized adult with COVID-19. National Institute of Health. 2020-Ongoing.

Management centre: FIBHULP


Carcas Sansuán AJ. Contrato de intensificación (INT19/00082). ISCIII. 2020-2021.


Management centre: FIBHULP

Carcas Sansuán AJ. Contrato Río Horteiga (CM19/00243). ISCIII. 2019-Ongoing.

Management centre: FIBHULP

Carcas Sansuán AJ. Identificación me-





1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

diante diferentes estrategias ómicas, de biomarcadores que permitan la mejora en la individualización de tacrolimus en pacientes pediátricos con trasplante renal (PI18/00136). ISCIII. 2019-2021.

Managment centre: FIBHULP

Frías Iniesta J. Población en riesgo de hipertermia maligna: cohorte ambispectiva (PI20/01444). ISCIII. 2021-2023.

Managment centre: FIBHULP

Frías Iniesta J. Unidad clínica de Investigación y Control de Ensayos Clínicos. CM. 2011-Ongoing.

Managment centre: FIBHULP

■ Cibers & Retics

Frías Iniesta J. Plataforma de Unidades de Investigación Clínica y Ensayos Clínicos. (PT17/0017/0013). ISCIII. (31/12/2021).

Managment centre: FIBHULP

Frías Iniesta J. European Clinical Research Infrastructures Network. EU. (31/12/2023).

Managment centre: FIBHULP

■ Clinical trials

Borobia Pérez, A. Ensayo clínico de fase II, comparativo, aleatorizado, adaptativo para evaluar la seguridad e inmunogenicidad de una dosis de cominarty® en sujetos que hayan recibido una dosis de devaxzeria.

Type: Clinical Trials, phase II.

HULP code: 5859 CombiVacS.

Sponsored by: Instituto Salud Carlosiii.

Signed date: 15/04/2021

Borobia Pérez, A. Estudio de fase III, multinacional, observador ciego, aleatorizado, controlado con placebo para demostrar la eficacia de una dosis única de la vacuna en investigación rsvpref3 oa de gsk en adultos de 60 años o más de edad.

Type: Clinical Trials, phase III.

HULP code: 5775 212494 (RSV OA=ADJ-006).

Sponsored by: Glaxosmithkline, S.A.

Signed date: 20/05/2021

Borobia Pérez, A. Estudio de fase III, multinacional, observador ciego, aleatorizado, controlado con placebo para demostrar la eficacia de una dosis única de la vacu-

na en investigación rsvpref3 oa de gsk en adultos de 60 años o más de edad.

Type: Clinical Trials, phase III.

HULP code: Appendix 1 5775.

Sponsored by: Glaxosmithkline, S.A.

Signed date: 30/06/2021

Borobia Pérez, A. Estudio fase III, observador-ciego, aleatorizado, internacional para evaluar la consistencia de lotes de la vacuna candidata de gsk para inmunización materna frente al vrs, así como, la respuesta inmune, seguridad y reactogenicidad de esta vacuna candidata de gsk frente al vrs en coadministración con la vacuna tetravalente d-qiv de gsk frente a gripe, en mujeres sanas no embarazadas de 18 a 49 años de edad.

Type: Clinical Trials, phase III.

HULP code: 5916 214709 (RSV MAT-010).

Sponsored by: Glaxosmithkline, S.A.

Signed date: 28/06/2021

■ Patents and trademarks

Lapunzina Badía P, Borobia Pérez AM, Carcas Sansuán AJ, Tenorio Castaño

JA, Arias Lajara P, Lubomirov Jristov R, authors; FIBHULP, UAM, assignees. Brand name: PharmArray. USM 86.004.412, CM 11.608.403; 2013 July 08, 2013 February 27.




Carcas Sansuán AJ, Borobia Pérez AM, authors; FIBHULP, assignee. Brand name: CRDataX. CM 13.681.614; 2015 May 28.



Lapunzina Badía PD, Borobia Pérez AM, Carcas Sansuán AJ, Tenorio Castaño JA, Arias Lajara P, Frías Iniesta J, Dapia García I, Muñoz M, authors; FIBHULP, UAM, assignees. Brand name: ClinPharmarray., CM15489511; 2016 May 31, 2016 September 07.





1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



3.6.4 Osteoarticular Surgery Research - GICOA Group

Publications: 40

Q1: 15

COMPOSITION



Enrique Gómez Barrena. Jefe de Sección de Cirugía Ortopédica y Traumatología. Hospital Universitario La Paz. Catedrático de Cirugía Ortopédica y Traumatología. Facultad de Medicina. Universidad Autónoma de Madrid

Samuel Antuña Antuña. Jefe de Sección en Cirugía Ortopédica y Traumatología. Hospital Universitario La Paz. Profesor Asociado en Cirugía Ortopédica y Traumatología. Facultad de Medicina. Universidad Autónoma de Madrid

Raúl Barco Laakso. Facultativo Especialista de Área en Cirugía Ortopédica y Traumatología. Hospital Universitario La Paz

Ana Cruz Pardos. Facultativo Especialista de Área en Cirugía Ortopédica y Traumatología. Hospital Universitario La Paz

Marta Domínguez García-Simón. Enfermera Coordinadora de Ensayos Clínicos. Universidad Autónoma de Madrid

Eduardo García Rey. Facultativo Especialista de Área en Cirugía Ortopédica y Traumatología. Hospital Universitario La Paz. Profesor Asociado en Cirugía Ortopédica y Traumatología. Facultad de Medicina. Universidad Autónoma de Madrid

Pablo Hernández Esteban. Facultativo Especialista de Área en Cirugía Ortopédica y Traumatología. Hospital Universitario La Paz

Carlos Agustín Hernández Gil. Facultativo Especialista de Área en Cirugía Ortopédica y Traumatología. Hospital Universitario La Paz

Norma Griset Padilla Eguiluz. Investigadora Predoctoral. Universidad Autónoma de Madrid


Carlos Emérito Rodríguez Merchán. Facultativo Emérito de Cirugía Ortopédica y Traumatología. Hospital Universitario La Paz

Juan Carlos Rubio Suárez. Jefe de Sección de Cirugía Ortopédica y Traumatología. Hospital Universitario La Paz

STRATEGIC OBJECTIVE

Orthopaedic implant studies are required to assess the results of implants, detect the causes of failure, and deepen our understanding of the prevention and solution of these failures. The medical, social, and economic relevance of orthopaedic implants, and their influence on quality of life, place this technology in the centre of translational research in orthopaedic surgery. Reconstruction based on biological

strategies and biomaterials is rapidly evolving, and cutting edge research on these topics may offer an advantage in clinical translational research. The group has also developed studies on sports medicine and ligament reconstruction, with various outcome approaches and devices that may enhance surgical results. In this context, a multidisciplinary clinical and basic research group on orthopaedic surgery deepens our understanding of a wide variety of current research topics in the field and provides further progress towards clinical translation.



1 Introduction

In order to contribute to new advances in the field, our main clinical and experimental objectives are addressed by a joint research line that covers issues related to bone and joint reconstruction. These issues include the following:

- Failed hip and knee prostheses, including the material, biological, and clinical mechanisms of failure. This research may lead to proposals for materials and design modifications in orthopaedic implants and reconstructive devices and techniques. Functional recovery of the patient is the ultimate goal, considering various scenarios from an experimental and clinical point of view.

- Regenerative medicine approaches to bone and joint reconstruction, to generate preclinical and clinical proposals for bone and joint regeneration and repair, both in traumatic and non-traumatic bone and soft-tissue injuries.

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

RESEARCH LINES

- Clinical and basic research in Orthopaedics implants, and in bone and joint reconstruction.

RESEARCH ACTIVITY

■ Doctoral theses

Machio Candela N. Tumores malignos de las glándulas salivales: estudio retrospectivo de los pacientes tratados en el Hospital La Paz entre 2008 y 2018 [dissertation]. Madrid: UAM: 2021(16/06/2021).

Director: Gómez Barrena E.

■ Publications

- de la Corte-Rodríguez H, Rodríguez-Merchán EC, Álvarez-Román MT, Jiménez-Yuste V. Applying world health organization 2020 guidelines on physical activity and sedentary behavior to people with hemophilia. *Expert Rev Hematol.* 2021; 14(5): 429-36. Review. IF: 2.819; Q3
- Encinas-Ullán CA, Gómez-Cardero P, Ruiz-Pérez JS, Rodríguez-Merchán EC. Dislocation of rotating-hinge total knee arthroplasty. *Efort Open Rev.* 2021; 6(2): 107-12. Article. IF: 4.775; Q1
- Esteban J, Gómez-Barrena E. An update about molecular biology techniques to detect orthopaedic implant-related infections. *EFORT Open Rev.* 2021; 6(2): 93-100. Article. IF: 4.775; Q1
- Fernández-Fernández R, Díaz-Freire P, Rubio-Suárez JC. Open reduction and navigated iliosacral screws for vertically unstable pelvic fractures. *Injury.* 2021; 52: S22-6. Article. IF: 2.687; Q2
- García-Rey E, Bizot P, García-Cimbrelo E. Ceramic-on-ceramic cementless total hip arthroplasty in patients aged 40 years or under: Do preopera-

tive conditions affect long-term results? *Orthop Traumatol-Sur.* 2021; 107(1): 102763. Article. IF: 2.425; Q3


- García-Rey E, Saldaña L, García-Cimbrelo E. Impaction bone grafting in hip re-revision surgery bone stock restoration and radiological migration of the acetabular component. *Bone Joint J.* 2021; 103B(3): 492-9. Article. IF: 5.385; D1
- García-Rey E. CORR Insights (R): Intraosseous regional prophylactic antibiotics decrease the risk of prosthetic joint infection in primary tka: a multicenter study. *Clin Orthop Relat R.* 2021; 479(11): 2513-5. Editorial Material. IF: 4.755; Q1
- Gavín C, Blanco FJ, Pablos JL, Caracuel MA, Rosas J, Gómez-Barrena E, Navarro F, Coronel MP, Gimeno M. One-year, efficacy and safety open label study, with a single injection of a new hyaluronan for knee OA: The SOYA trial. *J Pain Res.* 2021; 14: 2229-37. Article. IF: 2.832; Q3
- Gómez-Barrena E, Padilla-Eguiluz NG, Rosset P, Hernigou P, Baldini N, Ciapetti G, Gonzalo-Daganzo RM, Avendaño-Sola C, Rouard H, Gior-dano R, Dominici M, Schrezenmeier H, Layrolle P. Osteonecrosis of the femoral head safely healed with autologous, expanded, bone marrow-derived mesenchymal stromal cells in a multicentric trial with minimum 5 years follow-up. *J Clin Med.* 2021; 10(3): 508. Article. IF: 4.964; Q2
- Gómez-Barrena E, Padilla-Eguiluz NG. Implantation of autologous expanded mesenchymal stromal cells in hip osteonecrosis through percutaneous forage: evaluation of the operative technique. *J Clin Med.* 2021; 10(4): 743. Article. IF: 4.964; Q2
- Hachem AI, Rondanelli SR, Rius X, Barco R. Latar-

jet cerclage: The all-arthroscopic metal-free fixation. *Arthrosc Tech.* 2021; 10(2): e437-50. Article. Not Indexed

- Jiménez-Yuste V, Rodríguez-Merchán EC, Matsushita T, Holme PA. Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery. *Haemophilia.* 2021; 27(4): 519-30. Review. IF: 4.263; Q2
- Maestro-Paramio L, García-Rey E, Bensiamar F, Saldaña L. Osteoblast function in patients with idiopathic osteonecrosis of the femoral head IMPLICATIONS FOR A POSSIBLE NOVEL THERAPY. *Bone Joint Res.* 2021; 10(9): 619-28. Article. IF: 4.41; Q1
- Meglic U, Szakacs N, Menozzi M, Barco R, Alentorn-Geli E, Colozza A. Role of the interosseous membrane in post-traumatic forearm instability: instructional review. *Int Orthop.* 2021; 45(10): 2619-33. Review. IF: 3.479; Q2
- Merino-Rueda LR, Rubio-Sáez I, Mills S, Rubio-Suárez JC. Mortality after distal femur fractures in the elderly. *Injury.* 2021; 52: S71-5. Article. IF: 2.687; Q2
- Mills S, Ibarzábal-Gil A, Martínez-Díez JM, Pallares-Sanmartín J, Kalbakkij-Sánchez C, Rubio-Suárez JC, Losantos-García I, Rodríguez-Merchán EC. SARS-CoV-2 outbreak impact on a trauma unit. *World J Orthop.* 2021; 12(10): 751-9. Article. Not Indexed
- Padilla-Eguiluz NG, Gómez-Barrena E. Epidemiology of long bone non-unions in Spain. *Injury.* 2021; 52: S3-7. Article. IF: 2.687; Q2
- Perino G, De Martino I, Zhang LX, Xia ZD, Gallo J, Natsu S, Langton D, Huber M, Rakow A,

Schoon J, Gómez-Barrena E, Krenn V. The contribution of the histopathological examination to the diagnosis of adverse local tissue reactions in arthroplasty. *EFORT Open Rev.* 2021; 6(6): 399-419. Article. IF: 4.775; Q1

- Platt M, Hasselgren A, Román-Belmonte JM, de Oliveira MT, de La Corte-Rodríguez H, Olabarriaga SD, Rodríguez-Merchán EC, Mackey TK. Test, trace, and put on the blockchain?: a viewpoint evaluating the use of decentralized systems for algorithmic contact tracing to combat a global pandemic. *JMIR Public Health Surveill.* 2021; 7(4): e26460. Article. IF: 14.557; D1
- Rodríguez-Merchán EC, Davidson DJ, Liddle AD. Recent strategies to combat infections from biofilm-forming bacteria on orthopaedic implants. *Int J Mol Sci.* 2021; 22(19): 10243. Review. IF: 6.208; Q1
- Rodríguez-Merchán EC, de la Corte-Rodríguez H, Encinas-Ullán CA, Gómez-Cardero P. Complications of surgical reconstruction of multiligament injuries of the knee joint: diagnosis, prevention and treatment. *Efort Open Rev.* 2021; 6(10): 973-81. Article. IF: 4.775; Q1
- Rodríguez-Merchán EC, de la Corte-Rodríguez H. Pain management in people with hemophilia in childhood and young adulthood. *Expert Rev Hematol.* 2021; 14(6): 525-35. Review. IF: 2.819; Q3
- Rodríguez-Merchán EC, de Pablo-Moreno JA, Liras A. Gene therapy in hemophilia: Recent advances. *Int J Mol Sci.* 2021; 22(14): 7647. Review. IF: 6.208; Q1
- Rodríguez-Merchán EC, Encinas-Ullán CA, Gómez-Cardero P. Effectiveness of ankle fusion in patients with hemophilia, advanced ankle dege-



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

neration, and unbearable pain for whom nonsurgical and surgical treatments have been ineffective. *Expert Rev Hematol.* 2021; 14(6): 517-24. Review. IF: 2.819; Q3

- Rodríguez-Merchán EC, Gómez-Cardero P, Encinas-Ullán CA. Management of bone loss in revision total knee arthroplasty: therapeutic options and results. *EFORT Open Rev.* 2021; 6(11): 1073-86. Article. IF: 4.775; Q1
- Rodríguez-Merchán EC, Kachooei AR. Is there any difference in the survival of conversion tka after previous hto in compare to previous UKA? Factors to be considered when offering a surgery. *Arch Bone Jt Surg.* 2021; 9(4): 368-70. Editorial Material. Not Indexed
- Rodríguez-Merchán EC, Moracia-Ochagavía I. Tarsal tunnel syndrome: current rationale, indications and results. *EFORT Open Rev.* 2021; 6(12): 1140-7. Article. IF: 4.775; Q1
- Rodríguez-Merchán EC. A Review of recent developments in the molecular mechanisms of bone healing. *Int J Mol Sci.* 2021; 22(2): 767. Review. IF: 6.208; Q1
- Rodríguez-Merchán EC. Acute hematogenous infections after total knee arthroplasty: results of debridement, antibiotics, and implant retention. *Arch Bone Jt Surg.* 2021; 9(3): 249-54. Review. Not Indexed
- Rodríguez-Merchán EC. Anterior cruciate ligament reconstruction: is biological augmentation beneficial? *Int J Mol Sci.* 2021; 22(22): 12566. Review. IF: 6.208; Q1
- Rodríguez-Merchán EC. Enormous articular hemorrhage following arthroscopy, total joint replacement and other surgical operations in hemophilic patients due to arterial pseudoaneurysms: diagnosis and treatment. *Arch Bone Jt Surg.* 2021; 9(5): 475-9. Review. Not Indexed
- Rodríguez-Merchán EC. Haemophilic arthropathy: Contemporary management challenges and a future scenario. *Haemophilia.* 2021; 27(6): E765-67. Letter. IF: 4.263; Q2
- Rodríguez-Merchán EC. Hemophilic arthropathy: a teaching approach devoted to hemophilia treaters in under-development countries. *Expert Rev Hematol.* 2021; 14(10): 887-96. Review. IF: 2.819; Q3
- Rodríguez-Merchán EC. Patient satisfaction following primary total knee arthroplasty: contributing factors. *Arch Bone Jt Surg.* 2021; 9(4): 379-86. Review. Not Indexed
- Rodríguez-Merchán EC. Recent advances in surgery and its perioperative treatment in people with hemophilia. *Expert Rev Hematol.* 2021;

14(3): 271-9. Review. IF: 2.819; Q3

- Rodríguez-Merchán EC. What does the Cochrane database of systematic reviews say with regard to the surgical management of knee osteoarthritis? *Arch Bone Jt Surg.* 2021; 9(3): 247-8. Editorial Material. Not Indexed
- Román-Belmonte JM, de la Corte-Rodríguez H, Rodríguez-Merchán EC. Artificial intelligence in musculoskeletal conditions. *Front Biosci (Landmark Ed).* 2021; 26(11): 1340-8. Review. IF: 3.115; Q3
- Rubio-Yanchuck M, Rubio-Suarez JC, Rodríguez-Merchán EC. Factors that Influence Soft-tissue Injury in Fractures of the Distal Tibia. *Arch Bone Jt Surg.* 2021; 9(2): 152-7. Article. Not Indexed
- Vallés G, García-Rey E, Saldaña L, García-Cimbrello E, Vilaboa N. Wear of hip prostheses increases serum IGFBP-1 levels in patients with aseptic loosening. *Sci Rep-Uk.* 2021; 11(1): 576. Article. IF: 4.996; Q2
- Weitz JI, Strony J, Ageno W, Gailani D, Hylek EM, Lassen MR, Mahaffey KW, Notani RS, Roberts R, Segers A, Raskob GE, (Gómez-Barrena E). Milvexian for the prevention of venous thromboembolism. *New Engl J Med.* 2021; 385(23): 2161-72. Article. IF: 176.079; D1

■ Research projects

Gómez Barrena E. ORTHO-3, uso de células mesenquimales de donante expandidas para la regeneración ósea en osteonecrosis de cabeza femoral desarrollada tras trasplante de médula ósea (PI17/01844). ISCIII. 2018-2022.


Management centre: FIBHULP

Barco Laakso R. Artoplastía de cabeza radial anatómica versus espaciador de metal de vástago liso para traumatismo de codo. *Médical Simulator S. L.* 2018-Ongoing.

Management centre: FIBHULP

Barco Laakso R. Morfología radiocapitelar, un estudio anatómico. *Acumed LLC.* 2018-Ongoing.

Management centre: FIBHULP



Barco Laakso R. Terapia celular con células troncales derivadas del tejido adiposo (ASC) para mejorar el proceso de reparación en suturas tendinosas. Unión tendón-hueso (roturas del manguito rotador); unión tendón-músculo (roturas del tendón de aquiles). *Sociedad Española de Cirugía Ortopédica y Traumatología.* 2009-Ongoing.

Management centre: FIBHULP

Gómez Barrena E. Desinfección in vivo de implantes ortopédicos metálicos mediante calor generado por inducción electromagnética. *Fundación Mutua Madrileña.* 2020-Ongoing.

Management centre: FIBHULP

García Rey E. Identificación de factores moleculares implicados en la Osteonecrosis Idiopática: análisis del transcriptoma del tejido óseo (PI18/00643). *ISCIII.* 2018-Ongoing.


Management centre: FIBHULP

Gómez Barrena E. ORTHOpedic randomized clinical trial with expanded bone marrow MSC and bioceramics versus autograft in long bone nonUNIONS (ORTHOUNION). *UE.* 2017-2022.

Management centre: FIBHULP

■ Patents and trademarks

Arenas Vara MA, Conde del Campo A, De Damborenea González JJ, Matykina E, Esteban Moreno J, Gómez Barrena E, Pérez-Jorge Peremarch C, Pérez Tanoira R, inventors; CSIC, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, assignees. Titanium materials anodised with fluorine. P201030720, PCT/ES2011/070342; 2010 May 14



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



3.6.5 Research in Oral and Maxillofacial Surgery Group

Publications: 18

Q1: -

COMPOSITION

■ **José Luis Cebrián Carretero.** Jefe de Sección en Cirugía Oral y Maxilofacial. Hospital Universitario La Paz

■ **Ana Sastre Perona.** Investigadora Postdoctoral (Contrato Miguel Serveet Tipo I). FIBHULP

Estefanía Alonso Rodríguez. Facultativo Especialista de Área en Cirugía Oral y Maxilofacial. Hospital Universitario La Paz

Javier González Martín-Moro. Facultativo Especialista de Área en Cirugía Oral y Maxilofacial. Hospital Universitario La Paz

José Luis del Castillo Pardo de Vera. Facultativo Especialista de Área en Cirugía Oral y Maxilofacial. Hospital Universitario La Paz

María José Morán Soto. Facultativo Especialista de Área en Cirugía Oral y Maxilofacial. Hospital Universitario La Paz

Pedro Manuel Losa Muñoz. Facultativo Especialista de Área en Cirugía Oral y Maxilofacial. Hospital Universitario La Paz


STRATEGIC OBJECTIVE

Latest technologies applied to the field of planning and treatment in Head and Neck Oncology have allowed to improve the diagnosis and surgical treatment in Oral Cancer patients.

Our aim, with this project, is to establish a work-flow in which technological and technical advances were included as a part of the protocol of treatment for oral cavity cancer patients.

RESEARCH LINES

- Multidisciplinary Diagnosis and Treatment of Head and Neck Cancer
- Analysis of risk factors and prognosis in oral cavity cancer
- Diagnosis and treatment of postoperative pain
- Quality of life of the oncological patient
- Prevention of the consequences of the treatment of Head and Neck Cancer.



RESEARCH ACTIVITY

■ Publications

- Antúñez-Conde R, Cuellar CN, Escobar JIS, Díez-Montiel A, Cuellar IN, Orabona GD, de Vera JLDP, Vila CN, Carretero JLC. Intraosseous venous malformation of the zygomatic bone: comparison between virtual surgical planning and standard surgery with review of the literature. *J Clin Med.* 2021; 10(19): 4565. Review. IF: 4.964; Q2
- Contreras Albert M, Carretero JLC. Iatrogenic maxillary sinusitis by dental impression material. *Rev Cubana Estomatol.* 2021; 58(2): e2826. Article. Not Indexed
- de Vera JLDP, Cuellar CN, Cuellar IN, Carretero JLC, Martínez SB, Alonso MIGH, Sánchez-Pérez A, Zamorano-Leon JJ, López-Farre AJ, Vila CN. Clinical and surgical outcomes in extensive scalp reconstruction after oncologic resection: a comparison of anterolateral thigh, latissimus dorsi and omental free flaps. *J Clin Med.* 2021; 10(17): 3863. Article. IF: 4.964; Q2
- Gallego-Albertos CS, Vera JLDP, Llorente AV, Carretero JLC. Medication related osteonecrosis of the jaws (MRONJ): Factors related to recurrence after treatment with surgery and platelet rich plasma (PRP) placement. *Med Oral Patol Oral.* 2021; 26(6): E684-90. Article. IF: 2.883; Q2
- Garrido-Martínez P, Pena-Cardelles JF, Pozo-Kreilinger JJ, Esparza-Gómez G, Montesdeoca-García N, Cebrian-Carretero JL. Dental implants rehabilitation in a patient with head and neck radiotherapy for osteosarcoma in the jaw. A clinical case report. *J Clin Exp Dent.* 2021; 13(4): e418-21. Article. Not Indexed
- Garrido-Martínez P, Pena-Cardelles JF, Pozo-Kreilinger JJ, Esparza-Gómez G, Montesdeoca-García N, Cebrián-Carretero JL. Jaw in a day: Osseointegration of the implants in the patient's leg before reconstructive surgery of a maxilla with ameloblastoma. A 4-year follow-up case report. *J Clin Exp Dent.* 2021; 13(1): e81-7. Article. Not Indexed
- Hornillos de Villota M, Pozo Kreilinger JJ, del Castillo Pardo de Vera JL, Cebrián Carretero JL. Disseminated basosquamous carcinoma: a case report. *Rev Esp Cirug Oral y Maxilofac.* 2021; 43(4): 166-9. Article. Not Indexed
- Machío N, Pozo Kreilinger JJ, Blanco María B,

- del Castillo Pardo de Vera JL, Malet Contreras A, Burguenio García M, Cebrián Carretero JL. Malignant salivary gland tumors: a retrospective study of patients treated at La Paz hospital between 2008 and 2018. *Rev Esp Cirug Oral y Maxilofac.* 2021; 43(3): 90-5. Article. Not Indexed
- Pampín Martínez MM, del Castillo Pardo de Vera JL, Guiñales Díaz de Cevallos J, Dueso Delgado V, Cebrián Carretero JL. Reposicionamiento meniscal de la articulación temporomandibular con minitornillos de anclaje MITEK: estudio clínico y por RM a medio plazo. *Rev Esp Cirug Oral y Maxilofac.* 2021; 43(4): 134-9. Article. Not Indexed
- Pampín Martínez MM, Dueso Delgado V, Gómez García E, Cebrián Carretero JL. Técnica de suspensión de la fosa nasal en injerto óseo secundario en fisura alveolar unilateral: nota técnica. *Rev Esp Cirug Oral y Maxilofac.* 2021; 43(4): 162-5. Article. Not Indexed
- Pen JF, Moro-Rodríguez JE, Cebrián-Carretero JL, Pozo-Kreilinger JJ. Commentary on 'Relationship of programmed death ligand-1 expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma: A meta-analysis' (He et al., (2020) *Archives of Oral Biology*, 114, 104717). *Arch Oral Biol.* 2021; 132: 105274. Editorial Material. IF: 2.64; Q3
- Pena-Cardelles JF, Pozo-Kreilinger JJ, Roncador G, Esteban-Hernández J, Cebrián-Carretero JL, Moro-Rodríguez JE. Expression of clec9a in the oral cancer microenvironment. A preliminary immunohistochemical pilot study. *Med Oral Patol Oral.* 2021; 26(5): E651-60. Article. IF: 2.883; Q2
- Pena-Cardelles JF, Salgado-Peralvo AO, Garrido-Martínez P, Carretero JLC, Pozo-Kreilinger JJ, Moro-Rodríguez JE. Oral mucositis. Is it present in the immunotherapy of the immune checkpoint pd1/pd-1 against oral cancer? A systematic review. *Med Oral Patol Oral.* 2021; 26(4): E494-501. Review. IF: 2.883; Q2
- Ramos-Zayas A, López-Medrano F, Urquiza-Fornovi I, Zubillaga I, Gutiérrez R, Sánchez-Aniceto G, Acero J, Almeida F, Galdona A, Morán MJ, Pampín M, Cebrián JL. The impact of healthcare-associated infections in patients undergoing oncological microvascular head and neck reconstruction: a prospective multicentre study. *Cancers (Basel).* 2021; 13(9): 2109. Article. IF: 6.575; Q2

- Sánchez Gallego Albertos C, Pozo Kreilinger JJ, Fernández Baillo Gallego de la Sacristana N, Cebrián Carretero JL. Sacral metastasis of a low-grade acinar cell carcinoma of the parotid gland. *Rev Esp Cirug Oral y Maxilofac.* 2021; 43(2): 63-6. Article. Not Indexed
- Sánchez Gallego-Albertos C, Losa Muñoz P, Cebrián Carretero JL, Burguenio García M. Reconstrucción de defectos faciales complejos: pared lateral nasal y mejilla media. La importancia de los colgajos independientes. *Rev Esp Cirug Oral y Maxilofac.* 2021; 43(1): 44-7. Article. Not Indexed
- Serrano-García B, Bartrina-Rodríguez I, Zubeldia-Varela JM, Cebrián-Carretero JL, del-Castillo-Pardo-de-Vera JL, Pardo-Montero J, Gil-Martínez A. Preliminary study of the Craniofacial Pain and Disability Inventory-11: validation for patients with head and neck cancer. *Med Oral Patol Oral.* 2021; 26(5): E661-8. Article. IF: 2.883; Q2
- Tapia B, Garrido E, Cebrián JL, del Castillo JL, González J, Losantos I, Gilsanz F. Impact of goal directed therapy in head and neck oncological surgery with microsurgical reconstruction: free flap viability and complications. *Cancers (Basel).* 2021; 13(7): 1545. Article. IF: 6.575; Q2

■ Research projects

Cebrián Carretero JL. Expresión de moléculas inmunoregulatoras pd1/ pd-1 en el carcinoma oral de células escamosas. Osteoplac Innovations S.L.U. 2021-Ongoing.

Managment centre: FIBHULP

del Castillo Pardo de Vera JL. Determinación de la relación causal entre el empleo de bifosfonatos y el desarrollo de osteonecrosis en los maxilares. Aplicación de células madre mesenquimales para su tratamiento sobre modelo experimental animal. Varios Financiadores. 2015-Ongoing.

Managment centre: FIBHULP

■ Clinical trials

Cebrián Carretero JL. Ensayo clínico aleatorizado, doble ciego, controlado con placebo y con tratamiento activo, para evaluar la eficacia analgésica y la seguridad de una combinación oral de ibuprofeno (arginina)-tramadol hcl administrada a pacientes con dolor moderado a severo tras someterse a cirugía dental.

Type: Clinical Trials, phase III.

HULP code: 5961 FMLD-IOTRA2-47_FIII.

Sponsored by: Farmalider Sa.


Signed date: 18/10/2021"

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



1
Introduction

2
Executive
Summary

3
Information
Groups
by Area

4
Associated
Clinicians



3.6.6 Patients Safety and Quality Research Group

Publications: 24

Q1: 7

COMPOSITION

■ **Elena Ramírez García.** Facultativo Especialista de Área en Farmacología Clínica. Hospital Universitario La Paz

Miguel Avenza Jaén. Fisioterapeuta. Hospital Universitario La Paz

José Antonio Blázquez González. Jefe de Sección de Cirugía Vascul. Hospital Universitario La Paz

Nelson Buitrago Sánchez. Facultativo Especialista de Área en Radiología Pediátrica. Hospital Universitario La Paz

Luis Castro Parga. Facultativo Especialista en Anestesiología y Reanimación. Hospital Universitario La Paz

Susana Francisca Chajma Izquierdo. Facultativo Especialista en Medicina Física y Rehabilitación. Hospital Universitario La Paz

Pilar Durán de la Fuente. Facultativo Especialista en Anestesiología y Reanimación. Hospital Universitario La Paz

María Fernández-Velilla Peña. Facultativo Especialista en Radiología. Hospital Universitario La Paz

Miguel González Muñoz. Facultativo Especialista de Área en Inmunología. Hospital Universitario La Paz

Alberto Martín Vega. Facultativo Especialista de Área en Medicina Preventiva y Salud Pública. Hospital

Universitario La Paz

Bárbara Martínez de Miguel. Facultativo Especialista en Unidad de Radiofarmacia. Responsable del Sistema de Gestión Integrado de Calidad. Hospital Universitario La Paz

Ana Isabel Martínez Escandell. Unidad hospitalización quirúrgica. Hospital Universitario La Paz

Covadonga Mendieta Azcona. Facultativo Especialista en Cirugía Vascul. Hospital Universitario La Paz

Inés Narrillos Martín. Enfermera en Cirugía general y del Aparato digestivo. Hospital Universitario La Paz

José Jonay Ojeda Feo. Facultativo Especialista de Área en Medicina Preventiva y Salud Pública. Hospital Universitario La Paz


Paola Andrea Parra Ramírez. Facultativo Especialista de Área en Endocrinología y Nutrición. Hospital Universitario La Paz

Almudena Quintas Viqueira. Médico Adjunto en Medicina Preventiva. Hospital Universitario La Paz

Ana Robustillo Rodela. Jefe de Servicio de Medicina Preventiva. Hospital Universitario La Paz

Pascual Sanabria Carretero. Jefe de Sección Anestesiología Infantil. Hospital Universitario La Paz

Yuri Fabiola Villán Villan. Responsable de Seguridad del Paciente. Hospital Universitario La Paz



1
Introduction

2
Executive
Summary

3
Information
Groups
by Area

4
Associated
Clinicians

STRATEGIC OBJECTIVE

The occurrence of adverse events due to unsafe care is likely one of the 10 leading causes of death and disability in the world. Research into reducing harm to patients can lead to better health outcomes, as well as significant savings in healthcare costs.

Patient safety is the health care discipline that arises with the increasing complexity of health care systems and the consequent increase in harm to patients. Its objective is to prevent and reduce the risks, errors and damages suffered by patients during the provision of healthcare. A cornerstone of the discipline is continuous improvement based on learning from mistakes and adverse events.

RESEARCH LINES

- Culture of Patient Safety.
- Incident reporting system for notification and analysis of adverse events associated to Healthcare.
- Zero Infections related to Healthcare.
- Safe Surgery Saves Lives, whose purpose is to reduce the risks associated with surgery.
- Safe Medication, reduce the harm of medications.
- Zero venous thromboembolism, in order to reduce complications attributed to hospitalization.
- Safe Health Worker, Safe patients.
- Safe Transfusions, reduce adverse reactions to transfusion.
- Safe Radiations, to the right patient in the right area.
- Safe Diagnostics, reduce errors that can cause harm.
- Septicemia as a medical emergency.

RESEARCH ACTIVITY

■ Doctoral theses

Pedraza Sepúlveda L. Caracterización de la hepatitis por medicamentos en la población geriátrica: Programa de farmacovigilancia proactiva por señales de laboratorio[dissertation]. Madrid: UAM: 2021(22/10/2021).

Directors: Ramírez García E,
Carnicero Carreño JA. .

■ Publications

- Alarcón-Rodríguez J, Fernández-Velilla M, Urena-Vacas A, Martín-Pinacho JJ, Rigual-Bobillo JA, Jaureguizar-Oriol A, Gorospe-Sarasua L. Radiological management and follow-up of post-COVID-19 patients. *Radiologia*. 2021; 63(3): 258-69. Article. Not Indexed
- Alcalá CR, Borbolla AM, Pérez ER, Carretero PS, Barbero FR. Perioperative management of patients with arrhythmogenic syndromes refractory to medical treatment: A clinical case report. *Rev*


Esp Anestesiología Reanimación. 2021; 68(6): 353-6. Article. Not Indexed

- Araujo-Castro M, Lázaro CR, Ramírez PP, Centeno RG, Gimeno PG, Fernández-Ladreda MT, Núñez MAS, Marazuela M, Escobar-Morreale HF, Valderrabano P. Maximum adenoma diameter, regardless of uni- or bilaterality, is a risk factor for autonomous cortisol secretion in adrenal incidentalomas. *J Endocrinol Invest*. 2021; 44(11): 2349-57. Article. IF: 5.467; Q2
- Araujo-Castro M, Ramírez PP, Lázaro CR, Centeno RG, Gimeno PG, Fernández-Ladreda MT, Núñez MAS, Marazuela M, Escobar-Morreale HF, Valderrabano P. Accuracy of the dexamethasone suppression test for the prediction of autonomous cortisol secretion-related comorbidities in adrenal incidentalomas. *Horm-Int J Endocrinol*. 2021; 20(4): 735-44. Article. IF: 3.419; Q3
- Araujo-Castro M, Ramírez PP, Lázaro CR, Centeno RG, Gimeno PG, Fernández-Ladreda MT, Núñez MAS, Marazuela M, Escobar-Morreale HF, Valderrabano P. Predictors of tumour growth and autonomous cortisol secretion development during follow-up in non-functioning adrenal incidentalomas. *J Clin Med*. 2021; 10(23): 5509. Article. IF: 4.964; Q2

- Arcos SC, Lira F, Robertson L, González MR, Carballeda-Sangiao N, Sánchez-Alonso I, Zamorano L, Careche M, Jiménez-Ruiz Y, Ramos R, Llorens C, González-Muñoz M, Oliver A, Martínez JL, Navas A. Metagenomics Analysis Reveals an Extraordinary Inner Bacterial Diversity in Anisakids (Nematoda: Anisakidae) L3 Larvae. *Microorganisms*. 2021; 9(5): 1088. Article. IF: 4.926; Q2
- Borobia AM, García-García I, Díaz-García L, Rodríguez-Mariblanca A, de Soto LM, Villatoro JM, Meseguer ES, González JJ, Iniasta JF, García ER, Arribas JR, Carcas-Sansuán AJ. Health care workers' reasons for choosing between two different covid-19 prophylaxis trials in an acute pandemic context: single-center questionnaire study. *J Med Internet Res*. 2021; 23(2): e23441. Article. IF: 7.076; D1
- Cabañas R, Ramírez E, Bellón T. Identifying the culprit drug in severe cutaneous adverse reactions (SCARs). *Curr Treat Options Allergy*. 2021; 8(3): 194-209. Article. Not Indexed
- Cervera Gil O, Sanabria Carretero P, Castro L, Reinoso Barbero F, Polo López L, Andrés de la Torre C. Original and minimally invasive approach to a left-lung refractory atelectasis after reparation of an aortic recoarctation in a lactant:

Selective endobronchial CPAP. *Rev Esp Anestesiología Reanimación (Engl Ed)*. 2021; 68(7): 420-3. Article. Not Indexed

- Delgado A, Stewart S, Urroz M, Rodríguez A, Borobia AM, Akatbach-Bousaid I, González-Muñoz M, Ramírez E. Characterisation of drug-induced liver injury in patients with covid-19 detected by a proactive pharmacovigilance program from laboratory signals. *J Clin Med*. 2021; 10(19): 4432. Article. IF: 4.964; Q2
- García-García I, Dapia I, Montserrat J, de Soto LM, Bueno D, Díaz L, Queiruga J, Mariblanca AR, Guerra-García P, Ramirez E, Frías J, Martínez AP, Carcas-Sansuán AJ, Borobia AM. Experience of a strategy including cyp2c19 preemptive genotyping followed by therapeutic drug monitoring of voriconazole in patients undergoing allogeneic hematopoietic stem cell transplantation. *Front Pharmacol*. 2021; 12: 717932. Article. IF: 5.988; Q1
- Gil OC, Carretero PS, Castro L, Barbero FR, López LP, de la Torre CA. Original and minimally invasive approach to a left-lung refractory atelectasis after reparation of an aortic recoarctation in a lactant: Selective endobronchial CPAP. *Rev Esp Anestesiología Reanimación*. 2021; 68(7): 420-3. Article. Not Indexed



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

- Hernández-Vaquero D, Rodríguez-Caulo E, Vigil-Escalera C, Blanco-Herrera O, Berastegui E, Arias-Dachary J, Souaf S, Parody G, Laguna G, Adsuar A, Castella M, Valderrama JF, Pulitani I, Canovas S, Ferreira A, García-Valentín A, Carnero M, Pareja P, Corrales JA, Blazquez JA, Macías D, Fletcher-Sanfeliu D, Martínez D, Martín E, Adsuar A, Margarit J, Hernández-Estefanía R, Monguio E, Otero J, Silva J. Differences in life expectancy between men and women after aortic valve replacement. *Eur J Cardio-Thorac.* 2021; 60(3): 681-8. Article. IF: 4.534; Q1
- Loli-Ausejo D, Vilchez-Sánchez F, Cabañas R, Fiandor A, Lluch-Bernal M, González-Muñoz M, Domínguez-Ortega J. Basophil activation test in the diagnosis of hypersensitivity reactions to quinolones in a real-life setting. *Clin Exp Allergy.* 2021; 51(3): 503-7. Letter. IF: 5.401; Q2
- Meseguer ES, Elizalde MU, Borobia AM, Ramírez E. Valproic acid-induced liver injury: a case-control study from a prospective pharmacovigilance program in a tertiary hospital. *J Clin Med.* 2021; 10(6): 1153. Article. IF: 4.964; Q2
- Pedraza L, Laosa O, Rodríguez-Mañas L, Gutiérrez-Romero DF, Frías J, Carnicero JA, Ramirez E. Drug induced liver injury in geriatric patients detected by a two-hospital prospective pharmacovigilance program: a comprehensive analysis using the rousel uclaf causality assessment method. *Front Pharmacol.* 2021; 11(0): 600255. Article. IF: 5.988; Q1
- Ruiz-Sánchez JG, Ramírez PP, Catalán AL. A rare association of two endocrine tumours: non-functional oncocytic adrenocortical carcinoma and Papillary thyroid carcinoma. *Horm Mol Biol Clin Investig.* 2021; 42(2): 199-201. Article. Not Indexed
- Ruiz-Sánchez JG, Ramírez PP, Rojas-Marcos PM, Santamaría BL, Escola CA. In-patient manage-

ment protocol for diabetes insipidus associated with adipsia. Developed from a clinical case. *Endocrinol Diabetes Nutr.* 2021; 68(9): 668-70. Letter. IF: 1.833; Q4

- Sánchez-Alonso I, Carballeda-Sangiao N, González-Muñoz M, Arcos SC, Navas A, Careche M. Thermal patterns of heat treated Anisakis L3-infected fishery products allow separation into low, intermediate and high risk groups of potential use in risk management. *Food Control.* 2021; 124: 107837. Article. IF: 6.652; Q1
- Sánchez-Alonso I, Carballeda-Sangiao N, Rodríguez S, Tejada M, Navas A, Arcos SC, González-Muñoz M, Careche M. Anisakis simplex resistance to the action of gastric enzymes depends upon previous treatments applied to infected fish mince and affects antigen release. *J Sci Food Agr.* 2021; 101(9): 3908-16. Article. IF: 4.125; Q1
- Sánchez-Alonso I, Rodríguez S, Tejada M, Navas A, González-Muñoz M, Careche M. The artificial digestion method underestimates the viability of Anisakis simplex L3 present in processed fish products. *Food Waterborne Parasitol.* 2021; 23: e00121. Article. Not Indexed
- Velayos M, Estefanía K, Álvarez M, Sarmiento MC, Moratilla L, Sanabria P, Hernández F, López Santamaría MV. Healthcare staff as promoters of parental presence at anesthetic induction: Net Promoter Score survey. *World J Clin Pediatr.* 2021; 10(6): 159-67-. Article. Not Indexed; Not Indexed
- Vila-Nadal G, Román AF, Revuelto RH, Hernández-Maraver D, Fuentes AEK, García ER, Moreno RC. Efficacy of therapeutic plasma exchange in severe immune hemolytic anemia induced by a carboplatin desensitization procedure. *J Invest Allerg Clin.* 2021; 31(2): 178-9. Editorial Material. IF: 8.185; Q1

- Viqueira AQ, Romero CP, Rueda CT, Calles AMS, González JAB, Leyva MA. Mycobacterium chimera in heater-cooler devices: an experience in a tertiary hospital in Spain. *New Microbes New Infect.* 2021; 39: 100757. Article. Not Indexed

Research projects

Ramírez García E. Estudio farmacoepidemiológico para evaluar los eventos tromboembólicos de las inmunoglobulinas inespecíficas. Características diferenciales de los eventos arteriales y venosos. Terumo BCT Europe N.V. 2013-Ongoing.

Management centre: FIBHULP

González Muñoz M. Evaluación de la causalidad de las reacciones adversas a medicamentos de carácter grave: utilidad de los algoritmos, test in vitro, toxicología y farmacogenética. FIBHULP. 2019-Ongoing.

Management centre: FIBHULP

Sanabria Carretero P. Población en riesgo de hipertemia maligna: cohorte ambispectiva. FIBHULP. 2019-Ongoing.

Management centre: FIBHULP

Sanabria Carretero P. Mejora de la humanización de la asistencia sanitaria en el bloque quirúrgico infantil del Hospital La

Paz. Fundación Icomem Parala Educación y Formación Sanitarias. 2021-Ongoing.

Management centre: FIBHULP

Ramírez García E. Tareas de consultoría relacionadas con la evaluación de viabilidad de un potencial estudio observacional para evaluar el riesgo de anafilaxis en usuarios de hierro endovenoso. Research Triangle Institute, RTI Health Solutions. 2021-Ongoing.

Management centre: FIBHULP.

Patents and trademarks

Herrero Ambrosio A, Ramírez García E, Ojeda Feo JJ, Pérez Rodríguez J, Asensio Martín MJ, González Sánchez ML, Moro Agud M, Lorente Romeo M, López Nieto M, Gómez Rioja R, authors; FIBHULP, assignee. Brand name: SINOIRES. CM 13.080.056; 2014 July 14.





1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



3.6.7 Translational Research and Innovation in General and Digestive Surgery Group*



COMPOSITION

■ **Constantino Fondevila Campo.** Jefe de Servicio de Cirugía General y Digestiva. Hospital Universitario La Paz

Ramón Cantero Cid. Facultativo Especialista de Área en Cirugía General y de Aparato Digestivo. Hospital Universitario La Paz

Joaquín Gómez Ramírez. Coordinador Unidad de Cirugía Endocrina. Hospital Universitario La Paz

Amelia Hessheimer. Facultativo Especialista de Área en Cirugía General y de Aparato Digestivo. Hospital Universitario La Paz

Javier Muñoz Luque. Técnico de Grado Superior. CIBEREHD

Elisa York Pineda. Facultativo Especialista de Área en Cirugía General y de Aparato Digestivo. Hospital Universitario La Paz

Inés Rubio Pérez. Facultativo Especialista de Área en Cirugía General y de Aparato Digestivo. Hospital Universitario La Paz

Isabel Pascual Miguelañez. Facultativo Especialista de Área en Cirugía General y de Aparato Digestivo. Hospital Universitario La Paz

María Isabel Prieto Nieto. Facultativo Especialista de Área en Cirugía General y de Aparato Digestivo. Hospital Universitario La Paz

Javier Salinas Gómez. Facultativo Especialista de Área en Cirugía General y de Aparato Digestivo. Hospital Universitario La Paz

Mario Álvarez Gallego. Facultativo Especialista de Área en Cirugía General y de Aparato Digestivo. Hospital Universitario La Paz

Ramón Corripio Sánchez. Facultativo Especialista de Área en Cirugía General y de Aparato Digestivo. Hospital Universitario La Paz


Tania Funes Dueñas. Facultativo Especialista de Área en Cirugía General y de Aparato Digestivo. Hospital Universitario La Paz

Jordi Vengohechea Llorens. Investigador Predoctoral. Universidad de Barcelona

STRATEGIC OBJECTIVE

PROBLEM: Surgery and perioperative care encompass one of the most expensive and resource-intensive areas of clinical medicine. Surgical patients undergo complex interventions, with the goal of curing or at least relieving distressing symptoms from different medical conditions. These same interventions, however, may sometimes result ineffective in achieving this goal. Additionally, they can provoke complications (morbidity)

* Group recently created, december 2021



1
Introduction

and further affect a patient's physical, mental, and emotional states.

APPROACH: The Translational Research & Innovation in General Surgery Group (GITIC) is a multidisciplinary group comprised of surgeons, nurses, and biologists, with various areas of dedication and expertise. The GITIC team works together with the common goal of using surgical innovation and diverse research initiatives to offer the highest level of patient care possible today.

Given its broad knowledge base and skill set, projects that GITIC currently develops include lines of basic science and experimental research, translational and pre-clinical surgical models, clinical investigation, analysis of post-surgical outcomes, studies involving economic evaluation, the creation of mathematical models, and surgical device design and implementation.

In order to fulfill its broad research interests and initiatives, GITIC actively collaborates not only with other groups within Hospital Universitario La Paz and IdiPAZ but also other hospitals and public and private research institutions in Spain and abroad. The following is a list of some of GITIC's current collaborations:

- Donation & Transplantation Institute (DTI), Barcelona, España
- Guanguong Shunde Innovative Design Institution, Guangdong, China
- Hospital Virgen de la Salud, Toledo, España
- Universidad Internacional de Catalunya (UIC), Sant Cugat, España
- Policlinico Universitario "A. Gemelli", Università Cattolica del Sacro Cuore, Roma, Italia
- Instituto de Empresa (IE), Madrid, España.
- Tekniker, Gipuzkoa, España.

RESEARCH LINES

Injury, inflammation, organ failure, & transplantation:

- Assessment and implications of chronic inflammation in obesity
- Experimental models of end-stage liver disease and portal hypertension
- Applicability and results of liver transplantation in the treatment of acute-on-chronic liver failure
- Approaches to transplantation in patients with complex portal vein thrombosis
- Translation and clinical research in ischemia-reperfusion injury
- Novel preservation solutions and techniques of in situ and ex situ organ machine perfusion

- Clinical outcomes and strategies for improvement in donation after circulatory death (DCD) organ transplantation
- Assessment and clinical implications of markers of allograft dysfunction following liver transplantation

Surgical oncology:

- Evaluation of a novel polyfunctional immune liquid biopsy platform to predict and improve responses to cancer immunotherapy using innate immunomodulators
- Evaluation of the utility of cryoablation to provoke immune activation and response to immunotherapy in primary breast tumors
- Evaluation of the diagnostic and therapeutic role of novel immune checkpoints in colon cancer
- Development of three-dimensional in vitro organoid biomodels of colon cancer
- Combination of "omic" and imaging techniques to identify markers associated with response to neoadjuvant therapy in rectal cancer patients
- Effectiveness and safety of hyperthermic intraperitoneal chemotherapy in the prevention of peritoneal recurrence in high-risk colorectal cancer patients
- Immunological and molecular predictors of ovarian cancer arising in the background of endometriosis (Collaboration with H.U. La Paz Gynecology Service)

Surgical technology & innovation:

- Development and pre-clinical evaluation of a novel device for ex situ liver machine perfusion
- Development and clinical trial assessment on the safety and feasibility of a novel rectoscope for rectal cancer surgery
- Development and utility assessment of novel surgical drains
- Evaluation of novel surgical techniques strategies to reduce drainage following axillary lymphadenectomy in breast cancer therapy


Value-based care:

- Patient safety and prevention of perioperative infection
- Evaluation of "best possible outcomes" (benchmarks) in surgical care
- Assessment of perioperative complications, patient quality of life, and postoperative disability following general surgical operations
- Cost-effectiveness and cost-utility of postoperative cancer surveillance strategies
- Economic evaluation of novel surgical approaches and technologies

2
Executive
Summary

3
Information
Groups
by Area

4
Associated
Clinicians



Maternal Infant Child and Youth Research Area

3.7

Antonio Pérez Matínez
Cristina Calvo Rey

Documents: 269

Originals: 211

D1: 45

Q1: 116


- 3.7.1 Neonatology Group
- 3.7.2 Molecular Hepatology Group
- 3.7.3 Maternal and Fetal Medicine Group
- 3.7.4 Pediatric Respiratory, Systemic and Neurological Infections & Host Immune Response Group
- 3.7.5 Pediatric Systemic Infections; HIV, Tuberculosis, Imported and Emergent Diseases Group
- 3.7.6 Translational Research in Pediatric Oncology, Hematopoietic Transplantation and Cell Therapy Group
- 3.7.7 Congenital Malformations and Transplantation Group
- 3.7.8 Research in Endometriosis Group
- 3.7.9 Pediatric Diseases/Pediatric HIV Group (HUG)

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



Maternal Infant Child and Youth Research Area




1 Introduction


2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



Strategic Objectives	Development forecast for the coming years	Actions
<p>The mission of the Maternal, Child and Adolescent Health Area (MIA) is to contribute to the improvement of the health of society by reducing the negative impact of diseases in the pediatric population from birth to adolescence, as well as the mother-child binomial. This recently created area is made up of research groups that cover the entire spectrum of ages from women, through newborns, children and young people. It includes very varied areas of research and proposes to achieve a full development of the adults of the future. To achieve this, we promote and lead cooperative research of excellence,</p>	<p>Create a stable structure to promote research that encompasses all areas of perinatal medicine, child and adolescent medicine, and women with childbearing potential. Promote collaboration between groups in the area and provide a common space and shared infrastructure and resources that allow joint progress.</p>	<p>Create a portfolio of shared group resources, services and projects for the MIA area that facilitates common work. Hold work meetings to propose shared studies and strategic lines.</p>
<p>promoting innovation, a multidisciplinary approach, and the translation of scientific results into clinical practice.</p>	<p>Promote the search for both public and private funding for cooperative research within the MIA area. Promote participation in international projects.</p> <p>Promote the incorporation of new technologies in research to advance personalized and precision medicine and the transfer of research results to the scientific community and society: biomedical industry, health administration, general population and any other interlocutor and disseminate the main advances produced as a result of the research.</p>	<p>Facilitate the application request for European projects through the IdiPAZ Internalization Platform</p> <p>Promote at international level the different research groups of the area, identifying possible synergies between groups and centers, new partners and funding sources, as well as to forge strategic alliances.</p>



3.7.1 Neonatology Group

Publications: 48

Q1: 20

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



COMPOSITION

Adelina Pellicer Martínez. Jefe de Sección de Neonatología. Hospital Universitario La Paz

Susana Ares Segura. Facultativo Especialista de Área en Neonatología. Hospital Universitario La Paz

María Carmen Bravo Laguna. Facultativo Especialista de Área en Neonatología. Hospital Universitario La Paz

Antonio Buño Soto. Jefe de Servicio de Laboratorio de Urgencias. Hospital Universitario La Paz

Fernando Cabañas González. Facultativo Especialista de Área en Neonatología. Hospital Universitario La Paz. Profesor Titular. Departamento de Pediatría y Neonatología. Universidad Autónoma de Madrid

María Dolores Elorza Fernández. Jefe de Sección de Neonatología. Hospital Universitario La Paz

Miriam Martínez Biarge. Facultativo Especialista de Área en Neonatología. Hospital Hammer Smith Londres

María Teresa Montes Bueno. Enfermera. Hospital Universitario La Paz

María Jesús del Olmo Barros. Profesora Contratada. Universidad Autónoma de Madrid

Laura Sánchez García. Médico Adjunto en Neonatología. Hospital Universitario La Paz

Miguel Sáenz de Pipaón Marcos. Facultativo Especialista de Área en Neonatología. Hospital Universitario La Paz. Profesor Asociado. Universidad Autónoma de Madrid


Belén Sáenz-Rico de Santiago. Profesor Titular. Universidad Complutense de Madrid

Eva Valverde Núñez. Facultativo Especialista de Área en Neonatología. Hospital Universitario La Paz. Profesor Asociado. Universidad Autónoma de Madrid

STRATEGIC OBJECTIVE

Prevent structural damage to organs and systems in the high risk newborn.

Reduce the impact of the processes that occurred in the peri-neonatal stage in later life.



RESEARCH LINES

- Developmental Neurobiology
- Neonatal pulmonary and cardiovascular pathology
- Non-invasive monitoring, signal processing and machine learning
- Nutrition & Mycobiota
- Milkbank & breastfeeding
- Perinatal and neonatal infectology. Immunology and vaccines
- Neurodevelopment & Follow-up
- Quality improvement

1
Introduction

2
Executive
Summary

3
Information
Groups
by Area

4
Associated
Clinicians

RESEARCH ACTIVITY

■ Doctoral theses

Bell Fenellos, C. Factores predictivos de las alteraciones del desarrollo y las dificultades de aprendizaje en niños menores con síndrome 5P-. Aspectos biomédicos, genéticos, cognitivos y conductuales [dissertation]. Madrid: UCM: 2021(23/03/2021).

Directors: Sáenz-Rico de Santiago B, Nevado Blanco, Julián.

Monteagudo Vela M. Soporte mecánico circulatorio contemporáneo. De corta a larga duración; una opción real. [dissertation]. Madrid: UAM: 2021(25/06/2021).

Directors: García-Guereta Silva L, Aroca Peinado A.


■ Publications

- Aker K, Stoen R, Martínez-Biarge M, Thomas N. Questions about the HELIX trial. *Lancet Glob Health*. 2021; 9(12): E1651. Letter. IF: 38.927; D1
- Álvarez J, Real JMF, Guarnier F, Gueimonde M, Rodríguez JM, de Pipaón MS, Sanz Y. Gut microbes and health. *Gastroent Hepat-Barc*. 2021; 44(7): 519-35. Review. IF: 5.867; Q2
- Álvarez-Maestro M, Equibar A, Chanca P, Klett-Mingo M, Rivas JG, Buño-Soto A, de Bethencourt FR, Ferrer M. Androgen deprivation therapy in patients with prostate cancer increases serum levels of thromboxane a(2): cardiovascular implications. *Front Cardiovasc Med*. 2021; 8: 653126. Article. IF: 5.846; Q2

- Ara-Montojo MF, Escosa-García L, Alguacil-Guillen M, Seara N, Zozaya C, Plaza D, Schuffelmann-Gutiérrez C, de la Vega A, Fernández-Cambor C, Ramos-Boluda E, Romero-Gómez MP, Ruiz-Carrascoso G, Losantos-García I, Mellado-Pena MJ, Gómez-Gil R. Predictors of mortality and clinical characteristics among carbapenem-resistant or carbapenemase-producing Enterobacteriaceae bloodstream infections in Spanish children. *J Antimicrob Chemoth*. 2021; 76(1): 220-5. Article. IF: 5.758; Q1
- Arévalo MSG, Mahillo-Fernández I, Esteban LM, Andeyro-García M, Pérez RP, de Pipaón MS, Saviron-Cornudella R. Perinatal adverse effects in newborns with estimated loss of weight percentile between the third trimester ultrasound and delivery. The GROWIN study. *J Clin Med*. 2021; 10(20): 4643. Article. IF: 4.964; Q2
- Amáez J, Vega-Del-Val C, Hortiguela M, Benavente-Fernández I, Martínez-Biarge M, Sangrador CO, García-Alix A. Usefulness of video recordings for validating neonatal cephalopathy exams: a population-based cohort study. *Arch Dis Child-Fetal*. 2021; 106(5): F522-8. Article. IF: 6.643; D1
- Bravo MC, López-Ortego P, Sánchez L, Díez J, Cabañas F, Pellicer A. Randomised trial of dobutamine versus placebo for low superior vena cava flow in preterm infants: Long-term neurodevelopmental outcome. *J Paediatr Child H*. 2021; 57(6): 872-6. Article. IF: 1.929; Q3
- Bravo MC, Sánchez R, Blanco AI, Losantos I, Pellicer A. Predictive model of early spontaneous ductus arteriosus closure based on neonatologist performed echocardiography in preterm infants. *Front Pediatr*. 2021; 9: 644519. Article. IF: 3.569; Q2
- Caballero FF, Struijk EA, Lana A, Buño A, Rodríguez-Artalejo F, López-García E. Plasma acylcarnitines and risk of lower-extremity functional

impairment in older adults: a nested case-control study. *Sci Rep-Uk*. 2021; 11(1): 3350. Article. IF: 4.996; Q2

- Campoy C, Tonato AMC, Puente AD, de Pipaón MS, Verduci E, Koletzko B, Casanova IG, Larque E, Valenzuela R, Villares JMM, Gil A. Controversy about the critical role of long-chain polyunsaturated fatty acids, arachidonic acid (ARA) and docosahexaenoic acid (DHA), during infancy. *Nutr Hosp*. 2021; 38(5): 1101-12. Article. IF: 1.169; Q4
- Caro-Codón J, Lip GYH, Rey JR, Iniasta AM, Rosillo SO, Castrejón-Castrejón S, Rodríguez-Sotelo L, García-Veas JM, Marco I, Martínez LA, Martín-Polo L, Merino C, Martínez-Cossiani M, Buño A, González-Valle L, Herrero A, López-de-Sa E, Merino JL. Prediction of thromboembolic events and mortality by the CHADS(2) and the CHA(2) DS(2)-VASc in COVID-19. *Europace*. 2021; 23(6): 937-47. Article. IF: 5.486; Q2
- Caro-Codón J, Rey JR, Buño A, Iniasta AM, Rosillo SO, Castrejón-Castrejón S, Merino C, Marco I, Martínez LA, García-Veas JM, Martín-Polo L, Rodríguez-Sotelo L, Martínez-Cossiani M, González-Valle L, Herrero A, López-de-Sa E, Merino JL. Characterization of myocardial injury in a cohort of patients with SARS-CoV-2 infection. *Med Clin-Barcelona*. 2021; 157(6): 274-80. Article. IF: 3.2; Q2
- Caro-Codón J, Rey JR, Buño A, Iniasta AM, Rosillo SO, Castrejón-Castrejón S, Rodríguez-Sotelo L, Martínez LA, Marco I, Merino C, Martín-Polo L, García-Veas JM, Martínez-Cossiani M, González-Valle L, Herrero A, López-de-Sa E, Merino JL. Characterization of NT-proBNP in a large cohort of COVID-19 patients. *Eur J Heart Fail*. 2021; 23(3): 456-64. Article. IF: 17.349; D1
- Castro I, Arroyo R, Aparicio M, Martínez MA, Rovira J, Ares S, Cunha SC, Casal S, Fernandes JO, Schuhmacher M, Nadal M, Rodríguez JM, Fernández L. Dietary habits and relationship with the presence of main and trace elements, bisphenol a, tetrabromobisphenol a, and the lipid, microbiological and immunological profiles of breast milk. *Nutrients*. 2021; 13(12): 4346. Article. IF: 6.706; Q1
- Chen YT, Fuertes PR, Sáez PO, Villegas TV, Soto AB, Calle PF, Cardona CC, Mora JC, Canadas MJ, Tong HY, Borobia AM. Efficacy of a fast-track pathway for managing uncomplicated renal or ureteral colic in a hospital emergency department: the STONE randomized clinical trial of Sonography and Testing of a Nephrolithiasis Episode. *Emergencias*. 2021; 33(1): 23-8. Article. IF: 5.345; Q1
- Cordeiro M, Peinado H, Montes MT, Valverde E. Evaluation of the suitability and clinical applicability of different electrodes for aEEG/cEEG monitoring in the extremely premature infant. *An Pediatr*. 2021; 95(6): 423-30. Article. IF: 2.377; Q3
- Couce ML, de Pipaón MS. Bone mineralization and calcium phosphorus metabolism. *Nutrients*. 2021; 13(11): 3692. Editorial Material. IF: 6.706; Q1
- Dahdouh E, Lázaro-Perona F, Ruiz-Carrascoso G, García LS, de Pipaón MS, Mingorance J. Intestinal dominance by *Serratia marcescens* and *Serratia ureilytica* among neonates in the setting of an outbreak. *Microorganisms*. 2021; 9(11): 2271. Article. IF: 4.926; Q2
- de Lamas C, Sánchez-Pintos P, de Castro MJ, de Pipaón MS, Couce ML. Screen time and bone status in children and adolescents: a systematic review. *Front Pediatr*. 2021; 9: 675214. Review. IF: 3.569; Q2
- del Real NMG, García LS, Díez YB, Merlo RR, Ballestín AS, Lucas RJ, García ND. Importance of specialized paediatric and neonatal transport. Current situation in Spain: Towards a more equitable and universal future. *An Pediatr*. 2021; 95(6): 485. Article. IF: 2.377; Q3
- Díaz-Garzón J, Fernández-Calle P, Aarsand AK,



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Sandberg S, Buño A. Biological variation of venous acid-base status measurands in athletes. *Clin Chim Acta*. 2021; 523: 497-503. Article. IF: 6.314; Q1

- Escudero A, Ruz-Caracuel B, Bueno D, Martínez M, Rubio P, Regojo RM, Antolín E, Ybarra M, Martínez L, Pozo-Kreilinger JJ, Elorza MD, Pellicer A, Omeñaca F, Pérez-Martínez A. Genetic predisposition to fetal and neonatal cancer. *Clin Transl Oncol*. 2021; 23(6): 1179-84. Article. IF: 3.34; Q3
- Gabriel MAM, Goneche LD, Pérez IC, Vergeli MR, Buratti AF, Vicente AR, Arnal IO, Sánchez L, Díaz CA, Criado E, Molina TC, Carbonero SC, Satre CC, Morillo AFC. Baby friendly hospital initiative breastfeeding outcomes in mothers with covid-19 infection during the first weeks of the pandemic in Spain. *J Hum Lact*. 2021; 37(4): 639-648. Article. IF: 2.665; Q1
- García LS, Gómez-Torres N, Cabañas F, González-Sánchez R, López-Azorín M, Moral-Pumarega MT, Escuder-Vieco D, Cabanes-Alonso E, Castro I, Alba C, Gómez JMR, Pellicer A. Immediate prepartum SARS-CoV-2 status and immune profiling of breastmilk: a case-control study. *Front Immunol*. 2021; 12: 720716. Article. IF: 8.786; Q1
- García LS, Pellicer A, López-Martínez C, García-García ML, Casas I, Pozo F, Calvo C. Respiratory morbidity associated with viral respiratory infections during neonatal stage in premature infants. *Pediatr Pulm*. 2021; 56(5): 967-73. Article. IF: 4.09; Q1
- García-Alix A, Arnáez J, Arca G, Agut T, Alarcón A, Martín-Ancel A, Girabent-Farres M, Valverde E, Benavente-Fernández I. Development, reliability, and testing of a new rating scale for neonatal encephalopathy. *J Pediatr-Us*. 2021; 235: 83-91. Article. IF: 6.314; D1
- Gómez-Roig MD, Pascal R, Cahuana MJ, García-Algar O, Sebastiani G, Andréu-Fernández V, Martínez L, Rodríguez G, Iglesia I, Ortiz-Arrabal O, Mesa MD, Cabero MJ, Guerra L, Lurba E, Domínguez C, Zanini MJ, Foraster M, Larque E, Cabanas F, López-Azorín M, Pérez A, Loureiro B, Pallas-Alonso CR, Escuder-Vieco D, Vento M. Environmental exposure during pregnancy: influence on prenatal development and early life: a comprehensive review. *Fetal Diagn Ther*. 2021; 48(4): 245-57. Review. IF: 2.208; Q4
- González-Casás ML, González-Parra E, Fernández-Calle P, Buño-Soto A. FGF23: From academic nephrology to personalized patients' care. *Nefrología*. 2021; 41(3): 276-83. Review. IF: 3.084; Q2
- Lucas RJ, Boix H, García LS, Cernada M, Cue-

vas IDL, Couce ML. Recommendations on the skills profile and standards of the neonatal transport system in Spain. *An Pediatr*. 2021; 94(6): 420. Article. IF: 2.377; Q3

- Martínez-Biarge M, Gould S, de Alvare ADA, Marqués-Lopes I. Lack of supplementation, and not a vegan diet, as a cause of rickets in an infant. *Arch Pediatr*. 2021; 28(3): 255-6. Letter. IF: 1.82; Q4
- Méndez-Echevarría A, Pérez-Martínez A, del Valle LG, Ara MF, Melendo S, de Valbuena MR, Vázquez-Martínez JL, Morales-Martínez A, Remesal A, Sandor-Bajusz KA, Cabanas F, Calvo C. Compassionate use of remdesivir in children with COVID-19. *Eur J Pediatr*. 2021; 180(4): 1317-22. Article. IF: 3.86; Q1
- Mihatsch W, Martín ID, Barrios-Sabador V, Couce ML, Martos-Moreno GA, Argente J, Quero J, de Pipaón MS. Bone mineral density, body composition, and metabolic health of very low birth weight infants fed in hospital following current macronutrient recommendations during the first 3 years of life. *Nutrients*. 2021; 13(3): 1005. Article. IF: 6.706; Q1
- Mihatsch W, Thome U, de Pipaón MS. Update on calcium and phosphorus requirements of preterm infants and recommendations for enteral mineral intake. *Nutrients*. 2021; 13(5): 1470. Review. IF: 6.706; Q1
- Moreno-Sanz B, Montes MT, Antón M, Serrada MT, Cabrera M, Pellicer A. Scaling up the family integrated care model in a level III neonatal intensive care unit: a systematic approach to the methods and effort taken for implementation. *Front Pediatr*. 2021; 9: 682097. Article. IF: 3.569; Q2
- Ortega-García JA, Aguilar-Ros E, Ares-Segura S, Aguera-Arenas JJ, Pernas-Barahona A, de Pipaón MS, López FCI, Tortajada JFI. Occupational exposures, diet and storing: Recommendations to reduce environmental pollutants in breastfeeding. *An Pediatr*. 2021; 94(4): 261. Article. IF: 2.377; Q3
- Ortola R, García-Esquinas E, Buño-Soto A, Sotos-Prieto M, Struijk EA, Caballero FF, López-García E, Banegas JR, Rodríguez-Artalejo F. Healthy dietary patterns are associated with lower concentrations of growth differentiation factor 15 in older adults. *Am J Clin Nutr*. 2021; 113(6): 1619-26. Article. IF: 8.472; D1
- Peinado AA, López LP. Current perspective of neonatal heart surgery in Spain. *Cir Cardiov*. 2021; 28(1): 1-2. Editorial Material. Not Indexed
- Pellicer A, Fernández R, Jullien V, Gleeson C, Bravo MC, Ortego PL, Sánchez L, Ybarra M, Rojas-Anaya H, Cabanas F, Koch A, Smith A,

Rabe H. Pharmacokinetic study (phase I-II) of a new dobutamine formulation in preterm infants immediately after birth. *Pediatr Res*. 2021; 89(4): 981-6. Article. IF: 3953; Q1

- Rasmussen MI, Hansen ML, Pichler G, Dempsey E, Pellicer A, El-Khuffash A, Shashidhar A, Piris-Borregas S, Alsina M, Cetinkaya M, Chalak L, Ozkan H, Baserga M, Sirc J, Fuchs H, Ergeñekon E, Arruzza L, Mathur A, Stocker M, Vaccarello OO, Szczapa T, Sarafidis K, Krolak-Olejnik B, Memisoglu A, Reigstad H, Rafinska-Wazny E, Hatzidaki E, Peng Z, Gkentzi D, Viellevoye R, De Buyst J, Mastretta E, Wang P, Hahn GH, Bender L, Cornette L, Tkaczyk J, del Rio R, Fumagalli M, Papatoma E, Wilinska M, Naulaers G, Sadowska-Krawczenko I, Lecart C, Couce ML, Fredly S, Heuchan AM, Karen T, Greisen G. Extremely preterm infant admissions within the Safeboosc-III consortium during the covid-19 lockdown. *Front Pediatr*. 2021; 9: 647880. Article. IF: 3.569; Q2
- Rey J, Ramchandani BK, González-Rocafort A, Sánchez R, Polo L, Lamas MJ, Centella T, Uceda A, López-Ortego P, Aroca A. Neonatal cardiac surgery: Does weight matter?. *Cir Cardiov*. 2021; 28(1): 23-8. Article. Not Indexed
- Sánchez-Luna M, Colomer BF, Romero CD, Allen AA, Souto AB, Longueira FC, Badia MC, Pradell ZG, López MG, Herrera MCL, Bautista CR, García LS, Flores EZ. Neonates born to mothers with COVID-19: Data from the Spanish Society of Neonatology registry. *Pediatrics*. 2021; 147(2): e2020015065. Article. IF: 9.703; D1
- Santana LB, Wong EM, Álvarez-Troncoso J, García LS, Bartha JL, Regojo-Zapata RM. Maternal and perinatal outcomes and placental pathological examination of 29 SARS-CoV-2 infected patients in the third trimester of gestation. *J Obstet Gynaecol Re*. 2021; 47(6): 2131-9. Article. IF: 1.697; Q4
- Segura SA, Casano-Sancho P, Guindulain MC. Assessment of thyroid function in the preterm and/or very low birth weight newborn. *An Pediatr*. 2021; 95(4): 277. Article. IF: 2.377; Q3
- Serrera A, Rodríguez-Cuitino L, Cabañas F. Occult bacteremia due to *Kingella kingae* associated with herpetic gingivostomatitis. *Enferm Infect Micr Cl*. 2021; 39(7): 360-1. Letter. IF: 1.994; Q4
- Singh V, Kamaleswaran R, Chalfin D, Singh V, Chalfin D, Buño-Soto A, San Román J, Rojas-Kenney E, Molinaro R, von Sengbusch S, Hodjat P, Comaniciu D, Kamen A. A deep learning approach for predicting severity of COVID-19 patients using a parsimonious set of laboratory markers. *Iscience*. 2021; 24(12): 103523. Article. IF: 6.107; Q1

- Thoresen M, Jary S, Walloe L, Karlsson M, Martínez-Biarge M, Chakkrapani E, Cowan FM. MRI combined with early clinical variables are excellent outcome predictors for newborn infants undergoing therapeutic hypothermia after perinatal asphyxia. *Eclinicalmedicine*. 2021; 36: 100885. Article. IF: 17.033; D1
- van den Akker CHP, de Pipaón MS, van Goudoever JB. Proteins and amino acids. *World Rev Nutr Diet*. 2021; 122: 75-88. Article; Book Chapter. IF: 0.256; Q4
- Velacoracho JJ, de la Calle M, Taboas A, Rodríguez R, Herrero B, Elorza MD, Antolín E, Bartha JL. Congenital diaphragmatic hernia in twin gestation. *Clin Invest Ginecol Obstet*. 2021; 48(4): 100670. Article Not Indexed

■ Research projects

Aroca Peinado A. Bases moleculares y celulares de la regeneración cardiaca: desde los modelos animales al corazón humano (S2017/BMD-3875). CM. 2018-2021.

Management centre: FIBHULP


Bravo Laguna MC. Ensayo clínico multicéntrico sobre el tratamiento del ductus arterioso persistente ecocardiográficamente guiado en el recién nacido prematuro con ibuprofeno con perfusión continua intravenosa frente a bolos intravenosos: impacto en el pronóstico intestinal. Fundación Mutua Madrileña. 2016-2021.

Management centre: FIBHULP

Bravo Laguna MC. Ensayo clínico multicéntrico sobre el tratamiento del ductus arterioso persistente ecocardiográficamente guiado en el recién nacido prematuro con ibuprofeno en perfusión continua intravenosa frente a bolos intravenosos: impacto en el pronóstico intestinal (P116/00644). ISCIII. 2017-2021.

Management centre: FIBHULP

Bravo Laguna MC. Valoración cuantitativa de la repercusión hemodinámica del



1
Introduction

2
Executive
Summary

3
Information
Groups
by Area

4
Associated
Clinicians

ductus arterioso persistente y su tratamiento en el recién nacido de bajo peso. Neonatcare S. L. 2008-Ongoing.

Management centre: FIBHULP

Buño Soto A. Covid-19 severity score predictive model-technological feasibility, clinical acceptance, and potential impact upon patient management. Siemens Healthcare S.L. 2021-Ongoing.

Management centre: FIBHULP

Buño Soto A. Estudio en población cognitivamente sana (sin demencia) para la determinación de valores de referencia de una nueva técnica diagnóstica basada en espectroscopia Raman. Raman Health Technologies S. L. 2016-Ongoing.

Management centre: FIBHULP

Buño Soto A. Evaluación de un nuevo sistema analítico de inmunoensayo atellica solutions en el laboratorio core del Servicio de Análisis Clínicos. Siemens Healthcare S. L. 2017-Ongoing.

Management centre: FIBHULP

Buño Soto A. Recogida de muestras en deportistas de alto rendimiento para la evaluación de su variación biológica. FIBHULP. 2016-Ongoing.

Management centre: FIBHULP

Buño Soto A. Validación de un nuevo método para la detección de anticuerpos IGG e IGM anti Sars-Cov-2 en el analizador atellica solution. Siemens Healthcare S. L. 2020-Ongoing.

Management centre: FIBHULP

Pellicer Martínez S. Alliance for Family Integrated Care (FiCare) Implementation in Neonatal Intensive Care Units (RISEin-FAMILY). UE. 2020-2025.

Management centre: FIBHULP

Pellicer Martínez S. Desarrollo de un equipo de ultrasonidos para la ayuda al diagnóstico de meningitis. Neos New Born Solutions S. L. 2018-Ongoing.

Management centre: FIBHULP

Pellicer Martínez S. Estudio aleatorizado, doble ciego, de tres brazos controlado con placebo, sobre el tratamiento con dobutamina de la insuficiencia hemodinámica en el periodo postnatal inmediato (P118/01551). ISCIII. 2019-2021.

Management centre: FIBHULP

Pellicer Martínez S. Estudio retrospectivo de pacientes con sospecha de meningitis para identificar meningitis que requieran o no tratamiento mediante un modelo de IA. Neos New Born Solutions S. L. 2020-Ongoing.

Management centre: FIBHULP

Pellicer Martínez S. Online cerebral pressure autoregulation continuous monitoring as a neurobiomarker to guide assessment and intervention to prevent or minimise brain injury in the high-risk preterm infant. Abbvie Spain S. L. U. 2017-Ongoing.

Management centre: FIBHULP

Pellicer Martínez S. Salvaguardando el cerebro de nuestros niños más pequeños- ensayo clínico por iniciativa del investigador, pragmático, abierto, multinacional, aleatorizado fase III que evalúa el tratamiento basado en la monitorización con espectrometría cercana al infrarrojo versus tratamiento estándar en el niño prematuro. Fundación Mutua Madrileña. 2019-Ongoing.

Management centre: FIBHULP

Pellicer Martínez S. Seguridad de la lactancia materna en la infección confirmada por Sars-Cov-2 (COVID-19)

(COV20/01046). ISCIII. 2020-2021.

Management centre: FIBHULP

Sáenz de Pipan Marcos M. Efecto de la suplementación temprana con ácido docosahexanoico y ácido araquidónico sobre la incidencia de displasia broncopulmonar en niños extremadamente prematuros. European Society For Paediatric Gastroenterology, Hepatology and Nutrition. 2020-Ongoing.

Management centre: FIBHULP

Sáenz de Pipaón Marcos M. Efecto de la suplementación precoz con ácido araquidónico y ácido docosahexanoico en la evolución de las concentraciones plasmáticas y eritrocitarias de DHA en recién nacidos prematuros: ensayo controlado aleatorizado. Nestle España S. A. 2016-Ongoing.

Management centre: FIBHULP

Sáenz de Pipaón Marcos M. Fórmulas nutricionales para el control del déficit de ácido docosahexanoico dha y ácido araquidónico AA en niños extremadamente prematuros. Fundación Ramón Areces. 2021-Ongoing.

Management centre: FIBHULP

Sánchez García L; Sáenz de Pipaón Marcos M. Colonización de gestantes por bacterias multirresistentes y transmisión perinatal en <32 semanas: prevalencia y morbilidad. Fundación de la Sociedad Española de Neonatología. 2019-Ongoing.

Management centre: FIBHULP

■ Cibers & Retics

Cabañas González F. Research Network for Maternal and Child Health and Development. (RD16/0022/0004). ISCIII. (31/12/2021).

Management centre: FIBHULP

Bravo Laguna MC. Perinatal Mental Health and Birth-Related Trauma: Maximising best practice and optimal outcomes. (CA18211). EU. (31/12/2023).

Management centre: FIBHULP

■ Clinical trials

Ares Segura, S. Estudio de fase 3, multicéntrico, aleatorizado, con enmascaramiento parcial y controlado con palivizumab para evaluar la seguridad, la eficacia y la farmacocinética de mk-1654 en lactantes y niños con un riesgo elevado de enfermedad grave por el vrs.

Type: Clinical Trials, phase III.

HULP code: 5926 MK-1654-007.

Sponsored by: Merck Sharp And Dohme De España, S.A.

Signed date: 11/08/2021

Saenz De Pipaon Marcos, M. Estudio de investigación sobre nutrición: "efectos de la alimentación infantil con fórmula de leche de cabra o fórmula de leche de vaca sobre la dermatitis atópica (estudio giraffe).

Type: Estudio Producto Sanitario.


HULP code: 5649 DGC201911 GIRA-FFE.

Sponsored by: Dairy Goat Co-Operative Ltd.

Signed date: 21/04/2021.

■ Patents and trademarks

Segovia Iñigo C, Montes Bueno MT, inventors; Segovia Iñigo C, assignee. Positioning device for neonates (Utility model). U201330102; 2013 January 31.



3.7.2 Molecular Hepatology Group

Publications: 12
Q1: 6

COMPOSITION



■ **Paloma Jara Vega.** Emérito Asistencial. Hospital Universitario La Paz

■ **Loreto Hierro Llanillo.** Jefe de Sección Hepatología Pediátrica. Hospital Universitario La Paz

Carmen Camarena Grande. Médico Adjunto de Hepatología Pediátrica. Hospital Universitario La Paz

Ángela de la Vega Bueno. Médico Adjunto de Hepatología Pediátrica. Hospital Universitario La Paz

María Carmen Díaz Fernández. Jefe de Servicio de Hepatología Pediátrica. Hospital Universitario La Paz

Esteban Frauca Remacha. Médico Adjunto de Hepatología Pediátrica. Hospital Universitario La Paz

Gema Muñoz Bartolo. Médico Adjunto de Hepatología Pediátrica. Hospital Universitario La Paz

María Ángeles Pajares Tarancón. Investigador Científico. CSIC

Luiz Stark Aroeira. Investigador Postdoctoral. Hospital Universitario La Paz

David Vicent López. Investigador Senior (Contrato Miguel Servet - I2). Hospital Universitario La Paz

STRATEGIC OBJECTIVE

Our research interest is focused on the study of the molecular mechanisms underlying the most severe paediatric liver disorders, namely cholestasis, which results from the impaired secretion of bile from the liver to the intestine.

As such, it represents a clinical and biochemical syndrome that is produced by a wide variety of disease processes that affect the liver.

Individuals with cholestasis manifest jaundice, severe itching, malabsorption of fats and lipidsoluble vitamins and, in many cases, progressive liver damage. These clinical manifestations are due to the accumulation in blood and tissues of substances normally secreted in the bile, such as bilirubin, bile acids, and cholesterol and to the absence of bile from the intestine.


When manifested in early infancy, cholestasis is often life threatening and usually requires liver transplantation. Extrahepatic biliary atresia

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



1 Introduction

(EHBA), Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC) constitute the main paediatric cholestatic disorders. EHBA is an enigmatic disease of unknown aetiology, characterised by a precocious and accelerated obstruction of the biliary tree. Alagille syndrome is associated with mutations in the *Jag1* gene and is characterised by a paucity or absence of intrahepatic bile ducts. PFIC encompasses a heterogeneous group of autosomal recessive diseases that exhibit similar clinical features. These diseases are caused by mutations in proteins located in the canalicular membrane of the hepatocyte and in proteins involved in bile secretion, such as the

bile salt export pump (BSEP; ABCB11), the phospholipid transport protein MDR3 (ABCB4) and the aminophospholipid translocase FIC1 (ATP8B1). These cholestatic disorders constitute the most common indication for liver transplantation in childhood.

2 Executive Summary

RESEARCH ACTIVITY

Publications

- Ara-Montojo MF, Escosa-García L, Alguacil-Guillén M, Seara N, Zozaya C, Plaza D, Schuffelmann-Gutiérrez C, de la Vega A, Fernández-Cambor C, Ramos-Boluda E, Romero-Gómez MP, Ruiz-Carrascoso G, Losantos-García I, Mellado-Pena MJ, Gómez-Gil R. Predictors of mortality and clinical characteristics among carbapenem-resistant or carbapenemase-producing Enterobacteriaceae bloodstream infections in Spanish children. *J Antimicrob Chemother.* 2021; 76(1): 220-5. Article. IF: 5.758; Q1
- Baker A, Remacha EF, Canizales JT, Bravo-Gallego LY, Fitzpatrick E, Melgar AA, Bartolo GM, Guereta LG, Boluda ER, Mozo Y, Broniszczak D, Jarmuzek W, Kalicinski P, Maecker-Kolhoff B, Carlens J, Baumann U, Roy C, Chardot C, Benetti E, Cananzi M, Calore E, Dello Strologo L, Candusso M, Lopes MF, Brito MJ, Goncalves C, Do Carmo C, Stephenne X, Wennberg L, Stone R, Rascon J, Lindemans C, Turkiewicz D, Giraldi E, Nicastro E, D'Antiga L, Ackermann O, Vega PJ. Current practices on diagnosis, prevention and treatment of post-transplant lymphoproliferative disorder in pediatric patients after solid organ transplantation: Results of ERN TransplantChild healthcare working group survey. *Children (Basel).* 2021; 8(8): 661. Article. IF: 2.835; Q2
- Caballero-Marcos A, Salcedo M, Alonso-Fernández R, Rodríguez-Perálvarez M, Olmedo M, Morales JG, Cuervas-Mons V, Cachero A, Loiaz-Se-


- gurola C, Inarraiegui M, Castells L, Pascual S, Vinaixa-Aunes C, González-Grande R, Otero A, Tome S, Tejedor-Tejada J, Alamo-Martínez JM, González-Dieguez L, Noguera-López F, Blanco-Fernández G, Muñoz-Bartolo G, Bustamante FJ, Fabrega E, Romero-Cristobal M, Martín-Mateos R, del Río-Izquierdo J, Arias-Milla A, Calatayud L, Marcacuzco-Quinto AA, Fernández-Alonso V, Gómez-Gavara C, Colmenero J, Muñoz P, Pons JA. Changes in humoral immune response after SARS-CoV-2 infection in liver transplant recipients compared to immunocompetent patients. *Am J Transplant.* 2021; 21(8): 2876-84. Article. IF: 9.369; D1
- Colmenero J, Rodríguez-Perálvarez M, Salcedo M, Arias-Milla A, Muñoz-Serrano A, Graus J, Nuno J, Gastaca M, Bustamante-Schneider J, Cachero A, Llado L, Caballero A, Fernández-Yunquera A, Loiaz C, Fernández I, Fondevila C, Navasa M, Inarraiegui M, Castells L, Pascual S, Ramírez P, Vinaixa C, González-Dieguez ML, González-Grande R, Hierro L, Noguera F, Otero A, Alamo JM, Blanco-Fernández G, Fabrega E, García-Pajares F, Montero JL, Tome S, De la Rosa G, Pons JA. Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients. *J Hepatol.* 2021; 74(1): 148-55. Article. IF: 30.083; D1
- Dópico LR, Tung-Chen Y, Barco MP, García AM. Monitoring of the rehabilitation therapy of COVID-19 effort dyspnea. *Enferm Infect Micr Cl.* 2021; 39(5): 258-9. Letter. IF: 1.994; Q4

- Gonzales E, Hardikar W, Stormon M, Baker A, Hierro L, Gliwicz D, Lacaille F, Lachaux A, Sturm E, Setchell KDR, Kennedy C, Dorenbaum A, Steinmetz J, Desai NK, Wardle AJ, Garner W, Vig P, Jaecklin T, Sokal EM, Jacquemin E. Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study. *Lancet.* 2021; 398(10311): 1581-92. Article. IF: 202.731; D1
- Jonas MM, Rhee S, Kelly DA, del Valle-Segarra A, Feiterna-Sperling C, Gilmour S, González-Peralta RP, Hierro L, Leung DH, Ling SC, Lobzin Y, Lobritto S, Mizuochi T, Narkewicz MR, Sabharwal V, Wen J, Lon HK, Marcinak J, Topp A, Tripathi R, Sokal E. Pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir in children with chronic HCV: Part 2 of the DORA study. *Hepatology.* 2021; 74(1): 19-27. Article. IF: 17.298; D1
- Lloyd C, Arshad A, Jara P, Burdelski M, Gridelli B, Manzanares J, Colledan M, Jacquemin E, Reding R, Baumann U, Kelly D. Long-term follow-up of a randomized trial of tacrolimus or cyclosporine a microemulsion in children post liver transplantation. *Transplant Direct.* 2021; 7(10): e765. Article. Not Indexed
- Markiewicz-Kijewska M, Kalicinski P, Canizales JT, Di Giorgio A, Baumann U, Jorns C, Baker A, Lopes MF, Remacha EF, López-Granados E, Vega PJ, Basso MS, Kowalewski G, Kaminska D, Ferreira S, Liccardo D, Pietrobattista A, Spada M. ABO Incompatible liver transplantation in children: a

- 20 year experience from centres in the Transplantchild european reference network. *Children (Basel).* 2021; 8(9): 760. Article. IF: 2.835; Q2
- Pascau MJ, Pruneda L, de Barbieri I, Correia M, López B, Guijarro E, Sofio G, Remacha EF, Vega PJ. Social resources for transplanted children and families in european union hospitals of ERN transplantchild. *Children (Basel).* 2021; 8(9): 723. Article. IF: 2.835; Q2
- Tome LF, Aroeira LGS, Bartolo GM, Bueno AD, Grande CC, Remacha EF, Barbancho DL, Díez MA, Blanco MJQ, Guerra L, Santamaria ML, Llanillo LH. Citrin deficiency: Early severe cases in a European country. *Clin Res Hepatol Gas.* 2021; 45(4): 101595. Letter. IF: 3.189; Q3
- van Wessel DBE, Thompson RJ, Gonzales E, Jankowska I, Shneider BL, Sokal E, Grammatikopoulos T, Kadaristiana A, Jacquemin E, Spraul A, Lipinski P, Czubkowski P, Rock N, Shagrani M, Broering D, Algoufi T, Mazhar N, Nicastro E, Kelly D, Nebbia G, Arnell H, Fischler B, Hulscher JBF, Serranti D, Arikian C, Debray D, Lacaille F, Goncalves C, Hierro L, Bartolo GM, Mozer-Glassberg Y, Azaz A, Brecelj J, Dezsofi A, Calvo PL, Krebs-Schmitt D, Hartleif S, van der Woerd WL, Wang JS, Li LT, Durmaz O, Kerker N, Jorgensen MH, Fischer R, Jiménez-Rivera C, Alam S, Cananzi M, Laverdure N, Ferreira CT, Ordóñez F, Wang H, Sency V, Kim KM, Chen HL, Carvalho E, Fabre A, Bernabeu JQ, Alonso EM, Sokol RJ, Suchy FJ, Loomes KM, McKiernan PJ, Rosenthal P, Turmelle Y, Rao GS, Horsien S, Kamath BM,

3 Information Groups by Area

4 Associated Clinicians



Rogalidou M, Karnsakul WW, Hansen B, Verkade HJ. Impact of genotype, serum bile acids, and surgical biliary diversion on native liver survival in FIC1 deficiency. *Hepatology*. 2021; 74(2): 892-906. Article. IF: 17.298; D1

■ Research projects

Hierro Llanillo L. Desarrollo de métodos de diagnóstico molecular de enfermedades hepáticas infantiles de carácter hereditario. Fundación Pfizer. 2005-Ongoing.

Management centre: FIBHULP

Hierro Llanillo L. Diagnóstico molecular de enfermedades hepáticas infantiles de carácter hereditario. Fundación ACS. 2012-Ongoing.

Management centre: FIBHULP

Hierro Llanillo L. Estableciendo una base de datos como parte de la red europea de referencia en enfermedades raras hepáticas. R-liver. Asociación Nacional para la Defensa y Ayuda de Afectados por Hepatitis C. 2019-Ongoing.

Management centre: FIBHULP

Hierro Llanillo L. Tomoxliver: estudio de la disfunción del hepatocito desde un abordaje multidisciplinar (S2017/BMD-3817). CM. 2018-2021.

Management centre: FIBHULP

Hierro Llanillo L. Validación de marcadores genéticos y moleculares para el diagnóstico de atresia biliar (PI20/01496). ISCIII. 2021-2023.

Management centre: FIBHULP

Jara Vega P. Estudio epidemiológico, observacional sobre el riesgo de desarrollo de síndrome linfoproliferativo en pacientes pediátricos trasplantados hepáticos, en el HULP. Roche Farma S. A.

2008-Ongoing.

Management centre: FIBHULP

Jara Vega P. Novel strategies in paediatric transplantation. Varios Financiadores. 2020-Ongoing.

Management centre: FIBHULP

Jara Vega P. PaEdiatric Transplantation European Registry (PETER). UE. 2019-2023.

Management centre: FIBHULP

Vicent López D. Caracterización clínica del nuevo factor de riesgo cardiovascular trimetilamina-D-óxido en pacientes diabéticos obesos. Sección de Endocrinología y Nutrición Severo Ochoa. 2015-Ongoing.

Management centre: FIBHULP

Vicent López D. Contrato Miguel Servet Categoría C (CES06/007). ISCIII. 2008-2025.

Management centre: FIBHULP

■ Cibers & Retics

Hierro Llanillo L. ERN on Hepatological diseases. EU. (31/12/2023).

Management centre: FIBHULP

Jara Vega P. ERN on Transplantation in children. EU. (31/12/2023).

Management centre: FIBHULP




1 Introduction

2 Executive Summary

3 Information Groups by Area


4 Associated Clinicians



3.7.3 Maternal and Fetal Medicine Group

Publications: 35

Q1: 10



COMPOSITION

■ **José Luis Bartha Rasero.** Jefe de Servicio de Obstetricia y Ginecología. Hospital Universitario La Paz. Catedrático de Obstetricia y Ginecología. Universidad Autónoma de Madrid

Alejandra Abascal Saiz. Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz

Eugenia Antolín Alvarado. Jefe de Sección de Obstetricia y Ginecología. Hospital Universitario La Paz. Profesor asociado. Universidad Autónoma de Madrid

Marta Cortés León. Médico Especialista en Ginecología y Obstetricia. Hospital Universitario La Paz

Marcos Javier Cuerva González. Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz

Inmaculada Duyos Mateo. Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz

María Amparo Gimeno Sanmartín. Médico Especialista en Ginecología y Obstetricia. Hospital Universitario La Paz

María del Mar González Arlazón. Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz

María de la Calle Fernández-Miranda. Jefa de Sección de Tocología de Alto Riesgo y Obstetricia Médica. Hospital Universitario La Paz. Profesora asociada. Universidad Autónoma de Madrid

María de la Cruz González Álvarez. Facultativo Es-

pecialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz

Beatriz Herrero Ruiz. Médico Adjunto de la Sección de Ecografía y Medicina Fetal. Hospital Universitario La Paz

Sara López Magallón. Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz

Francisco López Sánchez. Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz

Fernando Magdaleno Dans. Jefe de Sección de Obstetricia y Ginecología. Hospital Universitario La Paz. Profesor asociado. Universidad Autónoma de Madrid

María Elena Martín Boado. Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz

Nuría Martínez Sánchez. Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz

Marta Luisa Muner Hernando. Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz

Inmaculada Orensanz Fernández. Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz

Roberto Rodríguez González. Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz


Laura Sotillo Mallo. Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



1
Introduction

2
Executive
Summary

3
Information
Groups
by Area

4
Associated
Clinicians

STRATEGIC OBJECTIVE

To evaluate the implication of placental energy metabolism in obstetric conditions.

Finding new biomarkers in gestational diabetes mellitus and macrosomia.
Find new biomarkers of fetal and perinatal neurological damage and establish new prevention strategies.

New biomarkers in poor placentation.

Pathophysiology and new lines of treatment of fetal heart damage in Anti-Ro positive women.

Fetal therapy.

Infectious diseases. Microbiota.

RESEARCH LINES

- Diabetes mellitus, obesity and metabolic syndrome in pregnancy.
Energy metabolism in pregnancy
- Poor placentation
- Fetal Neurodevelopment
- Inflammation, autoimmunity and pregnancy
- Fetal Therapy
- Infectious diseases. Microbiota

RESEARCH ACTIVITY

■ Doctoral theses

López Cavanillas B. Virus del papiloma humano y citología anómala anal de mujeres en riesgo. Análisis de la prevalencia del virus del papiloma humano y citología anómala anal en mujeres diagnosticadas de neoplasia intraepitelial cervical de alto grado [dissertation]. Madrid: UAM: 2021(16/12/2021).

Directors: Hernández Gutiérrez A,
Bartha Raseró JL.

■ Publications

- Abascal-Saiz A, Fuente-Luelmo E, Haro M, de la Calle M, Ramos-Álvarez MP, Perdomo G, Bartha JL. Placental compartmentalization of lipid metabolism: implications for singleton and twin pregnancies. *Reprod Sci.* 2021; 28(4): 1150-60. Article. IF: 2.924; Q3
- Alonso-Espias M, Martínez-Sánchez N, Robles-Marhuenda A, Martín-Boado ME, Regojo-Zapata RM, Bartha JL. Diagnosis of amyopathic dermatomyositis after two intrauterine fetal deaths. *Obstet Med.* 2021; 14(2): 109-12. Article. Not Indexed
- Antolín E, Herrero B, Rodríguez R, Illescas T, Duyos I, Gimeno A, Sotillo L, Abascal A, Orensanz I, Hernández A, Bartha JL. How to organize a Fetal Medicine Unit in the context of COVID-19 pandemic. Safe measures for obstetric scans and


equipment cleaning. *Clin Invest Ginecol Obstet.* 2021; 48(1): 3-13. Article. Not Indexed

- Avendaño-Ortiz J, Lozano-Rodríguez R, Martín-Quirós A, Terrón V, Maroun-Eid C, Montalbán-Hernández K, Valentin-Quiroga J, García-Garrido MA, del Val EM, del Balzo-Castillo A, Peinado M, Gómez L, Herrero-Benito C, Rubio C, Casavilla-Dueñas JC, Gómez-Campelo P, Pascual-Iglesias A, del Fresno C, Aguirre LA, López-Collazo E. The immune checkpoints storm in COVID-19: Role as severity markers at emergency department admission. *Clin Transl Med.* 2021; 11(10): e573. Letter. IF: 8.554; Q1
- Bartha JL, Duyós I, de la Calle M, Herrero B, Rodríguez R, Antolín E. Severe fetal anemia after umbilical cord occlusion leading to severe neurological injury in monochorionic twins. *J Matern-Fetal Neo M.* 2021; 34(12): 2030-2. Article. IF: 2.323; Q3
- Belinchón I, Velasco M, Ara-Martín M, Alonso SA, Rodríguez OB, Pulido LF, García-Bustinduy M, Martínez-López JA, Sánchez NM, Ferriols AP, Pascual EP, Díaz RR, Ruiz-Villaverde R, Ferrer RT, Villa AV, Carrascosa JM. Management of psoriasis during preconception, pregnancy, postpartum, and breastfeeding: A consensus statement. *Actas Dermosifiliogr.* 2021; 112(3): 225-41. Article. Not Indexed
- Boria F, Maseda R, Albizuri F, de la Calle M. Intravenous immunoglobulin therapy for gestational pemphigoid refractory to conventional treatment. *Actas Dermosifiliogr.* 2021; 112(1): 83-5. Letter. Not Indexed
- Burgos EMP, Zapata RMR, Miranda MT, Alvarado EA, de la Calle M. Spontaneous twin anemia-polycythemia sequence from two donors to a

recipient in a monochorionic triamniotic pregnancy: Case report and review of the literature. *J Obstet Gynaecol Re.* 2021; 47(12): 4450-55. Review. IF: 1.697; Q4

- Calvo VE, Melguizo SC, Abascal-Sai A, Acebal LF, Sánchez-Migallon A, Recarte PP, Marin CC, Puig BM, Fernández PGD, Velasco ON, Conty MLD, Martínez-Pérez O. Perinatal outcomes of pregnancies resulting from assisted reproduction technology in SARS-CoV-2-infected women: a prospective observational study. *Fertil Steril.* 2021; 116(3): 731-40. Article. IF: 7.49; D1
- Cobo T, Aldecoa V, Bartha JL, Bugatto F, Carrillo-Badillo MP, Comas C, Diago-Almeda V, Ferrero S, Goya M, Herraiz I, Martí-Malgosa L, Olivella A, Paules C, Vives A, Figueras F, Palacio M, Gratacos E. Assessment of an intervention to optimize antenatal management of women admitted with preterm labour and intact membranes using amniocentesis-based predictive risk models: study protocol for a randomised controlled trial (OPTIM-PTL Study). *BMJ Open.* 2021; 11(9): e054711. Article. IF: 3.006; Q2
- Criado MD, Garrido CF, San Martín EM, Arboleya CG, Gómez-Arroyo B, González-Donapetry P, Baquero-Artigao F, de la Calle M, Quiles-Melero I, Calvo C. Is anantenatal screening for chlamydia trachomatis necessary in the current society?. *Pediatr Infect Dis J.* 2021; 40(11): 1034-45. Article. IF: 3.806; Q1
- Cristóbal I, Boado EM, Magdaleno F, Antolín E, Bartha JL, de la Calle M. Brain astrocytomas and pregnancy: an obstetric challenge. *Clin Invest Ginecol Obstet.* 2021; 48(3): 100664. Article. Not Indexed

- Dajti I, Valenzuela JI, Boccalatte LA, Gemelli NA, Smith DE, Dudi-Venkata NN, Kroon HM, Sammour T, Roberts M, Mitchell D, Fernández-López AJ, (et al). Machine learning risk prediction of mortality for patients undergoing surgery with perioperative SARS-CoV-2: the COVIDSurg mortality score. *Brit J Surg.* 2021; 108(11): 1274-92. Article. IF: 11.122; D1
- de la Calle M, Bartha JL, García L, Cuerva MJ, Ramiro-Cortijo D. Women aged over 40 with twin pregnancies have a higher risk of adverse obstetrical outcomes. *Int J Env Res Pub He.* 2021; 18(24): 13117. Article. IF: 4.614; Q1
- de la Calle M, Bartha JL, López CM, Turiel M, Martínez N, Arribas SM, Ramiro-Cortijo D. Younger age in adolescent pregnancies is associated with higher risk of adverse outcomes. *Int J Env Res Pub He.* 2021; 18(16): 8514. Article. IF: 4.614; Q1
- de la Calle M, Bartha JL, Serrano H, Ramiro-Cortijo D. Obstetric outcomes in the surviving fetus after intrauterine fetal death in bichorionic twin gestations. *Children (Basel).* 2021; 8(10): 927. Article. IF: 2.835; Q2
- de la Calle M, Delgado JL, Verlohren S, Escudero AI, Bartha JL, Campillos JM, de la Cruz AA, Chantraine F, Hernández JAG, Herraiz I, Llurba E, Kurka H, Guo G, Sillman J, Hund M, Marin AP. Gestational age-specific reference ranges for the sftt-1/plgf immunoassay ratio in twin pregnancies. *Fetal Diagn Ther.* 2021; 48(4): 288-96. Article. IF: 2.208; Q4
- Delgado P, Robles A, López JAM, Saez-Comet L, Almaraz ER, Martínez-Sánchez N, Ugarte A, Velasquez-Casasempere P, Marco B, Espinosa G, Galindo M,



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

- Casellas M, Ruiz-Iratorza G, Martínez-Taboada V, Bartha JL. Pregnancy control in patients with systemic lupus erythematosus/antiphospholipid syndrome. Part 3: Childbirth. Puerperium. Breast-feeding contraception. Newborn. *Reumatol Clin.* 2021; 17(4): 183-186. Article. Not Indexed
- Dobert M, Varouxaki AN, Mu AC, Syngelaki A, Ciobanu A, Akolekar R, Matallana CD, Cicero S, Greco E, Singh M, Janga D, Gil MD, Jani JC, Bartha JL, Maclagan K, Wright D, Nicolaides KH. Pravastatin versus placebo in pregnancies at high risk of term preeclampsia. *Circulation.* 2021; 144(9): 670-9. Article. IF: 39.918; D1
 - Engels V, Medina M, Antolín E, Ros C, Amaro A, De-Guirior C, Manzour N, Sotillo L, de la Cuesta R, Rodríguez R, San-Frutos L, Peralta S, Martín-Martínez A, Alcazar JL. Feasibility, tolerability, and safety of hysterosalpingo-foam sonography (hyfosal), multicenter, prospective Spanish study. *J Gynecol Obstet Hum Reprod.* 2021; 50(5): 102004. Article. IF: 2.156; Q4
 - Escudero A, Ruz-Caracuel B, Bueno D, Martínez M, Rubio P, Regojo RM, Antolín E, Ybarra M, Martínez L, Pozo-Kreiling JJ, Elorza MD, Pellicer A, Omeñaña F, Pérez-Martínez A. Genetic predisposition to fetal and neonatal cancer. *Clin Transl Oncol.* 2021; 23(6): 1179-84. Article. IF: 3.34; Q3
 - Espinosa G, Galindo-Izquierdo M, Puig BM, Caro MC, Beltran PD, López JAM, Sánchez NM, Robles-Marhuenda A, Almaraz ER, Saez-Comet L, Ugarte A, Vela-Casasempere P, Bartha JL, Ruiz-Iratorza G, Martínez-Taboada VM. Pregnancy control in patients with systemic lupus erythematosus and antiphospholipid syndrome. Part 1: Infertility, ovarian preservation and preconception assessment. Consensus Document of the Spanish Society of Gynaecology and Obstetrics (SEGO), the Spanish Society of Internal Medicine (SEMI) and the Spanish Society of Rheumatology (SER). *Reumatol Clin.* 2021; 17(2): 61-6. Article. Not Indexed
 - Espinosa JA, Cuerva MJ, Nieto L, García-Casarrubios P, Leal MA, Bartha JL. Length of uterine cavity after second phase of postpartum period in women requesting long-acting reversible contraception. *J Obstet Gynaecol.* 2021; 41(1): 162-3. Article. IF: 1.226; Q4
 - García-Ruiz I, Sulleiro E, Serrano B, Fernández-Buhigas I, Rodríguez-Gómez L, Fernández DSN, Antón-Pagarolas A, Esperalba-Esquerria J, Frick MA, Camba F, Navarro-Jiménez A, Fernández-Hidalgo N, Maiz N, Carreras E, Suy A. Congenital infection of SARS-CoV-2 in live-born neonates: a population-based descriptive study. *Clin Microbiol Infect.* 2021; 27(10): 1521. Article. IF: 13.31; D1
 - López-Cavanillas B, Benítez CG, Serrano M,

- Sendagorta E, Hernández A, Bartha JL. Analysis of the prevalence of human papillomavirus and abnormal anal cytology in women at risk. *J Obstet Gynaecol.* 2021; 41(7): 1139-44. Article. IF: 1.226; Q4
- Martínez-Sánchez N, Fernández-Miranda MD, Bartha JL. Safety profile of treatments administered in COVID-19 infection in pregnant women. *Clin Invest Ginecol Obstet.* 2021; 48(3): 100663. Review. Not Indexed
 - Martínez-Sánchez N, Marhuenda AR, Fernández-Miranda MD, Bartha JL. First trimester combined screening test for aneuploidies in anti-Ro carriers pregnant women. *Clin Rheumatol.* 2021; 40(7): 2699-705. Article. IF: 3.65; Q3
 - Ramiro-Cortijo D, de la Calle M, Benítez V, Gila-Díaz A, Moreno-Jiménez B, Arribas SM, Garrosa E. Maternal psychological and biological factors associated to gestational complications. *J Pers Med.* 2021; 11(3): 183. Article. IF: 3.508; Q2
 - Ramiro-Cortijo D, de la Calle M, Gila-Díaz A, Moreno-Jiménez B, Martín-Cabrejas MA, Arribas SM, Garrosa E. Maternal resources, pregnancy concerns, and biological factors associated to birth weight and psychological health. *J Clin Med.* 2021; 10(4): 695. Article. IF: 4.964; Q2
 - Rehal A, Benko Z, Matallana CD, Syngelaki A, Janga D, Cicero S, Akolekar R, Singh M, Chaveeva P, Burgos J, Molina FS, Savvidou M, De la Calle M, Persico N, Rojas MSQ, Sau A, Greco E, O'Gorman N, Plasencia W, Pereira S, Jani JC, Valino N, Gil MD, Maclagan K, Wright A, Wright D, Nicolaides KH. Early vaginal progesterone versus placebo in twin pregnancies for the prevention of spontaneous preterm birth: a randomized, double-blind trial. *Am J Obstet Gynecol.* 2021; 224(1): 86.e1-19. Article. IF: 10.693; D1
 - Santana LB, Wong EM, Álvarez-Troncoso J, García LS, Bartha JL, Regojo-Zapata RM. Maternal and perinatal outcomes and placental pathologic examination of 29 SARS-CoV-2 infected patients in the third trimester of gestation. *J Obstet Gynaecol Re.* 2021; 47(6): 2131-9. Article. IF: 1.697; Q4
 - Sukhwani M, Antolín E, Herrero B, Rodríguez R, de la Calle M, López F, Bartha JL. Management and perinatal outcome of selective intrauterine growth restriction in monochorionic pregnancies. *J Matern-Fetal Neo M.* 2021; 34(23): 3838-43. Article. IF: 2.323; Q3
 - Suy A, García-Ruiz I, Carbonell M, García-Manau P, Rodo C, Maiz N, Sulleiro E, Anton A, Esperalba J, Fernández-Hidalgo N, Frick MA, Camba F, Pumarola T, Carreras E. Gestation and COVID-19: clinical and microbiological observational study (Gesta-COVID19). *BMC Pregnancy Childb.* 2021;

- 21(1): 78. Article. IF: 3.105; Q2
- Velacoracho JJ, de la Calle M, Taboas A, Rodríguez R, Herrero B, Elorza MD, Antolín E, Bartha JL. Congenital diaphragmatic hernia in twin gestation. *Clin Invest Ginecol Obstet.* 2021; 48(4): 100670. Article. Not Indexed
 - Zafarmand MH, Goossens SMTA, Tajik P, Bossuyt PMM, Asztalos EV, Gardener GJ, Willan AR, Roumen FJME, Mol BW, Barrett Y, (de la calle M). Planned Cesarean or planned vaginal delivery for twins: secondary analysis of randomized controlled trial. *Ultrasound Obstet Gyn.* 2021; 57(4): 582-91. Article. IF: 8.678; D1

Research projects

Antolín Alvarado E. Modelos predictivos de daño neurológico y riesgo cardiovascular mediante la integración de técnicas de imagen y biomarcadores en la gestación monocorial. *Biología de sistemas (PI19/00904).* ISCIII. 2020-2022.

Management centre: FIBHULP

Bartha Rasero JL. Biología de sistemas para la búsqueda de marcadores precoces de placentación deficiente (PI19/00915). ISCIII. 2020-2022.

Management centre: FIBHULP

Bartha Rasero JL. Implicación de la oxidación mitocondrial de ácidos grasos placentaria en la patogénesis y clínica de la preeclampsia. *Laboratorios Farmacéuticos Rovi S. A.* 2016-Ongoing.

Management centre: FIBHULP

Clinical trials

Bartha Rasero JL. Estudio fase 2/3 controlado con placebo, aleatorizado, cegado para el observador, para evaluar la seguridad, la tolerabilidad y la inmunogenicidad de una vacuna candidata de arn (bnt162b2) del SARS-CoV-2, contra COVID-19 en mujeres embarazadas sanas de 18 años de edad y mayores.

Type: Clinical Trials, phase III.
HULP code: 5822 C4591015.
Sponsored by: Pfizer, S.L.U.
Signed date: 06/04/2021

Bartha Rasero JL. Estudio de fase III, doble ciego, aleatorizado y controlado con placebo para evaluar la seguridad, la reactogenicidad y la respuesta inmunitaria de una dosis intramuscular única de la vacuna materna contra el virus respiratorio sincitial (VRS) no potenciada en mujeres embarazadas de alto riesgo de 15 a 49 años y los lactantes nacidos de las madres vacunadas.


Type: Clinical Trials, phase III.
HULP code: 5888B 214725 (RSV MAT-012).
Sponsored by: Glaxosmithkline, S.A.
Signed date: 03/06/2021

Bartha Rasero JL. Optimización del manejo antenatal del manejo de las mujeres con amenaza de parto pretérmino mediante modelos de predicción: estudio clínico randomizado multicéntrico abierto (optimptl).

Type: Clinical Trials, phase III.
HULP code: 5980 OPTIM-PTL.
Sponsored by: Fundacio Clinic Per A La Recerca Biomedica.
Signed date: 09/09/2021

Bartha Rasero JL. Ensayo en fase III, aleatorizado, doble ciego o con enmascaramiento para el observador, controlado con placebo, para evaluar la eficacia y seguridad de una vacuna de subunidad f prefusión contra el virus respiratorio sincitial (vrs) en lactantes nacidos de mujeres vacunadas durante el embarazo.

Type: Clinical Trials, phase III.
HULP code: Appendix 1 5526.
Sponsored by: Pfizer, S.L.U.
Signed date: 25/10/2021



3.7.4 Pediatric Respiratory, Systemic and Neurological Infections & Host Immune Response Group

Publications: 56

Q1: 31

COMPOSITION

Maria Cabrerizo



Cristina Calvo



Rosa Albañil



María Luz García García



Teresa del Rosal



Ana Méndez Echeverría



Inmaculada Casas

Cristina Calvo Rey. Jefe de Sección del Servicio de Pediatría Hospitalaria, Enfermedades Infecciosas y Tropicales. Hospital Universitario La Paz

María Rosa Albañil Ballesteros. Pediatra Titular. Centro de Salud de Cuzco. Atención Primaria

Sonia Alcolea Ruiz. Investigadora Predoctoral. Hospital Universitario La Paz

María Mercedes Bueno Campaña. Facultativo Especialista de Área en Pediatría. Hospital Fundación de Alcorcón

María Cabrerizo Sanz. Investigador titular. Instituto de Salud Carlos III

Inmaculada Casas Flechas. Científico Titular de OPIs. Instituto de Salud Carlos III

Teresa del Rosal Rabes. Médico Adjunto de Pediatría Hospitalaria y Enfermedades Infecciosas y Tropicales. Hospital Universitario La Paz

María Luz García García. Jefe de Servicio de Pediatría. Hospital Universitario Severo Ochoa

Paula García Sánchez. Médico Adjunto en Servicio de Urgencias Pediátricas. Hospital Universitario La Paz

Mónica González Esguevillas. Ayudante de Investigación. Centro Nacional de Microbiología. Instituto de Salud Carlos III

Carlos Grasa Lozano. Contrato Rio Hortega. Hospital Universitario La Paz

Jara Hurtado Gallego. Investigadora Postdoctoral. CIBER

María de la Montaña Iglesias Caballero. Titulado Superior ATP. Centro Nacional de Microbiología. Instituto de Salud Carlos III

Ana María Méndez Echevarría. Facultativo Especialista de Área en Pediatría General. Hospital Universitario La Paz

Mar Molinero Calamita. Colaboradora I+D+I. Centro Nacional de Microbiología. Instituto de Salud Carlos III

Almudena Otero Sánchez. Ayudante de Investigación I+D+I. Centro Nacional de Microbiología. Instituto de Salud Carlos III

Juan Francisco Pozo Sánchez. Investigador Titular de OPIs. Unidad de Virus Respiratorios y Gripe. Instituto de Salud Carlos III


Clara Udaondo Gascón. Facultativo Especialista en Reumatología Pediátrica. Hospital Universitario La Paz

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

STRATEGIC OBJECTIVE

Infectious diseases are the most frequent pathology in childhood. Our group is focused in the study of paediatric infections with special attention to those associated to viruses.

The acute respiratory infections (ARIs) of lower respiratory tract are the most frequent infectious diseases in humans and these suppose at least 4 million of deaths yearly in the world. A high proportion of these infections are related with viral aetiology and particularly in children. In our country, the viral ARIs are one of the most frequent causes of hospitalization in children less than 2 years old. Using the metagenomics and applying an adapted method designed and developed for ARIs study, we will have achieved an increased knowledge of viral infections in hospitalized children of all ages, as well as in outpatients. Metagenomics could allow recognizing new viruses and also permits a deeper knowledge of traditional respiratory virus groups. Any new technological tool and its application to respiratory infection will mean an improvement in the diagnosis and monitoring of these types of infections and their immediate use is specified for resolving alerts in public health associated with respiratory viral infections is like the case of MERS-CoV, avian flu, or other influenza pandemics. The pandemic caused by SARS-CoV-2 and the COVID-19 disease in childhood has occupied a large part of the research of our group since its appearance. We are also interested in the study of the immunological response of the infants to the viral infections, and the mechanisms that allow develop recurrent wheezing, or asthma (the most frequent chronic disease in children).

Emerging viral infections have also an important role in the pathology in childhood. Recently picornaviruses, mainly human parechovirus and enterovirus are causing outbreaks and several neurological infections, morbidity and mortality. They were associated with a wide

range of pathologies, from febrile syndrome to respiratory, neurological or systemic diseases. In newborns, these infections can be severe, even fatal. Surveillance of these polio-like diseases is a public health concern and it is one of our group objectives.

Finally, to study viral infections in high risk group of children (newborn, chronic lung diseases, immunodeficiencies, oncologic patients, rheumatic diseases...) is also a priority in our group.

RESEARCH LINES

- Respiratory viral infections in hospitalized children. Viral metagenomic methods applied to the severe infections of the lower respiratory tract. SARS-CoV-2 infections in children.
- Respiratory viral infections in children in Primary Care. Diagnosis and treatment of infectious diseases in Primary Care.
- Respiratory viral infections in high risk group of children (newborn, chronic lung diseases, immunodeficiencies, oncologic patients...). Torqueto virus in immunocompromised children.
- Applying of new technologies as echography to value risk conditions in viral infections.
- Immune response of the children and interleukins profile in infants with respiratory viral infections and correlation with the development of recurrent wheezing in the first years of life. Role of microbiome.
- Detection and characterization of enterovirus (EV) and parechovirus (PeV) systemic and neurological infections in children.
- Neurological development in children with EV and PeV infections.
- Kawasaki disease
- Osteoarticular infections
- Infections in children with rheumatic diseases.

RESEARCH ACTIVITY

■ Doctoral theses

Master Theses

Guerig Rodríguez NE. Bacteriemia por *Pseudomonas aeruginosa* en niños y adolescentes. Perfil de resistencias a carbapenémicos, datos clínicos y factores

de riesgo asociados a mortalidad. [dissertation]. Madrid: UCM: 2021(01/10/2021).

Directors: Calvo Rey C, Baquero Artigao F.

Final Degree Theses

Hernaiz Ferrer AI. ¿Es el asma un factor de riesgo en niños para la infección

COVID-19? [dissertation]. Madrid: UAX: 2021(01/06/2021).

Director: Calvo Rey C.


Platero Dueñas L. Professionals' knowledge and clinical practice related to pets in transplanted children. results from an international survey. [dissertation]. Ma-

drid: UAM: 2021(01/06/2022).

Director: Méndez Echevarría A.

Agular Platero E. Mascotas, zoonosis y niños inmunodeprimidos. ¿Qué saben las familias? [dissertation]. Madrid: UAM: 2021(01/06/2021).

Director: Méndez Echevarría A.



Publications

- Aguilera-Alonso D, Murias S, Garde AMDA, Soriano-Arandes A, Pareja M, Otheo E, Moraleda C, Tagarro A, Calvo C. Prevalence of thrombotic complications in children with SARS-CoV-2. *Arch Dis Child*. 2021; 106(11): 1129-32. Article. IF: 4.92; Q1
- Alcalde CF, Fernández MG, Moreno MN, Rey CC, Romero IF, Martín SN. COVID-19 ocular findings in children: a case series. *World J Pediatr*. 2021; 17(3): 329-34. Letter. IF: 9.186; D1
- Alonso L, Méndez-Echevarría A, Rudilla F, Mozo Y, Soler-Palacin P, Sisinni L, Bueno D, Riviere J, de Paz R, Sánchez-Zapardiel E, Querol S, Rodríguez-Pena R, López-Granados E, Gimeno R, de Heredia CD, Pérez-Martínez A. Failure of viral-specific t cells administered in pre-transplant settings in children with inborn errors of immunity. *J Clin Immunol*. 2021; 41(4): 748-55. Article. IF: 8.542; Q1
- Barrios-Tascón A, Miura M, Domínguez-Rodríguez S, Fernández-Cooke E, Sarquella-Brugada G, Tagarro A. Ventricular repolarization parameters and coronary involvement in kawasaki disease. *J Pediatr-U.S.* 2021; 236: 108-12. Article. IF: 6314; D1
- Benschop KSM, Albert J, Antón A, Andres C, Aranzamendi M, Armannsdóttir B, Bailly JL, Baldanti F, Baldvinsdóttir GE, Beard S, Berginc N, Bottcher S, Blomqvist S, Bubba L, Calvo C, Cabrerizo M, Cavallero A, Celma C, Ceriotti F, Costa I, Cottrell S, del Cuerpo M, Dean J, Dembinski JL, Diedrich S, Díez-Domingo J, Dorenberg D, Duizer E, Dyrdak R, Fanti D, Farkas A, Feeney S, Flipse J, De Gascun C, Galli C, Georgieva I, Gifford L, Guimomar R, Honemann M, Ikonen N, Jeannoel M, Josset L, Keeren K, López-Labrador FX, Maier M, McKenna J, Meijer A, Mengual-Chulia B, Midgley SE, Mirand A, Montes M, Moore C, Morley U, Murk JL, Nikolaeva-Glomb L, Numanovic S, Ovgioni M, Palminha P, Pariani E, Pellegrinelli L, Piralla A, Pietsch C, Pineiro L, Rabella N, Rainetova P, Rentería SCU, Romero MP, Reyniers M, Roorda L, Savolainen-Kopra C, Schuffenecker I, Soynova A, Swanink CM, Ursic T, Verweij JJ, Vila J, Vuorinen T, Simmonds P, Fischer TK, Harvala H. Re-emergence of enterovirus D68 in Europe after easing the COVID-19 lockdown, September 2021. *Euro Surveill*. 2021; 26(45): 2100998. Article. IF: 21.286; D1
- Benschop KSM, Broberg EK, Hodcroft E, Schmitz D, Albert J, Baicus A, Bailly JL, Baldvinsdóttir G, Berginc N, Blomqvist S, Bottcher S, Brytting M, Bujaki E, Cabrerizo M, Celma C, Cinek O, Claas ECJ, Cremer J, Dean J, Dembinski JL, Demchynyna I, Diedrich S, Dudman S, Dunning J, Dyrdak R, Emmanouil M, Farkas A, De Gascun C,

- Fournier G, Georgieva I, González-Sanz R, Van Hooydonk-Elving J, Jaaskelainen AJ, Jancauskaitė K, Keeren K, Fischer TK, Krokstad S, Nikolaeva-Glomb L, Novakova L, Midgley SE, Mirand A, Molenkamp R, Morley U, Mossong J, Muralyte S, Murk JL, Nguyen T, Nordbo SA, Osterback R, Pas S, Pellegrinelli L, Pogka V, Prochazka B, Rainetova P, Van Ranst M, Roorda L, Schuffenecker I, Schuurman R, Stoyanova A, Templeton K, Verweij JJ, Voulgari-Kokota A, Vuorinen T, Wolhants E, Wolthers KC, Zakikhany K, Neher R, Harvala H, Simmonds P. Molecular epidemiology and evolutionary trajectory of emerging echovirus 30, Europe. *Emerg Infect Dis*. 2021; 27(6): 1616-26. Article. IF: 16.126; D1
- Blázquez-Gamero D, Epalza C, Cadenas JAA, Gero LC, Calvo C, Rodríguez-Molino P, Méndez M, Santos MD, Fumado V, Guzmán MF, Soriano-Arandes A, Jiménez AB, Penin M, Cobo-Vázquez E, Pareja M, Lobato Z, Serna M, Delgado R, Moraleda C, Tagarro A. Fever without source as the first manifestation of SARS-CoV-2 infection in infants less than 90 days old. *Eur J Pediatr*. 2021; 180(7): 2099-106. Article. IF: 3.86; Q1
- Bretón-Martínez JR, Alcolea A, Quintero-García D, Méndez-Echevarría A, Ramos E, Bueno F, Colomina J, Mari-López J, Crehuel-Gaudiza E, García-Rodríguez J, Martínez-Costa C. Non-wild-type cryptococcosis in a child with multivisceral organ transplant who owned bird pets. *Transpl Infect Dis*. 2021; 23(3): e13558. Article. Not Indexed
- Calvo C, Tagarro A, Echevarría AM, Colomer BF, Ballesteros MRA, Bassat Q, Pena MJM. COVID-19 pandemic. What have we learned? *An Pediatr*. 2021; 95(5): 382. Article. IF: 2.377; Q3
- Calvo C, Udaondo C. COVID-19 in children with rheumatic diseases in the Spanish national cohort EPICO-AEP. *J Rheumatol*. 2021; 48(7): 1190-2. Letter. IF: 5.346; Q2
- Cendejas-Bueno E, Peinado H, Baquero-Artigao F, Falces-Romero I, Calvo-Rey C, La Banda-Montalvo L, García-Rodríguez J. Off-label use of T2Candida (R) test in vitreous humor for diagnosing invasive candidiasis: a clinical report. *Future Microbiol*. 2021; 16(9): 619-21. Article. IF: 3.553; Q3
- Clemente D, Udaondo C, de Inocencio J, Nieto JC, Del Río PG, Fernández AG, Palomo JA, Bachiller-Corral J, Robledillo JCL, Longo CM, Leon L, Abasolo L, Boteanu A. Clinical characteristics and COVID-19 outcomes in a regional cohort of pediatric patients with rheumatic diseases. *Pediatr Rheumatol*. 2021; 19(1): 162. Article. IF: 3.413; Q2
- Colmenero-Velázquez A, Esteso G, del Rosal T, Apalategui AC, Reyburn H, López-Granados E. Marked changes in innate immunity associated

- with a mild course of COVID-19 in identical twins with athymia and absent circulating T cells. *J Allergy Clin Immunol*. 2021; 147(2): 567-8. Letter. IF: 14.29; D1
- Criado MD, Garrido CF, San Martín EM, Arbolea CG, Gómez-Arroyo B, González-Donapetry P, Baquero-Artigao F, de la Calle M, Quiles-Melero I, Calvo C. Is an antenatal screening for chlamydia trachomatis necessary in the current society? *Pediatr Infect Dis J*. 2021; 40(11): 1034-45. Article. IF: 3.806; Q1
- de Ceano-Vivas M, García ML, Velázquez A, del Valle FM, Menasalvas A, Cilla A, Epalza C, Romero MP, Cabrerizo M, Calvo C. Neurodevelopmental outcomes of infants younger than 90 days old following enterovirus and parechovirus infections of the central nervous system. *Front Pediatr*. 2021; 9: 719119. Article. IF: 3.569; Q2
- Díez-Fuertes F, Iglesias-Caballero M, García-Pérez J, Monzón S, Jiménez P, Varona S, Cuesta I, Zaballos A, Jiménez M, Checa L, Pozo F, Pérez-Olmeda M, Thomson MM, Alcami J, Casas I. A founder effect led early SARS-CoV-2 transmission in Spain. *J Virol*. 2021; 95(3): e01583-20. Article. IF: 6.549; Q2
- Domínguez-Rodríguez S, Villaverde S, Sanz-Santaeufemia FJ, Grasa C, Soriano-Arandes A, Saavedra-Lozano J, Fumado V, Epalza C, Serna-Pascual M, Alonso-Cadenas JA, Rodríguez-Molino P, Pujol-Morro J, Aguilera-Alonso D, Simo S, Villanueva-Medina S, Iglesias-Bouzas MI, Mellado MJ, Herrero B, Melendo S, De la Torre M, Del Rosal T, Soler-Palacin P, Calvo C, Urretavizcaya-Martínez M, Pareja M, Ara-Montojo F, del Prado YR, Gallego N, Ramos MI, Cobos E, Tagarro A, Moraleda C. A Bayesian model to predict COVID-19 severity in children. *Pediatr Infect Dis J*. 2021; 40(8): E287-93. Article. IF: 3.806; Q1
- Fernández-Cooke E, Grasa CD, Domínguez-Rodríguez S, Tascón AB, Sánchez-Manubens J, Antón J, Mercader B, Villalobos E, Camacho M, Gómez MLN, Benavent MO, Giral G, Bustillo M, Naranjo AMB, Rocandio B, Rodríguez-González M, Cuadros EN, Santos JA, Moreno D, Calvo C. Prevalence and clinical characteristics of sars-cov-2 confirmed and negative kawasaki disease patients during the pandemic in Spain. *Front Pediatr*. 2021; 8: 617039. Article. IF: 3.569; Q2
- Gambaro F, Pérez AB, Aguera E, Prot M, Martínez-Martínez L, Cabrerizo M, Simon-Lorieri E, Fernández-García MD. Genomic surveillance of enterovirus associated with aseptic meningitis cases in southern Spain, 2015-2018. *Sci Rep-Uk*. 2021; 11(1): 21523. Article. IF: 4.996; Q2
- García LS, Pellicer A, López-Martínez C, García-García ML, Casas I, Pozo F, Calvo C. Respiratory


- morbidity associated with viral respiratory infections during neonatal stage in premature infants. *Pediatr Pulm*. 2021; 56(5): 967-73. Article. IF: 4.09; Q1
- Goldman DL, Aldrich ML, Hagmann SHF, Bamford A, Camacho-González A, Lapadula G, Lee P, Bonfanti P, Carter CC, Zhao Y, Telep L, Pikora C, Naik S, Marshall N, Katsarolis I, Das M, DeZure A, Desai P, Cao HY, Chokkalingam AP, Osinusi A, Brainard DM, Méndez-Echevarría A. Compassionate use of remdesivir in children with severe COVID-19. *Pediatrics*. 2021; 147(5): e2020047803. Article. IF: 9.703; D1
- Grasa CD, Gómez-Gil MR, Pacheco SS, del Rosal T, Moreno F, Gerig N, Fernández BO, Calvo C, Baquero-Artigao F. Compassionate use of cefiderocol for VIM metallo-beta-lactamase-producing *Pseudomonas aeruginosa* infection in a toddler with Burkitt lymphoma. *J Glob Antimicrob Resist*. 2021; 26: 91-2. Letter. IF: 4.349; Q2
- Jiménez-García R, Nogueira J, Retuerta-Oliva A, Sainz T, Cano-Fernández J, Flores-Pérez P, Méndez-Echevarría A, Villalobos-Pinto E, Calleja-Gero L, Sanz-Santaeufemia FJ, Romero MP, del Rosal T, Baquero-Artigao F, Grasa C, Calvo C. Pneumonia in hospitalized children during sars-cov-2 pandemic. is it all covid-19? comparison between covid and non-covid pneumonia. *Pediatr Infect Dis J*. 2021; 40(3): E111-3. Article. IF: 3.806; Q1
- Kissling E, Hooiveld M, Martín VS, Martínez-Baz I, William N, Vilcu AM, Mazagatos C, Domegan L, de Lusignan S, Meijer A, Machado A, Brytting M, Casado I, Murray JLK, Belhiliil S, Larrauri A, O'Donnell J, Tsang R, de Lange M, Rodrigues AP, Riess M, Castilla J, Hamilton M, Falchi A, Pozo F, Dunford L, Cogdale J, Jansen T, Guiomar R, Enkirch T, Burgui C, Sigerson D, Blanchon T, Ochoa EMM, Connell J, Ellis J, van Gageldonk-Lafeber R, Kislaya I, Rose AMC, Valenciano M, (Calvo Rey C). Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021. *Euro Surveill*. 2021; 26(29): 2100670. Article. IF: 21.286; D1
- López JN, Grasa C, Calvo C, López-Hortelano MG. Long-term symptoms of COVID-19 in children. *Acta Paediatr*. 2021; 110(7): 2282-3. Letter. IF: 4.056; Q1
- López JN, Lozano CG, Ruiz CO, García LA, Falces-Romero I, Calvo C, Hortelano MGL. Telemedicine follow-ups for COVID-19: Experience in a tertiary hospital. *An Pediatr*. 2021; 95(5): 336-44. Article. IF: 2.377; Q3
- López MDC, Cabrerizo M, Herrador BRG, Masa-

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Calles J, Alarcon-Linares ME, Allende A, Cano EA, Boada MIB, Gudino EC, Fernández-Balbuena S, Duenas AF, Fernández-García MD, Hernández LG, Ortuzar VG, López-Perea N, Martínez-Salcedo E, Moreno-Docon A, Gavin MO, Garduno IR, Moros MJS, Soria FS, Sánchez AL, Rodríguez BS. An imported case of vaccine-derived poliovirus type 2, Spain in the context of the ongoing polio Public Health Emergency of International Concern, September 2021. *Euro Surveill.* 2021 ;26(50): 2101068. Article. IF: 21.286; D1

• López SL, del Rosal T, Bueno SJ, Baquero-Artigao F. Septicemia and meningitis associated with *Haemophilus influenzae* type b vaccine failure. *Enferm Infect Micr Cl.* 2021; 39(8): 417-8. Letter. IF: 1.994; Q4

• Martínez-López N, Muñoz-Almagro C, Launes C, Navascues A, Imaz-Pérez M, Reina J, Romero MP, Calvo C, Ruiz-García M, Megias G, Valencia-Ramos J, Otero A, Cabrero M. Surveillance for enteroviruses associated with hand, foot, and mouth disease, and other mucocutaneous symptoms in Spain, 2006-2020. *Viruses-Basel.* 2021; 13(5): 781. Article. IF: 5.818; Q2

• Martínez-Planas A, Baquero-Artigao F, Santiago B, Fortuny C, Méndez-Echevarría A, Del Rosal T, Bustillo-Alonso M, Gale I, Guerrero C, Blazquez-Gamero D, Canet A, Lillo M, Calavia O, Cuadros EN, Falcon-Neyra L, Soriano-Arandes A, Van Ingen J, Tebruegge M, Noguera-Julian A. Interferon-gamma release assays differentiate between mycobacterium avium complex and tuberculous lymphadenitis in children. *J Pediatr-Ur.* 2021; 236: 211-8. Article. IF: 6.314; D1

• McArdle AJ, Vito O, Patel H, Seaby EG, Shah PY, Wilson C, Broderick C, Nijman R, Tremoulet AH, Munblit D, Ulloa-Gutiérrez R, Carter MJ, De TS, Hoggart C, Whittaker E, Herberg JA, Kaforou M, Cunningham AJ, Levin M, (Méndez Echevarría A). Treatment of multisystem inflammatory syndrome in children. *New Engl J Med.* 2021; 385(1): 11-22. Article. IF: 176.079; D1

• Méndez-Echevarría A, Caminoa MB, del Rosal T, Casas I, Pozo F, Pascual-Pascual SI, García-Romero M, Camara C, Calvo C. The role of respiratory viruses in children with ataxia-telangiectasia. *Viruses-Basel.* 2021; 13(5): 867. Article. IF: 5.818; Q2

• Méndez-Echevarría A, Sainz T, de Felipe B, Alcolea S, Olbrich P, Goycochea-Valdivia WA, Escosa-García L, Cobo L, Calvo C, Neth O. High rates of SARS-CoV-2 family transmission in children of healthcare workers during the first pandemic wave in Madrid, Spain Serologic Study. *Pediatr Infect Dis J.* 2021; 40(5): E185-8. Article. IF: 3.806; Q1

• Méndez-Echevarría A, Sainz T, Falces-Romero

I, de Felipe B, Escolano L, Alcolea S, Pertinéz L, Neth O, Calvo C. Long-term persistence of anti-SARS-CoV-2 antibodies in a pediatric population. *Pathogens.* 2021; 10(6): 700. Article. IF: 4.531; Q2

• Méndez-Echevarría A, Sandor-Bajusz KA, Calvo C. Severe sinus bradycardia associated with remdesivir in a child with severe SARS-COV-2 infection-reply. *Eur J Pediatr.* 2021; 180(5): 1629-30. Editorial Material. IF: 3.86; Q1

• Miranda-Barrios J, Bravo-Queipo-de-Llano B, Baquero-Artigao F, Granados-Fernández M, Novál S, Rabanal I, Méndez-Echevarría A, del Rosal T, Sainz T, Aracil J, Calvo C. Preseptal versus orbital cellulitis in children: an observational study. *Pediatr Infect Dis J.* 2021; 40(11): 969-74. Article. IF: 3.806; Q1

• Monte-Serrano J, García-Gil MF, García-García M, Casas-Flecha I, Matovelle-Ochoa C, Ara-Martín M. Granuloma annulare triggered by SARS-CoV-2 infection: Immunohistochemical staining. *Dermatol Ther.* 2021; 34(3): e14897. Letter. IF: 3.858; Q2

• Moraleda C, Serna-Pascual M, Soriano-Arandes A, Simo S, Epalza C, Santos M, Grasa C, Rodríguez M, Soto B, Gallego N, Ruiz Y, Urretavizcaya-Martinez M, Pareja M, Sanz-Santaefemia FJ, Fumado V, Lanaspá M, Jordan I, Prieto L, Belda S, Toral-Vázquez B, Rincon E, Gil-Villanueva N, Méndez-Echevarría A, Castillo-Serrano A, Riviere JG, Soler-Palacin P, Rojo P, Tagarro A. Multi-inflammatory syndrome in children related to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Spain. *Clin Infect Dis.* 2021; 72(9): E397-401. Article. IF: 20.999; D1

• Penedo RP, Lucas MR, Walther LAAS, Benavent AT, Losada MLC, Andrio LB, Poves ABR, Campana MB. MR-Proadrenomedullin as biomarker of renal damage in urinary tract infection in children. *BMC Pediatr.* 2021; 21(1): 292. Article. IF: 2.567; Q3

• Penela-Sánchez D, González-de-Audicana J, Armero G, Henares D, Esteve C, de-Sevilla MF, Ricart S, Jordan I, Brotons P, Cabrero M, Muñoz-Almagro C, Launes C. Lower respiratory tract infection and genus enterovirus in children requiring intensive care: clinical manifestations and impact of viral co-infections. *Viruses-Basel.* 2021; 13(10): 2059. Article. IF: 5.818; Q2

• Pérez EM, Shephard JLV, García-Morato MB, Marhuenda AR, Nodal EMO, Bobano GP, Casado IG, Fresno LS, Echevarría AM, Rabes TD, Martínez LA, López-Granados E, Pena RR. Variants in CASP10, a diagnostic challenge: Single center experience and review of the literature. *Clin Immunol.* 2021; 230: 108812. Review. IF: 10.19; Q1

• Pérez-Tarazona S, Esteban SR, García-García ML, Sánchez MA, Messa ID, Valarezo TA, Medina OM, Callejón AC, Calderín EMC, Rodríguez SA, Vidal RA, Posadas AS, Colomer JC, Miro XD, Castaneda MB, Porto-Domínguez AV. Respiratory outcomes of new bronchopulmonary dysplasia in adolescents: A multicenter study. *Pediatr Pulm.* 2021; 56(5): 1205-14. Article. IF: 4.09; Q1

• Quintana-Ortega C, Seoane-Reula E, Fernández L, Camacho M, Olbrich P, Neth O, Murias S, Udaondo C, Remesal A, Calvo C, Alcobendas R. Colchicine treatment in children with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome: A multicenter study in Spain. *Eur J Rheumatol.* 2021; 8(2): 73-8. Article. Not Indexed

• Román F, Méndez-Echevarría A, Del Rosal T, García-Vera C, Escosa-García L, Agud M, Chaves F, Gutiérrez-Fernández J, de Gopegui ER, Ruiz-Carrascoso G, Ruiz-Gallego MD, Bernet A, Quevedo SM, Fernández-Verdugo AM, Sainz T, Calvo C. Characterization of methicillin-resistant *Staphylococcus aureus* strains colonizing the nostrils of Spanish children. *Microbiologyopen.* 2021; 10(5): e1235. Article. IF: 3.904; Q3

• Sainz T, Delgado J, Méndez-Echevarría A, Santiago B, López-Varela E, Aguilera-Alonso D, Saavedra-Lozano J, Rodríguez-Fernández R, Holguin A, Navarro ML, Muñoz-Fernández MA, Rivero-Calle I, Solana MJ, López-Herce J, Calvo C. The clinical relevance of the microbiome when managing paediatric infectious diseases-Narrative review. *Acta Paediatr.* 2021; 110(2): 441-9. Review. IF: 4.056; Q1

• Sainz T, Pignataro V, Bonifazi D, Ravera S, Mella-do MJ, Pérez-Martínez A, Escudero A, Ceci A, Calvo C. Human microbiome in children, at the crossroad of social determinants of health and personalized medicine. *Children (Basel).* 2021; 8(12): 1191. Article. IF: 2.835; Q2

• Sainz T, Udaondo C, Méndez-Echevarría A, Calvo C. Lung ultrasound for evaluation of COVID-19 in children. *Arch Bronconeumol.* 2021; 57: 94-6. Letter. IF: 6.333; Q1

• Sastre B, García-García ML, Canas JA, Calvo C, Rodrigo-Muñoz JM, Casas I, Mahillo-Fernández I, del Pozo V. Bronchiolitis and recurrent wheezing are distinguished by type 2 innate lymphoid cells and immune response. *Pediatr Allerg Imm-Uk.* 2021; 32(1): 51-9. Article. IF: 5.464; D1

• Tagarro A, Epalza C, Santos M, Sanz-Santaefemia FJ, Otheo E, Moraleda C, Calvo C. Screening and severity of coronavirus disease 2019 (COVID-19) in children in Madrid, Spain. *JAMA Pediatr.* 2021; 175(3): 316-7. Letter. IF: 26.796; D1

• Tagarro A, Moraleda C, Calvo C. Scientific ambiguity in the time of coronavirus disease 2019 Reply. *JAMA Pediatr.* 2021; 175(3): 318-9. Letter. IF: 26.796; D1

• Tapiador MAM, Alcalá FJC, Alonso AR, Amores CM, Pena MJM, Rey CC. Current situation of children with medical complexity: An experience between primary and hospital care. *Aten Prim.* 2021; 53(6): 102046. Article. IF: 2.206; Q3


• Tapiador MAM, Alcalá FJC, Alonso AR, Rey CC. Children with medical complexity. What is the way? *An Pediatr.* 2021; 95(4): 284-5. Letter. IF: 2.377; Q3

• Torres-Fernández D, Casellas A, Mellado MJ, Calvo C, Bassat Q. Acute bronchiolitis and respiratory syncytial virus seasonal transmission during the COVID-19 pandemic in Spain: A national perspective from the pediatric Spanish Society (AEP). *J Clin Virol.* 2021; 145: 105027. Article. IF: 14.481; D1

• Vasconcelos MK, Loens K, Sigfrid L, Iosifidis E, Epalza C, Dona D, Matheussen V, Papachristou S, Roilides E, Gijon M, Rojo P, Minotti C, Da Dalt L, Islam S, Jarvis J, Syggelou A, Tsolia M, Nyang'wa MN, Keers S, Renk H, Gemmel AL, D'Amore C, degli Atti MC, Sánchez CRT, Martinon-Torres F, Burokiene S, Goetghebuer T, Spoulou V, Riordan A, Calvo C, Gkentzi D, Hufnagel M, Openshaw PJ, de Jong MD, Koopmans M, Goossens H, Ieven M, Fraaij PLA, Giaquinto C, Bielicki JA, Horby P, Sharland M. Aetiology of acute respiratory infection in preschool children requiring hospitalisation in Europe-results from the PÉD-MERMAIDS multicentre case-control study. *BMJ Open Respir Res.* 2021 ;8(1): e000887. Article. IF: 5.059; Q2

• Velasco M, Galán MI, Casas ML, Pérez-Fernández E, Martínez-Ponce D, González-Pineiro Bz, Castilla V, Guijarro C, (Bueno Campaña M). Impact of previous coronavirus disease 2019 on immune response after a single dose of bnt162b2 severe acute respiratory syndrome coronavirus 2 vaccine. *Open Forum Infect Dis.* 2021; 8(7): ofab299. Article. IF: 4.423; Q2

• Villaverde S, Domínguez-Rodríguez S, Sabrido G, Pérez-Jorge C, Plata M, Romero MP, Grasa CD, Jiménez AB, Heras E, Broncano A, Núñez MD, Illan M, Merino P, Soto B, Molina-Arana D, Bermejo A, Mendoza P, Gijón M, Pérez-Moneo B, Moraleda C, Tagarro A. Diagnostic accuracy of the panbio severe acute respiratory syndrome coronavirus 2 antigen rapid test compared with reverse-transcriptase polymerase chain reaction testing of nasopharyngeal samples in the pediatric population. *J Pediatr-Ur.* 2021; 232: 287-9. Article. IF: 6.314; D1



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

■ Research projects

Albañil Ballesteros R. Manejo diagnóstico y terapéutico de la infección del tracto urinario (ITU) en atención primaria (AP) pediátrica. Asociación Española de Pediatría de Atención Primaria. 2019-2021.

Managment centre: Fundación Pediatría y Salud

Cabrerizo Sanz M. Investigación de las infecciones neurológicas graves en niños causadas por enterovirus emergentes en España: EV-A71 y EV-D68 (PI18CIII/00017). ISCIII-AESI. 2019-2021.

Managment centre: ISCIII/CNM Virología

Calvo Rey C, Alcamí A. Transmisión de SARAS.CoV2 por el aire: detección en hospitales y tecnologías innovadoras. (COV20/00144). ISCIII. Fondos COVID. 2020-2021.

Managment centre: FIBHULP

Calvo Rey C. Contrato de intensificación (INT19/00009). ISCIII. 2020-2021.

Managment centre: FIBHULP

Calvo Rey C. Contrato garantía juvenil técnico laboratorio (PEJ2019_TL/BMD_12351). CM. 2020-2021.

Managment centre: FIBHULP

Calvo Rey C. Contrato predoctoral (PEJD-2018-PRE/BMD-9430). CM. 2019-2020.

Managment centre: FIBHULP

Calvo Rey C. Infecciones en niños con artritis idiopática juvenil. Fundación SEIP. 2017-Ongoing.

Managment centre: FIBHULP

Calvo Rey C. Infecciones osteoarticulares en pediatría. Estudio prospectivo multicéntrico. Fundación de la Asociación Española de Pediatría. 2017-Ongoing.

Managment centre: FIBHULP

Calvo Rey C. Infecciones respiratorias virales en recién nacidos de muy bajo peso. Fundación Neumomadrid. 2017-2021.

Managment centre: FIBHULP

Calvo Rey C. Infecciones virales respiratorias en recién nacidos de muy bajo peso, respuesta inmunológica e implantaciones pronósticas (PI18/00167). ISCIII. 2019-2021.

Managment centre: FIBHULP

Casas Flecha I. Coordinación de actividades de investigación en el CNM para realizar una respuesta integradora frente a la pandemia por Sars-Cov2 en España (MPY222-20 COVID19). ISCIII-AESI. 2020-2021.

Managment centre: ISCIII/CNM Virología

Casas Flecha I. Enhancing Whole Genome Sequencing (WGS) and/or Reverse Transcription Polymerase Chain Reaction (RT-PCR) national infrastructures and capacities to respond to the Covid-19 pandemic in Spain. (Union Europea-Grant/2021/PHF/23776). EU. 2021-2022.

Managment centre: ISCIII/CNM Virología

Casas Flecha I. Los virus respiratorios en las IRAs de recién nacidos y pacientes pediátricos: asociación con la gravedad del episodio agudo y con el desarrollo de asma y sibilancias recurrentes a largo plazo (PI18CIII/00009). ISCIII-AESI. 2018-2021.

Managment centre: ISCIII/CNM Virología

Casas Flecha I. Multidisciplinary European network for research, prevention and control of the COVID-19 Pandemic (Union Europea 101003673). EU. 2020-2022.

Managment centre: ISCIII/CNM Virología

del Rosal Rabés T. Aplicación de las técnicas moleculares al estudio etiológico de la neumonía atípica o indeterminada en niños hospitalizados. Asociación Espa-

ñola de Pediatría de Atención Primaria. 2019-Ongoing.

Managment centre: FIBHULP

del Rosal Rabés T. Infecciones por virus respiratorios y células NK en vías respiratorias en niños receptores de trasplante de progenitores hematopoyéticos. Estudio prospectivo. European Society of Pediatric Infectious Diseases. 2017-2021.

Managment centre: FIBHULP

García García ML. Asociación de los distintos perfiles del viroma, la microbiota y la respuesta inmune con la gravedad de la bronquiolitis viral aguda y con el desarrollo de sibilancias recurrentes. UAX. 2019-Ongoing.

Managment centre: Fundación UAX

García García ML. Influencia de la microbiota y de la respuesta inmune en la gravedad de la bronquiolitis aguda y en el desarrollo posterior de asma. SEPAR. 2021-2023.

Managment centre: Fundación Puerta de Hierro

Grasa Lozano CD. Contrato Río Hortega (CM19/00015). ISCIII. 2020-2022.

Managment centre: FIBHULP

Grasa Lozano CD. FungiPED: Registry of IFI in paediatrics and establishment of optimal cut-off for BDG in children. Gilead. 2021-2022.

Managment centre: FIBHULP

Méndez Echecarría AM. Niños inmunodeprimidos y mascotas. ¿Por qué, cómo, cuándo...? Recomendaciones basadas en evidencias para pacientes inmunodeprimidos y sus mascotas. MAPFRE. 2021-2022.

Managment centre: FIBHULP

Méndez Echevarría AM, Calvo Rey C, Escosa García L. Colonización por Sta-

phylococcus Aureus resistente a meticilina en niños sanos de la comunidad. Estudio Cosaco. Estudio multicéntrico de ámbito nacional. Fundación de la Asociación Española de Pediatría. 2018-Ongoing.

Managment centre: FIBHULP

Méndez Echevarría AM, Calvo Rey C. Caracterización de colonizaciones por microorganismos potencialmente patógenos en niños inmunodeprimidos y sus mascotas. Fundación de la Asociación Española de Pediatría. 2021-2022.

Managment centre: FIBHULP

Méndez Echevarría AM, Calvo Rey C. Colonización por s.aureus resistente a meticilina en niños sanos de la comunidad (Estudio Cosaco): estudio multicéntrico nacional (PI18/00372). ISCIII. 2019-2021.

Managment centre: FIBHULP

Méndez Echevarría AM, Calvo Rey C. Explorando la epidemiología del Sars-Cov-2 en un entorno de alto riesgo para caracterizar la dinámica de transmisión entre los contactos del hogar, centrándose en el papel de los niños y las mascotas. Estudio Sanicov: un estudio de cohorte prospectivo. Merck Sharp and Dohme de España S. A. 2020-Ongoing.


Managment centre: FIBHULP

Udaondo Gascón C. Banco de imágenes de capilaroscopias en población pediátrica. Sociedad Española de Reumatología Pediatría. 2019-Ongoing.

Managment centre: FIBHULP

Udaondo Gascón C. PROYECTO VAC REU: Inmunogenicidad de la vacuna frente a SARS-CoV-2 en adolescentes con patología reumática y comparación con un grupo control. Sociedad Española de Reumatología Pediatría. 2021-2023.

Managment centre: FIBHULP



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

■ Clinical trials

Calvo Rey, C. La carga de la infección por vsr en niños pequeños europeos (estudio brice).

Type: Estudios No EPA.

HULP code: PI-4484 BRICE.

Sponsored by: Julius Clinical Research.

Signed date: 01/03/2021

Calvo Rey, C. Estudio de fase III, doble ciego, aleatorizado y controlado con placebo para evaluar la seguridad, la reactividad y la respuesta inmunitaria de una dosis intramuscular única de la vacuna materna contra el virus respiratorio sincitial (vrs) no potenciada en mujeres embarazadas de alto riesgo de 15 a 49 años y los lactantes nacidos de las madres vacunadas.

Type: Clinical Trials, phase III.

HULP code: 5888 214725 (RSV MAT-012).

Sponsored by: Glaxosmithkline, S.A.

Signed date: 03/06/2021

Calvo Rey, C. Estudio de fase II, aleatorizado, doble ciego, controlado con placebo y de 2 partes, para evaluar pautas de tratamiento de edp-938 en pacientes de 28 días a 24 meses de edad con infección por el virus respiratorio sincitial (vrs).

Type: Clinical Trials, phase II.

HULP code: 5717 EDP938-201.

Sponsored by: Enanta Pharmaceuticals, Inc.

Signed date: 05/07/2021

Calvo Rey, C. Estudio en fase IIb abierto para evaluar la seguridad, tolerabilidad e inmunogenicidad de menabcwy en lactantes sanos de 2 y 6 meses.

Type: Clinical Trials, phase IIb.

HULP code: Appendix 1 5716.

Sponsored by: Pfizer, S.L.U.

Signed date: 01/09/2021

Calvo Rey, C. Ensayo multicéntrico, abierto y con un solo grupo para evaluar la seguridad, la farmacocinética y la actividad antivírica de fostemsavir en combinación con un tratamiento de base optimizado (tbo) en niños y adolescentes infectados por el vih-1 cuyo tratamiento antirretrovírico combinado (tarv) actual fracasa y que presentan resistencia a antirretrovíricos (arv) de doble o triple clase.

Type: Clinical Trials, phase II.

HULP code: 5839 PENTA 22/Viiv 212968.

Sponsored by: Fondazione Penta Onlus.

Signed date: 10/08/2021

Grasa Lozano, CD. Estudio de fase 4, abierto y multicéntrico para evaluar la seguridad, la tolerabilidad y la inmunogenicidad de Vaxelis™ en niños sanos que han recibido anteriormente un ciclo infantil de vacunación primaria de dos dosis de Vaxelis™ o Hexyon.

Type: Clinical Trials, phase IV.

HULP code: 6053 V419-016.

Sponsored by: Merck Sharp And Dohme De España, S.A.

Signed date: 04/12/2021

Méndez Echevarría, AM. Estudio multicéntrico, sin enmascaramiento, en el que se evalúa la farmacocinética y la seguridad de baricitinib en pacientes pediátricos (desde 1 año hasta menos de 18 años de edad) hospitalizados con COVID-19.

Type: Clinical Trials, phase III.

HULP code: 5913 I4V-MC-KHAB.

Sponsored by: Lilly, S.A.

Signed date: 06/09/2021

Méndez Echevarría, AM. Estudio de fase II, abierto, no controlado, de dosis única para evaluar la seguridad, tolerabilidad y farmacocinética, y la aparición de anticuerpos antifármaco para nirsevimab en niños inmunodeprimidos de ≤ 24 meses de edad.

Type: Clinical Trials, phase II.

HULP code: 5965 D5290C00008.

Sponsored by: Astrazeneca Ab.

Signed date: 13/10/2021

Udaondo Gascón, C. Estudio de fase 3 multicéntrico, doble ciego, aleatorizado, controlado con placebo y de grupos paralelos para evaluar la eficacia, seguridad y farmacocinética de apremilast en niños de 5 a menos de 18 años de edad con artritis psoriásica juvenil activa (peapod, por sus siglas en inglés).

Type: Clinical Trials, phase III.

HULP code: 5673 20190529.

Sponsored by: Amgen, S.A.

Signed date: 18/01/2021

Udaondo Gascón, C. Estudio de fase 3 multicéntrico, doble ciego, aleatorizado, controlado con placebo y de grupos paralelos para evaluar la eficacia, seguridad y farmacocinética de apremilast en niños de 5 a menos de 18 años de edad con artritis psoriásica juvenil activa (peapod, por sus siglas en inglés).

Type: Clinical Trials, phase III.

HULP code: Appendix 2 5673.

Sponsored by: Amgen, S.A.

Signed date: 21/05/2021

Udaondo Gascón, C. Estudio de fase 3 multicéntrico, doble ciego, aleatorizado, controlado con placebo y de grupos paralelos para evaluar la eficacia, seguridad y farmacocinética de apremilast en niños de 5 a menos de 18 años de edad con artritis psoriásica juvenil activa (peapod, por sus siglas en inglés).

Type: Clinical Trials, phase III.

HULP code: Appendix 3 5673.

Sponsored by: Amgen, S.A.

Signed date: 14/09/2021

Udaondo Gascón, C. Estudio abierto de dosis múltiples para evaluar la farmacocinética, la seguridad y la tolerabilidad de upadacitinib en pacientes pediátricos con artritis idiopática juvenil de evolución poliarticular.


Type: Clinical Trials, phase III.

HULP code: Appendix 1 5188.

Sponsored by: Abbvie Deutschland GmbH.

Signed date: 14/07/2021.





3.7.5 Pediatric Systemic Infections; HIV, Tuberculosis, Imported and Emergent Diseases Group

Publications: 44


Q1: 24

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



COMPOSITION

■ **Talía Sainz Costa.** Facultativo Especialista de Área en Pediatría. Hospital Universitario La Paz. Profesor asociado. Universidad Autónoma de Madrid

Jorge Atucha Margolles. Técnico de Laboratorio. FIBHULP

Fernando Baquero Artigao. Facultativo Especialista de Área de Pediatría. Colaborador Clínico Docente. Universidad Autónoma de Madrid

Jorge Bustamante Amador. Investigador Predoctoral. Hospital Universitario La Paz

Francisco José Climent Alcalá. Facultativo Especialista de Área de Pediatría. Unidad de Patología Compleja. Hospital Universitario La Paz. Colaborador docente. Universidad Autónoma de Madrid

Lucía Escolano Taravilla. Investigador predoctoral, UAM. FEA Servicio de Pediatría. HULP. Hospital Universitario La Paz

Luis Escosa García. Facultativo Especialista de Área en Pediatría. Hospital Universitario La Paz

Jaime Delgado Pérez. Investigador Predoctoral. Hospital Universitario La Paz

Miguel García Boyano. Investigador Predoctoral. Hospital Universitario La Paz


Marta García Fernández de Villalta. Facultativo Especialista de Área de Pediatría. Hospital Universitario La Paz. Colaborador Clínico Docente. Universidad Autónoma de Madrid

María Milagros García López de Hortelano. Médico Adjunto de Pediatría Hospitalaria y Enfermedades Infecciosas y Tropicales. Hospital Universitario La Paz

Isabel Mellado Sola. Investigador Predoctoral. Hospital Universitario La Paz

Roi Piñeiro Pérez. Jefe del Servicio de Pediatría. Hospital Universitario General de Villalba

Paula Rodríguez Molino. Investigador Río Hortega. Médico Adjunto Servicio de Pediatría. Hospital Universitario La Paz



1
Introduction

2
Executive
Summary

3
Information
Groups
by Area

4
Associated
Clinicians

STRATEGIC OBJECTIVE

Vertically acquired HIV infection in children: Comorbidities, biomarkers, HIV reservoir, new therapeutic approaches.

Epidemiology of Paediatric Tuberculosis in Spain: molecular epidemiology of drug resistant strains, new diagnostic tools and new drugs for TB: Pharmacodynamics in children and TB-drugs Off-label use in paediatrics.

Congenital infections: burden of disease, prompt diagnosis and in-utero and postnatal management, host immune response.

Epidemiology of imported and emergent diseases in children: Identification and management of emergent outbreaks. Immuno-pathogenesis, preventive measures and management. Covid-19 in children
Immunization strategies in children: immune response in high risk patient's vaccine effectiveness and barriers.

Social Determinants of Health in Pediatrics

Infection and immunity: microbiome at the crossroad of immunity and allergy.

RESEARCH LINES

Vertically acquired HIV infection in children

- Immuno-pathogenesis: Immune-activation, inflammation and biomarkers
- Epidemiology, immuno-virological factors
- Comorbidities, long term follow-up, cardiovascular risk, bone disorders, metabolic abnormalities, neurocognitive impairment, renal dysfunction.
- Antiretroviral treatment: new drugs, resistances, dosage, toxicity in children, simplification strategies.
- HIV eradication: barriers, HIV reservoir, new antiretroviral drugs and other strategies to achieve HIV replication control.
- Gut Microbiota and bacterial translocation intestinal as modulating factors for inflammation and Immune-activation in HIV-infected children.
- Transition to adult care: barriers, strategies to maintain adherence to care.

Epidemiology of paediatric Tuberculosis (TB)

- Molecular Epidemiology of paediatric TB: resistant strains.

- Epidemiology of paediatric TB. paediatric cases as a sentinel for burden of diseases.
- Immuno-pathogenesis: New diagnostic tools in special Populations: HIV-infected, ID patients
- Management of critical situations. Neonatal TB, multidrug resistant and extra-pulmonary TB.

Omics for the diagnosis of pediatric TB

- New fixed-dosed combinations. Off label drugs in children. Pharmacodynamic and pharmacokinetic.

Congenital infectious diseases

- Congenital Citomegalovirus and Toxoplasma infections: diagnostic barriers, prognostic factors, new therapeutic approaches.
- CHAGAS disease and congenital TB: diagnostic barriers, prognostic factors, pharmacokinetics in newborns and new drugs.

Epidemiology of imported and emergent diseases in children

- Paediatric International Outbreaks: Epidemiology and public health impact: Zika. Rabies. Dengue. Chikungunya. Haemorrhagic fevers, Mers-co.
- Imported diseases in Spain: epidemiology and special populations: adopted, migrant, refugees, travelers and ID children. Tropical and parasitic infections in children.
- COVID-19 disease in children: epidemiology, diagnostic markers, treatment.

Immunization strategies in children, including high risk patients


- Immunization and vaccine response in special populations: immunocompromised children, transplant recipients, chronic patients, HIV-infected, migrants.
- Vaccine immunogenicity: barriers in paediatric populations.
- New challenges in vaccinology

Microbiome in pediatric infectious diseases

- Microbiome-related biomarkers in food allergy and intolerances
- Microbiome-related biomarkers in childhood TB and other respiratory infections

Social Determinants of Health in Pediatrics

The burden of chronic disease in childhood



RESEARCH ACTIVITY

■ Doctoral theses

Master Theses

Chávez Castro E. Incidencia de VIH en adolescentes durante periodo 2018-2019 en clinica periferica de la seguridad social de Costa Rica[dissertation]. Madrid: URJC: 2021(17/06/2021).

Director: Sainz Costa T.

Rodríguez Molino P. Profilaxis postexposición frente al VIH en niños, adolescentes y adultos jóvenes[dissertation]. Madrid: URJC: 2021(17/06/2021).

Director: Sainz Costa T.

Nogueira López J. Implementación de las medidas de prevención de la transmisión vertical de VIH en España[dissertation]. Madrid: URJC: 2021(17/06/2021).

Director: Sainz Costa T.

Gerig Rodríguez N. Bacteriemia por pseudomonas aeruginosa en niños y adolescentes. Perfil de resistencias a carbapenémicos, datos clínicos y factores de riesgo asociados a mortalidad[dissertation]. Madrid: UCM: 2021(17/06/2021).

Director: Baquero Artigao F.

Final Degree Theses

Soria Alcaide E. Ganancia ponderal con los inhibidores de la integrasa. [dissertation]. Madrid: UAM: 2021(01/06/2021).

Director: Sainz Costa T.

■ Publications

• Aguilera-Alonso D, Sainz T, de Ory SJ, Bernardino I, Díez C, Torres B, Merino D, Iribarren JA, Portilla I, Ríos MJ, Ibarra S, Sanz J, Bellon JM,

Carrasco I, Muñoz-Fernández MA, Ramos JT, Navarro ML. Clinical, Immunological, and virological outcomes among youths with perinatal hiv after transition to adult units in Spain from 1997 to 2016. *JAIDS-J Acq Imm Def.* 2021; 86(2): 240-7. Article. IF: 3.771; Q3

• Ara-Montojo MF, Bustamante J, Sainz T, Pérez S, Jiménez-Moreno B, Ruiz-Carrascoso G, Rodríguez-Molino P, Villota J, García-López-Hortelano M, Mellado-Pena MJ. Intestinal giardiasis in children: Five years' experience in a reference unit. *Travel Med Infect Di.* 2021; 42: 102082. Article. IF: 20.441; D1

• Ara-Montojo MF, Escosa-García L, Alguacil-Guillen M, Seara N, Zozaya C, Plaza D, Schuffelmann-Gutiérrez C, de la Vega A, Fernández-Cambor C, Ramos-Boluda E, Romero-Gómez MP, Ruiz-Carrascoso G, Losantos-García I, Mellado-Pena MJ, Gómez-Gil R. Predictors of mortality and clinical characteristics among carbapenem-resistant or carbapenemase-producing Enterobacteriaceae bloodstream infections in Spanish children. *J Antimicrob Chemoth.* 2021; 76(1): 220-5. Article. IF: 5.758; Q1

• Archidona CM, Rodríguez MAC, Pérez AP, Pérez RP. Online with your pediatrician. *An Pediatr.* 2021; 94(3): 198-9. Letter. IF: 2.377; Q3

• Arévalo MSG, Mahillo-Fernández I, Esteban LM, Andeyro-García M, Pérez RP, de Pipaón MS, Saviron-Cornudella R. Perinatal adverse effects in newborns with estimated loss of weight percentile between the third trimester ultrasound and delivery. The GROWIN Study. *J Clin Med.* 2021; 10(20): 4643. Article. IF: 4.964; Q2

• Barrios-Tascón A, Miura M, Domínguez-Rodríguez S, Fernández-Cooke E, Sarquella-Brugada G, Tagarro A, (Baquero Artigao F). Ventricular repolarization parameters and coronary involvement in Kawasaki disease. *J Pediatr-Us.* 2021; 236: 108-12. Article. IF: 6.314; D1

• Bejarano-García MM, Ruiz-Saez B, Zamora B, de Aragón AM, García-Navarro C, de Ory SJ, Velo C, Ramos JT, Sainz T, Escosa L, Núñez-Enamorado N, Stephan-Otto C, Navarro ML, González-Tome MI. Brain activity in well-controlled perinatally human immunodeficiency virus-infected young adults: a functional magnetic resonance imaging pilot study. *Rev Neurologia.* 2021; 72(10): 343-50. Article. IF: 1.235; Q4

• Blázquez-Gamero D, Epalza C, Cadenas JAA, Gero LC, Calvo C, Rodríguez-Molino P, Méndez

M, Santos MD, Fumado V, Guzman MF, Soriano-Arandes A, Jiménez AB, Penin M, Cobo-Vázquez E, Pareja M, Lobato Z, Serna M, Delgado R, Moraleda C, Tagarro A. Fever without source as the first manifestation of SARS-CoV-2 infection in infants less than 90 days old. *Eur J Pediatr.* 2021; 180(7): 2099-106. Article. IF: 3.86; Q1

• Bustamante J, Pérez-Muñoz S, Sainz T, López-Hortelano MG, Montero-Vega D, Mellado MJ. Is there autochthonous strongyloidiasis in Spanish children? *Eur J Pediatr.* 2021; 180(5): 1641-5. Article. IF: 3.86; Q1

• Campos M, Sempere J M, Galán J C, Moya A, Llorens C, de-Los-Angeles C, Baquero-Artigao F, Cantón R, Baquero F. Simulating the impact of non-pharmaceutical interventions limiting transmission in COVID-19 epidemics using a membrane computing model. *Microlife.* 2021; 2: uqab011. Article. Not Indexed

• Carrasco I, Tarancón-Díez L, Vázquez-Alejo E, de Ory SJ, Sainz T, Apilanez M, Epalza C, Guillén S, Ramos JT, Díez C, Bernardino JI, Iribarren JA, Zamora A, Muñoz-Fernández MA, Navarro ML. Innate and adaptive abnormalities in youth with vertically acquired HIV through a multicentre cohort in Spain. *J Int Aids Soc.* 2021; 24(10): e25804. Article. IF: 6.707; Q1

• Cendejas-Bueno E, Falces-Romero I, Laplaza-González M, Escosa-García L, Schuffelmann-Gutiérrez C, Romero-Gómez MP, Verdu-Sánchez C, Calderón-Llopis B, Amores-Hernández I, Peman J, Gómez-Zamora A, Río-García M, Menéndez-Suso JJ, Rodríguez-Álvarez D, Duran-Lorenzo I, Pérez-Acosta E, Rubio MR, Álvarez-Rojas E, Martínez-Romillo PD, Goded-Rambaud F, de Lorenzo AG, Maseda E, Mingorance J, de la Oliva P, García-Rodríguez J. Candidemia diagnosis with t2 nuclear magnetic resonance in a picu: a new approach. *Pediatr Crit Care Me.* 2021; 22(2): E109-14. Article. IF: 3.971; Q1

• Cendejas-Bueno E, Peinado H, Baquero-Artigao F, Falces-Romero I, Calvo-Rey C, La Banda-Montalvo L, García-Rodríguez J. Off-label use of T2Candida (R) test in vitreous humor for diagnosing invasive candidiasis: a clinical report. *Future Microbiol.* 2021; 16(9): 619-21. Article. IF: 3.553; Q3

• Cendejas-Bueno E, Romero-Gómez MP, Escosa-García L, Jiménez-Rodríguez S, Mingorance J, García-Rodríguez J. Lower nasopharyngeal viral loads in pediatric population. The missing

piece to understand SARS-CoV-2 infection in children? *J Infection.* 2021; 83(2): E18-9. Letter. IF: 38.637; D1

• Chappell E, Turkova A, Goetghebuer T, Jackson C, Chiappini E, Galli L, Gingaras C, Judd A, Spoulou V, Lisi C, Anson S, Wolfs T, Marczyńska M, Ene L, Plotnikova Y, Voronin E, Samarina A, Yannoulis A (et al). Malignancies among children and young people with HIV in Western and Eastern Europe and Thailand. *AIDS.* 2021; 35(12): 1973-85. Article. IF: 4.632; Q2

• Consuegra I, Gasco S, Serramia MJ, Jiménez JL, Mellado MJ, Muñoz-Fernández MA. Establishment of a miRNA profile in paediatric HIV-1 patients and its potential as a biomarker for effectiveness of the combined antiretroviral therapy. *Sci Rep-Uk.* 2021; 11(1): 23477. Article. IF: 4.996; Q2

• Criado MD, Garrido CF, Gil CB, Baquero-Artigao F. Chlamydia trachomatis pneumonia: An underdiagnosed and potentially severe disease. *Enferm Infect Micr Cl.* 2021; 39(5): 265-6. Letter. IF: 1.994; Q4

• Criado MD, Garrido CF, San Martín EM, Arboleya CG, Gómez-Arroyo B, González-Donapetry P, Baquero-Artigao F, de la Calle M, Quiles-Melero I, Calvo C. Is an antenatal screening for chlamydia trachomatis necessary in the current society? *Pediatr Infect Dis J.* 2021; 40(11): 1034-45. Article. IF: 3.806; Q1

• de Ory SJ, Beltrán-Páez C, Gutiérrez-López M, Santos MD, Prieto L, Sainz T, Guillén S, Aguilera-Alonso D, Díez C, Bernardino JI, Mellado MJ, Ramos JT, Holguin A, Navarro M. Prevalence of M184V and K65R in proviral DNA from PBMCs in HIV-infected youths with lamivudine/emtricitabine exposure. *J Antimicrob Chemoth.* 2021; 76(7): 1886-92. Article. IF: 5.758; Q1

• Domínguez-Riscart J, Soria-Alcaide E, Mellado MJ, Sainz T. The issue of body mass index increase in adolescents living with HIV on ART. *Pediatr Infect Dis J.* 2021; 40(8): E319-21. Letter. IF: 3.806; Q1


• Domínguez-Rodríguez S, Villaverde S, Sanz-Santaeufemia FJ, Grasa C, Soriano-Arandes A, Saavedra-Lozano J, Fumado V, Epalza C, Serna-Pascual M, Alonso-Cadenas JA, Rodríguez-Molino P, Pujol-Morro J, Aguilera-Alonso D, Simo S, Villanueva-Medina S, Iglesias-Bouzas MI, Mellado MJ, Herrero B, Melendo S, De la Torre M, Del Rosal T, Soler-Palacin P, Calvo C, Urretavizcaya

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



1
Introduction

2
Executive
Summary

3
Information
Groups
by Area


4
Associated
Clinicians

Martínez M, Pareja M, Ara-Montojo F, del Prado YR, Gallego N, Ramos MI, Cobos E, Tagarro A, Moraleda C. A Bayesian model to predict covid-19 severity in children. *Pediatr Infect Dis J.* 2021; 40(8): E287-93. Article. IF: 3.806; Q1

- García-Boyano M, Caballero-Caballero JM, García LE, Alvaríno MG, Banares MJB, Alcalá FJC. Optimal dosing of bemiparin for deep vein thrombosis treatment in children: a retrospective study. *Blood Coagul Fibrin.* 2021; 32(7): 526-7. Letter. IF: 1.061; Q4
- García-Boyano M, Caballero-Caballero JM, Rodríguez-Álvarez D, de Villalta MGF, Alcalá FJC. Spanish case of acute encephalopathy with biphasic seizures and late reduced diffusion: are we only seeing the tip of the iceberg?. *Pediatr Infect Dis J.* 2021; 40(2): E98. Letter. IF: 3.806; Q1
- Grasa CD, Gómez-Gil MR, Pacheco SS, del Rosal T, Moreno F, Gerig N, Fernández BO, Calvo C, Baquero-Artigao F. Compassionate use of cefiderocol for VIM metallo-beta-lactamase-producing *Pseudomonas aeruginosa* infection in a toddler with Burkitt lymphoma. *J Glob Antimicrob Resist.* 2021; 26: 91-2. Letter. IF: 4.349; Q2
- Jiménez-García R, Nogueira J, Retuerta-Oliva A, Sainz T, Cano-Fernández J, Flores-Pérez P, Méndez-Echevarría A, Villalobos-Pinto E, Calleja-Gero L, Sanz-Santaefemia FJ, Romero MP, del Rosal T, Baquero-Artigao F, Grasa C, Calvo C. Pneumonia in hospitalized children during Sars-Cov-2 pandemic. Is it all covid-19? comparison between covid and non-covid pneumonia. *Pediatr Infect Dis J.* 2021; 40(3): E111-3. Article. IF: 3.806; Q1
- López SL, del Rosal T, Bueno SJ, Baquero-Artigao F. Septicemia and meningitis associated with *Haemophilus influenzae* type b vaccine failure. *Enferm Infecc Microbiol.* 2021; 39(8): 417-8. Letter. IF: 1.994; Q4
- Martínez-Planas A, Baquero-Artigao F, Santiago B, Fortuny C, Méndez-Echevarría A, Del Rosal T, Bustillo-Alonso M, Gale I, Guerrero C, Blázquez-Gamero D, Canet A, Lillo M, Calavia O, Cuadros EN, Falcon-Neyra L, Soriano-Arandes A, Van Ingen J, Tebruegge M, Noguera-Julian A. Interferon-gamma release assays differentiate between mycobacterium avium complex and tuberculous lymphadenitis in children. *J Pediatr-U.S.* 2021; 236: 211-8. Article. IF: 6.314; D1
- Méndez-Echevarría A, Sainz T, de Felipe B, Alcolea S, Olbrich P, Goycochea-Valdivia WA, Escosa-García L, Cobo L, Calvo C, Neth O. High rates of SARS-CoV-2 family transmission

in children of healthcare workers during the first pandemic wave in Madrid, Spain: serologic study. *Pediatr Infect Dis J.* 2021; 40(5): E185-8. Article. IF: 3.806; Q1

- Méndez-Echevarría A, Sainz T, Falces-Romero I, de Felipe B, Escolano L, Alcolea S, Pertinax L, Neth O, Calvo C. Long-term persistence of anti-SARS-CoV-2 antibodies in a pediatric population. *Pathogens.* 2021; 10(6): 700. Article. IF: 4.531; Q2
- Miranda-Barríos J, Bravo-Queipo-de-Llano B, Baquero-Artigao F, Granados-Fernández M, Novas S, Rabanal I, Méndez-Echevarría A, del Rosal T, Sainz T, Aracil J, Calvo C. Preseptal versus orbital cellulitis in children: An observational study. *Pediatr Infect Dis J.* 2021; 40(11): 969-74. Article. IF: 3.806; Q1
- Nogueira López J, Grasa Lozano C, Ots Ruiz C, Alonso García L, Falces-Romero I, Calvo C, García-López Hortelano M. Telemedicine follow-ups for COVID-19: Experience in a tertiary hospital. *An Pediatr (Engl Ed).* 2021; 95(5): 336-44. Article. Not Indexed
- Pérez RP, Campos LM, Ortega MJC. Obtaining a urine sample through the perineal bag without replacement: Analysis of the contamination rate. Author's reply. *An Pediatr.* 2021; 94(4): 273-4. Letter. IF: 2.377; Q3
- Pérez RP, Cuadros EN, Marrodan BR, Fernández RE, Lemus MAG, Blanco SM, Calvo C. Off-label pediatric medicines in Spain. *An Pediatr.* 2021; 94(3): 188. Article. IF: 2.377; Q3
- Ramos MI, Sánchez BS, Orellana DM, Tato LMP, Martín SG, Gómez MLN, Rabes TD, García LE, Francia MAR, Mosquera JB, Arnal IO, Galligo EM, Beneitez MCV, Saez FJR, García IS, Sánchez AB, Caballero IC, Amador JTR. Safety and experience with combined antiretroviral prophylaxis in newborn at high-risk of perinatal HIV infection, in a cohort of mother living with HIV-infant pairs. *Pediatr Infect Dis J.* 2021; 40(12): 1096-100. Article. IF: 3.806; Q1
- Román F, Méndez-Echevarría A, del Rosal T, García-Vera C, Escosa-García L, Agud M, Chaves F, Gutiérrez-Fernández J, de Gopegui ER, Ruiz-Carrasco G, Ruiz-Gallego MD, Bernet A, Quevedo SM, Fernández-Verdugo AM, Sainz T, Calvo C. Characterization of methicillin-resistant *Staphylococcus aureus* strains colonizing the nostrils of Spanish children. *Microbiologyopen.* 2021; 10(5): e1235. Article. IF: 3.904; Q3
- Ruiz-Sáez B, García MMB, de Aragón AM, Gil-Correa M, Melero H, Malpica NA, de Ory SJ, Zamora B, Guillén S, Rojo P, Falcón-Neyra L,



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

- Álvarez A, Fernández P, Lorente-Jareno ML, Ramos JT, Sainz T, Velo C, Navarro ML, González-Tome MI. Effects of perinatal HIV-infection on the cortical thickness and subcortical gray matter volumes in young adulthood. *Medicine*. 2021; 100(15): e25403. Article. IF: 1.817; Q3
- Sainz T, Pignataro V, Bonifazi D, Ravera S, Mellado MJ, Pérez-Martínez A, Escudero A, Ceci A, Calvo C. Human microbiome in children, at the crossroad of social determinants of health and personalized medicine. *Children (Basel)*. 2021; 8(12): 1191. Article. IF: 2.835; Q2
 - Sainz T, Udaondo C, Méndez-Echevarría A, Calvo C. Lung ultrasound for evaluation of COVID-19 in children. *Arch Bronconeumol*. 2021; 57: 94-6. Letter. IF: 6.333; Q1
 - Sánchez AB, De Ory SJ, Frick MA, Ruiz AIM, Couceiro JA, Mellado MJ, Bisbal O, Iglesias HA, Montero M, Roca C, Samperiz G, Cervero M, Miralles C, Guash CF, Carrasco I, Navarro ML, Amador JTR. Mortality in perinatally HIV-infected adolescents after transition to adult care in Spain. *Pediatr Infect Dis J*. 2021; 40(4): 347-50. Article. IF: 3.806; Q1
 - Santos-Pérez JL, Delgado-Mainar P, Toro-Rueda C, Baquero-Artigao F. Surgical site infection by *Mycobacterium senegalense* in a pediatric patient. *Enferm Infec Micr Cl*. 2021; 39(5): 259-61. Letter. IF: 1.994; Q4
 - Soler-García A, Gamell A, Santiago B, Monsonis M, Cobo-Vázquez E, Bustillo-Alonso M, Tagarro A, Pérez-Gorricho B, Espiau M, Piqueras AI, Korta-Murua JJ, Rodríguez-Molino P, Lobato Z, Pérez-Porcuna T, Tebruegge M, Noguera-Julian A. QuantiFERON-TB gold plus assay specificity in children and adolescents with suspected tuberculosis-a multicenter cross-sectional study in Spain. *Pediatr Infect Dis J*. 2021; 40(9): E348-51. Article. IF: 3.806; Q1
 - Tagarro A, García-Salido A, Martínez EV, Vega-Piris L, Mellado MJ. Low COVID-19 mortality in Spanish children. *Lancet Child Adolesc Health*. 2021; 5(6): E24-5. Letter. IF: 37.746; D1
 - Torres-Fernández D, Casellas A, Mellado MJ, Calvo C, Bassat Q. Acute bronchiolitis and respiratory syncytial virus seasonal transmission during the COVID-19 pandemic in Spain: A national perspective from the pediatric Spanish Society (AEP). *J Clin Virol*. 2021; 145: 105027. Article. IF: 14.481; D1
 - Villaverde S, Domínguez-Rodríguez S, Sabrido G, Pérez-Jorge C, Plata M, Romero MP, Grasa CD, Jiménez AB, Heras E, Broncano A, Nunez MD, Illán M, Merino P, Soto B, Molina-Arana D,

Bermejo A, Mendoza P, Gijón M, Pérez-Moneo B, Moraleda C, Tagarro A. Diagnostic accuracy of the panbio severe acute respiratory syndrome coronavirus 2 antigen rapid test compared with reverse-transcriptase polymerase chain reaction testing of nasopharyngeal samples in the pediatric population. *J Pediatr-Us*. 2021; 232: 287-9. Article. IF: 6.314; D1

■ Research projects

Baquero Artigao F. Colonización por *s. pneumoniae* en niños españoles sanos menores de 5 años y con otitis media aguda: impacto de la vacunación sistémica neumocócica 13-valente conjugada. un estudio nacional multicéntrico. (MISP 61316). Merck Sharp And Dohme De España S.A. 2021-Ongoing.

Management centre: FIBHULP

Delgado Pérez J. Contrato garantía juvenil, técnico de laboratorio (PEJ2018-003755-A). MICINN. 2019-2021.

Management centre: FIBHULP

Mellado Peña MJ. Efecto de una intervención nutricional inmunomoduladora sobre la microbiota, translocación bacteriana, inflamación/activación inmune y respuesta a vacunas en la infección por el VIH en niños. Estudio piloto Pediabiota. European Society of Pediatric Infectious Diseases. 2014-Ongoing.

Management centre: FIBHULP

Mellado Peña MJ. Respuesta a vacunas en niños y adolescentes infectados por el VIH en tratamiento antirretroviral: el cociente CD4/CD8 como predictor de respuesta. FIBHULP. 2017-Ongoing.

Management centre: FIBHULP

Mellado Peña MJ. Valoración de riesgo cardiovascular en niños y adolescentes infectados por el VIH. Asociación para el

Estudio de las Enfermedades Infecciosas. 2017-Ongoing.

Management centre: FIBHULP

Rodríguez Molino P. Estudio de la respuesta vacunal en muestras de sangre seca en población pediátrica (DRIVE study (PI4888)). European Society of Pediatric Infectious Diseases. 2021-ongoing.

Management centre: FIBHULP

Rodríguez Molino P. Impacto del covid-19 materno en la respuesta inmune de los niños. Fundación de la Asociación Española De Pediatría. 2021-Ongoing.

Management centre: FIBHULP

Sainz Costa T. Aplicación de técnicas ómicas para el diagnóstico de tuberculosis en niños y adolescentes: CHILD-TB OMICS (PI20/01490). ISCIII. 2021-2023.

Management centre: FIBHULP

Sainz Costa T. Capacitación de personal sanitario en VIH y ETS en adolescentes (GLD17/0135). Gilead S.A. 2017-ongoing.

Management centre: SEIMC-GESIDA

Sainz Costa T. Hígado graso no alcohólico y esteatohepatitis en niños y adolescentes infectados por el VIH (PI17/01283). ISCIII. 2018-2022.

Management centre: FIBHULP

Sainz Costa T. Microbioma intestinal y respuesta inmune: implicación en la alergia a proteínas de la leche de vaca no IgE mediada (PI3699). Asociación Española de Pediatría. 2015-2022.

Management centre: SEIMC-GESIDA

Sainz Costa T. Utilidad de la ecografía torácica en la indicación de ventilación no invasiva en la bronquiolitis aguda del lactante hospitalizado. Estudio de cohorte

(PI2525). European Society of Pediatric Infectious Diseases. 2017-Ongoing.

Management centre: FIBHULP

■ Clinical trials

Mellado Peña, MJ. Ensayo en fase III, aleatorizado, doble ciego para evaluar la seguridad de una vacuna conjugada antineumocócica 20-valente en lactantes sanos.

Type: Clinical Trials, phase III.

HULP code: Appendix 1 5557.

Sponsored by: Pfizer, S.L.U.

Signed date: 24/05/2021

Sainz Costa, T. A phase IV, single-blind, randomised, controlled, multi-country study to evaluate the immunogenicity and safety of GSK's INFARIX HEXA (DTPA-HBV-IPV Hib) versus MCM vaccine BV's VAXELIS (DTAP5-HBV-IPV-HIB), when administered intramuscularly according to a 2, 4 and 12 month schedule in healthy infants and toddlers.

Type: Clinical Trials, phase IV.

HULP code: 5753 212645.


Sponsored by: Glaxosmithkline Biologicals S.A.

Signed date: 26/03/2021.

■ Patents and trademarks

Mellado MJ, Piñero R, authors; ASOCIACION ESPAÑOLA DE PEDIATRIA (AEPED), assignee. Brand name: PEDIAMÉCUM; ESM 3079824; 2013 June 13.





3.7.6 Translational Research in Pediatric Oncology, Hematopoietic Transplantation and Cell Therapy Group

Publications: 32
Q1: 13

COMPOSITION



Antonio Pérez Martínez. Facultativo Especialista de Área en Pediatría, Oncología y Hematología. Hospital Universitario La Paz

David Bueno Sánchez. Facultativo Especialista de Área en Pediatría, Oncología y Hematología. Hospital Universitario La Paz

Eva Couto Serrano. Asistente Ejecutiva. Hospital Universitario La Paz

Adela Escudero López. Investigadora Postdoctoral. Hospital Universitario La Paz

Cristina Ferreras Puente. Investigadora Postdoctoral. IdiPAZ

Berta González Martínez. Facultativo Especialista de Área en Pediatría, Oncología y Hematología. Hospital Universitario La Paz

Carla Martín Cortázar. Investigadora Postdoctoral. IdiPAZ

Pilar Guerra García. Facultativo Especialista de Área en Pediatría, Oncología y Hematología. Hospital Universitario La Paz

Alfonso Navarro Zapata. Investigador Predoctoral. Hospital Universitario La Paz

Pedro María Rubio Aparicio. Facultativo Especialista de Área en Pediatría, Oncología y Hematología. Hospital Universitario La Paz

Beatriz Ruz Caracuel. Investigadora Bioinformática. Hospital Universitario La Paz

Sonsoles San Román Pacheco. Facultativo Especialista de Área en Pediatría, Oncología y Hematología. Hospital Universitario La Paz

STRATEGIC OBJECTIVE

Our research program focuses on the molecular and immunological characterization of childhood cancer; the development of cell therapies, primarily through the susceptibility of tumor cells to Natural Killer cells; and the optimization of hematopoietic stem cells transplantation.

RESEARCH LINES


- Analysis of solid/hematological tumors samples to determine their susceptibility to cell therapy, at functional, protein expression and genetic level.
- Cell therapy with activated NK cells in childhood cancer.

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



1
Introduction

2
Executive
Summary

3
Information
Groups
by Area

4
Associated
Clinicians

- Hematopoietic progenitor transplantation as a platform for cell therapy.
- Cell therapy with memory T lymphocytes as adoptive immunotherapy in transplantation of haematopoietic progenitors.
- Optimization of cell therapy by the generation of an NKG2D antigenic chimeric receptor (NKG2DCAR). Evaluation of its specificity, persistence and activity (in vitro and in vivo) for the treatment of childhood cancer.
- Optimization of CAR T cell therapy using nanotechnology and epigenetic regulators

- Induction of immunological tolerance in solid organ transplantation through the induction of hematopoietic mixed chimerism by cell therapy.
- Development of academic clinical trials and collaborations with the pharmaceutical industry as a strategy for the development of new therapies more effective and with fewer side effects in childhood cancer.
- Cell therapy with cytokine induced-memory like NK cells for pediatric solid tumors.
- Cell therapy with memory T lymphocytes from COVID-19 convalescent donors as an innovative therapy for COVID-19.

RESEARCH ACTIVITY

■ Doctoral theses

Master Theses

Catalán Lambán A. Utilidad clínica del análisis del microbioma en el cancer pediátrico[dissertation]. La Rioja: UNIR: 2021(17/09/2021).

Director: Pérez Martínez A.

Final Degree Theses

González Moure B. Diagnostico avanzado del retinoblastoma[dissertation]. Madrid: UAM: 2021(01/06/2021).

Director: Escudero López A.

■ Publications

- Alonso L, Méndez-Echevarría A, Rudilla F, Mozo Y, Soler-Palacin P, Sisinni L, Bueno D, Riviere J, de Paz R, Sánchez-Zapardiel E, Querol S, Rodríguez-Pena R, López-Granados E, Gimeno R, de Heredia CD, Pérez-Martínez A. Failure of viral-specific T cells administered in pre-transplant settings in children with inborn errors of immunity. *J Clin Immunol.* 2021; 41(4): 748-55. Article. IF: 8.542; Q1
- Bakhtiar S, Salzmann-Manrique E, Blok HJ, Eike-DJ, Hazelaar S, Ayas M, Toren A, Goldstein G, Moshous D, Locatelli F, Merli P, Michel G,

Ozturk G, Schulz A, Heilmann C, Ifversen M, Wynn RF, Aleinikova O, Bertrand Y, Tbakhi A, Veys P, Karakukcu M, Kupesz A, Ghavamzadeh A, Handgretinger R, Unal E, Pérez-Martínez A, Gokce M, Porta F, Aksu T, Karasu G, Badell I, Ljungman P, Skorobogatova E, Yesilipek A, Zuckerman T, Bredius RRG, Stepensky P, Shadur B, Slatter M, Gennery AR, Albert MH, Bader P, Lankester A. Allogeneic hematopoietic stem cell transplantation in leukocyte adhesion deficiency type I and III. *Blood Adv.* 2021; 5(1): 262-73. Article. IF: 7.637; Q1


- Cardoso L, Galán-Gómez V, Corral-Sánchez MD, Pérez-Martínez A, Riesco S, Isidoro-García M, Escudero A. Juvenile myelomonocytic leukemia in CBL syndrome associated with germline splice-site mutations: Two case reports and a literature review. *Clin Case Rep.* 2021; 9(5): e04260. Review. Not Indexed
- Díaz MA, Gasior M, Molina B, Pérez-Martínez A, González-Vicent M. Ex-vivo T-cell depletion in allogeneic hematopoietic stem cell transplantation: New clinical approaches for old challenges. *Eur J Haematol.* 2021; 107(1): 38-47. Review. IF: 3.674; Q3
- Escudero A, Ruz-Caracuel B, Bueno D, Martínez M, Rubio P, Regojo RM, Antolín E, Ybarra M, Martínez L, Pozo-Kreiling JJ, Elorza MD, Pellicer A, Omeñaca F, Pérez-Martínez A. Genetic predisposition to fetal and neonatal cancer. *Clin Transl Oncol.* 2021; 23(6): 1179-84. Article. IF: 3.34; Q3
- Fernández A, Navarro-Zapata A, Escudero A, Matamala N, Ruz-Caracuel B, Mirones I, Pernas A, Cobo M, Casado G, Lanzarot D, Rodríguez-

Antolín C, Vela M, Ferreras C, Mestre C, Viejo A, Leivas A, Martínez J, Fernández L, Pérez-Martínez A. Optimizing the procedure to manufacture clinical-grade nk cells for adoptive immunotherapy. *Cancers (Basel).* 2021; 13(3): 577. Article. IF: 6.575; Q2

- Ferreras C, Fernández L, Clares-Villa L, Ibáñez-Navarro M, Martín-Cortazar C, Esteban-Rodríguez I, Saceda J, Pérez-Martínez A. Facing CAR T cell challenges on the deadliest paediatric brain tumours. *Cells.* 2021; 10(11): 2940. Review. IF: 7.666; Q2
- Ferreras C, Pascual-Miguel B, Mestre-Duran C, Navarro-Zapata A, Clares-Villa L, Martín-Cortázar C, De Paz R, Marcos A, Vicario JL, Balas A, García-Sánchez F, Eguizabal C, Solano C, Mora-Rillo M, Soria B, Pérez-Martínez A. SARS-CoV-2-specific memory T lymphocytes from COVID-19 convalescent donors: identification, biobanking, and large-scale production for adoptive cell therapy. *Front Cell Dev Biol.* 2021; 9: 620730. Article. IF: 6.081; Q1
- Fuster JL, Bautista F, González B, Fernández JM, Rives S, Dapena JL. Blinatumomab to improve the outcome of children with relapsed B-cell acute lymphoblastic leukemia. *Clin Transl Oncol.* 2021; 23(9): 1963-66. Letter. IF: 3.34; Q3
- García LMG, Escudero A, Mestre C, Soler JLF, Martínez AP, Valero JMV, Vela M, Ruz B, Navarro A, Fernández L, Fernández A, Leivas A, Martínez-López J, Ferreras C, De Paz R, Blanquer M, Galán V, González B, Corral D, Sisinni L, Mirones I, Balas A, Vicario JL, Valle P, Borobia AM, Pérez-Martínez A. Phase 2 clinical trial of infusing ha-

ploidentical K562-mb15-41BBLe activated and expanded natural killer cells as consolidation therapy for pediatric acute myeloblastic leukemia. *Clin Lymph Myelom Leuk.* 2021; 21(5): 328-37. Article. IF: 2.822; Q3

- García-García I, Dapia I, Montserrat J, de Soto LM, Bueno D, Díaz L, Queiruga J, Mariblanca AR, Guerra-García P, Ramírez E, Frías J, Martínez AP, Carcas-Sansuán AJ, Borobia AM. Experience of a strategy including cyp2c19 preemptive genotyping followed by therapeutic drug monitoring of voriconazole in patients undergoing allogeneic hematopoietic stem cell transplantation. *Front Pharmacol.* 2021; 12: 717932. Article. IF: 5.988; Q1
- García-García I, Guerra-García P, Ferreras C, Borobia AM, Carcas AJ, Queiruga-Parada J, Vicario JL, Mirones I, Solano C, Eguizabal C, Soria B, Pérez-Martínez A. A phase I/II dose-escalation multi-center study to evaluate the safety of infusion of natural killer cells or memory T cells as adoptive therapy in coronavirus pneumonia and/or lymphopenia: RELEASE study protocol. *Trials.* 2021; 22(1): 674. Article. IF: 2.728; Q4
- García-Solis B, van den Rym A, Pérez-Caraballo JJ, Al-Ayoubi A, Alazami AM, Lorenzo L, Cubillos-Zapata C, López-Collazo E, Pérez-Martínez A, Allende LM, Markle J, Fernández-Arquero M, Sánchez-Ramon S, Recio MJ, Casanova JL, Mohammed R, Martínez-Barricarte R, de Diego RP. Clinical and immunological features of human BCL10 deficiency. *Front Immunol.* 2021; 12: 786572. Article. IF: 8.786; Q1
- Gasior M, Ferreras C, de Paz R, Bueno D, Mozo Y, Sisinni L, Canizales JT, González B, Olivass-



1
Introduction

2
Executive
Summary

3
Information
Groups
by Area

4
Associated
Clinicians

Mazon R, Marcos A, Romero AB, Constanzo A, Mirones I, Fernández-Arroyo A, Balas A, Vicario JL, Escudero A, Yuste VJ, Pérez-Martínez A. The role of early natural killer cell adoptive infusion before engraftment in protecting against human herpesvirus-6B encephalitis after naive T-cell-depleted allogeneic stem cell transplantation. *Transfusion*. 2021; 61(5): 1505-17. Article. IF: 3.337; Q3

- Gómez-Santos C, González-Vicent M, Molina B, Deltoro N, Herrero B, Ruiz J, Pérez-Martínez A, Díaz MA. Comparison of clinical outcomes between unrelated single umbilical cord blood and ex-vivo T-cell depleted haploidentical transplantation in children with hematological malignancies. *World J Pediatr*. 2021; 17(6): 609-18. Article. IF: 9.186; D1
- Herrera L, Santos S, Vesga MA, Carrascosa T, García-Ruiz JC, Pérez-Martínez A, Juan ME, Eguizabal C. The race of CAR therapies: CAR-NK cells for fighting B-cell hematological cancers. *Cancers (Basel)*. 2021; 13(21): 5418. Review. IF: 6.575; Q2
- Kabat MG, Bueno D, Sisinni L, De Paz R, Mozo Y, Perona R, Arias-Salgado EG, Rosich B, Marcos A, Romero AB, Constanzo A, Jiménez-Yuste V, Pérez-Martínez A. Selective T-cell depletion targeting CD45RA as a novel approach for HLA-mismatched hematopoietic stem cell transplantation in pediatric nonmalignant hematological diseases. *Int J Hematol*. 2021; 114(1): 116-23. Article. IF: 2.319; Q4
- Leivas A, Risueno RM, Guzmán A, Sánchez-Vega L, Pérez M, Megias D, Fernández L, Alonso R, Pérez-Martínez A, Rapado I, Martínez-López J. Natural killer cells efficiently target multiple myeloma clonogenic tumor cells. *Cancer Immunol Immun*. 2021; 70(10): 2911-24. Article. IF: 6.63; Q1
- Leivas A, Valeri A, Córdoba L, García-Ortiz A, Ortiz A, Sánchez-Vega L, Grana-Castro O, Fernández L, Carreno-Tarragona G, Pérez M, Megias D, Paciello ML, Sánchez-Pina J, Pérez-Martínez A, Lee DA, Powell DJ, Rio P, Martínez-López J. NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma. *Blood Cancer J*. 2021; 11(8): 146. Article. IF: 9.812; Q1
- Leon-Triana O, Pérez-Martínez A, Ramírez-Orellana M, Pérez-García VM. Dual-target CAR-Ts with On- and Off-tumour activity may override immune suppression in solid cancers: a mathematical proof of concept. *Cancers (Basel)*. 2021; 13(4): 703. Article. IF: 6.575; Q2
- Leon-Triana O, Sabir S, Calvo GF, Belmonte-Beitia J, Chulian S, Martínez-Rubio A, Rosa M, Pérez-Martínez A, Ramírez-Orellana M, Pérez-

García VM. CAR T cell therapy in B-cell acute lymphoblastic leukaemia: Insights from mathematical models. *Commun Nonlinear Sci*. 2021; 94: 105570. Article. IF: 4.186; D1

- Martínez-Rubio A, Chulian S, Goni CB, Orellana MR, Martínez AP, Navarro-Zapata A, Ferreras C, Pérez-García VM, Rosa M. A Mathematical description of the bone marrow dynamics during CAR T-cell therapy in b-cell childhood acute lymphoblastic leukemia. *Int J Mol Sci*. 2021; 22(12): 6371. Article. IF: 6.208; Q1
- Mozo Y, Bueno D, Sisinni L, Fernández-Arroyo A, Rosich B, Martínez AP, Benítez-Carabante MI, Alonso L, Uria ML, de Heredia CD, Mestre-Duran C, Pascual CFB, Torres J, Losantos I, Escudero A, Ruz-Caracuel B. Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity. *Pediatr Hemat Oncol*. 2021; 38(4): 331-45. Article. IF: 2.07; Q3
- Pérez-García VM, Leon-Triana O, Rosa M, Pérez-Martínez A. CAR T cells for T-cell leukemias: Insights from mathematical models. *Commun Nonlinear Sci*. 2021; 96: 105684. Article. IF: 4.186; D1
- Pérez-Martínez A, Guerra-García P, Melgosa M, Frauca E, Fernández-Cambor C, Remesal A, Calvo C. Clinical outcome of SARS-CoV-2 infection in immunosuppressed children in Spain. *Eur J Pediatr*. 2021; 180(3): 967-71. Article. IF: 3.86; Q1
- Pérez-Martínez A, Mora-Rillo M, Ferreras C, Guerra-García P, Pascual-Miguel B, Mestre-Duran C, Borobia AM, Carcas AJ, Queiruga-Parada J, García I, Sánchez-Zapardiel E, Gasior M, De Paz R, Marcos A, Vicario JL, Balas A, Moreno MA, Eguizabal C, Solano C, Arribas JR, Buckley RD, Montejano R, Soria B. Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE). *Eclinicalmedicine*. 2021; 39: 101086. Article. IF: 17.033; D1
- Rubio-San-Simón A, Alvaro RH, Ribelles AJ, Heredia AC, Guerra-García P, Verdu-Amoros J, Andrés M, Canete A, Rives S, Pérez-Martínez A, Mora J, Patino-García A, Lassaleta A, Llorc A, Ramírez M,


Mata C, Gallego S, Martín-Broto J, Cruz O, La Madrid AM, Solano P, Romera IM, Fernández-Teijeiro A, Bautista F, Moreno L. The paediatric cancer clinical research landscape in Spain: a 13-year multicentre experience of the new agents group of the Spanish Society of Paediatric Haematology and Oncology (SEHOP). *Clin Transl Oncol*. 2021; 23(12): 2489-96. Article. IF: 3.34; Q3

- Rubio-San-Simón A, Verdu-Amoros J, Hladun R, Juan-Ribelles A, Molero M, Guerra-García P, Pérez-Martínez A, Castaneda A, Canete A, de Rojas T, Moreno L, Bautista F. Challenges in early phase clinical trials for childhood cancer during the COVID-19 pandemic: a report from the new agents group of the Spanish Society of Paediatric Haematology and Oncology (SEHOP). *Clin Transl Oncol*. 2021; 23(1): 183-9. Article. IF: 3.34; Q3
- Sainz T, Pignataro V, Bonifazi D, Ravera S, Mellado MJ, Pérez-Martínez A, Escudero A, Ceci A, Calvo C. Human microbiome in children, at the crossroad of social determinants of health and personalized medicine. *Children (Basel)*. 2021; 8(12): 1191. Article. IF: 2.835; Q2
- Sánchez MDC, Gómez VG, Urgelles AS, de Sa-bando DPL,

Aparicio PR, Martínez LM, Gamarra EA, Kreilinger JJP, Zapata RMR, Gutiérrez JCL, Alvarado EA, Martín FG, Torres AMS, Manzano EM, del Valle LG, Pérez-Martínez A. Treatment of infantile fibrosarcoma associated to an abdominal aortic aneurysm with larotrectinib: a case report. *Pediatr Hemat Oncol*. 2021; 38(5): 504-9. Article. IF: 2.07; Q3

- Vega-García N, Pérez-Jaume S, Esperanza-Cebollada E, Vicente-Garces C, Torredadell M, Jiménez-Velasco A, Ortega M, Llop M, Abad L, Vagace JM, Minguela A, Pratorcora M, Sánchez-García J, García-Calderón CB, Gómez-Casares MT, Martín-Clavero E, Escudero A, Martínez-Gallo MR, Muñoz L, Velasco MR, García-Morín M, Catala A, Pascual A, Velasco P, Fernández JM, Lassaleta A, Fuster JL, Badell I, Molinos-Quintana A, Molines A, Guerra-García P, Pérez-Martínez A, García-Abos M, Ortiz RR, Pisa S, Adan R, de





1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Heredia CD, Dapena JL, Rives S, Ramírez-Orellana M, Camos M. measurable residual disease assessed by flow-cytometry is a stable prognostic factor for pediatric T-cell acute lymphoblastic leukemia in consecutive SEHOP protocols whereas the impact of oncogenetics depends on treatment. *Front Pediatr.* 2021; 8: 614521. Article. IF: 3.569; Q2

- Vicent MG, de Heredia CD, de Pablo JG, Molina B, Regueiro A, Martínez AP, Palomo P, Corral LL, García E, Fernández JM, Pérez A, Jiménez MJ, Guerreiro M, Vallejo C, Gallardo AI, López O, Benito A, Marsal J, Duarte M, Bento L, Badell I, Pedraza A, Ubieta AJ, González P, Centurión IG, Costilla L, Belendez C, Esquirol A, Espigado I, Lavilla E, Díaz MA. Defibrotide in hematopoietic stem cell transplantation: A multicenter survey study of the Spanish Hematopoietic Stem Cell Transplantation Group (GETH). *Eur J Haematol.* 2021; 106(6): 842-50. Article. IF: 3.674; Q3
- Wertheimer T, Dohse M, Afram G, Weber D, Heidenreich M, Holler B, Kattner AS, Neubauer A, Mielke S, Ljungman P, Holler E, Herr W, Edinger M, Martínez AP, Fante M, Wolff D. Abatacept as salvage therapy in chronic graft-versus-host disease-a retrospective analysis. *Ann Hematol.* 2021; 100(3): 779-87. Article. IF: 4.03; Q2

■ Research projects

Escudero López A. Identificación de biomarcadores genéticos que ayuden a predecir la evolución del trasplante de progenitores hematopoyéticos en edad pediátrica (PI17/01921). ISCIII. 2018-2021.

Managment centre: FIBHULP

Pérez Martínez A. Ensayo clínico fase II de infusión intratumoral/intraventricular de células CART-NKG2D o NKIL15 en niños, adolescentes y adultos jóvenes con tumores de alto grado recurrentes/refractarios del sistema nervioso central (CINK-CAR) (ICI19/00052). ISCIII. 2020-2023.

Managment centre: FIBHULP

Pérez Martínez A. Inmunoterapia en neuroblastomas pediátricos: tratamiento dirigido a las células tumorales iniciado-

ras de la metástasis: tratamiento dirigido a las células tumorales iniciadoras de la metástasis (PEJ2018-002874). MINECO. 2019-2021.

Managment centre: FIBHULP

Navarro Zapata A. Contrato predoctoral (PEJD-2018-PRE/BMD-9122). CM. 2019-2021.

Managment centre: FIBHULP

Pérez Martínez A. Infusión de células natural killer aloreactivas o estimuladas post trasplante haploidéntico de progenitores hematopoyéticos en pacientes pediátricos con neoplasias hematológicas (PHINK) (PI18/01301). ISCIII. 2019-2021.

Managment centre: FIBHULP

Pérez Martínez A. A phase I trial of memory t cells expressing an anti-NKG2D chimeric antigen receptor in children, adolescents and young adults with advanced sarcoma. Fundación Asociación Española Contra el Cáncer. 2019-Ongoing.

Managment centre: FIBHULP

Pérez Martínez A. Diseño del receptor antigenico quimerico NKG2D (CAR-NKG2D) como terapia celular en los sarcomas infantiles. ONG Otromundoes posible. 2019-Ongoing.

Managment centre: FIBHULP

Pérez Martínez A. Ensayo clínica fase I/II, multicéntrico abierto, de infusión de células NK activadas para el tratamiento de niños, adolescentes y adultos jóvenes con sarcomas. Fundación La Sonrisa de Alex. 2017-Ongoing.

Managment centre: FIBHULP

Pérez Martínez A. Estudio mediante tecnología de alto rendimiento de la predisposición hereditaria al cáncer infantil.

CM. 2017-Ongoing.

Managment centre: FIBHULP

Pérez Martínez A. Inmunoterapia en neuroblastomas pediátricos: tratamiento dirigido a las células tumorales iniciadoras de la metástasis. Fundación Cris Contra el Cáncer. 2019-Ongoing.

Managment centre: FIBHULP

Pérez Martínez A. Receptor antigénico quimérico NKG2D para el tratamiento de pacientes pediátricos con leucemia aguda y leucemia mielomonocítica juvenil: validación a escala clínica y primer estudio de seguridad en pacientes: (Gaby cells: Cart-CD45RA-NKG2D+). Fundación Uno Entre Cien Mil. 2018-Ongoing.

Managment centre: FIBHULP

Pérez Martínez A. Receptor antigénico quimérico NKG2D para el tratamiento de pacientes pediátricos con leucemia aguda y leucemia mielomonocítica juvenil: validación escala clínica y primer estudio de seguridad en pacientes. Fundación Cris Contra el Cáncer. 2019-Ongoing.

Managment centre: FIBHULP

Pérez Martínez A. The implications of ruxolitinib in NK cell immune reconstitution after pediatric HSCT. Novartis Farmacéutica S. A. 2019-Ongoing.

Managment centre: FIBHULP

Pérez Martínez, A; de la Oliva Senovilla, P. Implementación de una escala pediátrica de valoración de alerta temprana en pacientes pediátricos hospitalizados con patología hemato-oncológica y trasplante de progenitores hematopoyéticos como plan de mejora de la calidad y seguridad asistencial. Fundación Aladina. 2020-Ongoing.

Managment centre: FIBHULP

Pérez Martínez A. Optimización de la terapia celular NK en sarcomas pediátricos mediante el uso nanopartículas multifuncionalizadas. PI-1567. Fundación Cris Contra El Cáncer. 2013-Ongoing.

Managment centre: FIBHULP

Pérez Martínez A. NK cell team-2: inmunoterapia con células natural killer en el niño. Fundación Cris Contra El Cáncer. 2014-Ongoing.

Managment centre: FIBHULP

Pérez Martínez A. Inmunoterapia con células natural killer en el cáncer infantil. Ayuntamiento de Pedroñeras. 2015-Ongoing.

Managment centre: FIBHULP

Pérez Martínez A. Terapia celular basada en el receptor quimerico nkg2d (car-nkg2d) para la leucemia infantil. Fundación Uno Entre Cien Mil. 2015-Ongoing.

Managment centre: FIBHULP

Pérez Martínez A. Inmunoterapia en sarcomas: combinación del anticuerpo anti-cxcr4 y la terapia celular nk. Fundación La Sonrisa de Alex. 2016-Ongoing.

Managment centre: FIBHULP


Pérez Martínez A. Unidad de investigación y de terapias avanzadas en hematología infantil. Fundación Cris Contra El Cáncer. 2016-Ongoing.

Managment centre: FIBHULP

Pérez Martínez A. Análisis genético, transcriptómico y proteómico para identificar antígenos diana de terapia CAR-T en leucemia mielomonocítica juvenil. Fundación Cris Contra El Cáncer. 2021-Ongoing.

Managment centre: FIBHULP

Pérez Martínez A. Evaluación de riesgos



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

y aplicación de medidas de calidad en manejo de pacientes onco-hematológicos después de un trasplante de progenitores hematopoyético. Jazz Pharmaceuticals Iberia S.L. 2021-Ongoing.

Management centre: FIBHULP

Rubio Aparicio PM. Actualización y renovación de la actividad en el servicio de oncología pediátrica del Hospital Universitario La Paz. Varios. 2014-Ongoing.

Management centre: FIBHULP

Pérez Martínez A, Martín Cortázar C. Memory-like NK cells: a new therapy for Ewing sarcoma (MEMO4EWING) (PI-5071). Fundación APSATUR. Girasoles para Izarbe. 2021-2023.

Management centre: FIBHULP

■ Clinical trials

Bueno Sánchez, D. Estudio de fase 2b, abierto y de un solo grupo para evaluar la farmacocinética, la eficacia, la seguridad y la tolerabilidad de letermovir en participantes pediátricos desde el nacimiento hasta menos de 18 años con riesgo de sufrir infección y/o enfermedad por cmv después de un trasplante alogénico de células madre hematopoyéticas (tcmh).

Type: Clinical Trials, phase II.

HULP code: Appendix 3 5199 MK-8228-030.

Sponsored by: Merck Sharp And Dohme De España, S.A.

Signed date: 26/03/2021

Bueno Sánchez, D. Estudio de fase 2b, abierto y de un solo grupo para evaluar la farmacocinética, la eficacia, la seguridad y la tolerabilidad de letermovir en participantes pediátricos desde el nacimiento hasta menos de 18 años con riesgo de

sufrir infección y/o enfermedad por cmv después de un trasplante alogénico de células madre hematopoyéticas (tcmh).

Type: Clinical Trials, phase II.

HULP code: Appendix 4 5199 MK-8228-030.

Sponsored by: Merck Sharp And Dohme De España, S.A.

Signed date: 02/12/2021

Bueno Sánchez, D. Estudio observacional retrospectivo de pacientes adultos y pediátricos con microangiopatía trombótica (mat) después de un trasplante de células madre hematopoyéticas (tcmh).

Type: Estudios No EPA.

HULP code: PI-4902 ALX-TMA-501.

Sponsored by: Alexion Pharmaceutical Inc.

Signed date: 13/10/2021

Bueno Sánchez, D. Un estudio de fase III, abierto, de un solo grupo, multicéntrico de ravulizumab junto al mejor tratamiento sintomático en participantes pediátricos (de 1 mes a <18 años) con microangiopatía trombótica (mat) después de un trasplante de células madre hematopoyéticas (tcmh).

Type: Clinical Trials, phase III.

HULP code: 5653 ALXN1210-TMA-314.

Sponsored by: Alexion Pharmaceutical Inc.

Signed date: 09/02/2021

Bueno Sánchez, D. Un estudio de fase III, abierto, de un solo grupo, multicéntrico de ravulizumab junto al mejor tratamiento sintomático en participantes pediátricos (de 1 mes a <18 años) con microangiopatía trombótica (mat) después de un trasplante de células madre hematopoyéticas (tcmh).

Type: Clinical Trials, phase III.

HULP code: Appendix 1 5653.

Sponsored by: Alexion Pharmaceutical Inc.

Signed date: 25/11/2021

González Martínez, B. Ensayo internacional de fase 3 en leucemia linfoblástica agudapositiva para cromosoma filadelfia (Ila ph+) de evaluación del imatinib en combinación con dos diferentes esquemas de quimioterapia citotóxica.

Type: Clinical Trials, phase III.

HULP code: 5565 EsPhALL2017/CO-GAALL1631.

Sponsored by: Sociedad Española De Hematología Y Oncología Pediátrica.

Signed date: 02/06/2021

González Martínez, B. Estudio de fase Ib/2 de carfilzomib en combinación con quimioterapia de inducción en niños con leucemia linfoblástica aguda recurrente o resistente.

Type: Clinical Trials, phase I.

HULP code: 5745 20140106.

Sponsored by: Amgen, S.A.

Signed date: 04/05/2021

González Martínez, B. Ibfm ambi2018 - registro prospectivo sobre leucemia de línea ambigua infantil.

Type: Estudios, phase EPA-SP.

HULP code: PI-4261 iBFM AMBI2018.

Sponsored by: Sociedad Española De Hematología Y Oncología Pediátrica.

Signed date: 10/11/2021

González Martínez, B. Intreall HR 2010 - International study for treatment of high risk childhood relapsed ALL 2010.

Type: Clinical Trials, phase II.

HULP code: 4870 IntReALL HR 2010.

Sponsored by: Sociedad Española De Hematología Y Oncología Pediátrica.

Signed date: 15/11/2021

Pérez Martínez, A. Estudio de fase 1/2 multicéntrico para evaluar la seguridad y eficacia de kte-x19 en sujetos pediátricos

y adolescentes con leucemia linfoblástica aguda de precursores de linfocitos b recidivante/refractaria o linfoma no hodgkin de linfocitos b recidivante/refractario (zuma-4).

Type: Clinical Trials, phase I.

HULP code: 5794 KTE-C19-104.

Sponsored by: Kite Pharma, Inc.



Signed date: 21/08/2021.

■ Patents and trademarks

Mayán Santos M, Acea Nebriil B, Varela Eirín M, Rodríguez-Candela Mateos M, Díaz Carballa CC, Fonseca Capdevila E, Barrio LC, Escudero López A, inventors; Fundación Profesor Novoa Santos- Instituto de Investigación Biomédica de A Coruña (INIBIC), assignees. Composición para el tratamiento de los efectos secundarios de la radioterapia y/o quimioterapia. PCT/ES2020/070269: 2020 April 27

Vela Cuenca M, González Navarro P, Valentín Quiroga J, Escudero López A, Pérez Martínez A, Fernández Casanova L, inventors; FIBHULP, CNIO, assignees. Anti-CXCR4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy. 62/642,313 US Provisional Application, IB2019/052042; 2018 March 13.

Pérez Martínez A, Ferreras Puente C,B, inventors; UAM, FIBHULP, Universidad Miguel Hernández de Elche (UMH), Fundación de la Comunitat Valenciana para la gestión del Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), assignees. Memory T cells as adoptive cell therapy for viral infections. EP20382850.4 (EP3974029), PCT/EP2021/076516; 2020 September 25.



3.7.7 Congenital Malformations and Transplantation Group*



COMPOSITION

■ **Francisco Hernández Oliveros.** Facultativo Especialista de Área en Cirugía Pediátrica. Hospital Universitario La Paz

STRATEGIC OBJECTIVE

Anesthesia, pain management and perioperative intensive care: To develop new procedures for improving safety and efficacy in anesthetic procedures, and to investigate the multiple problems of pain management and anaesthesia support.

Vascular anomalies: To investigate genetic and molecular mechanisms involved in the pathogenesis of vascular anomalies, and to evaluate new treatments.

Cardiovascular surgery: To assess different organ perfusion devices and to develop new strategies for graft perfusion.

Congenital malformations: To gain knowledge on the cellular and molecular mechanisms of malformations using animal models, organ and cell cultures and eventually genetically engineered animals.

Ophthalmologic pathology: To investigate genetic and molecular mechanisms involved in the pathogenesis of ocular malformations and ocular rare diseases.

Transplantation: To investigate new strategies for graft tolerance/avoidance of rejection and to analyze the impact of donation after circulatory death with normothermic reperfusion in pediatric transplantation. Additionally, the management of the conditions leading to organ failure would be included in our topics, like

intestinal rehabilitation (intestinal transplantation), liver tumours (liver transplantation) and severe uropathies (renal transplantation).

RESEARCH LINES

- Paediatric surgical specialties are extremely complex due to the wide spectrum of diseases included in their scope. Many of the problems are related to rare diseases and their treatment frequently requires complex procedures.
- Clinical care of paediatric surgical patients is a long-term task that requires a wide knowledge of the pathology and multidisciplinary committees. Surgical corrections usually consist of multi-step procedures, some of them in the neonatal period while others might be required in young adults.
- This line is therefore characterized by an unusually large spectrum since it encompasses the study of the cellular and molecular mechanisms leading to malformations, the biology of the malformed fetus and embryo, the prenatal chances for intervention on the malformations, and the postnatal operative and perioperative surgical and anesthetic management, including complex procedures as transplantation.


* Group recently created, december 2021

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians




1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



3.7.8 Research in Endometriosis Group*

COMPOSITION

Alicia Hernández Gutiérrez. Facultativo Especialista de Área en Ginecología y Obstetricia. Unidad de Ginecología Oncológica. Hospital Universitario La Paz. Profesor Asociado. Universidad Autónoma de Madrid

Perdo N. Barri Soldevilla. Director del Departamento de Obstetricia, Ginecología y Reproducción Humana. Fundación Dexeus Mujer

Covadonga Álvarez López. Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz

Mario Álvarez Maestro. Facultativo Especialista de Área en Urología. Hospital Universitario La Paz

Martina Aida Angelés Fité. Ginecóloga especialista en Oncología. Institut Universitaire Du Cancer De Toulouse

Ónica María Armijo Suárez. Facultativo Especialista de Área en Ginecología y Obstetricia. Unidad de Reproducción Asistida. Hospital Universitario La Paz

María Carbonel López. Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz

Ana López Carrasco. Facultativo Especialista de

Área en Ginecología y Obstetricia. Hospital Universitario La Paz

Myriam García Segovia. Médico Adjunto en Ginecología. Hospital Universitario La Paz

Juan Antonio García Velasco. Director Médico. IVI - RMA

Silvia Iniesta Pérez. Ginecóloga especialista en Reproducción. Hospital Ruber Internacional

Alejandra Martínez Rodríguez-Marin. Subdirector del Departamento de Oncología Quirúrgica. Institut Universitaire Du Cancer De Toulouse

Blanca Martínez Serrano. Facultativo Especialista de Área en Anestesiología. Hospital Universitario La Paz

Cristina Redondo Guisasola. Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz

Patricia Isabel Salas Bolívar. Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz


Emanuela Spagnolo. Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz

STRATEGIC OBJECTIVE

Endometriosis is a debilitating gynaecological disease, responsible of pain and infertility with consequent worsening of women's quality of life. The prevalence is estimated on 10% of the fertile age women,

with an impact on quality of life and reproductive health. Despite its high prevalence and the great scientific activity generated around this disease, we are facing a problem whose etiology remains unknown. Although it is a chronic illness, which begins to cause symptoms very early in a large number of cases, there is still no predictive

* Group recently created, december 2021



1
Introduction

2
Executive
Summary

3
Information
Groups
by Area

4
Associated
Clinicians

marker of the disease, no method of early diagnosis, or any way to modify its clinical course, which is highly variable, producing great uncertainty in affected women. Despite of great advances have been made in the treatment of the disease from a global perspective that included women's fertility and pain control, there is still no etiological treatment or any form of cure.


The endometriosis research group is committed to the following objectives in the next 5 years: to develop a scientific project for FIS 2023, to encourage young researchers, to organize a Master's Degree in Laparoscopy and Endometriosis, to increase the number of final degree projects and final master's projects, to improve the training of gynecological specialty trainee and promote internships abroad, to write publications of the results of our ongoing projects (mainly FIS 2020), to design a website for the HULP- Endometriosis group and to announce monthly workshops of patients with doctors and professionals from the Endometriosis Unit. We also set ourselves the challenge of recognizing the Endometriosis Unit-CSUR (National reference Unit) and promoting gender equality in research and innovation.

The strategies proposed to achieve these objectives are as follows: Participation in the FIBHULP "Mentor Program", to promote collaboration between senior researcher and junior researcher to carry out research projects, congresses communication, to enable specialist trainee and junior gynecologists to perform the "Winner Project", (an educational program for Endoscopic Gynecological Surgery with 3 levels of progression), to encourage collaboration with providers in the endoscopic sector such as Storz, Olympus and Striker. In addition, we have support from IdiPaz Biostatistics and IdiPAZ Biobank (PT20 / 00004) integrated into the National Network of Biobanks of Spain, technical assistance from the HULP Computer and Bioengineering Service, as well as active collaboration with national associations of patients and announcement of events in "La Paz Informa".

Moreover, the Endometriosis Unit of Hospital La Paz has numerous strategic alliances, at the national level (Hospital Clínic of Barcelona, Hospital General of Valencia, Clínica Dexeus Barcelona) and also internationally (Oncopole -Oncology Institute of Toulouse, France; University Hospital of Bologna, Italy; University Hospital of Liège, Belgium; University Hospital of Siena, Italy); University Hospital of Malmo, Stockholm).

RESEARCH LINES

- Investigation of immunological and molecular factors involved in the pathogenesis of endometriosis.
- Investigation of biomarkers to predict the risk of endometriosis malignant transformation. Our objective is to identify a panel of immune system markers and specific genetic mutations to predict endometriosis patients at increased risk of developing ovarian cancer and to identify factors that allow the use of immunotherapy in this type of cancer. In both pathologies (endometriosis and ovarian cancer), the dysfunction of the immune system favours the progression of the disease. In February 2021, the Endometriosis Group received a Health Research Fund by Health Research Institut Carlos III for the project: "Molecular and immunological factors with predictive value in endometriosis associated ovarian cancer".
- Research of new non-hormonal drugs to control symptoms and disease progression.
- Clinical research and new technologies: the advantages of Fluorescence Guided Surgery (FGS). In our operating rooms (Hospital Maternal, HULP) we use modern technology that allows real-time visualization of certain anatomical structures and helps the surgeon to reduce intraoperative stress and improve performance. Recently, the intraoperative use of indocyanine green (ICG) has shown advantages in intestinal surgery for endometriosis. ICG is a dye that is injected intravenously and rapidly reaches the blood vessels of the abdominal organs and allows the emission of fluorescence in the spectral range of the infrared ray. In this way, the vascularization of the colorectal anastomosis can be assessed after bowel resection in patients with endometriosis. We are currently investigating the use of a macromolecule linked to ICG that allows the dye to remain longer in vascularized tissues (rectum), and with a single injection at the start of surgery. This technique is also useful for delimiting endometriotic nodules before removing them.
- Clinical research focusing on the early diagnosis of endometriosis in adolescent patients (European Multicentre Project: Erasmus Project).



3.7.9 Pediatric Diseases/Pediatric HIV Group (HUG)*



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

COMPOSITION

■ **Andrés José Alcaraz Romero.** Jefe de servicio de Pediatría. Hospital Universitario de Getafe

STRATEGIC OBJECTIVE

Actively participate in networks and research projects in pediatric infectious diseases

Actively participate in networks and research projects in neonatology

Conduct studies of new drugs and new therapeutic windows such as cell therapy in osteogenesis imperfecta.

Involve the group's researchers to collaborate in clinical trials.

RESEARCH LINES

- Endocrinologic pathology
- Infectious pathology
- Neonatologic pathology
- Cardiac pathology
- Digestive pathology
- Pneumological pathology and allergy



* This group became part of IdiPAZ through the signing of a new legal agreement in June 2021

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



Associated Clinicians

4

- 4.1 Biostatistic Group
- 4.2 Endocrinology and Nutrition Group
- 4.3 Nutrinvest Group
- 4.4 Ophthalmology Group
- 4.5 Orthopedic Surgery and Traumatology Group
- 4.6 Pediatric Anesthesiology and Reanimation Service Group
- 4.7 Plastic and Reconstructive Surgery Group
- 4.8 Radiotherapy Oncology Group



1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



4.1 Biostatistic Group

Publications: 14
Q1: 4



Group Leader

■ Mariana Díaz Almirón

Composition

Itsaso Losantos García

RESEARCH AREA

- Surgery, transplantation and health technology

RESEARCH ACTIVITY

■ Publications

- Andrés AM, Talayero P, Sánchez AA, Galán AS, Rodríguez JS, Jiménez AB, Sacristán RG, Stringa P, Gobbi RP, Lázaro ML, Almirón MD, Boluda ER, Santamaría ML, Oliveros FH. Delayed introduction of sirolimus in paediatric intestinal transplant

recipients: indications and long-term benefits. *Transpl Int.* 2021; 34(10): 1895-907. Article. IF: 3.842; Q1

- Añón JM, Arellano MS, Pérez-Márquez M, Díaz-Alvarino C, Marquez-Alonso JA, Rodríguez-Pelaez J, Nanwani-Nanwani K, Martín-Pellicer A, Civantos B, López-Fernández A, Seises I,

García-Nerin J, Figueira JC, Casero H, Vejo J, Agrifoglio A, Cachafeiro L, Díaz-Almirón M, Villar J. The role of routine FIBERoptic bronchoscopy monitoring during percutaneous dilatational TRACHEostomy (FIBERTRACH): a study protocol for a randomized, controlled clinical trial. *Trials.* 2021; 22(1): 423. Article. IF: 2.728; Q4

- Berenguer J, Borobia AM, Ryan P, Rodríguez-Bano J, Bellón JM, Jarrín I, Carratala J, Pachón J, Carcas AJ, Yllescas M, Arribas JR. Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score. *Thorax.* 2021; 76(9): 920-9. Article. IF: 9.102; Q1

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

- Cabetas MGT, Martínez PL, Nacher IJ, Almirón MD, Auñón PZ, Ambrosio AH. Real-world experience of palbociclib and ribociclib: novel oral therapy in metastatic breast cancer. *Int J Clin Pharm-Net*. 2021; 43(4): 893-9. Article. IF: 2.305; Q4
- Canizales JT, Ferreras C, Pascual A, Alonso L, Regueiro A, Plaza M, Hurtado JMP, Benito A, Couselo JM, Fuster JL, Díaz-Almirón M, Bueno D, Mozo Y, López AG, Vicario JL, Balas A, Sisinni L, de Heredia CD, Pérez-Martínez A. Haploidentical transplantation in pediatric non-malignant diseases: A retrospective analysis on behalf of the Spanish Group for Hematopoietic Transplantation (GETH). *Eur J Haematol*. 2021; 106(2): 196-204. Article. IF: 3.674; Q3
- Esteban-Cantos A, Rodríguez-Centeno J, Barruz P, Alejos B, Saiz-Medrano G, Nevado J, Martín A, Gaya F, de Miguel R, Bernardino JI, Montejano R, Mena-Garay B, Cadinanos J, Florence E, Mulcahy F, Banhegyi D, Antinori A, Pozniak A, Wallet C, Raffi F, Rodes B, Arribas JR. Epigenetic age acceleration changes 2 years after antiretroviral therapy initiation in adults with HIV: a substudy of the NEAT001/ANRS143 randomised trial. *Lancet HIV*. 2021; 8(4): e197-e205. Article. IF: 16.07; D1
- Feliú J, Pinto A, Basterretxea L, López-San Vicente B, Paredero I, Llabres E, Jiménez-Muñárriz B, Antonio-Rebollo M, Losada B, Espinosa E, Girones R, Custodio AB, Muñoz MD, Díaz-Almirón M, Gómez-Mediavilla J, Torregrosa MD, Soler

- G, Cruz P, Higuera O, González-Montalvo JI, Molina-Garrido MJ. Development and validation of an early mortality risk score for older patients treated with chemotherapy for cancer. *J Clin Med*. 2021; 10(8): 1615. Article. IF: 4.964; Q2
- Fernández MG, Villamañán E, Jiménez-Nacher I, Moreno F, Plasencia C, Gaya F, Herrero A, Balsa A. Cost evolution of biological drugs in rheumatoid arthritis patients in a tertiary hospital: Influential factors on price. *Reumatol Clin*. 2021; 17(6): 335-42. Article. Not Indexed
- González-Tascon CC, Díaz EG, García IL. Epidural analgesia in the obese obstetric patient: a retrospective and comparative study with non-obese patients at a tertiary hospital. *Braz J Anesthesiol*. 2021; 71(3): 214-20. Article. Not Indexed
- Hernández-Brejjo B, Plasencia-Rodríguez C, Navarro-Compán V, García-Hoz C, Nieto-Ganán I, Sobrino C, Bachiller-Corral J, Díaz-Almirón M, Martínez-Feito A, Jurado T, Lapuente-Suánzes P, Bonilla G, Pijoan-Moratalla C, Roy G, Vázquez-Díaz M, Balsa A, Villar LM, Pascual-Salcedo D, Rodríguez-Martín E. Remission induced by TNF inhibitors plus methotrexate is associated with changes in peripheral naive B cells in patients with rheumatoid arthritis. *Front Med (Lausanne)*. 2021; 8: 683990. Article. IF: 5.058; Q2
- Mills S, Ibarzábal-Gil A, Martínez-Díez JM, Pallares-Sanmartín J, Kalbakdjij-Sánchez C, Rubio-Suárez JC, Losantos-García I, Rodríguez-

- Merchán EC. SARS-CoV-2 outbreak impact on a trauma unit. *World J Orthop*. 2021; 12(10): 751-9. Article. Not Indexed
- Pastor S, de Celis E, García IL, de Leciñana MA, Fuentes B, Díez-Tejedor E. Development of the Madrid stroke programme: Milestones and changes in stroke trends and mortality from 1997 to 2017. *Neuroepidemiology*. 2021; 55(2): 135-40. Article. IF: 5.393; Q1
- Rosas-Alonso R, Queiruga J, Arias P, del Monte A, Yuste F, Rodríguez-Antolín C, Losantos-García I, Borobia AM, Rodríguez-Novoa S. Analytical validation of a laboratory-development multigene pharmacogenetic assay. *Pharmacogenet Genom*. 2021; 31(8): 177-84. Article. IF: 2; Q4
- Tapia B, Garrido E, Cebrián JL, del Castillo JL, González J, Losantos I, Gilsanz F. Impact of goal directed therapy in head and neck oncological surgery with microsurgical reconstruction: Free flap viability and complications. *Cancers (Basel)*. 2021; 13(7): 1545. Article. IF: 6.575; Q2

■ Research projects

Díaz Almirón M. Plataforma bioestadística. Fundación de la Sociedad Española de Alergología e Inmunología Clínica. 2017-Ongoing.

Management centre: FIBHULP

■ Patents and trademarks

Ibáñez de Cáceres I, de Castro Carpeño J, Jiménez Hernández J, Rodríguez Antolín C, Vera Puente O, Rosas Alonso R, Pernía Arias O, Losantos García I, inventors; FIBHULP, assignee. Method for determining the response to treatment of a patient affected by non-small cell lung carcinoma (NSCLC). EP19382614.6 (Publication Number pending); 2019 July 19.



4.2 Endocrinology and Nutrition Group

Publications: 18

Q1: 2



Group Leader

■ **Cristina Álvarez Escola**

Composition

Paola Parra Ramírez

Beatriz Lecumberri Santamaría

RESEARCH AREA

- Large system pathology

RESEARCH ACTIVITY

■ Publications

- Araujo-Castro M, Centeno RG, López-García MC, Lamas C, Álvarez-Escola C, Gutiérrez MC, Blanco-Carrera C, Novoa PD, Valdés N, Gimeno PG, Fernández-Ladreda MT, Ojeda CM, Hualpa JCP, Mora M, Vidal O, Romero AS, Hanzu FA,

dos Santos VG. Risk factors for intraoperative complications in pheochromocytomas. *Endocr-Relat Cancer*. 2021; 28(11): 695-703. Article. IF: 5.9; Q1

- Araujo-Castro M, Centeno RG, López-García MC, Escola CA, Gutiérrez MC, Carrera CB, Novoa PD, Gallego NV, Hanzu FA, Gimeno PG, Fernández-

Ladreda MT, Hualpa JCP, Porta MM, Álvaro JL, Pian H, Caracuel IR, Dehesa AS, Dos Santos VG, Romero AS, Oliveira CL. Surgical outcomes in the pheochromocytoma surgery. Results from the PHEO-RISK STUDY. *Endocrine*. 2021; 74(3): 676-84. Article. IF: 3.925; Q3

- Araujo-Castro M, Lázaro CR, Ramírez PP, Cen-

teno RG, Gimeno PG, Fernández-Ladreda MT, Núñez MAS, Marazuela M, Escobar-Morreale HF, Valderrabano P. Maximum adenoma diameter, regardless of uni- or bilaterality, is a risk factor for autonomous cortisol secretion in adrenal incidentalomas. *J Endocrinol Invest*. 2021; 44(11): 2349-57. Article. IF: 5.467; Q2

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

- Araujo-Castro M, Ramírez PP, Lázaro CR, Centeno RG, Gimeno PG, Fernández-Ladreda MT, Núñez MAS, Marazuela M, Escobar-Morreale HF, Valderrabano P. Accuracy of the dexamethasone suppression test for the prediction of autonomous cortisol secretion-related comorbidities in adrenal incidentalomas. *Horm-Int J Endocrinol.* 2021; 20(4): 735-44. Article. IF: 3.419; Q3
- Araujo-Castro M, Ramírez PP, Lázaro CR, Centeno RG, Gimeno PG, Fernández-Ladreda MT, Núñez MAS, Marazuela M, Escobar-Morreale HF, Valderrabano P. Predictors of tumour growth and autonomous cortisol secretion development during follow-up in non-functioning adrenal incidentalomas. *J Clin Med.* 2021; 10(23): 5509. Article. IF: 4.964; Q2
- Díez JJ, Anda E, Sastre J, Corral BP, Álvarez-Escola C, Manjón L, Paja M, Sambo M, Fernández PS, Carrera CB, Galofre JC, Navarro E, Zafón C, Sanz E, Oleaga A, Bandres O, Donnay S, Megia A, Picallo M, Ragnarsson CS, Baena-Nieto G, Fernández-García JC, Lecumberri B, de la Vega MS, Romero-Lluch AR, Iglesias P. Late recovery of parathyroid function after total thyroidectomy: A case-control study. *Horm Metab Res.* 2021; 53(10): 654-61. Article. IF: 2.788; Q4
- Díez JJ, Anda E, Sastre J, Pérez-Corral B, Álvarez-Escola C, Manjón L, Paja M, Sambo M, Santiago-Fernández P, Blanco-Carrera C, Galofre JC, Navarro E, Zafón C, Sanz E, Oleaga A, Bandres O, Donnay S, Megia A, Picallo M, Sánchez-Ragnarsson C, Baena-Nieto G, Fernández-García JC, Lecumberri B, de la Vega MS, Romero-Lluch AR, Iglesias P. Recovery of parathyroid function in patients with thyroid cancer treated by total thyroidectomy: An analysis of 685 patients with hypoparathyroidism at discharge of surgery. *Endocrinol Diabetes Nutr.* 2021; 68(6): 398-407. Article. IF: 1.833; Q4
- García-Carbonero R, Teresa FM, Mercader-Cidoncha E, Mitjavila-Casanovas M, Robledo M, Tena I, Álvarez-Escola C, Aristegui M, Bella-Cueto MR,

- Ferrer-Albiach C, Hanzu FA. Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas. *Clin Transl Oncol.* 2021; 23(10): 1995-2019. Article. IF: 3.34; Q3
- García-Moreno RM, Moreno-Domínguez O, Castelo-Fernández B, Yébenes-Gregorio L, Torres-Sánchez I, Álvarez-Escola C. An unusual case of hypopituitarism as an adverse effect of vandetanib and remission of breast metastases in a patient with medullary thyroid cancer. *Oncol Res Treat.* 2021; 44(10): 568-72. Article. IF: 2.844; Q4
- Gil J, Marqués-Pamies M, Jordá M, Fajardo-Montanana C, García-Martínez A, Sampederro M, Serra G, Salinas I, Blanco A, Valassi E, Sesmilo G, Carrato C, Cámara R, Lamas C, Casano-Sancho P, Álvarez CV, Bernabeu I, Webb SM, Pico A, Marazuela M, Puig-Domingo M. Molecular determinants of enhanced response to somatostatin receptor ligands after debulking in large GH-producing adenomas. *Clin Endocrinol.* 2021; 94(5): 811-9. Article. IF: 3.523; Q3
- Iglesias P, Nocete I, Rodríguez MDM, Venegas-Moreno E, Ares J, Biagetti B, Berrocal VR, Guerrero-Pérez F, Vicente A, Villar-Taibo R, Cordido F, Paja M, Glerean M, Rivera NG, Fuentes ED, Blanco C, Álvarez-Escola C, Martín T, Webb SM, Bernabeu I, Villabona C, Soto-Moreno A, Gaztambide S, Díez JJ. Craniopharyngioma in the elderly: A multicenter and nationwide study in Spain. *Neuroendocrinology.* 2021; 111(10): 925-36. Article. IF: 5.135; Q2
- Monteagudo M, Martínez P, Leandro-García LJ, Martínez-Montes AM, Calsina B, Pulgarín-Alfaro M, Díaz-Talavera A, Mellid S, Letón R, Gil E, Pérez-Martínez M, Megias D, Torres-Ruiz R, Rodríguez-Perales S, González P, Caleiras E, Jiménez-Villa S, Roncador G, Álvarez-Escola C, Regojo RM, Calatayud M, Guadalix S, Curras-Freixes M, Rapizzi E, Canu L, Nolting S, Remde H, Fassnacht M, Bechmann N, Eisenhofer G, Mannelli M, Beuschlein F, Quinkler M, Rodríguez-Antona C,

- Cascon A, Blasco MA, Montero-Conde C, Robledo M. Analysis of telomere maintenance related genes reveals NOP10 as a new metastatic-risk marker in pheochromocytoma/paraganglioma. *Cancers (Basel).* 2021; 13(19): 4758. Article. IF: 6.575; Q2
- Pérez-López C, Álvarez-Escola C, Guerrero AI. Therapeutic approach to non-functioning pituitary adenomas. *Med Clin-Barcelona.* 2021; 156(6): 284-9. Article. IF: 3.2; Q2
- Pérez-López C, Palpán AJ, Sáez-Alegre M, Zamarrón A, Alfonso C, Álvarez-Escola C, Isla A. Volumetric study of nonfunctioning pituitary adenomas: Predictors of gross total resection. *World Neurosurg.* 2021; 147: E206-14. Article. IF: 2.21; Q3
- Puig-Domingo M, Bernabéu I, Pico A, Biagetti B, Gil J, Álvarez-Escola C, Jorda M, Marqués-Pamies M, Soldevila B, Gálvez MA, Cámara R, Aller J, Lamas C, Marazuela M. Pasireotide in the personalized treatment of acromegaly. *Front Endocrinol (Lausanne).* 2021; 12: 648411. Review. IF: 6.055; Q1
- Ruiz-Sánchez JG, Ramírez PP, Catalán AL. A rare association of two endocrine tumours: non-functional oncocytic adrenocortical carcinoma and Papillary thyroid carcinoma. *Horm Mol Biol Clin Invest.* 2021; 42(2): 199-201. Article. Not Indexed
- Ruiz-Sánchez JG, Ramírez PP, Rojas-Marcos PM, Santamaria BL, Escola CA. In-patient management protocol for diabetes insipidus associated with adipsia. Developed from a clinical case. *Endocrinol Diabetes Nutr.* 2021; 68(9): 668-70. Letter. IF: 1.833; Q4
- Sánchez CV, Flores AP, Domínguez VR, Pérez AZ, Álvarez-Escola C, López CP. Role of pituitary stalk and gland radiological status on endocrine function and outcome after endoscopic transsphenoidal surgery for non-functioning pituitary adenomas. *Endocrine.* 2021; 73(2): 416-23. Article. IF: 3.925; Q3

■ Clinical trials

Álvarez Escolá, C. Estudio aleatorizado y doble ciego para evaluar la eficacia y la seguridad de cabozantinib (xl184) con dosis de 60 mg/día en comparación con 140 mg/día en pacientes con cáncer Metálico de tiroides metastásico progresivo.

Type: Clinical Trials, phase IV.
HULP code: Appendix 1 4351.
Sponsored by: Exelixis, Inc.
Signed date: 28/01/2021

Álvarez Escolá, C. Estudio observacional para la caracterización molecular del carcinoma de tiroides en la población española-proyecto molthy". (spanish observational study for molecular characterization of thyroid carcinoma-molthy project.

Type: Estudios, phase EPA-OD.
HULP code: PI-4708 TTCC-2020-02.
Sponsored by: Grupo Español De Tratamiento De Tumores De Cabeza Y Cuello.
Signed date: 19/04/2021

4.3 Nutrinvest Group

Publications: 7

Q1: 1



Group Leader

■ **Bricia López Plaz**

Composition

Samara Palma Milla
Edwin Fernández Cruz
Marlhyn Valero Pérez
Natalia García Vázquez
Marina Morato Martínez
Lucía Arcos Castellanos
Laura Mola Reyes
Rosa María García Moreno

RESEARCH AREA

- Surgery, transplantation and health technology

RESEARCH ACTIVITY

■ Publications

- Candela CG, Milla SP, Lozano EC, Di Martino M, Alcolea NG, Roldán JO, de la Rica AS, Lagunas DP. Immunonutrition in fast-track surgical patients - Evidence review and adapted algorithm. Nutr Hosp. 2021; 38(3): 601-21. Review.

IF: 1.169; Q4

- Cruz EF, Plaza BL, Santurino C, Candela CG. Nutritional composition and nutritional claims of Canary Islands banana. Nutr Hosp. 2021; 38(6): 1248-56. Article. IF: 1.169; Q4
- Kohen VL, del Portillo RC, Pérez MV, Álvarez MTM, Alija MJC, Matia-Martín MP, Candela CG.

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

Nutritional education protocol in the treatment of eating disorders in the clinical and care settings. *Nutr Hosp.* 2021; 38(4): 857-70. Article. IF: 1.169; Q4

- Morales D, Shetty SA, López-Plaza B, Gómez-Candela C, Smidt H, Marin FR, Soler-Rivas C. Modulation of human intestinal microbiota in a clinical trial by consumption of a beta-d-glucan-enriched extract obtained from *Lentinula edodes*. *Eur J Nutr.* 2021; 60(6): 3249-65. Article. IF: 4.865; Q2
- Morato-Martínez M, Santurino C, López-Plaza B, Arcos-Castellanos L, Clavero-Fraile M, Milla SP, Valero M, Candela CG. A standardized, integral nutritional intervention and physical activity program reduces body weight in women newly diagnosed with breast cancer. *Nutr Hosp.* 2021; 38(3): 575-84. Article. IF: 1.169; Q4
- Rojo-Tirado MA, Benito PJ, Ruiz JR, Ortega FB, Romero-Moraleda B, Butragueno J, Bermejo LM, Castro EA, Gómez-Candela C. Body composition changes after a weight loss intervention: A 3-year follow-up study. *Nutrients.* 2021; 13(1): 164. Article. IF: 6.706; Q1
- Wanden-Berghe C, Casas NV, Compes CC, Boluda ER, Cunill JLP, Jiménez MIM. Home and Ambulatory Artificial Nutrition (NADYA) Group report: home parenteral nutrition in Spain, 2019. *Nutr Hosp.* 2021; 38(6): 1304-9. Article. IF: 1.169; Q4

■ Research projects

López Plaza B. Prespectiva de la actividad investigadora de la unidad de nutrición clínica y dietética. Abbott Laboratories S.A. 2008-Ongoing.

Managment centre: FIBHULP

López Plaza B. Satisfood: desarrollo y validación de alimentos saciantes mediante la integración de las señales pre y postingestivas. Creaciones Aromaticas Indus-

triales S.A. 2017-Ongoing.

Managment centre: FIBHULP

López Plaza B. Ensayo clínico para evaluar el efecto del consumo de dos microalgas unicelulares sobre biomarcadores del síndrome metabólico en sujetos con sobrepeso/obesidad y el perfil lipídico alterado. Anfac-Cecopesca. 2018-Ongoing.

Managment centre: FIBHULP

López Plaza B. Puesta en marcha del ensayo clínico Estudio clínico-nutricional para evaluar las propiedades de una dieta suplementada con alimentos de alto contenido proteico sobre marcadores de salud músculo-esquelética de un colectivo de personas mayores institucionalizadas frágiles con riesgo de sufrir sarcopenia. Delafruit, S.L.U. (Go Fruselva). 2019-Ongoing.

Managment centre: FIBHULP

López Plaza B. Plataforma de nutrición y alimentación. Abbott Laboratories S.A. 2019-Ongoing.

Managment centre: FIBHULP

López Plaza B. Puesta en marcha del Ensayo clínico para evaluar el efecto de una cepa probiótica sobre los síntomas de la intolerancia a la lactosa. Biopolis S.L. 2020-Ongoing.

Managment centre: FIBHULP

López Plaza B. Puesta en marcha del ensayo clínico para evaluar el índice glicémico de un suplemento nutricional oral

(SNO) hipercalórico/hiperproteico enriquecido en calcio, vitamina d y dha en población adulta sana. Fundacio Eurecat. 2021-Ongoing.

Managment centre: FIBHULP

Palma Milla S. Estudio observacional para el conocimiento de los factores de riesgo asociados al cáncer de mama en mujeres de reciente diagnóstico de la enfermedad en la Comunidad de Madrid. Abbott Laboratories S.A. 2017-Ongoing.

Managment centre: FIBHULP

■ Clinical trials

López Plaza, B. Ensayo clínico nutricional para evaluar el efecto del consumo habitual de un probiótico con alta actividad b-galactosidasa sobre los síntomas de la intolerancia a la lactosa en un colectivo de personas con intolerancia a la lactosa.

Type: Estudio Producto Alimentario.

HULP code: 5758 PROBIOLAC.

Sponsored by: Delafruit,Slu (Go Fruselva).

Signed date: 18/02/2021"

López Plaza, B. Ensayo clínico para evaluar el índice glucémico de un suplemento nutricional oral (sno) hipercalórico/hiperproteico enriquecido en calcio, vitamina d y dha en población adulta sana.

Type: Estudios, fase EPA-OD.

HULP code: 5921 TERATROFO.

Sponsored by: Fundacio Eurecat.

Signed date: 19/11/2021

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



4.4 Ophthalmology Group

Publications: 14

Q1: 3



Group Leader

■ **Félix Armadá Maresca**

Composition

Almudena del Hierro Zarzuelo
Álvaro Arbizu-Duralde
Ana Boto de los Bueis
Ana María Martín Ucero
Ana Ramos Castrillo
Antonio Pérez Esteban
Beatriz Manzano Muñoz
Cosme Lavín Dapena
Gloria E. Amorena Santesteban
Irene Rosa Pérez
Javier Coca Robinot
Jesús Fraile Maya

Jose Vicente Dabad Moreno
Julia Esther Murillo Doria
Lilian Martínez Godoy
Margarita Sánchez-Orgaz
María Capote Díez
María Del Pino Ciudad Betegón
Oriana D'Anna Mardero
Paola Vázquez Colomo
Ricardo Romero-Martín
Rosa Cordero Ros
Rosa Langa Hontoria
Sara Díez Arandilla
Sofía De Manuel Triantáfilo

RESEARCH AREA

- Large system pathology

RESEARCH ACTIVITY

■ Doctoral theses

Toledo Negrete JJ. Estudio de tumores melanocíticos coroideas con angiografía por tomografía de coherencia óptica. [dissertation]. Madrid: UAM: 2021(25/08/2021).

Directors: Asencio-Durán M, Cajjal Morales C.

■ Publications

- Alcalde CF, Fernández MG, Moreno MN, Rey CC, Romero IF, Martín SN. COVID-19 ocular findings in children: a case series. *World J Pediatr.* 2021; 17(3): 329-34. Letter. IF: 9.186; D1
- Feito-Rodríguez M, Mayor-Ibarguren A, Cámara-Hijón C, Montero-Vega D, Servera-Negre G, Ruiz-Bravo E, Nozal P, Rodríguez-Peralto JL, Enguita AB, Bravo-Gallego LY, Granados-Fernández M, Fernández-Alcalde C, Fernández-Heredero A, Alonso-Riano M, Jiménez-Yuste V, Nuno-González A, de Lucas-Laguna R, López-Granados E, Herranz-Pinto P. Chilblain-like lesions and COVID-19 infection: A prospective observational study at Spain's ground zero. *J Am Acad Dermatol.* 2021; 84(2): 507-9. Letter. IF: 15.487; D1
- Fernández-Alcalde C, Nieves-Moreno M, Noval S, Peralta JM, Montano VEE, del Pozo A, Santos-Simarro F, Vallespin E. Molecular and genetic mechanism of non-syndromic congenital cataracts. Mutation screening in spanish families. *Genes (Basel).* 2021; 12(4): 580. Article. IF: 4.141; Q2
- Gili P, Kim-Yeon N, de Manuel-Triantafilo S, Modamio-Gardeta L, Leal-González M, Yangüela J.

Diagnosis of optic nerve head drusen using enhanced depth imaging optical coherence tomography. *Eur J Ophthalmol.* 2021; 31(6): 3476-82. Article. IF: 1.922; Q4

- Lavin-Dapena C, Cordero-Ros R, D'Anna O, Mogollon I. XEN 63 gel stent device in glaucoma surgery: A 5-years follow-up prospective study. *Eur J Ophthalmol.* 2021; 31(4): 1829-35. Article. IF: 1.922; Q4
- Miranda-Barrios J, Bravo-Queipo-de-Llano B, Baquero-Artigao F, Granados-Fernández M, Noval S, Rabanal I, Méndez-Echevarría A, del Rosal T, Sainz T, Aracil J, Calvo C. Preseptal versus orbital cellulitis in children: An observational study. *Pediatr Infect Dis J.* 2021; 40(11): 969-74. Article. IF: 3.806; Q1
- Narváez Palazón C, Sánchez Ventosa A, Nieves Moreno M, Redondo Ibáñez A, Gómez de Llano Sánchez R. Study of reliability and validity of VOG Perea and GazeLab and calculation of the variability of their measurements. *Arch Soc Esp Oftalmol (Engl Ed).* 2021; 96(3): 127-32-. Article. Not Indexed
- Nieves-Moreno M, Granados M, Noval S. Authors' response to chalazia, a late manifestation of primary immunodeficiency disorders. *Ocul Immunol Inflamm.* 2021; 29(2): 265. Letter. IF: 3.728; Q2
- Nieves-Moreno M, Granados M, Noval S. Primary immunodeficiency diseases presenting with chalazia as the first manifestation. *Ocul Immunol Inflamm.* 2021; 29(2): 257-9. Letter. IF: 3.728; Q2
- Nieves-Moreno M, Noval S, Peralta J, Palomares-Bralo M, del Pozo A, García-Minaur S, Santos-Simarro F, Vallespin E. Expanding the phenotypic spectrum of PAX6 mutations: From congenital cataracts to nystagmus. *Genes (Basel).* 2021; 12(5): 707. Article. IF: 4.141; Q2

- Nieves-Moreno M, Yeo D, Patel HI, Reddy MA. The frequency of severe corneal opacities in premature infants. *J Aapos.* 2021; 25(4): 221.e1-5. Article. IF: 1.325; Q4
- Perea-Romero I, Gordo G, Iancu IF, del Pozo-Valero M, Almoguera B, Blanco-Kelly F, Carreno E, Jiménez-Rolando B, López-Rodríguez R, Lorda-Sánchez I, Martín-Mérida I, de Ayala LP, Riveiro-Álvarez R, Rodríguez-Pinilla E, Tahsin-Swafiri S, Trujillo-Tiebas MJ, García-Sandoval B, Minguez P, Ávila-Fernández A, Cortón M, Ayuso C. Genetic landscape of 6089 inherited retinal dystrophies affected cases in Spain and their therapeutic and extended epidemiological implications. *Sci Rep-Uk.* 2021; 11(1): 1526. Article. IF: 4.996; Q2
- Ramos-Ruperto L, Busca-Arenzana C, Boto-de los Bueis A, Schlincker A, Arnalich-Fernández F, Robles-Marhuenda A. Cancer-associated retinopathy and treatment with intravenous immunoglobulin therapy. A seldom used approach? *Ocul Immunol Inflamm.* 2021; 29(2): 399-402. Letter. IF: 3.728; Q2
- Spieß K, Calvo JP. Outcomes of Ahmed glaucoma valve in paediatric glaucoma following congenital cataract surgery in persistent foetal vasculature. *Eur J Ophthalmol.* 2021; 31(3): 1070-8. Article. IF: 1.922; Q4

■ Research projects

Armada Maresca F. Centro tecnológico para el estudio y tratamiento integrado de los desórdenes neurológicos (NEUROCENTRO-CM) (S2017/BMD-3760). CM. 2018-2022.

Managment centre: FIBHULP

■ Clinical trials

Boto De Los Bueis, A. Registro de infecciones corneales asociadas al uso de lentes de contacto.

Type: Estudios No EPA.

HULP code: PI-3949 REGINFECOR-LC.

Sponsored by: Sociedad Española de Oftalmología (SEO).

Signed date: 04/02/2021

Vázquez Colomo, P. Eficacia y tolerabilidad de RD03/2016 (solución oftálmica de levofloxacin; ketorolacotrometamol 0,5 + 0,5% m/v) para el tratamiento de la conjuntivitis bacteriana en adultos: estudio clínico en fase II de no inferioridad, multicéntrico, aleatorizado, enmascarado para el evaluador. Estudio MIRAKLE.

Type: Clinical Trials, phase II.

HULP code: 5778 LEVOKE-TO_02-2020.

Sponsored by: Ntc Srl.

Signed date: 30/09/2021.

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



4.5 Orthopedic Surgery and Traumatology Group

Publications: 20

Q1: 4



Group Leader

■ **Francisco Javier Sánchez Pérez-Gruoso**

Composition

Irene Barrientos Ruiz
Juan Cabello Blanco
Rafael Carbonell Escobar
Nicomedes Fernández-Baíllo
Gaspar González Morán
Luis Rodrigo Merino Rueda

Eduardo Ortiz Cruz
Manuel Peleteiro Pensado
Mar Pérez Martín-Buitrago
Francisco Javier Pizones Arce
Jose Miguel Sánchez Márquez
Eloy Dario Tabeayo Álvarez
Alfonso Vaquero Picado
Juan Ignacio Viñuales García

RESEARCH AREA

- Surgery, transplantation and health technology

RESEARCH ACTIVITY

■ Publications

- Bourghli A, Boissiere L, Kieser D, Larriou D, Pizones J, Alanay A, Pellise F, Kleinstuck F, Obeid I. Multiple-rod constructs do not reduce pseudarthrosis and rod fracture after pedicle subtraction osteotomy for adult spinal deformity correction but improve quality of life. Neurospine. 2021; 18(4): 816-23. Article. IF: 3.374; Q2

- Bourghli A, Boissiere L, Konbaz F, Al Eissa S, Al-Habib A, Qian BP, Qiu Y, Hayashi K, Pizones J, Ames C, Vital JM, Obeid I. On the pedicle subtraction osteotomy technique and its modifications during the past two decades: a complementary classification to the Schwab's spinal osteotomy classification. Spine Deform. 2021; 9(2): 515-28. Article. Not Indexed
- Cruz-Pardos A, García-Rey E, Fernández-Fernán-

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians

dez R, Ortega-Chamarro J. Do trabecular metal cups achieve better results when compared to hemispherical porous titanium cups in acetabular revision surgery? *Hip Int.* 2021; 31(6): 774-81. Article. IF: 1.756; Q3

- Encinas-Ullán CA, Gómez-Cardero P, Ruiz-Pérez JS, Rodríguez-Merchán EC. Dislocation of rotating-hinge total knee arthroplasty. *EFORT Open Rev.* 2021; 6(2): 107-12. Article. IF: 4.775; Q1
- Fernández-Fernández R, Díaz-Freire P, Rubio-Suárez JC. Open reduction and navigated Iliosacral screws for vertically unstable pelvic fractures. *Injury.* 2021; 52: S22-6. Article. IF: 2.687; Q2
- Fernández-Fernández R, Onorbe-San Francisco FF, Gil-Garay E. Long-term outcomes of a titanium-encased ceramic liner total hip arthroplasty (15 to 21Year Results). *J Arthroplasty.* 2021; 36(11): 3697-702. Article. IF: 4.435; Q1
- Figueras C, Matamalas A, Pizones J, Moreno-Manzanaro L, Betegon J, Bago J. The relationship of kinesiophobia with pain and quality of life in idiopathic scoliosis. *Spine.* 2021; 46(21): 1455-60. Article. IF: 3.241; Q2
- Fusini F, Pizones J, Moreno-Manzanaro L, Márquez JMS, Talavera G, Fernández-Baillo N, Pérez-Gruoso FJS. How to select the lower instrumented vertebra in traditional growing rods index surgery. *Int J Spine Surg.* 2021; 15(3): 577-84. Article. Not Indexed
- García Rey E, Cruz Pardos A, Ortega Chamarro J. Mortality as a competition risk factor in the survival analysis of the results of the type of fixation of the total hip prosthesis in octogenarian patients. *Rev Esp Cir Ortop Traumatol (Engl Ed).* 2021; 65(2): 99-107. Article. Not Indexed
- Gómez-Luque J, Cruz-Pardos A, Garabito-Cocina A, Ortega-Chamarro J, García-Rey E. Topical, intravenous tranexamic acid and their combined use are equivalent in reducing blood loss after primary total hip arthroplasty. *Rev Esp Cir Ortop Traumatol (Engl Ed).* 2021; 65(5): 349-54. Article. Not Indexed
- Iwai C, Pizones J, Boissiere L, Jakinapally S, Yilgor C, Larriue D, Pellise F, Vital JM, Bourghli A, Obeid I. Static and dynamic sagittal lumbar apex: a new concept for the assessment of lum-

bar lordosis distribution in spinal deformity. *Eur Spine J.* 2021; 30(5): 1155-63. Article. IF: 2.721; Q2

- Kieser DC, Boissiere L, Bourghli A, Hayashi K, Cawley D, Yilgor C, Alanay A, Acaroglu E, Kleinstueck F, Pizones J, Pellise F, Pérez-Gruoso FJS, Obeid I. Obeid-coronal malalignment classification is age related and independently associated to personal reported outcome measurement scores in the nonfused spine. *Neurospine.* 2021; 18(3): 475-80. Article. IF: 3.374; Q2
- Kieser DC, Bourghli A, Larriue D, Cawley DT, Hayashi K, Jakinapally S, Pizones J, Boissiere L, Obeid I. Impact of COVID-19 on the pain and disability of patients with adult spinal deformity. *Spine Deform.* 2021; 9(4): 1073-6. Article. Not Indexed
- Merino-Rueda LR, Rubio-Sáez I, Mills S, Rubio-Suárez JC. Mortality after distal femur fractures in the elderly. *Injury.* 2021; 52: S71-5. Article. IF: 2.687; Q2
- Mills S, Ibarzábal-Gil A, Martínez-Díez JM, Pallares-Sanmartín J, Kalbkdij-Sánchez C, Rubio-Suárez JC, Losantos-García I, Rodríguez-Merchán EC. SARS-CoV-2 outbreak impact on a trauma unit. *World J Orthop.* 2021; 12(10): 751-9. Article. Not Indexed
- Mo AZ, Miller PE, Pizones J, Helenius I, Ruf M, El-Hawary R, de Oliveira RG, Ovadia D, Kawakami N, Crawford H, Odent T, Yazici M, Johnson MB, Miyanji F, Hedequist DJ. The reliability of the AOSpine thoracolumbar spine injury classification system in children: an international validation study. *J Child Orthop.* 2021; 15(5): 472-8. Article. IF: 1.917; Q3
- Núñez-Pereira S, Serra-Burriel M, Vila-Casademunt A, Hayashi K, Haddad S, Pizones J, Kleinstueck F, Obeid I, Alanay A, Pellise F. The dynamics of satisfaction in surgical and non-surgical adult spinal deformity patients. *Eur Spine J.* 2021; 30(5): 1235-46. Article. IF: 2.721; Q2
- Rodríguez-Merchán EC, de la Corte-Rodríguez H, Encinas-Ullán CA, Gómez-Cardero P. Complications of surgical reconstruction of multiligament injuries of the knee joint: diagnosis, prevention and treatment. *EFORT Open Rev.* 2021; 6(10): 973-81. Article. IF: 4.775; Q1

- Rodríguez-Merchán EC, Encinas-Ullán CA, Gómez-Cardero P. Effectiveness of ankle fusion in patients with hemophilia, advanced ankle degeneration, and unbearable pain for whom nonsurgical and surgical treatments have been ineffective. *Expert Rev Hematol.* 2021; 14(6): 517-24. Review. IF: 2.819; Q3
- Rodríguez-Merchán EC, Gómez-Cardero P, Encinas-Ullán CA. Management of bone loss in revision total knee arthroplasty: therapeutic options and results. *EFORT Open Rev.* 2021; 6(11): 1073-86. Article. IF: 4.775; Q1

Research projects

Pizones Arce FJ. PI-1167: clinical outcomes following conservatives and surgical treatment of adult spine deformity (). Fundacio Hospital Vall D'Hebron. 2012-Ongoing.

Managment centre: FIBHULP

Barrientos Ruiz I. Ensayo clinico aleatorizado, doble ciego, 3 brazos, para evaluar el impacto de la perdida sanguinea tras la administracion de tres pautas de acido tranexamico en pacientes intervenidos por sarcomas oseos o de partes blandas (). Fundacion Sociedad Española De Cirugía Ortopédica Y Traumatología Fundación Secot. 2016-Ongoing.

Managment centre: FIBHULP

Fernández-Baillo Gallego de la Sacristana N. Programa de formacion científica en el area de cirugia de columna, programa de intensificacion (). Johnson & Johnson, S.A.. 2019-Ongoing.

Managment centre: FIBHULP

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



4.6 Pediatric Anesthesiology and Reanimation Service Group

Publications:

7

Q1:

2



Group Leader

■ **Francisco Reinoso Barbero**

Composition

Emilio Rodríguez Pérez
Luis Castro Parga
Ana Lahoz Ramón
María Ángeles Herranz Ortega
Esperanza Jiménez Mateos
Pilar Durán de la Fuente
Gema Campo García
Raquel Pérez González
Marta Vázquez Moyano
Elena Fernández Dueñas
Mercedes Alonso Prieto
Pilar Morán Martín
Lina Builes Cardona
Ana Ortega Floria
Patricio González Pizarro
Raquel García Gómez
Iván Huercio Martínez
Laura López García
Sara Cabezudo Ballesteros
Gabriela Alcaraz García Tejedor

RESEARCH AREA

• Maternal Infant Child and youth research

RESEARCH ACTIVITY

■ Publications

- Alcalá CR, Borbolla AM, Pérez ER, Carretero PS, Barbero FR. Perioperative management of patients with arrhythmogenic syndromes refractory to medical treatment: A clinical case report. *Rev Esp Anesthesiol Reanim*. 2021; 68(6): 353-6. Article. Not Indexed
- Berenguer J, Borobia AM, Ryan P, Rodríguez-Baño J, Bellón JM, Jarrín I, Carratala J, Pachón J, Carcas AJ, Yllescas M, Arribas JR. Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score. *Thorax*. 2021; 76(9): 920-9. Article. IF: 9.102; Q1
- Gil OC, Carretero PS, Castro L, Barbero FR, López LP, de la Torre CA. Original and minimally invasive approach to a left-lung refractory atelectasis after reparation of an aortic recoarctation in a lactant: Selective endobronchial CPAP. *Rev Esp Anesthesiol Reanim*. 2021; 68(7): 420-3. Article. Not Indexed
- Gutiérrez-Gutiérrez B, del Toro MD, Borobia AM, Carcas A, Jarrín I, Yllescas M, Ryan P, Pachón J, Carratala J, Berenguer J, Arribas JR, Rodríguez-Baño J. Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study. *Lancet Infect Dis*. 2021; 21(6): 783-92. Article. IF: 71.421; D1
- Miro J, Mico JA, Reinoso-Barbero F. The management of pediatric chronic pain in Spain: a web-based survey study. *Curr Med Res Opin*. 2021;

37(2): 303-10. Article. IF: 2.705; Q3

- Segura-Grau E, Sebastián JD, Reinoso-Barbero F. The influence of age on the anatomical variability of sciatic nerve divisions in the thigh: an ultrasound study. *Surg Radiol Anat*. 2021; 43(12): 2031-7. Article. IF: 1.354; Q3
- Velayos M, Estefania K, Álvarez M, Sarmiento MC, Moratilla L, Sanabria P, Hernández F, López Santamaria MV. Healthcare staff as promoters of parental presence at anesthetic induction: Net Promoter Score survey. *World J Clin Pediatr*. 2021; (10): 159-67. Article. IF: Not Indexed

■ Research projects

González Pizarro P. Evaluación clínica pediátrica de monitor conox. Quantum Medical S.L.U. 2020-Ongoing.

Managment centre: FIBHULP

González Pizarro P. Validación del test de aire como método de detección de atelectasias perioperatorias en pediatría: un estudio prospectivo. Mr Global (Mindray). 2020-Ongoing.

Managment centre: FIBHULP

Reinoso Barbero F. Estudio observacional de la influencia de la distracción por

videojuegos electronicos en los niños ingresados por enfermedades oncológicas. Fundacion Juegaterapia. 2015-Ongoing.

Managment centre: FIBHULP

Reinoso Barbero F. Jornadas científicas sobre el manejo de la vía aérea en anestesia inhalatoria pediátrica con desflurano. Baxter S.L. 2018-Ongoing.

Managment centre: FIBHULP

Reinoso Barbero F. Successful ultrasound guidance for tap blocks decreases the need for rescue analgesia after open appendectomy in children. Baxter S.L. 2011-Ongoing.

Managment centre: FIBHULP

Reinoso Barbero F. Surgical pleth index in the paediatric population: a prospective observational single-center study. GE Precision Healthcare Lld. 2020-Ongoing.

Managment centre: FIBHULP

Reinoso Barbero F. Tercer curso de accesos vasculares ecoguiados en pediatría. Vygon SAU. 2018-Ongoing.

Managment centre: FIBHULP

■ Clinical trials

González Pizarro, P. Validación del test de aire como método de detección de atelectasias perioperatorias en pediatría: un estudio prospectivo.

Type: Estudios No EPA.

HULP code: 5518 PEDIATRIC AIT TEST.

Sponsored by: González Pizarro, Patricio.

Signed date: 12/07/2021

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



4.7 Plastic and Reconstructive Surgery Group

Publications: **3**

Q1: **2**



Group Leader

■ **José Ramón Martínez Méndez**

Composition

César Casado Sánchez

Luis Lándín Jarillo

Pedro Bolado Gutiérrez

Jorge Bonastre Julia

Álvaro González Miranda

Elena Bravo Brañas

Carmen Iglesias Urraca

Marta García Redondo

Shirin zarbakhsh Etemadi

Alexandar Lovic Jazbec

RESEARCH AREA

- Surgery, transplantation and health technology

RESEARCH ACTIVITY

■ Doctoral theses

Corrales Benítez C. Recuperación funcional de la mano quemada tras desbridamiento enzimático[dissertation]. Madrid: UAM: 2021(15/10/2021).

Directors: Martínez Méndez JR, González Miranda A.

Master Theses

Arribas Peña A. Efectos de la antibioterapia en la enfermedad leve o moderada por covid-19 en pacientes ambulatorios del área norte de madrid [dissertation]. Madrid: Universidad San Pablo CEU:

2021(14/05/2021).

Director: González Miranda A.

Final Degree Theses

Cámara Martínez C. Complicaciones en colgajos fasciocutáneos de diseño subfascial y adelgazados. Comparación de incidencias y complicaciones de los mismos [dissertation]. Madrid: UAM: 2021(30/05/2021).

Director: Bonastre Julia J.

Cid San Miguel A. Monitorización de la perfusión tisular en colgajos fasciocutáneos, diseño subfascial contra diseño

adelgazado[dissertation]. Madrid: UAM: 2021(30/05/2021).

Director: Bonastre Julia J.

■ Publications

- Varela R, Landín L. Reply: Outcomes of DIEP flap and fluorescent angiography: A randomized controlled clinical Trial. *Plast Reconstr Surg.* 2021; 147(4): 702E-702E. Letter. IF: 5.169; Q1
- Pérez-Rodríguez J, Manzanares-Retamosa ML, Bolado-Gutiérrez P, Lovic A. Two-level lesion of the suprascapular nerve in obstetric brachial plexus palsy: a case report. *J Hand Surg-Eur Vol.* 2021; 46(7): 788-9. Letter. IF: 2.206; Q3
- Varela R, Landín L. Reply: Outcomes of DIEP flap and fluorescent angiography: A randomi-

zed controlled clinical Trial. *Plast Reconstr Surg.* 2021; 147(3): 558E-9. Letter. IF: 5.169; Q1

■ Research projects

Casado Sánchez C. Evaluación experimental de la fibrosis y su prevención en trasplante de tejido compuestos. FIBHULP. 2019-Ongoing.

Managment centre: FIBHULP

Bonastre Juliá J. Inducción de tolerancia con galactomanano en un modelo de trasplante de extremidad posterior en ratas. FIBHULP. 2016-Ongoing.

Managment centre: FIBHULP



4.8 Radiotherapy Oncology Group

Publications: 3

Q1: 1



Group Leader

■ Rosa María Morera López

Composition

Isabel Rodríguez Rodríguez

Ana castaños Cantos

Ana Escribano Uzkudum

Luis Alberto Glaría Enríquez

Belén Belinchón Olmedo

Aúrea Manso de Lema

Lara Miralles

Beatriz Bebén Méndez

Elisabet González del Portillo

María Isabel Garrido Botella

Marta Rodríguez Roldán

María Macarena Reja Ubach

Mercedes González Cantero

Rafael Rosel Aller

RESEARCH AREA

- Cancer and human molecular genetics

RESEARCH ACTIVITY

■ Doctoral theses

González del Portillo E. Evaluación del efecto sinérgico entre radioterapia y moduladores de la autofagia [dissertation]. Salamanca: Universidad de Salamanca: 2021(15/04/2021).

Directors: González Sarmiento R, Pérez Romasanta LA.

Master Theses

Reja Ubach M. Toxicidad aguda de hipofraccionamiento en cáncer de pulmón

[dissertation]. Madrid: Universidad Francisco de Vitoria: 2021(21/09/2021).

Director: Manso de Lema A.

Garrido Botella MI. Results of radical treatment in locally advanced cervical cancer [dissertation]. Madrid: Universidad Francisco de Vitoria: 2021(15/09/2021).

Director: Rodríguez Rodríguez I.

Rodríguez Roldán M. Single center experience on safety and efficacy of LDR brachytherapy [dissertation]. Madrid: Universidad Francisco de Vitoria:

2021(15/09/2021).

Director: Alberto Glaría L.

■ Publications

- de Lucas RH, Fernández MN, Gómez-Camano A, López RM, de la Torre IF, Tomás AD, Muñoz-Garzón V, Bermudo CL, Rueda AM. Quality of life in patients with breakthrough cancer pain in radiation oncology departments in Spain: the CAVIDIOR study. *Future Oncol.* 2021; 17(8): 943-54. Article. IF: 3.674; Q3
- Leon-Triana O, Pérez-Beteta J, Albillo D, de Mendivil AO, Pérez-Romasanta L, González-

Del Portillo E, Llorente M, Carballo N, Arana E, Pérez-García VM. Brain metastasis response to stereotactic radio surgery: A mathematical approach. *Mathematics (Basel).* 2021; 9(7): 716. Article. IF: 2.592; D1

- Lozano A, Marruecos J, Rubio J, Farre N, Gómez-Millán J, Morera R, Planas I, Lanzuela M, Vázquez-Masedo MG, Cascallar L, Giralt J, Escames G, Valentí V, Grima P, Bosser R, Tarrago C, Mesia R. Randomized placebo-controlled phase II trial of high-dose melatonin mucoadhesive oral gel for the prevention and treatment of oral mucositis in patients with head and neck cancer undergoing radiation therapy concurrent with systemic treatment. *Clin Transl Oncol.* 2021; 23(9): 1801-10. Article. IF: 3.34; Q3

Scientific Report

2021 IdiPAZ

Instituto de Investigación
Hospital Universitario La Paz

IdiPAZ Sostenible



 **Hospital Universitario
La Paz**
SaludMadrid Hospital Carlos III
Hospital Cantoblanco

 **Hospital Universitario La Paz**
Fundación para la Investigación Biomédica
SaludMadrid  **Comunidad de Madrid**

UAM

Universidad Autónoma
de Madrid

 **Hospital Universitario
de Getafe**
SaludMadrid

 **Universidad
Europea**